PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Grund, B; Baker, JV; Deeks, SG; Wolfson, J; Wentworth, D; Cozzi-Lepri, A; Cohen, CJ; Phillips, A; Lundgren, JD; Neaton, JD				Grund, Birgit; Baker, Jason V.; Deeks, Steven G.; Wolfson, Julian; Wentworth, Deborah; Cozzi-Lepri, Alessandro; Cohen, Calvin J.; Phillips, Andrew; Lundgren, Jens D.; Neaton, James D.		INSIGHT SMART ESPRIT SILCAAT Study	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; INFLAMMATORY MARKERS; REGRESSION DILUTION; RISK; MORTALITY; CANCER; COAGULATION; STROKE; ASSOCIATIONS	Background Despite effective antiretroviral treatment (ART), HIV-positive individuals are at increased risk of serious non-AIDS conditions (cardiovascular, liver and renal disease, and cancers), perhaps due in part to ongoing inflammation and/or coagulation. To estimate the potential risk reduction in serious non-AIDS conditions or death from any cause that might be achieved with treatments that reduce inflammation and/or coagulation, we examined associations of interleukin-6 (IL-6), D-dimer, and high-sensitivity C-reactive protein (hsCRP) levels with serious non-AIDS conditions or death in 3 large cohorts. Methods In HIV-positive adults on suppressive ART, associations of IL-6, D-dimer, and hsCRP levels at study entry with serious non-AIDS conditions or death were studied using Cox regression. Hazard ratios (HR) adjusted for age, gender, study, and regression dilution bias (due to within-person biomarker variability) were used to predict risk reductions in serious non-AIDS conditions or death associated with lower "usual" levels of IL-6 and D-dimer. Results Over 4.9 years of mean follow-up, 260 of the 3766 participants experienced serious non-AIDS conditions or death. IL-6, D-dimer and hsCRP were each individually associated with risk of serious non-AIDS conditions or death, HR = 1.45 (95% CI: 1.30 to 1.63), 1.28 (95% CI: 1.14 to 1.44), and 1.17 (95% CI: 1.09 to 1.26) per 2x higher biomarker levels, respectively. In joint models, IL-6 and D-dimer were independently associated with serious non-AIDS conditions or death, with consistent results across the 3 cohorts and across serious non-AIDS event types. The association of IL-6 and D-dimer with serious non-AIDS conditions or death was graded and persisted throughout follow-up. For 25% lower "usual" IL-6 and D-dimer levels, the joint biomarker model estimates a 37% reduction (95% CI: 28 to 46%) in the risk of serious non-AIDS conditions or death if the relationship is causal. Conclusions Both IL-6 and D-dimer are independently associated with serious non-AIDS conditions or death among HIV-positive adults with suppressed virus. This suggests that treatments that reduce IL-6 and D-dimer levels might substantially decrease morbidity and mortality in patients on suppressive ART. Clinical trials are needed to test this hypothesis.	[Grund, Birgit] Univ Minnesota, Sch Stat, Minneapolis, MN 55455 USA; [Baker, Jason V.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Baker, Jason V.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Deeks, Steven G.] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Wolfson, Julian; Wentworth, Deborah; Neaton, James D.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; [Cozzi-Lepri, Alessandro; Phillips, Andrew] UCL, London, England; [Cohen, Calvin J.] Gilead Sci Inc, Med Affairs Dept, 353 Lakeside Dr, Foster City, CA 94404 USA; [Lundgren, Jens D.] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of London; University College London; Gilead Sciences; Rigshospitalet; University of Copenhagen	Grund, B (corresponding author), Univ Minnesota, Sch Stat, Minneapolis, MN 55455 USA.	birgit@ccbr.umn.edu	Grund, Birgit/G-7054-2016; Phillips, Andrew N/B-4427-2008; Lundgren, Jens/AAE-6876-2019	Grund, Birgit/0000-0003-4275-7880; Phillips, Andrew N/0000-0003-2384-4807; Deeks, Steven/0000-0001-6371-747X	National Institutes of Health (NIH); Chiron-Novartis; National Institute of Allergy and Infectious Diseases (NIAID) [U01-AI068641, U01-AI046362, U01-AI042170, U01-AI46957, 3U 01-AI068641-0451, 3U01-AI06841-0551]; Gilead Sciences; Medical Research Council [MC_UU_12023/23] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046362, U01AI042170, U01AI068641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chiron-Novartis; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Gilead Sciences(Gilead Sciences); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The trials analyzed in this manuscript were supported by grants from the National Institutes of Health (NIH) and Chiron-Novartis. The National Institute of Allergy and Infectious Diseases (NIAID) funded the INSIGHT SMART [U01-AI068641, U01-AI046362, U01-AI042170] and ESPRIT [U01-AI068641, U01-AI46957] trials and the biomarker analyses [3U 01-AI068641-0451, 3U01-AI06841-0551]. The SILCAAT and ESPRIT trials were supported by grants from Chiron-Novartis. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Individual authors: Gilead Sciences currently provides salary support for CJC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. CJC was previously employed by the Community Research Initiative New England, Boston, MA, and joined Gilead Sciences only after the data analysis and the first draft of the manuscript were completed. Otherwise, none of the authors received any third-party funding for the study design, data analysis or writing of this manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; Achhra AC, 2012, AIDS, V26, P1707, DOI 10.1097/QAD.0b013e328355d659; Achhra AC, 2010, AIDS, V24, P1877, DOI 10.1097/QAD.0b013e32833b1b26; Allin KH, 2009, J CLIN ONCOL, V27, P2217, DOI 10.1200/JCO.2008.19.8440; [Anonymous], 2014, LANG ENV STAT COMP; Baker JV, 2011, JAIDS-J ACQ IMM DEF, V56, P36, DOI 10.1097/QAI.0b013e3181f7f61a; Bash LD, 2009, AM J KIDNEY DIS, V53, P596, DOI 10.1053/j.ajkd.2008.10.044; Borges AH, 2013, AIDS, V27, P1433, DOI 10.1097/QAD.0b013e32835f6b0c; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Butler SL, 2011, JAIDS-J ACQ IMM DEF, V58, P297, DOI 10.1097/QAI.0b013e31822ccfcc; CIOMS Working Group, 2009, INTR GUID STAND MEDD; Danesh J, 2001, CIRCULATION, V103, P2323; Danesh J, 2008, PLOS MED, V5, P600, DOI 10.1371/journal.pmed.0050078; Di Castelnuovo A, 2014, THROMB HAEMOSTASIS, V112, P941, DOI 10.1160/TH14-04-0297; Di Castelnuovo A, 2013, HAEMATOLOGICA, V98, P1476, DOI 10.3324/haematol.2012.083410; Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454; El-Sadr WM, 2008, ANN INTERN MED, V149, P289, DOI 10.7326/0003-4819-149-5-200809020-00003; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Folsom AR, 2009, AM J HEMATOL, V84, P349, DOI 10.1002/ajh.21429; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; Il'yasova D, 2005, CANCER EPIDEM BIOMAR, V14, P2413, DOI 10.1158/1055-9965.EPI-05-0316; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Knuiman MW, 1998, ANN EPIDEMIOL, V8, P56, DOI 10.1016/S1047-2797(97)00107-5; Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Luc G, 2003, ARTERIOSCL THROM VAS, V23, P1255, DOI 10.1161/01.ATV.0000079512.66448.1D; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Mocroft A, 2013, AIDS, V27, P907, DOI 10.1097/QAD.0b013e32835cb766; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Nordell AD, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000844; Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967; Rajasuriar R, 2013, AIDS, V27, P1199, DOI 10.1097/QAD.0b013e32835ecb8b; Ridker PM, 2009, J THROMB HAEMOST, V7, P332, DOI 10.1111/j.1538-7836.2009.03404.x; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Sakkinen PA, 1999, AM J EPIDEMIOL, V149, P261; Smith A, 2005, CIRCULATION, V112, P3080, DOI 10.1161/CIRCULATIONAHA.105.557132; Tian G, 2015, SCI REP-UK, V5, DOI 10.1038/srep11394; Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216; Triant VA, 2009, JAIDS-J ACQ IMM DEF, V51, P268, DOI 10.1097/QAI.0b013e3181a9992c; Tripodi A, 2011, NEW ENGL J MED, V365, P147, DOI 10.1056/NEJMra1011170	43	123	124	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0155100	10.1371/journal.pone.0155100	http://dx.doi.org/10.1371/journal.pone.0155100			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171281	Green Published, gold			2023-01-03	WOS:000376588600116
J	Li, SS; Zhu, A; Benes, V; Costea, PI; Hercog, R; Hildebrand, F; Huerta-Cepas, J; Nieuwdorp, M; Salojarvi, J; Voigt, AY; Zeller, G; Sunagawa, S; de Vos, WM; Bork, P				Li, Simone S.; Zhu, Ana; Benes, Vladimir; Costea, Paul I.; Hercog, Rajna; Hildebrand, Falk; Huerta-Cepas, Jaime; Nieuwdorp, Max; Salojarvi, Jarkko; Voigt, Anita Y.; Zeller, Georg; Sunagawa, Shinichi; de Vos, Willem M.; Bork, Peer			Durable coexistence of donor and recipient strains after fecal microbiota transplantation	SCIENCE			English	Article							BACTERIA	Fecal microbiota transplantation (FMT) has shown efficacy in treating recurrent Clostridium difficile infection and is increasingly being applied to other gastrointestinal disorders, yet the fate of native and introduced microbial strains remains largely unknown. To quantify the extent of donor microbiota colonization, we monitored strain populations in fecal samples from a recent FMT study on metabolic syndrome patients using single-nucleotide variants in metagenomes. We found extensive coexistence of donor and recipient strains, persisting 3 months after treatment. Colonization success was greater for conspecific strains than for new species, the latter falling within fluctuation levels observed in healthy individuals over a similar time frame. Furthermore, same-donor recipients displayed varying degrees of microbiota transfer, indicating individual patterns of microbiome resistance and donor-recipient compatibilities.	[Li, Simone S.; Zhu, Ana; Costea, Paul I.; Hildebrand, Falk; Huerta-Cepas, Jaime; Voigt, Anita Y.; Zeller, Georg; Sunagawa, Shinichi; Bork, Peer] European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany; [Li, Simone S.] Univ New S Wales, Sch Biotechnol & Bimolecular Sci, Sydney, NSW 2052, Australia; [Benes, Vladimir; Hercog, Rajna] European Mol Biol Lab, Genom Core Facil, D-69117 Heidelberg, Germany; [Nieuwdorp, Max] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Nieuwdorp, Max] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, NL-1018 HV Amsterdam, Netherlands; [Nieuwdorp, Max] Univ Gothenburg, Wallenberg Lab, S-41345 Gothenburg, Sweden; [Salojarvi, Jarkko; de Vos, Willem M.] Univ Helsinki, Dept Vet Biosci, FIN-00014 Helsinki, Finland; [Salojarvi, Jarkko] Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; [Voigt, Anita Y.] Univ Heidelberg Hosp, Inst Pathol, Dept Appl Tumor Biol, D-69120 Heidelberg, Germany; [Voigt, Anita Y.; Bork, Peer] Heidelberg Univ, Mol Med Partnership Unit, D-69120 Heidelberg, Germany; [Voigt, Anita Y.; Bork, Peer] European Mol Biol Lab, D-69120 Heidelberg, Germany; [de Vos, Willem M.] Wageningen Univ, Microbiol Lab, NL-6703 HB Wageningen, Netherlands; [de Vos, Willem M.] Univ Helsinki, Dept Bacteriol & Immunol, Immunobiol Res Program, Helsinki 00014, Finland; [Bork, Peer] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Bork, Peer] Univ Wurzburg, Bioctr, Dept Bioinformat, D-97074 Wurzburg, Germany	European Molecular Biology Laboratory (EMBL); University of New South Wales Sydney; European Molecular Biology Laboratory (EMBL); University of Amsterdam; Vrije Universiteit Amsterdam; University of Gothenburg; University of Helsinki; University of Helsinki; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Wageningen University & Research; University of Helsinki; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Wurzburg	Sunagawa, S; Bork, P (corresponding author), European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany.; de Vos, WM (corresponding author), Univ Helsinki, Dept Vet Biosci, FIN-00014 Helsinki, Finland.; Bork, P (corresponding author), Heidelberg Univ, Mol Med Partnership Unit, D-69120 Heidelberg, Germany.; Bork, P (corresponding author), European Mol Biol Lab, D-69120 Heidelberg, Germany.; de Vos, WM (corresponding author), Wageningen Univ, Microbiol Lab, NL-6703 HB Wageningen, Netherlands.; de Vos, WM (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Immunobiol Res Program, Helsinki 00014, Finland.; Bork, P (corresponding author), Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany.; Bork, P (corresponding author), Univ Wurzburg, Bioctr, Dept Bioinformat, D-97074 Wurzburg, Germany.	sunagawa@embl.de; willem.devos@wur.nl; bork@embl.de	Zeller, Georg/M-6484-2013; Huerta-Cepas, Jaime/H-5093-2013; Sunagawa, Shinichi/Q-5950-2019; Bork, Peer/F-1813-2013; Salojärvi, Jarkko/E-9103-2016; Hildebrand, Falk/K-1914-2014	Zeller, Georg/0000-0003-1429-7485; Huerta-Cepas, Jaime/0000-0003-4195-5025; Sunagawa, Shinichi/0000-0003-3065-0314; Bork, Peer/0000-0002-2627-833X; Salojärvi, Jarkko/0000-0002-4096-6278; Li, Simone S/0000-0002-0073-3656; Costea, Paul Igor/0000-0003-1645-3947; Hildebrand, Falk/0000-0002-0078-8948; Voigt, Anita Yvonne/0000-0002-6794-0385	European Union [600375]; VIDI grant [016146327]; CVON grant (IN-CONTROL); European Research Council [268985, 250172]; Academy of Finland [141140, 2718324]; Netherlands Organization for Scientific Research [024.002.002]; Metagenomics in Cardiometabolic Diseases project [FP7-HEALTH-2012-INNOVATION-I-305312]; International Human Microbiome Standards project [HEALTH-F4-2010-261376]; Australian Postgraduate Award; EMBL Australia International Ph.D. Fellowship; AstraZeneca plc; Danone; Eli Lilly and Company	European Union(European Commission); VIDI grant; CVON grant (IN-CONTROL); European Research Council(European Research Council (ERC)European Commission); Academy of Finland(Academy of Finland); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Metagenomics in Cardiometabolic Diseases project; International Human Microbiome Standards project; Australian Postgraduate Award(Australian Government); EMBL Australia International Ph.D. Fellowship; AstraZeneca plc(AstraZeneca); Danone(Danone Nutricia); Eli Lilly and Company(Eli Lilly)	We thank M. R. Wilkins, A. Typas and members of the Bork group, as well as B. Klaus from the Centre for Statistical Data. Analysis at the Er ocean Molecular Biology Laboratory (EMBL) for helpful discussions. We acknowledge the EMBL Genomics Core Facility for sequencing support and Y. P. Yuan and the EMBL Information Technology Core Facility for support with high-performance computing. S.S.L. is the recipient of an Australian Postgraduate Award and EMBL Australia International Ph.D. Fellowship. F.H. received. funding through the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 600375 M.N. is supported by a VIDI 2013 grant (016146327) as well as a CVON 2012 grant (IN-CONTROL) This work hies received funding through the CancerBiorne and MicrobesInside projects (European Research Council project references 268985 and 250172), the Academy of Finland (grants 141140 and 2718324 the Netherlands Organization for Scientific Research (Spinoza Prize and SIAM Gravity grant 024.002.002), the Metagenomics in Cardiometabolic Disease project (FP7-HEALTH-2012-INNOVATION-I-305312) mm the International Human Microbiome Standards project (HEALTH-F4-2010-261376). M.N. and W.M.dV. are founders and. scientific advisory board. members of Caelus Health. M.N. and W.M.dV. are inventors on the patent application entitled "Method for preventing and/or treating insulin resistance" (WO 2013032328 also published as CA2851602A1, CN104244733A, EP2753187A1 US20140294774) filed. 30 August 2012 by Academic Medical Centre Amsterdam and Wageningen University. M.N. is a scientific advisory board member of Seres Therapeutics Inc., and has received, funds for speaking from AstraZeneca plc, Danone, and Eli Lilly and Company. Study sequence data reported in this paper are deposited in the European Nucleotide Archive under accession number PRJEB12357. Author contributions: P.B., S.S., and S.S.L. conceived and managed the project. S.S.L. and P.B. wrote the manuscript with input from all other authors. W.M.dV., M.N., and A.Y.V. designed study protocol, recruited subjects and obtained samples. R.H. and V.B. performed metagenomic shotgun sequencing. S.S.L., S.S., A.Z., P.I.C., IS., G.Z., F.H. and designed and performed data analysis.	Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; ANDERSON JD, 1973, J MED MICROBIOL, V6, P461, DOI 10.1099/00222615-6-4-461; Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; de Vos WM, 2013, MICROB BIOTECHNOL, V6, P316, DOI 10.1111/1751-7915.12047; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Fuentes S, 2014, ISME J, V8, P1621, DOI 10.1038/ismej.2014.13; Greenblum S, 2015, CELL, V160, P583, DOI 10.1016/j.cell.2014.12.038; Luo CW, 2015, NAT BIOTECHNOL, V33, P1045, DOI 10.1038/nbt.3319; Maurice CF, 2013, CELL, V152, P39, DOI 10.1016/j.cell.2012.10.052; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Portal-Celhay C, 2012, INFECT IMMUN, V80, P1288, DOI 10.1128/IAI.05522-11; ROBINSBROWNE RM, 1981, AM J CLIN NUTR, V34, P514, DOI 10.1093/ajcn/34.4.514; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Schloissnig S, 2013, NATURE, V493, P45, DOI 10.1038/nature11711; Seedorf H, 2014, CELL, V159, P253, DOI 10.1016/j.cell.2014.09.008; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; Sharon I, 2013, GENOME RES, V23, P111, DOI 10.1101/gr.142315.112; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Smith MB, 2014, NATURE, V506, P290, DOI 10.1038/506290a; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Sunagawa S, 2013, NAT METHODS, V10, P1196, DOI [10.1038/NMETH.2693, 10.1038/nmeth.2693]; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Voigt AY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0639-8; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Weingarden A, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0070-0; Zhu A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0646-9	28	315	328	9	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	2016	352	6285					586	589		10.1126/science.aad8852	http://dx.doi.org/10.1126/science.aad8852			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5ZA	27126044				2023-01-03	WOS:000374998600045
J	Virchow, JC; Backer, V; Kuna, P; Prieto, L; Nolte, H; Villesen, HH; Ljorring, C; Riis, B; de Blay, F				Virchow, J. Christian; Backer, Vibeke; Kuna, Piotr; Prieto, Luis; Nolte, Hendrik; Villesen, Hanne Hedegaard; Ljorring, Christian; Riis, Bente; de Blay, Frederic			Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRASS-POLLEN IMMUNOTHERAPY; OF-LIFE QUESTIONNAIRE; RHINITIS; VALIDATION; CHILDREN; ALK	IMPORTANCE The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy-related asthma. OBJECTIVES To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. DESIGN, SETTINGS, AND PARTICIPANTS Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitis. Key exclusion criteria were FEV1 less than 70% of predicted value or hospitalization due to asthma within 3 months before randomization. Efficacy was assessed during the last 6 months of the trial when ICS was reduced by 50% for 3 months and then completely withdrawn for 3 months. INTERVENTIONS 1: 1: 1 randomization to once-daily treatment with placebo (n = 277) or HDM SLIT tablet (dosage groups: 6 SQ-HDM [n = 275] or 12 SQ-HDM [n = 282]) in addition to ICS and the short-acting beta(2)-agonist salbutamol. MAIN OUTCOMES AND MEASURES Primary outcome was time to first moderate or severe asthma exacerbation during the ICS reduction period. Secondary outcomes were deterioration in asthma symptoms, change in allergen-specific immunoglobulin G4 (IgG4), change in asthma control or asthma quality-of-life questionnaires, and adverse events. RESULTS Among 834 randomized patients (mean age, 33 years [range, 17-83]; women, 48%), 693 completed the study. The 6SQ-HDM and 12SQ-HDM doses both significantly reduced the risk of a moderate or severe asthma exacerbation compared with placebo (hazard ratio [HR]: 0.72 [95% CI, 0.52-0.99] for the 6SQ-HDM group, P = .045, and 0.69 [95% CI, 0.50-0.96] for the 12 SQ-HDM group, P = .03). The absolute risk differences based on the observed data (full analysis set) in the active groups vs the placebo group were 0.09 (95% CI, 0.01-0.15) for the 6SQ-HDM group and 0.10 (95% CI, 0.02-0.16) for the 12SQ-HDM group. There was no significant difference between the 2 active groups. Compared with placebo, there was a reduced risk of an exacerbation with deterioration in asthma symptoms (HR, 0.72 [95% CI, 0.49-1.02] for the 6SQ-HDM group, P = .11, and 0.64 [95% CI, 0.42-0.96] for the 12SQ-HDM group, P = .03) and a significant increase in allergen-specific IgG4. However, there was no significant difference for change in asthma control questionnaire or asthma quality-of-life questionnaire for either dose. There were no reports of severe systemic allergic reactions. The most frequent adverse events were mild to moderate oral pruritus (13% for the 6SQ-HDM group, 20% for the 12SQ-HDM group, and 3% for the placebo group), mouth edema, and throat irritation. CONCLUSIONS AND RELEVANCE Among adults with HDM allergy-related asthma not well controlled by ICS, the addition of HDM SLIT to maintenance medications improved time to first moderate or severe asthma exacerbation during ICS reduction, with an estimated absolute reduction at 6 months of 9 to 10 percentage points; the reduction was primarily due to an effect on moderate exacerbations. Treatment-related adverse events were common at both active doses. Further studies are needed to assess long-term efficacy and safety.	[Virchow, J. Christian] Univ Rostock, Dept Pulmonol Intens Care Med, Ernst Heydemannstr 6, D-18057 Rostock, Germany; [Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med, Copenhagen, Denmark; [Kuna, Piotr] Med Univ Lodz, Div Internal Med Asthma & Allergy, Lodz, Poland; [Prieto, Luis] Univ Valencia, Dept Med, E-46003 Valencia, Spain; [Nolte, Hendrik] Merck Res Labs, White House Stn, NJ USA; [Villesen, Hanne Hedegaard; Ljorring, Christian; Riis, Bente] Global Clin Dev ALK, Horsholm, Denmark; [de Blay, Frederic] Strasbourg Univ, Univ Hosp Strasbourg, Chest Dis Dept, Strasbourg, France	University of Rostock; University of Copenhagen; Bispebjerg Hospital; Medical University Lodz; University of Valencia; Merck & Company; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Virchow, JC (corresponding author), Univ Rostock, Dept Pulmonol Intens Care Med, Ernst Heydemannstr 6, D-18057 Rostock, Germany.	jc.h.virchow@sunrise.ch	Backer, Vibeke/AAQ-9379-2021; Prieto, Luis Enrique/HFZ-7903-2022	Kuna, Piotr/0000-0003-2401-0070	ALK, Denmark	ALK, Denmark	This trial was sponsored by ALK, Denmark.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; de Blay F, 2014, RESP MED, V108, P1430, DOI 10.1016/j.rmed.2014.07.017; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH HARM TRIP GUID T; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kocabas CN, 2005, PEDIATR PULM, V40, P235, DOI 10.1002/ppul.20247; Kupczyk M, 2004, ANN ALLERG ASTHMA IM, V92, P453, DOI 10.1016/S1081-1206(10)61782-6; Maneechotesuwan K, 2007, CHEST, V132, P98, DOI 10.1378/chest.06-2982; Meier U, 2006, PHARM STAT, V5, P253, DOI 10.1002/pst.210; Meltzer EO, 2012, EUR RESPIR J, V39, P279, DOI 10.1183/09031936.00020310; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Ronborg S, 2016, J MED ECON, P1; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Virchow J, 2011, ALLERGY, V66, P630; Virchow JC, 2015, RESP MED, V109, P547, DOI 10.1016/j.rmed.2015.01.012; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; World Medical Association, DECL HELS ETH PRINC; Zielen S, 2010, J ALLERGY CLIN IMMUN, V126, P942, DOI 10.1016/j.jaci.2010.06.002	35	242	249	2	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2016	315	16					1715	1725		10.1001/jama.2016.3964	http://dx.doi.org/10.1001/jama.2016.3964			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK2QK	27115376	Bronze, Green Published			2023-01-03	WOS:000374759300019
J	Heinritz, SN; Weiss, E; Eklund, M; Aumiller, T; Louis, S; Rings, A; Messner, S; Camarinha-Silva, A; Seifert, J; Bischoff, SC; Mosenthin, R				Heinritz, Sonja N.; Weiss, Eva; Eklund, Meike; Aumiller, Tobias; Louis, Sandrine; Rings, Andreas; Messner, Sabine; Camarinha-Silva, Amelia; Seifert, Jana; Bischoff, Stephan C.; Mosenthin, Rainer			Intestinal Microbiota and Microbial Metabolites Are Changed in a Pig Model Fed a High-Fat/Low-Fiber or a Low-Fat/High-Fiber Diet	PLOS ONE			English	Article							CHAIN FATTY-ACIDS; GUT MICROBIOTA; HEALTH-BENEFITS; WEIGHT-GAIN; DIVERSITY; BIFIDOBACTERIA; FERMENTATION; PREDICTION; CHILDREN; BACTERIA	The intestinal microbiota and its metabolites appear to be an important factor for gastrointestinal function and health. However, research is still needed to further elaborate potential relationships between nutrition, gut microbiota and host's health by means of a suitable animal model. The present study examined the effect of two different diets on microbial composition and activity by using the pig as a model for humans. Eight pigs were equally allotted to two treatments, either fed a low-fat/high-fiber (LF), or a high-fat/low-fiber (HF) diet for 7 weeks. Feces were sampled at day 7 of every experimental week. Diet effects on fecal microbiota were assessed using quantitative real-time PCR, DNA fingerprinting and meta-proteomics. Furthermore, fecal short-chain fatty acid (SCFA) profiles and ammonia concentrations were determined. Gene copy numbers of lactobacilli, bifidobacteria (P<0.001) and Faecalibacterium prausnitzii (P<0.05) were higher in the LF pigs, while Enterobacteriaceae were more abundant in the HF pigs (P<0.001). Higher numbers of proteins affiliated to Enterobacteriaceae were also present in the HF samples. Proteins for polysaccharide breakdown did almost exclusively originate from Prevotellaceae. Total and individual fecal SCFA concentrations were higher for pigs of the LF treatment (P<0.05), whereas fecal ammonia concentrations did not differ between treatments (P>0.05). Results provide evidence that beginning from the start of the experiment, the LF diet stimulated beneficial bacteria and SCFA production, especially butyrate (P<0.05), while the HF diet fostered those bacterial groups which have been associated with a negative impact on health conditions. These findings correspond to results in humans and might strengthen the hypothesis that the response of the porcine gut microbiota to a specific dietary modulation is in support of using the pig as suitable animal model for humans to assess diet-gut-microbiota interactions.	[Heinritz, Sonja N.; Weiss, Eva; Eklund, Meike; Aumiller, Tobias; Messner, Sabine; Camarinha-Silva, Amelia; Seifert, Jana; Mosenthin, Rainer] Univ Hohenheim, Inst Anim Sci, Stuttgart, Germany; [Louis, Sandrine; Rings, Andreas; Bischoff, Stephan C.] Univ Hohenheim, Dept Nutr Med, Stuttgart, Germany	University Hohenheim; University Hohenheim	Mosenthin, R (corresponding author), Univ Hohenheim, Inst Anim Sci, Stuttgart, Germany.	rainer.mosenthin@uni-hohenheim.de	Silva, Amélia Camarinha/AAB-5584-2019	Camarinha Silva, Amelia/0000-0001-7814-6569; Aumiller, Tobias/0000-0001-6836-0297; Seifert, Jana/0000-0002-7690-8539	University of Hohenheim	University of Hohenheim	The work was supported by a grant of the University of Hohenheim. There is no specific grant number. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JW, 2009, NUTR REV, V67, P188, DOI 10.1111/j.1753-4887.2009.00189.x; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293; Moreira APB, 2012, BRIT J NUTR, V108, P801, DOI 10.1017/S0007114512001213; BRAY J. ROGER, 1957, ECOL MONOGR, V27, P325, DOI 10.2307/1942268; Bublitz DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101456; Clarke K.R., 2001, CHANGE MARINE COMMUN; Damms-Machado A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/806248; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; Drissi F, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.6; Elias JE, 2005, NAT METHODS, V2, P667, DOI 10.1038/NMETH785; Fava F, 2013, INT J OBESITY, V37, P216, DOI 10.1038/ijo.2012.33; FRASER J. R., 1959, Journal of the Science of Food and Agriculture, V10, P506, DOI 10.1002/jsfa.2740100910; Frese SA, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0091-8; Fung KYC, 2012, BRIT J NUTR, V108, P820, DOI 10.1017/S0007114512001948; Gonzalez LM, 2015, TRANSL RES, V166, P12, DOI 10.1016/j.trsl.2015.01.004; Guo X, 2008, LETT APPL MICROBIOL, V47, P367, DOI 10.1111/j.1472-765X.2008.02408.x; Haange SB, 2012, J PROTEOME RES, V11, P5406, DOI 10.1021/pr3006364; Heinritz SN, 2013, NUTR RES REV, V26, P191, DOI 10.1017/S0954422413000152; Hermes RG, 2009, J ANIM SCI, V87, P3569, DOI 10.2527/jas.2008-1241; Jehmlich N, 2008, RAPID COMMUN MASS SP, V22, P2889, DOI 10.1002/rcm.3684; Kaczmarczyk MM, 2012, METABOLISM, V61, P1058, DOI 10.1016/j.metabol.2012.01.017; Kadooka Y, 2010, EUR J CLIN NUTR, V64, P636, DOI 10.1038/ejcn.2010.19; Kailasapathy K, 2000, IMMUNOL CELL BIOL, V78, P80, DOI 10.1046/j.1440-1711.2000.00886.x; Kalliomaki M, 2008, AM J CLIN NUTR, V87, P534, DOI 10.1093/ajcn/87.3.534; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Kim HB, 2011, VET MICROBIOL, V153, P124, DOI 10.1016/j.vetmic.2011.05.021; Leser TD, 2002, APPL ENVIRON MICROB, V68, P673, DOI 10.1128/AEM.68.2.673-690.2002; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Loh G, 2006, J NUTR, V136, P1198, DOI 10.1093/jn/136.5.1198; Looft T, 2014, ISME J, V8, P1566, DOI 10.1038/ismej.2014.12; Luoto R, 2010, BRIT J NUTR, V103, P1792, DOI 10.1017/S0007114509993898; Matise I, 2000, VET PATHOL, V37, P318, DOI 10.1354/vp.37-4-318; Mikkelsen LL, 2003, APPL ENVIRON MICROB, V69, P654, DOI 10.1128/AEM.69.1.654-658.2003; Millet S, 2010, CRIT REV FOOD SCI, V50, P605, DOI 10.1080/10408390802565939; Million M, 2013, INT J OBESITY, V37, P1460, DOI 10.1038/ijo.2013.20; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; National Research Council (NRC), 2012, NUTR REQ SWIN, DOI DOI 10.17226/13298; Naumann C., 1997, VDLUFA METHODENBUCH, VIII; NOBLET J, 1994, J ANIM SCI, V72, P344, DOI 10.2527/1994.722344x; PALMQUIST DL, 1994, J NUTR, V124, pS1377; Pang XY, 2007, ISME J, V1, P156, DOI 10.1038/ismej.2007.23; Pedersen R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056612; Pettigrew J. E., 1991, Swine Nutrition., P133; Pieper R, 2012, J NUTR, V142, P661, DOI 10.3945/jn.111.156190; Piepho HP, 2004, J COMPUT GRAPH STAT, V13, P456, DOI 10.1198/1061860043515; Pluske JR, 2002, NUTR RES REV, V15, P333, DOI 10.1079/NRR200242; Purushe J, 2010, MICROB ECOL, V60, P721, DOI 10.1007/s00248-010-9692-8; Ramirez-Farias C, 2009, BRIT J NUTR, V101, P541, DOI 10.1017/S0007114508019880; Remely M, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.1000253; Santacruz A, 2010, BRIT J NUTR, V104, P83, DOI 10.1017/S0007114510000176; Schwiertz A, 2010, OBESITY, V18, P190, DOI 10.1038/oby.2009.167; Shen JA, 2010, ARCH MICROBIOL, V192, P959, DOI 10.1007/s00203-010-0628-y; Simpson PJ, 2003, J BACTERIOL, V185, P2571, DOI 10.1128/JB.185.8.2571-2581.2003; Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417; Smith AG, 2010, LIVEST SCI, V133, P148, DOI 10.1016/j.livsci.2010.06.049; Nguyen TLA, 2015, DIS MODEL MECH, V8, P1, DOI 10.1242/dmm.017400; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Wagnerberger S, 2012, BRIT J NUTR, V107, P1727, DOI 10.1017/S0007114511004983; Wang J, 2010, CARBOHYD POLYM, V82, P419, DOI 10.1016/j.carbpol.2010.04.082; Wang M, 2015, ILAR J, V56, P63, DOI 10.1093/ilar/ilv006; Weiss E, 2016, J SCI FOOD AGR, V96, P2230, DOI 10.1002/jsfa.7340; Winer BJ, 1991, STATISTICAL PRINCIPL; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; Wu ST, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-444; Yan H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059581; Yu ZT, 2004, BIOTECHNIQUES, V36, P808, DOI 10.2144/04365ST04; ZIJLSTRA JB, 1977, CLIN CHIM ACTA, V78, P243, DOI 10.1016/0009-8981(77)90312-6; Zumbrun SD, 2013, P NATL ACAD SCI USA, V110, pE2126, DOI 10.1073/pnas.1222014110	71	95	100	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2016	11	4							e0154329	10.1371/journal.pone.0154329	http://dx.doi.org/10.1371/journal.pone.0154329			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK4OR	27100182	gold, Green Submitted, Green Published			2023-01-03	WOS:000374898500183
J	Roumelioti, ME; Nolin, T; Unruh, ML; Argyropoulos, C				Roumelioti, Maria Eleni; Nolin, Thomas; Unruh, Mark L.; Argyropoulos, Christos			Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico	PLOS ONE			English	Review							RESIDUAL RENAL-FUNCTION; DIALYSIS-RELATED AMYLOIDOSIS; GLOMERULAR-FILTRATION RATE; HIGH-FLUX HEMODIALYSIS; SERUM BETA(2)-MICROGLOBULIN LEVEL; POST-DILUTION HEMODIAFILTRATION; PERIPHERAL ARTERIAL-DISEASE; PROTEIN-BOUND SOLUTES; ALL-CAUSE MORTALITY; ONLINE HEMODIAFILTRATION	Background Beta-2 Microglobulin (beta 2M) is a prototypical "middle molecule" uremic toxin that has been associated with a higher risk of death in hemodialysis patients. A quantitative description of the relative importance of factors determining beta 2M concentrations among patients with impaired kidney function is currently lacking. Methods Herein we undertook a systematic review of existing studies reporting patient level data concerning generation, elimination and distribution of beta M-2 in order to develop a population model of beta M-2 kinetics. We used this model and previously determined relationships between predialysis beta M-2 concentration and survival, to simulate the population distribution of predialysis beta M-2 and the associated relative risk (RR) of death in patients receiving conventional thrice-weekly hemodialysis with low flux (LF) and high flux (HF) dialyzers, short (SD) and long daily (LD) HF hemodialysis sessions and on-line hemodiafiltration at different levels of residual renal function (RRF). Results We identified 9 studies of 106 individuals and 156 evaluations of or more compartmental kinetic parameters of beta M-2. These studies used a variety of experimental methods to determine beta M-2 kinetics ranging from isotopic dilution to profiling of intra/inter dialytic concentration changes. Most of the patients (74/106) were on dialysis with minimal RRF, thus facilitating the estimation of non-renal elimination kinetics of beta M-2. In large scale (N = 10000) simulations of individuals drawn from the population of beta M-2 kinetic parameters, we found that, higher dialytic removal materially affects beta M-2 exposures only when RRF (renal clearance of beta M-2) was below 2 ml/min. In patients initiating conventional HF hemodialysis, total loss of RRF was predicted to be associated with a RR of death of more than 20%. Hemodiafiltration and daily dialysis may decrease the high risk of death of anuric patients by 10% relative to conventional, thrice weekly HF dialysis. Only daily long sessions of hemodialysis consistently reduced mortality risk between 7-19% across the range of beta M-2 generation rate. Conclusions Preservation of RRF should be considered one of the therapeutic goals of hemodialysis practice. Randomized controlled trials of novel dialysis modalities may require large sample sizes to detect an effect on clinical outcomes even if they enroll anuric patients. The developed population model for beta M-2 may allow personalization of hemodialysis prescription and/or facilitate the design of such studies by identifying patients with higher beta M-2 generation rate.	[Roumelioti, Maria Eleni; Unruh, Mark L.; Argyropoulos, Christos] Univ New Mexico, Sch Med, Hlth Sci Ctr, Div Nephrol,Dept Internal Med, Albuquerque, NM 87131 USA; [Nolin, Thomas] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Nolin, Thomas] Univ Pittsburgh, Sch Med, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Nolin, Thomas] Univ Pittsburgh, Sch Pharm, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA; [Nolin, Thomas] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	University of New Mexico; University of New Mexico's Health Sciences Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Argyropoulos, C (corresponding author), Univ New Mexico, Sch Med, Hlth Sci Ctr, Div Nephrol,Dept Internal Med, Albuquerque, NM 87131 USA.	argchris@hotmail.com	Nolin, Thomas/AAB-7311-2020; Argyropoulos, Christos/I-2803-2019	Nolin, Thomas/0000-0003-4339-1382; Argyropoulos, Christos/0000-0002-9679-7805				ACCHIARDO S, 1989, AM J KIDNEY DIS, V13, P70, DOI 10.1016/S0272-6386(89)80119-2; AMICI G, 1993, NEPHRON, V65, P469, DOI 10.1159/000187533; Amighi J, 2011, STROKE, V42, P1826, DOI 10.1161/STROKEAHA.110.600312; Astor BC, 2012, AM J KIDNEY DIS, V59, P653, DOI 10.1053/j.ajkd.2011.11.042; BAILEY RR, 1978, NEW ZEAL MED J, V87, P168; Bammens B, 2003, KIDNEY INT, V64, P2238, DOI 10.1046/j.1523-1755.2003.00310.x; Bianchi C, 2001, RENAL FAILURE, V23, P419, DOI 10.1081/JDI-100104725; Blankestijn PJ, 2010, KIDNEY INT, V77, P581, DOI 10.1038/ki.2009.541; Brown P H, 1988, Nephrol Dial Transplant, V3, P169; CAMPISTOL JM, 1993, AM J KIDNEY DIS, V22, P691, DOI 10.1016/S0272-6386(12)80432-X; CHANARD J, 1993, KIDNEY INT, V43, pS83; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Cheung AK, 1999, J AM SOC NEPHROL, V10, P117; Cheung AK, 2008, CLIN J AM SOC NEPHRO, V3, P69, DOI 10.2215/CJN.02340607; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; Cianciolo G, 2007, INT J ARTIF ORGANS, V30, P864, DOI 10.1177/039139880703001003; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; Danesh F, 2001, SEMIN DIALYSIS, V14, P80, DOI 10.1046/j.1525-139x.2001.00035.x; Daugirdas JT, 2013, KIDNEY INT; Dobre M, 2013, CLIN J AM SOC NEPHRO, V8, P322, DOI 10.2215/CJN.04260412; Donadio C, 2001, J PHARMACEUT BIOMED, V24, P835, DOI 10.1016/S0731-7085(00)00550-1; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Eloot S, 2012, SEMIN DIALYSIS, V25, P505, DOI 10.1111/j.1525-139X.2012.01107.x; Eloot S, 2012, NEPHROL DIAL TRANSPL, V27, P3278, DOI 10.1093/ndt/gfs060; FLOEGE J, 1991, J LAB CLIN MED, V118, P153; Foster MC, 2013, AM J KIDNEY DIS; FRANCOIS B, 1982, NEPHROLOGIE, V3, P116; Fry AC, 2007, BLOOD PURIFICAT, V25, P295, DOI 10.1159/000104870; Fung ET, 2008, VASC MED, V13, P217, DOI 10.1177/1358863X08089276; GOTCH F, 1989, CONTRIB NEPHROL, V74, P132; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; Haufe CC, 2001, KIDNEY INT, V59, pS177, DOI 10.1046/j.1523-1755.2001.59780177.x; Hiatt WR, 2012, VASC MED, V17, P386, DOI 10.1177/1358863X12463491; Jadoul M, 2001, SEMIN DIALYSIS, V14, P86, DOI 10.1046/j.1525-139x.2001.00037.x; JAHN B, 1991, KIDNEY INT, V40, P285, DOI 10.1038/ki.1991.212; JUNG K, 1987, J CLIN CHEM CLIN BIO, V25, P499; Kals J, 2011, SCAND J CLIN LAB INV, V71, P257, DOI 10.3109/00365513.2011.558108; KANAMORI T, 1995, KIDNEY INT, V47, P1453, DOI 10.1038/ki.1995.203; KARLSSON FA, 1980, EUR J CLIN INVEST, V10, P293, DOI 10.1111/j.1365-2362.1980.tb00036.x; KARLSSON FA, 1980, SCAND J CLIN LAB INV, V40, P27; Kazama JJ, 2006, J BONE MINER METAB, V24, P182, DOI 10.1007/s00774-005-0669-5; Kim KM, 2011, CLIN NEPHROL, V75, P458, DOI 10.5414/CNP75458; Kiss E, 2005, AM J ROENTGENOL, V185, P1460, DOI 10.2214/AJR.04.1309; Lee C J, 1994, ASAIO J, V40, P62; Lesko LJ, 2012, CLIN PHARMACOL THER, V92, P458, DOI 10.1038/clpt.2012.113; Leypoldt JK, 1997, ASAIO J, V43, P904, DOI 10.1097/00002480-199711000-00011; Liabeuf S, 2012, KIDNEY INT, V82, P1297, DOI 10.1038/ki.2012.301; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; Maduell F, 2013, J AM SOC NEPHROL, V24, P487, DOI 10.1681/ASN.2012080875; Maduell F, 2012, NEPHROL DIAL TRANSPL, V27, P1619, DOI 10.1093/ndt/gfr491; MAEDA K, 1990, NEPHRON, V56, P118, DOI 10.1159/000186118; MCCARTHY JT, 1994, J LAB CLIN MED, V123, P495; Meert N, 2011, NEPHROL DIAL TRANSPL, V26, P2624, DOI 10.1093/ndt/gfq803; Nead KT, 2013, AM J CARDIOL, V111, P851, DOI 10.1016/j.amjcard.2012.11.055; ODELL RA, 1991, KIDNEY INT, V39, P909, DOI 10.1038/ki.1991.114; Ok E, 2013, NEPHROL DIAL TRANSPL, V28, P192, DOI 10.1093/ndt/gfs407; Okuno S, 2009, NEPHROL DIAL TRANSPL, V24, P571, DOI 10.1093/ndt/gfn521; Pan HQ, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas058; Pearl J, 2009, STAT SURV, V3, P96, DOI 10.1214/09-SS057; Penne EL, 2010, CLIN J AM SOC NEPHRO, V5, P80, DOI 10.2215/CJN.03340509; PERARNAU B, 1990, NATURE, V346, P751, DOI 10.1038/346751a0; RAVNSKOV U, 1972, SCAND J CLIN LAB INV, V30, P71, DOI 10.3109/00365517209081093; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; Schiffl H, 2013, INT UROL NEPHROL, V45, P1389, DOI 10.1007/s11255-012-0336-4; SCHOELS M, 1993, AM J KIDNEY DIS, V21, P394, DOI 10.1016/S0272-6386(12)80267-8; Shafi T, 2012, CLIN J AM SOC NEPHRO, V7, P1435, DOI 10.2215/CJN.02240312; Shin MJ, 2012, CLIN EXP NEPHROL, V16, P456, DOI 10.1007/s10157-011-0583-1; Sirich TL, 2012, NEPHROL DIAL TRANSPL, V27, P1574, DOI 10.1093/ndt/gfr691; Stiller S, 2002, INT J ARTIF ORGANS, V25, P411, DOI 10.1177/039139880202500511; Takesawa S, 1988, JPN J ARTIF ORGANS, V17, P42; Tattersall J, 2007, CONTRIB NEPHROL, V158, P201, DOI 10.1159/000107251; Turner CF, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar043; United States Renal Data System (USRDS), 2013, USRDS 2013 ANN DAT R; van der Wal WM, 2011, NEPHROL DIAL TRANSPL, V26, P2978, DOI 10.1093/ndt/gfq856; Vanholder R, 2008, J NEPHROL, V21, P146; Vanholder R, 2009, SEMIN DIALYSIS, V22, P323, DOI 10.1111/j.1525-139X.2009.00574.x; Vilar E, 2011, SEMIN DIALYSIS, V24, P487, DOI 10.1111/j.1525-139X.2011.00968.x; VINCENT C, 1992, KIDNEY INT, V42, P1434, DOI 10.1038/ki.1992.438; VINCENT C, 1980, ACTA CLIN BELG, V35, P2; Ward RA, 2000, J AM SOC NEPHROL, V11, P2344, DOI 10.1681/ASN.V11122344; Ward RA, 2006, KIDNEY INT, V69, P1431, DOI 10.1038/sj.ki.5000048; WIBELL LB, 1976, ACTA CLIN BELG, V31, P14; Wilson AM, 2007, CIRCULATION, V116, P1396, DOI 10.1161/CIRCULATIONAHA.106.683722; Winchester JF, 2003, ADV RENAL REPLACE TH, V10, P279, DOI 10.1053/j.arrt.2003.11.003; Wizemann V, 2000, NEPHROL DIAL TRANSPL, V15, P43, DOI 10.1093/oxfordjournals.ndt.a027963; Xu XQ, 2001, ASAIO J, V47, P623, DOI 10.1097/00002480-200111000-00011; Yamamoto S, 2005, BBA-PROTEINS PROTEOM, V1753, P4, DOI 10.1016/j.bbapap.2005.09.006; Zhang LP, 2008, AAPS J, V10, P552, DOI 10.1208/s12248-008-9062-3; Zingraff J, 1988, Nephrol Dial Transplant, V3, P284; Zumrutdal A, 2005, NEPHROLOGY, V10, P453, DOI 10.1111/j.1440-1797.2005.00475.x	91	20	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0153157	10.1371/journal.pone.0153157	http://dx.doi.org/10.1371/journal.pone.0153157			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27055286	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000373608000089
J	Primrose, RJ; Zaveri, T; Bakke, AJ; Ziegler, GR; Moskowitz, HR; Hayes, JE				Primrose, Rachel J.; Zaveri, Toral; Bakke, Alyssa J.; Ziegler, Gregory R.; Moskowitz, Howard R.; Hayes, John E.			Drivers of Vaginal Drug Delivery System Acceptability from Internet-Based Conjoint Analysis	PLOS ONE			English	Article							HIV VACCINE ACCEPTABILITY; SEXUAL PLEASURE; CLINICAL-TRIAL; AFRICAN WOMEN; YOUNG-WOMEN; BLACK-WOMEN; MICROBICIDE; PREFERENCES; GEL; FEASIBILITY	Vaginal microbicides potentially empower women to protect themselves from HIV and other sexually transmitted infections (STIs), especially when culture, religion, or social status may prevent them from negotiating condom use. The open literature contains minimal information on factors that drive user acceptability of women's health products or vaginal drug delivery systems. By understanding what women find to be most important with regard to sensory properties and product functionality, developers can iteratively formulate a more desirable product. Conjoint analysis is a technique widely used in market research to determine what combination of elements influence a consumer's willingness to try or use a product. We applied conjoint analysis here to better understand what sexually-active woman want in a microbicide, toward our goal of formulating a product that is highly acceptable to women. Both sensory and non-sensory attributes were tested, including shape, color, wait time, partner awareness, messiness/leakage, duration of protection, and functionality. Heterosexually active women between 18 and 35 years of age in the United States (n = 302) completed an anonymous online conjoint survey using IdeaMap software. Attributes (product elements) were systematically presented in various combinations; women rated these combinations of a 9-point willingness-to-try scale. By coupling systematic combinations and regression modeling, we can estimate the unique appeal of each element. In this population, a multifunctional product (i.e., broad spectrum STI protection, coupled with conception) is far more desirable than a microbicide targeted solely for HIV protection; we also found partner awareness and leakage are potentially strong barriers to use.	[Primrose, Rachel J.; Zaveri, Toral; Bakke, Alyssa J.; Hayes, John E.] Penn State Univ, Sensory Evaluat Ctr, University Pk, PA 16802 USA; [Primrose, Rachel J.; Zaveri, Toral; Bakke, Alyssa J.; Ziegler, Gregory R.; Hayes, John E.] Penn State Univ, Coll Agr Sci, Dept Food Sci, University Pk, PA 16802 USA; [Moskowitz, Howard R.] Mind Genom Associates Inc, White Plains, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hayes, JE (corresponding author), Penn State Univ, Sensory Evaluat Ctr, University Pk, PA 16802 USA.; Hayes, JE (corresponding author), Penn State Univ, Coll Agr Sci, Dept Food Sci, University Pk, PA 16802 USA.	jeh40@psu.edu	Hayes, John E/A-5893-2008	Hayes, John E/0000-0001-9065-6326; Ziegler, Gregory/0000-0002-3881-649X	National Institute of Allergy and Infectious Diseases [R33AI094514]; Mind Genomics Associates, Inc.; Mind Genomics Associates; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI094514] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Mind Genomics Associates, Inc.; Mind Genomics Associates; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grant R33AI094514 from the National Institute of Allergy and Infectious Diseases (www.niaid.nih.gov) to JEH and GRZ, and Mind Genomics Associates, Inc. Mind Genomics Associates donated use of the IdeaMap software platform, and provided support in the form of salaries for author HRM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6; [Anonymous], 2014, NAT SURV SEX HLTH BE; [Anonymous], 2014, FACT SHEET MICR; [Anonymous], 2014, PENNS 2013 STAT HLTH; [Anonymous], 2012, GLOB REP UNAIDS REP; Beusterien KM, 2005, VALUE HEALTH, V8, P453, DOI 10.1111/j.1524-4733.2005.00036.x; Centers for Disease Control and Prevention, 2014, HIV AM WOM; Cole AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015111; Colquhoun TA, 2012, J BERRY RES, V2, P45, DOI 10.3233/JBR-2011-027; Devlin B, 2013, ANTIVIR RES, V100, pS3, DOI 10.1016/j.antiviral.2013.09.025; Fetherston SM, 2013, EUR J PHARM SCI, V48, P406, DOI 10.1016/j.ejps.2012.12.002; Foley M, 2009, APPETITE, V52, P554, DOI 10.1016/j.appet.2009.01.006; Giguere R, 2012, CULT HEALTH SEX, V14, P151, DOI 10.1080/13691058.2011.630099; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Green PE, 2001, INTERFACES, V31, pS56, DOI 10.1287/inte.31.3s.56.9676; GREEN PE, 1990, J MARKETING      OCT, P3; Hammett TM, 2000, SEX TRANSM DIS, V27, P119, DOI 10.1097/00007435-200002000-00011; Hoffman S, 2010, ARCH SEX BEHAV, V39, P748, DOI 10.1007/s10508-009-9509-3; Holt BY, 2006, J WOMENS HEALTH, V15, P281, DOI 10.1089/jwh.2006.15.281; Jansen S, 2009, J HOUS BUILT ENVIRON, V24, P271, DOI 10.1007/s10901-009-9149-x; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SSA, 2011, LANCET, V378, pE23, DOI 10.1016/S0140-6736(11)61136-7; Kinsler JJ, 2012, AIDS BEHAV, V16, P1436, DOI 10.1007/s10461-011-0045-5; Lee SJ, 2012, INT J STD AIDS, V23, P235, DOI 10.1258/ijsa.2011.011189; Levin LA, 2012, HORTSCIENCE, V47, P1658, DOI 10.21273/HORTSCI.47.11.1658; Li BD, 2013, ANTIVIR RES, V97, P280, DOI 10.1016/j.antiviral.2012.12.024; Li BD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054975; Mahan ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105614; Mahan ED, 2011, CONTRACEPTION, V84, P184, DOI 10.1016/j.contraception.2010.11.012; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; MJI-DesignLab, 2014, IDEAMAP R WHIT PLAIN; Morrow K, 2003, J WOMENS HEALTH, V12, P655, DOI 10.1089/154099903322404302; Moskowitz HR, 2012, PHYSIOL BEHAV, V107, P606, DOI 10.1016/j.physbeh.2012.04.009; Moskowitz HR, 2005, CRIT REV FOOD SCI, V45, P165, DOI 10.1080/10408690590956350; Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476; Prevention CoDCa, 2014, INC PREV COST SEX TR; Rees H, 2015, C RETR OPP INF CROI; Reiff M, 2008, J WOMENS HEALTH, V17, P1345, DOI 10.1089/jwh.2008.0886; Robertson Angela M, 2013, Glob Public Health, V8, P619, DOI 10.1080/17441692.2012.762412; Rosen M, 2015, CONTRACEPTION; Saulo AA, 2011, FOOD QUAL PREFER, V22, P422, DOI 10.1016/j.foodqual.2011.02.005; Tanner AE, 2008, J ADOLESCENT HEALTH, V43, P349, DOI 10.1016/j.jadohealth.2008.02.017; Tanner A, 2009, J SEX RES, V46, P15, DOI 10.1080/00224490802398407; Terris-Prestholt F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083193; van den Berg JJ, 2014, AIDS BEHAV, V18, P862, DOI 10.1007/s10461-013-0652-4; van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118; Weaver J, 2013, CAN J PUBLIC HEALTH, V104, pE413, DOI 10.17269/cjph.104.3915; WHO, 2012, GLOB INC PREV SEL CU; Zaveri T, 2012, SOC SENS PROF 3 TECH; Zaveri Toral, 2014, Pharmaceutics, V6, P512, DOI 10.3390/pharmaceutics6030512; Zaveri Toral, 2014, Pharmaceutics, V6, P366, DOI 10.3390/pharmaceutics6030366	51	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2016	11	3							e0150896	10.1371/journal.pone.0150896	http://dx.doi.org/10.1371/journal.pone.0150896			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3NW	26999009	Green Submitted, gold, Green Published			2023-01-03	WOS:000372694700018
J	Scher, HI				Scher, Howard I.			Defining new standards of care for men with prostate cancer	LANCET			English	Editorial Material							ANDROGEN-DEPRIVATION THERAPY; DOCETAXEL		[Scher, Howard I.] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA; [Scher, Howard I.] Weill Cornell Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University	Scher, HI (corresponding author), Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA.; Scher, HI (corresponding author), Weill Cornell Med Coll, New York, NY USA.	scherh@mskcc.org						Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; Huggins C, 1942, ANN SURG, V115, P1192, DOI 10.1097/00000658-194206000-00030; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Sweeney C, 2014, J CLIN ONCOL S, V32, P5; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Templeton AJ, 2013, ANN ONCOL, V24, P2972, DOI 10.1093/annonc/mdt397; Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2	11	1	2	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	2016	387	10024					1135	1137		10.1016/S0140-6736(15)01235-0	http://dx.doi.org/10.1016/S0140-6736(15)01235-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG9OB	27025318	hybrid			2023-01-03	WOS:000372412000004
J	Liu, Z; Jiang, ZG; Fang, HX; Li, CW; Mi, AZ; Chen, J; Zhang, XW; Cui, SP; Chen, DQ; Ping, XG; Li, F; Li, CL; Tang, SH; Luo, ZH; Zeng, Y; Meng, ZB				Liu, Zhao; Jiang, Zhigang; Fang, Hongxia; Li, Chunwang; Mi, Aizi; Chen, Jing; Zhang, Xiaowei; Cui, Shaopeng; Chen, Daiqiang; Ping, Xiaoge; Li, Feng; Li, Chunlin; Tang, Songhua; Luo, Zhenhua; Zeng, Yan; Meng, Zhibin			Perception, Price and Preference: Consumption and Protection of Wild Animals Used in Traditional Medicine	PLOS ONE			English	Article							TIGERS; ATTITUDES; BUSHMEAT; DEMAND	A wide array of wildlife species, including many animals, are used in traditional medicines across many medicinal systems, including in Traditional Chinese Medicine (TCM). Due to over-exploitation and habitat loss, the populations of many animals commonly used in TCM have declined and are unable to meet market demand. A number of measures have been taken to try to reduce the impact that this large and growing market for TCM may have on wild animal species. Consumer preferences and behavior are known to play an important role in the consumption and protection of wild animals used in traditional medicine, and thus are likely to be an important factor in the success of many of these mechanisms-particularly given the significant percentage of TCMs that are over-the-counter products (access to which is not mediated by practitioners). In this study we conducted questionnaires and designed stated preference experiments embodying different simulation scenarios using a random sample of the population in Beijing to elicit individuals' knowledge, perceptions and preferences toward wild or farmed animal materials and their substitutes used in traditional Chinese medicine. We found that respondents had a stated preference for wild materials over farm-raised and other alternatives because they believe that the effectiveness of wild-sourced materials is more credible than that of other sources. However, we also found that, although respondents used TCM products, they had a poor understanding of the function or composition of either traditional Chinese medicines or proprietary Chinese medicines (PCM), and paid little attention to the composition of products when making purchasing decisions. Furthermore, awareness of the need for species protection, or "conservation consciousness" was found to play an important role in willingness to accept substitutions for wild animal materials, while traditional animal medicinal materials (TAMs) derived from well-known endangered species, such as bear bile and tiger bone, show relatively higher substitutability. These results suggest that there is still hope for conservation measures which seek to promote a transition to farmed animal, plant and synthetic ingredients and provide clear directions for future social marketing, education and engagement efforts.	[Liu, Zhao; Jiang, Zhigang; Fang, Hongxia; Li, Chunwang; Chen, Jing; Zhang, Xiaowei; Cui, Shaopeng; Chen, Daiqiang; Ping, Xiaoge; Li, Feng; Li, Chunlin; Tang, Songhua; Luo, Zhenhua; Zeng, Yan; Meng, Zhibin] Chinese Acad Sci, Inst Zool, Key Lab Anim Ecol & Conservat Biol, Beijing, Peoples R China; [Liu, Zhao; Fang, Hongxia; Li, Chunwang; Chen, Jing; Zhang, Xiaowei; Cui, Shaopeng; Chen, Daiqiang; Ping, Xiaoge; Li, Feng; Li, Chunlin; Luo, Zhenhua] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Liu, Zhao] Hexi Univ, Coll Agr & Biotechnol, Zhangye, Peoples R China; [Mi, Aizi] China Agr Univ, Coll Biol Sci, Beijing 100094, Peoples R China; [Jiang, Zhigang; Zeng, Yan; Meng, Zhibin] Endangered Species Sci Commiss Peoples Republ Chi, Beijing, Peoples R China; [Li, Chunlin] Anhui Univ, Sch Resources & Environm Engn, Hefei 230039, Peoples R China; [Luo, Zhenhua] Cent China Normal Univ, Sch Life Sci, Mol & Behav Ecol Res Grp, Wuhan, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Hexi University; China Agricultural University; Anhui University; Central China Normal University	Jiang, ZG (corresponding author), Chinese Acad Sci, Inst Zool, Key Lab Anim Ecol & Conservat Biol, Beijing, Peoples R China.; Jiang, ZG (corresponding author), Endangered Species Sci Commiss Peoples Republ Chi, Beijing, Peoples R China.	jiangzg@ioz.ac.cn	Zhang, Xiao-Wei/AAO-8212-2020; Zeng, Yan/U-5030-2019; Jiang, Zhigang/E-4598-2014	Zhang, Xiao-Wei/0000-0002-9441-2182; Jiang, Zhigang/0000-0003-2154-8588	Chinese Academy of Sciences [KSCX2-EW-Z-4]; Ministry of Science and Technology of China [2013FY110300]; Natural Science Foundation of China [31372175]	Chinese Academy of Sciences(Chinese Academy of Sciences); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Knowledge Innovation Project of the Chinese Academy of Sciences (KSCX2-EW-Z-4), the Basic Science Special Project of Ministry of Science and Technology of China (2013FY110300), and the Natural Science Foundation of China (No. 31372175).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Andriamalala Gildas, 2013, Conservation Evidence, V10, P37; [Anonymous], 2003, EXPT DESIGN DATA ANA; Bateman I.J., 2002, EC VALUATION STATED, DOI DOI 10.4337/9781781009727; Beijing Statistic Information Net, 2010, 6 POP CENS BEIJ; CFDA (China Food and Drug Adiministration), 2001, NOT PUBL DIR OV THE; Challender DWS, 2014, FRONT ECOL ENVIRON, V12, P203, DOI 10.1890/1540-9295-12.4.203; Chen SL, 2005, INFORM TRADITIONAL C, V22, P3; CITES (Convention on International Trade in Endangered Species of threatened species), 1997, CITES 10 M C PART CI; CPC (Chinese Pharmacopoeia Commission), 2010, PHARM PEOPL REP CHIN; Darnton A, 2008, UK GSR BEHAV CHANGE; De Vaus D.A., 2002, SURVEYS SOCIAL RES, Vfifth; Dutton AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021243; Gao XQ, 2009, EC RES GUIDE, V33, P178; Gratwicke B, 2008, CONSERV BIOL, V22, P222, DOI 10.1111/j.1523-1739.2007.00802.x; Gratwicke B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002544; Hu SL, 2007, ASIA PACIFIC TRADITI, V3, P5; IUCN (International Union for Conservation of Nature), 2012, 2012 IUCN RED LIST T; Kirkpatrick RC, 2010, CONSERV BIOL, V24, P655, DOI 10.1111/j.1523-1739.2010.01468.x; Kish L., 1987, STAT DESIGN RES; Kotler P, 1989, SOCIAL MARKETING STR; MOST (Ministry of Science and Technology of the People' Republic of China), 2003, RES REP STRAT POS TR; Musante K., 2010, PARTICIPANT OBSERVAT; Nelsen R.B., 1999, INTRO COPULAS, V139; Nowell K., 2007, TAMING TIGER TRADE; Qi YH, 2010, CHINESE GEN PRACTICE, V7, P748; Schiffman L., 2004, CONSUMER BEHAV; SINO-TCM (China National Group Corporation of Traditional and Herbal Medicine), 1995, TRAD CHIN MED RES CH; SINO-TCM (China National Group Corporation of Traditional and Herbal Medicine), 1995, COMM TRAD CHIN MED C; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Verissimo D., 2013, CONSERV EVIDENCE, V10, P29; Wasser R.M., 2010, UNDERSTANDING MOTIVA; Wilkie DS, 2005, CONSERV BIOL, V19, P268, DOI 10.1111/j.1523-1739.2005.00372.x; Wilkie DS, 2001, CONSERV BIOL, V15, P761, DOI 10.1046/j.1523-1739.2001.015003761.x; Wilkie DS, 2000, SCIENCE, V287, P975; Yang DD, 2007, INTEGR ZOOL, V2, P19, DOI 10.1111/j.1749-4877.2007.00043.x; Zhang L, 2008, BIODIVERS CONSERV, V17, P1493, DOI 10.1007/s10531-008-9358-8; Zhang L, 2014, BIODIVERS CONSERV, V23, P2371, DOI 10.1007/s10531-014-0708-4; Zhong Yao Cai Tian Di net, 2011, MON REP MARK PRIC AP; Zhou ZH, 2004, CONSERV BIOL, V18, P1386, DOI 10.1111/j.1523-1739.2004.00251.x; Zhou Zhihua, 2005, Shengwu Duoyangxing, V13, P462	41	35	36	4	85	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0145901	10.1371/journal.pone.0145901	http://dx.doi.org/10.1371/journal.pone.0145901			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5ZW	26930487	Green Published, Green Submitted, gold			2023-01-03	WOS:000371434500003
J	Cota, GF; de Sousa, MR; Fereguetti, TO; Saleme, PS; Alvarisa, TK; Rabello, A				Cota, Glaucia Fernandes; de Sousa, Marcos Roberto; Fereguetti, Tatiani Oliveira; Saleme, Priscila Said; Alvarisa, Thais Kawagoe; Rabello, Ana			The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							CONTROLLED CLINICAL-TRIAL; SODIUM STIBOGLUCONATE; KETOCONAZOLE; ALLOPURINOL; EFFICACY; RISK	Introduction There are few drugs with proven efficacy in cutaneous leishmaniasis (CL), and pentavalent antimonial derivatives are still the main first-line therapeutic agents worldwide, despite their recognized high toxicities. Randomized controlled clinical trials assessing the efficacy and safety of new therapeutic modalities are of high priority, and the definition of the design of such trials raises debate about the use of placebo as a comparator. To support the use of placebo as a comparator, two main points need to be addressed: 1- the cure rate without any therapeutic intervention and 2- the damage caused by CL and its impact on patients. Objective The aim of this study was to systematically assess the spontaneous cure rate for American CL and to broaden the discussion about placebo use in CL trials. Methods The PRISMA guidelines for systematic reviews and the Cochrane manual were followed. The sources used were the PubMed and LILACS databases. Studies were included if they reported cure rates using placebo or no treatment in American CL. Results Thirteen studies of a total of 352 patients were ultimately included in this review. The summarized global cure rates for all Leishmania species according to the intention-to-treat analyses performed at approximately three ("initial cure") and nine ("definitive cure") months after "no treatment" or placebo use were 26% (CI95%: 16 to 40%) and 26% (CI95%: 16 to 38%), respectively. Notably, a significantly lower cure rate was observed for L. braziliensis infection (6.4%, CI95%: 0.2 to 20%) than for L. mexicana infection (44%, CI95%: 19 to 72%), p = 0.002. Of note, relapse occurred in 20% of patients with initial healing (CI95%: 9.2 to 38.9%). Conclusion These results clearly demonstrate a low spontaneous cure rate following no-treatment or placebo use, confirming that this strategy for the control group in CL studies expose patients to greater morbidity, especially for CL caused by L. braziliensis. Therefore, from this point, the crucial questionto consider regarding placebo use isthe seriousness of the suffering caused by this disease.	[Cota, Glaucia Fernandes; Rabello, Ana] Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Clin Res & Publ Policy Infect & Parasit Dis, Belo Horizonte, MG, Brazil; [de Sousa, Marcos Roberto] Univ Fed Minas Gerais, Postgrad Program Adult Hlth Sci, Belo Horizonte, MG, Brazil; [Fereguetti, Tatiani Oliveira; Saleme, Priscila Said; Alvarisa, Thais Kawagoe] Fundacao Hosp Estado Minas Gerais FHEMIG, Hosp Eduardo de Menezes, Belo Horizonte, MG, Brazil	Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais	Cota, GF (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Clin Res & Publ Policy Infect & Parasit Dis, Belo Horizonte, MG, Brazil.	cota@cpqrr.fiocruz.br	Cota, Glaucia/ABC-5378-2020	Cota, Glaucia/0000-0003-0538-7403	CNPq (National Counsel of Technological and Scientific Development) [311641/2009-1]	CNPq (National Counsel of Technological and Scientific Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Ana Rabello is currently receiving a grant [311641/2009-1] from CNPq (National Counsel of Technological and Scientific Development). The authors received no specific funding for this work.	64th World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]; [Anonymous], 1997, Cardiovasc Res, V35, P2; [Anonymous], 2013, LEISHM AM REC TRAT C; Arana BA, 2001, AM J TROP MED HYG, V65, P466, DOI 10.4269/ajtmh.2001.65.466; Bailey MS, 2007, CLIN DERMATOL, V25, P203, DOI 10.1016/j.clindermatol.2006.05.008; Blum J, 2012, INT HEALTH, V4, P153, DOI 10.1016/j.inhe.2012.06.004; Chico M., 1995, Biomedica, V15, P116; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Gonzalez U, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004834.pub2; Gonzalez U, 2010, CLIN INFECT DIS, V51, P409, DOI 10.1086/655134; Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]; GUDERIAN RH, 1991, AM J TROP MED HYG, V45, P92, DOI 10.4269/ajtmh.1991.45.92; Hendrickx EP, 1998, AM J TROP MED HYG, V59, P889, DOI 10.4269/ajtmh.1998.59.889; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; Machado-Coelho GLL, 2005, T ROY SOC TROP MED H, V99, P55, DOI 10.1016/j.trstmh.2003.08.001; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528; NAVIN TR, 1990, AM J TROP MED HYG, V42, P43, DOI 10.4269/ajtmh.1990.42.43; Neva FA, 1997, T ROY SOC TROP MED H, V91, P473, DOI 10.1016/S0035-9203(97)90290-X; Olliaro P, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002130; Reveiz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061843; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L; Soto J, 2006, T ROY SOC TROP MED H, V100, pS34, DOI 10.1016/j.trstmh.2006.02.022; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Soto J, 2013, CLIN INFECT DIS, V56, P1255, DOI 10.1093/cid/cit049; Soto JM, 2002, AM J TROP MED HYG, V66, P147, DOI 10.4269/ajtmh.2002.66.147; SOTOMANCIPE J, 1993, CLIN INFECT DIS, V16, P417, DOI 10.1093/clind/16.3.417; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x; Velez I, 1997, ANN INTERN MED, V126, P232, DOI 10.7326/0003-4819-126-3-199702010-00010; Wise ES, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001688; World Health Organization (WHO), 2007, 5 CONS M HIVLEISHMAN; Yamey G, 2002, BMJ-BRIT MED J, V325, P352; Yepez Y., 1995, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V35, P71	38	29	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2016	11	2							e0149697	10.1371/journal.pone.0149697	http://dx.doi.org/10.1371/journal.pone.0149697			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3DG	26894430	gold, Green Submitted, Green Published			2023-01-03	WOS:000371223400076
J	Hall, SS; Wright, HF; Mills, DS				Hall, Sophie Susannah; Wright, Hannah F.; Mills, Daniel Simon			What Factors Are Associated with Positive Effects of Dog Ownership in Families with Children with Autism Spectrum Disorder? The Development of the Lincoln Autism Pet Dog Impact Scale	PLOS ONE			English	Article							COMPANION ANIMALS; SOCIAL-SKILLS; ADOLESCENTS; INTERVENTIONS; THERAPY; LINKAGES; PARENTS	Scientific literature exploring the value of assistance dogs to children with autism spectrum disorder (ASD) is rapidly emerging. However, there is comparably less literature reporting the effects of pet (as opposed to assistance) dogs to these children. In particular, there are no known validated scales which assess how children may alter their behaviours in the presence of the dog, to evaluate the efficacy of pet dogs to these families. Additionally, given the highly individualised nature of ASD it is likely that some children and families gain more benefits from dog ownership than others, yet no research has reported the effect of individual differences. This pilot study reports the development of a 28-item scale based on the perceived impact of a pet dog on a child with autism by parents (Lincoln Autism Pet Dog Impact Scale-LAPDIS). The scale is comprised of three mathematically derived factors: Adaptability, Social Skills and Conflict Management. We assessed how individual differences (aspects) may be associated with scores on these three factors. Family Aspects and Dog Aspects were not significantly associated with ratings on the three factors, but Child Aspects (including: contact with horses, child age, disability level and language abilities) were related to impact of the dog on all factors. Training Aspects were related to scores on Social Skills (formal training with children with ASD and dogs and attendance at PAWS workshops run by Dogs for Good). These results suggest that individual differences associated with the child and the training approach may be important considerations for a positive impact from dog ownership on families with children with ASD. Differences in family features and the dog may not be so important, but may be worthy of further investigations given the early stage of development in this field.	[Hall, Sophie Susannah; Wright, Hannah F.; Mills, Daniel Simon] Lincoln Univ, Sch Life Sci, Lincoln, Lincs, England	University of Lincoln	Hall, SS (corresponding author), Lincoln Univ, Sch Life Sci, Lincoln, Lincs, England.	shall@lincoln.ac.uk		Hall, Sophie/0000-0002-9847-8269	Morris Animal Foundation [D14HA-008]; Big Lottery Fund [RGT/1/010334400]; Big Lottery [RGT/1/010334400]	Morris Animal Foundation; Big Lottery Fund; Big Lottery	The study was partly supported by the Morris Animal Foundation, http://www.morrisanimalfoundation.org/, Grant ID/Title: D14HA-008 / Long Term Effects of Pet Dogs on Families with Children with Autism. Funding was awarded to DSM. The study was also partly supported by the Big Lottery Fund, https://www.biglotteryfund.org.uk/, Grant ID: RGT/1/010334400. This was awarded to Peter Gorbing, Dogs for the Disabled CEO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The survey was part of a larger project funded by the Big Lottery (Grant Name: Pet dogs for children with Autism research project, Grant ID: RGT/1/010334400) awarded to Dogs for Good (previously known as Dogs for the Disabled). A follow-up project funded by the Morris Animal Foundation (ID: D14HA-008, awarded to D. Mills) allowed for the analysis and write up of the survey. The project was a collaboration between the University of Lincoln (UK), National Autistic Society (London, UK) and Dogs for Good (previously Dogs for the Disabled), Banbury, UK. Dogs for Good contributors: Peter Gorbing, Helen McCain, Dr Corri Waitt, PAWS project team (Katie Bristow-Wade, Amy Davies, Kate Thomas). The study was guided by a formal advisory group: Dr Lorna Wing, Jo Stevens. Dr Lorna Wing, Dr Bob Michell, Denis Lane, Dr Jane Fossey, Professor Shaun Lawson, Peter Gorbing, Helen McCain, Susan Aston and Sarah Milne. We also thank the parents who gave up their time to participate in this study. We also thank Jessica Hardiman (previously University of Lincoln, now Dogs for Good), Annette Hames (University of Lincoln) and Richard Mills (National Autistic Society) for their support.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; ATTWOOD T, 1998, ASPERGERS SYNDROME G; Autism Speaks, 2010, IS AUT TREAT; Baker JK, 2011, J FAM PSYCHOL, V25, P601, DOI 10.1037/a0024409; Bass M, 2009, J AUTISM DEV DISORD, V39, P1261, DOI 10.1007/s10803-009-0734-3; Beetz A, 2012, FRONT PSYCHOL, V3, DOI [10.3389/fpsyg.2012.00234, 10.3389/fpsyg.2012.00352]; Bellini S., 2006, FOCUS AUTISM DEV DIS, V21, P138, DOI [DOI 10.1177/10883576060210030201, 10.1177/10883576060210030201]; Bellini S, 2007, REM SPEC EDUC, V28, P153, DOI 10.1177/07419325070280030401; Berry A, 2013, J ALTERN COMPLEM MED, V19, P73, DOI 10.1089/acm.2011.0835; Burgoyne L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004786; Burrows KE, 2008, QUAL HEALTH RES, V18, P1642, DOI 10.1177/1049732308327088; Bystrom KM, 2015, ANTHROZOOS, V28, P263, DOI 10.2752/089279315X14219211661813; Carlisle GK, 2015, J AUTISM DEV DISORD, V45, P1137, DOI 10.1007/s10803-014-2267-7; Carlisle GK, 2014, J PEDIATR NURS, V29, P114, DOI 10.1016/j.pedn.2013.09.005; Cattell R. B., 1978, SCI USE FACTOR ANAL, DOI [DOI 10.1007/978-1-4684-2262-7_5, 10.1007/978-1-4684-2262-7_5]; Comrey A. L., 1992, 1 COURSE FACTOR ANAL; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Fidell, 2007, EXPT DESIGNS USING A; FRIEDMANN E, 1983, J NERV MENT DIS, V171, P461, DOI 10.1097/00005053-198308000-00002; Gabriels RL, 2012, RES AUTISM SPECT DIS, V6, P578, DOI 10.1016/j.rasd.2011.09.007; Gee NR, 2014, ANTHROZOOS, V27, P513, DOI 10.2752/089279314X14072268687763; Gorsuch R. L., 1983, FACTOR ANAL; Grandgeorge M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041739; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Howlin P, 2005, J NEURAL TRANSM-SUPP, P101; Hume K, 2005, TOP EARLY CHILD SPEC, V25, P195, DOI 10.1177/02711214050250040101; Hurley RSE, 2007, J AUTISM DEV DISORD, V37, P1679, DOI 10.1007/s10803-006-0299-3; Kelly AB, 2008, J ABNORM CHILD PSYCH, V36, P1069, DOI 10.1007/s10802-008-9234-8; Kline R. B, 2015, PRINCIPLES PRACTICE, V2nd; Kohane IS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033224; Konst MJ, 2013, RES AUTISM SPECT DIS, V7, P1068, DOI 10.1016/j.rasd.2013.05.006; La Greca AM, 1998, J ABNORM CHILD PSYCH, V26, P83, DOI 10.1023/A:1022684520514; Lanning BA, 2014, J AUTISM DEV DISORD, V44, P1897, DOI 10.1007/s10803-014-2062-5; Mills D, 2014, VET REC, V174, P269, DOI 10.1136/vr.g1929; Mukaddes NM, 2010, WORLD J BIOL PSYCHIA, V11, P486, DOI [10.3109/15622970902789130, 10.1080/15622970902789130]; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; O'Haire M, 2010, J VET BEHAV, V5, P226, DOI 10.1016/j.jveb.2010.02.002; O'Haire ME, 2013, J AUTISM DEV DISORD, V43, P1606, DOI 10.1007/s10803-012-1707-5; O'Haire ME, 2015, DEV PSYCHOBIOL; Prothmann A, 2009, ANTHROZOOS, V22, P161, DOI 10.2752/175303709X434185; REDEFER LA, 1989, J AUTISM DEV DISORD, V19, P461, DOI 10.1007/BF02212943; Reichow Brian, 2013, Evid Based Child Health, V8, P266, DOI 10.1002/ebch.1903; Silva K, 2011, J ALTERN COMPLEM MED, V17, P655, DOI 10.1089/acm.2010.0436; Simpson Richard L., 2004, AUTISM SPECTRUM DISO; Smith, 2005, LIFE JOURNEY AUTISM; Solomon O, 2010, ETHOS, V38, P143, DOI 10.1111/j.1548-1352.2010.01085.x; Somervill J.W., 2009, N AM J PSYCHOL, V11, P111; Tantam D, 2000, AUTISM, V4, P47, DOI DOI 10.1177/1362361300004001004; Viau R, 2010, PSYCHONEUROENDOCRINO, V35, P1187, DOI 10.1016/j.psyneuen.2010.02.004; Volkmar F. R., 1997, HDB AUTISM PERVASIVE, P173, DOI DOI 10.1002/9780470939345.CH11; Ward SC, 2013, J AUTISM DEV DISORD, V43, P2190, DOI 10.1007/s10803-013-1773-3; Welsh M, 2001, J SCHOOL PSYCHOL, V39, P463, DOI 10.1016/S0022-4405(01)00084-X; Wright H, 2015, PET DOGS IM IN PRESS; Wright H, HUM ANIM IN IN PRESS; Wright H, 2015, J AUTISM DEV DISORD, P1	55	14	14	5	82	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2016	11	2							e0149736	10.1371/journal.pone.0149736	http://dx.doi.org/10.1371/journal.pone.0149736			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3DG	26894820	gold, Green Published, Green Accepted			2023-01-03	WOS:000371223400079
J	Jansen, PA; Grontvedt, RN; Tarpai, A; Helgesen, KO; Horsberg, TE				Jansen, Peder A.; Grontvedt, Randi N.; Tarpai, Attila; Helgesen, Kari O.; Horsberg, Tor Einar			Surveillance of the Sensitivity towards Antiparasitic Bath-Treatments in the Salmon Louse (Lepeophtheirus salmonis)	PLOS ONE			English	Article							SEA LICE; EMAMECTIN BENZOATE; REDUCED SENSITIVITY; DRUG-RESISTANCE; ATLANTIC; SALAR; AQUACULTURE; BIOASSAY; COPEPODA; FARMS	The evolution of drug resistant parasitic sea lice is of major concern to the salmon farming industry worldwide and challenges sustainable growth of this enterprise. To assess current status and development of L. salmonis sensitivity towards different pesticides used for parasite control in Norwegian salmon farming, a national surveillance programme was implemented in 2013. The programme aims to summarize data on the use of different pesticides applied to control L. salmonis and to test L. salmonis sensitivity to different pesticides in farms along the Norwegian coast. Here we analyse two years of test-data from biological assays designed to detect sensitivity-levels towards the pesticides azamethiphos and deltamethrin, both among the most common pesticides used in bath-treatments of farmed salmon in Norway in later years. The focus of the analysis is on how different variables predict the binomial outcome of the bioassay tests, being whether L. salmonis are immobilized/die or survive pesticide exposure. We found that local kernel densities of bath treatments, along with a spatial geographic index of test-farm locations, were significant predictors of the binomial outcome of the tests. Furthermore, the probability of L. salmonis being immobilized/dead after test-exposure was reduced by odds-ratios of 0.60 (95% CI: 0.42-0.86) for 2014 compared to 2013 and 0.39 (95% CI: 0.36-0.42) for low concentration compared to high concentration exposure. There were also significant but more marginal effects of parasite gender and developmental stage, and a relatively large random effect of test-farm. We conclude that the present data support an association between local intensities of bath treatments along the coast and the outcome of bioassay tests where salmon lice are exposed to azamethiphos or deltamethrin. Furthermore, there is a predictable structure of L. salmonis phenotypes along the coast in the data, characterized by high susceptibility to pesticides in the far north and far south, but low susceptibility in mid Norway. The study emphasizes the need to address local susceptibility to pesticides and the need for restrictive use of pesticides to preserve treatment efficacy.	[Jansen, Peder A.; Grontvedt, Randi N.; Tarpai, Attila] Norwegian Vet Inst, Oslo, Norway; [Helgesen, Kari O.; Horsberg, Tor Einar] Sea Lice Res Ctr, NMBU Sch Vet Sci, Oslo, Norway; [Jansen, Peder A.] Univ Bergen, Dept Biol, Sea Lice Res Ctr, Bergen, Norway	Norwegian Veterinary Institute; Norwegian University of Life Sciences; University of Bergen	Jansen, PA (corresponding author), Norwegian Vet Inst, Oslo, Norway.	Peder.jansen@vetinst.no			Norwegian Food safety Authority	Norwegian Food safety Authority	The Norwegian Food safety Authority, http://www.mattilsynet.no/, is responsible for management of fish health. Thereby, they fund the Surveillance program for salmon louse resistance to antiparasitics. The paper reports data from this activity.	Aaen SM, 2015, TRENDS PARASITOL, V31, P72, DOI 10.1016/j.pt.2014.12.006; Aldrin M, 2011, J R SOC INTERFACE, V8, P1346, DOI 10.1098/rsif.2010.0737; Aldrin M, 2010, PREV VET MED, V93, P51, DOI 10.1016/j.prevetmed.2009.09.010; [Anonymous], 2015, FORUTSIGBAR MILJOMES; Besnier F, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-937; Cleveland W. S., 1992, LOCAL REGRESSION MOD, DOI 10.1201/9780203738535; Denholm I, 2002, PEST MANAG SCI, V58, P528, DOI 10.1002/ps.482; Dohoo I., 2003, VET EPIDEMIOLOGY RES; Fallang A, 2005, DIS AQUAT ORGAN, V65, P129, DOI 10.3354/dao065129; Glover KA, 2011, MAR ECOL PROG SER, V427, P161, DOI 10.3354/meps09045; Grontvedt R. J., 2015, SURVEILLANCE PROGRAM; Helgesen KO, 2014, J FISH DIS, V37, P877, DOI 10.1111/jfd.12223; Helgesen KO, 2013, J FISH DIS, V36, P261, DOI 10.1111/jfd.12053; Jansen PA, 2012, P ROY SOC B-BIOL SCI, V279, P2330, DOI 10.1098/rspb.2012.0084; JONES MW, 1992, J FISH DIS, V15, P197, DOI 10.1111/j.1365-2761.1992.tb00654.x; Jones PG, 2012, DIS AQUAT ORGAN, V102, P53, DOI 10.3354/dao02517; Kaur K, 2015, PLOS ONE UNPUB; Kaur K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124220; Kristoffersen AB, 2013, PREV VET MED, V111, P165, DOI 10.1016/j.prevetmed.2013.03.015; Kristoffersen AB, 2014, EPIDEMICS-NETH, V9, P31, DOI 10.1016/j.epidem.2014.09.007; Kristoffersen AB, 2013, PREV VET MED, V109, P136, DOI 10.1016/j.prevetmed.2012.08.012; Leclercq E, 2014, PEST MANAG SCI, V70, P1274, DOI 10.1002/ps.3692; Lees F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001549; Ljungfeldt LER, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471-2148-14-108; Marin SL, 2015, PREV VET MED, V122, P33, DOI 10.1016/j.prevetmed.2015.09.017; McEwan GF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139128; R Development Coar Team, 2014, R LANG ENV STAT COMP; Read AF, 2011, P NATL ACAD SCI USA, V108, P10871, DOI 10.1073/pnas.1100299108; Roth M, 1996, AQUACULTURE, V140, P217, DOI 10.1016/0044-8486(95)01181-1; Sevatdal S, 2005, AQUACULTURE, V244, P19, DOI 10.1016/j.aquaculture.2004.11.009; Sevatdal S, 2003, AQUACULTURE, V218, P21, DOI 10.1016/S0044-8486(02)00339-3; Skiftesvik AB, 2014, MAR BIOL RES, V10, P289, DOI 10.1080/17451000.2013.810760; Tjensvoll K, 2006, DIS AQUAT ORGAN, V68, P251, DOI 10.3354/dao068251; Todd CD, 2004, CAN J FISH AQUAT SCI, V61, P1176, DOI 10.1139/F04-069; Torrissen O, 2013, J FISH DIS, V36, P171, DOI 10.1111/jfd.12061; Viljugrein H, 2009, DIS AQUAT ORGAN, V88, P35, DOI 10.3354/dao02151	36	18	18	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2016	11	2							e0149006	10.1371/journal.pone.0149006	http://dx.doi.org/10.1371/journal.pone.0149006			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3CO	26889677	Green Published, Green Submitted, gold			2023-01-03	WOS:000371221500019
J	Le Roy, B; Tixier, L; Pereira, B; Sauvanet, P; Buc, E; Petorin, C; Dechelotte, P; Pezet, D; Balayssac, D				Le Roy, Bertrand; Tixier, Lucie; Pereira, Bruno; Sauvanet, Pierre; Buc, Emmanuel; Petorin, Caroline; Dechelotte, Pierre; Pezet, Denis; Balayssac, David			Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study	PLOS ONE			English	Article							ORGANIC CATION TRANSPORTERS; 1ST-LINE TREATMENT; 3 SLC22A3; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; SURVIVAL; PREDICTOR; MEMBRANE; OCT1	Background Adjuvant chemotherapy for colorectal cancer is mainly based on the combination of 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4). The pharmacological target of oxaliplatin remains intracellular and therefore dependent on its entry into cells. The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy. The aim of this study was to perform a retrospective study to assess the relation between the expression of oxaliplatin transporters in colorectal cancer before chemotherapy and the response to FOLFOX-4 adjuvant chemotherapy in responder and non-responder patients. Methods This retrospective study was conducted at a single center (University Hospital of ClermontFerrand, France). The target population was patients with resectable colorectal cancer operated between 2006 and 2013. Inclusion criteria were defined for the responder patients as no cancer recurrence 3 years after the end of chemotherapy, and for the non-responder patients as cancer recurrence within 1 year. Other inclusion criteria were stages IIb-IV cancers, first-line adjuvant FOLFOX-4 chemotherapy, and the availability of resected primary tumor samples. Exclusion criteria were preoperative chemotherapy and/or radiotherapy, a targeted therapy, other anticancer drugs, cancer recurrence between the first and the third year after the end of chemotherapy and follow-up < 3 years. Immunostaining of oxaliplatin transporters (OCT1, 2, 3, CTR1 and ATP7B) and Ki-67 was assessed in tumor samples. Results Retrospectively, 31 patients have been selected according to inclusion and exclusion criteria (15 responders and 16 non-responders). Before FOLFOX-4 regimen, OCT3 expression was significantly lower in responder patients compared to non-responders (p<0.001). According to multivariate analysis, OCT3 remains an independent criterion for adjuvant FOLFOX chemotherapy response (p = 0.039). No significant relation is reported between chemotherapy response and the expression of OCT1 (p = 0.49), OCT2 (p = 0.09), CTR1 (p = 0.45), ATP7B (p = 0.94) and Ki-67 (p = 0.34) in tumors. Conclusions High expression of OCT3 could be an independent factor related to resistance to FOLFOX-4 chemotherapy.	[Le Roy, Bertrand; Sauvanet, Pierre; Buc, Emmanuel; Petorin, Caroline; Pezet, Denis] CHU Clermont Ferrand, Serv Chirurg & Oncol Digest, F-63003 Clermont Ferrand, France; [Tixier, Lucie; Dechelotte, Pierre] CHU Clermont Ferrand, Serv Anatomopathol, F-63003 Clermont Ferrand, France; [Pereira, Bruno; Balayssac, David] CHU Clermont Ferrand, Delegat Rech Clin & Innovat, F-63003 Clermont Ferrand, France; [Sauvanet, Pierre; Buc, Emmanuel; Pezet, Denis] INRA, INSERM, UdA U1071, USC 2018,M2iSH, F-63001 Clermont Ferrand, France; [Dechelotte, Pierre] Univ Auvergne, R2D2, EA 7281, F-63001 Clermont Ferrand, France; [Balayssac, David] INSERM, U1107, Neurodol, F-63001 Clermont Ferrand, France	CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Balayssac, D (corresponding author), CHU Clermont Ferrand, Delegat Rech Clin & Innovat, F-63003 Clermont Ferrand, France.; Balayssac, D (corresponding author), INSERM, U1107, Neurodol, F-63001 Clermont Ferrand, France.	dbalayssac@chu-clermontferrand.fr	Balayssac, David/AAZ-3007-2020; Pezet, Denis/I-4423-2017; Balayssac, David/K-2265-2015	Balayssac, David/0000-0002-6126-6588; Pezet, Denis/0000-0001-9416-2876; Pereira, Bruno/0000-0003-3778-7161; Tixier, Lucie/0000-0002-1325-3141; Le Roy, Bertrand/0000-0002-4668-9275				COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; Gallagher DJ, 2010, ONCOLOGY-BASEL, V78, P237, DOI 10.1159/000315730; Gupta S, 2012, J PHARMACOL EXP THER, V341, P16, DOI 10.1124/jpet.111.190561; Han T, 2013, MOL PHARMACOL, V84, P182, DOI 10.1124/mol.112.084517; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jennison C, 1999, GROUP SEQUENTIAL MET; Jonker JW, 2001, MOL CELL BIOL, V21, P5471, DOI 10.1128/MCB.21.16.5471-5477.2001; Kitada N, 2008, CANCER CHEMOTH PHARM, V62, P577, DOI 10.1007/s00280-007-0640-3; Lee N, 2014, J BIOL CHEM, V289, P27055, DOI 10.1074/jbc.M114.570564; Ma YL, 2010, MED ONCOL, V27, P304, DOI 10.1007/s12032-009-9210-3; Martinez-Balibrea E, 2009, INT J CANCER, V124, P2905, DOI 10.1002/ijc.24273; Mulgaonkar A, 2013, ANTIMICROB AGENTS CH, V57, P2705, DOI 10.1128/AAC.02289-12; Muller J, 2005, BIOCHEM PHARMACOL, V70, P1851, DOI 10.1016/j.bcp.2005.09.011; Nies AT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022163; NOETHER GE, 1987, J AM STAT ASSOC, V82, P645, DOI 10.2307/2289477; Noordhuis P, 2008, BIOCHEM PHARMACOL, V76, P53, DOI 10.1016/j.bcp.2008.04.007; Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9; Pawlik TM, 2005, ANN SURG, V241, P715, DOI 10.1097/01.sla.0000160703.75808.7d; Phua LC, 2013, CANCER CHEMOTH PHARM, V71, P817, DOI 10.1007/s00280-012-2054-0; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Tang SC, 2013, CURR OPIN PHARMACOL, V13, P853, DOI 10.1016/j.coph.2013.08.011; Tashiro A, 2014, AM J CANCER RES, V4, P528; Tatsumi S, 2014, INT J CLIN EXP PATHO, V7, P204; Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645; Tzvetkov MV, 2013, BIOCHEM PHARMACOL, V86, P666, DOI 10.1016/j.bcp.2013.06.019; Yokoo S, 2008, DRUG METAB DISPOS, V36, P2299, DOI 10.1124/dmd.108.023168; Yonezawa A, 2006, J PHARMACOL EXP THER, V319, P879, DOI 10.1124/jpet.106.110346; Zhang SZ, 2006, CANCER RES, V66, P8847, DOI 10.1158/0008-5472.CAN-06-0769	33	11	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148739	10.1371/journal.pone.0148739	http://dx.doi.org/10.1371/journal.pone.0148739			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859833	Green Published, Green Submitted, gold			2023-01-03	WOS:000370038400072
J	Eikenberg, JD; Savla, J; Marinik, EL; Davy, KP; Pownall, J; Baugh, ME; Flack, KD; Boshra, S; Winett, RA; Davy, BM				Eikenberg, Joshua D.; Savla, Jyoti; Marinik, Elaina L.; Davy, Kevin P.; Pownall, John; Baugh, Mary E.; Flack, Kyle D.; Boshra, Soheir; Winett, Richard A.; Davy, Brenda M.			Prediabetes Phenotype Influences Improvements in Glucose Homeostasis with Resistance Training	PLOS ONE			English	Article							IMPAIRED FASTING GLUCOSE; LIFE-STYLE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; GLYCEMIC CONTROL; INSULIN SENSITIVITY; DIABETES-MELLITUS; SKELETAL-MUSCLE; TOLERANCE; EXERCISE; PEOPLE	Purpose To determine if prediabetes phenotype influences improvements in glucose homeostasis with resistance training (RT). Methods Older, overweight individuals with prediabetes (n = 159; aged 60 +/- 5 yrs; BMI 33 +/- 4 kg/m(2)) completed a supervised RT program twice per week for 12 weeks. Body weight and composition, strength, fasting plasma glucose, 2-hr oral glucose tolerance, and Matsuda-Defronza estimated insulin sensitivity index (ISI) were assessed before and after the intervention. Participants were categorized according to their baseline prediabetes phenotype as impaired fasting glucose only (IFG) (n = 73), impaired glucose tolerance only (IGT) (n = 21), or combined IFG and IGT (IFG/IGT) (n = 65). Results Chest press and leg press strength increased 27% and 18%, respectively, following the 12-week RT program (both p<0.05). Waist circumference (-1.0%; pre 109.3 +/- 10.3 cm, post 108.2 +/- 10.6 cm) and body fat (-0.6%; pre 43.7 +/- 6.8%, post 43.1 +/- 6.8%) declined, and lean body mass (+1.3%; pre 52.0 +/- 10.4 kg, post 52.7 +/- 10.7 kg) increased following the intervention. Fasting glucose concentrations did not change (p>0.05) following the intervention. However, 2-hr oral glucose tolerance improved in those with IGT (pre 8.94 +/- 0.72 mmol/l, post 7.83 +/- 1.11 mmol/l, p<0.05) and IFG/IGT (pre 9.66 +/- 1.11mmol/l, post 8.60 +/- 2.00 mmol/l) but not in those with IFG (pre 6.27 +/- 1.28mmol/l, post 6.33 +/- 1.55 mmol/l). There were no significant changes in ISI or glucose area under the curve following the RT program. Conclusions RT without dietary intervention improves 2-hr oral glucose tolerance in individuals with prediabetes. However, the improvements in glucose homeostasis with RT appear limited to those with IGT or combined IFG and IGT.	[Eikenberg, Joshua D.; Boshra, Soheir] Virginia Tech Caril Sch Med, Caril Clin, Dept Internal Med, Roanoke, VA USA; [Savla, Jyoti] Virginia Tech, Ctr Gerontol, Blacksburg, VA USA; [Savla, Jyoti] Virginia Tech, Dept Human Dev, Blacksburg, VA USA; [Marinik, Elaina L.; Davy, Kevin P.; Pownall, John; Baugh, Mary E.; Flack, Kyle D.; Davy, Brenda M.] Virginia Tech, Dept Human Nutr Foods & Exercise, Blacksburg, VA USA; [Winett, Richard A.] Virginia Tech, Dept Psychol, Blacksburg, VA USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Eikenberg, JD (corresponding author), Virginia Tech Caril Sch Med, Caril Clin, Dept Internal Med, Roanoke, VA USA.	jdeikenberg@carilionclinic.org	Savla, Jyoti/J-7125-2015; Savla, Jyoti/N-6085-2019	Savla, Jyoti/0000-0001-7142-3770; Savla, Jyoti/0000-0001-7142-3770; Flack, Kyle/0000-0001-7622-4770; Baugh, Mary Elizabeth/0000-0002-3469-7040	National Institute of Diabetes and Digestive and Kidney Diseases (US) [NCT01112709]	National Institute of Diabetes and Digestive and Kidney Diseases (US)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (US) grant number NCT01112709 (RAW and BMD are the principal investigators on this grant), URL: http://www.niddk.nih.gov/Pages/default.aspx.	Abdul-Ghani MA, 2006, DIABETES CARE, V29, P1130, DOI 10.2337/dc05-2179; Abdul-Ghani MA, 2006, DIABETES, V55, P1430, DOI 10.2337/db05-1200; Abdul-Ghani MA, 2009, CURR DIABETES REP, V9, P193, DOI 10.1007/s11892-009-0032-7; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; Baldi JC, 2003, INT J SPORTS MED, V24, P419, DOI 10.1055/s-2003-41173; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; Basu R, 2013, J CLIN ENDOCR METAB, V98, pE409, DOI 10.1210/jc.2012-3056; Buford TW, 2012, PREV MED, V55, P34, DOI 10.1016/j.ypmed.2012.05.001; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Cauza E, 2005, ARCH PHYS MED REHAB, V86, P1527, DOI 10.1016/j.apmr.2005.01.007; Dunstan DW, 2006, DIABETES CARE, V29, P2586, DOI 10.2337/dc06-1310; Dunstan DW, 2002, DIABETES CARE, V25, P1729, DOI 10.2337/diacare.25.10.1729; Dunstan DW, 1998, DIABETES RES CLIN PR, V40, P53, DOI 10.1016/S0168-8227(98)00027-8; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Fenicchia LM, 2004, METABOLISM, V53, P284, DOI 10.1016/j.metabol.2003.10.007; Geirsdottir OG, 2012, J GERONTOL A-BIOL, V67, P1259, DOI 10.1093/gerona/gls096; Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004; Grontved A, 2012, ARCH INTERN MED, V172, P1306, DOI 10.1001/archinternmed.2012.3138; Holten MK, 2004, DIABETES, V53, P294, DOI 10.2337/diabetes.53.2.294; Ibanez J, 2005, DIABETES CARE, V28, P662, DOI 10.2337/diacare.28.3.662; Iglay HB, 2007, AM J CLIN NUTR, V85, P1005, DOI 10.1093/ajcn/85.4.1005; Ishii T, 1998, DIABETES CARE, V21, P1353, DOI 10.2337/diacare.21.8.1353; Joseph LJO, 2001, DIABETES CARE, V24, P1863, DOI 10.2337/diacare.24.11.1863; Kanat M, 2011, ACTA DIABETOL, V48, P209, DOI 10.1007/s00592-011-0285-x; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Lau C, 2009, J NUTR, V139, P588, DOI 10.3945/jn.108.100339; Lindahl B, 1999, J INTERN MED, V246, P105, DOI 10.1046/j.1365-2796.1999.00537.x; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Marinik EL, 2014, CONTEMP CLIN TRIALS, V37, P19, DOI 10.1016/j.cct.2013.11.006; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029; Mensink M, 2003, OBES RES, V11, P1588, DOI 10.1038/oby.2003.211; Muthen LK, 2002, STRUCT EQU MODELING, V9, P599, DOI 10.1207/S15328007SEM0904_8; Nathan DM, 2007, DIABETES CARE, V30, P753, DOI 10.2337/dc07-9920; Oldroyd JC, 2006, DIABETES RES CLIN PR, V72, P117, DOI 10.1016/j.diabres.2005.09.018; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; SATORRA A, 1985, PSYCHOMETRIKA, V50, P83, DOI 10.1007/BF02294150; SMUTOK MA, 1994, INT J SPORTS MED, V15, P283, DOI 10.1055/s-2007-1021061; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wasada T, 2004, DIABETOLOGIA, V47, P759, DOI 10.1007/s00125-004-1339-1; Weyer C, 1999, DIABETES, V48, P2197, DOI 10.2337/diabetes.48.11.2197; Whaley MH, 2006, ACSMS GUIDELINES FOR, Vxxi	46	17	21	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0148009	10.1371/journal.pone.0148009	http://dx.doi.org/10.1371/journal.pone.0148009			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840904	Green Submitted, gold, Green Published			2023-01-03	WOS:000369550200075
J	De Luca, M; Dona, D; Montagnani, C; Lo Vecchio, A; Romanengo, M; Tagliabue, C; Centenari, C; D'Argenio, P; Lundin, R; Giaquinto, C; Galli, L; Guarino, A; Esposito, S; Sharland, M; Versporten, A; Goossens, H; Nicolini, G				De Luca, Maia; Dona, Daniele; Montagnani, Carlotta; Lo Vecchio, Andrea; Romanengo, Marta; Tagliabue, Claudia; Centenari, Chiara; D'Argenio, Patrizia; Lundin, Rebecca; Giaquinto, Carlo; Galli, Luisa; Guarino, Alfredo; Esposito, Susanna; Sharland, Mike; Versporten, Ann; Goossens, Herman; Nicolini, Giangiacomo			Antibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? Data from the ARPEC Project	PLOS ONE			English	Article							INFECTIOUS-DISEASES-SOCIETY; COMMUNITY-ACQUIRED PNEUMONIA; POINT PREVALENCE SURVEY; HOSPITALIZED-PATIENTS; ANTIMICROBIAL USE; CARE; PREVENTION; GUIDELINES; MANAGEMENT; IMPACT	Background Antimicrobials are the most commonly prescribed drugs. Many studies have evaluated antibiotic prescriptions in the paediatric outpatient but few studies describing the real antibiotic consumption in Italian children's hospitals have been published. Point-prevalence survey (PPS) has been shown to be a simple, feasible and reliable standardized method for antimicrobials surveillance in children and neonates admitted to the hospital. In this paper, we presented data from a PPS on antimicrobial prescriptions carried out in 7 large Italian paediatric institutions. Methods A 1-day PPS on antibiotic use in hospitalized neonates and children was performed in Italy between October and December 2012 as part of the Antibiotic Resistance and Prescribing in European Children project (ARPEC). Seven institutions in seven Italian cities were involved. The survey included all admitted patients less than 18 years of age present in the ward at 8: 00 am on the day of the survey, who had at least one on-going antibiotic prescription. For all patients data about age, weight, underlying disease, antimicrobial agent, dose and indication for treatment were collected. Results The PPS was performed in 61 wards within 7 Italian institutions. A total of 899 patients were eligible and 349 (38.9%) had an on-going prescription for one or more antibiotics, with variable rates among the hospitals (25.7% -53.8%). We describe antibiotic prescriptions separately in neonates (<30 days old) and children (> = 30 days to <18 years old). In the neonatal cohort, 62.8% received antibiotics for prophylaxis and only 37.2% on those on antibiotics were treated for infection. Penicillins and aminoglycosides were the most prescribed antibiotic classes. In the paediatric cohort, 64.4% of patients were receiving antibiotics for treatment of infections and 35.5% for prophylaxis. Third generation cephalosporins and penicillin plus inhibitors were the top two antibiotic classes. The main reason for prescribing antibiotic therapy in children was lower respiratory tract infections (LRTI), followed by febrile neutropenia/fever in oncologic patients, while, in neonates, sepsis was the most common indication for treatment. Focusing on prescriptions for LRTI, 43.3% of patients were treated with 3rd generation cephalosporins, followed by macrolides (26.9%), quinolones (16.4%) and carbapenems (14.9%) and 50.1% of LRTI cases were receiving more than one antibiotic. For neutropenic fever/fever in oncologic patients, the preferred antibiotics were penicillins with inhibitors (47.8%), followed by carbapenems (34.8%), aminoglycosides (26.1%) and glycopeptides (26.1%). Overall, the 60.9% of patients were treated with a combination therapy. Conclusions Our study provides insight on the Italian situation in terms of antibiotic prescriptions in hospitalized neonates and children. An over-use of third generation cephalosporins both for prophylaxis and treatment was the most worrisome finding. A misuse and abuse of carbapenems and quinolones was also noted. Antibiotic stewardship programs should immediately identify feasible targets to monitor and modify the prescription patterns in children's hospital, also considering the continuous and alarming emergence of MDR bacteria.	[De Luca, Maia; D'Argenio, Patrizia] Bambino Gesu Pediat Hosp, Immunol & Infect Dis Unit, Rome, Italy; [Dona, Daniele; Lundin, Rebecca; Giaquinto, Carlo] Univ Padua, Dept Woman & Child Hlth, Div Pediat Infect Dis, Padua, Italy; [Montagnani, Carlotta; Galli, Luisa] Anna Meyer Childrens Univ Hosp, Dept Paediat Med, Paediat Infect Dis Unit, Florence, Italy; [Lo Vecchio, Andrea; Guarino, Alfredo] Univ Naples Federico II, Dept Translat Med Sci, Sect Pediat, Naples, Italy; [Romanengo, Marta] G Gaslini Childrens Hosp, Acute Care & Emergency Dept, Genoa, Italy; [Tagliabue, Claudia; Esposito, Susanna] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Pediat Highly Intens Care Unit, Milan, Italy; [Centenari, Chiara] Versilia Hosp, Paediat Unit, Lido Di Camaiore, Italy; [Sharland, Mike] St Georges Univ London, Div Clin Sci, Infect & Immun, London, England; [Versporten, Ann; Goossens, Herman] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, B-2020 Antwerp, Belgium; [Nicolini, Giangiacomo] San Martino Hosp, Pediat Unit, Belluno, Italy	IRCCS Bambino Gesu; University of Padua; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Naples Federico II; University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Ospedale Versilia; St Georges University London; University of Antwerp; ULSS 1 Dolomiti; Ospedale di Belluno	De Luca, M (corresponding author), Bambino Gesu Pediat Hosp, Immunol & Infect Dis Unit, Rome, Italy.	maiadeluca@gmail.com	Nicolini, Giangiacomo/AHA-0955-2022; montagnani, carlotta/AAB-7849-2019; Donà, Daniele/W-7088-2019; Romanengo, Marta/AAB-5053-2021; Giaquinto, Carlo/AAB-5016-2020; Tagliabue, Claudia/K-2706-2016; Vecchio, Andrea Lo/AAC-6042-2022; D'Argenio, Patrizia/ABA-3852-2021; Esposito, Susanna/K-3475-2016; Guarino, Alfredo/AAC-4812-2022; De Luca, Maia/AAI-1048-2019	Nicolini, Giangiacomo/0000-0003-4259-4540; Donà, Daniele/0000-0001-7105-2105; Romanengo, Marta/0000-0002-1833-037X; Tagliabue, Claudia/0000-0003-0293-933X; Esposito, Susanna/0000-0003-4103-2837; Guarino, Alfredo/0000-0003-0199-0336; De Luca, Maia/0000-0001-7549-3514; sharland, mike/0000-0001-8626-8291; Montagnani, Carlotta/0000-0001-5950-4965; Lundin, Rebecca/0000-0002-8380-4834; Lo Vecchio, Andrea/0000-0003-4181-6842; GIAQUINTO, CARLO/0000-0001-9365-0413				Amadeo B, 2010, J ANTIMICROB CHEMOTH, V65, P2247, DOI 10.1093/jac/dkq309; Andriole VT, 2005, CLIN INFECT DIS, V41, pS113, DOI 10.1086/428051; [Anonymous], 2014, BUONE PRATICHE CONTR; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI 10.2146/ajhp120568; Buccellato E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139097; Ciofi Degli Atti M, 2008, EURO SURVEILL, V13; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; Cotten CM, 2009, PEDIATRICS, V123, P58, DOI 10.1542/peds.2007-3423; Dellit TH, 2008, INFECT CONT HOSP EP, V29, P525, DOI 10.1086/588160; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Esposito S, 2001, EUR J CLIN MICROBIOL, V20, P647; European Centre for Disease Prevention and Control, 2014, ANN REP EARS NET; Evans HL, 2007, CRIT CARE MED, V35, P89, DOI 10.1097/01.CCM.0000251496.61520.75; Gagliotti C, 2006, INFECTION, V34, P155, DOI 10.1007/s15010-006-5106-8; Gerdes JS, 2004, PEDIATR CLIN N AM, V51, P939, DOI 10.1016/j.pcl.2004.03.009; Hajdu A, 2007, J HOSP INFECT, V66, P378, DOI 10.1016/j.jhin.2007.04.018; Hecker MT, 2003, ARCH INTERN MED, V163, P972, DOI 10.1001/archinte.163.8.972; Inglis GDT, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004338.pub3; Inglis GDT, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004697.pub3; Jardine LA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006179.pub2; Jenkins TC, 2011, ARCH INTERN MED, V171, P1072, DOI 10.1001/archinternmed.2011.29; Lietman P S, 1995, Drugs, V49 Suppl 2, P159; Lutsar I, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-215; Mills GD, 2005, BMJ-BRIT MED J, V330, P456, DOI 10.1136/bmj.38334.591586.82; National Institute for Health and Care Excellence (NICE), CLOSTR DIFF INF RISK; Nicolini G, 2014, J PEDIAT INF DIS-GER, V9, P1, DOI 10.3233/JPI-140405; Osvald EC, 2014, ARCH DIS CHILDHOOD-E, V99, P98, DOI 10.1136/archdischild-2013-304629; Pan A, 2013, J GLOB ANTIMICROB RE, V1, P175, DOI 10.1016/j.jgar.2013.05.004; Patel SJ, 2009, PEDIATR INFECT DIS J, V28, P1047, DOI 10.1097/INF.0b013e3181b12484; Potocki M, 2003, INFECTION, V31, P398, DOI 10.1007/s15010-003-4130-1; Powell KR, 2006, PEDIATRICS, V118, P1287, DOI 10.1542/peds.2006-1722; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Roberts RR, 2009, CLIN INFECT DIS, V49, P1175, DOI 10.1086/605630; Rossignoli A, 2007, EUR J CLIN PHARMACOL, V63, P1099, DOI 10.1007/s00228-007-0376-3; Schulman J, 2015, PEDIATRICS, V135, P826, DOI 10.1542/peds.2014-3409; Scottish Antimicrobial Prescribing Group (SAPG), REP ANT RES US HUM 2; Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891; Stam J, 2012, ACTA PAEDIATR, V101, P929, DOI 10.1111/j.1651-2227.2012.02728.x; Stern A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005590.pub3; Sviestina I, 2014, EUR J HOSP PHARM, V22; US Department of Health and Human Services Centers for Disease Control and Prevention., 2013, ANT RES THREATS US; Vaccheri A, 2002, J ANTIMICROB CHEMOTH, V50, P989, DOI 10.1093/jac/dkf239; Vaccheri A, 2008, J ANTIMICROB CHEMOTH, V61, P953, DOI 10.1093/jac/dkn010; van der Meer JWM, 2001, CLIN MICROBIOL INFEC, V7, P12, DOI 10.1046/j.1469-0691.7.s6.3.x; VanderStichele RH, 2006, J ANTIMICROB CHEMOTH, V58, P159, DOI 10.1093/jac/dkl147; Versporten A, 2016, J ANTIMICROB CHEMOTH; Viale P, 2015, CLIN MICROBIOL INFEC, V21, P242, DOI 10.1016/j.cmi.2014.10.020	48	50	51	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2016	11	5							e0154662	10.1371/journal.pone.0154662	http://dx.doi.org/10.1371/journal.pone.0154662			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3XH	27182926	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000376279500008
J	Mayor, S				Mayor, Susan			Mediterranean diet reduces cardiovascular events in people with heart disease, study shows	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Stewart RAH, 2016, EUR HEART J, V37, P1993, DOI 10.1093/eurheartj/ehw125	1	3	3	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	2016	353								i2348	10.1136/bmj.i2348	http://dx.doi.org/10.1136/bmj.i2348			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2RF	27114468				2023-01-03	WOS:000375482000006
J	Ayad, S; Babazade, R; Elsharkawy, H; Nadar, V; Lokhande, C; Makarova, N; Khanna, R; Sessler, DI; Turan, A				Ayad, Sabry; Babazade, Rovnat; Elsharkawy, Hesham; Nadar, Vinayak; Lokhande, Chetan; Makarova, Natalya; Khanna, Rashi; Sessler, Daniel I.; Turan, Alparslan			Comparison of Transversus Abdominis Plane Infiltration with Liposomal Bupivacaine versus Continuous Epidural Analgesia versus Intravenous Opioid Analgesia	PLOS ONE			English	Article							COLORECTAL SURGERY; OPEN-LABEL; TAP BLOCK; EFFICACY; MOTOR; PAIN	Epidural analgesia is considered the standard of care but cannot be provided to all patients Liposomal bupivacaine has been approved for field blocks such as transversus abdominis plane (TAP) blocks but has not been clinically compared against other modalities. In this retrospective propensity matched cohort study we thus tested the primary hypothesis that TAP infiltration are noninferior (not worse) to continuous epidural analgesia and superior (better) to intravenous opioid analgesia in patients recovering from major lower abdominal surgery. 318 patients were propensity matched on 18 potential factors among three groups (106 per group): 1) TAP infiltration with bupivacaine liposome; 2) continuous Epidural analgesia with plain bupivacaine; and; 3) intravenous patient-controlled analgesia (IV PCA). We claimed TAP noninferior (not worse) over Epidural if TAP was noninferior (not worse) on total morphine-equivalent opioid and time-weighted average pain score (10-point scale) within first 72 hours after surgery with noninferiority deltas of 1 (10-point scale) for pain and an increase less of 20% in the mean morphine equivalent opioid consumption. We claimed TAP or Epidural groups superior (better) over IV PCA if TAP or Epidural was superior on opioid consumption and at least noninferior on pain outcome. Multivariable linear regressions within the propensity-matched cohorts were used to model total morphine-equivalent opioid dose and time-weighted average pain score within first 72 hours after surgery; joint hypothesis framework was used for formal testing. TAP infiltration were noninferior to Epidural on both primary outcomes (p<0.001). TAP infiltration were noninferior to IV PCA on pain scores (p = 0.001) but we did not find superiority on opioid consumption (p = 0.37). We did not find noninferiority of Epidural over IV PCA on pain scores (P = 0.13) and nor did we find superiority on opioid consumption (P = 0.98). TAP infiltration with liposomal bupivacaine and continuous epidural analgesia were similar in terms of pain and opioid consumption, and not worse in pain compared with IV PCA. TAP infiltrations might be a reasonable alternative to epidural analgesia in abdominal surgical patients. A large randomized trial comparing these techniques is justified.	[Ayad, Sabry] Fairview Hosp, Dept Anesthesiol & Pain Management, Cleveland, OH USA; [Ayad, Sabry] Cleveland Clin, Dept Outcomes Res, Anesthesiol Inst Cleveland, Cleveland, OH 44106 USA; [Babazade, Rovnat] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Babazade, Rovnat] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA; [Elsharkawy, Hesham] Cleveland Clin, Dept Gen Anesthesiol, Inst Anesthesiol, Cleveland, OH 44106 USA; [Elsharkawy, Hesham; Nadar, Vinayak; Lokhande, Chetan; Makarova, Natalya; Khanna, Rashi; Sessler, Daniel I.; Turan, Alparslan] Cleveland Clin, Dept Outcomes Res, Inst Anesthesiol, Cleveland, OH 44106 USA; [Makarova, Natalya] Cleveland Clin, Dept Qualitat Hlth Sci, Inst Anesthesiol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Texas System; University of Texas Medical Branch Galveston; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Turan, A (corresponding author), Cleveland Clin, Dept Outcomes Res, Inst Anesthesiol, Cleveland, OH 44106 USA.	turana@ccf.org	Sessler, Daniel/D-3504-2011; ayad, sabry/ABA-8262-2020	Sessler, Daniel/0000-0001-9932-3077; AYAD, SABRY/0000-0002-6728-9297	Pacira Pharmaceuticals, Inc.	Pacira Pharmaceuticals, Inc.	The study was supported by Pacira Pharmaceuticals, Inc. The sponsor was not involved in data acquisition, analysis, nor interpretation of the results. This manuscript was written by the investigators. None of the authors has a personal financial interest in this research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], MAJ SURG PROC WER DE; Austin PC, 2009, BIOMETRICAL J, V51, P171, DOI 10.1002/bimj.200810488; CEDERHOLM I, 1994, REGION ANESTH, V19, P18; Chahar Praveen, 2012, J Pain Res, V5, P257, DOI 10.2147/JPR.S27894; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Findlay JM, 2012, SURG-J R COLL SURG E, V10, P361, DOI 10.1016/j.surge.2012.07.005; Finnerty O, 2013, MINERVA ANESTESIOL, V79, P1415; Finnerty O, 2012, CURR OPIN ANESTHESIO, V25, P610, DOI 10.1097/ACO.0b013e328357b165; Ganapathy S, 2015, EUR J ANAESTH, V32, P797, DOI 10.1097/EJA.0000000000000345; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Kadam VR, 2013, ANAESTH INTENS CARE, V41, P476, DOI 10.1177/0310057X1304100407; Kadam VR, 2011, J ANESTH, V25, P786, DOI 10.1007/s00540-011-1201-9; Konigsrainer I, 2009, ANAESTHESIA, V64, P27, DOI 10.1111/j.1365-2044.2008.05655.x; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Mascha EJ, 2012, ANESTH ANALG, V114, P1304, DOI 10.1213/ANE.0b013e3182504435; Niraj G, 2014, ANAESTHESIA, V69, P348, DOI 10.1111/anae.12546; Niraj G, 2011, ANAESTHESIA, V66, P465, DOI 10.1111/j.1365-2044.2011.06700.x; Rosenbaum PR, 1983, CENTRAL ROLE PROPENS, DOI [10.1093/biomet/70.1.41, DOI 10.1093/BIOMET/70.1.41]; Spanjersberg WR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007635.pub2; Turan A, 2013, CLIN J PAIN, V29, P1050, DOI 10.1097/AJP.0b013e318287a258; Vissers KCP, 2010, PAIN PRACT, V10, P85, DOI 10.1111/j.1533-2500.2009.00335.x; Wu YQ, 2013, ANESTH ANALG, V117, P507, DOI 10.1213/ANE.0b013e318297fcee	22	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0153675	10.1371/journal.pone.0153675	http://dx.doi.org/10.1371/journal.pone.0153675			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ6AH	27082959	gold, Green Published			2023-01-03	WOS:000374291800043
J	Ramsden, CE; Zamora, D; Majchrzak-Hong, S; Faurot, KR; Broste, SK; Frantz, RP; Davis, JM; Ringel, A; Suchindran, CM; Hibbeln, JR				Ramsden, Christopher E.; Zamora, Daisy; Majchrzak-Hong, Sharon; Faurot, Keturah R.; Broste, Steven K.; Frantz, Robert P.; Davis, John M.; Ringel, Amit; Suchindran, Chirayath M.; Hibbeln, Joseph R.			Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LINOLEIC-ACID METABOLITES; SERUM-CHOLESTEROL RESPONSE; N-6 FATTY-ACIDS; SECONDARY PREVENTION; REPLACEMENT THERAPY; DISEASE; RISK; METAANALYSIS; MORTALITY; LIPIDS	OBJECTIVE To examine the traditional diet-heart hypothesis through recovery and analysis of previously unpublished data from the Minnesota Coronary Experiment (MCE) and to put findings in the context of existing diet-heart randomized controlled trials through a systematic review and meta-analysis. DESIGN The MCE (1968-73) is a double blind randomized controlled trial designed to test whether replacement of saturated fat with vegetable oil rich in linoleic acid reduces coronary heart disease and death by lowering serum cholesterol. Recovered MCE unpublished documents and raw data were analyzed according to hypotheses prespecified by original investigators. Further, a systematic review and meta-analyses of randomized controlled trials that lowered serum cholesterol by providing vegetable oil rich in linoleic acid in place of saturated fat without confounding by concomitant interventions was conducted. SETTING One nursing home and six state mental hospitals in Minnesota, United States. PARTICIPANTS Unpublished documents with completed analyses for the randomized cohort of 9423 women and men aged 20-97; longitudinal data on serum cholesterol for the 2355 participants exposed to the study diets for a year or more; 149 completed autopsy files. INTERVENTIONS Serum cholesterol lowering diet that replaced saturated fat with linoleic acid (from corn oil and corn oil polyunsaturated margarine). Control diet was high in saturated fat from animal fats, common margarines, and shortenings. MAIN OUTCOME MEASURES Death from all causes; association between changes in serum cholesterol and death; and coronary atherosclerosis and myocardial infarcts detected at autopsy. RESULTS The intervention group had significant reduction in serum cholesterol compared with controls (mean change from baseline -13.8% v -1.0%; P<0.001). Kaplan Meier graphs showed no mortality benefit for the intervention group in the full randomized cohort or for any prespecified subgroup. There was a 22% higher risk of death for each 30 mg/dL (0.78 mmol/L) reduction in serum cholesterol in covariate adjusted Cox regression models (hazard ratio 1.22, 95% confidence interval 1.14 to 1.32; P<0.001). There was no evidence of benefit in the intervention group for coronary atherosclerosis or myocardial infarcts. Systematic review identified five randomized controlled trials for inclusion (n= 10 808). In meta-analyses, these cholesterol lowering interventions showed no evidence of benefit on mortality from coronary heart disease (1.13, 0.83 to 1.54) or all cause mortality (1.07, 0.90 to 1.27). CONCLUSIONS Available evidence from randomized controlled trials shows that replacement of saturated fat in the diet with linoleic acid effectively lowers serum cholesterol but does not support the hypothesis that this translates to a lower risk of death from coronary heart disease or all causes. Findings from the Minnesota Coronary Experiment add to growing evidence that incomplete publication has contributed to overestimation of the benefits of replacing saturated fat with vegetable oils rich in linoleic acid.	[Ramsden, Christopher E.; Majchrzak-Hong, Sharon; Ringel, Amit; Hibbeln, Joseph R.] NIAAA, Sect Nutr Neurosci, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA; [Ramsden, Christopher E.; Faurot, Keturah R.] Univ N Carolina, Dept Phys Med & Rehabil, Program Integrat Med, Chapel Hill, NC USA; [Zamora, Daisy; Davis, John M.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA; [Broste, Steven K.] Medtronic, Minneapolis, MN USA; [Frantz, Robert P.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; [Davis, John M.] Univ Illinois, Inst Psychiat, Chicago, IL USA; [Suchindran, Chirayath M.] UNC Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Medtronic; Mayo Clinic; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of North Carolina; University of North Carolina Chapel Hill	Ramsden, CE (corresponding author), NIAAA, Sect Nutr Neurosci, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA.; Ramsden, CE (corresponding author), Univ N Carolina, Dept Phys Med & Rehabil, Program Integrat Med, Chapel Hill, NC USA.	Chris.Ramsden@nih.gov	Zamora, Daisy/ABG-5162-2021; Ramsden, Christopher/AAW-9516-2021	Frantz, Robert/0000-0003-4128-3978; Zamora, Daisy/0000-0003-2114-5156; Ramsden, Christopher/0000-0002-4058-7630; Faurot, Keturah/0000-0001-6122-7821	US Public Health Service; National Heart Institute through R01 mechanism [HE09686]; intramural program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health; University of North Carolina Program on Integrative Medicine (National Institutes of Health) [T-32 AT003378]; National Center for Complementary & Integrative Health [T32AT003378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000115, ZIAAA000235] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Heart Institute through R01 mechanism; intramural program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health; University of North Carolina Program on Integrative Medicine (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The MCE was funded by the US Public Health Service and the National Heart Institute through the R01 mechanism (grant HE09686). The intramural program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, and the University of North Carolina Program on Integrative Medicine (National Institutes of Health grant T-32 AT003378) supported data recovery and evaluation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US Public Health Service.	ANDERSON JT, 1961, J NUTR, V75, P388, DOI 10.1093/jn/75.4.388; [Anonymous], 1974, DHEW PUBL NIH, V(NIH) 75-628; [Anonymous], 1977, DIET GOALS US; [Anonymous], 1984, NIH CONSENSUS STATE, V5, P1; [Anonymous], 2015, WHO STAT PUBL DISCL; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Blanchard H, 2013, PROSTAG LEUKOTR ESS, V88, P383, DOI 10.1016/j.plefa.2013.03.006; Blasbalg TL, 2011, AM J CLIN NUTR, V93, P950, DOI 10.3945/ajcn.110.006643; Brewer ER, 1975, CIRCULATION S2, V51, P1; Broste SK, 1981, LIFETABLE ANAL MINNE; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CAMEJO G, 1976, ATHEROSCLEROSIS, V24, P341, DOI 10.1016/0021-9150(76)90126-X; CAPLAN AL, 1984, HUM PATHOL, V15, P1105, DOI 10.1016/S0046-8177(84)80304-4; Chemin J, 2014, PFLUG ARCH EUR J PHY, V466, P689, DOI 10.1007/s00424-014-1467-5; Chowdhury R, 2014, ANN INTERN MED, V160, P398, DOI 10.7326/M13-1788; DAWSON EA, 1975, CIRCULATION, V52, P271; Diffenderfer MR, 2014, CURR OPIN LIPIDOL, V25, P221, DOI 10.1097/MOL.0000000000000067; ENIG MG, 1990, J AM COLL NUTR, V9, P471, DOI 10.1080/07315724.1990.10720404; Executive Committee on Diet and Heart Disease, 1968, NAT DIET HEART STUD; Farvid MS, 2014, CIRCULATION, V130, P1568, DOI 10.1161/CIRCULATIONAHA.114.010236; Feldstein AE, 2010, J LIPID RES, V51, P3046, DOI 10.1194/jlr.M007096; Ferreiro-Vera C, 2013, FOOD CHEM, V136, P576, DOI 10.1016/j.foodchem.2012.08.081; Frantz I., 1971, CHEM ANAL 3 WE UNPUB; FRANTZ ID, 1975, CIRCULATION, V52, P4; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; Frantz Jr ID, 1967, RO1 HE 0986 02 SUPPL; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; GETZ GS, 1969, AM J MED, V46, P657, DOI 10.1016/0002-9343(69)90018-7; Godlee F, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5641; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Guesnet P, 2011, PROSTAG LEUKOTR ESS, V85, P353, DOI 10.1016/j.plefa.2011.08.003; He JH, 2011, EXP BIOL MED, V236, P1116, DOI 10.1258/ebm.2011.011128; JAMA, 1970, JAMA, V214, P1303, DOI DOI 10.1001/JAMA.1970.03180070069012; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1974, AM J CLIN NUTR, V27, P188, DOI 10.1093/ajcn/27.2.188; KEYS A, 1957, LANCET, V2, P959; Keys A., 1967, RO1 HE 0986 03 RES G; Kirpich IA, 2013, ALCOHOL, V47, P257, DOI 10.1016/j.alcohol.2013.01.005; Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-12-ED1; Kuipers RS, 2010, BRIT J NUTR, V104, P1666, DOI 10.1017/S0007114510002679; Lehman R, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d8158; Liu HL, 2015, AM J PATHOL, V185, P43, DOI 10.1016/j.ajpath.2014.09.007; Maki KC, 2014, ADV NUTR, V5, P7, DOI 10.3945/an.113.004929; Marmesat S, 2012, FOOD CHEM, V135, P2333, DOI 10.1016/j.foodchem.2012.06.128; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Naci H, 2013, EUR J PREV CARDIOL, V20, P641, DOI 10.1177/2047487313480435; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Oh K, 2005, AM J EPIDEMIOL, V161, P161, DOI 10.1093/aje/kwi026; Otto MCD, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000506; Patwardhan AM, 2010, J CLIN INVEST, V120, P1617, DOI 10.1172/JCI41678; Patwardhan AM, 2009, P NATL ACAD SCI USA, V106, P18820, DOI 10.1073/pnas.0905415106; Ramasamy I, 2014, CLIN CHEM LAB MED, V52, P1695, DOI 10.1515/cclm-2013-0358; RAMSDEN CE, 2013, BMJ-BRIT MED J, V346, pe8707, DOI DOI 10.1136/BMJ.E8707; Ramsden CE, MOL PAIN IN PRESS; Ramsden CE, 2015, J PAIN, V16, P707, DOI 10.1016/j.jpain.2015.04.007; Ramsden CE, 2013, PAIN, V154, P2441, DOI 10.1016/j.pain.2013.07.028; Ramsden CE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8707; Ramsden CE, 2012, PROSTAG LEUKOTR ESS, V87, P135, DOI 10.1016/j.plefa.2012.08.004; Rockwood MRH, 2011, CAN GERIATR J, V14, P2; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SHERWIN R, 1978, AM J EPIDEMIOL, V108, P92, DOI 10.1093/oxfordjournals.aje.a112607; SPADY DK, 1992, SEMIN LIVER DIS, V12, P373, DOI 10.1055/s-2008-1040407; SPIEKERMAN RE, 1962, CIRCULATION, V25, P57, DOI 10.1161/01.CIR.25.1.57; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; The Coronary Drug Project, 1972, JAMA-J AM MED ASSOC, V220, P996, DOI [10.1001/jama.1972.03200070084015, DOI 10.1001/JAMA.1972.03200070084015]; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; THOMPSON LU, 1983, CAN I FOOD SC TECH J, V16, P246, DOI 10.1016/S0315-5463(83)72257-1; U. S. Department of Agriculture, 2010, USDA NAT NUTR DAT ST; US Department of Agriculture Agricultural Research Service, WHAT WE EAT AM; Van Assche K, 2015, KENNEDY INST ETHIC J, V25, P67, DOI 10.1353/ken.2015.0000; Vangaveti V, 2010, THER ADV ENDOCRINOL, V1, P51, DOI 10.1177/2042018810375656; Willett WC, 2007, J CARDIOVASC MED, V8, pS42, DOI 10.2459/01.JCM.0000289275.72556.13; Wilson R, 2002, FREE RADICAL BIO MED, V32, P162, DOI 10.1016/S0891-5849(01)00780-8; Wu JHY, 2014, CIRCULATION, V130, P1245, DOI 10.1161/CIRCULATIONAHA.114.011590; Young SS, 2011, SIGNIFICANCE, V8, P116, DOI DOI 10.1111/J.1740-9713.2011.00506.X	78	220	226	1	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 12	2016	353								i1246	10.1136/bmj.i1246	http://dx.doi.org/10.1136/bmj.i1246			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ7ER	27071971	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000374375200001
J	Liu, Y; Li, XM; Xie, C; Luo, XZ; Bao, YG; Wu, B; Hu, YC; Zhong, Z; Liu, C; Li, MJ				Liu, Yan; Li, Xuemei; Xie, Chen; Luo, Xiuzhen; Bao, Yonggang; Wu, Bin; Hu, Yuchi; Zhong, Zhong; Liu, Chang; Li, MinJie			Prevention Effects and Possible Molecular Mechanism of Mulberry Leaf Extract and its Formulation on Rats with Insulin-Insensitivity	PLOS ONE			English	Article							MORUS-ALBA L.; OXIDATIVE STRESS; IN-VIVO; GLUCOSE; DIET; EXPRESSION; 4-HYDROXYISOLEUCINE; STREPTOZOTOCIN; LIPOGENESIS; ADIPOCYTES	For centuries, mulberry leaf has been used in traditional Chinese medicine for the treatment of diabetes. This study aims to test the prevention effects of a proprietary mulberry leaf extract (MLE) and a formula consisting of MLE, fenugreek seed extract, and cinnamon cassia extract (MLEF) on insulin resistance development in animals. MLE was refined to contain 5% 1-deoxynojirimycin by weight. MLEF was formulated by mixing MLE with cinnamon cassia extract and fenugreek seed extract at a 6:5:3 ratio (by weight). First, the acute toxicity effects of MLE on ICR mice were examined at 5 g/kg BW dose. Second, two groups of normal rats were administrated with water or 150 mg/kg BW MLE per day for 29 days to evaluate MLE's effect on normal animals. Third, to examine the effects of MLE and MLEF on model animals, sixty SD rats were divided into five groups, namely, (1) normal, (2) model, (3) high-dose MLE (75 mg/kg BW) treatment; (4) low-dose MLE (15 mg/kg BW) treatment; and (5) MLEF (35 mg/kg BW) treatment. On the second week, rats in groups (2)-(5) were switched to high-energy diet for three weeks. Afterward, the rats were injected (ip) with a single dose of 105 mg/kg BW alloxan. After four more days, fasting blood glucose, post-prandial blood glucose, serum insulin, cholesterol, and triglyceride levels were measured. Last, liver lysates from animals were screened with 650 antibodies for changes in the expression or phosphorylation levels of signaling proteins. The results were further validated by Western blot analysis. We found that the maximum tolerance dose of MLE was greater than 5 g/kg in mice. The MLE at a 150 mg/kg BW dose showed no effect on fast blood glucose levels in normal rats. The MLE at a 75 mg/kg BW dose and MLEF at a 35 mg/kg BW dose, significantly (p < 0.05) reduced fast blood glucose levels in rats with impaired glucose and lipid metabolism. In total, 34 proteins with significant changes in expression and phosphorylation levels were identified. The changes of JNK, IRS1, and PDK1 were confirmed by western blot analysis. In conclusion, this study demonstrated the potential protective effects of MLE and MLEF against hyperglycemia induced by high-energy diet and toxic chemicals in rats for the first time. The most likely mechanism is the promotion of IRS1 phosphorylation, which leads to insulin sensitivity restoration.	[Liu, Yan; Li, MinJie] Res & Dev Ctr Amway China, Shanghai, Peoples R China; [Li, Xuemei; Hu, Yuchi] Beijing Ctr Hlth Food & Cosmet Control, Beijing Inst Drug Control, Beijing, Peoples R China; [Zhong, Zhong] Bot Century Beijing Co Ltd, Beijing, Peoples R China; [Bao, Yonggang] Beijing Pepnoch Co Ltd, Beijing, Peoples R China; [Xie, Chen; Luo, Xiuzhen; Wu, Bin; Liu, Chang] Chinese Acad Med Sci, Inst Med Plant Dev, 151 Malianwa North Rd, Beijing 100193, Peoples R China; [Xie, Chen; Luo, Xiuzhen; Wu, Bin; Liu, Chang] Peking Union Med Coll, 151 Malianwa North Rd, Beijing 100193, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Plant Development - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Li, MJ (corresponding author), Res & Dev Ctr Amway China, Shanghai, Peoples R China.; Liu, C (corresponding author), Peking Union Med Coll, 151 Malianwa North Rd, Beijing 100193, Peoples R China.	cliu@implad.ac.cn; Liz.Li@amway.com	Liu, Chang/A-1148-2014		Botanic Century (Beijing) Co., Ltd.	Botanic Century (Beijing) Co., Ltd.	The authors YL and MJL are paid employees of Amway, China. The author YGB is a paid employee of Beijing Pepnoch Co., Ltd. The author Zhong Zhong is a paid employee of Botanic Century (Beijing) Co., Ltd. The funder provided support in the form of salaries for authors (YL, YGB, ZZ and MJL), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Andallu B, 2007, J MED FOOD, V10, P41, DOI 10.1089/jmf.2005.034; Andallu B, 2001, CLIN CHIM ACTA, V314, P47, DOI 10.1016/S0009-8981(01)00632-5; [Anonymous], 2012, METH EV ASS ANT FUNC; Bouderba S, 2014, J DIABETES, V6, P184, DOI 10.1111/1753-0407.12083; Broca C, 1999, AM J PHYSIOL-ENDOC M, V277, pE617, DOI 10.1152/ajpendo.1999.277.4.E617; Dong XC, 2006, J CLIN INVEST, V116, P101, DOI 10.1172/JCI25735; Fritsche L, 2008, CURR MED CHEM, V15, P1316, DOI 10.2174/092986708784534956; Jaiswal N, 2012, EUR J NUTR, V51, P893, DOI 10.1007/s00394-012-0374-9; Kimura T, 2007, J AGR FOOD CHEM, V55, P5869, DOI 10.1021/jf062680g; Kobayashi Y, 2010, BIOSCI BIOTECH BIOCH, V74, P2385, DOI 10.1271/bbb.100392; Lee YJ, 2011, AM J CHINESE MED, V39, P39, DOI 10.1142/S0192415X11008634; Leiter Edward H, 2013, Curr Protoc Mouse Biol, V3, P9; Lim HH, 2013, EXP BIOL MED, V238, P1160, DOI 10.1177/1535370213498982; Liu YN, 2014, NUTR RES, V34, P450, DOI 10.1016/j.nutres.2014.04.007; Lu ZL, 2011, PHYTOMEDICINE, V18, P298, DOI 10.1016/j.phymed.2010.08.008; Naowaboot J, 2012, AM J CHINESE MED, V40, P163, DOI 10.1142/S0192415X12500139; Pelech S, 2008, J PROTEOME RES, V7, P2860, DOI 10.1021/pr800082a; Qin B, 2010, HORM METAB RES, V42, P187, DOI 10.1055/s-0029-1242746; Qin BL, 2003, DIABETES RES CLIN PR, V62, P139, DOI 10.1016/S0168-8227(03)00173-6; Rowland AF, 2011, TRAFFIC, V12, P672, DOI 10.1111/j.1600-0854.2011.01178.x; Sauvaire Y, 1998, DIABETES, V47, P206, DOI 10.2337/diabetes.47.2.206; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Verspohl EJ, 2005, PHYTOTHER RES, V19, P203, DOI 10.1002/ptr.1643; Yu Hai, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1394	24	20	20	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0152728	10.1371/journal.pone.0152728	http://dx.doi.org/10.1371/journal.pone.0152728			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27054886	Green Submitted, Green Published, gold			2023-01-03	WOS:000373608000038
J	Conboy, L; Gerke, T; Hsu, KY; St John, M; Goldstein, M; Schnyer, R				Conboy, Lisa; Gerke, Travis; Hsu, Kai-Yin; St John, Meredith; Goldstein, Marc; Schnyer, Rosa			The Effectiveness of Individualized Acupuncture Protocols in the Treatment of Gulf War Illness: A Pragmatic Randomized Clinical Trial	PLOS ONE			English	Article							UNITED-STATES; PAIN; QUALITY; VETERANS; COMPLEX	Background Gulf War Illness is a Complex Medical Illness characterized by multiple symptoms, including fatigue, sleep and mood disturbances, cognitive dysfunction, and musculoskeletal pain affecting veterans of the first Gulf War. No standard of care treatment exists. Methods This pragmatic Randomized Clinical Trial tested the effects of individualized acupuncture treatments offered in extant acupuncture practices in the community; practitioners had at least 5 years of experience plus additional training provided by the study. Veterans with diagnosed symptoms of Gulf War Illness were randomized to either six months of biweekly acupuncture treatments (group 1, n = 52) or 2 months of waitlist followed by weekly acupuncture treatments (group 2, n = 52). Measurements were taken at baseline, 2, 4 and 6 months. The primary outcome is the SF-36 physical component scale score (SF-36P) and the secondary outcome is the McGill Pain scale. Results Of the 104 subjects who underwent randomization, 85 completed the protocol (82%). A clinically and statistically significant average improvement of 9.4 points (p = 0.03) in the SF-36P was observed for group 1 at month 6 compared to group 2, adjusting for baseline pain. The secondary outcome of McGill pain index produced similar results; at 6 months, group 1 was estimated to experience a reduction of approximately 3.6 points (p = 0.04) compared to group 2. Conclusions Individualized acupuncture treatment of sufficient dose appears to offer significant relief of physical disability and pain for veterans with Gulf War Illness. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Gulf War Illness Research Program under Award No. W81XWH-09-2-0064. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.	[Conboy, Lisa; Hsu, Kai-Yin; St John, Meredith] New England Sch Acupuncture, Newton, MA USA; [Gerke, Travis] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL USA; [Gerke, Travis] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA; [Goldstein, Marc] Boston Vet Healthcare Syst, Jamaica Plain Campus, Boston, MA USA; [Schnyer, Rosa] Univ Texas Austin, Austin, TX 78712 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Austin	Conboy, L (corresponding author), New England Sch Acupuncture, Newton, MA USA.	Lisa_conboy@hms.harvard.edu	Conboy, Lisa/ABC-5173-2021	Conboy, Lisa/0000-0003-2218-7841	Office of the Assistant Secretary of Defense for Health Affairs through the Gulf War Illness Research Program [W81XWH-09-2-0064]	Office of the Assistant Secretary of Defense for Health Affairs through the Gulf War Illness Research Program	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Gulf War Illness Research Program under Award No. W81XWH-09-2-0064. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.	Allen JJB, 1998, PSYCHOL SCI, V9, P397, DOI 10.1111/1467-9280.00074; Allen JJB, 2006, J CLIN PSYCHIAT, V67, P1665, DOI 10.4088/JCP.v67n1101; Berman BM, 1999, J FAM PRACTICE, V48, P213; Blanchard MS, 2006, AM J EPIDEMIOL, V163, P66, DOI 10.1093/aje/kwj008; Bullock M L, 1997, J Altern Complement Med, V3, P31, DOI 10.1089/acm.1997.3.31; Burke A, 2006, J ALTERN COMPLEM MED, V12, P639, DOI 10.1089/acm.2006.12.639; Cassidy CM, 1998, J ALTERN COMPLEM MED, V4, P17, DOI 10.1089/acm.1998.4.1-17; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P443; Cohen J., 2013, STAT POWER ANAL BEHA; Conboy L, 2012, CONTEMP CLIN TRIALS, V33, P557, DOI 10.1016/j.cct.2012.02.006; Duncan Barbara, 2007, Acupunct Med, V25, P137; Fireman Z, 2001, DIGESTION, V64, P100, DOI 10.1159/000048847; Goertz CMH, 2006, MIL MED, V171, P1010, DOI 10.7205/MILMED.171.10.1010; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Halekoh U, 2006, J STAT SOFTW, V15, P1, DOI 10.18637/jss.v015.i02; Hollifield M, 2007, J NERV MENT DIS, V195, P504, DOI 10.1097/NMD.0b013e31803044f8; Hull A, 2012, BMC COMPLEMENT AL S1, V12, P194; Jena S, 2008, CEPHALALGIA, V28, P969, DOI 10.1111/j.1468-2982.2008.01640.x; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Kang HK, 2009, OCCUP ENVIRON MED, V51, P401, DOI DOI 10.1097/JOM.0B013E3181A2FEEB; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; KING G, 2000, AM J POLIT SCI, V0044; Lao L, 1996, J Altern Complement Med, V2, P27, DOI 10.1089/acm.1996.2.27; Manber R, 2004, J AFFECT DISORDERS, V83, P89, DOI 10.1016/j.jad.2004.05.009; Manheimer Eric, 2006, Acupunct Med, V24 Suppl, pS7; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Napadow V, 2008, J ALTERN COMPLEM MED, V14, P861, DOI 10.1089/acm.2008.SAR-3; Niemtzow RC, 2006, J ALTERN COMPLEM MED, V12, P597, DOI 10.1089/acm.2006.597; Ozakinci G, 2006, ENVIRON HEALTH PERSP, V114, P1553, DOI 10.1289/ehp.9251; Paterson C, 2004, J ALTERN COMPLEM MED, V10, P791; Pilkington K.KirkwoodG, 2007, ACUPUNCT MED, V12, P1; Steele L, 2012, ENVIRON HEALTH PERSP, V120, P112, DOI 10.1289/ehp.1003399; Tukmachi Emad, 2004, Acupunct Med, V22, P14; Vickers AJ, 2004, HEALTH TECHNOL ASSES, V8, P1; Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x; Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006	41	20	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0149161	10.1371/journal.pone.0149161	http://dx.doi.org/10.1371/journal.pone.0149161			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH9NC	27031099	Green Published, gold			2023-01-03	WOS:000373121800003
J	Hu, JJ; Zhang, CL; Yan, JQ; Wang, RK; Wang, Y; Xu, M				Hu, Jiajia; Zhang, Chengliang; Yan, Jianqin; Wang, Ruike; Wang, Ying; Xu, Mu			Sufentanil and Bupivacaine Combination versus Bupivacaine Alone for Spinal Anesthesia during Cesarean Delivery: A Meta-Analysis of Randomized Trials	PLOS ONE			English	Article							LOW-DOSE BUPIVACAINE; INTRATHECAL MORPHINE; HYPERBARIC BUPIVACAINE; INDUCED PRURITUS; FENTANYL; SECTION; OPIOIDS; ANALGESIA; EFFICACY; SURGERY	Objective The addition of lipophilic opioids to local anesthetics for spinal anesthesia has become a widely used strategy for cesarean anesthesia. A meta-analysis to quantify the benefits and risks of combining sufentanil with bupivacaine for patients undergoing cesarean delivery was conducted. Methods A comprehensive literature search without language or date limitation was performed to identify clinical trials that compared the addition of sufentanil to bupivacaine with bupivacaine alone for spinal anesthesia in healthy parturients choosing cesarean delivery. The Q and I-2 tests were used to assess heterogeneity of the data. Data from each trial were combined using relative ratios (RRs) for dichotomous data or weighted mean differences (WMDs) for continuous data and corresponding 95% confidence intervals (95% CIs) for each trial. Sensitivity analysis was conducted by removing one study a time to assess the quality and consistency of the results. Begg's funnel plots and Egger's linear regression test were used to detect any publication bias. Results This study included 9 trials containing 578 patients in the final meta-analysis. Sufentanil addition provided a better analgesia quality with less breakthrough pain during surgery than bupivacaine alone (RR = 0.10, 95% CI 0.06 to 0.18, P < 0.001). Sensory block onset time was shorter and first analgesic request time was longer in sufentanil added group compared with the bupivacaine-alone group (WMD = -1.0 min, 95% CI -1.5 to -0.58, P < 0.001 and WMD = 133 min, 95% CI 75 to 213, P < 192, respectively). There was no significant difference in the risk of hypotension and vomiting between these two groups. But pruritus was more frequentely reported in the group with sufentanil added (RR = 7.63, 95% CI 3.85 to 15.12, P < 0.001). Conclusion Bupivacaine and sufentanil combination is superior to that of bupivacaine alone for spinal anesthesia for cesarean delivery in analgesia quality. Women receiving the combined two drugs had less breakthrough pain, shorter sensory block onset time, and longer first analgesic request time. However, the addition of sufentanil to bupivacaine increased the incidence of pruritus.	[Hu, Jiajia; Yan, Jianqin; Wang, Ruike; Xu, Mu] Cent South Univ, Xiangya Hosp, Dept Anesthesiol, Changsha, Hunan, Peoples R China; [Zhang, Chengliang] Cent South Univ, Xiangya Hosp, Dept Cardiovasc Surg, Changsha, Hunan, Peoples R China; [Wang, Ying] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Dept Anesthesiol, Fuzhou, Peoples R China	Central South University; Central South University; Fujian Medical University	Yan, JQ (corresponding author), Cent South Univ, Xiangya Hosp, Dept Anesthesiol, Changsha, Hunan, Peoples R China.	jqyan480@gmail.com			Xiangya Clinical Research Fund [2013L13]; National Natural Science Foundation of China [81400921]	Xiangya Clinical Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Xiangya Clinical Research Fund 2013L13 (JY), Internal to Xiangya hospital of Central South University; National Natural Science Foundation of China 81400921 (YW), External fund to our organisations. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolabi BB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004350.pub3; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Bang YS, 2012, KOREAN J ANESTHESIOL, V63, P321, DOI 10.4097/kjae.2012.63.4.321; Braga ADFD, 2003, EUR J ANAESTH, V20, P631; Braga AA, 2012, REV BRAS ANESTESIOL, V62, P775, DOI 10.1016/S0034-7094(12)70178-2; Chinachoti Thitima, 2013, Journal of the Medical Association of Thailand, V96, P589; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Davies SJ, 1997, ANESTH ANALG, V85, P607, DOI 10.1097/00000539-199709000-00022; Demiraran Yavuz, 2006, J Anesth, V20, P274, DOI 10.1007/s00540-006-0437-2; Ginosar Y, 2013, BR J ANAESTH; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Knobloch K, 2011, J CRANIO MAXILL SURG, V39, P91, DOI 10.1016/j.jcms.2010.11.001; Krajnik M, 2001, J PAIN SYMPTOM MANAG, V21, P151, DOI 10.1016/S0885-3924(00)00256-6; Kumar Kamal, 2013, J Anaesthesiol Clin Pharmacol, V29, P303, DOI 10.4103/0970-9185.117045; LABELLA FS, 1978, LIFE SCI, V23, P1797, DOI 10.1016/0024-3205(78)90111-X; Lee JH, 2011, KOREAN J ANESTHESIOL, V60, P103, DOI 10.4097/kjae.2011.60.2.103; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Meylan N, 2009, BRIT J ANAESTH, V102, P156, DOI 10.1093/bja/aen368; Ngan Kee WD, 2010, CURR OPIN ANESTHESIO, V23, P304, DOI 10.1097/ACO.0b013e328337ffc6; Ngiam S. K. K., 1998, SMJ, V39, P290; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Qiu MT, 2012, CNS NEUROSCI THER, V18, P426, DOI 10.1111/j.1755-5949.2012.00306.x; Raffaeli W, 2006, EUR J ANAESTH, V23, P605, DOI 10.1017/S026502150600038X; RANDALLS B, 1991, BRIT J ANAESTH, V66, P314, DOI 10.1093/bja/66.3.314; Schmelz M, 2009, ANAESTHESIST, V58, P61, DOI 10.1007/s00101-008-1478-8; Shah MK, 2000, ANAESTHESIA, V55, P1008, DOI 10.1046/j.1365-2044.2000.01618-2.x; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Veena A, 2010, ANAESTH PAIN INTENSI, V14, P99; Vyas Nitika, 2010, J Anaesthesiol Clin Pharmacol, V26, P488; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	35	15	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152605	10.1371/journal.pone.0152605	http://dx.doi.org/10.1371/journal.pone.0152605			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27032092	Green Submitted, Green Published, gold			2023-01-03	WOS:000373121800101
J	Emokpae, AA; Mabogunje, CA; Imam, ZO; Olusanya, BO				Emokpae, Abieyuwa A.; Mabogunje, Cecilia A.; Imam, Zainab O.; Olusanya, Bolajoko O.			Heliotherapy for Neonatal Hyperbilirubinemia in Southwest, Nigeria: A Baseline Pre-Intervention Study	PLOS ONE			English	Article							FILTERED-SUNLIGHT; EXCHANGE TRANSFUSIONS; INTENSIVE-CARE; JAUNDICE; PHOTOTHERAPY; MANAGEMENT; NEWBORNS; KERNICTERUS; MORBIDITY; INFANTS	Background A novel filtered-sunlight phototherapy (FSPT) device has been demonstrated to be safe and efficacious for treating infants with neonatal jaundice in resource-constrained tropical settings. We set out to provide baseline data for evaluating the clinical impact of this device in a referral pediatric hospital. Methods We reviewed the medical records of infants admitted for neonatal hyperbilirubinemia in an inner-city Children's Hospital in Lagos, between January 2012 and December 2014 to determine the pattern, treatment and outcomes during the pre-intervention period. Factors associated with adverse outcomes were identified through multivariable logistic regression. Results Of the 5,229 neonatal admissions over the period, a total of 1,153 (22.1%) were admitted for neonatal hyperbilirubinemia. Complete records for 1,118 infants were available for analysis. The incidence of acute bilirubin encephalopathy (ABE) and exchange transfusion (ET) were 17.0% (95% CI: 14.9%-19.3%) and 31.5% (95% CI: 28.8%-34.3%) respectively. A total of 61 (5.5%, 95% CI: 4.3%-6.9%) of the jaundiced infants died. Weight on admission, peak total serum bilirubin (TSB), sepsis and exposure to hemolytic products were predictive of ABE, while age on admission, peak TSB, ABO incompatibility and ABE were predictive of ET. Rhesus incompatibility, asphyxia, exposure to hemolytic substances and ABE were associated with elevated mortality risk, while ET was a protective factor. Lack of routine irradiance monitoring and steady energy supply were frequent challenges for conventional blue-light phototherapy. Conclusions Severe hyperbilirubinemia is associated with high rates of ABE and ET in this setting, and remains a significant contributor to neonatal admissions and mortality. To be impactful, FSPT, complemented with improved diagnostic facilities, should effectively curtail jaundice-related adverse outcomes in this and comparable settings.	[Emokpae, Abieyuwa A.; Mabogunje, Cecilia A.; Imam, Zainab O.] Massey St Childrens Hosp, Lagos, Nigeria; [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, 286A Corp Dr, Lagos, Nigeria		Olusanya, BO (corresponding author), Ctr Hlth Start Initiat, 286A Corp Dr, Lagos, Nigeria.	bolajoko.olusanya@uclmail.net	Olusanya, Bolajoko O./F-4504-2012	Olusanya, Bolajoko O./0000-0002-3826-0583				Abu-Ekteish F, 2000, ANN TROP PAEDIATR, V20, P57, DOI 10.1080/02724930092084; American Academy of Pediatrics Subcommittee on Hyperbilirrubinemia, 2004, PEDIATRICS, V114, P297, DOI DOI 10.1542/PEDS.114.1.297; Basnet S, 2011, PEDIATRICS, V128, pE986, DOI 10.1542/peds.2010-3657; Bhutani VK, 2013, PEDIATR RES, V74, P86, DOI 10.1038/pr.2013.208; Bhutani VK, 2011, SEMIN PERINATOL, V35, P192, DOI 10.1053/j.semperi.2011.02.015; Burke BL, 2009, PEDIATRICS, V123, P524, DOI 10.1542/peds.2007-2915; Calado CS, 2009, PEDIATR EMERG CARE, V25, P244, DOI 10.1097/PEC.0b013e31819e361d; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; Cheesbrough M, 2006, DISTRICT LAB PRACTIC, P362; Chitty HE, 2013, J PAEDIATR CHILD H, V49, P825, DOI 10.1111/jpc.12290; Cline BK, 2013, J TROP PEDIATRICS, V59, P321, DOI 10.1093/tropej/fmt027; Disu EA, 2015, NIGER J CLIN PRACT, V18, P102, DOI 10.4103/1119-3077.146989; Gamaleldin R, 2011, PEDIATRICS, V128, pE925, DOI 10.1542/peds.2011-0206; Habib HS, 2013, JCPSP-J COLL PHYSICI, V23, P715, DOI 10.2013/JCPSP.715719; Hameed NN, 2011, NEONATOLOGY, V100, P57, DOI 10.1159/000321990; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hess Dean R, 2004, Respir Care, V49, P1171; Iskander I., 2012, Eastern Mediterranean Health Journal, V18, P882; Kaplan M, 2008, PEDIATR RES, V63, P109, DOI 10.1203/PDR.0b013e31815b8e7e; Mabogunje CA, 2016, WORLD J CLI IN PRESS; Maisels MJ, 2015, CAN MED ASSOC J, V187, P335, DOI 10.1503/cmaj.122117; Narang A, 2005, INDIAN PEDIATR, V42, P989; National Institute for Health and Clinical Excellence, 2010, NEON JAUND CLIN GUID; Ogunlesi T A, 2007, Niger J Med, V16, P354; Olusanya BO, 2016, NIGER J CLIN PRACT, V19, P1, DOI 10.4103/1119-3077.173703; Olusanya BO, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0358-z; Olusanya BO, 2014, ACTA PAEDIATR, V103, P1102, DOI 10.1111/apa.12735; Olusanya BO, 2014, ARCH DIS CHILD, V99, P1117, DOI 10.1136/archdischild-2013-305506; Olusanya BO, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-180; Opondo C, 2009, TROP MED INT HEALTH, V14, P1165, DOI 10.1111/j.1365-3156.2009.02358.x; Owa JA, 2009, WORLD J PEDIATR, V5, P51, DOI 10.1007/s12519-009-0009-2; Pejaver Ranjan Kumar, 2000, Indian Journal of Pediatrics, V67, P883, DOI 10.1007/BF02723951; Rasul CH, 2010, MALAYS J MED SCI, V17, P40; Salas AA, 2008, ACTA PAEDIATR, V97, P754, DOI 10.1111/j.1651-2227.2008.00743.x; Slusher TM, 2015, NEW ENGL J MED, V373, P1115, DOI 10.1056/NEJMoa1501074; Slusher TM, 2014, PEDIATRICS, V133, pE1568, DOI 10.1542/peds.2013-3500; SLUSHER TM, 1995, J PEDIATR-US, V126, P102, DOI 10.1016/S0022-3476(95)70510-4; Steiner LA, 2007, PEDIATRICS, V120, P27, DOI 10.1542/peds.2006-2910; Watchko JF, 2013, NEW ENGL J MED, V369, P2021, DOI 10.1056/NEJMra1308124; World Health Organization, 2013, POCK BOOK HOSP CAR C; Zhang L, 2015, MED SCI MONITOR, V21, P1668	41	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2016	11	3							e0151375	10.1371/journal.pone.0151375	http://dx.doi.org/10.1371/journal.pone.0151375			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3OX	27003893	Green Submitted, Green Published, gold			2023-01-03	WOS:000372697400031
J	Morgan, MSC; Pearle, MS				Morgan, Monica S. C.; Pearle, Margaret S.			Medical management of renal stones	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; URINARY OXALATE EXCRETION; LOW-ANIMAL-PROTEIN; KIDNEY-STONES; POTASSIUM CITRATE; JUICE CONSUMPTION; DIETARY-PROTEIN; ORANGE-JUICE; IDIOPATHIC HYPERCALCIURIA; CALCIUM NEPHROLITHIASIS	The prevalence of kidney stones is increasing in industrialized nations, resulting in a corresponding rise in economic burden. Nephrolithiasis is now recognized as both a chronic and systemic condition, which further underscores the impact of the disease. Diet and environment play an important role in stone disease, presumably by modulating urine composition. Dietary modification as a preventive treatment to decrease lithogenic risk factors and prevent stone recurrence has gained interest because of its potential to be safer and more economical than drug treatment. However, not all abnormalities are likely to be amenable to dietary therapy, and in some cases drugs are necessary to reduce the risk of stone formation. Unfortunately, no new drugs have been developed for stone prevention since the 1980s when potassium citrate was introduced, perhaps because the long observation period needed to demonstrate efficacy discourages investigators from embarking on clinical trials. Nonetheless, effective established treatment regimens are currently available for stone prevention.	[Morgan, Monica S. C.; Pearle, Margaret S.] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Pearle, MS (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.	margaret.pearle@utsouthwestern.edu						Ahlstrand C, 1995, RENAL STONES ASPECTS, P195; ALAOPAS M, 1987, SCAND J UROL NEPHROL, V21, P311, DOI 10.3109/00365598709180789; American Urological Association (AUA), 2014, MED MAN KIDN STON AU; Aras B, 2008, UROL RES, V36, P313, DOI 10.1007/s00240-008-0152-6; BARCELO P, 1993, J UROLOGY, V150, P1761, DOI 10.1016/S0022-5347(17)35888-3; Baxmann AC, 2003, KIDNEY INT, V63, P1066, DOI 10.1046/j.1523-1755.2003.00815.x; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; Borghi L, 1999, NEPHRON, V81, P31, DOI 10.1159/000046296; BORGHI L, 1993, J CARDIOVASC PHARM, V22, pS78; Borghi L, 1999, KIDNEY INT, V55, P2397, DOI 10.1046/j.1523-1755.1999.00483.x; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; BROCKS P, 1981, LANCET, V2, P124, DOI 10.1016/S0140-6736(81)90302-0; Bushinsky DA, 2001, AM J PHYSIOL-RENAL, V281, pF1058, DOI 10.1152/ajprenal.0355.2000; COE FL, 1977, ANN INTERN MED, V87, P404, DOI 10.7326/0003-4819-87-4-404; Coe FL, 2005, J CLIN INVEST, V115, P2598, DOI 10.1172/JCI26662; Curhan GC, 2004, ARCH INTERN MED, V164, P885, DOI 10.1001/archinte.164.8.885; Curhan GC, 1999, J AM SOC NEPHROL, V10, P840; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; Curhan GC, 2001, KIDNEY INT, V59, P2290, DOI 10.1046/j.1523-1755.2001.00746.x; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DeBerardinis RJ, 2008, J UROLOGY, V180, P2620, DOI 10.1016/j.juro.2008.08.057; Domrongkitchaiporn S, 2004, KIDNEY INT, V65, P1835, DOI 10.1111/j.1523-1755.2004.00587.x; Dussol B, 2008, NEPHRON CLIN PRACT, V110, pC185, DOI 10.1159/000167271; ETTINGER B, 1988, J UROLOGY, V139, P679, DOI 10.1016/S0022-5347(17)42599-7; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; Ettinger B, 1997, J UROLOGY, V158, P2069, DOI 10.1016/S0022-5347(01)68155-2; Fernandez-Rodriguez A, 2006, Actas Urol Esp, V30, P305; Ferraro PM, 2013, CLIN J AM SOC NEPHRO, V8, P1389, DOI 10.2215/CJN.11661112; Fink HA, 2013, ANN INTERN MED, V158, P535, DOI 10.7326/0003-4819-158-7-201304020-00005; Gettman MT, 2005, J UROLOGY, V174, P590, DOI 10.1097/01.ju.0000165168.68054.f8; Goldfarb DS, 2013, CLIN J AM SOC NEPHRO, V8, P1960, DOI 10.2215/CJN.01760213; Goldfarb DS, 2001, J UROLOGY, V166, P263, DOI 10.1016/S0022-5347(05)66142-3; Hatch M, 2006, KIDNEY INT, V69, P691, DOI 10.1038/sj.ki.5000162; Healy KA, 2013, J ENDOUROL, V27, P374, DOI 10.1089/end.2012.0216; Heller HJ, 1999, J AM COLL NUTR, V18, p373S, DOI 10.1080/07315724.1999.10718901; Hess B, 1998, NEPHROL DIAL TRANSPL, V13, P2241, DOI 10.1093/ndt/13.9.2241; Hiatt RA, 1996, AM J EPIDEMIOL, V144, P25, DOI 10.1093/oxfordjournals.aje.a008851; Holmes RP, 2004, UROL RES, V32, P311, DOI 10.1007/s00240-004-0437-3; Holmes RP, 2001, KIDNEY INT, V59, P270, DOI 10.1046/j.1523-1755.2001.00488.x; Honow R, 2003, BRIT J NUTR, V90, P295, DOI 10.1079/BJN2003897; Hoppe B, 2012, NAT REV NEPHROL, V8, P467, DOI 10.1038/nrneph.2012.113; HOSKING DH, 1983, J UROLOGY, V130, P1115, DOI 10.1016/S0022-5347(17)51711-5; Hoyer-Kuhn H, 2014, CLIN J AM SOC NEPHRO, V9, P468, DOI 10.2215/CJN.06820613; Huen SC, 2007, J UROLOGY, V177, P1238, DOI 10.1016/j.juro.2006.11.040; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; JAEGER P, 1986, NEW ENGL J MED, V315, P1120, DOI 10.1056/NEJM198610303151803; Kang DE, 2007, J UROLOGY, V177, P1358, DOI 10.1016/j.juro.2006.11.058; Kang DE, 2007, J UROLOGY, V177, P591; Kang DE, 2007, J UROLOGY, V177, P62; Kaufman DW, 2008, J AM SOC NEPHROL, V19, P1197, DOI 10.1681/ASN.2007101058; Knight J, 2007, UROL RES, V35, P111, DOI 10.1007/s00240-007-0090-8; Koff SG, 2007, UROLOGY, V69, P1013, DOI 10.1016/j.urology.2007.02.008; KOK DJ, 1990, J CLIN ENDOCR METAB, V71, P861, DOI 10.1210/jcem-71-4-861; Krishnamurthy MS, 2003, J UROLOGY, V169, P2030, DOI 10.1097/01.ju.0000062527.37579.49; LAERUM E, 1984, ACTA MED SCAND, V215, P383; Lemann J, 1999, NEPHRON, V81, P18; LINDELL A, 1995, NEPHRON, V71, P407, DOI 10.1159/000188760; Maalouf NM, 2011, J CLIN ENDOCR METAB, V96, P3733, DOI 10.1210/jc.2011-1531; Madore F, 1998, AM J HYPERTENS, V11, P46, DOI 10.1016/S0895-7061(97)00371-3; Matsumoto ED, 2006, J UROLOGY, V176, P132, DOI 10.1016/S0022-5347(06)00565-9; Mattoo A, 2008, SEMIN NEPHROL, V28, P181, DOI 10.1016/j.semnephrol.2008.01.011; Mendonca CDG, 2003, J RENAL NUTR, V13, P39, DOI 10.1053/jren.2003.50002; MICHELAKAKIS H, 1993, J INHERIT METAB DIS, V16, P1042, DOI 10.1007/BF00711523; Milose JC, 2014, J UROLOGY, V191, P376, DOI 10.1016/j.juro.2013.08.080; Mission Pharmacal, THIOL TIOPR TABL PAC; Moe OW, 2006, J NEPHROL, V19, pS53; MORTENSEN J T, 1986, International Urology and Nephrology, V18, P265, DOI 10.1007/BF02082712; Nayan M, 2012, CUAJ-CAN UROL ASSOC, V6, P30, DOI 10.5489/cuaj.11131; Ng C S, 2001, Curr Opin Urol, V11, P353, DOI 10.1097/00042307-200107000-00003; Ng CS, 1999, J ENDOUROL, V13, P647, DOI 10.1089/end.1999.13.647; NICAR MJ, 1984, J UROLOGY, V131, P430, DOI 10.1016/S0022-5347(17)50438-3; Noori N, 2014, AM J KIDNEY DIS, V63, P456, DOI 10.1053/j.ajkd.2013.11.022; NORMAN RW, 1990, J UROLOGY, V143, P1193, DOI 10.1016/S0022-5347(17)40222-9; Nouvenne A, 2010, AM J CLIN NUTR, V91, P565, DOI 10.3945/ajcn.2009.28614; Odvina CV, 2006, CLIN J AM SOC NEPHRO, V1, P1269, DOI 10.2215/CJN.00800306; OHKAWA M, 1992, BRIT J UROL, V69, P571, DOI 10.1111/j.1464-410X.1992.tb15624.x; Ortiz-Alvarado O, 2011, UROLOGY, V77, P1054, DOI 10.1016/j.urology.2010.08.002; Pak CYC, 2011, J UROLOGY, V185, P915, DOI 10.1016/j.juro.2010.10.067; PAK CYC, 1980, AM J MED, V69, P19, DOI 10.1016/0002-9343(80)90495-7; PAK CYC, 1986, J UROLOGY, V136, P1003, DOI 10.1016/S0022-5347(17)45188-3; Pak CYC, 2001, J UROLOGY, V165, P378, DOI 10.1097/00005392-200102000-00006; PAK CYC, 1986, KIDNEY INT, V30, P422, DOI 10.1038/ki.1986.201; Parks JH, 2002, J UROLOGY, V167, P1607, DOI 10.1016/S0022-5347(05)65163-4; Passman CM, 2009, J ENDOUROL, V23, P347, DOI 10.1089/end.2008.0225; Pearle MS, 2014, J UROLOGY, V192, P316, DOI 10.1016/j.juro.2014.05.006; Pearle MS, 2005, J UROLOGY, V173, P848, DOI 10.1097/01.ju.0000152082.14384.d7; PECES R, 1991, NEPHRON, V57, P421, DOI 10.1159/000186306; Penniston KL, 2007, UROLOGY, V70, P856, DOI 10.1016/j.urology.2007.06.1115; Rimer JD, 2010, SCIENCE, V330, P337, DOI 10.1126/science.1191968; RODMAN JS, 1984, CLIN NEPHROL, V22, P273; RODRIGUEZ LM, 1995, NEPHRON, V71, P416, DOI 10.1159/000188761; Romero Victoriano, 2010, Rev Urol, V12, pe86; Rule AD, 2009, CLIN J AM SOC NEPHRO, V4, P804, DOI 10.2215/CJN.05811108; Sahota A, 2012, J INHERIT METAB DIS, V35, pS27; Saigal CS, 2005, KIDNEY INT, V68, P1808, DOI 10.1111/j.1523-1755.2005.00599.x; Sakhaee K, 2012, J CLIN ENDOCR METAB, V97, P1847, DOI 10.1210/jc.2011-3492; Scales CD, 2007, J UROLOGY, V177, P979, DOI 10.1016/j.juro.2006.10.069; Scales CD, 2012, EUR UROL, V62, P160, DOI 10.1016/j.eururo.2012.03.052; Seltzer MA, 1996, J UROLOGY, V156, P907, DOI 10.1016/S0022-5347(01)65659-3; SHUSTER J, 1992, J CLIN EPIDEMIOL, V45, P911, DOI 10.1016/0895-4356(92)90074-W; SMITH MJV, 1977, J UROLOGY, V117, P690, DOI 10.1016/S0022-5347(17)58588-2; SOUCIE JM, 1994, KIDNEY INT, V46, P893, DOI 10.1038/ki.1994.347; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; Sumorok NT, 2012, UROL RES, V40, P237, DOI 10.1007/s00240-011-0418-2; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; Tang MH, 2008, AM J CLIN NUTR, V87, P1262, DOI 10.1093/ajcn/87.5.1262; Taylor EN, 2005, JAMA-J AM MED ASSOC, V293, P455, DOI 10.1001/jama.293.4.455; Taylor EN, 2005, KIDNEY INT, V68, P1230, DOI 10.1111/j.1523-1755.2005.00516.x; Taylor EN, 2013, J UROLOGY, V190, P1255, DOI 10.1016/j.juro.2013.03.074; Taylor EN, 2010, CLIN J AM SOC NEPHRO, V5, P2315, DOI 10.2215/CJN.04420510; Taylor EN, 2009, J AM SOC NEPHROL, V20, P2253, DOI 10.1681/ASN.2009030276; Terris MK, 2001, UROLOGY, V57, P26, DOI 10.1016/S0090-4295(00)00884-0; Tracy CR, 2014, J UROLOGY, V192, P137, DOI 10.1016/j.juro.2014.01.093; Traxer O, 2003, J UROLOGY, V170, P397, DOI 10.1097/01.ju.0000076001.21606.53; Turk C, 2016, EUR UROL, V69, P468, DOI 10.1016/j.eururo.2015.07.040; Turk C, 2011, 29 EAU ANN C STOCKH; URIBARRI J, 1989, ANN INTERN MED, V111, P1006, DOI 10.7326/0003-4819-111-12-1006; Von Unruh GE, 2004, J AM SOC NEPHROL, V15, P1567, DOI 10.1097/01.ASN.0000127864.26968.7F; WABNER CL, 1993, J UROLOGY, V149, P1405, DOI 10.1016/S0022-5347(17)36401-7; Wallace RB, 2011, AM J CLIN NUTR, V94, P270, DOI 10.3945/ajcn.110.003350; Yasui T, 2008, UROLOGY, V71, P209, DOI 10.1016/j.urology.2007.09.034; Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200; ZERWEKH JE, 1983, KIDNEY INT, V23, P838, DOI 10.1038/ki.1983.103; Zuckerman Jack M, 2009, Rev Urol, V11, P134	125	71	77	1	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	2016	352								i52	10.1136/bmj.i52	http://dx.doi.org/10.1136/bmj.i52			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH1XO	26977089				2023-01-03	WOS:000372578500015
J	Li, XH; Cui, J; Yu, Y; Li, W; Hou, YJ; Wang, X; Qin, DP; Zhao, C; Yao, XS; Zhao, J; Pei, G				Li, Xiaohang; Cui, Jin; Yu, Yang; Li, Wei; Hou, Yujun; Wang, Xin; Qin, Dapeng; Zhao, Cun; Yao, Xinsheng; Zhao, Jian; Pei, Gang			Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce beta-Amyloid Production and Improve Cognitive Impairments	PLOS ONE			English	Article							GAMMA-SECRETASE CLEAVAGE; PRECURSOR PROTEIN TRAFFICKING; TARGET-DIRECTED LIGANDS; ALZHEIMERS-DISEASE; THERAPEUTIC STRATEGIES; TRANSMEMBRANE DOMAIN; CASCADE HYPOTHESIS; MOUSE MODEL; WATER-MAZE; IN-VIVO	Decline of cognitive function is the hallmark of Alzheimer's disease (AD), regardless of the pathological mechanism. Traditional Chinese medicine has been used to combat cognitive impairments and has been shown to improve learning and memory. Radix Polygalae (RAPO) is a typical and widely used herbal medicine. In this study, we aimed to follow the beta-amyloid (A beta) reduction activity to identify active constituent(s) of RAPO. We found that Onjisaponin B of RAPO functioned as RAPO to suppress A beta production without direct inhibition of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and gamma-secretase activities. Our mechanistic study showed that Onjisaponin B promoted the degradation of amyloid precursor protein (APP). Further, oral administration of Onjisaponin B ameliorated A beta pathology and behavioral defects in APP/PS1 mice. Taken together, our results indicate that Onjisaponin B is effective against AD, providing a new therapeutic agent for further drug discovery.	[Li, Xiaohang; Cui, Jin; Li, Wei; Hou, Yujun; Wang, Xin; Zhao, Cun; Zhao, Jian; Pei, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai, Peoples R China; [Li, Xiaohang; Cui, Jin; Li, Wei; Wang, Xin; Zhao, Cun] Chinese Acad Sci, Univ Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Yu, Yang; Qin, Dapeng; Yao, Xinsheng] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou, Guangdong, Peoples R China; [Zhao, Jian] Tongji Univ, Shanghai East Hosp, Sch Med, Translat Med Ctr Stem Cell Therapy, Shanghai 200092, Peoples R China; [Pei, Gang] Tongji Univ, Collaborat Innovat Ctr Brain Sci, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Jinan University; Tongji University; Tongji University	Zhao, J; Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai, Peoples R China.; Zhao, J (corresponding author), Tongji Univ, Shanghai East Hosp, Sch Med, Translat Med Ctr Stem Cell Therapy, Shanghai 200092, Peoples R China.; Pei, G (corresponding author), Tongji Univ, Collaborat Innovat Ctr Brain Sci, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.	jzhao@sibs.ac.cn; gpei@sibs.ac.cn	Zhao, Jian/E-2008-2019; Hou, Yujun/AFX-2626-2022	Zhao, Jian/0000-0002-8862-0591; Hou, Yujun/0000-0003-1778-1176; Li, Xiaohang/0000-0002-7316-2196; Wang, Xin/0000-0001-6250-910X	National Natural Science Foundation of China [31371419]; Ministry of Health [2012BAI10B03]; Shanghai Municipal Commission for Science and Technology [13401900600, 14DZ1900402]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health; Shanghai Municipal Commission for Science and Technology	This research was supported by the National Natural Science Foundation of China (31371419), Ministry of Health (2012BAI10B03) and Shanghai Municipal Commission for Science and Technology (13401900600, 14DZ1900402).	Agholme L, 2012, J ALZHEIMERS DIS, V31, P343, DOI 10.3233/JAD-2012-120001; Agis-Torres A, 2014, CURR NEUROPHARMACOL, V12, P2, DOI 10.2174/1570159X113116660047; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Bai XF, 2009, THROMB HAEMOSTASIS, V102, P1212, DOI 10.1160/TH09-01-0038; Bajda M, 2011, CURR MED CHEM, V18, P4949, DOI 10.2174/092986711797535245; Baranello RJ, 2015, CURR ALZHEIMER RES, V12, P32, DOI 10.2174/1567205012666141218140953; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; Cavieres VA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136313; Cheong MH, 2011, J ETHNOPHARMACOL, V137, P1402, DOI 10.1016/j.jep.2011.08.008; Choi JG, 2011, J ETHNOPHARMACOL, V134, P414, DOI 10.1016/j.jep.2010.12.030; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cui J, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.21; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 2015, ANNU REV PHARMACOL, V55, P419, DOI 10.1146/annurev-pharmtox-010814-124309; Di Domenico F, 2013, BBA-MOL BASIS DIS, V1832, P1249, DOI 10.1016/j.bbadis.2013.04.013; El Ayadi A, 2012, P NATL ACAD SCI USA, V109, P13416, DOI 10.1073/pnas.1206786109; Gallagher JJ, 2013, NEURODEGENER DIS, V11, P33, DOI 10.1159/000337458; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; GIANNAKOPOULOS P, 1994, ACTA NEUROPATHOL, V87, P456; Guzior N, 2015, CURR MED CHEM, V22, P373; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HEINONEN O, 1995, NEUROSCIENCE, V64, P375, DOI 10.1016/0306-4522(94)00422-2; Hiltunen M, 2006, J BIOL CHEM, V281, P32240, DOI 10.1074/jbc.M603106200; Hou YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111215; Imbimbo BP, 2011, CURR TOP MED CHEM, V11, P1555; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Jardanhazi-Kurutz D, 2010, NEUROCHEM INT, V57, P375, DOI 10.1016/j.neuint.2010.02.001; Jiang Yong LJ, China patent CN, Patent No. [1315497C. 2005 2005-07-20, 1315497C]; Jung ES, 2015, SCI REP-UK, V5, DOI 10.1038/srep08805; Karakida F, 2007, BIOL PHARM BULL, V30, P514, DOI 10.1248/bpb.30.514; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin ZH, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/692621; Liu P, 2010, PHYTOMEDICINE, V17, P794, DOI 10.1016/j.phymed.2010.01.004; Liu P, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/642128; Liu XS, 2013, CELL RES, V23, P351, DOI 10.1038/cr.2012.167; May BH, 2013, J ACUPUNCT MERIDIAN, V6, P2, DOI 10.1016/j.jams.2012.11.009; McKinnon C, 2014, ANTIOXID REDOX SIGN, V21, P2302, DOI 10.1089/ars.2013.5802; Mitani Y, 2012, J NEUROSCI, V32, P2037, DOI 10.1523/JNEUROSCI.4264-11.2012; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni YX, 2006, NAT MED, V12, P1390, DOI 10.1038/nm1485; Nijholt DAT, 2011, CURR MED CHEM, V18, P2459; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Oh JJ, 2013, TROP J PHARM RES, V12, P755, DOI 10.4314/tjpr.v12i5.14; Parihar MS, 2004, J CLIN NEUROSCI, V11, P456, DOI 10.1016/j.jocn.2003.12.007; Reiserer RS, 2007, GENES BRAIN BEHAV, V6, P54, DOI 10.1111/j.1601-183X.2006.00221.x; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; Sommer B, 2002, CURR OPIN PHARMACOL, V2, P87, DOI 10.1016/S1471-4892(01)00126-6; Steinhilb ML, 2002, J NEUROCHEM, V80, P1019, DOI 10.1046/j.0022-3042.2002.00764.x; Sun Yan, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P1199; Sun ZK, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-6; Svedruzic ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050759; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Tomita Taisuke, 2012, Rinsho Shinkeigaku, V52, P1165; Villegas S, 2015, MED CLIN-BARCELONA, V145, P76, DOI 10.1016/j.medcli.2014.05.023; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang X, 2015, J ALZHEIMERS DIS, V47, P927, DOI 10.3233/JAD-150313; Wang Y, 2015, J ALZHEIMERS DIS, V45, P1185, DOI 10.3233/JAD-143183; Watanabe T, 2012, J NEUROSCI, V32, P3352, DOI 10.1523/JNEUROSCI.5659-11.2012; Wehr MC, 2006, NAT METHODS, V3, P985, DOI 10.1038/nmeth967; Weitz TM, 2014, AM J PATHOL, V184, P2855, DOI 10.1016/j.ajpath.2014.07.004; West S, 2015, BRIT J CLIN PHARMACO, V80, P221, DOI 10.1111/bcp.12621; Wu AG, 2013, INT J MOL SCI, V14, P22618, DOI 10.3390/ijms141122618; Yabe T, 1997, PHYTOMEDICINE, V4, P199, DOI 10.1016/S0944-7113(97)80068-2; Yin YI, 2007, J BIOL CHEM, V282, P23639, DOI 10.1074/jbc.M704601200; Younkin SG, 1991, BRAIN PATHOL, V1, P253, DOI 10.1111/j.1750-3639.1991.tb00668.x; Zhang H, 2008, PHYTOMEDICINE, V15, P587, DOI 10.1016/j.phymed.2007.12.004; Zhao H, 2015, MOL MED REP, V12, P2771, DOI 10.3892/mmr.2015.3781	77	33	46	3	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0151147	10.1371/journal.pone.0151147	http://dx.doi.org/10.1371/journal.pone.0151147			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26954017	Green Submitted, gold, Green Published			2023-01-03	WOS:000371991300088
J	Richards, C				Richards, Cecile			Protecting and Expanding Access to Birth Control	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Richards, Cecile] Planned Parenthood Federat Amer & Planned Parenth, New York, NY USA		Richards, C (corresponding author), Planned Parenthood Federat Amer & Planned Parenth, New York, NY USA.							Becker NV, 2015, HEALTH AFFAIR, V34, P1204, DOI 10.1377/hlthaff.2015.0127; Department of Health and Human Services, 2015, ASPE DAT POINT AFF C; Kost K, 2014, US TEENAGE PREGNANCI; Thompson KM, 2016, AM J PUBLIC HLTH	4	5	5	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	2016	374	9					801	803		10.1056/NEJMp1601150	http://dx.doi.org/10.1056/NEJMp1601150			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DF2FT	26962898				2023-01-03	WOS:000371158400001
J	Agarwal, A; Zhang, W; Kuo, YF; Sharma, G				Agarwal, Amitesh; Zhang, Wei; Kuo, YongFang; Sharma, Gulshan			Process and Outcome Measures among COPD Patients with a Hospitalization Cared for by an Advance Practice Provider or Primary Care Physician	PLOS ONE			English	Article							NURSE-PRACTITIONERS; GENERAL-PRACTITIONERS; ASSISTANTS; READMISSION; COST	Objectives To examine the process and outcomes of care of COPD patients by Advanced Practice Providers (APPs) and primary care physicians. Methods We conducted a cross sectional retrospective cohort study of Medicare beneficiaries with COPD who had at least one hospitalization in 2010. We examined the process measures of receipt of spirometry evaluation, influenza and pneumococcal vaccine, use of COPD medications, and referral to a pulmonary specialist visit. Outcome measures were emergency department (ER) visit, number of hospitalizations and 30-day readmission in 2010. Results A total of 7,257 Medicare beneficiaries with COPD were included. Of these, 1,999 and 5,258 received primary care from APPs and primary care physicians, respectively. Patients in the APP group were more likely to be white, younger, male, residing in non-metropolitan areas and have fewer comorbidities. In terms of process of care measures, APPs were more likely to prescribe short acting bronchodilators (adjusted odds ratio [aOR] = 1.18, 95% Confidence Interval [CI] 1.05-1.32), oxygen therapy (aOR = 1.25, 95% CI 1.12-1.40) and consult a pulmonary specialist (aOR = 1.39, 95% CI 1.23-1.56), but less likely to give influenza and pneumococcal vaccinations. Patients receiving care from APPs had lower rates of ER visits for COPD (aOR = 0.84, 95% CI 0.71-0.98) and had a higher follow-up rate with pulmonary specialist within 30 days of hospitalization for COPD (aOR = 1.25, 95% CI 1.07-1.48) than those cared for by physicians. Conclusions Compared to patients cared for by physicians, patients cared for by APPs were more likely to receive short acting bronchodilator, oxygen therapy and been referred to pulmonologist, however they had lower rates of vaccination probably due to lower age group. Patients cared for by APPs were less like to visit an ER for COPD compared to patients care for by physicians, conversely there was no differences in hospitalization or readmission for COPD between MDs and APPs.	[Agarwal, Amitesh; Zhang, Wei; Sharma, Gulshan] Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA; [Kuo, YongFang] Univ Texas Med Branch, Off Biostat, Galveston, TX 77555 USA; [Kuo, YongFang; Sharma, Gulshan] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Agarwal, A (corresponding author), Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA.	anagarwa@utmb.edu	Sharma, Gulshan/AAC-5804-2019		Agency for Healthcare Research and Quality [R01-HS020642, R24-HS022134]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS020642, R24HS022134] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by the Agency for Healthcare Research and Quality R01-HS020642 and R24-HS022134.	Chen PGC, 2014, MED CARE, V52, P95, DOI 10.1097/MLR.0000000000000046; Costa DK, 2014, CHEST, V146, P1566, DOI 10.1378/chest.14-0566; DesRoches CM, 2013, NURS OUTLOOK, V61, P400, DOI 10.1016/j.outlook.2013.05.005; Dierick-van Daele ATM, 2009, J ADV NURS, V65, P391, DOI 10.1111/j.1365-2648.2008.04888.x; Everett C, 2013, HEALTH AFFAIR, V32, P1942, DOI 10.1377/hlthaff.2013.0506; Fairman JA, 2011, NEW ENGL J MED, V364, P193, DOI 10.1056/NEJMp1012121; Fordyce MA., 2007, 2005 PHYS SUPPLY DIS; Gavish R, 2015, CHEST, V148, P375, DOI 10.1378/chest.14-1453; Hollinghurst S, 2006, BRIT J GEN PRACT, V56, P530; Hooker RS, 2012, HEALTH SOC CARE COMM, V20, P20, DOI 10.1111/j.1365-2524.2011.01021.x; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; Huang ES, 2013, HEALTH AFFAIR, V32, P614, DOI 10.1377/hlthaff.2012.0913; Hughes DR, 2015, JAMA INTERN MED, V175, P101, DOI 10.1001/jamainternmed.2014.6349; Iglehart JK, 2013, NEW ENGL J MED, V368, P1935, DOI 10.1056/NEJMhpr1301084; Jennings JH, 2014, CHEST J; Kuo YF, 2013, HEALTH AFFAIR, V32, P1236, DOI 10.1377/hlthaff.2013.0072; Laurant M, 1996, COCHRANE DATABASE OF; Lenz ER, 2002, DIABETES EDUCATOR, V28, P590, DOI 10.1177/014572170202800413; Litaker David, 2003, J Interprof Care, V17, P223, DOI 10.1080/1356182031000122852; Martinez-Gonzalez NA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-214; Mittman DE, 2002, BMJ-BRIT MED J, V325, P485, DOI 10.1136/bmj.325.7362.485; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; Newhouse R. P., 2011, NURSING EC, V29, P230; Petterson SM, 2012, ANN FAM MED, V10, P503, DOI 10.1370/afm.1431; Phillips RL, 2014, MED CARE, V52, P97, DOI 10.1097/MLR.0000000000000047; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048	28	14	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2016	11	2							e0148522	10.1371/journal.pone.0148522	http://dx.doi.org/10.1371/journal.pone.0148522			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF2IA	26910566	gold, Green Published, Green Submitted			2023-01-03	WOS:000371164700008
J	Kol, A; Walker, NJ; Nordstrom, M; Borjesson, DL				Kol, A.; Walker, N. J.; Nordstrom, M.; Borjesson, D. L.			Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; INFLAMMATORY-BOWEL-DISEASE; T-CELLS; HEALTHY DOGS; IN-VITRO; DIFFERENTIATION; EXPRESSION; CYTOKINE; BLOOD; TISSUES	Detrimental Th17 driven inflammatory and autoimmune disease such as Crohn's disease, graft versus host disease and multiple sclerosis remain a significant cause of morbidity and mortality worldwide. Multipotent stromal/stem cell (MSC) inhibit Th17 polarization and activation in vitro and in rodent models. As such, MSC based therapeutic approaches are being investigated as novel therapeutic approaches to treat Th17 driven diseases in humans. The significance of naturally occurring diseases in dogs is increasingly recognized as a realistic platform to conduct pre-clinical testing of novel therapeutics. Full characterization of Th17 cells in dogs has not been completed. We have developed and validated a flow-cytometric method to detect Th17 cells in canine blood. We further demonstrate that Th17 and other IL17 producing cells are present in tissues of dogs with naturally occurring chronic inflammatory diseases. Finally, we have determined the kinetics of a canine specific Th17 polarization in vitro and demonstrate that canine MSC inhibit Th17 polarization in vitro, in a PGE2 independent mechanism. Our findings provide fundamental research tools and suggest that naturally occurring diseases in dogs, such as inflammatory bowel disease, may be harnessed to translate novel MSC based therapeutic strategies that target the Th17 pathway.	[Kol, A.; Walker, N. J.; Nordstrom, M.; Borjesson, D. L.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California Davis	Borjesson, DL (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.	dlborjesson@ucdavis.edu		Kol, Amir/0000-0003-2324-6962	Center of Companion Animal Health, UC Davis School of Veterinary Medicine [2015-06-F]; California Institute for Regenerative Medicine's Stem Cell Training Program; ARCS foundation	Center of Companion Animal Health, UC Davis School of Veterinary Medicine; California Institute for Regenerative Medicine's Stem Cell Training Program; ARCS foundation	This work was supported by the Center of Companion Animal Health, UC Davis School of Veterinary Medicine (Grant # 2015-06-F) and a generous gift from Mr. Dick and Carolyn Randall. AK was supported by the California Institute for Regenerative Medicine's Stem Cell Training Program and a scholarship from the ARCS foundation.	Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Awano T, 2009, P NATL ACAD SCI USA, V106, P2794, DOI [10.1073/pnas.0905845106, 10.1073/pnas.0812297106]; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chao K, 2014, J GASTROEN HEPATOL, V29, P1808, DOI 10.1111/jgh.12592; Chatterjee D, 2014, BLOOD, V123, P594, DOI 10.1182/blood-2013-09-524827; Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood-2008-05-155408; Clark KC, 2015, STEM CELL REV; Collins FS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002747; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Eysteinsdottir JH, 2013, SCAND J IMMUNOL, V78, P529, DOI 10.1111/sji.12114; Fellman CL, 2011, VET IMMUNOL IMMUNOP, V140, P175, DOI 10.1016/j.vetimm.2010.11.005; Firth FA, 2015, ARCH DERMATOL RES, V307, P333, DOI 10.1007/s00403-015-1540-8; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Ghannam S, 2010, J IMMUNOL, V185, P302, DOI 10.4049/jimmunol.0902007; Gullick NJ, 2013, CLIN EXP IMMUNOL, V174, P292, DOI 10.1111/cei.12167; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Honkanen J, 2010, J IMMUNOL, V185, P1959, DOI 10.4049/jimmunol.1000788; Igarashi H, 2015, VET IMMUNOL IMMUNOP, V164, P160, DOI 10.1016/j.vetimm.2015.02.005; Jain P, 2012, HAEMATOL-HEMATOL J, V97, P599, DOI 10.3324/haematol.2011.047316; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kenealy SJ, 2003, J NEUROIMMUNOL, V143, P7, DOI [10.1016/j.jneuroim.2003.08.005, 10.1016/j.jneuroim.2003.08.009]; Knights D, 2013, GUT, V62, P1505, DOI 10.1136/gutjnl-2012-303954; Kol A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9116; Kol A, 2014, STEM CELLS DEV, V23, P1831, DOI 10.1089/scd.2014.0128; Kondo T, 2009, J IMMUNOL, V182, P1794, DOI 10.4049/jimmunol.0801347; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Lin S, 2014, P NATL ACAD SCI USA, V111, P17224, DOI 10.1073/pnas.1413624111; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Liu XX, 2015, IMMUNOL RES, V61, P219, DOI 10.1007/s12026-014-8612-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53; Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216; Marinoni B, 2014, AUTOIMMUN HIGHLIGHTS, V5, P9, DOI 10.1007/s13317-013-0057-4; McGeachy MJ, 2013, J LEUKOCYTE BIOL, V94, P921, DOI 10.1189/jlb.0313113; Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022; Obermajer N, 2014, J IMMUNOL, V193, P4988, DOI 10.4049/jimmunol.1401776; Ohta H, 2013, VET IMMUNOL IMMUNOP, V155, P259, DOI 10.1016/j.vetimm.2013.07.006; Olsson M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001332; Park ES, 2013, VET PATHOL, V50, P1127, DOI 10.1177/0300985813488957; Paulissen SMJ, 2013, J IMMUNOL, V191, P1364, DOI 10.4049/jimmunol.1300274; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Pianta S, 2014, STEM CELL REV; Raychaudhuri SK, 2015, CLIN RHEUMATOL; Rei M, 2015, CANCER RES, V75, P798, DOI 10.1158/0008-5472.CAN-14-3228; Schmitz S, 2014, SCAND J IMMUNOL, V80, P85, DOI 10.1111/sji.12186; Schmitz S, 2012, VET IMMUNOL IMMUNOP, V146, P87, DOI 10.1016/j.vetimm.2012.01.013; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039333; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Valli JL, 2010, VET IMMUNOL IMMUNOP, V134, P218, DOI 10.1016/j.vetimm.2009.09.023; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wang GD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2814; Wilbe M, 2010, NAT GENET, V42, P250, DOI 10.1038/ng.525; Xu H, 2012, MUCOSAL IMMUNOL, V5, P658, DOI 10.1038/mi.2012.39; Yamamoto K, 2015, NAT REV RHEUMATOL, V11, P375, DOI 10.1038/nrrheum.2015.7; Yen HR, 2009, J IMMUNOL, V183, P7161, DOI 10.4049/jimmunol.0900368; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zerhouni EA, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000341	63	16	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148568	10.1371/journal.pone.0148568	http://dx.doi.org/10.1371/journal.pone.0148568			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26872054	Green Published, gold			2023-01-03	WOS:000370054100037
J	Xu, Y; Ji, RJ; Wei, RL; Yin, B; He, FP; Luo, BY				Xu, Yang; Ji, Renjie; Wei, Ruili; Yin, Bo; He, Fangping; Luo, Benyan			The Efficacy of Hyperbaric Oxygen Therapy on Middle Cerebral Artery Occlusion in Animal Studies: A Meta-Analysis	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RAT MODEL; HEMORRHAGIC TRANSFORMATION; EMBOLIC STROKE; INFARCT VOLUME; MCAO RATS; REPERFUSION INJURY; OXIDATIVE DAMAGE; BRAIN ISCHEMIA	Background Inconsistent results have been reported for hyperbaric oxygen therapy (HBO) for acute stroke. We conducted a systematic review and meta-analysis to evaluate the benefit of HBO in animal studies of middle cerebral artery occlusion (MCAO). Methods A systematic search of the literature published prior to September 2015 was performed using Embase, Medline (OvidSP), Web of Science and PubMed. Keywords included "hyperoxia" OR "hyperbaric oxygen" OR "HBO" AND "isch(a)emia" OR "focal cerebral ischemia" OR "stroke" OR "infarct" OR "middle cerebral artery occlusion (MCAO)." The primary endpoints were the infarct size and/or neurological outcome score evaluated after HBO treatment in MCAO. Heterogeneity was analyzed using Cochrane Library's RevMan 5.3.5. Results Fifty-one studies that met the inclusion criteria were identified among the 1198 studies examined. When compared with control group data, HBO therapy resulted in infarct size reduction or improved neurological function (32% decrease in infarct size; 95% confidence interval (CI), range 28%-37%; p < 0.00001). Mortality was 18.4% in the HBO group and 26.7% in the control group (RR 0.72, 95% CI, 0.54-0.98; p = 0.03). Subgroup analysis showed that a maximal neuro-protective effect was reached when HBO was administered immediately after MCAO with an absolute atmospheric pressure (ATA) of 2.0 (50% decrease; 95% CI, 43% -57% decrease; p < 0.0001) and more than 6 hours HBO treatment (53% decrease; 95% CI, 41%-64% decrease; p = 0.0005). Conclusions HBO had a neuro-protective effect and improved survival in animal models of MCAO, especially in animals given more than 6 hours of HBO and when given immediately after MCAO with 2.0 ATA.	[Xu, Yang; Ji, Renjie; Wei, Ruili; He, Fangping; Luo, Benyan] Zhejiang Univ, Affiliated Hosp 1, Brain Med Ctr, Sch Med,Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China; [Yin, Bo] Wuhan Univ, Renmin Hosp, Dept Neurol, Wuhan 430072, Peoples R China	Zhejiang University; Wuhan University	Luo, BY (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Brain Med Ctr, Sch Med,Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China.	luobenyan@zju.edu.cn	Yang, Xu/AGR-8189-2022; mohamady, mahin/G-2175-2016	Yang, Xu/0000-0001-8778-3885; 	National Natural Science Foundation of China [81271272]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81271272) by BL. The funder designed the experiments and made the decision to publish.	Acka G, 2007, PHYSIOL RES, V56, P369, DOI 10.33549/physiolres.930907; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; Badr AE, 2001, AM J PHYSIOL-REG I, V280, pR766, DOI 10.1152/ajpregu.2001.280.3.R766; Badr AE, 2001, BRAIN RES, V916, P85, DOI 10.1016/S0006-8993(01)02867-0; Beynon C, 2007, NEUROSCI LETT, V425, P141, DOI 10.1016/j.neulet.2007.07.009; Bian HT, 2015, EXP NEUROL, V265, P22, DOI 10.1016/j.expneurol.2014.12.016; Carson S, 2005, CLIN REHABIL, V19, P819, DOI 10.1191/0269215505cr907oa; Chang CF, 2000, EXP NEUROL, V166, P298, DOI 10.1006/exnr.2000.7506; Chavko M, 2001, BRAIN RES, V900, P227, DOI 10.1016/S0006-8993(01)02301-0; Chen CH, 2012, SCI WORLD J, DOI 10.1100/2012/694703; Chen LF, 2014, J FORMOS MED ASSOC, V113, P620, DOI 10.1016/j.jfma.2014.03.012; Sanchez EC, 2013, CRIT CARE NURS Q, V36, P290, DOI 10.1097/CNQ.0b013e318294e9e3; Demchenko IT, 2000, NITRIC OXIDE-BIOL CH, V4, P597, DOI 10.1006/niox.2000.0313; Edwards Dorothy F, 2006, J Stroke Cerebrovasc Dis, V15, P151, DOI 10.1016/j.jstrokecerebrovasdis.2006.04.001; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Eschenfelder CC, 2008, CEREBROVASC DIS, V25, P193, DOI 10.1159/000113856; Garcia-Covarrubias L, 2000, Gac Med Mex, V136, P45; Gu GJ, 2008, J APPL PHYSIOL, V104, P1185, DOI 10.1152/japplphysiol.00323.2007; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Harman F, 2012, NEUROSCIENCES, V17, P121; Henninger N, 2006, EXP NEUROL, V201, P316, DOI 10.1016/j.expneurol.2006.04.011; Hou HH, 2007, PHYSIOL MEAS, V28, P963, DOI 10.1088/0967-3334/28/8/017; Huang KL, 2000, NEUROSCI LETT, V293, P159, DOI 10.1016/S0304-3940(00)01493-2; Huang ZX, 2007, BRAIN RES, V1153, P204, DOI 10.1016/j.brainres.2007.03.061; Imai K, 2006, NEUROL MED-CHIR, V46, P373, DOI 10.2176/nmc.46.373; [蒋杞英 Jiang Jiying], 2006, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V21, P890; KAWAMURA S, 1990, SURG NEUROL, V34, P101, DOI 10.1016/0090-3019(90)90104-W; Korkmaz A, 2008, NEUROCHEM RES, V33, P160, DOI 10.1007/s11064-007-9428-4; Kuppers-Tiedt L, 2011, ACTA NEUROCHIR SUPPL, V111, P167, DOI 10.1007/978-3-7091-0693-8_28; Lei XM, 2015, MOL MED REP, V12, P3688, DOI 10.3892/mmr.2015.3857; Li JS, 2009, NEUROSCIENCE, V159, P1309, DOI 10.1016/j.neuroscience.2009.01.011; Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007; Li Z, 2008, BRAIN RES, V1196, P151, DOI 10.1016/j.brainres.2007.12.039; Liu JR, 2010, NEUROPATH APPL NEURO, V36, P211, DOI 10.1111/j.1365-2990.2009.01047.x; Liu R, 2013, BRAIN RES, V1514, P83, DOI 10.1016/j.brainres.2013.01.023; Lou M, 2007, NEUROSCIENCE, V146, P555, DOI 10.1016/j.neuroscience.2007.01.046; Lou M, 2006, BRAIN RES BULL, V69, P109, DOI 10.1016/j.brainresbull.2005.11.009; Lou M, 2004, STROKE, V35, P578, DOI 10.1161/01.STR.0000111599.77426.A0; Lu YX, 2014, EUR J PHARMACOL, V728, P93, DOI 10.1016/j.ejphar.2014.01.066; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; Mu J, 2013, NEUROBIOL DIS, V51, P133, DOI 10.1016/j.nbd.2012.11.003; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Pablos MI, 1997, J APPL PHYSIOL, V83, P354, DOI 10.1152/jappl.1997.83.2.354; Paciaroni M, 2009, EUR NEUROL, V61, P321, DOI 10.1159/000210544; Prass K, 2000, BRAIN RES, V871, P146, DOI 10.1016/S0006-8993(00)02264-2; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Rink C, 2010, J CEREBR BLOOD F MET, V30, P1275, DOI 10.1038/jcbfm.2010.7; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; Schabitz WR, 2004, STROKE, V35, P1175, DOI 10.1161/01.STR.0000125868.86298.8e; Sena E, 2007, STROKE, V38, P388, DOI 10.1161/01.STR.0000254462.75851.22; Soejima Y, 2013, EXP NEUROL, V247, P737, DOI 10.1016/j.expneurol.2013.03.019; Soejima Y, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-9; Sun L, 2008, STROKE, V39, P1000, DOI 10.1161/STROKEAHA.107.490599; Sun L, 2014, NEUROSCI LETT, V577, P1, DOI 10.1016/j.neulet.2014.05.060; Sun L, 2011, BRAIN RES, V1415, P103, DOI 10.1016/j.brainres.2011.07.064; Sunami K, 2000, CRIT CARE MED, V28, P2831, DOI 10.1097/00003246-200008000-00025; Veltkamp R, 2005, BRAIN RES, V1037, P134, DOI 10.1016/j.brainres.2005.01.006; Veltkamp R, 2000, BRAIN RES, V853, P68, DOI 10.1016/S0006-8993(99)02250-7; Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79; Veltkamp R, 2006, BRAIN RES, V1107, P185, DOI 10.1016/j.brainres.2006.05.108; Wang RY, 2012, EUR J APPL PHYSIOL, V112, P215, DOI 10.1007/s00421-011-1976-2; WEINSTEIN PR, 1987, NEUROSURGERY, V20, P518, DOI 10.1227/00006123-198704000-00002; Xiong LZ, 2000, CHINESE MED J-PEKING, V113, P836; Xue LB, 2008, NEUROL RES, V30, P389, DOI 10.1179/174313208X300413; Yan WJ, 2013, J CEREBR BLOOD F MET, V33, P396, DOI 10.1038/jcbfm.2012.179; Yan WJ, 2011, BRAIN RES, V1402, P109, DOI 10.1016/j.brainres.2011.05.049; Yang ZJ, 2010, EUR J APPL PHYSIOL, V108, P513, DOI 10.1007/s00421-009-1229-9; Yin DL, 2005, NEUROCRIT CARE, V2, P206, DOI 10.1385/NCC:2:2:206; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Yin W, 2002, BRAIN RES, V926, P165, DOI 10.1016/S0006-8993(01)03304-2; Zhou Jian-Guang, 2012, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V28, P38	72	11	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148324	10.1371/journal.pone.0148324	http://dx.doi.org/10.1371/journal.pone.0148324			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859390	Green Published, Green Submitted, gold			2023-01-03	WOS:000370038400031
J	Faisy, C; Meziani, F; Planquette, B; Clavel, M; Gacouin, A; Bornstain, C; Schneider, F; Duguet, A; Gibot, S; Lerolle, N; Ricard, JD; Sanchez, O; Djibre, M; Ricome, JL; Rabbat, A; Heming, N; Urien, S; Esvan, M; Katsahian, S				Faisy, Christophe; Meziani, Ferhat; Planquette, Benjamin; Clavel, Marc; Gacouin, Arnaud; Bornstain, Caroline; Schneider, Francis; Duguet, Alexandre; Gibot, Sebastien; Lerolle, Nicolas; Ricard, Jean-Damien; Sanchez, Olivier; Djibre, Michel; Ricome, Jean-Louis; Rabbat, Antoine; Heming, Nicholas; Urien, Saik; Esvan, Maxime; Katsahian, Sandrine		DIABOLO Investigators	Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-FAILURE; THERAPEUTIC APPLICATIONS; CARBONIC-ANHYDRASES; METABOLIC ALKALOSIS; ACUTE EXACERBATIONS; BICARBONATE; INHIBITORS	IMPORTANCE Acetazolamide has been used for decades as a respiratory stimulant for patients with chronic obstructive pulmonary disease (COPD) and metabolic alkalosis, but no large randomized placebo-controlled trial is available to confirm this approach. OBJECTIVE To determine whether acetazolamide reduces mechanical ventilation duration in critically ill patients with COPD and metabolic alkalosis. DESIGN, SETTING, AND PARTICIPANTS The DIABOLO study, a randomized, double-blind, multicenter trial, was conducted from October 2011 through July 2014 in 15 intensive care units (ICUs) in France. A total of 382 patients with COPD who were expected to receive mechanical ventilation for more 24 hours were randomized to the acetazolamide or placebo group and 380 were included in an intention-to treat analysis. INTERVENTIONS Acetazolamide (500-1000 mg, twice daily) vs placebo administered intravenously in cases of pure or mixed metabolic alkalosis, initiated within 48 hours of ICU admission and continued during the ICU stay for a maximum of 28 days. MAIN OUTCOMES AND MEASURES The primary outcome was the duration of invasive mechanical ventilation via endotracheal intubation or tracheotomy. Secondary outcomes included changes in arterial blood gas and respiratory parameters, weaning duration, adverse events, use of noninvasive ventilation after extubation, successful weaning, the duration of ICU stay, and in-ICU mortality. RESULTS Among 382 randomized patients, 380 (mean age, 69 years; 272 men[71.6%]; 379 [99.7%] with endotracheal intubation) completed the study. For the acetazolamide group (n = 187), compared with the placebo group (n = 193), no significant between-group differences were found for median duration of mechanical ventilation (-16.0 hours; 95% CI, -36.5 to 4.0 hours; P = .17), duration of weaning off mechanical ventilation (-0.9 hours; 95% CI, -4.3 to 1.3 hours; P = .36), daily changes of minute-ventilation (-0.0L/min; 95% CI, -0.2 to 0.2 L/min; P = .72), or partial carbon-dioxide pressure in arterial blood (-0.3 mm Hg; 95% CI, -0.8 to 0.2 mm Hg; P = .25), although daily changes of serum bicarbonate (between-group difference, -0.8 mEq/L; 95% CI, -1.2 to -0.5 mEq/L; P < .001) and number of days with metabolic alkalosis (between-group difference, -1; 95% CI, -2 to -1 days; P < .001) decreased significantly more in the acetazolamide group. Other secondary outcomes also did not differ significantly between groups. CONCLUSIONS AND RELEVANCE Among patients with COPD receiving invasive mechanical ventilation, the use of acetazolamide, compared with placebo, did not result in a statistically significant reduction in the duration of invasive mechanical ventilation. However, the magnitude of the difference was clinically important, and it is possible that the study was underpowered to establish statistical significance.	[Faisy, Christophe; Sanchez, Olivier; Heming, Nicholas; Esvan, Maxime; Katsahian, Sandrine] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Paris, France; [Meziani, Ferhat] Hop Univ Strasbourg, Med Intens Care Unit, Nouvel Hop Civil, Strasbourg, France; [Meziani, Ferhat] Strasbourg Univ, Federat Med Translat Strasbourg, EA 7293, Strasbourg, France; [Planquette, Benjamin] Andre Mignot Hosp, Medicosurg Intens Care Unit, Le Chesnay, France; [Clavel, Marc] Limoges Univ Hosp, Med Intens Care Unit, Limoges, France; [Gacouin, Arnaud] Rennes Univ Hosp, Med Intens Care Unit, Rennes, France; [Bornstain, Caroline] Le Raincy Montfermeil Hosp, Med Intens Care Unit, Montfermeil, France; [Schneider, Francis] Hautepierre Hosp, Strasbourg Med Intens Care Unit, Strasbourg, France; [Duguet, Alexandre] Hop La Pitie Salpetriere, Dept Resp & Intens Care Med, Paris, France; [Gibot, Sebastien] Nancy Univ Hosp, Med Intens Care Unit, Nancy, France; [Lerolle, Nicolas] Angers Univ Hosp, Med Intens Care Unit, Angers, France; [Ricard, Jean-Damien] Hop Louis Mourier, Medicosurg Intens Care Unit, F-92701 Colombes, France; [Djibre, Michel] Tenon Hosp, Medicosurg Intens Care Unit, Paris, France; [Ricome, Jean-Louis] Poissy St Germain Hosp, Med Intens Care Unit, Poissy, France; [Rabbat, Antoine; Urien, Saik] Cochin Hosp, Med Intens Care Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre Hospitalier de Versailles; CHU Limoges; CHU Rennes; Universite de Rennes; CHU Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Nancy; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Faisy, C (corresponding author), Hop Europeen Georges Pompidou, Med Intens Care Unit, 20 Rue Leblanc, F-75015 Paris, France.	christophe.faisy@egp.aphp.fr	DUFOUR, Nicolas N/U-4634-2018; François, Bruno/O-8404-2016; Legriel, Stephane/J-1307-2017; PLANQUETTE, Benjamin/AAL-7166-2021; Urien, Saïk/G-3240-2013	DUFOUR, Nicolas N/0000-0002-1359-6689; François, Bruno/0000-0002-2531-1652; Legriel, Stephane/0000-0003-4782-6734; Urien, Saïk/0000-0002-1065-0600; /0000-0002-4171-1672; SANCHEZ, Olivier/0000-0003-1633-8391; Troche, Gilles/0000-0002-8150-6630; KATSAHIAN, Sandrine/0000-0002-7261-0671; herbrecht, jean-etienne/0000-0002-6415-5330; Helms, Julie/0000-0003-0895-6800	French Ministry of Health; sanofi-aventis France	French Ministry of Health; sanofi-aventis France(Sanofi-Aventis)	The work was supported by the French Ministry of Health and sanofi-aventis France.	Bahloul Mabrouk, 2015, Int J Crit Illn Inj Sci, V5, P3, DOI 10.4103/2229-5151.152296; BERTHELSEN P, 1982, INTENS CARE MED, V8, P269, DOI 10.1007/BF01716736; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Breen D, 2002, THORAX, V57, P29, DOI 10.1136/thorax.57.1.29; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Faisy C, 2010, INTENS CARE MED, V36, P859, DOI 10.1007/s00134-010-1795-7; Glidden DV, 2004, STAT MED, V23, P369, DOI 10.1002/sim.1599; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Gursel G, 2005, RESPIRATION, V72, P61, DOI 10.1159/000083402; Heming N, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0100443, 10.1371/journal.pone.0086313]; Heming N, 2012, CRIT CARE, V16, DOI 10.1186/cc11323; Heming N, 2011, CRIT CARE, V15, DOI 10.1186/cc10448; HODGKIN JE, 1980, CRIT CARE MED, V8, P725, DOI 10.1097/00003246-198012000-00005; Holland AE, 2003, CHEST, V124, P490, DOI 10.1378/chest.124.2.490; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Kassamali R, 2011, CARDIOL REV, V19, P276, DOI 10.1097/CRD.0b013e31822b4939; KRINTEL JJ, 1983, ACTA ANAESTH SCAND, V27, P252, DOI 10.1111/j.1399-6576.1983.tb01946.x; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Liborio AB, 2015, INTENS CARE MED, V41, P479, DOI 10.1007/s00134-015-3649-9; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Moran JL, 1998, CRIT CARE MED, V26, P71, DOI 10.1097/00003246-199801000-00019; Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Swenson ER, 1998, EUR RESPIR J, V12, P1242, DOI 10.1183/09031936.98.12061242; Webster NR, 1999, CRIT REV CL LAB SCI, V36, P497, DOI 10.1080/10408369991239286; Zilberberg MD, 2009, CHEST, V135, P1157, DOI 10.1378/chest.08-1928	29	37	39	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2016	315	5					480	488		10.1001/jama.2016.0019	http://dx.doi.org/10.1001/jama.2016.0019			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC2LZ	26836730	Bronze			2023-01-03	WOS:000369049500017
J	Gaudry, S; Hajage, D; Schortgen, F; Martin-Lefevre, L; Pons, B; Boulet, E; Boyer, A; Chevrel, G; Lerolle, N; Carpentier, D; de Prost, N; Lautrette, A; Bretagnol, A; Mayaux, J; Nseir, S; Megarbane, B; Thirion, M; Forel, JM; Maizel, J; Yonis, H; Markowicz, P; Thiery, G; Tubach, F; Ricard, JD; Dreyfuss, D				Gaudry, Stephane; Hajage, David; Schortgen, Frederique; Martin-Lefevre, Laurent; Pons, Bertrand; Boulet, Eric; Boyer, Alexandre; Chevrel, Guillaume; Lerolle, Nicolas; Carpentier, Dorothee; de Prost, Nicolas; Lautrette, Alexandre; Bretagnol, Anne; Mayaux, Julien; Nseir, Saad; Megarbane, Bruno; Thirion, Marina; Forel, Jean-Marie; Maizel, Julien; Yonis, Hodane; Markowicz, Philippe; Thiery, Guillaume; Tubach, Florence; Ricard, Jean-Damien; Dreyfuss, Didier		AKIKI Study Grp	Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; ACCELERATED INITIATION; ORGAN FAILURE; DIALYSIS; MANAGEMENT; AKI; IMPACT; ICU	BACKGROUND The timing of renal-replacement therapy in critically ill patients who have acute kidney injury but no potentially life-threatening complication directly related to renal failure is a subject of debate. METHODS In this multicenter randomized trial, we assigned patients with severe acute kidney injury (Kidney Disease: Improving Global Outcomes [KDIGO] classification, stage 3 [stages range from 1 to 3, with higher stages indicating more severe kidney injury]) who required mechanical ventilation, catecholamine infusion, or both and did not have a potentially life-threatening complication directly related to renal failure to either an early or a delayed strategy of renal-replacement therapy. With the early strategy, renal-replacement therapy was started immediately after randomization. With the delayed strategy, renal-replacement therapy was initiated if at least one of the following criteria was met: severe hyperkalemia, metabolic acidosis, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter, or oliguria for more than 72 hours after randomization. The primary outcome was overall survival at day 60. RESULTS A total of 620 patients underwent randomization. The Kaplan-Meier estimates of mortality at day 60 did not differ significantly between the early and delayed strategies; 150 deaths occurred among 311 patients in the early-strategy group (48.5%; 95% confidence interval [CI], 42.6 to 53.8), and 153 deaths occurred among 308 patients in the delayed-strategy group (49.7%, 95% CI, 43.8 to 55.0; P = 0.79). A total of 151 patients (49%) in the delayed-strategy group did not receive renal-replacement therapy. The rate of catheter-related bloodstream infections was higher in the early-strategy group than in the delayed-strategy group (10% vs. 5%, P = 0.03). Diuresis, a marker of improved kidney function, occurred earlier in the delayed-strategy group (P<0.001). CONCLUSIONS In a trial involving critically ill patients with severe acute kidney injury, we found no significant difference with regard to mortality between an early and a delayed strategy for the initiation of renal-replacement therapy. A delayed strategy averted the need for renal-replacement therapy in an appreciable number of patients.	[Gaudry, Stephane; Ricard, Jean-Damien; Dreyfuss, Didier] Hop Louis Mourier, AP HP, Serv Reanimat Med Chirurg, F-92701 Colombes, France; [Gaudry, Stephane; Hajage, David; Tubach, Florence] Univ Paris Diderot, Sorbonne Paris Cite, Epidemiol Clin Evaluat Econom Appl Populat Vuln, Paris, France; [Gaudry, Stephane; Hajage, David; Tubach, Florence] INSERM, ECEVE, CIC EC 1425, F-75654 Paris 13, France; [Hajage, David] Hop Louis Mourier, AP HP, Dept Epidemiol & Rech Clin, CIC EC 1425, Colombes, France; [Mayaux, Julien; Megarbane, Bruno] Univ Paris Diderot, Serv Pneumol & Reanimat Med, Grp Hosp Pitie SalpetriereMayaux,u1144, APHP,Reanimat Med & Toxicol,Hop Lariboisiere,INSE, Paris, France; [Tubach, Florence] Hop Bichat Claude Bernard, AP HP, Dept Epidemiol & Rech Clin, CIC EC 1425, Paris, France; [Ricard, Jean-Damien; Dreyfuss, Didier] Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cite, Paris, France; [Schortgen, Frederique] Hop Univ Henri Mondor, AP HP, Serv Reanimat Med, Paris, France; [de Prost, Nicolas] Hop Univ Henri Mondor, Dept Hosp Univ Ageing Thorax Vessels, Cardiovasc & Resp Manifestat Acute Lung Injur & S, APHP,Serv Reanima Med, Colombes, France; [de Prost, Nicolas] Univ Paris Est Creteil Val Marne, Creteil, France; [Martin-Lefevre, Laurent] Ctr Hosp Gen, Reanimat Med Chirurg, La Roche Sur Yon, France; [Pons, Bertrand; Thiery, Guillaume] CHU Pointe Pitre Abymes, Serv Reanimat, Pointe A Pitre, Guadeloupe, France; [Boulet, Eric] CH Rene Dubos, Reanimat Polyvalente, Pontoise, France; [Boyer, Alexandre] Hop Pellegrin, Reanimat Med CHU Bordeaux, F-33076 Bordeaux, France; [Chevrel, Guillaume] CH Sud Francilien, Serv Reanimat, Corbeil Essonnes, France; [Lerolle, Nicolas] Univ Angers, CHU Angers, Dept Reanimat Med & Med Hyperbar, Angers, France; [Carpentier, Dorothee] CHU Rouen, Reanimat Med, Rouen, France; [Lautrette, Alexandre] CHU Clermont Ferrand, Hop Gabriel Montpied, Reanimat Med, Clermont Ferrand, France; [Bretagnol, Anne] Hop La Source, Ctr Hosp Reg Orleans, Reanimat Med Chirurg, Orleans, France; [Nseir, Saad] Univ Lille, Fac Med, CHU Lille, Ctr Reanimat, Lille, France; [Thirion, Marina] CH Victor Dupouy, Reanimat Polyvalente, Argenteuil, France; [Forel, Jean-Marie] Hop Nord Marseille, Serv Reanimat Detresses Resp Aigues & Infect Serv, Marseille, France; [Maizel, Julien] CHU Picardie, INSERM, U1088, Serv Reanimat Med, Amiens, France; [Yonis, Hodane] Hop Croix Rousse, Reanimat Med, Lyon, France; [Markowicz, Philippe] CH Cholet, Reanimat, Cholet, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Louis-Mourier - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHD Vendee; CHU Guadeloupe; Centre Hospitalier Rene Dubos, Pontoise; CHU Bordeaux; Centre Hospitalier Sud Francilien; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Rouen; CHU Clermont Ferrand; Centre Hospitalier Regional d'Orleans; Universite de Lille - ISITE; CHU Lille; Universite de Lille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU Lyon	Dreyfuss, D (corresponding author), Hop Louis Mourier, Intens Care Unit, 178 Rue Renouillers, F-92110 Colombes, France.	didier.dreyfuss@aphp.fr	Roux, Damien/C-5618-2014; Hoste, Eric/A-6353-2008; Hajage, David/D-5226-2014	Roux, Damien/0000-0002-6103-6416; Hoste, Eric/0000-0001-9301-8055; Hajage, David/0000-0002-8475-4090; BOYER, Alexandre/0000-0003-4384-8872; de Prost, Nicolas/0000-0002-4833-4320; Nseir, Saad/0000-0002-7618-0357; Darmon, Michael/0000-0003-4198-8038; Schortgen, Frederique/0000-0003-1756-7508; Megarbane, Bruno/0000-0002-2522-2764	French Ministry of Health; French Ministry of Health	French Ministry of Health; French Ministry of Health	Funded by the French Ministry of Health; ClinicalTrials.gov number, NCT01932190.	[Anonymous], 2011, KIDNEY INT S, V2, P89; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Barbar SD, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-270; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bonventre JV, 2008, NEW ENGL J MED, V359, P82, DOI 10.1056/NEJMe0803765; Bonventre JV, 2013, CLIN J AM SOC NEPHRO, V8, P1606, DOI 10.2215/CJN.06040613; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Chou YH, 2011, CRIT CARE, V15, DOI 10.1186/cc10252; Clark E, 2012, NEPHROL DIAL TRANSPL, V27, P2761, DOI 10.1093/ndt/gfr740; Elseviers MM, 2010, CRIT CARE, V14, DOI 10.1186/cc9355; Gaudry S, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0718-x; Gaudry S, 2014, J CRIT CARE, V29, P1022, DOI 10.1016/j.jcrc.2014.07.014; Gibney N, 2008, CLIN J AM SOC NEPHRO, V3, P876, DOI 10.2215/CJN.04871107; Guerin C, 2000, AM J RESP CRIT CARE, V161, P872, DOI 10.1164/ajrccm.161.3.9809066; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Jamale TE, 2013, AM J KIDNEY DIS, V62, P1116, DOI 10.1053/j.ajkd.2013.06.012; Karrison TG, 2003, CONTROL CLIN TRIALS, V24, P506, DOI 10.1016/S0197-2456(03)00092-8; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KIDNEY INT S, V2, P19, DOI DOI 10.1038/KISUP.2011.32; KLEINKNECHT D, 1972, KIDNEY INT, V1, P190, DOI 10.1038/ki.1972.26; Legrand M, 2013, INTENS CARE MED, V39, P101, DOI 10.1007/s00134-012-2706-x; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Payen D, 2009, CRIT CARE MED, V37, P803, DOI 10.1097/CCM.0b013e3181962316; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schneider AG, 2013, INTENS CARE MED, V39, P987, DOI 10.1007/s00134-013-2864-5; Schneider AG, 2012, NEPHROL DIAL TRANSPL, V27, P947, DOI 10.1093/ndt/gfr501; Seabra VF, 2008, AM J KIDNEY DIS, V52, P272, DOI 10.1053/j.ajkd.2008.02.371; Shingarev R, 2011, SEMIN DIALYSIS, V24, P164, DOI 10.1111/j.1525-139X.2011.00828.x; Smith OM, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-320; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vaara ST, 2014, CLIN J AM SOC NEPHRO, V9, P1577, DOI 10.2215/CJN.12691213; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Vinsonneau C, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0093-5; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Wald R, 2014, CRIT CARE MED, V42, P1933, DOI 10.1097/CCM.0000000000000432; Whitehead J, 1999, STAT MED, V18, P2271	40	575	616	5	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	2016	375	2					122	133		10.1056/NEJMoa1603017	http://dx.doi.org/10.1056/NEJMoa1603017			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ9KY	27181456	Bronze			2023-01-03	WOS:000379530000005
J	McIlvennan, CK; Allen, LA				McIlvennan, Colleen K.; Allen, Larry A.			Palliative care in patients with heart failure	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; VENTRICULAR ASSIST DEVICES; SHARED DECISION-MAKING; QUALITY-OF-LIFE; LONG-TERM TRENDS; OLDER-ADULTS; CLINICIAN ATTITUDES; ADVANCE DIRECTIVES; EUROPEAN-SOCIETY; POLICY STATEMENT	Despite advances in cardiac therapy, heart failure (HF) remains a progressive, highly symptomatic, and deadly disease that places great demands on patients, caregivers, and healthcare systems. Palliative care is a multidisciplinary approach to care that focuses on communication, shared decision making, and advance care planning; provides relief from pain and other distressing symptoms; integrates psychological and spiritual aspects of care; and offers a support system to help families cope during illness and bereavement. Palliative care has applications across the stages of heart failure, including early in the course of illness, often in conjunction with other therapies that are intended to prolong life. However, the incorporation of palliative care into the management of heart failure has been suboptimal for several reasons: uncertainty in the disease trajectory, failure to reward communication between healthcare providers and patients, siloed care, lack of knowledge, overlay of comorbidity and frailty, life saving devices with complex trade-offs, and a limited evidence base. This review will summarize the current literature on the emerging role of palliative care in patients with heart failure and the challenges and opportunities for its integration into routine care. It will discuss current initiatives and future directions of the collaborative relationship between the palliative care and heart failure disciplines.	[McIlvennan, Colleen K.; Allen, Larry A.] Univ Colorado, Sch Med, Div Cardiol, Sect Adv Heart Failure & Transplantat, Aurora, CO 80045 USA; [McIlvennan, Colleen K.; Allen, Larry A.] Univ Colorado, Sch Med, Adult & Child Ctr Hlth Outcomes & Res & Delivery, Aurora, CO 80045 USA; [McIlvennan, Colleen K.; Allen, Larry A.] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Allen, LA (corresponding author), Univ Colorado, Sch Med, B130, Aurora, CO 80045 USA.	larry.allen@ucdenver.edu	Allen, Larry/AAI-1323-2020		National Institutes of Health; Patient-Centered Outcomes Research Institute	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI)	We have read and understood BMJ policy on declaration of interests and declare the following interests: LAA discloses institutional research grant support from National Institutes of Health and Patient-Centered Outcomes Research Institute; and consulting relationships with St Jude, Janssen, and Novartis.	Afilalo J, 2014, J AM COLL CARDIOL, V63, P747, DOI 10.1016/j.jacc.2013.09.070; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Allen LA, 2008, JAMA-J AM MED ASSOC, V299, P2533, DOI 10.1001/jama.299.21.2533; Allen LA, 2012, CIRCULATION, V125, P1928, DOI 10.1161/CIR.0b013e31824f2173; American Board of Internal Medicine, HOSP PALL CAR POL; American Heart Association/American Stroke Assocation, PRINC PALL CAR; Apatira L, 2008, ANN INTERN MED, V149, P861, DOI 10.7326/0003-4819-149-12-200812160-00005; Austin CA, 2015, JAMA INTERN MED, V175, P1213, DOI 10.1001/jamainternmed.2015.1679; Bekelman DB, 2007, J CARD FAIL, V13, P643, DOI 10.1016/j.cardfail.2007.05.005; Bekelman DB, 2014, J PALLIAT MED, V17, P145, DOI 10.1089/jpm.2013.0143; Bekelman DB, 2011, J PALLIAT MED, V14, P815, DOI 10.1089/jpm.2010.0508; Bekelman DB, 2009, J GEN INTERN MED, V24, P592, DOI 10.1007/s11606-009-0931-y; Bloomfield GS, 2013, CURR CARDIOL REV, V9, P157, DOI 10.2174/1573403X11309020008; Bocchi EA, 2009, ARQ BRAS CARDIOL, V93, P1, DOI 10.1590/S0066-782X2009002000001; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Brush S, 2010, J HEART LUNG TRANSPL, V29, P1337, DOI 10.1016/j.healun.2010.07.001; Cacciatore F, 2005, EUR J CLIN INVEST, V35, P723, DOI 10.1111/j.1365-2362.2005.01572.x; Caldwell PH, 2007, CAN J CARDIOL, V23, P791, DOI 10.1016/S0828-282X(07)70829-2; Carson P, 2005, J AM COLL CARDIOL, V46, P2329, DOI 10.1016/j.jacc.2005.09.016; Center to Advance Palliative Care, GROWTH PALL CAR US H; Centers for Medicare and Medicaid Services, PROP POL PAYM QUAL P; Centers for Medicare and Medicaid Services, DEC MEM VENTR ASS DE; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Chaudhry SI, 2010, J AM COLL CARDIOL, V55, P309, DOI 10.1016/j.jacc.2009.07.066; Cheang MH, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000188; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; ClinicalTrials.gov, COLL CAR ALL SYMPT A; Daley A, 2006, PALLIATIVE MED, V20, P593, DOI 10.1177/0269216306071060; Dionne-Odom JN, 2014, J PALLIAT MED, V17, P995, DOI 10.1089/jpm.2013.0680; Dunlay SM, 2015, PALLIATIVE MED, V29, P260, DOI 10.1177/0269216314556565; Dunlay SM, 2012, CIRC-CARDIOVASC QUAL, V5, P283, DOI 10.1161/CIRCOUTCOMES.112.966036; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Elwyn G, 2010, MED DECIS MAKING, V30, P701, DOI 10.1177/0272989X10386231; Evangelista LS, 2012, J PALLIAT MED, V15, P1316, DOI 10.1089/jpm.2012.0228; Faris R, 2002, EUR J HEART FAIL, V4, P541, DOI 10.1016/S1388-9842(02)00101-0; Feldman D, 2013, J HEART LUNG TRANSPL, V32, P157, DOI 10.1016/j.healun.2012.09.013; Fendler TJ, 2015, HEART FAIL CLIN, V11, P479, DOI 10.1016/j.hfc.2015.03.010; Freedland KE, 2015, JAMA INTERN MED, V175, P1773, DOI 10.1001/jamainternmed.2015.5220; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Frosch DL, 1999, AM J PREV MED, V17, P285, DOI 10.1016/S0749-3797(99)00097-5; Gadoud A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113188; Gohler A, 2006, J CARD FAIL, V12, P554, DOI 10.1016/j.cardfail.2006.03.003; Goldstein N, 2010, ANN INTERN MED, V152, P296, DOI 10.7326/0003-4819-152-5-201003020-00007; Golin CE, 2000, J AM GERIATR SOC, V48, pS52, DOI 10.1111/j.1532-5415.2000.tb03141.x; Goodman DC, TRENDS VARIATION END; Gozalo P, 2015, NEW ENGL J MED, V372, P1823, DOI 10.1056/NEJMsa1408705; Grady KL, 2000, CIRCULATION, V102, P2443, DOI 10.1161/01.CIR.102.19.2443; Greener DT, 2014, J PALLIAT MED, V17, P1115, DOI 10.1089/jpm.2013.0658; Gundersen Health System, RESP CHOIC ADV CAR P; Halpern SD, 2015, NEW ENGL J MED, V373, P2001, DOI 10.1056/NEJMp1509664; Halpern SD, 2015, ANN INTERN MED, V162, P224, DOI 10.7326/M14-2476; Hammes BJ, 2010, J AM GERIATR SOC, V58, P1249, DOI 10.1111/j.1532-5415.2010.02956.x; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Harding R, 2008, J PAIN SYMPTOM MANAG, V36, P149, DOI 10.1016/j.jpainsymman.2007.09.012; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Heo S, 2008, AM J CRIT CARE, V17, P124; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Hill L, 2015, EUR J CARDIOVASC NUR; Hill L, 2015, PALLIATIVE MED, V29, P310, DOI 10.1177/0269216314550374; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Iqbal J, 2010, EUR J HEART FAIL, V12, P1002, DOI 10.1093/eurjhf/hfq114; Jaarsma T, 2013, EUR J CARDIOVASC NUR, V12, P230, DOI [10.1177/1474515113476605, 10.1177/1474515112449539]; Jaarsma T, 2009, EUR J HEART FAIL, V11, P433, DOI 10.1093/eurjhf/hfp041; Jhund PS, 2009, CIRCULATION, V119, P515, DOI 10.1161/CIRCULATIONAHA.108.812172; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Joint Commission, 2015, COMPR CERT MAN DIS S; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Kavalieratos D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000544; Kavalieratos D, 2014, J PALLIAT MED, V17, P475, DOI 10.1089/jpm.2013.0526; Kirkpatrick JN, 2012, AM J CARDIOL, V109, P91, DOI 10.1016/j.amjcard.2011.08.011; Koberich S, 2015, J PUBLIC HEALTH RES, V4, DOI 10.4081/jphr.2015.556; Kraynik SE, 2014, J PAIN SYMPTOM MANAG, V48, P471, DOI 10.1016/j.jpainsymman.2013.09.010; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P374, DOI 10.1161/CIRCOUTCOMES.111.962217; Krumholz HM, 1998, CIRCULATION, V98, P648, DOI 10.1161/01.CIR.98.7.648; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Laribi S, 2012, EUR J HEART FAIL, V14, P234, DOI 10.1093/eurjhf/hfr182; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Matlock DD, 2011, PACE, V34, P1634, DOI 10.1111/j.1540-8159.2011.03237.x; Matlock DD, 2014, CIRC-CARDIOVASC QUAL, V7, P487, DOI 10.1161/CIRCOUTCOMES.113.000289; Matlock DD, 2012, PROG CARDIOVASC DIS, V55, P274, DOI 10.1016/j.pcad.2012.10.007; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; McIlvennan CK, 2016, JAMA INTERN IN PRESS; McIlvennan CK, 2015, CIRC-CARDIOVASC QUAL, V8, P172, DOI 10.1161/CIRCOUTCOMES.114.001276; McIlvennan CK, 2014, CIRC-HEART FAIL, V7, P1003, DOI 10.1161/CIRCHEARTFAILURE.114.001391; McIlvennan CK, 2014, CIRC-CARDIOVASC QUAL, V7, P374, DOI 10.1161/CIRCOUTCOMES.113.000729; McMurray JJV, 1998, EUR HEART J, V19, pP9; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Mentz RJ, 2014, AM HEART J, V168, P645, DOI 10.1016/j.ahj.2014.07.018; Meyer Theo E, 2014, Curr Heart Fail Rep, V11, P188, DOI 10.1007/s11897-014-0195-7; Morrison RS, 2011, HEALTH AFFAIR, V30, P454, DOI 10.1377/hlthaff.2010.0929; National Hospice and Palliative Care Organization, FACTS HOSP PALL CAR; Nazarian S, 2005, AM HEART J, V150, P955, DOI 10.1016/j.ahj.2005.01.012; Neumann T, 2009, DTSCH ARZTEBL INT, V106, P269, DOI 10.3238/arztebl.2009.0269; Nordgren Lena, 2003, Eur J Cardiovasc Nurs, V2, P213; O'Connor CM, 2010, J AM COLL CARDIOL, V56, P692, DOI 10.1016/j.jacc.2010.03.068; Oxberry SG, 2011, EUR J HEART FAIL, V13, P1006, DOI 10.1093/eurjhf/hfr068; Pasalic D, 2015, AM J HOSP PALLIAT CA; Ponikowski P, 2014, ESC HEART FAIL, V1, P4, DOI 10.1002/ehf2.12005; ROGER VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI [DOI 10.1001/JAMA.292.3.344, 10.1001/jama.292.3.344]; Rumsfeld JS, 2013, CIRCULATION, V127, P2233, DOI 10.1161/CIR.0b013e3182949a2e; Sabatino CP, 2010, MILBANK Q, V88, P211, DOI 10.1111/j.1468-0009.2010.00596.x; Saczynski JS, 2013, J AM GERIATR SOC, V61, P26, DOI 10.1111/jgs.12062; Segal DI, 2005, INT J PALLIAT NURS, V11, P135, DOI 10.12968/ijpn.2005.11.3.18033; Setoguchi S, 2010, AM HEART J, V160, P139, DOI 10.1016/j.ahj.2010.03.038; Shore S, 2015, JACC-HEART FAIL, V3, P906, DOI 10.1016/j.jchf.2015.06.012; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Swetz KM, 2013, EUR J HEART FAIL, V15, P1262, DOI 10.1093/eurjhf/hft094; Swetz Keith M, 2011, Curr Heart Fail Rep, V8, P212, DOI 10.1007/s11897-011-0060-x; Swetz KM, 2011, MAYO CLIN PROC, V86, P493, DOI 10.4065/mcp.2010.0747; Tanvetyanon T, 2003, CRIT CARE MED, V31, P60, DOI 10.1097/00003246-200301000-00009; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Thompson JS, 2015, JACC-HEART FAIL, V3, P965, DOI 10.1016/j.jchf.2015.09.007; Tse DMW, 2007, PALLIATIVE MED, V21, P425, DOI 10.1177/0269216307079825; Tu JV, 2009, CAN MED ASSOC J, V180, pE118, DOI 10.1503/cmaj.081197; University of Ottawa, 2010, OTT DEC SUPP FRAM; von Gunten CF, 2002, JAMA-J AM MED ASSOC, V287, P875, DOI 10.1001/jama.287.7.875; who, WHO DEF PALL CAR; Wong CY, 2011, AM J MED, V124, P136, DOI 10.1016/j.amjmed.2010.08.017; Worldwide Palliative Care Alliance, GLOB ATL PALL CAR EN; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	123	89	90	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 14	2016	353								i1010	10.1136/bmj.i1010	http://dx.doi.org/10.1136/bmj.i1010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DJ7EU	27079896				2023-01-03	WOS:000374375500001
J	Riu, M; Chiarello, P; Terradas, R; Sala, M; Garcia-Alzorriz, E; Castells, X; Grau, S; Cots, F				Riu, Marta; Chiarello, Pietro; Terradas, Roser; Sala, Maria; Garcia-Alzorriz, Enric; Castells, Xavier; Grau, Santiago; Cots, Francesc			Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; SUSCEPTIBLE STAPHYLOCOCCUS-AUREUS; CARE-ACQUIRED INFECTION; PSEUDOMONAS-AERUGINOSA; RISK-FACTORS; RESISTANT; IMPACT; INTERVENTION; LENGTH; STAY	Aim To calculate the incremental cost of nosocomial bacteremia caused by the most common organisms, classified by their antimicrobial susceptibility. Methods We selected patients who developed nosocomial bacteremia caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa. These microorganisms were analyzed because of their high prevalence and they frequently present multidrug resistance. A control group consisted of patients classified within the same allpatient refined-diagnosis related group without bacteremia. Our hospital has an established cost accounting system (full-costing) that uses activity-based criteria to analyze cost distribution. A logistic regression model was fitted to estimate the probability of developing bacteremia for each admission (propensity score) and was used for propensity score matching adjustment. Subsequently, the propensity score was included in an econometric model to adjust the incremental cost of patients who developed bacteremia, as well as differences in this cost, depending on whether the microorganism was multidrug-resistant or multidrug-sensitive. Results A total of 571 admissions with bacteremia matched the inclusion criteria and 82,022 were included in the control group. The mean cost was (sic)25,891 for admissions with bacteremia and (sic)6,750 for those without bacteremia. The mean incremental cost was estimated at (sic)15,151 (CI, (sic)11,570 to (sic)18,733). Multidrug-resistant P. aeruginosa bacteremia had the highest mean incremental cost, (sic)44,709 (CI, (sic)34,559 to (sic)54,859). Antimicrobial-susceptible E. coli nosocomial bacteremia had the lowest mean incremental cost, (sic)10,481 (CI, (sic)8,752 to (sic)12,210). Despite their lower cost, episodes of antimicrobial-susceptible E. coli nosocomial bacteremia had a major impact due to their high frequency. Conclusions Adjustment of hospital cost according to the organism causing bacteremia and antibiotic sensitivity could improve prevention strategies and allow their prioritization according to their overall impact and costs. Infection reduction is a strategy to reduce resistance.	[Riu, Marta; Chiarello, Pietro; Sala, Maria; Garcia-Alzorriz, Enric; Castells, Xavier; Cots, Francesc] IMIM Hosp Mar Med Res Inst, Barcelona, Spain; [Riu, Marta; Chiarello, Pietro; Terradas, Roser; Grau, Santiago] Univ Autonoma Barcelona, E-08193 Barcelona, Spain; [Terradas, Roser] Hosp del Mar, Sch Nursing, Barcelona, Spain; [Sala, Maria; Castells, Xavier] Hosp del Mar, Dept Epidemiol & Evaluat, Barcelona, Spain; [Sala, Maria; Castells, Xavier] Redissec Red Invest Serv Sanitarios Enfermedades, Madrid, Spain; [Grau, Santiago] Hosp del Mar, Dept Pharm, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Riu, M (corresponding author), IMIM Hosp Mar Med Res Inst, Barcelona, Spain.; Riu, M (corresponding author), Univ Autonoma Barcelona, E-08193 Barcelona, Spain.	20138@hospitaldelmar.cat	Buron, Andrea/E-5705-2016; Castells, Xavier/S-7798-2016; Serra, Maria Sala/O-9420-2019; Sala, Maria/H-2562-2013	Buron, Andrea/0000-0003-3590-1303; Castells, Xavier/0000-0002-2528-0382; Serra, Maria Sala/0000-0002-9955-8746; Sala, Maria/0000-0002-9955-8746; Riu, Marta/0000-0003-4702-3472; Cots, Francesc/0000-0003-0238-8902; Chiarello, Pietro/0000-0001-7019-6000; Terradas-Robledo, Roser/0000-0002-7689-1183				Allue N, 2014, GAC SANIT, V28, P48, DOI 10.1016/j.gaceta.2013.06.004; Ben-David D, 2009, INFECT CONT HOSP EP, V30, P453, DOI 10.1086/596731; Beyersmann J, 2009, INFECT CONT HOSP EP, V30, P273, DOI 10.1086/596020; Burden AR, 2012, J CLIN ANESTH, V24, P555, DOI 10.1016/j.jclinane.2012.04.006; Carlet J., 2014, WORLD ALLIANCE ANTIB; Farinas MC, 2013, ENFERM INFEC MICR CL, V31, P402, DOI 10.1016/j.eimc.2013.03.016; Cohen B, 2010, MED CARE, V48, P767, DOI 10.1097/MLR.0b013e3181e358b9; Cots F, 2010, COST ACTIVITAT ASSIS; Cots F, 2012, GEST EVALUACION COST, V13, P369; Defez C, 2008, J HOSP INFECT, V68, P130, DOI 10.1016/j.jhin.2007.11.005; Disease EC for, 2009, BACT CHALL TIM REACT; European Centre for Disease Prevention and Control, 2012, ANT RES SURV EUR 201; Filice GA, 2010, INFECT CONT HOSP EP, V31, P365, DOI 10.1086/651094; Freixas N, 2013, CLIN MICROBIOL INFEC, V19, P838, DOI 10.1111/1469-0691.12049; Fukuda H, 2011, J HOSP INFECT, V77, P93, DOI 10.1016/j.jhin.2010.10.006; Ghadiri H, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/890797; Goto M, 2013, CLIN MICROBIOL INFEC, V19, P501, DOI 10.1111/1469-0691.12195; Graves N, 2007, INFECT CONT HOSP EP, V28, P280, DOI 10.1086/512642; Greene LLR, 2013, INFECT CONTROL TODAY; Harbarth S, 2003, J HOSP INFECT, V54, P258, DOI 10.1016/S0195-6701(03)00150-6; Hoenigl M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104702; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Instituto Nacional de Estadistica, IND PREC CONS; Jensen US, 2011, CLIN MICROBIOL INFEC, V17, P1148, DOI 10.1111/j.1469-0691.2011.03587.x; Kilgore Meredith, 2008, Am J Infect Control, V36, DOI 10.1016/j.ajic.2008.10.004; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Lautenbach E, 2010, INFECT CONT HOSP EP, V31, P47, DOI 10.1086/649021; Lee SY, 2006, INFECT CONT HOSP EP, V27, P1226, DOI 10.1086/507962; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Morales E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-122; Neidell MJ, 2012, CLIN INFECT DIS, V55, P807, DOI 10.1093/cid/cis552; Nielsen KL, 2012, J ANTIMICROB CHEMOTH, V67, P1325, DOI 10.1093/jac/dks051; Park SY, 2011, INFECTION, V39, P141, DOI 10.1007/s15010-011-0100-1; Pirson M, 2005, J HOSP INFECT, V59, P33, DOI 10.1016/j.jhin.2004.07.006; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Riu M, 2015, ENFERM INFEC MICR CL, P5; Riu M, 2012, ENFERM INFEC MICR CL, V30, P137, DOI 10.1016/j.eimc.2011.11.006; Roberts RR, 2010, MED CARE, V48, P1026, DOI 10.1097/MLR.0b013e3181ef60a2; Roberts RR, 2009, CLIN INFECT DIS, V49, P1175, DOI 10.1086/605630; Rodriguez-Bano J, 2010, J CLIN MICROBIOL, V48, P1726, DOI 10.1128/JCM.02353-09; Rubio-Terres C, 2010, CLIN MICROBIOL INFEC, V16, P722, DOI 10.1111/j.1469-0691.2009.02902.x; Schwaber MJ, 2007, J ANTIMICROB CHEMOTH, V60, P913, DOI 10.1093/jac/dkm318; Septimus E, 2014, INFECT CONT HOSP EP, V35, P797, DOI [10.1086/676535, 10.1017/S0899823X00193808]; Tansarli GS, 2013, EXPERT REV ANTI-INFE, V11, P321, DOI [10.1586/eri.13.4, 10.1586/ERI.13.4]; Terradas R, 2011, ENFERM INFEC MICR CL, V29, P14, DOI 10.1016/j.eimc.2010.06.007; US Department of Health and Human Services Centers for Disease Control and Prevention., 2013, ANT RES THREATS US; Yilmaz G, 2007, INFECT CONT HOSP EP, V28, P689, DOI 10.1086/517976	47	20	25	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0153076	10.1371/journal.pone.0153076	http://dx.doi.org/10.1371/journal.pone.0153076			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27055117	Green Published, gold			2023-01-03	WOS:000373608000072
J	Gonzalez, E; Diez, JJ; Bajo, MA; del Peso, G; Grande, C; Rodriguez, O; Diaz-Almiron, M; Iglesias, P; Selgas, R				Gonzalez, Elena; Diez, Juan J.; Auxiliadora Bajo, M.; del Peso, Gloria; Grande, Cristina; Rodriguez, Olaia; Diaz-Almiron, Mariana; Iglesias, Pedro; Selgas, Rafael			Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; INSULIN-RESISTANCE; RENAL-FUNCTION; GLUCOSE; DYSFUNCTION	Background Human fibroblast growth factor 21 (FGF-21) is an endocrine liver hormone that stimulates adipocyte glucose uptake independently of insulin, suppresses hepatic glucose production and is involved in the regulation of body fat. Peritoneal dialysis (PD) patients suffer potential interference with FGF-21 status with as yet unknown repercussions. Objectives The aim of this study was to define the natural history of FGF-21 in PD patients, to analyze its relationship with glucose homeostasis parameters and to study the influence of residual renal function and peritoneal functional parameters on FGF-21 levels and their variation over time. Methods We studied 48 patients with uremia undergoing PD. Plasma samples were routinely obtained from each patient at baseline and at 1, 2 and 3 years after starting PD therapy. Results Plasma FGF-21 levels substantially increased over the first year and were maintained at high levels during the remainder of the study period (253 pg/ml (59; 685) at baseline; 582 pg/ml (60.5-949) at first year and 647 pg/ml (120.5-1116.6) at third year) (p<0.01). We found a positive correlation between time on dialysis and FGF-21 levels (p<0.001), and also, those patients with residual renal function (RRF) had significantly lower levels of FGF-21 than those without RRF (rho-0.484, p<0.05). Lastly, there was also a significant association between FGF-21 levels and peritoneal protein losses (PPL), independent of the time on dialysis (rho 0.410, p<0.05). Conclusion Our study shows that FGF-21 plasma levels in incident PD patients significantly increase during the first 3 years. This increment is dependent on or is associated with RRF and PPL (higher levels in patients with lower RRF and higher PPL). FGF-21 might be an important endocrine agent in PD patients and could act as hormonal signaling to maintain glucose homeostasis and prevent potential insulin resistance. These preliminary results suggest that FGF-21 might play a protective role as against the development of insulin resistance over time in patients undergoing a continuous glucose load.	[Gonzalez, Elena; Auxiliadora Bajo, M.; del Peso, Gloria; Selgas, Rafael] La Paz Univ Hosp, REDinREN, FRIAT IRSIN, Dept Nephrol,IdiPAZ, Madrid, Spain; [Diez, Juan J.; Grande, Cristina; Iglesias, Pedro] Univ Hosp Ramon Y Cajal, Dept Endocrinol, Madrid, Spain; [Rodriguez, Olaia] La Paz Univ Hosp, REDinREN, FRIAT IRSIN, Dept Biochem,IdiPAZ, Madrid, Spain; [Diaz-Almiron, Mariana] La Paz Univ Hosp, REDinREN, FRIAT IRSIN, Biostat Sect,IdiPAZ, Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario Ramon y Cajal; Hospital Universitario La Paz; Hospital Universitario La Paz	Iglesias, P (corresponding author), Univ Hosp Ramon Y Cajal, Dept Endocrinol, Madrid, Spain.	piglo65@gmail.com	Iglesias, Pedro/AAC-1016-2020; González, Elena/A-2635-2017; Diez, Juan J./W-1803-2017; Bajo, Maria A/ABF-6991-2020; Iglesias, P/AAU-1011-2020	Iglesias, Pedro/0000-0003-0126-1985; González, Elena/0000-0003-2003-4737; Diez, Juan J./0000-0002-2017-0694; Bajo, Maria A/0000-0001-7364-557X; Iglesias, P/0000-0003-0126-1985	Rio Hortega Grant Program from the ISCIII; Extramural Grant Program from Baxter; Health Research Fund [FIS-12/00241]; REDinREN program from the ISCIII-FEDER Funds, IRSIN-FRIAT	Rio Hortega Grant Program from the ISCIII; Extramural Grant Program from Baxter; Health Research Fund(Instituto de Salud Carlos III); REDinREN program from the ISCIII-FEDER Funds, IRSIN-FRIAT	This study was partially funded with the Rio Hortega Grant Program from the ISCIII, the Extramural Grant Program from Baxter, Health Research Fund FIS-12/00241 and the REDinREN program from the ISCIII-FEDER Funds, IRSIN-FRIAT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Crasto C, 2012, J AM GERIATR SOC, V60, P792, DOI 10.1111/j.1532-5415.2011.03879.x; Cuevas-Ramos D, 2012, CURR OPIN PEDIATR, V24, P523, DOI 10.1097/MOP.0b013e3283557d22; Han SH, 2012, PERITON DIALYSIS INT, V32, P149, DOI 10.3747/pdi.2010.00111; Han SH, 2010, METABOLISM, V59, P1656, DOI 10.1016/j.metabol.2010.03.018; Hindricks J, 2014, CLIN ENDOCRINOL, V80, P918, DOI 10.1111/cen.12380; Holmes CJ, 2000, PERITON DIALYSIS INT, V20, pS37; Iglesias P, 2012, EUR J ENDOCRINOL, V167, P301, DOI 10.1530/EJE-12-0357; Kharitonenkov A, 2009, CURR OPIN PHARMACOL, V9, P805, DOI 10.1016/j.coph.2009.07.001; Kralisch S, 2011, CURR OPIN CLIN NUTR, V14, P354, DOI 10.1097/MCO.0b013e328346a326; Krediet RT, 2013, CLIN KIDNEY J, V6, P568, DOI 10.1093/ckj/sft122; Lin ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018398; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Ohta Hiroya, 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P302; Olauson H, 2013, CURR OPIN NEPHROL HY, V22, P397, DOI 10.1097/MNH.0b013e32836213ee; Sanchez-Villanueva R, 2013, NEFROLOGIA, V33, P85, DOI 10.3265/Nefrologia.pre2012.Nov.11430; SELGAS R, 1994, AM J KIDNEY DIS, V23, P64, DOI 10.1016/S0272-6386(12)80814-6; Selgas R, PERIT DIAL INT, V25, P68; Semba RD, 2012, J CLIN ENDOCR METAB, V97, P1375, DOI 10.1210/jc.2011-2823; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; Ulu SM, 2014, INT UROL NEPHROL, V46, P2409, DOI 10.1007/s11255-014-0753-7; Wu HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030337	21	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151698	10.1371/journal.pone.0151698	http://dx.doi.org/10.1371/journal.pone.0151698			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1YG	26986485	Green Submitted, gold, Green Published			2023-01-03	WOS:000372580300115
J	Kobayashi, T; Nishijima, T; Teruya, K; Aoki, T; Kikuchi, Y; Oka, S; Gatanaga, H				Kobayashi, Tetsuro; Nishijima, Takeshi; Teruya, Katsuji; Aoki, Takahiro; Kikuchi, Yoshimi; Oka, Shinichi; Gatanaga, Hiroyuki			High Mortality of Disseminated Non-Tuberculous Mycobacterial Infection in HIV-Infected Patients in the Antiretroviral Therapy Era	PLOS ONE			English	Article							AVIUM COMPLEX INFECTION; DISEASE; SURVIVAL; COHORT; AIDS	Background Little information is available on the mortality and risk factors associated with death in disseminated non-tuberculous mycobacterial infection (dNTM) in HIV-infected patients in the ART-era. Methods In a single-center study, HIV-infected dNTM with positive NTM culture from sterile sites between 2000 and 2013 were analysed. The clinical characteristics at commencement of anti-mycobacterial treatment (baseline) were compared between those who survived and died. Results Twenty-four patients were analyzed. [The median CD4 27/mu L (range 2-185)]. Mycobacterium avium and M. intracellulare accounted for 20 (83%) and 3 (13%) of isolated NTM. NTM bacteremia was diagnosed in 15 (63%) patients. Seven (29%) patients died, and NTM bacteremia was significantly associated with mortality (p = 0.022). The baseline CD4 count was significantly lower in the non-survivors than the survivors (median 7/mu L versus 49, p = 0.034). Concomitant AIDS-defining diseases or malignancies were not associated with mortality. Immune-reconstitution syndrome (IRS) occurred to 19 (79%) patients (8 paradoxical and 11 unmasking), and prognosis tended to be better in unmasking-IRS than the other patients (n = 13) (p = 0.078). Patients with paradoxical-IRS had marginally lower CD4 count and higher frequency of bacteremia than those with unmasking-IRS (p = 0.051, and 0.059). Treatment with systemic corticosteroids was applied in 63% and 55% of patients with paradoxical and unmasking-IRS, respectively. Conclusion dNTM in HIV-infected patients resulted in high mortality even in the ART-era. NTM bacteremia and low CD4 count were risk factors for death, whereas patients presented with unmasking-IRS had marginally better prognosis. IRS occurred in 79% of the patients, suggesting difficulty in the management of dNTM.	[Kobayashi, Tetsuro; Nishijima, Takeshi; Teruya, Katsuji; Aoki, Takahiro; Kikuchi, Yoshimi; Oka, Shinichi; Gatanaga, Hiroyuki] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan; [Oka, Shinichi; Gatanaga, Hiroyuki] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan	National Center for Global Health & Medicine - Japan; Kumamoto University	Nishijima, T (corresponding author), Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan.	tnishiji@acc.ncgm.go.jp	Kobayashi, Tetsuro/GZG-7054-2022		Japanese Ministry of Health, Labour, and Welfare [H23-AIDS-001, H24-AIDS-003]	Japanese Ministry of Health, Labour, and Welfare(Ministry of Health, Labour and Welfare, Japan)	This work was supported by Grant-in Aids for AIDS Research from the Japanese Ministry of Health, Labour, and Welfare (H23-AIDS-001; H24-AIDS-003). The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967; Chou CH, 2011, SCAND J INFECT DIS, V43, P8, DOI 10.3109/00365548.2010.519345; Grant PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011416; Haddow LJ, 2009, CLIN INFECT DIS, V49, P1424, DOI 10.1086/630208; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; HORSBURGH CR, 1994, J INFECT DIS, V170, P573, DOI 10.1093/infdis/170.3.573; Karakousis PC, 2004, LANCET INFECT DIS, V4, P557, DOI 10.1016/S1473-3099(04)01130-2; Laupland KB, 2009, CRIT CARE MED, V37, pS273, DOI 10.1097/CCM.0b013e3181aa6117; LEWIS AG, 1960, ANN INTERN MED, V53, P273, DOI 10.7326/0003-4819-53-2-273; Miguez-Burbano MJ, 2006, INT J INFECT DIS, V10, P47, DOI 10.1016/j.ijid.2004.11.005; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; Nishijima T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022661; Phillips P, 2005, CLIN INFECT DIS, V41, P1483, DOI 10.1086/497269; Ristola MA, 1999, J INFECTION, V39, P61, DOI 10.1016/S0163-4453(99)90104-4; Rossi M, 2001, SWISS MED WKLY, V131, P471; SHAPIRO AL, 1991, OTOLARYNG HEAD NECK, V105, P419, DOI 10.1177/019459989110500312; SLAP GB, 1984, JAMA-J AM MED ASSOC, V252, P1321, DOI 10.1001/jama.252.10.1321; Wohl DA, 2009, HIV CLIN TRIALS, V10, P143, DOI 10.1310/hct1003-143	19	21	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151682	10.1371/journal.pone.0151682	http://dx.doi.org/10.1371/journal.pone.0151682			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1YG	26985832	Green Submitted, Green Published, gold			2023-01-03	WOS:000372580300111
J	Norrie, J				Norrie, John			ICON-6: the danger of changing study design midstream	LANCET			English	Editorial Material							DOUBLE-BLIND; PHASE-III; COLORECTAL-CANCER; CEDIRANIB		[Norrie, John] Univ Aberdeen, Hlth Serv Res Unit, Ctr Healthcare Randomised Trials CHaRT, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Norrie, J (corresponding author), Univ Aberdeen, Hlth Serv Res Unit, Ctr Healthcare Randomised Trials CHaRT, Aberdeen AB25 2ZD, Scotland.	j.norrie@abdn.ac.uk						Batchelor TT, 2013, J CLIN ONCOL, V31, P3212, DOI 10.1200/JCO.2012.47.2464; [Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation and Research (CDER) Food and Drug Administration US Department of Health and Human Services], 2010, GUID IND AD DES CLIN; Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031; Jennison C., 2010, GROUP SEQUENTIAL ADA; Ledermann JA, 2013, EUR CANC C AMST NETH; Ledermann JA, 2016, LANCET, V387, P1066, DOI 10.1016/S0140-6736(15)01167-8; Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355; Spiegelhalter DJ, 2003, BAYESIAN APPROACHES; Symonds RP, 2015, LANCET ONCOL, V16, P1515, DOI 10.1016/S1470-2045(15)00220-X	9	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	2016	387	10023					1031	1032		10.1016/S0140-6736(16)00658-9	http://dx.doi.org/10.1016/S0140-6736(16)00658-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG0SD	27025174	hybrid, Green Submitted			2023-01-03	WOS:000371775000005
J	Hartmann-Boyce, J; Aveyard, P				Hartmann-Boyce, Jamie; Aveyard, Paul			THERAPEUTICS Drugs for smoking cessation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NICOTINE REPLACEMENT THERAPY; VARENICLINE; REDUCTION; SAFETY; RISK		[Hartmann-Boyce, Jamie; Aveyard, Paul] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Observ Quarter, Oxford OX2 6GG, England	University of Oxford	Hartmann-Boyce, J (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Observ Quarter, Oxford OX2 6GG, England.	Jamie.hartmann-boyce@phc.ox.ac.uk		Aveyard, Paul/0000-0002-1802-4217	Medical Research Council [MR/K023195/1] Funding Source: researchfish; National Institute for Health Research [09/110/01] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Barnes J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001008.pub2; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Coleman T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078; Ebbert JO, 2015, JAMA-J AM MED ASSOC, V313, P687, DOI 10.1001/jama.2015.280; Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487; Ferguson SG, 2012, ADDICTION, V107, P1349, DOI 10.1111/j.1360-0443.2012.03801.x; Gibbons RD, 2013, AM J PSYCHIAT, V170, P1460, DOI 10.1176/appi.ajp.2013.12121599; Hajek P, 2011, ARCH INTERN MED, V171, P770, DOI 10.1001/archinternmed.2011.138; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; Lindson N, 2011, PSYCHOPHARMACOLOGY, V214, P579, DOI 10.1007/s00213-010-2069-3; McRobbie Hayden, 2014, Cochrane Database Syst Rev, pCD010216, DOI 10.1002/14651858.CD010216.pub2; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Moore David, 2009, BMJ, V338, pb1024, DOI 10.1136/bmj.b1024; National Institute for Health and Care Excellence, 2008, SMOK CESS SERV; Prochaska JJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2856; Shahab L., 2012, COST EFFECTIVENESS P; Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218; Stapleton J, 1998, Stat Methods Med Res, V7, P187, DOI 10.1191/096228098671391775; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub2; Thase ME, 2008, J CLIN PSYCHOPHARM, V28, P302, DOI 10.1097/JCP.0b013e318172424e; Tobacco Use and Dependence Guideline Panel, 2008, TREATING TOBACCO USE; White AR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub4; Woolacott N F, 2002, Health Technol Assess, V6, P1; Zimovetz EA, 2011, J EVAL CLIN PRACT, V17, P288, DOI 10.1111/j.1365-2753.2010.01439.x	26	12	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	2016	352								i571	10.1136/bmj.i571	http://dx.doi.org/10.1136/bmj.i571			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF1QU	26907501				2023-01-03	WOS:000371115100002
J	Dua, TK; Dewanjee, S; Khanra, R; Joardar, S; Barma, S; Das, S; Zia-Ul-Haq, M; De Feo, V				Dua, Tarun K.; Dewanjee, Saikat; Khanra, Ritu; Joardar, Swarnalata; Barma, Sujata; Das, Shilpa; Zia-Ul-Haq, M.; De Feo, Vincenzo			Cytoprotective and Antioxidant Effects of an Edible Herb, Enhydra fluctuans Lour. (Asteraceae), against Experimentally Induced Lead Acetate Intoxication	PLOS ONE			English	Article							OXYGEN SPECIES ROS; OXIDATIVE STRESS; APOPTOSIS; CADMIUM; INVOLVEMENT; IMAGE; ACID; QUANTIFICATION; INJURY	Background Enhydra fluctuans Lour. (Asteraceae), an edible aquatic herb, is traditionally employed against toxic effects of heavy metals in India. The present study was planned to discover the protective effect of edible extract of E. fluctuans (AEEF) against Pb toxicity. Methods The cytoprotective role of AEEF was determined on murine hepatocytes employing MTT assay and Hoechst staining. The effects on lipid peroxidation, protein carbonylation, endogenous redox systems and the transcription levels of apoptotic proteins were studied after incubating the hepatocytes with AEEF (400 mu g/ml) + Pb-acetate (6.8 mu M). The defensive role of AEEF (100 mg/kg) against Pb-acetate (5 mg/kg) intoxication was measured in mice by in vivo assays. Biochemical, haematological and histological parameters, intracellular Pb burden and redox status were measured. Results AEEF exhibited a concentration dependent cytoprotective effect against Pb-induced cytotoxicity in vitro. Pb-acetate incubation significantly (p < 0.01) altered the extents of ROS production up arrow, protein carbonylation up arrow, lipid peroxidation up arrow, endogenous antioxidant enzymes down arrow and GSH down arrow in vitro. Besides, Pb-acetate significantly (p < 0.01) induced apoptosis in the hepatocytes apparent from the altered expressions of apoptotic proteins viz. Apaf-1 up arrow, Bad up arrow, Bcl-2 down arrow, Cyt C up arrow, cleaved caspases up arrow, Bid up arrow and Fas up arrow. However, AEEF (400 mu g/ml) could significantly (p < 0.05-0.01) attenuate the Pb-acetate mediated toxic manifestation in vitro. In in vivo assay, Pb-acetate (5 mg/kg) treated mice exhibited significantly (p < 0.01) high intracellular Pb content. A high Pb-burden within the tissues caused significant (p < 0.05-0.01) patho-physiological alterations viz. ROS production up arrow, protein carbonylation up arrow, lipid peroxidation up arrow, DNA fragmentation up arrow, ATPformation up arrow, mitochondrial co-enzymes Q down arrow, endogenous antioxidant enzymes down arrow and GSH down arrow within the selected tissues. The haematological and serum biochemical parameters were significantly (p < 0.05-0.01) different in the Pb-acetate treated mice. Finally, histological assessment imposed significant toxic occurrence within the organs of Pb-intoxicated animals. However, concurrent administration of AEEF (100 mg/kg) could significantly (p < 0.05-0.01) reinstate the Pb-acetate mediated toxicity. Conclusion Presence of metal chelators and phyto-antioxidants within AEEF would offer overall protection through promoting Pb clearance coupled with restoring redox balance.	[Dua, Tarun K.; Dewanjee, Saikat; Khanra, Ritu; Joardar, Swarnalata; Barma, Sujata; Das, Shilpa] Jadavpur Univ, Dept Pharmaceut Technol, Adv Pharmacognosy Res Lab, Kolkata 700032, India; [Zia-Ul-Haq, M.] Patent Off, Karchi 75400, Pakistan; [De Feo, Vincenzo] Univ Salerno, Dept Pharm, I-84084 Salerno, Italy	Jadavpur University; University of Salerno	Dewanjee, S (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Adv Pharmacognosy Res Lab, Kolkata 700032, India.; De Feo, V (corresponding author), Univ Salerno, Dept Pharm, I-84084 Salerno, Italy.	s.dewanjee@yahoo.com; defeo@unisa.it	KHANRA, RITU/AAV-4351-2021; De Feo, Vincenzo/AAF-2293-2019; Dua, Tarun Kumar/AAM-4891-2020; Dewanjee, Saikat/U-9778-2017	De Feo, Vincenzo/0000-0002-1070-3207; Dua, Tarun Kumar/0000-0001-5136-7564; Dewanjee, Saikat/0000-0001-9085-4226	Council for Scientific and Industrial Research (CSIR), New Delhi, India [09/096(773)/2013-EMR-I]	Council for Scientific and Industrial Research (CSIR), New Delhi, India(Council of Scientific & Industrial Research (CSIR) - India)	The financial support of the Council for Scientific and Industrial Research (CSIR), New Delhi, India is gratefully acknowledged through Senior Research Fellowship to Mr. Tarun K. Dua [Council for Scientific and Industrial Research-senior research fellowship Ref. No.: 09/096(773)/2013-EMR-I dated 15th March, 2013].; The financial support of the Council for Scientific and Industrial Research (CSIR), New Delhi, India is gratefully acknowledged through Senior Research Fellowship to Mr. Tarun K. Dua [Council for Scientific and Industrial Research-senior research fellowship Ref. No.: 09/096(773)/2013-EMR-I dated 15th March, 2013]. Authors are thankful to Jadavpur University, Kolkata, India for providing necessary facilities for this study. All authors are thankful to Prof. Biswajit Mukherjee, Department of Pharmaceutical Technology, Jadavpur University for his kind help for histological studies. Finally, the authors would like to say thanks to the reviewers for their time and valuable comments to improve the quality of this manuscript.	Ahmad RS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0436-x; ALI E, 1972, TETRAHEDRON, V28, P2285, DOI 10.1016/S0040-4020(01)93572-0; Bolner A, 2011, CLIN LAB, V57, P859; Chander K, 2014, FOOD CHEM TOXICOL, V68, P297, DOI 10.1016/j.fct.2014.02.012; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Das AK, 2010, FOOD CHEM TOXICOL, V48, P1210, DOI 10.1016/j.fct.2010.02.012; Das AK, 2010, FOOD CHEM TOXICOL, V48, P326, DOI 10.1016/j.fct.2009.10.020; Das AK, 2010, ENVIRON TOXICOL PHAR, V29, P64, DOI 10.1016/j.etap.2009.10.002; DEFIGUEIREDO RJP, 1995, NEUROBIOL AGING, V16, P211, DOI 10.1016/0197-4580(94)00151-0; Dewanjee S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139831; Dewanjee S, 2014, ENZYME MICROB TECH, V66, P1, DOI 10.1016/j.enzmictec.2014.07.006; Dewanjee S, 2013, FOOD CHEM TOXICOL, V60, P188, DOI 10.1016/j.fct.2013.07.043; Dewanjee S, 2013, FOOD CHEM TOXICOL, V55, P78, DOI 10.1016/j.fct.2012.12.040; Dewanjee S, 2009, FOOD CHEM TOXICOL, V47, P2679, DOI 10.1016/j.fct.2009.07.038; Dua TK, 2016, REDOX REP, V21, P147, DOI 10.1179/1351000215Y.0000000021; Dua TK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0598-6; Dua TK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0430-3; Flora Gagan, 2012, Interdiscip Toxicol, V5, P47, DOI 10.2478/v10102-012-0009-2; Ghosh J, 2010, FOOD CHEM, V123, P1062, DOI 10.1016/j.foodchem.2010.05.062; Gurer H, 2000, FREE RADICAL BIO MED, V29, P927, DOI 10.1016/S0891-5849(00)00413-5; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hong KJ, 2000, CHEMOSPHERE, V41, P345, DOI 10.1016/S0045-6535(99)00489-0; Hsu PC, 2002, TOXICOLOGY, V180, P33, DOI 10.1016/S0300-483X(02)00380-3; Jackie Tan, 2011, BMC Res Notes, V4, P67, DOI 10.1186/1756-0500-4-67; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Khanra R, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0364-1; Kim JD, 1996, AGING-CLIN EXP RES, V8, P123, DOI 10.1007/BF03339566; Kuri Sourov, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P299, DOI 10.12980/APJTB.4.2014C677; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; Lin KT, 1997, BIOCHEM BIOPH RES CO, V230, P115, DOI 10.1006/bbrc.1996.5897; Mansoor TA, 2013, J ETHNOPHARMACOL, V149, P463, DOI 10.1016/j.jep.2013.06.051; Matovic V, 2015, FOOD CHEM TOXICOL, V78, P130, DOI [10.1016/jict.2015.02.011, 10.1016/j.fct.2015.02.011]; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pal S, 2011, TOXICOLOGY, V283, P129, DOI 10.1016/j.tox.2011.03.006; PHS (Public Health Service), 1986, PUBL HLTH SERV POL H; Rahman MT, 2002, FITOTERAPIA, V73, P707, DOI 10.1016/S0367-326X(02)00212-5; Rangan GK, 2007, NEPHROLOGY, V12, P553, DOI 10.1111/j.1440-1797.2007.00855.x; Ruegg MA, 2014, HISTOPATHOLOGY HEMAT; Saeed K, 2015, J PAK MED ASSOC, V65, P43; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sultan MT, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0853-7; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Wu DD, 2015, MED GAS RES, V5, DOI 10.1186/s13618-014-0022-y; ZHANG YY, 1995, J NUTR, V125, P446	47	21	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148757	10.1371/journal.pone.0148757	http://dx.doi.org/10.1371/journal.pone.0148757			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859407	gold, Green Published, Green Submitted			2023-01-03	WOS:000370038400076
J	Winstein, CJ; Wolf, SL; Dromerick, AW; Lane, CJ; Nelsen, MA; Lewthwaite, R; Cen, SY; Azen, SP				Winstein, Carolee J.; Wolf, Steven L.; Dromerick, Alexander W.; Lane, Christianne J.; Nelsen, Monica A.; Lewthwaite, Rebecca; Cen, Steven Yong; Azen, Stanley P.		ICARE Investigative Team	Effect of a Task-Oriented Rehabilitation Program on Upper Extremity Recovery Following Motor Stroke The ICARE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSTRAINT-INDUCED MOVEMENT; THERAPY; IMPROVEMENT; IMPAIRMENT; EXERCISE; TIME	IMPORTANCE Clinical trials suggest that higher doses of task-oriented training are superior to current clinical practice for patients with stroke with upper extremity motor deficits. OBJECTIVE To compare the efficacy of a structured, task-oriented motor training program vs usual and customary occupational therapy (UCC) during stroke rehabilitation. DESIGN, SETTING, AND PARTICIPANTS Phase 3, pragmatic, single-blind randomized trial among 361 participants with moderate motor impairment recruited from 7 US hospitals over 44 months, treated in the outpatient setting from June 2009 to March 2014. INTERVENTIONS Structured, task-oriented upper extremity training (Accelerated Skill Acquisition Program[ASAP]; n = 119); dose-equivalent occupational therapy (DEUCC; n = 120); or monitoring-only occupational therapy (UCC; n = 122). The DEUCC group was prescribed 30 one hour sessions over 10 weeks; the UCC group was only monitored, without specification of dose. MAIN OUTCOMES AND MEASURES The primary outcome was 12-month change in log-transformed Wolf Motor Function Test time score (WMFT, consisting of a mean of 15 timed arm movements and hand dexterity tasks). Secondary outcomes were change in WMFT time score (minimal clinically important difference [MCID] = 19 seconds) and proportion of patients improving >= 25 points on the Stroke Impact Scale (SIS) hand function score (MCID = 17.8 points). RESULTS Among the 361 randomized patients (mean age, 60.7 years; 56% men; 42% African American; mean time since stroke onset, 46 days), 304 (84%) completed the 12-month primary outcome assessment; in intention-to-treat analysis, mean group change scores (log WMFT, baseline to 12 months) were, for the ASAP group, 2.2 to 1.4 (difference, 0.82); DEUCC group, 2.0 to 1.2 (difference, 0.84); and UCC group, 2.1 to 1.4 (difference, 0.75), with no significant between group differences (ASAP vs DEUCC: 0.14; 95% CI, -0.05 to 0.33; P = .16; ASAP vs UCC: -0.01; 95% CI, -0.22 to 0.21; P = .94; and DEUCC vs UCC: -0.14; 95% CI, -0.32 to 0.05; P = .15). Secondary outcomes for the ASAP group were WMFT change score, -8.8 seconds, and improved SIS, 73%; DEUCC group, WMFT, -8.1 seconds, and SIS, 72%; and UCC group, WMFT, -7.2 seconds, and SIS, 69%, with no significant pairwise between-group differences (ASAP vs DEUCC: WMFT, 1.8 seconds; 95% CI, -0.8 to 4.5 seconds; P = .18; improved SIS, 1%; 95% CI, -12% to 13%; P = .54; ASAP vs UCC: WMFT, -0.6 seconds, 95% CI, -3.8 to 2.6 seconds; P = .72; improved SIS, 4%; 95% CI,-9% to 16%; P = .48; and DEUCC vs UCC: WMFT, -2.1 seconds; 95% CI, -4.5 to 0.3 seconds; P = .08; improved SIS, 3%; 95% CI, -9% to 15%; P = .22). A total of 168 serious adverse events occurred in 109 participants, resulting in 8 patients withdrawing from the study. CONCLUSIONS AND RELEVANCE Among patients with motor stroke and primarily moderate upper extremity impairment, use of a structured, task-oriented rehabilitation program did not significantly improve motor function or recovery beyond either an equivalent or a lower dose of UCC upper extremity rehabilitation. These findings do not support superiority of this program among patients with motor stroke and primarily moderate upper extremity impairment.	[Winstein, Carolee J.; Lane, Christianne J.; Nelsen, Monica A.; Lewthwaite, Rebecca; Cen, Steven Yong; Azen, Stanley P.] Univ So Calif, 1540 Alcazar St,CHP 155, Los Angeles, CA 90033 USA; [Wolf, Steven L.] Emory Univ, Atlanta, GA 30322 USA; [Dromerick, Alexander W.] MedStar Natl Rehabil Hosp, Washington, DC USA	University of Southern California; Emory University	Winstein, CJ (corresponding author), Univ So Calif, 1540 Alcazar St,CHP 155, Los Angeles, CA 90033 USA.	winstein@usc.edu	Benham, Sara/N-2627-2018; Wolf, Steve/F-6588-2010	Benham, Sara/0000-0002-2102-6678; Wolf, Steve/0000-0002-9446-8995; Winstein, Carolee/0000-0001-9789-4626; Mohapatra, Sambit/0000-0001-7714-5281	National Institutes of Health, the National Institute of Neurological Disorders and Stroke; National Center for Medical Rehabilitation Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01NS056256]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS056256, R01NS058755] Funding Source: NIH RePORTER	National Institutes of Health, the National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Center for Medical Rehabilitation Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The ICARE trial was funded jointly by the National Institutes of Health, the National Institute of Neurological Disorders and Stroke (primary), and the National Center for Medical Rehabilitation Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant U01NS056256). Each author received support from this grant during the conduct of the study.	AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Ang JHY, 2006, INT J REHABIL RES, V29, P357; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Bravi L, 2007, TOP STROKE REHABIL, V14, P68, DOI 10.1310/tsr1406-68; Cohen J., 2013, STAT POWER ANAL BEHA; Cumming G, 2001, EDUC PSYCHOL MEAS, V61, P532, DOI 10.1177/00131640121971374; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Hart T, 2014, ARCH PHYS MED REHAB, V95, pS33, DOI 10.1016/j.apmr.2013.05.032; Hubbard IJ, 2009, OCCUP THER INT, V16, P175, DOI 10.1002/oti.275; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; James GA, 2009, TOP STROKE REHABIL, V16, P270, DOI 10.1310/tsr1604-270; Kaplan RM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132382; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Lang CE, 2008, ARCH PHYS MED REHAB, V89, P1693, DOI 10.1016/j.apmr.2008.02.022; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Lum PS, 2009, TOP STROKE REHABIL, V16, P237, DOI 10.1310/tsr1604-237; Minelli C, 2009, NEUROL INT, V1, P10, DOI 10.4081/ni.2009.e4; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Page SJ, 2002, NEUROREHAB NEURAL RE, V16, P290, DOI 10.1177/154596802401105225; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P14, DOI 10.1016/S0003-9993(03)00481-7; Platz T, 2004, RESTOR NEUROL NEUROS, V22, P301; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Rosenbaum L, 2013, NEW ENGL J MED, V368, P959, DOI 10.1056/NEJMms1301576; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Tretriluxana J, 2013, TOP STROKE REHABIL, V20, P151, DOI 10.1310/tsr2002-151; Winstein C, 2014, J NEUROL PHYS THER, V38, P190, DOI 10.1097/NPT.0000000000000046; Winstein CJ, 2015, PROG BRAIN RES, V218, P331, DOI 10.1016/bs.pbr.2015.01.004; Winstein CJ, 2015, STROKE RECOVERY AND REHABILITATION, SECOND EDITION, P320; Winstein CJ, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-5; Wolf SL, 2006, ARCH PHYS MED REHAB, V87, P443, DOI 10.1016/j.apmr.2005.10.006; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Wolf SL, 2007, RESTOR NEUROL NEUROS, V25, P549; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Yozbatiran N, 2008, NEUROREHAB NEURAL RE, V22, P78, DOI 10.1177/1545968307305353	41	177	183	3	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2016	315	6					571	581		10.1001/jama.2016.0276	http://dx.doi.org/10.1001/jama.2016.0276			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD0UJ	26864411	Green Accepted, Bronze			2023-01-03	WOS:000369635200016
J	Montminy, ML; Gauvin, V; Turcotte, S; Milot, A; Douville, Y; Bairati, I				Montminy, Myriam L.; Gauvin, Valerie; Turcotte, Stephane; Milot, Alain; Douville, Yvan; Bairati, Isabelle			Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease	PLOS ONE			English	Article							MISSED OPPORTUNITIES; HIGH-RISK; RAMIPRIL; CLAUDICATION; IMPROVEMENT; QUALITY; SOCIETY; IMPACT	Background Guidelines recommend that patients with peripheral arterial disease should be medically treated to reduce the occurrence of serious cardiovascular events. Despite these recommendations, studies conducted in the early 2000s reported that medical therapies for secondary cardiovascular prevention are not given systematically to patients with peripheral arterial disease (PAD). We identified factors associated with the prescription of preventive therapies in patients with symptomatic PAD. Methods and Findings Consecutive patients with symptomatic peripheral arterial disease (n = 362) treated between 2008 and 2010 in one tertiary care center (CHU de Quebec, Canada) were considered. Data were collected from the medical charts. The main outcome was the combined prescription of three therapies: 1) statins, 2) antiplatelets, 3) angiotensin-convertingenzyme inhibitors or angiotensin receptor blockers. The mean age was 70 years and 43% had a pre-existing coronary artery disease. Antiplatelet therapy was the most prescribed drug (83%). A total of 52% of the patients received the three combined therapies. Less than 10% of patients had a known contraindication to one class of medication. Having at least three cardiovascular risk factors (Odds Ratio (OR) = 4.51; 95% CI: 2.76-7.37) was the factor most strongly associated with the prescription of the combined therapies. Preexisting coronary artery disease (OR = 2.28; 95% CI: 1.43-3.65) and history of peripheral vascular surgery (OR = 2.30; 95% CI: 1.37-3.86) were two factors independently associated with the prescription of the combined therapies. However, peripheral arterial disease patients with chronic critical limb ischemia were less likely to receive the combined therapies (OR = 0.53; 95% CI: 0.32-0.87) than those with claudication. The retrospective nature of this study, not allowing for an exhaustive report of the contraindication to medication prescription, is the main limitation. Conclusion About half of the patients with peripheral arterial disease were not optimally managed. Patients with multiple cardiovascular risk factors were more likely to receive the combined therapies. We still need to better understand the barriers and facilitators to the application of the guidelines.	[Montminy, Myriam L.; Gauvin, Valerie; Douville, Yvan] Ctr Hosp Univ Quebec, Dept Vasc Surg, Quebec City, PQ, Canada; [Montminy, Myriam L.; Turcotte, Stephane] Ctr Hosp Univ Quebec, Res Ctr, Quebec City, PQ, Canada; [Milot, Alain] Ctr Hosp Univ Quebec, Dept Vasc Med, Quebec City, PQ, Canada; [Bairati, Isabelle] Ctr Hosp Univ Quebec, Dept Publ Hlth, Quebec City, PQ, Canada	Laval University; Laval University; Laval University; Laval University	Montminy, ML (corresponding author), Ctr Hosp Univ Quebec, Dept Vasc Surg, Quebec City, PQ, Canada.; Montminy, ML (corresponding author), Ctr Hosp Univ Quebec, Res Ctr, Quebec City, PQ, Canada.	myriam.letourneau-montminy.1@ulaval.ca						Abramson BL, 2005, CAN J CARDIOL, V21, P997; Ardati AK, 2012, CIRC-CARDIOVASC INTE, V5, P850, DOI 10.1161/CIRCINTERVENTIONS.112.975862; Aronow WS, 2003, AM J CARDIOL, V92, P711, DOI 10.1016/S0002-9149(03)00833-6; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Cacoub Patrice P, 2009, Atherosclerosis, V204, pe86, DOI 10.1016/j.atherosclerosis.2008.10.023; Cassar K, 2003, EUR J VASC ENDOVASC, V26, P262, DOI 10.1053/ejvs.2002.1948; Charlson ME, 2002, NEW METHOD CLASSIFYI, P1; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; Heart Protection Study Collaborative Group, 2007, J VASC SURG, V45, P644; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hosmer DW, 2004, APPL LOGISTIC REGRES, P392; Khan S, 2007, EUR J VASC ENDOVASC, V33, P442, DOI 10.1016/j.ejvs.2006.11.010; Kidney disease outcomes quality initiative (KDOQI), KIDNEY DIS OUTCOMES, V39, pS46, DOI [10.1053/ajkd.2002.30943, DOI 10.1053/AJKD.2002.30943]; Kundhal KK, 2007, CAN J CARDIOL, V23, P357, DOI 10.1016/S0828-282X(07)70768-7; Mukherjee D, 2002, CIRCULATION, V106, P1909, DOI 10.1161/01.CIR.0000035649.39669.CE; Ostergren J, 2004, EUR HEART J, V25, P17, DOI 10.1016/j.ehj.2003.10.033; Pampalon R, 2000, Chronic Dis Can, V21, P104; Rooke TW, 2011, CATHETER CARDIOVASC; Subherwal S, 2012, CIRCULATION, V126, P1345, DOI 10.1161/CIRCULATIONAHA.112.108787; Tendera M, 2011, EUR HEART J, V32, P2851, DOI 10.1093/eurheartj/ehr211; Welten GMJM, 2008, J AM COLL CARDIOL, V51, P1588, DOI 10.1016/j.jacc.2007.11.077; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	25	7	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0148069	10.1371/journal.pone.0148069	http://dx.doi.org/10.1371/journal.pone.0148069			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26849679	Green Published, Green Submitted, gold			2023-01-03	WOS:000369554000037
J	Gadalean, F; Lighezan, D; Stoian, D; Schiller, O; Timar, R; Timar, B; Bob, F; Donciu, MD; Munteanu, M; Mihaescu, A; Covic, A; Schiller, A				Gadalean, Florica; Lighezan, Daniel; Stoian, Dana; Schiller, Oana; Timar, Romulus; Timar, Bogdan; Bob, Flaviu; Donciu, Mihaela Dora; Munteanu, Mircea; Mihaescu, Adelina; Covic, Adrian; Schiller, Adalbert			The Survival of Roma Minority Patients on Chronic Hemodialysis Therapy - A Romanian Multicenter Survey	PLOS ONE			English	Article							RACIAL DISPARITIES; HIGHER PREVALENCE; KIDNEY-DISEASE; UNITED-STATES; RISK-FACTORS; RACE; MORTALITY; ETHNICITY; BONE; AGE	Objective The Roma minority represents the largest ethnic group in Central and South-East European countries. Data regarding the mortality in Roma hemodialysis subjects are limited. We evaluated the 3 year mortality of ESRD Roma patients treated with hemodialysis (HD). Study Design and Setting Our prospective cohort study included 600 ESRD patients on HD therapy recruited from 7 HD centers, from the main geographical regions of Romania. The median age of the patients was 56 (19) years, 332 (55.3%) being males, 51 (8.5%) having Roma ethnicity. Results Roma ESRD patients initiate dialysis at a younger age, 47.8 years vs. 52.3 years (P = 0.017), present higher serum albumin (P = 0.013) and higher serum phosphate levels (P = 0.021). In the Roma group, the overall 3 year mortality was higher when compared to Caucasians (33.3% vs. 24.8%). Themultivariate survival analysis revealed that being of Roma ethnicity is an independent risk factor for mortality (HR = 1.74; 95% CI = 1.04-2.91; P = 0.035). Conclusions Roma patients with ESRD initiate HD therapy at a younger age as compared to Caucasians. They have a higher 3 year mortality rate and are dying at a younger age. Roma ethnicity represents an independent risk factor for mortality in our cohort.	[Gadalean, Florica; Bob, Flaviu; Mihaescu, Adelina; Schiller, Adalbert] Victor Babes Univ Med & Pharm, Cty Emergency Hosp, Dept Nephrol, Timisoara, Romania; [Lighezan, Daniel] Victor Babes Univ Med & Pharm, Dept Internal Med, Municipal Clin Emergency Hosp, Timisoara, Romania; [Stoian, Dana] Victor Babes Univ Med & Pharm, Municipal Hosp, Dept Obstet & Gynecol, Timisoara, Romania; [Schiller, Oana] B Braun Avitum Dialysis Ctr Timisoara, Timisoara, Romania; [Timar, Romulus; Munteanu, Mircea] Victor Babes Univ Med & Pharm, Cty Emergency Hosp, Dept Diabet & Metab Dis, Timisoara, Romania; [Timar, Bogdan] Victor Babes Univ Med & Pharm, Cty Emergency Hosp, Dept Med Informat & Biostat, Timisoara, Romania; [Donciu, Mihaela Dora; Covic, Adrian] Univ Med Gr T Popa Iasi, Hosp CI Parhon Iasi, Dept Nephrol & Internal Med, Iasi, Romania	Victor Babes University of Medicine & Pharmacy, Timisoara; Victor Babes University of Medicine & Pharmacy, Timisoara; Victor Babes University of Medicine & Pharmacy, Timisoara; Victor Babes University of Medicine & Pharmacy, Timisoara; Victor Babes University of Medicine & Pharmacy, Timisoara; Grigore T Popa University of Medicine & Pharmacy	Stoian, D (corresponding author), Victor Babes Univ Med & Pharm, Municipal Hosp, Dept Obstet & Gynecol, Timisoara, Romania.	danastoian611@hotmail.com	Mihaescu, Adelina/AAL-3378-2020; Mihaela-Dora, Donciu/HGB-1446-2022; Stoian, Dana/W-4777-2019; Covic, Adrian/G-5017-2016; Schiller, Adalbert A./AAT-8957-2021	Mihaescu, Adelina/0000-0002-3220-6623; Stoian, Dana/0000-0002-0926-9511; Covic, Adrian/0000-0002-9985-2486; 	University of Medicine and Pharmacy "Victor Babes'' Timisoara [PIII-C2-PCFI-2015/2016]	University of Medicine and Pharmacy "Victor Babes'' Timisoara	This research project was funded by an internal grant from the University of Medicine and Pharmacy "Victor Babes'' Timisoara, PIII-C2-PCFI-2015/2016, www.umft.ro. AS received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Bogdanovic D, 2007, CROAT MED J, V48, P720; Choi AI, 2011, AM J KIDNEY DIS, V58, P228, DOI 10.1053/j.ajkd.2011.02.388; Collins A, 2014, AM J KIDNEY DIS, V63, pE1; Cook B, 2013, INT J PUBLIC HEALTH, V58, P885, DOI 10.1007/s00038-013-0518-6; Crews DC, 2014, CURR OPIN NEPHROL HY, V23, P298, DOI 10.1097/01.mnh.0000444822.25991.f6; Crews DC, 2010, AM J KIDNEY DIS, V55, P992, DOI 10.1053/j.ajkd.2009.12.032; de Courten BV, 2003, DIABETES RES CLIN PR, V62, P95, DOI 10.1016/S0168-8227(03)00162-1; Drew DA, 2014, CLIN J AM SOC NEPHRO, V9, P1426, DOI 10.2215/CJN.00770114; Garcia-Garcia Guillermo, 2015, Can J Kidney Health Dis, V2, P18, DOI 10.1186/s40697-015-0050-0; Hurtado A, 2005, KIDNEY INT, V68, pS62, DOI 10.1111/j.1523-1755.2005.09711.x; Jackson Y, 2015, Rev Med Suisse, V11, P735; Jorgetti V, 2014, KIDNEY INT, V85, P1283, DOI 10.1038/ki.2013.443; Kalantar-Zadeh K, 2012, AM J KIDNEY DIS, V60, P182, DOI 10.1053/j.ajkd.2012.02.321; Kalantar-Zadeh K, 2010, J BONE MINER RES, V25, P2448, DOI 10.1002/jbmr.177; Kato Akihiko, 2013, Nephrourol Mon, V5, P932, DOI 10.5812/numonthly.9449; Kaysen GA, 2003, AM J KIDNEY DIS, V42, P1200, DOI 10.1053/j.ajkd.2003.08.021; KDIGO Clinical Practice Guideline for the Diagnosis Evaluation Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), 2009, KID INT S113S, V76, pS1; Kolvek G, 2014, INT J PUBLIC HEALTH, V59, P1023, DOI 10.1007/s00038-014-0609-z; Kolvek G, 2012, INT J PUBLIC HEALTH, V57, P751, DOI 10.1007/s00038-012-0365-x; Lertdumrongluk P, 2013, SEMIN DIALYSIS, V26, P36, DOI 10.1111/sdi.12025; Li H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116774; Logan BR, 2008, BIOMETRICS, V64, P733, DOI 10.1111/j.1541-0420.2007.00975.x; Malluche HH, 2011, J BONE MINER RES, V26, P1368, DOI 10.1002/jbmr.309; Michos A, 2008, J MED VIROL, V80, P791, DOI 10.1002/jmv.21134; Molnar MZ, 2012, INT UROL NEPHROL, V44, P945, DOI 10.1007/s11255-011-0088-6; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nicholas SB, 2013, SEMIN NEPHROL, V33, P409, DOI 10.1016/j.semnephrol.2013.07.002; Noori N, 2010, CLIN J AM SOC NEPHRO, V5, P683, DOI 10.2215/CJN.08601209; Norris KC, 2005, KIDNEY INT, V68, P914, DOI 10.1111/j.1523-1755.2005.00485.x; Pappa E, 2015, INT J ENV RES PUB HE, V12, P6669, DOI 10.3390/ijerph120606669; Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345; Pippias M, 2015, CLIN KIDNEY J, V8, P248, DOI 10.1093/ckj/sfv014; Plantinga L, 2013, INT J HEALTH GEOGR, V12, DOI 10.1186/1476-072X-12-17; Rhee CM, 2014, AM J NEPHROL, V39, P183, DOI 10.1159/000358497; Rosenberger J, 2014, CENT EUR J PUBL HEAL, V22, pS28, DOI 10.21101/cejph.a3898; Scialla JJ, 2015, AM J NEPHROL, V42, P25, DOI 10.1159/000438999; Sivic Suad, 2013, Med Arch, V67, P60; Sridhar NR, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-242; Streja E, 2011, JAMA-J AM MED ASSOC, V306, P2215, DOI 10.1001/jama.2011.1714; THOMAS JD, 1987, LANCET, V2, P377; Tripath G, 2008, CLIN BIOCHEM, V41, P525, DOI 10.1016/j.clinbiochem.2008.01.009; Vart P, 2015, CLIN J AM SOC NEPHRO, V10, P562, DOI 10.2215/CJN.09030914; Vart P, 2013, CLIN J AM SOC NEPHRO, V8, P1685, DOI 10.2215/CJN.12521212; Voko Z, 2009, J EPIDEMIOL COMMUN H, V63, P455, DOI 10.1136/jech.2008.079715; Yan GF, 2013, CLIN J AM SOC NEPHRO, V8, P953, DOI 10.2215/CJN.09180912; Zitt E, 2011, CLIN J AM SOC NEPHRO, V6, P2650, DOI 10.2215/CJN.03780411	47	5	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155271	10.1371/journal.pone.0155271	http://dx.doi.org/10.1371/journal.pone.0155271			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27196564	Green Published, gold, Green Submitted			2023-01-03	WOS:000376291100034
J	Gulland, A				Gulland, Anne			Libby Wilson OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item												annecgulland@yahoo.co.uk						WILSON L, PUBLICATION LIST	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2016	353								i2854	10.1136/bmj.i2854	http://dx.doi.org/10.1136/bmj.i2854			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GD	27199152				2023-01-03	WOS:000376447700018
J	Taylor, BL; Cavanagh, K; Strauss, C				Taylor, Billie Lever; Cavanagh, Kate; Strauss, Clara			The Effectiveness of Mindfulness-Based Interventions in the Perinatal Period: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							MAJOR DEPRESSIVE DISORDER; MATERNAL SELF-EFFICACY; COGNITIVE THERAPY; POSTPARTUM DEPRESSION; PSYCHIATRIC-DISORDERS; POSTNATAL DEPRESSION; STRESS REDUCTION; PSYCHOLOGICAL DISTRESS; RELATIONSHIP EDUCATION; MENTAL-DISORDERS	Perinatal mental health difficulties are associated with adverse consequences for parents and infants. However, the potential risks associated with the use of psychotropic medication for pregnant and breastfeeding women and the preferences expressed by women for non-pharmacological interventions mean it is important to ensure that effective psychological interventions are available. It has been argued that mindfulness-based interventions may offer a novel approach to treating perinatal mental health difficulties, but relatively little is known about their effectiveness with perinatal populations. This paper therefore presents a systematic review and meta-analysis of the effectiveness of mindfulness-based interventions for reducing depression, anxiety and stress and improving mindfulness skills in the perinatal period. A systematic review identified seventeen studies of mindfulness-based interventions in the perinatal period, including both controlled trials (n = 9) and pre-post uncontrolled studies (n = 8). Eight of these studies also included qualitative data. Hedge's g was used to assess uncontrolled and controlled effect sizes in separate meta-analyses, and a narrative synthesis of qualitative data was produced. Pre- to post-analyses showed significant reductions in depression, anxiety and stress and significant increases in mindfulness skills post intervention, each with small to medium effect sizes. Completion of the mindfulness-based interventions was reasonable with around three quarters of participants meeting study-defined criteria for engagement or completion where this was recorded. Qualitative data suggested that participants viewed mindfulness interventions positively. However, between-group analyses failed to find any significant post-intervention benefits for depression, anxiety or stress of mindfulness-based interventions in comparison to control conditions: effect sizes were negligible and it was conspicuous that intervention group participants did not appear to improve significantly more than controls in their mindfulness skills. The interventions offered often deviated from traditional mindfulness-based cognitive therapy or mindfulness-based stress reduction programmes, and there was also a tendency for studies to focus on healthy rather than clinical populations, and on antenatal rather than postnatal populations. It is argued that these and other limitations with the included studies and their interventions may have been partly responsible for the lack of significant between-group effects. The implications of the findings and recommendations for future research are discussed.	[Taylor, Billie Lever; Strauss, Clara] Sussex Partnership NHS Fdn Trust, Brighton, E Sussex, England; [Cavanagh, Kate; Strauss, Clara] Univ Sussex, Sch Psychol, Brighton, E Sussex, England	University of Sussex	Strauss, C (corresponding author), Sussex Partnership NHS Fdn Trust, Brighton, E Sussex, England.; Strauss, C (corresponding author), Univ Sussex, Sch Psychol, Brighton, E Sussex, England.	c.y.strauss@sussex.ac.uk		Strauss, Clara/0000-0002-0303-763X; Lever Taylor, Billie/0000-0002-6865-3425; Cavanagh, Kate/0000-0002-9863-1462				Appleby L, 1998, BRIT J PSYCHIAT, V173, P209, DOI 10.1192/bjp.173.3.209; Austin MP, 2008, J AFFECT DISORDERS, V105, P35, DOI 10.1016/j.jad.2007.04.001; Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504; Barnum SE, 2013, COGNITIVE THER RES, V37, P71, DOI 10.1007/s10608-012-9456-5; Battle CL, 2013, J PSYCHIATR PRACT, V19, P443, DOI 10.1097/01.pra.0000438183.74359.46; Bauer A, 2014, COSTS PERINATAL MENT; Beattie Jill, 2014, Aust Nurs Midwifery J, V22, P39; Beddoe AE, 2009, JOGNN-J OBST GYN NEO, V38, P310, DOI 10.1111/j.1552-6909.2009.01023.x; Bledsoe SE, 2006, RES SOCIAL WORK PRAC, V16, P109, DOI 10.1177/1049731505282202; Byrne J, 2014, J MIDWIFERY WOM HEAL, V59, P192, DOI 10.1111/jmwh.12075; Camody J, 2008, J BEHAV MED, V31, P23, DOI [10.1007/s10865-007-9130-7, DOI 10.1007/S10865-007-9130-7]; Cash M., 2010, MINDFULNESS, V1, P177; Chan KY, 2015, J GLOB HEALTH, V5, P163, DOI 10.7189/jogh.05.010412; Chiesa A, 2011, PSYCHIAT RES, V187, P441, DOI 10.1016/j.psychres.2010.08.011; Cohen J., 2013, STAT POWER ANAL BEHA; Cornsweet Barber C, 2013, MIDIRS MIDWIFERY DIG, V23, P449; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Cuijpers P, 2008, J CLIN PSYCHOL, V64, P103, DOI 10.1002/jclp.20432; Dagher RK, 2012, J OCCUP ENVIRON MED, V54, P210, DOI 10.1097/JOM.0b013e31823fdf85; Deeks J J, 2003, Health Technol Assess, V7, piii; Department of Health, 2009, IMPR ACC PSYCH THER; Dimidjian S, 2016, J CONSULT CLIN PSYCH, V84, P134, DOI 10.1037/ccp0000068; Dimidjian S, 2015, ARCH WOMEN MENT HLTH, V18, P85, DOI 10.1007/s00737-014-0468-x; Duncan LG, 2010, J CHILD FAM STUD, V19, P190, DOI 10.1007/s10826-009-9313-7; Dunn C, 2012, ARCH WOMEN MENT HLTH, V15, P139, DOI 10.1007/s00737-012-0264-4; Eberhard-Gran M, 2002, ACTA PSYCHIAT SCAND, V106, P426, DOI 10.1034/j.1600-0447.2002.02408.x; Eberth J, 2012, MINDFULNESS, V3, P174, DOI 10.1007/s12671-012-0101-x; Fisher C, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-126; Fjorback LO, 2011, ACTA PSYCHIAT SCAND, V124, P102, DOI 10.1111/j.1600-0447.2011.01704.x; Gambrel LE, 2015, J MARITAL FAM THER, V41, P25, DOI 10.1111/jmft.12065; Gambrel LE, 2015, J MARITAL FAM THER, V41, P5, DOI 10.1111/jmft.12066; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Goodman JH, 2014, ARCH WOMEN MENT HLTH, V17, P373, DOI 10.1007/s00737-013-0402-7; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Gu J, 2015, CLIN PSYCHOL REV, V37, P1, DOI 10.1016/j.cpr.2015.01.006; Guardino CM, 2014, PSYCHOL HEALTH, V29, P334, DOI 10.1080/08870446.2013.852670; Hall HG, 2016, WOMEN BIRTH, V29, P62, DOI 10.1016/j.wombi.2015.08.006; Hedges L.V, 1985, STAT METHODS META AN, DOI [10.1016/C2009-0-03396-0, DOI 10.1016/C2009-0-03396-0]; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Howard LM, 2014, LANCET, V384, P1775, DOI 10.1016/S0140-6736(14)61276-9; Hughes Annie, 2009, Br J Midwifery, V17, P630; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Khoury B, 2015, J PSYCHOSOM RES, V78, P519, DOI 10.1016/j.jpsychores.2015.03.009; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Li J, 2016, BEHAV RES THER, V77, P96, DOI 10.1016/j.brat.2015.12.010; Miklowitz DJ, 2015, COGNITIVE THER RES, V39, P590, DOI 10.1007/s10608-015-9681-9; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; Muzik Maria, 2012, Complement Ther Clin Pract, V18, P235, DOI 10.1016/j.ctcp.2012.06.006; National Institute for Health and Care Excellence, 2014, ANT POSTN MENT HLTH; National Institute for Health and Clinical Excellence, 2009, DEPR TREATM MAN DEPR; Oates M, 2003, BRIT MED BULL, V67, P219, DOI 10.1093/bmb/ldg011; OHARA MW, 1990, J ABNORM PSYCHOL, V99, P3, DOI 10.1037/0021-843X.99.1.3; PAK AV, 2013, ADV ENVIRON BIOL, V7, P4203; Paulson JF, 2010, JAMA-J AM MED ASSOC, V303, P1961, DOI 10.1001/jama.2010.605; Perez-Blasco J, 2013, ARCH WOMEN MENT HLTH, V16, P227, DOI 10.1007/s00737-013-0337-z; Piet J, 2011, CLIN PSYCHOL REV, V31, P1032, DOI 10.1016/j.cpr.2011.05.002; Roberts LR, 2015, ISSUES MENT HEALTH N, V36, P222, DOI 10.3109/01612840.2014.962676; Rosenthal R., 1993, METAANALYTIC PROCEDU; Sockol LE, 2015, J AFFECT DISORDERS, V177, P7, DOI 10.1016/j.jad.2015.01.052; Sockol LE, 2011, CLIN PSYCHOL REV, V31, P839, DOI 10.1016/j.cpr.2011.03.009; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; Teasdale JD, 1999, CLIN PSYCHOL PSYCHOT, V6, P146, DOI 10.1002/(SICI)1099-0879(199905)6:2<146::AID-CPP195>3.0.CO;2-E; UK Mindfulness-based teacher trainer network, 2011, GOOD PRACT GUID TEAC; Vesga-Lopez O, 2008, ARCH GEN PSYCHIAT, V65, P805, DOI 10.1001/archpsyc.65.7.805; Vieten C, 2008, ARCH WOMEN MENT HLTH, V11, P67, DOI 10.1007/s00737-008-0214-3; Vollestad J, 2012, BRIT J CLIN PSYCHOL, V51, P239, DOI 10.1111/j.2044-8260.2011.02024.x; Warriner S, 2012, BRIT J MIDWIFERY, V20, P194, DOI DOI 10.12968/BJ0M.2012.20.3.194; Williams JMG, 2014, J CONSULT CLIN PSYCH, V82, P275, DOI 10.1037/a0035036; Wilson DB, 2011, METAANALYSIS MACROS; Wilson K. G, 1999, ACCEPTANCE COMMITMEN; Woolhouse H, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0369-z; Zhang HY, 2015, MINDFULNESS, V6, P663, DOI 10.1007/s12671-014-0304-4	75	92	94	4	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2016	11	5							e0155720	10.1371/journal.pone.0155720	http://dx.doi.org/10.1371/journal.pone.0155720			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DM3XH	27182732	Green Accepted, Green Published, gold			2023-01-03	WOS:000376279500062
J	Freedman, SB; Willan, AR; Boutis, K; Schuh, S				Freedman, Stephen B.; Willan, Andrew R.; Boutis, Kathy; Schuh, Suzanne			Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL REHYDRATION SOLUTIONS; EMERGENCY-DEPARTMENT; DEHYDRATION SCALE; ACUTE DIARRHEA; INFANTS; VALIDATION; WATER; ONDANSETRON; TOO	IMPORTANCE Gastroenteritis is a common pediatric illness. Electrolyte maintenance solution is recommended to treat and prevent dehydration. Its advantage in minimally dehydrated children is unproven. OBJECTIVE To determine if oral hydration with dilute apple juice/preferred fluids is noninferior to electrolyte maintenance solution in children with mild gastroenteritis. DESIGN, SETTING, AND PARTICIPANTS Randomized, single-blind noninferiority trial conducted between the months of October and April during the years 2010 to 2015 in a tertiary care pediatric emergency department in Toronto, Ontario, Canada. Study participants were children aged 6 to 60 months with gastroenteritis and minimal dehydration. INTERVENTIONS Participants were randomly assigned to receive color-matched half-strength apple juice/preferred fluids (n=323) or apple-flavored electrolyte maintenance solution (n=324). Oral rehydration therapy followed institutional protocols. After discharge, the half-strength apple juice/preferred fluids group was administered fluids as desired; the electrolyte maintenance solution group replaced losses with electrolyte maintenance solution. MAIN OUTCOMES AND MEASURES The primary outcome was a composite of treatment failure defined by any of the following occurring within 7 days of enrollment: intravenous rehydration, hospitalization, subsequent unscheduled physician encounter, protracted symptoms, crossover, and 3% or more weight loss or significant dehydration at in-person follow-up. Secondary outcomes included intravenous rehydration, hospitalization, and frequency of diarrhea and vomiting. The noninferiority margin was defined as a difference between groups of 7.5% for the primary outcome and was assessed with a 1-sided a=.025. If noninferiority was established, a 1-sided test for superiority was conducted. RESULTS Among 647 randomized children (mean age, 28.3 months; 331 boys [51.1%]; 441 (68.2%) without evidence of dehydration), 644 (99.5%) completed follow-up. Children who were administered dilute apple juice experienced treatment failure less often than those given electrolyte maintenance solution (16.7% vs 25.0%; difference, -8.3%; 97.5% CI, -infinity to -2.0%; P < .001 for inferiority and P = .006 for superiority). Fewer children administered apple juice/preferred fluids received intravenous rehydration (2.5% vs 9.0%; difference, -6.5%; 99% CI, -11.6% to -1.8%). Hospitalization rates and diarrhea and vomiting frequency were not significantly different between groups. CONCLUSIONS AND RELEVANCE Among children with mild gastroenteritis and minimal dehydration, initial oral hydration with dilute apple juice followed by their preferred fluids, compared with electrolyte maintenance solution, resulted in fewer treatment failures. In many high-income countries, the use of dilute apple juice and preferred fluids as desired may be an appropriate alternative to electrolyte maintenance fluids in children with mild gastroenteritis and minimal dehydration.	[Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp, Res Inst, 2888 Shaganappi Trail, Calgary, AB T3B 6A8, Canada; [Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp, Sect Pediat Emergency Med, Calgary, AB, Canada; [Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp, Gastroenterol Sect, Calgary, AB, Canada; [Willan, Andrew R.] Univ Toronto, Hosp Sick Children, Res Inst,Fac Med, Ontario Child Hlth Support Unit,Dalla Lana Sch Pu, Toronto, ON M5G 1X8, Canada; [Boutis, Kathy; Schuh, Suzanne] Hosp Sick Children, Div Pediat Emergency Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Boutis, Kathy; Schuh, Suzanne] Child Hlth Evaluat Sci, Toronto, ON, Canada; [Boutis, Kathy; Schuh, Suzanne] Univ Toronto, Hosp Sick Children, Res Inst, Dept Pediat,Fac Med, Toronto, ON M5G 1X8, Canada	Alberta Childrens Hospital; University of Calgary; Alberta Childrens Hospital; University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Freedman, SB (corresponding author), Univ Calgary, Dept Pediat, Sect Emergency Med, 2888 Shaganappi Trail, Calgary, AB T3B 6A8, Canada.; Freedman, SB (corresponding author), Univ Calgary, Dept Pediat, Gastroenterol Sect, 2888 Shaganappi Trail, Calgary, AB T3B 6A8, Canada.; Freedman, SB (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, 2888 Shaganappi Trail, Calgary, AB T3B 6A8, Canada.	stephen.freedman@albertahealthservices.ca	Freedman, Stephen/H-9102-2012	Freedman, Stephen/0000-0003-2319-6192	Physician Services Incorporated Foundation [10q1011]; Alberta Children's Hospital Foundation Professorship in Child Health and Wellness	Physician Services Incorporated Foundation; Alberta Children's Hospital Foundation Professorship in Child Health and Wellness	This study was supported by a grant provided by the Physician Services Incorporated Foundation (grant 10q1011). Dr Freedman holds the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness.	American Academy of Pediatrics, 2004, PEDIATRICS, V114, P507, DOI [DOI 10.1542/PEDS.114.2.507, 10.1542/peds.114.2.507]; Bailey B, 2010, ACAD EMERG MED, V17, P583, DOI 10.1111/j.1553-2712.2010.00767.x; Briefel RR, 2004, J AM DIET ASSOC, V104, pS31, DOI 10.1016/j.jada.2003.10.020; Bruce RC, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.6.e4; Cheng A, 2011, PAED CHILD HEALT-CAN, V16, P177, DOI 10.1093/pch/16.3.177; COHEN MB, 1993, NEW ENGL J MED, V329, P211, DOI 10.1056/NEJM199307153290319; CPMP, 2001, BRIT J CLIN PHARMACO, V52, P223; Duggan C, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e29; Duggan C, 1996, J PEDIATR GASTR NUTR, V22, P56, DOI 10.1097/00005176-199601000-00009; FINBERG L, 1986, AM J DIS CHILD, V140, P524, DOI 10.1001/archpedi.1986.02140200034019; Freedman SB, 2006, NEW ENGL J MED, V354, P1698, DOI 10.1056/NEJMoa055119; Freedman SB, 2013, J PEDIATR GASTR NUTR, V57, P612, DOI 10.1097/MPG.0b013e3182a1dd93; Freedman SB, 2011, PEDIATRICS, V127, pE287, DOI 10.1542/peds.2010-2214; Freedman SB, 2010, ARCH PEDIAT ADOL MED, V164, P696, DOI 10.1001/archpediatrics.2010.129; Freedman SB, 2009, PEDIATRICS, V123, P841, DOI [10.1542/peds.2008-1570, 10.1542/peds.2008-0113]; Frifdman JN, 2004, J PEDIATR-US, V145, P201, DOI 10.1016/j.jpeds.2004.05.035; Goldman RD, 2008, PEDIATRICS, V122, P545, DOI 10.1542/peds.2007-3141; Gorelick MH, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e6; Gravel J, 2010, ARCH PEDIATRIE, V17, P1645, DOI 10.1016/j.arcped.2010.09.009; Guarino A, 2014, J PEDIATR GASTR NUTR, V59, P132, DOI 10.1097/MPG.0000000000000375; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Karpas A, 2009, PEDIATR EMERG CARE, V25, P301, DOI 10.1097/PEC.0b013e3181a34144; Kharbanda AB, 2013, J PEDIATR-US, V163, P230, DOI 10.1016/j.jpeds.2012.12.013; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Leshem E, 2014, PEDIATRICS, V134, P15, DOI 10.1542/peds.2013-3849; Leung A, 2006, PAED CHILD HEALT-CAN, V11, P527; Miyamoto K, 2012, ACTA PAEDIATR, V101, pE390, DOI 10.1111/j.1651-2227.2012.02765.x; National Institute for Health and Clinical Excellence, 2009, DIARRH VOM CAUS GAST; Ozuah PO, 2002, PEDIATRICS, V109, P259, DOI 10.1542/peds.109.2.259; Parkin PC, 2010, CLIN PEDIATR, V49, P235, DOI 10.1177/0009922809336670; Rao SSC, 2006, JPEN-PARENTER ENTER, V30, P433, DOI 10.1177/0148607106030005433; REIS EC, 1994, PEDIATRICS, V93, P708; Santucci KA, 1998, ARCH PEDIAT ADOL MED, V152, P142; Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Tam RK, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-149; Teach SJ, 1997, CLIN PEDIATR, V36, P395, DOI 10.1177/000992289703600703; Valois S, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-23; World Health Organization, 2005, TREATM DIARRH MAN PH	40	32	33	2	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2016	315	18					1966	1974		10.1001/jama.2016.5352	http://dx.doi.org/10.1001/jama.2016.5352			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2JP	27131100	Bronze			2023-01-03	WOS:000375461100014
J	Wen, TX; Zhang, ZN; Wong, KKL				Wen, Tingxi; Zhang, Zhongnan; Wong, Kelvin K. L.			Multi-Objective Algorithm for Blood Supply via Unmanned Aerial Vehicles to the Wounded in an Emergency Situation	PLOS ONE			English	Article							BEE COLONY ALGORITHM; ROUTING PROBLEM; GENETIC ALGORITHM; GREEN LOGISTICS; OPTIMIZATION; SEARCH	Unmanned aerial vehicle (UAV) has been widely used in many industries. In the medical environment, especially in some emergency situations, UAVs play an important role such as the supply of medicines and blood with speed and efficiency. In this paper, we study the problem of multi-objective blood supply by UAVs in such emergency situations. This is a complex problem that includes maintenance of the supply blood's temperature model during transportation, the UAVs' scheduling and routes' planning in case of multiple sites requesting blood, and limited carrying capacity. Most importantly, we need to study the blood's temperature change due to the external environment, the heating agent (or refrigerant) and time factor during transportation, and propose an optimal method for calculating the mixing proportion of blood and appendage in different circumstances and delivery conditions. Then, by introducing the idea of transportation appendage into the traditional Capacitated Vehicle Routing Problem (CVRP), this new problem is proposed according to the factors of distance and weight. Algorithmically, we use the combination of decomposition-based multi-objective evolutionary algorithm and local search method to perform a series of experiments on the CVRP public dataset. By comparing our technique with the traditional ones, our algorithm can obtain better optimization results and time performance.	[Wen, Tingxi; Zhang, Zhongnan] Xiamen Univ, Software Sch, Xiamen, Fujian, Peoples R China; [Wong, Kelvin K. L.] Univ Western Sydney, Sch Med, Sydney, NSW, Australia	Xiamen University; Western Sydney University	Zhang, ZN (corresponding author), Xiamen Univ, Software Sch, Xiamen, Fujian, Peoples R China.	zhongnan_zhang@xmu.edu.cn	Wong, Kelvin/AAL-8636-2021; Wong, Kelvin Kian Loong/ABA-3915-2021	Wong, Kelvin Kian Loong/0000-0002-8600-1105	Science and Technology Key Project of Fujian Province, China [2014H0044]; Science and Technology Guiding Project of Fujian Province, China [2015H0037, 2016H0035]; Science and Technology Project of Xiamen, China [3502Z20153026]	Science and Technology Key Project of Fujian Province, China; Science and Technology Guiding Project of Fujian Province, China; Science and Technology Project of Xiamen, China	This research is supported by the Science and Technology Key Project of Fujian Province, China (No. 2014H0044); Science and Technology Guiding Project of Fujian Province, China (No. 2015H0037, No. 2016H0035); Science and Technology Project of Xiamen, China (No. 3502Z20153026). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarado-Iniesta A, 2013, EXPERT SYST APPL, V40, P4785, DOI 10.1016/j.eswa.2013.02.029; Aras N, 2011, TRANSPORT RES C-EMER, V19, P866, DOI 10.1016/j.trc.2010.08.003; Azapagic A., 1999, J CLEAN PROD, V7, P135, DOI DOI 10.1016/S0959-6526(98)00051-1; Baker BM, 2003, COMPUT OPER RES, V30, P787, DOI 10.1016/S0305-0548(02)00051-5; Bell JE, 2004, ADV ENG INFORM, V18, P41, DOI 10.1016/j.aei.2004.07.001; Berman R, 2008, PHYS TODAY, V31, P56; Bernard M, 2011, J FIELD ROBOT, V28, P914, DOI 10.1002/rob.20401; Blood S, 2006, CHINESE MED J, P429; BODIN L, 1983, COMPUT OPER RES, V10, P63, DOI 10.1016/0305-0548(83)90030-8; Chiang WC, 1996, ANN OPER RES, V63, P3, DOI 10.1007/BF02601637; Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017; Deb K., 2001, MULTIOBJECTIVE OPTIM, V1st; Dekker R, 2012, EUR J OPER RES, V219, P671, DOI 10.1016/j.ejor.2011.11.010; Durillo JJ, 2011, ADV ENG SOFTW, V42, P760, DOI 10.1016/j.advengsoft.2011.05.014; Gen M., 1999, GENETIC ALGORITHMS E; GENDREAU M, 1994, MANAGE SCI, V40, P1276, DOI 10.1287/mnsc.40.10.1276; Grefenstette J., 1985, P THE 1 INT C GENETI, P160; Holland J, 1975, ADAPTATION NATURAL A; Kara I, 2006, EUR J OPER RES, V174, P1449, DOI 10.1016/j.ejor.2005.03.008; Lin YC, 2012, IEEE INT CONF ROBOT, P3588, DOI 10.1109/ICRA.2012.6225112; Mazzeo S., 2004, ELECT NOTES DISCRETE, V18, P181, DOI [10.1016/j.endm.2004.06.029, DOI 10.1016/J.ENDM.2004.06.029]; Novoa C, 2009, EUR J OPER RES, V196, P509, DOI 10.1016/j.ejor.2008.03.023; Osman I. H., 1996, METAHEURISTICS, P1, DOI [10.1007/978-1-4613-1361-8_1, DOI 10.1007/978-1-4613-1361-8_1]; Ro K., 2007, 45 AIAA AER SCI M EX, P596; Semsch E, 2009, 2009 IEEE/WIC/ACM INTERNATIONAL JOINT CONFERENCES ON WEB INTELLIGENCE (WI) AND INTELLIGENT AGENT TECHNOLOGIES (IAT), VOL 2, P82; Szeto WY, 2011, EUR J OPER RES, V215, P126, DOI 10.1016/j.ejor.2011.06.006; Ubeda S, 2011, INT J PROD ECON, V131, P44, DOI 10.1016/j.ijpe.2010.04.041; Vidal T, 2013, COMPUT OPER RES, V40, P475, DOI 10.1016/j.cor.2012.07.018; Vidal T, 2012, OPER RES, V60, P611, DOI 10.1287/opre.1120.1048; Wen TX, 2015, 2015 IEEE INTERNATIONAL CONFERENCE ON DATA SCIENCE AND DATA INTENSIVE SYSTEMS, P153, DOI 10.1109/DSDIS.2015.36; Zhang QF, 2007, IEEE T EVOLUT COMPUT, V11, P712, DOI 10.1109/TEVC.2007.892759; Zhang SZ, 2014, TRANSPORT RES D-TR E, V31, P85, DOI 10.1016/j.trd.2014.05.015	33	27	27	4	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2016	11	5							e0155176	10.1371/journal.pone.0155176	http://dx.doi.org/10.1371/journal.pone.0155176			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8BN	27163361	Green Published, gold, Green Submitted			2023-01-03	WOS:000376585700031
J	Deyo, RA; Mirza, SK				Deyo, Richard A.; Mirza, Sohail K.			Herniated Lumbar Intervertebral Disk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BACK-PAIN; NONOPERATIVE TREATMENT; SPINAL MANIPULATION; BED REST; SCIATICA; SURGERY; TRIAL; RADICULOPATHY; STEROIDS; HISTORY	A 41-year-old man reports the sudden onset of low back and left leg pain. The symptoms began while he was doing yard work and pulling out large bushes. Since the onset of the pain 2 days ago, it has worsened, although he took a single dose of ibuprofen when the pain began. The patient has no clinically significant medical history, and the physical examination is normal other than severe pain in the left leg with a straight-leg-raising maneuver to 40 degrees. He says, "I'm sure I slipped a disk," and he requests magnetic resonance imaging (MRI) of the low back. What testing and treatment would you recommend?	[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA; [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA; [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA; [Deyo, Richard A.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97239 USA; [Mirza, Sohail K.] Dartmouth Geisel Sch Med, Dept Orthopaed Surg, Hanover, NH USA; [Mirza, Sohail K.] Dartmouth Geisel Sch Med, Dartmouth Inst, Hanover, NH USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Dartmouth College; Dartmouth College	Deyo, RA (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code FM, Portland, OR 97239 USA.	deyor@ohsu.edu			NuVasive from the International Society for the Study of the Lumbar Spine	NuVasive from the International Society for the Study of the Lumbar Spine	Dr. Deyo reports receiving a financial award from NuVasive as part of a lifetime achievement award from the International Society for the Study of the Lumbar Spine. No other potential conflict of interest relevant to this article was reported.	Al-Shoha A, 2012, SPINE, V37, pE1567, DOI 10.1097/BRS.0b013e318270280e; Andersson G, 2014, BURDEN MUSCULOSKELET; Battie MC, 2004, SPINE, V29, P2679, DOI 10.1097/01.brs.0000146457.83240.eb; Brinjikji W, 2015, AM J NEURORADIOL, V36, P811, DOI 10.3174/ajnr.A4173; Bronfort G, 2014, ANN INTERN MED, V161, P381, DOI 10.7326/M14-0006; BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013; Carragee EJ, 1999, SPINE, V24, P2346, DOI 10.1097/00007632-199911150-00010; Chaparro LE, 2014, SPINE, V39, P556, DOI 10.1097/BRS.0000000000000249; Chou R, 2015, ANN INTERN MED, V163, P373, DOI 10.7326/M15-0934; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2011, ANN INTERN MED, V154, P181, DOI 10.7326/0003-4819-154-3-201102010-00008; Chou R, 2009, SPINE, V34, P1066, DOI 10.1097/BRS.0b013e3181a1390d; Cohen SP, 2012, ANN INTERN MED, V156, P551, DOI [10.7326/0003-4819-156-8-201204170-00397, 10.7326/0003-4819-156-8-201204170-00002]; Desai A, 2011, J NEUROSURG-SPINE, V14, P647, DOI 10.3171/2011.1.SPINE10426; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Deyo RA, 2000, MED CARE, V38, P959, DOI 10.1097/00005650-200009000-00009; Fairbank Jeremy, 2011, Evid Based Spine Care J, V2, P27, DOI 10.1055/s-0031-1274754; Fardon DF, 2014, SPINE J, V14, P2525, DOI 10.1016/j.spinee.2014.04.022; Fernandez M, 2015, SPINE, V40, P1457, DOI 10.1097/BRS.0000000000001036; Friedly JL, 2014, NEW ENGL J MED, V371, P11, DOI 10.1056/NEJMoa1313265; Goldberg H, 2015, JAMA-J AM MED ASSOC, V313, P1915, DOI 10.1001/jama.2015.4468; Kreiner DS, 2014, SPINE J, V14, P180, DOI 10.1016/j.spinee.2013.08.003; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Lurie JD, 2014, SPINE, V39, P3, DOI 10.1097/BRS.0000000000000088; Martin BI, 2012, SPINE J, V12, P89, DOI 10.1016/j.spinee.2011.11.010; Mixter W.J., 1934, NEW ENGL J MED, V211, P210, DOI [10.1056/NEJM193408022110506, DOI 10.1056/NEJM193408022110506]; Oliphant D, 2004, J MANIP PHYSIOL THER, V27, P197, DOI 10.1016/j.jmpt.2003.12.023; Osterman H, 2006, SPINE, V31, P2409; Overdevest GM, 2014, SPINE J, V14, P1817, DOI 10.1016/j.spinee.2013.07.456; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; Pinto RZ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e497; Rhee JM, 2006, J BONE JOINT SURG AM, V88A, P2070; Roncoroni C, 2011, RHEUMATOLOGY, V50, P1603, DOI 10.1093/rheumatology/ker151; Ropper AH, 2015, NEW ENGL J MED, V372, P1240, DOI 10.1056/NEJMra1410151; Santilli Valter, 2006, Spine J, V6, P131, DOI 10.1016/j.spinee.2005.08.001; Shriver MF, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15281; Smith JS, 2012, SPINE, V37, P1975, DOI 10.1097/BRS.0b013e318257fada; Sorensen IG, 2011, SPINE, V36, P1541, DOI 10.1097/BRS.0b013e3181f9b8d4; Suri P, 2012, ARCH PHYS MED REHAB, V93, P690, DOI 10.1016/j.apmr.2011.11.028; van der Windt DAWM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007431.pub2; Verwoerd AJH, 2014, SPINE J, V14, P2028, DOI 10.1016/j.spinee.2013.11.049; Vroomen PCAJ, 2002, J NEUROL NEUROSUR PS, V72, P630, DOI 10.1136/jnnp.72.5.630; Vroomen PCAJ, 1999, NEW ENGL J MED, V340, P418, DOI 10.1056/NEJM199902113400602; Vroomen PCAJ, 2002, BRIT J GEN PRACT, V52, P119; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Webster BS, 2014, SPINE, V39, P1433, DOI 10.1097/BRS.0000000000000408; Wegner I, 2013, COCHRANE DB SYST REV, V8; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441; Weinstein JN, 2006, SPINE, V31, P2707, DOI 10.1097/01.brs.0000248132.15231.fe	49	130	152	4	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 5	2016	374	18					1763	1772		10.1056/NEJMcp1512658	http://dx.doi.org/10.1056/NEJMcp1512658			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL0RY	27144851				2023-01-03	WOS:000375341500009
J	Prochazka, AV				Prochazka, Allan V.			Varenicline increased smoking cessation at 24 weeks in patients hospitalized with ACS and motivated to quit	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Prochazka, AV (corresponding author), Denver VA Med Ctr, Denver, CO USA.							Grandi SM, 2013, CAN J CARDIOL, V29, P1704, DOI 10.1016/j.cjca.2013.09.014; Jang JS, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.002226; Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218; WILHELMSSON C, 1975, LANCET, V1, P416	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2016	164	8					JC43	JC43		10.7326/ACPJC-2016-164-6-043	http://dx.doi.org/10.7326/ACPJC-2016-164-6-043			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ5OH	27089092				2023-01-03	WOS:000374257900005
J	Perez, GIP; Gao, Z; Jourdain, R; Ramirez, J; Gany, F; Clavaud, C; Demaude, J; Breton, L; Blaser, MJ				Perez, Guillermo I. Perez; Gao, Zhan; Jourdain, Roland; Ramirez, Julia; Gany, Francesca; Clavaud, Cecile; Demaude, Julien; Breton, Lionel; Blaser, Martin J.			Body Site Is a More Determinant Factor than Human Population Diversity in the Healthy Skin Microbiome	PLOS ONE			English	Article							BACTERIAL COMMUNITIES; CUTANEOUS BACTERIAL; FUNGAL POPULATIONS; ABCC11 ALLELE; ODOR; QUANTITATION; GREENGENES; PSORIASIS; DISEASE; PROFILE	We studied skin microbiota present in three skin sites (forearm, axilla, scalp) in men from six ethnic groups living in New York City. Methods. Samples were obtained at baseline and after four days following use of neutral soap and stopping regular hygiene products, including shampoos and deodorants. DNA was extracted using the MoBio Power Lyzer kit and 16S rRNA gene sequences determined on the IIlumina MiSeq platform, using QIIME for analysis. Results. Our analysis confirmed skin swabbing as a useful method for sampling different areas of the skin because DNA concentrations and number of sequences obtained across subject libraries were similar. We confirmed that skin location was the main factor determining the composition of bacterial communities. Alpha diversity, expressed as number of species observed, was greater in arm than on scalp or axilla in all studied groups. We observed an unexpected increase in a-diversity on arm, with similar tendency on scalp, in the South Asian group after subjects stopped using their regular shampoos and deodorants. Significant differences at phylum and genus levels were observed between subjects of the different ethnic origins at all skin sites. Conclusions. We conclude that ethnicity and particular soap and shampoo practices are secondary factors compared to the ecological zone of the human body in determining cutaneous microbiota composition.	[Perez, Guillermo I. Perez; Gao, Zhan; Blaser, Martin J.] NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA; [Jourdain, Roland; Clavaud, Cecile; Demaude, Julien; Breton, Lionel] LOreal Res & Innovat, Aulnay Sous Bois, France; [Ramirez, Julia; Gany, Francesca] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Demaude, Julien] LOreal Res & Innovat, Clark, NJ USA; [Blaser, Martin J.] Vet Affairs Med Ctr, New York Harbor Dept, New York, NY USA	New York University; NYU Langone Medical Center; L'Oreal Group; Memorial Sloan Kettering Cancer Center; L'Oreal Group; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Perez, GIP (corresponding author), NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.	perezg02@med.nyu.edu	Perez, Guillermo Perez/AAJ-3761-2020	Perez Perez, Guillermo/0000-0002-0131-5798; Gao, Zhan/0000-0003-0976-8836	Diane Belfer program in Human Microbial Ecology from the National Institutes of Health [UH2 AR057506-01S1]; L'Oreal Research and Innovation grant; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [UH2AR057506] Funding Source: NIH RePORTER	Diane Belfer program in Human Microbial Ecology from the National Institutes of Health; L'Oreal Research and Innovation grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported in part by the Diane Belfer program in Human Microbial Ecology, UH2 AR057506-01S1 from the National Institutes of Health, and L'Oreal Research and Innovation grant. Cecile Clavaud, Roland Jourdain, Julien Demaude, and Lionel Breton are employees of L'Oreal Research & Innovation.	Aagaard K, 2013, FASEB J, V27, P1012, DOI 10.1096/fj.12-220806; Akaza N, 2015, J DERMATOL; Alekseyenko AV, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-31; Alexeyev OA, 2013, EXP DERMATOL, V22, P443, DOI 10.1111/exd.12160; Alexis AE, 2012, J DRUGS DERMATOL, V11, pS30; Belkaid Y, 2014, SCIENCE, V346, P954, DOI 10.1126/science.1260144; Blaser MJ, 2013, ISME J, V7, P85, DOI 10.1038/ismej.2012.81; Callewaert C, 2014, APPL ENVIRON MICROB, V80, P6611, DOI 10.1128/AEM.01422-14; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Clavaud C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058203; Clemente JC, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500183; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Eilers KG, 2012, SOIL BIOL BIOCHEM, V50, P58, DOI 10.1016/j.soilbio.2012.03.011; EVANS CA, 1976, J CLIN MICROBIOL, V3, P576; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Flores GE, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0531-y; Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104; Gao Z, 2010, J CLIN MICROBIOL, V48, P3575, DOI 10.1128/JCM.00597-10; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Grice EA, 2012, ANNU REV GENOM HUM G, V13, P151, DOI 10.1146/annurev-genom-090711-163814; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Harker M, 2014, J DERMATOL SCI, V73, P23, DOI 10.1016/j.jdermsci.2013.08.016; Hospodsky D, 2014, MICROBIOL-SGM, V160, P1144, DOI 10.1099/mic.0.075390-0; Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417; Li W, 2014, MICROBIOL RES, V169, P686, DOI 10.1016/j.micres.2014.02.008; Marples M. J., 1965, ECOLOGY HUMAN SKIN; Martin A, 2010, J INVEST DERMATOL, V130, P529, DOI 10.1038/jid.2009.254; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Pappas A, 2013, DERM-ENDOCRINOL, V5, P319, DOI 10.4161/derm.25366; Picardo M, 2014, J CLIN GASTROENTEROL, V48, pS85, DOI 10.1097/MCG.0000000000000241; SanMiguel A, 2015, CELL MOL LIFE SCI, V72, P1499, DOI 10.1007/s00018-014-1812-z; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Stanford JA, 2013, SEMIN IMMUNOL, V25, P370, DOI [10.1016/j.smim.2013.09.005, DOI 10.1016/J.SMIM.2013.09.005]; Statnikov A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02620; Walters WA, 2011, BIOINFORMATICS, V27, P1159, DOI 10.1093/bioinformatics/btr087; Wang LL, 2015, EXP DERMATOL, V24, P398, DOI 10.1111/exd.12684; Weyrich LS, 2015, AUSTRALAS J DERMATOL, V56, P268, DOI 10.1111/ajd.12253; Wylie KM, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0071-7; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yoshiura K, 2006, NAT GENET, V38, P324, DOI 10.1038/ng1733	46	84	84	2	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2016	11	4							e0151990	10.1371/journal.pone.0151990	http://dx.doi.org/10.1371/journal.pone.0151990			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9IK	27088867	Green Published, gold, Green Submitted			2023-01-03	WOS:000374527000003
J	Wu, SH; Fisher-Hoch, SP; Reininger, B; McCormick, JB				Wu, Shenghui; Fisher-Hoch, Susan P.; Reininger, Belinda; McCormick, Joseph B.			Recommended Levels of Physical Activity Are Associated with Reduced Risk of the Metabolic Syndrome in Mexican-Americans	PLOS ONE			English	Article							INSULIN-RESISTANCE; PREVALENCE; EXERCISE; RELIABILITY; COMMUNITY; OBESITY; WEIGHT; DIET	Purpose To measure the association between physical activity and the metabolic syndrome risk in Mexican-Americans. Methods Participants were drawn from the Cameron County Hispanic Cohort (n = 3,414), a randomly selected Mexican-American cohort in Texas on the US-Mexico border. Moderate and vigorous physical activity was assessed using reliable and validated instruments. The metabolic syndrome was defined as having 3 or more metabolic abnormalities. Results One thousand five hundred and twenty-four participants of the cohort (45.02%) were found to have the metabolic syndrome. Compared to participants who did not meet US physical activity guidelines, participants who met physical activity guidelines of 150 moderate and vigorous minutes per week (>= 600 MET adjusted minutes) had 36% lower risk for the metabolic syndrome (OR = 0.64; 95% CI: 0.42-0.98), and participants with total minutes per week of moderate and vigorous/strenuous activity greater than 743 MET adjusted minutes had 37% lower risk for the metabolic syndrome (OR = 0.63; 95% CI: 0.42-0.94) compared with their counterparts, after adjusting for age, gender, annual household income, body mass index, smoking and alcohol drinking status, total portions of fruit and vegetable intake, census tracts and blocks, and survey version for physical activity. Conclusions Meeting or exceeding physical activity guidelines significantly was inversely associated with the risk for the metabolic syndrome in Mexican-Americans. Improving levels of physical activity appears to be an effective target for the metabolic syndrome prevention and control among Mexican-Americans independent of other factors.	[Wu, Shenghui] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, Laredo Campus, Laredo, TX USA; [Fisher-Hoch, Susan P.; McCormick, Joseph B.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Epidemiol, Brownsville Campus, Brownsville, TX USA; [Reininger, Belinda] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Hlth Promot & Hlth Behav, Brownsville Campus, Brownsville, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	McCormick, JB (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Epidemiol, Brownsville Campus, Brownsville, TX USA.	Joseph.b.mccormick@uth.tmc.edu		McCormick, Joseph/0000-0002-5844-8102	National Institute on Minority Health and Health Disparities [MD000170 P2]; National Center for Advancing Translational Science [CTSA UL1 TR000371]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD000170] Funding Source: NIH RePORTER	National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Center for Advancing Translational Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by the National Institute on Minority Health and Health Disparities (http://www.nimhd.nih.gov/), Grant # MD000170 P2 and the National Center for Advancing Translational Science (http://www.ncats.nih.gov/), Grant # CTSA UL1 TR000371. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bauman A, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-21; Carroll S, 2004, SPORTS MED, V34, P371, DOI 10.2165/00007256-200434060-00004; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dang MM, 2009, THESIS U TEXAS HLTH; Fisher-Hoch SP, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110298; Fisher-Hoch SP, 2010, PREV CHRONIC DIS, V7; Ford ES, 2010, J DIABETES, V2, P180, DOI 10.1111/j.1753-0407.2010.00078.x; Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65; GOFIN G, 2015, MED SCI SPORTS EXERC, V29, pS36; Groop L, 2000, BRIT J NUTR, V83, pS39; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Hagberg JM, 2000, SPORTS MED, V30, P193, DOI 10.2165/00007256-200030030-00004; Hallal PC, 2010, J PHYS ACT HEALTH, V7, pS259, DOI 10.1123/jpah.7.s2.s259; Harrell Frank E., 2001, REGRESSION MODELING; He D, 2014, ENDOCRINE, V46, P231, DOI 10.1007/s12020-013-0110-0; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Meigs JB, 2002, AM J MANAG CARE, V8, pS283; Mendez-Hernandez P, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-276; RAUH MJD, 1992, INT J EPIDEMIOL, V21, P966, DOI 10.1093/ije/21.5.966; Reininger BM, 2015, SOC SCI MED, V143, P98, DOI 10.1016/j.socscimed.2015.08.029; Reininger BM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1850-y; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Torjesen PA, 1997, DIABETES CARE, V20, P26, DOI 10.2337/diacare.20.1.26; US Department of Agriculture, 2013, CHOOS MY PLAT VEG; US Department of Agriculture, 2013, CHOOS MY PLAT FOOD G; USDHHS, 2008, PHYS ACT GUID AM; Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617; World Health Organization, 2010, GLOB REC PHYS ACT HL; Zhu SK, 2004, METABOLISM, V53, P1503, DOI 10.1016/j.metabol.2004.04.017; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295	30	24	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0152896	10.1371/journal.pone.0152896	http://dx.doi.org/10.1371/journal.pone.0152896			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27054324	Green Published, gold, Green Submitted			2023-01-03	WOS:000373608000051
J	Spitoni, GF; Pireddu, G; Galati, G; Sulpizio, V; Paolucci, S; Pizzamiglio, L				Spitoni, Grazia Fernanda; Pireddu, Giorgio; Galati, Gaspare; Sulpizio, Valentina; Paolucci, Stefano; Pizzamiglio, Luigi			Caloric Vestibular Stimulation Reduces Pain and Somatoparaphrenia in a Severe Chronic Central Post-Stroke Pain Patient: A Case Study	PLOS ONE			English	Article							SENSORY ABNORMALITIES; BODY	Central post-stroke pain is a neuropathic syndrome characterized by intolerable contralesional pain and, in rare cases, somatic delusions. To date, there is limited evidence for the effective treatments of this disease. Here we used caloric vestibular stimulation to reduce pain and somatoparaphrenia in a 57-year-old woman suffering from central post-stroke pain. Resting-state functional magnetic resonance imaging was used to assess the neurological effects of this treatment. Following vestibular stimulation we observed impressive improvements in motor skills, pain, and somatic delusions. In the functional connectivity study before the vestibular stimulation, we observed differences in the patient's left thalamus functional connectivity, with respect to the thalamus connectivity of a control group (N = 20), in the bilateral cingulate cortex and left insula. After the caloric stimulation, the left thalamus functional connectivity with these regions, which are known to be involved in the cortical response to pain, disappeared as in the control group. The beneficial use of vestibular stimulation in the reduction of pain and somatic delusion in a CPSP patient is now documented by behavioral and imaging data. This evidence can be applied to theoretical models of pain and body delusions.	[Spitoni, Grazia Fernanda; Pireddu, Giorgio; Galati, Gaspare; Sulpizio, Valentina] Univ Roma La Sapienza, Dept Psychol, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Spitoni, Grazia Fernanda; Pireddu, Giorgio; Galati, Gaspare; Sulpizio, Valentina; Paolucci, Stefano; Pizzamiglio, Luigi] IRCCS Santa Lucia Fdn, Neuropsychol Lab, Rome, Italy	Sapienza University Rome; IRCCS Santa Lucia	Spitoni, GF (corresponding author), Univ Roma La Sapienza, Dept Psychol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.; Spitoni, GF (corresponding author), IRCCS Santa Lucia Fdn, Neuropsychol Lab, Rome, Italy.	grazia.spitoni@uniroma1.it	Galati, Gaspare/F-3277-2011	Galati, Gaspare/0000-0002-0640-4247	Ministero della Salute (Italy) [RF-2009-1547884]	Ministero della Salute (Italy)(Ministry of Health, Italy)	This work was supported by Grant RF-2009-1547884 received from Ministero della Salute (Italy) (http://www.salute.gov.it) to IRCCS Fondazione Santa Lucia (Rome, Italy).	BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; Boivie J, 2006, HAND CLINIC, V81, P715, DOI 10.1016/S0072-9752(06)80052-7; Bottini G, 2005, NEUROLOGY, V65, P1278, DOI 10.1212/01.wnl.0000182398.14088.e8; Bowsher D, 1996, J NEUROL NEUROSUR PS, V61, P62, DOI 10.1136/jnnp.61.1.62; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; Cogliano R, 2012, CORTEX, V48, P758, DOI 10.1016/j.cortex.2011.08.008; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Craig AD, 2007, CENTRAL NEUROPATHIC, P81; Craig ADB, 1998, PAIN FORUM, V7, P1; Dieterich M, 2005, BRAIN, V128, P2052, DOI 10.1093/brain/awh551; Gandola M, 2012, CORTEX, V48, P1165, DOI 10.1016/j.cortex.2011.06.012; Garcia-Larrea L, 2013, PAIN, V154, pS29, DOI 10.1016/j.pain.2013.09.001; Garcia-Larrea L, 2010, BRAIN, V133, P2528, DOI 10.1093/brain/awq220; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Hanihara T, 2009, PSYCHOSOMATICS, V50, P534, DOI 10.1176/appi.psy.50.5.534; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; Henry JL, 2008, PAIN RES MANAG, V13, P41, DOI 10.1155/2008/754260; Kim JH, 2007, J NEUROSCI, V27, P4995, DOI 10.1523/JNEUROSCI.0716-07.2007; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Mast FW, 2006, NEUROPSYCHOLOGIA, V44, P101, DOI 10.1016/j.neuropsychologia.2005.04.005; McGeoch PD, 2008, J NEUROL NEUROSUR PS, V79, P1298, DOI 10.1136/jnnp.2008.146738; Medford N, 2010, BRAIN STRUCT FUNCT, V214, P535, DOI 10.1007/s00429-010-0265-x; Montes C, 2005, PAIN, V113, P223, DOI 10.1016/j.pain.2004.09.044; Okada N, 2014, INT J ORAL MAX SURG, V43, P933, DOI 10.1016/j.ijom.2014.02.013; Pizzamiglio L, 2001, CORTEX, V37, P11, DOI 10.1016/S0010-9452(08)70555-0; Ramachandran VS, 2007, MED HYPOTHESES, V69, P486, DOI 10.1016/j.mehy.2006.12.036; Riddoch G, 1938, LANCET, V1, P1093; Rode G, 2012, NEUROPSYCHOLOGIA, V50, P245, DOI 10.1016/j.neuropsychologia.2011.11.018; Rode G, 1998, SCAND J REHABIL MED, V30, P9; Sprenger T, 2012, BRAIN, V135, P2536, DOI 10.1093/brain/aws153; Vallar G, 2009, EXP BRAIN RES, V192, P533, DOI 10.1007/s00221-008-1562-y	32	12	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2016	11	3							e0151213	10.1371/journal.pone.0151213	http://dx.doi.org/10.1371/journal.pone.0151213			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9LB	27028404	Green Published, Green Submitted, gold			2023-01-03	WOS:000373116500020
J	Oh, SA; Yea, JW; Kang, MK; Park, JW; Kim, SK				Oh, Se An; Yea, Ji Woon; Kang, Min Kyu; Park, Jae Won; Kim, Sung Kyu			Analysis of the Setup Uncertainty and Margin of the Daily ExacTrac 6D Image Guide System for Patients with Brain Tumors	PLOS ONE			English	Article							ACCURACY; INCLUSION	This study evaluated the setup uncertainties for brain sites when using BrainLAB's ExacTrac X-ray 6D system for daily pretreatment to determine the optimal planning target volume (PTV) margin. Between August 2012 and April 2015, 28 patients with brain tumors were treated by daily image-guided radiotherapy using the BrainLAB ExacTrac 6D image guidance system of the Novalis-Tx linear accelerator. DUONTM (Orfit Industries, Wijnegem, Belgium) masks were used to fix the head. The radiotherapy was fractionated into 27-33 treatments. In total, 844 image verifications were performed for 28 patients and used for the analysis. The setup corrections along with the systematic and random errors were analyzed for six degrees of freedom in the translational (lateral, longitudinal, and vertical) and rotational (pitch, roll, and yaw) dimensions. Optimal PTV margins were calculated based on van Herk et al.'s [margin recipe = 2.5 Sigma + 0.7 sigma-3 mm] and Stroom et al.'s [margin recipe = 2 Sigma + 0.7 sigma] formulas. The systematic errors (Sigma) were 0.72, 1.57, and 0.97mmin the lateral, longitudinal, and vertical translational dimensions, respectively, and 0.72 degrees, 0.87 degrees, and 0.83 degrees in the pitch, roll, and yaw rotational dimensions, respectively. The random errors (sigma) were 0.31, 0.46, and 0.54mm in the lateral, longitudinal, and vertical rotational dimensions, respectively, and 0.28 degrees, 0.24 degrees, and 0.31 in the pitch, roll, and yaw rotational dimensions, respectively. According to van Herk et al.' s and Stroom et al.' s recipes, the recommended lateral PTV margins were 0.97 and 1.66mm, respectively; the longitudinalmargins were 1.26 and 3.47mm, respectively; and the vertical margins were 0.21 and 2.31mm, respectively. Therefore, daily setup verifications using the BrainLAB ExacTrac 6D image guide system are very useful for evaluating the setup uncertainties and determining the setup margin.	[Oh, Se An; Yea, Ji Woon; Park, Jae Won; Kim, Sung Kyu] Yeungnam Univ, Dept Radiat Oncol, Med Ctr, Daegu, South Korea; [Yea, Ji Woon; Kim, Sung Kyu] Yeungnam Univ, Dept Radiat Oncol, Coll Med, Daegu, South Korea; [Kang, Min Kyu] Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea	Yeungnam University; Yeungnam University; Kyungpook National University	Kim, SK (corresponding author), Yeungnam Univ, Dept Radiat Oncol, Med Ctr, Daegu, South Korea.; Kim, SK (corresponding author), Yeungnam Univ, Dept Radiat Oncol, Coll Med, Daegu, South Korea.	skkim3@ynu.ac.kr	KANG, MIN KYU/ACI-8824-2022	KANG, MIN KYU/0000-0002-7962-7054; Oh, SeAn/0000-0002-8835-2814	Yeungnam University [214A480005]	Yeungnam University	This work was supported by the 2014 Yeungnam University Research Grant(214A480005). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beltran C, 2011, INT J RADIAT ONCOL, V79, P1266, DOI 10.1016/j.ijrobp.2009.12.057; Das S., 2010, J APPL CLIN MED PHYS, V12; Dzyubak O, 2014, MED PHYS, V41, DOI 10.1118/1.4896101; Gevaert T, 2012, INT J RADIAT ONCOL, V82, P1627, DOI 10.1016/j.ijrobp.2011.01.052; Gilbeau L, 2001, RADIOTHER ONCOL, V58, P155, DOI 10.1016/S0167-8140(00)00280-2; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Hong LX, 2009, INT J RADIAT ONCOL, V73, P556, DOI 10.1016/j.ijrobp.2008.09.055; Infusino E, 2015, J APPL CLIN MED PHYS, V16, P99, DOI 10.1120/jacmp.v16i2.5102; Kataria T, 2011, J CANCER RES THER, V7, P40, DOI 10.4103/0973-1482.80457; Linthout N, 2007, RADIOTHER ONCOL, V83, P168, DOI 10.1016/j.radonc.2007.04.015; Miyabe Y, 2011, MED PHYS, V38, P2535, DOI 10.1118/1.3578607; Oh YK, 2014, J APPL CLIN MED PHYS, V15, P85, DOI 10.1120/jacmp.v15i2.4418; OHSEAN, 2013, [PROGRESS in MEDICAL PHYSICS, 의학물리], V24, P145, DOI 10.14316/pmp.2013.24.3.145; Remeijer P, 2000, INT J RADIAT ONCOL, V46, P1281, DOI 10.1016/S0360-3016(99)00468-X; Shi C., 2012, J APPL CLIN MED PHYS, V13; Shiraishi K., 2014, VALIDATION PLANNING, V2014; Stanley DN, 2014, J APPL CLIN MED PHYS, V15, P81, DOI 10.1120/jacmp.v15i6.4877; Stroom JC, 1999, INT J RADIAT ONCOL, V43, P905, DOI 10.1016/S0360-3016(98)00468-4; van Herk M, 2000, INT J RADIAT ONCOL, V47, P1121, DOI 10.1016/S0360-3016(00)00518-6; van Herk M, 2004, SEMIN RADIAT ONCOL, V14, P52, DOI 10.1053/j.semradonc.2003.10.003; van Herk M, 2002, INT J RADIAT ONCOL, V52, P1407, DOI 10.1016/S0360-3016(01)02805-X; Yin F.-F., 2009, ROLE IN ROOM KV XRAY, V104; Zaghloul MS, 2010, CLIN ONCOL-UK, V22, P850, DOI 10.1016/j.clon.2010.08.006; Zhou JN, 2010, MED DOSIM, V35, P31, DOI 10.1016/j.meddos.2009.01.005	24	14	18	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2016	11	3							e0151709	10.1371/journal.pone.0151709	http://dx.doi.org/10.1371/journal.pone.0151709			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH5EH	27019082	Green Published, Green Submitted, gold			2023-01-03	WOS:000372807800018
J	Bhagavathula, AS; Elnour, AA; Jamshed, SQ; Shehab, A				Bhagavathula, Akshaya Srikanth; Elnour, Asim Ahmed; Jamshed, Shazia Qasim; Shehab, Abdulla			Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and MetaAnalysis	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; RESIDENT DOCTORS; EPIDEMIOLOGY; STUDENTS; COST	Background Spontaneous or voluntary reporting of suspected adverse drug reactions (ADRs) is one of the vital roles of all health professionals. In India, under-reporting of ADRs by health professionals is recognized as one of the leading causes of poor ADR signal detection. Therefore, reviewing the literature can provide a better understanding of the status of knowledge, attitude and practice (KAP) of Pharmacovigilance (PV) activities by health professionals. Methods A systematic review was performed through Pubmed, Scopus, Embase and Google Scholar scientific databases. Studies pertaining to KAP of PV and ADR reporting by Indian health professionals between January 2011 and July 2015 were included in a meta-analysis. Results A total of 28 studies were included in the systematic review and 18 of them were selected for meta-analysis. Overall, 55.6%(95% CI 44.4-66.9; p<0.001) of the population studied were not aware of the existence of the Pharmacovigilance Programme in India (PvPI), and 31.9% (95% CI 16.3-47.4; p<0.001) thought that "all drugs available in the market are safe". Furthermore, 28.7% (95% CI 16.4-40.9; p<0.001) of them were not interested in reporting ADRs and 74.5%, (95% CI 67.9-81.9; p<0.001) never reported any ADR to PV centers. Conclusion There was an enormous gap of KAP towards PV and ADR reporting, particularly PV practice in India. There is therefore an urgent need for educational awareness, simplification of the ADR reporting process, and implementation of imperative measures to practice PV among healthcare professionals. In order to understand the PV status, PvPI should procedurally assess the KAP of health professionals PV activities in India.	[Bhagavathula, Akshaya Srikanth] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Clin Pharm, Gondar, Ethiopia; [Elnour, Asim Ahmed] Fac Pharm, Fatima Coll Heath Sci, Dept Clin Pharm, FCHS Al Ain Campus, Al Ain, U Arab Emirates; [Jamshed, Shazia Qasim] Int Islamic Univ Malaysia, Dept Pharm Practice, Kulliyyah Pharm, Kuantan, Pahang, Malaysia; [Shehab, Abdulla] UAE Univ, Dept Internal Med, Coll Med & Hlth Sci, Al Ain, U Arab Emirates	University of Gondar; International Islamic University Malaysia; United Arab Emirates University	Bhagavathula, AS (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Clin Pharm, Gondar, Ethiopia.	akshaypharmd@gmail.com	Elnour, Asim/AAE-4405-2019; Jamshed, Shazia/AAF-6525-2020; Bhagavathula, Akshaya/GQH-1302-2022; Elnour, Asim/ABI-6308-2020; Bhagavathula, Akshaya Srikanth/G-6649-2015	Elnour, Asim/0000-0002-4143-7810; Jamshed, Shazia/0000-0003-0773-0463; Bhagavathula, Akshaya Srikanth/0000-0002-0581-7808				Ahmad Akram, 2013, Perspect Clin Res, V4, P204, DOI 10.4103/2229-3485.120168; Aithal S, 2014, INT J PHARM BIO SCI, V5, P108; Al Hamid A, 2014, BRIT J CLIN PHARMACO, V78, P202, DOI 10.1111/bcp.12293; Amrita P, 2012, INDIAN J PHARM PRACT, V5, P42; [Anonymous], 2012, REGULATORY SCENARIO; Bansode AA, 2015, J EVOL MED DENT SCI-, V4, P207, DOI 10.14260/jemds/2015/33; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; Bisht M, 2014, ISRN PHARM; Bismas P, 2007, INDIAN J PHARMACOL, V39, P124; Chanchu S, 2014, INT J SCI RES, V3, P1434; Chopra Deepti, 2011, Int J Risk Saf Med, V23, P227, DOI 10.3233/JRS-2011-0543; Choudary AK, 2013, INTERNET J PHARM, V12, P1566; Desai Chetna K, 2011, Perspect Clin Res, V2, P129, DOI 10.4103/2229-3485.86883; Gupta Pooja, 2014, Malar Res Treat, V2014, P837427, DOI 10.1155/2014/837427; Gupta Sandeep Kumar, 2015, Perspect Clin Res, V6, P45, DOI 10.4103/2229-3485.148816; Haidich AB, 2010, HIPPOKRATIA, V14, P29; Hakkarainen KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033236; Hardeep, 2013, J CLIN DIAGN RES, V7, P97, DOI 10.7860/JCDR/2012/4883.2680; Kamtane PA, 2012, ASIAN J PHARMA CLIN, V5, P210; Karelia BN, 2014, INT J BASIC CLIN PHA, V3, P50, DOI DOI 10.5455/2319-2003.IJBCP20140202; Khan LM, 2013, EUR J CLIN PHARMACOL, V69, P1985, DOI 10.1007/s00228-013-1563-z; Khan Sarfaraz Alam, 2013, J Nat Sci Biol Med, V4, P191, DOI 10.4103/0976-9668.107289; Kharkar Mala, 2012, Perspect Clin Res, V3, P90, DOI 10.4103/2229-3485.100651; Kiran LJ, 2014, SCHOLARS J APPL MED, V2, P399; Kumar MB, 2012, INDIAN J PHARM PRACT, V5, P51; Lahite RJ, 2015, FRONT PHARMACOL, DOI [10.3389/fphar.2015.00194, DOI 10.3389/FPHAR.2015.00194]; Lopez-Gonzalez E, 2009, DRUG SAFETY, V32, P19, DOI 10.2165/00002018-200932010-00002; Maharani B, 2013, NAT J BASIC MED SCI, V3, P294; Mishra H, 2013, J PHARMACOVIGILANCE, V1, P1; Olsson S, 2008, INDIAN J PHARMACOL, V40, pS28; Pal SN, 2013, DRUG SAFETY, V36, P75, DOI 10.1007/s40264-012-0014-6; Panja B, 2015, INDIAN J PHARMACOL, V47, P126, DOI 10.4103/0253-7613.150382; Patel K J, 2007, BMC Clin Pharmacol, V7, P8, DOI 10.1186/1472-6904-7-8; Pimpalkhute Sonali A, 2012, Indian J Med Sci, V66, P55; Prakasam Arul, 2012, Pharmacy Pract (Granada), V10, P222; Prakash S, 2007, INDIAN J PHARMACOL, V39, P123, DOI 10.4103/0253-7613.33430; Radhakrishnan Rajesh, 2011, International Journal of PharmTech Research, V3, P678; Rajakannan T, 2012, J CLIN PHARMACOL, V52, P559, DOI 10.1177/0091270011398867; Ravinandan AP, 2015, ASIAN J PHARM CLIN R, V8, P262; Rehan HS, 2012, INDIAN J PHARMACOL, V44, P699, DOI 10.4103/0253-7613.103253; Rehan HS, 2009, EUR J INTERN MED, V20, P3, DOI 10.1016/j.ejim.2008.04.019; Rishi RK, 2012, ADV PHARMACOEPIDEM D, V1, P1; Sanghavi Dhara R, 2013, Int J Risk Saf Med, V25, P197, DOI 10.3233/JRS-130598; Sengupta A, 2013, 19 IRDC, P23; Shankar P. Ravi, 2006, Indian Journal of Pharmacology, V38, P316; Sridevi SA, 2014, INT J PHARM TOXICOL, V4, P151; Suke Sanvidhan G, 2015, Online J Public Health Inform, V7, pe223, DOI 10.5210/ojphi.v7i2.5595; Tandon VR, 2015, INDIAN J PHARMACOL, V47, P65, DOI 10.4103/0253-7613.150344; Thomas TM, 2013, INT J PHARM CLIN SCI, V2, P82; Torwane N., 2015, J NAT ACCRED BOARD H, V2, P23; Upadhyaya HB, 2015, J ADV PHARM TECHNOL, V6, P29, DOI 10.4103/2231-4040.150369; Upadhyaya P, 2012, THER CLIN RISK MANAG, V8, P307, DOI 10.2147/TCRM.S31482; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; World Health Organization, 2002, HOEDMQSM20022 WHO; World Health Organization, 2002, SAF MED GUID DET REP	55	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0152221	10.1371/journal.pone.0152221	http://dx.doi.org/10.1371/journal.pone.0152221			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3SV	27010447	Green Submitted, Green Published, gold			2023-01-03	WOS:000372708000114
J	Yeoh, PL; Hornetz, K; Dahlui, M				Yeoh, Ping Ling; Hornetz, Klaus; Dahlui, Maznah			Antenatal Care Utilisation and Content between Low-Risk and High-Risk Pregnant Women	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; PRENATAL-CARE; ADEQUACY; POPULATION; OUTCOMES; DETERMINANTS; MORTALITY; EDUCATION; SERVICES; INDEXES	Background The purpose of antenatal care is to monitor and improve the wellbeing of the mother and foetus. The World Health Organization recommends risk-oriented strategy that includes: (i) routine care to all women, (ii) additional care for women with moderately severe diseases and complications, (iii) specialised obstetrical and neonatal care for women with severe diseases and complications. Antenatal care is concerned with adequate care in order to be effective. Measurement for adequacy of antenatal care often applies indexes that assess initiation of care and number of visits. In addition, adequacy of care content should also be assessed. Results of studies in developed settings demonstrate that women without risk factors use antenatal services more frequently than recommended. Such over-utilisation is problematic for low-resourced settings. Moreover, studies show that a substantial proportion of high-risk women had utilisation or content of care below the recommended standard. Yet studies in developing countries have seldom included a comparison between low-risk and high-risk women. The purpose of the study was therefore to assess adequacy of care and pregnancy outcomes for the different risk groups. Methods A retrospective study using a multistage sampling technique, at public-funded primary health care clinics was conducted. Antenatal utilisation level was assessed using a modified Adequacy of Prenatal Care Utilisation index that measures the timing for initiation of care and observed-to-expected visits ratio. Adequacy of antenatal care content assessed compliance to routine care based on the local guidelines. Results Intensive or "adequate-plus" antenatal care utilisation as defined by the modified index was noted in over half of the low-risk women. On the other hand, there were 26% of the high-risk women without the expected intensive utilisation. Primary-or non-educated high-risk women were less likely to have a higher antenatal care utilisation level compared with tertiary educated ones (OR = 0.20, P = 0.003). Half of all women had <80% of the recommended antenatal care content. A higher proportion of high-risk than low-risk women scored <80% of the routine care content (p<0.015). The majority of the additional laboratory tests were performed on high-risk women. Provision of antenatal education showed comparatively poor compliance to guidelines, more than half of the antenatal advice topics assessed were rarely provided to the women. High-risk women were associated with a higher prevalence of adverse pregnancy outcome. Conclusions Disproportionate utilisation of antenatal care according to risk level of pregnancy indicates the need for better scheduling of care. The risk-oriented approach often results in a tendency to focus on the risk conditions of the women. Training interventions are recommended to improve communication and to help healthcare professionals understand the priorities of the women. Further studies are required to assess the reason for disproportionate utilisation of antenatal care according to risk level and how delivery of antenatal advice can be improved, reviewing both user and provider perspectives.	[Yeoh, Ping Ling; Dahlui, Maznah] Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia; [Hornetz, Klaus] German Dev Cooperat, Berlin, Germany; [Yeoh, Ping Ling] Mediconsult Sdn Bhd, Ampang, Malaysia	Universiti Malaya	Yeoh, PL (corresponding author), Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia.; Yeoh, PL (corresponding author), Mediconsult Sdn Bhd, Ampang, Malaysia.	pingling@mediconsult.com.my	DAHLUI, MAZNAH/B-8976-2010; Dahlui, Maznah/F-9665-2010	DAHLUI, MAZNAH/0000-0003-4923-9410; 	Mediconsult Sdn. Bhd. Malaysia; University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant [E000010-20001]	Mediconsult Sdn. Bhd. Malaysia; University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant	Ping Ling Yeoh is supported by Mediconsult Sdn. Bhd. Malaysia for a PhD study. This work is part of the STeMM Programme supported by the University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant (Grant number E000010-20001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The first author is supported by Mediconsult Sdn. Bhd. Malaysia for a PhD study. This work is part of the STeMM Programme supported by the University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant (Grant number E000010-20001). The authors wish to acknowledge the contribution of Dr Ophelia Mendoza, Adjunct Professor at Department of Epidemiology and Biostatistics, College of Public Health, University of the Philippines, for the advice on sampling and sample size estimate; Prof Dr Karuthan Chinna and Prof Dr Sanjay Rampal of Department of Social and Preventive Medicine, University of Malaya, for the advice on data analysis; and the Department of Health, Selangor for allowing the study to be conducted.	[AHMAC] Australian Health Ministers' Advisory Council, 2014, CLIN PRACT GUID ANT; Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; Alexander GR, 2001, PUBLIC HEALTH REP, V116, P306; American Academy of Pediatrics (AAP) and American College of Obstetricians and Gynecologists (ACOG), 2012, GUID PER CAR; [Anonymous], 2013, MALAYSIA HEAL SYST R, V3, P103; [Anonymous], [No title captured]; [Anonymous], 2008, ANT CAR ROUT CAR HLT; Chen XK, 2007, AUST NZ J OBSTET GYN, V47, P122, DOI 10.1111/j.1479-828X.2007.00697.x; Department of Statistics, 2011, POP HOUS CENS MAL PO; Dowswell T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub2; Fan LD, 2009, HEALTH PLACE, V15, P952, DOI 10.1016/j.healthplace.2009.03.005; Grimes HA, 2014, MIDWIFERY, V30, pE26, DOI 10.1016/j.midw.2013.10.007; Handler A, 2012, MATERN CHILD HLTH J, V16, P393, DOI 10.1007/s10995-011-0763-3; Hanson L, 2009, J MIDWIFERY WOM HEAL, V54, P458, DOI 10.1016/j.jmwh.2009.08.002; Hildingsson I, 2013, WOMEN BIRTH, V26, pE9, DOI 10.1016/j.wombi.2012.06.002; Hossain AHMK, 2010, ASIA-PAC J PUBLIC HE, V22, P395, DOI 10.1177/1010539510366177; Institute for Public Health (IPH), 2008, 3 NATL HLTH MORB SUR, V1; Jordan RG, 2009, J MIDWIFERY WOM HEAL, V54, P191, DOI 10.1016/j.jmwh.2009.02.001; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; Koroukian SM, 2002, J CLIN EPIDEMIOL, V55, P296, DOI 10.1016/S0895-4356(01)00471-1; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Krans EE, 2012, AM J OBSTET GYNECOL, V206, P398, DOI 10.1016/j.ajog.2011.06.082; Lee S, 2014, MIDWIFERY, V30, P403, DOI 10.1016/j.midw.2013.04.010; LIBBUS MK, 1991, BIRTH-ISS PERINAT C, V18, P78, DOI 10.1111/j.1523-536X.1991.tb00064.x; Lindmark G, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P2; Mason E, 2014, LANCET; Ministry of Health, REK KES IB; Ministry of Health, 2010, PER CAR MAN; Ministry of Health Malaysia, 2014, HLTH IND 2014 IND MO; Ministry of Health Malaysia, 2012, ANN REP FAM HLTH 201; Ministry of Health Malaysia, 1991, ANN REP 1990 MOH MAL; Ministry of Health Malaysia, 2003, HLTH IND 2003 IND MO; Pathmanathan I., 2003, INT BANK RECONSTRUCT; Petrou S, 2003, EUR J OBSTET GYN R B, V106, P40, DOI 10.1016/S0301-2115(02)00215-4; Proctor S, 1998, BIRTH-ISS PERINAT C, V25, P85, DOI 10.1046/j.1523-536x.1998.00085.x; Raatikainen K, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-268; Ren ZH, 2011, MIDWIFERY, V27, pE260, DOI 10.1016/j.midw.2010.10.016; Titaley CR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-485; VanderWeele TJ, 2009, J CLIN EPIDEMIOL, V62, P438, DOI 10.1016/j.jclinepi.2008.08.001; Vecino-Ortiz AI, 2008, HEALTH POLICY, V86, P363, DOI 10.1016/j.healthpol.2007.12.002; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Vonderheid SC, 2007, WESTERN J NURS RES, V29, P258, DOI 10.1177/0193945906296568; Wennberg AL, 2013, MIDWIFERY, V29, P1027, DOI 10.1016/j.midw.2012.09.005; Whitworth M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007058.pub2; WHO, 2014, WORLD HLTH STAT 2014; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization, 2009, WHO REC INT IMPR MAT; World Health Organization, 2004, FAR MOR PREGN WOM GE; Yeoh PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135301	50	29	30	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0152167	10.1371/journal.pone.0152167	http://dx.doi.org/10.1371/journal.pone.0152167			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH3SV	27010482	gold, Green Published, Green Submitted			2023-01-03	WOS:000372708000102
J	Pesaro, AEP; Katz, M; Katz, JN; Barbas, CSV; Makdisse, MR; Correa, AG; Franken, M; Pereira, C; Serrano, CV; Lopes, RD				Pesaro, Antonio Eduardo P.; Katz, Marcelo; Katz, Jason N.; Valente Barbas, Carmen Silvia; Makdisse, Marcia R.; Correa, Alessandra G.; Franken, Marcelo; Pereira, Carolina; Serrano, Carlos V., Jr.; Lopes, Renato D.			Mechanical Ventilation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Retrospective Observational Study	PLOS ONE			English	Article							CARDIOGENIC PULMONARY-EDEMA; POSITIVE AIRWAY PRESSURE; NONINVASIVE VENTILATION; EFFICACY; SAFETY	Purpose Patients with acute myocardial infarction (AMI) and respiratory impairment may be treated with either invasive or non-invasive mechanical ventilation (MV). However, there has been little testing of non-invasive MV in the setting of AMI. Our objective was to evaluate the incidence and associated clinical outcomes of patients with AMI who were treated with noninvasive or invasive MV. Methods This was a retrospective observational study in which consecutive patients with AMI (n = 1610) were enrolled. The association between exclusively non-invasive MV, invasive MV and outcomes was assessed by multivariable models. Results Mechanical ventilation was used in 293 patients (54% invasive and 46% exclusively noninvasive). In-hospital mortality rates for patients without MV, with exclusively non-invasive MV, and with invasive MV were 4.0%, 8.8%, and 39.5%, respectively (P<0.001). The median lengths of hospital stay were 6 (5.8-6.2), 13 (11.2-4.7), and 28 (18.0-37.9) days, respectively (P<0.001). Exclusively non-invasive MV was not associated with in-hospital death (adjusted HR = 0.90, 95% CI 0.40-1.99, P = 0.79). Invasive MV was strongly associated with a higher risk of in-hospital death (adjusted HR = 3.07, 95% CI 1.79-5.26, P<0.001). Conclusions In AMI setting, 18% of the patients required MV. Almost half of these patients were treated with exclusively non-invasive strategies with a favorable prognosis, while patients who needed to be treated invasively had a three-fold increase in the risk of death. Future prospective randomized trials are needed to compare the effectiveness of invasive and non-invasive MV for the initial approach of respiratory failure in AMI patients.	[Pesaro, Antonio Eduardo P.; Katz, Marcelo; Valente Barbas, Carmen Silvia; Makdisse, Marcia R.; Correa, Alessandra G.; Franken, Marcelo; Pereira, Carolina; Serrano, Carlos V., Jr.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil; [Katz, Jason N.] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA; [Valente Barbas, Carmen Silvia] Univ Sao Paulo, Sch Med, Dept Pulm, Heart Inst INCOR, Sao Paulo, SP, Brazil; [Serrano, Carlos V., Jr.] Univ Sao Paulo, Sch Med, Heart Inst INCOR, Sao Paulo, Brazil; [Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Lopes, Renato D.] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, SP, Brazil	Hospital Israelita Albert Einstein; University of North Carolina; University of North Carolina Chapel Hill; Universidade de Sao Paulo; Universidade de Sao Paulo; Duke University; Universidade Federal de Sao Paulo (UNIFESP)	Pesaro, AEP (corresponding author), Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.	antonioepp@einstein.br	Serrano, Carlos Vicente/I-2729-2013; Barbas, Carmen Silvia Valente/H-1048-2013; Makdisse, Marcia/AAY-9814-2020	Barbas, Carmen Silvia Valente/0000-0002-3922-6256; Pesaro, Antonio/0000-0003-3133-4989; MAKDISSE, MARCIA/0000-0001-7522-9430				Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Kouraki K, 2011, CLIN RES CARDIOL, V100, P235, DOI 10.1007/s00392-010-0235-6; Lazzeri C, 2013, CARDIOL J, V20, P612, DOI 10.5603/CJ.2013.0161; Lee MS, 2013, INFECT CONT HOSP EP, V34, P657, DOI 10.1086/670991; Lesage A, 2004, CRIT CARE MED, V32, P100, DOI 10.1097/01.CCM.0000098605.58349.76; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; Makdisse M, 2013, EINSTEIN-SAO PAULO, V11, P357, DOI 10.1590/S1679-45082013000300016; Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730; Park M, 2004, CRIT CARE MED, V32, P2407, DOI 10.1097/01.CCM.0000147770.20400.10; Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1; Serra-Prat M, 2011, J AM GERIATR SOC, V59, P186, DOI 10.1111/j.1532-5415.2010.03227.x; Sevransky JE, 2003, CLIN GERIATR MED, V19, P205, DOI 10.1016/S0749-0690(02)00065-4; Takeda S, 1998, JPN CIRC J, V62, P553, DOI 10.1253/jcj.62.553; Tsai TH, 2011, CRIT CARE MED, V39, P436, DOI 10.1097/CCM.0b013e318206ccc3; Barbas CSV, 2013, CRIT CARE MED, V41, P2058, DOI 10.1097/CCM.0b013e31828c25f2; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; Vital FM, 2008, COCHRANE DB SYST REV, V16; Weng CL, 2010, ANN INTERN MED, V152, P590, DOI 10.7326/0003-4819-152-9-201005040-00009; Winck JC, 2006, CRIT CARE, V10, DOI 10.1186/cc4905; Yamamoto T, 2012, CIRC J, V76, P2586, DOI 10.1253/circj.CJ-12-0517	21	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151302	10.1371/journal.pone.0151302	http://dx.doi.org/10.1371/journal.pone.0151302			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26977804	Green Submitted, Green Published, gold			2023-01-03	WOS:000372572800057
J	Treffry-Goatley, A; Lessells, R; Sykes, P; Barnighausen, T; de Oliveira, T; Moletsane, R; Seeley, J				Treffry-Goatley, Astrid; Lessells, Richard; Sykes, Pam; Baernighausen, Till; de Oliveira, Tulio; Moletsane, Relebohile; Seeley, Janet			Understanding Specific Contexts of Antiretroviral Therapy Adherence in Rural South Africa: A Thematic Analysis of Digital Stories from a Community with High HIV Prevalence	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; TREATMENT PROGRAM; IMPROVE ADHERENCE; SCALE-UP; CARE; MEDICATION; INTERVENTIONS; BARRIERS; AIDS	Near-perfect adherence to antiretroviral therapy (ART) is required to achieve the best possible prevention and treatment outcomes. Yet, there have been particular concerns about the challenges of adherence among patients living in resource-limited settings in sub-Saharan Africa. The primary objective of this study was to explore adherence in a low-resourced, rural community of high HIV prevalence in South Africa and to identify specific individual and structural factors that can either challenge or support adherence in this context. We applied digital stories as a qualitative research tool to gain insights into personal contexts of HIV and ART adherence. Through an inductive thematic analysis of twenty story texts, soundtracks and drawings, we explored experiences, understandings, and contexts of the participants and identified potential barriers and facilitators for those on lifelong treatment. We found that many of the stories reflected a growing confidence in the effectiveness of ART, which should be viewed as a key facilitator to successful adherence since this attitude can promote disclosure and boost access to social support. Nevertheless, stories also highlighted the complexity of the issues that individuals and households face as they deal with HIV and ART in this setting and it is clear that an overburdened local healthcare system has often struggled to meet the demands of a rapidly expanding epidemic and to provide the necessary medical and emotional support. Our analysis suggests several opportunities for further research and the design of novel health interventions to support optimal adherence. Firstly, future health promotion campaigns should encourage individuals to test together, or at least accompany each other for testing, to encourage social support from the outset. Additionally, home-based testing and ART club interventions might be recommended to make it easier for individuals to adhere to their treatment regimens and to provide a sense of support and solidarity.	[Treffry-Goatley, Astrid; Lessells, Richard; Baernighausen, Till; de Oliveira, Tulio; Seeley, Janet] Univ KwaZulu Natal, Africa Ctr Populat Hlth, Durban, Kwazulu Natal, South Africa; [Treffry-Goatley, Astrid; Moletsane, Relebohile] Univ KwaZulu Natal, Sch Educ, Durban, Kwazulu Natal, South Africa; [Lessells, Richard] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England; [Sykes, Pam] Digital Storytelling South Africa, Cape Town, South Africa; [Baernighausen, Till] Harvard Univ, Dept Global Hlth & Populat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [de Oliveira, Tulio] Univ KwaZulu Natal, Sch Lab Med & Med Sci, Coll Hlth Sci, Durban, Kwazulu Natal, South Africa; [de Oliveira, Tulio] UCL, Res Dept Infect, London, England; [Seeley, Janet] London Sch Hyg & Trop Med, Anthropol & Hlth, London WC1, England	University of Kwazulu Natal; University of Kwazulu Natal; University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; University of Kwazulu Natal; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Treffry-Goatley, A (corresponding author), Univ KwaZulu Natal, Africa Ctr Populat Hlth, Durban, Kwazulu Natal, South Africa.; Treffry-Goatley, A (corresponding author), Univ KwaZulu Natal, Sch Educ, Durban, Kwazulu Natal, South Africa.	astridtg@gmail.com	Bärnighausen, Till/Y-2388-2019	de Oliveira, Tulio/0000-0002-3027-5254; Sykes, Pam/0000-0001-5032-5709; Seeley, Janet/0000-0002-0583-5272; de Oliveira (nee Treffry-Goatley), Astrid/0000-0002-2489-9255; Lessells, Richard/0000-0003-0926-710X	Wellcome Trust International Engagement Award;  [WT099669MA]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD084233] Funding Source: NIH RePORTER	Wellcome Trust International Engagement Award; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	ATG received a Wellcome Trust International Engagement Award. TDO and RM were co-applicant on the grant ( Award number WT099669MA) http://www.wellcome.ac.uk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Bam K, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0846-8; Bemelmans M, 2014, TROP MED INT HEALTH, V19, P968, DOI 10.1111/tmi.12332; Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413; Bor J, 2011, TROP MED INT HEALTH, V16, P988, DOI 10.1111/j.1365-3156.2011.02795.x; Chaiyachati KH, 2014, AIDS, V28, pS187, DOI 10.1097/QAD.0000000000000252; Cueva M, 2013, INT J CIRCUMPOL HEAL, V72, DOI 10.3402/ijch.v72i0.21301; Doyal L, 2014, LANCET, V384, P2102, DOI 10.1016/S0140-6736(14)62362-X; Grenard JL, 2011, J GEN INTERN MED, V26, P1175, DOI 10.1007/s11606-011-1704-y; Grimsrud A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19984; Gubrium A, 2009, HEALTH PROMOT PRACT, V10, P186, DOI 10.1177/1524839909332600; Houlihan CF, 2011, INT J EPIDEMIOL, V40, P318, DOI 10.1093/ije/dyp402; Kagee A, 2011, GLOB PUBLIC HEALTH, V6, P83, DOI 10.1080/17441691003796387; Katz IT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18640; Krass I, 2015, DIABETIC MED, V32, P725, DOI 10.1111/dme.12651; Lambert J., 2009, DIGITAL STORYTELLING; Lessells RJ, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-116; Luque-Fernandez MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056088; Manasa J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072152; Mayosi BM, 2009, LANCET, V374, P934, DOI 10.1016/S0140-6736(09)61087-4; Michel J, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-20; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Moletsane R, 2009, INT J QUAL STUD EDUC, V22, P315, DOI 10.1080/09518390902835454; Moshabela M, 2011, AIDS BEHAV, V15, P842, DOI 10.1007/s10461-010-9747-3; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2; Mutevedzi PC, 2010, B WORLD HEALTH ORGAN, V88, P593, DOI 10.2471/BLT.09.069419; Peltzer K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-111; Petersen I, 2014, PATIENT EDUC COUNS, V95, P201, DOI 10.1016/j.pec.2014.02.001; Riessman C.K., 2008, NARRATIVE METHODS HU; Riessman CatherineKohler., 2004, SAGE ENCY SOCIAL SCI, P705; Ross AJ, 2011, AFR J PRIM HEALTH CA, V3, DOI 10.4102/phcfm.v3i1.196; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; South African National AIDS Council (SANAC), 2014, PEOPL LIV HIV STIGM; Stirratt MJ, 2006, AIDS BEHAV, V10, P483, DOI 10.1007/s10461-006-9106-6; Wilkinson L, 2013, SO AFRICAN J HIV MED, P14; Zaidi J, 2013, AIDS, V27, P2301, DOI 10.1097/QAD.0b013e328362e832	36	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 29	2016	11	2							e0148801	10.1371/journal.pone.0148801	http://dx.doi.org/10.1371/journal.pone.0148801			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5WU	26928455	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000371424200003
J	Hansen-Flaschen, J				Hansen-Flaschen, John			What Now? What Next?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hansen-Flaschen, John] Univ Penn, Dept Med, Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania	Hansen-Flaschen, J (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA.	jflash@uphs.upenn.edu							0	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2016	315	8					755	756		10.1001/jama.2016.0227	http://dx.doi.org/10.1001/jama.2016.0227			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE5VH	26903332				2023-01-03	WOS:000370700500009
J	Dimala, CA; Atashili, J; Mbuagbaw, JC; Wilfred, A; Monekosso, GL				Dimala, Christian Akem; Atashili, Julius; Mbuagbaw, Josephine C.; Wilfred, Akam; Monekosso, Gottlieb L.			Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naive Patients at the Limbe Regional Hospital, Cameroon	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; BLOOD-PRESSURE; INSULIN-RESISTANCE; GLUCOSE; INDIVIDUALS; INHIBITORS; COHORT; IMPACT	Background Highly active antiretroviral therapy (HAART) has greatly reduced the morbidity and mortality of HIV/AIDS patients but has also been associated with increased metabolic complications and cardiovascular diseases. Data on the association between HAART and hypertension (HTN) in Africa are scarce. Objectives Primarily to compare the prevalence of HTN in HIV/AIDS patients on HAART and HAART-naive patients in Limbe, Cameroon; and secondarily to assess other socio-demographic and clinical factors associated with HTN in this population. Methods A cross-sectional study was conducted at the Limbe Regional Hospital HIV treatment center between April and June 2013, involving 200 HIV/AIDS patients (100 on first-line HAART regimens for at least 12 months matched by age and sex to 100 HAART-naive patients). HTN was defined as a systolic blood pressure (BP) >= 140 mmHg and/or diastolic BP >= 90 mmHg. Results The prevalence of HTN in patients on HAART was twice (38%; 95% CI: 28.5-48.3) that of the HAART-naive patients (19%; 95% CI, 11.8-28.1), p = 0.003. In multivariate analyses adjusted for age, gender, smoking, family history of HTN, and BMI-defined overweight, HAART was associated with HTN, the adjusted odds ratio of the HAART-treated versus HAART-naive group was 2.20 (95% CI: 1.07-4.52), p = 0.032. HTN was associated with older age and male gender, in the HAART group and with BMI-defined overweight in the HAART-naive group. Conclusion The prevalence of hypertension in HIV/AIDS patients in Limbe stands out to be elevated, higher in patients on HAART compared to those not on treatment. Blood pressure and cardiovascular risk factors should be routinely monitored. Other factors such as diet, weight control and physical exercise should also be considered.	[Dimala, Christian Akem] London Sch Hyg & Trop Med, London WC1, England; [Atashili, Julius; Mbuagbaw, Josephine C.; Wilfred, Akam; Monekosso, Gottlieb L.] Univ Buea, Fac Hlth Sci, Buea, Cameroon	University of London; London School of Hygiene & Tropical Medicine	Dimala, CA (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	akdimch@yahoo.com		Akem Dimala, Christian/0000-0002-0064-0126				[Anonymous], 2009, FAST FACTS HIV TREAT; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Bergersen BM, 2003, EUR J CLIN MICROBIOL, V22, P731, DOI 10.1007/s10096-003-1034-z; Bloomfield GS, 2014, JAIDS-J ACQ IMM DEF, V67, pS40, DOI 10.1097/QAI.0000000000000257; Brown TT, 2005, AIDS, V19, P1375, DOI 10.1097/01.aids.0000181011.62385.91; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Cattelan AM, 2001, AIDS, V15, P805, DOI 10.1097/00002030-200104130-00021; Chow DC, 2003, HIV CLIN TRIALS, V4, P411, DOI 10.1310/5E7Q-PGWB-16UE-J48U; Ekali LG, 2013, DIABETES METAB, V39, P71, DOI 10.1016/j.diabet.2012.08.012; Eng J, 2003, RADIOLOGY, V227, P309, DOI 10.1148/radiol.2272012051; Fleischman A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1666, DOI 10.1152/ajpendo.00550.2006; Gazzaruso C, 2003, J HYPERTENS, V21, P1377, DOI 10.1097/00004872-200307000-00028; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; de la Serna JIB, 2010, ENFERM INFEC MICR CL, V28, P32, DOI 10.1016/j.eimc.2008.07.005; Institut National de la Statistique, 2011, RAPP PREL PREV VIH; Jerico C, 2005, AM J HYPERTENS, V18, P1396, DOI 10.1016/j.amjhyper.2005.05.016; Jung O, 2004, NEPHROL DIAL TRANSPL, V19, P2250, DOI 10.1093/ndt/gfh393; Khatib OM., 2005, CLIN GUIDELINES MANA; Mateen FJ, 2013, J HYPERTENS, V31, P1372, DOI 10.1097/HJH.0b013e328360de1c; Muhammad Sanusi, 2013, Niger Med J, V54, P185, DOI 10.4103/0300-1652.114591; Palacios R, 2006, HIV MED, V7, P10, DOI 10.1111/j.1468-1293.2005.00333.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Seaberg EC, 2005, AIDS, V19, P953, DOI 10.1097/01.aids.0000171410.76607.f8; Sherer R., 2014, Journal of the International Association of Providers of AIDS Care, V13, P342, DOI 10.1177/2325957414530473; Ssinabulya I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089537; Thiebaut R, 2005, ANTIVIR THER, V10, P811; Yone EWP, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-33	28	48	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0148100	10.1371/journal.pone.0148100	http://dx.doi.org/10.1371/journal.pone.0148100			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6PR	26862763	gold, Green Published			2023-01-03	WOS:000370046600043
J	Groeme, R; Airouche, S; Kopecny, D; Jaekel, J; Savko, M; Berjont, N; Bussieres, L; Le Mignon, M; Jagic, F; Zieglmayer, P; Baron-Bodo, V; Bordas-Le Floch, V; Mascarell, L; Briozzo, P; Moingeon, P				Groeme, Rachel; Airouche, Sabi; Kopecny, David; Jaekel, Judith; Savko, Martin; Berjont, Nathalie; Bussieres, Laetitia; Le Mignon, Maxime; Jagic, Franck; Zieglmayer, Petra; Baron-Bodo, Veronique; Bordas-Le Floch, Veronique; Mascarell, Laurent; Briozzo, Pierre; Moingeon, Philippe			Structural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUST-MITE ALLERGEN; DICHROISM SPECTROSCOPIC DATA; PROTEIN SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; CYSTEINE PROTEASE; DERMATOPHAGOIDES-PTERONYSSINUS; ACTIVATION MECHANISM; PROTEOLYTIC ACTIVITY; PRO-SEQUENCE; DER-P-1	Allergy to the short ragweed (Ambrosia artemisiifolia) pollen is a major health problem. The ragweed allergen repertoire has been recently expanded with the identification of Amb a 11, a new major allergen belonging to the cysteine protease family. To better characterize Amb a 11, a recombinant proform of the molecule with a preserved active site was produced in Escherichia coli, refolded, and processed in vitro into a mature enzyme. The enzymatic activity is revealed by maturation following an autocatalytic processing resulting in the cleavage of both N- and C-terminal propeptides. The 2.05-angstrom resolution crystal structure of pro-Amb a 11 shows an overall typical C1A cysteine protease fold with a network of molecular interactions between the N-terminal propeptide and the catalytic triad of the enzyme. The allergenicity of Amb a 11 was confirmed in a murine sensitization model, resulting in airway inflammation, production of serum IgEs, and induction of Th2 immune responses. Of note, inflammatory responses were higher with the mature form, demonstrating that the cysteine protease activity critically contributes to the allergenicity of the molecule. Collectively, our results clearly demonstrate that Amb a 11 is a bona fide cysteine protease exhibiting a strong allergenicity. As such, it should be considered as an important molecule for diagnosis and immunotherapy of ragweed pollen allergy.	[Groeme, Rachel; Airouche, Sabi; Jaekel, Judith; Berjont, Nathalie; Bussieres, Laetitia; Le Mignon, Maxime; Baron-Bodo, Veronique; Bordas-Le Floch, Veronique; Mascarell, Laurent; Moingeon, Philippe] Stallergenes Greer, Res & Dev, F-92160 Antony, France; [Kopecny, David] Palacky Univ, Fac Sci, Dept Prot Biochem & Prote, Ctr Reg Hana Biotechnol & Agr Res, Slechtitelu 27, CZ-78371 Olomouc, Czech Republic; [Savko, Martin] SOLEIL Synchrotron, PROXIMA 2A, St Aubin BP 48, F-91192 Gif Sur Yvette, France; [Jagic, Franck; Briozzo, Pierre] AgroParisTech, INRA, Inst Jean Pierre Bourgin, F-78026 Versailles, France; [Zieglmayer, Petra] Allergy Ctr Vienna West, Vienna Challenge Chamber, A-1150 Vienna, Austria	Stallergenes Greer; Palacky University Olomouc; SOLEIL Synchrotron; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Moingeon, P (corresponding author), Stallergenes Greer, Res & Dev, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.	pmoingeon@stallergenes.com	Kopecny, David/ABH-4250-2020; Zieglmayer, Petra/AAG-1006-2020	Kopecny, David/0000-0002-4309-4284; 	Stallergenes; Convention Industrielles de Formation par la Recherche (CIFRE) fellowship from the Association Nationale de la Recherche et de la Technologie; National Program of Sustainability I Grant from the Czech Ministry of Education, Youth and Sports [LO1204]	Stallergenes; Convention Industrielles de Formation par la Recherche (CIFRE) fellowship from the Association Nationale de la Recherche et de la Technologie; National Program of Sustainability I Grant from the Czech Ministry of Education, Youth and Sports	This work was supported in part by Stallergenes. R. G., S. A., J. J., N. B., L. B., M. L. M., V. B.-B., V. B.-L. F., L. M., and P. M. are employees at Stallergenes SAS.r Supported by a Convention Industrielles de Formation par la Recherche (CIFRE) fellowship from the Association Nationale de la Recherche et de la Technologie.r Supported by National Program of Sustainability I Grant LO1204 from the Czech Ministry of Education, Youth and Sports.	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asero R, 2006, CLIN EXP ALLERGY, V36, P658, DOI 10.1111/j.1365-2222.2006.02477.x; Bordas-Le Floch V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136258; Bouley J, 2015, J ALLERGY CLIN IMMUN, V136, P1055, DOI 10.1016/j.jaci.2015.03.001; Bricogne G., 2011, BUSTER VERSION 2 1 0; Bromme D, 2004, METHODS, V32, P199, DOI 10.1016/S1046-2023(03)00212-3; Burbach GJ, 2009, ALLERGY, V64, P664, DOI 10.1111/j.1398-9995.2009.01975.x; Burtin D, 2009, CLIN EXP ALLERGY, V39, P760, DOI 10.1111/j.1365-2222.2009.03201.x; Bussieres L, 2010, INT ARCH ALLERGY IMM, V153, P141, DOI 10.1159/000312631; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chevigne A, 2007, J MOL BIOL, V374, P170, DOI 10.1016/j.jmb.2007.08.025; Choudhury D, 2009, PHYTOCHEMISTRY, V70, P465, DOI 10.1016/j.phytochem.2009.02.001; Comoy EE, 1998, J IMMUNOL, V160, P2456; Cunningham PT, 2012, INT ARCH ALLERGY IMM, V158, P347, DOI 10.1159/000334280; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Demidyuk Ilya V, 2010, Biomol Concepts, V1, P305, DOI 10.1515/bmc.2010.025; Dutta S, 2011, FEBS J, V278, P3012, DOI 10.1111/j.1742-4658.2011.08221.x; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Floch VBL, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0565-6; Gadermaier G, 2008, ALLERGY, V63, P1543, DOI 10.1111/j.1398-9995.2008.01780.x; Gadermaier G, 2014, METHODS, V66, P55, DOI 10.1016/j.ymeth.2013.06.014; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; Gunawan Hendra, 2008, Allergol Int, V57, P83, DOI 10.2332/allergolint.O-07-507; Gunawan H, 2008, INT ARCH ALLERGY IMM, V147, P276, DOI 10.1159/000144035; Henriquez OA, 2013, INT FORUM ALLERGY RH, V3, P630, DOI 10.1002/alr.21168; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Kaulmann G, 2006, PROTEIN SCI, V15, P2619, DOI 10.1110/ps.062401806; Lees JG, 2004, ANAL BIOCHEM, V332, P285, DOI 10.1016/j.ab.2004.06.002; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; Nandana V, 2014, PROTEIN EXPRES PURIF, V103, P16, DOI 10.1016/j.pep.2014.08.003; Novinec Marko, 2013, Biomol Concepts, V4, P287, DOI 10.1515/bmc-2012-0054; Okomoto T, 1999, J BIOL CHEM, V274, P11390, DOI 10.1074/jbc.274.16.11390; Oswalt Matthew L, 2008, Allergy Asthma Clin Immunol, V4, P130, DOI 10.1186/1710-1492-4-3-130; PAUL W, 1995, PLANT PHYSIOL, V108, P261, DOI 10.1104/pp.108.1.261; Razafindratsita A, 2007, J ALLERGY CLIN IMMUN, V120, P278, DOI 10.1016/j.jaci.2007.04.009; Reubsaet L, 2013, J ALLERGY CLIN IMMUN, V132, P1440, DOI 10.1016/j.jaci.2013.06.028; Roy S, 2012, ACTA CRYSTALLOGR D, V68, P1591, DOI 10.1107/S0907444912038607; Schmid M, 1998, PLANTA, V206, P466, DOI 10.1007/s004250050423; Sivaraman J, 1999, PROTEIN SCI, V8, P283; Smith M, 2013, ENVIRON INT, V61, P115, DOI 10.1016/j.envint.2013.08.005; Stack CM, 2008, J BIOL CHEM, V283, P9896, DOI 10.1074/jbc.M708521200; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Than ME, 2004, J MOL BIOL, V336, P1103, DOI 10.1016/j.jmb.2003.12.075; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Wiederanders B, 2003, ACTA BIOCHIM POL, V50, P691; Wiederanders B, 2003, CURR PROTEIN PEPT SC, V4, P309, DOI 10.2174/1389203033487081; Yi MH, 2015, CYTOKINE, V75, P356, DOI 10.1016/j.cyto.2015.07.011	55	15	16	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2016	291	25					13076	13087		10.1074/jbc.M115.702001	http://dx.doi.org/10.1074/jbc.M115.702001			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DR2YT	27129273	hybrid, Green Published			2023-01-03	WOS:000379770500016
J	Mutsaerts, MAQ; van Oers, AM; Groen, H; Burggraaff, JM; Kuchenbecker, WKH; Perquin, DAM; Koks, CAM; van Golde, R; Kaaijk, EM; Schierbeek, JM; Oosterhuis, GJE; Broekmans, FJ; Bemelmans, WJE; Lambalk, CB; Verberg, MFG; van der Veen, F; Klijn, NF; Mercelina, PEAM; van Kasteren, YM; Nap, AW; Brinkhuis, EA; Vogel, NEA; Mulder, RJAB; Gondrie, ETCM; de Bruin, JP; Sikkema, JM; de Greef, MHG; ter Bogt, NCW; Land, JA; Mol, BWJ; Hoek, A				Mutsaerts, Meike A. Q.; van Oers, Anne M.; Groen, Henk; Burggraaff, Jan M.; Kuchenbecker, Walter K. H.; Perquin, Denise A. M.; Koks, Carolien A. M.; van Golde, Ron; Kaaijk, Eugenie M.; Schierbeek, Jaap M.; Oosterhuis, Gerrit J. E.; Broekmans, Frank J.; Bemelmans, Wanda J. E.; Lambalk, Cornelis B.; Verberg, Marieke F. G.; van der Veen, Fulco; Klijn, Nicole F.; Mercelina, Patricia E. A. M.; van Kasteren, Yvonne M.; Nap, Annemiek W.; Brinkhuis, Egbert A.; Vogel, Niels E. A.; Mulder, Robert J. A. B.; Gondrie, Ed T. C. M.; de Bruin, Jan P.; Sikkema, J. Marko; de Greef, Mathieu H. G.; ter Bogt, Nancy C. W.; Land, Jolande A.; Mol, Ben W. J.; Hoek, Annemieke			Randomized Trial of a Lifestyle Program in Obese Infertile Women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; POLYCYSTIC-OVARY-SYNDROME; WEIGHT-LOSS; OVERWEIGHT; PREGNANCY; RISK; SUBFERTILE; IMPROVEMENT; MANAGEMENT; ENDOCRINE	BACKGROUND Small lifestyle-intervention studies suggest that modest weight loss increases the chance of conception and may improve perinatal outcomes, but large randomized, controlled trials are lacking. METHODS We randomly assigned infertile women with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 29 or higher to a 6-month lifestyle intervention preceding treatment for infertility or to prompt treatment for infertility. The primary outcome was the vaginal birth of a healthy singleton at term within 24 months after randomization. RESULTS We assigned women who did not conceive naturally to one of two treatment strategies: 290 women were assigned to a 6-month lifestyle-intervention program preceding 18 months of infertility treatment (intervention group) and 287 were assigned to prompt infertility treatment for 24 months (control group). A total of 3 women withdrew consent, so 289 women in the intervention group and 285 women in the control group were included in the analysis. The discontinuation rate in the intervention group was 21.8%. In intention-to-treat analyses, the mean weight loss was 4.4 kg in the intervention group and 1.1 kg in the control group (P< 0.001). The primary outcome occurred in 27.1% of the women in the intervention group and 35.2% of those in the control group (rate ratio in the intervention group, 0.77; 95% confidence interval, 0.60 to 0.99). CONCLUSIONS In obese infertile women, a lifestyle intervention preceding infertility treatment, as compared with prompt infertility treatment, did not result in higher rates of a vaginal birth of a healthy singleton at term within 24 months after randomization. (Funded by the Netherlands Organization for Health Research and Development; Netherlands Trial Register number, NTR1530.)	[Mutsaerts, Meike A. Q.; van Oers, Anne M.; Land, Jolande A.; Hoek, Annemieke] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, POB 30001, NL-9400 RB Groningen, Netherlands; [Mutsaerts, Meike A. Q.] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, NL-9400 RB Groningen, Netherlands; [Groen, Henk] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9400 RB Groningen, Netherlands; [de Greef, Mathieu H. G.] Univ Groningen, Univ Med Ctr Groningen, Inst Human Movement Sci, NL-9400 RB Groningen, Netherlands; [Vogel, Niels E. A.] Martini Hosp, Dept Obstet & Gynecol, Groningen, Netherlands; [de Greef, Mathieu H. G.] Hanze Univ Appl Sci, Res & Innovat Grp Hlth Care & Nursing, Groningen, Netherlands; [Burggraaff, Jan M.] Scheper Hosp, Dept Obstet & Gynecol, Emmen, Netherlands; [Kuchenbecker, Walter K. H.] Isala Clin, Dept Obstet & Gynecol, Zwolle, Netherlands; [Perquin, Denise A. M.] Med Ctr Leeuwarden, Dept Obstet & Gynecol, Leeuwarden, Netherlands; [Koks, Carolien A. M.] Maxima Med Ctr, Dept Obstet & Gynecol, Veldhoven, Netherlands; [van Golde, Ron] Maastricht Univ, Med Ctr, Dept Obstet & Gynecol, NL-6200 MD Maastricht, Netherlands; [Kaaijk, Eugenie M.] Onze Lieve Vrouw Hosp, Dept Obstet & Gynecol, Amsterdam, Netherlands; [Lambalk, Cornelis B.] Vrije Univ Amsterdam, Dept Obstet & Gynecol, Med Ctr, Amsterdam, Netherlands; [van der Veen, Fulco] Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Schierbeek, Jaap M.] Deventer Hosp, Dept Obstet & Gynecol, Deventer, Netherlands; [Oosterhuis, Gerrit J. E.] St Antonius Hosp, Dept Obstet & Gynecol, Nieuwegein, Netherlands; [Broekmans, Frank J.] Univ Utrecht, Dept Reprod Med, Div Female & Baby, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Bemelmans, Wanda J. E.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Verberg, Marieke F. G.] Med Spectrum Twente, Dept Obstet & Gynecol, Enschede, Netherlands; [Klijn, Nicole F.] Leiden Univ, Med Ctr, Dept Gynecol & Reprod Med, Leiden, Netherlands; [Mercelina, Patricia E. A. M.] Atrium Med Ctr, Dept Obstet & Gynecol, Heerlen, Netherlands; [van Kasteren, Yvonne M.] Med Ctr Alkmaar, Dept Obstet & Gynecol, Alkmaar, Netherlands; [Nap, Annemiek W.] Rijnstate Hosp, Dept Obstet & Gynecol, Arnhem, Netherlands; [Brinkhuis, Egbert A.] Meander Med Ctr, Dept Obstet & Gynecol, Amersfoort, Netherlands; [Mulder, Robert J. A. B.] Laurentius Hosp, Dept Obstet & Gynecol, Roermond, Netherlands; [Gondrie, Ed T. C. M.] Orbis Med Ctr, Dept Obstet & Gynecol, Sittard, Netherlands; [de Bruin, Jan P.] Jeroen Bosch Hosp, Dept Obstet & Gynecol, Shertogenbosch, Netherlands; [Sikkema, J. Marko] Zorggroep Twente Hosp, Dept Obstet & Gynecol, Almelo, Netherlands; [ter Bogt, Nancy C. W.] Acute Zorg Euregio, Enschede, Netherlands; [Mol, Ben W. J.] Univ Adelaide, Sch Paediat & Reprod Hlth, Robinson Res Inst, Adelaide, SA, Australia; [Mol, Ben W. J.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Martini Hospital; Isala Clinics; Medical Center Leeuwarden; Maxima Medical Center; Maastricht University; Onze Lieve Vrouwe Gasthuis Hospital; Vrije Universiteit Amsterdam; University of Amsterdam; Deventer Hospital; St. Antonius Hospital Utrecht; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Medical Spectrum Twente; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Atrium Medical Center; Medical Center Of Alkmaar; Rijnstate Hospital; Meander Medisch Centrum; Orbis Medical Center; Jeroen Bosch Ziekenhuis; Robinson Research Institute; University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI)	Hoek, A (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, POB 30001, NL-9400 RB Groningen, Netherlands.	a.hoek@umcg.nl	NAP, Annemiek/ABE-1897-2021; Groen, Henk/B-2163-2013	Groen, Henk/0000-0002-6629-318X; Lambalk, Cornelis/0000-0003-3947-5129	Netherlands Organization for Health Research and Development	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development)	Funded by the Netherlands Organization for Health Research and Development; Netherlands Trial Register number, NTR1530.	[Anonymous], 1995, HUM REPROD, V10, P1549; [Anonymous], 2008, CBO GUID DIAGN BEH O; Aune D, 2014, JAMA-J AM MED ASSOC, V311, P1536, DOI 10.1001/jama.2014.2269; Bayram N, 2004, BMJ-BRIT MED J, V328, P192, DOI 10.1136/bmj.328.7433.192; Clark AM, 1998, HUM REPROD, V13, P1502, DOI 10.1093/humrep/13.6.1502; Cnattingius S, 2013, JAMA-J AM MED ASSOC, V309, P2362, DOI 10.1001/jama.2013.6295; Correa A, 2013, NUTR REV, V71, pS68, DOI 10.1111/nure.12058; Custers IM, 2012, HUM REPROD, V27, P444, DOI 10.1093/humrep/der389; Dutch Society of Obstetrics and Gynaecology ( NVOG), DAT SHEET; EUROCAT, MINOR ANOMALIES FOR; GUZICK DS, 1994, FERTIL STERIL, V61, P598; Huber-Buchholz MM, 1999, J CLIN ENDOCR METAB, V84, P1470, DOI 10.1210/jc.84.4.1470; Hunault CC, 2004, HUM REPROD, V19, P2019, DOI 10.1093/humrep/deh365; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; Kiran TSU, 2005, BJOG-INT J OBSTET GY, V112, P768, DOI 10.1111/j.1471-0528.2004.00546.x; Kuchenbecker WKH, 2014, OBESITY, V22, P537, DOI 10.1002/oby.20452; Kuchenbecker WKH, 2010, J CLIN ENDOCR METAB, V95, P2107, DOI 10.1210/jc.2009-1915; Legro RS, 2007, NEW ENGL J MED, V356, P551, DOI 10.1056/NEJMoa063971; Legro RS, 2014, HUM REPROD, V29, P2075, DOI 10.1093/humrep/deu218; Metwally M, 2008, FERTIL STERIL, V90, P714, DOI 10.1016/j.fertnstert.2007.07.1290; Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943; Mutsaerts MAQ, 2013, HUM REPROD, V28, P979, DOI 10.1093/humrep/det026; Mutsaerts MAQ, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-22; National Institute for Clinical Excellence, 2004, FERTILITY ASSESSMENT; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Ovesen P, 2011, OBSTET GYNECOL, V118, P305, DOI 10.1097/AOG.0b013e3182245d49; Pfeifer S, 2015, FERTIL STERIL, V104, P1116, DOI 10.1016/j.fertnstert.2015.08.018; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ramlau-Hansen CH, 2007, HUM REPROD, V22, P1634, DOI 10.1093/humrep/dem035; RICHEDWARDS JW, 1994, AM J OBSTET GYNECOL, V171, P171, DOI 10.1016/0002-9378(94)90465-0; Rittenberg V, 2011, REPROD BIOMED ONLINE, V23, P421, DOI 10.1016/j.rbmo.2011.06.018; Tarlatzis BC, 2008, HUM REPROD, V23, P462, DOI 10.1093/humrep/dem426; ter Bogt NCW, 2009, AM J PREV MED, V37, P270, DOI 10.1016/j.amepre.2009.06.011; Tranquilli AL, 2014, PREGNANCY HYPERTENS, V4, P97, DOI [10.1016/j.preghy.2014.02.001, 10.1016/j.preghy.2014.04.017, 10.1016/j.preghy.2014.04.007]; Tsagareli V, 2006, FERTIL STERIL, V86, P227, DOI 10.1016/j.fertnstert.2005.12.041; van der Steeg JW, 2008, HUM REPROD, V23, P324, DOI 10.1093/humrep/dem371; Visser GHA, 2009, EARLY HUM DEV, V85, P737, DOI 10.1016/j.earlhumdev.2009.09.008; Voedingscentrum, MIJN EETM SCAN JE DA; Vrebosch L, 2012, OBES SURG, V22, P1568, DOI 10.1007/s11695-012-0740-y	39	143	146	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2016	374	20					1942	1953		10.1056/NEJMoa1505297	http://dx.doi.org/10.1056/NEJMoa1505297			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM1OX	27192672	Green Published, Bronze			2023-01-03	WOS:000376116600007
J	Snow, R				Snow, Rosamund			Self harm and the emergency department	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rsnow@bmj.com						Hawton K, 2015, J AFFECT DISORDERS, V175, P147, DOI 10.1016/j.jad.2014.12.062; National Institute for Health and Care Excellence, 2013, QUAL STAND SELF HARM; Royal College of Psychiatrists, 2006, BATT SERV PEOPL WHO	3	7	7	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	2016	353								i1150	10.1136/bmj.i1150	http://dx.doi.org/10.1136/bmj.i1150			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ7ET	27076483	Green Published, Bronze			2023-01-03	WOS:000374375400001
J	Reade, MC; Eastwood, GM; Bellomo, R; Bailey, M; Bersten, A; Cheung, B; Davies, A; Delaney, A; Ghosh, A; van Haren, F; Harley, N; Knight, D; McGuiness, S; Mulder, J; O'Donoghue, S; Simpson, N; Young, P				Reade, Michael C.; Eastwood, Glenn M.; Bellomo, Rinaldo; Bailey, Michael; Bersten, Andrew; Cheung, Benjamin; Davies, Andrew; Delaney, Anthony; Ghosh, Angaj; van Haren, Frank; Harley, Nerina; Knight, David; McGuiness, Shay; Mulder, John; O'Donoghue, Steve; Simpson, Nicholas; Young, Paul		DahLIA Investigators Australian	Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; SEDATION SCALE; UNIT PATIENTS; CAM-ICU; RELIABILITY; MIDAZOLAM; VALIDITY	IMPORTANCE Effective therapy has not been established for patients with agitated delirium receiving mechanical ventilation. OBJECTIVE To determine the effectiveness of dexmedetomidine when added to standard care in patients with agitated delirium receiving mechanical ventilation. DESIGN, SETTING, AND PARTICIPANTS The Dexmedetomidine to Lessen ICU Agitation (DahLIA) study was a double-blind, placebo-controlled, parallel-group randomized clinical trial involving 74 adult patients in whom extubation was considered inappropriate because of the severity of agitation and delirium. The study was conducted at 15 intensive care units in Australia and New Zealand from May 2011 until December 2013. Patients with advanced dementia or traumatic brain injury were excluded. INTERVENTIONS Bedside nursing staff administered dexmedetomidine (or placebo) initially at a rate of 0.5 mu g/kg/h and then titrated to rates between 0 and 1.5 mu g/kg/h to achieve physician-prescribed sedation goals. The study drug or placebo was continued until no longer required or up to 7 days. All other care was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES Ventilator-free hours in the 7 days following randomization. There were 21 reported secondary outcomes that were defined a priori. RESULTS Of the 74 randomized patients (median age, 57 years; 18 [24%] women), 2 withdrew consent later and 1 was found to have been randomized incorrectly, leaving 39 patients in the dexmedetomidine group and 32 patients in the placebo group for analysis. Dexmedetomidine increased ventilator-free hours at 7 days compared with placebo (median, 144.8 hours vs 127.5 hours, respectively; median difference between groups, 17.0 hours [95% CI, 4.0 to 33.2 hours]; P = .01). Among the 21 a priori secondary outcomes, none were significantly worse with dexmedetomidine, and several showed statistically significant benefit, including reduced time to extubation (median, 21.9 hours vs 44.3 hours with placebo; median difference between groups, 19.5 hours [95% CI, 5.3 to 31.1 hours]; P < .001) and accelerated resolution of delirium (median, 23.3 hours vs 40.0 hours; median difference between groups, 16.0 hours [95% CI, 3.0 to 28.0 hours]; P = .01). Using hierarchical Cox modeling to adjust for imbalanced baseline characteristics, allocation to dexmedetomidine was significantly associated with earlier extubation (hazard ratio, 0.47 [95% CI, 0.27-0.82]; P = .007). CONCLUSIONS AND RELEVANCE Among patients with agitated delirium receiving mechanical ventilation in the intensive care unit, the addition of dexmedetomidine to standard care compared with standard care alone (placebo) resulted in more ventilator-free hours at 7 days. The findings support the use of dexmedetomidine in patients such as these.	[Reade, Michael C.] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia; [Reade, Michael C.] Australian Def Force, Joint Hlth Command, Brisbane, Qld, Australia; [Eastwood, Glenn M.; Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo] Univ Melbourne, Sch Med, Melbourne, Vic, Australia; [Bailey, Michael] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Bersten, Andrew] Flinders Med Ctr, Adelaide, SA, Australia; [Cheung, Benjamin] Toowoomba Hosp, Toowoomba, Qld, Australia; [Davies, Andrew] Peninsula Hlth, Melbourne, Vic, Australia; [Delaney, Anthony] Royal North Shore Hosp Sydney, Sydney, NSW, Australia; [Ghosh, Angaj] Northern Hosp, Melbourne, Vic, Australia; [van Haren, Frank] Canberra Hosp, Canberra, ACT, Australia; [Harley, Nerina] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Knight, David] Christchurch Hosp, Christchurch, New Zealand; [McGuiness, Shay] Auckland City Hosp, Auckland, New Zealand; [Mulder, John] Western Hosp, Melbourne, Vic, Australia; [O'Donoghue, Steve] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Simpson, Nicholas] Geelong Hosp, Geelong, Vic, Australia; [Young, Paul] Wellington Hosp, Wellington, New Zealand; [Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand	University of Queensland; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University; Flinders Medical Centre; Royal North Shore Hospital; Australian National University; Canberra Hospital; Royal Melbourne Hospital; Christchurch Hospital New Zealand; Auckland City Hospital; Western Hospital; Royal Brisbane & Women's Hospital; Geelong Hospital; Medical Research Institute Of New Zealand	Reade, MC (corresponding author), Univ Queensland, Hlth Sci Bldg, Herston, Qld 4029, Australia.	m.reade@uq.edu.au	/X-2859-2019; Reade, Michael/G-7035-2012; Van Haren, Frank/G-1335-2015; Bailey, Michael J/A-4499-2012; Delaney, Anthony/AAE-3365-2019; cheung, benjamin k/F-6452-2014; Roberts, Jason A/F-6272-2010	/0000-0002-2067-7276; Reade, Michael/0000-0003-1570-0707; Van Haren, Frank/0000-0001-8037-4229; Bailey, Michael J/0000-0002-5551-1401; cheung, benjamin k/0000-0002-6139-7756; Roberts, Jason A/0000-0001-6218-435X; Bellomo, Rinaldo/0000-0002-1650-8939; Young, Paul/0000-0002-3428-3083; Bersten, Andrew/0000-0001-9908-394X; McGuinness, Shay/0000-0003-0620-4787; Delaney, Anthony/0000-0002-1015-7146	Hospira Australia; Wellington Hospital Research Office; Austin Hospital Intensive Care Specialists Trust Fund	Hospira Australia; Wellington Hospital Research Office; Austin Hospital Intensive Care Specialists Trust Fund	This study was partly funded by Hospira Australia through an unrestricted grant of A$25000 plus free study drug supply. Individual site funding was supplemented by grants from the Wellington Hospital Research Office and the Austin Hospital Intensive Care Specialists Trust Fund.	Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2007, CRIT CARE MED, V35, P112, DOI 10.1097/01.CCM.0000251925.18961.CA; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Hart Graeme K, 2008, Crit Care Resusc, V10, P83; Hoy SM, 2011, DRUGS, V71, P1481, DOI 10.2165/11207190-000000000-00000; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Lehmann E.L., 2006, NONPARAMETRICS STAT; Mo Y, 2013, ANN PHARMACOTHER, V47, P869, DOI 10.1345/aph.1AR708; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Reade MC, 2012, CRIT CARE RESUSC, V14, P236; Reade MC, 2009, CRIT CARE, V13, DOI 10.1186/cc7890; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Therapeutic Goods Administration, 2014, DEXM HYDR PREC PROD; van den Boogaard M, 2012, CRIT CARE MED, V40, P112, DOI 10.1097/CCM.0b013e31822e9fc9; Yapici N, 2011, HEART SURG FORUM, V14, pE93, DOI 10.1532/HSF98.201011102	25	212	227	0	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2016	315	14					1460	1468		10.1001/jama.2016.2707	http://dx.doi.org/10.1001/jama.2016.2707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ0EE	26975647	Bronze			2023-01-03	WOS:000373873800012
J	de Vries, JD; van Hooff, MLM; Geurts, SAE; Kompier, MAJ				de Vries, Juriena D.; van Hooff, Madelon L. M.; Geurts, Sabine A. E.; Kompier, Michiel A. J.			Exercise as an Intervention to Reduce Study-Related Fatigue among University Students: A Two-Arm Parallel Randomized Controlled Trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; EXECUTIVE FUNCTIONS; LEISURE-TIME; BURNOUT; SLEEP; PERFORMANCE; HEALTH; ADULTS; METHODOLOGY; EXHAUSTION	Background Many university students experience high levels of study-related fatigue. This high prevalence, and the negative impact of fatigue on health and academic performance, call for prevention and reduction of these symptoms. The primary aim of the current study was to investigate to what extent an exercise intervention is effective in reducing three indicators of study-related fatigue (emotional exhaustion, overall fatigue, and need for recovery). Effects of exercise on secondary outcomes (sleep quality, self-efficacy, physical fitness, and cognitive functioning) were also investigated. Methods Participants were students with high levels of study-related fatigue, currently not exercising or receiving other psychological or pharmacological treatments, and with no medical cause of fatigue. They were randomly assigned to either a six-week exercise intervention (low-intensity running three times a week, n = 49) or wait list (no intervention, n = 48). All participants were measured before the intervention (T0), and immediately after the intervention (T1). Exercisers were also investigated 4 weeks (T2) and 12 weeks (T3) after the intervention. Results Participants in the exercise condition showed a larger decrease in two of the three indicators of study-related fatigue (i.e., overall fatigue and need for recovery) as compared to controls. Additionally, sleep quality and some indicators of cognitive functioning improved more among exercisers than among controls. No effects were found for self-efficacy, and physical fitness. The initial effects of the exercise intervention lasted at follow-up (T2 and T3). At 12-week follow up (T3), 80% of participants in the exercise condition still engaged in regular exercise, and further enhancements were seen for emotional exhaustion, overall fatigue, and sleep quality. Conclusions These results underline the value of low-intensity exercise for university students with high levels of study-related fatigue. The follow-up effects that were found in this study imply that the intervention has the potential to promote regular exercise and accompanying beneficial effects in the longer run.	[de Vries, Juriena D.; van Hooff, Madelon L. M.; Geurts, Sabine A. E.; Kompier, Michiel A. J.] Radboud Univ Nijmegen, Inst Behav Sci, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	de Vries, JD (corresponding author), Radboud Univ Nijmegen, Inst Behav Sci, NL-6525 ED Nijmegen, Netherlands.	j.devries@psych.ru.nl	Geurts, Sabine/ABC-2479-2021	Geurts, Sabine/0000-0001-5125-5693				Abdi H., 2007, ENCY MEASUREMENT STA, V2, P651, DOI DOI 10.4135/9781412952644.N299; Balogun JA, 1996, PERCEPT MOTOR SKILL, V83, P21, DOI 10.2466/pms.1996.83.1.21; Bernaards CM, 2006, OCCUP ENVIRON MED, V63, P10, DOI 10.1136/oem.2004.017541; Bodner ME, 2000, SPORTS MED, V30, P31, DOI 10.2165/00007256-200030010-00004; Bosquet L, 2002, SPORTS MED, V32, P675, DOI 10.2165/00007256-200232110-00002; Bosscher RJ, 1998, BEHAV RES THER, V36, P339, DOI 10.1016/S0005-7967(98)00025-4; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks Ka, 2013, J Nov Physiother, V3; Campos Juliana Alvares Duarte Bonini, 2012, Rev. bras. epidemiol., V15, P155, DOI 10.1590/S1415-790X2012000100014; Carson RL, 2010, J HEALTH PSYCHOL, V15, P905, DOI 10.1177/1359105309360697; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Cohen J., 2013, STAT POWER ANAL BEHA; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Conconi F, 1996, INT J SPORTS MED, V17, P509, DOI 10.1055/s-2007-972887; Craft LL, 2005, PSYCHOL SPORT EXERC, V6, P151, DOI 10.1016/j.psychsport.2003.11.003; Curcio G, 2006, SLEEP MED REV, V10, P323, DOI 10.1016/j.smrv.2005.11.001; De Vries J, 2004, BRIT J HEALTH PSYCH, V9, P279; Deligkaris P, 2014, WORK STRESS, V28, P107, DOI 10.1080/02678373.2014.909545; Driver HS, 2000, SLEEP MED REV, V4, P387, DOI 10.1053/smrv.2000.0110; Ekstedt M, 2006, SCAND J WORK ENV HEA, V32, P121, DOI 10.5271/sjweh.987; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Gerber Markus, 2013, BMC Res Notes, V6, P78, DOI 10.1186/1756-0500-6-78; Geurts S., 2014, BRIDGING OCCUPATIONA, P193, DOI DOI 10.1007/978-94-007-5640-3_12; Geurts SAE, 2006, SCAND J WORK ENV HEA, V32, P482, DOI 10.5271/sjweh.1053; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010; Hockey R., 2013, PSYCHOL FATIGUE WORK; Hreljac A, 2004, MED SCI SPORT EXER, V36, P845, DOI 10.1249/01.MSS.0000126803.66636.DD; IBM Corp Released, 2010, IBM SPSS STAT WINDOW; Jackson EM, 2006, PSYCHOPHYSIOLOGY, V43, P57, DOI 10.1111/j.1469-8986.2006.00373.x; Jacobs S.R., 2003, J COLL STUDENT DEV, V44, P291, DOI [DOI 10.1353/CSD.2003.0028, 10.1353/csd.2003.0028]; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jonsdottir IH, 2010, PREV MED, V51, P373, DOI 10.1016/j.ypmed.2010.07.019; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Larun L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003200.pub3; Law DW, 2007, J AM COLL HEALTH, V55, P239, DOI 10.3200/JACH.55.4.239-245; Lindheimer JB, 2015, SPORTS MED, V45, P693, DOI 10.1007/s40279-015-0303-1; Lingard H., 2007, J ED BUILT ENV, V2, P90, DOI [10.11120/jebe.2007.02010090, DOI 10.11120/JEBE.2007.02010090]; Loy BD, 2013, FATIGUE, V1, P223, DOI 10.1080/21641846.2013.843266; Mailey EL, 2010, PSYCHOL HEALTH MED, V15, P646, DOI 10.1080/13548506.2010.498894; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1996, MASLACH BURNOUT INVE; McAuley E, 2013, ROUTLEDGE HDB PHYS A, P224; Meijman T.F., 1994, METEN PSYCHOSOCIALE; Meijman TF, 1992, HDB A O PSYCHOL; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Mohr DC, 2009, PSYCHOTHER PSYCHOSOM, V78, P275, DOI 10.1159/000228248; Oosterholt BG, 2015, J PSYCHOSOM RES, V78, P445, DOI 10.1016/j.jpsychores.2014.11.003; Oosterholt BG, 2014, STRESS, V17, P400, DOI 10.3109/10253890.2014.949668; Oosterholt BG, 2012, SCAND J WORK ENV HEA, V38, P358, DOI 10.5271/sjweh.3256; Otto M.W., 2011, EXERCISE MOOD ANXIET; Pagnin D, 2014, ACAD PSYCHIATR, V38, P438, DOI 10.1007/s40596-014-0093-z; Persinger R, 2004, MED SCI SPORT EXER, V36, P1632, DOI 10.1249/01.MSS.0000074690.03001.98; Poljac E, 2010, Q J EXP PSYCHOL, V63, P401, DOI 10.1080/17470210902990803; Puetz TW, 2008, PSYCHOTHER PSYCHOSOM, V77, P167, DOI 10.1159/000116610; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rook JW, 2006, EUR J WORK ORGAN PSY, V15, P218, DOI 10.1080/13594320500513962; Roth T, 2007, J CLIN SLEEP MED, V3, pS7, DOI [10.5664/jcsm.26929, DOI 10.5664/JCSM.26929]; Salmon P, 2001, CLIN PSYCHOL REV, V21, P33, DOI 10.1016/S0272-7358(99)00032-X; Schaufeli W. B., 2001, PSYCHOLOOG, V36, P9, DOI DOI 10.1037/T05561-000; Schaufeli WB, 2002, J CROSS CULT PSYCHOL, V33, P464, DOI 10.1177/0022022102033005003; Schmidt E, 2015, PSYCHOL KLACHTEN OND; Shoji K, 2015, ANXIETY STRESS COPIN, V14, P1, DOI DOI 10.1080/10615806.2015.1058369; Sibbald B, 1998, BRIT MED J, V316, P201; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Sonnentag S, 2012, CURR DIR PSYCHOL SCI, V21, P114, DOI 10.1177/0963721411434979; van de Water ATM, 2011, J SLEEP RES, V20, P183, DOI 10.1111/j.1365-2869.2009.00814.x; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; van Veldhoven M, 2003, OCCUP ENVIRON MED, V60, P3; Verburgh L, 2014, BRIT J SPORT MED, V48, P973, DOI 10.1136/bjsports-2012-091441; Vossensteyn Hans, 2013, INT EXPERIENCES STUD; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004	76	28	28	1	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152137	10.1371/journal.pone.0152137	http://dx.doi.org/10.1371/journal.pone.0152137			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH9NC	27031610	Green Published, gold			2023-01-03	WOS:000373121800037
J	Dustin, ML				Dustin, Michael L.			Killers on sterols	NATURE			English	Editorial Material							ACYL-COENZYME; CELL		[Dustin, Michael L.] Univ Oxford, Kennedy Inst Rheumatol, Oxford OX3 7FY, England	University of Oxford	Dustin, ML (corresponding author), Univ Oxford, Kennedy Inst Rheumatol, Oxford OX3 7FY, England.	michael.dustin@kennedy.ox.ac.uk	Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				Beal AM, 2009, IMMUNITY, V31, P632, DOI 10.1016/j.immuni.2009.09.004; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Dustin ML, 2014, CANCER IMMUNOL RES, V2, P1023, DOI 10.1158/2326-6066.CIR-14-0161; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832; Mingueneau M, 2013, NAT IMMUNOL, V14, P619, DOI 10.1038/ni.2590; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang W, 2016, NATURE, V531, P651, DOI 10.1038/nature17412; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741	13	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2016	531	7596					583	584		10.1038/nature17310	http://dx.doi.org/10.1038/nature17310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH8EX	26982727				2023-01-03	WOS:000373027400024
J	Chan, JK; Brady, MF; Penson, RT; Huang, H; Birrer, MJ; Walker, JL; DiSilvestro, PA; Rubin, SC; Martin, LP; Davidson, SA; Huh, WK; O'Malley, DM; Boente, MP; Michael, H; Monk, BJ				Chan, J. K.; Brady, M. F.; Penson, R. T.; Huang, H.; Birrer, M. J.; Walker, J. L.; DiSilvestro, P. A.; Rubin, S. C.; Martin, L. P.; Davidson, S. A.; Huh, W. K.; O'Malley, D. M.; Boente, M. P.; Michael, H.; Monk, B. J.			Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; EVERY 3 WEEKS; EPITHELIAL OVARIAN; BREAST-CANCER; OPEN-LABEL; ADJUVANT TREATMENT; PRIMARY PERITONEAL; FALLOPIAN-TUBE; SOLID TUMORS; BEVACIZUMAB	BACKGROUND A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ovarian cancer. We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients receiving and those not receiving bevacizumab. METHODS We prospectively stratified patients according to whether they elected to receive bevacizumab and then randomly assigned them to receive either paclitaxel, administered intravenously at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose equivalent to an area under the curve [AUC] of 6) for six cycles or paclitaxel, administered weekly at a dose of 80 mg per square meter, plus carboplatin (AUC, 6) for six cycles. The primary end point was progression-free survival. RESULTS A total of 692 patients were enrolled, 84% of whom opted to receive bevacizumab. In the intention-to-treat analysis, weekly paclitaxel was not associated with longer progression-free survival than paclitaxel administered every 3 weeks (14.7 months and 14.0 months, respectively; hazard ratio for disease progression or death, 0.89; 95% confidence interval [CI], 0.74 to 1.06; P=0.18). Among patients who did not receive bevacizumab, weekly paclitaxel was associated with progression-free survival that was 3.9 months longer than that observed with paclitaxel administered every 3 weeks (14.2 vs. 10.3 months; hazard ratio, 0.62; 95% CI, 0.40 to 0.95; P=0.03). However, among patients who received bevacizumab, weekly paclitaxel did not significantly prolong progression-free survival, as compared with paclitaxel administered every 3 weeks (14.9 months and 14.7 months, respectively; hazard ratio, 0.99; 95% CI, 0.83 to 1.20; P=0.60). A test for interaction that assessed homogeneity of the treatment effect showed a significant difference between treatment with bevacizumab and without bevacizumab (P=0.047). Patients who received weekly paclitaxel had a higher rate of grade 3 or 4 anemia than did those who received paclitaxel every 3 weeks (36% vs. 16%), as well as a higher rate of grade 2 to 4 sensory neuropathy (26% vs. 18%); however, they had a lower rate of grade 3 or 4 neutropenia (72% vs. 83%). CONCLUSIONS Overall, weekly paclitaxel, as compared with paclitaxel administered every 3 weeks, did not prolong progression-free survival among patients with ovarian cancer. (Funded by the National Cancer Institute and Genentech; GOG-0262 ClinicalTrials.gov number, NCT01167712.)	[Chan, J. K.] Calif Pacific Palo Alto Med Fdn, Sutter Canc Res Inst, 3838 Calif St,Unit 410, San Francisco, CA 94118 USA; [Brady, M. F.; Huang, H.] Roswell Pk Canc Inst, Stat & Data Ctr, NRG Oncol Gynecol Oncol Grp, Buffalo, NY 14263 USA; [Penson, R. T.; Birrer, M. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Walker, J. L.] Univ Oklahoma, Oklahoma City, OK USA; [DiSilvestro, P. A.] Brown Univ, Women & Infants Hosp, Providence, RI USA; [Rubin, S. C.] Univ Penn, Philadelphia, PA 19104 USA; [Martin, L. P.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Davidson, S. A.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Huh, W. K.] Univ Alabama Birmingham, Birmingham, AL USA; [O'Malley, D. M.] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA; [Boente, M. P.] Minnesota Oncol Hematol Oncol Serv, Edina, MN USA; [Michael, H.] Indiana Univ Sch Med, Carmel, IN USA; [Monk, B. J.] Univ Arizona, Ctr Canc, Phoenix, AZ USA; [Monk, B. J.] Creighton Univ, Sch Med, Phoenix, AZ USA; [Monk, B. J.] St Josephs Hosp, Phoenix, AZ USA	Roswell Park Cancer Institute; Harvard University; Massachusetts General Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; Brown University; Women & Infants Hospital Rhode Island; University of Pennsylvania; Fox Chase Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Alabama System; University of Alabama Birmingham; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Indiana University System; University of Arizona; Creighton University; St. Joseph's Hospital and Medical Center	Chan, JK (corresponding author), Calif Pacific Palo Alto Med Fdn, Sutter Canc Res Inst, 3838 Calif St,Unit 410, San Francisco, CA 94118 USA.	chanjohn@sutterhealth.org	OMalley, David/E-3789-2011; Rubin, Stephen/U-8535-2019	Rubin, Stephen/0000-0003-3688-5333; OMalley, David/0000-0002-2828-0177	National Cancer Institute; Genentech; NATIONAL CANCER INSTITUTE [U10CA037517, U10CA180855, UG1CA189867, U10CA027469, U10CA180850, U10CA101165, P30CA006927, U10CA180822, U10CA180868] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Genentech(Roche HoldingGenentech); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and Genentech; GOG-0262 ClinicalTrials.gov number, NCT01167712.	Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Basen-Engquist K, 2001, J CLIN ONCOL, V19, P1809, DOI 10.1200/JCO.2001.19.6.1809; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Boso V, 2014, PHARMACOGENOMICS, V15, P1845, DOI [10.2217/pgs.14.127, 10.2217/PGS.14.127]; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Chan JK, 2006, OBSTET GYNECOL, V108, P521, DOI 10.1097/01.AOG.0000231680.58221.a7; Chan JK, 2014, ONCOLOGIST, V19, P523, DOI 10.1634/theoncologist.2013-0322; Cohn DE, 2011, J CLIN ONCOL, V29, P1247, DOI 10.1200/JCO.2010.32.1075; Dalton HJ, 2012, GYNECOL ONCOL, V124, P199, DOI 10.1016/j.ygyno.2011.09.028; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fuh KC, 2015, GYNECOL ONCOL, V136, P491, DOI 10.1016/j.ygyno.2014.10.009; Green MC, 2005, J CLIN ONCOL, V23, P5983, DOI 10.1200/JCO.2005.06.232; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; Hertz DL, 2013, PHARMACOGENOMICS, V14, P1065, DOI [10.2217/PGS.13.90, 10.2217/pgs.13.90]; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Jain RK, 2014, SCI AM, V310, P46, DOI 10.1038/scientificamerican0214-46; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Katsumata N, 2013, LANCET ONCOL, V14, P1020, DOI 10.1016/S1470-2045(13)70363-2; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Lau DH, 1999, CANCER BIOTHER RADIO, V14, P31, DOI 10.1089/cbr.1999.14.31; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pignata S, 2014, LANCET ONCOL, V15, P396, DOI 10.1016/S1470-2045(14)70049-X; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Rustin GJS, 2001, J CLIN ONCOL, V19, P4054, DOI 10.1200/JCO.2001.19.20.4054; Seidman AD, 2008, J CLIN ONCOL, V26, P1642, DOI 10.1200/JCO.2007.11.6699; Seidman AD, 2013, CLIN BREAST CANCER, V13, P239, DOI 10.1016/j.clbc.2013.02.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340	36	233	245	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	2016	374	8					738	748		10.1056/NEJMoa1505067	http://dx.doi.org/10.1056/NEJMoa1505067			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE6BB	26933849	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000370716600007
J	Ouyang, M; White, EE; Ren, H; Guo, Q; Zhang, I; Gao, H; Yanyan, S; Chen, XB; Weng, YM; Da Fonseca, A; Shah, S; Manuel, ER; Zhang, LY; Vonderfecht, SL; Alizadeh, D; Berlin, JM; Badie, B				Ouyang, Mao; White, Ethan E.; Ren, Hui; Guo, Qin; Zhang, Ian; Gao, Hang; Yanyan, Song; Chen, Xuebo; Weng, Yiming; Da Fonseca, Anna; Shah, Sunny; Manuel, Edwin R.; Zhang, Leying; Vonderfecht, Steven L.; Alizadeh, Darya; Berlin, Jacob M.; Badie, Behnam			Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model	PLOS ONE			English	Article							RECURRENT GLIOBLASTOMA; MICE; MELANOMA; DELIVERY; GROWTH; CANCER; CELLS; TRIAL; OLIGODEOXYNUCLEOTIDE; MACROPHAGES	Even when treated with aggressive current therapies, most patients with glioblastoma survive less than two years. Rapid tumor growth, an invasive nature, and the blood-brain barrier, which limits the penetration of large molecules into the brain, all contribute to the poor tumor response associated with conventional therapies. Immunotherapy has emerged as a therapeutic approach that may overcome these challenges. We recently reported that single-walled carbon nanotubes (SWCNTs) can be used to dramatically increase the immunotherapeutic efficacy of CpG oligonucleotides in a mouse model of glioma. Following implantation in the mouse brain, the tumor cell line used in these previous studies (GL261) tends to form a spherical tumor with limited invasion into healthy brain. In order to evaluate SWCNT/CpG therapy under more clinically-relevant conditions, here we report the treatment of a more invasive mouse glioma model (K-Luc) that better recapitulates human disease. In addition, a CpG sequence previously tested in humans was used to formulate the SWCNT/CpG which was combined with temozolomide, the standard of care chemotherapy for glioblastoma patients. We found that, following two intracranial administrations, SWCNT/CpG is well-tolerated and improves the survival of mice bearing invasive gliomas. Interestingly, the efficacy of SWCNT/CpG was enhanced when combined with temozolomide. This enhanced anti-tumor efficacy was correlated to an increase of tumor-specific cytotoxic activity in splenocytes. These results reinforce the emerging understanding that immunotherapy can be enhanced by combining it with chemotherapy and support the continued development of SWCNT/CpG.	[Ouyang, Mao] Cent S Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Hunan, Peoples R China; [White, Ethan E.; Berlin, Jacob M.] Irell & Manella Grad Sch Biol Sci City Hope, Duarte, CA 91010 USA; [White, Ethan E.; Weng, Yiming; Berlin, Jacob M.] City Hope Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Ren, Hui] Jilin Univ, Hosp 2, Dept Gen Surg, Changchun 130023, Jilin Province, Peoples R China; [Guo, Qin] Cent S Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha, Hunan, Peoples R China; [Zhang, Ian; Shah, Sunny; Zhang, Leying; Alizadeh, Darya; Badie, Behnam] City Hope Beckman Res Inst, Div Neurosurg, Duarte, CA 91010 USA; [Gao, Hang] Jilin Univ, Hosp 1, Dept Bone & Joint Surg, Changchun 130023, Jilin Province, Peoples R China; [Yanyan, Song] Jilin Univ, Hosp 2, Dept Nephrol, Changchun 130023, Jilin Province, Peoples R China; [Chen, Xuebo] Jilin Univ, China Japan Union Hosp, Dept Gen Surg, Changchun 130023, Jilin Province, Peoples R China; [Da Fonseca, Anna] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Morfogenese Celular, Rio De Janeiro, Brazil; [Manuel, Edwin R.] City Hope Beckman Res Inst, Dept Virol, Div Translat Vaccine Res, Duarte, CA 91010 USA; [Vonderfecht, Steven L.] City Hope Beckman Res Inst, Div Comparat Med, Duarte, CA 91010 USA; [Badie, Behnam] City Hope Beckman Res Inst, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA	Central South University; City of Hope; Beckman Research Institute of City of Hope; Jilin University; Central South University; City of Hope; Beckman Research Institute of City of Hope; Jilin University; Jilin University; Jilin University; Universidade Federal do Rio de Janeiro; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Berlin, JM (corresponding author), Irell & Manella Grad Sch Biol Sci City Hope, Duarte, CA 91010 USA.; Berlin, JM (corresponding author), City Hope Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA.; Badie, B (corresponding author), City Hope Beckman Res Inst, Div Neurosurg, Duarte, CA 91010 USA.; Badie, B (corresponding author), City Hope Beckman Res Inst, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA.	jberlin@coh.org; bbadie@coh.org	da Fonseca, Anna Carolina Carvalho/AAQ-7440-2020; da Fonseca, Anna Carolina Carvalho/C-5825-2015	da Fonseca, Anna Carolina Carvalho/0000-0002-8366-3146; da Fonseca, Anna Carolina Carvalho/0000-0002-8366-3146; Manuel, Edwin/0000-0002-4602-7060	Kenneth T. and Eileen L. Norris Foundation; STOP Cancer; National Cancer Institute of the National Institutes of Health [P30CA33572];  [R01CA155769];  [R21CA189223];  [R21 NS081594]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA155769, R21CA189223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS081594] Funding Source: NIH RePORTER	Kenneth T. and Eileen L. Norris Foundation; STOP Cancer; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors would like to thank R01CA155769, R21CA189223, R21 NS081594, The Kenneth T. and Eileen L. Norris Foundation and STOP Cancer for research funding. Research reported in this publication included work performed in the Light Microscopy Digital Imaging Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572.	Alizadeh D, 2014, CANCER RES, V74, P2663, DOI 10.1158/0008-5472.CAN-14-0301; Alizadeh D, 2010, CLIN CANCER RES, V16, P3399, DOI 10.1158/1078-0432.CCR-09-3087; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Badie B, 2013, IMMUNOTHERAPY-UK, V5, P1, DOI [10.2217/IMT.12.148, 10.2217/imt.12.148]; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.005; Carpentier A, 2006, NEURO-ONCOLOGY, V8, P60, DOI 10.1215/S1522851705000475; Carpentier A, 2010, NEURO-ONCOLOGY, V12, P401, DOI 10.1093/neuonc/nop047; Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f; Drezek RA, 2010, NAT NANOTECHNOL, V5, P168, DOI 10.1038/nnano.2010.37; Fadul CE, 2011, NEURO-ONCOLOGY, V13, P393, DOI 10.1093/neuonc/noq204; Fan HT, 2012, CLIN CANCER RES, V18, P5628, DOI 10.1158/1078-0432.CCR-12-1911; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Gomez GG, 2006, GENE THER MOL BIOL, V10A, P133; Hurt RH, 2006, CARBON, V44, P1028, DOI 10.1016/j.carbon.2005.12.023; Jahrsdorfer Bernd, 2008, Update Cancer Ther, V3, P27, DOI 10.1016/j.uct.2007.11.003; Kim HK, 2012, BIOMACROMOLECULES, V13, P636, DOI 10.1021/bm2014119; Kolosnjaj-Tabi J, 2010, ACS NANO, V4, P1481, DOI 10.1021/nn901573w; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee TH, 2009, SCAND J IMMUNOL, V70, P85, DOI 10.1111/j.1365-3083.2009.02273.x; Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978; Liu Z, 2008, P NATL ACAD SCI USA, V105, P1410, DOI 10.1073/pnas.0707654105; Manuel ER, 2011, CANCER RES, V71, P4183, DOI 10.1158/0008-5472.CAN-10-4676; Morimoto Y, 2012, NANOTOXICOLOGY, V6, P766, DOI 10.3109/17435390.2011.620719; Neyns B, 2010, CANCER-AM CANCER SOC, V116, P2868, DOI 10.1002/cncr.25035; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Pulskamp K, 2007, TOXICOL LETT, V168, P58, DOI 10.1016/j.toxlet.2006.11.001; Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135; Sanchez-Perez LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059082; Schipper ML, 2008, NAT NANOTECHNOL, V3, P216, DOI 10.1038/nnano.2008.68; Sengupta S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831090; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Terada K, 2006, GENE THER, V13, P705, DOI 10.1038/sj.gt.3302717; Weber JS, 2009, CANCER, V115, P3944, DOI 10.1002/cncr.24473; Yamashita K, 2010, INFLAMMATION, V33, P276, DOI 10.1007/s10753-010-9182-7; ZALIPSKY S, 1993, BIOCONJUGATE CHEM, V4, P296, DOI 10.1021/bc00022a008; Zhang LY, 2009, GLIA, V57, P1458, DOI 10.1002/glia.20863; Zhao DC, 2011, CLIN CANCER RES, V17, P771, DOI 10.1158/1078-0432.CCR-10-2444	38	28	28	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2016	11	2							e0148139	10.1371/journal.pone.0148139	http://dx.doi.org/10.1371/journal.pone.0148139			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9NL	26829221	Green Submitted, Green Published, gold			2023-01-03	WOS:000369548200069
J	Jayson, GC; Kerbel, R; Ellis, LM; Harris, AL				Jayson, Gordon C.; Kerbel, Robert; Ellis, Lee M.; Harris, Adrian L.			Antiangiogenic therapy in oncology: current status and future directions	LANCET			English	Review							PHASE-III TRIAL; METASTATIC COLORECTAL-CANCER; RENAL-CELL CARCINOMA; ADVANCED HEPATOCELLULAR-CARCINOMA; RECURRENT OVARIAN-CANCER; PANCREATIC NEUROENDOCRINE TUMORS; RESISTANT PROSTATE-CANCER; TYROSINE KINASE INHIBITOR; ANTI-ANGIOGENIC THERAPY; BREAST-CANCER	Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been validated as a target in several tumour types through randomised trials, incorporating vascular endothelial growth factor (VEGF) pathway inhibitors into the therapeutic armoury. Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and pancreatic neuroendocrine tumours are sensitive to these drugs, others such as prostate cancer, pancreatic adenocarcinoma, and melanoma are resistant. Even when drugs have yielded significant results, improvements in progression-free survival, and, in some cases, overall survival, are modest. Thus, a crucial issue in development of these drugs is the search for predictive biomarkers-tests that predict which patients will, and will not, benefit before initiation of therapy. Development of biomarkers is important because of the need to balance efficacy, toxicity, and cost. Novel combinations of these drugs with other antiangiogenics or other classes of drugs are being developed, and the appreciation that these drugs have immunomodulatory and other modes of action will lead to combination regimens that capitalise on these newly understood mechanisms.	[Jayson, Gordon C.] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England; [Jayson, Gordon C.] Univ Manchester, Christie Hosp, Manchester, Lancs, England; [Kerbel, Robert] Univ Toronto, Sunnybrook Res Inst, Biol Sci Platform, Toronto, ON, Canada; [Ellis, Lee M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Ellis, Lee M.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Harris, Adrian L.] Univ Oxford, Churchill Hosp, Dept Med Oncol, Oxford, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Oxford	Jayson, GC (corresponding author), Christie Hosp, Manchester M20 4BX, Lancs, England.	gordon.jayson@ics.manchester.ac.uk	Harris, Adrian L/ABA-3343-2020; Jayson, Gordon/O-8224-2015	Harris, Adrian L/0000-0003-1376-8409; Jayson, Gordon/0000-0002-8515-8944	Genentech; Roche; Cerulean; Hoffman La Roche; AstraZeneca; Eli Lilly; Cerulean Pharma; Angiocrine Biosciences; Triphase Accelerator; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; Cancer Research UK [16466, 18974, 11359] Funding Source: researchfish; Medical Research Council [G0300648] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; Wellbeing of Women [RG1705] Funding Source: researchfish	Genentech(Roche HoldingGenentech); Roche(Roche Holding); Cerulean; Hoffman La Roche; AstraZeneca(AstraZeneca); Eli Lilly(Eli Lilly); Cerulean Pharma; Angiocrine Biosciences; Triphase Accelerator; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellbeing of Women(Wellbeing of Women (WoW))	LME reports personal fees from Genentech, Roche, and Cerulean. GCJ reports research grants from Hoffman La Roche and AstraZeneca and consultation fees from AstraZeneca. RK declares consulting fees from Eli Lilly, Cerulean Pharma, Angiocrine Biosciences, and Triphase Accelerator, and honoraria from Boehringer-Ingelheim and Regeneron. ALH declares no competing interests.	Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505; Backen A, 2014, CLIN CANCER RES, V20, P4549, DOI 10.1158/1078-0432.CCR-13-3248; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bridges EM, 2011, BIOCHEM PHARMACOL, V81, P1183, DOI 10.1016/j.bcp.2011.02.016; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9; Bruix J, 2015, LANCET ONCOL, V16, P1344, DOI 10.1016/S1470-2045(15)00198-9; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Collinson F, 2013, CLIN CANCER RES, V19, P5227, DOI 10.1158/1078-0432.CCR-13-0489; Corrie PG, 2014, LANCET ONCOL, V15, P620, DOI 10.1016/S1470-2045(14)70110-X; de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0; Dupuis-Girod S, 2012, JAMA-J AM MED ASSOC, V307, P948, DOI 10.1001/jama.2012.250; Earl HM, 2015, LANCET ONCOL, V16, P656, DOI 10.1016/S1470-2045(15)70137-3; Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287; Emblem KE, 2013, NAT MED, V19, P1178, DOI 10.1038/nm.3289; Escudier B, 2012, NAT REV CLIN ONCOL, V9, P327, DOI 10.1038/nrclinonc.2012.59; Fakhrejahani E, 2014, JPN J CLIN ONCOL, V44, P197, DOI 10.1093/jjco/hyt201; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Gerald D, 2013, CANCER RES, V73, P1649, DOI 10.1158/0008-5472.CAN-12-4697; Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Grothey A, 2013, LANCET ONCOL, V14, P2, DOI 10.1016/S1470-2045(12)70516-8; Guerin E, 2013, CANCER RES, V73, P2743, DOI 10.1158/0008-5472.CAN-12-4183; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj.bjc.6600315; Heidenreich A, 2013, ANN ONCOL, V24, P329, DOI 10.1093/annonc/mds505; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053; Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hutson TE, 2014, J CLIN ONCOL, V32, P760, DOI 10.1200/JCO.2013.50.3961; Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410; Kangsamaksin T, 2015, CANCER DISCOV, V5, P182, DOI 10.1158/2159-8290.CD-14-0650; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Kudo M, 2014, HEPATOLOGY, V60, P1697, DOI 10.1002/hep.27290; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Kung AL, 2007, ADV CANCER RES, V96, P191, DOI 10.1016/S0065-230X(06)96007-2; Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145; Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0; Ledermann JA, 2013, EUR J CANCER, V49, pS5; Liang WH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109757; Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Michaelson MD, 2014, J CLIN ONCOL, V32, P76, DOI 10.1200/JCO.2012.48.5268; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Monk BJ, 2014, LANCET ONCOL, V15, P799, DOI 10.1016/S1470-2045(14)70244-X; Motz GT, 2011, NAT REV IMMUNOL, V11, P702, DOI 10.1038/nri3064; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Nagy JA, 2012, CLIN EXP METASTAS, V29, P657, DOI 10.1007/s10585-012-9500-6; O'Connor JPB, 2012, CLIN CANCER RES, V18, P6588, DOI 10.1158/1078-0432.CCR-12-1501; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pezzella F, 1996, EUR J CANCER, V32A, P2494, DOI 10.1016/S0959-8049(96)00377-2; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059; Rini BI, 2014, J CLIN ONCOL, V32, P752, DOI 10.1200/JCO.2013.50.5305; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470; Schmidinger M, 2010, CANCER TREAT REV, V36, P416, DOI 10.1016/j.ctrv.2010.01.003; Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Simpkins F, 2007, GYNECOL ONCOL, V107, P118, DOI 10.1016/j.ygyno.2007.06.004; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Sitohy B, 2011, CANCER RES, V71, P7021, DOI 10.1158/0008-5472.CAN-11-1693; Smith DC, 2014, CLIN CANCER RES, V20, P6295, DOI 10.1158/1078-0432.CCR-14-1373; Subbiah V, 2012, J CLIN ONCOL, V30, pE64, DOI 10.1200/JCO.2011.38.2614; Sun M, 2014, INT J NEPHROL RENOV, V7, P401, DOI 10.2147/IJNRD.S48496; Szabo V, 2015, J PATHOL, V235, P384, DOI 10.1002/path.4464; Tang TC, 2010, NEOPLASIA, V12, P928, DOI 10.1593/neo.10804; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023; vFerrara N., 2002, NAT REV CANCER, V2, P795; von Minckwitz G, 2014, LANCET ONCOL, V15, P1269, DOI 10.1016/S1470-2045(14)70439-5; Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	113	504	534	11	214	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2016	388	10043					518	529		10.1016/S0140-6736(15)01088-0	http://dx.doi.org/10.1016/S0140-6736(15)01088-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS2EK	26853587				2023-01-03	WOS:000380559400032
J	Wedzicha, JA; Banerji, D; Chapman, KR; Vestbo, J; Roche, N; Ayers, T; Thach, C; Fogel, R; Patalano, F; Vogelmeier, CF				Wedzicha, Jadwiga A.; Banerji, Donald; Chapman, Kenneth R.; Vestbo, Jorgen; Roche, Nicolas; Ayers, Timothy; Thach, Chau; Fogel, Robert; Patalano, Francesco; Vogelmeier, Claus F.		FLAME Investigators	Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; TO-SEVERE COPD; INHALED CORTICOSTEROIDS; BLOOD EOSINOPHILS; PARALLEL-GROUP; LUNG-FUNCTION; DOUBLE-BLIND; EXACERBATIONS; EFFICACY; SAFETY	BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear. METHODS We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 mu g) plus the LAMA glycopyrronium (50 mu g) once daily or the LABA salmeterol (50 mu g) plus the inhaled glucocorticoid fluticasone (500 mu g) twice daily. The primary outcome was the annual rate of all COPD exacerbations. RESULTS A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95% confidence interval [CI], 0.83 to 0.96; P = 0.003). The indacaterol-glycopyrronium group had a longer time to the first exacerbation than did the salmeterol-fluticasone group (71 days [95% CI, 60 to 82] vs. 51 days [95% CI, 46 to 57]; hazard ratio, 0.84 [95% CI, 0.78 to 0.91], representing a 16% lower risk; P < 0.001). The annual rate of moderate or severe exacerbations was lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95% CI, 0.75 to 0.91; P < 0.001), and the time to the first moderate or severe exacerbation was longer in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (hazard ratio, 0.78; 95% CI, 0.70 to 0.86; P < 0.001), as was the time to the first severe exacerbation (hazard ratio, 0.81; 95% CI, 0.66 to 1.00; P = 0.046). The effect of indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood eosinophil count. The incidence of adverse events and deaths was similar in the two groups. The incidence of pneumonia was 3.2% in the indacaterol-glycopyrronium group and 4.8% in the salmeterol-fluticasone group (P = 0.02). CONCLUSIONS Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. (Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.)	[Wedzicha, Jadwiga A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Vestbo, Jorgen] Univ Manchester, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Vestbo, Jorgen] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Banerji, Donald; Thach, Chau; Fogel, Robert] Novartis Pharmaceut, E Hanover, NJ USA; [Chapman, Kenneth R.] Univ Hlth Network, Asthma & Airway Ctr, Toronto, ON, Canada; [Chapman, Kenneth R.] Univ Toronto, Toronto, ON, Canada; [Roche, Nicolas] Univ Paris 05, Serv Pneumol, AP HP, EA2511, Paris, France; [Patalano, Francesco] Novartis Pharma AG, Basel, Switzerland; [Vogelmeier, Claus F.] Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med Pulm & Crit Care Med, Marburg, Germany	Imperial College London; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Novartis; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Novartis; Philipps University Marburg; University Hospital of Giessen & Marburg	Wedzicha, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, COPD Res Grp, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	j.wedzicha@imperial.ac.uk	Roche, Nicolas/AAE-9206-2021; Saryal, Sevgi/AAP-7879-2020; Patalano, Francesco/AAE-6510-2021; Vestbo, Jorgen/Y-2912-2019; Roche, Nicolas/AAP-4445-2021; Ambrosino, Nicolino/AAC-2005-2020; DESLEE, Gaetan/G-2625-2013; Nayci, Sibel/A-6015-2016	Saryal, Sevgi/0000-0001-5062-5226; Ambrosino, Nicolino/0000-0002-5331-1393; roche, nicolas/0000-0002-3162-5033; Field, Stephen/0000-0002-6682-4155; DESLEE, Gaetan/0000-0002-4919-5916; Pothirat, Chaicharn/0000-0003-0616-7066; Vestbo, Jorgen/0000-0001-6355-6362; Nayci, Sibel/0000-0002-8415-5717; Janssens, Wim/0000-0003-1830-2982; Vukcevic, Miodrag/0000-0002-6218-3848; Antczak, Adam/0000-0003-3430-3088; Bodtger, Uffe/0000-0002-1231-9209	Novartis; National Institute for Health Research [NF-SI-0510-10270, NF-SI-0513-10077] Funding Source: researchfish	Novartis(Novartis); National Institute for Health Research(National Institute for Health Research (NIHR))	Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.	[Anonymous], 2000, POINTS CONS SWITCH S; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Bateman ED, 2013, EUR RESPIR J, V42, P1484, DOI 10.1183/09031936.00200212; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2011, CHEST, V139, P505, DOI 10.1378/chest.09-2992; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Crim C, 2009, EUR RESPIR J, V34, P641, DOI 10.1183/09031936.00193908; de Torres JP, 2002, CHEST, V121, P1092, DOI 10.1378/chest.121.4.1092; Donaldson GC, 2015, AM J RESP CRIT CARE, V192, P943, DOI 10.1164/rccm.201412-2269OC; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Donohue JF, 2015, RESP MED, V109, P870, DOI 10.1016/j.rmed.2015.04.018; Dransfield MT, 2014, RESP MED, V108, P1171, DOI 10.1016/j.rmed.2014.05.008; FDA, 2010, GUID IND NON CLIN TR; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2015, GLOB STRAT DIAGN MAN; Jones Paul W, 2005, COPD, V2, P75; Jones PW, 2014, EUR RESPIR J, V44, P1156, DOI 10.1183/09031936.00038814; Kerwin E, 2012, EUR RESPIR J, V40, P1106, DOI 10.1183/09031936.00040712; Langsetmo L, 2008, AM J RESP CRIT CARE, V177, P396, DOI 10.1164/rccm.200708-1290OC; Magnussen H, 2014, NEW ENGL J MED, V371, P1285, DOI 10.1056/NEJMoa1407154; Mahler DA, 2015, AM J RESP CRIT CARE, V192, P1068, DOI 10.1164/rccm.201505-1048OC; Muellerova H, 2015, CHEST, V147, P999, DOI 10.1378/chest.14-0655; National Institute for Health and Care Excellence (NICE), 2019, CHRON OBSTR PULM DIS; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021; Price D, 2013, PRIM CARE RESP J, V22, P92, DOI 10.4104/pcrj.2012.00092; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Toy EL, 2010, COPD, V7, P214, DOI 10.3109/15412555.2010.481697; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Vogelmeier CF, 2013, LANCET RESP MED, V1, P51, DOI 10.1016/S2213-2600(12)70052-8; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Wedzicha JA, 2015, RESP MED, V109, P105, DOI 10.1016/j.rmed.2014.10.011; Wedzicha JA, 2013, LANCET RESP MED, V1, P199, DOI 10.1016/S2213-2600(13)70052-3; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC; Zhong NS, 2015, INT J CHRONIC OBSTR, V10, P1015, DOI 10.2147/COPD.S84436	38	562	603	4	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2016	374	23					2222	2234		10.1056/NEJMoa1516385	http://dx.doi.org/10.1056/NEJMoa1516385			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO6VB	27181606	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000377920500006
J	Dimala, CA; Atashili, J; Mbuagbaw, JC; Wilfred, A; Monekosso, GL				Dimala, Christian Akem; Atashili, Julius; Mbuagbaw, Josephine C.; Wilfred, Akam; Monekosso, Gottlieb L.			A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naive Patients at the Limbe Regional Hospital, Cameroon	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; INSULIN SENSITIVITY; PREVALENCE; MELLITUS; TYPE-2; GLUCOSE; METABOLISM; RESISTANCE	Background Highly active antiretroviral therapy (HAART) has been associated with dysglycaemia. However, there is scarce data on the risk of developing diabetes mellitus (DM) in HIV/AIDS patients in Africa. Objectives Primarily to quantify and compare the risk of having diabetes mellitus in HIV/AIDS patients on HAART and HAART-naive patients in Limbe, Cameroon; and secondarily to determine if there is an association between HAART and increased DM risk. Methods A cross-sectional study was conducted at the Limbe Regional Hospital HIV treatment center between April and June 2013, involving 200 HIV/AIDS patients (100 on first-line HAART regimens for at least 12 months matched by age and gender to 100 HAART-naive patients). The Diabetes Risk Score (DRS) was calculated using a clinically validated model based on routinely recorded primary care parameters. A DRS >= 7% was considered as indicative of an increased risk of developing DM. Results The median DRS was significantly higher in patients on HAART (2.30%) than in HAARTnaive patients (1.62%), p = 0.002. The prevalence of the increased DM risk (DRS >= 7%) was significantly higher in patients on HAART, 31% (95% CI: 22.13-41.03) than in HAART-naive patients, 17% (95% CI: 10.23-25.82), p = 0.020. HAART was significantly associated with an increased DM risk, the odds ratio of the HAART group compared to the HAARTnaive group was 2.19 (95% CI: 1.12-4.30, p = 0.020). However, no association was found after adjusting for BMI-defined overweight, hypertension, age, sex, family history of DM and smoking (Odds ratio = 1.22, 95% CI: 0.42-3.59, p = 0.708). Higher BMI and hypertension accounted for the increased risk of DM in patients on HAART. Also, more than 82% of the participants were receiving or had ever used Zidovudine based HAART regimens. Conclusion HIV/AIDS patients on HAART could be at a greater risk of having DM than HAART-naive patients as a result of the effect of HAART on risk factors of DM such as BMI and blood pressure.	[Dimala, Christian Akem] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England; [Atashili, Julius; Mbuagbaw, Josephine C.; Wilfred, Akam; Monekosso, Gottlieb L.] Univ Buea, Fac Hlth Sci, Buea, Cameroon	University of London; London School of Hygiene & Tropical Medicine	Dimala, CA (corresponding author), Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	akdimch@yahoo.com		Akem Dimala, Christian/0000-0002-0064-0126	Dimala Family	Dimala Family	This project was funded by the Dimala Family. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araujo S, 2014, EUR J ENDOCRINOL, V171, P545, DOI 10.1530/EJE-14-0337; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Bergersen BM, 2004, EUR J CLIN MICROBIOL, V23, P625, DOI 10.1007/s10096-004-1177-6; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; Capeau J, 2012, AIDS, V26, P303, DOI 10.1097/QAD.0b013e32834e8776; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Dave JA, 2011, JAIDS-J ACQ IMM DEF, V57, P284, DOI 10.1097/QAI.0b013e318221863f; De Wit S, 2008, DIABETES CARE, V31, P1224, DOI 10.2337/dc07-2013; Dimala CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148100; Ekali LG, 2013, DIABETES METAB, V39, P71, DOI 10.1016/j.diabet.2012.08.012; Gazzaruso C, 2003, J HYPERTENS, V21, P1377, DOI 10.1097/00004872-200307000-00028; Glumer C, 2006, DIABETES CARE, V29, P410, DOI 10.2337/diacare.29.02.06.dc05-0945; Griffin SJ, 2000, DIABETES-METAB RES, V16, P164, DOI 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO;2-R; Hadigan C, 2014, ENDOCRIN METAB CLIN, V43, P685, DOI 10.1016/j.ecl.2014.05.003; Khatib OM., 2005, CLIN GUIDELINES MANA; Manuthu E M, 2008, East Afr Med J, V85, P10; Muhammad Sanusi, 2013, Niger Med J, V54, P185, DOI 10.4103/0300-1652.114591; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Nguemaim N. F., 2012, Journal of Medical Sciences (Pakistan), V12, P131, DOI 10.3923/jms.2012.131.140; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rasmussen LD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044575; Riyaten P, 2015, JAIDS-J ACQ IMM DEF, V69, P453, DOI 10.1097/QAI.0000000000000647; Samaras K, 2009, JAIDS-J ACQ IMM DEF, V50, P499, DOI 10.1097/QAI.0b013e31819c291b; Seaberg EC, 2005, AIDS, V19, P953, DOI 10.1097/01.aids.0000171410.76607.f8; van Vonderen MGA, 2010, JAIDS-J ACQ IMM DEF, V53, P186, DOI 10.1097/QAI.0b013e3181c190f4; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Warriner AH, 2014, INFECT DIS CLIN N AM, V28, P457, DOI 10.1016/j.idc.2014.05.003	27	18	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155560	10.1371/journal.pone.0155560	http://dx.doi.org/10.1371/journal.pone.0155560			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27195956	Green Submitted, gold, Green Published			2023-01-03	WOS:000376291100061
J	Yang, AD; Bilimoria, KY				Yang, Anthony D.; Bilimoria, Karl Y.			Accurately Measuring Hospital Venous Thromboembolism Prevention Efforts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURVEILLANCE; ASSOCIATION; COMPOSITE; RATES		[Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair,20th Floor, Chicago, IL 60611 USA; [Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [Yang, Anthony D.; Bilimoria, Karl Y.] NW Mem Hosp, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern Memorial Hospital	Yang, AD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair,20th Floor, Chicago, IL 60611 USA.	anthony.yang@northwestern.edu						Bates SM, 2012, CHEST, V141, pE351S, DOI 10.1378/chest.11-2299; Bilimoria KY, 2013, JAMA-J AM MED ASSOC, V310, P1482, DOI 10.1001/jama.2013.280048; Gould MK, 2012, CHEST, V141, pE227S, DOI 10.1378/chest.11-2297; Holcomb CN, 2015, JAMA SURG, V150, P520, DOI 10.1001/jamasurg.2015.35; Ju MH, 2014, ANN SURG, V260, P558, DOI 10.1097/SLA.0000000000000897; Kinnier CV, 2016, MED CARE, V54, P210, DOI 10.1097/MLR.0000000000000474; Kinnier CV, 2014, JAMA-J AM MED ASSOC, V312, P286, DOI 10.1001/jama.2014.1841; Rajaram R, 2015, JAMA-J AM MED ASSOC, V313, P897, DOI 10.1001/jama.2015.52	8	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2016	315	19					2113	+		10.1001/jama.2016.5422	http://dx.doi.org/10.1001/jama.2016.5422			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL9PN	27187304				2023-01-03	WOS:000375975300022
J	Sullivan, HW; Aikin, KJ; Chung-Davies, E; Wade, M				Sullivan, Helen W.; Aikin, Kathryn J.; Chung-Davies, Eunice; Wade, Michael			Prescription Drug Promotion from 2001-2014: Data from the US Food and Drug Administration	PLOS ONE			English	Article							CONSUMER; TELEVISION; EXPOSURE	The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in prescription drug promotion over time is to assess the number of promotional pieces submitted to the U.S. Food and Drug Administration (FDA). Form FDA 2253 collects information such as the date submitted and the type of material submitted. We analyzed data from Forms FDA 2253 received from 2001-2014. We examined the frequency of submissions by audience (consumer and healthcare professional) and type of promotional material. There was a noted increase in prescription drug promotion submissions across all media in the early 2000s. Although non-Internet promotion submissions have since plateaued, Internet promotion continued to increase. These results can help public health advocates and regulators focus attention and resources.	[Sullivan, Helen W.; Aikin, Kathryn J.; Chung-Davies, Eunice; Wade, Michael] US FDA, Silver Spring, MD USA	US Food & Drug Administration (FDA)	Sullivan, HW (corresponding author), US FDA, Silver Spring, MD USA.	Helen.Sullivan@fda.hhs.gov		Sullivan, Helen/0000-0001-7621-7554				Abrams T., 2012, FOOD DRUG LAW I ADV; Alperstein Neil M, 2014, Health Mark Q, V31, P231, DOI 10.1080/07359683.2014.936291; [Anonymous], 2014, OTHER POSTMARKETING; Brownfield ED, 2004, J HEALTH COMMUN, V9, P491, DOI 10.1080/10810730490523115; Bulik BS, 2011, AD AGE; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781; Hesse BW, 2010, NEW ENGL J MED, V362, P859, DOI 10.1056/NEJMc0909595; Kornfield R, 2015, AM J PREV MED, V48, P575, DOI 10.1016/j.amepre.2014.12.001; Kornfield R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055504; Krahn J., 2013, WHAT ARE ADULTS DOIN; Liang BA, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1775; Mackey TK, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0885-1; Makovsky PR, 2016, 6 ANN MAK KELT PULS; Mintzes B, 2012, ANNU REV PUBL HEALTH, V33, P259, DOI 10.1146/annurev-publhealth-031811-124540; Niederdeppe J, 2013, J GEN INTERN MED, V28, P886, DOI 10.1007/s11606-013-2379-3; Pew Research Center, 2015, HLTH FACT SHEET; Sheehan KB, 2007, J ADVERTISING, V36, P123, DOI 10.2753/JOA0091-3367360310; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; U.S. Food and Drug Administration, 2015, OPDP FDA 2253 REQ AD	21	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2016	11	5							e0155035	10.1371/journal.pone.0155035	http://dx.doi.org/10.1371/journal.pone.0155035			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KV	27149513	Green Published, gold, Green Submitted			2023-01-03	WOS:000375676800109
J	Sabler, IM; Berkovitch, M; Sandbank, J; Kozer, E; Dagan, Z; Goldman, M; Bahat, H; Stav, K; Zisman, A; Klin, B; Abu-Kishk, I				Sabler, Itay M.; Berkovitch, Matitiahu; Sandbank, Judith; Kozer, Eran; Dagan, Zahi; Goldman, Michael; Bahat, Hilla; Stav, Kobi; Zisman, Amnon; Klin, Baruch; Abu-Kishk, Ibrahim			Exposure to Hyperbaric Oxygen Intensified Vancomycin-Induced Nephrotoxicity in Rats	PLOS ONE			English	Article							OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; RENAL-FUNCTION; HIGH-PRESSURE; CELLS; DYSFUNCTION; MECHANISMS; EXPRESSION; PROTECTION	It has been suggested that oxidative stress is a potential mechanism for vancomycin-induced nephrotoxicity and hyperbaric oxygen therapy (HBO) has been shown to be effective in treating renal toxicity that has been pharmacologically induced in animal models. The aim of this study was to investigate the effect of HBO therapy on vancomycin-induced nephrotoxicity in rats. The study group comprised 36 Sprague Dawley male rats. We treated 30 with 500 mg/kg of intraperitoneal vancomycin once a day for 7 days. Half of these rats received a daily 1-hour treatment with HBO at 2 Atmospheres (ATM) on the same 7 days and formed the HBO+ group. The other 15 subjects received no HBO treatment (HBO-group). The remaining six rats served as the control group, three received HBO treatments alone and no treatment was administered to the other three rats. Laboratory results were obtained on day 8 and the intervention and control groups were compared. Rats in the HBO + group gained less weight than the HBO-group (11.6 grams vs 22.6 grams; P = 0,008) and had significantly higher serum blood urea nitrogen (99.6 vs 52.6 mg/dL; P< 0.001), serum creatinine (0.42 vs 0.16 mg/dL; P = 0.001) and magnesium (3.6 vs 3.1mg/dL; P = 0.014). The vancomycin blood levels were also higher in the HBO+ group (27.8 vs 6.7 mu g/mL; P = 0.078). There were no pathological kidney changes in the control group. All the kidneys from the treated groups (vancomycin + HBO and vancomycin HBO-) showed moderate to severe histopathological changes with no statistical significance between them. This study demonstrated that exposure to hyperbaric oxygen intensified vancomycin-induced nephrotoxicity in rats.	[Sabler, Itay M.; Stav, Kobi; Zisman, Amnon] Tel Aviv Univ, Sackler Sch Med, Dept Urol, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel; [Berkovitch, Matitiahu; Dagan, Zahi] Tel Aviv Univ, Sackler Sch Med, Clin Pharmacol Unit, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel; [Sandbank, Judith] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel; [Kozer, Eran; Klin, Baruch; Abu-Kishk, Ibrahim] Tel Aviv Univ, Sackler Sch Med, Div Pediat, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel; [Goldman, Michael; Bahat, Hilla] Tel Aviv Univ, Sackler Sch Med, Pediat Nephrol Serv, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine	Abu-Kishk, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Div Pediat, Assaf Harofeh Med Ctr, IL-69978 Tel Aviv, Israel.	abukishki@gmail.com	Stav, Kobi/AAH-1523-2019					APPEL GB, 1986, AM J KIDNEY DIS, V8, P75, DOI 10.1016/S0272-6386(86)80116-0; ARONOFF GR, 1981, ANTIMICROB AGENTS CH, V19, P306, DOI 10.1128/AAC.19.2.306; Aydinoz S, 2007, RENAL FAILURE, V29, P257, DOI 10.1080/08860220601166487; Berkovitch M, 2014, SCI WORLD J, DOI 10.1155/2014/105069; Chen LF, 2014, J FORMOS MED ASSOC, V113, P620, DOI 10.1016/j.jfma.2014.03.012; Cisek LJ, 1998, J ENDOUROL, V12, P95, DOI 10.1089/end.1998.12.95; Dieterich C, 2009, TOXICOL SCI, V107, P258, DOI 10.1093/toxsci/kfn203; Djurhuus R, 1999, UNDERSEA HYPERBAR M, V26, P75; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Gregorevic P, 2001, EUR J APPL PHYSIOL, V86, P24, DOI 10.1007/s004210100503; Hong S, 2007, AM J MED SCI, V334, P296, DOI 10.1097/MAJ.0b013e3180a6ec1e; Huang SHS, 2011, TRANSL RES, V157, P357, DOI 10.1016/j.trsl.2011.01.002; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Kellum John A, 2002, Curr Opin Crit Care, V8, P509, DOI 10.1097/00075198-200212000-00005; KIM YS, 1991, J NEUROSCI RES, V29, P100, DOI 10.1002/jnr.490290111; King DW, 2004, TOXICOL IN VITRO, V18, P797, DOI 10.1016/j.tiv.2004.03.013; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086/491709; Lin H, 2012, J TRAUMA ACUTE CARE, V72, P1220, DOI 10.1097/TA.0b013e318246ee70; MARRE R, 1984, J ANTIMICROB CHEMOTH, V14, P253, DOI 10.1093/jac/14.3.253; Mrsic-Pelcic J, 2004, NEUROCHEM INT, V44, P585, DOI 10.1016/j.neuint.2003.10.004; Nakamura T, 1996, J PHARM PHARMACOL, V48, P1197, DOI 10.1111/j.2042-7158.1996.tb03920.x; Nishino Y, 2003, FREE RADICAL RES, V37, P373, DOI 10.1080/1071576031000061002; Oktem F, 2005, TOXICOLOGY, V215, P227, DOI 10.1016/j.tox.2005.07.009; Piantadosi CA, 2008, FREE RADICAL BIO MED, V45, P562, DOI 10.1016/j.freeradbiomed.2008.05.013; Rachmilewitz D, 1998, GUT, V43, P512, DOI 10.1136/gut.43.4.512; SOKOL PP, 1991, J PHARMACOL EXP THER, V259, P1283; THOM SR, 1987, UNDERSEA BIOMED RES, V14, P485; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; Wada K, 2000, ACT NEUR S, V76, P285; ZAMBONI WA, 1993, PLAST RECONSTR SURG, V91, P1110, DOI 10.1097/00006534-199305000-00022	30	11	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0152554	10.1371/journal.pone.0152554	http://dx.doi.org/10.1371/journal.pone.0152554			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27092557	Green Published, Green Submitted, gold			2023-01-03	WOS:000374541200006
J	Yang, YT; Kozhimannil, KB; Snowden, JM				Yang, Y. Tony; Kozhimannil, Katy B.; Snowden, Jonathan M.			Pharmacist-Prescribed Birth Control in Oregon and Other States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Yang, Y. Tony] George Mason Univ, Dept Hlth Adm & Policy, MS 1J3,4400 Univ Dr, Fairfax, VA 22030 USA; [Kozhimannil, Katy B.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA; [Snowden, Jonathan M.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	George Mason University; University of Minnesota System; University of Minnesota Twin Cities; Oregon Health & Science University	Yang, YT (corresponding author), George Mason Univ, Dept Hlth Adm & Policy, MS 1J3,4400 Univ Dr, Fairfax, VA 22030 USA.	ytyang@gmu.edu						Belluck P, 2015, NY TIMES, pA14; Centers for Disease Control and Prevention, REPR HLTH DAT STAT REPR HLTH DAT STAT; Committee on Gynecologic Practice American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P1527, DOI 10.1097/01.AOG.0000423818.85283.bd; Dehlendorf C, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2014.01.037; Grindlay K, 2013, CONTRACEPTION, V88, P91, DOI 10.1016/j.contraception.2012.11.021; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Sonfield A., GUTTMACHER POLICY RE	7	11	11	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2016	315	15					1567	1568		10.1001/jama.2016.2327	http://dx.doi.org/10.1001/jama.2016.2327			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ5ZK	27019133				2023-01-03	WOS:000374289300012
J	Berterame, S; Erthal, J; Thomas, J; Fellner, S; Vosse, B; Clare, P; Hao, W; Johnson, DT; Mohar, A; Pavadia, J; Samak, AKE; Sipp, W; Sumyai, V; Suryawati, S; Toufiq, J; Yans, R; Mattick, RP				Berterame, Stefano; Erthal, Juliana; Thomas, Johny; Fellner, Sarah; Vosse, Benjamin; Clare, Philip; Hao, Wei; Johnson, David T.; Mohar, Alejandro; Pavadia, Jagjit; Samak, Ahmed Kamal Eldin; Sipp, Werner; Sumyai, Viroj; Suryawati, Sri; Toufiq, Jallal; Yans, Raymond; Mattick, Richard P.			Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study	LANCET			English	Article							PALLIATIVE CARE; EUROPEAN COUNTRIES; INCOME COUNTRIES; PAIN RELIEF; MEDICINES; AVAILABILITY; CONSUMPTION; POLICY; CANCER; ACCESSIBILITY	Background Despite opioid analgesics being essential for pain relief, use has been inadequate in many countries. We aim to provide up-to-date worldwide, regional, and national data for changes in opioid analgesic use, and to analyse the relation of impediments to use of these medicines. Methods We calculated defined daily doses for statistical purposes (S-DDD) per million inhabitants per day of opioid analgesics worldwide and for regions and countries from 2001 to 2013, and we used generalised estimating equation analysis to assess longitudinal change in use. We compared use data against the prevalence of some health disorders needing opioid use. We surveyed 214 countries or territories about impediments to availability of these medicines, and used regression analyses to establish the strength of associations between impediments and use. Findings The S-DDD of opioid analgesic use more than doubled worldwide between 2001-03 and 2011-13, from 1417 S-DDD (95% CI -732 to 3565; totalling about 3.01 billion defined daily doses per annum) to 3027 S-DDD (-1162 to 7215; totalling about 7.35 billion defined daily doses per annum). Substantial increases occurred in North America (16 046 S-DDD [95% CI 4032-28 061] to 31 453 S-DDD [8121-54 785]), western and central Europe (3079 S-DDD [1274-4883] to 9320 S-DDD [3969-14 672]), and Oceania (2275 S-DDD [763-3787] to 9136 S-DDD [2508-15 765]). Countries in other regions have shown no substantial increase in use. Impediments to use included an absence of training and awareness in medical professionals, fear of dependence, restricted financial resources, issues in sourcing, cultural attitudes, fear of diversion, international trade controls, and onerous regulation. Higher number of impediments reported was significantly associated with lower use (unadjusted incidence rate ratio 0.39 [95% CI 0.29-0.52]; p<0.0001), but not when adjusted for gross domestic product and human development index (0.91 [0.73-1.14]; p=0.4271). Interpretation Use of opioid analgesics has increased, but remains low in Africa, Asia, Central America, the Caribbean, South America, and eastern and southeastern Europe. Identified impediments to use urgently need to be addressed by governments and international agencies.	[Berterame, Stefano; Erthal, Juliana; Thomas, Johny; Fellner, Sarah; Vosse, Benjamin] Vienna Int Ctr, Secretariat Int Narcot Control Board, Vienna, Austria; [Hao, Wei; Johnson, David T.; Mohar, Alejandro; Pavadia, Jagjit; Samak, Ahmed Kamal Eldin; Sipp, Werner; Sumyai, Viroj; Suryawati, Sri; Toufiq, Jallal; Yans, Raymond; Mattick, Richard P.] Vienna Int Ctr, Int Narcot Control Board, Vienna, Austria; [Clare, Philip; Mattick, Richard P.] Univ New S Wales, Fac Med, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Hao, Wei] Cent S Univ, Mental Hlth Inst, Psychiat, Changsha, Hunan, Peoples R China; [Mohar, Alejandro] Univ Nacl Autonoma Mexico, Inst Biomed, Inst Nacl Cancerol, Unidad Epidemiol, Tlalpan, DF, Mexico; [Sumyai, Viroj] Mahidol Univ, Assoc Southeast Asian Nations, Inst Hlth Dev, Salaya, Nakhonphathom, Thailand; [Suryawati, Sri] GadjahMada Univ, Fac Med, Dept Pharmacol & Therapeut, Div Med Policy & Management, Yogyakarta, Indonesia; [Toufiq, Jallal] Univ Mohammed 5, Fac Med, Rabat, Morocco; [Toufiq, Jallal] Hop Univ Psychiat Arrazi, Sale, Morocco	University of New South Wales Sydney; Central South University; Instituto Nacional de Cancerologia (INCAN); Universidad Nacional Autonoma de Mexico; Mahidol University; Gadjah Mada University; Mohammed First University of Oujda; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat	Berterame, S (corresponding author), Vienna Int Ctr, Int Narcot Control Board, A-1400 Vienna, Austria.	stefano.berterame@incb.org	Clare, Philip J/N-7884-2015; Suryawati, Sri/AEV-8357-2022	Clare, Philip J/0000-0002-2009-7386; Suryawati, Sri/0000-0002-3127-2493; Erthal-Williamson, Juliana/0000-0001-7564-0529	International Narcotics Control Board, UN	International Narcotics Control Board, UN	International Narcotics Control Board, UN.	Anand S, 1994, HUMAN DEV INDEX METH; [Anonymous], [No title captured]; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Cherny NI, 2013, ANN ONCOL, V24, P7, DOI 10.1093/annonc/mdt498; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Clark F, 2015, LANCET, V386, P231, DOI 10.1016/S0140-6736(15)61264-8; Cleary J, 2013, ANN ONCOL, V24, P24, DOI 10.1093/annonc/mdt500; De Lima L, 2014, J PAIN SYMPTOM MANAG, V48, P649, DOI 10.1016/j.jpainsymman.2013.12.237; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; Ferlay J, GLOBOCAN 2012 V1 0; Hastie Barbara A, 2014, J Pain Palliat Care Pharmacother, V28, P259, DOI 10.3109/15360288.2014.941132; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; *INT NARC CONTR BO, 1989, DEM SUPPL OP MED SCI; *INT NARC CONTR BO, 1996, AV OP MED NEEDS; International Narcotics Control Board, 2014, NARC DRUGS EST WORLD; International Narcotics Control Board, 2011, AV INT CONTR DRUGS E; International Narcotics Control Board, 2015, REP 2014; International Narcotics Control Board, 2015, NARC DRUGS EST WORLD; Joint United Nations Programme on HIV/AIDS, 2013, GLOB REP UNAIDS REP; Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471; Knaul FM, 2015, LANCET GLOB HEALTH, V3, P35; Knaul FM, 2015, LANCET, V386, P722, DOI 10.1016/S0140-6736(15)60289-6; Krakauer EL, 2015, J PAIN SYMPTOM MANAG, V49, P916, DOI 10.1016/j.jpainsymman.2014.10.012; Liberman J, 2011, PUBLIC HEALTH, V125, P840, DOI 10.1016/j.puhe.2011.09.032; Linge-Dahl L, 2015, J PALLIAT MED, V18, P1033, DOI 10.1089/jpm.2015.0051; Lohman D, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-8; Meghani SH, 2012, PAIN MED, V13, P5, DOI 10.1111/j.1526-4637.2011.01289.x; Nickerson JW, 2014, LANCET, V383, P1802, DOI 10.1016/S0140-6736(14)60874-6; Paudel BD, 2015, J PAIN SYMPTOM MANAG, V49, P111, DOI 10.1016/j.jpainsymman.2014.02.011; Seya Marie-Josephine, 2011, J Pain Palliat Care Pharmacother, V25, P6, DOI 10.3109/15360288.2010.536307; Silbermann M, 2015, LANCET, V385, P1620, DOI 10.1016/S0140-6736(15)60791-7; Steedman MR, 2014, HEALTH AFFAIR, V33, P1612, DOI 10.1377/hlthaff.2014.0379; Svendsen K, 2011, PALLIATIVE MED, V25, P725, DOI 10.1177/0269216311398300; The Lancet, 2015, LANCET, V386, P2445; UNDP, HUM DEV IND ITS COMP; Unger-Saldana K, 2014, WORLD J CLIN ONCOL, V5, P465, DOI 10.5306/wjco.v5.i3.465; United Nations Office on Drugs and Crime, 2009, INT DRUG CONTR CONV; Vranken MJM, 2014, J PAIN SYMPTOM MANAG, V48, P1135, DOI 10.1016/j.jpainsymman.2014.02.013; World Bank, GDP PER CAP CURR US; World Health Organization, GLOB HLTH OBS DAT RE	40	327	332	2	57	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2016	387	10028					1644	1656		10.1016/S0140-6736(16)00161-6	http://dx.doi.org/10.1016/S0140-6736(16)00161-6			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ3ZL	26852264				2023-01-03	WOS:000374145100032
J	de Carvalho, SS; Silva, ACSE; Sabino, AD; Evangelista, FCG; Gomes, KB; Dusse, LMS; Rios, DRA				de Carvalho, Sara Santos; Simoes e Silva, Ana Cristina; Sabino, Adriano de Paula; Gontijo Evangelista, Fernanda Cristina; Gomes, Karina Braga; SantAna Dusse, Luci Maria; Alves Rios, Danyelle Romana			Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor beta 1 in Patients Undergoing Hemodialysis	PLOS ONE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; PLASMA T-PA; RENIN-ANGIOTENSIN; GENE POLYMORPHISM; INSERTION/DELETION POLYMORPHISM; CARDIOVASCULAR MORTALITY; DELETION POLYMORPHISM; SALT SENSITIVITY; RENAL-DISEASE; SYSTEM	Background There is substantial evidence that chronic renal and cardiovascular diseases are associated with coagulation disorders, endothelial dysfunction, inflammation and fibrosis. Angiotensin-Converting Enzyme Insertion/Deletion polymorphism (ACE I/D polymorphism) has also be linked to cardiovascular diseases. Therefore, this study aimed to compare plasma levels of ultrassensible C-reactive protein (usCRP), PAI-1, D-dimer and TGF-beta 1 in patients undergoing HD with different ACE I/D polymorphisms. Methods The study was performed in 138 patients at ESRD under hemodialysis therapy for more than six months. The patients were divided into three groups according to the genotype. Genomic DNA was extracted from blood cells (leukocytes). ACE I/D polymorphism was investigated by single polymerase chain reaction (PCR). Plasma levels of D-dimer, PAI-1 and TGF-beta 1 were measured by enzyme-linked immunosorbent assay (ELISA), and the determination of plasma levels of usCRP was performed by immunonephelometry. Data were analyzed by the software SigmaStat 2.03. Results Clinical characteristics were similar in patients with these three ACE I/D polymorphisms, except for interdialytic weight gain. I allele could be associated with higher interdialytic weight gain (P = 0.017). Patients genotyped as DD and as ID had significantly higher levels of PAI-1 than those with II genotype. Other laboratory parameters did not significantly differ among the three subgroups (P = 0.033). Despite not reaching statistical significance, plasma levels of usCRP were higher in patients carrying the D allele. Conclusion ACE I/D polymorphisms could be associated with changes in the regulation of sodium, fibrinolytic system, and possibly, inflammation. Our data showed that high levels of PAI-1 are detected when D allele is present, whereas greater interdialytic gain is associated with the presence of I allele. However, further studies with different experimental designs are necessary to elucidate the mechanisms involved in these associations.	[de Carvalho, Sara Santos; Alves Rios, Danyelle Romana] Univ Fed Sao Joao del Rei, Campus Ctr Oeste Dona Lindu, Divinopolis, MG, Brazil; [Simoes e Silva, Ana Cristina] Univ Fed Minas Gerais, Fac Med, Dept Pediat, Interdisciplinary Lab Med Invest, Belo Horizonte, MG, Brazil; [Sabino, Adriano de Paula; Gontijo Evangelista, Fernanda Cristina; Gomes, Karina Braga; SantAna Dusse, Luci Maria] Univ Fed Minas Gerais, Dept Clin & Toxicol Anal, Fac Pharm, Belo Horizonte, MG, Brazil	Universidade Federal de Sao Joao del-Rei; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Rios, DRA (corresponding author), Univ Fed Sao Joao del Rei, Campus Ctr Oeste Dona Lindu, Divinopolis, MG, Brazil.	danyelleromana@gmail.com	Simões e Silva, Ana Cristina/A-4409-2013; Sabino, Adriano de Paula/W-4538-2019; Rios, Danyelle Romana Alves/AAR-4367-2021; Sabino, Adriano de Paula/I-5120-2014; Evangelista, Fernanda/AAX-4787-2021	Simões e Silva, Ana Cristina/0000-0001-9222-3882; Sabino, Adriano de Paula/0000-0001-8562-8689; Rios, Danyelle Romana Alves/0000-0001-6377-241X; 	FAPEMIG; CNPq/Brazil	FAPEMIG(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); CNPq/Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by FAPEMIG and CNPq/Brazil. LMSD and KBG are grateful for a CNPq Research Fellowship (PQ).	Agarwal I, 2014, AM J EPIDEMIOL, V179, P1331, DOI 10.1093/aje/kwu067; Alvarez R, 1998, CARDIOVASC RES, V40, P375, DOI 10.1016/S0008-6363(98)00179-5; Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x; Arikan H, 2009, RENAL FAILURE, V31, P438, DOI 10.1080/08860220902963772; Asselbergs FW, 2007, GENOMICS, V89, P362, DOI 10.1016/j.ygeno.2006.11.004; Aucella F, 2003, NEPHROL DIAL TRANSPL, V18, P1142, DOI 10.1093/ndt/gfg118; Burns KD, 2000, AM J KIDNEY DIS, V36, P449, DOI 10.1053/ajkd.2000.16192; Caprioli J, 2008, CAN J PHYSIOL PHARM, V86, P505, DOI 10.1139/Y08-045; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; Devaraj S, 2003, CIRCULATION, V107, P398, DOI 10.1161/01.CIR.0000052617.91920.FD; Dusse LM, 2011, CLIN CHIM ACTA, V412, P17, DOI 10.1016/j.cca.2010.09.030; Felmeden D C, 2000, J Renin Angiotensin Aldosterone Syst, V1, P240, DOI 10.3317/jraas.2000.036; Franco V, 2006, J AM COLL NUTR, V25, p247S, DOI 10.1080/07315724.2006.10719574; Giner V, 2000, HYPERTENSION, V35, P512, DOI 10.1161/01.HYP.35.1.512; Guney AI, 2013, GENET MOL RES, V12, P6895, DOI 10.4238/2013.December.19.8; HAMSTEN A, 1987, LANCET, V2, P3; Hiraga H, 1996, HYPERTENSION, V27, P569, DOI 10.1161/01.HYP.27.3.569; Husain Kazim, 2015, World J Biol Chem, V6, P209, DOI 10.4331/wjbc.v6.i3.209; Ishimitsu T, 2004, AM J KIDNEY DIS, V44, P466, DOI 10.1053/j.ajkd.2004.04.050; Jablonski Kristen L, 2014, F1000Prime Rep, V6, P72, DOI 10.12703/P6-72; Kim DK, 1997, ARTERIOSCL THROM VAS, V17, P3242, DOI 10.1161/01.ATV.17.11.3242; Kim S, 2000, PHARMACOL REV, V52, P11; Kirmizis D, 2006, MED SCI MONITOR, V12, pCR55; Kunz R, 1998, J AM SOC NEPHROL, V9, P1653; Lopez-Gomez JM, 2005, KIDNEY INT, V67, pS63, DOI 10.1111/j.1523-1755.2005.09314.x; Malgorzewicz S, 2013, INT J MOL MED, V31, P503, DOI 10.3892/ijmm.2013.1234; Mallamaci F, 2000, AM J HYPERTENS, V13, P433, DOI 10.1016/S0895-7061(99)00195-8; Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P562, DOI 10.1161/01.ATV.18.4.562; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; Milburn JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067799; Moore JH, 2002, CLIN GENET, V62, P53, DOI 10.1034/j.1399-0004.2002.620107.x; Munhoz Terezinha P., 2005, Rev. Bras. Hematol. Hemoter., V27, P87, DOI 10.1590/S1516-84842005000200006; Oda H, 2000, Adv Perit Dial, V16, P152; Pasceri V, 2000, CIRCULATION, V102, P2165; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; Pontremoli R, 2000, KIDNEY INT, V57, P561, DOI 10.1046/j.1523-1755.2000.t01-1-00876.x; RIDKER PM, 1993, CIRCULATION, V87, P1969, DOI 10.1161/01.CIR.87.6.1969; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Rosenberg MA, 2014, AM HEART J, V167, P723, DOI 10.1016/j.ahj.2014.01.010; Sabovic M, 2005, PATHOPHYSIOL HAEMO T, V34, P274, DOI 10.1159/000093107; Sakhteh M, 2014, J RENIN-ANGIO-ALDO S, P1; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; Shah PK, 2000, CIRCULATION, V101, P1758, DOI 10.1161/01.CIR.101.15.1758; Stenvinkel P, 2002, NEPHROL DIAL TRANSPL, V17, P33, DOI 10.1093/ndt/17.suppl_8.33; Suliman Mohamed E, 2008, Saudi J Kidney Dis Transpl, V19, P329; Taal MW, 2000, CURR OPIN NEPHROL HY, V9, P651, DOI 10.1097/00041552-200011000-00011; Tronvik E, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-4; UEDA S, 1995, HYPERTENSION, V25, P1266, DOI 10.1161/01.HYP.25.6.1266; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; Yamagishi K, 2007, AM J HYPERTENS, V20, P751, DOI 10.1016/j.amjhyper.2007.01.018; Yamamoto K, 2005, CARDIOVASC RES, V66, P276, DOI 10.1016/j.cardiores.2004.11.013; Yaren A, 2008, EXP BIOL MED, V233, P32, DOI 10.3181/0705-RM-141; Zhang ZZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046495	54	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2016	11	3							e0150613	10.1371/journal.pone.0150613	http://dx.doi.org/10.1371/journal.pone.0150613			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9KB	27022914	gold, Green Submitted, Green Published			2023-01-03	WOS:000373113900007
J	Pan, D; Vargas-Morales, O; Zern, B; Anselmo, AC; Gupta, V; Zakrewsky, M; Mitragotri, S; Muzykantov, V				Pan, Daniel; Vargas-Morales, Omayra; Zern, Blaine; Anselmo, Aaron C.; Gupta, Vivek; Zakrewsky, Michael; Mitragotri, Samir; Muzykantov, Vladimir			The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells	PLOS ONE			English	Article							BIOTINYLATED ERYTHROCYTES; PLASMINOGEN-ACTIVATOR; DRUG-DELIVERY; INDUCED LYSIS; COMPLEMENT; MEMBRANE; ADSORPTION; BINDING; THROMBOPROPHYLAXIS; BIODISTRIBUTION	Red blood cells (RBCs) can be used for vascular delivery of encapsulated or surface-bound drugs and carriers. Coupling to RBC prolongs circulation of nanoparticles (NP, 200 nm spheres, a conventional model of polymeric drug delivery carrier) enabling their transfer to the pulmonary vasculature without provoking overt RBC elimination. However, little is known about more subtle and potentially harmful effects of drugs and drug carriers on RBCs. Here we devised high-throughput in vitro assays to determine the sensitivity of loaded RBCs to osmotic stress and other damaging insults that they may encounter in vivo (e.g. mechanical, oxidative and complement insults). Sensitivity of these tests is inversely proportional to RBC concentration in suspension and our results suggest that mouse RBCs are more sensitive to damaging factors than human RBCs. Loading RBCs by NP at 1: 50 ratio did not affect RBCs, while 10-50 fold higher NP load accentuated RBC damage by mechanical, osmotic and oxidative stress. This extensive loading of RBC by NP also leads to RBCs agglutination in buffer; however, addition of albumin diminished this effect. These results provide a template for analyses of the effects of diverse cargoes loaded on carrier RBCs and indicate that: i) RBCs can tolerate carriage of NP at doses providing loading of millions of nanoparticles per microliter of blood; ii) tests using protein-free buffers and mouse RBCs may overestimate adversity that may be encountered in humans.	[Pan, Daniel; Vargas-Morales, Omayra; Zern, Blaine; Muzykantov, Vladimir] Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Pan, Daniel; Vargas-Morales, Omayra; Zern, Blaine; Muzykantov, Vladimir] Univ Penn, Perelman Sch Med, Ctr Translat Targeted Therapeut & Nanomed, Philadelphia, PA 19104 USA; [Anselmo, Aaron C.; Gupta, Vivek; Zakrewsky, Michael; Mitragotri, Samir] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; [Anselmo, Aaron C.; Gupta, Vivek; Zakrewsky, Michael; Mitragotri, Samir] Univ Calif Santa Barbara, Ctr Bioengn, Santa Barbara, CA 93106 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Muzykantov, V (corresponding author), Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Muzykantov, V (corresponding author), Univ Penn, Perelman Sch Med, Ctr Translat Targeted Therapeut & Nanomed, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu		Anselmo, Aaron/0000-0003-3290-7857; Gupta, Vivek/0000-0002-3618-8178	National Heart, Lung, and Blood Institute (NHLBI) [R01 HL121134-02, T32 HL07915, T32 HL07748]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007915, R01HL121134, T32HL007748] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Heart, Lung, and Blood Institute (NHLBI): R01 HL121134-02, Muzykantov, Vladimir R, Drug delivery by carrier erythrocytes; T32 HL07915, Shaddy, Robert E and Levy, Robert J (co-PI), Training in Molecular Therapeutics for Pediatric Cardiology; and T32 HL07748, Fisher, AB (PI) Training in Lung Cell and Molecular Biology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anselmo AC, 2015, BIOMATERIALS, V68, P1, DOI 10.1016/j.biomaterials.2015.07.043; Anselmo AC, 2014, J CONTROL RELEASE, V190, P531, DOI 10.1016/j.jconrel.2014.03.050; Anselmo AC, 2013, ACS NANO, V7, P11129, DOI 10.1021/nn404853z; Atukorale PU, 2015, NANOSCALE, V7, P11420, DOI 10.1039/c5nr01355k; Barodka VM, 2014, BLOOD CELL MOL DIS, V52, P230, DOI 10.1016/j.bcmd.2013.10.004; BARTOSZ G, 1991, GERONTOLOGY, V37, P33, DOI 10.1159/000213251; BECKER PS, 1986, J BIOL CHEM, V261, P4620; Brazile D, 1996, J PHARM SCI, V84, P493; Chambers E, 2007, EXP BIOL MED, V232, P958; Chen LQ, 2015, CHEM RES TOXICOL, V28, P501, DOI 10.1021/tx500479m; CLEMENS MR, 1987, CHEM PHYS LIPIDS, V45, P251, DOI 10.1016/0009-3084(87)90068-5; Cremel M, 2013, INT J PHARMACEUT, V443, P39, DOI 10.1016/j.ijpharm.2012.12.044; Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257; Down LA, 2011, ANN BIOMED ENG, V39, P1632, DOI 10.1007/s10439-011-0262-0; Evans BC, 2013, JOVE-J VIS EXP, DOI 10.3791/50166; Gersh KC, 2011, BLOOD, V117, P4964, DOI 10.1182/blood-2010-10-310409; Godfrin Y, 2012, EXPERT OPIN BIOL TH, V12, P127, DOI 10.1517/14712598.2012.631909; GONZALES R, 1984, CANCER RES, V44, P4137; Grey JL, 2012, BIOCHEMISTRY-US, V51, P6838, DOI 10.1021/bi300693k; Gundersen SI, 2007, BIOTECHNOL BIOENG, V96, P1199, DOI 10.1002/bit.21204; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HEBBEL RP, 1990, BLOOD, V76, P1015; Kontos S, 2013, P NATL ACAD SCI USA, V110, pE60, DOI 10.1073/pnas.1216353110; Koshkaryev A, 2013, ADV DRUG DELIVER REV, V65, P24, DOI 10.1016/j.addr.2012.08.009; Kuypers FA, 1998, J HEART VALVE DIS, V7, P387; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Li CM, 2014, ACS APPL MATER INTER, V6, P13956, DOI 10.1021/am503332z; Lin JS, 2015, BBA-GEN SUBJECTS, V1850, P419, DOI 10.1016/j.bbagen.2014.11.016; Liu ZH, 2010, BIOMATERIALS, V31, P3364, DOI 10.1016/j.biomaterials.2010.01.021; Mandal D, 2003, J BIOL CHEM, V278, P52551, DOI 10.1074/jbc.M306914200; Mukthavaram R, 2014, J CONTROL RELEASE, V183, P146, DOI 10.1016/j.jconrel.2014.03.038; Murad KT, 1999, BLOOD, V93, P2121, DOI 10.1182/blood.V93.6.2121.406a30_2121_2127; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; MUZYKANTOV V R, 1985, Journal of Applied Biochemistry, V7, P223; Muzykantov VR, 2010, EXPERT OPIN DRUG DEL, V7, P403, DOI 10.1517/17425241003610633; MUZYKANTOV VR, 1987, AM J PATHOL, V128, P276; MUZYKANTOV VR, 1992, BIOCHIM BIOPHYS ACTA, V1107, P119, DOI 10.1016/0005-2736(92)90336-K; Muzykantov VR, 1996, BIOTECHNOL APPL BIOC, V24, P41; MUZYKANTOV VR, 1993, J IMMUNOL METHODS, V158, P183, DOI 10.1016/0022-1759(93)90212-P; MUZYKANTOV VR, 1991, BIOCHEM J, V273, P393, DOI 10.1042/bj2730393; Muzykantov VR, 1996, ANAL BIOCHEM, V241, P109, DOI 10.1006/abio.1996.0384; MUZYKANTOV VR, 1993, FEBS LETT, V318, P108, DOI 10.1016/0014-5793(93)80002-C; MUZYKANTOV VR, 1992, INT J ARTIF ORGANS, V15, P622, DOI 10.1177/039139889201501010; MUZYKANTOV VR, 1991, FEBS LETT, V280, P112, DOI 10.1016/0014-5793(91)80216-P; Nagababu E, 2013, FREE RADICAL RES, V47, P164, DOI 10.3109/10715762.2012.756138; Nagababu E, 2008, FREE RADICAL RES, V42, P824, DOI 10.1080/10715760802459879; Nagababu E, 2010, LIFE SCI, V86, P133, DOI 10.1016/j.lfs.2009.11.015; Perry JL, 2012, NANO LETT, V12, P5304, DOI 10.1021/nl302638g; Rossi Luiga, 2005, Expert Opin Drug Deliv, V2, P311, DOI 10.1517/17425247.2.2.311; SALLAM AM, 1984, BIORHEOLOGY, V21, P783; Scott MD, 1997, P NATL ACAD SCI USA, V94, P7566, DOI 10.1073/pnas.94.14.7566; Serafini S, 2004, TRANSFUS MED HEMOTH, V31, P92, DOI 10.1159/000078042; Villa CH, 2015, THER DELIV, V6, P795, DOI [10.4155/TDE.15.34, 10.4155/tde.15.34]; WAGNER GM, 1987, BLOOD, V69, P1777; WAUGH RE, 1992, BLOOD, V79, P1351; Yen JH, 2014, J ARTIF ORGANS, V17, P178, DOI 10.1007/s10047-014-0755-3; Zaitsev S, 2006, BLOOD, V108, P1895, DOI 10.1182/blood-2005-11-012336; Zaitsev S, 2012, BLOOD, V119, P4779, DOI 10.1182/blood-2011-12-398149; Zaitsev S, 2010, BLOOD, V115, P5241, DOI 10.1182/blood-2010-01-261610; Zaitzev S, 2010, J PHARMACOL EXP THER, V332, P1022, DOI 10.1124/jpet.109.159194; Zhao YN, 2011, ACS NANO, V5, P1366, DOI 10.1021/nn103077k	61	82	83	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2016	11	3							e0152074	10.1371/journal.pone.0152074	http://dx.doi.org/10.1371/journal.pone.0152074			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3OX	27003833	Green Published, Green Submitted, gold			2023-01-03	WOS:000372697400073
J	Sandberg, JC; Bjorck, IME; Nilsson, AC				Sandberg, Jonna C.; Bjorck, Inger M. E.; Nilsson, Anne C.			Rye-Based Evening Meals Favorably Affected Glucose Regulation and Appetite Variables at the Following Breakfast; A Randomized Controlled Study in Healthy Subjects	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; CHAIN FATTY-ACIDS; SUBSEQUENT STANDARDIZED BREAKFAST; FOOD-INTAKE; ENERGY-INTAKE; INSULIN SENSITIVITY; DIABETES-MELLITUS; INCREASES SATIETY; RESISTANT STARCH; DIETARY FIBER	Background Whole grain has shown potential to prevent obesity, cardiovascular disease and type 2 diabetes. Possible mechanism could be related to colonic fermentation of specific indigestible carbohydrates, i.e. dietary fiber (DF). The aim of this study was to investigate effects on cardiometabolic risk factors and appetite regulation the next day when ingesting rye kernel bread rich in DF as an evening meal. Method Whole grain rye kernel test bread (RKB) or a white wheat flour based bread (reference product, WWB) was provided as late evening meals to healthy young adults in a randomized cross-over design. The test products RKB and WWB were provided in two priming settings: as a single evening meal or as three consecutive evening meals prior to the experimental days. Test variables were measured in the morning, 10.5-13.5 hours after ingestion of RKB or WWB. The postprandial phase was analyzed for measures of glucose metabolism, inflammatory markers, appetite regulating hormones and short chain fatty acids (SCFA) in blood, hydrogen excretion in breath and subjective appetite ratings. Results With the exception of serum CRP, no significant differences in test variables were observed depending on length of priming (P>0.05). The RKB evening meal increased plasma concentrations of PYY (0-120 min, P<0.001), GLP-1 (0-90 min, P<0.05) and fasting SCFA (acetate and butyrate, P<0.05, propionate, P = 0.05), compared to WWB. Moreover, RKB decreased blood glucose (0-120 min, P = 0.001), serum insulin response (0-120 min, P<0.05) and fasting FFA concentrations (P<0.05). Additionally, RKB improved subjective appetite ratings during the whole experimental period (P<0.05), and increased breath hydrogen excretion (P<0.001), indicating increased colonic fermentation activity. Conclusion The results indicate that RKB evening meal has an anti-diabetic potential and that the increased release of satiety hormones and improvements of appetite sensation could be beneficial in preventing obesity. These effects could possibly be mediated through colonic fermentation.	[Sandberg, Jonna C.; Bjorck, Inger M. E.; Nilsson, Anne C.] Lund Univ, Food Hlth Sci Ctr, SE-22100 Lund, Sweden	Lund University	Sandberg, JC (corresponding author), Lund Univ, Food Hlth Sci Ctr, SE-22100 Lund, Sweden.	jonna.sandberg@food-health-science.lu.se		Nilsson, Anne/0000-0002-9780-7876	Antidiabetic Food Centre, a VINNOVA VINN Excellence Center at Lund University [2013/46]	Antidiabetic Food Centre, a VINNOVA VINN Excellence Center at Lund University	This study was supported by the Antidiabetic Food Centre, a VINNOVA VINN Excellence Center at Lund University (grant number 2013/46). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akerberg AKE, 1998, J NUTR, V128, P651; Andersson AAM, 2014, J CEREAL SCI, V59, P294, DOI 10.1016/j.jcs.2014.01.003; ASP NG, 1983, J AGR FOOD CHEM, V31, P476, DOI 10.1021/jf00117a003; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Belfort R, 2005, DIABETES, V54, P1640, DOI 10.2337/diabetes.54.6.1640; BJORCK IME, 1992, J SCI FOOD AGR, V58, P541, DOI 10.1002/jsfa.2740580414; Brighenti F., 1998, FUNCTIONAL PROPERTIE, P150; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cani PD, 2009, AM J CLIN NUTR, V90, P1236, DOI 10.3945/ajcn.2009.28095; de Munter JSL, 2007, PLOS MED, V4, P1385, DOI 10.1371/journal.pmed.0040261; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; Frolich W, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.18503; Fssrch K, 2015, DIABETES; Guo Y, 2006, OBESITY, V14, P1562, DOI 10.1038/oby.2006.180; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; Gutzwiller JP, 1999, GUT, V44, P81, DOI 10.1136/gut.44.1.81; Hansen HB, 2004, J AGR FOOD CHEM, V52, P2282, DOI 10.1021/jf0307191; Ibrugger S, 2014, APPETITE, V80, P248, DOI 10.1016/j.appet.2014.05.026; Isaksson H., 2008, FOOD NUTR RES, V52; Isaksson H, 2012, PHYSIOL BEHAV, V105, P877, DOI 10.1016/j.physbeh.2011.10.023; Isaksson H, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-31; Isaksson H, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-39; Johansson EV, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-46; Kaji L, 2014, DIGESTION, V89, P31, DOI 10.1159/000356211; Karaki SI, 2008, J MOL HISTOL, V39, P135, DOI 10.1007/s10735-007-9145-y; le Roux CW, 2006, ENDOCRINOLOGY, V147, P3, DOI 10.1210/en.2005-0972; Lee YS, 2014, METABOLISM, V63, P9, DOI 10.1016/j.metabol.2013.09.010; Li QC, 2010, REGUL PEPTIDES, V159, P72, DOI 10.1016/j.regpep.2009.11.003; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Muscelli E, 2008, DIABETES, V57, P1340, DOI 10.2337/db07-1315; Nielsen TS, 2014, BRIT J NUTR, V112, P1837, DOI 10.1017/S000711451400302X; Nilsson A, 2006, EUR J CLIN NUTR, V60, P1092, DOI 10.1038/sj.ejcn.1602423; Nilsson AC, 2015, BR J NUTR, P1; Nilsson AC, 2008, J NUTR, V138, P732, DOI 10.1093/jn/138.4.732; Nilsson AC, 2008, AM J CLIN NUTR, V87, P645, DOI 10.1093/ajcn/87.3.645; Nilsson AC, 2010, J NUTR, V140, P1932, DOI 10.3945/jn.110.123604; Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162; Priebe MG, 2010, AM J CLIN NUTR, V91, P90, DOI 10.3945/ajcn.2009.28521; Rosen LAH, 2011, J AGR FOOD CHEM, V59, P12149, DOI 10.1021/jf2019837; Rosen LAH, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-42; Rosen LA, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-7; Tarini J, 2010, APPL PHYSIOL NUTR ME, V35, P9, DOI 10.1139/H09-119; Tasyurek HM, 2014, DIABETES-METAB RES, V30, P354, DOI 10.1002/dmrr.2501; Tazoe H, 2009, BIOMED RES-TOKYO, V30, P149, DOI 10.2220/biomedres.30.149; Tolhurst G, 2012, DIABETES, V61, P364, DOI 10.2337/db11-1019; Tsuchiya T, 2010, CLIN ENDOCRINOL, V73, P484, DOI 10.1111/j.1365-2265.2010.03835.x; Verdich C, 2001, J CLIN ENDOCR METAB, V86, P4382, DOI 10.1210/jc.86.9.4382; Williams PG, 2008, NUTR REV, V66, P171, DOI 10.1111/j.1753-4887.2008.00022.x; WOLEVER TMS, 1991, AM J CLIN NUTR, V53, P681, DOI 10.1093/ajcn/53.3.681; WOLEVER TMS, 1989, AM J GASTROENTEROL, V84, P1027; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; World Health Organization, 2015, GLOB STAT REP NONC D; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Ye EQ, 2012, J NUTR, V142, P1304, DOI 10.3945/jn.111.155325; Zander M, 2002, LANCET, V359, P824, DOI 10.1016/S0140-6736(02)07952-7	56	36	36	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2016	11	3							e0151985	10.1371/journal.pone.0151985	http://dx.doi.org/10.1371/journal.pone.0151985			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1ZE	26990559	Green Published, Green Submitted, gold			2023-01-03	WOS:000372582800127
J	Yang, SS; Deng, HC; Zhang, QZ; Xie, J; Zeng, H; Jin, XL; Ling, ZX; Shan, QY; Liu, MM; Ma, YF; Tang, J; Wei, QP				Yang, Shasha; Deng, Huacong; Zhang, Qunzhou; Xie, Jing; Zeng, Hui; Jin, Xiaolong; Ling, Zixi; Shan, Qiaoyun; Liu, Momo; Ma, Yuefei; Tang, Juan; Wei, Qianping			Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling	PLOS ONE			English	Article							BINDING PROTEIN 10; CELL PROLIFERATION; APOPTOSIS; MICE; DISRUPTION; ADAPTER; CANCER; INJURY; LIPIDS; GAMMA	Growth factor receptor-bound protein 10 (Grb10) is an adaptor protein that can negatively regulate the insulin-like growth factor 1 receptor (IGF-1R). The IGF1-1R pathway is critical for cell growth and apoptosis and has been implicated in kidney diseases; however, it is still unknown whether Grb10 expression is up-regulated and plays a role in diabetic nephropathy. Catalpol, a major active ingredient of a traditional Chinese medicine, Rehmannia, has been reported to possess anti-inflammatory and anti-aging activities and then used to treat diabetes. Herein, we aimed to assess the therapeutic effect of catalpol on a mouse model diabetic nephropathy and the potential role of Grb10 in the pathogenesis of this diabetes-associated complication. Our results showed that catalpol treatment improved diabetes-associated impaired renal functions and ameliorated pathological changes in kidneys of diabetic mice. We also found that Grb10 expression was significantly elevated in kidneys of diabetic mice as compared with that in non-diabetic mice, while treatment with catalpol significantly abrogated the elevated Grb10 expression in diabetic kidneys. On the contrary, IGF-1 mRNA levels and IGF-1R phosphorylation were significantly higher in kidneys of catalpol-treated diabetic mice than those in non-treated diabetic mice. Our results suggest that elevated Grb10 expression may play an important role in the pathogenesis of diabetic nephropathy through suppressing IGF-1/IGF-1R signaling pathway, which might be a potential molecular target of catalpol for the treatment of this diabetic complication.	[Yang, Shasha; Xie, Jing; Zeng, Hui; Jin, Xiaolong; Ling, Zixi; Shan, Qiaoyun; Liu, Momo; Ma, Yuefei; Tang, Juan; Wei, Qianping] Chongqing Med Univ, Affiliated Hosp 1, Dept Geriatr, Chongqing, Peoples R China; [Deng, Huacong] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing, Peoples R China; [Zhang, Qunzhou] Univ Penn, Sch Dent Med, Dept Oral Surg & Pharmacol, Philadelphia, PA 19104 USA	Chongqing Medical University; Chongqing Medical University; University of Pennsylvania	Wei, QP (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Geriatr, Chongqing, Peoples R China.	wqp68894940@163.com			National Key Clinical Specialties Construction Program of China [[2013]544]; Chongqing Postgraduate Research Innovation Project [CYS14120]	National Key Clinical Specialties Construction Program of China; Chongqing Postgraduate Research Innovation Project	This work was supported by National Key Clinical Specialties Construction Program of China (No. [2013]544), The Chongqing Postgraduate Research Innovation Project (CYS14120). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Uzri A, 2013, PEDIATR NEPHROL, V28, P2323, DOI 10.1007/s00467-013-2570-0; Alarcon-Aguilar FJ, 2000, J ETHNOPHARMACOL, V72, P21, DOI 10.1016/S0378-8741(00)00202-6; [Anonymous], 2012, SYST URD USRDS 2012; Bi J, 2013, TOXICOL IN VITRO, V27, P543, DOI 10.1016/j.tiv.2012.09.023; Chen CJ, 2013, J RADIAT RES, V54, P76, DOI 10.1093/jrr/rrs080; Chen WN, 2013, BRIT J PHARMACOL, V169, P1140, DOI 10.1111/bph.12200; Deng YP, 2003, J BIOL CHEM, V278, P39311, DOI 10.1074/jbc.M304599200; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Dong Z, 2013, PHYTOMEDICINE, V20, P1023, DOI 10.1016/j.phymed.2013.04.007; Dufresne AM, 2005, ENDOCRINOLOGY, V146, P4399, DOI 10.1210/en.2005-0150; Faraj M, 2004, BIOCHEM CELL BIOL, V82, P170, DOI 10.1139/o03-078; Fu K, 2014, INT IMMUNOPHARMACOL, V23, P400, DOI 10.1016/j.intimp.2014.07.011; Gao N, 2014, INT J MOL SCI, V15, P19394, DOI 10.3390/ijms151119394; Giovannone B, 2003, J BIOL CHEM, V278, P31564, DOI 10.1074/jbc.M211572200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Holt LJ, 2012, FASEB J, V26, P3658, DOI 10.1096/fj.11-199349; Hu ZQ, 2010, MOL BIOL REP, V37, P3547, DOI 10.1007/s11033-010-0002-9; Ising C, 2015, EMBO MOL MED, V7, P275, DOI 10.15252/emmm.201404916; Kang BPS, 2003, AM J PHYSIOL-RENAL, V284, pF455, DOI 10.1152/ajprenal.00137.2002; Lawal AO, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0040-y; Lawrence JM, 2004, ATHEROSCLEROSIS, V174, P141, DOI 10.1016/j.atherosclerosis.2004.01.016; Lee MJ, 2010, J ETHNOPHARMACOL, V132, P497, DOI 10.1016/j.jep.2010.07.057; Li L, 2013, CLIN EXP PHARMACOL P, V40, P841, DOI 10.1111/1440-1681.12160; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Ma L, 2013, J NEUROENDOCRINOL, V25, P626, DOI 10.1111/jne.12040; Mokbel N, 2014, J CELL PHYSIOL, V229, P1753, DOI 10.1002/jcp.24628; Mroue R, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005235; O-Sullivan I, 2008, CANCER RES, V68, P2463, DOI 10.1158/0008-5472.CAN-07-5685; Prokopenko I, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004235; Smith FM, 2007, MOL CELL BIOL, V27, P5871, DOI 10.1128/MCB.02087-06; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Varga ZV, 2015, BBA-MOL BASIS DIS, V1852, P232, DOI 10.1016/j.bbadis.2014.06.030; White KE, 2000, J AM SOC NEPHROL, V11, P1667, DOI 10.1681/ASN.V1191667; Xie JL, 2014, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2014-91; Yang S, 2005, AM J PHYSIOL-RENAL, V289, pF1144, DOI 10.1152/ajprenal.00094.2005; Yin DK, 2014, J ETHNOPHARMACOL, V151, P667, DOI 10.1016/j.jep.2013.11.025; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang JJ, 2012, DIABETES, V61, P3189, DOI 10.2337/db12-0249; Zhou HC, 2014, CHINESE MED J-PEKING, V127, P916, DOI 10.3760/cma.j.issn.0366-6999.20132137; Zhu JL, 2015, INT J CLIN EXP MED, V8, P2038	40	11	14	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151857	10.1371/journal.pone.0151857	http://dx.doi.org/10.1371/journal.pone.0151857			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1YG	26986757	Green Published, Green Submitted, gold			2023-01-03	WOS:000372580300141
J	DiNofia, AM; Salazar, E; Seif, AE; Li, YM; Huang, YSV; Bagatell, R; Fisher, BT; Aplenc, R				DiNofia, Amanda M.; Salazar, Elizabeth; Seif, Alix E.; Li, Yimei; Huang, Yuan-Shung Vera; Bagatell, Rochelle; Fisher, Brian T.; Aplenc, Richard			Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States	PLOS ONE			English	Article							PROTEASOME INHIBITOR BORTEZOMIB; ACUTE LYMPHOBLASTIC-LEUKEMIA; ANTIBODY-MEDIATED REJECTION; ONCOLOGY GROUP; PEDIATRIC-PATIENTS; PHASE-I; THERAPEUTIC ADVANCES; CHILDHOOD LEUKEMIA; SOLID TUMORS; TRANSPLANT	This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.	[DiNofia, Amanda M.; Salazar, Elizabeth; Seif, Alix E.; Li, Yimei; Bagatell, Rochelle; Aplenc, Richard] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Seif, Alix E.; Bagatell, Rochelle; Fisher, Brian T.; Aplenc, Richard] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Li, Yimei; Fisher, Brian T.; Aplenc, Richard] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Huang, Yuan-Shung Vera; Fisher, Brian T.; Aplenc, Richard] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA; [Fisher, Brian T.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	DiNofia, AM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.	dinofiaa@email.chop.edu	; Seif, Alix/B-9918-2013	Fisher, Brian/0000-0002-8224-4281; Seif, Alix/0000-0002-1799-2582	National Cancer Institute [R01CA165277, 5T32CA009679-24]; National Institute of Child Health and Human Development [5T32HD064567-05]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD064567] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009679, P30CA016520, R01CA165277] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	RA's work on this project was supported by the National Cancer Institute grant: R01CA165277 (http://www.cancer.gov). AD's work on this project was supported by the National Institute of Child Health and Human Development grant: 5T32HD064567-05 (https://www.nichd.nih.gov) and the National Cancer Institute grant: 5T32CA009679-24 (http://www.cancer.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blaney SM, 2004, J CLIN ONCOL, V22, P4804, DOI 10.1200/JCO.2004.12.185; Claes DJ, 2014, PEDIATR TRANSPLANT, V18, pE100, DOI 10.1111/petr.12256; Garg PP, 2000, J AM SOC NEPHROL, V11, P958, DOI 10.1681/ASN.V115958; Horton TM, 2007, CLIN CANCER RES, V13, P1516, DOI 10.1158/1078-0432.CCR-06-2173; Horton TM, 2015, BRIT J HAEMATOL, V170, P118, DOI 10.1111/bjh.13388; Horton TM, 2014, PEDIATR BLOOD CANCER, V61, P1754, DOI 10.1002/pbc.25117; Kavcic M, 2013, J PEDIATR-US, V162, P1252, DOI 10.1016/j.jpeds.2012.11.038; Khandelwal P, 2014, BIOL BLOOD MARROW TR, V20, pS174, DOI 10.1016/j.bbmt.2014.06.032; May LJ, 2014, PEDIATR TRANSPLANT, V18, pE280, DOI 10.1111/petr.12347; Mehta B, 2014, PEDIATR BLOOD CANCER, V61, P2324, DOI 10.1002/pbc.25172; Messinger Y, 2010, PEDIATR BLOOD CANCER, V55, P254, DOI 10.1002/pbc.22456; Messinger YH, 2012, BLOOD, V120, P285, DOI 10.1182/blood-2012-04-418640; Morrow WR, 2012, TRANSPLANTATION, V93, P319, DOI 10.1097/TP.0b013e31823f7eea; Muscal JA, 2013, PEDIATR BLOOD CANCER, V60, P390, DOI 10.1002/pbc.24271; Richardson PG, 2004, ANN MED, V36, P304, DOI 10.1080/07853890410030877; United Stated Census Bureau, 2015, STAT COUNT QUICK FAC; van Balen T, 2014, EUR J HAEMATOL, V92, P80, DOI 10.1111/ejh.12206; Zinn MD, 2014, PEDIATR TRANSPLANT, V18, P469, DOI 10.1111/petr.12300	18	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151362	10.1371/journal.pone.0151362	http://dx.doi.org/10.1371/journal.pone.0151362			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26978062	Green Published, gold, Green Submitted			2023-01-03	WOS:000372572800067
J	Guilcher, SJT; Bronskill, SE; Guan, J; Wodchis, WP				Guilcher, Sara J. T.; Bronskill, Susan E.; Guan, Jun; Wodchis, Walter P.			Who Are the High-Cost Users? A Method for Person-Centred Attribution of Health Care Spending	PLOS ONE			English	Article							EXPENDITURES	Objective To develop person-centered episodes of care (PCE) for community-dwelling individuals in the top fifth percentile of Ontario health care expenditures in order to: (1) describe the main clinical groupings for spending; and (2) identify patterns of spending by health sector (e.g. acute care, home care, physician billings) within and across PCE. Data sources Data were drawn from population-based administrative databases for all publicly funded health care in Ontario, Canada in 2010/11. Study design This study is a retrospective cohort study. Data collection/extraction methods A total of 587,982 community-dwelling individuals were identified among those accounting for the top 5% of provincial health care expenditures between April 1, 2010 and March 31, 2011. PCE were defined as starting with an acute care admission and persisting through subsequent care settings and providers until individuals were without health system contact for 30 days. PCE were classified according to the clinical grouping for the initial admission. PCE and non-PCE costs were calculated and compared to provide a comprehensive measurement of total health system costs for the year. Principal findings Among this community cohort, 697,059 PCE accounted for nearly 70% ($11,815.3 million (CAD)) of total annual publicly-funded expenditures on high-cost community-dwelling individuals. The most common clinical groupings to start a PCE were Acute Planned Surgical (35.2%), Acute Unplanned Medical (21.0%) and Post-Admission Events (10.8%). Median PCE costs ranged from $3,865 (IQR = $1,712-$10,919) for Acute Planned Surgical to $20,687 ($12,207-$39,579) for Post-Admission Events. Inpatient acute ($8,194.5 million) and inpatient rehabilitation ($434.6 million) health sectors accounted for the largest proportions of allocated PCE spending over the year. Conclusions Our study provides a novel methodological approach to categorize high-cost health system users into meaningful person-centered episodes. This approach helps to explain how costs are attributable within individuals across sectors and has applications in episode-based payment formulas and quality monitoring.	[Guilcher, Sara J. T.] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Guilcher, Sara J. T.; Bronskill, Susan E.; Wodchis, Walter P.] Hlth Syst Performance Res Network, Toronto, ON, Canada; [Guilcher, Sara J. T.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City Hlth, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Guilcher, Sara J. T.; Bronskill, Susan E.; Guan, Jun; Wodchis, Walter P.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Bronskill, Susan E.; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Wodchis, Walter P.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	Guilcher, SJT (corresponding author), Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.; Guilcher, SJT (corresponding author), Hlth Syst Performance Res Network, Toronto, ON, Canada.; Guilcher, SJT (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City Hlth, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Guilcher, SJT (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.	sara.guilcher@utoronto.ca		wodchis, walter/0000-0003-2494-7031; Guilcher, Sara/0000-0002-9552-9139	Health System Performance Research Network (HSPRN) at the University of Toronto; Canadian Institutes for Health Research Strategic Training Initiative in Health Research [ACHIEVE] at the Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, Ontario; Canadian Institutes of Health Research (CIHR); health research grant (Public reporting on seniors' health and service expansion impact) [04601AC]; Institute for Clinical Evaluative Sciences (ICES); HSPRN - Ontario Ministry of Health and Long-Term Care (MOHLTC) [06034]	Health System Performance Research Network (HSPRN) at the University of Toronto; Canadian Institutes for Health Research Strategic Training Initiative in Health Research [ACHIEVE] at the Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, Ontario; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); health research grant (Public reporting on seniors' health and service expansion impact); Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); HSPRN - Ontario Ministry of Health and Long-Term Care (MOHLTC)	During the time of this work, SJTG was supported by the Health System Performance Research Network (HSPRN) at the University of Toronto and the Canadian Institutes for Health Research Strategic Training Initiative in Health Research [ACHIEVE] at the Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, Ontario. SEB was supported by a New Investigator Award in the Area of Aging from the Canadian Institutes of Health Research (CIHR). This study was supported by a health research grant (Public reporting on seniors' health and service expansion impact-#04601AC), the Institute for Clinical Evaluative Sciences (ICES) and HSPRN (#06034), which are funded by the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the MOHLTC is intended or should be inferred.	[Anonymous], 1997, JOHNS HOPKINS U ACG; Austin PC, 2011, MED CARE, V49, P932, DOI 10.1097/MLR.0b013e318215d5e2; BERK ML, 1992, HEALTH AFFAIR, V11, P145, DOI 10.1377/hlthaff.11.4.145; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Billings J, 2006, CASE FINDING ALGORIT; Bodenheimer T, 2005, ANN INTERN MED, V143, P26, DOI 10.7326/0003-4819-143-1-200507050-00007; Bodenheimer T, 2009, NEW ENGL J MED, V361, P1521, DOI 10.1056/NEJMp0907185; Calver J, 2006, MED J AUSTRALIA, V184, P393, DOI 10.5694/j.1326-5377.2006.tb00289.x; Canadian Institute for Health Information, 2013, CAN HOSP REP PROJ TE; Chisholm D, 2010, IMPROVING HLTH SYSTE, P10; Conway P, 2011, HEALTH SERV RES, V46, P479, DOI 10.1111/j.1475-6773.2010.01212.x; Deber R, APSA 2009 TOR M; Fitzpatrick T, 2015, AM J PREV MED, V49, P161, DOI 10.1016/j.amepre.2015.02.018; Gelenberg Alan J, 2010, J Clin Psychiatry, V71, pe06, DOI 10.4088/JCP.8001tx17c; Glazier R, 2012, COMPARISON PRIMARY C; Glazier Richard H, 2009, CMAJ, V180, pE72, DOI 10.1503/cmaj.081316; Jaakkimainen L., 2006, PRIMARY CARE ONTARIO; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Juurlink D, 2006, CANADIAN I HLTH INFO; Kralij B, 2008, MEASURING RURALITY R; Lemstra M, 2009, CAN J PUBLIC HEALTH, V100, P180, DOI 10.1007/BF03405536; Lynn J, 2007, MILBANK Q, V85, P185, DOI 10.1111/j.1468-0009.2007.00483.x; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Radcliff Tiffany A, 2005, Hosp Top, V83, P17, DOI 10.3200/HTPS.83.3.17-24; Reid Robert, 2003, J Health Serv Res Policy, V8, P215, DOI 10.1258/135581903322403281; Reschovsky JD, 2011, HEALTH SERV RES, V46, P997, DOI 10.1111/j.1475-6773.2011.01242.x; Roos Noralou, 2003, J Health Serv Res Policy, V8, P5; ROOS NP, 1989, MILBANK Q, V67, P347, DOI 10.2307/3350220; Stanton M.W., 2005, RES ACTION; Statistics Canada, POP YEAR PROV TERR 2; Stinchcombe A, 2014, Chronic Dis Inj Can, V34, P171; Thorpe KE, 2010, HEALTH AFFAIR, V29, P718, DOI 10.1377/hlthaff.2009.0474; Vaillancourt Samuel, 2014, Healthc Pap, V14, P37; Wodchis WP, 2016, CAN MED ASSOC J, V188, P182, DOI 10.1503/cmaj.150064; Wodchis WP, 2012, CONCENTRATION HLTH C; Wodchis WP, 2013, GUIDELINES PERSON LE; Zuvekas SH, 2007, HEALTH AFFAIR, V26, P249, DOI 10.1377/hlthaff.26.1.249	38	29	29	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0149179	10.1371/journal.pone.0149179	http://dx.doi.org/10.1371/journal.pone.0149179			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DG0EB	26937955	Green Submitted, Green Published, gold			2023-01-03	WOS:000371735200016
J	Ding, GL; Chen, JL; Chopp, M; Li, L; Yan, T; Li, QJ; Cui, CC; Davarani, SPN; Jiang, Q				Ding, Guangliang; Chen, Jieli; Chopp, Michael; Li, Lian; Yan, Tao; Li, Qingjiang; Cui, Chengcheng; Davarani, Siamak P. N.; Jiang, Quan			Cell Treatment for Stroke in Type Two Diabetic Rats Improves Vascular Permeability Measured by MRI	PLOS ONE			English	Article							MARROW STROMAL CELLS; CONTRAST-ENHANCED MRI; ANGIOGENESIS; INJURY; MODEL; TRANSPLANTATION; STREPTOZOTOCIN; PATHOGENESIS; MELLITUS; DAMAGE	Treatment of stroke with bone marrow stromal cells (BMSC) significantly enhances brain remodeling and improves neurological function in non-diabetic stroke rats. Diabetes is a major risk factor for stroke and induces neurovascular changes which may impact stroke therapy. Thus, it is necessary to test our hypothesis that the treatment of stroke with BMSC has therapeutic efficacy in the most common form of diabetes, type 2 diabetes mellitus (T2DM). T2DM was induced in adult male Wistar rats by administration of a high fat diet in combination with a single intraperitoneal injection (35mg/kg) of streptozotocin. These rats were then subjected to 2h of middle cerebral artery occlusion (MCAo). T2DM rats received BMSC (5x10(6), n = 8) or an equal volume of phosphate-buffered saline (PBS) (n = 8) via tail-vein injection at 3 days after MCAo. MRI was performed one day and then weekly for 5 weeks post MCAo for all rats. Compared with vehicle treated control T2DM rats, BMSC treatment of stroke in T2DM rats significantly (p<0.05) decreased blood-brain barrier disruption starting at 1 week post stroke measured using contrast enhanced T-1-weighted imaging with gadopentetate, and reduced cerebral hemorrhagic spots starting at 3 weeks post stroke measured using susceptibility weighted imaging, although BMSC treatment did not reduce the ischemic lesion volumes as demarcated by T-2 maps. These MRI measurements were consistent with histological data. Thus, BMSC treatment of stroke in T2DM rats initiated at 3 days after stroke significantly reduced ischemic vascular damage, although BMSC treatment did not change infarction volume in T2DM rats, measured by MRI.	[Ding, Guangliang; Chen, Jieli; Chopp, Michael; Li, Lian; Yan, Tao; Li, Qingjiang; Cui, Chengcheng; Davarani, Siamak P. N.; Jiang, Quan] Henry Ford Hosp, Dept Neurol, 2799 West Grand Blvd, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA; [Yan, Tao] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China	Henry Ford Health System; Henry Ford Hospital; Oakland University; Tianjin Medical University	Jiang, Q (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 West Grand Blvd, Detroit, MI 48202 USA.	qjiang1@hfhs.org	Nejad-Davarani, Siamak/AAH-8399-2021; Yan, Tao/B-2930-2012	Yan, Tao/0000-0003-3138-4468; Ding, Guangliang/0000-0003-1286-5901; Nejad-Davarani, Siamak/0000-0002-2415-6689; Li, Lian/0000-0003-0097-1184	NIH [RO1 NS083078, NS064134, AG037506, R41 S080329]; American Heart Association (AHA) [14GRNT20460026]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R41NS080329, R01NS083078, R01NS064134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG037506] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association (AHA)(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was financially supported by NIH RO1 NS083078 (JC), NS064134 (QJ), AG037506 (MC), R41 S080329 (JC), and American Heart Association (AHA) 14GRNT20460026 (JC). The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.	Aryal MP, 2014, NMR BIOMED, V27, P1230, DOI 10.1002/nbm.3178; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cameron N, 2003, DIABETES RES CLIN PR, V61, pS35, DOI 10.1016/S0168-8227(03)00123-2; Chen JL, 2011, STROKE, V42, P3551, DOI 10.1161/STROKEAHA.111.627174; Chen JL, 2011, STROKE, V42, P445, DOI 10.1161/STROKEAHA.110.596486; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Ding G, 2014, NEUROSCIENCE, V271, P1, DOI 10.1016/j.neuroscience.2014.04.025; Ding GL, 2008, STROKE, V39, P1563, DOI 10.1161/STROKEAHA.107.502146; Ding GL, 2017, J CEREBR BLOOD F MET, V37, P241, DOI 10.1177/0271678X15622464; Ding GL, 2015, STROKE, V46, P507, DOI 10.1161/STROKEAHA.114.007538; Ergul A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-33; Ergul A, 2009, VASC PHARMACOL, V51, P44, DOI 10.1016/j.vph.2009.02.004; Ewing JR, 2013, NMR BIOMED, V26, P1028, DOI 10.1002/nbm.2996; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Idris I, 2006, INT J CLIN PRACT, V60, P48, DOI 10.1111/j.1368-5031.2006.00682.x; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liberman G, T1 MAPPING USING VAR; Martini SR, 2007, J CEREBR BLOOD F MET, V27, P435, DOI 10.1038/sj.jcbfm.9600355; Piotrowski P, 2003, FOLIA NEUROPATHOL, V41, P167; Reed MJ, 2000, METABOLISM, V49, P1390, DOI 10.1053/meta.2000.17721; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Skovso S, 2014, J DIABETES INVEST, V5, P349, DOI 10.1111/jdi.12235; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wei N, 2013, CNS NEUROSCI THER, V19, P753, DOI 10.1111/cns.12123; Yan T, 2015, STROKE, V46, P2599, DOI 10.1161/STROKEAHA.115.009870; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yu DY, 2001, CLIN EXP OPHTHALMOL, V29, P164; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054	31	10	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149147	10.1371/journal.pone.0149147	http://dx.doi.org/10.1371/journal.pone.0149147			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26900843	Green Published, Green Submitted, gold			2023-01-03	WOS:000371276100042
J	Lapointe-Shaw, L; Tran, KL; Coyte, PC; Hancock-Howard, RL; Powis, J; Poutanen, SM; Hota, S				Lapointe-Shaw, Lauren; Tran, Kim L.; Coyte, Peter C.; Hancock-Howard, Rebecca L.; Powis, Jeff; Poutanen, Susan M.; Hota, Susy			Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection	PLOS ONE			English	Article							FECAL MICROBIOTA TRANSPLANTATION; ORAL VANCOMYCIN; 1ST RECURRENCE; DISEASE; FIDAXOMICIN; THERAPY; EPIDEMIOLOGY; COLONOSCOPY; METRONIDAZOLE; DIARRHEA	Objective To assess the cost-effectiveness of six treatment strategies for patients diagnosed with recurrent Clostridium difficile infection (CDI) in Canada: 1. oral metronidazole; 2. oral vancomycin; 3. oral fidaxomicin; 4. fecal transplantation by enema; 5. fecal transplantation by nasogastric tube; and 6. fecal transplantation by colonoscopy. Perspective Public insurer for all hospital and physician services. Setting Ontario, Canada. Methods A decision analytic model was used to model costs and lifetime health effects of each strategy for a typical patient experiencing up to three recurrences, over 18 weeks. Recurrence data and utilities were obtained from published sources. Cost data was obtained from published sources and hospitals in Toronto, Canada. The willingness-to-pay threshold was $50,000/QALY gained. Results Fecal transplantation by colonoscopy dominated all other strategies in the base case, as it was less costly and more effective than all alternatives. After accounting for uncertainty in all model parameters, there was an 87% probability that fecal transplantation by colonoscopy was the most beneficial strategy. If colonoscopy was not available, fecal transplantation by enema was cost-effective at $1,708 per QALY gained, compared to metronidazole. In addition, fecal transplantation by enema was the preferred strategy if the probability of recurrence following this strategy was below 8.7%. If fecal transplantation by any means was unavailable, fidaxomicin was cost-effective at an additional cost of $25,968 per QALY gained, compared to metronidazole. Conclusion Fecal transplantation by colonoscopy (or enema, if colonoscopy is unavailable) is cost-effective for treating recurrent CDI in Canada. Where fecal transplantation is not available, fidaxomicin is also cost-effective.	[Lapointe-Shaw, Lauren; Powis, Jeff; Poutanen, Susan M.; Hota, Susy] Univ Toronto, Dept Med, Toronto, ON, Canada; [Lapointe-Shaw, Lauren; Tran, Kim L.; Poutanen, Susan M.; Hota, Susy] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Coyte, Peter C.; Hancock-Howard, Rebecca L.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Powis, Jeff] Toronto East Gen Hosp, Dept Med, Toronto, ON, Canada; [Poutanen, Susan M.] Mt Sinai Hosp, Dept Med & Med Microbiol, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Toronto East General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Lapointe-Shaw, L (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Lapointe-Shaw, L (corresponding author), Univ Hlth Network, Dept Med, Toronto, ON, Canada.	lauren.lapointe.shaw@mail.utoronto.ca	Hota, Susy/L-1903-2019; Poutanen, Susan M/F-9640-2012; Poutanen, Susan M./N-8066-2019; Hancock-Howard, Rebecca Laura/AIE-8302-2022; Lapointe-Shaw, Lauren/ABG-2601-2021	Poutanen, Susan M/0000-0003-4747-2550; Poutanen, Susan M./0000-0003-4747-2550; Hancock-Howard, Rebecca Laura/0000-0002-0997-988X; Lapointe-Shaw, Lauren/0000-0003-4485-6719; Powis, Jeff/0000-0003-2053-6083	University of Toronto; Cubist Pharmaceuticals	University of Toronto(University of Toronto); Cubist Pharmaceuticals	This project did not utilize any specific project-related financial support. Dr. Lauren Lapointe-Shaw is supported by the Clinician Scientist Training Program at the University of Toronto. Dr. Susy Hota has received clinic funding and advisory honoraria from Cubist Pharmaceuticals, the makers of fidaxomicin. Dr. Susan Poutanen has received advisory board and/or speaker honoraria from Optimer, Merck, Cubist, Sunovian, Hoffman-LaRoche, Paladin Labs, Pathogenica, and Accelerate Diagnostics.	Aas J, 2003, CLIN INFECT DIS, V36, P580, DOI 10.1086/367657; Ahmad A, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-133; Allen-Vercoe E, 2012, CAN J GASTROENTEROL, V26, P457, DOI 10.1155/2012/213828; [Anonymous], 2013, MONTHLY AVERAGE EXCH; BARTLETT JG, 1980, GASTROENTEROLOGY, V78, P431; Bartsch SM, 2013, CLIN INFECT DIS, V57, P555, DOI 10.1093/cid/cit346; Belmares J, 2007, J INFECTION, V55, P495, DOI 10.1016/j.jinf.2007.09.015; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Collins CE, 2014, J AM COLL SURGEONS, V218, P1141, DOI 10.1016/j.jamcollsurg.2014.01.053; Comely OA, 2012, CLIN INFECT DIS, V55, pS154, DOI 10.1093/cid/cis462; Cornely OA, 2012, LANCET INFECT DIS, V12, P281, DOI 10.1016/S1473-3099(11)70374-7; Crook DW, 2012, CLIN INFECT DIS, V55, pS93, DOI 10.1093/cid/cis499; Debast SB, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12418; Eyre DW, 2012, CLIN INFECT DIS, V55, pS77, DOI 10.1093/cid/cis356; Garborg K, 2010, SCAND J INFECT DIS, V42, P857, DOI 10.3109/00365548.2010.499541; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Government of Canada, 2013, EXPL CAR WAG REP; Gravel D, 2004, CLOSTRIDIUM DIFFICIL; Gravel D, 2009, CLIN INFECT DIS, V48, P568, DOI 10.1086/596703; Halabi WJ, 2013, J AM COLL SURGEONS, V217, P802, DOI 10.1016/j.jamcollsurg.2013.05.028; Health Canada, 2015, FEC MICR THER US TRE; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kassam Z, 2012, ARCH INTERN MED, V172, P191, DOI 10.1001/archinte.172.2.191; Kelly CR, 2012, J CLIN GASTROENTEROL, V46, P145, DOI 10.1097/MCG.0b013e318234570b; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Konijeti GG, 2014, CLIN INFECT DIS, V58, P1507, DOI 10.1093/cid/ciu128; Law Michael R, 2013, Healthc Policy, V8, P17; Lee KM, 2017, GUID EC EV HLTH TECH, V4th; Levin TR, 2006, ANN INTERN MED, V145, P880, DOI 10.7326/0003-4819-145-12-200612190-00004; Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812; Lund-Tonnesen Stein, 1998, Tidsskrift for den Norske Laegeforening, V118, P1027; Lynne V., 1999, INFECT CONT HOSP EP, V20, P43, DOI [10.1086/501553, DOI 10.1086/501553]; Macconnachie AA, 2009, QJM-INT J MED, V102, P781, DOI 10.1093/qjmed/hcp118; Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037; McFarland LV, 1999, INFECT CONT HOSP EP, V20, P43, DOI 10.1086/501553; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; MCFARLAND LV, 1995, AM J INFECT CONTROL, V23, P295, DOI 10.1016/0196-6553(95)90060-8; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; Mellow Mark H, 2011, J Okla State Med Assoc, V104, P89; Ministry of Health and Long Term Care, 2013, SCHED OF BEN; Ministry of Health and Long-term Care, EXEPTIONAL ACCES PRO; Mittmann N, 1999, PHARMACOECONOMICS, V15, P369, DOI 10.2165/00019053-199915040-00004; Mohseninejad L, 2013, EUR J HEALTH ECON, V14, P947, DOI 10.1007/s10198-012-0441-4; Naimark DMJ, 2013, MED DECIS MAKING, V33, P961, DOI 10.1177/0272989X13501558; O'Brien JA, 2007, INFECT CONT HOSP EP, V28, P1219, DOI 10.1086/522676; Patel NC, 2013, MAYO CLIN PROC, V88, P799, DOI 10.1016/j.mayocp.2013.04.022; Pepin J, 2006, CLIN INFECT DIS, V42, P758, DOI 10.1086/501126; Poutanen SM, 2004, CAN MED ASSOC J, V171, P51, DOI 10.1503/cmaj.1031189; Rassias, 1998, Crit Care, V2, P25, DOI 10.1186/cc120; Roberts M, 2012, VALUE HEALTH, V15, P804, DOI 10.1016/j.jval.2012.06.016; Rohlke F, 2010, J CLIN GASTROENTEROL, V44, P567, DOI 10.1097/MCG.0b013e3181dadb10; Sharara N, 2008, CAN J GASTROENTEROL, V22, P565, DOI 10.1155/2008/854984; Statistics Canada, 2015, CONS PRIC IND HLTH P; Statistics Canada, 2015, TABL 7A COMPL LIF TA; Stranges PM, 2013, VALUE HEALTH, V16, P297, DOI 10.1016/j.jval.2012.11.004; U.S. National Institutes of Health, 2013, OR VANC FOLL FEC TRA; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vardakas KZ, 2012, INT J ANTIMICROB AG, V40, P1, DOI 10.1016/j.ijantimicag.2012.01.004; Wagner M, 2014, CAN J INFECT DIS MED, V25, P87, DOI 10.1155/2014/793532; Walker AS, 2013, CLIN INFECT DIS, V56, P1589, DOI 10.1093/cid/cit127; Wenisch C, 1996, CLIN INFECT DIS, V22, P813, DOI 10.1093/clinids/22.5.813; Yoon SS, 2010, J CLIN GASTROENTEROL, V44, P562, DOI 10.1097/MCG.0b013e3181dac035; Zipursky JS, 2014, CAN J GASTROENTEROL, V28, P319, DOI 10.1155/2014/403828	64	41	41	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149521	10.1371/journal.pone.0149521	http://dx.doi.org/10.1371/journal.pone.0149521			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901316	Green Published, Green Submitted, gold			2023-01-03	WOS:000371276100090
J	Peternel, L; Noda, T; Petric, T; Ude, A; Morimoto, J; Babic, J				Peternel, Luka; Noda, Tomoyuki; Petric, Tadej; Ude, Ales; Morimoto, Jun; Babic, Jan			Adaptive Control of Exoskeleton Robots for Periodic Assistive Behaviours Based on EMG Feedback Minimisation	PLOS ONE			English	Article							MOVEMENT; DESIGN; TORQUE; NORMALIZATION; ADAPTATION; MODEL	In this paper we propose an exoskeleton control method for adaptive learning of assistive joint torque profiles in periodic tasks. We use human muscle activity as feedback to adapt the assistive joint torque behaviour in a way that the muscle activity is minimised. The user can then relax while the exoskeleton takes over the task execution. If the task is altered and the existing assistive behaviour becomes inadequate, the exoskeleton gradually adapts to the new task execution so that the increased muscle activity caused by the new desired task can be reduced. The advantage of the proposed method is that it does not require biomechanical or dynamical models. Our proposed learning system uses Dynamical Movement Primitives (DMPs) as a trajectory generator and parameters of DMPs are modulated using Locally Weighted Regression. Then, the learning system is combined with adaptive oscillators that determine the phase and frequency of motion according to measured Electromyography (EMG) signals. We tested the method with real robot experiments where subjects wearing an elbow exoskeleton had to move an object of an unknown mass according to a predefined reference motion. We further evaluated the proposed approach on a wholearm exoskeleton to show that it is able to adaptively derive assistive torques even for multiple-joint motion.	[Peternel, Luka; Petric, Tadej; Ude, Ales; Babic, Jan] Jozef Stefan Inst, Dept Automat Biocybernet & Robot, Ljubljana, Slovenia; [Peternel, Luka; Noda, Tomoyuki; Morimoto, Jun] ATR Computat Neurosci Labs, Dept Brain Robot Interface, Kyoto, Japan	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute	Peternel, L (corresponding author), Jozef Stefan Inst, Dept Automat Biocybernet & Robot, Ljubljana, Slovenia.; Peternel, L (corresponding author), ATR Computat Neurosci Labs, Dept Brain Robot Interface, Kyoto, Japan.	luka.peternel@ijs.si	Ude, Aleš/ABB-7839-2020; Peternel, Luka/AAX-9766-2021; Petric, Tadej/AAS-2471-2021	Ude, Aleš/0000-0003-3677-3972; Peternel, Luka/0000-0002-8696-3689; Petric, Tadej/0000-0002-3407-4206; Babic, Jan/0000-0002-1870-8264; Noda, Tomoyuki/0000-0002-1055-5080	Japanese Ministry of Education, Culture, Sports, Science and Technology SRPBS; European Commission FP-7 through the CoDyCo project [600716]; European Commission Horizon through the SPEXOR project [687662]; Japanese Ministry of Internal Affairs and Communications under contract entitled " Novel and innovative R&D making use of brain structures"; Cabinet Office Government of Japan ImPACT; New Energy andIndustrial Technology Development Organization; Slovene Human Resources Development and Scholarship Fund [146, 163]; Japanese Ministry of Internal Affairs and Communications SCOPE; Japanese Ministry of Education, Culture, Sports, Science and Technology KAKENHI [23120004]; Japan Science and Technology Agency SICP; Japan Society for the Promotion of Science and Slovenian Ministry of Education, Science and Sport: Japan-Slovenia research Cooperative Program; Japan Society for the Promotion of Science KAKENHI [24700203]	Japanese Ministry of Education, Culture, Sports, Science and Technology SRPBS; European Commission FP-7 through the CoDyCo project; European Commission Horizon through the SPEXOR project; Japanese Ministry of Internal Affairs and Communications under contract entitled " Novel and innovative R&D making use of brain structures"; Cabinet Office Government of Japan ImPACT; New Energy andIndustrial Technology Development Organization(New Energy and Industrial Technology Development Organization (NEDO)); Slovene Human Resources Development and Scholarship Fund; Japanese Ministry of Internal Affairs and Communications SCOPE; Japanese Ministry of Education, Culture, Sports, Science and Technology KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Science and Technology Agency SICP; Japan Society for the Promotion of Science and Slovenian Ministry of Education, Science and Sport: Japan-Slovenia research Cooperative Program; Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Japanese Ministry of Education, Culture, Sports, Science and Technology SRPBS; by European Commission FP-7 through the CoDyCo project (#600716); by European Commission Horizon 2020 through the SPEXOR project (#687662)"; by Japanese Ministry of Internal Affairs and Communications under contract entitled " Novel and innovative R&D making use of brain structures"; by Cabinet Office Government of Japan ImPACT; and by a project commissioned by New Energy andIndustrial Technology Development Organization. LP was supported by Slovene Human Resources Development and Scholarship Fund (146. and 163. JR)<SUP>2</SUP>. JM was supported by Japanese Ministry of Internal Affairs and Communications SCOPE; by Japanese Ministry of Education, Culture, Sports, Science and Technology KAKENHI (#23120004); by Japan Science and Technology Agency SICP; and by Japan Society for the Promotion of Science and Slovenian Ministry of Education, Science and Sport: Japan-Slovenia research Cooperative Program. TN was supported by Japan Society for the Promotion of Science KAKENHI (#24700203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguirre-Ollinger G, 2013, IEEE INT C INT ROBOT, P1182, DOI 10.1109/IROS.2013.6696500; Babic J, 2011, ADAPT BEHAV, V19, P250, DOI 10.1177/1059712311411112; Beyl P, 2014, IEEE-ASME T MECH, V19, P1046, DOI 10.1109/TMECH.2013.2268942; Cavallaro EE, 2006, IEEE T BIO-MED ENG, V53, P2387, DOI 10.1109/TBME.2006.880883; Chou CP, 1996, IEEE T ROBOTIC AUTOM, V12, P90, DOI 10.1109/70.481753; De Luca CJ, 2010, J BIOMECH, V43, P1573, DOI 10.1016/j.jbiomech.2010.01.027; De Luca CJ, 1997, J APPL BIOMECH, V13, P135, DOI 10.1123/jab.13.2.135; Dollar AM, 2008, IEEE T ROBOT, V24, P144, DOI 10.1109/TRO.2008.915453; Earp JE, 2013, J ELECTROMYOGR KINES, V23, P238, DOI 10.1016/j.jelekin.2012.08.015; Ferris DP, 2006, GAIT POSTURE, V23, P425, DOI 10.1016/j.gaitpost.2005.05.004; Fleischer C, 2008, IEEE T ROBOT, V24, P872, DOI 10.1109/TRO.2008.926860; Gams A, 2013, IEEE T BIO-MED ENG, V60, P1636, DOI 10.1109/TBME.2013.2240682; Gams A, 2009, AUTON ROBOT, V27, P3, DOI 10.1007/s10514-009-9118-y; Hermens H.J, 1999, SENIAM EUROPEAN RECO; Hesse S, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-30; Hildebrandt A, 2005, P AMER CONTR CONF, P680, DOI 10.1109/ACC.2005.1470036; Ijspeert AJ, 2002, 2002 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-3, PROCEEDINGS, P958, DOI 10.1109/IRDS.2002.1041514; Ijspeert AJ, 2013, NEURAL COMPUT, V25, P328, DOI 10.1162/NECO_a_00393; Kandel E. R., 2000, PRINCIPLES NEURAL SC; Kawamoto H., 2002, 2002 IEEE International Conference on Systems, Man and Cybernetics. Conference Proceedings (Cat. No.02CH37349), DOI 10.1109/ICSMC.2002.1173328; Kazerooni H, 2006, INT J ROBOT RES, V25, P561, DOI 10.1177/0278364906065505; Kiguchi K, 2001, IEEE T SYST MAN CY B, V31, P353, DOI 10.1109/3477.931520; Kong KC, 2006, IEEE-ASME T MECH, V11, P428, DOI 10.1109/TMECH.2006.878550; Lenzi T, 2012, IEEE T BIO-MED ENG, V59, P2180, DOI 10.1109/TBME.2012.2198821; Noda T, 2014, IEEE INT C INT ROBOT, P3573, DOI 10.1109/IROS.2014.6943062; Noda T, 2012, IEEE-RAS INT C HUMAN, P21, DOI 10.1109/HUMANOIDS.2012.6651494; Noda T, 2013, IEEE INT CONF ROBOT, P2657, DOI 10.1109/ICRA.2013.6630942; Peternel L, 2015, PROCEEDINGS OF THE 17TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS (ICAR), P34, DOI 10.1109/ICAR.2015.7251430; Peternel L, 2015, IEEE INT CONF ROBOT, P1497, DOI 10.1109/ICRA.2015.7139387; Peternel L, 2014, AUTON ROBOT, V36, P123, DOI 10.1007/s10514-013-9361-0; Petric T, 2014, IEEE INT CONF ROBOT, P4770, DOI 10.1109/ICRA.2014.6907557; Petric T, 2011, INT J ROBOT RES, V30, P1775, DOI 10.1177/0278364911421511; Pratt JE, 2004, IEEE INT CONF ROBOT, P2430, DOI 10.1109/ROBOT.2004.1307425; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Righetti L, 2006, PHYSICA D, V216, P269, DOI 10.1016/j.physd.2006.02.009; Ronsse R, 2011, MED BIOL ENG COMPUT, V49, P1173, DOI 10.1007/s11517-011-0816-1; Ronsse R, 2011, IEEE T BIO-MED ENG, V58, P1001, DOI 10.1109/TBME.2010.2089629; Rosen J, 2001, IEEE T SYST MAN CY A, V31, P210, DOI 10.1109/3468.925661; Sardellitti I, 2007, 2007 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-9, P1828; Schaal S, 1998, NEURAL COMPUT, V10, P2047, DOI 10.1162/089976698300016963; Song R, 2005, MED BIOL ENG COMPUT, V43, P473, DOI 10.1007/BF02344728; Sugar TG, 2007, IEEE T NEUR SYS REH, V15, P336, DOI 10.1109/TNSRE.2007.903903; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; Tsagarakis NG, 2003, AUTON ROBOT, V15, P21, DOI 10.1023/A:1024484615192; Ugurlu B, 2014, HUMAN MACHINE SYSTEM, VPP, P1; Ugurlu B, 2015, IEEE INT C INT ROBOT, P1633, DOI 10.1109/IROS.2015.7353586; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; Veneman JF, 2007, IEEE T NEUR SYS REH, V15, P379, DOI 10.1109/TNSRE.2007.903919; Wang DH, 2014, IEEE-ASME T MECH, V19, P1268, DOI 10.1109/TMECH.2013.2278207; Yang DP, 2009, J BIONIC ENG, V6, P255, DOI 10.1016/S1672-6529(08)60119-5; Yang DP, 2012, INT J HUM ROBOT, V9, DOI 10.1142/S0219843612500077; YANG JF, 1984, ARCH PHYS MED REHAB, V65, P517; Zoss AB, 2006, IEEE-ASME T MECH, V11, P128, DOI 10.1109/TMECH.2006.871087	53	91	96	6	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2016	11	2							e0148942	10.1371/journal.pone.0148942	http://dx.doi.org/10.1371/journal.pone.0148942			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3BP	26881743	Green Published, gold, Green Submitted			2023-01-03	WOS:000371219000036
J	Hall, E; Bishop, DC; Gee, TI				Hall, Emma; Bishop, Daniel C.; Gee, Thomas I.			Effect of Plyometric Training on Handspring Vault Performance and Functional Power in Youth Female Gymnasts	PLOS ONE			English	Article							RELIABILITY; ELITE	This study aimed to determine the effect of plyometric training (PT) when added to habitual gymnastic training (HT) on handspring vault (HV) performance variables. Twenty youth female competitive gymnasts (Age: 12.5 +/- 1.67 y) volunteered to participate and were randomly assigned to two independent groups. The experimental plyometric training group (PTG) undertook a six-week plyometric program, involving two additional 45 min PT sessions a week, alongside their HT, while the control group (CG) performed regular HT only. Videography was used (120 Hz) in the sagittal plane to record both groups performing three HVs for both the baseline and post-intervention trials. Furthermore, participants completed a countermovement jump test (CMJ) to assess the effect of PT on functional power. Through the use of Quintic biomechanics software, significant improvements (P < 0.05) were found for the PTG for run-up velocity, take-off velocity, hurdle to board distance, board contact time, table contact time and post-flight time and CMJ height. However, there were no significant improvements on pre-flight time, shoulder angle or hip angle on the vault for the PTG. The CG demonstrated no improvement for all HV measures. A sport-specific PT intervention improved handspring vault performance measures and functional power when added to the habitual training of youth female gymnasts. The additional two hours plyometric training seemingly improved the power generating capacity of movement-specific musculature, which consequently improved aspects of vaulting performance. Future research is required to examine the whether the improvements are as a consequence of the additional volume of sprinting and jumping activities, as a result of the specific PT method or a combination of these factors.	[Hall, Emma; Bishop, Daniel C.; Gee, Thomas I.] Lincoln Univ, Sch Sport & Exercise Sci, Lincoln, NE 68505 USA		Gee, TI (corresponding author), Lincoln Univ, Sch Sport & Exercise Sci, Lincoln, NE 68505 USA.	tgee@lincoln.ac.uk		Gee, Thomas/0000-0001-7253-2055; Bishop, Daniel/0000-0002-2094-7045				Aagaard P, 2003, EXERC SPORT SCI REV, V31, P61, DOI 10.1097/00003677-200304000-00002; Adams K., 1992, J STRENGTH COND RES, V6, P36, DOI DOI 10.1519/00124278-199202000-00006; Ahmet A, 2013, SERB J SPORTS SCI, V7, P45; Arazi H, 2012, S AFR J RES SPORT PH, V34, P1; Arkaev L., 2004, GYMNASTICS CREATE CH; Atikovic A, 2012, J HUM KINET, V35, P119, DOI 10.2478/v10078-012-0085-6; BALE P, 1990, SPORTS MED, V10, P139, DOI 10.2165/00007256-199010030-00001; Ball NB, 2009, J STRENGTH COND RES, V23, P1433, DOI 10.1519/JSC.0b013e3181a4e97f; Bencke J, 2002, SCAND J MED SCI SPOR, V12, P171, DOI 10.1034/j.1600-0838.2002.01128.x; Bishop DC, 2009, J STRENGTH COND RES, V23, P2137, DOI 10.1519/JSC.0b013e3181b866d0; Bobbert MF, 1996, MED SCI SPORT EXER, V28, P1402, DOI 10.1097/00005768-199611000-00009; Bradshaw EJ, 2014, P INT C BIOM SPORT 1; Bradshaw E, 2010, SPORT BIOMECH, V9, P79, DOI 10.1080/14763141.2010.488298; Bradshaw Elizabeth J, 2004, Sports Biomech, V3, P249, DOI 10.1080/14763140408522844; Chimera NJ, 2004, J ATHL TRAINING, V39, P24; FIG (Federation International de Gymnastique), 2013, 2013 COD POINTS WOM; Ford P, 2011, J SPORT SCI, V29, P389, DOI 10.1080/02640414.2010.536849; Hopkins WG, 2003, SPREADSHEET ANAL STR; Jemni M, 2006, J STRENGTH COND RES, V20, P899; Kums T, 2005, BIOL SPORT, V22, P237; Lockwood K, 2004, SPORT J, V7, P184; Makanuk H, 2010, HUMAN MOVEMENT, V11, P17; Marina M, 2014, J STRENGTH COND RES, V28, P1015, DOI 10.1519/JSC.0000000000000247; Meylan C, 2009, J STRENGTH COND RES, V23, P2605, DOI 10.1519/JSC.0b013e3181b1f330; Potteiger JA, 1999, J STRENGTH COND RES, V13, P275, DOI 10.1519/00124278-199908000-00016; Ramirez-Campillo R, 2013, J STRENGTH COND RES, V27, P2714, DOI 10.1519/JSC.0b013e318280c9e9; Slinde F, 2008, J STRENGTH COND RES, V22, P640, DOI 10.1519/JSC.0b013e3181660475; TAKEI Y, 1990, INT J SPORT BIOMECH, V6, P29, DOI 10.1123/ijsb.6.1.29; Takei Y, 1998, J APPL BIOMECH, V14, P190, DOI 10.1123/jab.14.2.190; Vassal K, 2010, J HUM SPORT EXERC, V7, P34	30	83	90	3	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148790	10.1371/journal.pone.0148790	http://dx.doi.org/10.1371/journal.pone.0148790			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859381	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000370038400085
J	Prodan, CI				Prodan, Calin I.			Platelets after intracerebral haemorrhage: more is not better	LANCET			English	Editorial Material							TRANSFUSION; THERAPY; STROKE; GROWTH		[Prodan, Calin I.] Univ Oklahoma, Dept Neurol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; [Prodan, Calin I.] Vet Adm Med Ctr, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Prodan, CI (corresponding author), Univ Oklahoma, Dept Neurol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.; Prodan, CI (corresponding author), Vet Adm Med Ctr, Oklahoma City, OK 73104 USA.	calin-prodan@ouhsc.edu						Baharoglu MI, 2016, LANCET; Borissoff JI, 2011, NEW ENGL J MED, V364, P1746, DOI 10.1056/NEJMra1011670; Charania R, 2011, TRANSFUSION, V51, P2690, DOI 10.1111/j.1537-2995.2011.03179.x; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Folman CC, 2001, TRANSFUSION, V41, P517, DOI 10.1046/j.1537-2995.2001.41040517.x; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Stolla M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00028; Thompson BB, 2010, NEUROLOGY, V75, P1333, DOI 10.1212/WNL.0b013e3181f735e5	12	7	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2016	387	10038					2577	2578		10.1016/S0140-6736(16)30478-0	http://dx.doi.org/10.1016/S0140-6736(16)30478-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP3JX	27178480				2023-01-03	WOS:000378390500005
J	Patel, AN; Henry, TD; Quyyumi, AA; Schaer, GL; Anderson, RD; Toma, C; East, C; Remmers, AE; Goodrich, J; Desai, AS; Recker, D; DeMaria, A				Patel, Amit N.; Henry, Timothy D.; Quyyumi, Arshed A.; Schaer, Gary L.; Anderson, R. David; Toma, Catalin; East, Cara; Remmers, Ann E.; Goodrich, James; Desai, Akshay S.; Recker, David; DeMaria, Anthony		IxCELL-DCM Investigators	Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial	LANCET			English	Article							AUTOLOGOUS BONE-MARROW; MULTICELLULAR THERAPY; MONONUCLEAR-CELLS; PROGENITOR CELLS; STEM-CELLS; CARDIOMYOPATHY; MORTALITY; DELIVERY	Background Ixmyelocel-T is an expanded, multicellular therapy produced from a patient's own bone marrow by selectively expanding two key types of bone marrow mononuclear cells: CD90+ mesenchymal stem cells and CD45+ CD14+ auto-fluorescent+ activated macrophages. Early phase clinical trials suggest that intramyocardial delivery of ixmyelocel-T might improve clinical, functional, symptomatic, and quality-of-life outcomes in patients with heart failure due to ischaemic dilated cardiomyopathy. We aimed to assess the safety and efficacy of catheter-based transendocardial injection of ixmyelocel-T cell therapy in patients with heart failure and reduced ejection fractions. Methods In this randomised, double-blind, placebo-controlled phase 2B trial (ixCELL-DCM), patients from 31 sites in North America with New York Heart Association class III or IV symptomatic heart failure due to ischaemic dilated cardiomyopathy, who had left ventricular ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ineligible for revascularisation procedures were randomly assigned (1: 1) to receive ixmyelocel-T or placebo at the time of bone marrow aspiration and followed for 12 months. Randomisation was done through an interactive (voice/web) response system. The pharmacist, treating physician, and coordinator at each site were unblinded, but the the follow-up team was completely blinded. The primary endpoint was a composite of all-cause death, cardiovascular admission to hospital, and unplanned clinic visits to treat acute decompensated heart failure based on the blinded adjudication of an independent clinical endpoint committee. Primary efficacy endpoint analyses and safety analyses were done by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01670981. Findings Between April 2, 2013, and Jan 28, 2015, 126 participants were randomly assigned to receive either ixmyelocel-T (n=66) or placebo (n=60). 114 (90%) patients comprised the modified intention-to-treat population and 109 (87%) patients were included in the per-protocol primary efficacy analysis (58 in the ixmyelocel-T group and 51 in the placebo group). The primary efficacy endpoint was observed in 47 patients: 50 events in 25 (49%) of 51 patients in the placebo group and 38 events in 22 (38%) of 58 patients in the ixmyelocel-T group, which represents a 37% reduction in cardiac events compared with placebo (risk ratio 0.63 [95% CI 0.42-0.97]; p= 0.0344). 41 (75%) of 51 participants in the placebo group had serious adverse events versus 31 (53%) of 58 in the ixmyelocel-T group (p= 0.0197). Interpretation To the best of our knowledge, ixCELL-DCM is the largest cell therapy study done in patients with heart failure so far. The transendocardial delivery of ixmyelocel-T in patients with heart failure and reduced ejection fraction due to ischaemic dilated cardiomyopathy resulted in a significant reduction in adjudicated clinical cardiac events compared with placebo leading to improved patient outcomes.	[Patel, Amit N.] Univ Utah Hlth Care, Salt Lake City, UT USA; [Henry, Timothy D.] Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA; [Quyyumi, Arshed A.] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Schaer, Gary L.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Anderson, R. David] Univ Florida, Gainesville, FL USA; [Toma, Catalin] Univ Pittsburgh, Pittsburgh, PA USA; [East, Cara] Baylor Univ, Med Ctr, Dallas, TX USA; [Remmers, Ann E.; Goodrich, James; Recker, David] Vericel Corp, Cambridge, MA USA; [Desai, Akshay S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [DeMaria, Anthony] Univ Calif San Diego, San Diego, CA 92103 USA	Utah System of Higher Education; University of Utah; University of Utah Hospital; Cedars Sinai Medical Center; Emory University; Rush University; State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor University; Baylor University Medical Center; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Henry, TD (corresponding author), Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA.; Patel, AN (corresponding author), Univ Utah, Sch Med, Dept Surg Cardiac, 3c127, Salt Lake City, UT 84132 USA.	Amit.Patel@hsc.utah.edu; henryt@cshs.org	Desai, Akshay/ABE-7250-2020	Anderson, R. David/0000-0003-3490-3286; Remmers, Ann/0000-0002-2465-7651	Vericel Corporation	Vericel Corporation	Vericel Corporation.	Agnetti G, 2015, BIOMED RES INT, V2015, P265; Assmus B, 2007, CIRC RES, V100, P1234, DOI 10.1161/01.RES.0000264508.47717.6b; Bartel RL, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt117; Bartunek J, 2013, J AM COLL CARDIOL, V61, P2329, DOI 10.1016/j.jacc.2013.02.071; Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; Chiong M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.130; Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7; Fisher SA, 2016, CLIN PHARMACOL THER, V100, P88, DOI 10.1002/cpt.344; Heldman AW, 2014, JAMA-J AM MED ASSOC, V311, P62, DOI 10.1001/jama.2013.282909; Henry T. D., 2016, CELL TRANSPLANT; Henry TD, 2014, CIRC RES, V115, P730, DOI 10.1161/CIRCRESAHA.115.304554; Kilic A, 2015, J THORAC DIS, V7, P2158, DOI 10.3978/j.issn.2072-1439.2015.10.64; Kissel CK, 2007, J AM COLL CARDIOL, V49, P2341, DOI 10.1016/j.jacc.2007.01.095; Ledford KJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0007-3; Ledford KJ, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt345; Leistner DM, 2011, EUR HEART J, V32, P485, DOI 10.1093/eurheartj/ehq430; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; McLaren DP, 2016, CARDIOL J, V23, P155, DOI 10.5603/CJ.a2016.0005; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Patel AN, 2015, STEM CELL TRANSL MED, V4, P1021, DOI 10.5966/sctm.2015-0070; Patel AN, 2015, HEART FAIL CLIN, V11, P275, DOI 10.1016/j.hfc.2014.12.006; Perin EC, 2015, CIRC RES, V117, P576, DOI 10.1161/CIRCRESAHA.115.306332; Perin EC, 2012, JAMA-J AM MED ASSOC, V307, P1717, DOI 10.1001/jama.2012.418; Pocock SJ, 2012, EUR HEART J, V33, P176, DOI 10.1093/eurheartj/ehr352; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186	26	101	102	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2016	387	10036					2412	2421		10.1016/S0140-6736(16)30137-4	http://dx.doi.org/10.1016/S0140-6736(16)30137-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO1ST	27059887				2023-01-03	WOS:000377560100034
J	Hjortrup, PB; Haase, N; Wetterslev, J; Perner, A				Hjortrup, Peter Buhl; Haase, Nicolai; Wetterslev, Jorn; Perner, Anders			Associations of Hospital and Patient Characteristics with Fluid Resuscitation Volumes in Patients with Severe Sepsis: Post Hoc Analyses of Data from a Multicentre Randomised Clinical Trial	PLOS ONE			English	Article							GOAL-DIRECTED RESUSCITATION; HYDROXYETHYL STARCH 130/0.4; CRITICALLY-ILL; INTENSIVE-CARE; FAILURE; SCORE	Purpose Fluid resuscitation is a key intervention in patients with sepsis and circulatory impairment. The recommendations for continued fluid therapy in sepsis are vague, which may result in differences in clinical practice. We aimed to evaluate associations between hospital and patient characteristics and fluid resuscitation volumes in ICU patients with severe sepsis. Methods We explored the 6S trial database of ICU patients with severe sepsis needing fluid resuscitation randomised to hydroxyethyl starch 130/0.42 vs. Ringer's acetate. Our primary outcome measure was fluid resuscitation volume and secondary outcome total fluid input administered from 24 hours before randomisation until the end of day 3 post-randomisation. We performed multivariate analyses with hospital and patient baseline characteristics as covariates to assess associations with fluid volumes given. Results We included 654 patients who were in the ICU for 3 days and had fluid volumes available. Individual trial sites administered significantly different volumes of fluid resuscitation and total fluid input after adjusting for baseline variables (P<0.001). Increased lactate, higher cardiovascular and renal SOFA subscores, lower respiratory SOFA subscore and surgery were all independently associated with increased fluid resuscitation volumes. Conclusions Hospital characteristics adjusted for patient baseline values were associated with differences in fluid resuscitation volumes given in the first 3 days of severe sepsis. The data indicate variations in clinical practice not explained by patient characteristics emphasizing the need for RCTs assessing fluid resuscitation volumes fluid in patients with sepsis.	[Hjortrup, Peter Buhl; Haase, Nicolai; Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Wetterslev, Jorn] Rigshosp, Copenhagen Univ Hosp, Copenhagen Trial Unit, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Perner, Anders] Ctr Res Intens Care, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Hjortrup, PB (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	peter.buhl.hjortrup@regionh.dk	Wetterslev, Jørn/ABF-1251-2020	Wetterslev, Jørn/0000-0001-7778-1771; Perner, Anders/0000-0002-4668-0123	Danish Research Councils; B Braun Melsungen	Danish Research Councils(Det Frie Forskningsrad (DFF)); B Braun Melsungen	The authors received no specific funding for this work. The 6S trial was funded by the Danish Research Councils and B Braun Melsungen delivered trial fluids to all trial sites. Neither the funders nor B Braun had any role in the conduct of the trial or the analyses or reporting of the data.	Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; Aman J, 2012, CRIT CARE MED, V40, P2742, DOI 10.1097/CCM.0b013e31825f7ab5; Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Bihari S, 2013, SHOCK, V40, P28, DOI 10.1097/SHK.0b013e31829727f1; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; Crowe BJ, 2010, PHARM STAT, V9, P269, DOI 10.1002/pst.389; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Garcia MIM, 2015, INTENS CARE MED, V41, P1247, DOI 10.1007/s00134-015-3898-7; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Perner A, 2015, INTENS CARE MED, V41, P1667, DOI 10.1007/s00134-015-3900-4; Perner A, 2014, INTENS CARE MED, V40, P927, DOI 10.1007/s00134-014-3311-y; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Perner A, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-24; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356	24	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155767	10.1371/journal.pone.0155767	http://dx.doi.org/10.1371/journal.pone.0155767			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27196104	Green Published, gold, Green Submitted			2023-01-03	WOS:000376291100097
J	Haddad, A; Davis, AM				Haddad, Ashley; Davis, Andrew M.			Tobacco Smoking Cessation in Adults and Pregnant Women Behavioral and Pharmacotherapy Interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES	GUIDELINE TITLE Tobacco Smoking Cessation in Adults and Pregnant Women: Behavioral and Pharmacotherapy Interventions DEVELOPER US Preventive Services Task Force (USPSTF) RELEASE DATE October 20, 2015 PRIOR VERSIONS April 21, 2009; November 13, 2003 FUNDING SOURCE US Agency for Healthcare Research and Quality (AHRQ) TARGET POPULATION All adults aged 18 years or older, including pregnant women MAJOR RECOMMENDATIONS Ask all adults about tobacco use; if using, advise patients to quit. Provide behavioral interventions to all adults who use tobacco regardless of pregnancy status. Prescribe Food and Drug Administration (FDA)-approved cessation pharmacotherapy to all nonpregnant adults who use tobacco (grade A recommendations). There is insufficient evidence to recommend pharmacologic interventions for tobacco cessation in pregnant adults (I statement). There is also insufficient evidence to recommend use of electronic nicotine delivery systems for tobacco cessation in any adults ( I statement).	[Haddad, Ashley; Davis, Andrew M.] Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave,MC2007,Room B221, Chicago, IL 60637 USA	University of Chicago	Haddad, A (corresponding author), Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave,MC2007,Room B221, Chicago, IL 60637 USA.	ashley.haddad@uchospitals.edu			US Agency for Healthcare Research and Quality (AHRQ)	US Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	US Agency for Healthcare Research and Quality (AHRQ)	Agaku IT, 2014, MMWR-MORBID MORTAL W, V63, P542; Centers for Disease Control and Prevention, PRAMSTAT SYST; Fiore MC, 2008, CLIN PRACTICE GUIDEL; Jamal A, 2014, MMWR-MORBID MORTAL W, V63, P1108; Leventhal AM, 2015, JAMA-J AM MED ASSOC, V314, P700, DOI 10.1001/jama.2015.8950; Luquis RR, 2015, HEALTH PROMOT PRACT, V16, P745, DOI 10.1177/1524839914561516; Patnode CD, 2015, BEHAV COUNSELING PHA; Siu AL, 2015, ANN INTERN MED, V163, P622, DOI 10.7326/M15-2023; US Department of Health and Human Services, HLTH CONS SMOK 50 YE; US Preventive Serv Task Force, 2009, ANN INTERN MED, V150, P551, DOI 10.7326/0003-4819-150-8-200904210-00009	10	12	12	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2016	315	18					2011	2012		10.1001/jama.2016.2535	http://dx.doi.org/10.1001/jama.2016.2535			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2JP	27163990				2023-01-03	WOS:000375461100019
J	Guo, Y; Johnson, MA; Mehrabian, Z; Mishra, MK; Kannan, R; Miller, NR; Bernstein, SL				Guo, Yan; Johnson, Mary A.; Mehrabian, Zara; Mishra, Manoj K.; Kannan, Rangaramanujam; Miller, Neil R.; Bernstein, Steven L.			Dendrimers Target the Ischemic Lesion in Rodent and Primate Models of Nonarteritic Anterior Ischemic Optic Neuropathy	PLOS ONE			English	Article							SINGLE INTRAVITREAL INJECTION; SUSTAINED NEUROPROTECTION; INFLAMMATION; THERAPY; NEUROINFLAMMATION; INFARCT; PGJ(2); CELLS	Introduction Polyamidoamine dendrimer nanoparticles (similar to 4 nanometers) are inert polymers that can be linked to biologically active compounds. These dendrimers selectively target and accumulate in inflammatory cells upon systemic administration. Dendrimer-linked compounds enable sustained release of therapeutic compounds directly at the site of damage. The purpose of this study was to determine if dendrimers can be used to target the optic nerve (ON) ischemic lesion in our rodent and nonhuman primate models of nonarteritic anterior ischemic optic neuropathy (NAION), a disease affecting >10,000 individuals in the US annually, and for which there currently is no effective treatment. Methods NAION was induced in male Long-Evans rats (rNAION) and in one adult male rhesus monkey (pNAION) using previously described procedures. Dendrimers were covalently linked to near-infrared cyanine-5 fluorescent dye (D-Cy5) and injected both intravitreally and systemically (in the rats) or just systemically (in the monkey) to evaluate D-Cy5 tissue accumulation in the eye and optic nerve following induction of NAION. Results Following NAION induction, Cy-5 dendrimers selectively accumulated in astrocytes and circulating macrophages. Systemic dendrimer administration provided the best penetration of the ON lesion site when injected shortly after induction. Systemic administration 1 day post-induction in the pNAION model gave localization similar to that seen in the rats. Conclusions Dendrimers selectively target the ischemic ON lesion after induction of both rNAION and pNAION. Systemic nanoparticle-linked therapeutics thus may provide a powerful, targeted and safe approach to NAION treatment by providing sustained and focused treatment of the cells directly affected by ischemia.	[Guo, Yan; Johnson, Mary A.; Mehrabian, Zara; Bernstein, Steven L.] Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA; [Mishra, Manoj K.; Kannan, Rangaramanujam] Johns Hopkins Sch Med, Ctr Nanomed, Dept Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21287 USA; [Miller, Neil R.] Johns Hopkins Sch Med, Div Neuroophthalmol, Dept Ophthalmol, Baltimore, MD 21287 USA; [Bernstein, Steven L.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Bernstein, SL (corresponding author), Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.; Bernstein, SL (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA.	sbernstein@som.umaryland.edu		Bernstein, Steven/0000-0001-7758-0136	NEI [RO1EY01530, RO1EY019529, RO1EY025304]; NIBIB [RO1 EB018306]; Johns Hopkins Optic Nerve Research Fund; NATIONAL EYE INSTITUTE [P30EY001765, R01EY019529, R01EY015304, R01EY028193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB018306] Funding Source: NIH RePORTER	NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Johns Hopkins Optic Nerve Research Fund; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was funded by NEI RO1EY01530 and RO1EY019529 to SLB, RO1EY025304 to RK (https://nei.nih.gov), NIBIB RO1 EB018306 to RK (http://www.nibib.nih.gov), and Johns Hopkins Optic Nerve Research Fund to NRM.	Arnold AC, 2003, J NEURO-OPHTHALMOL, V23, P157, DOI 10.1097/00041327-200306000-00012; ARNOLD AC, 1994, J NEURO-OPHTHALMOL, V14, P66; Bernstein SL, 2003, INVEST OPHTH VIS SCI, V44, P4153, DOI 10.1167/iovs.03-0274; Chen CS, 2008, INVEST OPHTH VIS SCI, V49, P2985, DOI 10.1167/iovs.07-1651; Denes A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-164; Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7; Hayreh SS, 2008, GRAEF ARCH CLIN EXP, V246, P1029, DOI 10.1007/s00417-008-0805-8; Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010; JOHNSON LN, 1994, J NEURO-OPHTHALMOL, V14, P38; Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013; Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232; Kannan RM, 2014, J INTERN MED, V276, P579, DOI 10.1111/joim.12280; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Lesniak WG, 2013, MOL PHARMACEUT, V10, P4560, DOI 10.1021/mp400371r; Miller NR, 2015, EYE, V29, P65, DOI 10.1038/eye.2014.144; Miller NR, 2014, INVEST OPHTH VIS SCI, V55, P7047, DOI 10.1167/iovs.14-14063; Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e; Nicholson JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050021; Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1; Salgado C, 2011, ARCH OPHTHALMOL-CHIC, V129, P1583, DOI 10.1001/archophthalmol.2011.351; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tesser RA, 2003, OPHTHALMOLOGY, V110, P2031, DOI 10.1016/S0161-6420(03)00804-2; Touitou V, 2013, INVEST OPHTH VIS SCI, V54, P7402, DOI 10.1167/iovs.13-12055; Wang B, 2009, INT J PHARMACEUT, V377, P159, DOI 10.1016/j.ijpharm.2009.04.050; Zhang C, 2009, BRAIN RES, V1264, P67, DOI 10.1016/j.brainres.2008.12.075	25	26	27	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2016	11	4							e0154437	10.1371/journal.pone.0154437	http://dx.doi.org/10.1371/journal.pone.0154437			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK8XM	27128315	Green Submitted, Green Published, gold			2023-01-03	WOS:000375212600030
J	Heidker, RM; Caiozzi, GC; Ricketts, ML				Heidker, Rebecca M.; Caiozzi, Gianella C.; Ricketts, Marie-Louise			Grape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver	PLOS ONE			English	Article							FARNESOID-X RECEPTOR; LOWERS PLASMA-CHOLESTEROL; LOWER TRIGLYCERIDE LEVELS; MICROSOMAL TRIGLYCERIDE; TRANSFER PROTEIN; CHOLIC-ACID; STEROL 12-ALPHA-HYDROXYLASE; LIPID-ACCUMULATION; NUCLEAR RECEPTOR; FXR	Bile acid (BA) sequestrants, lipid-lowering agents, may be prescribed as a monotherapy or combination therapy to reduce the risk of coronary artery disease. Over 33% of adults in the United States use complementary and alternative medicine strategies, and we recently reported that grape seed procyanidin extract (GSPE) reduces enterohepatic BA recirculation as a means to reduce serum triglyceride (TG) levels. The current study was therefore designed to assess the effects on BA, cholesterol and TG homeostatic gene expression following co-administration with GSPE and the BA sequestrant, cholestyramine (CHY). Eight-week old male C57BL/6 mice were treated for 4 weeks with either a control or 2% CHY-supplemented diet, after which, they were administered vehicle or GSPE for 14 hours. Liver and intestines were harvested and gene expression was analyzed. BA, cholesterol, non-esterified fatty acid and TG levels were also analyzed in serum and feces. Results reveal that GSPE treatment alone, and co-administration with CHY, regulates BA, cholesterol and TG metabolism differently than CHY administration alone. Notably, GSPE decreased intestinal apical sodium-dependent bile acid transporter (Asbt) gene expression, while CHY significantly induced expression. Administration with GSPE or CHY robustly induced hepatic BA biosynthetic gene expression, especially cholesterol 7 alpha-hydroxylase (Cyp7a1), compared to control, while co-administration further enhanced expression. Treatment with CHY induced both intestinal and hepatic cholesterologenic gene expression, while co-administration with GSPE attenuated the CHY-induced increase in the liver but not intestine. CHY also induced hepatic lipogenic gene expression, which was attenuated by co-administration with GSPE. Consequently, a 25% decrease in serum TG levels was observed in the CHY+GSPE group, compared to the CHY group. Collectively, this study presents novel evidence demonstrating that GSPE provides additive and complementary efficacy as a lipid-lowering combination therapy in conjunction with CHY by attenuating hepatic cholesterol synthesis, enhancing BA biosynthesis and decreasing lipogenesis, which warrants further investigation.	[Heidker, Rebecca M.; Caiozzi, Gianella C.; Ricketts, Marie-Louise] Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA; [Caiozzi, Gianella C.] Hosp Urgencia Asistencia Publ, Portugal 125, Santiago, Chile	Nevada System of Higher Education (NSHE); University of Nevada Reno	Ricketts, ML (corresponding author), Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA.	mricketts@cabnr.unr.edu		Ricketts, Marie-Louise/0000-0002-8306-7563	University of Nevada, Reno; USDA National Institute of Food and Agriculture [Hatch-NEV0738, W-3122]; CONICYT Bicentennial Becas-Chile Scholarship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103554] Funding Source: NIH RePORTER	University of Nevada, Reno; USDA National Institute of Food and Agriculture(United States Department of Agriculture (USDA)); CONICYT Bicentennial Becas-Chile Scholarship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding was provided by the University of Nevada, Reno and USDA National Institute of Food and Agriculture (Hatch-NEV0738 and Multistate project W-3122: Beneficial and Adverse Effects of Natural Chemicals on Human Health and Food Safety) to MLR. GCC was the recipient of a CONICYT Bicentennial Becas-Chile Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERNHARDSSON C, 1973, BIOCHEM BIOPH RES CO, V54, P1030, DOI 10.1016/0006-291X(73)90797-3; Bhatnagar S, 2009, J BIOL CHEM, V284, P10023, DOI 10.1074/jbc.M808818200; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CASSIDY MM, 1980, DIGEST DIS SCI, V25, P504, DOI 10.1007/BF01315212; CASSIDY MM, 1985, DIGEST DIS SCI, V30, P468, DOI 10.1007/BF01318181; CDC, 2015, UNDERLYING CAUSE DEA; Chiang John Y. L., 1998, Frontiers in Bioscience, V3, pD176; Clarke TC, 2015, NATL HLTH STAT REPOR, P1; CROUSE JR, 1987, AM J MED, V83, P243, DOI 10.1016/0002-9343(87)90692-9; Dawson PA, 2005, J BIOL CHEM, V280, P6960, DOI 10.1074/jbc.M412752200; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; Dawson PA, 2009, J LIPID RES, V50, P2340, DOI 10.1194/jlr.R900012-JLR200; Del Bas JM, 2008, MOL NUTR FOOD RES, V52, P1172, DOI 10.1002/mnfr.200800054; DIETSCHY JM, 1971, J CLIN INVEST, V50, P872, DOI 10.1172/JCI106559; DIETSCHY JM, 1968, J CLIN INVEST, V47, P166, DOI 10.1172/JCI105725; DIETSCHY JM, 1965, J CLIN INVEST, V44, P1311, DOI 10.1172/JCI105237; DIETSCHY JM, 1971, AM J CLIN NUTR, V24, P70; Downing LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140267; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; Feng D, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-40; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hayashi AA, 2011, AM J PHYSIOL-GASTR L, V301, pG326, DOI 10.1152/ajpgi.00425.2010; Heidker RM, 2016, MOL NUTR FOOD RES, V60, P727, DOI 10.1002/mnfr.201500795; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Hou R, 2009, ENDOCRIN METAB CLIN, V38, P79, DOI 10.1016/j.ecl.2008.11.007; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Insull W, 2006, SOUTH MED J, V99, P257, DOI 10.1097/01.smj.0000208120.73327.db; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jahn D, 2015, CYTOKINE GROWTH F R, V26, P625, DOI 10.1016/j.cytogfr.2015.07.016; Kamisako T, 2007, J GASTROEN HEPATOL, V22, P1832, DOI 10.1111/j.1440-1746.2007.04910.x; Kobayashi M, 2007, DIABETES, V56, P239, DOI 10.2337/db06-0353; Li H, 2005, AM J PHYSIOL-GASTR L, V288, pG60, DOI 10.1152/ajpgi.00170.2004; Li H, 2004, METABOLISM, V53, P927, DOI 10.1016/j.metabol.2004.01.017; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; LINDSEY CA, 1965, J LIPID RES, V6, P173; Lundasen T, 2006, J INTERN MED, V260, P530, DOI 10.1111/j.1365-2796.2006.01731.x; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Del Bas JM, 2009, MOL NUTR FOOD RES, V53, P805, DOI 10.1002/mnfr.200800364; Modica Salvatore, 2011, Curr Protoc Mouse Biol, V1, P289, DOI 10.1002/9780470942390.mo100226; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; Out C, 2012, CURR OPIN LIPIDOL, V23, P43, DOI 10.1097/MOL.0b013e32834f0ef3; Pandak WM, 2001, GASTROENTEROLOGY, V120, P1801, DOI 10.1053/gast.2001.24833; Praslickova D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050810; Schmitt J, 2015, LIVER INT, V35, P1133, DOI 10.1111/liv.12456; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Seok S, 2013, J BIOL CHEM, V288, P23252, DOI 10.1074/jbc.M113.452037; SHEPHERD J, 1989, CARDIOLOGY, V76, P65, DOI 10.1159/000174548; SRERE PA, 1950, J BIOL CHEM, V182, P629; Sugimoto-Kawabata K, 2013, J LIPID RES, V54, P1255, DOI 10.1194/jlr.M032839; Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; West KL, 2003, ATHEROSCLEROSIS, V171, P201, DOI 10.1016/j.atherosclerosis.2003.08.019; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; Yamakoshi J, 2002, FOOD CHEM TOXICOL, V40, P599, DOI 10.1016/S0278-6915(02)00006-6; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200	61	20	20	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2016	11	4							e0154305	10.1371/journal.pone.0154305	http://dx.doi.org/10.1371/journal.pone.0154305			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5OX	27111442	Green Submitted, Green Published, gold			2023-01-03	WOS:000374970600055
J	Zuckerman, RB; Sheingold, SH; Orav, EJ; Ruhter, J; Epstein, AM				Zuckerman, Rachael B.; Sheingold, Steven H.; Orav, E. John; Ruhter, Joel; Epstein, Arnold M.			Readmissions, Observation, and the Hospital Readmissions Reduction Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REHOSPITALIZATIONS	BACKGROUND The Hospital Readmissions Reduction Program, which is included in the Affordable Care Act (ACA), applies financial penalties to hospitals that have higher-than-expected readmission rates for targeted conditions. Some policy analysts worry that reductions in readmissions are being achieved by keeping returning patients in observation units instead of formally readmitting them to the hospital. We examined the changes in readmission rates and stays in observation units over time for targeted and nontargeted conditions and assessed whether hospitals that had greater increases in observation-service use had greater reductions in readmissions. METHODS We compared monthly, hospital-level rates of readmission and observation-service use within 30 days after hospital discharge among Medicare elderly beneficiaries from October 2007 through May 2015. We used an interrupted time-series model to determine when trends changed and whether changes differed between targeted and nontargeted conditions. We assessed the correlation between changes in readmission rates and use of observation services after adoption of the ACA in March 2010. RESULTS We analyzed data from 3387 hospitals. From 2007 to 2015, readmission rates for targeted conditions declined from 21.5% to 17.8%, and rates for nontargeted conditions declined from 15.3% to 13.1%. Shortly after passage of the ACA, the readmission rate declined quickly, especially for targeted conditions, and then continued to fall at a slower rate after October 2012 for both targeted and nontargeted conditions. Stays in observation units for targeted conditions increased from 2.6% in 2007 to 4.7% in 2015, and rates for nontargeted conditions increased from 2.5% to 4.2%. Within hospitals, there was no significant association between changes in observation-unit stays and readmissions after implementation of the ACA. CONCLUSIONS Readmission trends are consistent with hospitals' responding to incentives to reduce readmissions, including the financial penalties for readmissions under the ACA. We did not find evidence that changes in observation-unit stays accounted for the decrease in readmissions.	[Zuckerman, Rachael B.; Sheingold, Steven H.; Orav, E. John; Ruhter, Joel; Epstein, Arnold M.] Off Assistant Secreary Planning & Evaluat, Dept Hlth & Human Serv, Washington, DC USA; [Orav, E. John] Brigham & Womens Hosp, Div Gen Internal Med, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Orav, E. John] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zuckerman, RB (corresponding author), ASPE Off Hlth Policy, Dept Hlth & Human Serv, 200 Independence Ave SW,Rm 447D, Washington, DC 20201 USA.	rachael.zuckerman@hhs.gov						[Anonymous], 2007, REP C MED PAYM POL; [Anonymous], 2014, 2014 MEASURES UPDATE; [Anonymous], 2014, 2014 MEASURE UPDATES; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Carey K, 2015, HEALTH AFFAIR, V34, P978, DOI 10.1377/hlthaff.2014.1408; Centers for Medicare and Medicaid Services, 2015, ACC CAR ORG 2015 PRO; Centers for Medicare & Medicaid Services, 2011, HOSP ENG NETW CONN H; Centers for Medicare Medicaid Services, 2014, MED HOSP QUAL CHARTB; *CTR MED MED SERV, HOSP COMP DOWNL DAT; Gerhardt G, 2014, MED MED RES REV, V4; Gerhardt G, 2013, MED MED RES REV, V3; Himmelstein D, 2015, HLTH AFF BLOD   0817; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Medicare Payment Advisory Commission, 2008, REP C REF DEL SYST; Medicare Payment Advisory Commission, 2013, ECLINICALMEDICINE, DOI DOI 10.1016/J.ECLINM.2020.100495; Weaver C., 2015, WALL STREET J; Carlson Joe, 2013, Mod Healthc, V43, P8	17	565	568	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	2016	374	16					1543	1551		10.1056/NEJMsa1513024	http://dx.doi.org/10.1056/NEJMsa1513024			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ7IA	26910198	Bronze			2023-01-03	WOS:000374383900007
J	Verstraelen, H; Vervaet, C; Remon, JP				Verstraelen, Hans; Vervaet, Chris; Remon, Jean-Paul			Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome	PLOS ONE			English	Article							MUCOSAL IRRITATION TEST; BACTERIAL-VAGINOSIS; ORAL METRONIDAZOLE; LOCAL TOLERANCE; HEALTH; MECHANISMS; GLYCOGEN; FLUID; FORMULATIONS; NONOXYNOL-9	Bacterial vaginosis is a prevalent state of dysbiosis of the vaginal microbiota with wide-ranging impact on human reproductive health. Based on recent insights in community ecology of the vaginal microbiome, we hypothesize that sustained vaginal DL-lactic acid enrichment will enhance the recruitment of lactobacilli, while counteracting bacterial vaginosis-associated bacteria. We therefore aimed to develop an intravaginal device that would be easy to insert and remove, while providing sustained DL-lactic acid release into the vaginal lumen. The final prototype selected is a vaginal ring matrix system consisting of a mixture of ethylene vinyl acetate and methacrylic acid -methyl methacrylate copolymer loaded with 150 mg DL -lactic acid with an UD-lactic acid ratio of 1:1. Preclinical safety assessment was performed by use of the Slug Mucosal Irritation test, a non-vertebrate assay to evaluate vaginal mucosal irritation, which revealed no irritation. Clinical safety was evaluated in a phase I trial with six healthy nulliparous premenopausal volunteering women, with the investigational drug left in place for 7 days. Colposcopic monitoring according to the WHO/CONRAD guidelines for the evaluation of vaginal products, revealed no visible cervicovaginal mucosal changes. No adverse events related to the investigational product occurred. Total release from the intravaginal ring over 7 days was estimated through high performance liquid chromatography at 37.1 (standard deviation 0.9) mg DL -lactic acid. Semisolid lactic acid formulations have been studied to a limited extent in the past and typically consist of a large volume of excipients and very high doses of lactic acid, which is of major concern to mucosal safety. We have documented the feasability of enriching the vaginal environment with pure DL -lactic acid with a prototype intravaginal ring. Though the efficacy of this platform remains to be established possibly requiring further development, this approach may offer a novel avenue to modulate and protect the vaginal microbiota.	[Verstraelen, Hans] Univ Ghent, Dept Obstet & Gynaecol, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Vervaet, Chris; Remon, Jean-Paul] Univ Ghent, Dept Pharmaceut, Lab Pharmaceut Technol, Fac Pharmaceut Sci, B-9000 Ghent, Belgium	Ghent University; Ghent University	Verstraelen, H (corresponding author), Univ Ghent, Dept Obstet & Gynaecol, Fac Med & Hlth Sci, B-9000 Ghent, Belgium.	hans.verstraelen@ugent.be	Verstraelen, Hans/A-5602-2008; Verstraelen, Hans/AAA-8694-2019	Verstraelen, Hans/0000-0002-4070-1587	Ghent University Industrial Research Fund (IOF) [F2011/IOF-Advanced/131]	Ghent University Industrial Research Fund (IOF)	The study was funded by the Ghent University Industrial Research Fund (IOF) under grant number F2011/IOF-Advanced/131, http://www.techtransfer.ugent.be/en/support-for-academics/industrial-research-fund. HV, CV, and JPR obtained funding through this grant for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adriaens E, 2002, TOXICOL APPL PHARM, V182, P169, DOI 10.1006/taap.2002.9444; Adriaens E, 2008, SEX TRANSM DIS, V35, P512, DOI 10.1097/OLQ.0b013e3181644669; Aldunate M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00164; Aldunate M, 2013, J ANTIMICROB CHEMOTH, V68, P2015, DOI 10.1093/jac/dkt156; ANDERSCH B, 1990, GYNECOL OBSTET INVES, V30, P114, DOI 10.1159/000293230; Aroutcheva A, 2001, AM J OBSTET GYNECOL, V185, P375, DOI 10.1067/mob.2001.115867; Bilardi JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074378; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; BOEKE AJP, 1993, GENITOURIN MED, V69, P388; Brache V, 2010, CONTRACEPTION, V82, P418, DOI 10.1016/j.contraception.2010.04.012; Bradshaw CS, 2006, J INFECT DIS, V193, P1478, DOI 10.1086/503780; Brotman RM, 2011, J CLIN INVEST, V121, P4610, DOI 10.1172/JCI57172; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Decena DCD, 2006, J OBSTET GYNAECOL RE, V32, P243, DOI 10.1111/j.1447-0756.2006.00383.x; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Dhondt MMM, 2005, EUR J PHARM BIOPHARM, V60, P419, DOI 10.1016/j.ejpb.2005.01.012; Dhondt MMM, 2004, SEX TRANSM DIS, V31, P229, DOI 10.1097/01.OLQ.0000118422.62336.FA; Fichorova RN, 2015, TOXICOL APPL PHARM, V285, P198, DOI 10.1016/j.taap.2015.02.017; Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047; Gong Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107758; GREAVES WL, 1988, OBSTET GYNECOL, V72, P799; Hay P, 2009, CURR OPIN INFECT DIS, V22, P82, DOI 10.1097/QCO.0b013e32832180c6; Hladik F, 2015, ELIFE, V4, DOI 10.7554/eLife.04525; HOLST E, 1990, SCAND J INFECT DIS, V22, P625, DOI 10.3109/00365549009027109; Homayouni A, 2014, J LOW GENIT TRACT DI, V18, P79, DOI 10.1097/LGT.0b013e31829156ec; Huang HH, 2014, ARCH GYNECOL OBSTET, V289, P1225, DOI 10.1007/s00404-013-3117-0; Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Karlyshev AV, 2014, GENOME ANNOUNCEMENTS, V2, DOI 10.1128/genomeA.01221-13; Koumans EH, 2007, SEX TRANSM DIS, V34, P864, DOI 10.1097/OLQ.0b013e318074e565; Linhares I. M., 2011, AM J OBSTET GYNECOL, V120, P1, DOI [10.1016/j.ajog.2010.07.010, DOI 10.1016/J.AJOG.2010.07.010, DOI 10.1016/J.AJ0G.2010.07.010]; Lopes dos Santos Santiago G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045281; Macklaim JM, 2011, P NATL ACAD SCI USA, V108, P4688, DOI 10.1073/pnas.1000086107; Martin DH, 2012, AM J MED SCI, V343, P2, DOI 10.1097/MAJ.0b013e31823ea228; Martin R, 2009, INT MICROBIOL, V11, P261, DOI 10.2436/20.1501.01.70; Mastromarino P, 2013, NEW MICROBIOL, V36, P229; Mendes-Soares H, 2014, J BACTERIOL, V196, P1458, DOI 10.1128/JB.01439-13; Mirmonsef P, 2015, MENOPAUSE, V22, P702, DOI 10.1097/GME.0000000000000397; Mirmonsef P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102467; Mirmonsef P, 2012, AIDS RES HUM RETROV, V28, P76, DOI [10.1089/AID.2011.0071, 10.1089/aid.2011.0071]; Nasioudis D, 2015, REPROD SCI, V22, P1393, DOI 10.1177/1933719115581000; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; O'Hanlon DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080074; O'Hanlon DE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-200; Ojala T, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1070; Payne SC, 2010, J AM ACAD NURSE PRAC, V22, P101, DOI 10.1111/j.1745-7599.2009.00474.x; PHEIFER TA, 1978, NEW ENGL J MED, V298, P1429, DOI 10.1056/NEJM197806292982601; Power SE, 2013, GENOME ANNOUNCEMENTS, V1, DOI 10.1128/genomeA.01070-13; Ravel J, 2012, MBIO, V3, DOI 10.1128/mBio.00370-12; Reid G, 2015, AM J REPROD IMMUNOL, V73, P1, DOI 10.1111/aji.12319; Senok AC, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006289.pub2; Sirota I, 2014, SEMIN REPROD MED, V32, P35, DOI 10.1055/s-0033-1361821; Smith-McCune K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129769; Sobel JD, 2006, AM J OBSTET GYNECOL, V194, P1283, DOI 10.1016/j.ajog.2005.11.041; Spear GT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132646; Spear GT, 2014, J INFECT DIS, V210, P1019, DOI 10.1093/infdis/jiu231; Srinivasan S, 2015, MBIO, V6, DOI 10.1128/mBio.00204-15; Stumpf RM, 2013, AM J PHYS ANTHROPOL, V152, P119, DOI 10.1002/ajpa.22395; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; van de Wijgert JHHM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105998; van Oostrum N, 2013, HUM REPROD, V28, P1809, DOI 10.1093/humrep/det096; Verstraelen H, 2013, CURR OPIN INFECT DIS, V26, P86, DOI 10.1097/QCO.0b013e32835c20cd; Verstraelen H, 2009, EXPERT REV ANTI-INFE, V7, P1109, DOI [10.1586/eri.09.87, 10.1586/ERI.09.87]; Verstraelen H, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-116; WHO/CONRAD, 2004, MAN STAND COLP EV VA; Witkin SS, 2015, BJOG-INT J OBSTET GY, V122, P213, DOI 10.1111/1471-0528.13115; Witkin SS, 2013, MBIO, V4, DOI 10.1128/mBio.00460-13; Yeoman CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056111; Yildirim S, 2014, ISME J, V8, P2431, DOI 10.1038/ismej.2014.90	69	12	12	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0153441	10.1371/journal.pone.0153441	http://dx.doi.org/10.1371/journal.pone.0153441			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27093291	gold, Green Published, Green Submitted			2023-01-03	WOS:000374541200021
J	Hawkes, N				Hawkes, Nigel			THE BMJ AWARDS 2016 Anaesthesia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	2016	353								i1841	10.1136/bmj.i1841	http://dx.doi.org/10.1136/bmj.i1841			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ0LL	27044650				2023-01-03	WOS:000373894800002
J	Li, JJ; Chen, K; Li, SN; Liu, T; Wang, F; Xia, YJ; Lu, J; Zhou, YQ; Guo, CY				Li, Jingjing; Chen, Kan; Li, Sainan; Liu, Tong; Wang, Fan; Xia, Yujing; Lu, Jie; Zhou, Yingqun; Guo, Chuanyong			Pretreatment with Fucoidan from Fucus vesiculosus Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; A-INDUCED HEPATITIS; KAPPA-B ACTIVATION; CONCANAVALIN-A; TNF-ALPHA; AUTOIMMUNE HEPATITIS; CYTOKINE EXPRESSION; MICE; AUTOPHAGY; PATHWAY	This study aimed to explore the effects of fucoidan from Fucus vesiculosus on concanavalin A (ConA)-induced acute liver injury in mice. Pretreatment with fucoidan protected liver function indicated by ALT, AST and histopathological changes by suppressing inflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma). In addition, intrinsic and extrinsic apoptosis mediated by Bax, Bid, Bcl-2, Bcl-xL and Caspase 3, 8, and 9 were inhibited by fucoidan and the action was associated with the TRADD/TRAF2 and JAK2/STAT1 signal pathways. Our results demonstrated that fucoidan from Fucus vesiculosus alleviated ConA-induced acute liver injury via the inhibition of intrinsic and extrinsic apoptosis mediated by the TRADD/TRAF2 and JAK2/STAT1 pathways which were activated by TNF-alpha and IFN-gamma. These findings could provide a potential powerful therapy for T cell-related hepatitis.	[Li, Jingjing; Chen, Kan; Li, Sainan; Liu, Tong; Wang, Fan; Xia, Yujing; Lu, Jie; Zhou, Yingqun; Guo, Chuanyong] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China	Tongji University	Zhou, YQ; Guo, CY (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China.	yqzh02@163.com; guochuanyong@hotmail.com		Li, Sainan/0000-0002-1880-6294; Guo, Chuanyong/0000-0002-6527-4673	Natural Science Foundation of China [81270515, 81500466]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (grant No. 81270515; 81500466). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azuma K, 2012, MAR DRUGS, V10, P2337, DOI 10.3390/md10102337; Baker SJ, 1996, ONCOGENE, V12, P1; Bird GM, 1931, BIOCHEM J, V25, P403, DOI 10.1042/bj0250403; Chen K, 2014, PPAR RES, V2014, DOI 10.1155/2014/215631; Cheng P, 2014, DRUG DES DEV THER, V8, P1277, DOI 10.2147/DDDT.S66573; Cui YQ, 2012, CNS NEUROSCI THER, V18, P827, DOI 10.1111/j.1755-5949.2012.00372.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Do H, 2010, J NUTR BIOCHEM, V21, P671, DOI 10.1016/j.jnutbio.2009.03.013; Erusalimsky JD, 2007, ARTERIOSCL THROM VAS, V27, P2524, DOI 10.1161/ATVBAHA.107.151167; Gambin Anna, 2013, JAKSTAT, V2, pe24672, DOI 10.4161/jkst.24672; GANTNER F, 1995, HEPATOLOGY, V21, P190, DOI 10.1002/hep.1840210131; Garcia FAO, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-283; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; Granert C, 1999, INFECT IMMUN, V67, P2071, DOI 10.1128/IAI.67.5.2071-2074.1999; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Kang GH, 2012, J NEUROL SCI, V318, P25, DOI 10.1016/j.jns.2012.04.013; Kawano N, 2007, J NUTR SCI VITAMINOL, V53, P315, DOI 10.3177/jnsv.53.315; Ksontini R, 1998, J IMMUNOL, V160, P4082; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kunstle G, 1999, HEPATOLOGY, V30, P1241, DOI 10.1002/hep.510300517; Kusters S, 1996, GASTROENTEROLOGY, V111, P462, DOI 10.1053/gast.1996.v111.pm8690213; Kvansakul M, 2014, METHOD ENZYMOL, V544, P49, DOI 10.1016/B978-0-12-417158-9.00003-0; Kylin H., 1913, Z PHYSL CHEM, V83, P3, DOI DOI 10.1515/bchm2.1913.83.3.171; Lee DH, 2015, EUR J PHARMACOL, V749, P39, DOI 10.1016/j.ejphar.2014.11.048; Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022; Li JJ, 2015, MAR DRUGS, V13, P3368, DOI 10.3390/md13063368; Li JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120440; LOHSE AW, 1990, HEPATOLOGY, V11, P24, DOI 10.1002/hep.1840110106; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; NISHINO T, 1994, CARBOHYD RES, V255, P213, DOI 10.1016/S0008-6215(00)90980-7; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Park B, 2011, BIOCHEM PHARMACOL, V82, P1134, DOI 10.1016/j.bcp.2011.07.062; Park Mi Sun, 2014, Genes Cancer, V5, P470; PERCIVAL EGV, 1950, J CHEM SOC, P717, DOI 10.1039/jr9500000717; Thinh PD, 2013, MAR DRUGS, V11, P1456, DOI 10.3390/md11051456; Raghavendran HRB, 2011, INT IMMUNOPHARMACOL, V11, P157, DOI 10.1016/j.intimp.2010.11.002; Saito A, 2006, HEPATOL RES, V35, P190, DOI 10.1016/j.hepres.2006.03.012; Sass G, 2002, CYTOKINE, V19, P115, DOI 10.1006/cyto.2002.1948; Schmeisser H, 2014, J INTERF CYTOK RES, V34, P71, DOI 10.1089/jir.2013.0128; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Senthilkumar K, 2013, INT J BIOL MACROMOL, V60, P366, DOI 10.1016/j.ijbiomac.2013.06.030; Shen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087977; Shen M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/461536; Soares PAG, 2011, J CHROMATOGR B, V879, P457, DOI 10.1016/j.jchromb.2010.12.030; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Tao YY, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-449; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Wang HX, 2012, WORLD J GASTROENTERO, V18, P119, DOI 10.3748/wjg.v18.i2.119; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Ward J, 2015, EUR J TRAUMA EMERG S, V41, P229, DOI 10.1007/s00068-015-0521-0; Xue ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043483	51	22	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2016	11	4							e0152570	10.1371/journal.pone.0152570	http://dx.doi.org/10.1371/journal.pone.0152570			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI0QF	27035150	Green Published, gold, Green Submitted			2023-01-03	WOS:000373201200023
J	Cherkin, DC; Sherman, KJ; Balderson, BH; Cook, AJ; Anderson, ML; Hawkes, RJ; Hansen, KE; Turner, JA				Cherkin, Daniel C.; Sherman, Karen J.; Balderson, Benjamin H.; Cook, Andrea J.; Anderson, Melissa L.; Hawkes, Rene J.; Hansen, Kelly E.; Turner, Judith A.			Effect of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care on Back Pain and Functional Limitations in Adults With Chronic Low Back Pain A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTIONS; YOGA	IMPORTANCE Mindfulness-based stress reduction (MBSR) has not been rigorously evaluated for young and middle-aged adults with chronic low back pain. OBJECTIVE To evaluate the effectiveness for chronic low back pain of MBSR vs cognitive behavioral therapy (CBT) or usual care. DESIGN, SETTING, AND PARTICIPANTS Randomized, interviewer-blind, clinical trial in an integrated health care system in Washington State of 342 adults aged 20 to 70 years with chronic low back pain enrolled between September 2012 and April 2014 and randomly assigned to receive MBSR (n = 116), CBT (n = 113), or usual care (n = 113). INTERVENTIONS CBT (training to change pain-related thoughts and behaviors) and MBSR (training in mindfulness meditation and yoga) were delivered in 8 weekly 2-hour groups. Usual care included whatever care participants received. MAIN OUTCOMES AND MEASURES Coprimary outcomes were the percentages of participants with clinically meaningful (>= 30%) improvement from baseline in functional limitations (modified Roland Disability Questionnaire [RDQ]; range, 0-23) and in self-reported back pain bothersomeness (scale, 0-10) at 26weeks. Outcomes were also assessed at 4, 8, and 52 weeks. RESULTS There were 342 randomized participants, the mean (SD) [range] age was 49.3 (12.3) [20-70] years, 224 (65.7%) were women, mean duration of back pain was 7.3 years (range, 3 months-50 years), 123 (53.7%) attended 6 or more of the 8 sessions, 294 (86.0%) completed the study at 26 weeks, and 290 (84.8%) completed the study at 52 weeks. In intent-to-treat analyses at 26 weeks, the percentage of participants with clinically meaningful improvement on the RDQ was higher for those who received MBSR (60.5%) and CBT (57.7%) than for usual care (44.1%) (overall P =.04; relative risk [RR] for MBSR vs usual care, 1.37 [95% CI, 1.06-1.77]; RR for MBSR vs CBT, 0.95 [95% CI, 0.77-1.18]; and RR for CBT vs usual care, 1.31 [95% CI, 1.01-1.69]). The percentage of participants with clinically meaningful improvement in pain bothersomeness at 26 weeks was 43.6% in the MBSR group and 44.9% in the CBT group, vs 26.6% in the usual care group (overall P =.01; RR for MBSR vs usual care, 1.64 [95% CI, 1.15-2.34]; RR for MBSR vs CBT, 1.03 [95% CI, 0.78-1.36]; and RR for CBT vs usual care, 1.69 [95% CI, 1.18-2.41]). Findings for MBSR persisted with little change at 52 weeks for both primary outcomes. CONCLUSIONS AND RELEVANCE Among adults with chronic low back pain, treatment with MBSR or CBT, compared with usual care, resulted in greater improvement in back pain and functional limitations at 26 weeks, with no significant differences in outcomes between MBSR and CBT. These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain.	[Cherkin, Daniel C.; Sherman, Karen J.; Balderson, Benjamin H.; Cook, Andrea J.; Anderson, Melissa L.; Hawkes, Rene J.; Hansen, Kelly E.] Grp Hlth Res Inst, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA; [Cherkin, Daniel C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Cherkin, Daniel C.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; [Sherman, Karen J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Cook, Andrea J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Turner, Judith A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Turner, Judith A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cherkin, DC (corresponding author), Grp Hlth Res Inst, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA.	cherkin.d@ghc.org			National Center for Complementary and Integrative Health (NICCIH) of the National Institutes of Health (NIH) [R01AT006226]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT006226] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health (NICCIH) of the National Institutes of Health (NIH); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Research reported in this article was supported by the National Center for Complementary and Integrative Health (NICCIH) of the National Institutes of Health (NIH) under award number R01AT006226.	Blacker M., 2009, STRESS REDUCTION CLI; Cherkin DC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-211; Cherkin DC, 2011, ANN INTERN MED, V155, P1, DOI 10.7326/0003-4819-155-1-201107050-00002; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Cramer H, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-162; Ehde DM, 2014, AM PSYCHOL, V69, P153, DOI 10.1037/a0035747; Fjorback LO, 2011, ACTA PSYCHIAT SCAND, V124, P102, DOI 10.1111/j.1600-0447.2011.01704.x; Guy W., 1976, EARLY CLIN DRUG EVAL; Henschke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002014.pub3; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Lamb SE, 2012, PAIN, V153, P494, DOI 10.1016/j.pain.2011.11.016; Lamb SE, 2010, LANCET, V375, P916, DOI 10.1016/S0140-6736(09)62164-4; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mafi JN, 2013, JAMA INTERN MED, V173, P1573, DOI 10.1001/jamainternmed.2013.8992; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Moreno S, 2013, PSYCHOSOM MED, V75, P600, DOI 10.1097/PSY.0b013e31829a8904; Morone NE, 2016, JAMA INTERN MED, V176, P329, DOI 10.1001/jamainternmed.2015.8033; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Otis J. D., 2007, MANAGING CHRONIC PAI; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; R Core Team, R LANG ENV STAT COMP; Reiner K, 2013, PAIN MED, V14, P230, DOI 10.1111/pme.12006; Richmond H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134192; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Sherman KJ, 2011, ARCH INTERN MED, V171, P2019, DOI 10.1001/archinternmed.2011.524; Skapinakis Petros, 2007, Evid Based Med, V12, P149, DOI 10.1136/ebm.12.5.149; Turk DC, 2005, PAIN SURVIVAL GUIDE; Turner JA., 2001, BONICAS MANAGEMENT P, P1751; Veehof MM, 2011, PAIN, V152, P533, DOI 10.1016/j.pain.2010.11.002; Von Korff M, 2005, PAIN, V113, P323, DOI 10.1016/j.pain.2004.11.007; Von Korff M., 2011, HDB PAIN ASSESSMENT, P455; Wang ML, 2006, BIOMETRICAL J, V48, P302, DOI 10.1002/bimj.200510188; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	328	338	11	161	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2016	315	12					1240	1249		10.1001/jama.2016.2323	http://dx.doi.org/10.1001/jama.2016.2323			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DH0YQ	27002445	Green Accepted, Bronze			2023-01-03	WOS:000372511100010
J	Dreischulte, T; Donnan, P; Grant, A; Hapca, A; McCowan, C; Guthrie, B				Dreischulte, Tobias; Donnan, Peter; Grant, Aileen; Hapca, Adrian; McCowan, Colin; Guthrie, Bruce			Safer Prescribing - A Trial of Education, Informatics, and Financial Incentives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG EVENTS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRIMARY-CARE; HOSPITAL ADMISSIONS; RISK; PERFORMANCE; MULTICENTER; INHIBITORS; DESIGN; PAY	BACKGROUND High-risk prescribing and preventable drug-related complications are common in primary care. We evaluated whether the rates of high-risk prescribing by primary care clinicians and the related clinical outcomes would be reduced by a complex intervention. METHODS In this cluster-randomized, stepped-wedge trial conducted in Tayside, Scotland, we randomly assigned participating primary care practices to various start dates for a 48-week intervention comprising professional education, informatics to facilitate review, and financial incentives for practices to review patients' charts to assess appropriateness. The primary outcome was patient-level exposure to any of nine measures of high-risk prescribing of nonsteroidal antiinflammatory drugs (NSAIDs) or selected antiplatelet agents (e.g., NSAID prescription in a patient with chronic kidney disease or coprescription of an NSAID and an oral anticoagulant without gastroprotection). Prespecified secondary outcomes included the incidence of related hospital admissions. Analyses were performed according to the intention-to-treat principle, with the use of mixed-effect models to account for clustering in the data. RESULTS A total of 34 practices underwent randomization, 33 of which completed the study. Data were analyzed for 33,334 patients at risk at one or more points in the preintervention period and for 33,060 at risk at one or more points in the intervention period. Targeted high-risk prescribing was significantly reduced, from a rate of 3.7% (1102 of 29,537 patients at risk) immediately before the intervention to 2.2% (674 of 30,187) at the end of the intervention (adjusted odds ratio, 0.63; 95% confidence interval [CI], 0.57 to 0.68; P<0.001). The rate of hospital admissions for gastrointestinal ulcer or bleeding was significantly reduced from the preintervention period to the intervention period (from 55.7 to 37.0 admissions per 10,000 person-years; rate ratio, 0.66; 95% CI, 0.51 to 0.86; P=0.002), as was the rate of admissions for heart failure (from 707.7 to 513.5 admissions per 10,000 person-years; rate ratio, 0.73; 95% CI, 0.56 to 0.95; P=0.02), but admissions for acute kidney injury were not (101.9 and 86.0 admissions per 10,000 person-years, respectively; rate ratio, 0.84; 95% CI, 0.68 to 1.09; P=0.19). CONCLUSIONS A complex intervention combining professional education, informatics, and financial incentives reduced the rate of high-risk prescribing of antiplatelet medications and NSAIDs and may have improved clinical outcomes.	[Dreischulte, Tobias] Univ Dundee, NHS Tayside, Med Governance Unit, Dundee, Scotland; [Donnan, Peter; Hapca, Adrian; Guthrie, Bruce] Univ Dundee, Populat Hlth Sci Div, Dundee, Scotland; [Grant, Aileen] Univ Stirling, Sch Hlth Sci, Stirling FK9 4LA, Scotland; [McCowan, Colin] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland	University of Dundee; University of Dundee; University of Stirling; University of Glasgow	Guthrie, B (corresponding author), Univ Dundee, Mackenzie Bldg,Kirsty Semple Way, Dundee DD2 4BF, Scotland.	b.guthrie@dundee.ac.uk	Grant, Aileen M/J-4839-2018; Dreischulte, Tobias/E-6686-2012; Guthrie, Bruce/HHM-9696-2022	Grant, Aileen/0000-0001-6146-101X; McCowan, Colin/0000-0002-9466-833X; Donnan, Peter/0000-0001-7828-0610; Guthrie, Bruce/0000-0003-4191-4880	Scottish Government Chief Scientist Office; Chief Scientist Office [ARPG/07/02] Funding Source: researchfish	Scottish Government Chief Scientist Office; Chief Scientist Office	Funded by the Scottish Government Chief Scientist Office; ClinicalTrials.gov number, NCT01425502.	Aspden P, 2007, QUALITY CHASM SERIES; Australian Childrens Education and Care Quality Authority, 2022, NQF SNAPSH STAT SECT; Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Crabtree BF, 2011, MED CARE, V49, pS28, DOI 10.1097/MLR.0b013e3181cad65c; Cribb A, 1997, HEALTH CARE ANAL, V5, P292, DOI 10.1007/BF02678527; Davidoff AJ, 2015, J AM GERIATR SOC, V63, P486, DOI 10.1111/jgs.13320; Dreischulte T, 2015, KIDNEY INT, V88, P396, DOI 10.1038/ki.2015.101; Dreischulte T, 2012, THER ADV DRUG SAF, V3, P175, DOI 10.1177/2042098612444867; Dreischulte T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-24; Dreischulte Tobias, 2012, BMC Clin Pharmacol, V12, P5, DOI 10.1186/1472-6904-12-5; Forsetlund L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003030.pub2; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gislason GH, 2009, ARCH INTERN MED, V169, P141, DOI 10.1001/archinternmed.2008.525; Gooch K, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.02.015; Grant AM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004153; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Guthrie B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3514; Hakkarainen KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033236; Hallas J, 2006, BMJ-BRIT MED J, V333, P726, DOI 10.1136/bmj.38947.697558.AE; Harrison MJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6423; Hawkey CJ, 2003, GUT, V52, P600, DOI 10.1136/gut.52.4.600; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Huerta C, 2005, AM J KIDNEY DIS, V45, P531, DOI 10.1053/j.ajkd.2004.12.005; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; IMS Institute for Health Care Informatics, 2013, AV COSTS US HEALTHC; Leendertse AJ, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-4; Martin DO, 1996, EPIDEMIOLOGY, V7, P29, DOI 10.1097/00001648-199601000-00006; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Roland M, 2014, NEW ENGL J MED, V370, P1944, DOI 10.1056/NEJMhpr1316051; Thomsen LA, 2007, ANN PHARMACOTHER, V41, P1411, DOI 10.1345/aph.1H658; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	35	92	93	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2016	374	11					1053	1064		10.1056/NEJMsa1508955	http://dx.doi.org/10.1056/NEJMsa1508955			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DG4TR	26981935	Green Published, Green Accepted			2023-01-03	WOS:000372066100009
J	Saynes-Vasquez, A; Vibrans, H; Vergara-Silva, F; Caballero, J				Saynes-Vasquez, Alfredo; Vibrans, Heike; Vergara-Silva, Francisco; Caballero, Javier			Intracultural Differences in Local Botanical Knowledge and Knowledge Loss among the Mexican Isthmus Zapotecs	PLOS ONE			English	Article							INDIGENOUS KNOWLEDGE; CULTURAL-CHANGE; ETHNOBOTANICAL KNOWLEDGE; NATURAL-RESOURCES; MEDICINAL-PLANTS; MAYA; SIERRA; COMMUNITIES; MANAGEMENT; DIVERSITY	This study reports on the socio-demographic and locality factors that influence ethnobiological knowledge in three communities of Zapotec indigenous people of the Isthmus of Tehuantepec, Mexico. It uses local botanical nomenclature as a proxy for general ethnobiological knowledge. In each of these communities (one urban and two rural), 100 adult men were interviewed aided with a field herbarium. Fifty had a background in farming, and 50 worked in the secondary or tertiary sector as their main economic activity, totaling 300 interviews. Using a field herbarium with samples of 30 common and rare wild regional species, we documented visual recognition, knowledge of the local life form, generic and specific names and uses (five knowledge levels measuring knowledge depth). The relationship between sociodemographic variables and knowledge was analyzed with simple correlations. Differences between the three communities and the five knowledge levels were then evaluated with a discriminant analysis. A general linear analysis identified factors and covariables that influenced the observed differences. Differences between the groups with different economic activities were estimated with a t-test for independent samples. Most of the relationships found between sociodemographic variables and plant knowledge were expected: age and rurality were positively related with knowledge and years of formal schooling was negatively related. However, the somewhat less rural site had more traditional knowledge due to local circumstances. The general linear model explained 70-77% of the variation, a high value. It showed that economic activity was by far the most important factor influencing knowledge, by a factor of five. The interaction of locality and economic activity followed. The discriminant analysis assigned interviewees correctly to their localities in 94% of the cases, strengthening the evidence for intracultural variation. Both sociodemographic and historic intracultural differences heavily influence local knowledge.	[Saynes-Vasquez, Alfredo; Vibrans, Heike] Colegio Postgrad, Postgrad Bot, Campus Montecillo, Montecillo, Texcoco, Mexico; [Vergara-Silva, Francisco; Caballero, Javier] Univ Nacl Autonoma Mexico, Inst Biol, Jardin Bot, Ciudad Univ, Mexico City 04510, DF, Mexico	Colegio de Postgraduados - Mexico; Universidad Nacional Autonoma de Mexico	Vibrans, H (corresponding author), Colegio Postgrad, Postgrad Bot, Campus Montecillo, Montecillo, Texcoco, Mexico.	heike@colpos.mx		Vergara-Silva, Francisco/0000-0001-5024-268X; Vibrans, Heike/0000-0002-1800-4320	Posgrado en Ciencias Biologicas of the Universidad Nacional Autonoma de Mexico (UNAM); Consejo Nacional de Ciencias y Tecnologia (CONACyT); National Council of Science and Technology (CONACyT), Mexico;  [172714]	Posgrado en Ciencias Biologicas of the Universidad Nacional Autonoma de Mexico (UNAM); Consejo Nacional de Ciencias y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Council of Science and Technology (CONACyT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); 	The study was financed by grants to the first author for his doctoral and postdoctoral studies from the Posgrado en Ciencias Biologicas of the Universidad Nacional Autonoma de Mexico (UNAM) and the Consejo Nacional de Ciencias y Tecnologia (CONACyT); this institution is the national science foundation of Mexico and is funded by the government. There was no other specific funding. The first author file number (which identifies the grants) is 172714. The website is http://www.conacyt.mx/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We are very grateful to Ovet Fuentes Trujillo (Juchitan), Andres Sanchez (Ejido Zapata), Victoriano Manuel Gomez, Rubicel Santiago Guerra and Roque Jimenez (Santa Maria Xadani), Octavio Morales and Rogelio de Sales (San Blas Atempa) and finally Juan Luis Sanchez (Ejido Alvaro Obregon) for their hospitality, willingness to share their knowledge, and collaboration with this research. The authors also thank the Posgrado en Ciencias Biologicas of the Universidad Nacional Autonoma de Mexico (UNAM) and the National Council of Science and Technology (CONACyT), Mexico, for academic and financial support for the Ph.D. and postdoc studies of the first author. Rafael Torres Colin and Veronica Juarez Jaimes of the MEXU herbarium helped to confirm some plant identifications. Polo Gomez kindly provided assistance with the statistical analysis. Arturo Nava, Kenia Velazco and Patricia Martinez gave valuable support in fieldwork. The Botany Department of the Colegio de Postgraduados, Texcoco, supported the final stages of the paper by hosting the first author for a postdoctoral stay. Finally, the suggestions of the anonymous reviewers improved the manuscript.	Arguello Suarez, 2013, CAMINO TEHUANTEPEC D; Atran S, 2002, CURR ANTHROPOL, V43, P421, DOI 10.1086/339528; Atran S, 1999, P NATL ACAD SCI USA, V96, P7598, DOI 10.1073/pnas.96.13.7598; Ayantunde A, 2008, HUM ECOL, V36, P881, DOI 10.1007/s10745-008-9200-7; Barnard Alan., 2000, HIST THEORY ANTHR; Beltran-Rodriguez L, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-14; Berlin B., 1992, ETHNOBIOLOGICAL CLAS, DOI [DOI 10.1515/9781400862597, 10.1515/9781400862597]; Berlin B., 1972, LANG SOC, V1, P51, DOI [10.1017/S0047404500006540, DOI 10.1017/S0047404500006540]; BINFORD L, 1985, J LAT AM STUD, V17, P179, DOI 10.1017/S0022216X0000924X; Binford L., 1993, ZAPOTEC STRUGGLES HI; BOSTER JS, 1986, AM ANTHROPOL, V88, P428, DOI 10.1525/aa.1986.88.2.02a00100; Brown C.H., 1981, Journal of Anthropological Research, V37, P61; BURTON M, 1979, AM ANTHROPOL, V81, P841, DOI 10.1525/aa.1979.81.4.02a00050; Camou-Guerrero A, 2008, HUM ECOL, V36, P259, DOI 10.1007/s10745-007-9152-3; Campbell H, 1994, ZAPOTEC RENAISSANCE; Campbell HB, 1989, REV MEX SOCIOL, V51, P247, DOI 10.2307/3540686; Case RJ, 2005, ECON BOT, V59, P356, DOI 10.1663/0013-0001(2005)059[0356:FIMIKA]2.0.CO;2; Cortes-Gonzalez, 2007, THESIS U NACL AUTONO; Cruz S, 1992, ETNIAS DESARROLLO RE; Luna-Jose AD, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-24; Diamond J, 1999, FOLKBIOLOGY, P17; Fernandez MacGregor G., 1954, ISTMO TEHUANTEPEC ES; Frei B, 1998, J APPL BOT-ANGEW BOT, V72, P82; Frei B, 1998, PHYTOMEDICINE, V5, P177, DOI 10.1016/S0944-7113(98)80025-1; Frei B, 2000, ECON BOT, V54, P73, DOI 10.1007/BF02866601; Frei B, 1998, J ETHNOPHARMACOL, V62, P149, DOI 10.1016/S0378-8741(98)00051-8; GARRO LC, 1986, AM ANTHROPOL, V88, P351, DOI 10.1525/aa.1986.88.2.02a00040; Gimenez G., 2007, ESTUDIOS CULTURA IDE; Goodenough WH, 1957, REPORT 7TH ANN ROUND, P167; Hunn E.S., 2001, BIOCULTURAL DIVERSIT; Hunn ES, 2002, ETHNOBIOLOGY BIOCULT; Hunn Eugene, 2008, ZAPOTEC NATURAL HIST; Instituto Nacional de Estadistica y Geografia (INEGI), 2000, 12 CNES GEN POBL VIV; Kakudidi EK, 2004, AFR J ECOL, V42, P57, DOI 10.1111/j.1365-2028.2004.00462.x; Kottak CP, 2004, HUM ORGAN, V63, P501, DOI 10.17730/humo.63.4.g35k2c3t0tpyqgh3; Kuper A, 1999, CULTURE ANTHR ACCOUN; Lizarralde M., 2001, BIOCULTURAL DIVERSIT, P265; Luna-Jose A de L, 2006, THESIS COLEGIO POSTG; Machuca Gallegos L, 2013, REPRESENTADO PASADO; Maffi L, 2005, ANNU REV ANTHROPOL, V34, P599, DOI 10.1146/annurev.anthro.34.081804.120437; Maldonado-Almanza B, 2013, THESIS U NACL AUTONO; Manzo C, 2011, COMUNALIDAD RESISTEN; Marcus J, 2001, CUAD, V7, P5; Marcus Joyce, 1996, ZAPOTEC CIVILIZATION; Marino Flores A, 1963, DISTRIBUCION MUNICIP; Martin G.J., 1995, ETHNOBOTANY METHODS; Martinez-Balleste A, 2006, ECOL SOC, V11; Medin DL, 1999, FOLKBIOLOGY, P1; Messer E., 1978, ZAPOTEC PLANT KNOWLE; Nahmad Salomon., 2014, VISION ACTORES SOCIA; Nazarea V, 1998, HUM ORGAN, V57, P159, DOI 10.17730/humo.57.2.n8844vw5085w71x7; Nesheim I, 2006, HUM ECOL, V34, P99, DOI 10.1007/s10745-005-9004-y; Nguyen MLT, 2003, ECON BOT, V57, P472, DOI 10.1663/0013-0001(2003)057[0472:COFPKB]2.0.CO;2; Norton JB, 1998, J ARID ENVIRON, V39, P331, DOI 10.1006/jare.1998.0397; Ohmagari K, 1997, HUM ECOL, V25, P197, DOI 10.1023/A:1021922105740; Pelto P., 1975, AM ETHNOL, V2, P1, DOI DOI 10.1525/AE.1975.2.1.02A00010; Peterson Royce A, 1975, PRESTIGIO AFILIACION; Pickett V, 1967, HDB MIDDLE AM INDIAN; Pickett V. and collaborators, 1988, VOCABULARIO ZAPOTECO; Reko B., 1945, MITOBOTANICA ZAPOTEC; Ross N, 2002, HUM ORGAN, V61, P125, DOI 10.17730/humo.61.2.9bhqghxvpfh2qebc; Ross N, 2002, LACANDON MAYA INTERG, P585; Saynes-Vasquez A, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-40; Saynes-Vazquez FE, 2002, THESIS U ARIZONA; Shenton J, 2011, ETHOS, V39, P349, DOI 10.1111/j.1548-1352.2011.01197.x; Sokal RR, 1994, BIOMETRY PRINCIPLES; Thompson RA, 1974, WINDS TOMORROW SOCIA; Toledo A, 1995, GEOPOLITICA DESARROL; Trejo I, 2002, BIODIVERS CONSERV, V11, P2063, DOI 10.1023/A:1020876316013; Turner NJ, 2000, ECOL APPL, V10, P1275, DOI 10.1890/1051-0761(2000)010[1275:TEKAWO]2.0.CO;2; Tylor E.B., 1871, PRIMITIVE CULTURE RE, V6th ed.; Valdes Luz Maria, 1995, INDIOS CENSOS POBLAC; Vandebroek I, 2004, SOC SCI MED, V59, P837, DOI 10.1016/j.socscimed.2003.11.030; Voeks RA, 2004, ECON BOT, V58, pS294, DOI 10.1663/0013-0001(2004)58[S294:FTFAMP]2.0.CO;2; VSSsquez Donato Acuca, 2001, CUADERNOS ANO, V7, P21; Weller S C, 1993, Med Anthropol, V15, P109; Wester Lyndon, 1995, Journal of Ethnobiology, V15, P71; Whitecotton J.W., 1977, ZAPOTECS PRINCES PRI; Yates S, 2004, ECON BOT, V58, P72, DOI 10.1663/0013-0001(2004)058[0072:EKOBAM]2.0.CO;2; Zarger RK, 2004, CURR ANTHROPOL, V45, P413, DOI 10.1086/420908; Zent S, 2001, BIOCULTURAL DIVERSIT, P90; Zent S., 1999, ETHNOECOLOGY KNOWLED, P90	82	17	17	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151693	10.1371/journal.pone.0151693	http://dx.doi.org/10.1371/journal.pone.0151693			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH1YG	26986077	Green Submitted, Green Published, gold			2023-01-03	WOS:000372580300113
J	Jain, A; Cifu, AS				Jain, Atul; Cifu, Adam S.			Prevention, Diagnosis, and Treatment of Postthrombotic Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPRESSION		[Jain, Atul] Mayo Clin, Div Consultat Med, Scottsdale, AZ USA; [Jain, Atul] Mayo Clin, Div Prevent Occupat & Aerosp Med, Scottsdale, AZ USA; [Cifu, Adam S.] Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of Chicago	Cifu, AS (corresponding author), Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu						Barwell JR, 2004, LANCET, V363, P1854, DOI 10.1016/S0140-6736(04)16353-8; Cohen JM, 2012, CHEST, V141, P308, DOI 10.1378/chest.11-1175; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Fox MA, 2008, J VASC INTERV RADIOL, V19, P981, DOI 10.1016/j.jvir.2008.03.022; Jull AB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001733.pub3; Kahn SR, 2014, CIRCULATION, V130, P1636, DOI 10.1161/CIR.0000000000000130; Kearon Clive, 2012, Chest, V141, pe419S, DOI 10.1378/chest.11-2301; O'Meara S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000265.pub3	9	5	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2016	315	10					1048	1049		10.1001/jama.2016.0225	http://dx.doi.org/10.1001/jama.2016.0225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF7LW	26954414				2023-01-03	WOS:000371540200018
J	Jack, A				Jack, Andrew			PHARMACEUTICALS Can anyone stop the illegal sale of medicines online?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Jack, Andrew] Financial Times, London, England		Jack, A (corresponding author), Financial Times, London, England.	Andrew.jack@ft.com		Jack, Andrew/0000-0001-9679-2898				European Medicines Agency, FALS MED; NHS Choices, DANG BUYING YOUR MED	2	6	6	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2016	352								i1317	10.1136/bmj.i1317	http://dx.doi.org/10.1136/bmj.i1317			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG4NH	26951841				2023-01-03	WOS:000372048400004
J	Kuragano, T; Kitamura, K; Matsumura, O; Matsuda, A; Hara, T; Kiyomoto, H; Murata, T; Fujimoto, S; Hase, H; Joki, N; Fukatsu, A; Inoue, T; Itakura, Y; Nakanishi, T				Kuragano, Takahiro; Kitamura, Kenichiro; Matsumura, Osamu; Matsuda, Akihiko; Hara, Taiga; Kiyomoto, Hideyasu; Murata, Toshiaki; Fujimoto, Shouichi; Hase, Hiroki; Joki, Nobuhiko; Fukatsu, Atushi; Inoue, Toru; Itakura, Yukihiro; Nakanishi, Takeshi			ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage	PLOS ONE			English	Article							ERYTHROPOIESIS-STIMULATING AGENTS; CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; EPOETIN-ALPHA; IMPROVES ANEMIA; SERUM FERRITIN; HEPCIDIN; METABOLISM; RESISTANCE; MORTALITY	Objective It has been reported that hyporesponsiveness to erythropoiesis-stimulating agent (ESA) is associated with adverse events in patients on maintenance hemodialysis (MHD). However, it has not been determined whether higher iron storage is associated with an improved response, including better survival, to ESA. Design and Method We measured serum ferritin, hemoglobin (Hb), and transferrin saturation (TSAT) levels every three months for two years in 1,095 MHD patients. The weekly dose of ESA to Hb ratio was also calculated as an index of ESA responsiveness (ERI). Results A significant correlation (p<0.001, R = 0.89) between ferritin and Hb was only observed in the patients with ferritin levels < 50 ng/mL. High-dose (>= 50 mg/week) intravenous iron administration, female sex, low serum albumin, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use were significant predictors of a high ERI value (>280); however, serum ferritin and TSAT levels did not predict a higher ERI. In the time-dependent Cox hazard model, the risk for a composite event in the patients with a high ERI (>= 280) and a high ferritin level (>= 100 ng/mL) was significantly greater (hazard ratio [HR], 2.09, P = 0.033) than that for patients with a high ERI and a low ferritin (<100 ng/mL) level. Conclusion Hb was dependent upon ferritin levels in patients with ferritin levels < 50 ng/mL but not in patients with ferritin levels >= 50 ng/mL. Patients with hyporesponsiveness to ESA had a greater risk of composite events, but ERI was unrelated to iron storage.	[Kuragano, Takahiro; Nakanishi, Takeshi] Hyogo Coll Med, Dept Internal Med, Div Kidney & Dialysis, Nishinomiya, Hyogo 6638501, Japan; [Kitamura, Kenichiro] Univ Yamanashi, Dept Internal Med 3, Fac Med, Chuo Ku, Yamanashi, Japan; [Matsumura, Osamu; Matsuda, Akihiko] Saitama Med Univ, Dept Nephrol & Blood Purificat, Saitama Med Ctr, Kawagoe, Saitama, Japan; [Hara, Taiga] Kagawa Univ, Div Nephrol & Dialysis, Dept Cardiorenal & Cerebrovasc Med, Fac Med, Takamatsu, Kagawa 760, Japan; [Kiyomoto, Hideyasu] Tohoku Univ, Div Integrated Nephrol & Telemed, Tohoku Med Megabank Org, Sendai, Miyagi 980, Japan; [Murata, Toshiaki] Fukuoka Univ, Dept Internal Med, Fac Med, Div Nephrol & Rheumatol, Fukuoka 81401, Japan; [Fujimoto, Shouichi] Miyazaki Univ, Dept Hemovasc Med & Artificial Organs, Fac Med, Miyazaki, Japan; [Hase, Hiroki; Joki, Nobuhiko] Toho Univ, Dept Nephrol, Ohashi Med Ctr, Tokyo, Japan; [Fukatsu, Atushi] Yachiyo Hosp, Dept Internal Med, Anjo, Japan; [Inoue, Toru] Higashikouri Hosp, Dept Internal Med, Osaka, Japan; [Itakura, Yukihiro] Itakura Clin, Dept Internal Med, Tokorozawa, Saitama, Japan	Hyogo College of Medicine; University of Yamanashi; Saitama Medical University; Kagawa University; Tohoku University; Fukuoka University; University of Miyazaki; Toho University	Kuragano, T (corresponding author), Hyogo Coll Med, Dept Internal Med, Div Kidney & Dialysis, Nishinomiya, Hyogo 6638501, Japan.	kuragano@hyo-med.ac.jp		xing zhi, shi zhi/0000-0003-3289-5681				Albitar S, 1997, NEPHROL DIAL TRANSPL, V12, P514, DOI 10.1093/ndt/12.3.514; Bacchetta J, 2014, J AM SOC NEPHROL, V25, P564, DOI 10.1681/ASN.2013040355; Bradbury BD, 2008, AM J KIDNEY DIS, V51, P62, DOI 10.1053/j.ajkd.2007.09.015; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Coyne DW, 2007, J AM SOC NEPHROL, V18, P975, DOI 10.1681/ASN.2006091034; DEISS A, 1983, SEMIN HEMATOL, V20, P81; Di Iorio BR, 2004, BLOOD PURIFICAT, V22, P423, DOI 10.1159/000080234; FUNK DD, 1970, J NUCL MED, V11, P107; Goicoechea M, 1998, NEPHRON, V78, P23, DOI 10.1159/000044877; GOULD AB, 1990, EUR J PHARMACOL, V181, P225, DOI 10.1016/0014-2999(90)90082-H; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Ishigami J, 2013, CLIN EXP NEPHROL, V17, P106, DOI 10.1007/s10157-012-0659-6; Kalantar-Zadeh K, 2009, AM J KIDNEY DIS, V53, P823, DOI 10.1053/j.ajkd.2008.12.040; Kilpatrick RD, 2008, CLIN J AM SOC NEPHRO, V3, P1077, DOI 10.2215/CJN.04601007; Kuragano T, 2014, KIDNEY INT, V86, P845, DOI 10.1038/ki.2014.114; Kuragano T, 2010, AM J NEPHROL, V31, P534, DOI 10.1159/000312381; Le Meur Y, 2001, AM J KIDNEY DIS, V38, P510, DOI 10.1053/ajkd.2001.26839; Le Meur Y, 2011, NEPHRON CLIN PRACT, V117, pc373, DOI [10.1159/000321521, DOI 10.1159/000321521]; Litton E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4822; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P1, DOI 10.1093/ndt/gfh1024; Mallick S, 2012, BLOOD PURIFICAT, V33, P238, DOI 10.1159/000335256; McCullough PA, 2013, AM J NEPHROL, V37, P549, DOI 10.1159/000351175; Minutolo R, 2012, NEPHROL DIAL TRANSPL, V27, P2880, DOI 10.1093/ndt/gfs007; Nakanishi T, 2013, AM J MED, V126; REEVES WB, 1981, J RETICULOENDOTH SOC, V29, P173; Rozen-Zvi B, 2008, AM J KIDNEY DIS, V52, P897, DOI 10.1053/j.ajkd.2008.05.033; Solomon SD, 2010, NEW ENGL J MED, V363, P1146, DOI 10.1056/NEJMoa1005109; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; Tibshirani R, J R STAT SOC B, V58, P267; Vaziri ND, 2013, AM J KIDNEY DIS, V61, P992, DOI 10.1053/j.ajkd.2012.10.027; Winnicki W, 2012, EUR J CLIN INVEST, V42, P1087, DOI 10.1111/j.1365-2362.2012.02699.x; Zaritsky J, 2009, CLIN J AM SOC NEPHRO, V4, P1051, DOI 10.2215/CJN.05931108	32	17	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2016	11	3							e0147328	10.1371/journal.pone.0147328	http://dx.doi.org/10.1371/journal.pone.0147328			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0AN	26933949	Green Published, gold, Green Submitted			2023-01-03	WOS:000371724200004
J	Snyder, PJ; Bhasin, S; Cunningham, GR; Matsumoto, AM; Stephens-Shields, AJ; Cauley, JA; Gill, TM; Barrett-Connor, E; Swerdloff, RS; Wang, C; Ensrud, KE; Lewis, CE; Farrar, JT; Cella, D; Rosen, RC; Pahor, M; Crandall, JP; Molitch, ME; Cifelli, D; Dougar, D; Fluharty, L; Resnick, SM; Storer, TW; Anton, S; Basaria, S; Diem, SJ; Hou, X; Mohler, ER; Parsons, JK; Wenger, NK; Zeldow, B; Landis, JR; Ellenberg, SS				Snyder, P. J.; Bhasin, S.; Cunningham, G. R.; Matsumoto, A. M.; Stephens-Shields, A. J.; Cauley, J. A.; Gill, T. M.; Barrett-Connor, E.; Swerdloff, R. S.; Wang, C.; Ensrud, K. E.; Lewis, C. E.; Farrar, J. T.; Cella, D.; Rosen, R. C.; Pahor, M.; Crandall, J. P.; Molitch, M. E.; Cifelli, D.; Dougar, D.; Fluharty, L.; Resnick, S. M.; Storer, T. W.; Anton, S.; Basaria, S.; Diem, S. J.; Hou, X.; Mohler, E. R., III; Parsons, J. K.; Wenger, N. K.; Zeldow, B.; Landis, J. R.; Ellenberg, S. S.		Testosterone Trials Investigators	Effects of Testosterone Treatment in Older Men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; PHYSICAL FUNCTION; BODY-COMPOSITION; MUSCLE STRENGTH; THERAPY; RISK; MORTALITY; COGNITION; EVENTS	BACKGROUND Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials - the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. RESULTS Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P = 0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. CONCLUSIONS In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.)	[Snyder, P. J.] Univ Penn, Perelman Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; [Stephens-Shields, A. J.; Farrar, J. T.; Hou, X.; Zeldow, B.; Landis, J. R.; Ellenberg, S. S.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Cifelli, D.; Dougar, D.; Fluharty, L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Mohler, E. R., III] Univ Penn, Perelman Sch Med, Dept Med, Div Cardiovasc Dis,Sect Vasc Med, Philadelphia, PA 19104 USA; [Bhasin, S.; Storer, T. W.; Basaria, S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Res Program Mens Hlth Aging & Metab, Boston, MA 02115 USA; [Rosen, R. C.] New England Res Inst, Watertown, MA USA; [Cunningham, G. R.] Baylor Coll Med, Dept Med, Div Diabet Endocrinol & Metab, Houston, TX 77030 USA; [Cunningham, G. R.] Baylor Coll Med, Dept Mol & Cellular Biol, Div Diabet Endocrinol & Metab, Houston, TX 77030 USA; [Cunningham, G. R.] Baylor St Lukes Med Ctr, Houston, TX USA; [Matsumoto, A. M.] Univ Washington, Sch Med, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA; [Matsumoto, A. M.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Cauley, J. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; [Gill, T. M.] Yale Univ, Sch Med, Div Geriatr Med, New Haven, CT USA; [Barrett-Connor, E.] Univ Calif San Diego, Sch Med, Dept Internal Med, La Jolla, CA 92093 USA; [Barrett-Connor, E.] Univ Calif San Diego, Sch Med, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA; [Swerdloff, R. S.; Wang, C.] Harbor UCLA Med Ctr, Div Endocrinol, Torrance, CA 90509 USA; [Swerdloff, R. S.; Wang, C.] Los Angeles Biomed Res Inst, Torrance, CA USA; [Parsons, J. K.] Univ Calif San Diego, Moores Comprehens Canc Ctr, Dept Urol, San Diego, CA 92103 USA; [Ensrud, K. E.; Diem, S. J.] Univ Minnesota, Dept Med, Div Epidemiol & Community Hlth, Box 736 UMHC, Minneapolis, MN 55455 USA; [Ensrud, K. E.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Lewis, C. E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Cella, D.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Molitch, M. E.] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; [Pahor, M.; Anton, S.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA; [Crandall, J. P.] Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10467 USA; [Crandall, J. P.] Albert Einstein Coll Med, Div Geriatr, Bronx, NY 10467 USA; [Resnick, S. M.] NIA, NIH, Lab Behav Neurosci, Baltimore, MD 21224 USA; [Wenger, N. K.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; HealthCore, Inc; Baylor College of Medicine; Baylor College of Medicine; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Alabama System; University of Alabama Birmingham; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Emory University	Snyder, PJ (corresponding author), Univ Penn, Perelman Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	pjs@mail.med.upenn.edu	Cauley, Jane A/N-4836-2015; Farrar, John T/AAP-4788-2021; Matsumoto, Alvin/AAH-6096-2020; Gill, Thomas M./H-7043-2019	Cauley, Jane A/0000-0003-0752-4408; Farrar, John T/0000-0001-8656-5157; Gill, Thomas M./0000-0002-6450-0368; Ensrud, Kristine/0000-0002-9069-3036; Landis, J Richard/0000-0001-8099-0988; Basaria, Shehzad/0000-0003-1749-8549	National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK060455, P60DK079626, P30DK079626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024827, K24AG021507, U01AG030644, P30AG028740, R01AG037679, K07AG043587, P30AG021342] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.	Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Cauley JA, 2015, J GERONTOL A-BIOL, V70, P1105, DOI 10.1093/gerona/glv031; Cella D, 2002, J PAIN SYMPTOM MANAG, V24, P547, DOI 10.1016/S0885-3924(02)00529-8; Corona G, 2014, EXPERT OPIN DRUG SAF, V13, P1327, DOI 10.1517/14740338.2014.950653; Derogatis LR, 1997, J SEX MARITAL THER, V23, P291; Finkle WD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085805; FOLLMANN D, 1995, BIOMETRICS, V51, P151, DOI 10.2307/2533322; Gray PB, 2005, J CLIN ENDOCR METAB, V90, P3838, DOI 10.1210/jc.2005-0247; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lee KK, 2003, J ANDROL, V24, P688; LITTLE RJA, 1993, J AM STAT ASSOC, V88, P125, DOI 10.1080/01621459.1993.10594302; Liverman CT, 2004, TESTOSTERONE AGING C; Muller A, 2007, BJU INT, V100, P117, DOI 10.1111/j.1464-410X.2007.06915.x; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857; Sharma R, 2015, EUR HEART J, V36, P2706, DOI 10.1093/eurheartj/ehv346; Snyder PJ, 2014, CLIN TRIALS, V11, P362, DOI 10.1177/1740774514524032; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Srinivas-Shankar U, 2010, J CLIN ENDOCR METAB, V95, P639, DOI 10.1210/jc.2009-1251; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Terza JV, 2008, J HEALTH ECON, V27, P531, DOI 10.1016/j.jhealeco.2007.09.009; Thompson IM, 2006, J NATL CANCER I, V98, P529, DOI 10.1093/jnci/djj131; Travison TG, 2011, J GERONTOL A-BIOL, V66, P1090, DOI 10.1093/gerona/glr100; Vaughan C, 2007, J ANDROL, V28, P875, DOI 10.2164/jandrol.107.002931; Vigen R, 2013, JAMA-J AM MED ASSOC, V310, P1829, DOI 10.1001/jama.2013.280386; Ware J.E., 2000, MANUAL INTERPRETATIO; Ware JE, 2005, SF 36 PHYS MENTAL HL; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wu FCW, 2008, J CLIN ENDOCR METAB, V93, P2737, DOI 10.1210/jc.2007-1972; Xu L, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-108	34	473	485	2	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	2016	374	7					611	624		10.1056/NEJMoa1506119	http://dx.doi.org/10.1056/NEJMoa1506119			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD9ER	26886521	Green Accepted, Bronze			2023-01-03	WOS:000370229000007
J	de Bruijn, HS; Brooks, S; van der Ploeg-van den Heuvel, A; ten Hagen, TLM; de Haas, ERM; Robinson, DJ				de Bruijn, Henriette S.; Brooks, Sander; van der Ploeg-van den Heuvel, Angelique; ten Hagen, Timo L. M.; de Haas, Ellen R. M.; Robinson, Dominic J.			Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin	PLOS ONE			English	Article							TOPICAL 5-AMINOLEVULINIC ACID; BASAL-CELL CARCINOMA; 2-FOLD ILLUMINATION SCHEMES; PROTOPORPHYRIN-IX; AMINOLEVULINIC-ACID; METHYL AMINOLEVULINATE; FOLLOW-UP; LIPOSOMES; DERIVATIVES; GUIDELINES	Background Light fractionation significantly increases the efficacy of 5-aminolevulinic acid (ALA) based photodynamic therapy (PDT) using the nano-emulsion based gel formulation BF-200. PDT using BF-200 ALA has recently been clinically approved and is under investigation in several phase III trials for the treatment of actinic keratosis. This study is the first to compare BF-200 ALA with ALA in preclinical models. Results In hairless mouse skin there is no difference in the temporal and spatial distribution of protoporphyrin IX determined by superficial imaging and fluorescence microscopy in frozen sections. In the skin-fold chamber model, BF-200 ALA leads to more PpIX fluorescence at depth in the skin compared to ALA suggesting an enhanced penetration of BF-200 ALA. Light fractionated PDT after BF-200 ALA application results in significantly more visual skin damage following PDT compared to a single illumination. Both ALA formulations show the same visual skin damage, rate of photobleaching and change in vascular volume immediately after PDT. Fluorescence immunohistochemical imaging shows loss of VE-cadherin in the vasculature at day 1 post PDT which is greater after BF-200 ALA compared to ALA and more profound after light fractionation compared to a single illumination. Discussion The present study illustrates the clinical potential of light fractionated PDT using BF-200 ALA for enhancing PDT efficacy in (pre-) malignant skin conditions such as basal cell carcinoma and vulval intraepithelial neoplasia and its application in other lesion such as cervical intraepithelial neoplasia and oral squamous cell carcinoma where current approaches have limited efficacy.	[de Bruijn, Henriette S.; van der Ploeg-van den Heuvel, Angelique; Robinson, Dominic J.] Erasmus MC, Dept Otolaryngol & Head & Neck Surg, Ctr Opt Diagnost & Therapy, Rotterdam, Netherlands; [Brooks, Sander; de Haas, Ellen R. M.] Erasmus MC, Dept Dermatol, Rotterdam, Netherlands; [ten Hagen, Timo L. M.] Erasmus MC, Dept Surg Oncol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Bruijn, HS (corresponding author), Erasmus MC, Dept Otolaryngol & Head & Neck Surg, Ctr Opt Diagnost & Therapy, Rotterdam, Netherlands.	h.debruijn@erasmusmc.nl			Biofrontera Pharmaceuticals AG	Biofrontera Pharmaceuticals AG	This study was supported by Biofrontera Pharmaceuticals AG (http://biofrontera.com/en/) to DJR in a grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand S, 2011, CANCER RES, V71, P6040, DOI 10.1158/0008-5472.CAN-11-0805; Blake E, 2013, PHOTODIAGN PHOTODYN, V10, P575, DOI 10.1016/j.pdpdt.2013.06.006; Braathen LR, 2007, J AM ACAD DERMATOL, V56, P125, DOI 10.1016/j.jaad.2006.06.006; Choi MC, 2015, LASER SURG MED, V47, P566, DOI 10.1002/lsm.22384; de Bruijn HS, 2006, J PHOTOCH PHOTOBIO B, V85, P184, DOI 10.1016/j.jphotobiol.2006.07.004; de Bruijn HS, 2007, PHOTOCH PHOTOBIO SCI, V6, P1325, DOI 10.1039/b708340h; de Bruijn HS, 2006, PHOTODERMATOL PHOTO, V22, P238, DOI 10.1111/j.1600-0781.2006.00240.x; de Bruijn HS, 2013, PHOTOCH PHOTOBIO SCI, V12, P241, DOI 10.1039/c2pp25287b; de Bruijn HS, 2008, J PHOTOCH PHOTOBIO B, V92, P91, DOI 10.1016/j.jphotobiol.2008.05.005; de Bruijn HS, 1999, CANCER RES, V59, P901; de Haas ERM, 2006, J INVEST DERMATOL, V126, P2679, DOI 10.1038/sj.jid.5700460; de Vijlder HC, 2012, ACTA DERM-VENEREOL, V92, P641, DOI 10.2340/00015555-1448; Dirschka T, 2013, BRIT J DERMATOL, V168, P825, DOI 10.1111/bjd.12158; Dreher F, 1997, J CONTROL RELEASE, V45, P131, DOI 10.1016/S0168-3659(96)01559-3; Foldvari M, 2010, MOL PHARMACEUT, V7, P751, DOI 10.1021/mp900283x; Fotinos N, 2006, PHOTOCHEM PHOTOBIOL, V82, P994, DOI 10.1562/2006-02-03-IR-794; Gerritsen MJP, 2009, DERMATOLOGY, V218, P193, DOI 10.1159/000183753; Helgesen ALO, 2015, BRIT J DERMATOL, V173, P1156, DOI 10.1111/bjd.14033; Hillemanns P, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.10.1107; Jerjes W, 2011, LASER SURG MED, V43, P192, DOI 10.1002/lsm.21036; Juzeniene A, 2002, PHOTOCHEM PHOTOBIOL, V76, P329, DOI 10.1562/0031-8655(2002)076<0329:TAOAAA>2.0.CO;2; Kawczyk-Krupka A, 2012, PHOTODIAGN PHOTODYN, V9, P148, DOI 10.1016/j.pdpdt.2011.12.007; Kriska T, 2005, ARCH BIOCHEM BIOPHYS, V433, P435, DOI 10.1016/j.abb.2004.09.025; Lesar A, 2007, PHOTODIAGN PHOTODYN, V4, P224, DOI 10.1016/j.pdpdt.2007.09.002; Maisch T, 2007, PHOTOCH PHOTOBIO SCI, V6, P545, DOI 10.1039/b614770d; Maisch T, 2010, EXP DERMATOL, V19, pE302, DOI 10.1111/j.1600-0625.2009.01001.x; Middelburg TA, 2013, PHOTODIAGN PHOTODYN, V10, P703, DOI 10.1016/j.pdpdt.2013.09.002; Middelburg TA, 2014, PHOTOCHEM PHOTOBIOL, V90, P896, DOI 10.1111/php.12271; Moan J, 2003, INT J CANCER, V103, P132, DOI 10.1002/ijc.10802; MOAN J, 1990, J PHOTOCH PHOTOBIO B, V6, P343, DOI 10.1016/1011-1344(90)85104-5; Morton C, 2015, EUR J DERMATOL; Morton CA, 2008, BRIT J DERMATOL, V159, P1245, DOI 10.1111/j.1365-2133.2008.08882.x; Neittaanmaki-Perttu N, 2014, BRIT J DERMATOL, V171, P1172, DOI 10.1111/bjd.13326; Oh EK, 2011, EUR J PHARM SCI, V44, P149, DOI 10.1016/j.ejps.2011.07.003; RATCLIFFE SL, 1995, BRIT J CANCER, V71, P300, DOI 10.1038/bjc.1995.60; Robinson DJ, 2000, PHOTOCHEM PHOTOBIOL, V72, P794, DOI 10.1562/0031-8655(2000)072<0794:TAAPTO>2.0.CO;2; Robinson DJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P61, DOI 10.1111/j.1751-1097.1999.tb05307.x; Robinson DJ, 2003, PHOTOCHEM PHOTOBIOL, V77, P319, DOI 10.1562/0031-8655(2003)077<0319:DATOTF>2.0.CO;2; Robinson DJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P140, DOI 10.1562/0031-8655(1998)067<0140:FPOAIP>2.3.CO;2; Seynhaeve ALB, 2007, CANCER RES, V67, P9455, DOI 10.1158/0008-5472.CAN-07-1599; Star WM, 2006, ACTA DERM-VENEREOL, V86, P412, DOI 10.2340/00015555-0129; van der Veen N, 1999, PHOTOCHEM PHOTOBIOL, V70, P921, DOI 10.1562/0031-8655(1999)070<0921:PEAVIH>2.3.CO;2; ZELLMER S, 1995, BBA-BIOMEMBRANES, V1237, P176, DOI 10.1016/0005-2736(95)00100-H	43	20	20	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148850	10.1371/journal.pone.0148850	http://dx.doi.org/10.1371/journal.pone.0148850			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26872051	Green Submitted, Green Published, gold			2023-01-03	WOS:000370054100064
J	Endres, HG; Kaufmann-Kolle, P; Steeb, V; Bauer, E; Bottner, C; Thurmann, P				Endres, Heinz G.; Kaufmann-Kolle, Petra; Steeb, Valerie; Bauer, Erik; Boettner, Caroline; Thuermann, Petra			Association between Potentially Inappropriate Medication (PIM) Use and Risk of Hospitalization in Older Adults: An Observational Study Based on Routine Data Comparing PIM Use with Use of PIM Alternatives	PLOS ONE			English	Article							BEERS CRITERIA; POLYPHARMACY; POPULATION; MANAGEMENT; PEOPLE; IMPACT; DRUGS	Objective The safety of potentially inappropriate medications (PIMs) in elderly patients is still debated. Using the PRISCUS list, we examined the incident all-cause hospitalization risk associated with PIMs compared to PIM alternatives during the 180 days post individual first pharmacy dispensing (index date). Methods Routine claims data from a German health insurer on 392,337 ambulatory patients aged >= 65 years, were used to estimate adjusted hazard ratios (HRs) for hospitalization associated with incident PIM use. Observation period was January 2009-December 2010. Users of PIM alternatives, as defined by the PRISCUS list, were the reference group. Patients with PIM dispensing or hospital stay in a six month "washout" period (second half of 2008) were excluded. All potential confounders were determined in the half year before the individual index date. Results In the total cohort 60.7% were female. Median age was 73 years. Of 79,041 incident PIM users, 58.4% had PIMs dispensed in one quarter of 2009 or 2010, 19.3% in two quarters, and 22.3% in three or more quarters. There were 126,535 hospitalizations during the observation period, and 47,470 of them occurred within 180 days post first dispensing. Multivariable Cox regression analysis revealed PIM use as a significant risk factor for hospitalization (HR 1.378; 95% CI 1.349-1.407) compared to use of PIM alternatives. Conclusions PIM use compared to use of PIM alternatives is associated with an increased risk of all-cause hospitalization in the 180 days following individual index date. Future analyses comparing a single PIM with its corresponding alternative may help identify those PIMs responsible for this.	[Endres, Heinz G.; Kaufmann-Kolle, Petra; Steeb, Valerie; Bauer, Erik; Boettner, Caroline] AQUA Inst Goettingen, Gottingen, Germany; [Thuermann, Petra] Univ Witten Herdecke, Chair Clin Pharmacol, Fac Hlth, Witten, Germany	Witten Herdecke University	Endres, HG (corresponding author), AQUA Inst Goettingen, Gottingen, Germany.	heinz.endres@aqua-institut.de		Thurmann, Petra/0000-0001-9724-1422				Albert SM, 2010, DRUG AGING, V27, P407, DOI 10.2165/11315990-000000000-00000; Amann U, 2012, DTSCH ARZTEBL INT, V109, P69, DOI 10.3238/arztebl.2012.0069; Bauer TK, 2012, PHARMACOEPIDEM DR S, V21, P1321, DOI 10.1002/pds.3357; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Benetos A, 2015, JAMA-J AM MED ASSOC, V314, P170, DOI 10.1001/jama.2015.7517; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Chang CB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094350; Eggli Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-25; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fromm MF, 2013, EUR J CLIN PHARMACOL, V69, P975, DOI 10.1007/s00228-012-1425-0; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Hamar GB, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0834-z; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Henschel Frank, 2015, Drugs Real World Outcomes, V2, P249; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Jano E, 2007, ANN PHARMACOTHER, V41, P438, DOI 10.1345/aph.1H473; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; Narayan Sujita W, 2015, Drugs Real World Outcomes, V2, P137; Price SD, 2014, DRUG AGING, V31, P311, DOI 10.1007/s40266-014-0164-6; Prinja Shankar, 2010, Indian J Community Med, V35, P217, DOI 10.4103/0970-0218.66859; Reich O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105425; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, V71, P861, DOI 10.1007/s00228-015-1860-9; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Schubert I, 2013, PHARMACOEPIDEM DR S, V22, P719, DOI 10.1002/pds.3429; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Zimmermann T, 2013, BUNDESGESUNDHEITSBLA, V56, P941, DOI 10.1007/s00103-013-1767-5	28	53	55	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0146811	10.1371/journal.pone.0146811	http://dx.doi.org/10.1371/journal.pone.0146811			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840396	gold, Green Submitted, Green Published			2023-01-03	WOS:000369550200016
J	Mac Sweeney, R; McAuley, DF				Mac Sweeney, Rob; McAuley, Daniel F.			Acute respiratory distress syndrome	LANCET			English	Review							ACUTE LUNG INJURY; TIDAL-VOLUME VENTILATION; END-EXPIRATORY PRESSURE; HIGH-FREQUENCY OSCILLATION; CONTROLLED CLINICAL-TRIAL; CARE-UNIT MORTALITY; PULMONARY-ARTERY; MECHANICAL VENTILATION; RECRUITMENT MANEUVERS; PRONE POSITION	Acute respiratory distress syndrome presents as hypoxia and bilateral pulmonary infiltrates on chest imaging in the absence of heart failure sufficient to account for this clinical state. Management is largely supportive, and is focused on protective mechanical ventilation and the avoidance of fluid overload. Patients with severe hypoxaemia can be managed with early short-term use of neuromuscular blockade, prone position ventilation, or extracorporeal membrane oxygenation. The use of inhaled nitric oxide is rarely indicated and both beta(2) agonists and late corticosteroids should be avoided. Mortality remains at approximately 30%.	[Mac Sweeney, Rob; McAuley, Daniel F.] Royal Victoria Hosp, Reg Intens Care Unit, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland	Queens University Belfast	McAuley, DF (corresponding author), Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.	d.f.mcauley@qub.ac.uk		McAuley, Daniel/0000-0002-3283-1947	GlaxoSmithKline; Bayer; Peptinnovate; SOBI; MRC [MC_G1002460, G0701690] Funding Source: UKRI; Medical Research Council [G0701690, MC_G1002460] Funding Source: researchfish; Public Health Agency [COM/4700/12, EAT/4908/13, EAT/4210/09] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); Bayer(Bayer AG); Peptinnovate; SOBI; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Public Health Agency	DM reports fees for consultancy from GlaxoSmithKline, Bayer, Peptinnovate, and SOBI. His institution has received funds for his undertaking of bronchoscopy as part of a clinical trial funded by GlaxoSmithKline. He is also a named inventor on a patent for a pharmacotherapy for the treatment of acute respiratory distress syndrome held by his institution. RMS declares no competing interests.	ABERLE DR, 1988, RADIOLOGY, V168, P73, DOI 10.1148/radiology.168.1.3380985; Acosta-Herrera M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00020; Adhikari NKJ, 2014, CRIT CARE MED, V42, P404, DOI 10.1097/CCM.0b013e3182a27909; Agarwal R, 2010, RESP CARE, V55, P1653; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542; ASHBAUGH DG, 1967, LANCET, V2, P319; Avila Maria Olinda Nogueira, 2014, J Bras Nefrol, V36, P379; Barbas Carmen Sílvia Valente, 2014, Rev. bras. ter. intensiva, V26, P215, DOI 10.5935/0103-507X.20140034; Barbas Carmen Sílvia Valente, 2014, Rev. bras. ter. intensiva, V26, P89, DOI 10.5935/0103-507X.20140017; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Baumann HJ, 2008, SURGERY, V143, P426, DOI 10.1016/j.surg.2007.06.003; Bein T, 2013, INTENS CARE MED, V39, P847, DOI 10.1007/s00134-012-2787-6; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bellani G, 2009, CRIT CARE MED, V37, P2216, DOI 10.1097/CCM.0b013e3181aab31f; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bihari S, 2013, SHOCK, V40, P28, DOI 10.1097/SHK.0b013e31829727f1; Boyle AJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-166; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brown LM, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-25; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cardinal-Fernandez P, 2015, CHEST, V147, P7, DOI 10.1378/chest.14-0874; Chacko B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008807.pub2; Charbonney E, 2009, J CRIT CARE, V24, P122, DOI 10.1016/j.jcrc.2008.01.008; Claesson J, 2015, ACTA ANAESTH SCAND, V59, P286, DOI 10.1111/aas.12449; Copetti R, 2008, CARDIOVASC ULTRASOUN, V6, DOI 10.1186/1476-7120-6-16; Craig TR, 2010, CRIT CARE MED, V38, P114, DOI 10.1097/CCM.0b013e3181b43050; Curley G, 2011, CRIT CARE, V15, DOI 10.1186/cc9994; Dasenbrook EC, 2011, RESP CARE, V56, P568, DOI 10.4187/respcare.01011; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; de Hemptinne Q, 2009, CHEST, V135, P944, DOI 10.1378/chest.08-1741; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Duggal A, 2015, MINERVA ANESTESIOL, V81, P567; Enghard P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0756-5; Esteban A, 2004, ANN INTERN MED, V141, P440, DOI 10.7326/0003-4819-141-6-200409210-00009; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; Ferguson ND, 2004, INTENS CARE MED, V30, P1111, DOI 10.1007/s00134-004-2163-2; Ferguson ND, 2005, CRIT CARE MED, V33, P2228, DOI 10.1097/01.CCM.0000181529.08630.49; Ferguson ND, 2005, J CRIT CARE, V20, P147, DOI 10.1016/j.jcrc.2005.03.001; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Figueroa-Casas JB, 2013, J CRIT CARE, V28, P352, DOI 10.1016/j.jcrc.2012.12.002; Frank JA, 2005, CRIT CARE MED, V33, P181, DOI 10.1097/01.CCM.0000150663.45778.C4; Frank JA, 2006, AM J PHYSIOL-LUNG C, V291, pL1191, DOI 10.1152/ajplung.00055.2006; Frohlich S, 2013, BRIT J ANAESTH, V111, P696, DOI 10.1093/bja/aet165; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gattinoni L, 2005, INTENS CARE MED, V31, P776, DOI 10.1007/s00134-005-2627-z; Gattinoni L, 2010, MINERVA ANESTESIOL, V76, P448; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Gowda MS, 1997, CRIT CARE MED, V25, P41, DOI 10.1097/00003246-199701000-00010; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; Guerin C, 2015, INTENS CARE MED, V41, P222, DOI 10.1007/s00134-014-3583-2; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Guerin C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-9; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Hoste EA, 2014, BRIT J ANAESTH, V113, P740, DOI 10.1093/bja/aeu300; IBERTI TJ, 1994, CRIT CARE MED, V22, P1674; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; Kao KC, 2006, CRIT CARE, V10, DOI 10.1186/cc4981; KOMADINA KH, 1991, CHEST, V100, P1647, DOI 10.1378/chest.100.6.1647; Kregenow DA, 2006, CRIT CARE MED, V34, P1, DOI 10.1097/01.CCM.0000194533.75481.03; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kumar A, 2004, CRIT CARE MED, V32, P691, DOI 10.1097/01.CCM.0000114996.68110.C9; Li JT, 2015, J IMMUNOL, V195, P87, DOI 10.4049/jimmunol.1500054; Linko R, 2009, INTENS CARE MED, V35, P1352, DOI 10.1007/s00134-009-1519-z; Liu C, 2014, J TRANSL INTERN MED, V2, P107, DOI 10.4103/2224-4018.141831; Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432; Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC; Marik PE, 2013, CRIT CARE MED, V41, P1774, DOI 10.1097/CCM.0b013e31828a25fd; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; Martinez O, 2009, ARCH BRONCONEUMOL, V45, P291, DOI 10.1016/j.arbres.2008.05.010; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; McAuley DF, 2002, INTENS CARE MED, V28, P414, DOI 10.1007/s00134-002-1248-z; McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Meade MO, 2000, AM J RESP CRIT CARE, V161, P85, DOI 10.1164/ajrccm.161.1.9809003; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Modrykamien A, 2011, CLEV CLIN J MED, V78, P101, DOI 10.3949/ccjm.78a.10032; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; MUIR AL, 1975, J APPL PHYSIOL, V38, P786, DOI 10.1152/jappl.1975.38.5.786; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NASH G, 1967, NEW ENGL J MED, V276, P368, DOI 10.1056/NEJM196702162760702; Needham DM, 2015, AM J RESP CRIT CARE, V191, P177, DOI 10.1164/rccm.201409-1598OC; Needham DM, 2013, AM J RESP CRIT CARE, V188, P567, DOI 10.1164/rccm.201304-0651OC; Needham DM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2124; Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Papazian L, 2007, CRIT CARE MED, V35, P755, DOI 10.1097/01.CCM.0000257325.88144.30; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Patel SR, 2004, CHEST, V125, P197, DOI 10.1378/chest.125.1.197; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Perkins GD, 2008, THORAX, V63, P215, DOI 10.1136/thx.2007.080382; Perkins GD, 2007, THORAX, V62, P36, DOI 10.1136/thx.2006.059410; Pinheiro Bruno Valle, 2007, J. bras. pneumol., V33, P423, DOI 10.1590/S1806-37132007000400011; Pontes-Arruda A, 2008, JPEN-PARENTER ENTER, V32, P596, DOI 10.1177/0148607108324203; Preiser JC, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0737-8; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Reilly John P, 2014, Ann Am Thorac Soc, V11, P728, DOI 10.1513/AnnalsATS.201308-280OC; Reinhart K, 2012, INTENS CARE MED, V38, P368, DOI 10.1007/s00134-012-2472-9; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Ruan SY, 2014, CRIT CARE, V18, DOI 10.1186/cc13819; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Schultz MJ, 2007, ANESTHESIOLOGY, V106, P1226, DOI 10.1097/01.anes.0000267607.25011.e8; Seeley E, 2008, THORAX, V63, P994, DOI 10.1136/thx.2007.093658; Shari G, 2011, RESP CARE, V56, P576, DOI 10.4187/respcare.00901; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Shyamsundar M, 2013, CRIT CARE, V17, DOI 10.1186/cc12710; Sigurdsson MI, 2013, ACTA ANAESTH SCAND, V57, P37, DOI 10.1111/aas.12001; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Stapleton RD, 2011, CRIT CARE MED, V39, P1655, DOI 10.1097/CCM.0b013e318218669d; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Sud S, 2008, CAN MED ASSOC J, V178, P1153, DOI 10.1503/cmaj.071802; Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Tang BMP, 2009, CRIT CARE MED, V37, P1594, DOI 10.1097/CCM.0b013e31819fb507; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5; Thille AW, 2013, AM J RESP CRIT CARE, V187, P761, DOI 10.1164/rccm.201211-1981OC; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; van Zanten ARH, 2014, JAMA-J AM MED ASSOC, V312, P514, DOI 10.1001/jama.2014.7698; Vargas M, 2014, SCI WORLD J, DOI 10.1155/2014/852356; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; Villar J, 2015, CRIT CARE MED, V43, P346, DOI 10.1097/CCM.0000000000000703; Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4; Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716; Zhan QY, 2012, CRIT CARE MED, V40, P455, DOI 10.1097/CCM.0b013e318232d75e; Zhu DJ, 2014, INTENS CARE MED, V40, P504, DOI 10.1007/s00134-014-3244-5	152	230	267	5	81	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2016	388	10058					2416	2430		10.1016/S0140-6736(16)00578-X	http://dx.doi.org/10.1016/S0140-6736(16)00578-X			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB5RB	27133972	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000387436900029
J	Jabbour, E; Kantarjian, H				Jabbour, Elias; Kantarjian, Hagop			Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; LYMPHOCYTIC-LEUKEMIA; RITUXIMAB; MULTICENTER; PHASE-2; TRIAL		[Jabbour, Elias; Kantarjian, Hagop] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jabbour, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	ejabbour@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; DeAngel DJ, 2015, 20 C EUR HEM ASS VIE; Gokbuget N, 2015, AM SOC HAEM 57 ANN M; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Jabbour E, 2015, AM SOC HAEM 57 ANN M; Jabbour E, 2015, LANCET ONCOL, V16, P1547, DOI 10.1016/S1470-2045(15)00207-7; Jabbour E, 2015, BLOOD, V125, P4010, DOI 10.1182/blood-2014-08-596403; Kantarjian H, 2013, CANCER-AM CANCER SOC, V119, P2728, DOI 10.1002/cncr.28136; Maury S, 2015, AM SOC HAEM 57 ANN M; Ribrag V, 2016, LANCET; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2	12	5	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2016	387	10036					2360	2361		10.1016/S0140-6736(16)00164-1	http://dx.doi.org/10.1016/S0140-6736(16)00164-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO1ST	27080497				2023-01-03	WOS:000377560100009
J	Dursteler, KM; Vogel, M				Dursteler, Kenneth M.; Vogel, Marc			Effective drug therapy for cocaine dependence: a milestone	LANCET			English	Editorial Material							CONTINGENCY MANAGEMENT; TRIAL; METAANALYSIS; METHADONE		[Dursteler, Kenneth M.; Vogel, Marc] Psychiat Univ Clin Basel, Wilhelm Klein Str 27, CH-4012 Basel, Switzerland	University of Basel	Dursteler, KM (corresponding author), Psychiat Univ Clin Basel, Wilhelm Klein Str 27, CH-4012 Basel, Switzerland.	kenneth.duersteler@upkbs.ch	Dürsteler, Kenneth Michael/AAJ-2374-2021; Vogel, Marc/CAG-0220-2022	Dürsteler, Kenneth Michael/0000-0003-1552-5822; Vogel, Marc/0000-0002-3088-0331				Aubin HJ, 2014, BRIT J CLIN PHARMACO, V77, P324, DOI 10.1111/bcp.12116; Benishek LA, 2014, ADDICTION, V109, P1426, DOI 10.1111/add.12589; Brokowski L, 2014, AM J HEALTH-SYST PH, V71, P634, DOI 10.2146/ajhp130543; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Dursteler KM, 2015, SUBST ABUSE REHABIL, V6, P61, DOI 10.2147/SAR.S50807; Dursteler-MacFarland KM, 2013, J CLIN PSYCHOPHARM, V33, P104, DOI 10.1097/JCP.0b013e31827bfff4; Grabowski J, 2004, NEUROPSYCHOPHARMACOL, V29, P969, DOI 10.1038/sj.npp.1300392; Nuijten M, 2016, LANCET; Petitjean SA, 2014, DRUG ALCOHOL DEPEN, V145, P94, DOI 10.1016/j.drugalcdep.2014.09.785; Prendergast M, 2006, ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x; Shearer J, 2003, ADDICTION, V98, P1137, DOI 10.1046/j.1360-0443.2003.00447.x; Strain EC, 1999, JAMA-J AM MED ASSOC, V281, P1000, DOI 10.1001/jama.281.11.1000; Vogel M, J PSYCHOACT IN PRESS	13	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2016	387	10034					2171	2173		10.1016/S0140-6736(16)00563-8	http://dx.doi.org/10.1016/S0140-6736(16)00563-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN1IZ	27015910				2023-01-03	WOS:000376820800009
J	Van Spall, HGC				Van Spall, Harriette G. C.			Transitional care with telemonitoring did not reduce readmission after hospitalization for heart failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Van Spall, Harriette G. C.] McMaster Univ, Hamilton, ON, Canada	McMaster University	Van Spall, HGC (corresponding author), McMaster Univ, Hamilton, ON, Canada.			Van Spall, Harriette Gillian Christine/0000-0002-8370-4569				Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; O'Connor CM, 2010, AM HEART J, V159, P841, DOI 10.1016/j.ahj.2010.02.023	3	2	2	5	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2016	164	10					JC59	JC59		10.7326/ACPJC-2016-164-10-059	http://dx.doi.org/10.7326/ACPJC-2016-164-10-059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL8GF	27182925				2023-01-03	WOS:000375878500010
J	Perlis, RH; Perlis, CS				Perlis, Roy H.; Perlis, Clifford S.			Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs	PLOS ONE			English	Article							OF-INTEREST	Background The U.S. Physician Payments Sunshine Act mandates the reporting of payments or items of value received by physicians from drug, medical device, and biological agent manufacturers. The impact of these payments on physician prescribing has not been examined at large scale. Methods We linked public Medicare Part D prescribing data and Sunshine Act data for 2013. Physician payments were examined descriptively within specialties, and then for association with prescribing costs and patterns using regression models. Models were adjusted for potential physician-level confounding features, including sex, geographic region, and practice size. Results Among 725,169 individuals with Medicare prescribing data, 341,644 had documented payments in the OPP data (47.1%). Among all physicians receiving funds, mean payment was $1750 (SD $28336); median was $138 (IQR $48-$394). Across the 12 specialties examined, a dose-response relationship was observed in which greater payments were associated with greater prescribing costs per patient. In adjusted regression models, being in the top quintile of payment receipt was associated with incremental prescribing cost per patient ranging from $27 (general surgery) to $2931 (neurology). Similar associations were observed with proportion of branded prescriptions written. Conclusions While distribution and amount of payments differed widely across medical specialties, for each of the 12 specialties examined the receipt of payments was associated with greater prescribing costs per patient, and greater proportion of branded medication prescribing. We cannot infer a causal relationship, but interventions aimed at those physicians receiving the most payments may present an opportunity to address prescribing costs in the US.	[Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA; [Perlis, Clifford S.] Temple Univ Hlth Syst, Dept Dermatol, Philadelphia, PA USA	Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Perlis, RH (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.	rperlis@mgh.harvard.edu						Alkhaled L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004880; [Anonymous], 2015, TALK YOUR DOCT PHARM; [Anonymous], 2013, COMP SOC SEC LAWS TR; [Anonymous], 2015, NPPES DATA DISSEMINA; Austin PC, 2004, STAT MED, V23, P411, DOI 10.1002/sim.1601; Boccuti C, 2013, MEDICARE PATIENTS AC; Cain DM, 2005, J LEGAL STUD, V34, P1, DOI 10.1086/426699; Campbell EG, 2007, NEW ENGL J MED, V356, P1742, DOI 10.1056/NEJMsa064508; Coster D., 2015, ENCY BIOSTATISTICS; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; Field MJ., 2009, CONFLICT INTEREST ME; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Hampson LA, 2006, NEW ENGL J MED, V355, P2330, DOI 10.1056/NEJMsa064160; Hoadley J, 2015, SECTION 1 PART D ENR; Loewenstein G, 2012, JAMA-J AM MED ASSOC, V307, P669, DOI 10.1001/jama.2012.154; Santhakumar S, 2015, JAMA-J AM MED ASSOC, V313, P23, DOI 10.1001/jama.2014.15472; Searle S.R., 2006, LINEAR MODELS UNBALA; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	19	80	82	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2016	11	5							e0155474	10.1371/journal.pone.0155474	http://dx.doi.org/10.1371/journal.pone.0155474			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3XH	27183221	gold, Green Submitted, Green Published			2023-01-03	WOS:000376279500042
J	Huang, Q; Song, HQ; Ji, XM; Cheng, WY; Feng, J; Wu, J; Ma, QF				Huang, Qiang; Song, Hai-qing; Ji, Xun-ming; Cheng, Wei-yang; Feng, Juan; Wu, Jian; Ma, Qing-feng			Generalization of the Right Acute Stroke Prevention Strategies in Reducing in-Hospital Delays	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; TO-IMAGING TIME; INTRAVENOUS THROMBOLYSIS; NEEDLE TIME; IMPROVEMENT; IMPLEMENTATION; INTERVENTION; OUTCOMES; REGISTRY	The aim of this study was to reduce the door-to-needle (DTN) time of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) through a comprehensive, hospital-based implementation strategy. The intervention involved a systemic literature review, identifying barriers to rapid IVT treatment at our hospital, setting target DTN time intervals, and building an evolving model for IVT candidate selection. The rate of non-in-hospital delay (DTN time <= 60 min) was set as the primary endpoint. A total of 348 IVT cases were enrolled in the study (202 and 146 in the pre- and post-intervention group, respectively). The median age was 61 years in both groups; 25.2% and 26.7% of patients in the pre- and post-intervention groups, respectively, were female. The post-intervention group had higher rates of dyslipidemia and minor stroke [defined as National Institutes of Health Stroke Scale (NIHSS) <= 3]; less frequent atrial fibrillation; higher numbers of current smokers, heavy drinkers, referrals, and multi-model head imaging cases; and lower NIHSS scores and blood sugar level (all P < 0.05). All parameters including DTN, door-to-examination, door-to-imaging, door-to-laboratory, and final-test-to-needle times were improved post-intervention (all P < 0.05), with net reductions of 63, 2, 4, 28, and 23 min, respectively. The rates of DTN time <= 60 min and onset-to-needle time <= 180 min were significantly improved by the intervention (pre: 9.9% vs. post: 60.3%; P < 0.001 and pre: 23.3% vs. post: 53.4%; P < 0.001, respectively), which was accompanied by an increase in the rate of neurological improvement (pre: 45.5% vs. post: 59.6%; P = 0.010), while there was no change in incidence of mortality or systemic intracranial hemorrhage at discharge (both P > 0.05). These findings indicate that it is possible to achieve a DTN time <= 60 min for up to 60% of hospitals in the current Chinese system, and that this logistical change can yield a notable improvement in the outcome of IVT patients.	[Huang, Qiang; Song, Hai-qing; Cheng, Wei-yang; Feng, Juan; Ma, Qing-feng] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China; [Ji, Xun-ming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China; [Huang, Qiang; Wu, Jian] Tsinghua Univ, Med Ctr, Beijing Tsinghua Changgung Hosp, Dept Neurol, Beijing 100084, Peoples R China	Capital Medical University; Capital Medical University; Tsinghua University	Ma, QF (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.; Wu, J (corresponding author), Tsinghua Univ, Med Ctr, Beijing Tsinghua Changgung Hosp, Dept Neurol, Beijing 100084, Peoples R China.	wujianxuanwu@126.com; m.qingfeng@163.com	Ji, Xunming/AAN-3370-2021					Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Ahmed N, 2013, JAMA NEUROL, V70, P837, DOI 10.1001/jamaneurol.2013.406; Blumenthal D, 2015, NEW ENGL J MED, V372, P1281, DOI 10.1056/NEJMp1410425; Breuer L, 2013, EUR NEUROL, V69, P317, DOI 10.1159/000345702; Casolla B, 2013, J NEUROL, V260, P635, DOI 10.1007/s00415-012-6693-1; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Ferrari J, 2013, J NEUROL, V260, P2271, DOI 10.1007/s00415-013-6964-5; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Fonarow GC, 2011, STROKE, V42, P2983, DOI 10.1161/STROKEAHA.111.621342; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Gadhia J, 2010, STROKE, V41, P300, DOI 10.1161/STROKEAHA.109.566935; Huang Q, 2015, PLOS ONE, V10; [黄镪 Huang Qiang], 2016, [中国脑血管病杂志, Chinese Journal of Cerebrovascular Diseases], V13, P13; Huang Q, 2015, INT J STROKE, V10, pE80, DOI 10.1111/ijs.12568; Itrat A, 2015, JAMA NEUROL, P1; Lahr MMH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079049; Liu M., 2015, CHIN J NEUROL, V48, P246; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Nolte CH, 2013, J STROKE CEREBROVASC, V22, P149, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.004; Rudd M, 2012, EMERG MED J, V29, P704, DOI 10.1136/emermed-2011-200582; Sauser K, 2014, JAMA NEUROL, V71, P1155, DOI 10.1001/jamaneurol.2014.1528; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Scott PA, 2013, LANCET NEUROL, V12, P139, DOI 10.1016/S1474-4422(12)70311-3; Soulleihet V, 2014, AM J EMERG MED, V32, P225, DOI 10.1016/j.ajem.2013.11.018; Thortveit ET, 2014, ACTA NEUROL SCAND, V130, P248, DOI 10.1111/ane.12204; Wang YL, 2011, STROKE, V42, P1658, DOI 10.1161/STROKEAHA.110.604249	28	5	7	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154972	10.1371/journal.pone.0154972	http://dx.doi.org/10.1371/journal.pone.0154972			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	27152854	gold, Green Submitted, Green Published			2023-01-03	WOS:000375677000053
J	Tan, TXZ; Quek, NXE; Koh, ZX; Nadkarni, N; Singaram, K; Ho, AFW; Ong, MEH; Wong, TH				Tan, Timothy Xin Zhong; Quek, Nathaniel Xin Ern; Koh, Zhi Xiong; Nadkarni, Nivedita; Singaram, Kanageswari; Ho, Andrew Fu Wah; Ong, Marcus Eng Hock; Wong, Ting Hway			The Effect of Availability of Manpower on Trauma Resuscitation Times in a Tertiary Academic Hospital	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT; TEAM; MORTALITY; PERFORMANCE; CARE	Background For trauma patients, delays to assessment, resuscitation, and definitive care affect outcomes. We studied the effects of resuscitation area occupancy and trauma team size on trauma team resuscitation speed in an observational study at a tertiary academic institution in Singapore. Methods From January 2014 to January 2015, resuscitation videos of trauma team activated patients with an Injury Severity Score of 9 or more were extracted for review within 14 days by independent reviewers. Exclusion criteria were patients dead on arrival, inter-hospital transfers, and up-triaged patients. Data captured included manpower availability (trauma team size and resuscitation area occupancy), assessment (airway, breathing, circulation, logroll), interventions (vascular access, imaging), and process-of-care time intervals (time to assessment/intervention/adjuncts, time to imaging, and total time in the emergency department). Clinical data were obtained by chart review and from the trauma registry. Results Videos of 70 patients were reviewed over a 13-month period. The median time spent in the emergency department was 154.9 minutes (IQR 130.7-207.5) and the median resuscitation team size was 7, with larger team sizes correlating with faster process-of-care time intervals: time to airway assessment (p = 0.08) and time to disposition (p = 0.04). The mean resuscitation area occupancy rate (RAOR) was 1.89 +/- 2.49, and the RAOR was positively correlated with time spent in the emergency department (p = 0.009). Conclusion Our results suggest that adequate staffing for trauma teams and resuscitation room occupancy are correlated with faster trauma resuscitation and reduced time spent in the emergency department.	[Tan, Timothy Xin Zhong; Quek, Nathaniel Xin Ern] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore; [Koh, Zhi Xiong; Ho, Andrew Fu Wah; Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore, Singapore; [Nadkarni, Nivedita] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore; [Singaram, Kanageswari; Wong, Ting Hway] Singapore Gen Hosp, Trauma Serv, Dept Gen Surg, Singapore, Singapore; [Ong, Marcus Eng Hock] Duke NUS Grad Med Sch, Hlth Serv & Syst Res, Singapore, Singapore	National University of Singapore; Singapore General Hospital; National University of Singapore; Singapore General Hospital; National University of Singapore	Wong, TH (corresponding author), Singapore Gen Hosp, Trauma Serv, Dept Gen Surg, Singapore, Singapore.	wong.ting.hway@sgh.com.sg	Ho, Andrew Fu Wah/F-6213-2016	Ho, Andrew Fu Wah/0000-0003-4338-3876; Tan, Timothy Xin Zhong/0000-0001-5938-2304; KOH, ZHI XIONG/0000-0001-6440-1709; Wong, Ting Hway/0000-0001-9234-4529				Adedeji OA, 1996, POSTGRAD MED J, V72, P587, DOI 10.1136/pgmj.72.852.587; Alavi-Moghaddam M, 2012, ARCH TRAUMA RES, V1, P101, DOI 10.5812/atr.7177; American College of Surgeons Committee on Trauma, 2014, RESOURCES OPTIMAL CA; Cassera MA, 2009, AM J SURG, V198, P216, DOI 10.1016/j.amjsurg.2008.10.016; Cole E, 2006, J CLIN NURS, V15, P1257, DOI 10.1111/j.1365-2702.2006.01566.x; DRISCOLL PA, 1992, INJURY, V23, P111, DOI 10.1016/0020-1383(92)90044-S; DRISCOLL PA, 1992, INJURY, V23, P107, DOI 10.1016/0020-1383(92)90043-R; DRISCOLL PA, 1992, INJURY, V23, P151, DOI 10.1016/S0020-1383(05)80033-6; Georgiou A, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-66; Gjeraa K, 2014, ACTA ANAESTH SCAND, V58, P775, DOI 10.1111/aas.12336; Groenestege-Kreb DT, 2014, BRIT J ANAESTH, V113, P258, DOI 10.1093/bja/aeu236; Guttmann A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2983; Ho AFW, 2015, PREHOSP EMERG CARE, V19, P409, DOI 10.3109/10903127.2014.980477; HOYT DB, 1988, J TRAUMA, V28, P435, DOI 10.1097/00005373-198804000-00003; Kelleher DC, 2014, PEDIATR EMERG CARE, V30, P248, DOI 10.1097/PEC.0000000000000106; Mowery NT, 2011, J TRAUMA, V70, P1317, DOI 10.1097/TA.0b013e3182175199; Ong MEH, 2013, RESUSCITATION, V84, P508, DOI 10.1016/j.resuscitation.2012.07.033; Scottish Trauma Audit Group, 2012, STAG TRAUM AUD; Wong TH, 2013, EUR J TRAUMA EMERG S, V39, P495, DOI 10.1007/s00068-013-0292-4; Wong TH, 2012, EUR J TRAUMA, P467; Wong TH, 2013, J TRAUMA ACUTE CARE, V74, P780, DOI 10.1097/TA.0b013e3182826d5f	21	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2016	11	5							e0154595	10.1371/journal.pone.0154595	http://dx.doi.org/10.1371/journal.pone.0154595			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KB	27136299	Green Published, Green Submitted, gold			2023-01-03	WOS:000375674800032
J	Chan, K; Mandeville, KL				Chan, Kenneth; Mandeville, Kate L.			Improving access to NCD medicines through collaboration	LANCET			English	Editorial Material									[Chan, Kenneth] UCL, Royal Free Hosp, London NW3 2PF, England; [Mandeville, Kate L.] London Sch Hyg & Trop Med, London WC1, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine	Chan, K (corresponding author), UCL, Royal Free Hosp, London NW3 2PF, England.	kennethchan1@nhs.net	chan, Kenneth/GSN-8133-2022	Chan, Kenneth/0000-0002-5571-7549; Mandeville, Kate/0000-0002-5525-1574				Chalkidou K, 2014, LANCET ONCOL, V15, pE119, DOI 10.1016/S1470-2045(13)70547-3; Hargreaves JR, 2011, LANCET, V378, P1885, DOI 10.1016/S0140-6736(11)60687-9; International Federation of Pharmaceutical Manufacturers and Associations, DEV WORLD HLTH PARTN; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; UN, 2015, SUST DEV GOALS GOALS; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; WHO, 2010, DIFF PRIC PHARM REV; World Health Organization, 2011, WORLD MED SIT 2011 M; World Health Organization, 2015, MOD LIST ESS MED 19; World Health Organization, 2016, GLOB REP PSOR	11	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	2016	387	10029					1704	1705		10.1016/S0140-6736(16)00275-0	http://dx.doi.org/10.1016/S0140-6736(16)00275-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DJ9OD	27116264				2023-01-03	WOS:000374541900009
J	Wandeler, G; Musukuma, K; Zurcher, S; Vinikoor, MJ; Llenas-Garcia, J; Aly, MM; Mulenga, L; Chi, BH; Ehmer, J; Hobbins, MA; Bolton-Moore, C; Hoffmann, CJ; Egger, M				Wandeler, Gilles; Musukuma, Kalo; Zuercher, Samuel; Vinikoor, Michael J.; Llenas-Garcia, Jara; Aly, Mussa M.; Mulenga, Lloyd; Chi, Benjamin H.; Ehmer, Jochen; Hobbins, Michael A.; Bolton-Moore, Carolyn; Hoffmann, Christopher J.; Egger, Matthias		IeDEA-Southern Africa	Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia	PLOS ONE			English	Article							1ST-LINE ANTIRETROVIRAL THERAPY; SUB-SAHARAN AFRICA; COINFECTED PATIENTS; VIRUS INFECTION; TENOFOVIR; EPIDEMIOLOGY; PREVALENCE; VALIDATION; LAMIVUDINE; MUTATIONS	Background Few data on the virological determinants of hepatitis B virus (HBV) infection are available from southern Africa. Methods We enrolled consecutive HIV-infected adult patients initiating antiretroviral therapy (ART) at two urban clinics in Zambia and four rural clinics in Northern Mozambique between May 2013 and August 2014. HBsAg screening was performed using the Determine (R) rapid test. Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive patients. Risk factors for HBV infection were evaluated using Chi-square and Mann-Whitney tests and associations between baseline characteristics and high level HBV replication explored in multivariable logistic regression. Results Seventy-eight of 1,032 participants in Mozambique (7.6%, 95% confidence interval [CI]: 6.1-9.3) and 90 of 797 in Zambia (11.3%, 95% CI: 9.3-13.4) were HBsAg-positive. HBsAg-positive individuals were less likely to be female compared to HBsAg-negative ones (52.3% vs. 66.1%, p<0.001). Among 156 (92.9%) HBsAg-positive patients with an available measurement, median HBV viral load was 13,645 IU/mL (interquartile range: 192-8,617,488 IU/mL) and 77 (49.4%) had high values (>20,000 UI/mL). HBsAg-positive individuals had higher levels of ALT and AST compared to HBsAg-negative ones (both p<0.001). In multivariable analyses, male sex (adjusted odds ratio: 2.59, 95% CI: 1.22-5.53) and CD4 cell count below 200/mu l (2.58, 1.20-5.54) were associated with high HBV DNA. HBV genotypes A1 (58.8%) and E (38.2%) were most prevalent. Four patients had probable resistance to lamivudine and/or entecavir. Conclusion One half of HBsAg-positive patients demonstrated high HBV viremia, supporting the early initiation of tenofovir-containing ART in HIV/HBV-coinfected adults.	[Wandeler, Gilles] Univ Bern, Univ Hosp Bern, Dept Infect Dis, Bern, Switzerland; [Wandeler, Gilles; Egger, Matthias] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Wandeler, Gilles] Univ Dakar, Dept Infect Dis, Dakar, Senegal; [Musukuma, Kalo; Vinikoor, Michael J.; Mulenga, Lloyd; Bolton-Moore, Carolyn] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Zuercher, Samuel] Univ Bern, Inst Infect Dis, Bern, Switzerland; [Vinikoor, Michael J.; Bolton-Moore, Carolyn] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Llenas-Garcia, Jara] SolidarMed, Ancuabe, Mozambique; [Aly, Mussa M.] Nucleo Invest Operat Pemba, Pemba, Mozambique; [Chi, Benjamin H.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Ehmer, Jochen; Hobbins, Michael A.] SolidarMed, Luzern, Switzerland; [Hoffmann, Christopher J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Egger, Matthias] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; University of Cape Town	Wandeler, G (corresponding author), Univ Bern, Univ Hosp Bern, Dept Infect Dis, Bern, Switzerland.; Wandeler, G (corresponding author), Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.; Wandeler, G (corresponding author), Univ Dakar, Dept Infect Dis, Dakar, Senegal.	gilles.wandeler@ispm.unibe.ch	Prozesky, Hans Walter/ABE-6956-2020; Wandeler, Gilles/ABB-2961-2020	Prozesky, Hans Walter/0000-0001-9715-3449; Llenas-Garcia, Jara/0000-0001-9125-7706; Egger, Matthias/0000-0001-7462-5132; Hoffmann, Christopher/0000-0002-9422-0519; Bolton Moore, Carolyn/0000-0001-9103-7746	National Institute of Allergy and Infectious Diseases [5U01-AI069924-05]; Fogarty International Center of the National Institutes of Health [1K01TW009998]; Ambizione-PROSPER fellowship from the Swiss National Science Foundation [PZ00P3_154730]; FOGARTY INTERNATIONAL CENTER [K01TW009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050410, U01AI069924] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Ambizione-PROSPER fellowship from the Swiss National Science Foundation; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institute of Allergy and Infectious Diseases (Grant number 5U01-AI069924-05) and Fogarty International Center (Grant number 1K01TW009998) of the National Institutes of Health. GW was supported by an Ambizione-PROSPER fellowship from the Swiss National Science Foundation (PZ00P3_154730). Support for Zambian laboratory capacity building came from the HIV Research Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank all study participants and staff of all participating sites. This study was supported by the National Institute of Allergy and Infectious Diseases (Grant number 5U01-AI069924-05) and Fogarty International Center (Grant number 1K01TW009998) of the National Institutes of Health. GW was supported by an Ambizione-PROSPER fellowship from the Swiss National Science Foundation (PZ00P3_154730). Support for Zambian laboratory capacity building came from the HIV Research Trust.	Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004; Amini-Bavil-Olyaee S, 2009, HEPATOLOGY, V49, P1158, DOI 10.1002/hep.22790; Aoudjane S, 2014, CLIN INFECT DIS, V59, P1618, DOI 10.1093/cid/ciu630; Barth RE, 2010, INT J INFECT DIS, V14, pE1024, DOI 10.1016/j.ijid.2010.06.013; Brunelle MN, 2005, HEPATOLOGY, V41, P1391, DOI 10.1002/hep.20723; Chadwick D, 2012, J ANTIMICROB CHEMOTH, V67, P2939, DOI 10.1093/jac/dks333; Childs K, 2013, AIDS, V27, P1443, DOI 10.1097/QAD.0b013e32836011c2; Cunha L, 2007, J MED VIROL, V79, P1832, DOI 10.1002/jmv.21010; Day SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059346; Delaney WE, 2006, ANTIMICROB AGENTS CH, V50, P2471, DOI 10.1128/AAC.00138-06; Egger M, 2012, INT J EPIDEMIOL, V41, P1256, DOI 10.1093/ije/dyr080; Hamers RL, 2013, JAIDS-J ACQ IMM DEF, V64, P174, DOI 10.1097/QAI.0b013e3182a60f7d; Hawkins C, 2013, AIDS, V27, P919, DOI 10.1097/QAD.0b013e32835cb9c8; Hill A, 2015, J VIRUS ERAD, V1, P103; Hoffmann CJ, 2008, CLIN INFECT DIS, V47, P1479, DOI 10.1086/593104; Hoffmann CJ, 2007, AIDS, V21, P1301, DOI 10.1097/QAD.0b013e32814e6b08; Idoko J, 2009, CLIN INFECT DIS, V49, P1268, DOI 10.1086/605675; Kapembwa KC, 2011, J GLOB INFECT DIS, V3, P269, DOI 10.4103/0974-777X.83534; Lacombe K, 2005, AIDS, V19, P907, DOI 10.1097/01.aids.0000171404.07995.5c; Makondo E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046345; Mallory MA, 2011, J VIROL METHODS, V177, P31, DOI 10.1016/j.jviromet.2011.06.009; Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001; Matthews PC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134037; Schildgen O, 2006, NEW ENGL J MED, V354, P1807, DOI 10.1056/NEJMoa051214; Sheldon J, 2005, ANTIVIR THER, V10, P727; Stabinski L, 2015, JAIDS-J ACQ IMM DEF, V68, pS274, DOI 10.1097/QAI.0000000000000496; Stokx J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-141; Vinikoor MJ, 2015, J CLIN VIROL, V72, P20, DOI 10.1016/j.jcv.2015.08.019; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Wandeler G, 2013, J INFECT DIS, V208, P1454, DOI 10.1093/infdis/jit351; WHO, 2015, WHO GUID PREV CAR TR	31	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152043	10.1371/journal.pone.0152043	http://dx.doi.org/10.1371/journal.pone.0152043			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27032097	Green Published, Green Submitted, gold			2023-01-03	WOS:000373121800031
J	Bueno, FG; Moreira, EA; de Morais, GR; Pacheco, IA; Baesso, ML; Leite-Mello, EVD; de Mello, JCP				Bueno, Fernanda Giacomini; Moreira, Eduarda Antunes; de Morais, Gutierrez Rodrigues; Pacheco, Isabela Almeida; Baesso, Mauro Luciano; de Souza Leite-Mello, Eneri Vieira; Palazzo de Mello, Joao Carlos			Enhanced Cutaneous Wound Healing In Vivo by Standardized Crude Extract of Poincianella pluviosa	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ANTIOXIDANT ACTIVITY; VITRO; FORMULATION; MECHANISMS; PHYSIOLOGY; OINTMENT; PLANTS	Wound healing is a complex process that involves several biological events, and a delay in this process may cause economic and social problems for the patient. The search continues for new alternative treatments to aid healing, including the use of herbal medicines. Members of the genus Caesalpinia are used in traditional medicine to treat wounds. The related species Poincianella pluviosa (DC.) L.P. Queiroz increases the cell viability of keratinocytes and fibroblasts and stimulates the proliferation of keratinocytes in vitro. The crude extract (CE) from bark of P. pluviosa was evaluated in the wound-healing process in vivo, to validate the traditional use and the in vitro activity. Standardized CE was incorporated into a gel and applied on cutaneous wounds (TCEG) and compared with the formulation without CE (Control) for 4, 7, 10, or 14 days of treatment. The effects of the CE on wound re-epithelialization; cell proliferation; permeation, using photoacoustic spectroscopy (PAS); and proteins, including vascular endothelial growth factor (VEGF), superoxide dismutase 2 (SOD-2) and cyclooxygenase 2 (COX-2) were evaluated. The TCEG stimulated the migration of keratinocytes at day 4 and proliferation on the following days, with a high concentration of cells in metaphase at 7 days. Type I collagen formed more rapidly in the TCEG. PAS showed that the CE had permeated through the skin. TCEG stimulated VEGF at day 4 and SOD-2 and COX-2 at day 7. The results suggest that the CE promoted the regulation of proteins and helped to accelerate the processes involved in healing, promoting early angiogenesis. This led to an increase in the re-epithelialized surface, with significant mitotic activity. Maturation of collagen fibers was also enhanced, which may affect the resistance of the extracellular matrix. PAS indicated a correlation between the rate of diffusion and biological events during the healing process. The CE from P. pluviosa appears promising as an aid in healing.	[Bueno, Fernanda Giacomini; Moreira, Eduarda Antunes; Palazzo de Mello, Joao Carlos] Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Palafito, Dept Farm, Maringa, Parana, Brazil; [de Morais, Gutierrez Rodrigues; Baesso, Mauro Luciano] Univ Estadual Maringa, Dept Fis, Grp Fenomenos Fototerm, Maringa, Parana, Brazil; [Pacheco, Isabela Almeida; de Souza Leite-Mello, Eneri Vieira] Univ Estadual Maringa, Dept Ciencias Morfol, Maringa, Parana, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa	de Mello, JCP (corresponding author), Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Palafito, Dept Farm, Maringa, Parana, Brazil.	mello@uem.br	Mello, Joao Carlos Palazzo de/B-9418-2013	Mello, Joao Carlos Palazzo de/0000-0002-7532-3395	CAPES; CNPq; Fundacao Araucaria	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC))	We thank CAPES, CNPq, and Fundacao Araucaria for financial support. Additionally, we would like to thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - JCPM #303391/2009-0. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank CAPES, CNPq, and Fundacao Araucaria for financial support. We are very grateful to M.E.C. Cancino, A. Arantes, and C.R. Novello for technical assistance. Thanks are due to Dr. Janet W. Reid, JWR Associates, Trumansburg, New York, for English revision.	Abe M, 2001, INT J LEGAL MED, V114, P232, DOI 10.1007/s004140000170; Agyare C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/632927; Amarowicz R, 2004, FOOD CHEM, V84, P551, DOI 10.1016/S0308-8146(03)00278-4; An K, 2012, ASIAN J PHARM RES HE, V4, P90; auf dem Keller U, 2006, J INVEST DERM SYMP P, V11, P106, DOI 10.1038/sj.jidsymp.5650001; Zanin JLB, 2012, MOLECULES, V17, P7887, DOI 10.3390/molecules17077887; Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bueno FG, 2012, QUIM NOVA, V35, P822, DOI 10.1590/S0100-40422012000400031; Bueno FG, 2014, FITOTERAPIA, V99, P252, DOI 10.1016/j.fitote.2014.10.007; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Chopda M., 2009, ETHNOBOT LEAFL, V2009, P1; DAYAN D, 1989, HISTOCHEMISTRY, V93, P27, DOI 10.1007/BF00266843; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39; Gantwerker EA, 2011, FACIAL PLAST SURG CL, V19, P441, DOI 10.1016/j.fsc.2011.06.009; Gentleman E, 2003, BIOMATERIALS, V24, P3805, DOI 10.1016/S0142-9612(03)00206-0; Goncalves RV, 2010, BRAZ J MED BIOL RES, V43, P350, DOI 10.1590/S0100-879X2010007500022; Gulcin I, 2010, ARAB J CHEM, V3, P43, DOI 10.1016/j.arabjc.2009.12.008; Gupta A, 2008, WOUND REPAIR REGEN, V16, P784, DOI 10.1111/j.1524-475X.2008.00431.x; Gupta VK, 1999, PHARMACEUT RES, V16, P1602, DOI 10.1023/A:1018916907263; Hernandes L, 2010, BRAZ J PHARM SCI, V46, P431, DOI 10.1590/S1984-82502010000300005; Kanta Jiri, 2011, Acta Medica (Hradec Kralove), V54, P97; Kapoor M, 2004, AM J PATHOL, V165, P299, DOI 10.1016/S0002-9440(10)63297-X; Kayano ACAV, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-112; Khare CP, 2004, INDIAN HERBAL REMEDI; Kumara B, 2007, J ETHNOPHARMACOL, V114, P103, DOI 10.1016/j.jep.2007.08.010; MUJAGIC H, 1983, CANCER RES, V43, P3591; Nayak BS, 2009, EVID-BASED COMPL ALT, V6, P351, DOI 10.1093/ecam/nem127; Patil K. S., 2005, Journal of Natural Remedies, V5, P26; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Ratnam DV, 2006, J CONTROL RELEASE, V113, P189, DOI 10.1016/j.jconrel.2006.04.015; Rocha JCB, 2007, ANAL CHIM ACTA, V587, P132, DOI 10.1016/j.aca.2007.01.002; Sano H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050212; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004; Schmidt C, 2009, J ETHNOPHARMACOL, V122, P523, DOI 10.1016/j.jep.2009.01.022; Schreml S, 2010, EXP DERMATOL, V19, P222; Sehn E, 2009, ANAL CHIM ACTA, V635, P115, DOI 10.1016/j.aca.2009.01.019; Silva-Corazza PER, 2010, LAT AM J PHARM, V29, P830; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smith AN, 2010, EXP CELL RES, V316, P48, DOI 10.1016/j.yexcr.2009.08.001; Tam JCW, 2011, J ETHNOPHARMACOL, V134, P831, DOI 10.1016/j.jep.2011.01.032; Tandara AA, 2004, WORLD J SURG, V28, P294, DOI 10.1007/s00268-003-7400-2; Tawaha K, 2007, FOOD CHEM, V104, P1372, DOI 10.1016/j.foodchem.2007.01.064; Tewtrakul S, 2015, PHYTOTHER RES, V29, P850, DOI 10.1002/ptr.5321; Velnar T, 2009, J INT MED RES, V37, P1528, DOI 10.1177/147323000903700531; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; Walter MNM, 2010, EXP CELL RES, V316, P1271, DOI 10.1016/j.yexcr.2010.02.026; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835	51	13	13	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0149223	10.1371/journal.pone.0149223	http://dx.doi.org/10.1371/journal.pone.0149223			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938058	Green Published, Green Submitted, gold			2023-01-03	WOS:000371735200017
J	Chen, YZ; Zhang, W; Huang, YK; Gao, F; Fang, XL				Chen, Yanzuo; Zhang, Wei; Huang, Yukun; Gao, Feng; Fang, Xiaoling			In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide	PLOS ONE			English	Article							CELL LUNG-CANCER; MIXED MICELLES; MULTIDRUG-RESISTANCE; BREAST-CANCER; POLYMER THERAPEUTICS; BLOCK-COPOLYMERS; P-GLYCOPROTEIN; DELIVERY; DRUG; RGD	The treatment of squamous carcinoma, especially multidrug resistance (MDR) tumors, represents one of the most formidable challenges in oncology. In this study, integrin-mediated Pluronic-based micellar system (c(RGDyK)-FP-DP) was proposed as a drug delivery system to enhance the in vivo anti-tumor efficacy in MDR human squamous carcinoma (KBv)bearing. Following the recognition by integrin proteins express on the cell surface, cellular uptake and in vitro anti-tumor efficacy of c(RGDyK)-FP-DP were better than conventional PF-DP in KBv cells. The tumor homing specificity and further in vivo anticancer efficacy of c (RGDyK)-FP-DP were performed using subcutaneous KBv tumor-bearing mice model, respectively. Compared with PF-DP, c(RGDyK)-FP-DP demonstrated more drug accumulation in tumor and relatively less drug accumulation in heart, and an extended median survival time in the KBv tumor-bearing mice model. Furthermore, preliminary in vivo subacute toxicity evaluation was also conducted by the measurement of histopathology, blood cell counts and clinical biochemistry parameters. Results showed that no obvious toxicity was observed to the hematological system or heart after a series of intravenous administration of c(RGDyK)-FP-DP. In conclusion, our results suggested that c(RGDyK) peptide conjugated Pluronic micelles could be a promising vehicle for enhancing the treatment of MDR human squamous carcinoma.	[Chen, Yanzuo; Huang, Yukun; Gao, Feng] E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut, Shanghai 200237, Peoples R China; [Chen, Yanzuo; Zhang, Wei; Fang, Xiaoling] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery, Minist Educ, Shanghai 201203, Peoples R China; [Chen, Yanzuo; Zhang, Wei; Fang, Xiaoling] Fudan Univ, Sch Pharm, PLA, Shanghai 201203, Peoples R China; [Chen, Yanzuo] Fudan Univ, State Key Lab Mol Engn Polymers, Dept Macromol Sci, Shanghai 200433, Peoples R China; [Zhang, Wei] Eastern Virginia Med Sch, Dept Obstet & Gynecol, CONRAD, Arlington, VA 22209 USA	East China University of Science & Technology; Fudan University; Fudan University; Fudan University; Eastern Virginia Medical School	Chen, YZ (corresponding author), E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut, Shanghai 200237, Peoples R China.; Chen, YZ; Fang, XL (corresponding author), Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery, Minist Educ, Shanghai 201203, Peoples R China.; Chen, YZ; Fang, XL (corresponding author), Fudan Univ, Sch Pharm, PLA, Shanghai 201203, Peoples R China.; Chen, YZ (corresponding author), Fudan Univ, State Key Lab Mol Engn Polymers, Dept Macromol Sci, Shanghai 200433, Peoples R China.	chenyz@ecust.edu.cn; xlfang@shmu.edu.cn			National Natural Science Foundation of China [30901862]; Postdoctoral Science Foundation of China [2014M550222]; Shanghai Postdoctoral Sustentation Fund [14R21410500]; National Basic Research Program of China [2013CB932500]; Fundamental Research Funds for the Central Universities [22A201514055 ECUST]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); Shanghai Postdoctoral Sustentation Fund; National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (30901862) (http://www.nsfc.gov.cn/publish/portal1/) (YC) who had a role in the decision to publish, preparation of the manuscript; the Postdoctoral Science Foundation of China (2014M550222) (http://jj.chinapostdoctor.org.cn/V1/Program1/Default.aspx) (YC) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; the Shanghai Postdoctoral Sustentation Fund (14R21410500) (http://www.stcsm.gov.cn/) (YC) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; the National Basic Research Program of China (2013CB932500) (http://www.most.gov.cn/) (XF) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; and the Fundamental Research Funds for the Central Universities (22A201514055 ECUST) (http://www.moe.gov.cn/) (FG) who had a role in the decision to publish.	AbuHammad S, 2013, GENOMICS, V101, P213, DOI 10.1016/j.ygeno.2012.11.009; Ahmed F, 2006, J CONTROL RELEASE, V116, P150, DOI 10.1016/j.jconrel.2006.07.012; Alakhova DY, 2014, MOL PHARMACEUT, V11, P2566, DOI 10.1021/mp500298q; Bais MV, 2015, ORAL ONCOL, V51, P476, DOI 10.1016/j.oraloncology.2015.01.012; Ballas LK, 2014, LANCET ONCOL, V15, P1419, DOI 10.1016/S1470-2045(14)71114-3; Berger W, 2005, J CANCER RES CLIN, V131, P355, DOI 10.1007/s00432-004-0653-9; Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530; Chen LC, 2013, INT J NANOMED, V8, P73, DOI 10.2147/IJN.S38221; Chen YZ, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S86827; Chen YZ, 2015, INT J PHARMACEUT, V488, P44, DOI 10.1016/j.ijpharm.2015.04.048; Chen YZ, 2013, INT J PHARMACEUT, V452, P421, DOI 10.1016/j.ijpharm.2013.05.015; Chen YZ, 2013, INT J NANOMED, V8, P1463, DOI 10.2147/IJN.S42368; Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104; Chuprajob T, 2014, BIOORG MED CHEM LETT, V24, P2839, DOI 10.1016/j.bmcl.2014.04.105; de Hoon JPJ, 2012, BBA-REV CANCER, V1825, P197, DOI 10.1016/j.bbcan.2012.01.001; Eldar-Boock A, 2011, BIOMATERIALS, V32, P3862, DOI 10.1016/j.biomaterials.2011.01.073; Gustafson DL, 2005, CANCER LETT, V220, P161, DOI 10.1016/j.canlet.2004.09.007; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang XY, 2013, BIOMATERIALS, V34, P2969, DOI 10.1016/j.biomaterials.2012.12.049; Jiang XY, 2011, BIOMATERIALS, V32, P9457, DOI 10.1016/j.biomaterials.2011.08.055; Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3; Lee S, 2012, J CONTROL RELEASE, V164, P213, DOI 10.1016/j.jconrel.2012.05.043; Liu Y, 2010, MOL PHARMACEUT, V7, P863, DOI 10.1021/mp100012s; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Mahajan V, 2012, MOL THERAPY; Mei L, 2014, INT J PHARMACEUT, V468, P26, DOI 10.1016/j.ijpharm.2014.04.008; Qiu LY, 2006, PHARM RES-DORDR, V23, P1, DOI 10.1007/s11095-005-9046-2; Retsky M, 2001, BREAST CANCER RES TR, V65, P217, DOI 10.1023/A:1010626302152; Sakurai Y, 2014, J CONTROL RELEASE, V173, P110, DOI 10.1016/j.jconrel.2013.10.003; Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang YZ, 2007, INT J PHARM, V337, P63, DOI 10.1016/j.ijpharm.2006.12.033; Wei Z, 2013, EUR J PHARM BIOPHARM, V83, P266, DOI 10.1016/j.ejpb.2012.09.014; Wei Z, 2010, EUR J PHARM BIOPHARM, V75, P341, DOI 10.1016/j.ejpb.2010.04.017; Wei Z, 2009, INT J PHARMACEUT, V376, P176, DOI 10.1016/j.ijpharm.2009.04.030; WEISBLUM B, 1974, CHROMOSOMA, V46, P255; Yi X, 2014, J CONTROL RELEASE, V191, P34, DOI 10.1016/j.jconrel.2014.05.044; Zhang W, 2011, BIOMATERIALS, V32, P5934, DOI 10.1016/j.biomaterials.2011.04.075; Zhang W, 2011, BIOMATERIALS, V32, P2894, DOI 10.1016/j.biomaterials.2010.12.039	41	19	21	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0149952	10.1371/journal.pone.0149952	http://dx.doi.org/10.1371/journal.pone.0149952			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5ZW	26930626	Green Submitted, Green Published, gold			2023-01-03	WOS:000371434500076
J	Zhou, J; Li, X; Huang, KC; Jia, Y; Tang, FX; Sun, HY; Zhang, Y; Zhang, QH; Ma, D; Li, S				Zhou, Jin; Li, Xiong; Huang, Kecheng; Jia, Yao; Tang, Fangxu; Sun, Haiying; Zhang, Yuan; Zhang, Qinghua; Ma, Ding; Li, Shuang			Young Cervical Cancer Patients May Be More Responsive than Older Patients to Neoadjuvant Chemotherapy Followed by Radical Surgery	PLOS ONE			English	Article							STAGE IB; ONCOLOGY-GROUP; CARCINOMA; WOMEN; TRIAL; HYSTERECTOMY; PROGNOSIS; SURVIVAL; JAPAN; AGE	Objective To evaluate the effects of age and the clinical response to neoadjuvant chemotherapy (NACT) in patients with cervical cancer who received neoadjuvant chemotherapy followed by radical surgery. Methods A total of 1,014 patients with advanced cervical cancer who received NACT followed by radical surgery were retrospectively selected. Patients were divided into young (aged <= 35 years, n = 177) and older (aged >35 years, n = 837) groups. We compared the short-term responses and survival rates between the groups. The five-year disease-free survival (DFS) and overall survival (OS) rates were stratified by age, NACT response, and FIGO stage. Results The overall response rate was 86.8% in the young group and 80.9% in the older group. The young patients had an earlier FIGO stage (P<0.001), a higher rate of adenocarcinoma (P = 0.022), and more lymph node metastasis (P = 0.033) than the older patients. The presence of adenocarcinoma as the histological type (P = 0.024) and positive lymph node metastasis (P<0.001) were identified as independent risk factors for survival. When stratified by age and clinical response, young patients with no response to NACT had a worse clinicopathological condition compared with the other subgroups. Compared with non-responders, responders to NACT had a higher five-year DFS rate (80.1% versus 71.8%; P = 0.019) and OS rate (82.6% versus 71.8%; P = 0.003) among the young patients but not among the older patients. Conclusions Responders to NACT aged 35 years or younger benefitted the most from NACT, while the young non-responders benefitted the least. Age might represent an important factor to consider when performing NACT in patients with cervical cancer.	[Zhou, Jin; Li, Xiong; Huang, Kecheng; Jia, Yao; Tang, Fangxu; Sun, Haiying; Ma, Ding; Li, Shuang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China; [Zhou, Jin] Wuhan Univ, Ctr Canc, Renmin Hosp, Wuhan 430072, Hubei, Peoples R China; [Li, Xiong; Zhang, Qinghua] Cent Hosp Wuhan, Dept Gynecol & Obstet, Wuhan, Peoples R China; [Zhang, Yuan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology	Ma, D; Li, S (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China.; Zhang, QH (corresponding author), Cent Hosp Wuhan, Dept Gynecol & Obstet, Wuhan, Peoples R China.	zhangqh66@qq.com; dma@tjh.tjmu.edu.cn; lee5190008@126.com	li, xiong/ABG-2578-2020	li, xiong/0000-0003-0203-2973; Li, Shuang/0000-0002-9193-0320	Key Basic Research and Development Program Foundation of China (973 Program) [2015CB553903]; National Natural Science Foundation of China [91529102, 81572571, 81402160, 81302267, 81230038, 81230052, 30973472, 81001151, 81071663, 30973205, 30973184, 81090414, 81272422, 81172464, 81101964]	Key Basic Research and Development Program Foundation of China (973 Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was endorsed by the Key Basic Research and Development Program Foundation of China (973 Program; No. 2015CB553903) and was supported by grants from the National Natural Science Foundation of China (NO. 91529102; 81572571; 81402160; 81302267; 81230038; 81230052; 30973472; 81001151; 81071663; 30973205; 30973184; 81090414; 81272422; 81172464; 81101964).	[Anonymous], 2012, GLOBACAN 2012 DAT CE; Aoki Y, 2001, GYNECOL ONCOL, V83, P263, DOI 10.1006/gyno.2001.6371; Bamias A, 2005, ANN ONCOL, V16, P307, DOI 10.1093/annonc/mdi039; Benedetti-Panici P, 2002, J CLIN ONCOL, V20, P179, DOI 10.1200/JCO.20.1.179; Buda A, 2015, INT J GYNECOL CANCER, V25, P1468, DOI 10.1097/IGC.0000000000000515; Cai HB, 2010, INT J GYNECOL CANCER, V20, P1240, DOI 10.1111/IGC.0b013e3181ecec79; Chang TC, 2000, J CLIN ONCOL, V18, P1740, DOI 10.1200/JCO.2000.18.8.1740; Chemoradiotherapy for cervical cancer meta-analysis collaboration, 2008, J CLIN ONCOL, V26, P5802, DOI DOI 10.1200/JCO.2008.16.4368; Chen HJ, 2008, GYNECOL ONCOL, V110, P308, DOI 10.1016/j.ygyno.2008.05.026; deSouza NM, 2004, BRIT J CANCER, V90, P2326, DOI 10.1038/sj.bjc.6601870; HALL SW, 1983, LANCET, V2, P731; Hu T, 2012, EUR J CANCER, V48, P2353, DOI 10.1016/j.ejca.2012.03.015; Huang HJ, 2003, INT J GYNECOL CANCER, V13, P204, DOI 10.1046/j.1525-1438.2003.13004.x; Katsumata N, 2013, BRIT J CANCER, V108, P1957, DOI 10.1038/bjc.2013.179; Kokawa K, 2010, EUR J GYNAECOL ONCOL, V31, P37; Lai CH, 1999, INT J GYNECOL CANCER, V9, P28; Lau HY, 2009, INT J GYNECOL OBSTET, V107, P220, DOI 10.1016/j.ijgo.2009.07.029; Li S, 2013, ONCOLOGIST, V18, P1101, DOI 10.1634/theoncologist.2013-0123; Look KY, 1997, GYNECOL ONCOL, V67, P255, DOI 10.1006/gyno.1997.4886; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P107, DOI 10.1016/j.ijgo.2009.02.009; POKA R, 1994, INT J GYNECOL OBSTET, V46, P33, DOI 10.1016/0020-7292(94)90306-9; STANHOPE CR, 1980, GYNECOL ONCOL, V10, P188, DOI 10.1016/0090-8258(80)90080-3; Wang J, 2015, MOL CLIN ONCOL, V3, P363, DOI 10.3892/mco.2014.465; Wen H, 2012, INT J GYNECOL CANCER, V22, P296, DOI 10.1097/IGC.0b013e31823610a1; World Health Organization, 1979, WHO HDB REP RES CANC, P16	25	2	4	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149534	10.1371/journal.pone.0149534	http://dx.doi.org/10.1371/journal.pone.0149534			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901776	Green Published, gold, Green Submitted			2023-01-03	WOS:000371276100094
J	Buckley, NA; Dawson, AH; Isbister, GK				Buckley, Nicholas A.; Dawson, Andrew H.; Isbister, Geoffrey K.			Treatments for paracetamol poisoning	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACTIVATED-CHARCOAL; INTRAVENOUS ACETYLCYSTEINE; N-ACETYLCYSTEINE; MULTICENTER; TRIAL		[Buckley, Nicholas A.; Dawson, Andrew H.; Isbister, Geoffrey K.] NSW Poisons Informat Ctr, Sydney, NSW, Australia; [Buckley, Nicholas A.; Dawson, Andrew H.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Buckley, Nicholas A.; Dawson, Andrew H.] Royal Prince Alfred Hosp, Dept Clin Toxicol, Sydney, NSW, Australia; [Isbister, Geoffrey K.] Univ Newcastle, Clin Toxicol Res Grp, Newcastle, NSW 2300, Australia	University of Sydney; University of Sydney; University of Newcastle	Buckley, NA (corresponding author), NSW Poisons Informat Ctr, Sydney, NSW, Australia.; Buckley, NA (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.; Buckley, NA (corresponding author), Royal Prince Alfred Hosp, Dept Clin Toxicol, Sydney, NSW, Australia.	Nicholas.buckley@sydney.edu.au	Isbister, Geoffrey K/G-8052-2015; Dawson, Andrew H/U-8041-2019; Buckley, Nicholas A/D-4030-2012	Isbister, Geoffrey K/0000-0003-1519-7419; Dawson, Andrew H/0000-0002-8047-397X; Buckley, Nicholas A/0000-0002-6326-4711				18th Expert Committee on the Selection and Use of Essential Medicines, 2011, 18 EXP COMM SEL US E; Bateman DN, 2014, BRIT J CLIN PHARMACO, V78, P610, DOI 10.1111/bcp.12362; Bateman DN, 2014, LANCET, V383, P697, DOI 10.1016/S0140-6736(13)62062-0; Brok J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003328.pub2; Buckley NA, 1999, J TOXICOL-CLIN TOXIC, V37, P753, DOI 10.1081/CLT-100102452; CLARK R, 1973, LANCET, V1, P66; Cooper GM, 2005, QJM-INT J MED, V98, P655, DOI 10.1093/qjmed/hci102; Eddleston M, 2008, LANCET, V371, P579, DOI 10.1016/S0140-6736(08)60270-6; Ferner RE, 2001, BRIT J CLIN PHARMACO, V52, P573, DOI 10.1046/j.0306-5251.2001.01490.x; Gosselin S, 2014, CLIN TOXICOL, V52, P856, DOI 10.3109/15563650.2014.946994; Humphreys RA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2043; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; Kerr F, 2005, ANN EMERG MED, V45, P402, DOI 10.1016/j.annemergmed.2004.08.040; Medicines and Healthcare Products Regulatory Agency, 2016, TREAT PAR OV INTR AC; Pakravan N, 2008, CLIN TOXICOL, V46, P697, DOI 10.1080/15563650802245497; Park B Kevin, 2015, BMJ Clin Evid, V2015; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; Sandilands EA, 2009, CLIN TOXICOL, V47, P81, DOI 10.1080/15563650802665587; Senarathna S M D K Ganga, 2012, BMC Clin Pharmacol, V12, P6, DOI 10.1186/1472-6904-12-6; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Spiller HA, 2007, J EMERG MED, V33, P141, DOI 10.1016/j.jemermed.2007.02.016; Thanacoody HKR, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-20; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; Wong A, 2016, CLIN TOXICOL, V54, P115, DOI 10.3109/15563650.2015.1115055	24	9	9	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	2016	353								i2579	10.1136/bmj.i2579	http://dx.doi.org/10.1136/bmj.i2579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GC	27193197				2023-01-03	WOS:000376447600001
J	Guancial, EA; Kilari, D; Xiao, GQ; Abu-Farsakh, SH; Baran, A; Messing, EM; Kim, ES				Guancial, Elizabeth A.; Kilari, Deepak; Xiao, Guang-Qian; Abu-Farsakh, Sohaib H.; Baran, Andrea; Messing, Edward M.; Kim, Eric S.			Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer	PLOS ONE			English	Article							COPPER TRANSPORTER CTR1; UROTHELIAL CARCINOMA; EXPRESSION; METHOTREXATE; GEMCITABINE; VINBLASTINE; DOXORUBICIN; CYSTECTOMY; ERCC1	Background Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC. Methods A cohort of 19 clinically annotated, archived, fresh frozen RC specimens from patients with MIBC treated with Pt-based NAC was identified [ypT0 (pathologic complete response, pCR), N = 4; <= ypT1N0M0 (pathologic partial response, pPR), N = 6; >= ypT2 (minimal pathologic response/progression), N = 9)]. RC specimens from 2 patients with MIBC who did not receive NAC and 1 treated with a non-Pt containing NAC regimen were used as negative controls. Total Pt concentration in normal adjacent urothelial tissue and bladder tumors from RC specimens was measured by flameless atomic absorption spectrophotometry. Results Total Pt concentration in normal urothelium differed by tumor pathologic response (P = 0.011). Specimens with pCR had the highest Pt concentrations compared to those with pPR (P = 0.0095) or no response/progression (P = 0.020). There was no significant difference in Pt levels in normal urothelium and tumor between pPR and no response/progression groups (P = 0.37; P = 0.25, respectively). Conclusions: Our finding of increased intracellular Pt in RC specimens with pCR following NAC for MIBC compared to those with residual disease suggests that enhanced Pt accumulation may be an important determinant of Pt sensitivity. Factors that modulate intracellular Pt concentration, such as expression of Pt transporters, warrant further investigation as predictive biomarkers of response to Pt-based NAC in MIBC.	[Guancial, Elizabeth A.; Kim, Eric S.] Univ Rochester, Dept Med, James P Wilmot Canc Inst, Rochester, NY USA; [Kilari, Deepak] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Xiao, Guang-Qian; Abu-Farsakh, Sohaib H.] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA; [Baran, Andrea] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA; [Messing, Edward M.] Univ Rochester, Dept Urol, Rochester, NY USA	University of Rochester; Medical College of Wisconsin; University of Rochester; University of Rochester; University of Rochester	Guancial, EA (corresponding author), Univ Rochester, Dept Med, James P Wilmot Canc Inst, Rochester, NY USA.	elizabeth_guancial@urmc.rochester.edu		Baran, Andrea/0000-0002-7975-8919; Guancial, Elizabeth/0000-0002-6518-5179	Wilmot Cancer Institute Investigator Award Program at the University of Rochester Medical Center	Wilmot Cancer Institute Investigator Award Program at the University of Rochester Medical Center	ESK received institutional funding for this project through the Wilmot Cancer Institute Investigator Award Program at the University of Rochester Medical Center. (No grant number or URL available.) The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Als AB, 2008, ACTA ONCOL, V47, P110, DOI 10.1080/02841860701499382; [Anonymous], 1999, Lancet, V354, P533; Baras AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131245; Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435; Bellmunt J, 2010, J CLIN ONCOL, V28, P1850, DOI 10.1200/JCO.2009.25.4599; Bono AV, 2005, EUR UROL, V48, P189, DOI 10.1016/j.eururo.2005.04.005; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Cai Y, 2015, ONCOTARGET, DOI 10.18632/oncotarget.3620; Choueiri TK, 2014, J CLIN ONCOL, V32, P1889, DOI 10.1200/JCO.2013.52.4785; Dinney CPN, 2014, UROL ONCOL-SEMIN ORI, V32, P1108, DOI 10.1016/j.urolonc.2013.10.021; Font A, 2011, ANN ONCOL, V22, P139, DOI 10.1093/annonc/mdq333; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Kassouf W, 2007, EUR UROL, V52, P769, DOI 10.1016/j.eururo.2007.03.086; Kilari D, 2016, ANTICANCER RES, V36, P495; Kim ES, 2014, LUNG CANCER, V85, P88, DOI 10.1016/j.lungcan.2014.04.005; Kim ES, 2012, J CLIN ONCOL, V30, P3345, DOI 10.1200/JCO.2011.40.8120; Kim KH, 2010, APMIS, V118, P941, DOI 10.1111/j.1600-0463.2010.02648.x; Kim M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133371; Klatte T., 2015, J UROL; Koga H, 2000, INT J ONCOL, V16, P1003; Landon CD, 2013, INT J HYPERTHER, V29, P528, DOI 10.3109/02656736.2013.790563; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; Mustacchi G, 2015, CRIT REV ONCOL HEMAT, V95, P78, DOI 10.1016/j.critrevonc.2015.02.002; Petrelli F, 2014, EUR UROL, V65, P350, DOI 10.1016/j.eururo.2013.06.049; Samimi G, 2004, MOL PHARMACOL, V66, P25, DOI 10.1124/mol.66.1.25; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Schmid SC, 2013, ANTICANCER RES, V33, P3731; Sfakianos JP, 2015, UROL CLIN N AM, V42, P181, DOI 10.1016/j.ucl.2015.01.002; SIDDIK ZH, 1987, ANAL BIOCHEM, V163, P21, DOI 10.1016/0003-2697(87)90087-X; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068	31	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2016	11	5							e0155503	10.1371/journal.pone.0155503	http://dx.doi.org/10.1371/journal.pone.0155503			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3YJ	27187160	gold, Green Published			2023-01-03	WOS:000376282300040
J	Maiguy-Foinard, A; Blanchemain, N; Barthelemy, C; Decaudin, B; Odou, P				Maiguy-Foinard, Aurelie; Blanchemain, Nicolas; Barthelemy, Christine; Decaudin, Bertrand; Odou, Pascal			Influence of a Double-Lumen Extension Tube on Drug Delivery: Examples of Isosorbide Dinitrate and Diazepam	PLOS ONE			English	Article							CERTIFIED REFERENCE MATERIALS; POLYVINYL-CHLORIDE; FLOW-RATE; INFUSION; STERILIZATION; NITROGLYCERIN; FEASIBILITY; IRRADIATION; MIGRATION; PHTHALATE	Purpose Plastic materials such as polyurethane (PUR), polyethylene (PE), polypropylene (PP) and polyvinyl chloride (PVC) are widely used in double-lumen extension tubing. The purposes of our study were to 1) compare in vitro drug delivery through the double extension tubes available on the market 2) assess the plastic properties of PUR in infusion devices and their impact on drug delivery. Methods The study compared eight double-lumen extension tubes in PUR, co-extruded (PE/PVC) plastic and plasticised PVC from different manufacturers. Isosorbide dinitrate and diazepam were used as model compounds to evaluate their sorption on the internal surface of the infusion device. Control experiments were performed using norepinephrine known not to absorb to plastics. Drug concentrations delivered at the egress of extension tubes were determined over time by an analytical spectrophotometric UV-Vis method. The main characteristics of plastics were also determined. Results Significant differences in the sorption phenomenon were observed among the eight double-lumen extension tubes and between pairs of extension tubes. Mean concentrations of isosorbide dinitrate delivered at the egress of double-lumen extension tubes after a 150-minute infusion (mean values +/- standard deviation in percentage of the initial concentrations in the prepared syringes) ranged between 80.53 +/- 1.66 (one of the PUR tubes) and 92.84 +/- 2.73 (PE/PVC tube). The same parameters measured during diazepam infusion ranged between 48.58 +/- 2.88 (one of the PUR tubes) and 85.06 +/- 3.94 (PE/PVC tube). The double-lumen extension tubes in PUR were either thermosetting (resin) or thermoplastic according to reference. Conclusions Clinicians must be aware of potential drug interactions with extension tube materials and so must consider their nature as well as the sterilisation method used before selecting an infusion device.	[Maiguy-Foinard, Aurelie; Barthelemy, Christine; Decaudin, Bertrand; Odou, Pascal] Univ Lille, EA 7365, GRITA, Grp Rech Formes Injectables & Technol Associees, F-59000 Lille, France; [Maiguy-Foinard, Aurelie; Decaudin, Bertrand; Odou, Pascal] CHU Lille, Inst Pharm, F-59000 Lille, France; [Blanchemain, Nicolas] Univ Lille, F-59000 Lille, France; [Blanchemain, Nicolas] INSERM, U1008, Controlled Drug Delivery Syst & Biomat, F-59000 Lille, France	Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Decaudin, B (corresponding author), Univ Lille, EA 7365, GRITA, Grp Rech Formes Injectables & Technol Associees, F-59000 Lille, France.; Decaudin, B (corresponding author), CHU Lille, Inst Pharm, F-59000 Lille, France.	bertrand.decaudin@univ-lille2.fr	Nicolas, Blanchemain/GWV-3651-2022; BARTHELEMY, Christine/A-8968-2017; Decaudin, Bertrand/E-5828-2010	BARTHELEMY, Christine/0000-0001-9774-1857; Decaudin, Bertrand/0000-0001-8267-5594	Department of Biopharmacy, Galenic and Hospital Pharmacy, Lille 2 University, UDSL, EA GRIIOT, UFR Pharmacie, Lille, France	Department of Biopharmacy, Galenic and Hospital Pharmacy, Lille 2 University, UDSL, EA GRIIOT, UFR Pharmacie, Lille, France	This study was funded by intramural funds from the Department of Biopharmacy, Galenic and Hospital Pharmacy, Lille 2 University, UDSL, EA GRIIOT, UFR Pharmacie, Lille, France.	Al Salloum H, 2015, INT J PHARM, VS0378-5173, P30353; Baccaro S, 2003, NUCL INSTRUM METH B, V208, P195, DOI 10.1016/S0168-583X(03)00886-3; Bartels K, 2009, ANESTH ANALG, V109, P1156, DOI 10.1213/ane.0b013e3181b220c9; da Silva FF, 2008, POLYM DEGRAD STABIL, V93, P2199, DOI 10.1016/j.polymdegradstab.2008.07.024; Decaudin B, 2009, ANESTH ANALG, V109, P1147, DOI 10.1213/ane.0b013e3181ae06e3; DEMUYNCK C, 1993, J PHARM PHARMACOL, V45, P139; Foinard A, 2013, Ann Fr Anesth Reanim, V32, pe107, DOI 10.1016/j.annfar.2013.06.017; Goullet D, 1992, Agressologie, V33 Spec No 3, P121; Hewson MP, 2000, J PAEDIATR CHILD H, V36, P216, DOI 10.1046/j.1440-1754.2000.00488.x; Hsieh Kuo-Huang, 1997, HDB THERMOPLASTICS, V16, P381; Jenke D, 2002, PDA J PHARM SCI TECH, V56, P332; Kambia NK, 2005, J PHARMACEUT BIOMED, V37, P259, DOI 10.1016/j.jpba.2004.10.020; Lovich MA, 2005, ANESTH ANALG, V100, P1048, DOI 10.1213/01.ANE.0000146942.51020.88; MARTENS HJ, 1990, AM J HOSP PHARM, V47, P369, DOI 10.1093/ajhp/47.2.369; Matthews I. P., 1994, Clinical Materials, V15, P191, DOI 10.1016/0267-6605(94)90082-5; Murray KA, 2013, EUR POLYM J, V49, P1782, DOI 10.1016/j.eurpolymj.2013.03.034; Nair PD, 1995, J BIOMATER APPL, V10, P121, DOI 10.1177/088532829501000203; SHINTANI H, 1995, J BIOMATER APPL, V10, P23, DOI 10.1177/088532829501000102; SHINTANI H, 1989, J ANAL TOXICOL, V13, P354, DOI 10.1093/jat/13.6.354; Shintani H, 1995, Biomed Instrum Technol, V29, P513; Stoffers NH, 2005, FOOD ADDIT CONTAM, V22, P173, DOI 10.1080/02652030400028076; Stoffers NH, 2004, FOOD ADDIT CONTAM, V21, P1203, DOI 10.1080/02652030400023911; Takehisa H, 2005, INT J PHARMACEUT, V297, P30, DOI 10.1016/j.ijpharm.2005.02.015; Tickner JA, 2001, AM J IND MED, V39, P100, DOI 10.1002/1097-0274(200101)39:1<100::AID-AJIM10>3.0.CO;2-Q; Treleano A, 2009, INT J PHARMACEUT, V369, P30, DOI 10.1016/j.ijpharm.2008.10.024; YLIRUUSI JK, 1982, AM J HOSP PHARM, V39, P1018, DOI 10.1093/ajhp/39.6.1018; YLIRUUSI JK, 1986, AM J HOSP PHARM, V43, P2795, DOI 10.1093/ajhp/43.11.2795; Zahid Najam, 2008, Diabetes Res Clin Pract, V80, pe11, DOI 10.1016/j.diabres.2008.02.013	28	8	8	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154917	10.1371/journal.pone.0154917	http://dx.doi.org/10.1371/journal.pone.0154917			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	27153224	Green Published, gold			2023-01-03	WOS:000375677000046
J	Nakibuuka, J; Sajatovic, M; Nankabirwa, J; Ssendikadiwa, C; Kalema, N; Kwizera, A; Byakika-Tusiime, J; Furlan, AJ; Kayima, J; Ddumba, E; Katabira, E				Nakibuuka, Jane; Sajatovic, Martha; Nankabirwa, Joaniter; Ssendikadiwa, Charles; Kalema, Nelson; Kwizera, Arthur; Byakika-Tusiime, Jayne; Furlan, Anthony J.; Kayima, James; Ddumba, Edward; Katabira, Elly			Effect of a 72 Hour Stroke Care Bundle on Early Outcomes after Acute Stroke: A Non Randomised Controlled Study	PLOS ONE			English	Article							QUALITY-OF-CARE; SEASONAL-VARIATION; MORTALITY; PATHWAYS; GUIDELINES; IMPACT; PREDICTORS; MANAGEMENT; REGISTERS; COUNCIL	Background Integrated care pathways (ICP) in stroke management are increasingly being implemented to improve outcomes of acute stroke patients. We evaluated the effect of implementing a 72 hour stroke care bundle on early outcomes among patients admitted within seven days post stroke to the national referral hospital in Uganda. Methods In a one year non-randomised controlled study, 127 stroke patients who had 'usual care' (control group) were compared to 127 stroke patients who received selected elements from an ICP (intervention group). Patients were consecutively enrolled (controls first, intervention group second) into each group over 5 month periods and followed to 30-days post stroke. Incidence outcomes (mortality and functional ability) were compared using chi square test and adjusted for potential confounders. Kaplan Meier survival estimates and log rank test for comparison were used for time to death analysis for all strokes and by stroke severity categories. Secondary outcomes were in-hospital mortality, median survival time and median length of hospital stay. Results Mortality within 7 days was higher in the intervention group compared to controls (RR 13.1, 95% CI 3.3-52.9). There was no difference in 30-day mortality between the two groups (RR 1.2, 95% CI 0.5-2.6). There was better 30-day survival in patients with severe stroke in the intervention group compared to controls (P = 0.018). The median survival time was 30 days (IQR 29-30 days) in the control group and 30 days (IQR 7-30 days) in the intervention group. In the intervention group, 41patients (32.3%) died in hospital compared to 23 (18.1%) in controls (P < 0.001). The median length of hospital stay was 8 days (IQR 5-12 days) in the controls and 4 days (IQR 2-7 days) in the intervention group. There was no difference in functional outcomes between the groups (RR 0.9, 95% CI 0.4-2.2). Conclusions While implementing elements of a stroke-focused ICP in a Ugandan national referral hospital appeared to have little overall benefit in mortality and functioning, patients with severe stroke may benefit on selected outcomes. More research is needed to better understand how and when stroke protocols should be implemented in sub-Saharan African settings.	[Nakibuuka, Jane; Nankabirwa, Joaniter; Kayima, James; Katabira, Elly] Makerere Univ, Dept Med, Sch Med, Coll Hlth Sci, Kampala, Uganda; [Sajatovic, Martha] Univ Hosp Case Med Ctr, Neurol & Behav Outcomes Ctr, Cleveland, OH USA; [Nakibuuka, Jane; Ssendikadiwa, Charles; Kalema, Nelson] Mulago Natl Referral Hosp, Dept Med, Kampala, Uganda; [Kwizera, Arthur] Makerere Univ, Dept Anaesthesia & Crit Care, Sch Med, Coll Hlth Sci, Kampala, Uganda; [Byakika-Tusiime, Jayne] Makerere Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Coll Hlth Sci, Kampala, Uganda; [Furlan, Anthony J.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Neurol Inst, Cleveland, OH 44106 USA; [Ddumba, Edward] Nkozi Univ, St Raphael St Francis Nsambya Hosp, Dept Med, Kampala, Uganda	Makerere University; Case Western Reserve University; Case Western Reserve University Hospital; Mulago National Referral Hospital; Makerere University; Makerere University; Case Western Reserve University; Case Western Reserve University Hospital	Nakibuuka, J (corresponding author), Makerere Univ, Dept Med, Sch Med, Coll Hlth Sci, Kampala, Uganda.; Nakibuuka, J (corresponding author), Mulago Natl Referral Hosp, Dept Med, Kampala, Uganda.	nakibuukajm@yahoo.com	Kalema, Nelson/AAZ-5730-2020	Kalema, Nelson/0000-0002-7118-704X; Kwizera, Arthur/0000-0002-7025-0465	Fogarty International Center; National Heart Lung and Blood Institute; National Institutes of Health [5R24 TW008861]; FOGARTY INTERNATIONAL CENTER [R24TW008861] Funding Source: NIH RePORTER	Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Research reported in this publication was supported by the Fogarty International Center, the National Heart Lung and Blood Institute, and the Common Fund of the National Institutes of Health under Award Number 5R24 TW008861. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Allen D, 2008, INT J EVID-BASED HEA, V6, P78, DOI [10.1111/j.1744-1609.2007.00098.x, 10.1111/j.1479-6988.2007.00098.x]; [Anonymous], 1985, Stroke, V16, P885; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Armstrong R, 2008, J PUBLIC HEALTH-UK, V30, P103, DOI 10.1093/pubmed/fdm082; Ayis SA, 2013, J NEUROL NEUROSUR PS, V84, P604, DOI 10.1136/jnnp-2012-303525; Black N, 1996, BRIT MED J, V312, P1215; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Chow S. C., 2003, SAMPLE SIZE CALCULAT; Collin C, 1988, Int Disabil Stud, V10, P61; Counsell C, 2001, CEREBROVASC DIS, V12, P159, DOI 10.1159/000047699; de Villiers L, 2009, INT J STROKE, V4, P89, DOI 10.1111/j.1747-4949.2009.00254.x; Des Jarlais DC, 2004, AJPH, V94, P3; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Heuschmann PU, 2004, ARCH INTERN MED, V164, P1761, DOI 10.1001/archinte.164.16.1761; Kwan J, 2005, STROKE, V36, P1348, DOI 10.1161/01.STR.0000165900.79946.55; Kwan J, 2004, AGE AGEING, V33, P362, DOI 10.1093/ageing/afh104; Kwan J, 2003, STROKE, V34, P587, DOI 10.1161/01.STR.0000054673.28010.1B; Kwan J, 2007, J CLIN NEUROSCI, V14, P189, DOI 10.1016/j.jocn.2006.01.026; Kwarisiima L, 2014, UGANDA AJNS, V33, P79; Lachin J. M., 2000, WILEY SER PROB STAT; Langhorne P, 2007, CEREBROVASC DIS, V23, P464, DOI 10.1159/000101751; Lichtman JH, 2013, STROKE, V44, P531, DOI 10.1161/STROKEAHA.112.670547; Nakibuuka J, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1252-8; National Health and Medical Research Council, 2009, EM DEP STROK TRANS I; Nor AM, 2005, LANCET NEUROL, V4, P727, DOI 10.1016/S1474-4422(05)70201-5; Panella M, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-223; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; SHEIKH K, 1983, J EPIDEMIOL COMMUN H, V37, P70, DOI 10.1136/jech.37.1.70; Sitoh Y. Y., 2000, SMJ Singapore Medical Journal, V41, P376; Somes J, 2007, J EMERG NURS, V33, P228, DOI 10.1016/j.jen.2006.12.010; Taylor WJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-16; TEASDALE G, 1974, LANCET, V2, P81; Thijs V, 2009, ACTA NEUROL BELG, V109, P247; UNSD, 2014, NAT POP HOUS CENS 20, P17; Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090; Wang Y, 2003, STROKE, V34, P1144, DOI 10.1161/01.STR.0000067703.71251.B6	38	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2016	11	5							e0154333	10.1371/journal.pone.0154333	http://dx.doi.org/10.1371/journal.pone.0154333			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KR	27145035	Green Published, gold, Green Submitted			2023-01-03	WOS:000375676400043
J	Napolitano, F; Napolitano, P; Garofalo, L; Recupito, M; Angelillo, IF				Napolitano, Francesco; Napolitano, Paola; Garofalo, Luca; Recupito, Marianna; Angelillo, Italo F.			Assessment of Continuity of Care among Patients with Multiple Chronic Conditions in Italy	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; MEDICATION ADHERENCE; ELDERLY-PEOPLE; OLDER-ADULTS; HEALTH; HOSPITALIZATION; MORTALITY; OUTCOMES; SYSTEM; COHORT	The aims of the present study were to evaluate the extent of continuity of care and to investigate its association with several factors among a sample of outpatients with chronic diseases in Italy. The survey was conducted, using face to face interview, from March to December 2014 in a random sample of 633 outpatients with chronic conditions who were going in cardiology, metabolic disorders, and respiratory ambulatory center of four hospitals. A multivariate ordered logistic regression model was used to identify factors associated with the outpatients continuity of care. The mean of the Bice-Boxerman continuity of care (COC) index related to the entire sample was 0.44, and 27.9%, 58.4%, 13.7% had a low, intermediate, and high value of the index based on the tertiles of the distribution. The results of the ordered logistic regression analysis showed that female patients, those older, those who had a lower score of Katz Index of independence in activities of daily living, those who had a lower Charlson et al. comorbidity score, and those who had no hospitalization in the last year, were significantly more likely to have a higher value of the COC index. Patients who had completed a secondary school education had significantly lower odds of having a high value of COC index in comparison to patients with a college degree educational level. Policy makers and clinicians involved in the care of patients should implement comprehensively and efficiently efforts in order to improve the continuity of care in patients with chronic diseases.	[Napolitano, Francesco; Napolitano, Paola; Garofalo, Luca; Recupito, Marianna; Angelillo, Italo F.] Univ Naples 2, Dept Expt Med, Via Luciano Armanni, Naples, Italy	Universita della Campania Vanvitelli	Angelillo, IF (corresponding author), Univ Naples 2, Dept Expt Med, Via Luciano Armanni, Naples, Italy.	italof.angelillo@unina2.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; Napolitano, Francesco/0000-0003-4694-2418				Bayliss EA, 2015, ANN FAM MED, V13, P123, DOI 10.1370/afm.1739; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Chan CL, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-405; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen CC, 2013, MED CARE, V51, P231, DOI 10.1097/MLR.0b013e31827da5b9; Chen CC, 2011, AM J MANAG CARE, V17, P420; Cheng SH, 2014, MED CARE, V52, P149, DOI 10.1097/MLR.0000000000000042; Cheng SH, 2011, HEALTH POLICY PLANN, V26, P157, DOI 10.1093/heapol/czq035; Cheng SH, 2010, ARCH INTERN MED, V170, P1671, DOI 10.1001/archinternmed.2010.340; Cho KH, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0745-z; Condelius A, 2008, ARCH GERONTOL GERIAT, V46, P41, DOI 10.1016/j.archger.2007.02.005; Fortney J, 2003, HEALTH SERV RES, V38, P1157, DOI 10.1111/1475-6773.00168; Gjevjon ER, 2014, J ADV NURS, V70, P553, DOI 10.1111/jan.12214; Hanafi NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134030; Hong JS, 2010, J KOREAN MED SCI, V25, P1259, DOI 10.3346/jkms.2010.25.9.1259; Hong JS, 2013, HEALTH POLICY, V109, P158, DOI 10.1016/j.healthpol.2012.09.009; Hussey PS, 2014, JAMA INTERN MED, V174, P742, DOI 10.1001/jamainternmed.2014.245; Ionescu-Ittu R, 2007, CAN MED ASSOC J, V177, P1362, DOI 10.1503/cmaj.061615; Santini ZI, 2015, SOC SCI MED, V147, P134, DOI 10.1016/j.socscimed.2015.10.061; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Leleu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071669; Lin IP, 2015, J AM BOARD FAM MED, V28, P222, DOI 10.3122/jabfm.2015.02.140141; Mazzella F, 2010, ARCH GERONTOL GERIAT, V51, P323, DOI 10.1016/j.archger.2010.01.011; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Napolitano F, 2016, EUR J PUBLIC HEALTH, V26, P48, DOI 10.1093/eurpub/ckv147; Nyqvist F, 2014, INT J BEHAV MED, V21, P337, DOI 10.1007/s12529-013-9307-0; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Pollack CE, 2013, MED CARE; Romano MJ, 2015, JAMA INTERN MED, V175, P1148, DOI 10.1001/jamainternmed.2015.1340; Russell D, 2012, PHYS THER, V92, P227, DOI 10.2522/ptj.20110171; Russell David, 2011, J Healthc Qual, V33, P33, DOI 10.1111/j.1945-1474.2011.00131.x; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Shin DW, 2014, ANN FAM MED, V12, P534, DOI 10.1370/afm.1685; Stata Corporation, 2007, STAT REF MAN REL 10; Steiner CA, 2013, PREV CHRONIC DIS, V10, DOI [10.5888/pcd10.120292e, 10.5888/pcd10.120292]; Tsai HY, 2015, INT J PUBLIC HEALTH, V60, P505, DOI 10.1007/s00038-015-0671-1; Worrall G, 2011, CAN FAM PHYSICIAN, V57, pE16	37	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2016	11	5							e0154940	10.1371/journal.pone.0154940	http://dx.doi.org/10.1371/journal.pone.0154940			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DL5KK	27140202	Green Published, gold, Green Submitted			2023-01-03	WOS:000375675700077
J	Ren, GX; Li, L; Hu, HJ; Li, YP; Liu, CS; Wei, SL				Ren, Guangxi; Li, Li; Hu, Huijuan; Li, Yanpeng; Liu, Chunsheng; Wei, Shengli			Influence of the Environmental Factors on the Accumulation of the Bioactive Ingredients in Chinese Rhubarb Products	PLOS ONE			English	Article							NITROGEN; CONSTITUENTS; ACTIVATION; EMODIN	To provide a basis for controlling the quality of rhubarb under artificial cultivation, the present work was designed to evaluate the contents of 14 active pharmaceutical ingredients (API) of rhubarb in major rhubarb production areas in China and analyze the correlations between the contents of API and such factors as species, geographic distribution and soil. The levels of fourteen API in rhubarb were measured using HPLC. The geographic distributions were collected using GPS and the nutrients in the soil were measured using the methods in the literature. The results showed that the levels of major API vary significantly among plants of different locations according to variance analysis. The species factor has few obvious effect on the overall properties of the rhubarb by the cluster analysis because of the two source species occurring in all divided three groups. However, Rheum tanguticum Maxim. ex Balf. is less effective at synthesizing and accumulating 9 API out of 14 than Rheum palmatum L. The correlation analysis and regression analysis also indicated that a lower latitude should be considered in the accumulation of API and a lower longitude should be considered to produce more compound anthraquinones. Lower levels of total P, rapidly available P and available molybdenum (Mo) and higher available K and available Zn in the soil were significantly correlated to accumulation of API in rhubarb. These results provide a basis for the clinical application and controlling the levels of the major API of rhubarb during artificial cultivation.	[Ren, Guangxi; Hu, Huijuan; Li, Yanpeng; Liu, Chunsheng; Wei, Shengli] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing, Peoples R China; [Li, Li] Capital Med Univ Beijing, Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China; [Li, Li] Beijing Inst Chinese Med, 13 Shuiche Hutong, Beijing, Peoples R China; [Wei, Shengli] Minist Educ, Engn Res Ctr Good Agr Practice Chinese Crude Drug, Beijing, Peoples R China	Beijing University of Chinese Medicine; Capital Medical University	Liu, CS; Wei, SL (corresponding author), Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing, Peoples R China.; Wei, SL (corresponding author), Minist Educ, Engn Res Ctr Good Agr Practice Chinese Crude Drug, Beijing, Peoples R China.	max_liucs@263.net; wsl7491@126.com		wei, shengli/0000-0003-1442-7120	National Natural Science Foundation of China [31170307, 31570331]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China (No. 31170307; 31570331). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, MINERAL NUTR PLANTS; Buckingham SE, 2010, BIOGEOCHEMISTRY, V100, P105, DOI 10.1007/s10533-010-9408-7; Cakmak I, 2000, NEW PHYTOL, V146, P185, DOI 10.1046/j.1469-8137.2000.00630.x; Chen W, 2011, CHIN TRADIT HERB DRU, V32, P39; He ZH, 2011, PHYTOMEDICINE, V18, P470, DOI 10.1016/j.phymed.2010.10.006; Jones DL, 2002, SOIL BIOL BIOCHEM, V34, P209, DOI 10.1016/S0038-0717(01)00175-4; Kemen AC, 2014, P NATL ACAD SCI USA, V111, P8679, DOI 10.1073/pnas.1401553111; Komatsu K, 2006, CHEM PHARM BULL, V54, P941, DOI 10.1248/cpb.54.941; Kon R, 2014, J ETHNOPHARMACOL, V152, P190, DOI 10.1016/j.jep.2013.12.055; Koyama J, 2007, J CHROMATOGR A, V1145, P183, DOI 10.1016/j.chroma.2007.01.076; Lee MS, 2008, BIOL PHARM BULL, V31, P2154, DOI 10.1248/bpb.31.2154; Li HuChen, 2003, World Forestry Research, V16, P17; Lin CC, 2006, J SEP SCI, V29, P2584, DOI 10.1002/jssc.200500307; Liu L, 2009, INT IMMUNOPHARMACOL, V9, P1568, DOI 10.1016/j.intimp.2009.09.013; Liu LingDi, 2007, Cotton Science, V19, P129; Miller AE, 2007, ECOLOGY, V88, P1832, DOI 10.1890/06-0946.1; Mishra SK, 2014, J NAT MED-TOKYO, V68, P363, DOI 10.1007/s11418-013-0810-z; Shi XY, 2004, THESIS CHINESE ACAD; Soil Survey Staff. Kf, 1990, SMSS TECHN MON, V19; State Pharmacopoeia Committee, 2015, PHARMACOPOEIA PEOPLE, P22; Wang JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024498; Wang SJ, 2008, PHYTOTHER RES, V22, P247, DOI 10.1002/ptr.2301; Wang WM, 2012, PHARMACOL REP, V64, P1216, DOI 10.1016/S1734-1140(12)70917-9; Wang XY, 2012, PHYTOCHEM ANALYSIS, V23, P684, DOI 10.1002/pca.2373; Wang Z, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-170; Weigelt A, 2005, OECOLOGIA, V142, P627, DOI 10.1007/s00442-004-1765-2; Xie Z., 1998, P 3 CHIN NAT S BIOD, V12, P230; Xiong HR, 2011, J ETHNOPHARMACOL, V133, P718, DOI 10.1016/j.jep.2010.10.059	28	14	16	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2016	11	5							e0154649	10.1371/journal.pone.0154649	http://dx.doi.org/10.1371/journal.pone.0154649			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KK	27138597	Green Published, gold, Green Submitted			2023-01-03	WOS:000375675700049
J	Frieden, TR; Houry, D				Frieden, Thomas R.; Houry, Debra			Reducing the Risks of Relief - The CDC Opioid-Prescribing Guideline	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PAIN		[Frieden, Thomas R.; Houry, Debra] Ctr Dis Control & Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Frieden, TR (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA USA.			Frieden, Thomas/0000-0002-4759-2256	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Braden JB, 2012, J PAIN, V13, P64, DOI 10.1016/j.jpain.2011.10.007; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Hina N, 2015, EUR J ANAESTH, V32, P255, DOI 10.1097/EJA.0000000000000197; Kaplovitch E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134550; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714	5	159	160	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	2016	374	16					1501	1504		10.1056/NEJMp1515917	http://dx.doi.org/10.1056/NEJMp1515917			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DJ7IA	26977701	Green Accepted, Bronze			2023-01-03	WOS:000374383900001
J	Loturco, I; Pereira, LA; Kobal, R; Maldonado, T; Piazzi, AF; Bottino, A; Kitamura, K; Abad, CCC; de Arruda, M; Nakamura, FY				Loturco, Irineu; Pereira, Lucas Adriano; Kobal, Ronaldo; Maldonado, Thiago; Piazzi, Alessandro Fromer; Bottino, Altamiro; Kitamura, Katia; Cal Abad, Cesar Cavinato; de Arruda, Miguel; Nakamura, Fabio Yuzo			Improving Sprint Performance in Soccer: Effectiveness of Jump Squat and Olympic Push Press Exercises	PLOS ONE			English	Article							VERTICAL JUMP; POWER; STRENGTH; ACCELERATION; FORCE; SPEED; HIP; AGILITY; PLAYERS; IMPULSE	Training at the optimum power load (OPL) is an effective way to improve neuromuscular abilities of highly trained athletes. The purpose of this study was to test the effects of training using the jump squat (JS) or Olympic push-press (OPP) exercises at the OPL during a short-term preseason on speed-power related abilities in high-level under-20 soccer players. The players were divided into two training groups: JS group (JSG) and OPP group (OPPG). Both groups undertook 12 power-oriented sessions, using solely JS or OPP exercises. Pre-and post-6 weeks of training, athletes performed squat jump (SJ), countermovement jump (CMJ), sprinting speed (5, 10, 20 and 30 m), change of direction (COD) and speed tests. To calculate the transfer effect coefficient (TEC) between JS and MPP OPP and the speed in 5, 10, 20, and 30 m, the ratio between the result gain (effect size [ES]) in the untrained exercise and result gain in the trained exercise was calculated. Magnitude based inference and ES were used to test the meaningful effects. The TEC between JS and VEL 5, 10, 20, and 30 m ranged from 0.77 to 1.29, while the only TEC which could be calculated between OPP and VEL 5 was rather low (0.2). In addition, the training effects of JS on jumping and speed related abilities were superior (ES ranging from small to large) to those caused by OPP (trivial ES). To conclude, the JS exercise is superior to the OPP for improving speed-power abilities in elite young soccer players.	[Loturco, Irineu; Pereira, Lucas Adriano; Kobal, Ronaldo; Kitamura, Katia; Cal Abad, Cesar Cavinato; Nakamura, Fabio Yuzo] NAR Nucleus High Performance Sport, Sao Paulo, SP, Brazil; [Maldonado, Thiago; Piazzi, Alessandro Fromer; Bottino, Altamiro] Palmeiras Sport Soc, Sao Paulo, SP, Brazil; [de Arruda, Miguel] Univ Estadual Campinas, Campinas, SP, Brazil; [Nakamura, Fabio Yuzo] Univ Estadual Londrina, Londrina, PR, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Londrina	Loturco, I (corresponding author), NAR Nucleus High Performance Sport, Sao Paulo, SP, Brazil.	irineu.loturco@terra.com.br	Loturco, Irineu/AAH-4916-2019; Kobal, Ronaldo/AAU-8415-2021; Nakamura, Fábio Yuzo/AAC-3069-2020; Pereira, Lucas/S-3110-2019; PEREIRA, LUCAS/HHZ-5877-2022	Loturco, Irineu/0000-0003-1309-2568; Kobal, Ronaldo/0000-0003-0243-2133; Nakamura, Fábio Yuzo/0000-0002-5336-3652; Pereira, Lucas/0000-0003-1079-2446; 				Adams K., 1992, J STRENGTH COND RES, V6, P36, DOI DOI 10.1519/00124278-199202000-00006; Barnes C, 2014, INT J SPORTS MED, V35, P1095, DOI 10.1055/s-0034-1375695; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Beardsley C, 2014, STRENGTH COND J, V36, P49, DOI 10.1519/SSC.0000000000000047; Bloomquist K, 2013, EUR J APPL PHYSIOL, V113, P2133, DOI 10.1007/s00421-013-2642-7; Bobbert MF, 1996, MED SCI SPORT EXER, V28, P1402, DOI 10.1097/00005768-199611000-00009; Chiu LZF, 2006, J STRENGTH COND RES, V20, P555; Cohen J., 2013, STAT POWER ANAL BEHA; Cronin JB, 2005, J STRENGTH COND RES, V19, P349; Delecluse C, 1997, SPORTS MED, V24, P147, DOI 10.2165/00007256-199724030-00001; Engebretsen AH, 2010, AM J SPORT MED, V38, P1147, DOI 10.1177/0363546509358381; Faude O, 2013, J SPORT SCI, V31, P1460, DOI 10.1080/02640414.2013.796065; Garnacho-Castano MV, 2015, J SPORT SCI MED, V14, P128; Harrison CB, 2015, INT J SPORTS MED, V36, P929, DOI 10.1055/s-0034-1396825; Hewit JK, 2012, INT J SPORTS SCI COA, V7, P493, DOI 10.1260/1747-9541.7.3.493; Hill-Haas SV, 2009, INT J SPORTS MED, V30, P636, DOI 10.1055/s-0029-1220730; Holmberg PM, 2013, STRENGTH COND J, V35, P79, DOI 10.1519/SSC.0b013e3182889f47; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hunter JP, 2005, J APPL BIOMECH, V21, P31, DOI 10.1123/jab.21.1.31; Impellizzeri FM, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.038497; Katis A, 2009, J SPORT SCI MED, V8, P374; Kilgallon M, 2010, STRENGTH COND J, V32, P26, DOI 10.1519/SSC.0b013e3181e92d37; Lake JP, 2014, J STRENGTH COND RES, V28, P2552, DOI 10.1519/JSC.0000000000000438; Lees A, 2004, J STRENGTH COND RES, V18, P787, DOI 10.1519/00124278-200411000-00018; Little T, 2005, J STRENGTH COND RES, V19, P76; Loturco I, 2015, J STRENGTH IN PRESS; Loturco I, 2015, INT J SPORT IN PRESS; Loturco I, 2016, J STRENGTH COND RES, V30, P109, DOI 10.1519/JSC.0000000000001075; Loturco I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140102; Loturco I, 2015, J STRENGTH COND RES, V29, P1966, DOI 10.1519/JSC.0000000000000849; Loturco I, 2015, J SPORT SCI, V33, P1283, DOI 10.1080/02640414.2015.1022574; Loturco I, 2015, J STRENGTH COND RES, V29, P758, DOI 10.1519/JSC.0000000000000660; Loturco I, 2014, J STRENGTH COND RES, V28, P1826, DOI 10.1519/JSC.0000000000000329; Loturco I, 2013, J SPORT SCI MED, V12, P109; Moss BM, 1997, EUR J APPL PHYSIOL, V75, P193, DOI 10.1007/s004210050147; Noon MR, 2015, J SPORTS SCI, V18, P1; Ohton DD, 1988, STRENGTH COND J, V10, P4; Plisk SS, 2003, STRENGTH COND J, V25, P19, DOI 10.1519/1533-4295(2003)025<0019:PS>2.0.CO;2; Rampinini E, 2007, J SPORT SCI, V25, P659, DOI 10.1080/02640410600811858; Requena B, 2011, J STRENGTH COND RES, V25, P2193, DOI 10.1519/JSC.0b013e3181e86132; Sanchez-Medina L, 2010, INT J SPORTS MED, V31, P123, DOI 10.1055/s-0029-1242815; Schache AG, 2011, MED SCI SPORT EXER, V43, P1260, DOI 10.1249/MSS.0b013e3182084929; Sheppard JM, 2006, J SPORT SCI, V24, P919, DOI 10.1080/02640410500457109; Sleivert G, 2004, EUR J APPL PHYSIOL, V91, P46, DOI 10.1007/s00421-003-0941-0; Stone MH, 2003, J STRENGTH COND RES, V17, P140; Tsiokanos A, 2002, ISOKINET EXERC SCI, V10, P107, DOI 10.3233/IES-2002-0092; Waller M, 2013, STRENGTH COND J, V35, P82, DOI 10.1519/SSC.0b013e318276c36e; Wilson JM, 2008, J STRENGTH COND RES, V22, P1705, DOI 10.1519/JSC.0b013e31817ae4a7; Yamauchi J, 2007, J STRENGTH COND RES, V21, P703, DOI 10.1519/00124278-200708000-00009; Zatsiorsky VM, 2006, SCI PRACTICE STRENGT	50	40	40	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2016	11	4							e0153958	10.1371/journal.pone.0153958	http://dx.doi.org/10.1371/journal.pone.0153958			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK4OR	27100085	Green Published, gold, Green Submitted			2023-01-03	WOS:000374898500110
J	Ahmed, S; Zhan, CS; Yang, YY; Wang, XK; Yang, TW; Zhao, ZY; Zhang, QY; Li, XH; Hu, XB				Ahmed, Shakeel; Zhan, Chuansong; Yang, Yanyan; Wang, Xuekui; Yang, Tewu; Zhao, Zeying; Zhang, Qiyun; Li, Xiaohua; Hu, Xuebo			The Transcript Profile of a Traditional Chinese Medicine, Atractylodes lancea, Revealing Its Sesquiterpenoid Biosynthesis of the Major Active Components	PLOS ONE			English	Article							SSR MARKER DEVELOPMENT; FUNCTIONAL-CHARACTERIZATION; BACTERIAL EXPRESSION; GENE-EXPRESSION; SYNTHASE GENES; ESSENTIAL OILS; RNA-SEQ; RHIZOMES; L.; EVOLUTION	Atractylodes lancea (Thunb.) DC., named "Cangzhu" in China, which belongs to the Asteraceae family. In some countries of Southeast Asia (China, Thailand, Korea, Japan etc.) its rhizome, commonly called rhizoma atractylodis, is used to treat many diseases as it contains a variety of sesquiterpenoids and other components of medicinal importance. Despite its medicinal value, the information of the sesquiterpenoid biosynthesis is largely unknown. In this study, we investigated the transcriptome analysis of different tissues of non-model plant A. lancea by using short read sequencing technology (Illumina). We found 62,352 high quality unigenes with an average sequence length of 913 bp in the transcripts of A. Lancea. Among these, 43,049 (69.04%), 30,264 (48.53%), 26,233 (42.07%), 17,881 (28.67%) and 29,057(46.60%) unigenes showed significant similarity (E-value<1e(-5)) to known proteins in Nr, KEGG, SWISS- PROT, GO, and COG databases, respectively. Of the total 62,352 unigenes, 43,049 (Nr Database) open reading frames were predicted. On the basis of different bioinformatics tools we identify all the enzymes that take part in the terpenoid biosynthesis as well as five different known sesquiterpenoids via cytosolic mevalonic acid (MVA) pathway and plastidal methylerythritol phosphate (MEP) pathways. In our study, 6, 864 Simple Sequence Repeats (SSRs) were also found as great potential markers in A. lancea. This transcriptomic resource of A. lancea provides a great contribution in advancement of research for this specific medicinal plant and more specifically for the gene mining of different classes of terpenoids and other chemical compounds that have medicinal as well as economic importance.	[Ahmed, Shakeel; Zhan, Chuansong; Yang, Yanyan; Wang, Xuekui; Yang, Tewu; Zhao, Zeying; Zhang, Qiyun; Li, Xiaohua; Hu, Xuebo] Huazhong Agr Univ, Dept Med Plant, Coll Plant Sci & Technol, Wuhan 430070, Peoples R China; [Ahmed, Shakeel; Zhan, Chuansong; Zhang, Qiyun; Li, Xiaohua; Hu, Xuebo] Huazhong Agr Univ, Ctr Plant Funct Components, Wuhan 430070, Peoples R China; [Ahmed, Shakeel; Zhan, Chuansong; Yang, Yanyan; Wang, Xuekui; Yang, Tewu; Zhao, Zeying; Zhang, Qiyun; Li, Xiaohua; Hu, Xuebo] Huazhong Agr Univ, Natl Reg Joint Engn Res Ctr Hubei Med Plant Breed, Wuhan 430070, Peoples R China; [Ahmed, Shakeel; Zhan, Chuansong; Yang, Yanyan; Wang, Xuekui; Yang, Tewu; Zhao, Zeying; Zhang, Qiyun; Li, Xiaohua; Hu, Xuebo] Huazhong Agr Univ, Engn Res Ctr Med Plants, Wuhan 430070, Peoples R China	Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University	Hu, XB (corresponding author), Huazhong Agr Univ, Dept Med Plant, Coll Plant Sci & Technol, Wuhan 430070, Peoples R China.; Hu, XB (corresponding author), Huazhong Agr Univ, Ctr Plant Funct Components, Wuhan 430070, Peoples R China.; Hu, XB (corresponding author), Huazhong Agr Univ, Natl Reg Joint Engn Res Ctr Hubei Med Plant Breed, Wuhan 430070, Peoples R China.; Hu, XB (corresponding author), Huazhong Agr Univ, Engn Res Ctr Med Plants, Wuhan 430070, Peoples R China.	xuebohu@mail.hzau.edu.cn	Awan, Shakeel Ahmed/AAG-2097-2019	Awan, Shakeel Ahmed/0000-0003-0086-2279	Fundamental Research Funds for the Central Universities Program [2014PY057]; Natural Science Foundation of Hubei Province, China [2015CFA091]	Fundamental Research Funds for the Central Universities Program; Natural Science Foundation of Hubei Province, China(Natural Science Foundation of Hubei Province)	This research was supported by the Fundamental Research Funds for the Central Universities Program No. 2014PY057 (XH) and Natural Science Foundation of Hubei Province, China, No. 2015CFA091 (XH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bennett MH, 2002, PHYTOCHEMISTRY, V60, P255, DOI 10.1016/S0031-9422(02)00103-6; Berger R.G., 2007, FLAVOURS FRAGRANCES; Bushman BS, 2011, THEOR APPL GENET, V123, P119, DOI 10.1007/s00122-011-1571-2; Cane D.E., 1999, COMPR NAT PROD CHEM, V2, P155, DOI [10.1016/B978-0-08-091283-7.00039-4, DOI 10.1016/B978-0-08-091283-7.00039-4]; Chapman MA, 2009, THEOR APPL GENET, V120, P85, DOI 10.1007/s00122-009-1161-8; Chen HP, 2015, CHEM BIODIVERS, V12, P593, DOI 10.1002/cbdv.201400161; Chou KC, 2013, MOL BIOSYST, V9, P1092, DOI 10.1039/c3mb25555g; Chung J, 2009, J KOREAN SOC INT AGR; CORNWELL PA, 1994, J PHARM PHARMACOL, V46, P261, DOI 10.1111/j.2042-7158.1994.tb03791.x; Crock J, 1997, P NATL ACAD SCI USA, V94, P12833, DOI 10.1073/pnas.94.24.12833; de Kraker JW, 1998, PLANT PHYSIOL, V117, P1381, DOI 10.1104/pp.117.4.1381; de Kraker JW, 2001, PLANT PHYSIOL, V125, P1930, DOI 10.1104/pp.125.4.1930; Di Sotto A, 2008, MUTAT RES-GEN TOX EN, V653, P130, DOI 10.1016/j.mrgentox.2008.04.004; Dillies MA, 2013, BRIEF BIOINFORM, V14, P671, DOI 10.1093/bib/bbs046; Dong SB, 2014, GENE, V544, P220, DOI 10.1016/j.gene.2014.04.031; Duan JA, 2008, ARCH PHARM RES, V31, P965, DOI 10.1007/s12272-001-1252-z; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Guo SG, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-454; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Herb ECoNCMMBC, 1999, HERB ECONCMMBC; Inagaki N, 2001, PLANTA MED, V67, P428, DOI 10.1055/s-2001-15822; Irmisch S, 2012, BMC PLANT BIOL, V12, DOI 10.1186/1471-2229-12-84; Iseli C, 1999, ESTSCAN PROGRAM DETE; Jia Chunxiao, 2004, Zhong Yao Cai, V27, P571; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kaur S, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-265; Kitajima J, 2003, CHEM PHARM BULL, V51, P673, DOI 10.1248/cpb.51.673; Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091; Kuchenbauer F, 2008, GENOME RES, V18, P1787, DOI 10.1101/gr.077578.108; Lange BM, 2013, PLANT BIOTECHNOL J, V11, P169, DOI 10.1111/pbi.12022; Legault J, 2007, J PHARM PHARMACOL, V59, P1643, DOI 10.1211/jpp.59.12.0005; Levin JZ, 2010, NAT METHODS, V7, P709, DOI [10.1038/NMETH.1491, 10.1038/nmeth.1491]; Li CF, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-245; Liu MH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1477-5; Liu Yanju, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2276; Liu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074441; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Masuda Y, 2015, J NAT MED-TOKYO, V69, P332, DOI 10.1007/s11418-015-0897-5; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Mizutani M, 2010, ANNU REV PLANT BIOL, V61, P291, DOI 10.1146/annurev-arplant-042809-112305; Na-Bangchang Kesara, 2014, Trop Med Health, V42, P3, DOI 10.2149/tmh.2014-S01; Nakai Y, 2003, J ETHNOPHARMACOL, V84, P51, DOI 10.1016/S0378-8741(02)00260-X; Neeraja CN, 2007, THEOR APPL GENET, V115, P767, DOI 10.1007/s00122-007-0607-0; Parshikov IA, 2014, PROCESS BIOCHEM, V49, P2086, DOI 10.1016/j.procbio.2014.09.005; Picaud S, 2005, PHYTOCHEMISTRY, V66, P961, DOI 10.1016/j.phytochem.2005.03.027; Picaud S, 2006, ARCH BIOCHEM BIOPHYS, V452, P17, DOI 10.1016/j.abb.2006.06.007; Prosser I, 2002, PHYTOCHEMISTRY, V60, P691, DOI 10.1016/S0031-9422(02)00165-6; Prosser I, 2004, ARCH BIOCHEM BIOPHYS, V432, P136, DOI 10.1016/j.abb.2004.06.030; Resch M, 1998, J NAT PROD, V61, P347, DOI 10.1021/np970430b; Resch M, 2001, PLANTA MED, V67, P437, DOI 10.1055/s-2001-15817; Sangwan RS, 2013, GENE, V525, P58, DOI 10.1016/j.gene.2013.04.057; Senior ML, 1998, CROP SCI, V38, P1088, DOI 10.2135/cropsci1998.0011183X003800040034x; Sharon-Asa L, 2003, PLANT J, V36, P664, DOI 10.1046/j.1365-313X.2003.01910.x; Simonsen H.T., 2013, NATURAL PRODUCTS, P3069, DOI DOI 10.1007/978-3-642-22144-6_134; Smith JSC, 1997, THEOR APPL GENET, V95, P163, DOI 10.1007/s001220050544; Sun XD, 2012, PLANT CELL REP, V31, P1823, DOI 10.1007/s00299-012-1295-z; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thiel T, 2003, THEOR APPL GENET, V106, P411, DOI 10.1007/s00122-002-1031-0; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; van der Hoeven RS, 2000, PLANT CELL, V12, P2283, DOI 10.1105/tpc.12.11.2283; Verma VK, 2007, SCI HORTIC-AMSTERDAM, V113, P231, DOI 10.1016/j.scienta.2007.03.019; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang HX, 2008, PHYTOCHEMISTRY, V69, P2088, DOI 10.1016/j.phytochem.2008.04.008; Wang KT, 2010, J PHARM PHARMACOL, V62, P381, DOI 10.1211/jpp.62.03.0014; Wang XW, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-400; Wang Y, 2002, GENOME, V45, P319, DOI 10.1139/G01-153; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wheat CW, 2010, GENETICA, V138, P433, DOI 10.1007/s10709-008-9326-y; Xia JH, 2012, PHYTOCHEMISTRY, V74, P178, DOI 10.1016/j.phytochem.2011.11.011; Xie FL, 2012, PLANTA, V236, P101, DOI 10.1007/s00425-012-1591-4; Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080464; Yang Y, 2014, GENE, V534, P155, DOI 10.1016/j.gene.2013.10.073; Yin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073767; Yu F, 2008, FEBS LETT, V582, P565, DOI 10.1016/j.febslet.2008.01.020; Yu Y, 2015, J ETHNOPHARMACOL, V160, P211, DOI 10.1016/j.jep.2014.10.066; Zhao CL, 2010, NAT PROD COMMUN, V5, P1147; Zhao WG, 2009, J INTEGR PLANT BIOL, V51, P1126, DOI 10.1111/j.1744-7909.2009.00883.x; Zhuang XF, 2012, PLANT J, V69, P70, DOI 10.1111/j.1365-313X.2011.04771.x; Zwenger S., 2008, Biotechnology and Molecular Biology Reviews, V3, P001	79	20	23	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2016	11	3							e0151975	10.1371/journal.pone.0151975	http://dx.doi.org/10.1371/journal.pone.0151975			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1ZE	26990438	Green Submitted, gold, Green Published			2023-01-03	WOS:000372582800126
J	Obanda, DN; Zhao, P; Richard, AJ; Ribnicky, D; Cefalu, WT; Stephens, JM				Obanda, Diana N.; Zhao, Peng; Richard, Allison J.; Ribnicky, David; Cefalu, William T.; Stephens, Jacqueline M.			Stinging Nettle (Urtica dioica L.) Attenuates FFA Induced Ceramide Accumulation in 3T3-L1 Adipocytes in an Adiponectin Dependent Manner	PLOS ONE			English	Article							ACID CERAMIDASE; BIOACTIVES; METABOLISM; ACTIVATION; CLEAVAGE; EXTRACT	Objective Excess dietary lipids result in the accumulation of lipid metabolites including ceramides that can attenuate insulin signaling. There is evidence that a botanical extract of Urtica dioica L. (stinging nettle) improves insulin action, yet the precise mechanism(s) are not known. Hence, we examined the effects of Urtica dioica L. (UT) on adipocytes. Research Design We investigated the effects of an ethanolic extract of UT on free fatty acid (palmitic acid) induced inhibition of insulin-stimulated Akt serine phosphorylation and modulation of ceramidase expression in 3T3-L1 adipocytes. Adipocytes were exposed to excess FFAs in the presence or absence of UT. Effects on adiponectin expression, ceramidase expression, ceramidase activity, ceramide accumulation and insulin signaling were determined. Results As expected, FFAs reduced adiponectin expression and increased the expression of ceramidase enzymes but not their activity. FFA also induced the accumulation of ceramides and reduced insulin-stimulated phosphorylation of Akt in adipocytes. The effects of FFA were partially reversed by UT. UT enhanced adiponectin expression and ceramidase activity in the presence of excess FFAs. UT abated ceramide accumulation and increased insulin sensitivity via enhanced Akt phosphorylation. A siRNA knockdown of adiponectin expression prevented UT from exerting positive effects on ceramidase activity but not Akt phosphorylation. Conclusions In adipocytes, the ability of UT to antagonize the negative effects of FFA by modulating ceramidase activity and ceramide accumulation is dependent on the presence of adiponectin. However, the ability of UT to enhance Akt phosphorylation is independent of adiponectin expression. These studies demonstrate direct effects of UT on adipocytes and suggest this botanical extract is metabolically beneficial.	[Obanda, Diana N.; Zhao, Peng; Richard, Allison J.; Cefalu, William T.; Stephens, Jacqueline M.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Ribnicky, David] Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08903 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Rutgers State University New Brunswick	Stephens, JM (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA.	jsteph1@lsu.edu	Zhao, Peng/G-3562-2019; Richard, Allison/N-1987-2017; Stephens, Jacqueline M/R-5217-2018		National Institutes of Health [P50AT002776-10]; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by P50AT002776-10 from the National Institutes of Health.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bergman Richard N., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P205; Bnouham M, 2003, FITOTERAPIA, V74, P677, DOI 10.1016/S0367-326X(03)00182-5; Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200; Farzami B, 2003, J ETHNOPHARMACOL, V89, P47, DOI 10.1016/S0378-8741(03)00220-4; Golalipour Mohammad Jafar, 2007, Pak J Biol Sci, V10, P1200, DOI 10.3923/pjbs.2007.1200.1204; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277; Karki S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Mehri A, 2011, INT J PHARMACOL, V7, P161, DOI 10.3923/ijp.2011.161.170; Obanda DN, 2014, NUTRITION, V30, pS59, DOI [10.1016/j.nut2014.03.006, 10.1016/j.nut.2014.03.006]; Obanda DN, 2012, DIABETES, V61, P597, DOI 10.2337/db11-0396; McLellan KCP, 2014, THER CLIN RISK MANAG, V10, P173, DOI 10.2147/TCRM.S39564; Richard AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098897; Riehemann K, 1999, FEBS LETT, V442, P89, DOI 10.1016/S0014-5793(98)01622-6; Shtraizent N, 2008, J BIOL CHEM, V283, P11253, DOI 10.1074/jbc.M709166200; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Zeidan YH, 2008, CURR DRUG TARGETS, V9, P653, DOI 10.2174/138945008785132358; Zhu Q, 2009, FEBS LETT, V583, P2136, DOI 10.1016/j.febslet.2009.05.047	22	8	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150252	10.1371/journal.pone.0150252	http://dx.doi.org/10.1371/journal.pone.0150252			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26939068	Green Submitted, gold, Green Published			2023-01-03	WOS:000371735200067
J	Yu, Y; Wang, K; Deng, JH; Sun, M; Jia, J; Wang, XM				Yu, Yan; Wang, Ke; Deng, Jiahui; Sun, Min; Jia, Jun; Wang, Xiaomin			Electroacupuncture Produces the Sustained Motor Improvement in 6-Hydroxydopamine-Lesioned Mice	PLOS ONE			English	Article							MEDIAL FOREBRAIN-BUNDLE; PARKINSONS-DISEASE; MOUSE MODEL; ACUPUNCTURE; STIMULATION; NEURONS; RATS; THERAPY; LESIONS; TIME	Clinical and research evidence has shown that electroacupuncture (EA) promotes recovery of motor function in patients with Parkinson's disease (PD). However, the "efficacy span" of EA treatment, especially the long-term effect of EA that is thought to last after the cessation of EA treatment, has not been investigated. The present study thus investigated and compared the effect of EA during and after chronic EA application on motor activity and dopamine lesions in a 6-hydroxydopamine (6-OHDA)-lesioned mouse model of PD. Chronic EA treatment (30 min a day, 6 days a week for 2 or 4 weeks) significantly attenuated motor deficiency and reduced dopamine neuron degeneration. Remarkably, EA showed a long-lasting effect after the cessation of EA stimulation. At 2 and 4 weeks after the termination of EA, EA continued to improve motor function in 6-OHDA-lesioned mice. Consistent with sustained behavioral effects, EA induced an enduring increase in the dopamine turnover ratio in the striatum 2 weeks after the cessation of EA treatment. Here we demonstrated that the therapeutic effect of EA outlasted the duration of EA application. During a relatively long period of time after the completion of EA treatment, EA is able to continue to improve motor function and enhance dopamine availability in 6-OHDA-lesioned PD mice.	[Jia, Jun; Wang, Xiaomin] Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis, Dept Neurobiol,Key Lab Neurodegenerat Disorders,M, Beijing 100069, Peoples R China; [Jia, Jun; Wang, Xiaomin] Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis, Dept Physiol,Key Lab Neurodegenerat Disorders,Min, Beijing 100069, Peoples R China	Capital Medical University; Capital Medical University	Jia, J; Wang, XM (corresponding author), Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis, Dept Neurobiol,Key Lab Neurodegenerat Disorders,M, Beijing 100069, Peoples R China.; Jia, J; Wang, XM (corresponding author), Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis, Dept Physiol,Key Lab Neurodegenerat Disorders,Min, Beijing 100069, Peoples R China.	jiajun@ccmu.edu.cn; xmwang@ccmu.edu.cn			National Basic Research Program of China [2011CB504100]; National Natural Science Foundation of China [81072858, 81473770, 31401024]; Beijing Natural Science Foundation [7152021]; Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions [CITTCD201304185]; Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges under the Beijing Municipality [IDHT20140514]; Seed Grant of International Alliance of Translational Neuroscience [PXM2014_014226_000015]; Postdoctoral Science Foundation of China [2014M561007]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions; Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges under the Beijing Municipality; Seed Grant of International Alliance of Translational Neuroscience; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This study was supported by the National Basic Research Program of China (2011CB504100; http://www.973.gov.cn), the National Natural Science Foundation of China (81072858, 81473770, 31401024; http://www.nsfc.gov.cn), Beijing Natural Science Foundation (7152021; http://www.bjkw.gov.cn), the Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions (CIT&TCD201304185; www.bjedu.gov.cn), the Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges under the Beijing Municipality (IDHT20140514; http://www.bjedu.gov.cn), the Seed Grant of International Alliance of Translational Neuroscience (PXM2014_014226_000015; http://www.bibd.org.cn), and Postdoctoral Science Foundation of China (2014M561007; http://jj.chinapostdoctor.org.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; Alvarez-Fischer D, 2008, EXP NEUROL, V210, P182, DOI 10.1016/j.expneurol.2007.10.012; Asakawa T, 2012, INTRACTABLE RARE DIS, V1, P144, DOI 10.5582/irdr.2012.v1.4.144; Boix J, 2015, BEHAV BRAIN RES, V284, P196, DOI 10.1016/j.bbr.2015.01.053; Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030; Cohen AD, 2011, BRAIN RES, V1370, P80, DOI 10.1016/j.brainres.2010.11.006; Cristian A, 2005, MOVEMENT DISORD, V20, P1185, DOI 10.1002/mds.20503; Deng JH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0302-z; Dewey RB, 2004, NEUROLOGY, V62, pS3, DOI 10.1212/WNL.62.6_suppl_4.S3; Grealish S, 2010, EUR J NEUROSCI, V31, P2266, DOI 10.1111/j.1460-9568.2010.07265.x; Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X; Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023; Jia J, 2010, BEHAV NEUROSCI, V124, P305, DOI 10.1037/a0018931; Jia J, 2009, BEHAV BRAIN RES, V205, P214, DOI 10.1016/j.bbr.2009.06.024; Kawagishi K, 2014, NEUROSCIENCE, V272, P29, DOI 10.1016/j.neuroscience.2014.04.050; Kim HJ, 2013, PARKINSONISM RELAT D, V19, P831, DOI 10.1016/j.parkreldis.2013.03.018; Kim HJ, 2014, J NEUROL SCI, V341, P1, DOI 10.1016/j.jns.2014.04.016; Kim SH, 2011, PLOS ONE, V6; Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2; Meissner W, 2002, NEUROSCI LETT, V328, P105, DOI 10.1016/S0304-3940(02)00463-9; Rabinstein AA, 2003, NEUROLOGIST, V9, P137, DOI 10.1097/00127893-200305000-00002; SAINTCYR JA, 1993, NEUROLOGY, V43, P47; Shiotsuki H, 2010, J NEUROSCI METH, V189, P180, DOI 10.1016/j.jneumeth.2010.03.026; Sun ZL, 2012, NEUROSCI LETT, V520, P32, DOI 10.1016/j.neulet.2012.05.021; Wang H. W., 2013, WORLD CHINESE MED, V8, P5, DOI DOI 10.1371/J0UNIAL.P0NE.0063225; Wang HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019790; Wang X, 2008, NEUROCHEM RES, V33, P1956, DOI 10.1007/s11064-008-9691-z; Yuan H, 2005, J NEUROSCI METH, V144, P35, DOI 10.1016/j.jneumeth.2004.10.004; Zeng BY, 2013, INT REV NEUROBIOL, V111, P141, DOI 10.1016/B978-0-12-411545-3.00007-9	29	13	13	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2016	11	2							e0149111	10.1371/journal.pone.0149111	http://dx.doi.org/10.1371/journal.pone.0149111			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3DG	26894437	Green Published, Green Submitted, gold			2023-01-03	WOS:000371223400032
J	Uyeki, TM; Mehta, AK; Davey, RT; Liddell, AM; Wolf, T; Vetter, P; Schmiedel, S; Grunewald, T; Jacobs, M; Arribas, JR; Evans, L; Hewlett, AL; Brantsaeter, AB; Ippolito, G; Rapp, C; Hoepelman, AIM; Rapp, C; Hoepelman, AIM; Gutman, J				Uyeki, Timothy M.; Mehta, Aneesh K.; Davey, Richard T., Jr.; Liddell, Allison M.; Wolf, Timo; Vetter, Pauline; Schmiedel, Stefan; Gruenewald, Thomas; Jacobs, Michael; Arribas, Jose R.; Evans, Laura; Hewlett, Angela L.; Brantsaeter, Arne B.; Ippolito, Giuseppe; Rapp, Christophe; Hoepelman, Andy I. M.; Rapp, Christophe; Hoepelman, Andy I. M.; Gutman, Julie		US-European Clinical Network	Clinical Management of Ebola Virus Disease in the United States and Europe	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVALESCENT PLASMA; CRITICAL-CARE; PATIENT; FEATURES	BACKGROUND Available data on the characteristics of patients with Ebola virus disease (EVD) and clinical management of EVD in settings outside West Africa, as well as the complications observed in those patients, are limited. METHODS We reviewed available clinical, laboratory, and virologic data from all patients with laboratory-confirmed Ebola virus infection who received care in U.S. and European hospitals from August 2014 through December 2015. RESULTS A total of 27 patients (median age, 36 years [range, 25 to 75]) with EVD received care; 19 patients (70%) were male, 9 of 26 patients (35%) had coexisting conditions, and 22 (81%) were health care personnel. Of the 27 patients, 24 (89%) were medically evacuated from West Africa or were exposed to and infected with Ebola virus in West Africa and had onset of illness and laboratory confirmation of Ebola virus infection in Europe or the United States, and 3 (11%) acquired EVD in the United States or Europe. At the onset of illness, the most common signs and symptoms were fatigue (20 patients [80%]) and fever or feverishness (17 patients [68%]). During the clinical course, the predominant findings included diarrhea, hypoalbuminemia, hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia; 14 patients (52%) had hypoxemia, and 9 (33%) had oliguria, of whom 5 had anuria. Aminotransferase levels peaked at a median of 9 days after the onset of illness. Nearly all the patients received intravenous fluids and electrolyte supplementation; 9 (33%) received noninvasive or invasive mechanical ventilation; 5 (19%) received continuous renalreplacement therapy; 22 (81%) received empirical antibiotics; and 23 (85%) received investigational therapies (19 [70%] received at least two experimental interventions). Ebola viral RNA levels in blood peaked at a median of 7 days after the onset of illness, and the median time from the onset of symptoms to clearance of viremia was 17.5 days. A total of 5 patients died, including 3 who had respiratory and renal failure, for a mortality of 18.5%. CONCLUSIONS Among the patients with EVD who were cared for in the United States or Europe, close monitoring and aggressive supportive care that included intravenous fluid hydration, correction of electrolyte abnormalities, nutritional support, and critical care management for respiratory and renal failure were needed; 81.5% of these patients who received this care survived.	[Uyeki, Timothy M.; Gutman, Julie] Ctr Dis Control & Prevent, Mail Stop A-20,1600 Clifton Rd NE, Atlanta, GA 30329 USA; [Mehta, Aneesh K.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA; [Davey, Richard T., Jr.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Liddell, Allison M.] Texas Hlth Presbyterian Hosp Dallas, Dallas, TX USA; [Wolf, Timo] Univ Hosp Frankfurt, Dept Infect Dis, Frankfurt, Germany; [Schmiedel, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Gruenewald, Thomas] Klinikum St Georg, Leipzig Treatment Ctr Highly Contagious Dis, Leipzig, Germany; [Vetter, Pauline] Univ Hosp Geneva, Div Infect Dis & Lab Virol, Geneva, Switzerland; [Jacobs, Michael] Royal Free London NHS Fdn Trust, Dept Infect, London, England; [Arribas, Jose R.] Hosp La Paz Carlos III IdiPAZ, Infect Dis Unit Madrid, Dept Internal Med, Madrid, Spain; [Evans, Laura] NYU, Bellevue Hosp Ctr, Sch Med, New York, NY 10016 USA; [Hewlett, Angela L.] Univ Nebraska Med Ctr, Omaha, NE USA; [Brantsaeter, Arne B.] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Brantsaeter, Arne B.] Oslo Univ Hosp, Dept Acute Med, Oslo, Norway; [Ippolito, Giuseppe] Lazzaro Spallanzani Natl Inst Infect Dis, Rome, Italy; [Rapp, Christophe] Begin Mil Hosp, Infect & Trop Dis Dept, St Mande, France; [Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands	Centers for Disease Control & Prevention - USA; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Geneva; University of London; University College London; Royal Free London NHS Foundation Trust; Bellevue Hospital Center; New York University; University of Nebraska System; University of Nebraska Medical Center; University of Oslo; University of Oslo; IRCCS Lazzaro Spallanzani; Utrecht University; Utrecht University Medical Center	Uyeki, TM (corresponding author), Ctr Dis Control & Prevent, Mail Stop A-20,1600 Clifton Rd NE, Atlanta, GA 30329 USA.	tuyeki@cdc.gov	Castilletti, Concetta/B-6545-2016; Vetter, Pauline/AAT-8066-2021; Arnalich, Francisco/J-8184-2017; nicastri, emanuele/K-7780-2016; Martin, Daniel S/F-7997-2010; Anda, Pedro/V-8436-2019; Wiesch, Julian Schulze zur/AAT-8452-2021; Di Caro, Antonino/K-6854-2016; Ippolito, Giuseppe/J-7207-2017; Wolf, Timo/AAQ-3521-2021; Mehta, Aneesh/B-8054-2012; Mora-Rillo, Marta/E-8211-2015; Arribas, Jose/A-1595-2015	Castilletti, Concetta/0000-0001-9819-236X; Vetter, Pauline/0000-0002-9902-5069; nicastri, emanuele/0000-0002-5606-8712; Anda, Pedro/0000-0001-9081-8188; Di Caro, Antonino/0000-0001-6027-3009; Wolf, Timo/0000-0002-3819-9540; Brantsaeter, Arne Broch/0000-0003-1723-0577; Mehta, Aneesh/0000-0002-6552-9162; Martin, Daniel/0000-0001-6220-8235; Addo, Marylyn/0000-0003-2836-9224; Arsuaga Vicente, Marta/0000-0001-5522-3728; Hopkins, Susan/0000-0001-5179-5702; Mora-Rillo, Marta/0000-0002-2735-5931; Arribas, Jose/0000-0002-7410-9450; de la Calle-Prieto, Fernando/0000-0003-2544-3492; Ippolito, Giuseppe/0000-0002-1076-2979; Taglietti, Fabrizio/0000-0001-6950-6040; Luth, Stefan/0000-0001-9946-0960; Salzer, Helmut J.F./0000-0003-0146-8310; Gunther, Stephan/0000-0002-6562-0230; Gruenewald, Thomas/0000-0002-2955-3085	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000984] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansumana R, 2015, NEW ENGL J MED, V372, P587, DOI 10.1056/NEJMc1413685; Aylward B, 2014, NEW ENGL J MED, V371, P1481, DOI 10.1056/NEJMoa1411100; Bah EI, 2015, NEW ENGL J MED, V372, P40, DOI 10.1056/NEJMoa1411249; Barry M, 2015, CLIN INFECT DIS, V60, P1821, DOI 10.1093/cid/civ202; Brett-Major DM, 2015, AM J TROP MED HYG, V92, P233, DOI 10.4269/ajtmh.14-0746; Chertow DS, 2014, NEW ENGL J MED, V371, P2054, DOI 10.1056/NEJMp1413084; Connor MJ, 2015, J AM SOC NEPHROL, V26, P31, DOI 10.1681/ASN.2014111057; Florescu DF, 2015, CLIN INFECT DIS, V61, P969, DOI 10.1093/cid/civ395; Fowler RA, 2014, AM J RESP CRIT CARE, V190, P733, DOI 10.1164/rccm.201408-1514CP; Hunt L, 2015, LANCET INFECT DIS, V15, P1292, DOI 10.1016/S1473-3099(15)00144-9; Johnson DW, 2015, CRIT CARE MED, V43, P1157, DOI 10.1097/CCM.0000000000000935; Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334; Kreuels B, 2014, NEW ENGL J MED, V371, P2394, DOI 10.1056/NEJMoa1411677; Lamontagne F, 2014, NEW ENGL J MED, V371, P1565, DOI 10.1056/NEJMp1411310; Liddell AM, 2015, ANN INTERN MED, V163, P81, DOI 10.7326/M15-0530; Lyon GM, 2014, NEW ENGL J MED, V371, P2402, DOI 10.1056/NEJMoa1409838; Parra JM, 2014, NEW ENGL J MED, V371, P2439, DOI 10.1056/NEJMc1412662; Martines RB, 2015, J PATHOL, V235, P153, DOI 10.1002/path.4456; Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0; O'Dempsey T, 2015, AM J TROP MED HYG, V92, P238, DOI 10.4269/ajtmh.14-0719; Qin EQ, 2015, CLIN INFECT DIS, V61, P491, DOI 10.1093/cid/civ319; Schibler M, 2015, LANCET INFECT DIS, V15, P1034, DOI 10.1016/S1473-3099(15)00229-7; Schieffelin JS, 2014, NEW ENGL J MED, V371, P2092, DOI 10.1056/NEJMoa1411680; Sueblinvong V, 2015, CRIT CARE MED, V43, P2066, DOI 10.1097/CCM.0000000000001197; WHO, 2015, EB SIT REP; Wolf T, 2015, LANCET, V385, P1428, DOI 10.1016/S0140-6736(14)62384-9	26	228	233	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	2016	374	7					636	646		10.1056/NEJMoa1504874	http://dx.doi.org/10.1056/NEJMoa1504874			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD9ER	26886522	Green Published, Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000370229000009
J	Williams, PB; Mangelsdorf, HH; Kontra, C; Nusbaum, HC; Hoeckner, B				Williams, Patrick B.; Mangelsdorf, Heather H.; Kontra, Carly; Nusbaum, Howard C.; Hoeckner, Berthold			The Relationship between Mental and Somatic Practices and Wisdom	PLOS ONE			English	Article							LOVING-KINDNESS; MOTOR-SKILLS; KNOWLEDGE; CHILDREN; ANXIETY; HANDS; MIND	In this study we sought to explore how experience with specific mental and somatic practices is associated with wisdom, using self-report measures of experience and wisdom. We administered standard surveys to measure wisdom and experience among four groups of practitioners of mental and somatic practices, namely, meditators, practitioners of the Alexander Technique, practitioners of the Feldenkrais Method, and classical ballet dancers. We additionally administered surveys of trait anxiety and empathy to all participants to explore possible mediating relationships of experience and wisdom by characteristics thought to be components of wisdom. Wisdom was higher on average among meditation practitioners, and lowest among ballet dancers, and this difference held when controlling for differences in age between practices, supporting the view that meditation is linked to wisdom and that ballet is not. However, we found that increased experience with meditation and ballet were both positively associated with wisdom, and that lowered trait anxiety mediated this positive association among meditation practitioners, and, non-significantly, among ballet dancers. These results suggest that not all practices that are purported to affect mental processing are related to wisdom to the same degree and different kinds of experience appear to relate to wisdom in different ways, suggesting different mechanisms that might underlie the development of wisdom with experience.	[Williams, Patrick B.; Mangelsdorf, Heather H.; Kontra, Carly; Nusbaum, Howard C.] Univ Chicago, Dept Psychol, 5848 S Univ Ave, Chicago, IL 60637 USA; [Hoeckner, Berthold] Univ Chicago, Dept Mus, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Williams, PB (corresponding author), Univ Chicago, Dept Psychol, 5848 S Univ Ave, Chicago, IL 60637 USA.	pbwilliams@uchicago.edu		Mangelsdorf, Heather/0000-0003-3621-3326	Templeton Grant from the John Templeton Foundation [37775]	Templeton Grant from the John Templeton Foundation	This study was supported by Templeton Grant ID#: 37775 from the John Templeton Foundation (www.templeton.org). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberts Hugo J E M, 2011, Mindfulness (N Y), V2, P73; Ardelt M, 2004, HUM DEV, V47, P257, DOI 10.1159/000079154; Ardelt M, 2003, RES AGING, V25, P275, DOI 10.1177/0164027503025003004; Ardelt M, 1998, J AGING STUD, V12, P291, DOI 10.1016/S0890-4065(98)90005-6; Ardelt M, 2010, J ADULT DEV, V17, P193, DOI 10.1007/s10804-009-9088-5; Bailey A., 2008, J UNCONVENTIONAL PAR, V1, P9; Baltes PB, 2000, AM PSYCHOL, V55, P122, DOI 10.1037/0003-066X.55.1.122; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Barrell G, 2013, MED PROBLEMS PERFORM, V18, P59; Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577, DOI 10.1017/S0140525X99532147; Benedikovicova J, 2008, STUD PSYCHOL, V50, P179; Bergen-Cico D, 2014, MINDFULNESS, V5, P505, DOI 10.1007/s12671-013-0205-y; Bergsma A, 2012, J HAPPINESS STUD, V13, P481, DOI 10.1007/s10902-011-9275-5; Blasing B, 2009, PSYCHOL SPORT EXERC, V10, P350, DOI 10.1016/j.psychsport.2008.10.001; Bodhidharma, 1987, ZEN TEACHING BODHIDH; Bohmig-Krumhaar SA, 2002, Z ENTWICKL PADAGOGIS, V34, P30, DOI 10.1026//0049-8637.34.1.30; Broaders SC, 2007, J EXP PSYCHOL GEN, V136, P539, DOI 10.1037/0096-3445.136.4.539; Calvo-Merino B, 2005, CEREB CORTEX, V15, P1243, DOI 10.1093/cercor/bhi007; Carney DR, 2010, PSYCHOL SCI, V21, P1363, DOI 10.1177/0956797610383437; Casasanto D, 2009, J EXP PSYCHOL GEN, V138, P351, DOI 10.1037/a0015854; Colzato LS, 2012, PSYCHON B REV, V19, P541, DOI 10.3758/s13423-012-0241-y; Duckworth AL, 2007, J PERS SOC PSYCHOL, V92, P1087, DOI 10.1037/0022-3514.92.6.1087; Ferrari M., 2013, SCI STUDY PERSONAL W; Ferrari M, 2011, RES HUM DEV, V8, P128, DOI 10.1080/15427609.2011.568869; Glck J., 2013, SCI STUDY PERSONAL W, P75, DOI [DOI 10.1007/978-94-007-7987-7_4, 10.1007/978-94-007-7987-7_4]; Goldin-Meadow S, 2009, PSYCHOL SCI, V20, P267, DOI 10.1111/j.1467-9280.2009.02297.x; Hauk O, 2004, NEURON, V41, P301, DOI 10.1016/S0896-6273(03)00838-9; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Hopper C., 1999, J BODYWORK MOVEMENT, V3, P238, DOI DOI 10.1016/S1360-8592(99)80010-2; Hutcherson CA, 2008, EMOTION, V8, P720, DOI 10.1037/a0013237; James Michelle, 1998, Aust J Physiother, V44, P49; Jeste DV, 2010, JAMA-J AM MED ASSOC, V304, P1602, DOI 10.1001/jama.2010.1458; Jola C, 2011, EXP BRAIN RES, V213, P257, DOI 10.1007/s00221-011-2743-7; Jolliffe D, 2006, J ADOLESCENCE, V29, P589, DOI 10.1016/j.adolescence.2005.08.010; Jones FP, 1997, FREEDOM CHANGE DEV S; Kiken LG, 2014, J RES PERS, V53, P22, DOI 10.1016/j.jrp.2014.08.002; Kiken LG, 2011, SOC PSYCHOL PERS SCI, V2, P425, DOI 10.1177/1948550610396585; Kitchener K., 1990, WISDOM ITS NATURE OR, P212, DOI [DOI 10.1017/CBO9781139173704.011, https://doi.org/10.1017/CBO9781139173704.011]; Kleiner S, 2009, SYMB INTERACT, V32, P236, DOI 10.1525/si.2009.32.3.236; Kontra C, 2015, PSYCHOL SCI, V26, P737, DOI 10.1177/0956797615569355; Kross E, 2012, J EXP PSYCHOL GEN, V141, P43, DOI 10.1037/a0024158; Lake B, 1985, Aust Fam Physician, V14, P1175; LESTE A, 1990, AM J DANCE THER, V12, P19, DOI 10.1007/BF00844312; Leung MK, 2013, SOC COGN AFFECT NEUR, V8, P34, DOI 10.1093/scan/nss076; Menezes C.B., 2015, PSYCHOL NEUROSCI, V8, P350, DOI DOI 10.1037/PNE0000015; Novack MA, 2014, PSYCHOL SCI, V25, P903, DOI 10.1177/0956797613518351; Ping R., UNPACKING G IN PRESS; Ping RM, 2008, DEV PSYCHOL, V44, P1277, DOI 10.1037/0012-1649.44.5.1277; Reniers RLEP, 2011, J PERS ASSESS, V93, P84, DOI 10.1080/00223891.2010.528484; RISKIND J H, 1982, Motivation and Emotion, V6, P273, DOI 10.1007/BF00992249; Shapiro SL, 2007, TRAIN EDUC PROF PSYC, V1, P105, DOI 10.1037/1931-3918.1.2.105; Sobel M.E., 1982, SOCIOL METHODOL, V13, P290, DOI 10.2307/ 270723; Soloway E, 1996, INT FELDENKRAIS FEDE, V3, P22; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Spielberger C. D., 1989, STATE TRAIT ANXIETY; Stallibrass C, 2002, CLIN REHABIL, V16, P695, DOI 10.1191/0269215502cr544oa; Staudinger U. M., 2013, SCI STUDY PERSONAL W, DOI [10.1007/978-90-481-9231-1_1, DOI 10.1007/978-94-007-7987-7_1]; Staudinger UM, 1996, J PERS SOC PSYCHOL, V71, P746, DOI 10.1037/0022-3514.71.4.746; STAUDINGER UM, 2006, SOCIAL STRUCTURES AG, P33; STEPPER S, 1993, J PERS SOC PSYCHOL, V64, P211, DOI 10.1037/0022-3514.64.2.211; Tiberius V., 2008, REFLECTIVE LIFE LIVI; Wilson M, 2002, PSYCHON B REV, V9, P625, DOI 10.3758/BF03196322	62	10	11	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2016	11	2							e0149369	10.1371/journal.pone.0149369	http://dx.doi.org/10.1371/journal.pone.0149369			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3CO	26890493	Green Published, Green Submitted, gold			2023-01-03	WOS:000371221500040
J	He, M; Lu, YB; Zhang, L; Zhang, HH; Gong, YS; Li, YQ				He, Mi; Lu, Yubao; Zhang, Lei; Zhang, Hehua; Gong, Yushun; Li, Yongqin			Combining Amplitude Spectrum Area with Previous Shock Information Using Neural Networks Improves Prediction Performance of Defibrillation Outcome for Subsequent Shocks in Out-Of-Hospital Cardiac Arrest Patients	PLOS ONE			English	Article							WAVE-FORM CHARACTERISTICS; VENTRICULAR-FIBRILLATION; CARDIOPULMONARY-RESUSCITATION; RHYTHM ANALYSIS; FREQUENCY; SUCCESS; VF; ELECTROCARDIOGRAM; RECURRENCE; ACCURACY	Objective Quantitative ventricular fibrillation (VF) waveform analysis is a potentially powerful tool to optimize defibrillation. However, whether combining VF features with additional attributes that related to the previous shock could enhance the prediction performance for subsequent shocks is still uncertain. Methods A total of 528 defibrillation shocks from199 patients experienced out-of-hospital cardiac arrest were analyzed in this study. VF waveform was quantified using amplitude spectrum area (AMSA) from defibrillator's ECG recordings prior to each shock. Combinations of AMSA with previous shock index (PSI) or/and change of AMSA (Delta AMSA) between successive shocks were exercised through a training dataset including 255shocks from 99patientswith neural networks. Performance of the combination methods were compared with AMSA based single feature prediction by area under receiver operating characteristic curve(AUC), sensitivity, positive predictive value (PPV), negative predictive value (NPV) and prediction accuracy (PA) through a validation dataset that was consisted of 273 shocks from 100patients. Results A total of61 (61.0%) patients required subsequent shocks (N = 173) in the validation dataset. Combining AMSA with PSI and.AMSA obtained highest AUC (0.904 vs. 0.819, p< 0.001) among different combination approaches for subsequent shocks. Sensitivity (76.5% vs. 35.3%, p< 0.001), NPV (90.2% vs. 76.9%, p = 0.007) and PA (86.1% vs. 74.0%, p = 0.005) were greatly improved compared with AMSA based single feature prediction with a threshold of 90% specificity. Conclusion In this retrospective study, combining AMSA with previous shock information using neural networks greatly improves prediction performance of defibrillation outcome for subsequent shocks.	[He, Mi; Gong, Yushun; Li, Yongqin] Third Mil Med Univ, Sch Biomed Engn, Chongqing 400038, Peoples R China; [Lu, Yubao] Third Mil Med Univ, Xinqiao Hosp, Emergency Dept, Chongqing 400038, Peoples R China; [Zhang, Lei] Third Mil Med Univ, Southwest Hosp, Emergency Dept, Chongqing 400038, Peoples R China; [Zhang, Hehua] Third Mil Med Univ, Daping Hosp, Dept Med Engn, Chongqing 400042, Peoples R China; [Zhang, Hehua] Third Mil Med Univ, Inst Surg Res, Chongqing 400042, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Army Medical University	Li, YQ (corresponding author), Third Mil Med Univ, Sch Biomed Engn, Chongqing 400038, Peoples R China.	leeoken@gmail.com		HE, Mi/0000-0001-9983-8863	National Nature Science Foundation of China [NSFC81271656, NSFC41301397]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Nature Science Foundation of China (NSFC81271656 and NSFC41301397). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayala U, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/872470; Bradley SM, 2010, RESUSCITATION, V81, P155, DOI 10.1016/j.resuscitation.2009.10.026; Brown CG, 1996, ANN EMERG MED, V27, P184, DOI 10.1016/S0196-0644(96)70346-3; Callaway CW, 2005, CURR OPIN CRIT CARE, V11, P192, DOI 10.1097/01.ccx.0000161725.71211.42; Conover Z, 2014, CIRC-ARRHYTHMIA ELEC, V7, P633, DOI 10.1161/CIRCEP.114.001506; Firoozabadi R, 2013, J ELECTROCARDIOL, V46, P473, DOI 10.1016/j.jelectrocard.2013.06.007; Gundersen K, 2008, RESUSCITATION, V78, P46, DOI 10.1016/j.resuscitation.2008.02.018; Gundersen K, 2008, RESUSCITATION, V76, P279, DOI 10.1016/j.resuscitation.2007.07.019; Hansen MB, 2014, RESUSCITATION, V85, P1681, DOI 10.1016/j.resuscitation.2014.08.038; Howe A, 2014, RESUSCITATION, V85, P343, DOI 10.1016/j.resuscitation.2013.11.021; Indik JH, 2006, RESUSCITATION, V69, P471, DOI 10.1016/j.resuscitation.2005.10.017; Indik JH, 2009, RESUSCITATION, V80, P1420, DOI 10.1016/j.resuscitation.2009.08.023; Inmaculada-C Alvarez, 2013, PANEL DATA TOOLBOX M; Krasteva V, 2010, ANN BIOMED ENG, V38, P1326, DOI 10.1007/s10439-009-9885-9; Kwok H, 2015, RESUSCITATION, V91, P26, DOI 10.1016/j.resuscitation.2015.02.031; Lin LY, 2010, RESUSCITATION, V81, P297, DOI 10.1016/j.resuscitation.2009.12.003; Lo MT, 2013, RESUSCITATION, V84, P1505, DOI 10.1016/j.resuscitation.2013.07.004; Marn-Pernat A, 2001, CRIT CARE MED, V29, P2360, DOI 10.1097/00003246-200112000-00019; Menegazzi JJ, 2004, CIRCULATION, V109, P926, DOI 10.1161/01.CIR.0000112606.41127.D2; Neurauter A, 2007, RESUSCITATION, V73, P253, DOI 10.1016/j.resuscitation.2006.10.002; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Olasveengen TM, 2009, RESUSCITATION, V80, P412, DOI 10.1016/j.resuscitation.2009.01.012; Podbregar M, 2003, RESUSCITATION, V57, P153, DOI 10.1016/S0300-9572(03)00030-3; Reynolds JC, 2012, RESUSCITATION, V83, P1497, DOI 10.1016/j.resuscitation.2012.04.013; Ristagno G, 2013, RESUSCITATION, V84, P1697, DOI 10.1016/j.resuscitation.2013.08.017; Salcido DD, 2009, RESUSCITATION, V80, P946, DOI 10.1016/j.resuscitation.2009.05.002; Schoene P, 2014, HEART RHYTHM, V11, P230, DOI 10.1016/j.hrthm.2013.10.049; Shanmugasundaram M, 2012, RESUSCITATION, V83, P1242, DOI 10.1016/j.resuscitation.2012.02.008; Sharad Shandilya, 2012, BMC MED INFORM DECIS, V12, P1; Sherman L, 2012, RESUSCITATION, V83, P511, DOI 10.1016/j.resuscitation.2011.09.026; Stiell IG, 2011, NEW ENGL J MED, V365, P787, DOI 10.1056/NEJMoa1010076; Strohmenger HU, 1996, RESUSCITATION, V31, P65, DOI 10.1016/0300-9572(95)00899-3; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Alem AP, 2003, RESUSCITATION, V59, P181, DOI 10.1016/S0300-9572(03)00208-9; Werther T, 2009, RESUSCITATION, V80, P1301, DOI 10.1016/j.resuscitation.2009.07.020; White RD, 2002, RESUSCITATION, V55, P17, DOI 10.1016/S0300-9572(02)00194-6; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Wu XB, 2013, RESUSCITATION, V84, P1704, DOI 10.1016/j.resuscitation.2013.08.005; Yang ZJ, 2005, RESUSCITATION, V64, P31, DOI 10.1016/j.resuscitation.2004.07.002	39	18	18	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0149115	10.1371/journal.pone.0149115	http://dx.doi.org/10.1371/journal.pone.0149115			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6PR	26863222	gold, Green Published, Green Submitted			2023-01-03	WOS:000370046600155
J	Shin, JY; Wey, M; Umutesi, HG; Sun, XL; Simecka, J; Heo, J				Shin, Jin-Young; Wey, Michael; Umutesi, Hope G.; Sun, Xiangle; Simecka, Jerry; Heo, Jongyun			Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						disulfide; immunosuppression; Ras-related C3 botulinum toxin substrate 1 (Rac1); redox regulation; T-cell; 6-TGNP-Rac1 adduct; CD4+cells; Rac1 inactivation; redox-sensitive GXXXXGK(ST)C motif; thiopurine prodrugs	GUANINE-NUCLEOTIDE EXCHANGE; INFLAMMATORY-BOWEL-DISEASE; THERAPY-RELATED CANCER; CARDIOVASCULAR-DISEASE; CELL-DIFFERENTIATION; MOLECULAR-MECHANISMS; BREAST-CANCER; RHO-GTPASES; RAS; ACTIVATION	6-Thiopurine (6-TP) prodrugs include 6-thioguanine and azathioprine. Both are widely used to treat autoimmune disorders and certain cancers. This study showed that a 6-thioguanosine triphosphate (6-TGTP), converted in T-cells from 6-TP, targets Rac1 to form a disulfide adduct between 6-TGTP and the redox-sensitive GXXXXGK(S/T)C motif of Rac1. This study also showed that, despite the conservation of the catalytic activity of RhoGAP (Rho-specific GAP) on the 6-TGTP-Rac1 adduct to produce the biologically inactive 6-thioguanosine diphosphate (6-TGDP)-Rac1 adduct, RhoGEF (Rho-specific GEF) cannot exchange the 6-TGDP adducted on Rac1 with free guanine nucleotide. The biologically inactive 6-TGDP-Rac1 adduct accumulates in cells because of the ongoing combined actions of RhoGEF and RhoGAP. Because other Rho GTPases, such as RhoA and Cdc42, also possess the GXXXXGK(S/T)C motif, the proposed mechanism for the inactivation of Rac1 also applies to RhoA and Cdc42. However, previous studies have shown that CD3/CD28-stimulated T-cells contain more activated Rac1 than other Rho GTPases such as RhoA and Cdc42. Accordingly, Rac1 is the main target of 6-TP in activated T-cells. This explains the T-cell-specific Rac1-targeting therapeutic action of 6-TP that suppresses the immune response. This proposed mechanism for the action of 6-TP on Rac1 performs a critical role in demonstrating the capability to design a Rac1-targeting chemotherapeutic agent(s) for autoimmune disorders. Nevertheless, the results also suggest that the targeting action of other Rho GTPases in other organ cells, such as RhoA in vascular cells, may be linked to cytotoxicities because RhoA plays a key role in vasculature functions.	[Shin, Jin-Young; Wey, Michael; Umutesi, Hope G.; Heo, Jongyun] Univ Texas Arlington, Dept Chem & Biochem, 700 Planetarium Pl, Arlington, TX 76019 USA; [Sun, Xiangle; Simecka, Jerry] Univ North Texas, Hlth Sci Ctr, Dept Cell Biol & Immunol, Ft Worth, TX 76107 USA; [Simecka, Jerry] Univ North Texas, Hlth Sci Ctr, UNT Syst Coll Pharm, Dept Pharmaceut Sci, Ft Worth, TX 76107 USA; [Shin, Jin-Young] Natl Inst Food & Drug Safety Evaluat, Biol Res Div, Osong Hlth Technol Adm Complex, Cheongwon Gun 363700, Chungcheongbuk, South Korea	University of Texas System; University of Texas Arlington; University of North Texas System; University of North Texas Denton; University of North Texas System; University of North Texas Denton; Ministry of Food & Drug Safety (MFDS), Republic of Korea; National Institute of Food & Drug Safety Evaluation	Heo, J (corresponding author), Univ Texas Arlington, Dept Chem & Biochem, 700 Planetarium Pl, Arlington, TX 76019 USA.	jheo@uta.edu			National Institutes of Health [1R15AI096146-01A1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI096146] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health Grant 1R15AI096146-01A1 (to J. H.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health..	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Azim AC, 2000, METHOD ENZYMOL, V325, P257; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Budzyn K, 2006, TRENDS PHARMACOL SCI, V27, P97, DOI 10.1016/j.tips.2005.12.002; Cernuda-Morollon E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012393; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; de Boer NKH, 2007, NAT CLIN PRACT GASTR, V4, P686, DOI 10.1038/ncpgasthep1000; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Dumont C, 2009, BLOOD, V113, P3990, DOI 10.1182/blood-2008-09-181180; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Gearry RB, 2005, J GASTROEN HEPATOL, V20, P1149, DOI 10.1111/j.1440-1746.2005.03832.x; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Guo F, 2008, J ELECTRON MATER, V37, P1, DOI 10.1007/s11664-007-0302-6; Heo J, 2006, BIOCHEMISTRY-US, V45, P2200, DOI 10.1021/bi051872m; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; Heo J, 2005, J MOL BIOL, V346, P1423, DOI 10.1016/j.jmb.2004.12.050; Heo J, 2005, J BIOL CHEM, V280, P31003, DOI 10.1074/jbc.M504768200; Heo JY, 2006, BIOCHEMISTRY-US, V45, P14481, DOI 10.1021/bi0610101; Heo J, 2011, BIOCHEMISTRY-US, V50, P5731, DOI 10.1021/bi200347y; Heo JY, 2011, ANTIOXID REDOX SIGN, V14, P689, DOI 10.1089/ars.2009.2984; Heo J, 2010, BIOCHEMISTRY-US, V49, P3965, DOI 10.1021/bi902090q; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hofbauer SW, 2014, BLOOD, V123, P2181, DOI 10.1182/blood-2013-08-523563; Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292; Karran P, 2006, BRIT MED BULL, V79-80, P153, DOI 10.1093/bmb/ldl020; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Langmuir PB, 2001, BEST PRACT RES CL HA, V14, P77, DOI 10.1053/beha.2000.0117; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Loirand G, 2010, NAT REV CARDIOL, V7, P637, DOI 10.1038/nrcardio.2010.136; Lopez-Martin C, 2011, GASTROENT HEPAT-BARC, V34, P385, DOI 10.1016/j.gastrohep.2011.03.023; McDonald E, 1996, CANCER RES, V56, P2250; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Nakamoto M, 2001, INT J ONCOL, V19, P971; Niedbala W, 2002, P NATL ACAD SCI USA, V99, P16186, DOI 10.1073/pnas.252464599; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Poppe D, 2006, J IMMUNOL, V176, P640, DOI 10.4049/jimmunol.176.1.640; Sato M, 1997, CANCER LETT, V112, P181, DOI 10.1016/S0304-3835(96)04581-8; Shimokawa H, 2007, TRENDS PHARMACOL SCI, V28, P296, DOI 10.1016/j.tips.2007.04.006; Skelton TS, 2010, TRANSPL IMMUNOL, V23, P185, DOI 10.1016/j.trim.2010.06.009; Smits K, 2010, HAEMATOL-HEMATOL J, V95, P367, DOI 10.3324/haematol.2009.006890; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Thapa SD, 2015, AM J MED SCI, V350, P175, DOI 10.1097/MAJ.0000000000000535; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; VISTICA DT, 1991, CANCER RES, V51, P2515; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Wey M, 2014, BIOCHEMISTRY-US, V53, P518, DOI 10.1021/bi401528n; Yan T, 2003, CLIN CANCER RES, V9, P2327; Zalcman G, 1999, Prog Mol Subcell Biol, V22, P85	54	25	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2016	291	26					13699	13714		10.1074/jbc.M115.694422	http://dx.doi.org/10.1074/jbc.M115.694422			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DR2YZ	27189938	Green Published, hybrid			2023-01-03	WOS:000379771100025
J	Zawertailo, L				Zawertailo, Laurie			Safety of smoking cessation drugs for mentally ill patients	LANCET			English	Editorial Material							VARENICLINE		[Zawertailo, Laurie] Univ Toronto, Ctr Addict & Mental Hlth, Dept Pharmacol & Toxicol, Fac Med, 175 Coll St, Toronto, ON MST 1P7, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Zawertailo, L (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, Dept Pharmacol & Toxicol, Fac Med, 175 Coll St, Toronto, ON MST 1P7, Canada.	laurie.zawertailo@camh.ca	Zawertailo, Laurie/L-2809-2019					Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Gibbons RD, 2013, AM J PSYCHIAT, V170, P1460, DOI 10.1176/appi.ajp.2013.12121599; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Hurt RD, 1996, JAMA-J AM MED ASSOC, V275, P1097, DOI 10.1001/jama.275.14.1097; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Pfizer Canada Inc, 2016, PROD MON CHAMP VAR T; Thomas KH, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1109; US Food and Drug Administration, 2014, CHANT SER NEUR ADV E; Valeant Canada, 2016, PROD MON ZYB BUPR HC; Wu Q, 2016, ADDICTION, V111, P1554, DOI 10.1111/add.13415	11	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2016	387	10037					2481	2482		10.1016/S0140-6736(16)30294-X	http://dx.doi.org/10.1016/S0140-6736(16)30294-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO7FG	27116919				2023-01-03	WOS:000377947200004
J	Saha, C; Kaushik, A; Das, A; Pal, S; Majumder, D				Saha, Chabita; Kaushik, Agrima; Das, Asmita; Pal, Sandip; Majumder, Debashis			Anthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer Treatment	PLOS ONE			English	Article							HUMAN SERUM-ALBUMIN; DOXORUBICIN; PLGA; NANOSPHERES; ADSORPTION; APOPTOSIS	Polymer nanoparticles are vehicles used for delivery of hydrophobic anti-cancer drugs, like doxorubicin, paclitaxel or chemopreventors like quercetin (Q). The present study deals with the synthesis and characterisation of nano formulations (NFs) from Q loaded PLGA (poly lactic-co-glycolic acid) nano particles (NPs) by surface modification. The surface of Q-loaded (NPs) is modified by coating with biopolymers like bovine serum albumin (BSA) or histones (His). Conventional chemotherapeutic drugs adriamycin (ADR) and mitoxantrone (MTX) are bound to BSA and His respectively before being coated on Q-loaded NPs to nano formulate NF1 and NF2 respectively. The sizes of these NFs are in the range 400500 nm as ascertained by SEM and DLS measurements. Encapsulation of Q in polymer NPs is confirmed from shifts in FT-IR, TGA and DSC traces of Q-loaded NPs compared to native PLGA and Q. Surface modification in NFs is evidenced by three distinct regions in their TEM images; the core, polymer capsule and the coated surface. Negative zeta potential of Q-loaded NPs shifted to positive potential on surface modification in NF1 and NF2. In vitro release of Q from the NFs lasted up to twenty days with an early burst release. NF2 is better formulation than NF1 as loading of MTX is 85% compared to 23% loading of ADR. Such NFs are expected to overcome multi-drug resistance (MDR) by reaching and treating the target cancerous cells by virtue of size, charge and retention.	[Saha, Chabita; Kaushik, Agrima; Das, Asmita; Pal, Sandip; Majumder, Debashis] Maulana Abul Kalam Azad Univ Technol, Dept Biotechnol, BF 142,Sect 1, Kolkata 700064, W Bengal, India	Maulana Abul Kalam Azad University of Technology	Saha, C (corresponding author), Maulana Abul Kalam Azad Univ Technol, Dept Biotechnol, BF 142,Sect 1, Kolkata 700064, W Bengal, India.	k.chabita@gmail.com	Saha, chabita/AAW-5020-2021	Das, Asmita/0000-0001-9846-1005	Department of Science and Technology, India [WOS-A CS 49/12]; Department of Science and Technology, India	Department of Science and Technology, India(Department of Science & Technology (India)); Department of Science and Technology, India(Department of Science & Technology (India))	This work was funded by Department of Science and Technology, India (www.dst.gov.in; Dr Chabita Saha; WOS-A CS 49/12).; Author Chabita Saha is thankful to Department of Science and Technology, India for financial support. The authors are thankful to Centre for Research in Nano Science and Nano Technology, Kolkata for providing us with FTIR, SEM and TEM facility. Thanks are also extended to UGC-DAE Centre for Research, Kolkata for providing DLS, Zeta Potential facility. The Vice-Chancellor of MAKAUT, Prof. S. K. Dey is acknowledged for his constant support and cooperation.	Agudelo D, 2016, INT J BIOL MACROMOL, V88, P354, DOI 10.1016/j.ijbiomac.2016.03.060; Agudelo D, PROBING BINDING SITE, DOI [10.1371/journal.pone.0043814, DOI 10.1371/JOURNAL.PONE.0043814]; Azimi O, 2011, MOLECULES, V16, P9792, DOI 10.3390/molecules16129792; Babu C., 2014, INT J DRUG DELIV, V6, P151, DOI [10.5138/ijdd.v6i2.1418, DOI 10.5138/IJDD.V6I2.1418]; Chen C, 2010, LIFE SCI, V87, P333, DOI 10.1016/j.lfs.2010.07.004; da Costa EM, 2002, THERMOCHIM ACTA, V392, P79, DOI 10.1016/S0040-6031(02)00087-4; Desai N, 2012, AAPS J, V14, P282, DOI 10.1208/s12248-012-9339-4; Duggan ST, 2011, DRUGS, V71, P2531, DOI 10.2165/11207510-000000000-00000; Ghosh D, 2012, DNA CELL BIOL, V31, P377, DOI 10.1089/dna.2011.1299; Graves RA, 2015, EUR J PHARM SCI, V76, P1, DOI 10.1016/j.ejps.2015.04.024; Heneczkowski M, 2001, Acta Pol Pharm, V58, P415; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hosainzadeh A, 2012, J BIOMOL STRUCT DYN, V29, P1013, DOI 10.1080/073911012010525029; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; Kim SH, 1998, EXP MOL MED, V30, P87, DOI 10.1038/emm.1998.13; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Kuznetsova IM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040845; Li XY, 2013, INT J MOL SCI, V14, P21647, DOI 10.3390/ijms141121647; LI Y, 1994, DRUG METAB DISPOS, V22, P566; Liu YH, 2013, NANOTOXICOLOGY, V7, P97, DOI 10.3109/17435390.2011.634079; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Manoochehri S, 2013, DARU, V21, DOI 10.1186/2008-2231-21-58; Nagavarma B. V. N., 2012, ASIAN J PHARM CLIN R, V5, P16; Nava-Arzaluz Maria G, 2012, Recent Pat Drug Deliv Formul, V6, P209; Nie SM, 2010, NANOMEDICINE-UK, V5, P523, DOI 10.2217/NNM.10.23; Peng HS, 2010, J NANOMATER, V2010, DOI 10.1155/2010/592901; Pirooznia N, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-20; Rahnama E, 2015, J BIOMOL STRUCT DYN, V33, P513, DOI 10.1080/07391102.2014.893540; Rai S, 2011, J BIOMED NANOTECHNOL, V7, P121, DOI 10.1166/jbn.2011.1231; Ravindran A, 2010, COLLOID SURFACE B, V76, P32, DOI 10.1016/j.colsurfb.2009.10.005; Sadat TMF, 2014, ASIAN PAC J CANCER P, V15, P517, DOI DOI 10.7314/APJCP.2014.15.2.517; Selvaraj K., 2013, INT J PHARM PHARM SC, V5, P743; Servagent-Noinville S, 2000, J COLLOID INTERF SCI, V221, P273, DOI 10.1006/jcis.1999.6576; Shi M, 2009, ADV FUNCT MATER, V19, P1689, DOI 10.1002/adfm.200801271; Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141; Swarnali I., 2011, INT J PHARM PHARM SC, V3, P181; Tan ML, 2009, J PHARM PHARMACOL, V61, P131, DOI 10.1211/jpp/61.02.0001; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Vega E, 2012, INT J NANOMED, V7, P1357, DOI 10.2147/IJN.S28481; VERRECCHIA T, 1993, J BIOMED MATER RES, V27, P1019, DOI 10.1002/jbm.820270807; Walgren RA, 2000, J PHARMACOL EXP THER, V294, P837; Wen J, 2012, J PHARM SCI-US, V101, P955, DOI 10.1002/jps.22820; You J, 2012, CANCER RES, V72, P4777, DOI 10.1158/0008-5472.CAN-12-1003; Zhang M, 2011, ADV EXP MED BIOL, V701, P283, DOI 10.1007/978-1-4419-7756-4_38; Zobel AM, 2000, PHARM BIOL, V38, P192, DOI 10.1076/1388-0209(200007)3831-SFT192	45	33	35	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155710	10.1371/journal.pone.0155710	http://dx.doi.org/10.1371/journal.pone.0155710			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27196562	gold, Green Submitted, Green Published			2023-01-03	WOS:000376291100087
J	Urrutia, J; Porteny, T; Daniels, N				Urrutia, Julian; Porteny, Thalia; Daniels, Norman			What does it mean to put new hepatitis C drugs on a list of essential medicines?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DIRECT-ACTING ANTIVIRALS; COST-EFFECTIVENESS; ACCESS; ACCOUNTABILITY; REASONABLENESS		[Urrutia, Julian; Porteny, Thalia] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Daniels, Norman] Harvard Univ, Dept Global Hlth & Populat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Urrutia, J (corresponding author), Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA.	jurrutia@fas.harvard.edu	Urrutia, Julian/HII-8237-2022	Urrutia, Julian/0000-0001-9708-2353	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000055] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 2015, NY TIMES; Bazargani YT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1583-4; Beyer P, 2014, INCREASING ACCESS HI; Canary LA, 2015, ANN INTERN MED, V163, P226, DOI 10.7326/M15-0320; Daniels N, 2000, BMJ-BRIT MED J, V321, P1300, DOI 10.1136/bmj.321.7272.1300; Daniels N, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1850; Daniels N, 2015, HEALTH SYST REFORM, V1, P229, DOI 10.1080/23288604.2014.1002705; Ford N, 2015, INT J DRUG POLICY, V26, P1088, DOI 10.1016/j.drugpo.2015.05.004; GLOBOCAN, 2012, EST CANC INC MORT PR; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Hill A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009586; Hill A, 2014, CLIN INFECT DIS, V58, P928, DOI 10.1093/cid/ciu012; Hill A, 2013, CURR OPIN HIV AIDS, V8, P34, DOI 10.1097/COH.0b013e32835b7f28; Hogerzeil HV, 2006, LANCET, V368, P305, DOI 10.1016/S0140-6736(06)69076-4; [Infectious Diseases Society of America American Association for the Study of Liver Diseases], 2016, REC TEST MAN TREAT H; Kirby J, 2015, PEDIATR BLOOD CANCER, V62, P204, DOI 10.1002/pbc.25273; Medecins Sans Frontieres, 2014, UNT WEB ANT PRIC RED; Norheim OF, 2014, MAKING FAIR CHOICES; REICH MR, 1987, HEALTH POLICY, V8, P39, DOI 10.1016/0168-8510(87)90129-1; Rein DB, 2015, CLIN INFECT DIS, V61, P157, DOI 10.1093/cid/civ220; [Servicios Sociales e Igualdad Ministerio de Sanidad], 2015, PLAN ESTR AB HEP C S; UNAIDS, GLOB REP UNAIDS REP; van de Ven N, 2015, HEPATOLOGY, V61, P1174, DOI 10.1002/hep.27641; Walensky RP, 2013, ANN INTERN MED, V158, P84, DOI 10.7326/0003-4819-158-2-201301150-00002; Ward JW, 2015, NEW ENGL J MED, V373, P2678, DOI 10.1056/NEJMe1513245; WHO, DAT PROC HIV HEP PRO; WHO, 2001, WHO MED STRAT REV PR; WHO, 2013, UN HLTH COV SUPP COU; WHO, 2015, ESS MED; WHO, 2015, PAT SIT KEY PROD TRE; Williams R, 2014, LANCET, V384, P1953, DOI 10.1016/S0140-6736(14)61838-9; World Bank, HLTH DAT; World Health Organization, 2015, 20 EXP COMM SEL US E	33	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2016	353								i2035	10.1136/bmj.i2035	http://dx.doi.org/10.1136/bmj.i2035			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK5ZL	27106956				2023-01-03	WOS:000374999700001
J	Ullah, R; Shah, MA; Tufail, S; Ismat, F; Imran, M; Iqbal, M; Mirza, O; Rhaman, M				Ullah, Raheem; Shah, Majid Ali; Tufail, Soban; Ismat, Fouzia; Imran, Muhammad; Iqbal, Mazhar; Mirza, Osman; Rhaman, Moazur			Activity of the Human Rhinovirus 3C Protease Studied in Various Buffers, Additives and Detergents Solutions for Recombinant Protein Production	PLOS ONE			English	Article							ETCH VIRUS PROTEASE; AFFINITY PURIFICATION; EXPRESSION; STABILITY; CLONING	Proteases are widely used to remove affinity and solubility tags from recombinant proteins to avoid potential interference of these tags with the structure and function of the fusion partner. In recent years, great interest has been seen in use of the human rhinovirus 3C protease owing to its stringent sequence specificity and enhanced activity. Like other proteases, activity of the human rhinovirus 3C protease can be affected in part by the buffer components and additives that are generally employed for purification and stabilization of proteins, hence, necessitate their removal by tedious and time-consuming procedures before proteolysis can occur. To address this issue, we examined the effect of elution buffers used for common affinity based purifications, salt ions, stability/solubility and reducing agents, and detergents on the activity of the human rhinovirus 3C protease using three different fusion proteins at 4 degrees C, a temperature of choice for purification of many proteins. The results show that the human rhinovirus 3C protease performs better at 4 degrees C than the frequently used tobacco etch virus protease and its activity was insensitive to most of the experimental conditions tested. Though number of fusion proteins tested is limited, we expect that these finding will facilitate the use of the human rhinovirus 3C protease in recombinant protein production for pharmaceutical and biotechnological applications.	[Ullah, Raheem; Shah, Majid Ali; Tufail, Soban; Ismat, Fouzia; Imran, Muhammad; Iqbal, Mazhar; Rhaman, Moazur] NIBGE, Hlth Biotechnol Div, Drug Discovery & Struct Biol Grp, Faisalabad, Pakistan; [Ullah, Raheem; Shah, Majid Ali; Iqbal, Mazhar; Rhaman, Moazur] Pakistan Inst Engn & Appl Sci, PO Nilore, Islamabad, Pakistan; [Mirza, Osman] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Copenhagen, Denmark; [Imran, Muhammad] Forman Christian Coll, Lahore, Pakistan	Pakistan Institute of Engineering & Applied Science; Pakistan Institute of Engineering & Applied Science; University of Copenhagen	Rhaman, M (corresponding author), NIBGE, Hlth Biotechnol Div, Drug Discovery & Struct Biol Grp, Faisalabad, Pakistan.; Rhaman, M (corresponding author), Pakistan Inst Engn & Appl Sci, PO Nilore, Islamabad, Pakistan.	moazur.rahman@fulbrightmail.org	Iqbal, Mazhar/C-5536-2019; Rahman, Moazur/C-5515-2019	Iqbal, Mazhar/0000-0002-8675-1125; Rahman, Moazur/0000-0003-2892-1250; Mirza, Osman Asghar/0000-0001-9435-0690	International Centre for Genetic Engineering and Biotechnology, Italy [CRP/PAK10-01]; Higher Education Commission of Pakistan	International Centre for Genetic Engineering and Biotechnology, Italy; Higher Education Commission of Pakistan(Higher Education Commission of Pakistan)	We thank Samar Hasnain, University of Liverpool, UK for provision of TEV protease construct and Andreas Engel, Case Western Reserve University, USA for HRV 3C construct. We thank Gerard Huysmans for critical comments and for improving the manuscript. This work was supported by the International Centre for Genetic Engineering and Biotechnology, Italy [ grant No. CRP/PAK10-01; ( awarded to M. Rahman)] and PhD studentships by Higher Education Commission of Pakistan ( awarded to Raheem Ullah and Majid Ali Shah).	Block H, 2009, METHOD ENZYMOL, V463, P439, DOI 10.1016/S0076-6879(09)63027-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Iram N, 2014, APPL MICROBIOL BIOT, V98, P1691, DOI 10.1007/s00253-013-5043-2; Leibly DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052482; Leong LEC, 1999, MOL BIOTECHNOL, V12, P269, DOI 10.1385/MB:12:3:269; Lundback AK, 2008, ANAL BIOCHEM, V382, P69, DOI 10.1016/j.ab.2008.07.018; Mao Yong-Jin, 2007, BMC Biochemistry, V8, P28, DOI 10.1186/1471-2091-8-28; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mohanty AK, 2003, PROTEIN EXPRES PURIF, V27, P109, DOI 10.1016/S1046-5928(02)00589-2; RIGGS P, 2001, CURR PROTOC MOL BIOL, P16; Rocco CJ, 2008, PLASMID, V59, P231, DOI 10.1016/j.plasmid.2008.01.001; Ruckenstein E, 2006, ADV COLLOID INTERFAC, V123, P97, DOI 10.1016/j.cis.2006.05.018; Schmidt TGM, 2007, NAT PROTOC, V2, P1528, DOI 10.1038/nprot.2007.209; Shah MS, 2016, BIOLOGICALS, V44, P19, DOI 10.1016/j.biologicals.2015.10.002; Simons P C, 1981, Methods Enzymol, V77, P235; Smyth DR, 2003, PROTEIN SCI, V12, P1313, DOI 10.1110/ps.0243403; Sun CS, 2012, PROTEIN EXPRES PURIF, V82, P226, DOI 10.1016/j.pep.2012.01.005; Vergis JM, 2011, PROTEIN EXPRES PURIF, V78, P139, DOI 10.1016/j.pep.2011.04.011; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Wang QM, 2001, VIROLOGY, V280, P80, DOI 10.1006/viro.2000.0760; Waugh DS, 2011, PROTEIN EXPRES PURIF, V80, P283, DOI 10.1016/j.pep.2011.08.005; Young CL, 2012, BIOTECHNOL J, V7, P620, DOI 10.1002/biot.201100155	24	22	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0153436	10.1371/journal.pone.0153436	http://dx.doi.org/10.1371/journal.pone.0153436			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27093053	Green Submitted, Green Published, gold			2023-01-03	WOS:000374541200019
J	de la Torre-Ubieta, L; Won, HJ; Stein, JL; Geschwind, DH				de la Torre-Ubieta, Luis; Won, Hyejung; Stein, Jason L.; Geschwind, Daniel H.			Advancing the understanding of autism disease mechanisms through genetics	NATURE MEDICINE			English	Review							PLURIPOTENT STEM-CELLS; COPY-NUMBER VARIATION; DE-NOVO MUTATIONS; MEDIATE SYNAPSE ELIMINATION; OF-FUNCTION MUTATIONS; IPSC-DERIVED NEURONS; MESSENGER-RNA LEVELS; MOUSE MODEL; SPECTRUM DISORDER; SOCIAL-INTERACTION	Progress in understanding the genetic etiology of autism spectrum disorders (ASD) has fueled remarkable advances in our understanding of its potential neurobiological mechanisms. Yet, at the same time, these findings highlight extraordinary causal diversity and complexity at many levels ranging from molecules to circuits and emphasize the gaps in our current knowledge. Here we review current understanding of the genetic architecture of ASD and integrate genetic evidence, neuropathology and studies in model systems with how they inform mechanistic models of ASD pathophysiology. Despite the challenges, these advances provide a solid foundation for the development of rational, targeted molecular therapies.	[de la Torre-Ubieta, Luis; Won, Hyejung; Stein, Jason L.; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Neurogenet Program, Los Angeles, CA 90095 USA; [de la Torre-Ubieta, Luis; Won, Hyejung; Stein, Jason L.; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Ctr Autism Res & Treatment, Los Angeles, CA 90095 USA; [Stein, Jason L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Stein, Jason L.] Univ N Carolina, UNC Neurosci Ctr, Chapel Hill, NC USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Geschwind, DH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Neurogenet Program, Los Angeles, CA 90095 USA.; Geschwind, DH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Ctr Autism Res & Treatment, Los Angeles, CA 90095 USA.	dhg@mednet.ucla.edu		de la Torre-Ubieta, Luis/0000-0001-8059-6243; Stein, Jason/0000-0003-4829-0513	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH060233, R00MH102357, R01MH094714, K99MH102357] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; Abrahams BS, 2010, ARCH NEUROL-CHICAGO, V67, P395, DOI 10.1001/archneurol.2010.47; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; Amaral DG, 2003, ANN NY ACAD SCI, V1000, P337, DOI 10.1196/annals.1280.015; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Anney R, 2012, HUM MOL GENET, V21, P4781, DOI 10.1093/hmg/dds301; Arnedo J, 2015, AM J PSYCHIAT, V172, P139, DOI 10.1176/appi.ajp.2014.14040435; Auerbach BD, 2011, NATURE, V480, P63, DOI 10.1038/nature10658; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Bailey KR, 2006, ILAR J, V47, P124, DOI 10.1093/ilar.47.2.124; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; Bassell GJ, 2008, NEURON, V60, P201, DOI 10.1016/j.neuron.2008.10.004; Baudouin SJ, 2012, SCIENCE, V338, P128, DOI 10.1126/science.1224159; Bedogni F, 2010, P NATL ACAD SCI USA, V107, P13129, DOI 10.1073/pnas.1002285107; Bejjani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038786; Belgard TG, 2014, MOL PSYCHIATR, V19, P405, DOI 10.1038/mp.2013.34; Ben-David E, 2013, MOL PSYCHIATR, V18, P1054, DOI 10.1038/mp.2012.148; Benson AD, 2013, BRAIN RES BULL, V99, P95, DOI 10.1016/j.brainresbull.2013.10.006; Berg JM, 2015, NEURON, V88, P1173, DOI 10.1016/j.neuron.2015.10.031; Berkel S, 2010, NAT GENET, V42, P489, DOI 10.1038/ng.589; Bernardet M, 2006, THESCIENTIFICWORLDJO, V6, P1164, DOI 10.1100/tsw.2006.220; Bernier R, 2014, CELL, V158, P263, DOI 10.1016/j.cell.2014.06.017; Betancur C, 2011, BRAIN RES, V1380, P42, DOI 10.1016/j.brainres.2010.11.078; Blatt GJ, 2001, J AUTISM DEV DISORD, V31, P537, DOI 10.1023/A:1013238809666; Blundell J, 2010, J NEUROSCI, V30, P2115, DOI 10.1523/JNEUROSCI.4517-09.2010; Bozdagi O, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-9; Bozdagi O, 2010, MOL AUTISM, V1, DOI 10.1186/2040-2392-1-15; Bronicki LM, 2015, EUR J HUM GENET, V23, P1482, DOI 10.1038/ejhg.2015.29; Bucan M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000536; Buffington SA, 2014, ANNU REV NEUROSCI, V37, P17, DOI 10.1146/annurev-neuro-071013-014100; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Burket JA, 2013, BRAIN RES BULL, V96, P62, DOI 10.1016/j.brainresbull.2013.05.003; Casanova MF, 2006, ACTA NEUROPATHOL, V112, P287, DOI 10.1007/s00401-006-0085-5; Castro J, 2014, P NATL ACAD SCI USA, V111, P9941, DOI 10.1073/pnas.1311685111; Chadman KK, 2008, AUTISM RES, V1, P147, DOI 10.1002/aur.22; Chang QA, 2006, NEURON, V49, P341, DOI 10.1016/j.neuron.2005.12.027; Chen JA, 2015, ANNU REV PATHOL-MECH, V10, P111, DOI 10.1146/annurev-pathol-012414-040405; Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Chuang HC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00280; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Cohen S, 2008, ANNU REV CELL DEV BI, V24, P183, DOI 10.1146/annurev.cellbio.24.110707.175235; Corradi A, 2014, HUM MOL GENET, V23, P90, DOI 10.1093/hmg/ddt401; Cotney J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7404; Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772; de Vrij FMS, 2008, NEUROBIOL DIS, V31, P127, DOI 10.1016/j.nbd.2008.04.002; Deogracias R, 2012, P NATL ACAD SCI USA, V109, P14230, DOI 10.1073/pnas.1206093109; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Dolmetsch R, 2011, CELL, V145, P831, DOI 10.1016/j.cell.2011.05.034; Duffney LJ, 2015, CELL REP, V11, P1400, DOI 10.1016/j.celrep.2015.04.064; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Ebert DH, 2013, NATURE, V493, P327, DOI 10.1038/nature11860; Ecker C, 2015, LANCET NEUROL, V14, P1121, DOI 10.1016/S1474-4422(15)00050-2; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; Ehninger D, 2011, TRENDS MOL MED, V17, P78, DOI 10.1016/j.molmed.2010.10.002; Ellegood J, 2015, MOL PSYCHIATR, V20, P118, DOI [10.1038/mp.2014.98, 10.1038/mp.2014.168]; Espuny-Camacho I, 2013, NEURON, V77, P440, DOI 10.1016/j.neuron.2012.12.011; Etherton M, 2011, P NATL ACAD SCI USA, V108, P13764, DOI 10.1073/pnas.1111093108; Etherton MR, 2009, P NATL ACAD SCI USA, V106, P17998, DOI 10.1073/pnas.0910297106; Ey E, 2012, GENES BRAIN BEHAV, V11, P928, DOI 10.1111/j.1601-183X.2012.00849.x; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; Fang WQ, 2014, CELL REP, V9, P1635, DOI 10.1016/j.celrep.2014.11.003; Fassio A, 2011, HUM MOL GENET, V20, P2297, DOI 10.1093/hmg/ddr122; Fatemi SH, 2010, J AUTISM DEV DISORD, V40, P743, DOI 10.1007/s10803-009-0924-z; Fatemi SH, 2002, BIOL PSYCHIAT, V52, P805, DOI 10.1016/S0006-3223(02)01430-0; Feng WJ, 2013, CELL STEM CELL, V13, P62, DOI 10.1016/j.stem.2013.05.002; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Fogel BL, 2012, HUM MOL GENET, V21, P4171, DOI 10.1093/hmg/dds240; FOLSTEIN S, 1977, NATURE, V265, P726, DOI 10.1038/265726a0; Fritschy JM, 2008, FRONT MOL NEUROSCI, V1, DOI 10.3389/neuro.02.005.2008; Gaugler T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039; Gauthier J, 2011, HUM GENET, V130, P563, DOI 10.1007/s00439-011-0975-z; Gdalyahu A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125633; Geschwind DH, 2008, CELL, V135, P391, DOI 10.1016/j.cell.2008.10.016; Geschwind DH, 2007, CURR OPIN NEUROBIOL, V17, P103, DOI 10.1016/j.conb.2007.01.009; Geschwind DH, 2015, LANCET NEUROL, V14, P1109, DOI 10.1016/S1474-4422(15)00044-7; Geschwind DH, 2015, SCIENCE, V349, P1489, DOI 10.1126/science.aaa8954; Geschwind DH, 2013, NEURON, V80, P633, DOI 10.1016/j.neuron.2013.10.045; Geschwind DH, 2011, TRENDS COGN SCI, V15, P409, DOI 10.1016/j.tics.2011.07.003; Geschwind DH, 2009, ANNU REV MED, V60, P367, DOI 10.1146/annurev.med.60.053107.121225; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Gillberg C., 1992, BIOL AUTISTIC SYNDRO, V2nd; Gilman SR, 2011, NEURON, V70, P898, DOI 10.1016/j.neuron.2011.05.021; Gkogkas CG, 2013, NATURE, V493, P371, DOI 10.1038/nature11628; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Gratten J, 2014, NAT NEUROSCI, V17, P782, DOI 10.1038/nn.3708; Gratten J, 2013, NAT GENET, V45, P234, DOI 10.1038/ng.2555; Grayton HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067114; Greer PL, 2008, NEURON, V59, P846, DOI 10.1016/j.neuron.2008.09.002; Griesi-Oliveira K, 2015, MOL PSYCHIATR, V20, P1350, DOI 10.1038/mp.2014.141; Griswold AJ, 2012, HUM MOL GENET, V21, P3513, DOI 10.1093/hmg/dds164; Gross C, 2015, CELL REP, V11, P681, DOI 10.1016/j.celrep.2015.03.065; Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305; Gunaydin LA, 2014, CELL, V157, P1535, DOI 10.1016/j.cell.2014.05.017; Gupta S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6748; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Han S, 2014, NEURON, V81, P1282, DOI 10.1016/j.neuron.2014.01.016; Han S, 2012, NATURE, V489, P385, DOI 10.1038/nature11356; Hansen DV, 2011, NEURON, V70, P645, DOI 10.1016/j.neuron.2011.05.006; Hansen DV, 2010, NATURE, V464, P554, DOI 10.1038/nature08845; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Hua JYY, 2004, NAT NEUROSCI, V7, P327, DOI 10.1038/nn1218; Huang TN, 2014, NAT NEUROSCI, V17, P240, DOI 10.1038/nn.3626; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Hutsler JJ, 2010, BRAIN RES, V1309, P83, DOI 10.1016/j.brainres.2009.09.120; Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005; Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Isshiki M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5742; Itsara A, 2010, GENOME RES, V20, P1469, DOI 10.1101/gr.107680.110; Jabtensky A, 2015, AM J PSYCHIAT, V172, P105, DOI 10.1176/appi.ajp.2014.14111452; Jacquemont S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001708; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Jamain S, 2008, P NATL ACAD SCI USA, V105, P1710, DOI 10.1073/pnas.0711555105; Jeste SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9874; Jeste SS, 2015, CURR OPIN NEUROL, V28, P110, DOI 10.1097/WCO.0000000000000181; Ji JL, 2015, EUR J HUM GENET, V23, P1473, DOI 10.1038/ejhg.2015.71; Jones W, 2013, NATURE, V504, P427, DOI 10.1038/nature12715; Kadoshima T, 2013, P NATL ACAD SCI USA, V110, P20284, DOI 10.1073/pnas.1315710110; Kasari C, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0512-6; Kasthuri N, 2015, CELL, V162, P648, DOI 10.1016/j.cell.2015.06.054; Kehrer C, 2008, FRONT MOL NEUROSCI, V1, DOI 10.3389/neuro.02/006.2008; Klei L, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-9; Kline DD, 2010, J NEUROSCI, V30, P5303, DOI 10.1523/JNEUROSCI.5503-09.2010; Kloth AD, 2015, ELIFE, V4, DOI 10.7554/eLife.06085; Krumm N, 2015, NAT GENET, V47, P582, DOI 10.1038/ng.3303; Krumm N, 2014, TRENDS NEUROSCI, V37, P95, DOI 10.1016/j.tins.2013.11.005; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; La Fata G, 2014, NAT NEUROSCI, V17, P1693, DOI 10.1038/nn.3870; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Langen M, 2011, NEUROSCI BIOBEHAV R, V35, P356, DOI 10.1016/j.neubiorev.2010.02.005; Langen M, 2011, NEUROSCI BIOBEHAV R, V35, P345, DOI 10.1016/j.neubiorev.2010.02.004; Laurence JA, 2005, CEREBELLUM, V4, P206, DOI 10.1080/14734220500208846; Lee EJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8168; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Lee SH, 2013, NAT GENET, V45, P984, DOI 10.1038/ng.2711; Lee SH, 2012, NAT GENET, V44, P247, DOI 10.1038/ng.1108; Lepski G, 2011, MOL CELL NEUROSCI, V47, P36, DOI 10.1016/j.mcn.2011.02.011; Levy D, 2011, NEURON, V70, P886, DOI 10.1016/j.neuron.2011.05.015; Li Y, 2013, CELL STEM CELL, V13, P446, DOI 10.1016/j.stem.2013.09.001; Lichtenstein P, 2010, AM J PSYCHIAT, V167, P1357, DOI 10.1176/appi.ajp.2010.10020223; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; Lim CS, 2014, GENE DEV, V28, P273, DOI 10.1101/gad.232470.113; Lim ET, 2013, NEURON, V77, P235, DOI 10.1016/j.neuron.2012.12.029; Lionel AC, 2013, HUM MOL GENET, V22, P2055, DOI 10.1093/hmg/ddt056; Lioy DT, 2011, NATURE, V475, P497, DOI 10.1038/nature10214; Lipton JO, 2014, NEURON, V84, P275, DOI 10.1016/j.neuron.2014.09.034; Long JM, 2004, GENES BRAIN BEHAV, V3, P51, DOI 10.1046/j.1601-183x.2003.00045.x; Lopez-Hurtado E., 2008, AM J BIOCH BIOTECHNO, V4, P130, DOI DOI 10.3844/AJBBSP.2008.130.145; Lowe JK, 2015, AM J PSYCHIAT, V172, P266, DOI 10.1176/appi.ajp.2014.14050576; Luckhardt C, 2014, J NEURAL TRANSM, V121, P1129, DOI 10.1007/s00702-014-1265-4; Lui JH, 2014, NATURE, V515, P264, DOI 10.1038/nature13973; Lyall K, 2014, JAMA PSYCHIAT, V71, P936, DOI 10.1001/jamapsychiatry.2014.476; Magri L, 2011, CELL STEM CELL, V9, P447, DOI 10.1016/j.stem.2011.09.008; Maier R, 2015, AM J HUM GENET, V96, P283, DOI 10.1016/j.ajhg.2014.12.006; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Mariani J, 2015, CELL, V162, P375, DOI 10.1016/j.cell.2015.06.034; Mariani J, 2012, P NATL ACAD SCI USA, V109, P12770, DOI 10.1073/pnas.1202944109; Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; Mayford M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005751; McCammon JM, 2015, ANNU REV GENOM HUM G, V16, P173, DOI 10.1146/annurev-genom-090314-050048; McPartland JC, 2011, CURR OPIN PEDIATR, V23, P628, DOI 10.1097/MOP.0b013e32834cb9c9; Mellios N, 2014, P NATL ACAD SCI USA, V111, P9947, DOI 10.1073/pnas.1309426111; Merkle FT, 2013, CELL STEM CELL, V12, P656, DOI 10.1016/j.stem.2013.05.016; Miles JH, 2011, GENET MED, V13, P278, DOI 10.1097/GIM.0b013e3181ff67ba; Miller JA, 2014, NATURE, V508, P199, DOI 10.1038/nature13185; Minshew NJ, 2007, ARCH NEUROL-CHICAGO, V64, P945, DOI 10.1001/archneur.64.7.945; Morgan JT, 2010, BIOL PSYCHIAT, V68, P368, DOI 10.1016/j.biopsych.2010.05.024; Morrow EM, 2008, SCIENCE, V321, P218, DOI 10.1126/science.1157657; Nakatani J, 2009, CELL, V137, P1235, DOI 10.1016/j.cell.2009.04.024; Napoli I, 2008, CELL, V134, P1042, DOI 10.1016/j.cell.2008.07.031; Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011; Nicholas CR, 2013, CELL STEM CELL, V12, P573, DOI 10.1016/j.stem.2013.04.005; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Nishimura Y, 2007, HUM MOL GENET, V16, P1682, DOI 10.1093/hmg/ddm116; Nishiyama M, 2012, MOL CELL BIOL, V32, P501, DOI 10.1128/MCB.06409-11; Noh HJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003523; Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989; O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835; Oblak A, 2009, AUTISM RES, V2, P205, DOI 10.1002/aur.88; Oblak AL, 2010, J NEUROCHEM, V114, P1414, DOI 10.1111/j.1471-4159.2010.06858.x; Oguro-Ando A, 2015, MOL PSYCHIATR, V20, P1069, DOI 10.1038/mp.2014.124; Osterweil EK, 2010, J NEUROSCI, V30, P15616, DOI 10.1523/JNEUROSCI.3888-10.2010; Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pankevich D. E., 2013, IMPROVING UTILITY TR; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031; Pasca AM, 2015, NAT METHODS, V12, P671, DOI [10.1038/nmeth.3415, 10.1038/NMETH.3415]; Pasca SP, 2011, NAT MED, V17, P1657, DOI 10.1038/nm.2576; Peca J, 2011, NATURE, V472, P437, DOI 10.1038/nature09965; Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257; Penagarikano O, 2011, CELL, V147, P235, DOI 10.1016/j.cell.2011.08.040; Pinto D, 2014, AM J HUM GENET, V94, P677, DOI 10.1016/j.ajhg.2014.03.018; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Piton A, 2013, EUR J HUM GENET, V21, P749, DOI 10.1038/ejhg.2012.243; Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011, Nat Genet, V43, P977, DOI 10.1038/ng.943; Redcay E, 2005, BIOL PSYCHIAT, V58, P1, DOI 10.1016/j.biopsych.2005.03.026; Ricciardi S, 2012, NAT CELL BIOL, V14, P911, DOI 10.1038/ncb2566; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Robinson EB, 2014, MOL PSYCHIATR, V19, P859, DOI 10.1038/mp.2013.125; Robinson EB, 2013, P NATL ACAD SCI USA, V110, P5258, DOI 10.1073/pnas.1211070110; Rogers SJ, 2014, J AUTISM DEV DISORD, V44, P2981, DOI 10.1007/s10803-014-2202-y; Rojas DC, 2014, NEUROIMAGE, V86, P28, DOI 10.1016/j.neuroimage.2013.01.045; Ronald A, 2011, AM J MED GENET B, V156B, P255, DOI 10.1002/ajmg.b.31159; Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413; Ronemus M, 2014, NAT REV GENET, V15, P133, DOI 10.1038/nrg3585; Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004; Rothwell PE, 2014, CELL, V158, P198, DOI 10.1016/j.cell.2014.04.045; Ru WJ, 2012, J MOL NEUROSCI, V47, P340, DOI 10.1007/s12031-012-9753-1; Rudie JD, 2012, NEURON, V75, P904, DOI 10.1016/j.neuron.2012.07.010; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Sanders SJ, 2011, NEURON, V70, P863, DOI 10.1016/j.neuron.2011.05.002; Sandin S, 2014, JAMA-J AM MED ASSOC, V311, P1770, DOI 10.1001/jama.2014.4144; Santini E, 2013, NATURE, V493, P411, DOI 10.1038/nature11782; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Schaaf CP, 2011, HUM MOL GENET, V20, P3366, DOI 10.1093/hmg/ddr243; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schmeisser MJ, 2012, NATURE, V486, P256, DOI 10.1038/nature11015; Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Sham PC, 2014, NAT REV GENET, V15, P335, DOI 10.1038/nrg3706; Shcheglovitov A, 2013, NATURE, V503, P267, DOI 10.1038/nature12618; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201; Skafidas E, 2014, MOL PSYCHIATR, V19, P504, DOI 10.1038/mp.2012.126; Sowers LP, 2013, MOL PSYCHIATR, V18, P1077, DOI 10.1038/mp.2013.71; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Stein JL, 2014, NEURON, V83, P69, DOI 10.1016/j.neuron.2014.05.035; Stessman HA, 2014, CELL, V156, P872, DOI 10.1016/j.cell.2014.02.002; Stoner R, 2014, NEW ENGL J MED, V370, P1209, DOI 10.1056/NEJMoa1307491; Strauss KA, 2006, NEW ENGL J MED, V354, P1370, DOI 10.1056/NEJMoa052773; Subramaniam S, 2005, J NEUROSCI, V25, P2838, DOI 10.1523/JNEUROSCI.5060-04.2005; Sudhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Sugathan A, 2014, P NATL ACAD SCI USA, V111, pE4468, DOI 10.1073/pnas.1405266111; Suzuki K, 2013, JAMA PSYCHIAT, V70, P49, DOI 10.1001/jamapsychiatry.2013.272; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048; Tang GM, 2014, NEURON, V83, P1131, DOI 10.1016/j.neuron.2014.07.040; Tetreault NA, 2012, J AUTISM DEV DISORD, V42, P2569, DOI 10.1007/s10803-012-1513-0; Tian D, 2015, NAT NEUROSCI, V18, P182, DOI 10.1038/nn.3911; Tian Y, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0075-5; Tiberi L, 2012, CURR OPIN CELL BIOL, V24, P269, DOI 10.1016/j.ceb.2012.01.010; Tuoc TC, 2013, DEV CELL, V25, P256, DOI 10.1016/j.devcel.2013.04.005; Tropea D, 2009, P NATL ACAD SCI USA, V106, P2029, DOI 10.1073/pnas.0812394106; Tsai NP, 2012, CELL, V151, P1581, DOI 10.1016/j.cell.2012.11.040; Tsai PT, 2012, NATURE, V488, P647, DOI 10.1038/nature11310; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; Vaags AK, 2012, AM J HUM GENET, V90, P133, DOI 10.1016/j.ajhg.2011.11.025; van de Lagemaat LN, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00394; van de Leemput J, 2014, NEURON, V83, P51, DOI 10.1016/j.neuron.2014.05.013; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vinkhuyzen AAE, 2013, ANNU REV GENET, V47, P75, DOI 10.1146/annurev-genet-111212-133258; Virkud YV, 2009, AM J MED GENET B, V150B, P328, DOI 10.1002/ajmg.b.30810; Vissers ME, 2012, NEUROSCI BIOBEHAV R, V36, P604, DOI 10.1016/j.neubiorev.2011.09.003; Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110; Volkmar FR, 2014, ANNU REV CLIN PSYCHO, V10, P193, DOI 10.1146/annurev-clinpsy-032813-153710; Wang SSH, 2014, NEURON, V83, P518, DOI 10.1016/j.neuron.2014.07.016; Wang XM, 2011, HUM MOL GENET, V20, P3093, DOI 10.1093/hmg/ddr212; Watson KK, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-21; Werker JF, 2015, ANNU REV PSYCHOL, V66, P173, DOI 10.1146/annurev-psych-010814-015104; Werling DM, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-13; Werling DM, 2013, P NATL ACAD SCI USA, V110, P4868, DOI 10.1073/pnas.1301602110; Wilkerson JR, 2014, CELL REP, V7, P1589, DOI 10.1016/j.celrep.2014.04.035; Willsey AJ, 2013, CELL, V155, P997, DOI 10.1016/j.cell.2013.10.020; Wingate M, 2014, MMWR SURVEILL SUMM, V63; Won H, 2012, NATURE, V486, P261, DOI 10.1038/nature11208; Wray NR, 2015, J ANIM BREED GENET, V132, P198, DOI 10.1111/jbg.12153; Yan QJ, 2005, NEUROPHARMACOLOGY, V49, P1053, DOI 10.1016/j.neuropharm.2005.06.004; Yerys BE, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0496-2; Yip J, 2008, J NEUROSCI RES, V86, P525, DOI 10.1002/jnr.21520; Yip J, 2007, ACTA NEUROPATHOL, V113, P559, DOI 10.1007/s00401-006-0176-3; Yip J, 2009, AUTISM RES, V2, P50, DOI 10.1002/aur.62; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Yu TW, 2013, NEURON, V77, P259, DOI 10.1016/j.neuron.2012.11.002; Zafeiriou DI, 2013, AM J MED GENET B, V162B, P327, DOI 10.1002/ajmg.b.32152; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641; Zhao X, 2007, P NATL ACAD SCI USA, V104, P12831, DOI 10.1073/pnas.0705803104; Zhou J, 2011, GENE DEV, V25, P1595, DOI 10.1101/gad.16750211; Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009; Zhou ZL, 2006, NEURON, V52, P255, DOI 10.1016/j.neuron.2006.09.037; Zikopoulos B, 2010, J NEUROSCI, V30, P14595, DOI 10.1523/JNEUROSCI.2257-10.2010; Zingg B, 2014, CELL, V156, P1096, DOI 10.1016/j.cell.2014.02.023	300	446	450	10	275	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2016	22	4					345	361		10.1038/nm.4071	http://dx.doi.org/10.1038/nm.4071			17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DI4GF	27050589	Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000373457700010
J	Hashimoto, A; Sato, T; Iyama, S; Yoshida, M; Ibata, S; Tatekoshi, A; Kamihara, Y; Horiguchi, H; Murase, K; Kawano, Y; Takada, K; Miyanishi, K; Kobune, M; Ichimiya, S; Kato, J				Hashimoto, Akari; Sato, Tsutomu; Iyama, Satoshi; Yoshida, Masahiro; Ibata, Soushi; Tatekoshi, Ayumi; Kamihara, Yusuke; Horiguchi, Hiroto; Murase, Kazuyuki; Kawano, Yutaka; Takada, Kohichi; Miyanishi, Koji; Kobune, Masayoshi; Ichimiya, Shingo; Kato, Junji			Narrow-Band Ultraviolet B Phototherapy Ameliorates Acute Graft-Versus-Host Disease of the Intestine by Expansion of Regulatory T Cells	PLOS ONE			English	Article							STEROID-REFRACTORY ACUTE; PITUITARY-ADRENAL AXIS; EXTRACORPOREAL PHOTOPHERESIS; ACUTE GVHD; THERAPY; UVB; TRANSPLANTATION; PREDNISONE; ANTIGENS; SOCIETY	Narrowband ultraviolet B (NB-UVB) has been widely used in dermatological phototherapy. As for the application of NB-UVB phototherapy to graft-versus-host disease (GVHD), we previously reported that it was highly efficacious for cutaneous lesions of acute GVHD (aGVHD) and that expansion of regulatory T (Treg) cells induced by NB-UVB might be one of the mechanisms. In order to examine whether NB-UVB irradiation through expansion of Treg cells is effective for the treatment of not only cutaneous aGVHD but also aGVHD of inner organs such as the intestine or liver, we conducted experiments in which a murine lethal aGVHD model, characterized by severe involvement of the intestine, was irradiated with NB-UVB. We found that NB-UVB irradiation improved the clinical score and survival rate. The pathological score of aGVHD was improved in all affected organs: intestine, liver, and skin. In the serum of mice irradiated with NB-UVB, the levels of Treg cells-associated cytokines such as transforming growth factor beta (TGF beta) and interleukin-10 (IL-10) were elevated. The numbers of infiltrating Treg cells in inflamed tissue of the intestine and those in spleen were increased in mice treated with NB-UVB. This is the first report demonstrating that NB-UVB phototherapy has the ability to ameliorate intestinal aGVHD through the expansion of Treg cells.	[Hashimoto, Akari; Sato, Tsutomu; Iyama, Satoshi; Yoshida, Masahiro; Ibata, Soushi; Tatekoshi, Ayumi; Kamihara, Yusuke; Horiguchi, Hiroto; Murase, Kazuyuki; Kawano, Yutaka; Takada, Kohichi; Miyanishi, Koji; Kobune, Masayoshi; Kato, Junji] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan; [Ichimiya, Shingo] Sapporo Med Univ, Sch Med, Res Inst Frontier Med, Dept Human Immunol, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University	Kato, J (corresponding author), Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan.	jkato@sapmed.ac.jp	Horiguchi, Hiroto/ADC-8272-2022; Iyama, Satoshi/AAA-6237-2019	Horiguchi, Hiroto/0000-0001-6811-3042; Goto, Akari/0000-0003-2582-851X; Miyanishi, Koji/0000-0002-6466-3458	Japan Society for the Promotion of Science [25461429]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by a Grant-in-Aid for Scientific Research (C: 25461429 to Tsutomu Sato, Satoshi Iyama, and Yutaka Kawano) from Japan Society for the Promotion of Science (https://www.jsps.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu-Dalle I, 2014, BIOL BLOOD MARROW TR, V20, P1677, DOI 10.1016/j.bbmt.2014.05.017; Akiyama T, 2012, WORLD J ORTHOP, V3, P142, DOI 10.5312/wjo.v3.i9.142; Brazzelli V, 2010, BRIT J DERMATOL, V162, P404, DOI 10.1111/j.1365-2133.2009.09503.x; Christensen ME, 2010, HAEMATOL-HEMATOL J, V95, P2102, DOI 10.3324/haematol.2010.028910; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Dawe RS, 1998, BRIT J DERMATOL, V138, P833; Dickinson AM, 2008, BEST PRACT RES CL HA, V21, P149, DOI 10.1016/j.beha.2008.03.004; Dignan FL, 2012, BRIT J HAEMATOL, V158, P30, DOI 10.1111/j.1365-2141.2012.09129.x; Feldstein JV, 2011, J AM ACAD DERMATOL, V65, P733, DOI 10.1016/j.jaad.2010.08.006; Flowers MED, 2008, BLOOD, V112, P2667, DOI 10.1182/blood-2008-03-141481; Girerd S, 2013, BONE MARROW TRANSPL, V48, P1243, DOI 10.1038/bmt.2013.16; Hannani D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00349; HINGS IM, 1993, TRANSPLANTATION, V56, P577, DOI 10.1097/00007890-199309000-00016; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Jagasia M, 2013, BIOL BLOOD MARROW TR, V19, P1129, DOI 10.1016/j.bbmt.2013.04.018; Kambham N, 2014, ADV ANAT PATHOL, V21, P301, DOI 10.1097/PAP.0000000000000032; Kaplan DH, 2004, J IMMUNOL, V173, P5467, DOI 10.4049/jimmunol.173.9.5467; Koreth J, 2011, NEW ENGL J MED, V365, P2055, DOI 10.1056/NEJMoa1108188; Kunisada M, 2007, J INVEST DERMATOL, V127, P2865, DOI 10.1038/sj.jid.5701001; Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; MacMillan ML, 2002, BIOL BLOOD MARROW TR, V8, P387, DOI 10.1053/bbmt.2002.v8.pm12171485; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P1150, DOI 10.1016/j.bbmt.2012.04.005; MARTIN PJ, 1990, BLOOD, V76, P1464, DOI 10.1182/blood.V76.8.1464.1464; Mielcarek M, 2009, BLOOD, V113, P2888, DOI 10.1182/blood-2008-07-168401; Miklos S, 2008, BIOL BLOOD MARROW TR, V14, P1004, DOI 10.1016/j.bbmt.2008.06.015; Panoskaltsis-Mortari A, 2011, AM J RESP CRIT CARE, V183, P1262, DOI 10.1164/rccm.2007-413ST; Reich A, 2013, INT J MOL SCI, V14, P8456, DOI 10.3390/ijms14048456; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Shin HJ, 2011, BLOOD, V118, P2342, DOI 10.1182/blood-2010-10-313684; Skobowiat C, 2013, BRIT J DERMATOL, V168, P595, DOI 10.1111/bjd.12096; Skobowiat C, 2016, EXP DERMATOL, V25, P120, DOI 10.1111/exd.12890; Skobowiat C, 2015, J INVEST DERMATOL, V135, P1638, DOI 10.1038/jid.2014.450; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; SLOMINSKI A, 2013, J STEROID BIOCHEM, V137, P107, DOI [DOI 10.1016/j.jsbmb.2013.02.006, 10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Thompson JS, 2010, BONE MARROW TRANSPL, V45, P712, DOI 10.1038/bmt.2009.215; Treister N, 2015, PHOTODERMATOL PHOTO, V31, P75, DOI 10.1111/phpp.12141; van Leeuwen L, 2002, BONE MARROW TRANSPL, V29, P151, DOI 10.1038/sj.bmt.1703328; Van Lint MT, 1998, BLOOD, V92, P2288; vanLeeuwen L, 1997, TRANSPLANTATION, V64, P1097, DOI 10.1097/00007890-199710270-00002; Ward DM, 2011, J CLIN APHERESIS, V26, P276, DOI 10.1002/jca.20300; Wong YS, 2015, PEDIATR DERMATOL, V32, pE221, DOI 10.1111/pde.12632	47	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152823	10.1371/journal.pone.0152823	http://dx.doi.org/10.1371/journal.pone.0152823			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27031239	Green Published, Green Submitted, gold			2023-01-03	WOS:000373121800144
J	Santos-Pontelli, TEG; Rimoli, BP; Favoretto, DB; Mazin, SC; Truong, DQ; Leite, JP; Pontes-Neto, OM; Babyar, SR; Reding, M; Bikson, M; Edwards, DJ				Santos-Pontelli, Taiza E. G.; Rimoli, Brunna P.; Favoretto, Diandra B.; Mazin, Suleimy C.; Truong, Dennis Q.; Leite, Joao P.; Pontes-Neto, Octavio M.; Babyar, Suzanne R.; Reding, Michael; Bikson, Marom; Edwards, Dylan J.			Polarity-Dependent Misperception of Subjective Visual Vertical during and after Transcranial Direct Current Stimulation (tDCS)	PLOS ONE			English	Article							GALVANIC-VESTIBULAR STIMULATION; NONINVASIVE BRAIN-STIMULATION; MOTOR CORTEX EXCITABILITY; RANDOMIZED-TRIALS; PERCEPTION; MODULATION; NEGLECT; STROKE; LATEROPULSION; RECOVERY	Pathologic tilt of subjective visual vertical (SVV) frequently has adverse functional consequences for patients with stroke and vestibular disorders. Repetitive transcranial magnetic stimulation (rTMS) of the supramarginal gyrus can produce a transitory tilt on SVV in healthy subjects. However, the effect of transcranial direct current stimulation (tDCS) on SVV has never been systematically studied. We investigated whether bilateral tDCS over the temporal-parietal region could result in both online and offline SVV misperception in healthy subjects. In a randomized, sham-controlled, single-blind crossover pilot study, thirteen healthy subjects performed tests of SVV before, during and after the tDCS applied over the temporal- parietal region in three conditions used on different days: right anode/left cathode; right cathode/left anode; and sham. Subjects were blind to the tDCS conditions. Montage-specific current flow patterns were investigated using computational models. SVV was significantly displaced towards the anode during both active stimulation conditions when compared to sham condition. Immediately after both active conditions, there were rebound effects. Longer lasting after-effects towards the anode occurred only in the right cathode/left anode condition. Current flow models predicted the stimulation of temporal-parietal regions under the electrodes and deep clusters in the posterior limb of the internal capsule. The present findings indicate that tDCS over the temporal-parietal region can significantly alter human SVV perception. This tDCS approach may be a potential clinical tool for the treatment of SVV misperception in neurological patients.	[Santos-Pontelli, Taiza E. G.; Rimoli, Brunna P.; Favoretto, Diandra B.; Mazin, Suleimy C.; Leite, Joao P.; Pontes-Neto, Octavio M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav Sci, BR-14049 Ribeirao Preto, SP, Brazil; [Truong, Dennis Q.; Bikson, Marom] CUNY City Coll, Neural Engn Lab, Dept Biomed Engn, New York, NY 10031 USA; [Babyar, Suzanne R.; Reding, Michael; Edwards, Dylan J.] Cornell Univ, Coll Med, Burke Med Res Inst, Noninvas Brain Stimulat & Human Motor Control Lab, White Plains, NY 10605 USA; [Babyar, Suzanne R.; Reding, Michael; Edwards, Dylan J.] Cornell Univ, Dept Neurol, Weill Med Coll, New York, NY 10021 USA	Universidade de Sao Paulo; City University of New York (CUNY) System; City College of New York (CUNY); Cornell University; Cornell University	Santos-Pontelli, TEG (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav Sci, BR-14049 Ribeirao Preto, SP, Brazil.	taiza@fmrp.usp.br	Edwards, Taiza GS/F-9214-2012; Leite, Joao/B-9070-2012; Pontes-Neto, Octavio Marques/G-4294-2012	Edwards, Taiza GS/0000-0003-3033-2981; Leite, Joao/0000-0003-0558-3519; Pontes-Neto, Octavio Marques/0000-0003-0317-843X; Babyar, Suzanne/0000-0002-3367-3717; Edwards, Dylan/0000-0001-7346-3100; Favoretto, Diandra/0000-0001-6853-1914	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil; NICHD of the National Institutes of Health - USA [R01HD069776]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD069776] Funding Source: NIH RePORTER	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NICHD of the National Institutes of Health - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by funds from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil. DJE was supported by NICHD of the National Institutes of Health - USA, under award number R01HD069776.; This work was supported by funds from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil. DJE was supported by NICHD of the National Institutes of Health-USA, under award number R01HD069776. The authors declare no competing financial interests.	Ahmad H, 2014, J VESTIBUL RES-EQUIL, V24, P453, DOI 10.3233/VES-140530; Arshad Q, 2014, BRAIN STIMUL, V7, P85, DOI 10.1016/j.brs.2013.07.002; Baier B, 2012, NEUROLOGY, V78, P728, DOI 10.1212/WNL.0b013e318248e544; Barra J, 2010, BRAIN, V133, P3552, DOI 10.1093/brain/awq311; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Batuecas-Caletrio A, 2013, ACTA OTO-LARYNGOL, V133, P475, DOI 10.3109/00016489.2012.757798; Bjasch D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049311; Bonan IV, 2007, J NEUROL NEUROSUR PS, V78, P49, DOI 10.1136/jnnp.2006.087791; Brandt T, 2000, NEUROREHAB NEURAL RE, V14, P1, DOI 10.1177/154596830001400101; Bronstein AM, 1999, ANN NY ACAD SCI, V871, P324, DOI 10.1111/j.1749-6632.1999.tb09195.x; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Cauquil AS, 2003, EXP BRAIN RES, V148, P414, DOI 10.1007/s00221-002-1326-z; Cocks K, 2013, J CLIN EPIDEMIOL, V66, P197, DOI 10.1016/j.jclinepi.2012.09.002; Cohen J., 2013, STAT POWER ANAL BEHA; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; Datta A, 2009, BRAIN STIMUL, V2, P201, DOI 10.1016/j.brs.2009.03.005; Dayan E, 2013, NAT NEUROSCI, V16, P838, DOI 10.1038/nn.3422; Dieterich M, 2003, CEREB CORTEX, V13, P994, DOI 10.1093/cercor/13.9.994; DIETERICH M, 1993, NEUROLOGY, V43, P1732, DOI 10.1212/WNL.43.9.1732; Donaldson PH, 2015, NEUROSCI BIOBEHAV R, V55, P547, DOI 10.1016/j.neubiorev.2015.05.017; Fertonani A, 2011, J NEUROSCI, V31, P15416, DOI 10.1523/JNEUROSCI.2002-11.2011; Giglia G, 2011, BRAIN STIMUL, V4, P294, DOI 10.1016/j.brs.2011.01.003; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd edn; Karnath HO, 2006, BRAIN, V129, P293, DOI 10.1093/brain/awh698; Karnath HO, 2001, NATURE, V411, P950, DOI 10.1038/35082075; Kerkhoff G, 1998, EXP BRAIN RES, V122, P108, DOI 10.1007/s002210050497; Kheradmand A, 2015, CEREB CORTEX, V25, P765, DOI 10.1093/cercor/bht267; Kyriakareli A, 2013, NEUROREPORT, V24, P808, DOI 10.1097/WNR.0b013e3283646e65; Laakso I, 2015, BRAIN STIMUL, V8, P906, DOI 10.1016/j.brs.2015.05.002; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lang N, 2007, INVEST OPHTH VIS SCI, V48, P5782, DOI 10.1167/iovs.07-0706; Lopez C, 2011, NEUROSCIENCE, V181, P134, DOI 10.1016/j.neuroscience.2011.02.009; Lopez C, 2011, BRAIN RES REV, V67, P119, DOI 10.1016/j.brainresrev.2010.12.002; Mars F, 2001, NEUROREPORT, V12, P2991, DOI 10.1097/00001756-200109170-00047; Martin DM, 2014, EXP BRAIN RES, V232, P3345, DOI 10.1007/s00221-014-4022-x; Min KK, 2007, OTOL NEUROTOL, V28, P520, DOI 10.1097/01.mao.0000271674.41307.f2; Nasseri P, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00054; Oppenlander K, 2015, NEUROPSYCHOLOGIA, V74, P178, DOI 10.1016/j.neuropsychologia.2015.03.004; Oppenlander K, 2015, NEUROPSYCHOLOGIA, V74, P170, DOI 10.1016/j.neuropsychologia.2014.10.039; Perennou DA, 2008, BRAIN, V131, P2401, DOI 10.1093/brain/awn170; Pergolizzi D, 2015, NEUROPSYCHOLOGIA, V66, P88, DOI 10.1016/j.neuropsychologia.2014.11.012; Rohrmeier C, 2013, OTOL NEUROTOL, V34, P297, DOI 10.1097/MAO.0b013e31827d0901; Rorden C, 2004, NAT REV NEUROSCI, V5, P813, DOI 10.1038/nrn1521; Rousseaux M, 2013, NEUROLOGY, V81, P1291, DOI 10.1212/WNL.0b013e3182a823a7; Saj A, 2006, NEUROPSYCHOLOGIA, V44, P1509, DOI 10.1016/j.neuropsychologia.2005.11.018; Schlaug G, 2008, ARCH NEUROL-CHICAGO, V65, P1571, DOI 10.1001/archneur.65.12.1571; Schulz KF, 2005, LANCET, V365, P1591, DOI 10.1016/S0140-6736(05)66461-6; Shin YI, 2015, NEUROPSYCHOLOGIA, V69, P154, DOI 10.1016/j.neuropsychologia.2015.02.002; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stinear CM, 2015, BRAIN STIMUL, V8, P1183, DOI 10.1016/j.brs.2015.06.015; Sunwoo H, 2013, NEUROSCI LETT, V554, P94, DOI 10.1016/j.neulet.2013.08.064; Tazoe T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114244; Truong DQ, 2013, NEUROIMAGE-CLIN, V2, P759, DOI 10.1016/j.nicl.2013.05.011; Turkeltaub PE, 2012, BRAIN STIMUL, V5, P201, DOI 10.1016/j.brs.2011.04.002; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Volkening K, 2014, NEUROSCI LETT, V581, P75, DOI 10.1016/j.neulet.2014.08.028; Wagner TA, 2004, IEEE T BIO-MED ENG, V51, P1586, DOI 10.1109/TBME.2004.827925; Yelnik AP, 2002, STROKE, V33, P2247, DOI 10.1161/01.STR.0000027212.26686.48; Zwergal A, 2009, NEUROLOGY, V72, P1689, DOI 10.1212/WNL.0b013e3181a55ecf	60	13	13	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152331	10.1371/journal.pone.0152331	http://dx.doi.org/10.1371/journal.pone.0152331			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27031726	Green Published, gold			2023-01-03	WOS:000373121800058
J	Rinalduzzi, S; Serafini, M; Capozza, M; Accornero, N; Missori, P; Trompetto, C; Fattapposta, F; Curra, A				Rinalduzzi, Steno; Serafini, Marco; Capozza, Marco; Accornero, Neri; Missori, Paolo; Trompetto, Carlo; Fattapposta, Francesco; Curra, Antonio			Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy	PLOS ONE			English	Article							DIABETIC SENSORY NEUROPATHY; PERIPHERAL NEUROPATHY; PROPRIOCEPTIVE CONTROL; INVERTED PENDULUM; MUSCLE-ACTIVITY; BALANCE CONTROL; POLYNEUROPATHY; ANKLE; MOVEMENTS; FALLS	Introduction Polyneuropathy leads to postural instability and an increased risk of falling. We investigated how impaired motor impairment and proprioceptive input due to neuropathy influences postural strategies. Methods Platformless bisegmental posturography data were recorded in healthy subjects and patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Each subject stood on the floor, wore a head and a hip electromagnetic tracker. Sway amplitude and velocity were recorded and the mean direction difference (MDD) in the velocity vector between trackers was calculated as a flexibility index. Results Head and hip postural sway increased more in patients with CIDP than in healthy controls. MDD values reflecting hip strategies also increased more in patients than in controls. In the eyes closed condition MDD values in healthy subjects decreased but in patients remained unchanged. Discussion Sensori-motor impairment changes the balance between postural strategies that patients adopt to maintain upright quiet stance. Motor impairment leads to hip postural strategy overweight (eyes open), and prevents strategy re-balancing when the sensory context predominantly relies on proprioceptive input (eyes closed).	[Rinalduzzi, Steno; Serafini, Marco] Sandro Pertini Hosp, Neurol & Neurophysiopathol Unit, Rome, Italy; [Capozza, Marco; Accornero, Neri; Fattapposta, Francesco] Univ Roma La Sapienza, Dept Neurol & Psychiat, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Missori, Paolo] Univ Roma La Sapienza, Neurosurg Unit, Policlin Umberto 1, Dept Neurol & Psychiat, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Trompetto, Carlo] Univ Genoa, Inst Neurol, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Curra, Antonio] Univ Roma La Sapienza, Dept Med Surg Sci & Biotechnol, A Fiorini Hosp, Acad Neurol Unit, Terracina, LT, Italy	Ospedale Sandro Pertini; Sapienza University Rome; Sapienza University Rome; University Hospital Sapienza Rome; University of Genoa; Sapienza University Rome	Rinalduzzi, S (corresponding author), Sandro Pertini Hosp, Neurol & Neurophysiopathol Unit, Rome, Italy.	r.steno@libero.it	Trompetto, Carlo/AAC-3550-2022	Trompetto, Carlo/0000-0003-3419-0669; Curra, Antonio/0000-0002-7945-8342				Accornero N, 1997, ELECTROMYOGR MOTOR C, V105, P213, DOI 10.1016/S0924-980X(97)96567-X; Allet L, 2012, MUSCLE NERVE, V45, P578, DOI 10.1002/mus.22325; Allum JHJ, 1998, GAIT POSTURE, V8, P214, DOI 10.1016/S0966-6362(98)00027-7; Andersen H, 1997, EUR NEUROL, V37, P239, DOI 10.1159/000117450; Andersen H, 1997, DIABETIC MED, V14, P221, DOI 10.1002/(SICI)1096-9136(199703)14:3<221::AID-DIA338>3.0.CO;2-K; Banks RW, 2009, J ANAT, V214, P859, DOI 10.1111/j.1469-7580.2009.01072.x; Bloem BR, 2002, EXP BRAIN RES, V142, P91, DOI 10.1007/s00221-001-0926-3; Butler AA, 2008, BRAIN RES, V1242, P244, DOI 10.1016/j.brainres.2008.03.094; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; Corriveau H, 2000, DIABETES CARE, V23, P1187, DOI 10.2337/diacare.23.8.1187; Creath R, 2005, NEUROSCI LETT, V377, P75, DOI 10.1016/j.neulet.2004.11.071; DAY BL, 1993, J PHYSIOL-LONDON, V469, P479, DOI 10.1113/jphysiol.1993.sp019824; DeMott TK, 2007, AM J PHYS MED REHAB, V86, P125, DOI 10.1097/PHM.0b013e31802ee1d1; DYCK PJ, 1980, ANN NEUROL, V8, P590, DOI 10.1002/ana.410080608; Finley JM, 2009, IEEE ENG MED BIO, P7265, DOI 10.1109/IEMBS.2009.5334730; FORSSBERG H, 1994, EXP BRAIN RES, V97, P515; Frohman EM, 1996, ANN NEUROL, V39, P529, DOI 10.1002/ana.410390415; Gorson KC, 2012, THER ADV NEUROL DISO, V5, P359, DOI 10.1177/1756285612457215; Gorson KC, 2010, J PERIPHER NERV SYST, V15, P326, DOI 10.1111/j.1529-8027.2010.00284.x; Gutierrez EM, 2001, CLIN BIOMECH, V16, P522, DOI 10.1016/S0268-0033(01)00034-1; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; HORAK FB, 1990, EXP BRAIN RES, V82, P167; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369, DOI 10.1152/jn.1986.55.6.1369; HORAK FB, 1989, NEUROBIOL AGING, V10, P727, DOI 10.1016/0197-4580(89)90010-9; Horlings CGC, 2008, CLIN NEUROPHYSIOL, V119, P2338, DOI 10.1016/j.clinph.2008.07.221; Koski CL, 2009, J NEUROL SCI, V277, P1, DOI 10.1016/j.jns.2008.11.015; KUO AD, 1993, PROG BRAIN RES, V97, P349; Lafond D, 2004, DIABETES CARE, V27, P173, DOI 10.2337/diacare.27.1.173; Ledin T, 1990, J Vestib Res, V1, P123; Loram ID, 2011, J PHYSIOL-LONDON, V589, P307, DOI 10.1113/jphysiol.2010.194712; Loram ID, 2009, J NEUROPHYSIOL, V102, P460, DOI 10.1152/jn.00007.2009; Loram ID, 2002, J PHYSIOL-LONDON, V540, P1111, DOI 10.1113/jphysiol.2001.013077; MacGilchrist C, 2010, DIABETIC MED, V27, P162, DOI 10.1111/j.1464-5491.2009.02914.x; MANCHESTER D, 1989, J GERONTOL MED SCI, V44, P118; MERGNER T, 1991, EXP BRAIN RES, V85, P389; Nardone A, 2007, CLIN NEUROPHYSIOL, V118, P538, DOI 10.1016/j.clinph.2006.11.012; Oppenheim U, 1999, DIABETES CARE, V22, P328, DOI 10.2337/diacare.22.2.328; PEARSON MB, 1985, AGE AGEING, V14, P49, DOI 10.1093/ageing/14.1.49; PEDOTTI A, 1989, EXP BRAIN RES, V74, P3; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; Rinalduzzi S, 2011, ACTA NEUROL SCAND, V123, P111, DOI 10.1111/j.1600-0404.2010.01349.x; Runge CF, 1999, GAIT POSTURE, V10, P161, DOI 10.1016/S0966-6362(99)00032-6; SIMONEAU GG, 1994, DIABETES CARE, V17, P1411, DOI 10.2337/diacare.17.12.1411; Son J, 2009, MUSCLE NERVE, V39, P150, DOI 10.1002/mus.21194; Torres-Oviedo G, 2007, J NEUROPHYSIOL, V98, P2144, DOI 10.1152/jn.01360.2006; Turcot K, 2012, DIABETES TECHNOL THE, V14, P403, DOI 10.1089/dia.2011.0181; UCCIOLI L, 1995, DIABETES CARE, V18, P339, DOI 10.2337/diacare.18.3.339; van der Linden MH, 2010, GAIT POSTURE, V31, P483, DOI 10.1016/j.gaitpost.2010.02.005; VANDERVOORT AA, 1989, EUR J APPL PHYSIOL O, V58, P389, DOI 10.1007/BF00643514; Yamamoto R, 2001, DIABETES RES CLIN PR, V52, P213, DOI 10.1016/S0168-8227(01)00236-4	50	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151629	10.1371/journal.pone.0151629	http://dx.doi.org/10.1371/journal.pone.0151629			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26977594	Green Published, gold, Green Submitted			2023-01-03	WOS:000372572800096
J	Zhang, TH; Casanova, R; Resnick, SM; Manson, JE; Baker, LD; Padual, CB; Kuller, LH; Bryan, RN; Espeland, MA; Davatzikos, C				Zhang, Tianhao; Casanova, Ramon; Resnick, Susan M.; Manson, Joann E.; Baker, Laura D.; Padual, Claudia B.; Kuller, Lewis H.; Bryan, R. Nick; Espeland, Mark A.; Davatzikos, Christos			Effects of Hormone Therapy on Brain Volumes Changes of Postmenopausal Women Revealed by Optimally-Discriminative Voxel-Based Morphometry	PLOS ONE			English	Article							ANTERIOR CINGULATE CORTEX; HEALTH INITIATIVE MEMORY; SUBCLINICAL CEREBROVASCULAR-DISEASE; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; WHIMS-MRI; MAGNETIC-RESONANCE; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX	Backgrounds The Women's Health Initiative Memory Study Magnetic Resonance Imaging (WHIMS-MRI) provides an opportunity to evaluate how menopausal hormone therapy (HT) affects the structure of older women's brains. Our earlier work based on region of interest (ROI) analysis demonstrated potential structural changes underlying adverse effects of HT on cognition. However, the ROI-based analysis is limited in statistical power and precision, and cannot provide fine-grained mapping of whole-brain changes. Methods We aimed to identify local structural differences between HT and placebo groups from WHIMS-MRI in a whole-brain refined level, by using a novel method, named Optimally-Discriminative Voxel-Based Analysis (ODVBA). ODVBA is a recently proposed imaging pattern analysis approach for group comparisons utilizing a spatially adaptive analysis scheme to accurately locate areas of group differences, thereby providing superior sensitivity and specificity to detect the structural brain changes over conventional methods. Results Women assigned to HT treatments had significant Gray Matter (GM) losses compared to the placebo groups in the anterior cingulate and the adjacent medial frontal gyrus, and the orbitofrontal cortex, which persisted after multiple comparison corrections. There were no regions where HT was significantly associated with larger volumes compared to placebo, although a trend of marginal significance was found in the posterior cingulate cortical area. The CEE-Alone and CEE+MPA groups, although compared with different placebo controls, demonstrated similar effects according to the spatial patterns of structural changes. Conclusions HT had adverse effects on GM volumes and risk for cognitive impairment and dementia in older women. These findings advanced our understanding of the neurobiological underpinnings of HT effects.	[Zhang, Tianhao; Bryan, R. Nick; Davatzikos, Christos] Univ Penn, Dept Radiol, Ctr Biomed Image Comp & Analyt, Philadelphia, PA 19104 USA; [Casanova, Ramon; Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA; [Resnick, Susan M.] NIA, Lab Behav Neurosci, Baltimore, MD 21224 USA; [Manson, Joann E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA; [Manson, Joann E.] Harvard Univ, Sch Med, Boston, MA USA; [Manson, Joann E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Baker, Laura D.] Wake Forest Sch Med, Dept Internal Med & Epidemiol, Winston Salem, NC USA; [Padual, Claudia B.] VA Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA; [Padual, Claudia B.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	University of Pennsylvania; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Wake Forest University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, TH (corresponding author), Univ Penn, Dept Radiol, Ctr Biomed Image Comp & Analyt, Philadelphia, PA 19104 USA.	tianhao.zhang@uphs.upenn.edu	Davatzikos, Christos/ABE-2057-2021	Davatzikos, Christos/0000-0002-1025-8561	National Heart, Lung, and Blood Institute; National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; NIH [R01AG14971]; NATIONAL INSTITUTE ON AGING [ZIAAG000190, R01AG014971] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The WHI program is funded by the National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov/), National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. TZ and CD were supported by NIH grant R01AG14971. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1998, PHANT TEST GUID ACR; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Berent-Spillson A, 2010, MENOPAUSE, V17, P692, DOI 10.1097/gme.0b013e3181cc49e9; Boccardi M, 2005, NEUROBIOL AGING, V26, P37, DOI 10.1016/j.neurobiolaging.2004.02.019; Boccardi M, 2006, MENOPAUSE, V13, P584, DOI 10.1097/01.gme.0000196811.88505.10; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Casanova R, 2011, MAGN RESON IMAGING, V29, P546, DOI 10.1016/j.mri.2010.12.001; Chaim TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110199; Coker LH, 2009, NEUROLOGY, V72, P125, DOI 10.1212/01.wnl.0000339036.88842.9e; Coker LH, 2014, NEUROLOGY, V82, P427, DOI 10.1212/WNL.0000000000000079; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Davatzikos C, 2001, NEUROIMAGE, V14, P1361, DOI 10.1006/nimg.2001.0937; Decety J, 2012, CEREB CORTEX, V22, P209, DOI 10.1093/cercor/bhr111; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Erickson KI, 2005, NEUROBIOL AGING, V26, P1205, DOI 10.1016/j.neurobiolaging.2004.11.009; Erus G, 2015, DIABETES CARE, V38, P97, DOI 10.2337/dc14-1196; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2010, J AM GERIATR SOC, V58, P1263, DOI 10.1111/j.1532-5415.2010.02953.x; Fellows LK, 2005, BRAIN, V128, P788, DOI 10.1093/brain/awh405; Friston K.J., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Goveas JS, 2011, J AFFECT DISORDERS, V132, P275, DOI 10.1016/j.jad.2011.01.020; Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Hakamata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075526; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Ihara M, 2010, ACTA NEUROPATHOL, V119, P579, DOI 10.1007/s00401-009-0635-8; Jaramillo SA, 2007, ACAD RADIOL, V14, P603, DOI 10.1016/j.acra.2007.02.001; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kabani N. J., 1998, 4 INT C FUNCT MAPP H; Kamitani Y, 2010, NEUROIMAGE, V49, P1949, DOI 10.1016/j.neuroimage.2009.06.040; Kiebel S., 2003, GEN LINEAR MODEL; Kjaer TW, 2002, NEUROIMAGE, V17, P1080, DOI 10.1006/nimg.2002.1230; Kolling N, 2012, SCIENCE, V336, P95, DOI 10.1126/science.1216930; Lord C, 2010, MENOPAUSE, V17, P846, DOI 10.1097/gme.0b013e3181e06b83; Lundstrom BN, 2003, NEUROIMAGE, V20, P1934, DOI 10.1016/j.neuroimage.2003.07.017; Maki PM, 2013, MENOPAUSE, V20, P695, DOI [10.1097/GME.0b013e3182960cf8, 10.1097/gme.0b013e3182960cf8]; Natrella M, 2010, NIST SEMATECH HDB ST; Nichols T, 2003, STAT METHODS MED RES, V12, P419, DOI 10.1191/0962280203sm341ra; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Pham DL, 1999, IEEE T MED IMAGING, V18, P737, DOI 10.1109/42.802752; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rasgon NL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089095; Resnick SM, 2009, NEUROLOGY, V72, P135, DOI 10.1212/01.wnl.0000339037.76336.cf; Resnick SM, 2002, JAMA-J AM MED ASSOC, V288, P2170, DOI 10.1001/jama.288.17.2170; Rosen HJ, 2002, NEUROLOGY, V58, P198, DOI 10.1212/WNL.58.2.198; Saltelli A, 2002, RISK ANAL, V22, P579, DOI 10.1111/0272-4332.00040; Shen DG, 2002, IEEE T MED IMAGING, V21, P1421, DOI 10.1109/TMI.2002.803111; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Stelzer J, 2013, NEUROIMAGE, V65, P69, DOI 10.1016/j.neuroimage.2012.09.063; Swartz RH, 2008, STROKE, V39, P822, DOI 10.1161/STROKEAHA.107.491936; Talairach J., 1988, CO PLANAR STEREOTAXI; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72; Thomas J, 2014, PSYCHONEUROENDOCRINO, V50, P167, DOI 10.1016/j.psyneuen.2014.08.012; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Whitmer RA, 2011, ANN NEUROL, V69, P163, DOI 10.1002/ana.22239; Zhang TH, 2015, SCHIZOPHRENIA BULL, V41, P74, DOI 10.1093/schbul/sbu136; Zhang TH, 2013, NEUROIMAGE, V79, P94, DOI 10.1016/j.neuroimage.2013.04.063; Zhang TH, 2011, IEEE T MED IMAGING, V30, P1441, DOI 10.1109/TMI.2011.2114362; Zhang Y, 2008, NEUROIMAGE, V42, P218, DOI 10.1016/j.neuroimage.2008.04.181	68	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2016	11	3							e0150834	10.1371/journal.pone.0150834	http://dx.doi.org/10.1371/journal.pone.0150834			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1UO	26974440	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000372570600034
J	Broen, MPG; Marsman, VAM; Kuijf, ML; Van Oostenbrugge, RJ; van Os, J; Leentjens, AFG				Broen, Martijn P. G.; Marsman, Vera A. M.; Kuijf, Mark L.; Van Oostenbrugge, Robert J.; van Os, Jim; Leentjens, Albert F. G.			Unraveling the Relationship between Motor Symptoms, Affective States and Contextual Factors in Parkinson's Disease: A Feasibility Study of the Experience Sampling Method	PLOS ONE			English	Article							MOMENTARY ASSESSMENT; DAILY-LIFE; DEPRESSION; ANXIETY; MOOD; FLUCTUATIONS; VALIDATION; QUALITY; ONSET	Background In Parkinson's disease (PD), the complex relationship between motor symptoms, affective states, and contextual factors remains to be elucidated. The Experience Sampling Method provides (ESM) a novel approach to this issue. Using a mobile device with a special purpose application (app), motor symptoms, affective states and contextual factors are assessed repeatedly at random moments in the flow of daily life, yielding an intensive time series of symptoms and experience. The aim of this study was to study the feasibility of this method. Method We studied the feasibility of a five-day period of ESM in PD and its ability to objectify diurnal fluctuations in motor symptom severity and their relation with affect and contextual factors in five PD patients with motor fluctuations. Results Participants achieved a high compliance, with 84% of assessment moments completed without disturbance of daily activities. The utility of the device was rated 8 on a 10-point scale. We were able to capture extensive diurnal fluctuations that were not revealed by routine clinical assessment. In addition, we were able to detect clinically relevant associations between motor symptoms, emotional fluctuations and contextual factors at an intra-individual level. Conclusions ESM represents a viable and novel approach to elucidate relationships between motor symptoms, affective states and contextual factors at the level of individual subjects. ESM holds promise for clinical practice and scientific research.	[Broen, Martijn P. G.; Kuijf, Mark L.; Van Oostenbrugge, Robert J.] Maastricht Univ, Med Ctr, Dept Neurol, NL-6200 MD Maastricht, Netherlands; [Marsman, Vera A. M.; van Os, Jim; Leentjens, Albert F. G.] Maastricht Univ, Med Ctr, Dept Psychiat & Psychol, NL-6200 MD Maastricht, Netherlands; [van Os, Jim] Kings Coll London, Kings Hlth Partners, Dept Psychosis Studies, Inst Psychiat, London WC2R 2LS, England	Maastricht University; Maastricht University; University of London; King's College London	Broen, MPG (corresponding author), Maastricht Univ, Med Ctr, Dept Neurol, NL-6200 MD Maastricht, Netherlands.	martijn.broen@mumc.nl	Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/V-8884-2019; van Os, Jim/C-2113-2014	van Os, Jim/0000-0002-7245-1586; 	Michael J Fox Foundation; Stichting Internationaal Parkinson Fonds; Elsevier Inc	Michael J Fox Foundation; Stichting Internationaal Parkinson Fonds; Elsevier Inc	M. Broen, V. Marsman, M. Kuijf and R. Van Oostenbrugge have nothing to disclose. J. van Os has potential financial competing interests since he received unrestricted investigator-led research grants or recompense for presenting research at meetings from Eli Lilly, Bristol-Myers Squibb, Lundbeck, Organon, Takeda, Janssen-Cilag, GlaxoSmithKline, AstraZeneca, Pfizer and Servier. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. A.F.G. Leentjens has potential financial competing interests since he received research grants from the Michael J Fox Foundation and the Stichting Internationaal Parkinson Fonds, as well as royalties from Reed-Elsevier, de Tijdstroom and Van Gorcum publishers. In addition he receives payment from Elsevier Inc as Editor-in-Chief of the Journal of Psychosomatic Research. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Barge-Schaapveld DQCM, 2002, J CLIN PSYCHIAT, V63, P477, DOI 10.4088/JCP.v63n0603; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Benka Wallen M, 2015, PHYS THER; CANTELLO R, 1986, J NEUROL NEUROSUR PS, V49, P1182, DOI 10.1136/jnnp.49.10.1182; CSIKSZENTMIHALYI M, 1987, J NERV MENT DIS, V175, P526, DOI 10.1097/00005053-198709000-00004; Csikszentmihalyi M., 2006, EXPERIENCE PSYCHOPAT; Delespaul P.A.E.G., 1995, ASSESSING SCHIZOPHRE; deRijk MC, 1997, NEUROLOGY, V48, P1277, DOI 10.1212/WNL.48.5.1277; Dunton GF, 2015, HEALTH PSYCHOL, V34, P1145, DOI 10.1037/hea0000223; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hartmann JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128095; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Houtveen JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072827; Hufford M.R., 2001, PROGR AMBULATORY ASS, P69; Jacobs N, 2011, BRIT J CLIN PSYCHOL, V50, P19, DOI 10.1348/014466510X491397; Jenkinson C, 1997, AGE AGEING, V26, P353, DOI 10.1093/ageing/26.5.353; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; Kramer I, 2014, WORLD PSYCHIATRY, V13, P68, DOI 10.1002/wps.20090; Leentjens AFG, 2012, PARKINSONISM RELAT D, V18, P1084, DOI 10.1016/j.parkreldis.2012.06.007; Leentjens AFG, 2014, MOVEMENT DISORD, V29, P1035, DOI 10.1002/mds.25919; Louter M, 2015, J NEUROL NEUROSUR PS, V86, P32, DOI 10.1136/jnnp-2013-306851; Mujagic Z, 2015, NEUROGASTROENT MOTIL, V27, P1295, DOI 10.1111/nmo.12624; Mulvaney SA, 2013, J MED INTERNET RES, V15, P130, DOI 10.2196/jmir.2413; Myin-Germeys I, 2009, PSYCHOL MED, V39, P1533, DOI 10.1017/S0033291708004947; NISSENBAUM H, 1987, PSYCHOL MED, V17, P899, DOI 10.1017/S0033291700000702; Odawara M, 2015, INT J BEHAV MED; Peeters F, 2006, EMOTION, V6, P383, DOI 10.1037/1528-3542.6.3.383; Rahman S, 2008, MOVEMENT DISORD, V23, P1428, DOI 10.1002/mds.21667; Richard IH, 2001, J NEUROPSYCH CLIN N, V13, P35, DOI 10.1176/appi.neuropsych.13.1.35; Richard Irene H, 2004, Cogn Behav Neurol, V17, P201; Sotgiu I, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00336; van de Leemput IA, 2014, P NATL ACAD SCI USA, V111, P87, DOI 10.1073/pnas.1312114110; van Os J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115254; van Os J, 2013, WORLD PSYCHIATRY, V12, P113, DOI 10.1002/wps.20046; Walz LC, 2014, J ANXIETY DISORD, V28, P925, DOI 10.1016/j.janxdis.2014.09.022; Wichers M, 2011, ACTA PSYCHIAT SCAND, V124, P262, DOI 10.1111/j.1600-0447.2011.01749.x; Wichers MC, 2009, NEUROPSYCHOPHARMACOL, V34, P923, DOI 10.1038/npp.2008.66	38	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2016	11	3							e0151195	10.1371/journal.pone.0151195	http://dx.doi.org/10.1371/journal.pone.0151195			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TL	26962853	gold, Green Published, Green Submitted			2023-01-03	WOS:000371993000119
J	Bredlau, AL				Bredlau, Amy-Lee			Where Do You Put the Pain?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bredlau, Amy-Lee] Med Univ S Carolina, Pediat Brain Tumor Program, Dept Pediat, Charleston, SC 29412 USA	Medical University of South Carolina	Bredlau, AL (corresponding author), Med Univ S Carolina, Pediat Brain Tumor Program, Dept Pediat, Charleston, SC 29412 USA.	bredlau@musc.edu							0	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2016	315	10					983	983		10.1001/jama.2015.17474	http://dx.doi.org/10.1001/jama.2015.17474			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF7LW	26954404				2023-01-03	WOS:000371540200008
J	Eliasen, M; Kreiner, S; Ebstrup, JF; Poulsen, CH; Lau, CJ; Skovbjerg, S; Fink, PK; Jorgensen, T				Eliasen, Marie; Kreiner, Svend; Ebstrup, Jeanette F.; Poulsen, Chalotte H.; Lau, Cathrine J.; Skovbjerg, Sine; Fink, Per K.; Jorgensen, Torben			Somatic Symptoms: Prevalence, Co-Occurrence and Associations with Self-Perceived Health and Limitations Due To Physical Health - A Danish Population-Based Study	PLOS ONE			English	Article							PAIN SITES; COMPLAINTS; DISABILITY; MODELS; NUMBER	A high number of somatic symptoms have been associated with poor health status and increased health care use. Previous studies focused on number of symptoms without considering the specific symptoms. The aim of the study was to investigate 1) the prevalence of 19 somatic symptoms, 2) the associations between the symptoms, and 3) the associations between the somatic symptoms, self-perceived health and limitations due to physical health accounting for the co-occurrence of symptoms. Information on 19 somatic symptoms, self-perceived health and limitations due to physical health was achieved from a population-based questionnaire survey of 36,163 randomly selected adults in the Capital Region of Denmark in 2006/07. Chain graph models were used to transparently identify and describe the associations between symptoms, self-perceived health and limitations due to physical health. In total, 94.9% of the respondents were bothered by one or more of the 19 somatic symptoms. The symptoms were associated in a complex structure. Still, recognisable patterns were identified within organ systems/body parts. When accounting for symptom co-occurrence; dizziness, pain in legs, respiratory distress and tiredness were all strongly directly associated with both of the outcomes (gamma>0.30). Chest pain was strongly associated with self-perceived health, and other musculoskeletal symptoms and urinary retention were strongly associated with limitations due to physical health. Other symptoms were either moderate or not statistically associated with the health status outcomes. Opposite, almost all the symptoms were strongly associated with the two outcomes when not accounting for symptom co-occurrence. In conclusion, we found that somatic symptoms were frequent and associated in a complex structure. The associations between symptoms and health status measures differed between the symptoms and depended on the co-occurrence of symptoms. This indicates an importance of considering both the specific symptoms and symptom co-occurrence in further symptom research instead of merely counting symptoms.	[Eliasen, Marie; Ebstrup, Jeanette F.; Poulsen, Chalotte H.; Lau, Cathrine J.; Skovbjerg, Sine; Jorgensen, Torben] Capital Reg Denmark, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Kreiner, Svend; Jorgensen, Torben] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark; [Poulsen, Chalotte H.] Capital Reg Denmark, Mental Hlth Ctr Copenhagen, Gentofte, Denmark; [Fink, Per K.] Aarhus Univ Hosp, Res Clin Funct Disorders & Psychosomat, DK-8000 Aarhus, Denmark; [Jorgensen, Torben] Aalborg Univ, Dept Clin Med, Aalborg, Denmark	University of Copenhagen; Aarhus University; Aalborg University	Eliasen, M (corresponding author), Capital Reg Denmark, Res Ctr Prevent & Hlth, Glostrup, Denmark.	marie.eliasen@regioh.dk	Fink, Per/AAA-2297-2021; Poulsen, Chalotte H/K-3111-2018; Jørgensen, Torben/Z-1335-2018	Poulsen, Chalotte H/0000-0001-6420-1918; Jorgensen, Torben/0000-0001-9453-2830; Eliasen, Marie Holm/0000-0002-1464-8719; Fink, Per/0000-0003-2921-4099; Juel Lau, Cathrine/0000-0001-5100-7518	Lundbeck Foundation [R155-2013-14070]; TrygFonden [7-11-0213]	Lundbeck Foundation(Lundbeckfonden); TrygFonden	The Lundbeck Foundation (www.lundbeckfoundation.com), grant number R155-2013-14070 and TrygFonden (www.trygfonden.dk), grant number 7-11-0213 funded the Danish study of Functional Disorders (DanFunD) which facilitated the study including providing salary to ME, SK, JFE, CHP and SS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bruusgaard D, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1085; Christensen AI, 2012, SCAND J PUBLIC HEALT, V40, P391, DOI 10.1177/1403494812451412; DAVIS JA, 1967, J AM STAT ASSOC, V62, P189, DOI 10.2307/2282922; Didelez V, 2010, STAT SCI, V25, P368, DOI 10.1214/10-STS340; Eriksen HR, 1999, SCAND J PUBLIC HEALT, V27, P63, DOI 10.1177/14034948990270010401; Fink P, 2007, PSYCHOSOM MED, V69, P30, DOI 10.1097/PSY.0b013e31802e46eb; Gierk B, 2014, JAMA INTERN MED, V174, P399, DOI 10.1001/jamainternmed.2013.12179; Glumer C., 2008, SUNDHEDSPROFIL REGIO; Glymour MM, 2008, MODERN EPIDEMIOLOGY, V3rd, P183; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Hartvigsen J, 2013, BEST PRACT RES CL RH, V27, P613, DOI 10.1016/j.berh.2013.09.008; Ihlebaek C, 2002, SCAND J PUBLIC HEALT, V30, P20, DOI 10.1080/140349401753481547; Kamaleri Y, 2008, EUR J PAIN, V12, P742, DOI 10.1016/j.ejpain.2007.11.005; Kamaleri Y, 2009, EUR J PAIN, V13, P426, DOI 10.1016/j.ejpain.2008.05.009; Kocalevent RD, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-91; Kreiner S., 1986, COMPSTAT. Proceedings in Computational Statistics. 7th Symposium, P43; KREINER S, 1987, SCAND J STAT, V14, P97; Kreiner S, 1998, ENCY BIOSTATISTICS, P2063; Kreiner S, 2009, DERIVING TESTING HYP; Kreiner S., 2003, INTRO DIGRAM; Lauritzen S.L., 1996, GRAPHICAL MODELS; Liu G, 1997, PSYCHOL MED, V27, P617, DOI 10.1017/S0033291797004844; McAteer A, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548910; Nimnuan C, 2001, J PSYCHOSOM RES, V51, P549, DOI 10.1016/S0022-3999(01)00224-0; Nordin S, 2013, SCAND J PSYCHOL, V54, P112, DOI 10.1111/sjop.12029; Patterson BJ, 2012, DISABIL HEALTH J, V5, P151, DOI 10.1016/j.dhjo.2012.03.001; Petrie KJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005374; Poulsen OM, 2013, SCAND J PUBLIC HEALT, V41, P150, DOI 10.1177/1403494812471909; Robbins JM, 1997, J NERV MENT DIS, V185, P606, DOI 10.1097/00005053-199710000-00003; Roelen CAM, 2010, WORK, V37, P15, DOI 10.3233/WOR-2010-1052; Toft U, 2014, EURJPUBLIC HEAL; Tomenson B, 2013, BRIT J PSYCHIAT, V203, P373, DOI 10.1192/bjp.bp.112.114405; Tsai CH, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-160; Tschudi-Madsen H, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-285; Whittaker J., 1990, WILEY SERIES PROBABI; Witthoft M, 2013, INT J BEHAV MED, V20, P172, DOI 10.1007/s12529-012-9237-2; Zijlema WL, 2013, J PSYCHOSOM RES, V74, P459, DOI 10.1016/j.jpsychores.2013.03.093	38	22	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0150664	10.1371/journal.pone.0150664	http://dx.doi.org/10.1371/journal.pone.0150664			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF5ZW	26930630	Green Published, Green Submitted, gold			2023-01-03	WOS:000371434500181
J	Chan, ACS; Qiu, Q; Choi, SW; Wong, SSC; Chan, ACY; Irwin, MG; Cheung, CW				Chan, Alfred Chor San; Qiu, Qiu; Choi, Siu Wai; Wong, Stanley Sau Ching; Chan, Albert Chi Yan; Irwin, Michael G.; Cheung, Chi Wai			Effects of Intra-Operative Total Intravenous Anaesthesia with Propofol versus Inhalational Anaesthesia with Sevoflurane on Post-Operative Pain in Liver Surgery: A Retrospective Case-Control Study	PLOS ONE			English	Article							PATIENT-CONTROLLED ANALGESIA; SPINAL-CORD; PHARMACOKINETICS; DESFLURANE; RECEPTORS; SELECTION; CIRRHOSIS; RESECTION; CHANNELS; MODEL	Background Patients receiving total intravenous anesthesia (TIVA) with propofol have been shown to experience less postoperative pain. We evaluated the post-operative analgesic effects of propofol compared with sevoflurane maintenance of anesthesia in liver surgery. This study was registered at ClinicalTrials.gov (NCT02179437). Methods In this retrospective study, records of patients who underwent liver surgery between 2010 and 2013 were reviewed. Ninety-five patients anesthetized with propofol TIVA were matched with 95 patients anesthetized with sevoflurane. Numeric pain rating scale (NRS) pain scores, postoperative morphine consumption, side effects and patients' satisfaction with pain relief were evaluated. Results The TIVA group reported lower NRS pain scores during coughing on postoperative days 1 and 2 but not 3 (p = 0.0127, p = 0.0472, p = 0.4556 respectively). They also consumed significantly less daily (p = 0.001 on day 1, p = 0.0231 on day 2, p = 0.0004 on day 3), accumulative (p = 0.001 on day 1, p < 0.0001 on day 2 and p = 0.0064 on day 3) and total morphine (p = 0.03) when compared with the sevoflurane group. There were no differences in total duration of intravenous patient controlled analgesia (PCA) morphine use and patient satisfaction. No difference was found in reported side effects. Conclusion Patients anesthetized with propofol TIVA reported less pain during coughing and consumed less daily, accumulative and total morphine after liver surgery.	[Chan, Alfred Chor San] Queen Mary Hosp, Dept Anaesthesiol, Hong Kong, Hong Kong, Peoples R China; [Qiu, Qiu; Choi, Siu Wai; Wong, Stanley Sau Ching; Irwin, Michael G.; Cheung, Chi Wai] Univ Hong Kong, Dept Anaesthesiol, Lab & Clin Res Inst Pain, Hong Kong, Hong Kong, Peoples R China; [Chan, Albert Chi Yan] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Cheung, CW (corresponding author), Univ Hong Kong, Dept Anaesthesiol, Lab & Clin Res Inst Pain, Hong Kong, Hong Kong, Peoples R China.	cheucw@hku.hk	Irwin, Michael Garnet/C-4286-2009; Chan, Albert/AAC-1642-2022; Irwin, Michael Garnet/GLR-9714-2022; /I-7963-2013	Irwin, Michael Garnet/0000-0001-5801-274X; Chan, Albert/0000-0002-1383-2952; Irwin, Michael Garnet/0000-0001-5801-274X; /0000-0002-8763-5687	Department of Anesthesiology at the University of Hong Kong	Department of Anesthesiology at the University of Hong Kong	This submission was funded by the Department of Anesthesiology at the University of Hong Kong. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An K, 2008, ANAESTHESIA, V63, P1187, DOI 10.1111/j.1365-2044.2008.05627.x; Antognini JF, 2000, CAN J ANAESTH, V47, P273, DOI 10.1007/BF03018926; Bandschapp O, 2010, ANESTHESIOLOGY, V113, P421, DOI 10.1097/ALN.0b013e3181e33ac8; Behne M, 1999, CLIN PHARMACOKINET, V36, P13, DOI 10.2165/00003088-199936010-00002; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Chandok N, 2010, MAYO CLIN PROC, V85, P451, DOI 10.4065/mcp.2009.0534; Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9; Cheung CW, 2012, J ORAL MAXIL SURG, V70, P25, DOI 10.1016/j.joms.2011.03.056; Cheung CW, 2009, EUR J PAIN, V13, P464, DOI 10.1016/j.ejpain.2008.05.013; Cho AR, 2013, ANESTH ANALG, V116, P685, DOI 10.1213/ANE.0b013e31827ee372; Costela JL, 1996, ACTA ANAESTH SCAND, V40, P741, DOI 10.1111/j.1399-6576.1996.tb04521.x; Fang Y, 2014, J GASTROEN HEPATOL, V29, P193, DOI 10.1111/jgh.12441; Fassoulaki A, 2008, ANESTH ANALG, V107, P1715, DOI 10.1213/ane.0b013e318182d84e; Feltracco P, 2014, TRANSPL P, V46, P2300, DOI 10.1016/j.transproceed.2014.07.023; Ganapathi S, 2015, BRIT J PAIN, V9, P78, DOI 10.1177/2049463714525140; Guindon J, 2007, ANESTH ANALG, V104, P1563, DOI 10.1213/01.ane.0000263278.05423.a3; Hand R Jr, 2001, AANA J, V69, P466; Hasani A, 2013, PAIN MED, V14, P442, DOI 10.1111/pme.12031; Honda M, 2014, J CLIN ONCOL, V32, P3200, DOI 10.1200/JCO.2014.55.9682; Hotbauer RK, 2004, ANESTHESIOLOGY, V100, P386, DOI 10.1097/00000542-200402000-00031; Kingston S, 2006, ANESTHESIOLOGY, V104, P763, DOI 10.1097/00000542-200604000-00021; Ko JS, 2009, LIVER TRANSPLANT, V15, P381, DOI 10.1002/lt.21625; Kumar G, 2014, ANAESTHESIA, V69, P1138, DOI 10.1111/anae.12713; Li M, 2012, ACTA ANAESTH SCAND, V56, P368, DOI 10.1111/j.1399-6576.2011.02603.x; Lyashchenko AK, 2007, J PHYSIOL-LONDON, V583, P37, DOI 10.1113/jphysiol.2007.136465; Ma X, 2013, ARCH BIOCHEM BIOPHYS, V533, P1, DOI 10.1016/j.abb.2013.03.002; Mu XB, 2010, NEUROSCI LETT, V484, P206, DOI 10.1016/j.neulet.2010.08.055; Nadeson R, 1997, J PHARMACOL EXP THER, V282, P1181; Niven Daniel J, 2012, Clin Epidemiol, V4, P99, DOI 10.2147/CLEP.S30816; Rudin A, 2007, ANESTH ANALG, V104, P1409, DOI 10.1213/01.ane.0000261847.26044.1d; Samir A, 2015, ANTIINFLAMMATORY EFF; Schultz NA, 2013, BRIT J SURG, V100, P138, DOI 10.1002/bjs.8996; SERVIN F, 1990, BRIT J ANAESTH, V65, P177, DOI 10.1093/bja/65.2.177; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Suttner S, 1999, ANESTH ANALG, V88, P77, DOI 10.1097/00000539-199901000-00015; Tan T, 2010, ANESTH ANALG, V111, P83, DOI 10.1213/ANE.0b013e3181c0ee9e; Taura P, 2003, ANESTH ANALG, V96, P475, DOI 10.1097/00000539-200302000-00033; Tibbs GR, 2013, J PHARMACOL EXP THER, V345, P363, DOI 10.1124/jpet.113.203620; Tsuchiya M, 2001, AM J RESP CRIT CARE, V163, P26, DOI 10.1164/ajrccm.163.1.9911120; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396	40	11	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149753	10.1371/journal.pone.0149753	http://dx.doi.org/10.1371/journal.pone.0149753			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901037	gold, Green Submitted, Green Published			2023-01-03	WOS:000371276100143
J	Andersen, TR; Schmidt, JF; Pedersen, MT; Krustrup, P; Bangsbo, J				Andersen, Thomas Rostgaard; Schmidt, Jakob Friis; Pedersen, Mogens Theisen; Krustrup, Peter; Bangsbo, Jens			The Effects of 52 Weeks of Soccer or Resistance Training on Body Composition and Muscle Function in+65-Year-Old Healthy Males - A Randomized Controlled Trial	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; CARDIOVASCULAR HEALTH; PHYSICAL-ACTIVITY; EXERCISE; FOOTBALL; PROTEIN; STRENGTH; PERFORMANCE; PREVENTION; PROFILE	The effects of 52 weeks of soccer or resistance training were investigated in untrained elderly men. The subjects aged 68.1 +/- 2.1 yrs were randomised into a soccer (SG; n = 9), a resistance (RG; n = 9) and a control group (CG; n = 8). The subjects in SG and RG, respectively, trained 1.7 +/- 0.3 and 1.8 +/- 0.3 times weekly on average during the intervention period. Muscle function and body composition were determined before and after 16 and 52 weeks of the intervention period. In SG, BMI was reduced by 1.5% and 3.0% (p<0.05) after 16 and 52 weeks, respectively, unchanged in RG and 2% higher (p<0.05) in CG after 52 weeks of the intervention period. In SG, the response to a glucose tolerance test was 16% lower (p<0.05) after 16 wks, but not after 52 wks, compared to before the intervention period, and unchanged in RG and CG. In SG, superoxide dismutase-2 expression was 59% higher (p<0.05) after 52 wks compared to before the intervention period, and unchanged in RG and CG. In RG, upper body lean mass was 3 and 2% higher (p<0.05) after 16 and 52 wks, respectively, compared to before the intervention period, and unchanged in SG and CG. In RG, Akt-2 expression increased by 28% (p<0.01) and follistatin expression decreased by 38% (p<0.05) during the 52-wk intervention period, and was unchanged in SG and CG. Thus, long-term soccer training reduces BMI and improves anti-oxidative capacity, while long-term resistance training impacts muscle protein enzyme expression and increases lean body mass in elderly men.	[Andersen, Thomas Rostgaard; Schmidt, Jakob Friis; Pedersen, Mogens Theisen; Krustrup, Peter; Bangsbo, Jens] Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen Ctr Team Sport & Hlth, Copenhagen, Denmark; [Schmidt, Jakob Friis] Gentofte Univ Hosp, Dept Cardiol, Gentofte, Denmark; [Krustrup, Peter] Univ Exeter, Coll Life & Environm Sci, Sport & Hlth Sci, Exeter, Devon, England	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Exeter	Bangsbo, J (corresponding author), Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen Ctr Team Sport & Hlth, Copenhagen, Denmark.	jbangsbo@nexs.ku.dk	Krustrup, Peter/D-2659-2019; Bangsbo, Jens/A-7192-2015; Pedersen, Mogens Theisen/C-6991-2015	Krustrup, Peter/0000-0002-1461-9838; Andersen, Thomas Rostgaard/0000-0002-0315-0202; Bangsbo, Jens/0000-0003-1305-9274; Pedersen, Mogens Theisen/0000-0002-3178-6320	FIFA - Medical Assessment and Research Centre (FMARC) (F-MARC Project) [31964]; Danish Ministry of Culture (Kulturministeriets Udvalg for Idraetsforskning) [TKIF 2010-027]; Nordea-fonden [02-2011-4360]; FIFA-Medical Assessment and Research Centre (F-MARC) [31964]	FIFA - Medical Assessment and Research Centre (FMARC) (F-MARC Project); Danish Ministry of Culture (Kulturministeriets Udvalg for Idraetsforskning); Nordea-fonden; FIFA-Medical Assessment and Research Centre (F-MARC)	The study was supported by the FIFA - Medical Assessment and Research Centre (FMARC) (F-MARC Project 31964; http://www.f-marc.com/), The Danish Ministry of Culture (Kulturministeriets Udvalg for Idraetsforskning) (TKIF 2010-027; http://kum.dk/), and Nordea-fonden (Grant code: 02-2011-4360; http://nordeafonden.dk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to sincerely thank the participants in the study for their efforts. Also, the technical and practical assistance of Peter Bergmann Pill, Morten Bredsgaard Randers Thomsen, Jens Jung Nielsen, Eva Wulff Helge, Martin Thomassen, Therese Hornstrup, Marie Von Hagman and Joshua Horton is greatly appreciated. The study was supported by the FIFA-Medical Assessment and Research Centre (F-MARC) (F-MARC Project 31964) The Danish Ministry of Culture (Kulturministeriets Udvalg for Idraetsforskning) (TKIF 2010-027) and Nordea-fonden (Grant code: 02-2011-4360). The authors have declared that no competing interests exist.	American College of Sports Medicine, 2009, Med Sci Sports Exerc, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c; Andersen LG, 2010, SCAND J PUBLIC HEALT, V38, P707, DOI 10.1177/1403494810380099; Andersen TR, 2014, SCAND J MED SCI SPOR, V24, P76, DOI 10.1111/sms.12245; Andersen TR, 2014, SCAND J MED SCI SPOR, V24, P43, DOI 10.1111/sms.12259; Bangsbo J, 2014, SCAND J MED SCI SPOR, V24, P147, DOI 10.1111/sms.12271; Bangsbo J, 2015, BRIT J SPORT MED, V49, P568, DOI 10.1136/bjsports-2015-094781; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273; Daugaard JR, 2001, ACTA PHYSIOL SCAND, V171, P267, DOI 10.1046/j.1365-201x.2001.00829.x; DELA F, 1994, DIABETES, V43, P862, DOI 10.2337/diabetes.43.7.862; Durstine J Larry, 2002, J Cardiopulm Rehabil, V22, P385, DOI 10.1097/00008483-200211000-00002; Duscha BD, 2012, INT J SPORTS MED, V33, P218, DOI 10.1055/s-0031-1291323; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Esmarck B, 2001, J PHYSIOL-LONDON, V535, P301, DOI 10.1111/j.1469-7793.2001.00301.x; FRONTERA WR, 1990, J APPL PHYSIOL, V68, P329, DOI 10.1152/jappl.1990.68.1.329; Fry CS, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-11; Gliemann L, 2013, J PHYSIOL-LONDON, V591, P5047, DOI 10.1113/jphysiol.2013.258061; Hamburg NM, 2007, ARTERIOSCL THROM VAS, V27, P2650, DOI 10.1161/ATVBAHA.107.153288; Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370; Helge EW, 2014, SCAND J MED SCI SPOR; Houmard JA, 1998, J APPL PHYSIOL, V85, P1337, DOI 10.1152/jappl.1998.85.4.1337; Krustrup P, 2009, BRIT J SPORT MED, V43, P825, DOI 10.1136/bjsm.2008.053124; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P237; McHugh ML, 2011, BIOCHEM MEDICA, V21, P203; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4; Mero AA, 2013, EUR J APPL PHYSIOL, V113, P641, DOI 10.1007/s00421-012-2466-x; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Nielsen G, 2014, SCAND J MED SCI SPOR, V24, P66, DOI 10.1111/sms.12275; Nielsen JL, 2012, J PHYSIOL-LONDON, V590, P4351, DOI 10.1113/jphysiol.2012.237008; Nordsborg N, 2008, J PHYSIOL-LONDON, V586, P1447, DOI 10.1113/jphysiol.2007.143073; Nyberg M, 2014, FREE RADIC BIOL MED; Oja P, 2015, BR J SPORTS MED; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Randers MB, 2010, SCAND J MED SCI SPOR, V20, P14, DOI 10.1111/j.1600-0838.2010.01069.x; Schmidt JF, 2013, SCAND J MED SCI SPOR; Schmidt JF, 2014, SCAND J MED SCI SPOR; Thomassen M, 2010, J APPL PHYSL; Tipton KD, 2013, NESTLE NUTR WORKS SE, V76, P73, DOI 10.1159/000350259; Weinert BT, 2003, J APPL PHYSIOL, V95, P1706, DOI 10.1152/japplphysiol.00288.2003	41	23	25	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2016	11	2							e0148236	10.1371/journal.pone.0148236	http://dx.doi.org/10.1371/journal.pone.0148236			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3BJ	26886262	gold, Green Published, Green Submitted			2023-01-03	WOS:000371218400020
J	Laliberte, C; Dunn, S; Pound, C; Sourial, N; Yasseen, AS; Millar, D; White, RR; Walker, M; Lacaze-Masmonteil, T				Laliberte, Corinne; Dunn, Sandra; Pound, Catherine; Sourial, Nadia; Yasseen, Abdool S., III; Millar, David; White, Ruth Rennicks; Walker, Mark; Lacaze-Masmonteil, Thierry			A Randomized Controlled Trial of Innovative Postpartum Care Model for Mother-Baby Dyads	PLOS ONE			English	Article							FEEDING SELF-EFFICACY; MATERNAL RECALL; HOME VISITS; SUPPORT; DISCHARGE; INFANTS; WORKERS; SCALE	Objective To evaluate the efficacy, safety, and maternal satisfaction of a newly established integrative postpartum community-based clinic providing comprehensive support for mothers during the first month after discharge from the hospital. Our primary interests were breastfeeding rates, readmission and patient satisfaction. Methods A randomized controlled trial was conducted in Ottawa, Canada, where 472 mothers were randomized via a 1: 2 ratio to either receive standard of care (n = 157) or to attend the postpartum breastfeeding clinic (n = 315). Outcome data were captured through questionnaires completed by the participants at 2, 4, 12 and 24 weeks postpartum. Unadjusted and adjusted logistic regression models were conducted to determine the effect of the intervention on exclusive breastfeeding at 12 weeks (primary outcome). Secondary outcomes included breastfeeding rate at 2, 4 and 24 weeks, breastfeeding self-efficacy scale, readmission rate, and satisfaction score. Results More mothers in the intervention group (n = 195, 66.1%) were exclusively breastfeeding at 12 weeks compared to mothers in the control group (n = 81, 60.5%), however no statistically significant difference was observed (OR = 1.28; 95% CI: 0.84-1.95)). The rate of emergency room visits at 2 weeks for the intervention group was 11.4% compared to the standard of care group (15.2%) (OR = 0.69; 95% CI: 0.39-1.23). The intervention group was significantly more satisfied with the overall care they received for breastfeeding compared to the control group (OR = 1.96; 95% CI: 3.50-6.88)). Conclusion This new model of care did not significantly increase exclusive breastfeeding at 12 weeks. However, there were clinically meaningful improvements in the rate of postnatal problems and satisfaction that support this new service delivery model for postpartum care. A community-based multidisciplinary postpartum clinic is feasible to implement and can provide appropriate and highly satisfactory care to mother-baby dyads. This model of care may be more beneficial in a population that is not already predisposed to breastfeed.	[Laliberte, Corinne; Dunn, Sandra; Pound, Catherine; Sourial, Nadia; Yasseen, Abdool S., III; Lacaze-Masmonteil, Thierry] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; [Dunn, Sandra; Yasseen, Abdool S., III] Better Outcomes Registry & Network Ontario, Ottawa, ON, Canada; [Pound, Catherine; Lacaze-Masmonteil, Thierry] Univ Ottawa, Dept Paediat, Ottawa, ON, Canada; [Millar, David] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [White, Ruth Rennicks; Walker, Mark] Ottawa Hosp, Res Inst, Obstet & Maternal Newborn Invest, Ottawa, ON, Canada; [Walker, Mark] Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Lacaze-Masmonteil, T (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada.; Lacaze-Masmonteil, T (corresponding author), Univ Ottawa, Dept Paediat, Ottawa, ON, Canada.	tlacaze@cheo.on.ca		Yasseen, Abdool S./0000-0001-9814-9249	Ontario Ministry of Health and Long-Term Care	Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario)	All phases of this study were supported by the Ontario Ministry of Health and Long-Term Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funds were distributed to and managed by the Children's Hospital of Eastern Ontario Research Institute, The Ottawa Hospital Research Institute, and BORN.	Abbass-Dick J, 2015, PEDIATRICS, V135, P102, DOI 10.1542/peds.2014-1416; [Anonymous], 2010, IND ASS INF CHILD FE; [Anonymous], 2013, QUAL BAS PROC CLIN H; Bilirubin Screening and Management of Hyperbilirubinemia, 2006, BIL SCREEN MAN HYP; Blyth RJ, 2004, J HUM LACT, V20, P30, DOI 10.1177/0890334403261109; Busch DW, 2014, J PEDIATR HEALTH CAR, V28, P486, DOI 10.1016/j.pedhc.2014.02.007; Cheng CY, 2006, J PERINAT EDUC, V15, P34, DOI 10.1624/105812406X119002; City of Ottawa PH, 2005, INF CAR SURV; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Darj E, 2000, UPSALA J MED SCI, V105, P57, DOI 10.1517/03009734000000047; Dennis CL, 2003, JOGNN-J OBST GYN NEO, V32, P734, DOI 10.1177/0884217503258459; Souza EFD, 2014, ACTA PAUL ENFERM, V27, P465, DOI 10.1590/1982-0194201400076; Dodge KA, 2014, AM J PUBLIC HEALTH, V104, pS136, DOI 10.2105/AJPH.2013.301361; Escobar GJ, 2001, PEDIATRICS, V108, P719, DOI 10.1542/peds.108.3.719; Jolly K, 2012, MIDWIFERY, V28, P740, DOI 10.1016/j.midw.2011.08.005; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LAUNER LJ, 1992, J EPIDEMIOL COMMUN H, V46, P203, DOI 10.1136/jech.46.3.203; Li RW, 2005, NUTR REV, V63, P103, DOI 10.1111/j.1753-4887.2005.tb00128.x; Mannan I, 2008, J PERINATOL, V28, P632, DOI 10.1038/jp.2008.64; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Parry JE, 2013, J HUM LACT, V29, P527, DOI 10.1177/0890334412474719; Paul IM, 2012, ARCH PEDIAT ADOL MED, V166, P263, DOI 10.1001/archpediatrics.2011.198; Pound CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119624; Pound CM, 2009, PAED CHILD HEALT-CAN, V14, P445, DOI 10.1093/pch/14.7.445; Public Health Agency of Canada, 2009, WHAT MOTH SAY CAN MA, P173; Quarles A, 1994, Matern Child Nurs J, V22, P102; Scott J A, 1999, Breastfeed Rev, V7, P5; Seagraves Kendra, 2013, Nurs Womens Health, V17, P498, DOI 10.1111/1751-486X.12078; Statistics Canada, CAN COMM HLTH SURV C; Steel O, 2002, CAN J PUBLIC HLTH, V94, P98; Stuebe AM, 2014, OBSTET GYNECOL, V123, P643, DOI 10.1097/AOG.0000000000000142; Thulier D, 2009, JOGNN-J OBST GYN NEO, V38, P259, DOI 10.1111/j.1552-6909.2009.01021.x; Wheeler BJ, 2013, JOGNN-J OBST GYN NEO, V42, P70, DOI 10.1111/j.1552-6909.2012.01431.x; Wisner KL, 2002, NEW ENGL J MED, V347, P194, DOI 10.1056/NEJMcp011542; World Health Organization, 2014, WHO REC POSTN CAR MO; Yang C, 2012, J PAEDIATR CHILD H, V48, P931, DOI 10.1111/j.1440-1754.2012.02519.x; Yang WC, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-145	38	13	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148520	10.1371/journal.pone.0148520	http://dx.doi.org/10.1371/journal.pone.0148520			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26871448	gold, Green Published, Green Submitted			2023-01-03	WOS:000370054100033
J	Fournier-Larente, J; Azelmat, J; Yoshioka, M; Hinode, D; Grenier, D				Fournier-Larente, Jade; Azelmat, Jabrane; Yoshioka, Masami; Hinode, Daisuke; Grenier, Daniel			The Daiokanzoto (TJ-84) Kampo Formulation Reduces Virulence Factor Gene Expression in Porphyromonas gingivalis and Possesses Anti-Inflammatory and Anti-Protease Activities	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; INFLAMMATORY RESPONSES; CREVICULAR FLUID; KAPPA-B; PERIODONTITIS; INTERLEUKIN-6; PATHOGENESIS; MEDICINE; RANTES; TISSUE	Kampo formulations used in Japan to treat a wide variety of diseases and to promote health are composed of mixtures of crude extracts from the roots, bark, leaves, and rhizomes of a number of herbs. The present study was aimed at identifying the beneficial biological properties of Daiokanzoto (TJ-84), a Kampo formulation composed of crude extracts of Rhubarb rhizomes and Glycyrrhiza roots, with a view to using it as a potential treatment for periodontal disease. Daiokanzoto dose-dependently inhibited the expression of major Porphyromonas gingivalis virulence factors involved in host colonization and tissue destruction. More specifically, Daiokanzoto reduced the expression of the fimA, hagA, rgpA, and rgpB genes, as determined by quantitative real-time PCR. The U937-3x kappa B-LUC monocyte cell line transfected with a luciferase reporter gene was used to evaluate the anti-inflammatory properties of Daiokanzoto. Daiokanzoto attenuated the P. gingivalis-mediated activation of the NF-kappa B signaling pathway. It also reduced the secretion of pro-inflammatory cytokines (IL-6 and CXCL8) by lipopolysaccharide-stimulated oral epithelial cells and gingival fibroblasts. Lastly, Daiokanzoto, dose-dependently inhibited the catalytic activity of matrix metalloproteinases (-1 and -9). In conclusion, the present study provided evidence that Daiokanzoto shows potential for treating and/or preventing periodontal disease. The ability of this Kampo formulation to act on both bacterial pathogens and the host inflammatory response, the two etiological components of periodontal disease, is of high therapeutic interest.	[Fournier-Larente, Jade; Azelmat, Jabrane; Grenier, Daniel] Univ Laval, Fac Med Dent, GREB, Quebec City, PQ, Canada; [Yoshioka, Masami] Univ Tokushima, Inst Biomed Sci, Dept Oral Hlth Sci & Social Welf, Grad Sch, Tokushima 770, Japan; [Hinode, Daisuke] Univ Tokushima, Inst Biomed Sci, Dept Hyg & Oral Hlth Sci, Grad Sch, Tokushima 770, Japan	Laval University; Tokushima University; Tokushima University	Grenier, D (corresponding author), Univ Laval, Fac Med Dent, GREB, Quebec City, PQ, Canada.	Daniel.Grenier@greb.ulaval.ca			Quebec Ministere de l'Economie, de l'Innovation et des Exportations [PSR-SIIRI-438]	Quebec Ministere de l'Economie, de l'Innovation et des Exportations	This study was supported by PSR-SIIRI-438 Quebec Ministere de l'Economie, de l'Innovation et des Exportations DG.	Andrian E, 2006, J DENT RES, V85, P392, DOI 10.1177/154405910608500502; Ara T, 2008, BIOL PHARM BULL, V31, P1141, DOI 10.1248/bpb.31.1141; Ara T, 2010, BIOL PHARM BULL, V33, P611, DOI 10.1248/bpb.33.611; Azelmat J, 2015, ARCH ORAL BIOL, V60, P342, DOI 10.1016/j.archoralbio.2014.11.006; Berezow AB, 2011, PERIODONTOL 2000, V55, P36, DOI 10.1111/j.1600-0757.2010.00350.x; Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; de Souza JAC, 2012, J APPL ORAL SCI, V20, P128, DOI 10.1590/S1678-77572012000200002; Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373; Gamonal J, 2001, J PERIODONTAL RES, V36, P194, DOI 10.1034/j.1600-0765.2001.360309.x; Gamonal J, 2000, J PERIODONTOL, V71, P1535, DOI 10.1902/jop.2000.71.10.1535; Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402; Hassell T M, 1993, Periodontol 2000, V3, P9, DOI 10.1111/j.1600-0757.1993.tb00230.x; Herrera D, 2008, J CLIN PERIODONTOL, V35, P45, DOI 10.1111/j.1600-051X.2008.01260.x; Hosseinzadeh H, 2015, PHYTOTHER RES, V29, P1868, DOI 10.1002/ptr.5487; Imamura T, 2003, J PERIODONTOL, V74, P111, DOI 10.1902/jop.2003.74.1.111; Irwin C R, 1998, Oral Dis, V4, P43; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Kolenbrander PE, 2000, ANNU REV MICROBIOL, V54, P413, DOI 10.1146/annurev.micro.54.1.413; Kubota T, 1996, ARCH ORAL BIOL, V41, P253, DOI 10.1016/0003-9969(95)00126-3; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Lamont RJ, 1998, MICROBIOL MOL BIOL R, V62, P1244, DOI 10.1128/MMBR.62.4.1244-1263.1998; Liao J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/436206; Liao J, 2013, PHARM BIOL, V51, P1538, DOI 10.3109/13880209.2013.801995; Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600-0757.2009.00321.x; Pizzo G, 2010, EUR J INTERN MED, V21, P496, DOI 10.1016/j.ejim.2010.07.011; Sapna G, 2014, ORAL DIS, V20, P538, DOI 10.1111/odi.12159; TAKAHASHI K, 1994, J PERIODONTOL, V65, P147, DOI 10.1902/jop.1994.65.2.147; Takashiba S, 2003, J PERIODONTOL, V74, P103, DOI 10.1902/jop.2003.74.1.103; Takeda O, 2014, ARCH ORAL BIOL, V59, P1130, DOI 10.1016/j.archoralbio.2014.06.010; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TENG YT, 1992, J PERIODONTAL RES, V27, P544, DOI 10.1111/j.1600-0765.1992.tb01830.x; Watanabe K, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq067; Yakubo S, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/535146; Yoshida K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112689; Zenobia C, 2015, VIRULENCE, V6, P236, DOI 10.1080/21505594.2014.999567	37	6	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148860	10.1371/journal.pone.0148860	http://dx.doi.org/10.1371/journal.pone.0148860			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859747	gold, Green Published			2023-01-03	WOS:000370038400098
J	Nguyen, TT; Parat, MO; Shaw, PN; Hewavitharana, AK; Hodson, MP				Nguyen, Thao T.; Parat, Marie-Odile; Shaw, Paul N.; Hewavitharana, Amitha K.; Hodson, Mark P.			Traditional Aboriginal Preparation Alters the Chemical Profile of Carica papaya Leaves and Impacts on Cytotoxicity towards Human Squamous Cell Carcinoma	PLOS ONE			English	Article							LEAF EXTRACT; TOXICITY; CANCER; L.	Carica papaya leaf decoction, an Australian Aboriginal remedy, has been used widely for its healing capabilities against cancer, with numerous anecdotal reports. In this study we investigated its in vitro cytotoxicity on human squamous cell carcinoma cells followed by metabolomic profiling of Carica papaya leaf decoction and leaf juice/brewed leaf juice to determine the effects imparted by the long heating process typical of the Aboriginal remedy preparation. MTT assay results showed that in comparison with the decoction, the leaf juice not only exhibited a stronger cytotoxic effect on SCC25 cancer cells, but also produced a significant cancer-selective effect as shown by tests on non-cancerous human keratinocyte HaCaT cells. Furthermore, evidence from testing brewed leaf juice on these two cell lines suggested that the brewing process markedly reduced the selective effect of Carica papaya leaf on SCC25 cancer cells. To tentatively identify the compounds that contribute to the distinct selective anticancer activity of leaf juice, an untargeted metabolomic approach employing Ultra High Performance Liquid Chromatography-Quadrupole Time of Flight-Mass Spectrometry followed by multivariate data analysis was applied. Some 90 and 104 peaks in positive and negative mode respectively were selected as discriminatory features from the chemical profile of leaf juice and >1500 putative compound IDs were obtained via database searching. Direct comparison of chromatographic and tandem mass spectral data to available reference compounds confirmed one feature as a match with its proposed authentic standard, namely pheophorbide A. However, despite pheophorbide A exhibiting cytotoxic activity on SCC25 cancer cells, it did not prove to be the compound contributing principally to the selective activity of leaf juice. With promising results suggesting stronger and more selective anticancer effects when compared to the Aboriginal remedy, Carica papaya leaf juice warrants further study to explore its activity on other cancer cell lines, as well as investigation to confirm the identity of compounds contributing to its selective effect, particularly those compounds altered by the long heating process applied during the traditional Aboriginal remedy preparation.	[Nguyen, Thao T.; Parat, Marie-Odile; Shaw, Paul N.; Hewavitharana, Amitha K.; Hodson, Mark P.] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia; [Hodson, Mark P.] Univ Queensland, Metabol Australia, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia	University of Queensland; University of Queensland	Hodson, MP (corresponding author), Univ Queensland, Sch Pharm, Brisbane, Qld, Australia.; Hodson, MP (corresponding author), Univ Queensland, Metabol Australia, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia.	m.hodson1@uq.edu.au	Hewavitharana, Amitha K/A-5533-2008; Shaw, Paul N/G-4418-2010; Hodson, Mark P/J-7609-2013; Parat, Marie-Odile/G-4410-2010; Shaw, Paul/Q-8454-2019	Hewavitharana, Amitha K/0000-0003-2935-9941; Shaw, Paul N/0000-0001-7154-592X; Hodson, Mark P/0000-0002-5436-1886; Parat, Marie-Odile/0000-0003-4895-7381; Shaw, Paul/0000-0001-7154-592X	Prime Minister's Australia Asia Endeavour Award from the Department of Education and Training [2997_2012]	Prime Minister's Australia Asia Endeavour Award from the Department of Education and Training	TTN was funded by a Prime Minister's Australia Asia Endeavour Award from the Department of Education and Training (2997_2012).	Afzan A, 2012, MOLECULES, V17, P4326, DOI 10.3390/molecules17044326; Ahmad Nisar, 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P330, DOI 10.1016/S2221-1691(11)60055-5; Arkhipov A., 2014, Pharmacognosy Communications, V4, P10; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cheng XL, 2011, FOOD CHEM, V129, P1785, DOI 10.1016/j.foodchem.2011.06.026; Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313; Emmanuelle Bournay UG-A, 2012, GLOB SOL UV IND; Food and Agriculture Organization, 2013, FAOSTAT PROD DAT; Gammulle A., 2012, ONLINE INT J MED PLA, V1, P21; Halim SZ, 2011, J MED PLANTS RES, V5, P1867; Hewitt H, 2000, W INDIAN MED J, V49, P32; Ismail Z, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/741470; JACKMAN RL, 1987, J FOOD BIOCHEM, V11, P201, DOI 10.1111/j.1745-4514.1987.tb00123.x; Krishna K. L., 2008, Natural Product Radiance, V7, P364; Leiter U, 2013, ADV EXP MED BIOL, V810, P120; Lucas TP, 1914, MOST WONDERFUL TREE; Mangal M, 2013, NUCLEIC ACIDS RES, V41, pD1124, DOI 10.1093/nar/gks1047; Mikhal'chik EV, 2004, B EXP BIOL MED+, V137, P560, DOI 10.1023/B:BEBM.0000042711.31775.f7; Morimoto C., 2008, US Patent, Patent No. 20080069907; Morton J. F., 1987, FRUITS WARM CLIMATES, P336; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nayak BS, 2007, INDIAN J EXP BIOL, V45, P739; Nguyen TTT, 2013, MOL NUTR FOOD RES, V57, P153, DOI 10.1002/mnfr.201200388; Otsuki N, 2010, J ETHNOPHARMACOL, V127, P760, DOI 10.1016/j.jep.2009.11.024; Qi LW, 2010, BIOCHEM PHARMACOL, V80, P947, DOI 10.1016/j.bcp.2010.06.023; Sirdaarta J., 2015, Pharmacognosy Communications, V5, P100, DOI 10.5530/pc.2015.2.2; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2014, ANTI-CANCER AGENT ME, V14, P77, DOI 10.2174/18715206113139990308; Slominski AT, 2014, INT J MOL SCI, V15, P17705, DOI 10.3390/ijms151017705; Subenthiran S., 2013, EVID-BASED COMPL ALT, V2013, P1, DOI [10.1155/2013/616737, DOI 10.1155/2013/616737]; Tietze HW, 2003, PAPAYA THE MED TREE; Vien D.T.H., 2013, ASEAN J CHEM ENG, V12, P43, DOI [10.22146/ajche.49742, DOI 10.22146/AJCHE.49742]; Wang CZ, 2006, J AGR FOOD CHEM, V54, P9936, DOI 10.1021/jf062467k; Xiang F, 2014, JAMA DERMATOL, V150, P1063, DOI 10.1001/jamadermatol.2014.762; Zunjar V, 2015, NAT PROD RES, V29, P2097, DOI 10.1080/14786419.2014.986658	35	24	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2016	11	2							e0147956	10.1371/journal.pone.0147956	http://dx.doi.org/10.1371/journal.pone.0147956			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9NL	26829042	gold, Green Submitted, Green Published			2023-01-03	WOS:000369548200047
J	Wloch, EG; Kuh, D; Cooper, R				Wloch, Elizabeth G.; Kuh, Diana; Cooper, Rachel			Is the Hierarchy of Loss in Functional Ability Evident in Midlife? Findings from a British Birth Cohort	PLOS ONE			English	Article							PHYSICAL PERFORMANCE; PATTERNS; DISABILITY; HEALTH; SCALE; IADL; ADL	Background Difficulties performing a range of physical tasks of daily living have been shown to develop in older populations in a typically observed sequence, known as the hierarchy of loss. Nearly all previous research has been undertaken using populations aged over 75. This study aimed to use cross-sectional and longitudinal data to test for evidence of the hierarchy of loss from midlife onwards. Methods The prevalence of reported difficulty undertaking 16 physical tasks in the MRC National Survey of Health and Development at age 60-64 were calculated, with Mokken scaling used to confirm the hierarchical order. Logistic regression was used to calculate the odds ratios of reporting difficulty performing tasks at the bottom of the hierarchy (i. e. feeding, washing and/or toileting) at age 60-64 by reported difficulty at the top of the hierarchy (i. e. gripping, walking and/or stair climbing) at age 43. Results At age 60-64, tasks associated with balance, strength and co-ordination, such as climbing stairs, were the first tasks participants reported difficulty with and tasks associated with upper limb mobility, such as feeding yourself, were the last. In a fully-adjusted model, participants who reported difficulty at the top of the hierarchy at age 43 were 2.85 (95% CI: 1.45-5.60) times more likely to report difficulty with tasks at the bottom of the hierarchy at age 60-64. Conclusion This study presents evidence of the hierarchy of loss in a younger population than previously observed suggesting that targeted interventions to prevent functional decline should not be delayed until old age.	[Wloch, Elizabeth G.; Kuh, Diana; Cooper, Rachel] UCL, MRC Unit Lifelong Hlth & Ageing, London, England	University of London; University College London	Wloch, EG (corresponding author), UCL, MRC Unit Lifelong Hlth & Ageing, London, England.	elizabeth.wloch.12@ucl.ac.uk	Kuh, Diana/L-6019-2014; Cooper, Rachel/ABE-3768-2021	Kuh, Diana/0000-0001-7386-2857; Cooper, Rachel/0000-0003-3370-5720	UK Medical Research Council [MC_UU_12019/4]; UK Medical Research Council; Medical Research Council [MC_UU_12019/4, 1212994] Funding Source: researchfish; MRC [MC_UU_12019/4] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the UK Medical Research Council (Programme code MC_UU_12019/4). EW is supported by a UK Medical Research Council PhD studentship. The study sponsors played no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bowling A, 2005, BRIT MED J, V331, P1548, DOI 10.1136/bmj.331.7531.1548; Chen HY, 2010, DISABIL REHABIL, V32, P1586, DOI 10.3109/09638280903551533; COOPER R, 2011, PLOS ONE, V0006; Cooper R, 2011, AM J PREV MED, V41, P376, DOI 10.1016/j.amepre.2011.06.035; Cosco TD, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002710; Depp CA, 2006, AM J GERIAT PSYCHIAT, V14, P6, DOI 10.1097/01.JGP.0000192501.03069.bc; Dunlop DD, 1997, AM J PUBLIC HEALTH, V87, P378, DOI 10.2105/AJPH.87.3.378; Ferrucci L, 2000, J AM GERIATR SOC, V48, P1618, DOI 10.1111/j.1532-5415.2000.tb03873.x; Ferrucci L, 1998, GERONTOLOGIST, V38, P286, DOI 10.1093/geront/38.3.286; Fried LP, 1996, J GERONTOL A-BIOL, V51, pM206, DOI 10.1093/gerona/51A.5.M206; Gerrard P, 2013, J GERIATR PHYS THER, V36, P87, DOI 10.1519/JPT.0b013e318268da23; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Jagger C, 2001, J AM GERIATR SOC, V49, P404, DOI 10.1046/j.1532-5415.2001.49083.x; KEMPEN GIJM, 1995, J CLIN EPIDEMIOL, V48, P1299, DOI 10.1016/0895-4356(95)00043-7; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; Kingston A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031665; Kuh D, 2014, P NUTR SOC, V73, P237, DOI 10.1017/S0029665113003923; Kuh Diana, 2011, Int J Epidemiol, V40, pe1, DOI 10.1093/ije/dyq231; Lindelow M, 1997, J EPIDEMIOL COMMUN H, V51, P549, DOI 10.1136/jech.51.5.549; Medical Research Council, 1976, QUEST RESP SYMPT INS; Murray ET, 2011, J GERONTOL A-BIOL, V66, P1350, DOI 10.1093/gerona/glr139; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Samson MM, 2000, AGE AGEING, V29, P235, DOI 10.1093/ageing/29.3.235; Seidel D, 2009, HUM FACTORS, V51, P669, DOI 10.1177/0018720809353597; Stafford M, 2013, EUR J AGEING, V10, P145, DOI 10.1007/s10433-013-0258-8; Wadsworth M, 2006, INT J EPIDEMIOL, V35, P49, DOI 10.1093/ije/dyi201; Weiss CO, 2007, J GERONTOL A-BIOL, V62, P167, DOI 10.1093/gerona/62.2.167; Wells JCK, 2007, BEST PRACT RES CL EN, V21, P415, DOI 10.1016/j.beem.2007.04.007; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Yeh CJ, 2012, DISABIL REHABIL, V34, P1271, DOI 10.3109/09638288.2011.641657	30	13	13	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2016	11	5							e0155815	10.1371/journal.pone.0155815	http://dx.doi.org/10.1371/journal.pone.0155815			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DM3YJ	27187493	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000376282300071
J	McCartney, M; Treadwell, J; Maskrey, N; Lehman, R				McCartney, Margaret; Treadwell, Julian; Maskrey, Neal; Lehman, Richard			Making evidence based medicine work for individual patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GUIDELINES; CARE		[McCartney, Margaret] Fulton St Med Ctr, Glasgow G13 1NG, Lanark, Scotland; [Treadwell, Julian] Hindon Surg, Salisbury, Wilts, England; [Maskrey, Neal] Keele Univ, Sch Pharm, Keele, Staffs, England; [Lehman, Richard] Cochrane UK, Oxford, England	Keele University; Cochrane Centre	McCartney, M (corresponding author), Fulton St Med Ctr, Glasgow G13 1NG, Lanark, Scotland.	margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Audit Commission, 2011, PAYING GPS; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Coulter A, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S2; Dumbreck S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h949; Freeman G, 2010, CONTINUITY OF CARE A; Gawande A, 2014, METROPOLITAN; Goldacre BM, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5081; Greenhalgh T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0437-x; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Harrison S, 2000, Policy Stud Rev, V17, P25, DOI 10.1111/j.1541-1338.2000.tb00955.x; Health Foundation, WHY DO SHAR DEC MAK; Heath I, 1995, MYST GEN PRACT; Hegarty K, 2009, BRIT J GEN PRACT, V59, P322, DOI 10.3399/bjgp09X420581; Huntley A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004746; Irving G, 2013, INT J CARDIOL, V168, P2304, DOI 10.1016/j.ijcard.2013.01.189; National Voices, SUPP SHAR DEC MAK; NHS, 2012, SHAR DEC MAK; NICE, 2014, PAT DEC AID ATR FIBR; NICE, 2014, PAT DEC AID TAK STAT; Snow R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003583; Steel N, 2014, J CLIN EPIDEMIOL, V67, P1251, DOI 10.1016/j.jclinepi.2014.05.020; Towards Optimized Practice, 2015, OPTIMIZED PRACTICE C; Tricoci P, 2009, JAMA-J AM MED ASSOC, V301, P831, DOI 10.1001/jama.2009.205	23	47	48	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	2016	353								i2452	10.1136/bmj.i2452	http://dx.doi.org/10.1136/bmj.i2452			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GB	27185764	Green Submitted			2023-01-03	WOS:000376447500002
J	Knoedler, JJ; Lieske, JC				Knoedler, John J.; Lieske, John C.			Non-steroidal anti-inflammatory drugs for renal colic	LANCET			English	Editorial Material							UNITED-STATES; DICLOFENAC; KETOROLAC; STONES		[Knoedler, John J.] Mayo Clin, Dept Urol, Rochester, MN 55902 USA; [Lieske, John C.] Mayo Clin, Dept Nephrol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Lieske, JC (corresponding author), Mayo Clin, Dept Nephrol, Rochester, MN 55902 USA.	lieske.john@mayo.edu	Lieske, John/ABA-4829-2020					Afshar K, 2015, COCHRANE DB SYST REV, V29; Brady KT, 2016, AM J PSYCHIAT, V173, P18, DOI 10.1176/appi.ajp.2015.15020262; Carter Michelle R, 2011, Emerg Med Pract, V13, P1; Chen Li Hui, 2014, NCHS Data Brief, P1; Cohen E, 1998, EUR J CLIN PHARMACOL, V54, P455, DOI 10.1007/s002280050492; Forrest JB, 2002, BRIT J ANAESTH, V88, P227, DOI 10.1093/bja/88.2.227; Ghani KR, 2014, J UROLOGY, V191, P90, DOI 10.1016/j.juro.2013.07.098; HOLDGATE A, 2005, COCHRANE DB SYST REV, V18; Pathan SA, 2016, LANCET, V387, P1999, DOI 10.1016/S0140-6736(16)00652-8; Romero Victoriano, 2010, Rev Urol, V12, pe86; Scales CD, 2012, EUR UROL, V62, P160, DOI 10.1016/j.eururo.2012.03.052; Stein A, 1996, AM J EMERG MED, V14, P385, DOI 10.1016/S0735-6757(96)90055-8	12	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2016	387	10032					1971	1972		10.1016/S0140-6736(16)00745-5	http://dx.doi.org/10.1016/S0140-6736(16)00745-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL8HJ	26993882				2023-01-03	WOS:000375881500004
J	Yang, CY; Powell, CA; Duan, YP; Shatters, R; Fang, JP; Zhang, MQ				Yang, Chuanyu; Powell, Charles A.; Duan, Yongping; Shatters, Robert; Fang, Jingping; Zhang, Muqing			Deciphering the Bacterial Microbiome in Huanglongbing-Affected Citrus Treated with Thermotherapy and Sulfonamide Antibiotics	PLOS ONE			English	Article							CANDIDATUS LIBERIBACTER ASIATICUS; INFECTED CITRUS; COMMUNITY STRUCTURE; HEAT-TOLERANT; DIVERSITY; DISEASE; MECHANISMS; PLANTS; ACID	Huanglongbing (HLB) is a serious citrus disease that threatens the citrus industry. In previous studies, sulfonamide antibiotics and heat treatment suppressed 'Candidatus Liberibacter asiaticus' (Las), but did not completely eliminate the Las. Furthermore, there are few reports studying the bacterial microbiome of HLB-affected citrus treated by heat and sulfonamide antibiotics. In this study, combinations of heat (45 degrees C or 40 degrees C) and sulfonamide treatment (sulfathiazole sodium-STZ, or sulfadimethoxine sodium-SDX) were applied to HLB-affected citrus. The bacterial microbiome of HLB-affected citrus following thermotherapy and/or chemotherapy was characterized by PhyloChip (TM) G3-based metagenomics. Our results showed that the combination of thermotherapy at 45 degrees C and chemotherapy with STZ and SDX was more effective against HLB than thermotherapy alone, chemotherapy alone, or a combination of thermotherapy at 40 degrees C and chemotherapy. The PhyloChip (TM) G3-based results indicated that 311 empirical Operational Taxonomic Units (eOTUs) were detected in 26 phyla. Cyanobacteria (18.01%) were dominant after thermo-chemotherapy. Thermotherapy at 45 degrees C decreased eOTUs (64.43%) in leaf samples, compared with thermotherapy at 40 degrees C (73.96%) or without thermotherapy (90.68%) and it also reduced bacterial family biodiversity. The eOTU in phylum Proteobacteria was reduced significantly and eOTU_28, representing "Candidatus Liberibacter," was not detected following thermotherapy at 45 degrees C. Following antibiotic treatment with SDX and STZ, there was enhanced abundance of specific eOTUs belonging to the families Streptomycetaceae, Desulfobacteraceae, Chitinophagaceae, and Xanthomonadaceae, which may be implicated in increased resistance to plant pathogens. Our study further develops an integrated strategy for combating HLB, and also provides new insight into the bacterial microbiome of HLB-affected citrus treated by heat and sulfonamide antibiotics.	[Yang, Chuanyu; Zhang, Muqing] Guangxi Univ, State Key Lab Conservat & Utilizat Subtrop Agrobi, Nanning 530005, Peoples R China; [Yang, Chuanyu; Powell, Charles A.; Zhang, Muqing] Univ Florida, IFAS, Indian River Res & Educ Ctr, Ft Pierce, FL 34945 USA; [Duan, Yongping; Shatters, Robert] USDA ARS, Hort Res Lab, Ft Pierce, FL 34945 USA; [Yang, Chuanyu; Fang, Jingping; Zhang, Muqing] Fujian Agr & Forestry Univ, Coll Crop Sci, Fuzhou 350002, Peoples R China	Guangxi University; State University System of Florida; University of Florida; United States Department of Agriculture (USDA); Fujian Agriculture & Forestry University	Zhang, MQ (corresponding author), Guangxi Univ, State Key Lab Conservat & Utilizat Subtrop Agrobi, Nanning 530005, Peoples R China.; Zhang, MQ (corresponding author), Univ Florida, IFAS, Indian River Res & Educ Ctr, Ft Pierce, FL 34945 USA.; Zhang, MQ (corresponding author), Fujian Agr & Forestry Univ, Coll Crop Sci, Fuzhou 350002, Peoples R China.	mqzhang@ufl.edu		yang, chuanyu/0000-0003-1194-208X; zhang, muqing/0000-0003-3138-3422; Shatters, Robert/0000-0002-3903-772X	US Citrus Research and Development Foundation (project CRDF) [584]; Guangxi Natural Science Foundation [2013GXNSFCCB019002]; Guangxi Programs for science and technology development [347004-7]	US Citrus Research and Development Foundation (project CRDF); Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province); Guangxi Programs for science and technology development	This work was financially supported by the US Citrus Research and Development Foundation (project CRDF#584) (http://citrusrdf.org/), the Guangxi Natural Science Foundation (project 2013GXNSFCCB019002), and the Guangxi Programs for science and technology development (project 347004-7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah TL, 2009, AFR J BIOTECHNOL, V8, P4007; AHLGREN IF, 1965, ECOLOGY, V46, P304, DOI 10.2307/1936333; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alvarez S, 2015, 2015 ANN M SO AGR EC; Bove JM, 2006, J PLANT PATHOL, V88, P7; Bove JM, 2007, IUBMB LIFE, V59, P346, DOI 10.1080/15216540701299326; Brain RA, 2008, ENVIRON SCI TECHNOL, V42, P8965, DOI 10.1021/es801611a; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Castenholz R.W., 1981, PROKARYOTES, P236, DOI [10.1007/978-3-662-13187-9_11, DOI 10.1007/978-3-662-13187-9_11]; Etxeberria E, 2009, PHYSIOL MOL PLANT P, V74, P76, DOI 10.1016/j.pmpp.2009.09.004; FLORACK DEA, 1994, PLANT MOL BIOL, V26, P25, DOI 10.1007/BF00039517; Furusawa C, 2009, BIOINFORMATICS, V25, P36, DOI 10.1093/bioinformatics/btn570; Gottwald T. R., 2007, Outlooks on Pest Management, V18, P274, DOI 10.1564/18dec09; Gottwald TR, 2010, ANNU REV PHYTOPATHOL, V48, P119, DOI 10.1146/annurev-phyto-073009-114418; Grasso GM, 1996, INT J WILDLAND FIRE, V6, P67, DOI 10.1071/WF9960067; Guo F, 2014, MICROB ECOL, V67, P829, DOI 10.1007/s00248-014-0389-2; Gutierrez IR, 2010, J SOIL SEDIMENT, V10, P537, DOI 10.1007/s11368-009-0168-8; Hammesfahr U, 2008, SOIL BIOL BIOCHEM, V40, P1583, DOI 10.1016/j.soilbio.2008.01.010; Hazen TC, 2010, SCIENCE, V330, P204, DOI 10.1126/science.1195979; Hell R, 1997, PLANTA, V202, P138, DOI 10.1007/s004250050112; Hodges A, 2012, EC IMPACTS CITRUS GR; Hoffman MT, 2013, PHYTOPATHOLOGY, V103, P15, DOI 10.1094/PHYTO-06-12-0138-R; JAGOUEIX S, 1994, INT J SYST BACTERIOL, V44, P379, DOI 10.1099/00207713-44-3-379; Kim MK, 2007, INT J SYST EVOL MICR, V57, P1721, DOI 10.1099/ijs.0.64964-0; King AJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00347; Li WB, 2006, J MICROBIOL METH, V66, P104, DOI 10.1016/j.mimet.2005.10.018; Lindow SE, 2003, APPL ENVIRON MICROB, V69, P1875, DOI 10.1128/AEM.69.4.1875-1883.2003; Lo X. H., 1983, Journal of the South China Agricultural College, V4, P97; Lopes SA, 2009, PLANT DIS, V93, P257, DOI 10.1094/PDIS-93-3-0257; Lyu CY, 2013, J SCI FOOD AGR, V93, P3165, DOI 10.1002/jsfa.6149; Martinez-Viveros O, 2010, J SOIL SCI PLANT NUT, V10, P293, DOI 10.4067/S0718-95162010000100006; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Mhedbi-Hajri N, 2011, ADHESION MECH PLANT, P71; Michelini L, 2013, PLANT PHYSIOL BIOCH, V67, P55, DOI 10.1016/j.plaphy.2013.02.027; Panswad T, 2003, WATER RES, V37, P409, DOI 10.1016/S0043-1354(02)00286-5; Pla L, 2004, J AGR BIOL ENVIR ST, V9, P42, DOI 10.1198/1085711043136; Renwick J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109798; Ryan KJ, 1994, MED MICROBIOLOGY; Sagaram US, 2009, APPL ENVIRON MICROB, V75, P1566, DOI 10.1128/AEM.02404-08; SCHWARZ RE, 1971, PLANT DIS REP, V55, P747; STOKSTAD ELR, 1987, J NUTR, V117, P1335, DOI 10.1093/jn/117.7.1335; Tang W., 1981, ACTA PHYTOPATHOL SIN, V8, P47; Thiele-Bruhn S, 2005, CHEMOSPHERE, V59, P457, DOI 10.1016/j.chemosphere.2005.01.023; Trivedi P, 2012, ISME J, V6, P363, DOI 10.1038/ismej.2011.100; Trivedi P, 2010, APPL ENVIRON MICROB, V76, P3427, DOI 10.1128/AEM.02901-09; Tyler HL, 2009, MOL PLANT MICROBE IN, V22, P1624, DOI 10.1094/MPMI-22-12-1624; Waites KB, 2004, CLIN MICROBIOL REV, V17, P697, DOI 10.1128/CMR.17.4.697-728.2004; Zeng YH, 2014, P NATL ACAD SCI USA, V111, P7795, DOI 10.1073/pnas.1400295111; Zhang MQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111032; Zhang MQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076331; Zhang MQ, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-112	51	22	24	3	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0155472	10.1371/journal.pone.0155472	http://dx.doi.org/10.1371/journal.pone.0155472			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171468	Green Submitted, Green Published, gold			2023-01-03	WOS:000376588600035
J	Snyder, A				Snyder, Alison			Holbrook Kohrt Obituary	LANCET			English	Biographical-Item												amsnyder@alum.mit.edu							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2016	387	10030					1810	1810		10.1016/S0140-6736(16)30329-4	http://dx.doi.org/10.1016/S0140-6736(16)30329-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK6SS	27203496	Bronze			2023-01-03	WOS:000375056100015
J	Hyvarinen, P; Makitie, A; Aarnisalo, AA				Hyvarinen, Petteri; Makitie, Antti; Aarnisalo, Antti A.			Self-Administered Domiciliary tDCS Treatment for Tinnitus: A Double-Blind Sham-Controlled Study	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; HUMAN MOTOR CORTEX; HANDICAP INVENTORY; CLINICAL-TRIALS; DEPRESSION; INTENSITY; NEUROSCIENCE; SUPPRESSION; MODULATION; GUIDELINES	Transcranial direct current stimulation (tDCS) has shown potential for providing tinnitus relief, although positive effects have usually been observed only during a short time period after treatment. In recent studies the focus has turned from one-session experiments towards multi-session treatment studies investigating long-term outcomes with double-blinded and sham-controlled study designs. Traditionally, tDCS has been administered in a clinical setting by a healthcare professional but in studies involving multiple treatment sessions, often a trade-off has to be made between sample size and the amount of labor needed to run the trial. Also, as the number of required visits to the clinic increases, the dropout rate is likely to rise proportionally. The aim of the current study was to find out if tDCS treatment for tinnitus could be patient-administered in a domiciliary setting and whether the results would be comparable to those from in-hospital treatment studies. Forty-three patients with chronic (> 6 months) tinnitus were involved in the study, and data on 35 out of these patients were included in final analysis. Patients received 20 minutes of left temporal area anodal (LTA) or bifrontal tDCS stimulation (2 mA) or sham stimulation (0.3 mA) for ten consecutive days. An overall reduction in the main outcome measure, Tinnitus Handicap Inventory (THI), was found (mean change -5.0 points, p < 0.05), but there was no significant difference between active and sham treatment outcomes. Patients found the tDCS treatment easy to administer and they all tolerated it well. In conclusion, self-administered domiciliary tDCS treatment for tinnitus was found safe and feasible and gave outcome results similar to recent randomized controlled long-term treatment trials. The results suggest better overall treatment response-as measured by THI-with domiciliary treatment than with in-hospital treatment, but this advantage is not related to the tDCS variant. The study protocol demonstrated in the current study is not restricted to tinnitus only.	[Hyvarinen, Petteri; Makitie, Antti; Aarnisalo, Antti A.] Univ Helsinki, Dept Otorhinolaryngol Head & Neck Surg, POB 220, FI-00029 Helsinki, Finland; [Hyvarinen, Petteri; Makitie, Antti; Aarnisalo, Antti A.] Helsinki Univ Hosp, Biomed Helsinki 1, POB 220, FI-00029 Helsinki, Finland; [Hyvarinen, Petteri] Aalto Univ, Dept Neurosci & Biomed Engn, Sch Sci, POB 12200, FI-00076 Espoo, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aalto University	Hyvarinen, P (corresponding author), Univ Helsinki, Dept Otorhinolaryngol Head & Neck Surg, POB 220, FI-00029 Helsinki, Finland.; Hyvarinen, P (corresponding author), Helsinki Univ Hosp, Biomed Helsinki 1, POB 220, FI-00029 Helsinki, Finland.; Hyvarinen, P (corresponding author), Aalto Univ, Dept Neurosci & Biomed Engn, Sch Sci, POB 12200, FI-00076 Espoo, Finland.	petteri.hyvarinen@aalto.fi		Hyvarinen, Petteri/0000-0002-6922-4331	Paulo Foundation; Jenny and Antti Wihuri Foundation; Avohoidon tutkimussaatio	Paulo Foundation; Jenny and Antti Wihuri Foundation; Avohoidon tutkimussaatio	PH has received personal grants from the Paulo Foundation (www.paulo.fi) and the Jenny and Antti Wihuri Foundation (www.wihurinrahasto.fi). PH, AM and AAA have received a research group grant from the Avohoidon tutkimussaatio (Research fund for outpatient care: http://www.aurora-tietokanta.fi/foundation/details/id/276/refc/lang). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by Avohoidon tutkimussaatio (Research Fund for Outpatient Care). PH would also like to thank the Jenny and Antti Wihuri Foundation and the Paulo Foundation for their financial support. The authors wish to thank Tuomas Neuvonen, Mika Nikander and Jani Virtanen from Sooma Oy for their valuable technical support and advice.	Baguley D, 2013, LANCET, V382, P1600, DOI 10.1016/S0140-6736(13)60142-7; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bikson M, 2009, CLIN NEUROPHYSIOL, V120, P1033, DOI 10.1016/j.clinph.2009.03.018; Cavalcanti K, 2015, BRAIN STIMUL, V8, P978, DOI 10.1016/j.brs.2015.06.019; Charvet LE, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00026; Coffman BA, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-108; De Ridder D, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00124; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Epp B, 2012, J ACOUST SOC AM, V132, pEL196, DOI 10.1121/1.4740462; Forogh B, 2016, NEUROL SCI, V37, P253, DOI 10.1007/s10072-015-2393-9; Frank E, 2012, J NEUROL, V259, P327, DOI 10.1007/s00415-011-6189-4; Fregni F, 2006, EUR J NEUROL, V13, P996, DOI 10.1111/j.1468-1331.2006.01414.x; Goebel G, INT J AUDIOL, V43, P600; Hagenacker T, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-78; Heimrath K, 2015, EUR J NEUROSCI, V41, P1580, DOI 10.1111/ejn.12908; Koehler SD, 2013, J NEUROSCI, V33, P19647, DOI 10.1523/JNEUROSCI.2788-13.2013; Landgrebe M, 2012, J PSYCHOSOM RES, V73, P112, DOI 10.1016/j.jpsychores.2012.05.002; Langguth B, 2013, LANCET NEUROL, V12, P920, DOI 10.1016/S1474-4422(13)70160-1; Leaver AM, 2011, NEURON, V69, P33, DOI 10.1016/j.neuron.2010.12.002; McCombe A, 2001, CLIN OTOLARYNGOL, V26, P388, DOI 10.1046/j.1365-2273.2001.00490.x; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Pal N, 2015, BRAIN STIMUL, V8, P1101, DOI 10.1016/j.brs.2015.06.014; Priori A, 1998, NEUROREPORT, V9, P2257, DOI 10.1097/00001756-199807130-00020; Rauschecker JP, 2010, NEURON, V66, P819, DOI 10.1016/j.neuron.2010.04.032; Roberts LE, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00040; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Schlee W, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-80; Schlee W, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-11; Shekhawat GS, 2015, NEUROREHAB NEURAL RE, V29, P837, DOI 10.1177/1545968314567152; Shekhawat GS, 2013, NEUROREHAB NEURAL RE, V27, P164, DOI 10.1177/1545968312459908; Smarr KL, 2011, ARTHRIT CARE RES, V63, pS454, DOI 10.1002/acr.20556; Valiengo L, 2013, DEPRESS ANXIETY, V30, P646, DOI 10.1002/da.22079; van der Loo E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007396; Vanneste S, 2011, EXP BRAIN RES, V210, P217, DOI 10.1007/s00221-011-2617-z; Weisz N, 2005, PLOS MED, V2, P546, DOI 10.1371/journal.pmed.0020153; Weisz N, 2006, HEARING RES, V222, P108, DOI 10.1016/j.heares.2006.09.003; Zeman F, 2011, OTOLARYNG HEAD NECK, V145, P282, DOI 10.1177/0194599811403882; Zobay O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120123	40	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2016	11	4							e0154286	10.1371/journal.pone.0154286	http://dx.doi.org/10.1371/journal.pone.0154286			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK8XE	27124116	Green Published, Green Submitted, gold			2023-01-03	WOS:000375211700065
J	Rantakokko, M; Portegijs, E; Viljanen, A; Iwarsson, S; Rantanen, T				Rantakokko, Merja; Portegijs, Erja; Viljanen, Anne; Iwarsson, Susanne; Rantanen, Taina			Mobility Modification Alleviates Environmental Influence on Incident Mobility Difficulty among Community-Dwelling Older People: A Two-Year Follow-Up Study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; COMPENSATORY STRATEGIES; DISABILITY; WALKING; ADULTS; BARRIERS; WOMEN; GAIT; PERFORMANCE; ADAPTATION	Background Environmental barriers increase risk for mobility difficulties in old age. Mobility difficulty is preceded by a phase where people try to postpone a difficulty through mobility modification. We studied whether perceived environmental mobility barriers outdoors correlate with mobility modification and mobility difficulty, predict development of mobility difficulty over a two-year follow-up, and whether mobility modification alleviates the risk for difficulty. Methods At baseline, 848 people aged 75-90 were interviewed face-to-face. Telephone follow-up interviews were conducted one (n = 816) and two years (n = 761) later. Environmental barriers to mobility were self-reported using a15-item structured questionnaire at baseline, summed and divided into tertiles (0, 1 and 2 or more barriers). Mobility difficulty was assessed as self-reported ability to walk 2 km at all assessment points and categorized into `no difficulty', 'no difficulty but mobility modifications' (reducing frequency, stopping walking, using an aid, slowing down or resting during the performance) and 'difficulty'. Results At baseline, 212 participants reported mobility modifications and 356 mobility difficulties. Those reporting one or multiple environmental barriers had twice the odds for mobility modifications and up to five times the odds for mobility difficulty compared to those reporting no environmental barriers. After multiple adjustments for health and functioning, reporting multiple environmental barriers outdoors continued to predict the development of incident mobility difficulty over the two-year follow-up. Mobility modifications attenuated the association. Conclusion For older people who successfully modify their performance, environmental influence on incident mobility difficulty can be diminished. Older people use mobility modification to alleviate environmental press on mobility.	[Rantakokko, Merja; Portegijs, Erja; Viljanen, Anne; Rantanen, Taina] Univ Jyvaskyla, Gerontol Res Ctr, Jyvaskyla, Finland; [Rantakokko, Merja; Portegijs, Erja; Viljanen, Anne; Rantanen, Taina] Univ Jyvaskyla, Dept Hlth Sci, Jyvaskyla, Finland; [Iwarsson, Susanne] Lund Univ, Dept Hlth Sci, Lund, Sweden	University of Jyvaskyla; University of Jyvaskyla; Lund University	Rantakokko, M (corresponding author), Univ Jyvaskyla, Gerontol Res Ctr, Jyvaskyla, Finland.; Rantakokko, M (corresponding author), Univ Jyvaskyla, Dept Hlth Sci, Jyvaskyla, Finland.	Merja.rantakokko@jyu.fi	Rantakokko, Merja/I-9779-2019; Rantakokko, Merja/HHC-5689-2022; Rantanen, Taina/O-6579-2016; Iwarsson, Susanne/I-7517-2013	Rantakokko, Merja/0000-0003-3546-1600; Rantanen, Taina/0000-0002-1604-1945; Portegijs, Erja/0000-0002-5205-9616; Viljanen, Anne/0000-0002-8428-3604; Iwarsson, Susanne/0000-0002-6670-7952	Academy of Finland [285747]; Academy of Finland Future of Living and Housing Program (ASU-LIVE) [255403]; Finnish Ministry of Education and Culture; Ribbingska Foundation in Lund, Sweden	Academy of Finland(Academy of Finland); Academy of Finland Future of Living and Housing Program (ASU-LIVE); Finnish Ministry of Education and Culture; Ribbingska Foundation in Lund, Sweden	This work was supported by Academy of Finland (grant number 285747 to [MR]); the Academy of Finland Future of Living and Housing Program (ASU-LIVE) (grant number 255403 to [TR]); the Finnish Ministry of Education and Culture to [TR and EP]; and the Ribbingska Foundation in Lund, Sweden to [SI]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balfour JL, 2002, AM J EPIDEMIOL, V155, P507, DOI 10.1093/aje/155.6.507; Baltes PB, 1990, SUCCESSFUL AGING PER; Booth ML, 2000, PREV MED, V31, P15, DOI 10.1006/pmed.2000.0661; Boyle PA, 2007, J AM GERIATR SOC, V55, P195, DOI 10.1111/j.1532-5415.2007.01038.x; Buchner DM, 2003, AM J PREV MED, V25, P214, DOI 10.1016/S0749-3797(03)00188-0; Clarke P, 2008, AM J EPIDEMIOL, V168, P506, DOI 10.1093/aje/kwn185; Ramos-Pichardo JD, 2014, ARCH GERONTOL GERIAT, V59, P122, DOI 10.1016/j.archger.2014.02.003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freedman VA, 2014, AM J PUBLIC HEALTH, V104, pE88, DOI 10.2105/AJPH.2013.301687; Fried LP, 2000, J GERONTOL A-BIOL, V55, pM43; Ganesh SP, 2011, ARCH PHYS MED REHAB, V92, P228, DOI 10.1016/j.apmr.2010.10.012; Gignac MAM, 2002, PSYCHOL AGING, V17, P520, DOI 10.1037//0882-7974.17.3.520; Gill TM, 2003, ARCH INTERN MED, V163, P1317, DOI 10.1001/archinte.163.11.1317; Gregory PC, 2011, J GERONTOL A-BIOL, V66, P577, DOI 10.1093/gerona/glr023; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Higgins TJ, 2014, J GERONTOL B-PSYCHOL, V69, P263, DOI 10.1093/geronb/gbt110; Lawton M.P., 1973, PSYCHOL ADULT DEV AG, P619, DOI DOI 10.1037/10044-020; LAWTON MP, 1968, GERONTOLOGIST, V8, P108, DOI 10.1093/geront/8.2.108; Lien LL, 2015, INT J ENV RES PUB HE, V12, P11954, DOI 10.3390/ijerph120911954; Manty M, 2007, ARCH PHYS MED REHAB, V88, P1108, DOI 10.1016/j.apmr.2007.06.016; Marigold DS, 2008, GAIT POSTURE, V27, P689, DOI 10.1016/j.gaitpost.2007.09.005; Rantakokko M, 2015, QUAL LIFE RES; Rantakokko M, 2014, J GERONTOL A-BIOL, V69, P1562, DOI 10.1093/gerona/glu069; Rantakokko M, 2012, AGE AGEING, V41, P118, DOI 10.1093/ageing/afr136; Rantakokko M, 2009, J AM GERIATR SOC, V57, P634, DOI 10.1111/j.1532-5415.2009.02180.x; Rantanen T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1018; Richardson JK, 2005, ARCH PHYS MED REHAB, V86, P1539, DOI 10.1016/j.apmr.2004.12.032; Rubin G., 1991, J AGING HEALTH, V3, P285, DOI [10.1177/089826439100300210, DOI 10.1177/089826439100300210]; Rush KL, 2011, CLIN NURS RES, V20, P81, DOI 10.1177/1054773810379401; Thies SB, 2005, GAIT POSTURE, V22, P26, DOI 10.1016/j.gaitpost.2004.06.004; Tsai LT, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1054; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Weiss CO, 2012, ARCH GERONTOL GERIAT, V54, pE329, DOI 10.1016/j.archger.2011.08.018; Wellmon R, 2013, GAIT POSTURE, V38, P198, DOI 10.1016/j.gaitpost.2012.11.009	34	13	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2016	11	4							e0154396	10.1371/journal.pone.0154396	http://dx.doi.org/10.1371/journal.pone.0154396			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DJ9WX	27104750	gold, Green Published, Green Submitted			2023-01-03	WOS:000374565100076
J	Danilowicz-Szymanowicz, L; Suchecka, J; Niemirycz-Makurat, A; Rozwadowska, K; Raczak, G				Danilowicz-Szymanowicz, Ludmila; Suchecka, Justyna; Niemirycz-Makurat, Agnieszka; Rozwadowska, Katarzyna; Raczak, Grzegorz			Autonomic Predictors of Hospitalization Due to Heart Failure Decompensation in Patients with Left Ventricular Systolic Dysfunction	PLOS ONE			English	Article							SYMPATHETIC-NERVOUS-SYSTEM; RATE-VARIABILITY; BAROREFLEX SENSITIVITY; PARASYMPATHETIC ACTIVITY; SUDDEN-DEATH; RISK; MORTALITY	Introduction Autonomic nervous system balance can be significantly deteriorated during heart failure exacerbation. However, it is still unknown whether these changes are only the consequence of heart failure decompensation or can also predict development thereof. Objectives were to verify if simple, non-invasive autonomic parameters, such as baroreflex sensitivity and short-term heart rate variability can provide independent of other well-known clinical parameters information on the risk of heart failure decompensation in patients with left ventricular systolic dysfunction. Methods In 142 stable patients with left ventricular ejection fraction <= 40%, baroreflex sensitivity and short-term heart rate variability, as well as other well-known clinical parameters, were analyzed. During 23 +/- 9 months of follow-up 19 patients were hospitalized due to the heart failure decompensation (EVENT). Results Pre-specified cut-off values of baroreflex sensitivity (<= 2.4 ms/mmHg) and low frequency power index of heart rate variability (<= 19 ms(2)) were significantly associated with the EVENTs (hazard ratio 4.43, 95% confidence interval [CI] 1.35-14.54 and 5.41, 95% CI 1.87-15.65 respectively). EVENTs were also associated with other parameters, such as left ventricular ejection fraction, NYHA class, diuretic use, renal function, brain natriuretic peptide and hemoglobin level, left atrial size, left and right ventricular heart failure signs. After adjusting baroreflex sensitivity and low frequency power index for each of the abovementioned parameters, autonomic parameters were still significant predictors of hospitalization due to the heart failure decompensation. Conclusion Simple, noninvasive autonomic indices can be helpful in identifying individuals with increased risk of hospitalization due to the heart failure decompensation among clinically stable patients with left ventricular systolic dysfunction, even when adjusted for other well-known clinical parameters.	[Danilowicz-Szymanowicz, Ludmila; Suchecka, Justyna; Niemirycz-Makurat, Agnieszka; Rozwadowska, Katarzyna; Raczak, Grzegorz] Med Univ Gdansk, Dept Cardiol & Electrotherapy, Gdansk, Poland	Fahrenheit Universities; Medical University Gdansk	Danilowicz-Szymanowicz, L (corresponding author), Med Univ Gdansk, Dept Cardiol & Electrotherapy, Gdansk, Poland.	ludwik@gumed.edu.pl	Danilowicz-Szymanowicz, Ludmila/AAG-7732-2019	Danilowicz-Szymanowicz, Ludmila/0000-0002-2269-1880; Rozwadowska, Katarzyna/0000-0002-8712-801X				Alvarez-Garcia J, 2015, EUR J HEART FAIL, V17, P818, DOI 10.1002/ejhf.287; BINKLEY PF, 1991, J AM COLL CARDIOL, V18, P464, DOI 10.1016/0735-1097(91)90602-6; Braga SS, 2006, INT J CARDIOL, V109, P118, DOI 10.1016/j.ijcard.2005.03.072; Camm AJ, 1996, EUR HEART J, V17, P354; Eckberg DL, 1992, HUMAN BAROREFLEXES H; ELLENBOGEN KA, 1989, CIRCULATION, V79, P51, DOI 10.1161/01.CIR.79.1.51; Fauchier L, 1999, J AM COLL CARDIOL, V33, P1203, DOI 10.1016/S0735-1097(99)00021-2; Floras JS, 2009, J AM COLL CARDIOL, V54, P375, DOI 10.1016/j.jacc.2009.03.061; Gademan MGJ, 2008, AM J PHYSIOL-HEART C, V295, pH755, DOI 10.1152/ajpheart.00170.2008; Galinier M, 2000, EUR HEART J, V21, P475, DOI 10.1053/euhj.1999.1875; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Huikuri HV, 1999, J AM COLL CARDIOL, V34, P1878, DOI 10.1016/S0735-1097(99)00468-4; Izaks GJ, 1999, JAMA-J AM MED ASSOC, V281, P1714, DOI 10.1001/jama.281.18.1714; Kishi T, 2012, J CARDIOL, V59, P117, DOI 10.1016/j.jjcc.2011.12.006; La Rovere MT, 2009, J AM COLL CARDIOL, V53, P193, DOI 10.1016/j.jacc.2008.09.034; La Rovere MT, 2003, CIRCULATION, V107, P565, DOI 10.1161/01.CIR.0000047275.25795.17; La Rovere MT, 1998, LANCET, V351, P478; Maestri R, 1998, COMPUT METH PROG BIO, V56, P37, DOI 10.1016/S0169-2607(98)00004-2; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Mortara A, 1997, CIRCULATION, V96, P3450; Nolan J, 1996, AM J CARDIOL, V77, P154, DOI 10.1016/S0002-9149(96)90587-1; NOLAN J, 1992, BRIT HEART J, V67, P482; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; Perkiomaki JS, 2010, ANN NONINVAS ELECTRO, V15, P250, DOI 10.1111/j.1542-474X.2010.00372.x; Piepoli MF, 2008, PACE, V31, P701, DOI 10.1111/j.1540-8159.2008.01073.x; Pinna GD, 2005, J AM COLL CARDIOL, V46, P1314, DOI 10.1016/j.jacc.2005.06.062; Pinna GD, 2002, CLIN SCI, V103, P81; Rydlewska A, 2011, CLIN AUTON RES, V21, P47, DOI 10.1007/s10286-010-0089-z; Sanchez-Lazaro IJ, 2011, INT J CARDIOL, V152, P83, DOI 10.1016/j.ijcard.2010.07.010; Shah SA, 2013, AM J CARDIOL, V112, P533, DOI 10.1016/j.amjcard.2013.04.018; Triposkiadis F, 2009, J AM COLL CARDIOL, V54, P1747, DOI 10.1016/j.jacc.2009.05.015	31	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2016	11	3							e0152372	10.1371/journal.pone.0152372	http://dx.doi.org/10.1371/journal.pone.0152372			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3TE	27015089	Green Submitted, Green Published, gold			2023-01-03	WOS:000372708900057
J	Perez-Tasigchana, RF; Leon-Munoz, LM; Lopez-Garcia, E; Banegas, JR; Rodriguez-Artalejo, F; Guallar-Castillon, P				Perez-Tasigchana, Raul F.; Leon-Munoz, Luz M.; Lopez-Garcia, Esther; Banegas, Jose R.; Rodriguez-Artalejo, Fernando; Guallar-Castillon, Pilar			Mediterranean Diet and Health-Related Quality of Life in Two Cohorts of Community-Dwelling Older Adults	PLOS ONE			English	Article							FOOD-FREQUENCY QUESTIONNAIRE; SPANISH VERSION; PHYSICAL-ACTIVITY; REFERENCE VALUES; MENTAL-HEALTH; POPULATION; ADHERENCE; CONSUMPTION; MORTALITY; SURVIVAL	Introduction In older adults, the Mediterranean diet is associated with lower risk of chronic diseases, but its association with health-related quality of life (HRQL) is still uncertain. This study assessed the association between the Mediterranean diet and HRQL in 2 prospective cohorts of individuals aged >= 60 years in Spain. Methods The UAM-cohort (n = 2376) was selected in 2000/2001 and followed-up through 2003. At baseline, diet was collected with a food frequency questionnaire, which was used to develop an 8-item index of Mediterranean diet (UAM-MDP). The Seniors-ENRICA cohort (n = 1911) was recruited in 2008/2010 and followed-up through 2012. At baseline, a diet history was used to obtain food consumption. Mediterranean diet adherence was measured with the PREDIMED score and the Trichopoulou's Mediterranean Diet Score (MSD). HRQL was assessed, at baseline and at the end of follow-up, with the physical and mental component summaries (PCS and MCS) of the SF-36 questionnaire in the UAM-cohort, and the SF-12v.2 questionnaire in the Seniors-ENRICA cohort. Analyses were conducted with linear regression, and adjusted for the main confounders including baseline HRQL. Results In the UAM-cohort, no significant associations between the UAM-MDP and the PCS or the MCS were found. In the Seniors-ENRICA cohort, a higher PREDIMED score was associated with a slightly better PCS; when compared with the lowest tertile of PREDIMED score, the beta coefficient (95% confidence interval) for PCS was 0.55 (-0.48 to 1.59) in the second tertile, and 1.34 (0.21 to 2.47) in the highest tertile. However, the PREDIMED score was non-significantly associated with a better MCS score. The MSD did not show an association with either the PCS or the MCS. Conclusions No clinically relevant association was found between the Mediterranean diet and HRQL in older adults in Spain.	[Perez-Tasigchana, Raul F.; Leon-Munoz, Luz M.; Lopez-Garcia, Esther; Banegas, Jose R.; Rodriguez-Artalejo, Fernando; Guallar-Castillon, Pilar] Univ Autonoma Madrid IdiPaz, Dept Prevent Med & Publ Hlth, Madrid, Spain		Guallar-Castillon, P (corresponding author), Univ Autonoma Madrid IdiPaz, Dept Prevent Med & Publ Hlth, Madrid, Spain.	mpilar.guallar@uam.es	Stefanadis, Christodoulos/ABH-2232-2020; Lopez-Garcia, Esther/A-8894-2019; Guallar-Castillon, Pilar/F-1533-2016; León-Muñoz, Luz M/H-8275-2017	Stefanadis, Christodoulos/0000-0001-5974-6454; Guallar-Castillon, Pilar/0000-0003-4759-6713; 	Sanofi-Aventis; FIS [09/162, PI11/01379, PI12/1166]; Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular; National Government of Ecuador through the National Institution of Higher Education, Science, Technology and Innovation-SENESCYT	Sanofi-Aventis(Sanofi-Aventis); FIS(Instituto de Salud Carlos III); Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular; National Government of Ecuador through the National Institution of Higher Education, Science, Technology and Innovation-SENESCYT	Baseline data collection of the ENRICA-Seniors cohort was funded by Sanofi-Aventis. Data collection during follow-up was funded by FIS a grant 09/162 (Ministry of Health of Spain). Specific funding for this analysis was obtained from FIS grants PI11/01379 and PI12/1166 (Ministry of Health of Spain), and from the "Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular". RFP-T received a grant from the National Government of Ecuador through the National Institution of Higher Education, Science, Technology and Innovation-SENESCYT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; Alonso J, 1998, MED CLIN-BARCELONA, V111, P410; Alonso J., 2000, MANUAL PUNTUACION VE; Amarantos E, 2001, J GERONTOL A-BIOL, V56, P54, DOI 10.1093/gerona/56.suppl_2.54; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS91; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515; Balboa-Castillo T, 2011, AM J PREV MED, V40, P39, DOI 10.1016/j.amepre.2010.10.005; Banegas JR, 2002, J HYPERTENS, V20, P2157, DOI 10.1097/00004872-200211000-00014; Bonaccio M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003003; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Dean M, 2008, APPETITE, V50, P308, DOI 10.1016/j.appet.2007.08.007; Domenech M, 2014, HYPERTENSION, V64, P69, DOI 10.1161/HYPERTENSIONAHA.113.03353; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837; Fito M, 2007, ARCH INTERN MED, V167, P1195, DOI 10.1001/archinte.167.11.1195; Grunert KG, 2007, APPETITE, V49, P486, DOI 10.1016/j.appet.2007.03.010; Guallar-Castillon P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086074; Guallar-Castillon P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e363; Sanchez PH, 2012, EUR J CLIN NUTR, V66, P360, DOI 10.1038/ejcn.2011.146; Hislop TG, 2006, J CLIN ONCOL, V24, P2311, DOI 10.1200/JCO.2005.04.3042; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Leon-Munoz LM, 2005, INT J OBESITY, V29, P1385, DOI 10.1038/sj.ijo.0803049; Leon-Munoz LM, 2014, J AM MED DIR ASS; Lopez-Garcia E, 2003, MED CLIN-BARCELONA, V120, P568, DOI 10.1157/13046436; Lopez-Garcia E, 2014, J ACAD NUTR DIET; Martinez-Gomez D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-47; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Munoz MA, 2009, BRIT J NUTR, V101, P1821, DOI 10.1017/S0007114508143598; Myint PK, 2007, PUBLIC HEALTH NUTR, V10, P34, DOI 10.1017/S1368980007222608; Plaisted CS, 1999, J AM DIET ASSOC, V99, pS84, DOI 10.1016/S0002-8223(99)00421-6; Pols MA, 1997, INT J EPIDEMIOL, V26, pS181, DOI 10.1093/ije/26.suppl_1.S181; Poulose SM, 2014, J NUTR, V144, p561S, DOI 10.3945/jn.113.184838; Rienks J, 2013, EUR J CLIN NUTR, V67, P75, DOI 10.1038/ejcn.2012.193; Rodriguez-Artalejo F, 2011, REV ESP CARDIOL, V64, P876, DOI 10.1016/j.recesp.2011.05.019; Sanchez-Villegas A, 2009, ARCH GEN PSYCHIAT, V66, P1090, DOI 10.1001/archgenpsychiatry.2009.129; Schiepers OJG, 2010, PROSTAG LEUKOTR ESS, V83, P31, DOI 10.1016/j.plefa.2010.02.030; Schmidt S, 2012, MED CLIN-BARCELONA, V139, P613, DOI 10.1016/j.medcli.2011.10.024; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Silvers KM, 2002, PUBLIC HEALTH NUTR, V5, P427, DOI 10.1079/PHN2001308; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169; Sorensen M, 1999, J SPORT SCI, V17, P369, DOI 10.1080/026404199365885; Trichopoulou A, 2007, EUR J EPIDEMIOL, V22, P871, DOI 10.1007/s10654-007-9190-6; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Vilagut G, 2008, MED CLIN-BARCELONA, V130, P726, DOI 10.1157/13121076; Wardle J, 2000, AM J MED, V108, P547, DOI 10.1016/S0002-9343(00)00330-2; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	48	31	32	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2016	11	3							e0151596	10.1371/journal.pone.0151596	http://dx.doi.org/10.1371/journal.pone.0151596			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3QJ	27008160	Green Published, Green Submitted, gold			2023-01-03	WOS:000372701200058
J	Howe, GA; Xiao, B; Zhao, HJ; Al-Zahrani, KN; Hasim, MS; Villeneuve, J; Sekhon, HS; Goss, GD; Sabourin, LA; Dimitroulakos, J; Addison, CL				Howe, Grant A.; Xiao, Bin; Zhao, Huijun; Al-Zahrani, Khalid N.; Hasim, Mohamed S.; Villeneuve, James; Sekhon, Harmanjatinder S.; Goss, Glenwood D.; Sabourin, Luc A.; Dimitroulakos, Jim; Addison, Christina L.			Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; EGFR INHIBITORS; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; MUTATIONS; GEFITINIB; FAK; ADENOCARCINOMAS; SENSITIVITY; ACTIVATION	Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TKIs), there is a need for additional therapeutic approaches in patients with wild-type EGFR. As a key component of downstream integrin signalling and known receptor cross-talk with EGFR, we hypothesized that targeting focal adhesion kinase (FAK) activity, which has also been shown to correlate with aggressive stage in NSCLC, would lead to enhanced activity of EGFR TKIs. As such, EGFR TKI-resistant NSCLC cells (A549, H1299, H1975) were treated with the EGFR TKI erlotinib and FAK inhibitors (PF-573,228 or PF-562,271) both as single agents and in combination. We determined cell viability, apoptosis and 3-dimensional growth in vitro and assessed tumor growth in vivo. Treatment of EGFR TKI-resistant NSCLC cells with FAK inhibitor alone effectively inhibited cell viability in all cell lines tested; however, its use in combination with the EGFR TKI erlotinib was more effective at reducing cell viability than either treatment alone when tested in both 2-and 3-dimensional assays in vitro, with enhanced benefit seen in A549 cells. This increased efficacy may be due in part to the observed inhibition of Akt phosphorylation when the drugs were used in combination, where again A549 cells demonstrated the most inhibition following treatment with the drug combination. Combining erlotinib with FAK inhibitor was also potent in vivo as evidenced by reduced tumor growth in the A549 mouse xenograft model. We further ascertained that the enhanced sensitivity was irrespective of the LKB1 mutational status. In summary, we demonstrate the effectiveness of combining erlotinib and FAK inhibitors for use in known EGFR wild-type, EGFR TKI resistant cells, with the potential that a subset of cell types, which includes A549, could be particularly sensitive to this combination treatment. As such, further evaluation of this combination therapy is warranted and could prove to be an effective therapeutic approach for patients with inherent EGFR TKI-resistant NSCLC.	[Howe, Grant A.; Xiao, Bin; Zhao, Huijun; Al-Zahrani, Khalid N.; Hasim, Mohamed S.; Villeneuve, James; Sabourin, Luc A.; Dimitroulakos, Jim; Addison, Christina L.] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON, Canada; [Al-Zahrani, Khalid N.; Sabourin, Luc A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Hasim, Mohamed S.; Dimitroulakos, Jim; Addison, Christina L.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Villeneuve, James] Univ Ottawa, Dept Surg, Ottawa, ON, Canada; [Sekhon, Harmanjatinder S.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Goss, Glenwood D.; Dimitroulakos, Jim; Addison, Christina L.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Addison, CL (corresponding author), Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON, Canada.; Addison, CL (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.; Addison, CL (corresponding author), Univ Ottawa, Dept Med, Ottawa, ON, Canada.	caddison@ohri.ca	Dimitroulakos, Jim/AAK-3398-2020	Hasim, Mohamed Shaad/0000-0002-0275-3378	Lung Cancer Research Foundation	Lung Cancer Research Foundation	This work was supported by a grant to CLA from the Lung Cancer Research Foundation (http://www.lungcancerresearchfoundation.org). The funders had no role in the study design, data collection or analysis, decision to publish or the preparation of this manuscript.	Al-Zahrani KN, 2014, DEV DYNAM, V243, P640, DOI 10.1002/dvdy.24106; Amann J, 2005, CANCER RES, V65, P226; Bagi CM, 2009, CANCER BIOL THER, V8, P856, DOI 10.4161/cbt.8.9.8246; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269; Cabrita MA, 2011, MOL ONCOL, V5, P517, DOI 10.1016/j.molonc.2011.10.004; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Carelli S, 2006, LUNG CANCER, V53, P263, DOI 10.1016/j.lungcan.2006.06.001; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Dutta PR, 2007, CANCER LETT, V254, P165, DOI 10.1016/j.canlet.2007.02.006; Ettinger DS, 2006, ONCOLOGIST, V11, P358, DOI 10.1634/theoncologist.11-4-358; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Friess T, 2005, CLIN CANCER RES, V11, P5300, DOI 10.1158/1078-0432.CCR-04-2642; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Golubovskaya VM, 2010, ANTI-CANCER AGENT ME, V10, P735; Hiscox S, 2011, BREAST CANCER RES TR, V125, P659, DOI 10.1007/s10549-010-0857-4; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Honeywell DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070515; Ju LX, 2010, J CELL BIOCHEM, V111, P1565, DOI 10.1002/jcb.22888; Kline ER, 2013, J BIOL CHEM, V288, P17663, DOI 10.1074/jbc.M112.444620; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Li C, 2013, CANCER GENE THER, V20, P101, DOI 10.1038/cgt.2012.91; Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Murray S, 2006, LUNG CANCER, V52, P225, DOI 10.1016/j.lungcan.2005.12.015; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Pino MS, 2006, CANCER RES, V66, P3802, DOI 10.1158/0008-5472.CAN-05-3753; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Schultze A, 2010, INVEST NEW DRUG, V28, P825, DOI 10.1007/s10637-009-9326-5; Schultze A, 2010, EXPERT OPIN INV DRUG, V19, P777, DOI 10.1517/13543784.2010.489548; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Suda K, 2012, CANCER METAST REV, V31, P807, DOI 10.1007/s10555-012-9391-7; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Yoon H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088587; Yu X, 2000, J CELL SCI, V113, P2139; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	52	29	30	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2016	11	3							e0150567	10.1371/journal.pone.0150567	http://dx.doi.org/10.1371/journal.pone.0150567			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TL	26962872	Green Published, gold			2023-01-03	WOS:000371993000042
J	Sun, QQ; Nie, SS; Wang, LX; Yang, F; Meng, ZM; Xiao, HY; Xiang, B; Li, XJ; Fu, XH; Wang, S				Sun, Qianqian; Nie, Shuangshuang; Wang, Lingxiao; Yang, Fan; Meng, Zhangming; Xiao, Hengyi; Xiang, Bing; Li, Xiujun; Fu, Xianghui; Wang, Shuang			Factors that Affect Pancreatic Islet Cell Autophagy in Adult Rats: Evaluation of a Calorie-Restricted Diet and a High-Fat Diet	PLOS ONE			English	Article							BETA-CELLS; GLUCOSE-TOLERANCE; IN-VIVO; APOPTOSIS; INSULIN; DEATH; CANCER; HOMEOSTASIS; LC3B; MICE	Aging may be a risk factor for type 2 diabetes in the elderly. Dietary intervention can affect glucose tolerance in adults, which may be due to body composition and islet cell autophagy. The aim of this study was to determine the effects of various dietary interventions on islet cell autophagy. Pancreatic tissue and blood samples were collected from Sprague Dawley rats (14-16 months old, n = 15 for each group) that received a normal diet (ND), a high-fat diet (HFD), or a calorie-restricted diet (CRD). The body weight (BW), visceral fat, serum lipid levels, fasting serum glucose, insulin levels, and beta/alpha cell area were determined in 14-16-(0-w), 16-18-(8-w), and 18-20(16-w)-month-old rats. Pancreatic islet autophagy (LC3B and LAMP2), AP (Acid Phosphatase) and apoptosis (apoptosis index, AI (TUNEL assay) and cleaved caspase-3) were detected using immunohistochemistry, ELISA and western blot. At 16 weeks, the expressions of LC3B, LAMP2 and AP markedly increased in both the HFD (P<0.01) and CRD (P<0.05) groups; however, an increase in the AI (P<0.05), cleaved caspase-3 and Beclin1 expression and a decrease in the expressions of BCL2 and BCLXL (P<0.05) were observed in only the HFD group. FFA, triglyceride levels, HOMA-IR, insulin levels and glucagon levels were significantly increased in the HFD group but decreased in the CRD group at 16 weeks (P<0.05). The degree of islet cell autophagy was potentially regulated by the levels of FFA and islet cell insulin and glucagon, which may have been due to the effects of Beclin1/BCL2.	[Sun, Qianqian; Nie, Shuangshuang; Wang, Lingxiao; Yang, Fan; Meng, Zhangming; Wang, Shuang] Sichuan Univ, Ctr Gerontol & Geriatr, West China Hosp, Chengdu 610064, Sichuan Provinc, Peoples R China; [Xiao, Hengyi] Sichuan Univ, West China Hosp, West China Med Sch, Lab Aging Res, Chengdu 610064, Sichuan Provinc, Peoples R China; [Xiang, Bing] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu 610064, Sichuan Provinc, Peoples R China; [Li, Xiujun] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu 610064, Sichuan Provinc, Peoples R China; [Fu, Xianghui] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan Provinc, Peoples R China; [Fu, Xianghui] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu 610064, Sichuan Provinc, Peoples R China; [Fu, Xianghui] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan Provinc, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Wang, S (corresponding author), Sichuan Univ, Ctr Gerontol & Geriatr, West China Hosp, Chengdu 610064, Sichuan Provinc, Peoples R China.	wangs0211@hotmail.com	wang, xiao/HGB-7081-2022; wang, xl/Y-8251-2019; Wang, Xin/GYU-1129-2022; Wang, Xin/AAN-8435-2021; li, xiu/GXV-1745-2022	wang, xiao/0000-0002-4088-3341; Wang, Xin/0000-0002-4457-7376; Fu, Xianghui/0000-0001-9808-3892	Science and Technology of Sichuan Province of China [2013FZ0054]	Science and Technology of Sichuan Province of China	Funding for this work came from the Science and Technology of Sichuan Province of China (2013FZ0054). The funder played an important role in the study design, data collection and analysis.	Button RW, 2015, NEUROSCI BULL, V31, P382, DOI 10.1007/s12264-015-1528-y; Chen S, 2013, CLIN CANCER RES, V19, P6853, DOI 10.1158/1078-0432.CCR-13-1617; Chu KY, 2015, DIABETOLOGIA, V58, P2074, DOI 10.1007/s00125-015-3665-x; Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009; Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x; Guo JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5420; He CC, 2012, NATURE, V481, P511, DOI 10.1038/nature10758; Hilderink J, 2015, J CELL MOL MED, V19, P1836, DOI 10.1111/jcmm.12555; Hur KY, 2010, DIABETES OBES METAB, V12, P20, DOI 10.1111/j.1463-1326.2010.01278.x; Kaniuk NA, 2007, DIABETES, V56, P930, DOI 10.2337/db06-1160; Keku TO, 2005, CANCER EPIDEM BIOMAR, V14, P2076, DOI 10.1158/1055-9965.EPI-05-0239; Lalaoui N, 2015, SEMIN CELL DEV BIOL, V39, P63, DOI 10.1016/j.semcdb.2015.02.003; Lee MS, 2014, TRENDS ENDOCRIN MET, V25, P620, DOI 10.1016/j.tem.2014.08.005; Lerman-Garber I, 2010, REV INVEST CLIN, V62, P312; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Maruyama Y, 2014, BIOCHEM BIOPH RES CO, V446, P309, DOI 10.1016/j.bbrc.2014.02.093; Masini M, 2009, DIABETOLOGIA, V52, P1083, DOI 10.1007/s00125-009-1347-2; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Qi ZF, 2015, TRANSL STROKE RES, V6, P198, DOI 10.1007/s12975-015-0393-y; Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145; Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5; Tessari P, 2013, DIABETES, V62, P2699, DOI 10.2337/db12-1127; Wang S, 2013, CLIN INVEST MED, V36, pE72; Weiss EP, 2006, AM J CLIN NUTR, V84, P1033; Xing BH, 2015, J PHYSIOL BIOCHEM, V71, P649, DOI 10.1007/s13105-015-0430-z; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Young ARJ, 2010, CURR OPIN CELL BIOL, V22, P234, DOI 10.1016/j.ceb.2009.12.005	30	15	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2016	11	3							e0151104	10.1371/journal.pone.0151104	http://dx.doi.org/10.1371/journal.pone.0151104			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TL	26963814	Green Published, Green Submitted, gold			2023-01-03	WOS:000371993000104
J	Kwon, SB; Kim, MJ; Yang, JM; Lee, HP; Hong, JT; Jeong, HS; Kim, ES; Yoon, DY				Kwon, Sae-Bom; Kim, Min-Je; Yang, Jin Mo; Lee, Hee-Pom; Hong, Jin Tae; Jeong, Heon-Sang; Kim, Eun Suk; Yoon, Do-Young			Cudrania tricuspidata Stem Extract Induces Apoptosis via the Extrinsic Pathway in SiHa Cervical Cancer Cells	PLOS ONE			English	Article							NF-KAPPA-B; CHLOROGENIC ACID; CARCINOMA CELLS; EXPRESSION; RECEPTOR; PROLIFERATION; MITOCHONDRIA; INHIBITION; ACTIVATION; WORLDWIDE	The focus of this study is the anti-cancer effects of Cudrania tricuspidata stem (CTS) extract on cervical cancer cells. The effect of CTS on cell viability was investigated in HPV-positive cervical cancer cells and HaCaT human normal keratinocytes. CTS showed significant dose-dependent cytotoxic effects in cervical cancer cells. However, there was no cytotoxic effect of CTS on HaCaT keratinocytes at concentrations of 0.125-0.5 mg/mL. Based on this cytotoxic effect, we demonstrated that CTS induced apoptosis by down-regulating the E6 and E7 viral oncogenes. Apoptosis was detected by DAPI staining, annexin V-FITC/PI staining, cell cycle analysis, western blotting, RT-PCR, and JC-1 staining in SiHa cervical cancer cells. The mRNA expression levels of extrinsic pathway molecules such as Fas, death receptor 5 (DR5), and TNF-related apoptosis-inducing ligand (TRAIL) were increased by CTS. Furthermore, CTS treatment activated caspase-3/caspase-8 and cleavage of poly (ADP-ribose) polymerase (PARP). However, the mitochondrial membrane potential and expression levels of intrinsic pathway molecules such as Bcl-2, Bcl-xL, Bax, and cytochrome C were not modulated by CTS. Taken together, these results indicate that CTS induced apoptosis by activating the extrinsic pathway, but not the intrinsic pathway, in SiHa cervical cancer cells. These results suggest that CTS can be used as a modulating agent in cervical cancer.	[Kwon, Sae-Bom; Kim, Min-Je; Yang, Jin Mo; Yoon, Do-Young] Konkuk Univ, Bio Mol Informat Ctr, Dept Biosci & Biotechnol, Seoul, South Korea; [Yang, Jin Mo] Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA; [Lee, Hee-Pom; Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Med Res Ctr, Osong, Chungbuk, South Korea; [Jeong, Heon-Sang] Chungbuk Natl Univ, Agr Life & Environm Sci, Cheongju, Chungbuk, South Korea; [Kim, Eun Suk] Chungcheongbukdo Bio CS, Osong, Chungbuk, South Korea	Konkuk University; University of Minnesota System; University of Minnesota Twin Cities; Chungbuk National University; Chungbuk National University	Yoon, DY (corresponding author), Konkuk Univ, Bio Mol Informat Ctr, Dept Biosci & Biotechnol, Seoul, South Korea.	ydy4218@konkuk.ac.kr			National Research Foundation of Korea (NRF) [2015R1A2A2A09001137]; Priority Research Centers Program [2012-0006686]; Pharma Teksol; Chungcheongbukdo Bio CS	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Priority Research Centers Program; Pharma Teksol(Dexcel Pharma); Chungcheongbukdo Bio CS	This research was supported by the basic program (2015R1A2A2A09001137) of the National Research Foundation of Korea (NRF), http://www.nrf.re.kr/nrf_eng_cms. D.Y. Yoon was supported partially by the Priority Research Centers Program (2012-0006686). The authors are grateful to Pharma Teksol and Chungcheongbukdo Bio CS for their intellectual and financial support of this project. There was no additional external funding received for this study.; This research was supported by the basic program (2015R1A2A2A09001137) of the National Research Foundation of Korea (NRF). (http://www.nrf.re.kr/nrf_eng_cms). D.Y. Yoon was supported partially by the Priority Research Centres Program (2012-0006686). The authors are grateful to PharmaTeksol and Chungcheongbukdo Bio CS for their intellectual and financial support of this project. There was no additional external funding received for this study.	Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bak Y, 2013, MOL BIOL REP, V40, P4507, DOI 10.1007/s11033-013-2544-0; Banjerdpongchai R, 2016, TUMOR BIOL, V37, P227, DOI 10.1007/s13277-015-3774-7; Belkaid A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-7; Bouzaiene NN, 2015, EUR J PHARMACOL, V766, P99, DOI [10.1016/j.etphar.2015.09.044, 10.1016/j.ejphar.2015.09.044]; Bufalo MC, 2013, J ETHNOPHARMACOL, V149, P84, DOI 10.1016/j.jep.2013.06.004; Burgos-Moron E, 2012, J AGR FOOD CHEM, V60, P7384, DOI 10.1021/jf300999e; Chen LX, 2016, J CHROMATOGR A, V1428, P134, DOI 10.1016/j.chroma.2015.10.037; Cho EJ, 2003, AM J CHINESE MED, V31, P907, DOI 10.1142/S0192415X03001648; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Denny L, 2012, DISCOV MED, V14, P125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jin CY, 2011, MOL NUTR FOOD RES, V55, P300, DOI 10.1002/mnfr.201000024; Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728; Kang DG, 2002, LIFE SCI, V70, P2599, DOI 10.1016/S0024-3205(02)01547-3; Kim MS, 2013, CELL BIOL TOXICOL, V29, P259, DOI 10.1007/s10565-013-9251-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Le MQ, 2015, BIOCHIMIE, V119, P52, DOI 10.1016/j.biochi.2015.10.006; Lee BW, 2005, J NAT PROD, V68, P456, DOI 10.1021/np030481a; Munagala R, 2015, CANCER LETT, V356, P536, DOI 10.1016/j.canlet.2014.09.037; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1992, CANCER SURV, V12, P197; Ong KW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032718; Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a; Park JH, 2008, FOOD CHEM TOXICOL, V46, P3684, DOI 10.1016/j.fct.2008.09.056; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rosendahl AH, 2015, CLIN CANCER RES, V21, P1877, DOI 10.1158/1078-0432.CCR-14-1748; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Vidya Priyadarsini R, 2010, Eur J Pharmacol, V649, P84, DOI 10.1016/j.ejphar.2010.09.020; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Yan Y, 2015, ANTI-CANCER DRUG, V26, P540, DOI 10.1097/CAD.0000000000000218; YEE C, 1985, AM J PATHOL, V119, P361; Yuan SJ, 2010, STRUCTURE, V18, P571, DOI 10.1016/j.str.2010.04.001	40	26	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150235	10.1371/journal.pone.0150235	http://dx.doi.org/10.1371/journal.pone.0150235			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26960190	Green Submitted, Green Published, gold			2023-01-03	WOS:000371992300040
J	Zheng, JD; Huo, XX; Huai, Y; Xiao, L; Jiang, H; Klena, J; Greene, CM; Xing, XS; Huang, JG; Liu, SL; Peng, YX; Yang, H; Luo, J; Peng, ZB; Liu, LL; Chen, MY; Chen, H; Zhang, YZ; Huang, DQ; Guan, XH; Feng, LZ; Zhan, FX; Hu, DJ; Varma, JK; Yu, HJ				Zheng, Jiandong; Huo, Xixiang; Huai, Yang; Xiao, Lin; Jiang, Hui; Klena, John; Greene, Carolyn M.; Xing, Xuesen; Huang, Jigui; Liu, Shali; Peng, Youxing; Yang, Hui; Luo, Jun; Peng, Zhibin; Liu, Linlin; Chen, Maoyi; Chen, Hui; Zhang, Yuzhi; Huang, Danqin; Guan, Xuhua; Feng, Luzhao; Zhan, Faxian; Hu, Dale J.; Varma, Jay K.; Yu, Hongjie			Epidemiology, Seasonality and Treatment of Hospitalized Adults and Adolescents with Influenza in Jingzhou, China, 2010-2012	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY SYNCYTIAL VIRUS; NEURAMINIDASE INHIBITORS; PRIMARY-CARE; RISK-FACTORS; INFECTION; MORTALITY; CORTICOSTEROIDS; VACCINATION; ILLNESS	Background After the 2009 influenza A (H1 N1) pandemic, we conducted hospital-based severe acute respiratory infection (SARI) surveillance in one central Chinese city to assess disease burden attributable to influenza among adults and adolescents. Methods We defined an adult SARI case as a hospitalized patient aged >= 15 years with temperature >= 38.0 degrees C and at least one of the following: cough, sore throat, tachypnea, difficulty breathing, abnormal breath sounds on auscultation, sputum production, hemoptysis, chest pain, or chest radiograph consistent with pneumonia. For each enrolled SARI case-patient, we completed a standardized case report form, and collected a nasopharyngeal swab within 24 hours of admission. Specimens were tested for influenza viruses by real-time reverse transcription polymerase chain reaction (rRT-PCR). We analyzed data from adult SARI cases in four hospitals in Jingzhou, China from April 2010 to April 2012. Results Of 1,790 adult SARI patients enrolled, 40% were aged >= 65 years old. The median duration of hospitalization was 9 days. Nearly all were prescribed antibiotics during theirhospitalization, less than 1% were prescribed oseltamivir, and 28% were prescribed corticosteroids. Only 0.1% reported receiving influenza vaccination in the past year. Of 1,704 samples tested, 16% were positive for influenza. Influenza activity in all age groups showed winter-spring and summer peaks. Influenza-positive patients had a longer duration from illness onset to hospitalization and a shorter duration from hospital admission to discharge or death compared to influenza negative SARI patients. Conclusions There is substantial burden of influenza-associated SARI hospitalizations in Jingzhou, China, especially among older adults. More effective promotion of annual seasonal influenza vaccination and timely oseltamivir treatment among high risk groups may improve influenza prevention and control in China.	[Zheng, Jiandong; Jiang, Hui; Peng, Zhibin; Feng, Luzhao; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China; [Huo, Xixiang; Xing, Xuesen; Liu, Linlin; Chen, Hui; Huang, Danqin; Guan, Xuhua; Zhan, Faxian] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China; [Huai, Yang; Klena, John; Greene, Carolyn M.; Zhang, Yuzhi; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Ctr Global Hlth, China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China; [Xiao, Lin; Huang, Jigui; Chen, Maoyi] Jingzhou Ctr Dis Control & Prevent, Jingzhou, Peoples R China; [Klena, John; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA; [Greene, Carolyn M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA; [Liu, Shali] Jingzhou Cent Hosp, Jingzhou, Peoples R China; [Peng, Youxing] Jingzhou First Peoples Hosp, Jingzhou, Peoples R China; [Yang, Hui] Jingzhou Second Peoples Hosp, Jingzhou, Peoples R China; [Luo, Jun] Jingzhou Maternal & Childrens Hosp, Jingzhou, Peoples R China; [Hu, Dale J.] NIAID, Vaccine Res Program, Div Aids, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Yu, HJ (corresponding author), Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China.	yuhj@chinacdc.cn	Yu, Hongjie/GZK-5351-2022		Cooperative Agreement Number [5U2GGH000018]; Centers for Disease Control and Prevention	Cooperative Agreement Number; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was supported by the Cooperative Agreement Number, 5U2GGH000018, funded by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Department of Health and Human Services.	Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Cowling BJ, 2014, VACCINE, V32, P5278, DOI 10.1016/j.vaccine.2014.07.084; Delabre RM, 2015, INFLUENZA OTHER RESP, V9, P43, DOI 10.1111/irv.12294; Dellinger RP, 2013, CRIT CARE MED, V41, P637, DOI [DOI 10.1097/CCM.0b013e31827e83af, DOI 10.1007/s00134-015-3827-9]; Feng Luzhao, 2014, Zhonghua Liu Xing Bing Xue Za Zhi, V35, P1295; Feng LZ, 2012, B WORLD HEALTH ORGAN, V90, P279, DOI 10.2471/BLT.11.096958; Feng LZ, 2010, VACCINE, V28, P6778, DOI 10.1016/j.vaccine.2010.07.064; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Garcia-Vidal C, 2007, EUR RESPIR J, V30, P951, DOI 10.1183/09031936.00027607; Guo KJ, 2014, BONE JOINT J, V96B, P259, DOI 10.1302/0301-620X.96B2.31935; Han K, 2011, CLIN INFECT DIS, V53, P326, DOI 10.1093/cid/cir398; Lapidus N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060127; Lee N, 2015, EUR RESPIR J, V45, P1642, DOI 10.1183/09031936.00169714; Mak DB, 2015, AUST NZ J OBSTET GYN, V55, P131, DOI 10.1111/ajo.12292; Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4; National Health and Family Planning Commission of the People's Republic of China, NOT REL HOSP SEV AC; Nessler K, 2014, VACCINE, V32, P7122, DOI 10.1016/j.vaccine.2014.10.026; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; Nicoli EJ, 2013, J INFECTION, V66, P512, DOI 10.1016/j.jinf.2013.02.007; Nie W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047926; Ortiz JR, 2009, EMERG INFECT DIS, V15, P1271, DOI 10.3201/eid1508.081422; Peng ZB, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0884-1; Shu YL, 2010, EMERG INFECT DIS, V16, P725, DOI 10.3201/eid1604.091578; Siempos II, 2008, J ANTIMICROB CHEMOTH, V62, P661, DOI 10.1093/jac/dkn283; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; The Chinese Center for Disease Control and Prevention, TECHN GUID NAT INFL; Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88; United States Center for Disease Control and Prevention, PEOPL HIGH RISK DEV; World Health Organization, WHO GLOB EP SURV STA; World Health Organization, 2011, WHO GLOB TECHN CONS; Yang P, 2014, VACCINE, V32, P5285, DOI 10.1016/j.vaccine.2014.07.083; Yu H, 2012, INFLUENZA OTHER RESP, V8, P53, DOI DOI 10.1111/IRV.12205; Yu Hongjie, 2008, PLoS One, V3, pe2985, DOI 10.1371/journal.pone.0002985; Yu HJ, 2011, CLIN INFECT DIS, V52, P457, DOI 10.1093/cid/ciq144; Yu HJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4779; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X; Zhang Y, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0764-5	38	13	14	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150713	10.1371/journal.pone.0150713	http://dx.doi.org/10.1371/journal.pone.0150713			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26958855	Green Published, gold, Green Submitted			2023-01-03	WOS:000371992300068
J	Guerrero, M; Crisafulli, E; Liapikou, A; Huerta, A; Gabarrus, A; Chetta, A; Soler, N; Torres, A				Guerrero, Monica; Crisafulli, Ernesto; Liapikou, Adamantia; Huerta, Arturo; Gabarrus, Albert; Chetta, Alfredo; Soler, Nestor; Torres, Antoni			Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION DECLINE; HOSPITALIZATION; PREDICTORS	Background and Objective Twenty per cent of chronic obstructive pulmonary disease (COPD) patients are readmitted for acute exacerbation (AECOPD) within 30 days of discharge. The prognostic significance of early readmission is not fully understood. The objective of our study was to estimate the mortality risk associated with readmission for acute exacerbation within 30 days of discharge in COPD patients. Methods The cohort (n = 378) was divided into patients readmitted (n = 68) and not readmitted (n = 310) within 30 days of discharge. Clinical, laboratory, microbiological, and severity data were evaluated at admission and during hospital stay, and mortality data were recorded at four time points during follow-up: 30 days, 6 months, 1 year and 3 years. Results Patients readmitted within 30 days had poorer lung function, worse dyspnea perception and higher clinical severity. Two or more prior AECOPD (HR, 2.47; 95% CI, 1.51-4.05) was the only variable independently associated with 30-day readmission. The mortality risk during the follow-up period showed a progressive increase in patients readmitted within 30 days in comparison to patients not readmitted; moreover, 30-day readmission was an independent risk factor for mortality at 1 year (HR, 2.48; 95% CI, 1.10-5.59). In patients readmitted within 30 days, the estimated absolute increase in the mortality risk was 4% at 30 days (number needed to harm NNH, 25), 17% at 6-months (NNH, 6), 19% at 1-year (NNH, 6) and 24% at 3 years ( NNH, 5). Conclusion In conclusion a readmission for AECOPD within 30 days is associated with a progressive increased long-term risk of death.	[Guerrero, Monica; Huerta, Arturo; Gabarrus, Albert; Soler, Nestor; Torres, Antoni] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, Resp Dept,Clin Inst Resp ICR,CIBERES, Barcelona, Spain; [Crisafulli, Ernesto; Chetta, Alfredo] Univ Parma, Dept Clin & Expt Med, Resp Dis & Lung Funct Unit, I-43100 Parma, Italy; [Liapikou, Adamantia] Sotiria Hosp, Resp Dept 6, Athens, Greece	CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Parma; University Hospital of Parma	Torres, A (corresponding author), Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, Resp Dept,Clin Inst Resp ICR,CIBERES, Barcelona, Spain.	ATORRES@clinic.ub.es	Torres, Antoni/H-6128-2017; Huerta, Arturo/T-9954-2019; Lliapikou, Adamadia/H-8512-2019; Crisafulli, Ernesto/AAB-9595-2019	Torres, Antoni/0000-0002-8643-2167; Huerta, Arturo/0000-0002-6191-4143; Crisafulli, Ernesto/0000-0001-7298-7084; Gabarrus, Albert/0000-0003-3492-1310; Chetta, Alfredo/0000-0002-0416-5334; Soler, Nestor/0000-0003-4371-3994				Almagro P, 2014, CHEST, V145, P972, DOI 10.1378/chest.13-1328; Blasi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101228; Celli BR, 2007, EUR RESPIR J, V29, P1224, DOI 10.1183/09031936.00109906; Citrome L, 2013, INT J CLIN PRACT, V67, P407, DOI 10.1111/ijcp.12142; Collett D., 1994, MODELLING SURVIVAL D; Crisafulli E., 2015, CLIN PULMONARY MED, V22, P172, DOI DOI 10.1097/CPM.0000000000000090; Crisafulli E, 2015, COPD, V12, P306, DOI 10.3109/15412555.2014.933954; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Garcia-Aymerich J, 2011, THORAX, V66, P585, DOI 10.1136/thx.2010.152876; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Hurst JR, 2006, AM J RESP CRIT CARE, V174, P867, DOI 10.1164/rccm.200604-506OC; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Hurst JR, 2009, AM J RESP CRIT CARE, V179, P369, DOI 10.1164/rccm.200807-1067OC; Makris D, 2007, RESP MED, V101, P1305, DOI 10.1016/j.rmed.2006.10.012; MIKE V, 1982, STAT MED RES METHODS; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Sethi S, 2008, AM J RESP CRIT CARE, V177, P491, DOI 10.1164/rccm.200708-1234OC; Shah T, 2015, CHEST, V147, P1219, DOI 10.1378/chest.14-2181; Sharif Roozbeh, 2014, Ann Am Thorac Soc, V11, P685, DOI 10.1513/AnnalsATS.201310-358OC; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Steer J, 2012, THORAX, V67, P117, DOI 10.1136/thoraxjnl-2011-200332; Suissa S, 2012, THORAX, V67, P957, DOI 10.1136/thoraxjnl-2011-201518; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Wedzicha JA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-181	24	63	63	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2016	11	3							e0150737	10.1371/journal.pone.0150737	http://dx.doi.org/10.1371/journal.pone.0150737			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0FG	26943928	Green Published, Green Submitted, gold			2023-01-03	WOS:000371739400042
J	He, M; Li, XR; Liu, Y; Zhong, J; Jiang, LY; Liu, Y; Chen, Q; Xie, Y; Zhang, QX				He, Miao; Li, Xinrong; Liu, Yang; Zhong, Juan; Jiang, Luyun; Liu, Ying; Chen, Qing; Xie, Yan; Zhang, Qinxiu			Electroacupuncture for Tinnitus: A Systematic Review	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; CONTROLLED TRIAL; ACUPUNCTURE	Background Treatment effects of electroacupuncture for patients with subjective tinnitus has yet to be clarified. Objectives To assess the effect of electroacupuncutre for alleviating the symptoms of subjective tinnitus. Methods Extensive literature searches were carried out in three English and four Chinese databases (PubMed, EMBASE, Cochrane Library, CNKI, Wanfang Chinese Digital Periodical and Conference Database, VIP, and ChiCTR). The date of the most recent search was 1 June 2014. Randomized controlled trials (RCTs) or quasi-RCTs were included. The titles, abstracts, and keywords of all records were reviewed by two authors independently. The data were collected and extracted by three authors. The risk of bias in the trials was assessed in accordance with the Cochrane Handbook, version 5.1.0. (http://www.handbook.cochrane.org). Eighty-nine studies were retrieved. After discarding 84 articles, five studies with 322 participants were identified. Assessment of the methodological quality of the studies identified weaknesses in all five studies. All studies were judged as having a high risk of selection and performance bias. The attrition bias was high in four studies. Incompleteness bias was low in all studies. Reporting bias was unclear in all studies. Because of the limited number of trials included and the various types of interventions and outcomes, we were unable to conduct pooled analyses. Conclusions Due to the poor methodological quality of the primary studies and the small sample sizes, no convincing evidence that electroacupuncture is beneficial for treating tinnitus could be found. There is an urgent need for more high-quality trials with large sample sizes for the investigation of electroacupuncture treatment for tinnitus.	[He, Miao; Zhong, Juan; Chen, Qing] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan Provinc, Peoples R China; [Li, Xinrong; Liu, Yang; Jiang, Luyun; Liu, Ying; Xie, Yan; Zhang, Qinxiu] Chengdu Univ Tradit Chinese Med, Teaching Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chengdu, Sichuan Provinc, Peoples R China	Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine	Zhang, QX (corresponding author), Chengdu Univ Tradit Chinese Med, Teaching Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chengdu, Sichuan Provinc, Peoples R China.	zhqinxiu@163.com		zhang, qinxiu/0000-0001-8746-0277	National Natural Science Foundation of China [81273985, 81473523]; National Science & Technology Pillar Program during the Twelfth Five-year Plan Period of China [2015BAI04B00]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Pillar Program during the Twelfth Five-year Plan Period of China	This study is partially funded by the National Natural Science Foundation of China (No. 81273985 & No. 81473523), National Science & Technology Pillar Program during the Twelfth Five-year Plan Period of China (No. 2015BAI04B00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ao XY, 2013, YUNNAN J TRADITIONAL, V34, P62; AXELSSON A, 1994, AUDIOLOGY, V33, P351; Chen CL, 2013, MODERN DIAGNOSIS TRE, V24, P555; de Azevedo Renata Frasson, 2007, Braz J Otorhinolaryngol, V73, P599; Di Nardo Walter, 2009, Int Tinnitus J, V15, P100; Ding L, 2011, J CAP MED U, V32, P46; He QS, 2009, MED INFORM, V22, P1004; He XM, 2012, J NEW CHINESE MED, V44, P98; Hoare DJ, 2011, LARYNGOSCOPE, V121, P1555, DOI 10.1002/lary.21825; Hobson J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006371.pub3; Jeon SW, 2012, J ALTERN COMPLEM MED, V18, P693, DOI 10.1089/acm.2011.0378; Jun Hyung Jin, 2013, Korean J Audiol, V17, P101, DOI 10.7874/kja.2013.17.3.101; Kim HJ, 2014, LARYNGOSCOPE, V124, P2155, DOI 10.1002/lary.24722; Kim JI, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-97; Konopka W, 2001, AURIS NASUS LARYNX, V28, P35, DOI 10.1016/S0385-8146(00)00086-9; Langguth B, 2009, EXPERT OPIN EMERG DR, V14, P687, DOI 10.1517/14728210903206975; Li SR, 2011, CHINESE J ETHNOMEDIC, V18, P104; Liu FY, 2016, EUR ARCH OTO-RHINO-L, V273, P285, DOI 10.1007/s00405-014-3341-7; Liu KQ, 2007, JIANGXI J TRADIT CHI, V38, P56; MARKS NJ, 1984, J LARYNGOL OTOL, V98, P1103, DOI 10.1017/S0022215100148091; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Park JB, 2000, ARCH OTOLARYNGOL, V126, P489, DOI 10.1001/archotol.126.4.489; Park SN, 2013, CLIN EXP OTORHINOLAR, V6, P214, DOI 10.3342/ceo.2013.6.4.214; PODOSHIN L, 1991, Ear Nose and Throat Journal, V70, P284; Qin G, 2011, J PR TRADIT CHIN INT, V25, P87; Qing C, 2014, J ACUPUNCTURE MOXIBU, V33, P466; Rogha M, 2011, J RES MED SCI, V16, P1217; Theodoroff SM, 2013, OTOL NEUROTOL, V34, P199, DOI 10.1097/MAO.0b013e31827b4d46; Wang KL, 2010, COMPLEMENT THER MED, V18, P249, DOI 10.1016/j.ctim.2010.09.005; Wang L, 2013, SHANGHAI J ACUPUNCTU, V32, P112; Wang X, 2014, J PRACTICAL TRADITIO, V30, P219; Wei M, 2012, J TRADITIONAL CHINES, V41, P40; Wu Y, 2008, CHIN J REHABIL, V23, P87; Yilmaz M, 2014, J CRANIOFAC SURG, V25, P1315, DOI 10.1097/SCS.0000000000000782; Yuan D, 2012, NEI MONGOL J TRADITI, V31, P56; Zhang LJ, 2009, J TRADITIONAL CHINES, V30, P882; Zhang XZ, 2002, CHINESE ACUPUNCTURE, V22, P91; Zhu WH, 2007, J TRADITIONAL CHINES, V28, P34; 孟照莉, 2007, [听力学及言语疾病杂志, Journal of Audiology and Speech Pathology], V15, P325; 夏华, 2004, [江西医学院学报, Acta Academiae Medicinae Jiangxi], V44, P137	40	17	17	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150600	10.1371/journal.pone.0150600	http://dx.doi.org/10.1371/journal.pone.0150600			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938213	Green Published, Green Submitted, gold			2023-01-03	WOS:000371735200116
J	Sun, XD; Xiao, YN; Tang, SY; Peng, ZH; Wu, JH; Wang, N				Sun, Xiaodan; Xiao, Yanni; Tang, Sanyi; Peng, Zhihang; Wu, Jianhong; Wang, Ning			Early HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM Populations	PLOS ONE			English	Article							AMPLIFIED HIV TRANSMISSION; ANTIRETROVIRAL THERAPY; LIFE EXPECTANCY; WITHIN-HOST; JIANGSU PROVINCE; INCOME COUNTRIES; DRUG-RESISTANCE; VIRAL LOAD; DYNAMICS; MORTALITY	Having a thorough understanding of the infectivity of HIV, time of initiating treatment and emergence of drug resistant virus variants is crucial in mitigating HIV infection. There are many challenges to evaluating the long-term effect of the Highly Active Antiretroviral Therapy (HAART) on disease transmission at the population level. We proposed an individual based model by coupling within-host dynamics and between-host dynamics and conduct stochastic simulation in the group of men who have sex with men (MSM). The mean actual reproduction number is estimated to be 3.6320 (95% confidence interval: [3.46, 3.80]) for MSM group without treatment. Stochastic simulations show that given relatively high (low) level of drug efficacy after emergence of drug resistant variants, early initiation of treatment leads to a less (greater) actual reproduction number, lower (higher) prevalence and less (more) incidences, compared to late initiation of treatment. This implies early initiation of HAART may not always lower the actual reproduction number and prevalence of infection, depending on the level of treatment efficacy after emergence of drug resistant virus variants, frequency of high-risk behaviors and etc. This finding strongly suggests early initiation of HAART should be implemented with great care especially in the settings where the effective drugs are limited. Coupling within-host dynamics with between-host dynamics can provide critical information about impact of HAART on disease transmission and thus help to assist treatment strategy design and HIV/AIDS prevention and control.	[Sun, Xiaodan; Xiao, Yanni] Xi An Jiao Tong Univ, Dept Appl Math, Xian 710049, Shaanxi, Peoples R China; [Tang, Sanyi] Shaanxi Normal Univ, Coll Math & Informat Sci, Xian, Shaanxi, Peoples R China; [Peng, Zhihang] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China; [Wu, Jianhong] York Univ, York Inst Hlth Res, Lab Ind & Appl Math, Ctr Dis Modelling, Toronto, ON M3J 2R7, Canada; [Wang, Ning] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDSSTD Prevent & Control, Beijing, Peoples R China	Xi'an Jiaotong University; Shaanxi Normal University; Nanjing Medical University; York University - Canada; Chinese Center for Disease Control & Prevention	Xiao, YN (corresponding author), Xi An Jiao Tong Univ, Dept Appl Math, Xian 710049, Shaanxi, Peoples R China.; Wang, N (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDSSTD Prevent & Control, Beijing, Peoples R China.	yxiao@xjtu.edu.cn; wangnbj@163.com	Wu, Jian/AAU-5221-2020; Wu, Jian/AAU-5221-2020	Wu, Jian/0000-0001-9933-7364; Wu, Jian/0000-0002-3394-1507	National Mega-project of Science Research [2012ZX10001-001]; National Natural Science Foundation of China (NSFC) [11171268, 11571273, 11471201]; Fundamental Research Funds for the Central Universities [08143042]; Jiangsu Province Science & Technology Project of Clinical Medicine [BL2014081]; Jiangsu Province Science & Technology Demonstration Project for Emerging Infectious Diseases Control and Prevention [BE2015714]; Natural Sciences and Research Council of Canada [NSERC 105588-2011 RGPIN]; Canadian Institute for Health Research [CIHR 289907]; Canada Research Chair Program (CRC); International Development and Research Center (IDRC) through its IDRC-CRC International Research Chair Program	National Mega-project of Science Research; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Jiangsu Province Science & Technology Project of Clinical Medicine; Jiangsu Province Science & Technology Demonstration Project for Emerging Infectious Diseases Control and Prevention; Natural Sciences and Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair Program (CRC)(Canada Research Chairs); International Development and Research Center (IDRC) through its IDRC-CRC International Research Chair Program	The authors are supported by the National Mega-project of Science Research No. 2012ZX10001-001(NW), by the National Natural Science Foundation of China (NSFC, 11171268, 11571273 (YX), 11471201 (ST)), and by the Fundamental Research Funds for the Central Universities (08143042 (YX)), by the Jiangsu Province Science & Technology Project of Clinical Medicine (BL2014081 (ZP)), by Jiangsu Province Science & Technology Demonstration Project for Emerging Infectious Diseases Control and Prevention (BE2015714 (ZP)), by the Natural Sciences and Research Council of Canada (NSERC 105588-2011 RGPIN (JW)), by the Canadian Institute for Health Research (CIHR 289907 (JW)), by the Canada Research Chair Program (CRC (JW)), and by the International Development and Research Center (IDRC (JW)) through its IDRC-CRC International Research Chair Program.	Amundsen EJ, 2004, EPIDEMIOL INFECT, V132, P1139, DOI 10.1017/S0950268804002997; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bao Yu-gang, 2009, Zhonghua Yu Fang Yi Xue Za Zhi, V43, P981; Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088; Cohen MS, 2005, J INFECT DIS, V191, P1391, DOI 10.1086/429414; Cohen MS, 2013, LANCET, V382, P1515, DOI 10.1016/S0140-6736(13)61998-4; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Coombs D, 2007, THEOR POPUL BIOL, V72, P576, DOI 10.1016/j.tpb.2007.08.005; Deirdre H, 2006, 13 C RETR OPP INF; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Feng ZL, 2013, MATH BIOSCI, V241, P49, DOI 10.1016/j.mbs.2012.09.004; Feng ZL, 2012, NONLINEAR DYNAM, V68, P401, DOI 10.1007/s11071-011-0291-0; Friedland GH, 1999, AIDS, V13, pS61; Gallant JE, 2013, CLIN INFECT DIS, V57, P884, DOI 10.1093/cid/cit382; Ghys PD, 2007, AIDS, V21, pS1, DOI 10.1097/01.aids.0000299404.99033.bf; Gilchrist MA, 2006, THEOR POPUL BIOL, V69, P145, DOI 10.1016/j.tpb.2005.07.002; Gilchrist MA, 2002, J THEOR BIOL, V218, P289, DOI 10.1006/jtbi.2002.3076; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Harrison KM, 2010, JAIDS-J ACQ IMM DEF, V53, P124, DOI 10.1097/QAI.0b013e3181b563e7; Hayes RJ, 2006, J INFECT DIS, V193, P604, DOI 10.1086/499606; He Huan, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P976; Hei Fa-xin, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P67; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Li H, 2011, NATL MED J CHINA, V92, P1443; Li JH, 2008, AUST NZ J PUBL HEAL, V32, P216, DOI 10.1111/j.1753-6405.2008.00219.x; Lou J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090985; Lou J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-S1-S10; Lundgren JD, 2013, CLIN INFECT DIS, V57, P888, DOI 10.1093/cid/cit381; Luo ST, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126893; Luo Y, 2013, ANHUI J PREV MED, V19, P83; Martcheva M, 2013, J BIOL DYNAM, V7, P161, DOI 10.1080/17513758.2013.820358; May M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6016; Medley GF, 2012, PARASITOLOGY S, V125, pS61; Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358; Nishiura H, 2010, INT J ENV RES PUB HE, V7, P291, DOI 10.3390/ijerph7010291; Nowak MA, 1996, SCIENCE, V274, P1008, DOI 10.1126/science.274.5289.1008; Nowak MA., 2000, VIRUS DYNAMICS MATH; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Perelson AS, 1999, SIAM REV, V41, P3, DOI 10.1137/S0036144598335107; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055312; Pilcher CD, 2006, 13 C RETR OPP INF DE; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rong LB, 2007, B MATH BIOL, V69, P2027, DOI 10.1007/s11538-007-9203-3; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Sugarman J, 2014, CLIN INFECT DIS, V59, pS32, DOI 10.1093/cid/ciu246; Sun XD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/413260; Tang SY, 2012, J THEOR BIOL, V308, P123, DOI 10.1016/j.jtbi.2012.05.022; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; Wahl LM, 2000, P ROY SOC B-BIOL SCI, V267, P835, DOI 10.1098/rspb.2000.1079; Wang Y, 2012, PRAC PREV MED, V19, P161; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293; Wilson DP, 2008, LANCET, V372, P314, DOI 10.1016/S0140-6736(08)61115-0; Xiao YN, 2013, ADV DRUG DELIVER REV, V65, P940, DOI 10.1016/j.addr.2013.04.005; Xiao YN, 2013, J THEOR BIOL, V317, P271, DOI 10.1016/j.jtbi.2012.09.037; Xu XX, 2013, MATH METHOD APPL SCI, V36, P234, DOI 10.1002/mma.2599; Yan HJ, 2014, AIDS BEHAV, V18, pS5, DOI 10.1007/s10461-013-0520-2; Yeghiazarian L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070578; Zhou YC, 2008, MATH BIOSCI ENG, V5, P403; Zhu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039414	65	28	29	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0150513	10.1371/journal.pone.0150513	http://dx.doi.org/10.1371/journal.pone.0150513			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5ZW	26930406	Green Submitted, Green Published, gold			2023-01-03	WOS:000371434500164
J	Hu, MG; Li, W; Li, LF; Houston, D; Wu, J				Hu, Maogui; Li, Wei; Li, Lianfa; Houston, Douglas; Wu, Jun			Refining Time-Activity Classification of Human Subjects Using the Global Positioning System	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; AIR-POLLUTION; ACCELEROMETER DATA; RANDOM FORESTS; ULTRAFINE PARTICLES; GPS TRACKING; EXPOSURE; TRAVEL; LOCATION; DISEASE	Background Detailed spatial location information is important in accurately estimating personal exposure to air pollution. Global Position System (GPS) has been widely used in tracking personal paths and activities. Previous researchers have developed time-activity classification models based on GPS data, most of them were developed for specific regions. An adaptive model for time-location classification can be widely applied to air pollution studies that use GPS to track individual level time-activity patterns. Methods Time-activity data were collected for seven days using GPS loggers and accelerometers from thirteen adult participants from Southern California under free living conditions. We developed an automated model based on random forests to classify major time-activity patterns (i.e. indoor, outdoor-static, outdoor-walking, and in-vehicle travel). Sensitivity analysis was conducted to examine the contribution of the accelerometer data and the supplemental spatial data (i.e. roadway and tax parcel data) to the accuracy of time-activity classification. Our model was evaluated using both leave-one-fold-out and leave-one-subject-out methods. Results Maximum speeds in averaging time intervals of 7 and 5 minutes, and distance to primary highways with limited access were found to be the three most important variables in the classification model. Leave-one-fold-out cross-validation showed an overall accuracy of 99.71%. Sensitivities varied from 84.62% (outdoor walking) to 99.90% (indoor). Specificities varied from 96.33% (indoor) to 99.98% (outdoor static). The exclusion of accelerometer and ambient light sensor variables caused a slight loss in sensitivity for outdoor walking, but little loss in overall accuracy. However, leave-one-subject-out cross-validation showed considerable loss in sensitivity for outdoor static and outdoor walking conditions. Conclusions The random forests classification model can achieve high accuracy for the four major time-activity categories. The model also performed well with just GPS, road and tax parcel data. However, caution is warranted when generalizing the model developed from a small number of subjects to other populations.	[Hu, Maogui; Li, Lianfa; Wu, Jun] Univ Calif Irvine, Program Publ Hlth, Coll Hlth Sci, Irvine, CA USA; [Li, Wei] Texas A&M Univ, Dept Landscape Architecture & Urban Planning, College Stn, TX USA; [Houston, Douglas] Univ Calif Irvine, Sch Social Ecol, Dept Planning Policy & Design, Irvine, CA USA; [Hu, Maogui; Li, Lianfa] Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, State Key Lab Resources & Environm Informat Syst, Beijing, Peoples R China; [Hu, Maogui] Jiangsu Ctr Collaborat Innovat Geog Informat Reso, Nanjing, Jiangsu, Peoples R China	University of California System; University of California Irvine; Texas A&M University System; Texas A&M University College Station; University of California System; University of California Irvine; Chinese Academy of Sciences; Institute of Geographic Sciences & Natural Resources Research, CAS	Wu, J (corresponding author), Univ Calif Irvine, Program Publ Hlth, Coll Hlth Sci, Irvine, CA USA.	junwu@uci.edu	Hu, Maogui/N-7105-2013	Hu, Maogui/0000-0002-7671-7863	UCI Academic Senate Council on Research, Computing and Libraries (CORCL); Active Living Accelerometer Loan Program	UCI Academic Senate Council on Research, Computing and Libraries (CORCL); Active Living Accelerometer Loan Program	The research was supported by the UCI Academic Senate Council on Research, Computing and Libraries (CORCL) Faculty Research and Travel Grant, and the research was supported by the Active Living Accelerometer Loan Program. Staff support was provided by the California Department of Transportation. It would not have been possible without the study participants who generously allowed us to track their activities for multiple days.	Ali Z, 2013, REC ADV SPAC TECHN R; Audrey S, 2013, EUR J PUBLIC HEALTH, V23, P475, DOI 10.1093/eurpub/cks081; Barrett J, 2009, 50 AIAA ASME ASCE AH, P1; Bohte W, 2009, TRANSPORT RES C-EMER, V17, P285, DOI 10.1016/j.trc.2008.11.004; Breen MS, 2014, J EXPO SCI ENV EPID, V24, P412, DOI 10.1038/jes.2014.13; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Briggs DJ, 2008, ENVIRON INT, V34, P12, DOI 10.1016/j.envint.2007.06.011; Brondeel R, 2015, MED SCI SPORTS EXERC; Brook Robert D., 2007, Reviews on Environmental Health, V22, P115; CHAN CC, 1991, ENVIRON SCI TECHNOL, V25, P964, DOI 10.1021/es00017a021; Chen Hong, 2008, Reviews on Environmental Health, V23, P243; Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003; Chung EH, 2005, TRANSPORT PLAN TECHN, V28, P381, DOI 10.1080/03081060500322599; Cooper AR, 2010, AM J PREV MED, V38, P178, DOI 10.1016/j.amepre.2009.10.036; de Nazelle A, 2011, ENVIRON INT, V37, P766, DOI 10.1016/j.envint.2011.02.003; Du J, 2007, TRANSPORT RES A-POL, V41, P220, DOI 10.1016/j.tra.2006.05.001; Duncan JS, 2009, J SCI MED SPORT, V12, P583, DOI 10.1016/j.jsams.2008.09.010; Duncan MJ, 2007, MED SCI SPORT EXER, V39, P1851, DOI 10.1249/mss.0b013e31811ff31e; Duncan MJ, 2007, AM J PREV MED, V33, P51, DOI 10.1016/j.amepre.2007.02.042; Elgethun K, 2007, J EXPO SCI ENV EPID, V17, P196, DOI 10.1038/sj.jes.7500496; Ellis K., 2013, P 4 INT SENSECAM PER, P88, DOI [10.1145/2526667.2526685, DOI 10.1145/2526667.2526685]; Ellis K, 2014, PHYSIOL MEAS, V35, P2191, DOI 10.1088/0967-3334/35/11/2191; Ellis K, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00036; eMarketer, 2014, WORLDW SMARTPH US GR; Englert N, 2004, TOXICOL LETT, V149, P235, DOI 10.1016/j.toxlet.2003.12.035; Evenson KR, 2013, MED SCI SPORT EXER, V45, P1981, DOI 10.1249/MSS.0b013e318293330e; Genuer R, 2010, PATTERN RECOGN LETT, V31, P2225, DOI 10.1016/j.patrec.2010.03.014; Gong L, 2014, PROCD SOC BEHV, V138, P557, DOI 10.1016/j.sbspro.2014.07.239; Gonzalez PA, 2010, IET INTELL TRANSP SY, V4, P37, DOI 10.1049/iet-its.2009.0029; Hapfelmeier A, 2013, COMPUT STAT DATA AN, V60, P50, DOI 10.1016/j.csda.2012.09.020; Houston D, 2013, ATMOS ENVIRON, V71, P148, DOI 10.1016/j.atmosenv.2013.02.002; Hurvitz PM, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00002; Kang B, 2013, MED SCI SPORT EXER, V45, P1419, DOI 10.1249/MSS.0b013e318285f202; Kohla B, 2014, ADV DATA MIN DATABAS, P134, DOI 10.4018/978-1-4666-6170-7.ch009; Kuhnlein M, 2014, REMOTE SENS ENVIRON, V141, P129, DOI 10.1016/j.rse.2013.10.026; Larsson P, 2001, MED SCI SPORT EXER, V33, P1919, DOI 10.1097/00005768-200111000-00018; Lee J, 2015, J APPL STAT, V42, P676, DOI 10.1080/02664763.2014.978270; Nethery E, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-33; Norton TT, 2013, EXP EYE RES, V114, P48, DOI 10.1016/j.exer.2013.05.004; Oreskovic NM, 2012, GEOSPATIAL HEALTH, V6, P263, DOI 10.4081/gh.2012.144; Park YS, 2013, ECOL INFORM, V13, P40, DOI 10.1016/j.ecoinf.2012.10.008; Pelucchi C, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-453; Phillips ML, 2001, J EXPO ANAL ENV EPID, V11, P207, DOI 10.1038/sj.jea.7500161; R Core Team, 2021, R LANG ENV STAT COMP; Rainham D, 2010, SOC SCI MED, V70, P668, DOI 10.1016/j.socscimed.2009.10.035; Riddick G, 2011, BIOINFORMATICS, V27, P220, DOI 10.1093/bioinformatics/btq628; Rodriguez DA, 2012, J PHYS ACT HEALTH, V9, P421, DOI 10.1123/jpah.9.3.421; Schantz P, 2009, MED SCI SPORT EXER, V41, P472, DOI 10.1249/MSS.0b013e3181877aaf; Schuessler N, 2009, TRANSPORT RES REC, P28, DOI 10.3141/2105-04; Sreenivas K, 2014, J INDIAN SOC REMOTE, V42, P577, DOI 10.1007/s12524-013-0332-x; Stillerman KP, 2008, REPROD SCI, V15, P631, DOI 10.1177/1933719108322436; Stopher P, 2008, TRANSPORT RES C-EMER, V16, P350, DOI 10.1016/j.trc.2007.10.002; Stumpf A, 2011, REMOTE SENS ENVIRON, V115, P2564, DOI 10.1016/j.rse.2011.05.013; Suh HH, 2000, ENVIRON HEALTH PERSP, V108, P625, DOI 10.2307/3454398; Tandon PS, 2013, AM J PREV MED, V44, P85, DOI 10.1016/j.amepre.2012.09.052; Thierry B, 2013, INT J HEALTH GEOGR, V12, DOI 10.1186/1476-072X-12-14; Van Dierendonck A. J., 1992, Navigation. Journal of the Institute of Navigation, V39, P265; Vitale M, 2014, WATER AIR SOIL POLL, V225, DOI 10.1007/s11270-014-1992-z; Westerdahl D, 2005, ATMOS ENVIRON, V39, P3597, DOI 10.1016/j.atmosenv.2005.02.034; Wu J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-47; Wu J, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-101; Wu J, 2010, ENVIRON HEALTH INSIG, V4, P93, DOI 10.4137/EHI.S6246; Xu X, 2005, J EXPO ANAL ENV EPID, V15, P6, DOI 10.1038/sj.jea.7500374; Zheng Y, 2008, 11 INT C WORLD WID W; Zhu YF, 2007, ENVIRON SCI TECHNOL, V41, P2138, DOI 10.1021/es0618797	65	10	11	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0148875	10.1371/journal.pone.0148875	http://dx.doi.org/10.1371/journal.pone.0148875			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3UU	26919723	Green Published, gold			2023-01-03	WOS:000371274400012
J	Dentico, D; Ferrarelli, F; Riedner, BA; Smith, R; Zennig, C; Lutz, A; Tononi, G; Davidson, RJ				Dentico, Daniela; Ferrarelli, Fabio; Riedner, Brady A.; Smith, Richard; Zennig, Corinna; Lutz, Antoine; Tononi, Giulio; Davidson, Richard J.			Short Meditation Trainings Enhance Non-REM Sleep Low-Frequency Oscillations	PLOS ONE			English	Article							GAMMA-BAND ACTIVITY; PSYCHOMETRIC EVALUATION; EEG; BRAIN; VALIDATION; ATTENTION; SCALE; NIGHT; PRACTITIONERS; CONSCIOUSNESS	Study Objectives We have recently shown higher parietal-occipital EEG gamma activity during sleep in long-term meditators compared to meditation-naive individuals. This gamma increase was specific for NREM sleep, was present throughout the entire night and correlated with meditation expertise, thus suggesting underlying long-lasting neuroplastic changes induced through prolonged training. The aim of this study was to explore the neuroplastic changes acutely induced by 2 intensive days of different meditation practices in the same group of practitioners. We also repeated baseline recordings in a meditation-naive cohort to account for time effects on sleep EEG activity. Design High-density EEG recordings of human brain activity were acquired over the course of whole sleep nights following intervention. Setting Sound-attenuated sleep research room. Patients or Participants Twenty-four long-term meditators and twenty-four meditation-naive controls. Interventions Two 8-h sessions of either a mindfulness-based meditation or a form of meditation designed to cultivate compassion and loving kindness, hereafter referred to as compassion meditation. Measurements and Results We found an increase in EEG low-frequency oscillatory activities (1-12 Hz, centered around 7-8 Hz) over prefrontal and left parietal electrodes across whole night NREM cycles. This power increase peaked early in the night and extended during the third cycle to high-frequencies up to the gamma range (25-40 Hz). There was no difference in sleep EEG activity between meditation styles in long-term meditators nor in the meditation naive group across different time points. Furthermore, the prefrontal-parietal changes were dependent on meditation life experience. Conclusions This low-frequency prefrontal-parietal activation likely reflects acute, meditation-related plastic changes occurring during wakefulness, and may underlie a top-down regulation from frontal and anterior parietal areas to the posterior parietal and occipital regions showing chronic, long-lasting plastic changes in long-term meditators.	[Dentico, Daniela; Ferrarelli, Fabio; Riedner, Brady A.; Smith, Richard; Zennig, Corinna; Tononi, Giulio] Univ Wisconsin, Dept Psychiat, 6001 Res Pk Blvd, Madison, WI 53719 USA; [Dentico, Daniela; Davidson, Richard J.] Univ Wisconsin, Waisman Ctr Brain Imaging & Behav, Madison, WI 53705 USA; [Dentico, Daniela; Davidson, Richard J.] Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53705 USA; [Lutz, Antoine] Univ Lyon 1, Lyon Neurosci Res Ctr, CNRS UMR5292, INSERM U1028, F-69500 Bron, France; [Lutz, Antoine; Davidson, Richard J.] Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Wisconsin System; University of Wisconsin Madison	Davidson, RJ (corresponding author), Univ Wisconsin, Waisman Ctr Brain Imaging & Behav, Madison, WI 53705 USA.; Davidson, RJ (corresponding author), Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53705 USA.; Davidson, RJ (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	rjdavids@wisc.edu	Ferrarelli, Fabio/D-3219-2019; LUTZ, Antoine/AAE-5114-2020; Dentico, Daniela/AAP-6736-2020	Ferrarelli, Fabio/0000-0003-0560-0227; LUTZ, Antoine/0000-0002-0258-3233; Dentico, Daniela/0000-0003-1050-0327; Davidson, Richard/0000-0002-8506-4964	National Center for Complementary and Alternative Medicine (NCCAM) [P01AT004952]; National Institute of Mental Health (NIMH) [R01-MH43454, P50-MH084051]; Fetzer Institute; John Templeton Foundation; National Institute of Child Health and Human Development [P30 HD003352-449015]; International Re-integration Grants (IRG) [FP7-PEOPLE-2009-RG]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [P01AT004952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043454, P50MH084051] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Fetzer Institute; John Templeton Foundation; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); International Re-integration Grants (IRG); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Center for Complementary and Alternative Medicine (NCCAM) P01AT004952 to GT, RJD and AL, grants from the National Institute of Mental Health (NIMH) R01-MH43454, P50-MH084051 to RJD, grants from the Fetzer Institute and the John Templeton Foundation to RJD, a core grant to the Waisman Center from the National Institute of Child Health and Human Development [P30 HD003352-449015], and an International Re-integration Grants (IRG), FP7-PEOPLE-2009-RG for AL.	AESCHBACH D, 1993, J SLEEP RES, V2, P70, DOI 10.1111/j.1365-2869.1993.tb00065.x; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Berkovich-Ohana A, 2012, CLIN NEUROPHYSIOL, V123, P700, DOI 10.1016/j.clinph.2011.07.048; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Buffalo EA, 2011, P NATL ACAD SCI USA, V108, P11262, DOI 10.1073/pnas.1011284108; Cahn BR, 2010, COGN PROCESS, V11, P39, DOI 10.1007/s10339-009-0352-1; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Corsi-Cabrera M, 2008, BRAIN RES, V1235, P82, DOI 10.1016/j.brainres.2008.06.052; Dentico D, 2015, 21 ANN MEEET ORG HUM; Dentico D, 2014, P 17 WORLD C PSYCH I, P94; DEROGATIS LR, 1977, BRIT J SOC CLIN PSYC, V16, P347, DOI 10.1111/j.2044-8260.1977.tb00241.x; Ermis U, 2010, J SLEEP RES, V19, P400, DOI 10.1111/j.1365-2869.2010.00831.x; FEINBERG I, 1979, PSYCHOPHYSIOLOGY, V16, P283, DOI 10.1111/j.1469-8986.1979.tb02991.x; Ferrarelli F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073417; Halasz P, 2004, J SLEEP RES, V13, P1, DOI 10.1111/j.1365-2869.2004.00388.x; Hipp JF, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00338; Hollingshead A.B., 1957, 2 FACTOR INDEX SOCIA; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Hung CS, 2013, SLEEP, V36, P59, DOI 10.5665/sleep.2302; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson LA, 2012, P NATL ACAD SCI USA, V109, P18583, DOI 10.1073/pnas.1207532109; Jung TP, 2001, P IEEE, V89, P1107, DOI 10.1109/5.939827; Landsness E, 2011, BRAIN, V134, P2222, DOI 10.1093/brain/awr152; Lee TMC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040054; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Lutz A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001897; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; MacLean, 1992, J Sleep Res, V1, P35; Maatta S, 2010, BRAIN RES BULL, V82, P118, DOI 10.1016/j.brainresbull.2010.01.006; Martinez D, 2010, CLIN NEUROPHYSIOL, V121, P704, DOI 10.1016/j.clinph.2010.01.005; Marzano C, 2011, J NEUROSCI, V31, P6674, DOI 10.1523/JNEUROSCI.0412-11.2011; Mason LI, 1997, SLEEP, V20, P102, DOI 10.1093/sleep/20.2.102; McKinney SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017351; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; Murphy M, 2009, P NATL ACAD SCI USA, V106, P1608, DOI 10.1073/pnas.0807933106; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Silber MH, 2007, J CLIN SLEEP MED, V3, P121; Slagter HA, 2007, PLOS BIOL, V5, P1228, DOI 10.1371/journal.pbio.0050138; Slagter HA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00017; Takahara M, 2002, PSYCHIAT CLIN NEUROS, V56, P257, DOI 10.1046/j.1440-1819.2002.00999.x; Travis F, 2010, CONSCIOUS COGN, V19, P1110, DOI 10.1016/j.concog.2010.01.007; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Voss U, 2009, SLEEP, V32, P1191, DOI 10.1093/sleep/32.9.1191; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	45	23	23	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0148961	10.1371/journal.pone.0148961	http://dx.doi.org/10.1371/journal.pone.0148961			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3VL	26900914	gold, Green Published, Green Submitted			2023-01-03	WOS:000371276100032
J	Lin, YW; Huang, HC; Lin, MF; Shyu, ML; Tsai, PL; Chang, HJ				Lin, Yu-Wen; Huang, Hui-Chuan; Lin, Mei-Feng; Shyu, Meei-Ling; Tsai, Po-Li; Chang, Hsiu-Ju			Influential Factors for and Outcomes of Hospitalized Patients with Suicide-Related Behaviors: A National Record Study in Taiwan from 1997-2010	PLOS ONE			English	Article							RISK-FACTORS; FOLLOW-UP; PHYSICAL ILLNESS; PRIMARY-CARE; ALCOHOL; INDIVIDUALS; DEPRESSION; MORTALITY; DISORDER; COHORT	Background Investigating the factors related to suicide is crucial for suicide prevention. Psychiatric disorders, gender, socioeconomic status, and catastrophic illnesses are associated with increased risk of suicide. Most studies have typically focused on the separate influences of physiological or psychological factors on suicide-related behaviors, and have rarely used national data records to examine and compare the effects of major physical illnesses, psychiatric disorders, and socioeconomic status on the risk of suicide-related behaviors. Objectives To identify the characteristics of people who exhibited suicide-related behaviors and the multiple factors associated with repeated suicide-related behaviors and deaths by suicide by examining national data records. Design This is a cohort study of Taiwan's national data records of hospitalized patients with suicide-related behaviors from January 1, 1997, to December 31, 2010. Participants The study population included all people in Taiwan who were hospitalized with a code indicating suicide or self-inflicted injury (E950-E959) according to the International Classification of Disease, Ninth Revision, Clinical Modification. Results Self-poisoning was the most common method of self-inflicted injury among hospitalized patients with suicide-related behaviors who used a single method. Those who were female, had been hospitalized for suicide-related behaviors at a younger age, had a low income, had a psychiatric disorder (i.e., personality disorder, major depressive disorder, bipolar disorder, schizophrenia, alcohol-related disorder, or adjustment disorder), had a catastrophic illness, or had been hospitalized for suicide-related behaviors that involved two methods of self-inflicted injury had a higher risk of hospitalization for repeated suicide-related behaviors. Those who were male, had been hospitalized for suicide-related behaviors at an older age, had low income, had schizophrenia, showed repeated suicide-related behaviors, had a catastrophic illness, or had adopted a single lethal method had an increased risk of death by suicide. Conclusions High-risk factors should be considered when devising suicide-prevention strategies.	[Lin, Yu-Wen; Huang, Hui-Chuan; Shyu, Meei-Ling; Chang, Hsiu-Ju] Taipei Med Univ, Coll Nursing, Sch Nursing, Taipei, Taiwan; [Lin, Mei-Feng] Natl Cheng Kung Univ, Dept Nursing, Tainan 701, Taiwan; [Tsai, Po-Li] Mackay Mem Hosp, Dept Surg, Div Colon & Rectal Surg, Taipei, Taiwan	Taipei Medical University; National Cheng Kung University; Mackay Memorial Hospital	Chang, HJ (corresponding author), Taipei Med Univ, Coll Nursing, Sch Nursing, Taipei, Taiwan.	hsiuju@tmu.edu.tw		Chang, Hsiu-Ju/0000-0002-8544-0712				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Blasco-Fontecilla H, 2009, ACTA PSYCHIAT SCAND, V119, P149, DOI 10.1111/j.1600-0447.2008.01284.x; Boisseau CL, 2013, COMPR PSYCHIAT, V54, P238, DOI 10.1016/j.comppsych.2012.07.062; Bolton JM, 2008, J CLIN PSYCHIAT, V69, P1139, DOI 10.4088/JCP.v69n0714; Cibis A, 2012, J AFFECT DISORDERS, V136, P9, DOI 10.1016/j.jad.2011.08.032; Goodwin RD, 2003, PSYCHOSOM MED, V65, P501, DOI 10.1097/01.PSY.0000041544.14277.EC; Gradus Jaimie L, 2010, Clin Epidemiol, V2, P23; Haukka J, 2008, AM J EPIDEMIOL, V167, P1155; Hawton K, 2005, BRIT J PSYCHIAT, V187, P9, DOI 10.1192/bjp.187.1.9; Hawton K, 2013, J AFFECT DISORDERS, V147, P17, DOI 10.1016/j.jad.2013.01.004; Hawton K, 2011, J AFFECT DISORDERS, V134, P320, DOI 10.1016/j.jad.2011.05.044; Holikatti P, 2010, BRIT J PSYCHIAT, V196, P415, DOI 10.1192/bjp.196.5.415; Kapur N, 2013, BRIT J PSYCHIAT, V202, P326, DOI 10.1192/bjp.bp.112.116111; Kuo CJ, 2012, BRIT J PSYCHIAT, V200, P405, DOI 10.1192/bjp.bp.111.099366; Landberg J, 2008, DRUG ALCOHOL REV, V27, P361, DOI 10.1080/09595230802093778; Logan J, 2011, ARCH GEN PSYCHIAT, V68, P935, DOI 10.1001/archgenpsychiatry.2011.85; Ministry of Health and Welfare Taiwan (R. O. C.), 2013, 10 LEAD CAUS DEATH T; Misono S, 2008, J CLIN ONCOL, V26, P4731, DOI 10.1200/JCO.2007.13.8941; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Pompili M, 2011, PSYCHIAT RES, V186, P300, DOI 10.1016/j.psychres.2010.09.003; Qin P, 2013, J INTERN MED, V273, P48, DOI 10.1111/j.1365-2796.2012.02572.x; Rudd MD, 2006, J CLIN PSYCHOL, V62, P157, DOI 10.1002/jclp.20219; Runeson B, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3222; Sher L, 2006, QJM-INT J MED, V99, P57, DOI 10.1093/qjmed/hci146; Silverman AB, 1996, CHILD ABUSE NEGLECT, V20, P709, DOI 10.1016/0145-2134(96)00059-2; Suominen K, 2004, AM J PSYCHIAT, V161, P562, DOI 10.1176/appi.ajp.161.3.562; Taiwanese Society of Suicidology, 2013, SURV AND RES; Tidemalm D, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2205; Uribe IP, 2013, J AFFECT DISORDERS, V150, P840, DOI 10.1016/j.jad.2013.03.013; Webb RT, 2012, ARCH GEN PSYCHIAT, V69, P256, DOI 10.1001/archgenpsychiatry.2011.1561; World Health Organization, 2013, HLTH TOP SUIC; Zaridze D, 2009, LANCET, V373, P2201, DOI 10.1016/S0140-6736(09)61034-5	32	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149559	10.1371/journal.pone.0149559	http://dx.doi.org/10.1371/journal.pone.0149559			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3VL	26900930	Green Published, gold			2023-01-03	WOS:000371276100098
J	Mao, HF; Chang, LH; Tsai, AYJ; Huang, WN; Wang, J				Mao, Hui-Fen; Chang, Ling-Hui; Tsai, Athena Yi-Jung; Huang, Wen-Ni; Wang, Jye			Developing a Referral Protocol for Community-Based Occupational Therapy Services in Taiwan: A Logistic Regression Analysis	PLOS ONE			English	Article							HOME-CARE; ELDERLY-PEOPLE; INTERVENTION; REHABILITATION; DEMENTIA; OUTCOMES; FEAR; PREVALENCE; DISABILITY; CAREGIVERS	Because resources for long-term care services are limited, timely and appropriate referral for rehabilitation services is critical for optimizing clients' functions and successfully integrating them into the community. We investigated which client characteristics are most relevant in predicting Taiwan's community-based occupational therapy (OT) service referral based on experts' beliefs. Data were collected in face-to-face interviews using the Multidimensional Assessment Instrument (MDAI). Community-dwelling participants (n = 221) >= 18 years old who reported disabilities in the previous National Survey of Long-term Care Needs in Taiwan were enrolled. The standard for referral was the judgment and agreement of two experienced occupational therapists who reviewed the results of the MDAI. Logistic regressions and Generalized Additive Models were used for analysis. Two predictive models were proposed, one using basic activities of daily living (BADLs) and one using instrumental ADLs (IADLs). Dementia, psychiatric disorders, cognitive impairment, joint range-of-motion limitations, fear of falling, behavioral or emotional problems, expressive deficits (in the BADL-based model), and limitations in IADLs or BADLs were significantly correlated with the need for referral. Both models showed high area under the curve (AUC) values on receiver operating curve testing (AUC = 0.977 and 0.972, respectively). The probability of being referred for community OT services was calculated using the referral algorithm. The referral protocol facilitated communication between healthcare professionals to make appropriate decisions for OT referrals. The methods and findings should be useful for developing referral protocols for other long-term care services.	[Mao, Hui-Fen] Natl Taiwan Univ, Sch Occupat Therapy, Coll Med, Taipei 10764, Taiwan; [Chang, Ling-Hui] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Dept Occupat Therapy, Tainan 70101, Taiwan; [Chang, Ling-Hui] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701, Taiwan; [Tsai, Athena Yi-Jung] Kaohsiung Med Univ, Dept Occupat Therapy, Kaohsiung, Taiwan; [Huang, Wen-Ni] I Shou Univ, Dept Phys Therapy, Kaohsiung, Taiwan; [Wang, Jye] Chang Jung Christian Univ, Dept Hlth Care Adm, Tainan, Taiwan	National Taiwan University; National Cheng Kung University; National Cheng Kung University; Kaohsiung Medical University; I Shou University; Chang Jung Christian University	Wang, J (corresponding author), Chang Jung Christian Univ, Dept Hlth Care Adm, Tainan, Taiwan.	jyewang@mail.cjcu.edu.tw	Chang, Ling-Hui/AAG-2410-2019	Chang, Ling Hui/0000-0003-4129-6947; MAO, HUI-FEN/0000-0002-4847-4243	Ministry of Health and Welfare, Taiwan (R.O.C.) [102N6021]; Ministry of Health and Welfare	Ministry of Health and Welfare, Taiwan (R.O.C.); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan)	This work was supported by Grant Number 102N6021 from the Ministry of Health and Welfare, Taiwan (R.O.C.), to AYJT (http://www.mohw.gov.tw/EN/Ministry/Index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the study participants and their caregivers for their cooperation and support, the Ministry of Health and Welfare officials responsible for LTC insurance planning in Taiwan, and the interviewers for their valuable contributions. This study is supported by a grant from the Ministry of Health and Welfare for Dr. Athena Yi-Jung Tsa. The findings and opinions expressed in this study are the sole responsibilities of the authors and do not necessarily represent the official position of the government of the Republic of China, Taiwan.	Archer KR, 2009, PHYS THER, V89, P893, DOI 10.2522/ptj.20080321; Buhr GT, 2006, J AM MED DIR ASSOC, V7, P180, DOI 10.1016/j.jamda.2005.12.003; Campbell JC, 2000, HEALTH AFFAIR, V19, P26, DOI 10.1377/hlthaff.19.3.26; CAOT, 2008, CAOT POS STAT OCC TH; Cheng L, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0203-1; Chiu HC, 2002, J AGING SOC POLICY, V13, P217; Chu TK, 2015, PUBLIC GOVERNANCE Q, V3, P108; Cohen-Mansfield J., 1991, INSTRUCTION MANUAL C; Crocker T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004294.pub3; Deb S, 2001, J INTELL DISABIL RES, V45, P495, DOI 10.1046/j.1365-2788.2001.00374.x; DEIMLING GT, 1986, J GERONTOL, V41, P778, DOI 10.1093/geronj/41.6.778; Dopp CME, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-70; Emerson E, 2001, RES DEV DISABIL, V22, P77, DOI 10.1016/S0891-4222(00)00061-5; Executive Yuan T ROC, 2010, NAT LONG TERM CAR NE; Executive Yuan Taiwan Reublic of China, 2014, REP CHIN YB; Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x; Gauthier R, 2006, OCCUPATIONAL THERAPY, V8, P10; Gitlin LN, 2006, J AM GERIATR SOC, V54, P950, DOI 10.1111/j.1532-5415.2006.00733.x; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Graff MJL, 2007, J GERONTOL A-BIOL, V62, P1002, DOI 10.1093/gerona/62.9.1002; Graff MJL, 2008, BMJ-BRIT MED J, V336, P134, DOI 10.1136/bmj.39408.481898.BE; Harding K, 2009, BRIT J OCCUP THER, V72, P153, DOI 10.1177/030802260907200403; Harris-Kojetin L., 2013, LONG TERM CARE SERVI; Hershkovitz A, 2007, ARCH PHYS MED REHAB, V88, P916, DOI 10.1016/j.apmr.2007.03.029; Hirdes JP, 2006, AGE AGEING, V35, P329, DOI 10.1093/ageing/afl036; Hirdes JP, 2004, GERONTOLOGIST, V44, P665, DOI 10.1093/geront/44.5.665; Hirdes JP, 1997, CAN J AGING, V16, P53; Hirdes JP., 2010, INTERRAI CONTACT ASS; Huang C. P., 2006, TAIWANESE J PSYCHIAT, V20, P3; Johnston KN, 2013, PRIM CARE RESP J, V22, P319, DOI 10.4104/pcrj.2013.00062; Kim SY, 2012, NEUROREHABILITATION, V31, P107, DOI 10.3233/NRE-2012-0779; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee Y.C., 2013, COMMUNITY DEV J, V141, P26; Legters K, 2002, PHYS THER, V82, P264, DOI 10.1093/ptj/82.3.264; MAHONEY F I, 1965, Md State Med J, V14, P61; Miller EA, 2012, J AGING SOC POLICY, V24, P101, DOI 10.1080/08959420.2012.659912; Ministry of Health and Welfare, 2007, PLAN 10 YEAR LONG TE; Mohammed R, 2013, PHYSIOTHER CAN, V65, P125, DOI 10.3138/ptc.2012-09; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Nursing and Health Care Division, 2013, LONG TERM CAR SERV N; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Polensek SH, 2009, INT J CLIN PRACT, V63, P1604, DOI 10.1111/j.1742-1241.2009.02104.x; Reisberg B, 1996, Int Psychogeriatr, V8 Suppl 3, P301; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Seymour CW, 2010, JAMA-J AM MED ASSOC, V304, P747, DOI 10.1001/jama.2010.1140; Steultjens EMJ, 2004, AGE AGEING, V33, P453, DOI 10.1093/ageing/afh174; Wahl HW, 2009, GERONTOLOGIST, V49, P355, DOI 10.1093/geront/gnp056; WALKER JE, 1991, AM J OCCUP THER, V45, P119, DOI 10.5014/ajot.45.2.119; Wang HH, 2012, KAOHSIUNG J MED SCI, V28, P465, DOI 10.1016/j.kjms.2012.04.002; WILLER B, 1981, AM J MENT DEF, V86, P252; Wu CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108548; Yee TW, 1996, J ROY STAT SOC B MET, V58, P481; Yee TW, 2013, VGAM VECTOR GEN LINE	55	3	3	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0148414	10.1371/journal.pone.0148414	http://dx.doi.org/10.1371/journal.pone.0148414			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6PR	26863544	Green Published, Green Submitted, gold			2023-01-03	WOS:000370046600068
J	Wales, K; Clemson, L; Lannin, N; Cameron, I				Wales, Kylie; Clemson, Lindy; Lannin, Natasha; Cameron, Ian			Functional Assessments Used by Occupational Therapists with Older Adults at Risk of Activity and Participation Limitations: A Systematic Review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; EARLY SUPPORTED DISCHARGE; QUALITY-OF-LIFE; FALL-PREVENTION PROGRAM; STROKE UNIT SERVICE; BARTHEL INDEX; HIP FRACTURE; HOME REHABILITATION; PHYSICAL FUNCTION; INSTRUMENTAL ACTIVITIES	Introduction The use of functional assessments to evaluate patient change is complicated by a lack of consensus as to which assessment is most suitable for use with older adults. Objective: To identify and appraise the properties of assessments used to evaluate functional abilities in older adults. Methods A systematic review of randomised controlled trials of occupational therapy interventions was conducted up to 2012 to identify assessments used to measure function. Two authors screened and extracted data independently. A second search then identified papers investigating measurement properties of each assessment. Studies from the second search were included if: i) published in English, ii) the assessment was not modified from its original published form, iii) study aim was to evaluate the quality of the tool, iv) and was original research. Translated versions of assessments were excluded. Measurement quality was rated using the COSMIN checklist and Terwee criteria. Results Twenty-eight assessments were identified from the systematic search of occupational therapy interventions provided to older adults. Assessments were of varied measurement quality and many had been adapted (although still evaluated as though the original tool had been administered) potentially altering the conclusions drawn about measurement quality. Synthesis of best evidence established 15 functional assessments have not been tested in an older adult population. Conclusions The Functional Autonomy Measurement System (SMAF) appears to be a promising assessment for use with older adults. Only two tools (the SMAF and the Assessment of Motor and Process Skills (AMPS)) were deemed to be responsive to change when applied to older adults. Health professionals should use functional assessments that have been validated with their population and in their setting. There are reliable and valid assessments to capture the functional performance of older adults in community and hospital settings, although further refinement of these assessments may be necessary.	[Wales, Kylie; Clemson, Lindy] Univ Sydney, Fac Hlth Sci, Ageing Work & Hlth Res Unit, Lidcombe, NSW, Australia; [Wales, Kylie; Clemson, Lindy] Univ Sydney, Fac Hlth Sci, Ctr Excellence Populat Ageing Res, Lidcombe, NSW, Australia; [Lannin, Natasha] La Trobe Univ, Sch Allied Hlth, Melbourne, Vic, Australia; [Lannin, Natasha] Alfred Hlth, Occupat Therapy Dept, Melbourne, Vic, Australia; [Cameron, Ian] Univ Sydney, Sydney Med Sch Northern, John Walsh Ctr Rehabil Res, St Leonards, NSW, Australia; [Clemson, Lindy] Univ Sydney, Ageing Work & Hlth Res Unit, Lidcombe, NSW, Australia; [Lannin, Natasha] Alfred Hlth, Dept Occupat Therapy, Commercial Rd, Melbourne, Vic, Australia; [Cameron, Ian] Royal N Shore Hosp, John Walsh Ctr Rehabil Res, Kolling Inst, St Leonards, NSW 2065, Australia	University of Sydney; University of Sydney; La Trobe University; University of Sydney; University of Sydney; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Wales, K (corresponding author), Univ Sydney, Fac Hlth Sci, Ageing Work & Hlth Res Unit, Lidcombe, NSW, Australia.; Wales, K (corresponding author), Univ Sydney, Fac Hlth Sci, Ctr Excellence Populat Ageing Res, Lidcombe, NSW, Australia.	kylie.wales@sydney.edu.au	Lannin, Natasha A/A-4195-2013	Lannin, Natasha A/0000-0002-2066-8345	Australian Post-Graduate Award; Centre of Excellence in Population Ageing Research Postgraduate scholarship; NHMRC	Australian Post-Graduate Award(Australian Government); Centre of Excellence in Population Ageing Research Postgraduate scholarship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors received no grant funding for this work. Kylie Wales was supported with an Australian Post-Graduate Award and a Centre of Excellence in Population Ageing Research Postgraduate scholarship. Lindy Clemson is a recipient of an NHMRC Career Development Research Fellowship and Ian Cameron is a recipient of an NHMRC Practitioner Fellowship.	Abizanda P, 2011, MATURITAS, V69, P273, DOI 10.1016/j.maturitas.2011.04.001; Albert SM, 2006, J GERONTOL A-BIOL, V61, P826, DOI 10.1093/gerona/61.8.826; Anderson C, 2000, STROKE, V31, P1024, DOI 10.1161/01.STR.31.5.1024; [Anonymous], 2013, WHAT DOES 2011 CENS; Askim T, 2004, CLIN REHABIL, V18, P238, DOI 10.1191/0269215504cr752oa; Australian Bureau of Statistics, 2012, CULTURAL DIVERSITY A; Avlund K., 2002, SCAND J OCCUP THER, V9, P17; Barer DH, 1993, CLIN REHABIL, V7, P271; Bautz-Holter E, 2002, DISABIL REHABIL, V24, P348, DOI 10.1080/09638280110093677; Berggren M, 2008, OSTEOPOROSIS INT, V19, P801, DOI 10.1007/s00198-007-0507-9; Bond MJ, 1998, CLIN REHABIL, V12, P228, DOI 10.1191/026921598676962688; Bowman J, 2006, BRIT J OCCUP THER, V69, P464, DOI DOI 10.1177/030802260606901005; Bredart A, 2015, PSYCHO-ONCOLOGY, V24, P382, DOI 10.1002/pon.3661; Burton LJ, 2013, DISABIL REHABIL, V35, P828, DOI 10.3109/09638288.2012.709305; Buurman BM, 2011, J CLIN EPIDEMIOL, V64, P619, DOI 10.1016/j.jclinepi.2010.07.005; Carswell A, 2002, CANADIAN J OCCUPATIO, V69, P84; Carter J, 1997, CLIN REHABIL, V11, P131, DOI 10.1177/026921559701100206; Clare L, 2010, AM J GERIAT PSYCHIAT, V18, P928, DOI 10.1097/JGP.0b013e3181d5792a; Clark F, 2001, J GERONTOL B-PSYCHOL, V56, pP60, DOI 10.1093/geronb/56.1.P60; Clark F, 1997, JAMA-J AM MED ASSOC, V278, P1321, DOI 10.1001/jama.278.16.1321; CLARK MS, 1995, AGING-CLIN EXP RES, V7, P174, DOI 10.1007/BF03324332; Clarke CE, 2009, J NEUROL NEUROSUR PS, V80, P976, DOI 10.1136/jnnp.2007.138586; Clemson L, 2010, AUST OCCUP THER J, V57, P42, DOI 10.1111/j.1440-1630.2009.00848.x; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Collin C, 1988, Int Disabil Stud, V10, P61; Commonwealth of Australia, 2015, MEAS REC AUSTR SPEC; Conroy S, 2010, AGE AGEING, V39, P704, DOI 10.1093/ageing/afq096; Corr S, 1995, CLIN REHABIL, V9, P291; Crotty M, 2003, ARCH PHYS MED REHAB, V84, P1237, DOI 10.1016/S0003-9993(03)00141-2; Crotty M, 2002, CLIN REHABIL, V16, P406, DOI 10.1191/0269215502cr518oa; Crotty M, 2008, AGE AGEING, V37, P628, DOI 10.1093/ageing/afn141; Cunliffe AL, 2004, AGE AGEING, V33, P246, DOI 10.1093/ageing/afh076; de Craen AJM, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010002; de Morton NA, 2008, ARCH PHYS MED REHAB, V89, P641, DOI 10.1016/j.apmr.2007.10.021; de Vet H, 2011, MEASUREMENT MED PRAC; Demers L, 2010, ARCH PHYS MED REHAB, V91, P233, DOI 10.1016/j.apmr.2009.10.007; Dennis M, 2000, J NEUROL NEUROSUR PS, V68, P47, DOI 10.1136/jnnp.68.1.47; Desrosiers J, 2003, ARCH GERONTOL GERIAT, V37, P157, DOI 10.1016/S0167-4943(03)00044-X; Doble S E, 1997, Int Psychogeriatr, V9, P25, DOI 10.1017/S1041610297004171; Doble S E, 1999, Int Psychogeriatr, V11, P399, DOI 10.1017/S1041610299006018; Doble SE, 1999, OCCUP THER J RES, V19, P203, DOI 10.1177/153944929901900303; Dobson F, 2012, OSTEOARTHR CARTILAGE, V20, P1548, DOI 10.1016/j.joca.2012.08.015; Duncan EAS, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-96; Eklund K, 2008, SCAND J OCCUP THER, V15, P68, DOI 10.1080/11038120701442963; Eyres L, 2005, AUST OCCUP THER J, V52, P218, DOI DOI 10.1111/J.1440-1630.2005.00498.X; Fagerberg B, 2000, STROKE, V31, P2578, DOI 10.1161/01.STR.31.11.2578; Fawcett AJL., 2007, PRINCIPLES ASSESSMEN; Fioravanti AM, 2012, CAN J OCCUP THER, V79, P167, DOI 10.2182/cjot.2012.79.3.6; Fjaertoft H, 2004, CLIN REHABIL, V18, P580, DOI 10.1191/0269215504cr773oa; Fjaertoft H, 2003, STROKE, V34, P2687, DOI 10.1161/01.STR.0000095189.21659.4F; Fjaertoft H, 2011, STROKE, V42, P1707, DOI 10.1161/STROKEAHA.110.601153; Fleming SA, 2004, AGE AGEING, V33, P384, DOI 10.1093/ageing/afh126; Fricke J, 1996, AUST OCCUP THER J, V44, P22; Fricke J, 1998, SCANDINAVIAN J OCCUP, V5, P180, DOI DOI 10.3109/11038129809035744; Gitlin LN, 2008, J GERONTOL A-BIOL, V63, P745, DOI 10.1093/gerona/63.7.745; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2005, J AGING HEALTH, V17, P148, DOI 10.1177/0898264304274184; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; GLADMAN JRF, 1993, AGE AGEING, V22, P419, DOI 10.1093/ageing/22.6.419; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Hagsten B, 2006, ACTA ORTHOP, V77, P114, DOI 10.1080/17453670610045786; Hagsten B, 2004, ACTA ORTHOP SCAND, V75, P177, DOI 10.1080/00016470412331294435; Hall K.M., 1993, J HEAD TRAUMA REHAB, DOI [10.1097/00001199-199308020-00008, DOI 10.1097/00001199-199308020-00008]; Harwood RH, 2000, CLIN REHABIL, V14, P527, DOI 10.1191/0269215500cr346oa; HEBERT R, 1988, AGE AGEING, V17, P293, DOI 10.1093/ageing/17.5.293; Hebert R, 1997, ARCH PHYS MED REHAB, V78, P1305, DOI 10.1016/S0003-9993(97)90301-4; Hebert R, 2002, FUNCTIONAL AUTONOMY; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Hendriks MRC, 2008, J AM GERIATR SOC, V56, P1390, DOI 10.1111/j.1532-5415.2008.01803.x; Hendriksen H, 2001, J ADV NURS, V36, P727, DOI 10.1046/j.1365-2648.2001.02038.x; Hinkka K, 2007, J REHABIL MED, V39, P473, DOI 10.2340/16501977-0078; Hobart JC, 2001, NEUROLOGY, V57, P639, DOI 10.1212/WNL.57.4.639; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; Jette DU, 2005, ARCH PHYS MED REHAB, V86, P1089, DOI 10.1016/j.apmr.2004.11.018; Lannin NA, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-42; Latham Trombly CA., 2008, CONCEPTUAL FDN PRACT; LAW M, 1989, AM J OCCUP THER, V43, P522, DOI 10.5014/ajot.43.8.522; Liddle J, 1996, AUST NZ J PUBL HEAL, V20, P574, DOI 10.1111/j.1467-842X.1996.tb01068.x; Lincoln NB, 2004, CLIN REHABIL, V18, P40, DOI 10.1191/0269215504cr700oa; Logan PA, 2005, BRIT MED J, V330, P137; Logan PA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2102; Mahoney RI, 1965, VISITING PROFESSOR N, P1; Mayo N, 1993, CANADIAN J REHABILIT, V7, P81; Mercier L, 2001, STROKE, V32, P2602, DOI 10.1161/hs1101.098154; Mokkink LB., 2012, COSMIN CHECKLIST MAN; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Newson RS, 2005, J GERONTOL B-PSYCHOL, V60, pP113, DOI 10.1093/geronb/60.3.P113; Nikolaus T, 1999, AGE AGEING, V28, P543, DOI 10.1093/ageing/28.6.543; Ollonqvist K, 2008, HEALTH SOC CARE COMM, V16, P115, DOI 10.1111/j.1365-2524.2007.00733.x; Pardessus V, 2002, AM J PHYS MED REHAB, V81, P247, DOI 10.1097/00002060-200204000-00002; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Pitkala K, 1998, J AM GERIATR SOC, V46, P1086, DOI 10.1111/j.1532-5415.1998.tb06645.x; REUBEN DB, 1995, J AM GERIATR SOC, V43, P17, DOI 10.1111/j.1532-5415.1995.tb06236.x; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Roderick P, 2001, AGE AGEING, V30, P303, DOI 10.1093/ageing/30.4.303; Rodgers H, 1997, CLIN REHABIL, V11, P280, DOI 10.1177/026921559701100403; Ronning OM, 1998, STROKE, V29, P779, DOI 10.1161/01.STR.29.4.779; Rudd AG, 1998, BRIT MED J, V316, P435; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Stamm TA, 2006, AUSTR OCCUPATIONAL T, V53, P9, DOI [10.1111/j.1440-1630.2005.00513.x, DOI 10.1111/J.1440-1630.2005.00513.X]; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; TUCKER MA, 1984, BRIT MED J, V289, P1209, DOI 10.1136/bmj.289.6453.1209; U.S. Department of Health and Human Services, 2013, PROF OLD AM 2013; Unsworth C., 2000, AUST OCCUP THER J, V47, P147, DOI [DOI 10.1046/J.1440-1630.2000.00239.X, 10.1046/j.1440-1630.2000.00239.x]; Van Peppen RPS, 2008, PHYSIOTHER RES INT, V13, P255, DOI 10.1002/pri.417; Vass M, 2005, J AM GERIATR SOC, V53, P563, DOI 10.1111/j.1532-5415.2005.53201.x; Vergauwen K, 2015, DISABIL REHABIL, V37, P1706, DOI 10.3109/09638288.2014.978507; Wales K, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-45; Wilkinson PR, 1997, QUAL HEALTH CARE, V6, P125, DOI 10.1136/qshc.6.3.125; World Health Organization (WHO), 2002, COMMON LANGUAGE FUNC; Wright J, 1998, PHYSIOTHERAPY, V84, P216, DOI DOI 10.1016/S0031-9406(05)65552-6; Yohannes AM, 1998, AGE AGEING, V27, P369, DOI 10.1093/ageing/27.3.369; Ziden L, 2008, CLIN REHABIL, V22, P1019, DOI 10.1177/0269215508096183; Zwakhalen Sandra M G, 2006, BMC Geriatr, V6, P3, DOI 10.1186/1471-2318-6-3	116	35	35	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0147980	10.1371/journal.pone.0147980	http://dx.doi.org/10.1371/journal.pone.0147980			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6MN	26859678	gold, Green Published, Green Submitted			2023-01-03	WOS:000370038400016
J	Sharma, S; van Teijlingen, E; Belizan, JM; Hundley, V; Simkhada, P; Sicuri, E				Sharma, Sheetal; van Teijlingen, Edwin; Belizan, Jose M.; Hundley, Vanora; Simkhada, Padam; Sicuri, Elisa			Measuring What Works: An Impact Evaluation of Women's Groups on Maternal Health Uptake in Rural Nepal	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; DEVELOPING-COUNTRIES; INSTITUTIONAL DELIVERY; ANTENATAL CARE; INTERVENTIONS; MORTALITY; SERVICES; CHILD; DETERMINANTS; DIFFERENCE	Background There is a need for studies evaluating maternal health interventions in low-income countries. This paper evaluates one such intervention designed to promote maternal health among rural women in Nepal. Methods and Results This was a five-year controlled, non-randomised, repeated cross-sectional study (2007, 2010, 2012) of a participatory community-based maternal health promotion intervention focusing on women's groups to improve maternal health services uptake. In total 1,236 women of childbearing age, who had their last child <= two years ago, were interviewed. Difference-in-Difference estimation assessed the effects of the intervention on selected outcome variables while controlling for a constructed wealth index and women's characteristics. In the first three years (from 2007 to the 2010), the intervention increased women's likelihood of attending for antenatal care at least once during pregnancy by seven times [OR = 7.0, 95% CI (2.3; 21.4)], of taking iron and folic acid by three times [OR = 3.0, 95% CI (1.2; 7.8)], and of seeking four or more antenatal care visits of two times, although not significantly [OR = 2.2, 95% CI (1.0; 4.7)]. Over five years, women were more likely to seek antenatal care at least once [OR = 3.0, 95% CI (1.5; 5.2)], to take iron/ folic acid [OR = 1.9, [95% CI (1.1; 3.2)], and to attend postnatal care [OR = 1.5, [95% CI (1.1; 2.2)]. No improvement was found on attending antenatal care in the first trimester, birthing at an institution or with a skilled birth attendant. Conclusion Community-based health promotion has a much stronger effect on the uptake of antenatal care and less on delivery care. Other factors not easily resolved through health promotion interventions may influence these outcomes, such as costs or geographical constraints. The evaluation has implications for policy and practice in public health, especially maternal health promotion.	[Sharma, Sheetal; van Teijlingen, Edwin; Hundley, Vanora] Bournemouth Univ, Fac Hlth & Social Sci, Poole BH12 5BB, Dorset, England; [Belizan, Jose M.] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina; [Simkhada, Padam] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 5UX, Merseyside, England; [Sicuri, Elisa] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain; [Sicuri, Elisa] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Infect Dis Epidemiol, Hlth Econ Grp, London, England	Bournemouth University; Liverpool John Moores University; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; Imperial College London	Sharma, S (corresponding author), Bournemouth Univ, Fac Hlth & Social Sci, Poole BH12 5BB, Dorset, England.	ssharma@bournemouth.ac.uk	van Teijlingen, Edwin R/A-3727-2010; Sicuri, Elisa/L-8012-2014	van Teijlingen, Edwin R/0000-0001-5523-8583; Sicuri, Elisa/0000-0002-2499-2732; Belizan, Jose/0000-0002-8412-3010; Simkhada, Padam/0000-0002-5706-6479; Sharma, Sheetal/0000-0003-2149-0806	Green Tara Trust (UK); Bournemouth University (UK)	Green Tara Trust (UK); Bournemouth University (UK)	This work was supported by Green Tara Trust (UK) and Bournemouth University (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam T, 2012, HEALTH POLICY PLANN, V27, P9, DOI 10.1093/heapol/czs086; Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Alderman H, 2009, PUBLIC HEALTH NUTR, V12, P667, DOI 10.1017/S1368980008002619; Asefa A, 2013, LANCET, V382, P9; Bennett L.., 2008, CASTE ETHNIC REGIONA; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Bhutta ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; Bonell CP, 2011, J EPIDEMIOL COMMUN H, V65, P582, DOI 10.1136/jech.2008.082602; Borghi J, 2006, TROP MED INT HEALTH, V11, P228, DOI 10.1111/j.1365-3156.2005.01546.x; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Central Bureau of Statistics, 2001, STAT YB NEP; Choulagai B, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-49; Christiansen G., 1999, EVALUATION QUALITY A; Coast E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108130; Datta J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-568; Davies M, 2005, HLTH PROMOTION THEOR; de Heer HD, 2011, AM J PUBLIC HEALTH, V101, P1907, DOI 10.2105/AJPH.2011.300177; Donnay F, 2000, INT J GYNECOL OBSTET, V70, P89, DOI 10.1016/S0020-7292(00)00236-8; Duflo Esther, 2012, Science, V336, P1398, DOI 10.1126/science.1224965; Ensor T, 2014, HLTH POL, V90, P247; Ensor T, 2014, B WORLD HEALTH ORGAN, V92, P51, DOI 10.2471/BLT.13.122721; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Furuta M, 2006, INT FAM PLAN PERSPEC, V32, P17, DOI 10.1363/3201706; Gibbon D, CLASS NOTES; Godin Gaston, 2007, Promot Educ, V14, P138; Howe LD, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-3; Irwin A, 2006, PLOS MED, V3, P749, DOI 10.1371/journal.pmed.0030106; J-PAL, 2015, IMP EV; Judd J, 2001, HEALTH PROMOT INT, V16, P367, DOI 10.1093/heapro/16.4.367; Kesterton AJ, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-30; Kestler E, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-73; Khanal V, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-4; Khanal V, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-19; Khandker S.R., 2010, HDB IMPACT EVALUATIO; Lee RB, 2012, ASIA PACIFIC E J HLT, V1; Li XF, 1996, INT J GYNECOL OBSTET, V54, P1, DOI 10.1016/0020-7292(96)02667-7; Liu XN, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-566; Malenga G, 2012, LANCET, V379, P2131, DOI 10.1016/S0140-6736(12)60369-9; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; McPherson RA, 2006, J HEALTH POPUL NUTR, V24, P479; Middleberg MI, 2003, PROMOTING REPRODUCTI; Milne L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0564-6; Ministry of Health and Population, 2012, NEP ANN REP 2009 201; Ministry of Health and Population Nepal, 2007, NEP DEM HLTH SURV 20; Muldoon KA, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-42; NICE, 2007, BEH CHANG PRINC EFF; Nour Nawal M, 2008, Rev Obstet Gynecol, V1, P77; Osrin D, 2009, B WORLD HEALTH ORGAN, V87, P772, DOI 10.2471/BLT.08.051060; Oxford Poverty and Human Development Initiative, 2013, NEP COUNTR BRIEF; Prost A, 2013, LANCET, V381, P1736, DOI 10.1016/S0140-6736(13)60685-6; Puri M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-29; Rauniar G P, 2012, Kathmandu Univ Med J (KUMJ), V10, P30; Reynolds HW, 2006, INT FAM PLAN PERSPEC, V32, P6, DOI 10.1363/3200606; Rosato M, 2012, INT HEALTH, V4, P176, DOI 10.1016/j.inhe.2012.03.007; Say L, 2007, B WORLD HEALTH ORGAN, V85, P812, DOI 10.2471/BLT.06.035659; Schlotter M, 2010, 4725 U MUN IZA IF I; Shrestha BP, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-136; Simkhada B, 2006, Kathmandu Univ Med J (KUMJ), V4, P258; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Simkhada B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-34; Simkhada P., 2009, Asian Journal of Epidemiology, V2, P44, DOI 10.3923/aje.2009.44.48; Subba N, 2014, J NOBEL MED COLL, V3, P10, DOI DOI 10.3126/jonmc.v3i1.10047; Teijlingen E. van, 2012, Health Renaissance, V10, P229; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; The World Bank, 2006, EXP IND EV GROUP WOR; Transparency International, 2014, 2014 ANTIC PUBL PROC; Tuntiseranee P, 1999, J EPIDEMIOL COMMUN H, V53, P624, DOI 10.1136/jech.53.10.624; United Nations Population Fund (UNFPA), 1995, INT C POP DEV GEND E; Vanderweele TJ, 2013, J AM STAT ASSOC, V108, P469, DOI 10.1080/01621459.2013.779832; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Waldinger F., 2010, DIFFERENCE IN DIFFER, V3; Warren C, 2006, OPPORTUNITIES FOR AF; Witter S, 2011, HLTH POLICY PLAN S2, V26, pii84; World Health Organization, 2012, DAIL IR FOL AC SUPPL; World Health Organization Department of Maternal N, 2013, WHO REC POSTN CAR MO; World Health Organization UNICEF, 2003, ANT CAR DEV COUNTR P; World Health Organization (WHO), 2001, WHO EUR SER; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R	80	12	12	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2016	11	5							e0155144	10.1371/journal.pone.0155144	http://dx.doi.org/10.1371/journal.pone.0155144			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DN2FT	27214032	Green Published, Green Accepted, gold			2023-01-03	WOS:000376880200007
J	Dyer, O				Dyer, Owen			Oncologist pays $300 000 to settle US claims of billing for fake cancer drug	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2016	353								i2861	10.1136/bmj.i2861	http://dx.doi.org/10.1136/bmj.i2861			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GD	27198575				2023-01-03	WOS:000376447700021
J	Blank, CU; Haanen, JB; Ribas, A; Schumacher, TN				Blank, Christian U.; Haanen, John B.; Ribas, Antoni; Schumacher, Ton N.			The "cancer immunogram"	SCIENCE			English	Editorial Material									[Blank, Christian U.; Haanen, John B.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Blank, Christian U.; Haanen, John B.; Schumacher, Ton N.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Ribas, Antoni] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; University of California System; University of California Los Angeles	Blank, CU (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.; Blank, CU; Schumacher, TN (corresponding author), Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands.	c.blank@nki.nl; t.schumacher@nki.nl	Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8534-2022; Haanen, John/AAD-8578-2022	Schumacher, Ton/0000-0003-0517-8804; Haanen, John/0000-0001-5884-7704; 					0	468	489	3	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 6	2016	352	6286					658	660		10.1126/science.aaf2834	http://dx.doi.org/10.1126/science.aaf2834			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DL1UC	27151852				2023-01-03	WOS:000375417100017
J	Santisteban, L; Teremetz, M; Bleton, JP; Baron, JC; Maier, MA; Lindberg, PG				Santisteban, Leire; Teremetz, Maxime; Bleton, Jean-Pierre; Baron, Jean-Claude; Maier, Marc A.; Lindberg, Pavel G.			Upper Limb Outcome Measures Used in Stroke Rehabilitation Studies: A Systematic Literature Review	PLOS ONE			English	Review							FUGL-MEYER ASSESSMENT; HEMIPARETIC PATIENTS; BOTULINUM-TOXIN; SPASTICITY; MOVEMENT; RECOVERY; RECOMMENDATIONS; RELIABILITY; KINEMATICS; STRATEGIES	Background Establishing which upper limb outcome measures are most commonly used in stroke studies may help in improving consensus among scientists and clinicians. Objective In this study we aimed to identify the most commonly used upper limb outcome measures in intervention studies after stroke and to describe domains covered according to ICF, how measures are combined, and how their use varies geographically and over time. Methods Pubmed, CinHAL, and PeDRO databases were searched for upper limb intervention studies in stroke according to PRISMA guidelines and477 studies were included. Results In studies 48different outcome measures were found. Only 15 of these outcome measures were used in more than 5% of the studies. The Fugl-Meyer Test (FMT) was the most commonly used measure (in 36% of studies). Commonly used measures covered ICF domains of body function and activity to varying extents. Most studies (72%) combined multiple outcome measures: the FMT was often combined with the Motor Activity Log (MAL), the Wolf Motor Function Test and the Action Research Arm Test, but infrequently combined with the Motor Assessment Scale or the Nine Hole Peg Test. Key components of manual dexterity such as selective finger movements were rarely measured. Frequency of use increased over a twelve-year period for the FMT and for assessments of kinematics, whereas other measures, such as the MAL and the Jebsen Taylor Hand Test showed decreased use over time. Use varied largely between countries showing low international consensus. Conclusions The results showed a large diversity of outcome measures used across studies. However, a growing number of studies used the FMT, a neurological test with good psychometric properties. For thorough assessment the FMT needs to be combined with functional measures. These findings illustrate the need for strategies to build international consensus on appropriate outcome measures for upper limb function after stroke.	[Santisteban, Leire] Univ Paris 05, Hop St Anne, Serv Med Phys & Readaptat, Paris, France; [Teremetz, Maxime; Maier, Marc A.; Lindberg, Pavel G.] Univ Paris 05, Sorbonne Paris Cite, CNRS, FR3636, Paris, France; [Bleton, Jean-Pierre] Fdn OPH Rothschild, Serv Neurol, Unite James Parkinson, Paris, France; [Bleton, Jean-Pierre; Baron, Jean-Claude] INSERM, U894, Ctr Psychiat & Neurosci, Paris, France; [Maier, Marc A.] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Lindberg, PG (corresponding author), Univ Paris 05, Sorbonne Paris Cite, CNRS, FR3636, Paris, France.	pavel.lindberg@inserm.fr	Maier, Marc/HGU-9498-2022; Lindberg, Pavel/P-9792-2019; Lindberg, Pavel G/E-5926-2017	Lindberg, Pavel/0000-0001-6976-6387; Lindberg, Pavel G/0000-0001-6976-6387; baron, jean-claude/0000-0002-5264-2588; Lindberg, Pavel/0000-0002-7507-7817; Santisteban, Leire/0000-0001-7049-7655; BLETON, Jean-Pierre/0000-0002-2313-2263				Alt Murphy M, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0292-6; Alt Murphy M, 2013, NEUROREHAB NEURAL RE, V27, P844, DOI 10.1177/1545968313491008; Auriat AM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00226; Backman C., 1992, CAN J OCCUP THER, V59, P208, DOI DOI 10.1177/000841749205900406; Bensmail D, 2010, NEUROREHAB NEURAL RE, V24, P141, DOI 10.1177/1545968309347683; Bushnell C, 2015, CIRC-CARDIOVASC QUAL, V8, pS163, DOI 10.1161/CIRCOUTCOMES.115.002098; Causby R, 2014, PERCEPT MOTOR SKILL, V118, P765, DOI 10.2466/25.27.PMS.118k27w2; Chen HM, 2009, NEUROREHAB NEURAL RE, V23, P435, DOI 10.1177/1545968308331146; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Cirstea MC, 2000, BRAIN, V123, P940, DOI 10.1093/brain/123.5.940; Reyes-Guzman ADL, 2014, CLIN BIOMECH, V29, P719, DOI 10.1016/j.clinbiomech.2014.06.013; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; Ellis MD, 2008, NEUROREHAB NEURAL RE, V22, P321, DOI 10.1177/1545968307313509; Gaverth J, 2014, J REHABIL MED, V46, P629, DOI 10.2340/16501977-1824; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Hsieh CL, 1998, AGE AGEING, V27, P107, DOI 10.1093/ageing/27.2.107; Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK; Isa T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00191; Jette DU, 2009, PHYS THER, V89, P125, DOI 10.2522/ptj.20080234; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Lin JH, 2009, PHYS THER, V89, P840, DOI 10.2522/ptj.20080285; Lindberg PG, 2007, NEUROREHAB NEURAL RE, V21, P551, DOI 10.1177/1545968307301886; Lindberg PG, 2016, EUR RADIOL, V26, P733, DOI 10.1007/s00330-015-3876-z; Lindberg PG, 2012, BRAIN RES, V1452, P96, DOI 10.1016/j.brainres.2012.03.007; Mandon L, 2016, NEUROREHAB NEURAL RE, V30, P209, DOI 10.1177/1545968315591704; Meyer S, 2015, NEUROREHABIL NEURAL; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Noorkoiv M, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-144; Nordin N, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-137; Page SJ, 2012, ARCH PHYS MED REHAB, V93, P2373, DOI 10.1016/j.apmr.2012.06.017; Parker V M, 1986, Int Rehabil Med, V8, P69; Pennati GV, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0133-x; Rand D, 2015, J STROKE CEREBROVASC, V24, P274, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.039; Roby-Brami A, 2003, BRAIN RES, V969, P217, DOI 10.1016/S0006-8993(03)02334-5; Schmidlin Eric, 2011, J Vis Exp, DOI 10.3791/3258; Sivan M, 2011, J REHABIL MED, V43, P181, DOI 10.2340/16501977-0674; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; Sullivan JE, 2013, PHYS THER, V93, P1383, DOI 10.2522/ptj.20120492; Teremetz M, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0054-0; Thompson-Butel AG, 2015, NEUROREHAB NEURAL RE, V29, P341, DOI 10.1177/1545968314547766; Tyryshkin K, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-47; Velstra IM, 2011, PM&R, V3, P846, DOI 10.1016/j.pmrj.2011.03.014; World Health Organization, INT CLASS FUNCT DIS; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004	53	161	169	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154792	10.1371/journal.pone.0154792	http://dx.doi.org/10.1371/journal.pone.0154792			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	27152853	gold, Green Submitted, Green Published			2023-01-03	WOS:000375677000035
J	Oczkowski, SJ; Chung, HO; Hanvey, L; Mbuagbaw, L; You, JJ				Oczkowski, Simon J.; Chung, Han-Oh; Hanvey, Louise; Mbuagbaw, Lawrence; You, John J.			Communication Tools for End-of-Life Decision-Making in Ambulatory Care Settings: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; TREATMENT PREFERENCES; SUSTAINING TREATMENT; DIALYSIS PATIENTS; ADVANCED CANCER; VIDEO IMAGES; NURSING-HOME	Background Patients with serious illness, and their families, state that better communication and decision-making with healthcare providers is a high priority to improve the quality of end-of-life care. Numerous communication tools to assist patients, family members, and clinicians in end-of-life decision-making have been published, but their effectiveness remains unclear. Objectives To determine, amongst adults in ambulatory care settings, the effect of structured communication tools for end-of-life decision-making on completion of advance care planning. Methods We searched for relevant randomized controlled trials (RCTs) or non-randomized intervention studies in MEDLINE, EMBASE, CINAHL, ERIC, and the Cochrane Database of Randomized Controlled Trials from database inception until July 2014. Two reviewers independently screened articles for eligibility, extracted data, and assessed risk of bias. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of evidence for each of the primary and secondary outcomes. Results Sixty-seven studies, including 46 RCTs, were found. The majority evaluated communication tools in older patients (age > 50) with no specific medical condition, but many specifically evaluated populations with cancer, lung, heart, neurologic, or renal disease. Most studies compared the use of communication tools against usual care, but several compared the tools to less-intensive advance care planning tools. The use of structured communication tools increased: the frequency of advance care planning discussions/discussions about advance directives (RR 2.31, 95% CI 1.25-4.26, p = 0.007, low quality evidence) and the completion of advance directives (ADs) (RR 1.92, 95% CI 1.43-2.59, p<0.001, low quality evidence); concordance between AD preferences and subsequent medical orders for use or non-use of life supporting treatment (RR 1.19, 95% CI 1.01-1.39, p = 0.028, very low quality evidence, 1 observational study); and concordance between the care desired and care received by patients (RR 1.17, 95% CI 1.05-1.30, p = 0.004, low quality evidence, 2 RCTs). Conclusions The use of structured communication tools may increase the frequency of discussions about and completion of advance directives, and concordance between the care desired and the care received by patients. The use of structured communication tools rather than an ad-hoc approach to end-of-life decision-making should be considered, and the selection and implementation of such tools should be tailored to address local needs and context.	[Oczkowski, Simon J.; Chung, Han-Oh; You, John J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Hanvey, Louise] Canadian Hosp Palliat Care Assoc, Ottawa, ON, Canada; [Mbuagbaw, Lawrence; You, John J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Mbuagbaw, Lawrence] St Josephs Healthcare Hamilton, Biostat Unit, Father Sean OSullivan Res Ctr, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Oczkowski, SJ (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	oczkowsj@mcmaster.ca	Oczkowski, Simon/AAL-6833-2020; Mbuagbaw, Lawrence/D-9381-2015	Oczkowski, Simon/0000-0002-2874-8948; Mbuagbaw, Lawrence/0000-0001-5855-5461	Technology Evaluation in the Elderly Network [KS 2014-06]	Technology Evaluation in the Elderly Network	This work was supported by a grant from the Technology Evaluation in the Elderly Network (http://www.tvn-nce.ca, #KS 2014-06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Au DH, 2012, CHEST, V141, P726, DOI 10.1378/chest.11-0362; Briggs LA, 2004, J PROF NURS, V20, P47, DOI 10.1016/j.profnurs.2003.12.001; Brown JB, 1999, J GEN INTERN MED, V14, P21, DOI 10.1046/j.1525-1497.1999.00276.x; Chan HYL, 2010, J CLIN NURS, V19, P3073, DOI 10.1111/j.1365-2702.2010.03353.x; Clayton JM, 2007, J CLIN ONCOL, V25, P715, DOI 10.1200/JCO.2006.06.7827; Deep KS, 2010, PATIENT EDUC COUNS, V81, P229, DOI 10.1016/j.pec.2010.02.004; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; Dyar S, 2012, J PALLIAT MED, V15, P890, DOI 10.1089/jpm.2012.0014; Einterz SF, 2014, J AM MED DIR ASSOC, V15, P251, DOI 10.1016/j.jamda.2013.11.020; El-Jawahri A, 2010, J CLIN ONCOL, V28, P305, DOI 10.1200/JCO.2009.24.7502; Engelhardt JB, 2006, AM J MANAG CARE, V12, P93; Engelhardt JB, 2009, AM J MANAG CARE, V15, P817; Epstein AS, 2013, J PALLIAT MED, V16, P623, DOI 10.1089/jpm.2012.0524; Fung AWT, 2010, AGING MENT HEALTH, V14, P994, DOI 10.1080/13607863.2010.501065; GRADE working group, GRADEPRO ONLINE SOFT; Grimaldo DA, 2001, ANESTHESIOLOGY, V95, P43, DOI 10.1097/00000542-200107000-00012; Gutheil IA, 2005, HEALTH SOC WORK, V30, P107, DOI 10.1093/hsw/30.2.107; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011; Hanson LC, 2005, J PALLIAT MED, V8, P1207, DOI 10.1089/jpm.2005.8.1207; Heiman H, 2004, AM J MED, V117, P318, DOI 10.1016/j.amjmed.2004.03.027; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; HIGH DM, 1993, GERONTOLOGIST, V33, P342, DOI 10.1093/geront/33.3.342; Hossler C, 2011, AMYOTROPH LATERAL SC, V12, P172, DOI 10.3109/17482968.2010.509865; Jones L, 2011, PALLIAT SUPPORT CARE, V9, P3, DOI 10.1017/S1478951510000490; Kirchhoff KT, 2010, J AM GERIATR SOC, V58, P1233, DOI 10.1111/j.1532-5415.2010.02760.x; Landry FJ, 1997, J GEN INTERN MED, V12, P412, DOI 10.1046/j.1525-1497.1997.00072.x; Barrio-Cantalejo IM, 2009, NURS ETHICS, V16, P93, DOI 10.1177/0969733008097995; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Murphy CP, 2000, J PROF NURS, V16, P21, DOI 10.1016/S8755-7223(00)80008-3; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Pearlman RA, 2005, ARCH INTERN MED, V165, P667, DOI 10.1001/archinte.165.6.667; Perry E, 2005, AM J KIDNEY DIS, V46, P111, DOI 10.1053/j.ajkd.2005.03.018; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; Reinke LF, 2011, AM J HOSP PALLIAT ME, V28, P147, DOI 10.1177/1049909110376807; Rhondali W, 2013, CANCER-AM CANCER SOC, V119, P2067, DOI 10.1002/cncr.27981; Richter K P, 1995, Arch Fam Med, V4, P609, DOI 10.1001/archfami.4.7.609; Rubin SM, 1994, JAMA; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; Schwartz CE, 2002, ARCH INTERN MED, V162, P1611, DOI 10.1001/archinte.162.14.1611; Siegert EA, 1996, ARCH FAM MED, V5, P207, DOI 10.1001/archfami.5.4.207; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; Singer PA, 1997, JOURNAL OF GENERAL; Smucker W D, 1993, J Am Board Fam Pract, V6, P473; Song MK, 2010, APPL NURS RES, V23, P65, DOI 10.1016/j.apnr.2008.05.002; Song MK, 2009, RES NURS HEALTH, V32, P260, DOI 10.1002/nur.20320; Song MK, 2005, MED CARE, V43, P1049, DOI 10.1097/01.mlr.0000178192.10283.b4; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Sudore RL, 2007, PATIENT EDUC COUNS, V69, P165, DOI 10.1016/j.pec.2007.08.015; Sudore RL, 2014, J PAIN SYMPTOM MANAG, V47, P674, DOI 10.1016/j.jpainsymman.2013.05.023; Sulmasy DP, 1996, J GEN INTERN MED, V11, P657, DOI 10.1007/BF02600156; Viera AJ, 2005, FAM MED, V37, P360; Volandes AE, 2007, ARCH INTERN MED, V167, P828, DOI 10.1001/archinte.167.8.828; Volandes AE, 2012, CANCER-AM CANCER SOC, V118, P4331, DOI 10.1002/cncr.27423; Volandes AE, 2012, J PALLIAT MED, V15, P805, DOI 10.1089/jpm.2011.0505; Volandes AE, 2011, J PALLIAT MED, V14, P169, DOI 10.1089/jpm.2010.0299; Volandes AE, 2010, MED DECIS MAKING, V30, P29, DOI 10.1177/0272989X09341587; Volandes AE, 2009, J AM MED DIR ASSOC, V10, P575, DOI 10.1016/j.jamda.2009.05.006; Volandes AE, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2159; Wilson KG, 2005, PATIENT EDUC COUNS, V57, P88, DOI 10.1016/j.pec.2004.04.004; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yamada R, 1999, J GEN INTERN MED, V14, P559, DOI 10.1046/j.1525-1497.1999.11208.x	68	55	56	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2016	11	4							e0150671	10.1371/journal.pone.0150671	http://dx.doi.org/10.1371/journal.pone.0150671			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DK5QZ	27119571	Green Published, gold, Green Submitted			2023-01-03	WOS:000374976200003
J	Kaushal, M; Byrnes, C; Khademian, Z; Duncan, N; Luban, NLC; Miller, JL; Fasano, RM; Meier, ER				Kaushal, Megha; Byrnes, Colleen; Khademian, Zarir; Duncan, Natalie; Luban, Naomi L. C.; Miller, Jeffery L.; Fasano, Ross M.; Meier, Emily Riehm			Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia	PLOS ONE			English	Article							SILENT CEREBRAL INFARCTS; RED-CELL; CEREBROVASCULAR ACCIDENTS; HYDROXYUREA SWITCH; MOYAMOYA SYNDROME; CNS INFARCTION; DISEASE; ADHESION; STROKE; BLOOD	Sickle cell anemia (SCA) is an inherited hemolytic anemia with compensatory reticulocytosis. Recent studies have shown that increased levels of reticulocytosis during infancy are associated with increased hospitalizations for SCA sequelae as well as cerebrovascular pathologies. In this study, absolute reticulocyte counts (ARC) measured prior to transfusion were analysed among a cohort of 29 pediatric SCA patients receiving chronic transfusion therapy (CTT) for primary and secondary stroke prevention. A cross-sectional flow cytometric analysis of the reticulocyte phenotype was also performed. Mean duration of CTT was 3.1 +/- 2.6 years. Fifteen subjects with magnetic resonance angiography (MRA) - vasculopathy had significantly higher mean ARC prior to initiating CTT compared to 14 subjects without MRA-vasculopathy (427.6 +/- 109.0 K/mu l vs. 324.8 +/- 109.2 K/mu l, p<0.05). No significant differences in hemoglobin or percentage sickle hemoglobin (HbS) were noted between the two groups at baseline. Reticulocyte phenotyping further demonstrated that the percentages of circulating immature [CD36(+), CD71(+)] reticulocytes positively correlated with ARC in both groups. During the first year of CTT, neither group had significant reductions in ARC. Among this group of children with SCA, cerebrovasculopathy on MRA at initiation of CTT was associated with increased reticulocytosis, which was not reduced after 12 months of transfusions.	[Kaushal, Megha; Byrnes, Colleen; Miller, Jeffery L.; Meier, Emily Riehm] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; [Kaushal, Megha; Luban, Naomi L. C.; Fasano, Ross M.; Meier, Emily Riehm] Childrens Natl Hlth Syst, Ctr Canc & Blood Disorders, Washington, DC USA; [Khademian, Zarir] Childrens Natl Hlth Syst, Div Diagnost Imaging & Radiol, Washington, DC USA; [Kaushal, Megha; Luban, Naomi L. C.; Fasano, Ross M.; Meier, Emily Riehm] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [Duncan, Natalie; Meier, Emily Riehm] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA; [Fasano, Ross M.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Children's National Health System; Children's National Health System; George Washington University; Indiana Hemophilia & Thrombosis Center; Emory University	Meier, ER (corresponding author), NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA.; Meier, ER (corresponding author), Childrens Natl Hlth Syst, Ctr Canc & Blood Disorders, Washington, DC USA.; Meier, ER (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA.; Meier, ER (corresponding author), Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA.	emeier@ihtc.org			Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; National Heart Lung and Blood Institute [HL110841]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL110841] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and a T32 from National Heart Lung and Blood Institute [HL110841]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; ANDERSON R, 1963, ARCH INTERN MED, V111, P286, DOI 10.1001/archinte.1963.03620270012003; Borrione P, 2010, INT J LAB HEMATOL, V32, P65, DOI 10.1111/j.1751-553X.2008.01128.x; Browne PV, 1996, J LAB CLIN MED, V127, P340, DOI 10.1016/S0022-2143(96)90181-X; Butthep P, 2015, BLOOD CELL MOL DIS, V54, P170, DOI 10.1016/j.bcmd.2014.11.007; COHEN AR, 1992, BLOOD, V79, P1657; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; Detterich JA, 2013, TRANSFUSION, V53, P1059, DOI 10.1111/j.1537-2995.2012.03961.x; Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144; Farrar JE, 2008, BLOOD, V112, P1582, DOI 10.1182/blood-2008-02-140012; Fasano RM, 2015, BLOOD CELL MOL DIS, V54, P17, DOI 10.1016/j.bcmd.2014.08.007; GABUZDA TG, 1967, BLOOD-J HEMATOL, V29, P126, DOI 10.1182/blood.V29.1.126.126; Gladwin MT, 2007, HAEMATOLOGICA, V93, P1, DOI 10.3324/haematol.12318; Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123; JONECKIS CC, 1993, BLOOD, V82, P3548; Josephson CD, 2007, TRANSFUS MED REV, V21, P118, DOI 10.1016/j.tmrv.2006.11.003; Kennedy BC, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13405; Koury MJ, 2005, BLOOD, V105, P2168, DOI 10.1182/blood-2004-02-0616; LUSHER JM, 1976, AM J HEMATOL, V1, P265, DOI 10.1002/ajh.2830010210; Meier ER, 2014, AM J HEMATOL, V89, P904, DOI 10.1002/ajh.23777; Meier ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070794; Meier ER, 2015, J PEDIAT; Odievre MH, 2008, HAEMATOLOGICA, V93, P502, DOI 10.3324/haematol.12070; Ohene-Frempong K, 1998, BLOOD, V91, P288; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; RUSSELL MO, 1976, J PEDIATR-US, V88, P382, DOI 10.1016/S0022-3476(76)80251-X; Sakamoto TM, 2013, CLIN BIOCHEM, V46, P1798, DOI 10.1016/j.clinbiochem.2013.09.011; SARNAIK S, 1979, AM J DIS CHILD, V133, P1254, DOI 10.1001/archpedi.1979.02130120046009; Setty BNY, 2002, BLOOD, V99, P1564, DOI 10.1182/blood.V99.5.1564; Silva CM, 2011, PEDIATR BLOOD CANCER, V56, P116, DOI 10.1002/pbc.22680; SUGIHARA K, 1992, BLOOD, V80, P2634; Tancabelic J, 1999, AM J HEMATOL, V60, P121, DOI 10.1002/(SICI)1096-8652(199902)60:2<121::AID-AJH6>3.0.CO;2-2; Telen MJ, 2000, SEMIN HEMATOL, V37, P130, DOI 10.1016/S0037-1963(00)90038-6; Trinh-Trang-Tan MM, 2010, HAEMATOL-HEMATOL J, V95, P730, DOI 10.3324/haematol.2009.017392; Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7; Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340; Ware RE, 2011, PEDIATR BLOOD CANCER, V57, P1011, DOI 10.1002/pbc.23145; Watkins NA, 2003, BLOOD, V102, P718, DOI 10.1182/blood-2002-11-3497; WAYNE AS, 1993, BLOOD, V81, P1109; WILIMAS J, 1980, J PEDIATR-US, V96, P205, DOI 10.1016/S0022-3476(80)80803-1; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; Zennadi R, 2008, TRANSFUS CLIN BIOL, V15, P23, DOI 10.1016/j.tracli.2008.04.009	43	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2016	11	4							e0153244	10.1371/journal.pone.0153244	http://dx.doi.org/10.1371/journal.pone.0153244			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5QB	27116614	gold, Green Published, Green Submitted			2023-01-03	WOS:000374973600017
J	Fleming, J; Farquhar, M; Brayne, C; Barclay, S				Fleming, Jane; Farquhar, Morag; Brayne, Carol; Barclay, Stephen		Cambridge City Over-75s Cohort	Death and the Oldest Old: Attitudes and Preferences for End-of-Life Care - Qualitative Research within a Population-Based Cohort Study	PLOS ONE			English	Article							SUSTAINING TREATMENT PREFERENCES; FAMILY CARERS; PEOPLE; PLACE; DEMENTIA; ADULTS; VIEWS; TRANSITIONS; HOMES; COMMUNICATION	Introduction Increasing longevity means more people will be dying in very old age, but little is known about the preferences of the 'oldest old' regarding their care at the end of life. Aims To understand very old people's preferences regarding care towards the end of life and attitudes towards dying, to inform policy and practice. Methods Qualitative data collection for n = 42 population-based cohort study participants aged 95101 (88% women, 42% in long-term-care): topic-guided interviews with n = 33 participants and n = 39 proxy informants, most with both (n = 30: 4 jointly + separate interviews for 26 dyads). Results Death was a part of life: these very old people mainly live day-to-day. Most were ready to die, reflecting their concerns regarding quality of life, being a nuisance, having nothing to live for and having lived long enough. Contrasting views were rare exceptions but voiced firmly. Most were not worried about death itself, but concerned more about the dying process and impacts on those left behind; a peaceful and pain-free death was a common ideal. Attitudes ranged from not wanting to think about death, through accepting its inevitable approach to longing for its release. Preferring to be made comfortable rather than have life-saving treatment if seriously ill, and wishing to avoid hospital, were commonly expressed views. There was little or no future planning, some consciously choosing not to. Uncertainty hampered end-of-life planning even when death was expected soon. Some stressed circumstances, such as severe dependency and others' likely decision-making roles, would influence choices. Carers found these issues harder to raise but felt they would know their older relatives' preferences, usually palliative care, although we found two discrepant views. Conclusions This study's rare data show >= 95-year-olds are willing to discuss dying and end-of-life care but seldom do. Formal documentation of wishes is extremely rare and may not be welcome. Although being "ready to die" and preferring a palliative approach predominated, these preferences cannot be assumed.	[Fleming, Jane; Brayne, Carol; Barclay, Stephen] Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge, England; [Fleming, Jane; Farquhar, Morag; Brayne, Carol; Barclay, Stephen; Cambridge City Over-75s Cohort] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Fleming, Jane; Farquhar, Morag; Barclay, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge, England	University of Cambridge; University of Cambridge; University of Cambridge	Fleming, J (corresponding author), Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge, England.; Fleming, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.; Fleming, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge, England.	jane.fleming@phpc.cam.ac.uk	Romero-Ortuno, Roman/AAP-9221-2020; Fleming, Jane/L-5300-2015; Brayne, Carol/AAA-4285-2020; Dening, Tom/E-1335-2013; Farquhar, Morag/C-5666-2015	Romero-Ortuno, Roman/0000-0002-3882-7447; Fleming, Jane/0000-0002-8127-2061; Brayne, Carol/0000-0001-5307-663X; Dening, Tom/0000-0003-3387-4241; Buck, Jackie/0000-0002-3598-2329; Farquhar, Morag/0000-0001-7991-7679	Abbeyfield Society; BUPA Foundation under Health and Care of Older People grant; National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish	Abbeyfield Society; BUPA Foundation under Health and Care of Older People grant; National Institute for Health Research(National Institute for Health Research (NIHR))	The authors thank all the past CC75C sponsors for financial support spanning two decades (see http://www.cc75c.group.cam.ac.uk/pages/grant/default.htm for full list of project grants), particularly the Abbeyfield Society for current funding and the BUPA Foundation for support under their Health and Care of Older People grant. CC75C was a member study of the National Institute for Health Research funded Collaboration for Leadership in Applied Health Research & Care (CLAHRC) for Cambridgeshire and Peterborough. All researchers were independent from funders. No funder sponsor played any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aaltonen M, 2014, J AM MED DIR ASSOC, V15, P643, DOI 10.1016/j.jamda.2014.04.018; Abba K, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-40; Barclay S, 2008, BRIT J GEN PRACT, V58, P229, DOI 10.3399/bjgp08X279724; Barclay S, 2014, BRIT J GEN PRACT, V64, pE576, DOI 10.3399/bjgp14X681397; Barclay S, 2009, BRIT J GEN PRACT, V59, P642, DOI 10.3399/bjgp09X454052; Bravell ME, 2010, PALLIAT SUPPORT CARE, V8, P335, DOI 10.1017/S1478951510000131; BruceJones P, 1996, J MED ETHICS, V22, P154, DOI 10.1136/jme.22.3.154; Carrese JA, 2002, BRIT MED J, V325, P125, DOI 10.1136/bmj.325.7356.125; Caswell G, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0032-0; Chan HYL, 2007, J CLIN NURS, V16, P2158, DOI 10.1111/j.1365-2702.2006.01891.x; Clarke A, 2010, J PAIN SYMPTOM MANAG, V40, P857, DOI 10.1016/j.jpainsymman.2010.02.027; Davidson S, 2013, END LIFE EVIDENCE RE; Davies E, 2004, BETTER PALLIATIVE CA; Dening KH, 2013, PALLIATIVE MED, V27, P409, DOI 10.1177/0269216312464094; Department of Health, 2008, END OF LIF CAR STRAT; Dickinson C, 2013, INT PSYCHOGERIATR, V25, P2011, DOI 10.1017/S1041610213001531; Ditto PH, 2006, MED DECIS MAKING, V26, P313, DOI 10.1177/0272989X06290494; Ditto PH, 2003, HEALTH PSYCHOL, V22, P605, DOI 10.1037/0278-6133.22.6.605; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; Dowling-Castronovo A, 2002, GERONTOLOGIST, V42, P82, DOI 10.1093/geront/42.suppl_3.54; Downey L, 2013, J PAIN SYMPTOM MANAG, V46, P9, DOI 10.1016/j.jpainsymman.2012.07.002; Engelberg RA, 2005, J PAIN SYMPTOM MANAG, V30, P498, DOI 10.1016/j.jpainsymman.2005.06.006; Evans CJ, 2014, BMJ SUPPORT PALLIAT, V4, P111; Fleming J, 2007, INT J EPIDEMIOL, V36, P40, DOI 10.1093/ije/dyl293; Fleming J, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483959; Garavan R, 2009, J AM GERIATR SOC, V57, P750, DOI 10.1111/j.1532-5415.2009.02197.x; Goodman C, 2013, INT J NURS STUD, V50, P1639, DOI 10.1016/j.ijnurstu.2013.06.008; Gott M, 2004, PALLIATIVE MED, V18, P460, DOI 10.1191/0269216304pm889oa; Gott M, 2013, HLTH SERV DELIV RES, V1; Gott M, 2011, BMJ-BRIT MED J, P342; Gouvernement du Quebec, 2014, ACT RESP END LIF CAR; Hallberg IR, 2004, AGING CLIN EXP RES, V16, P87; Hanratty B, 2012, J PAIN SYMPTOM MANAG, V44, P74, DOI 10.1016/j.jpainsymman.2011.08.006; Hunt KJ, 2014, J PALLIAT MED, V17, P176, DOI 10.1089/jpm.2013.0385; Janssen DJA, 2013, J PAIN SYMPTOM MANAG, V46, P826, DOI 10.1016/j.jpainsymman.2013.01.007; Kayser-Jones Jeanie, 2002, Gerontologist, V42 Spec No 3, P11; Klinkenberg M, 2004, SOC SCI MED, V59, P2467, DOI 10.1016/j.socscimed.2004.04.006; Lakasing Edin, 2014, Br J Community Nurs, V19, P130; Leeson G.W, 2014, INT J POPULATION RES, P1, DOI [10.1155/2014/521523, DOI 10.1155/2014/521523]; Lloyd-Williams M, 2007, J PAIN SYMPTOM MANAG, V34, P60, DOI 10.1016/j.jpainsymman.2006.09.028; Mathie E, 2012, PALLIATIVE MED, V26, P734, DOI 10.1177/0269216311412233; Morris ZS, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-89; Nahm ES, 2001, NURS ETHICS, V8, P533; National Palliative and End of Life Care Partnership, 2015, AMB PALL END LIF CAR; Nicholson C, 2012, SOC SCI MED, V75, P1426, DOI 10.1016/j.socscimed.2012.06.011; Oliver D., 2014, MAKING OUR HLTH CARE; Pasman HRW, 2013, J AM GERIATR SOC, V61, P1722, DOI 10.1111/jgs.12450; Perrels AJ, 2014, PALLIATIVE MED, V28, P220, DOI 10.1177/0269216313510341; Petkova H., 2012, UNDERSTANDING PLACE; Piers RD, 2013, PATIENT EDUC COUNS, V90, P323, DOI 10.1016/j.pec.2011.07.008; Rao R, 1997, Int Psychogeriatr, V9, P213, DOI 10.1017/S1041610297004365; Ritchie J, 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081; Seymour J, 2004, SOC SCI MED, V59, P57, DOI 10.1016/j.socscimed.2003.10.005; Seymour J., 2005, END OF LIFE CARE PRO; Seymour JE, 2011, PALLIATIVE MED, V25, P125, DOI 10.1177/0269216310387964; Sharp T, 2013, BRIT J GEN PRACT, V63, pE657, DOI 10.3399/bjgp13X673667; Tanner D., 2012, UNDERSTANDING IMPROV; Towsley GL, 2015, J PALLIATIVE MED, V18; van Eechoud IJ, 2014, J PAIN SYMPTOM MANAG, V47, P876, DOI 10.1016/j.jpainsymman.2013.06.007; van Wijngaarden E, 2015, SOC SCI MED, V138, P257, DOI 10.1016/j.socscimed.2015.05.015	60	55	58	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2016	11	4							e0150686	10.1371/journal.pone.0150686	http://dx.doi.org/10.1371/journal.pone.0150686			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DI6HK	27045734	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000373599600003
J	Martin, RE				Martin, Rainer E.			Going with the flow	SCIENCE			English	Editorial Material							MULTISTEP SYNTHESIS; CHEMISTRY		[Martin, Rainer E.] F Hoffmann La Roche Ltd, Med Chem, Roche Pharmaceut Res & Early Dev PRED, Roche Innovat Ctr Basel, Grenzacherstr 124, CH-4070 Basel, Switzerland	Roche Holding	Martin, RE (corresponding author), F Hoffmann La Roche Ltd, Med Chem, Roche Pharmaceut Res & Early Dev PRED, Roche Innovat Ctr Basel, Grenzacherstr 124, CH-4070 Basel, Switzerland.	rainer_e.martin@roche.com	Martin, Rainer E./AAB-4525-2020	Martin, Rainer E./0000-0001-7895-497X				Adamo A, 2016, SCIENCE, V352, P61, DOI 10.1126/science.aaf1337; Anastas P, 1998, GREEN CHEM THEORY PR; Baxendale IR, 2006, CHEM COMMUN, P2566, DOI 10.1039/b600382f; Hessel V, 2013, CHEMSUSCHEM, V6, P746, DOI 10.1002/cssc.201200766; Hopkin MD, 2010, CHEM COMMUN, V46, P2450, DOI 10.1039/c001550d; Kobayashi S, 2016, CHEM-ASIAN J, V11, P425, DOI 10.1002/asia.201500916; Levesque F, 2012, ANGEW CHEM INT EDIT, V51, P1706, DOI 10.1002/anie.201107446; Malet-Sanz L, 2012, J MED CHEM, V55, P4062, DOI 10.1021/jm2006029; McQuade DT, 2013, J ORG CHEM, V78, P6384, DOI 10.1021/jo400583m; Newton S, 2014, ANGEW CHEM INT EDIT, V53, P4915, DOI 10.1002/anie.201402056; Webb D, 2010, CHEM SCI, V1, P675, DOI 10.1039/c0sc00381f; Wegner J, 2011, CHEM COMMUN, V47, P4583, DOI 10.1039/c0cc05060a; Werner M, 2014, ANGEW CHEM INT EDIT, V53, P1704, DOI 10.1002/anie.201309301; Wiles C, 2009, FUTURE MED CHEM, V1, P1593, DOI 10.4155/FMC.09.132	14	4	4	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2016	352	6281					44	45		10.1126/science.aaf3065	http://dx.doi.org/10.1126/science.aaf3065			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH8JP	27034365				2023-01-03	WOS:000373039600027
J	Gil-Prieto, R; Pascual-Garcia, R; San-Roman-Montero, J; Martinez-Martin, P; Castrodeza-Sanz, J; Gil-de-Miguel, A				Gil-Prieto, Ruth; Pascual-Garcia, Raquel; San-Roman-Montero, Jesus; Martinez-Martin, Pablo; Castrodeza-Sanz, Javier; Gil-de-Miguel, Angel			Measuring the Burden of Hospitalization in Patients with Parkinson's Disease in Spain	PLOS ONE			English	Article							IMPACT; COMORBIDITIES; EPIDEMIOLOGY; ADMISSIONS; MORTALITY; LIFE	Introduction This epidemiological survey estimates the hospitalization burden related to Parkinson's Disease in Spain. Methods This observational retrospective survey was performed by reviewing data from the National Surveillance System for Hospital Data, which includes more than 98% of Spanish hospitals. All hospitalizations of patients with Parkinson's disease that were reported from 1997-2012 were analyzed. Codes were selected using the 9th International Classification of Diseases: ICD-9-CM: 332.0. Results A total of 438,513 hospital discharges of patients with Parkinson's Disease were reported during the study period. The annual hospitalization rate was 64.2 cases per 100,000. The average length of hospital stay was 10 days. The trend for the annual hospitalization rate differed significantly depending on whether Parkinson's disease was the main cause of hospitalization (n = 23,086, 1.14% annual increase) or was not the main cause of hospitalization (n = 415,427, 15.37% annual increase). The overall case-fatality rate among hospitalized patients was 10%. The case fatality rate among patient's hospitalized with Parkinson's disease as the main cause of hospitalization was 2.5%. The hospitalization rate and case-fatality rate significantly increased with age. The primary causes of hospitalization when Parkinson's disease was not coded as the main cause of hospitalization were as follows: respiratory system diseases (24%), circulatory system diseases (19%), injuries and poisoning, including fractures (12%), diseases of the digestive system (10%) and neoplasms (5%). The annual average cost for National Health Care System was (sic) 120 M, with a mean hospitalization cost of (sic)4,378. Conclusions Parkinson's disease poses a significant health threat in Spain, particularly in the elderly. While hospitalizations due to Parkinson's Disease are relatively stable over time, the number of patients presenting with Parkinson's disease as an important comorbidity has increased dramatically. Medical staff must be specifically trained to treat the particular needs of hospitalized patients suffering from Parkinson's disease as an important comorbidity.	[Gil-Prieto, Ruth; Pascual-Garcia, Raquel; Gil-de-Miguel, Angel] Rey Juan Carlos Univ, Area Prevent Med Publ Hlth, Madrid, Spain; [Gil-Prieto, Ruth; Gil-de-Miguel, Angel] Rey Juan Carlos Univ, Catedra Evaluac Resultados Salud, Madrid, Spain; [San-Roman-Montero, Jesus] Rey Juan Carlos Univ, Area Med, Madrid, Spain; [Martinez-Martin, Pablo] Natl Ctr Epidemiol, Madrid, Spain; [Martinez-Martin, Pablo] CIBERNED, Carlos III Inst Hlth, Madrid, Spain; [Castrodeza-Sanz, Javier] Univ Valladolid, Dept Prevent Med Publ Hlth, Valladolid, Spain	Universidad Rey Juan Carlos; Universidad Rey Juan Carlos; Universidad Rey Juan Carlos; CIBERNED; Instituto de Salud Carlos III; Universidad de Valladolid	Gil-Prieto, R (corresponding author), Rey Juan Carlos Univ, Area Prevent Med Publ Hlth, Madrid, Spain.; Gil-Prieto, R (corresponding author), Rey Juan Carlos Univ, Catedra Evaluac Resultados Salud, Madrid, Spain.	ruth.gil@urjc.es	Martinez-Martin, Pablo/N-9909-2019	Martinez-Martin, Pablo/0000-0003-0837-5280; GIL DE MIGUEL, ANGEL/0000-0003-1295-7101	cathedra "Evaluacion de Resultados en Salud; Abbvie	cathedra "Evaluacion de Resultados en Salud; Abbvie(AbbVie)	Funding sources for study: The cathedra "Evaluacion de Resultados en Salud. Rey Juan Carlos University" is sponsored by Abbvie.	Alvaro-Meca A, 2013, CANCER EPIDEMIOL, V37, P91, DOI 10.1016/j.canep.2012.09.001; Aminoff MJ, 2011, PARKINSONISM RELAT D, V17, P139, DOI 10.1016/j.parkreldis.2010.11.009; Barone P, 2009, MOVEMENT DISORD, V24, P1641, DOI 10.1002/mds.22643; Benito-Leon J, 2006, NEUROLOGY, V62, P734; Braga M, 2014, PARKINSONISM RELAT D, V20, P488, DOI 10.1016/j.parkreldis.2014.01.022; Chou KL, 2011, PARKINSONISM RELAT D, V17, P440, DOI 10.1016/j.parkreldis.2011.03.002; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; Diem-Zangerl A, 2009, MOVEMENT DISORD, V24, P819, DOI 10.1002/mds.22414; Dodel RC, 1998, PHARMACOECONOMICS, V14, P299, DOI 10.2165/00019053-199814030-00006; Dorsey ER, 2007, NEUROLOGY, V68, P384, DOI 10.1212/01.wnl.0000247740.47667.03; Gerlach OHH, 2013, PARKINSONISM RELAT D, V19, P737, DOI 10.1016/j.parkreldis.2013.04.017; Gil-Prieto R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000831; Guttman M, 2003, MOVEMENT DISORD, V18, P313, DOI 10.1002/mds.10333; Hassan A, 2013, PARKINSONISM RELAT D, V19, P949, DOI 10.1016/j.parkreldis.2013.06.006; Ishihara LS, 2007, J NEUROL NEUROSUR PS, V78, P1304, DOI 10.1136/jnnp.2006.100107; Leibson CL, 2006, MOVEMENT DISORD, V21, P446, DOI 10.1002/mds.20685; Lindgren P, 2005, EUR J NEUROL, V12, P68, DOI 10.1111/j.1468-1331.2005.01197.x; Low V, 2015, PARKINSONISM RELAT D, V21, P449, DOI 10.1016/j.parkreldis.2015.01.017; Lubomski M, 2015, J NEUROL NEUROSUR PS, V86, P324, DOI 10.1136/jnnp-2014-307822; Romero JP, 2012, TREMOR OTHER HYPERK, V2; Peiro S, 1999, REV NEUROLOGIA, V29, P651, DOI 10.33588/rn.2907.99330; Phillips AR, 2011, AGE AGEING, V40, P294, DOI 10.1093/ageing/afr022; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; Riedel O, 2014, PARKINSONISM RELAT D, V20, P1365, DOI 10.1016/j.parkreldis.2014.09.025; Rivero Cuadrado A., ANALISIS DESARROLLO; Schreyogg Jonas, 2006, Health Care Manag Sci, V9, P215, DOI 10.1007/s10729-006-9040-1; Tejedor-Alonso MA, 2015, ALLERGY, V70, P880, DOI 10.1111/all.12613; Willis AW, 2012, NEUROLOGY, V79, P1774, DOI 10.1212/WNL.0b013e3182703f92; Woodford H, 2005, MOVEMENT DISORD, V20, P1104, DOI 10.1002/mds.20485	29	12	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151563	10.1371/journal.pone.0151563	http://dx.doi.org/10.1371/journal.pone.0151563			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26977930	gold, Green Published, Green Submitted			2023-01-03	WOS:000372572800090
J	Park, MS; Yoon, W; Kim, JT; Choi, KH; Kang, SH; Kim, BC; Lee, SH; Choi, SM; Kim, MK; Lee, JS; Lee, EB; Cho, KH				Park, Man-Seok; Yoon, Woong; Kim, Joon-Tae; Choi, Kang-Ho; Kang, Seung-Ho; Kim, B. Chae; Lee, Seung-Han; Choi, Seong-Min; Kim, Myeong-Kyu; Lee, Ji-Sung; Lee, Eun-Bin; Cho, Ki-Hyun			Drip, Ship, and On-Demand Endovascular Therapy for Acute Ischemic Stroke	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; STENT-RETRIEVER THROMBECTOMY; INTRAVENOUS T-PA; MECHANICAL THROMBECTOMY; INTRAARTERIAL TREATMENT; THROMBOLYTIC THERAPY; RANDOMIZED-TRIAL; MANAGEMENT; ECASS; SAFE	Background The "drip and ship" approach can facilitate an early initiation of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS) at community hospitals. New endovascular treatment modalities, such as stent retrieval, have further improved the rate of safe and successful recanalization. We assessed the clinical outcomes of on-demand endovascular therapy in patients with AIS who were transported to a comprehensive stroke center under the "drip and ship" paradigm. Methods This retrospective study evaluated prospectively registered patients with acute large vessel occlusions in the anterior circulation who underwent endovascular recanalization after IVT at our regional comprehensive stroke center between January 2011 and April 2014. Clinical outcomes and neuroradiological findings were compared between patients who received IVT at the center (direct visit, DV) and at a community hospital (drip and ship, DS). Results Baseline characteristics such as age, initial National Institutes of Health Stroke Scale (NIHSS) score, and risk factors for stroke were similar, and most patients underwent endovascular therapy with a Solitaire stent (81.9% vs. 89.3% for DV and DS, respectively, P = 0.55). The average initial NIHSS score was 12.15 +/- 4.1 (12.06 vs. 12.39 for DV and DS, respectively, P = 0.719). The proportions of long-term favorable outcomes (modified Rankin Scale score <= 2 at 90 days) and successful recanalization (Thrombolysis in Cerebral Ischemia score >= 2b) were not significantly different (P = 0.828 and 0.158, respectively). The mortality rates and occurrences of symptomatic intracerebral hemorrhage were not significantly different (P = 0.999 and 0.267, respectively). Conclusions The "drip and ship" approach with subsequent endovascular therapy is a feasible treatment concept for patients with acute large vessel occlusion in the anterior circulation that could help improve clinical outcomes in patients with AIS.	[Park, Man-Seok; Kim, Joon-Tae; Kang, Seung-Ho; Kim, B. Chae; Lee, Seung-Han; Choi, Seong-Min; Kim, Myeong-Kyu; Lee, Eun-Bin; Cho, Ki-Hyun] Chonnam Natl Univ, Sch Med, Dept Neurol, Gwangju, South Korea; [Yoon, Woong] Chonnam Natl Univ, Dept Radiol, Sch Med, Gwangju, South Korea; [Choi, Kang-Ho] Chonnam Natl Univ, Dept Neurol, Hwasun Hosp, Hwasun, South Korea; [Park, Man-Seok; Yoon, Woong; Kim, Joon-Tae; Choi, Kang-Ho; Kang, Seung-Ho; Kim, Myeong-Kyu; Cho, Ki-Hyun] Chonnam Natl Univ Hosp, Gwangju Jeonnam Reg Cerebrovasc Ctr, Gwangju, South Korea; [Lee, Ji-Sung] Asan Med Ctr, Clin Res Ctr, Seoul, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University Hospital; Samsung; University of Ulsan; Asan Medical Center	Park, MS (corresponding author), Chonnam Natl Univ, Sch Med, Dept Neurol, Gwangju, South Korea.; Park, MS (corresponding author), Chonnam Natl Univ Hosp, Gwangju Jeonnam Reg Cerebrovasc Ctr, Gwangju, South Korea.	mspark@jnu.ac.kr	Yoon, Woong/A-2606-2016	Yoon, Woong/0000-0002-8598-3127; Lee, Seung-Han/0000-0002-4410-646X	Chonnam National University Hospital Biomedical Research Institute [CRI 14037-1]	Chonnam National University Hospital Biomedical Research Institute	This study was supported by grant (CRI 14037-1) from Chonnam National University Hospital Biomedical Research Institute. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold M, 2013, NEW ENGL J MED, V368, P2431, DOI [10.1056/NEJMc1304759, 10.1056/NEJMoa1213701]; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; Ernst R, 2000, STROKE, V31, P2552, DOI 10.1161/01.STR.31.11.2552; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Gratz PP, 2014, STROKE, V45, P152, DOI 10.1161/STROKEAHA.113.002591; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Higashida Randall, 2003, J Vasc Interv Radiol, V14, pS493; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Keris V, 2001, AM J NEURORADIOL, V22, P352; Kim J, 2014, STROKE, V45, P2391, DOI 10.1161/STROKEAHA.114.006134; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Mansoor S, 2013, J STROKE CEREBROVASC, V22, P969, DOI 10.1016/j.jstrokecerebrovasdis.2011.12.010; Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9; Noser EA, 2005, STROKE, V36, P292, DOI 10.1161/01.STR.0000152331.93770.18; Park Man-Seok, 2011, Chonnam Med J, V47, P99, DOI 10.4068/cmj.2011.47.2.99; Qureshi AI, 2012, CEREBROVASC DIS EXTR, V2, P1, DOI 10.1159/000335097; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1; Shaltoni HM, 2007, STROKE, V38, P80, DOI 10.1161/01.STR.0000251720.25337.b0; Silverman Isaac E, 2005, Conn Med, V69, P613; Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115; Tekle WG, 2012, STROKE, V43, P1971, DOI 10.1161/STROKEAHA.112.657817; Yoon YH, 2013, NEURORADIOLOGY, V55, P999, DOI 10.1007/s00234-013-1205-2	27	22	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150668	10.1371/journal.pone.0150668	http://dx.doi.org/10.1371/journal.pone.0150668			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938774	Green Published, gold			2023-01-03	WOS:000371735200130
J	Schultheiss, M; Schnichels, S; Hermann, T; Hurst, J; Feldkaemper, M; Arango-Gonzalez, B; Ueffing, M; Bartz-Schmidt, KU; Zeck, G; Spitzer, MS				Schultheiss, Maximilian; Schnichels, Sven; Hermann, Thoralf; Hurst, Jose; Feldkaemper, Marita; Arango-Gonzalez, Blanca; Ueffing, Marius; Bartz-Schmidt, Karl U.; Zeck, Guenther; Spitzer, Martin S.			Hypothermia Protects and Prolongs the Tolerance Time of Retinal Ganglion Cells against Ischemia	PLOS ONE			English	Article							LOCAL INTRAARTERIAL FIBRINOLYSIS; TISSUE-PLASMINOGEN ACTIVATOR; ARTERY-OCCLUSION; STROKE; RECOVERY; DAMAGE; TRIAL	Purpose Hypothermia has been shown to be neuroprotective in the therapy of ischemic stroke in the brain. To date no studies exist on the level of the inner retina and it is unclear if hypothermia would prolong the ischemic tolerance time of retinal ganglion cells, which are decisive in many ischemic retinopathies. Methods Bovine eyes were enucleated and stored either at 21 degrees C or 37 degrees C for 100 or 340 minutes, respectively. Afterwards the globes were dissected, the retina was prepared and either the spontaneous ganglion cell responses were measured or the retina was incubated as an organotypic culture for additional 24 hours. After incubation the retina was either processed for histology (H& E and DAPI staining) or real-time PCR (Thy-1 expression) was performed. Results Hypothermia prolonged ganglion cell survival up to 340 minutes under ischemic conditions. In contrast to eyes kept at 37 degrees C the eyes stored at 21 degrees C still showed spontaneous ganglion cell spiking (56.8% versus 0%), a 5.8 fold higher Thy-1 mRNA expression (not significant, but a trend) and a preserved retinal structure after 340 minutes of ischemia. Conclusion Hypothermia protects retinal ganglion cells against ischemia and prolongs their ischemic tolerance time.	[Schultheiss, Maximilian; Schnichels, Sven; Hurst, Jose; Bartz-Schmidt, Karl U.; Spitzer, Martin S.] Univ Eye Hosp Tubingen, Ctr Ophthalmol, Tubingen, Germany; [Hermann, Thoralf; Zeck, Guenther] Univ Tubingen, Nat & Med Sci Inst, Reutlingen, Germany; [Feldkaemper, Marita; Arango-Gonzalez, Blanca; Ueffing, Marius] Univ Tubingen, Inst Ophthalm Res, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schnichels, S (corresponding author), Univ Eye Hosp Tubingen, Ctr Ophthalmol, Tubingen, Germany.	sven.schnichels@med.uni-tuebingen.de	Arango-Gonzalez, Blanca/AAR-7427-2021; Zeck, Günther/H-7419-2013	Arango-Gonzalez, Blanca/0000-0002-9045-182X; Zeck, Günther/0000-0003-3998-9883; Hurst, Jose/0000-0002-8697-2569; Feldkaemper, Marita Pauline/0000-0001-6938-3714; Schnichels, Sven/0000-0002-2385-5517				Aldrich EM, 2008, STROKE, V39, P1746, DOI 10.1161/STROKEAHA.107.505404; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Baltmr A, 2010, EXP EYE RES, V91, P554, DOI 10.1016/j.exer.2010.08.009; Beatty S, 2000, BRIT J OPHTHALMOL, V84, P914, DOI 10.1136/bjo.84.8.914; Brandt SK, 2010, NEUROSCIENCE; Chen CS, 2011, STROKE, V42, P2229, DOI 10.1161/STROKEAHA.111.613653; Gumbinger C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3429; Hattenrach LO, 2008, AM J OPHTHALMOL, V146, P700, DOI 10.1016/j.ajo.2008.06.016; Hayreh SS, 2004, EXP EYE RES, V78, P723, DOI 10.1016/S0014-4835(03)00214-8; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nash MS, 1999, INVEST OPHTH VIS SCI, V40, P1293; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Quinones-Hinojosa A, 2003, NEUROSURGERY, V52, P1178, DOI 10.1227/01.NEU.0000057836.64972.A0; Salido EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061656; Schumacher M, 2010, OPHTHALMOLOGY, V117, P1367, DOI 10.1016/j.ophtha.2010.03.061; Stevens WD, 2002, STROKE, V33, P1107, DOI 10.1161/01.STR.0000014204.05597.0C; Stutzki H, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00038; Tamai K, 1997, BRIT J OPHTHALMOL, V81, P789, DOI 10.1136/bjo.81.9.789; Terao Y, 2009, NEUROSCI RES, V64, P75, DOI 10.1016/j.neures.2009.01.017; Wang XD, 2002, NEUROL RES, V24, P730, DOI 10.1179/016164102101200663; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Zeitler R, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3672224	23	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0148616	10.1371/journal.pone.0148616	http://dx.doi.org/10.1371/journal.pone.0148616			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26848953	Green Published, gold, Green Submitted			2023-01-03	WOS:000369554000137
J	Anthenelli, RM; Benowitz, NL; West, R; St Aubin, L; McRae, T; Lawrence, D; Ascher, J; Russ, C; Krishen, A; Evins, AE				Anthenelli, Robert M.; Benowitz, Neal L.; West, Robert; St Aubin, Lisa; McRae, Thomas; Lawrence, David; Ascher, John; Russ, Cristina; Krishen, Alok; Evins, A. Eden			Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial	LANCET			English	Article							SMOKING-CESSATION; ADVERSE EVENTS; RISK; SCHIZOPHRENIA; DEPRESSION; ABSTINENCE; SUICIDE	Background Substantial concerns have been raised about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion. Their efficacy relative to nicotine patch largely relies on indirect comparisons, and there is limited information on safety and efficacy in smokers with psychiatric disorders. We compared the relative neuropsychiatric safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without psychiatric disorders. Methods We did a randomised, double-blind, triple-dummy, placebo-controlled and active-controlled (nicotine patch; 21 mg per day with taper) trial of varenicline (1 mg twice a day) and bupropion (150 mg twice a day) for 12 weeks with 12-week non-treatment follow-up done at 140 centres (clinical trial centres, academic centres, and outpatient clinics) in 16 countries between Nov 30, 2011, and Jan 13, 2015. Participants were motivated-to-quit smokers with and without psychiatric disorders who received brief cessation counselling at each visit. Randomisation was computer generated (1: 1: 1: 1 ratio). Participants, investigators, and research personnel were masked to treatment assignments. The primary endpoint was the incidence of a composite measure of moderate and severe neuropsychiatric adverse events. The main efficacy endpoint was biochemically confirmed continuous abstinence for weeks 9-12. All participants randomly assigned were included in the efficacy analysis and those who received treatment were included in the safety analysis. The trial is registered at ClinicalTrials.gov (number NCT01456936) and is now closed. Findings 8144 participants were randomly assigned, 4116 to the psychiatric cohort (4074 included in the safety analysis) and 4028 to the non-psychiatric cohort (3984 included in the safety analysis). In the non-psychiatric cohort, 13 (1.3%) of 990 participants reported moderate and severe neuropsychiatric adverse events in the varenicline group, 22 (2.2%) of 989 in the bupropion group, 25 (2.5%) of 1006 in the nicotine patch group, and 24 (2.4%) of 999 in the placebo group. The varenicline-placebo and bupropion-placebo risk differences (RDs) for moderate and severe neuropsychiatric adverse events were -1.28 (95% CI -2.40 to -0.15) and -0.08 (-1.37 to 1.21), respectively; the RDs for comparisons with nicotine patch were -1.07 (-2.21 to 0.08) and 0.13 (-1.19 to 1.45), respectively. In the psychiatric cohort, moderate and severe neuropsychiatric adverse events were reported in 67 (6.5%) of 1026 participants in the varenicline group, 68 (6.7%) of 1017 in the bupropion group, 53 (5.2%) of 1016 in the nicotine patch group, and 50 (4.9%) of 1015 in the placebo group. The varenicline-placebo and bupropion-placebo RDs were 1.59 (95% CI -0.42 to 3.59) and 1.78 (-0.24 to 3.81), respectively; the RDs versus nicotine patch were 1.22 (-0.81 to 3.25) and 1.42 (-0.63 to 3.46), respectively. Varenicline-treated participants achieved higher abstinence rates than those on placebo (odds ratio [OR] 3.61, 95% CI 3.07 to 4.24), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75, 1.52 to 2.01). Those on bupropion and nicotine patch achieved higher abstinence rates than those on placebo (OR 2.07 [1.75 to 2.45] and 2.15 [1.82 to 2.54], respectively). Across cohorts, the most frequent adverse events by treatment group were nausea (varenicline, 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]), and headache (placebo, 10% [199 of 2014 participants]). Efficacy treatment comparison did not differ by cohort. Interpretation The study did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo. Varenicline was more effective than placebo, nicotine patch, and bupropion in helping smokers achieve abstinence, whereas bupropion and nicotine patch were more effective than placebo.	[Anthenelli, Robert M.] Univ Calif San Diego, San Diego, CA 92103 USA; [Benowitz, Neal L.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [West, Robert] UCL, London, England; [St Aubin, Lisa; McRae, Thomas; Lawrence, David; Russ, Cristina] Pfizer, New York, NY USA; [Ascher, John] GSK, Res Triangle Pk, NC USA; [Krishen, Alok] GSK, PAREXEL Int, Res Triangle Pk, NC USA; [Evins, A. Eden] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Evins, A. Eden] Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California San Diego; University of California System; University of California San Francisco; University of London; University College London; Pfizer; GlaxoSmithKline; GlaxoSmithKline; Parexel International; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Anthenelli, RM (corresponding author), Univ Calif San Diego, Dept Psychiat, Hlth Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ranthenelli@ucsd.edu	West, Robert/B-5414-2009	West, Robert/0000-0001-6398-0921	Pfizer; Cancer Research UK [14135] Funding Source: researchfish	Pfizer(Pfizer); Cancer Research UK(Cancer Research UK)	We thank the investigators and study site personnel involved in the study. They or their institutions were compensated for their contributions by Pfizer and GlaxoSmithKline. Editorial support (in the form of creating tables and figures, formatting references, collating review comments, and proofing and formatting for submission) was provided by Anne Jakobsen and Abegale Templar (Engage Scientific, Horsham, UK) and funded by Pfizer.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4, DOI [10.1176/appi.books.9780890420249, DOI 10.1176/APPI.BOOKS.9780890420249]; Anthenelli RM, 2013, ANN INTERN MED, V159, P390, DOI 10.7326/0003-4819-159-6-201309170-00005; Baker TB, 2016, JAMA-J AM MED ASSOC, V315, P371, DOI 10.1001/jama.2015.19284; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Cinciripini PM, 2013, JAMA PSYCHIAT, V70, P522, DOI 10.1001/jamapsychiatry.2013.678; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI 10.1001/jama.2013.285113; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Fiore M. C., 2008, TREATING TOBACCO USE; First M.B., 1994, USERS GUIDE SCID 5 P; Freedman R, 2007, AM J PSYCHIAT, V164, P1269, DOI 10.1176/appi.ajp.2007.07020326; Gibbons RD, 2013, AM J PSYCHIAT, V170, P1460, DOI 10.1176/appi.ajp.2013.12121599; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Hughes JR, 2003, NICOTINE TOB RES, V5, P13, DOI 10.1080/1462220031000070552; Institute for Safe Medication Practices, 2014, QUART WATCH MON FDA; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996, GUID GOOD CLIN PRACT; Kotz D, 2015, LANCET RESP MED, V3, P761, DOI 10.1016/S2213-2600(15)00320-3; Molero Y, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2388; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Pasternak B, 2013, ADDICTION, V108, P1336, DOI 10.1111/add.12165; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Smith AL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007301; Thomas KH, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1109; Thomas KH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5704; Tonstad S, 2010, DRUG SAFETY, V33, P289, DOI 10.2165/11319180-000000000-00000; US Food and Drug Administration, 2014, JOINT M PSYCH DRUGS; US Food and Drug Administration, 2009, FDA DRUG SAFETY NEWS, V2; Williams J.B.W., 2002, STRUCTURED CLIN INTE; World Medical Association, 2008, WORLD MED ASS DECL H; Yousefi M. K., 2011, J ADDICT RES THER, pS4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	520	534	5	53	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2016	387	10037					2507	2520		10.1016/S0140-6736(16)30272-0	http://dx.doi.org/10.1016/S0140-6736(16)30272-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO7FG	27116918	Green Submitted, Green Published			2023-01-03	WOS:000377947200028
J	Fazel, S; Wolf, A; Fiminska, Z; Larsson, H				Fazel, Seena; Wolf, Achim; Fiminska, Zuzanna; Larsson, Henrik			Mortality, Rehospitalisation and Violent Crime in Forensic Psychiatric Patients Discharged from Hospital: Rates and Risk Factors	PLOS ONE			English	Article							SEVERE MENTAL-ILLNESS; SUBSTANCE-ABUSE; AFTER-DISCHARGE; PERSONALITY-DISORDERS; PREMATURE MORTALITY; ALL-CAUSE; SCHIZOPHRENIA; OUTCOMES; RECIDIVISM; DIAGNOSIS	Objectives To determine rates and risk factors for adverse outcomes in patients discharged from forensic psychiatric services. Method We conducted a historical cohort study of all 6,520 psychiatric patients discharged from forensic psychiatric hospitals between 1973 and 2009 in Sweden. We calculated hazard ratios for mortality, rehospitalisation, and violent crime using Cox regression to investigate the effect of different psychiatric diagnoses and two comorbidities (personality or substance use disorder) on outcomes. Results Over mean follow-up of 15.6 years, 30% of patients died (n = 1,949) after discharge with an average age at death of 52 years. Over two-thirds were rehospitalised (n = 4,472, 69%), and 40% violently offended after discharge (n = 2,613) with a mean time to violent crime of 4.2 years. The association between psychiatric diagnosis and outcome varied-substance use disorder as a primary diagnosis was associated with highest risk of mortality and rehospitalisation, and personality disorder was linked with the highest risk of violent offending. Furthermore comorbid substance use disorder typically increased risk of adverse outcomes. Conclusion Violent offending, premature mortality and rehospitalisation are prevalent in patients discharged from forensic psychiatric hospitals. Individualised treatment plans for such patients should take into account primary and comorbid psychiatric diagnoses.	[Fazel, Seena; Wolf, Achim; Fiminska, Zuzanna] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	University of Oxford; Karolinska Institutet	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Larsson, Henrik/GYD-5161-2022; Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365	Wellcome Trust [095806]; Swedish Research Council	Wellcome Trust(Wellcome TrustEuropean Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by the Wellcome Trust (095806) (http://www.wellcome.ac.uk/) and the Swedish Research Council (http://www.vr.se/).	Baxter AJ, 2016, BRIT J PSYCHIAT, P115; Belfrage H, 2000, INT J LAW PSYCHIAT, V23, P509, DOI 10.1016/S0160-2527(00)00051-0; Bjorkly S., 2010, INT J FORENSIC MENT, V9, P343, DOI [10.1080/14999013.2010.534698, DOI 10.1080/14999013.2010.534698]; BOGENBERGER RP, 1987, INT J LAW PSYCHIAT, V10, P283, DOI 10.1016/0160-2527(87)90030-6; Bonta J, 2014, AGGRESS VIOLENT BEH, V19, P278, DOI 10.1016/j.avb.2014.04.014; Buchanan A, 1998, BRIT J PSYCHIAT, V172, P472, DOI 10.1192/bjp.172.6.472; Burns T, 2013, LANCET, V381, P1627, DOI 10.1016/S0140-6736(13)60107-5; Chang CK, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-77; Charette Y, 2015, CAN J PSYCHIAT, V60, P127, DOI 10.1177/070674371506000307; Chesney E, 2014, WORLD PSYCHIATRY, V13, P153, DOI 10.1002/wps.20128; Coid J, 1999, BRIT J PSYCHIAT, V175, P528, DOI 10.1192/bjp.175.6.528; Coid J, 2007, BRIT J PSYCHIAT, V190, P223, DOI 10.1192/bjp.bp.105.018788; Coid JW, 2015, INT J LAW PSYCHIAT, V38, P68, DOI 10.1016/j.ijlp.2015.01.009; Davies S, 2007, BRIT J PSYCHIAT, V191, P70, DOI 10.1192/bjp.bp.106.029215; Dixon L, 1999, SCHIZOPHR RES, V35, pS93, DOI 10.1016/S0920-9964(98)00161-3; Durcan G., 2011, PATHWAYS UNLOCKING S; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2016, LANCET PSYCHIAT, V3, P535, DOI 10.1016/S2215-0366(16)00103-6; Fazel S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4692; Fazel S, 2016, BRIT J PSYCHIAT, V208, P17, DOI 10.1192/bjp.bp.114.149997; Fazel S, 2014, LANCET, V384, P1206, DOI 10.1016/S0140-6736(14)60379-2; Fazel S, 2014, LANCET PSYCHIAT, V1, P44, DOI 10.1016/S2215-0366(14)70223-8; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Fleischman A, 2014, PSYCHOL MED, V44, P3051, DOI 10.1017/S0033291714000695; Fok MLY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100979; Frances A, 2013, WORLD PSYCHIATRY, V12, P111, DOI 10.1002/wps.20027; Grann M, 2004, BRIT MED J, V328, P1233, DOI 10.1136/bmj.328.7450.1233; Grann M, 1999, LAW HUMAN BEHAV, V23, P205, DOI 10.1023/A:1022372902241; Grann M, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-92; Harlow BL, 2007, ARCH GEN PSYCHIAT, V64, P42, DOI 10.1001/archpsyc.64.1.42; Health and Social Care Information Centre, 2011, MENT HLTH B; HOFFMANN H, 1994, ACTA PSYCHIAT SCAND, V89, P205, DOI 10.1111/j.1600-0447.1994.tb08093.x; Iozzino L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128536; Jacobs P., 2014, CRIMINAL JUSTICE FOR; JAMIESON L, 2005, INT J FORENSIC MENT, V4, P71, DOI DOI 10.1080/14999013.2005.10471214; Kelly TM, 2012, ADDICT BEHAV, V37, P11, DOI 10.1016/j.addbeh.2011.09.010; Korkeila JA, 1998, SOC PSYCH PSYCH EPID, V33, P528, DOI 10.1007/s001270050090; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lund C, 2013, INT J LAW PSYCHIAT; Maden A, 2004, BRIT MED J, V328, P1534, DOI 10.1136/bmj.38075.467569.EE; Miller, 2008, PSYCHOL SERV, V5, P118, DOI [10.1037/1541-1559.5.2.118, DOI 10.1037/1541-1559.5.2.118]; Moore S, 2015, ACTA PSYCHIAT SCAND, V132, P109, DOI 10.1111/acps.12431; Moran P, 2003, BRIT J PSYCHIAT, V182, P129, DOI 10.1192/bjp.182.2.129; National Institute for Health and Care Excellence, PSYCH SCHIZ AD TREAT; Nemeroff CB, 2013, BMC MED, V11, DOI [10.1186/1741-7015-11-202, 10.1186/1741-7015-11-132]; Nilsson T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025768; Nordentoft M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055176; Nyhlen A, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-122; Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; Priebe S, 2008, PSYCHIAT SERV, V59, P570, DOI 10.1176/ps.2008.59.5.570; Sellgren C, 2011, ACTA PSYCHIAT SCAND, V124, P447, DOI 10.1111/j.1600-0447.2011.01747.x; Short T, 2013, ACTA PSYCHIAT SCAND, V128, P306, DOI 10.1111/acps.12066; Singh JP, 2014, BRIT J PSYCHIAT, V204, P180, DOI 10.1192/bjp.bp.113.131938; Singh JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072484; Skipworth J, 2006, AUST NZ J PSYCHIAT, V40, P1003, DOI 10.1080/j.1440-1614.2006.01924.x; Svennerlind C, 2010, INT J LAW PSYCHIAT, V33, P220, DOI 10.1016/j.ijlp.2010.06.003; Swartz MS, 1998, AM J PSYCHIAT, V155, P226; Tabita B, 2012, NORD J PSYCHIAT, V66, P283, DOI 10.3109/08039488.2011.644578; THORNICROFT G, 1992, BRIT MED J, V305, P996, DOI 10.1136/bmj.305.6860.996; Thornicroft G, 2014, WORLD PSYCHIATRY, V13, P118, DOI 10.1002/wps.20114; Tosh G, 2014, COCHRANE DATABASE SY, V3; Wilson S, 2011, LANCET, V378, P110, DOI 10.1016/S0140-6736(10)62268-4; Witt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055942; Yu RQ, 2012, J PERS DISORD, V26, P775, DOI 10.1521/pedi.2012.26.5.775	67	26	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155906	10.1371/journal.pone.0155906	http://dx.doi.org/10.1371/journal.pone.0155906			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DM4BR	27196309	Green Submitted, gold, Green Published			2023-01-03	WOS:000376291100130
J	Lin, QQ; Li, Z; Wei, R; Lei, QF; Liu, YY; Cai, XD				Lin, Qianqian; Li, Zhong; Wei, Rui; Lei, Qingfeng; Liu, Yunyun; Cai, Xiaodong			Increased Risk of Post-Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke Patients with Leukoaraiosis: A Meta-Analysis	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; BLOOD-BRAIN-BARRIER; WHITE-MATTER LESIONS; CEREBRAL MICROBLEEDS; ANTIPLATELET THERAPY; POOLED ANALYSIS; ASSOCIATION; AGE; RECURRENCE	Background Leukoaraiosis is common in patients with acute ischemic stroke. The results from many studies investigating the association between leukoaraiosis and intracranial hemorrhage after thrombolysis remain conflicting. Methods A meta-analysis was performed to compare the risk of post-thrombolytic intracranial hemorrhage in patients with and without leukoaraiosis. Relevant reports were identified by searching PubMed, EmBase, Cochrane Library, and ISI Web of Science through December 2015 using a combination of subjective and random terms. Eligible studies that were original articles with a clear definition of leukoaraiosis and intracranial hemorrhage were selected and analyzed. Funnel plots, Egger's test, and Begg's test were conducted to assess the publication bias. Sensitivity analysis was also performed to evaluate the influence of each individual study. Results Eleven trials that enrolled 6912 participants were included. There was a significantly increased risk for acute ischemic stroke patients with leukoaraiosis (odds ratio: 1.89, 95% confidence interval 1.51-2.37, P< 0.001). Low heterogeneity and less publication bias was detected among these studies. The results of both computed tomography and magnetic resonance imaging performed on the subgroups of leukoaraiosis were significant. Furthermore, an association between leukoaraiosis and symptomatic intracranial hemorrhage was also confirmed. The odds ratios remained stable with no obvious variations on the sensitivity analysis. The limitations consisted of types of including trials and not matching some baseline variables. Conclusions The results of this meta-analysis show that leukoaraiosis approximately doubles the incidence of intracranial hemorrhage after thrombolytic therapy. However, it does not critically affect decision making regarding thrombolysis for patients with acute ischemic stroke. Additional investigations are required.	[Lin, Qianqian; Li, Zhong; Wei, Rui; Lei, Qingfeng; Liu, Yunyun; Cai, Xiaodong] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Li, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.	lzhong@mail.sysu.edu.cn			Natural Science Foundation of Guangdong Province, China [2015A030313128, 2014A030307025]; Key Science and Technology Project of Guangzhou Tianhe District, China [201404KW028]; Science and Technology Project of Shenzhen City, China [JCYJ20150403151851068]	Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Key Science and Technology Project of Guangzhou Tianhe District, China; Science and Technology Project of Shenzhen City, China	Support was provided by the Natural Science Foundation of Guangdong Province, China (No: 2015A030313128) to ZL [http://www.gdstc.gov.cn/]; The Natural Science Foundation of Guangdong Province, China (No: 2014A030307025) to ZL [http://www.gdstc.gov.cn/]; The Key Science and Technology Project of Guangzhou Tianhe District, China (No: 201404KW028) to ZL [http://www.thst.gov.cn/]; The Science and Technology Project of Shenzhen City, China (No: JCYJ20150403151851068) to ZL [http://www.szsti.gov.cn/services/plan/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alemany M, 2006, RADIOLOGY, V238, P240, DOI 10.1148/radiol.2381040551; Alshekhlee A, 2010, STROKE, V41, P2259, DOI 10.1161/STROKEAHA.110.588632; Aries MJH, 2010, EUR J NEUROL, V17, P866, DOI 10.1111/j.1468-1331.2010.02963.x; AWAD IA, 1986, STROKE, V17, P1084, DOI 10.1161/01.STR.17.6.1084; Bejot Y, 2016, REV NEUROL-FRANCE, V172, P59, DOI 10.1016/j.neurol.2015.07.013; Bernbaum M, 2015, J CEREBR BLOOD F MET, V35, P1610, DOI 10.1038/jcbfm.2015.92; Bridges LR, 2014, J NEUROPATH EXP NEUR, V73, P1026, DOI 10.1097/NEN.0000000000000124; Charidimou A, 2015, NEUROLOGY, V85, P927, DOI 10.1212/WNL.0000000000001923; Choi JH, 2011, J KOREAN NEUROSURG S, V50, P75, DOI 10.3340/jkns.2011.50.2.75; Costello CA, 2012, J CLIN NEUROSCI, V19, P360, DOI 10.1016/j.jocn.2011.08.014; Curtze S, 2015, STROKE, V46, P1554, DOI 10.1161/STROKEAHA.115.008941; Demchuk AM, 2008, CEREBROVASC DIS, V26, P120, DOI 10.1159/000139658; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; Fiehler J, 2007, STROKE, V38, P2738, DOI 10.1161/STROKEAHA.106.480848; Fiehler J, 2009, J NEUROIMAGING, V19, P311, DOI 10.1111/j.1552-6569.2008.00240.x; Gorner A, 2007, J NEUROL, V254, P284, DOI 10.1007/s00415-006-0311-z; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Gottesman RF, 2010, STROKE, V41, P3, DOI 10.1161/STROKEAHA.109.566992; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; Hacke W, 2004, LANCET, V363, P768; Henninger N, 2012, CEREBROVASC DIS, V33, P525, DOI 10.1159/000337335; Jokinen H, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00455; Kapeller P, 2003, STROKE, V34, P441, DOI 10.1161/01.STR.0000049766.26453.E9; Kato H, 2002, STROKE, V33, P1536, DOI 10.1161/01.STR.0000018012.65108.86; Kumral E, 2015, J STROKE CEREBROVASC, V24, P573, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.002; Lansberg MG, 2007, STROKE, V38, P2275, DOI 10.1161/STROKEAHA.106.480475; Lucatelli P, 2015, J NEURORADIOLOGY, DOI [10.1016/j.neufad.2015.11.003, DOI 10.1016/J.NEUFAD.2015.11.003]; McAlpine H, 2014, J STROKE CEREBROVASC, V23, P2431, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.012; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581; Neumann-Haefelin T, 2006, STROKE, V37, P2463, DOI 10.1161/01.STR.0000239321.53203.ea; Ntaios G, 2015, NEUROLOGY, V84, P1213, DOI 10.1212/WNL.0000000000001402; Palumbo V, 2007, NEUROLOGY, V68, P1020, DOI 10.1212/01.wnl.0000257817.29883.48; Peng B, 2013, CHINESE MED J-PEKING, V126, P3403, DOI 10.3760/cma.j.issn.0366-6999.20131822; Pluta R, 2008, ACT NEUR S, V102, P353, DOI 10.1007/978-3-211-85578-2_67; Schulz UG, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000261; Smith EE, 2002, NEUROLOGY, V59, P193, DOI 10.1212/WNL.59.2.193; Strbian D, 2011, Neurology, V77, P341, DOI 10.1212/WNL.0b013e3182267b8c; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tamura Y, 2015, GERIATR GERONTOL INT, V15, P34, DOI 10.1111/ggi.12666; Tanne D, 2002, CIRCULATION, V105, P1679, DOI 10.1161/01.CIR.0000012747.53592.6A; Uyttenboogaart M, 2008, ARCH NEUROL-CHICAGO, V65, P607, DOI 10.1001/archneur.65.5.noc70077; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; von Kummer R, 2002, STROKE, V33, P1446, DOI 10.1161/01.STR.0000016923.99605.75; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Wang DN, 2015, J STROKE CEREBROVASC, V24, P2728, DOI 10.1016/j.jstrokecerebrovasdis.2015.08.003; Wardlaw JM, 2015, LANCET NEUROL, V14, P485, DOI 10.1016/S1474-4422(15)00012-5; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331; Willer L, 2015, J STROKE CEREBROVASC, V24, P1126, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.018; Yadav BK, 2014, J STROKE CEREBROVASC, V23, P1199, DOI 10.1016/j.jstrokecerebrovasdis.2013.10.017; Yadav BK, 2015, J STROKE CEREBROVASC, V24, P1662, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.038; Yaghi S, 2015, JAMA NEUROL, V72, P1451, DOI 10.1001/jamaneurol.2015.2371; Zheng TH, 2012, CHIN J CEREBROVASC D, V9; Zupan M, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0416-z	56	18	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2016	11	4							e0153486	10.1371/journal.pone.0153486	http://dx.doi.org/10.1371/journal.pone.0153486			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9OU	27096292	gold, Green Submitted, Green Published			2023-01-03	WOS:000374543600039
J	Cleary, JF; Husain, A; Maurer, M				Cleary, James F.; Husain, Asra; Maurer, Martha			Increasing worldwide access to medical opioids	LANCET			English	Editorial Material							CANCER PAIN RELIEF; POLICY		[Cleary, James F.; Husain, Asra; Maurer, Martha] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Pain & Policy Studies Grp, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Cleary, JF (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Pain & Policy Studies Grp, Madison, WI 53792 USA.	jfcleary@wisc.edu						[Anonymous], 1977, WHO TECH REP SER, V615, P1; Berterame S., 2016, LANCET; Blengini C, 2003, EUR J CANCER CARE, V12, P28, DOI 10.1046/j.1365-2354.2003.00325.x; Centers for Disease Control and Prevention, 2012, PRESCR PAINK OV; Cleary J, 2013, ANN ONCOL, V24, P24, DOI 10.1093/annonc/mdt500; Cleary JF, 2010, PALLIATIVE MED, V24, P109, DOI 10.1177/0269216309360103; European Society for Medical Oncology, GLOB OP POL IN; Gilson AM, 2013, PALLIATIVE MED, V27, P105, DOI 10.1177/0269216312461973; Hastie Barbara A, 2014, J Pain Palliat Care Pharmacother, V28, P259, DOI 10.3109/15360288.2014.941132; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Milani B., 2011, WORLD MED SITUATION; World Health Organization, 2011, ENS BAL NAT POL CONT	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2016	387	10028					1597	1599	1644	10.1016/S0140-6736(16)00234-8	http://dx.doi.org/10.1016/S0140-6736(16)00234-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DJ3ZL	26852263				2023-01-03	WOS:000374145100007
J	Li, YL; Zhang, JL; Min, D; Zhou, HY; Lin, N; Li, QS				Li, Yun-lan; Zhang, Jiali; Min, Dong; Zhou Hongyan; Lin, Niu; Li, Qing-shan			Anticancer Effects of 1,3-Dihydroxy-2-Methylanthraquinone and the Ethyl Acetate Fraction of Hedyotis Diffusa Willd against HepG2 Carcinoma Cells Mediated via Apoptosis	PLOS ONE			English	Article							BCL-2 FAMILY-MEMBERS; CYTOCHROME-C; CANCER; ANTHRAQUINONES; RUBIADIN; PATHWAY; ARREST; P53	Hedyotis Diffusa Willd, used in Traditional Chinese Medicine, is a treatment for various diseases including cancer, owing to its mild effectiveness and low toxicity. The aim of this study was to identify the main anticancer components in Hedyotis Diffusa Willd, and explore mechanisms underlying their activity. Hedyotis Diffusa Willd was extracted and fractionated using ethyl acetate to obtain the H-Ethyl acetate fraction, which showed higher anticancer activity than the other fractions obtained against HepG2 cells with sulforhodamine B assays. The active component of the H-Ethyl acetate fraction was identified to be 1,3-dihydroxy-2-methy-lanthraquinone (DMQ) with much high inhibitory rate up to 48.9 +/- 3.3% and selectivity rate up to 9.4 +/- 4.5 folds (p<0.01) at 125 mu mol/L. HepG2 cells treated with the fraction and DMQ visualized morphologically using light and fluorescence microscopy. Annexin V-fluorescein isothiocyanate / propidium iodide staining flow cytometry, DNA ladder and cell cycle distribution assays. Mechanistic studies showed up-regulation of caspase-3, -8, and -9 proteases activities (p<0.001), indicating involvement of mitochondrial apoptotic and death receptor pathways. Further studies revealed that reactive oxygen species in DMQ and the fraction treated HepG2 cells increased (p<0.01) while mitochondrial membrane potential reduced significantly (p<0.001) compared to the control by flow cytometry assays. Western blot analysis showed that Bax, p53, Fas, FasL, p21 and cytoplasmic cytochrome C were up-regulated (p<0.01), while Bcl-2, mitochondrial cytochrome C, cyclin E and CDK 2 were down-regulated dose-dependently (p<0.01). The reverse transcriptase-polymerase chain reaction showed that mRNA expressions of p53 and Bax increased (p<0.001) while that of Bcl-2 decreased (p<0.001). Pre-treatment with caspase-8 inhibitor Z-IETD-FMK, or caspase-9 inhibitor Z-LEHD-FMK, attenuated the growth-inhibitory and apoptosis-inducing effects of DMQ and the fraction on HepG2 cells. These results suggested that DMQ and the H-Ethyl acetate fraction of Hedyotis Diffusa Willd showed potential anticancer effects. Furthermore, the mechanisms of action may involve mitochondrial apoptotic and death receptor pathways.	[Li, Yun-lan; Zhang, Jiali; Min, Dong; Zhou Hongyan; Lin, Niu; Li, Qing-shan] Shanxi Med Univ, Sch Pharmaceut Sci, Taiyuan 030001, Peoples R China	Shanxi Medical University	Li, YL; Li, QS (corresponding author), Shanxi Med Univ, Sch Pharmaceut Sci, Taiyuan 030001, Peoples R China.	liyunlanrr@163.com; sxlqs2012@163.com			Natural Science Foundation of Shanxi Province [2014011027-1]; Program for Science and Technology of Shanxi Province [20130313021-9]; Top Science and Technology Innovation Teams of Higher Learning Institutions of Shanxi Province; Program for the Top Young and Middle-aged Innovative Talents of Higher Learning Institutions of Shanxi Province; Foundation of Young Academic Leader in Shanxi Province; Shanxi Province Returnees Preferred Project; Education Reform and Research Project of the colleges and universities of Shanxi Province; Program for the Natural Science Foundation of Shanxi Province [2014011027-1]	Natural Science Foundation of Shanxi Province(Natural Science Foundation of Shanxi Province); Program for Science and Technology of Shanxi Province; Top Science and Technology Innovation Teams of Higher Learning Institutions of Shanxi Province; Program for the Top Young and Middle-aged Innovative Talents of Higher Learning Institutions of Shanxi Province; Foundation of Young Academic Leader in Shanxi Province; Shanxi Province Returnees Preferred Project; Education Reform and Research Project of the colleges and universities of Shanxi Province; Program for the Natural Science Foundation of Shanxi Province	This research was supported by the Natural Science Foundation of Shanxi Province (No. 2014011027-1), Program for Science and Technology of Shanxi Province (No. 20130313021-9), the Top Science and Technology Innovation Teams of Higher Learning Institutions of Shanxi Province, the Program for the Top Young and Middle-aged Innovative Talents of Higher Learning Institutions of Shanxi Province (2015), Foundation of Young Academic Leader in Shanxi Province, Shanxi Province Returnees Preferred Project in 2012, Education Reform and Research Project of the colleges and universities of Shanxi Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Financial supports form Program for the Natural Science Foundation of Shanxi Province (No. 2014011027-1), Program for Science and Technology of Shanxi Province (No. 20130313021-9), the Top Science and Technology Innovation Teams of Higher Learning Institutions of Shanxi Province, the Program for the Top Young and Middle-aged Innovative Talents of Higher Learning Institutions of Shanxi Province (2015), Foundation of Young Academic Leader in Shanxi Province, Shanxi Province Returnees Preferred Project in 2012, Education Reform and Research Project of the colleges and universities of Shanxi Province are gratefully acknowledged.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bouillet P, 2002, J CELL SCI, V115, P1567; Cillessen SAGM, 2010, J PATHOL, V220, P509, DOI 10.1002/path.2670; Comini LR, 2011, PHYTOMEDICINE, V18, P1093, DOI 10.1016/j.phymed.2011.05.008; Ekert PG, 2005, CURR OPIN CELL BIOL, V17, P626, DOI 10.1016/j.ceb.2005.09.001; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Harry A Rogoff, 2004, CELL CYCLE, V3, P845; Huang Wei-Hua, 2008, Zhongguo Zhong Yao Za Zhi, V33, P524; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Ju SM, 2015, PHARM BIOL, V53, P1002, DOI 10.3109/13880209.2014.952834; Kanokmedhakul K, 2005, J ETHNOPHARMACOL, V100, P284, DOI 10.1016/j.jep.2005.03.018; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuo YJ, 2015, IN VIVO, V29, P453; Ledgerwood EC, 2009, CLIN CANCER RES, V15, P420, DOI 10.1158/1078-0432.CCR-08-1172; Newton HB, 2005, EXPERT REV ANTICANC, V5, P355, DOI 10.1586/14737140.5.2.355; Niu Y, 2013, J ASIAN NAT PROD RES, V15, P550, DOI 10.1080/10286020.2013.781589; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Rao GMM, 2006, J ETHNOPHARMACOL, V103, P484, DOI 10.1016/j.jep.2005.08.073; Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-12; Vittar NBR, 2014, PHOTODIAGN PHOTODYN, V11, P182, DOI 10.1016/j.pdpdt.2014.02.002; Sayers TJ, 2011, CANCER IMMUNOL IMMUN, V60, P1173, DOI 10.1007/s00262-011-1008-4; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Tripathi YB, 1997, INDIAN J BIOCHEM BIO, V34, P302; Trivedi R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.429; Weyhenmeyer B., 2012, Experimental Oncology, V34, P192; Zhao J, 2012, CANCER LETT, V314, P8, DOI 10.1016/j.canlet.2011.09.040; Zheng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118276	28	28	28	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2016	11	4							e0151502	10.1371/journal.pone.0151502	http://dx.doi.org/10.1371/journal.pone.0151502			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ0KH	27064569	Green Published, gold, Green Submitted			2023-01-03	WOS:000373891000004
J	Doucette, A; Jiang, XH; Fryzek, J; Coalson, J; McLaurin, K; Ambrose, CS				Doucette, Abigail; Jiang, Xiaohui; Fryzek, Jon; Coalson, Jenna; McLaurin, Kimmie; Ambrose, Christopher S.			Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012	PLOS ONE			English	Article							DOWN-SYNDROME; PALIVIZUMAB PROPHYLAXIS; YOUNG-CHILDREN; PREVENTION; INFECTION; DISEASE; OUTCOMES; BURDEN; EPIDEMIOLOGY; EXPERIENCE	Background Respiratory syncytial virus (RSV) causes significant pediatric morbidity and is the most common cause of bronchiolitis. Bronchiolitis hospitalizations declined among US infants from 2000. 2009; however, rates in infants at high risk for RSV have not been described. This study examined RSV and unspecified bronchiolitis (UB) hospitalization rates from 1997. 2012 among US high-risk infants. Methods The Kids' Inpatient Database (KID) infant annual RSV (ICD-9 079.6, 466.11, 480.1) and UB (ICD-9 466.19, 466.1) hospitalization rates were estimated using weighted counts. Denominators were based on birth hospitalizations with conditions associated with high-risk for RSV: chronic perinatal respiratory disease (chronic lung disease [CLD]); congenital airway anomalies (CAA); congenital heart disease (CHD); Down syndrome (DS); and other genetic, metabolic, musculoskeletal, and immunodeficiency conditions. Preterm infants could not be identified. Hospitalizations were characterized by mechanical ventilation, inpatient mortality, length of stay, and total cost (2015$). Poisson and linear regression were used to test statistical significance of trends. Results RSV and UB hospitalization rates were substantially elevated for infants with higher-risk CHD, CLD, CAA and DS without CHD compared with all infants. RSV rates declined by 47.0% in CLD and 49.7% in higher-risk CHD infants; no other declines in high-risk groups were observed. UB rates increased in all high-risk groups except for a 22.5% decrease among higher-risk CHD. Among high-risk infants, mechanical ventilation increased through 2012 to 20.4% and 13.5% of RSV and UB hospitalizations; geometric mean cost increased to $31,742 and $25,962, respectively, and RSV mortality declined to 0.9%. Conclusions Among high-risk infants between 1997 and 2012, RSV hospitalization rates declined among CLD and higher-risk CHD infants, coincident with widespread RSV immunoprophylaxis use in these populations. UB hospitalization rates increased in all high-risk groups except higher-risk CHD, suggesting improvement in the health status of higher-risk CHD infants, potentially due to enhanced surgical interventions. Mechanical ventilation use and RSV and UB hospitalization costs increased while RSV mortality declined.	[Doucette, Abigail; Jiang, Xiaohui; Fryzek, Jon; Coalson, Jenna] Epidstat, Ann Arbor, MI USA; [McLaurin, Kimmie; Ambrose, Christopher S.] AstraZeneca, Gaithersburg, MD USA	AstraZeneca	Ambrose, CS (corresponding author), AstraZeneca, Gaithersburg, MD USA.	AmbroseC@MedImmune.com	Coalson, Jenna/AAD-6653-2020	Coalson, Jenna/0000-0002-8591-5642; Ambrose, Christopher/0000-0003-4175-7336	AstraZeneca; Epidstat	AstraZeneca(AstraZeneca); Epidstat	This research was funded by AstraZeneca. Employees of AstraZeneca (KM, CSA) were involved in the study design, decision to publish, and preparation of the manuscript. The funder provided support in the form of salaries for authors (KM, CSA), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. AstraZeneca provided Epidstat with research support for this study. Employees of Epidstat were involved in the study design (JF), data analysis (AD, XJ, JC), and preparation of the manuscript (AD, XJ, JF, JC). Epidstat provided support in the form of salaries for authors (AD, XJ, JF, JC), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Editorial assistance was provided by Complete Healthcare Communications, LLC (Chadds Ford, PA, USA) and funded by AstraZeneca.	Abramson JS, 2003, PEDIATRICS, V112, P1442; Arnold SR, 1999, PEDIATR INFECT DIS J, V18, P866, DOI 10.1097/00006454-199910000-00006; Bloemers BLP, 2007, PEDIATRICS, V120, pE1076, DOI 10.1542/peds.2007-0788; Centers for Disease Control and Prevention, RSV INFECTION AND IN; Checchia PA, 2011, PEDIATR CRIT CARE ME, V12, P580, DOI 10.1097/PCC.0b013e3182070990; Cohen SA, 2008, PEDIATR CARDIOL, V29, P382, DOI 10.1007/s00246-007-9039-5; Counihan ME, 2001, PEDIATR INFECT DIS J, V20, P646, DOI 10.1097/00006454-200107000-00003; Erikssen G, 2015, CIRCULATION, V131, P337, DOI 10.1161/CIRCULATIONAHA.114.012033; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Frogel M, 2008, J PERINATOL, V28, P511, DOI 10.1038/jp.2008.28; Groothuis Jessie R, 2011, Clin Epidemiol, V3, P245, DOI 10.2147/CLEP.S17189; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48; Iwane MK, 2013, J INFECT DIS, V208, pS165, DOI 10.1093/infdis/jit484; Langley GF, 2011, PEDIATR INFECT DIS J, V30, P510, DOI 10.1097/INF.0b013e3182184ae7; Makari D, 2015, CLIN PEDIATR, V54, P594, DOI 10.1177/0009922814546040; Mitchell I, 2006, PEDIATR PULM, V41, P1167, DOI 10.1002/ppul.20507; Mori M, 2014, J INFECT CHEMOTHER, V20, P455, DOI 10.1016/j.jiac.2014.05.001; Mullins JA, 2003, PEDIATR INFECT DIS J, V22, P857, DOI 10.1097/01.inf.0000090921.21313.d3; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Parnes C, 2003, PEDIATR PULM, V35, P484, DOI 10.1002/ppul.10288; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Romero JR, 2003, PEDIATR INFECT DIS J, V22, pS46, DOI 10.1097/00006454-200302001-00007; Sample NNI, AGENCY HEALTHCARE RE; Simoes EAF, 2002, RESP RES, V3, DOI 10.1186/rr187; Sorrentino M, 2000, PEDIATR INFECT DIS J, V19, P1068, DOI 10.1097/00006454-200011000-00007; Stagliano DR, 2015, J PEDIATR-US, V166, P703, DOI 10.1016/j.jpeds.2014.11.058; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; van der Bom T, 2011, NAT REV CARDIOL, V8, P50, DOI 10.1038/nrcardio.2010.166; Wonder C, NATALITY 2003 2006; Wonder C, 2007, NATALITY 2007 2013; Wonder C., NATALITY 1995 2002; Yi H, 2014, PEDIATRICS, V133, P1031, DOI 10.1542/peds.2013-3916; Zachariah P, 2012, J PEDIATR-US, V160, P827, DOI 10.1016/j.jpeds.2011.11.004; Zachariah P, 2011, PEDIATR INFECT DIS J, V30, P442, DOI 10.1097/INF.0b013e318201813b	39	51	52	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2016	11	4							e0152208	10.1371/journal.pone.0152208	http://dx.doi.org/10.1371/journal.pone.0152208			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6IX	27050095	gold, Green Published, Green Submitted			2023-01-03	WOS:000373603500030
J	Murdoch, K; Buckley, JD; McDonnell, MN				Murdoch, Kate; Buckley, Jonathan D.; McDonnell, Michelle N.			The Effect of Aerobic Exercise on Neuroplasticity within the Motor Cortex following Stroke	PLOS ONE			English	Article							THETA-BURST STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; PHYSICAL-ACTIVITY QUESTIONNAIRE; PAIRED ASSOCIATIVE STIMULATION; COGNITIVE FUNCTION; RESISTANCE EXERCISE; SINGLE BOUT; PLASTICITY; BRAIN; REHABILITATION	Background Aerobic exercise is associated with enhanced plasticity in the motor cortex of healthy individuals, but the effect of aerobic exercise on neuroplasticity following a stroke is unknown. Objective The aim of this study was to compare corticomotoneuronal excitability and neuroplasticity in the upper limb cortical representation following a single session of low intensity lower limb cycling, or a rest control condition. Methods We recruited chronic stroke survivors to take part in three experimental conditions in a randomised, cross-over design. Corticomotoneuronal excitability was examined using transcranial magnetic stimulation to elicit motor evoked potentials in the affected first dorsal interosseus muscle. Following baseline measures, participants either cycled on a stationary bike at a low exercise intensity for 30 minutes, or remained resting in a seated position for 30 minutes. Neuroplasticity within the motor cortex was then examined using an intermittent theta burst stimulation (iTBS) paradigm. During the third experimental condition, participants cycled for the 30 minutes but did not receive any iTBS. Results Twelve participants completed the study. We found no significant effect of aerobic exercise on corticomotoneuronal excitability when compared to the no exercise condition (P > 0.05 for all group and time comparisons). The use of iTBS did not induce a neuroplastic-like response in the motor cortex with or without the addition of aerobic exercise. Conclusions Our results suggest that following a stroke, the brain may be less responsive to non-invasive brain stimulation paradigms that aim to induce short-term reorganisation, and aerobic exercise was unable to induce or improve this response.	[Murdoch, Kate; McDonnell, Michelle N.] Univ S Australia, Int Ctr Allied Hlth Evidence, Sansom Inst Hlth Res, Sch Hlth Sci, Adelaide, SA 5001, Australia; [Buckley, Jonathan D.] Univ S Australia, ARENA, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia	University of South Australia; University of South Australia	McDonnell, MN (corresponding author), Univ S Australia, Int Ctr Allied Hlth Evidence, Sansom Inst Hlth Res, Sch Hlth Sci, Adelaide, SA 5001, Australia.	michelle.mcdonnell@unisa.edu.au	McDonnell, Michelle Nadine/B-9712-2009	McDonnell, Michelle Nadine/0000-0003-4445-0647; Buckley, Jonathan/0000-0003-0298-2186	Brain Foundation of Australia; National Stroke Foundation; National Health and Medical Research Council Research Training Fellowship [570133]	Brain Foundation of Australia; National Stroke Foundation; National Health and Medical Research Council Research Training Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by a Brain Foundation of Australia Research Grant (MM), http://brainfoundation.org.au/research, and a National Stroke Foundation Honours Research Grant (KM), https://strokefoundation.com.au/what-we-do/research/research-grants. MM was supported by a National Health and Medical Research Council Research Training Fellowship, ID 570133, http://www.nhmrc.gov.au/grants-funding/apply-funding/early-career-fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerley SJ, 2016, NEUROREHAB NEURAL RE, V30, P339, DOI 10.1177/1545968315595285; AIHW, 2013, STROK ITS MAN AUSTR; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; BOLTON CF, 1981, J NEUROL NEUROSUR PS, V44, P407, DOI 10.1136/jnnp.44.5.407; Borg G., 1998, BORGS PERCEIVED EXER; Butefisch CM, 2008, NEUROREHAB NEURAL RE, V22, P4, DOI 10.1177/1545968307301769; Cavalcanti P, 2012, CHRONOBIOL INT, V29, P1267, DOI 10.3109/07420528.2012.719960; Cirillo J, 2009, J PHYSIOL-LONDON, V587, P5831, DOI 10.1113/jphysiol.2009.181834; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Cumming TB, 2012, INT PSYCHOGERIATR, V24, P557, DOI 10.1017/S1041610211001980; Dewhurst S, 2005, EUR J APPL PHYSIOL, V94, P491, DOI 10.1007/s00421-005-1384-6; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Lazzaro V, 2006, STROKE, V37, P2850, DOI 10.1161/01.STR.0000244824.53873.2c; Di Lazzaro V, 2010, CEREB CORTEX, V20, P1523, DOI 10.1093/cercor/bhp216; Erickson KI, 2014, NEUROBIOL AGING, V35, pS20, DOI 10.1016/j.neurobiolaging.2014.03.034; Fogelholm M, 2006, MED SCI SPORT EXER, V38, P753, DOI 10.1249/01.mss.0000194075.16960.20; Freitas C, 2011, FRONT AGING NEUROSCI, V3, DOI [10.3389/fnagi.2011.00005, 10.3389/fnagi.2011.00006]; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hagstromer M, 2006, PUBLIC HEALTH NUTR, V9, P755, DOI 10.1079/PHN2005898; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Hao ZL, 2013, SAO PAULO MED J, V131, P440, DOI [10.1590/1516-3180.20131316T2, 10.1002/14651858.CD008862.pub2]; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hinder MR, 2014, BRAIN STIMUL, V7, P365, DOI 10.1016/j.brs.2014.01.004; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Karabanov A, 2015, BRAIN STIMUL, V8, P442, DOI 10.1016/j.brs.2015.01.404; Kim DH, 2015, NEUROREPORT, V26, P561, DOI 10.1097/WNR.0000000000000388; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lennon OC, 2011, J STROKE CEREBROVASC, V20, P465, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.020; Mang CS, 2014, J APPL PHYSIOL, V117, P1325, DOI 10.1152/japplphysiol.00498.2014; Mang CS, 2013, PHYS THER, V93, P1707, DOI 10.2522/ptj.20130053; Marzolini S, 2013, NEUROREHAB NEURAL RE, V27, P392, DOI 10.1177/1545968312465192; Masley S, 2009, J CLIN PSYCHOL MED S, V16, P186, DOI 10.1007/s10880-009-9159-6; McDonnell MN, 2013, J APPL PHYSIOL, V114, P1174, DOI 10.1152/japplphysiol.01378.2012; Moore SA, 2015, NEUROREHAB NEURAL RE, V29, P623, DOI 10.1177/1545968314562116; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; National Stroke Foundation, 2010, CLIN GUID STROK REH; Pedersen BK, 2006, ESSAYS BIOCHEM, V42, P105, DOI 10.1042/bse0420105; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Rimmer James H, 2005, Top Stroke Rehabil, V12, P17; Roig M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044594; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Sale MV, 2008, J NEUROSCI, V28, P8285, DOI 10.1523/JNEUROSCI.1963-08.2008; Singh AM, 2014, EXP BRAIN RES, V232, P3675, DOI 10.1007/s00221-014-4049-z; Snow NJ, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0146712, 10.1371/journal.pone.0150039]; Statton MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141393; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Talelli P, 2012, NEUROREHAB NEURAL RE, V26, P976, DOI 10.1177/1545968312437940; Teasell R, 2012, TOP STROKE REHABIL, V19, P457, DOI 10.1310/tsr1906-457; Todd G, 2010, CLIN NEUROPHYSIOL, V121, P441, DOI 10.1016/j.clinph.2009.11.089; Vallence AM, 2015, NEUROSCIENCE, V304, P266, DOI 10.1016/j.neuroscience.2015.07.043; ZANETTE G, 1995, EXP BRAIN RES, V107, P80; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	56	20	20	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2016	11	3							e0152377	10.1371/journal.pone.0152377	http://dx.doi.org/10.1371/journal.pone.0152377			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH5EH	27018862	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000372807800051
J	Roman, E; Garcia-Galceran, C; Torrades, T; Herrera, S; Marin, A; Donate, M; Alvarado-Tapias, E; Malouf, J; Nacher, L; Serra-Grima, R; Guarner, C; Cordoba, J; Soriano, G				Roman, Eva; Garcia-Galceran, Cristina; Torrades, Teresa; Herrera, Silvia; Marin, Ana; Donate, Maite; Alvarado-Tapias, Edilmar; Malouf, Jorge; Nacher, Laura; Serra-Grima, Ricard; Guarner, Carlos; Cordoba, Juan; Soriano, German			Effects of an Exercise Programme on Functional Capacity, Body Composition and Risk of Falls in Patients with Cirrhosis: A Randomized Clinical Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; PHYSICAL-EXERCISE; OLDER-ADULTS; LIVER-TRANSPLANTATION; PORTAL-HYPERTENSION; AEROBIC CAPACITY; MUSCLE STRENGTH; SARCOPENIA; MORTALITY; HEALTH	Patients with cirrhosis often have functional limitations, decreased muscle mass, and a high risk of falls. These variables could improve with exercise. The aim was to study the effects of moderate exercise on functional capacity, body composition and risk of falls in patients with cirrhosis. Twenty-three cirrhotic patients were randomized to an exercise programme (n = 14) or to a relaxation programme (n = 9). Both programmes consisted of a one-hour session 3 days a week for 12 weeks. At the beginning and end of the study, we measured functional capacity using the cardiopulmonary exercise test, evaluated body composition using anthropometry and dual energy X-ray absorptiometry, and estimated risk of falls using the Timed Up&Go test. In the exercise group, cardiopulmonary exercise test showed an increase in total effort time (p<0.001) and ventilatory anaerobic threshold time (p = 0.009). Upper thigh circumference increased and mid-arm and mid-thigh skinfold thickness decreased. Dual energy X-ray absorptiometry showed a decrease in fat body mass (-0.94 kg, 95%CI -0.48 to -1.41, p = 0.003) and an increase in lean body mass (1.05 kg, 95%CI 0.27 to 1.82, p = 0.01), lean appendicular mass (0.38 kg, 95%CI 0.06 to 0.69, p = 0.03) and lean leg mass (0.34 kg, 95%CI 0.10 to 0.57, p = 0.02). The Timed Up&Go test decreased at the end of the study compared to baseline (p = 0.02). No changes were observed in the relaxation group. We conclude that a moderate exercise programme in patients with cirrhosis improves functional capacity, increases muscle mass, and decreases body fat and the Timed Up&Go time.	[Roman, Eva; Garcia-Galceran, Cristina; Alvarado-Tapias, Edilmar; Nacher, Laura; Guarner, Carlos; Soriano, German] Hosp Santa Creu & Sant Pau, Inst Recerca IIB St Pau, Dept Gastroenterol, Barcelona, Spain; [Roman, Eva] Escola Univ Infermeria EUI St Pau, Barcelona, Spain; [Torrades, Teresa] Hosp Santa Creu & Sant Pau, Phys Med & Rehabil Dept, Barcelona, Spain; [Herrera, Silvia; Marin, Ana; Malouf, Jorge] Hosp Santa Creu & Sant Pau, Dept Internal Med, Barcelona, Spain; [Donate, Maite; Serra-Grima, Ricard] Hosp Santa Creu & Sant Pau, Dept Cardiol, Barcelona, Spain; [Roman, Eva; Guarner, Carlos; Cordoba, Juan; Soriano, German] Univ Autonoma Barcelona, Bellaterra, Cerdanyola Del, Spain; [Roman, Eva; Guarner, Carlos; Cordoba, Juan; Soriano, German] Inst Salud Carlos III, CIBERehd, Madrid, Spain; [Soriano, German] Hosp Valle De Hebron, Dept Internal Med, Liver Unit, Barcelona, Spain	Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III; Hospital Universitari Vall d'Hebron	Soriano, G (corresponding author), Hosp Santa Creu & Sant Pau, Inst Recerca IIB St Pau, Dept Gastroenterol, Barcelona, Spain.; Soriano, G (corresponding author), Univ Autonoma Barcelona, Bellaterra, Cerdanyola Del, Spain.; Soriano, G (corresponding author), Inst Salud Carlos III, CIBERehd, Madrid, Spain.; Soriano, G (corresponding author), Hosp Valle De Hebron, Dept Internal Med, Liver Unit, Barcelona, Spain.	gsoriano@santpau.cat	Sierra, Jorge Malouf/AAF-9797-2020; Roman, Eva/P-2377-2016	Sierra, Jorge Malouf/0000-0001-5185-520X; Guarner, Carlos/0000-0001-5957-9481; Roman, Eva/0000-0001-9084-8555; Soriano, German/0000-0002-9267-6811	Fundacion MAPFRE; Decathlon Foundation	Fundacion MAPFRE; Decathlon Foundation	This study was partially funded by Fundacion MAPFRE [www.fundacionmapfre.org] and Decathlon Foundation [www.fondationdecathlon.com] to buy the material and apparatus to perform the exercise and the relaxation programmes. The authors do not have any potential competing interest with the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandi JC, 1998, HEPATOLOGY, V28, P677, DOI 10.1002/hep.510280312; Berzigotti A, 2016, HEPATOLOGY, V63, P1026, DOI 10.1002/hep.28132; Berzigotti A, 2014, HEPATOLOGY, V60, p253A; Berzigotti A, 2011, HEPATOLOGY, V54, P555, DOI 10.1002/hep.24418; Carey EJ, 2010, LIVER TRANSPLANT, V16, P1373, DOI 10.1002/lt.22167; Caycedo Natalia, 2005, Rev Enferm, V28, P30; Centers for Disease Control and Prevention, 2011, TARG HEART RAT EST M; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Debette-Gratien M, 2015, TRANSPLANTATION, V99, P145, DOI 10.1097/TP.0000000000000245; Dereli EE, 2010, CLIN REHABIL, V24, P352, DOI 10.1177/0269215509358933; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; GarciaPagan JC, 1996, GASTROENTEROLOGY, V111, P1300, DOI 10.1053/gast.1996.v111.pm8898644; Guazzi M, 2012, CIRCULATION, V126, P2261, DOI 10.1161/CIR.0b013e31826fb946; Hunter GR, 2004, SPORTS MED, V34, P329, DOI 10.2165/00007256-200434050-00005; Jones JC, 2012, LIVER TRANSPLANT, V18, P146, DOI 10.1002/lt.22472; Kachaamy T, 2012, CLIN GASTROENTEROL H, V10, P100, DOI 10.1016/j.cgh.2011.11.002; Les I, 2010, EUR J GASTROEN HEPAT, V22, P221, DOI 10.1097/MEG.0b013e3283319975; Lucero C, CLIN LIVER DIS, V19, P507; Lukaski H, 1997, J NUTR, V127, pS994, DOI 10.1093/jn/127.5.994S; Montano-Loza AJ, 2014, WORLD J GASTROENTERO, V20, P8061, DOI 10.3748/wjg.v20.i25.8061; Montano-Loza AJ, 2012, CLIN GASTROENTEROL H, V10, P166, DOI 10.1016/j.cgh.2011.08.028; Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST; Pieber K, 2006, J REHABIL MED, V38, P322, DOI 10.1080/16501970600680288; Roman E, 2014, DIGEST DIS SCI, V59, P1966, DOI 10.1007/s10620-014-3086-6; Roman E, 2013, EUR J GASTROEN HEPAT, V25, P77, DOI 10.1097/MEG.0b013e3283589f49; Roman E, 2011, AM J GASTROENTEROL, V106, P476, DOI 10.1038/ajg.2010.413; Salo J, 1997, HEPATOLOGY, V25, P1338, DOI 10.1002/hep.510250606; Segura-Orti E, 2010, SEMIN DIALYSIS, V23, P422, DOI 10.1111/j.1525-139X.2010.00766.x; Soriano G, 2012, HEPATOLOGY, V55, P1922, DOI 10.1002/hep.25554; Steindorf K, 2014, ANN ONCOL, V25, P2237, DOI 10.1093/annonc/mdu374; Tabet JY, 2009, ARCH CARDIOVASC DIS, V102, P721, DOI 10.1016/j.acvd.2009.05.011; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Tsai CF, 2013, J HEPATOL, V58, P706, DOI 10.1016/j.jhep.2012.12.001; Viccaro LJ, 2011, J AM GERIATR SOC, V59, P887, DOI 10.1111/j.1532-5415.2011.03336.x; Wang J, 2000, ANN NY ACAD SCI, V904, P317; Wasserman K, 2012, PRINCIPLES EXERCISE; Zenith L, 2014, CLIN GASTROENTEROL H, V12, P1920, DOI 10.1016/j.cgh.2014.04.016	38	76	78	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0151652	10.1371/journal.pone.0151652	http://dx.doi.org/10.1371/journal.pone.0151652			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3SV	27011355	gold, Green Published, Green Submitted			2023-01-03	WOS:000372708000038
J	Spellberg, B; Srinivasan, A; Chambers, HF				Spellberg, Brad; Srinivasan, Arjun; Chambers, Henry F.			New Societal Approaches to Empowering Antibiotic Stewardship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Spellberg, Brad] Los Angeles Cty Univ Southern Calif, Med Ctr, Los Angeles, CA USA; [Spellberg, Brad] Univ So Calif, Keck Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90033 USA; [Srinivasan, Arjun] US Ctr Dis Control & Prevent, Atlanta, GA USA; [Chambers, Henry F.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Spellberg, B (corresponding author), LAC USC Med Ctr, 2051 Marengo St,C2K122, Los Angeles, CA 90033 USA.	bspellberg@dhs.lacounty.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI117211, R01AI103342, R21AI127954] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI117211, R21 AI127954] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1945, NY TIMES; Centers for Disease Control and Prevention, 2015, COR EL HOSP ANT STEW; Centers for Disease Control and Prevention (U. S.), 2013, ANT RES THREATS US; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Executive Office of the President President's Council of Advisor on Science and Technology, 2014, REP PRES COMB ANT RE; MCDERMOTT W, 1982, JOHNS HOPKINS MED J, V151, P302; Spellberg B, 2014, JAMA INTERN MED, V174, P432, DOI 10.1001/jamainternmed.2013.14019	7	59	62	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2016	315	12					1229	1230		10.1001/jama.2016.1346	http://dx.doi.org/10.1001/jama.2016.1346			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH0YQ	26914942	Green Accepted			2023-01-03	WOS:000372511100004
J	Christiansen, DH; Frost, P; Frich, LH; Falla, D; Svendsen, SW				Christiansen, David Hoyrup; Frost, Poul; Frich, Lars Henrik; Falla, Deborah; Svendsen, Susanne Wulff			The Use of Physiotherapy among Patients with Subacromial Impingement Syndrome: Impact of Sex, Socio-Demographic and Clinical Factors	PLOS ONE			English	Article							ARTHROSCOPIC ACROMIOPLASTY; EXERCISE STRATEGY; FOLLOW-UP; SHOULDER; DECOMPRESSION; REGISTER; SURGERY; SATISFACTION; BENEFITS; COHORT	Background Physiotherapy with exercises is generally recommended in the treatment of patients with subacromial impingement syndrome (SIS). Objective We aimed to investigate the use of physiotherapy in patients with SIS in Danish hospital settings as part of initial non-surgical treatment and after SIS-related surgery and to evaluate to which extent sex, socio-demographic and clinical factors predict the use of physiotherapy. Methods Using national health registers, we identified 57,311 patients who had a first hospital contact with a diagnosis of ICD-10, groups M75.1-75.9, 1 July 2007 to 30 June 2011. Records of physiotherapy were extracted within 52 weeks after first contact (or until surgery), and for surgically treated patients within 26 weeks after surgery. Predictors of the use of physiotherapy after first contact and after surgery were analysed as time-to-event. Results Within 52 weeks after first contact, 43% of the patients had physiotherapy and 30% underwent surgery. Within 26 weeks after surgery, 80% had a record of physiotherapy. After first contact and after surgery, exercise was part of physiotherapy in 65% and 84% of the patients, respectively. A public hospital contact, physiotherapy before hospital contact, administrative region, female sex, a diagnosis of other or unspecified disorders (M75.8-M75.9), and surgical procedure predicted higher use of physiotherapy. Low education level predicted slightly lower use of physiotherapy after first contact, but not after surgery. Conclusion In patients with SIS in Danish hospital settings, physiotherapy was more often used after surgery than as part of initial non-surgical treatment. The use of physiotherapy was less common among men than women, whereas unequal use of physiotherapy in relation to education level was not noticeable. The use of physiotherapy with exercises in initial nonsurgical treatment was relatively limited.	[Christiansen, David Hoyrup; Svendsen, Susanne Wulff] Reg Hosp West Jutland, Danish Ramazzini Ctr, Dept Occupat Med, Univ Res Clin, Herning, Denmark; [Frost, Poul] Aarhus Univ Hosp, Aarhus Hosp, Danish Ramazzini Ctr, Dept Occupat Med, DK-8000 Aarhus, Denmark; [Frich, Lars Henrik] Odense Univ Hosp, Dept Orthoped, DK-5000 Odense, Denmark; [Falla, Deborah] Univ Hosp Gottingen, Ctr Anesthesiol Emergency & Intens Care Med, Gottingen, Germany; [Falla, Deborah] Univ Gottingen, Univ Med Ctr, Gottingen Bernstein Ctr Computat Neurosci BCCN, Inst Neurorehabil Syst,Bernstein Focus Neurotechn, Gottingen, Germany	Aarhus University; University of Southern Denmark; Odense University Hospital; University of Gottingen; University of Gottingen	Christiansen, DH (corresponding author), Reg Hosp West Jutland, Danish Ramazzini Ctr, Dept Occupat Med, Univ Res Clin, Herning, Denmark.	David.Christiansen@vest.rm.dk	Christiansen, David Høyrup/ABE-7118-2021; Falla, Deborah/ABA-7734-2021	Christiansen, David Høyrup/0000-0001-7458-3921; Falla, Deborah/0000-0003-1689-6190; Frich, Lars Henrik/0000-0002-0147-4211	Danish Agency for Science, Technology and Innovation grant [09-066985]; Danish Ramazzini Centre	Danish Agency for Science, Technology and Innovation grant; Danish Ramazzini Centre	This work was supported by The Danish Agency for Science, Technology and Innovation grant number 09-066985, http://ufm.dk/en?set_language=en&cl=en, and the Danish Ramazzini Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen JS, 2011, SCAND J PUBLIC HEALT, V39, P34, DOI 10.1177/1403494810394718; Andersen NH, 1999, J SHOULDER ELB SURG, V8, P99, DOI 10.1016/S1058-2746(99)90000-9; Andersen PK, 2010, STAT METHODS MED RES, V19, P71, DOI 10.1177/0962280209105020; Biering K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049268; Braman JP, 2014, MED BIOL ENG COMPUT, V52, P211, DOI 10.1007/s11517-013-1074-1; Chaudhury S, 2010, NAT REV RHEUMATOL, V6, P217, DOI 10.1038/nrrheum.2010.25; Checroun A J, 1998, Bull Hosp Jt Dis, V57, P145; Danish Health and Medicines Authority, 2013, REC PREN CAR; de Witte PB, 2014, MED BIOL ENG COMPUT, V52, P221, DOI 10.1007/s11517-013-1075-0; Dickens VA, 2005, PHYSIOTHERAPY, V91, P159, DOI 10.1016/j.physio.2004.10.008; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; Hallgren HCB, 2014, BRIT J SPORT MED, V48, P1431, DOI 10.1136/bjsports-2013-093233; Hanratty CE, 2012, SEMIN ARTHRITIS RHEU, V42, P297, DOI 10.1016/j.semarthrit.2012.03.015; Hjollund NH, 2007, SCAND J PUBLIC HEALT, V35, P497, DOI 10.1080/14034940701271882; Holmgren T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e787; Holmgren T, 2012, J REHABIL MED, V44, P12, DOI 10.2340/16501977-0889; Jensen LD, 2011, SPINE, V36, pE791, DOI 10.1097/BRS.0b013e3181ef6243; Ketola S, 2009, J BONE JOINT SURG BR, V91B, P1326, DOI 10.1302/0301-620X.91B10.22094; Klintberg IH, 2011, J SHOULDER ELB SURG, V20, P598, DOI 10.1016/j.jse.2010.08.021; Klintberg IH, 2010, KNEE SURG SPORT TR A, V18, P394, DOI 10.1007/s00167-009-0963-1; Klintberg IH, 2008, CLIN REHABIL, V22, P951, DOI 10.1177/0269215508090771; Lewis JS, 2009, BRIT J SPORT MED, V43, P236, DOI 10.1136/bjsm.2008.052175; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Odenbring S, 2008, ARTHROSCOPY, V24, P1092, DOI 10.1016/j.arthro.2008.04.073; Rothman KJ, 2008, ANONYMOUS MODERN EPI, P481; Rudbeck M, 2013, J SHOULDER ELB SURG, V22, P1167, DOI 10.1016/j.jse.2012.12.003; Svendsen SW, 2012, SCAND J RHEUMATOL, V41, P59, DOI 10.3109/03009742.2011.595375; Ylinen J, 2013, EUR J PHYS REHAB MED, V49, P499	28	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0151077	10.1371/journal.pone.0151077	http://dx.doi.org/10.1371/journal.pone.0151077			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26954692	Green Published, gold, Green Submitted			2023-01-03	WOS:000371991300082
J	Cruz, MP; Andrade, CMF; Silva, KO; de Souza, EP; Yatsuda, R; Marques, LM; David, JP; David, JM; Napimoga, MH; Clemente-Napimoga, JT				Cruz, Mariluze P.; Andrade, Cassya M. F.; Silva, Kelle O.; de Souza, Erika P.; Yatsuda, Regiane; Marques, Lucas M.; David, Juceni P.; David, Jorge M.; Napimoga, Marcelo H.; Clemente-Napimoga, Juliana T.			Antinoceptive and Anti-inflammatory Activities of the Ethanolic Extract, Fractions and Flavones Isolated from Mimosa tenuiflora (Willd.) Poir (Leguminosae)	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; FORMALIN TEST; INFLAMMATORY HYPERALGESIA; NEUTROPHIL RECRUITMENT; DRUG DEVELOPMENT; PAIN; ACTIVATION; MECHANISMS; CYTOKINE	The bark of Mimosa tenuiflora (Willd.) Poiret (Leguminosae family), popularly known as "jurema preta" in Brazil, is used by the population of Contendas of Sincora (Bahia State, Brazil) for the treatment of coughs and wound healing. Thus, the aim of this study was to evaluate the antinociceptive and anti-inflammatory activities of the bark ethanol extract (EEMT) and solvent soluble fractions (hexane-H, DCM-D, EtOAc-E and BuOH-B) of the extract in vivo. Additionally, we synthesized 5,7-dihidroxy-4'-methoxyflavanone (isosakuranetin) and isolated the compound sakuranetin, and both compounds were also tested. The anti-inflammatory and antinociceptive assays performed were: writhing test; nociception induced by intraplantar formalin injection; leukocyte recruitment to the peritoneal cavity; evaluation of vascular permeability (Evans blue test); and evaluation of mechanical hypernociception (von Frey test). Production of TNF-alpha, IL-10, myeloperoxidase and the expression of ICAM-1 were also evaluated. Statistical analysis was performed by one-way ANOVA followed by the Bonferroni post-test (n = 8), with P < 0.05. The EEMT showed antinociceptive activities in writhing test (100-200 mg/kg), in the second phase of the formalin test (50-200 mg/kg), and in mechanical hypernociception (100 mg/kg). EEMT showed an anti-inflammatory effect by reducing neutrophil migration to the peritoneal cavity and in the plantar tissue detected by the reduction of myeloperoxidase activity (100 mg/kg), reduction of IL-10 levels and expression of ICAM-1 in the peritoneal exudate and the mesentery (100 mg/kg), respectively. The four soluble EEMT fractions showed good results in tests for antinociceptive (H, D, E, B) and anti-inflammation (H, D, E). Only sakuranetin showed reduction of the writhing and neutrophil migration (200 mg/kg). Thus, the EEMT and soluble fractions of M. tenuiflora bark demonstrated great antinociceptive and anti-inflammatory activities, as also sakuranetin. More studies should be conducted to elucidate the mechanism of action of this compound. To the best of our knowledge, this is the first report on the antinociceptive activity of the M. tenuiflora fractions and the bioactive isolated compound sakuranetin in vivo.	[Cruz, Mariluze P.; Andrade, Cassya M. F.; Silva, Kelle O.; de Souza, Erika P.; Yatsuda, Regiane; Marques, Lucas M.] Univ Fed Bahia, Inst Multidisciplinar Saude, Vitoria Da Conquista, BA, Brazil; [David, Juceni P.] Univ Fed Bahia, Fac Farm, Salvador, BA, Brazil; [Cruz, Mariluze P.; David, Jorge M.] Univ Fed Bahia, Inst Quim, Salvador, BA, Brazil; [Napimoga, Marcelo H.] Sao Leopoldo Mand Inst & Res Ctr, Lab Immunol & Mol Biol, Campinas, SP, Brazil; [Clemente-Napimoga, Juliana T.] Univ Estadual Campinas, Inst Biol, Campinas, SP, Brazil	Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Faculdade Sao Leopoldo Mandic; Universidade de Sao Paulo; Universidade Estadual de Campinas	David, JM (corresponding author), Univ Fed Bahia, Inst Quim, Salvador, BA, Brazil.	jmdavid@ufba.br	Clemente-Napimoga, Juliana T/E-5163-2013; Yatsuda, Regiane/L-1926-2018; Marques, Lucas M/L-2507-2018; David, Jorge Mauricio/AAK-7022-2020; Napimoga, Marcelo/S-2434-2019; Silva, Lucas/GQH-8201-2022; David, Juceni/AAX-8782-2020; David, Jorge M/G-4550-2012	Clemente-Napimoga, Juliana T/0000-0003-1068-3039; Yatsuda, Regiane/0000-0002-5018-9978; Marques, Lucas M/0000-0002-8276-8149; David, Jorge Mauricio/0000-0001-6375-9055; Napimoga, Marcelo/0000-0003-4472-365X; David, Juceni/0000-0001-9405-2327; 	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq [472605/2012-7]; Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB [PET0055/2012]; CNPq; CAPES; PRONEM/FAPESB	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); PRONEM/FAPESB	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq (472605/2012-7); Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB (PET0055/2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are grateful to the CNPq, CAPES and PRONEM/FAPESB for grants and fellowships. We are indebted to Dr. Manuela P. Cardoso, who recorded the HRESI Mass spectra.	Alves PM, 2008, ARQ ODONTOL, V44, P53; ANTON R, 1993, J ETHNOPHARMACOL, V38, P153, DOI 10.1016/0378-8741(93)90010-3; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Camargo-Ricalde S., 1994, CONTACTO, V5, P29; Camargo-Ricalde SL, 2000, REV BIOL TROP, V48, P939; Chen SM, 2008, CLIN EXP IMMUNOL, V153, P420, DOI 10.1111/j.1365-2249.2008.03707.x; Choi JH, 2012, J ETHNOPHARMACOL, V144, P379, DOI 10.1016/j.jep.2012.09.023; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Cunha TM, 2008, J LEUKOCYTE BIOL, V83, P824, DOI 10.1189/jlb.0907654; Cunha TM, 2010, P NATL ACAD SCI USA, V107, P4442, DOI 10.1073/pnas.0914733107; DeSmet PAGM, 1997, DRUGS, V54, P801, DOI 10.2165/00003495-199754060-00003; Duarte JC, 2008, 20 S PLANT MED BRAS, P248; Ehlers S, 2010, TRENDS IMMUNOL, V31, P184, DOI 10.1016/j.it.2010.02.003; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; FERREIRA SH, 1993, BRIT J PHARMACOL, V110, P1227, DOI 10.1111/j.1476-5381.1993.tb13946.x; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; Fine PG, 2009, PAIN MED, V10, pS79, DOI 10.1111/j.1526-4637.2009.00666.x; Gaujac A, 2013, MICROCHEM J, V109, P78, DOI 10.1016/j.microc.2012.03.033; GRETHER R, 1988, B SOC BOT MEX, V48, P151; Guilhon CC, 2011, J ETHNOPHARMACOL, V135, P406, DOI 10.1016/j.jep.2011.03.032; Guimaraes-Beelen PM, 2006, SMALL RUMINANT RES, V61, P35, DOI 10.1016/j.smallrumres.2005.01.007; Haridas V, 2001, P NATL ACAD SCI USA, V98, P11557, DOI 10.1073/pnas.191363498; HONOHAN T, 1976, J AGR FOOD CHEM, V24, P906, DOI 10.1021/jf60207a031; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; JIANG YL, 1991, PHYTOCHEMISTRY, V30, P2357, DOI 10.1016/0031-9422(91)83648-5; JIANG YL, 1991, J NAT PROD, V54, P1247, DOI 10.1021/np50077a002; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, J NEUROPHYSIOL, V81, P1104, DOI 10.1152/jn.1999.81.3.1104; Kim HP, 2004, J PHARMACOL SCI, V96, P229, DOI 10.1254/jphs.CRJ04003X; KOSTER R, 1959, FED PROC, V18, P412; Manson SC, 2009, RESP MED, V103, P975, DOI 10.1016/j.rmed.2009.01.003; Mazzon E, 2008, CLIN EXP IMMUNOL, V153, P136, DOI 10.1111/j.1365-2249.2008.03669.x; Miller LS, 2007, J IMMUNOL, V179, P6933, DOI 10.4049/jimmunol.179.10.6933; Morris Christopher J, 2003, Methods Mol Biol, V225, P115; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Nakamura Y, 1998, CANCER RES, V58, P4832; Napimoga MH, 2007, INT IMMUNOPHARMACOL, V7, P824, DOI 10.1016/j.intimp.2007.02.001; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Nunes BS, 2009, N-S ARCH PHARMACOL, V379, P609, DOI 10.1007/s00210-009-0397-9; Ohsaki A, 2006, CHEM PHARM BULL, V54, P1728, DOI 10.1248/cpb.54.1728; Bitencourt MAO, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/378235; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; POBER JS, 1987, J IMMUNOL, V138, P3319; Prasad AK, 2005, PURE APPL CHEM, V77, P25, DOI 10.1351/pac200577010025; Rivera-Arce E, 2007, J ETHNOPHARMACOL, V113, P400, DOI 10.1016/j.jep.2007.06.023; Rojewska E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138583; ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H; Ruiz PA, 2007, J NUTR, V137, P1208, DOI 10.1093/jn/137.5.1208; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4; Shu YZ, 1998, J NAT PROD, V61, P1053, DOI 10.1021/np9800102; Sjostrom J, 1999, ANAL METHODS WOOD CH; Souza GV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117501; Suleyman H, 2007, PHARMACOL REP, V59, P247; Szatmari S Z, 2003, Cochrane Database Syst Rev, pCD003119, DOI 10.1002/14651858.CD003119; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Toledo AC, 2013, BRIT J PHARMACOL, V168, P1736, DOI 10.1111/bph.12062; VACHER J, 1964, MED EXP, V11, P51; Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang Y, 2014, J ETHNOPHARMACOL, V151, P944, DOI 10.1016/j.jep.2013.12.003; Wei G, 2008, EUR J ORG CHEM, V2008, P3156, DOI 10.1002/ejoe.200800239; Xu JL, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0117801, 10.1371/journal.pone.0118099]; [No title captured]	66	30	32	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0150839	10.1371/journal.pone.0150839	http://dx.doi.org/10.1371/journal.pone.0150839			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26954375	Green Published, Green Submitted, gold			2023-01-03	WOS:000371991300054
J	Dotan, I; Roche, PJR; Paliouras, M; Mitmaker, EJ; Trifiro, MA				Dotan, Idit; Roche, Philip J. R.; Paliouras, Miltiadis; Mitmaker, Elliot J.; Trifiro, Mark A.			Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells	PLOS ONE			English	Article							STIMULATING HORMONE-RECEPTOR; EXTERNAL-BEAM RADIOTHERAPY; THYROTROPIN RECEPTOR; PHOTOTHERMAL THERAPY; THERMAL ABLATION; TSH RECEPTOR; TUMOR-CELLS; IN-VITRO; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODIES	Background The incidence of papillary thyroid carcinoma (PTC) has risen steadily over the past few decades as well as the recurrence rates. It has been proposed that targeted ablative physical therapy could be a therapeutic modality in thyroid cancer. Targeted bio-affinity functionalized multi-walled carbon nanotubes (BioNanofluid) act locally, to efficiently convert external light energy to heat thereby specifically killing cancer cells. This may represent a promising new cancer therapeutic modality, advancing beyond conventional laser ablation and other nanoparticle approaches. Methods Thyroid Stimulating Hormone Receptor (TSHR) was selected as a target for PTC cells, due to its wide expression. Either TSHR antibodies or Thyrogen or purified TSH (Thyrotropin) were chemically conjugated to our functionalized Bionanofluid. A diode laser system (532 nm) was used to illuminate a PTC cell line for set exposure times. Cell death was assessed using Trypan Blue staining. Results TSHR-targeted BioNanofluids were capable of selectively ablating BCPAP, a TSHR-positive PTC cell line, while not TSHR-null NSC-34 cells. We determined that a 2:1 BCPAP cell: alpha-TSHR-BioNanofluid conjugate ratio and a 30 second laser exposure killed approximately 60% of the BCPAP cells, while 65% and >70% of cells were ablated using Thyrotropin-and Thyrogen-BioNanofluid conjugates, respectively. Furthermore, minimal non-targeted killing was observed using selective controls. Conclusion A BioNanofluid platform offering a potential therapeutic path for papillary thyroid cancer has been investigated, with our in vitro results suggesting the development of a potent and rapid method of selective cancer cell killing. Therefore, BioNanofluid treatment emphasizes the need for new technology to treat patients with local recurrence and metastatic disease who are currently undergoing either re-operative neck explorations, repeated administration of radioactive iodine and as a last resort external beam radiation or chemotherapy, with fewer side effects and improved quality of life.	[Dotan, Idit; Roche, Philip J. R.; Paliouras, Miltiadis; Mitmaker, Elliot J.; Trifiro, Mark A.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Dotan, Idit; Paliouras, Miltiadis; Trifiro, Mark A.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Paliouras, Miltiadis; Mitmaker, Elliot J.] McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; [Trifiro, Mark A.] McGill Univ, Jewish Gen Hosp, Div Endocrinol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Paliouras, M; Mitmaker, EJ (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.; Paliouras, M (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Paliouras, M; Mitmaker, EJ (corresponding author), McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada.	miltiadis.paliouras@mcgill.ca; elliot.mitmaker@mcgill.ce			Israel Cancer Research Fund (ICRF)	Israel Cancer Research Fund (ICRF)	I.D. received salary support from the Israel Cancer Research Fund (ICRF).	Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Al-Saif O, 2010, J CLIN ENDOCR METAB, V95, P2187, DOI 10.1210/jc.2010-0063; Avetisyan YA, 2012, APPL OPTICS, V51, pC88, DOI 10.1364/AO.51.000C88; Baffou G, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3116645; Baffou G, 2014, NANOSCALE, V6, P8984, DOI 10.1039/c4nr01644k; Boca SC, 2011, CANCER LETT, V311, P131, DOI 10.1016/j.canlet.2011.06.022; BRABANT G, 1991, MOL CELL ENDOCRINOL, V82, pR7, DOI 10.1016/0303-7207(91)90018-N; Brierley JD, 2011, J CLIN ENDOCR METAB, V96, P2289, DOI 10.1210/jc.2011-1109; Brioli A, 2014, BRIT J HAEMATOL, V165, P441, DOI 10.1111/bjh.12805; Burke A, 2009, P NATL ACAD SCI USA, V106, P12897, DOI 10.1073/pnas.0905195106; Burlaka A., 2010, Experimental Oncology, V32, P48; Busuttil BE, 2001, J CLIN ENDOCR METAB, V86, P2315, DOI 10.1210/jc.86.5.2315; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chakravarty P, 2008, P NATL ACAD SCI USA, V105, P8697, DOI 10.1073/pnas.0803557105; Chang EH, 2015, BIOCHEM BIOPH RES CO, V468, P511, DOI 10.1016/j.bbrc.2015.10.136; Chen ST, 2000, J ENDOCRINOL, V165, P379, DOI 10.1677/joe.0.1650379; Chia SY, 2007, J CLIN ENDOCR METAB, V92, P468, DOI 10.1210/jc.2006-2088; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035; Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; Ford D, 2003, CLIN ONCOL-UK, V15, P337, DOI 10.1016/S0936-6555(03)00162-6; Giordano D, 2012, THYROID, V22, P911, DOI 10.1089/thy.2012.0011; Hashida Y, 2014, J CONTROL RELEASE, V173, P59, DOI 10.1016/j.jconrel.2013.10.039; Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x; Hudson DE, 2013, PHOTOMED LASER SURG, V31, P163, DOI 10.1089/pho.2012.3284; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jeffreys J, 2002, THYROID, V12, P1051, DOI 10.1089/105072502321085144; Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102; Kazaure HS, 2012, ANN SURG ONCOL, V19, P1874, DOI 10.1245/s10434-011-2129-x; Kloos Richard T, 2005, Curr Treat Options Oncol, V6, P323; Kumar S, 2011, J MOL ENDOCRINOL, V46, P155, DOI 10.1530/JME-11-0006; Lee N, 2006, ENDOCR-RELAT CANCER, V13, P971, DOI 10.1677/ERC-06-0039; Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s; Malic E, 2006, PHYS REV B, V74, P1; Marches R, 2009, INT J CANCER, V125, P2970, DOI 10.1002/ijc.24659; Maestro LM, 2013, NANOSCALE, V5, P7882, DOI 10.1039/c3nr01398g; McLeod DSA, 2013, LANCET, V381, P1046, DOI 10.1016/S0140-6736(12)62205-3; Melisi D, 2013, CURR OPIN PHARMACOL, V13, P536, DOI 10.1016/j.coph.2013.06.012; Melong JC, 2015, J OTOLARYNGOL-HEAD N, V44, DOI 10.1186/s40463-015-0093-3; Mendoza-Nava H, 2013, PHOTOMED LASER SURG, V31, P17, DOI 10.1089/pho.2012.3320; Moodley K, 2011, J NEUROL SCI, V302, P114, DOI 10.1016/j.jns.2010.11.027; Oda Y, 1998, J MOL ENDOCRINOL, V20, P233, DOI 10.1677/jme.0.0200233; Oda Y, 2000, THYROID, V10, P1051, DOI 10.1089/thy.2000.10.1051; Pacini F, 2006, EUR J ENDOCRINOL, V154, P787, DOI 10.1530/eje.1.02158; Panchapakesan B, 2005, NANOBIOTHCHNOLOGY, V1, P7; Park A, 2013, ENDOCRINOLOGY, V154, P1373, DOI 10.1210/en.2012-2010; Pattani VP, 2012, LASER SURG MED, V44, P675, DOI 10.1002/lsm.22072; PAULIN C, 1992, CR ACAD SCI III-VIE, V315, P493; Pilli T, 2009, THYROID, V19, P1333, DOI 10.1089/thy.2009.0195; Pokrass M, 2012, OPT MATER EXPRESS, V2, P825, DOI 10.1364/OME.2.000825; RAHMAN MM, 2014, SCI WORLD J, DOI DOI 10.1155/2014/; Ritts AC, 2011, POLYMERS-BASEL, V3, P2142, DOI 10.3390/polym3042142; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Schwartz DL, 2009, INT J RADIAT ONCOL, V74, P1083, DOI 10.1016/j.ijrobp.2008.09.023; Sellitti DF, 1997, THYROID, V7, P641, DOI 10.1089/thy.1997.7.641; Sia MA, 2010, J THROID RES, V2010, DOI 10.4061/2010/183461; Silver CE, 2011, HEAD NECK-J SCI SPEC, V33, P1052, DOI 10.1002/hed.21494; Simard EP, 2012, CA-CANCER J CLIN, V62, P118, DOI 10.3322/caac.20141; Torti SV, 2007, INT J NANOMED, V2, P707; Uchida H, 2013, SURG TODAY, V43, P848, DOI 10.1007/s00595-012-0353-z; Valyasevi RW, 1999, J CLIN ENDOCR METAB, V84, P2557, DOI 10.1210/jc.84.7.2557; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Wang L, 2013, PHARM RES-DORDR, V30, P2757, DOI 10.1007/s11095-013-1095-3; Wang SS, 2013, ONCOL LETT, V5, P368, DOI 10.3892/ol.2012.947; Wang ZF, 2011, TUMORI, V97, P540, DOI 10.1700/950.10410; Williams GR, 2011, ANN ENDOCRINOL-PARIS, V72, P68, DOI 10.1016/j.ando.2011.03.006; Wu A, 2013, P NATL ACAD SCI USA, V110, P16103, DOI 10.1073/pnas.1314385110; Yang ST, 2012, THERANOSTICS, V2, P271, DOI 10.7150/thno.3618; Zhu LQ, 2015, GASTROENTEROLOGY RES, P1; 2007, NANOTECHNOLOGY, V18, P9	71	13	13	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149723	10.1371/journal.pone.0149723	http://dx.doi.org/10.1371/journal.pone.0149723			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901566	Green Published, Green Submitted, gold			2023-01-03	WOS:000371276100135
J	Ogasawara, K; Yamada, K; Hatsugai, N; Imada, C; Nishimura, M				Ogasawara, Kimi; Yamada, Kenji; Hatsugai, Noriyuki; Imada, Chiaki; Nishimura, Mikio			Hexose Oxidase-Mediated Hydrogen Peroxide as a Mechanism for the Antibacterial Activity in the Red Seaweed Ptilophora subcostata	PLOS ONE			English	Article							ALGA CHONDRUS-CRISPUS; OXIDATIVE BURST; INNATE IMMUNITY; BACTERIAL FLAGELLIN; MARINE-ALGAE; DEFENSE; SYSTEM; PURIFICATION; MACROALGAE; PERCEPTION	Marine algae have unique defense strategies against microbial infection. However, their mechanisms of immunity remain to be elucidated and little is known about the similarity of the immune systems of marine algae and terrestrial higher plants. Here, we suggest a possible mechanism underlying algal immunity, which involves hexose oxidase (HOX)-dependent production of hydrogen peroxide (H2O2). We examined crude extracts from five different red algal species for their ability to prevent bacterial growth. The extract from one of these algae, Ptilophora subcostata, was particularly active and prevented the growth of gram-positive and -negative bacteria, which was completely inhibited by treatment with catalase. The extract did not affect the growth of either a yeast or a filamentous fungus. We partially purified from P. subcostata an enzyme involved in its antibacterial activity, which shared 50% homology with the HOX of red seaweed Chondrus crispus. In-gel carbohydrate oxidase assays revealed that P. subcostata extract had the ability to produce H2O2 in a hexose-dependent manner and this activity was highest in the presence of galactose. In addition, Bacillus subtilis growth was strongly suppressed near P. subcostata algal fronds on GYP agar plates. These results suggest that HOX plays a role in P. subcostata resistance to bacterial attack by mediating H2O2 production in the marine environment.	[Ogasawara, Kimi; Yamada, Kenji; Nishimura, Mikio] Natl Inst Nat Sci, Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan; [Ogasawara, Kimi; Imada, Chiaki] Tokyo Univ Marine Sci & Technol, Grad Sch Marine Sci & Technol, Minato Ku, 4-5-7 Konan, Tokyo 1088477, Japan; [Hatsugai, Noriyuki] Hokkaido Univ, Res Ctr Cooperat Projects, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Ogasawara, Kimi] Nagoya Univ, JST, ERATO, Higashiyama Live Holon Project,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan; [Ogasawara, Kimi] Nagoya Univ, Grad Sch Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan; [Yamada, Kenji] Kyoto Univ, Dept Bot, Grad Sch Sci, Kyoto 6068502, Japan; [Hatsugai, Noriyuki] Univ Minnesota, Dept Plant Biol, Microbial & Plant Genom Inst, St Paul, MN 55108 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Tokyo University of Marine Science & Technology; Hokkaido University; Japan Science & Technology Agency (JST); Nagoya University; Nagoya University; Kyoto University; University of Minnesota System; University of Minnesota Twin Cities	Ogasawara, K (corresponding author), Natl Inst Nat Sci, Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.; Ogasawara, K (corresponding author), Tokyo Univ Marine Sci & Technol, Grad Sch Marine Sci & Technol, Minato Ku, 4-5-7 Konan, Tokyo 1088477, Japan.; Ogasawara, K (corresponding author), Nagoya Univ, JST, ERATO, Higashiyama Live Holon Project,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.; Ogasawara, K (corresponding author), Nagoya Univ, Grad Sch Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	ogasawara.kimi@g.mbox.nagoya-u.ac.jp	Hatsugai, Noriyuki/O-9156-2015	Hatsugai, Noriyuki/0000-0002-5708-4263; Nishimura, Mikio/0000-0001-7960-9721	JST, ERATO	JST, ERATO(Japan Science & Technology Agency (JST))	This work was partly supported by JST, ERATO.	Bouarab K, 2004, PLANT PHYSIOL, V135, P1838, DOI 10.1104/pp.103.037622; Bouarab K, 1999, PLANT CELL, V11, P1635, DOI 10.1105/tpc.11.9.1635; Cabrita MT, 2010, MAR DRUGS, V8, P2301, DOI 10.3390/md8082301; Carter CJ, 2004, PLANT PHYSIOL, V134, P460, DOI 10.1104/pp.103.027482; Cook DE, 2015, ANNU REV PHYTOPATHOL, V53, P541, DOI 10.1146/annurev-phyto-080614-120114; Cosse A., 2007, ADV BOT RES, V46, P221, DOI DOI 10.1016/S0065-2296(07)46006-2; Egan S, 2014, ENVIRON MICROBIOL, V16, P925, DOI 10.1111/1462-2920.12288; Faulkner DJ, 2001, NAT PROD REP, V18, P1, DOI 10.1039/b006897g; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Gachon CMM, 2010, TRENDS PLANT SCI, V15, P633, DOI 10.1016/j.tplants.2010.08.005; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; Groen BW, 1997, EUR J BIOCHEM, V244, P858, DOI 10.1111/j.1432-1033.1997.00858.x; Hansen OC, 1997, J BIOL CHEM, V272, P11581; Hao ZG, 2003, INSECT BIOCHEM MOLEC, V33, P1155, DOI 10.1016/j.ibmb.2003.07.001; Hara-Nishimura I, 2011, CELL DEATH DIFFER, V18, P1298, DOI 10.1038/cdd.2011.70; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Kupper FC, 2001, PLANT PHYSIOL, V125, P278, DOI 10.1104/pp.125.1.278; Kwakman PHS, 2010, FASEB J, V24, P2576, DOI 10.1096/fj.09-150789; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Nicolson Susan W., 2007, P215, DOI 10.1007/978-1-4020-5937-7_5; Nylund GM, 2005, MAR ECOL PROG SER, V302, P27, DOI 10.3354/meps302027; Potin P, 1999, CURR OPIN MICROBIOL, V2, P276, DOI 10.1016/S1369-5274(99)80048-4; Potin P, 2002, CURR OPIN PLANT BIOL, V5, P308, DOI 10.1016/S1369-5266(02)00273-X; Rand T, 2006, FEBS J, V273, P2693, DOI 10.1111/j.1742-4658.2006.05285.x; SULLIVAN JD, 1973, BIOCHIM BIOPHYS ACTA, V309, P11, DOI 10.1016/0005-2744(73)90312-4; TAGG JR, 1971, APPL MICROBIOL, V21, P943, DOI 10.1128/AEM.21.5.943-943.1971; Torres MA, 2006, PLANT PHYSIOL, V141, P373, DOI 10.1104/pp.106.079467; Wang SS, 2013, J APPL PHYCOL, V25, P1215, DOI 10.1007/s10811-012-9911-4; Wang XJ, 2013, J APPL PHYCOL, V25, P1895, DOI 10.1007/s10811-013-0009-4; Weinberger F, 1999, J PHYCOL, V35, P747, DOI 10.1046/j.1529-8817.1999.3540747.x; Weinberger F, 2005, J EXP BOT, V56, P1317, DOI 10.1093/jxb/eri132; Weinberger F, 2007, BIOL BULL-US, V213, P290, DOI 10.2307/25066646; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Zambounis A, 2012, MOL BIOL EVOL, V29, P1263, DOI 10.1093/molbev/msr296	35	6	6	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2016	11	2							e0149084	10.1371/journal.pone.0149084	http://dx.doi.org/10.1371/journal.pone.0149084			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6RE	26867214	gold, Green Submitted, Green Published			2023-01-03	WOS:000370050700064
J	Nuijten, M; Blanken, P; van de Wetering, B; Nuijen, B; van den Brink, W; Hendriks, VM				Nuijten, Mascha; Blanken, Peter; van de Wetering, Ben; Nuijen, Bastiaan; van den Brink, Wim; Hendriks, Vincent M.			Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							USE DISORDERS; AGONIST-LIKE; PHARMACOTHERAPY; PRESCRIPTION; MEDICATION; ADHERENCE; EFFICACY; ADDICTS; ALCOHOL	Background Heroin-assisted treatment is effective for methadone treatment-refractory heroin-dependent patients, but continued comorbid cocaine dependence remains problematic. Sustained-release dexamfetamine is a promising agonist pharmacotherapy for cocaine dependence and we aimed to assess its acceptance, efficacy, and safety. Methods In this multicentre, randomised, double-blind, placebo-controlled trial, patients who were treatment-refractory, as indicated by at least two earlier failed treatments aimed at reducing or abstaining from cocaine use, and who regularly (>= 8 days/month) used crack-cocaine were enrolled from four heroin-assisted treatment centres in the Netherlands. Eligible patients were randomly assigned (1: 1) to receive either 12 weeks of daily, supervised prescription of 60 mg/day oral sustained-release dexamfetamine or placebo in addition to co-prescribed methadone and diacetylmorphine. Randomisation was done by the collaborating pharmacist, using a computer-generated random number sequence with stratification by treatment centre in blocks of four per stratum. Randomisation was masked to patients, staff, and researchers throughout the study. The primary outcome was the number of self-reported days of cocaine use during study treatment, assessed every 4 weeks. Primary and safety analyses were done in the intention-to-treat population. The study was registered with the European Union Drug Regulating Authorities Clinical Trials (EUdraCT 2013-004024-11) and with The Netherlands Trial Register (NTR2576). Findings Between Aug 8, 2014, and Feb 27, 2015, 111 patients were assessed for eligibility, of whom 73 were enrolled and randomised; 38 patients were assigned to the sustained-release dexamfetamine group and 35 to the placebo group. Sustained-release dexamfetamine treatment resulted in significantly fewer days of cocaine use than placebo treatment (mean 44.9 days [SD 29.4] vs 60.6 days [24.3], respectively [95% CI of difference 3.1-28.4]; p=0.031; Cohen's standardised effect size d=0.58). One or more adverse events were reported by 28 (74%) patients in the dexamfetamine group and by 16 (46%) patients in the placebo group. Most adverse events were transient and well-tolerated. Interpretation Sustained-release dexamfetamine is a well accepted, effective, and safe agonist pharmacotherapy for comorbid treatment-refractory cocaine dependence in heroin-dependent patients in heroin-assisted treatment. Future research should aim to replicate these findings in chronic cocaine-dependent and other stimulant-dependent patients in more routine treatment settings, including strategies to optimise treatment adherence like medication management interventions and contingency management.	[Nuijten, Mascha; Blanken, Peter; Hendriks, Vincent M.] Parnassia Addict Res Ctr PARC, Brijder Addict Treatment, Monsterseweg 83, NL-2553 RJ The Hague, Netherlands; [van de Wetering, Ben] Antes Grp, Rotterdam, Netherlands; [Nuijen, Bastiaan] Antoni van Leeuwenhoek Netherlands Canc Inst, Med Ctr Slotervaart, Amsterdam, Netherlands; [van den Brink, Wim] Univ Amsterdam, Acad Med Ctr, Ctr Psychiat, Amsterdam Inst Addict Res, Tafelbergweg 25, NL-1105 BC Amsterdam, Netherlands; [Hendriks, Vincent M.] Leiden Univ, Dept Child & Adolescent Psychiat, Med Ctr, Curium, Leiden, Netherlands	Parnassia Psychiatric Institute; Netherlands Cancer Institute; Slotervaart Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Nuijten, M (corresponding author), Parnassia Addict Res Ctr PARC, Brijder Addict Treatment, Monsterseweg 83, NL-2553 RJ The Hague, Netherlands.	mascha.nuijten@brijder.nl	Blanken, Peter/J-4209-2012	Blanken, Peter/0000-0003-4847-4259	Netherlands Organisation for Health Research and Development	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	Netherlands Organisation for Health Research and Development.	APA, 1994, DIAGN STAT MAN MENT; Blanken P, 2010, EUR NEUROPSYCHOPHARM, V20, pS105, DOI 10.1016/S0924-977X(10)70001-8; Castells X, 2010, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD007380.PUB3; Cottler L. B., 2000, COMPOSITE INT DIAGNO; De Wilde EF, 2005, EUR ADDICT RES, V11, P157, DOI 10.1159/000086396; de Wildt WAJM, 2005, ALCOHOL CLIN EXP RES, V29, P509, DOI 10.1097/01.ALC.0000158844.35608.48; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dursteler-MacFarland KM, 2013, J CLIN PSYCHOPHARM, V33, P104, DOI 10.1097/JCP.0b013e31827bfff4; Ferri M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003410.pub4; Galloway GP, 2011, CLIN PHARMACOL THER, V89, P276, DOI 10.1038/clpt.2010.307; Grabowski J, 2004, NEUROPSYCHOPHARMACOL, V29, P969, DOI 10.1038/sj.npp.1300392; Grabowski J, 2001, J CLIN PSYCHOPHARM, V21, P522, DOI 10.1097/00004714-200110000-00010; HENDRIKS VM, 1989, J SUBST ABUSE TREAT, V6, P133, DOI 10.1016/0740-5472(89)90041-X; Herin DV, 2010, ANN NY ACAD SCI, V1187, P76, DOI 10.1111/j.1749-6632.2009.05145.x; Leucht S, 2012, BRIT J PSYCHIAT, V200, P97, DOI 10.1192/bjp.bp.111.096594; Maisel NC, 2013, ADDICTION, V108, P275, DOI 10.1111/j.1360-0443.2012.04054.x; Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x; Marsden J, 2009, LANCET, V374, P1262, DOI 10.1016/S0140-6736(09)61420-3; Mooney ME, 2015, DRUG ALCOHOL DEPEN, V153, P94, DOI 10.1016/j.drugalcdep.2015.05.042; Nuijten M, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-135; Petry NM, 2012, AM J MED, V125, P888, DOI 10.1016/j.amjmed.2012.01.003; Prendergast M, 2006, ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x; Rehm J, 2001, LANCET, V358, P1417, DOI 10.1016/S0140-6736(01)06529-1; Schierenberg Alwin, 2012, Curr Drug Abuse Rev, V5, P320; Schmitz Joy M, 2012, Front Psychiatry, V3, P77, DOI 10.3389/fpsyt.2012.00077; Shearer J, 2003, ADDICTION, V98, P1137, DOI 10.1046/j.1360-0443.2003.00447.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sobell L. C., 1992, MEASURING ALCOHOL CO, P41, DOI [10.1007/978-1-4612-0357-5_3, 10.1007/978-1-4612-0357-5, DOI 10.1007/978-1-4612-0357-5_3]; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; Weiss RD, 2004, ADDICTION, V99, P1382, DOI 10.1111/j.1360-0443.2004.00884.x	30	48	48	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2016	387	10034					2226	2234		10.1016/S0140-6736(16)00205-1	http://dx.doi.org/10.1016/S0140-6736(16)00205-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN1IZ	27015909				2023-01-03	WOS:000376820800032
J	Chaves, TP; Fernandes, FHA; Santana, CP; Santos, JS; Medeiros, FD; Felismino, DC; Santos, VL; Catao, RMR; Coutinho, HDM; Medeiros, ACD				Chaves, Thiago P.; Fernandes, Felipe Hugo A.; Santana, Cleildo P.; Santos, Jocimar S.; Medeiros, Francinalva D.; Felismino, Delcio C.; Santos, Vanda L.; Catao, Raissa Mayer R.; Coutinho, Henrique Douglas M.; Medeiros, Ana Claudia D.			Evaluation of the Interaction between the Poincianella pyramidalis (Tul.) LP Queiroz Extract and Antimicrobials Using Biological and Analytical Models	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; MEDICINAL-PLANTS; ESSENTIAL OIL; CAESALPINIA-PYRAMIDALIS; CHEMICAL-COMPOSITION; ANTIBIOTIC-ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; PHENOLIC-COMPOUNDS; ETHANOL EXTRACT	Poincianella pyramidalis (Tul.) LP Queiroz (Fabaceae) is an endemic tree of northeastern Brazil, occurring mainly in the Caatinga. Its medicinal use is widespread and is an important therapeutic option against diarrhea, dysentery, and respiratory and urinary infections, among other diseases. In this study we determined the chemical marker and evaluated the interaction between P. pyramidalis extract and a commercial antimicrobial through the use of biological and analytical models. To obtain the extract, an ethanol-water mixture (50: 50 v/v) was used as solvent. It was nebulized in a spray dryer using colloidal silicon dioxide as a drying adjuvant. The extract (ENPp) was subjected to HPLC analysis to verify the presence of certain secondary metabolites. The Minimum Inhibitory Concentration (MIC) of the extract against Gram-negative bacteria was determined by broth microdilution and the MIC of synthetic antimicrobial drugs in the presence and absence of the extract. The antioxidant activity of ENPp was evaluated by the DPPH method. The compatibility between the antimicrobial and the extract was evaluated by thermal analysis (TG/DTA). The acute toxicity of the extract was evaluated in vivo in rodents. The results indicate significant additive action of the extract on synthetic antibiotics, considerable antioxidant activity and absence of toxicity. This extract shows high potential for the development of formulations for antimicrobial therapy when used with a vegetable-active ingredient.	[Chaves, Thiago P.; Fernandes, Felipe Hugo A.; Santana, Cleildo P.; Santos, Jocimar S.; Medeiros, Francinalva D.; Felismino, Delcio C.; Medeiros, Ana Claudia D.] Univ Estadual Paraiba, Lab Drug Assay & Dev, Campina Grande, Paraiba, Brazil; [Chaves, Thiago P.] Univ Fed Piaui, Dept Nat Sci, Bom Jesus, Piaui, Brazil; [Fernandes, Felipe Hugo A.] Univ Estadual Paulista, Sch Pharmaceut Sci, Sao Paulo, Brazil; [Santos, Vanda L.] Univ Estadual Paraiba, Pharmacol Lab, Campina Grande, Paraiba, Brazil; [Catao, Raissa Mayer R.] Univ Estadual Paraiba, Lab Res Microbiol, Campina Grande, Paraiba, Brazil; [Coutinho, Henrique Douglas M.] Univ Reg Cariri, Lab Microbiol & Mol Biol, Crato, CE, Brazil	Universidade Estadual da Paraiba; Universidade Federal do Piaui; Universidade Estadual Paulista; Universidade Estadual da Paraiba; Universidade Estadual da Paraiba; Universidade Regional do Cariri	Medeiros, ACD (corresponding author), Univ Estadual Paraiba, Lab Drug Assay & Dev, Campina Grande, Paraiba, Brazil.	analclaudia@uepb.edu.br	Coutinho, Henrique DM/E-1046-2013; Santos, Vanda/AAL-9445-2021; de Medeiros, Ana Cláudia Dantas/E-3387-2013	Coutinho, Henrique DM/0000-0002-6634-4207; de Medeiros, Ana Cláudia Dantas/0000-0002-8682-0178; Hugo Alencar Fernandes, Felipe/0000-0002-7210-4349; Santana, Cleildo/0000-0002-8097-7633; Catao, Raissa Mayer Ramalho/0000-0001-6077-8824	State University of Paraiba, Brazil	State University of Paraiba, Brazil	This manuscript was funded by the authors and the State University of Paraiba, Brazil.	Agra MF, 2007, J ETHNOPHARMACOL, V111, P383, DOI 10.1016/j.jep.2006.12.007; Alviano WS, 2008, ARCH ORAL BIOL, V53, P545, DOI 10.1016/j.archoralbio.2007.12.001; [Anonymous], 2004, PHARM CHEM J+, DOI DOI 10.1023/B:PHAC.0000048148.54165.55; Aqil Farrukh, 2006, Biotechnology Journal, V1, P1093, DOI 10.1002/biot.200600130; Aquino RP, 2013, INT J PHARMACEUT, V440, P188, DOI 10.1016/j.ijpharm.2012.07.074; Aruoma OI, 1998, J AM OIL CHEM SOC, V75, P199, DOI 10.1007/s11746-998-0032-9; Avent ML, 2011, INTERN MED J, V41, P441, DOI 10.1111/j.1445-5994.2011.02452.x; Baraldi C, 2014, J PHARMACEUT BIOMED, V100, P329, DOI 10.1016/j.jpba.2014.08.021; Barreto HM, 2014, EUR J INTEGR MED, V6, P560, DOI 10.1016/j.eujim.2014.03.011; Bernal P, 2013, MICROB BIOTECHNOL, V6, P445, DOI 10.1111/1751-7915.12044; Borges A, 2013, MICROB DRUG RESIST, V19, P256, DOI 10.1089/mdr.2012.0244; Borges-dos-Santos RR, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/510391; Cartaxo SL, 2010, J ETHNOPHARMACOL, V131, P326, DOI 10.1016/j.jep.2010.07.003; Chanwitheesuk A, 2007, FOOD CHEM, V100, P1044, DOI 10.1016/j.foodchem.2005.11.008; Chaves T.P., 2013, AFR J BIOTECHNOL, V12, P847; Choi DY, 2012, BRAIN RES BULL, V87, P144, DOI 10.1016/j.brainresbull.2011.11.014; CLSI-Clinical and Laboratory Standards Institute, 2012, M100S22 CLSI NIH; Coutinho HDM, 2011, J ESSENT OIL RES, V23, P24, DOI 10.1080/10412905.2011.9700443; Coutinho HDM, 2010, COMP IMMUNOL MICROB, V33, P467, DOI 10.1016/j.cimid.2009.08.001; Coutinho HDM, 2010, J MED FOOD, V13, P1024, DOI 10.1089/jmf.2009.0158; Coutinho HDM, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-13; Cruz MCS, 2007, J ETHNOPHARMACOL, V111, P409, DOI 10.1016/j.jep.2006.12.005; Dall'Agnol R, 2003, PHYTOMEDICINE, V10, P511, DOI 10.1078/094471103322331476; Davies S. C, 2014, ANN REPORT CHIEF MED; De Albuquerque UP, 2007, J ETHNOPHARMACOL, V114, P325, DOI 10.1016/j.jep.2007.08.017; de Sousa EO, 2013, NAT PROD RES, V27, P942, DOI 10.1080/14786419.2012.678351; De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; Denyer SP, 2002, J APPL MICROBIOL, V92, p35S, DOI 10.1046/j.1365-2672.92.5s1.19.x; Denyer SP, 1998, INT BIODETER BIODEGR, V41, P261, DOI 10.1016/S0964-8305(98)00023-7; Dhar P, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-259; Duh PD, 1999, FOOD SCI TECHNOL-LEB, V32, P269; Dunkle JA, 2014, P NATL ACAD SCI USA, V111, P6275, DOI 10.1073/pnas.1402789111; Farha MA, 2013, NAT BIOTECHNOL, V31, P120, DOI 10.1038/nbt.2500; Matias EFF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/164215; Figueredo FG, 2014, PHARM BIOL, V52, P560, DOI 10.3109/13880209.2013.853810; Florke OW, 2008, SILICA ULLMANNS ENCY, DOI [10.1002/14356007.a23_583.pub3, DOI 10.1002/14356007.A23_]; Garber J.C., 2010, COMMITTEE UPDATE GUI, P248; GIAMARELLOU H, 1984, ANTIMICROB AGENTS CH, V25, P534, DOI 10.1128/AAC.25.4.534; Gibbons S, 2004, NAT PROD REP, V21, P263, DOI 10.1039/b212695h; Gill EE, 2015, CHEM BIOL DRUG DES, V85, P56, DOI 10.1111/cbdd.12478; Gonzalez-Burgos E, 2012, CURR MED CHEM, V19, P5319, DOI 10.2174/092986712803833335; Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008; HALLIWELL B, 1995, CRIT REV FOOD SCI, V35, P7, DOI 10.1080/10408399509527682; Hancock REW, 1997, TRENDS MICROBIOL, V5, P37, DOI 10.1016/S0966-842X(97)81773-8; HATANO T, 1989, CHEM PHARM BULL, V37, P2016; Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008; Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132; Jayaraman P, 2010, INT J BIOL SCI, V6, P556; JUVEN BJ, 1994, J APPL BACTERIOL, V76, P626, DOI 10.1111/j.1365-2672.1994.tb01661.x; Kalan L, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399410001766; Karaiskos I, 2014, EXPERT OPIN PHARMACO, V15, P1351, DOI 10.1517/14656566.2014.914172; Kotra LP, 2000, ANTIMICROB AGENTS CH, V44, P3249, DOI 10.1128/AAC.44.12.3249-3256.2000; Kroyer G. T., 2004, Innovative Food Science & Emerging Technologies, V5, P101, DOI 10.1016/S1466-8564(03)00040-7; Kumar A, 2005, ADV DRUG DELIVER REV, V57, P1486, DOI 10.1016/j.addr.2005.04.004; Lima M. R. F. de, 2006, Journal of Ethnopharmacology, V105, P137, DOI 10.1016/j.jep.2005.10.026; Lucena R. F. P. de, 2008, Ethnobotany Research and Applications, V6, P3; Lucena RFP, 2007, ENVIRON MONIT ASSESS, V125, P281, DOI 10.1007/s10661-006-9521-1; Mabona U, 2013, J ETHNOPHARMACOL, V148, P45, DOI 10.1016/j.jep.2013.03.056; Macedo RO, 1999, J THERM ANAL CALORIM, V56, P1323, DOI 10.1023/A:1010102422381; Madikizela B, 2014, J ETHNOPHARMACOL, V156, P228, DOI 10.1016/j.jep.2014.09.003; Makkar H. P, 2007, PLANT SECONDARY META; MAKKAR HPS, 1993, J CHEM ECOL, V19, P613, DOI 10.1007/BF00984996; Masoud MS, 2015, J MOL STRUCT, V1084, P259, DOI 10.1016/j.molstruc.2014.11.049; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P727, DOI 10.1128/AAC.43.4.727; Monteiro Julio Marcelino, 2005, Rev. Árvore, V29, P999, DOI 10.1590/S0100-67622005000600020; Bitu VDN, 2014, NAT PROD RES, V28, P399, DOI 10.1080/14786419.2013.867343; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; O'Neil MJ, 2013, MERCK INDEX; OECD, 2000, OECD GUID DOC AC OR; OTSUKA M, 1990, INT J PHARM, V62, P65; Owens H.M., 2003, EXCIP RELAT, V30, P21, DOI DOI 10.1016/S0099-5428(03)30002-4; Pogue JM, 2015, CLIN MICROBIOL INFEC, V21, P302, DOI 10.1016/j.cmi.2014.12.025; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Prakash D, 2007, FOOD CHEM, V104, P783, DOI 10.1016/j.foodchem.2006.12.029; Prochazkova D, 2011, FITOTERAPIA, V82, P513, DOI 10.1016/j.fitote.2011.01.018; Queiroz LP, 2010, NEODIVERSITY, V5, P11, DOI DOI 10.13102/NE0D.51.3; Rahman A, 2015, PHARM ANAL ACTA, V6, P3, DOI [10.4172/2153-2435.10 0 0348, DOI 10.4172/2153-2435.1000348]; Ribeiro ARS, 2013, J ETHNOPHARMACOL, V147, P383, DOI 10.1016/j.jep.2013.03.023; Rios JL, 2005, J ETHNOPHARMACOL, V100, P80, DOI 10.1016/j.jep.2005.04.025; Roby MHH, 2013, IND CROP PROD, V43, P827, DOI 10.1016/j.indcrop.2012.08.029; Vaquero MJR, 2007, FOOD CONTROL, V18, P93, DOI 10.1016/j.foodcont.2005.08.010; Rossolini GM, 2014, CURR OPIN PHARMACOL, V18, P56, DOI 10.1016/j.coph.2014.09.006; Sadeek SA, 2011, SPECTROCHIM ACTA A, V78, P854, DOI 10.1016/j.saa.2010.12.048; Sanchez-Maldonado AF, 2011, J APPL MICROBIOL, V111, P1176, DOI 10.1111/j.1365-2672.2011.05141.x; Santana DG, 2012, J ETHNOPHARMACOL, V142, P445, DOI 10.1016/j.jep.2012.05.015; Santos CA, 2011, REV BRAS FARMACOGN, V21, P1077, DOI 10.1590/S0102-695X2011005000179; Saraiva AM, 2012, BRAZ J PHARM SCI, V48, P147, DOI 10.1590/S1984-82502012000100016; Savage PB, 2001, ANN MED, V33, P167, DOI 10.3109/07853890109002073; Schmidt B, 2008, METABOLISM, V57, pS3, DOI 10.1016/j.metabol.2008.03.001; Shakil S, 2008, J BIOMED SCI, V15, P5, DOI 10.1007/s11373-007-9194-y; Silva Ana Carolina Oliveira da, 2005, Acta Bot. Bras., V19, P17, DOI 10.1590/S0102-33062005000100003; Silva C. H. T. P. da, 2012, Journal of Medicinal Plants Research, V6, P4766; Silva FD, 2011, REV BRAS FARMACOGN, V21, P382, DOI 10.1590/S0102-695X2011005000054; Strlic M, 2002, J AGR FOOD CHEM, V50, P6313, DOI 10.1021/jf025636j; SUSTAR B, 1993, J THERM ANAL, V40, P475, DOI 10.1007/BF02546616; Taylor PW, 2013, INT J ANTIMICROB AG, V42, P195, DOI 10.1016/j.ijantimicag.2013.05.004; Tintino SR, 2014, ACTA BOT CROAT, V73, P281, DOI 10.2478/botcro-2013-0026; Vieira DRP, 2014, J ETHNOPHARMACOL, V155, P1441, DOI 10.1016/j.jep.2014.07.021; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; World Economic Forum, GLOB RISKS 2014; Wu YL, 1999, J ANTIMICROB CHEMOTH, V44, P389, DOI 10.1093/jac/44.3.389; Yen GC, 2002, FOOD CHEM, V79, P307, DOI 10.1016/S0308-8146(02)00145-0; Yilmaz Y, 2004, J AGR FOOD CHEM, V52, P255, DOI 10.1021/jf030117h	104	20	20	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2016	11	5							e0155532	10.1371/journal.pone.0155532	http://dx.doi.org/10.1371/journal.pone.0155532			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3ZU	27192209	Green Published, gold, Green Submitted			2023-01-03	WOS:000376286100062
J	Sondaal, SFV; Browne, JL; Amoakoh-Coleman, M; Borgstein, A; Miltenburg, AS; Verwijs, M; Klipstein-Grobusch, K				Sondaal, Stephanie Felicie Victoria; Browne, Joyce Linda; Amoakoh-Coleman, Mary; Borgstein, Alexander; Miltenburg, Andrea Solnes; Verwijs, Mirjam; Klipstein-Grobusch, Kerstin			Assessing the Effect of mHealth Interventions in Improving Maternal and Neonatal Care in Low- and Middle-Income Countries: A Systematic Review	PLOS ONE			English	Review							SHORT MESSAGE SERVICE; PREGNANT-WOMEN; MOBILE-PHONE; SOCIAL SUPPORT; SMART PHONE; HEALTH; FEASIBILITY; ZANZIBAR; PROGRAM; MOTHER	Introduction Maternal and neonatal mortality remains high in many low-and middle-income countries (LMIC). Availability and use of mobile phones is increasing rapidly with 90% of persons in developing countries having a mobile-cellular subscription. Mobile health (mHealth) interventions have been proposed as effective solutions to improve maternal and neonatal health. This systematic review assessed the effect of mHealth interventions that support pregnant women during the antenatal, birth and postnatal period in LMIC. Methods The review was registered with Prospero (CRD42014010292). Six databases were searched from June 2014-April 2015, accompanied by grey literature search using pre-defined search terms linked to pregnant women in LMIC and mHealth. Quality of articles was assessed with an adapted Cochrane Risk of Bias Tool. Because of heterogeneity in outcomes, settings and study designs a narrative synthesis of quantitative results of intervention studies on maternal outcomes, neonatal outcomes, service utilization, and healthy pregnancy education was conducted. Qualitative and quantitative results were synthesized with a strengths, weaknesses, opportunities, and threats analysis. Results In total, 3777 articles were found, of which 27 studies were included: twelve intervention studies and fifteen descriptive studies. mHealth interventions targeted at pregnant women increased maternal and neonatal service utilization shown through increased antenatal care attendance, facility-service utilization, skilled attendance at birth, and vaccination rates. Few articles assessed the effect on maternal or neonatal health outcomes, with inconsistent results. Conclusion mHealth interventions may be effective solutions to improve maternal and neonatal service utilization. Further studies assessing mHealth's impact on maternal and neonatal outcomes are recommended. The emerging trend of strong experimental research designs with randomized controlled trials, combined with feasibility research, government involvement and integration of mHealth interventions into the healthcare system is encouraging and can pave the way to improved decision making on best practice implementation of mHealth interventions.	[Sondaal, Stephanie Felicie Victoria; Browne, Joyce Linda; Amoakoh-Coleman, Mary; Borgstein, Alexander; Klipstein-Grobusch, Kerstin] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands; [Amoakoh-Coleman, Mary] Univ Ghana, Sch Publ Hlth, Legon, Accra, Ghana; [Borgstein, Alexander] Univ Oslo, Dept Community Med, Inst Hlth & Soc, Oslo, Norway; [Verwijs, Mirjam] Afya Connect 4 Change, Change Lake Zone, Mwanza, Tanzania; [Verwijs, Mirjam] Int Inst Commun & Dev, The Hague, Netherlands; [Klipstein-Grobusch, Kerstin] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Epidemiol & Biostat, Johannesburg, South Africa	Utrecht University; Utrecht University Medical Center; University of Ghana; University of Oslo; University of Witwatersrand	Sondaal, SFV (corresponding author), Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands.	stephanie.sondaal@gmail.com	Klipstein-Grobusch, Kerstin/F-5555-2016	Klipstein-Grobusch, Kerstin/0000-0002-5462-9889	FOGARTY INTERNATIONAL CENTER [D43TW009140] Funding Source: NIH RePORTER	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Agarwal S, 2014, JAMA-J AM MED ASSOC, V312, P229, DOI 10.1001/jama.2014.6371; Alam M, 2013, MAMA APONJON FORMATI; [Anonymous], 2013, BUILDING DIGITAL CAP; [Anonymous], 2013, NEED SUSTAINABILITY; [Anonymous], 2012, MOBILE TECHNOLOGY CO; [Anonymous], 2013, HLTH PREGNANCY HLTH; [Anonymous], 2014, UND NEEDS WANTS PREG; [Anonymous], 2011, AMPL IMP EX INT MOB; [Anonymous], 2013, HLTH COMM US MOB TEC; [Anonymous], 2012, JIVITA J MOBILE TECH; [Anonymous], 2013, EHEALTH INNOVATION W; Aranda-Jan CB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-188; Balogun MR, 2012, S AFR J CHILD HEALTH, V6, P76, DOI 10.7196/SAJCH.439; Bullock LFC, 2002, JOGNN, V31, P658, DOI 10.1177/088421702129005290; Bullock L, 2009, MATERN CHILD HLTH J, V13, P395, DOI 10.1007/s10995-008-0363-z; Bunik M, 2010, ACAD PEDIATR, V10, P21, DOI 10.1016/j.acap.2009.09.014; Datta SS, 2014, AUSTRALAS MED J, V7, P175, DOI 10.4066/AMJ.2014.1916; Dean AL, 2012, J TELEMED TELECARE, V18, P399, DOI 10.1258/jtt.2012.120118; Engle BKL, 2010, MOBILE PHONE INTERVE, P40; Flax VL, 2014, J NUTR, DOI [10.3945/jn.113.190124.increased, DOI 10.3945/JN.113.190124.INCREASED]; Gazmararian JA, 2014, MATERN CHILD HLTH J, V18, P223, DOI 10.1007/s10995-013-1258-1; Gazmararian JA, 2012, J HEALTH COMMUN, V17, P303, DOI 10.1080/10810730.2012.712618; Hannan J, 2013, J CLIN NURS, V22, P262, DOI 10.1111/j.1365-2702.2011.04065.x; Helms MM, 2010, J STRATEGY MANAG, V3, P215, DOI 10.1108/17554251011064837; Herman J, 2005, JOGNN-J OBST GYN NEO, V34, P713, DOI 10.1177/0884217505282019; Higgins J., 2011, COCHRAN HDB SYSTEMAT, V5; Huq L., 2012, INT J SOCIO ANTHRO, V4, P226, DOI [10.5897/IJSA11.134, DOI 10.5897/IJSA11.134]; Huq NL, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-52; Jalloh-Vos H, 2014, MOBILE HLTH CONNECTI; Jareethum Rossathum, 2008, Journal of the Medical Association of Thailand, V91, P458; Jennings L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1131; Jiang H, 2014, JAMA PEDIATR, V168, P471, DOI 10.1001/jamapediatrics.2014.58; Kaewkungwal J, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-69; Khorshid MR, 2014, J TELEMED TELECARE, V20, P201, DOI 10.1177/1357633X14533895; Kuo M-C, 2012, P INT C NURS INFORM, P228; Labrique AB, 2013, GLOB HEALTH-SCI PRAC, V1, P160, DOI 10.9745/GHSP-D-13-00031; Lau YK, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-284; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Lund S, 2012, BJOG-INT J OBSTET GY, V119, P1256, DOI 10.1111/j.1471-0528.2012.03413.x; Lund S, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.2941; Lund S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-29; MAMA South Africa, 2014, REIM MOB S AFR LESS; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Needs S, 2013, MHEALTH MNCH STATE E, P1; Noordam AC, 2011, TROP MED INT HEALTH, V16, P622, DOI 10.1111/j.1365-3156.2011.02747.x; Ormel H., 2013, MHEALTH EHEALTH INNO; Oyeyemi SO, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-8; Parker DR, 2007, NICOTINE TOB RES, V9, P1043, DOI 10.1080/14622200701591617; Pathak P., 2012, INDIA VACCINATION PI; Reeves ABC, 2008, INCLUDING NONRANDOMI; Ross R, 2013, J ASSOC NURSE AIDS C, V24, pE13, DOI 10.1016/j.jana.2012.08.005; Sanou B., 2014, WORLD 2014 ICT FACTS; Smith C, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-427; Stockwell MS, 2014, AM J PUBLIC HEALTH, V104, pE7, DOI 10.2105/AJPH.2013.301620; Tahir NM, 2013, INT J NURS STUD, V50, P16, DOI 10.1016/j.ijnurstu.2012.09.006; Tamrat T, 2012, MATERN CHILD HLTH J, V16, P1092, DOI 10.1007/s10995-011-0836-3; Tomlinson M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001382; Tong A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-181; Vinekar A, 2014, INDIAN J OPHTHALMOL, V62, P41, DOI 10.4103/0301-4738.126178; Wakadha H, 2013, VACCINE, V31, P987, DOI 10.1016/j.vaccine.2012.11.093; Wang H, 2014, LANCET, V384, P957; Watkins SC, 2013, EVALUATION INFORM CO; WHO, 2014, TRENDS MAT MORT 1990; World Bank, 2015, COUNTR LEND GROUPS; World Health Organization, 2011, WHO GLOB OBS EHEALTH; Yamamichi M, 2012, MOBILE APPL HLTH SEC	68	195	196	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2016	11	5							e0154664	10.1371/journal.pone.0154664	http://dx.doi.org/10.1371/journal.pone.0154664			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DL5KR	27144393	gold, Green Published, Green Submitted			2023-01-03	WOS:000375676400058
J	Hammel, P; Huguet, F; van Laethem, JL; Goldstein, D; Glimelius, B; Artru, P; Borbath, I; Bouche, O; Shannon, J; Andre, T; Mineur, L; Chibaudel, B; Bonnetain, F; Louvet, C				Hammel, Pascal; Huguet, Florence; van Laethem, Jean-Luc; Goldstein, David; Glimelius, Bengt; Artru, Pascal; Borbath, Ivan; Bouche, Olivier; Shannon, Jenny; Andre, Thierry; Mineur, Laurent; Chibaudel, Benoist; Bonnetain, Franck; Louvet, Christophe			Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHASE-III TRIAL; RADIATION; ADENOCARCINOMA; THERAPY; 5-FLUOROURACIL; RADIOTHERAPY; CONCURRENT; FOLFIRINOX; CARCINOMA; STOMACH	IMPORTANCE In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown. OBJECTIVES To assess whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy and to assess the effect of erlotinib on survival. DESIGN, SETTING, ANDPARTICIPANTS InLAP07, an international, open-label, phase3randomized trial, 449 patientswere enrolled between 2008and 2011. Follow-up ended in February 2013. INTERVENTIONS In the first randomization, 223 patients received 1000mg/m(2) weekly of gemcitabine alone and 219 patients received 1000mg/m(2) of gemcitabine plus 100mg/d of erlotinib. In the second randomization involving patients with progression-free disease after 4 months, 136 patients received 2 months of the same chemotherapy and 133 underwent chemoradiotherapy (54 Gy plus capecitabine). MAIN OUTCOMES AND MEASURES The primary outcomewas overall survival from the date of the first randomization. Secondary outcomeswere the effect of erlotinib and quality assurance of radiotherapy on overall survival, progression-free survival of gemcitabine-erlotinib and erlotinib maintenance with gemcitabine alone at the second randomization, and toxic effects. RESULTS A total of 442 of the 449 patients (232 men; median age, 63.3 years) enrolled underwent the first randomization. Of these, 269 underwent the second randomization. Interim analysis was performed when 221 patients died (109 in the chemoradiotherapy group and 112 in the chemotherapy group), reaching the early stopping boundaries for futility. With a median follow-up of 36.7 months, the median overall survival from the date of the first randomization was not significantly different between chemotherapy at 16.5 months (95% CI, 14.5-18.5 months) and chemoradiotherapy at 15.2 months (95% CI, 13.9-17.3 months; hazard ratio [HR], 1.03; 95% CI, 0.79-1.34; P = .83). Median overall survival from the date of the first randomization for the 223 patients receiving gemcitabine was 13.6 months (95% CI, 12.3-15.3 months) and was 11.9 months (95% CI, 10.4-13.5 months) for the 219 patients receiving gemcitabine plus erlotinib (HR, 1.19; 95% CI, 0.97-1.45; P = .09; 188 deaths vs 191 deaths). Chemoradiotherapy was associated with decreased local progression (32% vs 46%, P = .03) and no increase in grade 3 to 4 toxicity, except for nausea. CONCLUSIONS AND RELEVANCE In this open-label, randomized trial involving patients with locally advanced pancreatic cancer with disease controlled after 4 months of induction chemotherapy, there was no significant difference in overall survival with chemoradiotherapy compared with chemotherapy alone and there was no significant difference in overall survival with gemcitabine compared with gemcitabine plus erlotinib used as maintenance therapy.	[Hammel, Pascal] Hop Beaujon, AP HP, Dept Digest Oncol, F-92110 Clichy, France; [Huguet, Florence] Tenon Hosp, AP HP, Dept Radiotherapy, Paris, France; [van Laethem, Jean-Luc] Erasme Univ Hosp, Dept Gastroenterol, B-1070 Brussels, Belgium; [Goldstein, David] Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia; [Goldstein, David; Shannon, Jenny] Australasian Gastrointestinal Trials Grp AGITG, Camperdown, NSW, Australia; [Goldstein, David; Shannon, Jenny] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Glimelius, Bengt] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Uppsala, Sweden; [Artru, Pascal] Jean Mermoz Hosp, Dept Gastroenterol, Lyon, France; [Borbath, Ivan] Clin Univ St Luc, Dept Gastroenterol, B-1200 Brussels, Belgium; [Bouche, Olivier] Hop Robert Debre, Dept Gastroenterol, Reims, France; [Shannon, Jenny] Nepean Hosp NSW, Dept Med Oncol, Sydney, NSW, Australia; [Andre, Thierry] Hop St Antoine, AP HP, Dept Med Oncol, F-75571 Paris, France; [Mineur, Laurent] St Catherine Inst, Dept Radiotherapy & Med Oncol, Avignon, France; [Chibaudel, Benoist] Franco British Hosp Inst, Dept Med Oncol, Levallois Perret, France; [Chibaudel, Benoist] Oncol Multidisciplinary Res Grp GERCOR, Paris, France; [Bonnetain, Franck] Hosp Minjoz, Dept Methodol & Qual Life Oncol, Besancon, France; [Louvet, Christophe] Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of New South Wales Sydney; Uppsala University; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU de Reims; Universite de Reims Champagne-Ardenne; Nepean Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Franche-Comte; CHU Besancon; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite	Hammel, P (corresponding author), Hop Beaujon, AP HP, Serv Oncol Digest, 100 Blvd Gen Leclerc, F-92110 Clichy, France.	pascal.hammel@aphp.fr	goldstein, david/J-6711-2012; Pezet, Denis/I-4423-2017; André, Thierry P/N-8830-2017	Pezet, Denis/0000-0001-9416-2876; André, Thierry P/0000-0002-5103-7095; Chibaudel, Benoist/0000-0003-1279-2044; Hruby, George/0000-0003-4193-9682; Ychou, Marc/0000-0001-7378-9469; Borbath, Ivan/0000-0001-7598-214X; Kneebone, Andrew/0000-0002-7629-504X; LECOMTE, Thierry/0000-0001-5093-0212; Hammel, Pascal/0000-0002-4630-4996	Roche; French National Institute of Cancer (INCa)	Roche(Roche Holding); French National Institute of Cancer (INCa)(Institut National du Cancer (INCA) France)	This trial was supported by Roche and French National Institute of Cancer (INCa).	Abrams RA, 2012, INT J RADIAT ONCOL, V82, P809, DOI 10.1016/j.ijrobp.2010.11.039; Ben-Josef E, 2012, INT J RADIAT ONCOL, V84, P1166, DOI 10.1016/j.ijrobp.2012.02.051; Bidard FC, 2013, ANN ONCOL, V24, P2057, DOI 10.1093/annonc/mdt176; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chauffert B, 2008, ANN ONCOL, V19, P1592, DOI 10.1093/annonc/mdn281; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; DOUGLASS HO, 1988, JNCI-J NATL CANCER I, V80, P751; Faris JE, 2013, ONCOLOGIST, V18, P543, DOI 10.1634/theoncologist.2012-0435; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; HAZEL JJ, 1981, J CAN ASSOC RADIOL, V32, P164; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Huguet F, 2007, J CLIN ONCOL, V25, P326, DOI 10.1200/JCO.2006.07.5663; Huguet F, 2012, INT J RADIAT ONCOL, V83, P1355, DOI 10.1016/j.ijrobp.2011.11.050; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLAASSEN DJ, 1985, J CLIN ONCOL, V3, P373, DOI 10.1200/JCO.1985.3.3.373; Krishnan S, 2007, CANCER-AM CANCER SOC, V110, P47, DOI 10.1002/cncr.22735; Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904; Melidis C, 2014, INT J RADIAT ONCOL, V90, P1242, DOI 10.1016/j.ijrobp.2014.08.348; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mukherjee S, 2013, LANCET ONCOL, V14, P317, DOI 10.1016/S1470-2045(13)70021-4; Pietrasz D, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e15250; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sobin LH, 2002, TNM CLASSIJFICATION; Tempero MA, 2014, J NATL COMPR CANC NE, V12, P1083, DOI 10.6004/jnccn.2014.0106; VAUPEL JW, 1979, DEMOGRAPHY, V16, P439, DOI 10.2307/2061224; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369	28	565	582	8	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2016	315	17					1844	1853		10.1001/jama.2016.4324	http://dx.doi.org/10.1001/jama.2016.4324			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK9XF	27139057	Bronze			2023-01-03	WOS:000375284400013
J	Levy, SD; Alladina, JW; Hibbert, KA; Harris, RS; Bajwa, EK; Hess, DR				Levy, Sean D.; Alladina, Jehan W.; Hibbert, Kathryn A.; Harris, R. Scott; Bajwa, Ednan K.; Hess, Dean R.			High-flow oxygen therapy and other inhaled therapies in intensive care units	LANCET			English	Article							ACUTE RESPIRATORY-DISTRESS; NASAL CANNULA OXYGEN; ACUTE LUNG INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; NITRIC-OXIDE; PULMONARY-HYPERTENSION; NONINVASIVE VENTILATION; HELIUM-OXYGEN; REFRACTORY HYPOXEMIA; RANDOMIZED-TRIAL	In this Series paper, we review the current evidence for the use of high-flow oxygen therapy, inhaled gases, and aerosols in the care of critically ill patients. The available evidence supports the use of high-flow nasal cannulae for selected patients with acute hypoxaemic respiratory failure. Heliox might prevent intubation or improve gas flow in mechanically ventilated patients with severe asthma. Additionally, it might improve the delivery of aerosolised bronchodilators in obstructive lung disease in general. Inhaled nitric oxide might improve outcomes in a subset of patients with postoperative pulmonary hypertension who had cardiac surgery; however, it has not been shown to provide long-term benefit in patients with acute respiratory distress syndrome (ARDS). Inhaled prostacyclins, similar to inhaled nitric oxide, are not recommended for routine use in patients with ARDS, but can be used to improve oxygenation in patients who are not adequately stabilised with traditional therapies. Aerosolised bronchodilators are useful in mechanically ventilated patients with asthma and chronic obstructive pulmonary disease, but are not recommended for those with ARDS. Use of aerosolised antibiotics for ventilator-associated pneumonia and ventilator-associated tracheobronchitis shows promise, but the delivered dose can be highly variable if proper attention is not paid to the delivery method.	[Levy, Sean D.; Alladina, Jehan W.; Hibbert, Kathryn A.; Harris, R. Scott; Bajwa, Ednan K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm Crit Care & Sleep Med, Boston, MA USA; [Hess, Dean R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Resp Care, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Hess, DR (corresponding author), Massachusetts Gen Hosp, Resp Care, Boston, MA 02114 USA.	dhess@mgh.harvard.edu	Hess, Dean/AAL-3017-2020	Bajwa, Ednan/0000-0001-9026-1009	Merck; Philips Respironics; Medtronic Covidien; Bayer; McGraw-Hill; UpToDate; American Board of Internal Medicine	Merck(Merck & Company); Philips Respironics; Medtronic Covidien; Bayer(Bayer AG); McGraw-Hill; UpToDate; American Board of Internal Medicine	RSH receives consulting fees from Merck for service on a clinical adjudication committee for pneumonia events in a clinical trial. DRH reports personal fees from Philips Respironics, Medtronic Covidien, Bayer, McGraw-Hill, Jones and Bartlett, UpToDate, and the American Board of Internal Medicine. SDL, JWA, KAH, and EKB declare no competing interests.	Adhikari NKJ, 2014, CRIT CARE MED, V42, P404, DOI 10.1097/CCM.0b013e3182a27909; Afshari A, 2011, ANESTH ANALG, V112, P1411, DOI 10.1213/ANE.0b013e31820bd185; Ammar MA, 2015, ANN PHARMACOTHER, V49, P1105, DOI 10.1177/1060028015595642; Ardehali A, 2001, TRANSPLANTATION, V72, P112, DOI 10.1097/00007890-200107150-00022; Argenziano M, 1998, ANN THORAC SURG, V65, P340, DOI 10.1016/S0003-4975(97)01307-6; Ari A, 2012, J AEROSOL MED PULM D, V25, P319, DOI 10.1089/jamp.2011.0936; BEATY CD, 1989, CHEST, V96, P1360, DOI 10.1378/chest.96.6.1360; Beghetti M, 1998, ANN THORAC SURG, V66, P532, DOI 10.1016/S0003-4975(98)00447-0; Beurskens CJ, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/954814; Beurskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078159; Black SM, 1999, AM J PHYSIOL-HEART C, V277, pH1849, DOI 10.1152/ajpheart.1999.277.5.H1849; Brandao DC, 2009, J ASTHMA, V46, P356, DOI 10.1080/02770900902718829; Chanques G, 2013, MINERVA ANESTESIOL, V79, P1344; Christenson J, 2000, AM J RESP CRIT CARE, V161, P1443, DOI 10.1164/ajrccm.161.5.9806138; Corley A, 2011, BRIT J ANAESTH, V107, P998, DOI 10.1093/bja/aer265; CRAVEN DE, 1984, AM J MED, V77, P834, DOI 10.1016/0002-9343(84)90520-5; Cuthbertson BH, 1997, BRIT J ANAESTH, V78, P696, DOI 10.1093/bja/78.6.696; De Wet CJ, 2004, J THORAC CARDIOV SUR, V127, P1058, DOI 10.1016/j.jtcvs.2003.11.035; Dellinger RP, 1998, CRIT CARE MED, V26, P619, DOI 10.1097/00003246-199803000-00043; Diehl JL, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-24; Dzierba AL, 2014, PHARMACOTHERAPY, V34, P279, DOI 10.1002/phar.1365; Ehrmann S, 2016, INTENS CARE MED, V42, P192, DOI 10.1007/s00134-015-4114-5; El-Khatib MF, 2014, LUNG, V192, P377, DOI 10.1007/s00408-014-9570-0; FERNANDEZ A, 1994, INTENS CARE MED, V20, P199, DOI 10.1007/BF01704700; Foubert L, 1993, J Cardiothorac Vasc Anesth, V7, P506, DOI 10.1016/1053-0770(93)90200-5; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Frat JP, 2015, RESP CARE, V60, P170, DOI 10.4187/respcare.03075; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; Fuller BM, 2015, CHEST, V147, P1510, DOI 10.1378/chest.14-3161; Fullerton DA, 1996, ANN THORAC SURG, V61, P1856, DOI 10.1016/0003-4975(96)00046-X; Galindo VC, 2013, RESP CARE, V58, P241, DOI 10.4187/respcare.01371; Gerbeaux P, 2001, CRIT CARE MED, V29, P2322, DOI 10.1097/00003246-200112000-00015; GLUCK EH, 1990, CHEST, V98, P693, DOI 10.1378/chest.98.3.693; Guerin C, 1999, AM J RESP CRIT CARE, V159, P1036, DOI 10.1164/ajrccm.159.4.9710081; Hanhan U, 1993, RESP CARE, V38, P474; Harris KW, 2007, RESP CARE, V52, P1507; Hernandez G, 2016, JAMA-J AM MED ASSOC, V315, P1354, DOI 10.1001/jama.2016.2711; Hess DR, 2015, RESP CARE, V60, P880, DOI 10.4187/respcare.04042; Hess DR, 2006, RESPIR CARE, V51, P608; Holland A, 2013, COCHRANE DB SYST REV, V6; Inglessis I, 2004, J AM COLL CARDIOL, V44, P793, DOI 10.1016/j.jacc.2004.05.047; Jaber S, 2001, AM J RESP CRIT CARE, V164, P633, DOI 10.1164/ajrccm.164.4.2008027; Jolliet P, 2003, CRIT CARE MED, V31, P878, DOI 10.1097/01.CCM.0000055369.37620.EE; Jolliet P, 2015, INTENSIVE CARE ME S1, V3, pA422; Jones PG, 2016, RESP CARE, V61, P291, DOI 10.4187/respcare.04252; Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5; Khan TA, 2009, J THORAC CARDIOV SUR, V138, P1417, DOI 10.1016/j.jtcvs.2009.04.063; Kollef MH, 1997, CHEST, V112, P765, DOI 10.1378/chest.112.3.765; Kress JP, 2002, AM J RESP CRIT CARE, V165, P1317, DOI 10.1164/rccm.9907035; Leatherman J, 2015, CHEST, V147, P1671, DOI 10.1378/chest.14-1733; Longest PW, 2013, J AEROSOL MED PULM D, V26, P266, DOI 10.1089/jamp.2012.1006; Lu Q, 2012, ANESTHESIOLOGY, V117, P1335, DOI 10.1097/ALN.0b013e31827515de; Lu Q, 2011, AM J RESP CRIT CARE, V184, P106, DOI 10.1164/rccm.201011-1894OC; Lu Q, 2010, INTENS CARE MED, V36, P1147, DOI 10.1007/s00134-010-1879-4; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Maggiore SM, 2014, AM J RESP CRIT CARE, V190, P282, DOI 10.1164/rccm.201402-0364OC; Maggiore SM, 2010, CRIT CARE MED, V38, P145, DOI 10.1097/CCM.0b013e3181b78abe; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McGinn K, 2016, ANN PHARMACOTHER, V50, P22, DOI 10.1177/1060028015608865; Meade MO, 2003, AM J RESP CRIT CARE, V167, P1483, DOI 10.1164/rccm.2203034; Miguel-Montanes R, 2015, CRIT CARE MED, V43, P574, DOI 10.1097/CCM.0000000000000743; Moller W, 2015, J APPL PHYSIOL, V118, P1525, DOI 10.1152/japplphysiol.00934.2014; Mundel T, 2013, J APPL PHYSIOL, V114, P1058, DOI 10.1152/japplphysiol.01308.2012; Napolitano LM, 2010, CRIT CARE MED, V38, pE74, DOI 10.1097/CCM.0b013e3181cc5373; Nishimura M, 2016, RESP CARE, V61, P529, DOI 10.4187/respcare.04577; Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5; Oishi P, 2011, RESP CARE, V56, P1314, DOI 10.4187/respcare.01297; Olschewski H, 1998, INTENS CARE MED, V24, P631, DOI 10.1007/s001340050628; Palmer LB, 2008, CRIT CARE MED, V36, P2008, DOI 10.1097/CCM.0b013e31817c0f9e; Palmer Lucy B, 2015, Curr Opin Pulm Med, V21, P239, DOI 10.1097/MCP.0000000000000160; Palmer LB, 2014, AM J RESP CRIT CARE, V189, P1225, DOI 10.1164/rccm.201312-2161OC; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parke RL, 2015, RESP CARE, V60, P1397, DOI 10.4187/respcare.04028; Parke RL, 2013, RESP CARE, V58, P1621, DOI 10.4187/respcare.02358; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Restrepo MI, 2015, RESP CARE, V60, P762, DOI 10.4187/respcare.04208; Rittayamai N, 2015, RESP CARE, V60, P1377, DOI 10.4187/respcare.03837; Rittayamai N, 2014, RESP CARE, V59, P485, DOI 10.4187/respcare.02397; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698, DOI 10.1164/ajrccm.157.3.9704022; Rodrigo GJ, 2014, ANN ALLERG ASTHMA IM, V112, P29, DOI 10.1016/j.anai.2013.09.024; Searcy RJ, 2015, THER ADV RESPIR DIS, V9, P302, DOI 10.1177/1753465815599345; SEMIGRAN MJ, 1994, J AM COLL CARDIOL, V24, P982, DOI 10.1016/0735-1097(94)90859-1; Semler MW, 2016, AM J RESP CRIT CARE, V193, P273, DOI 10.1164/rccm.201507-1294OC; Senturk E, 2012, MINERVA ANESTESIOL, V78, P1005; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Sokol GM, 1999, CLIN CHEM, V45, P382; Sokol J, 2003, ANESTH ANALG, V97, P989, DOI [10.1213/01.ANE.0000078819.48523.26, 10.1213/01.ANE.0000078819.45523.26]; Sole-Lleonart C, 2016, RESP CARE, V61, P1008, DOI 10.4187/respcare.04519; Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871; Stephan F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI 10.1001/jama.2015.5213; Stork E, 1997, NEW ENGL J MED, V336, P597; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Torbic H, 2016, ANN PHARMACOTHER, V50, P106, DOI 10.1177/1060028015621308; Torbic H, 2013, J CRIT CARE, V28, P844, DOI 10.1016/j.jcrc.2013.03.006; Valachis A, 2015, CRIT CARE MED, V43, P527, DOI 10.1097/CCM.0000000000000771; van Heerden PV, 2000, CHEST, V117, P819, DOI 10.1378/chest.117.3.819; Venegas J, 2013, J AEROSOL MED PULM D, V26, P1, DOI 10.1089/jamp.2011.0944; Vourc'h M, 2015, INTENS CARE MED, V41, P1538, DOI 10.1007/s00134-015-3796-z; Weinberger B, 2001, TOXICOL SCI, V59, P5, DOI 10.1093/toxsci/59.1.5; YAHAGI N, 1995, ARTIF ORGANS, V19, P557, DOI 10.1111/j.1525-1594.1995.tb02378.x; Yu B, 2015, SCI TRANSL MED, V7; Zampieri FG, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0868-y	103	29	32	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2016	387	10030					1867	1878		10.1016/S0140-6736(16)30245-8	http://dx.doi.org/10.1016/S0140-6736(16)30245-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK6SS	27203510				2023-01-03	WOS:000375056100035
J	Lenzer, J				Lenzer, Jeanne			Experts and activists discuss how to get "right care" for patients Jeanne Lenzer reports on a growing movement aiming to overcome the medical and social barriers to appropriate care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												Jeanne.lenzer@gmail.com						Ebrahim S, 2016, J CLIN EPIDEMIOL, V70, P155, DOI 10.1016/j.jclinepi.2015.08.021; Fleming PS, 2016, J CLIN EPIDEMIOL, V78, P34, DOI 10.1016/j.jclinepi.2016.03.012; Gawande Atul, 2011, New Yorker, P40; OECD, 2015, HLTH STAT; Transparency International, GLOB CORR BAR 2013; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	6	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2016	353								i2406	10.1136/bmj.i2406	http://dx.doi.org/10.1136/bmj.i2406			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2RY	27129484				2023-01-03	WOS:000375484100005
J	Waniewski, J; Debowska, M; Wojcik-Zaluska, A; Ksiazek, A; Zaluska, W				Waniewski, Jacek; Debowska, Malgorzata; Wojcik-Zaluska, Alicja; Ksiazek, Andrzej; Zaluska, Wojciech			Quantification of Dialytic Removal and Extracellular Calcium Mass Balance during a Weekly Cycle of Hemodialysis	PLOS ONE			English	Article							DIALYSIS ADEQUACY INDEXES; CHRONIC KIDNEY-DISEASE; PERITONEAL-DIALYSIS; PARATHYROID-HORMONE; MATHEMATICAL-MODEL; KINETIC-MODEL; SERUM-CALCIUM; HOMEOSTASIS; PHOSPHATE; OUTCOMES	Objectives The removal of calcium during hemodialysis with low calcium concentration in dialysis fluid is generally slow, and the net absorption of calcium from dialysis fluid is often reported. The details of the calcium transport process during dialysis and calcium mass balance in the extracellular fluid, however, have not been fully studied. Methods Weekly cycle of three dialysis sessions with interdialytic breaks of 2-2-3 days was monitored in 25 stable patients on maintenance hemodialysis with calcium concentration in dialysis fluid of 1.35 mmol/L. Total and ionic calcium were frequently measured in blood and dialysate. The volume of fluid compartments was measured by bioimpedance. Results Weekly dialytic removal of 12.79 +/- 8.71 mmol calcium was found in 17 patients, whereas 9.48 +/- 8.07 mmol calcium was absorbed per week from dialysis fluid in 8 patients. Ionic calcium was generally absorbed from dialysis fluid, whereas complexed calcium (the difference of total and ionic calcium in dialysis fluid) was removed from the body. The concentration of total calcium in plasma increased slightly during dialysis. The mass of total and ionic calcium in extracellular fluid decreased during dialysis in patients with the dialytic removal of calcium from the body and did not change in patients with the absorption of calcium from dialysis fluid. Conclusions We conclude that about one third of patients on dialysis with calcium 1.35 mmol/L in dialysis fluid may absorb calcium from dialysis fluid and therefore individual prescriptions of calcium concentration in dialysis fluid should be considered for such patients.	[Waniewski, Jacek; Debowska, Malgorzata] Polish Acad Sci, Inst Biocybernet & Biomed Engn, Dept Math Modelling Physiol Proc, Warsaw, Poland; [Wojcik-Zaluska, Alicja] Med Univ Lublin, Dept Phys Therapy & Rehabil, Lublin, Poland; [Ksiazek, Andrzej; Zaluska, Wojciech] Med Univ Lublin, Dept Nephrol, Lublin, Poland	Polish Academy of Sciences; Nalecz Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Sciences; Medical University of Lublin; Medical University of Lublin	Debowska, M (corresponding author), Polish Acad Sci, Inst Biocybernet & Biomed Engn, Dept Math Modelling Physiol Proc, Warsaw, Poland.	mdebowska@ibib.waw.pl	Debowska, Malgorzata/F-3035-2015	Debowska, Malgorzata/0000-0001-8741-7930	National Science Centre (Poland) [N N518 289840]	National Science Centre (Poland)	This study was supported by the National Science Centre (Poland), grant no N N518 289840. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agar BU, 2011, CLIN J AM SOC NEPHRO, V6, P2854, DOI 10.2215/CJN.03860411; Basile C, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/540592; Basile C, 2012, AM J KIDNEY DIS, V59, P92, DOI 10.1053/j.ajkd.2011.08.033; Basile C, 2010, NEPHROL DIAL TRANSPL, V25, P1356, DOI 10.1093/ndt/gfp700; Casino FG, 1996, NEPHROL DIAL TRANSPL, V11, P1574; Casino FG, 2004, NEPHROL DIAL TRANSPL, V19, P1454, DOI 10.1093/ndt/gfh218; Debowska M., 2011, PROGR HEMODIALYSIS F, P3; Debowska M, 2007, ASAIO J, V53, P566, DOI 10.1097/MAT.0b013e31810c06d2; Debowska M, 2007, ARTIF ORGANS, V31, P61, DOI 10.1111/j.1525-1594.2007.00341.x; Debowska M, 2015, ARTIF ORGANS, V39, P1005, DOI 10.1111/aor.12489; Debowska M, 2015, NEPHROL DIAL TRANSPL, V30, P129, DOI 10.1093/ndt/gfu266; Debowska M, 2010, ARTIF ORGANS, V34, P412, DOI 10.1111/j.1525-1594.2009.00873.x; Drueke TB, 2009, NEPHROL DIAL TRANSPL, V24, P2990, DOI 10.1093/ndt/gfp365; Goldsmith DJA, 2010, NEPHROL DIAL TRANSPL, V25, P3823, DOI 10.1093/ndt/gfq513; Gonzalez-Parra E, 2014, BLOOD PURIFICAT, V38, P224, DOI 10.1159/000366126; Gotch F, 2007, BLOOD PURIFICAT, V25, P139, DOI 10.1159/000096891; Gotch F, 2010, BLOOD PURIFICAT, V29, P163, DOI 10.1159/000245924; Gotch FA, 2010, KIDNEY INT, V78, P343, DOI 10.1038/ki.2010.157; Gotch FA, 2009, NEPHROL DIAL TRANSPL, V24, P2994, DOI 10.1093/ndt/gfp360; Guyton A.C., 2006, TXB MED PHYSL; Jean G, 2013, NEPHROL DIAL TRANSPL, V28, P176, DOI 10.1093/ndt/gfs119; Karohl C, 2010, NEPHROL DIAL TRANSPL, V25, P1244, DOI 10.1093/ndt/gfp597; Leypoldt JK, 2003, NEPHROL DIAL TRANSPL, V18, P769, DOI 10.1093/ndt/gfg019; Malberti F, 2003, NEPHROL DIAL TRANSPL, V18, P37, DOI 10.1093/ndt/gfg1077; Messa P, 2009, BLOOD PURIFICAT, V27, P360, DOI 10.1159/000209249; Nikolov IG, 2009, BLOOD PURIFICAT, V27, P350, DOI 10.1159/000209248; NORDIN BEC, 1990, CLIN BIOCHEM, V23, P3, DOI 10.1016/0009-9120(90)90309-I; Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053; Pun PH, 2016, HEMODIAL INT, V20, P421, DOI 10.1111/hdi.12382; Raposo JF, 2002, J CLIN ENDOCR METAB, V87, P4330, DOI 10.1210/jc.2002-011870; Ross Morton A, 1997, NUTR MANAGMENT RENAL, P341; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Toussaint Nigel, 2006, Hemodial Int, V10, P326, DOI 10.1111/j.1542-4758.2006.00125.x; WANIEWSKI J, 1992, NEPHROL DIAL TRANSPL, V7, P50; Waniewski J, 2006, BLOOD PURIFICAT, V24, P355, DOI 10.1159/000093199; Waniewski J, 2014, ASAIO J, V60, P90, DOI 10.1097/MAT.0000000000000017; Waniewski J, 2010, BLOOD PURIFICAT, V30, P257, DOI 10.1159/000320764	37	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2016	11	4							e0153285	10.1371/journal.pone.0153285	http://dx.doi.org/10.1371/journal.pone.0153285			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ3UC	27073861	Green Published, gold, Green Submitted			2023-01-03	WOS:000374131200071
J	Land, WM; Liu, BY; Cordova, A; Fang, M; Huang, YF; Yao, WX				Land, William M.; Liu, Binya; Cordova, Alberto; Fang, Ming; Huang, Yufei; Yao, Wan X.			Effects of Physical Practice and Imagery Practice on Bilateral Transfer in Learning a Sequential Tapping Task	PLOS ONE			English	Article							MENTAL PRACTICE; INTERMANUAL TRANSFER; MUSCLE-CONTRACTIONS; INTERLIMB TRANSFER; PERFORMANCE; INCREASES; STRENGTH; FORCE	Recent research on bilateral transfer suggests that imagery training can facilitate the transfer of motor skill from a trained limb to that of an untrained limb above and beyond that of physical practice. To further explore this effect, the present study examined the influence of practice duration and task difficulty on the extent to which imagery training and physical training influences bilateral transfer of a sequential key pressing task. In experiment 1, participants trained on the key pressing task using their non-dominant arm under one of three conditions (physical practice, imagery practice, and no practice). In a subsequent bilateral transfer test, participants performed the sequential task using their untrained dominant arm in either an original order or mirror-ordered sequence. In experiment 2, the same procedures were followed as in experiment 1 except that participants trained with their dominant arm and performed the bilateral transfer task with their non-dominant arm. Results indicated that with extended practice beyond what has been employed in previous studies, physical practice is more effective at facilitating bilateral transfer compared to training with imagery. Interestingly, significant bilateral transfer was only observed for transfer from the non-dominant to the dominant arm with no differences observed between performing the task in an original or mirror ordered sequence. Overall, these findings suggest that imagery training may benefit bilateral transfer primarily at the initial stages of learning, but with extended training, physical practice leads to larger influences on transfer.	[Land, William M.; Liu, Binya; Cordova, Alberto; Yao, Wan X.] Univ Texas San Antonio, Dept Kinesiol Hlth & Nutr, San Antonio, TX USA; [Huang, Yufei] Univ Texas San Antonio, Dept Elect & Comp Engn, San Antonio, TX USA; [Fang, Ming] Yangzhou Univ, Coll Phys Educ, Yangzhou 225009, Jiangsu, Peoples R China	University of Texas System; University of Texas at San Antonio (UTSA); University of Texas System; University of Texas at San Antonio (UTSA); Yangzhou University	Yao, WX (corresponding author), Univ Texas San Antonio, Dept Kinesiol Hlth & Nutr, San Antonio, TX USA.	wanxiang.yao@utsa.edu	Huang, Yufei/AAU-2891-2021	Land, William/0000-0003-3244-1348				Amemiya K, 2010, BRAIN RES, V1343, P93, DOI 10.1016/j.brainres.2010.04.048; Arora S, 2011, ANN SURG, V253, P265, DOI 10.1097/SLA.0b013e318207a789; Ausenda CD, 2011, EUR J PHYS REHAB MED, V47, P417; Davis WW, 1898, STUD YALE PSYCHOL LA, V6, P18; Davis WW, 1900, STUDIES YALE PSYCHOL, V8, P64; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Fitts P.M., 1967, HUM PERFORM; Frank C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095175; Gentile AM., 1972, QUEST, V17, P3, DOI [10.1080/00336297.1972.10519717, DOI 10.1080/00336297.1972.10519717]; Guadagnoli MA, 2004, J MOTOR BEHAV, V36, P212, DOI 10.3200/JMBR.36.2.212-224; HICKS RE, 1974, AM J PSYCHOL, V87, P667, DOI 10.2307/1421973; Hikosaka O, 1999, TRENDS NEUROSCI, V22, P464, DOI 10.1016/S0166-2236(99)01439-3; HIRD JS, 1991, J SPORT EXERCISE PSY, V13, P281, DOI 10.1123/jsep.13.3.281; Krakauer JW, 1999, NAT NEUROSCI, V2, P1026, DOI 10.1038/14826; Lange K, 2006, EXP BRAIN RES, V168, P547, DOI 10.1007/s00221-005-0117-8; Lange RK, 2004, EXP BRAIN RES, V159, P161, DOI 10.1007/s00221-004-1942-x; LOGAN GD, 1988, HUM FACTORS, V30, P583, DOI 10.1177/001872088803000504; Lohse KR, 2010, J IMAGERY RES SPORT, V5, P1; PARLOW SE, 1990, BRAIN LANG, V39, P319, DOI 10.1016/0093-934X(90)90017-B; Sainburg RL, 2002, EXP BRAIN RES, V145, P437, DOI 10.1007/s00221-002-1140-7; SALTZMAN E, 1979, J MATH PSYCHOL, V20, P91, DOI 10.1016/0022-2496(79)90020-8; Teixeira LA, 2000, BRAIN COGNITION, V44, P455, DOI 10.1006/brcg.1999.1205; van Mier HI, 2006, NEUROPSYCHOLOGIA, V44, P939, DOI 10.1016/j.neuropsychologia.2005.08.010; Wang JS, 2004, J NEUROPHYSIOL, V92, P349, DOI 10.1152/jn.00960.2003; Wohldmann EL, 2008, J EXP PSYCHOL LEARN, V34, P823, DOI 10.1037/0278-7393.34.4.823; Yao WX, 2014, PERCEPT MOTOR SKILL, V118, P400, DOI 10.2466/23.25.PMS.118k19w1; Yao WX, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00561; YUE G, 1992, J NEUROPHYSIOL, V67, P1114, DOI 10.1152/jn.1992.67.5.1114	29	13	13	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2016	11	4							e0152228	10.1371/journal.pone.0152228	http://dx.doi.org/10.1371/journal.pone.0152228			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DI6IX	27050168	Green Published, Green Submitted, gold			2023-01-03	WOS:000373603500031
J	Pohle, S; Baty, F; Brutsche, M				Pohle, Susanne; Baty, Florent; Brutsche, Martin			In-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012	PLOS ONE			English	Article							UNITED-STATES; CANCER-RISK; FOLLOW-UP; MORTALITY; POPULATION	Sarcoidosis is a multisystem disease with an unpredictable and sometimes fatal course while the underlying pathomechanism is still unclear. Reasons of the increasing hospitalization rate and mortality in the United States remain in dispute but incriminated are a number of distinct comorbidities and risk factors as well as the application of more aggressive therapeutic agents. Studies reflecting the recent development in central Europe are lacking. Our aim was to investigate the recent mortality and hospitalization rates as well as the underlying comorbidities of hospitalized sarcoidosis patients in Switzerland. In this longitudinal, nested case-control study, a nation-wide database provided by the Swiss Federal Office for Statistics enclosing every hospital entry covering the years 2002-2012 (n = 15,627,573) was analyzed. There were 8,385 cases with a diagnosis of sarcoidosis representing 0.054% (8,385 / 15,627,573) of all hospitalizations in Switzerland. These cases were compared with age- and sex-matched controls without the diagnosis of sarcoidosis. Hospitalization and mortality rates in Switzerland remained stable over the observed time period. Comorbidity analysis revealed that sarcoidosis patients had significantly higher medication-related comorbidities compared to matched controls, probably due to systemic corticosteroids and immunosuppressive therapy. Sarcoidosis patients were also more frequently re-hospitalized (median annual hospitalization rate 0.28 [IQR 0.15-0.65] vs. 0.19 [IQR 0.13-0.36] per year; p < 0.001), had a longer hospital stay (6 [IQR 2-13] vs. 4 [IQR 1-8] days; p < 0.001), had more comorbidities (4 [IQR 2-7] vs. 2 [IQR 1-5]; p < 0.001), and had a significantly higher in-hospital mortality (2.6% [95% CI 2.3%-2.9%] vs. 1.8% [95% CI 1.5%-2.1%] (p < 0.001). A worse outcome was observed among sarcoidosis patients having co-occurrence of associated respiratory diseases. Moreover, age was an important risk factor for re-hospitalization.	[Pohle, Susanne; Baty, Florent; Brutsche, Martin] Cantonal Hosp St Gallen, Dept Pulm Med, St Gallen, Switzerland	Kantonsspital St. Gallen	Baty, F (corresponding author), Cantonal Hosp St Gallen, Dept Pulm Med, St Gallen, Switzerland.	florent.baty@kssg.ch		Brutsche, Martin/0000-0002-1612-3609	Lungenliga St. Gallen; Kantonsspital St. Gallen	Lungenliga St. Gallen; Kantonsspital St. Gallen	The study was supported by an unconditional research grant by the Lungenliga St. Gallen and an institutional grant by the Kantonsspital St. Gallen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was supported by an unconditional research grant by the Lungenliga St. Gallen and an institutional grant by the Kantonsspital St. Gallen.	Baty F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063285; Bonifazi M, 2015, CHEST, V147, P778, DOI 10.1378/chest.14-1475; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Deubelbeiss U, 2010, EUR RESPIR J, V35, P1088, DOI 10.1183/09031936.00197808; Duncan ME, 2012, INT J TUBERC LUNG D, V16, P38, DOI 10.5588/ijtld.11.0077; Foreman MG, 2006, SARCOIDOSIS VASC DIF, V23, P124; Gerke AK, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-19; Gideon NM, 1996, AM J MED, V100, P423, DOI 10.1016/S0002-9343(97)89518-6; Greenacre M.J., 2010, BIPLOTS IN PRACTICE; Ji J, 2009, ANN ONCOL, V20, P1121, DOI 10.1093/annonc/mdn767; Le Jeune I, 2007, RESP MED, V101, P2534, DOI 10.1016/j.rmed.2007.07.012; Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120; Nardi A, 2011, EUR RESPIR J, V38, P1368, DOI 10.1183/09031936.00187410; Oksanen J, 2010, MULTIVARIATE ANAL EC; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Romer FK, 1998, EUR RESPIR J, V12, P906, DOI 10.1183/09031936.98.12040906; Swigris JJ, 2011, CHEST, V140, P1261, DOI 10.1378/chest.11-0324; Swigris JJ, 2011, AM J RESP CRIT CARE, V183, P1524, DOI 10.1164/rccm.201010-1679OC; Tukey MH, 2013, SARCOIDOSIS VASC DIF, V30, P128; Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7	20	28	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151940	10.1371/journal.pone.0151940	http://dx.doi.org/10.1371/journal.pone.0151940			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1YG	26987059	gold, Green Submitted, Green Published			2023-01-03	WOS:000372580300156
J	Cho, KH; Park, EC; Nam, YS; Lee, SH; Nam, CM; Lee, SG				Cho, Kyoung Hee; Park, Eun-Cheol; Nam, Young Soon; Lee, Seon-Heui; Nam, Chung Mo; Lee, Sang Gyu			Impact of Market Competition on Continuity of Care and Hospital Admissions for Asthmatic Children: A Longitudinal Analysis of Nationwide Health Insurance Data 2009-2013	PLOS ONE			English	Article							AMBULATORY-CARE; ADULT PATIENTS; ADHERENCE; OUTCOMES	Background Ambulatory care-sensitive conditions, including asthma, can be managed with timely and effective outpatient care, thereby reducing the need for hospitalization. Objective This study assessed the relationship between market competition, continuity of care (COC), and hospital admissions in asthmatic children according to their health care provider. Methods A longitudinal design was employed with a 5-year follow-up period, between 2009 and 2013, under a Korean universal health insurance program. A total of 253 geographical regions were included in the analysis, according to data from the Korean Statistical Office. Data from 9,997 patients, aged <= 12 years, were included. We measured the COC over a 5-year period using the Usual Provider Continuity (UPC) index. Random intercept models were calculated to assess the temporal and multilevel relationship between market competition, COC, and hospital admission rate. Results Of the 9,997 patients, 243 (2.4%) were admitted to the hospital in 2009. In the multilevel regression analysis, as the Herfindahl-Hirschman Index increased by 1,000 points denoting decreased competitiveness), UPC scores also increased (beta = 0.001; p < 0.0001). In multilevel logistic regression analysis, the adjusted odds ratio (OR) for hospital admissions for individuals with lower COC scores (>= 2 ambulatory visits and a UPC index score of < 1) was 3.61 (95% CI: 2.98-4.38) relative to the reference group (>= 2 ambulatory visits and a UPC index score of 1). Conclusions Market competition appears to reduce COC; decreased COC was associated with a higher OR for hospital admissions.	[Cho, Kyoung Hee] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul 120749, South Korea; [Cho, Kyoung Hee; Park, Eun-Cheol; Lee, Sang Gyu] Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea; [Park, Eun-Cheol] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Nam, Young Soon] Hlth Insurance Review & Assessment Serv, Dept Qual Assessment, Wonju, South Korea; [Lee, Seon-Heui] Gachon Univ, Coll Nursing, Dept Nursing Sci, Songnam, South Korea; [Nam, Chung Mo] Yonsei Univ, Coll Med, Dept Biostat, Seoul, South Korea; [Lee, Sang Gyu] Yonsei Univ, Grad Sch Publ Hlth, Seoul 120749, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Gachon University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, SG (corresponding author), Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea.; Lee, SG (corresponding author), Yonsei Univ, Grad Sch Publ Hlth, Seoul 120749, South Korea.	leevan@yuhs.ac	Park, Eun-Cheol/O-5644-2019	Park, Eun-Cheol/0000-0002-2306-5398; Lee, Sang Gyu/0000-0003-4847-2421; Cho, Kyoung Hee/0000-0003-0753-1560; Nam, Chung Mo/0000-0003-0985-0928				Agency for Healthcare Research and Quality, 2004, GUID PREV QUAL IND H; AL-Jahdali H, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-80; Atlas SJ, 2009, ANN INTERN MED, V150, P325, DOI 10.7326/0003-4819-150-5-200903030-00008; Besanko D., 2009, EC STRATEGY; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Cabana MD, 2004, J FAM PRACTICE, V53, P974; Chen CC, 2012, BMC HEALTH SERV RES, V12, P405; den Exter AP, 2014, MED LAW REV, V22, P255, DOI 10.1093/medlaw/fwu009; Gleeson S, 2016, JAMA PEDIATR, V170, P259, DOI 10.1001/jamapediatrics.2015.3809; Health Insurance Review & Assessment Service, 2010, INTR INC SYST AMB PR; Hong JS, 2014, MED CARE, V52, P446, DOI 10.1097/MLR.0000000000000110; Hong JS, 2013, HEALTH POLICY, V109, P158, DOI 10.1016/j.healthpol.2012.09.009; Hong J, 2010, J KOREAN MED SCI, V25, P1754, DOI 10.3346/jkms.2010.25.12.1754; Hussey PS, 2014, JAMA INTER MED; Jeong HS, 2008, KOREAN J HLTH EC POL, V14, P151; Kim RY, 2011, INTRO NATL PATIENTS; Korea National Statistical Office, 2013, STAT ALL CAUS MORT 2; Korhonen K, 2009, WORLD J PEDIATR, V5, P177, DOI 10.1007/s12519-009-0034-1; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; Malcolm JC, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-303; 김재용, 2006, Diabetes and Metabolism Journal, V30, P377; Ministry of Helath & Welfare Health Insurance Review & Assessment Service, 2011, PROD DEV OECD HLTH C; Mooney G, 1994, KEY ISUUES HLTH EC; National Health Insurance Corporation, 2007, NAT HLTH INS PROGR K; Parchman ML, 2002, MED CARE, V40, P137, DOI 10.1097/00005650-200202000-00008; Pyun BY, 2007, J KOREAN MED ASSOC, V50, P1130, DOI 10.5124/jkma.2007.50.12.1130; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rust G, 2013, J ASTHMA, V50, P769, DOI 10.3109/02770903.2013.799687; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Song SO, 2014, DIABETES METAB J, V38, P395, DOI 10.4093/dmj.2014.38.5.395; The Korean Academy of Asthma AaCI, 2011, KOR ASTHM MAN GUID A; Uijen AA, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X649115; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; Wong HS, 2005, REV IND ORGAN, V26, P61, DOI 10.1007/s11151-004-6067-7	35	7	7	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150926	10.1371/journal.pone.0150926	http://dx.doi.org/10.1371/journal.pone.0150926			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DG3TF	26958850	Green Submitted, Green Published, gold			2023-01-03	WOS:000371992300086
J	Lipska, KJ; Krumholz, H; Soones, T; Lee, SJ				Lipska, Kasia J.; Krumholz, Harlan; Soones, Tacara; Lee, Sei J.			Polypharmacy in the Aging Patient A Review of Glycemic Control in Older Adults With Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INTENSIVE GLUCOSE CONTROL; CLINICAL-PRACTICE GUIDELINES; DRUG-DRUG INTERACTIONS; CARDIOVASCULAR OUTCOMES; RISK-FACTORS; FOLLOW-UP; SEVERE HYPOGLYCEMIA; INSULIN-RESISTANCE; HEMOGLOBIN A(1C); YOUNGER ADULTS	IMPORTANCE There is substantial uncertainty about optimal glycemic control in older adults with type 2 diabetes mellitus. OBSERVATIONS Four large randomized clinical trials (RCTs), ranging in size from 1791 to 11 440 patients, provide the majority of the evidence used to guide diabetes therapy. Most RCTs of intensive vs standard glycemic control excluded adults older than 80 years, used surrogate end points to evaluate microvascular outcomes and provided limited data on which subgroups are most likely to benefit or be harmed by specific therapies. Available data from randomized clinical trials suggest that intensive glycemic control does not reduce major macrovascular events in older adults for at least 10 years. Furthermore, intensive glycemic control does not lead to improved patient-centered microvascular outcomes for at least 8 years. Data from randomized clinical trials consistently suggest that intensive glycemic control immediately increases the risk of severe hypoglycemia 1.5-to 3-fold. Based on these data and observational studies, for the majority of adults older than 65 years, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher than 9% are likely to outweigh the benefits. However, the optimal target depends on patient factors, medications used to reach the target, life expectancy, and patient preferences about treatment. If only medications with low treatment burden and hypoglycemia risk (such as metformin) are required, a lower HbA1c targetmay be appropriate. If patients strongly prefer to avoid injections or frequent fingerstick monitoring, a higher HbA1c target that obviates the need for insulin may be appropriate. CONCLUSIONS AND RELEVANCE High-quality evidence about glycemic treatment in older adults is lacking. Optimal decisions need to be made collaboratively with patients, incorporating the likelihood of benefits and harms and patient preferences about treatment and treatment burden. For the majority of older adults, an HbA1c target between 7.5% and 9% will maximize benefits and minimize harms.	[Lipska, Kasia J.] Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA; [Krumholz, Harlan] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Krumholz, Harlan] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; [Krumholz, Harlan] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA; [Krumholz, Harlan] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA; [Soones, Tacara] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA; [Lee, Sei J.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; [Lee, Sei J.] San Francisco VA Med Ctr, San Francisco, CA USA	Yale University; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Lipska, KJ (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA.	kasia.lipska@yale.edu	, Harlan/AAI-2875-2020		Beeson Career Development Award from the National Institute on Aging; American Federation of Aging Research [K23AG048359, K23AG040779]; Early Career Award from the S. D. Bechtel Jr Foundation; NATIONAL INSTITUTE ON AGING [P30AG044281, P30AG021342, K23AG048359, K23AG040779] Funding Source: NIH RePORTER	Beeson Career Development Award from the National Institute on Aging; American Federation of Aging Research; Early Career Award from the S. D. Bechtel Jr Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Lipska's effort on this project was supported through the Beeson Career Development Award from the National Institute on Aging and the American Federation of Aging Research (K23AG048359). Dr Lee's effort on this project was supported through the Beeson Career Development Award from the National Institute on Aging and the American Federation of Aging Research (K23AG040779) and an Early Career Award from the S. D. Bechtel Jr Foundation.	Abdelhafiz AH, 2015, AGING DIS, V6, P156, DOI 10.14336/AD.2014.0330; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; [Anonymous], 2015, DIABETES CARE, V38, pS1, DOI 10.2337/dc15-S001; Benner JS, 2009, AM J HEALTH-SYST PH, V66, P1471, DOI 10.2146/ajhp080238; Bennett WL, 2011, ANN INTERN MED, V154, P602, DOI 10.7326/0003-4819-154-9-201105030-00336; Bloomfield HE, 2012, 09009 VAESP; Bloomgarden ZT, 2006, DIABETES CARE, V29, P2137, DOI 10.2337/dc06-1120; Bohlen K, 2012, DIABETES CARE, V35, P47, DOI 10.2337/dc11-1082; Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29; Cegelka A, 2013, J AM GERIATR SOC, V61, P2020, DOI 10.1111/jgs.12514; Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET; Chang AM, 2003, AM J PHYSIOL-ENDOC M, V284, pE7, DOI 10.1152/ajpendo.00366.2002; Cheng YLJ, 2013, DIABETES CARE, V36, P2690, DOI 10.2337/dc12-2074; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Cruz-Jentoft AJ, 2013, J AM GERIATR SOC, V61, P734, DOI 10.1111/jgs.12215; Doan J, 2013, ANN PHARMACOTHER, V47, P324, DOI 10.1345/aph.1R621; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Duckworth WC, 2011, J DIABETES COMPLICAT, V25, P355, DOI 10.1016/j.jdiacomp.2011.10.003; Feil DG, 2011, J AM GERIATR SOC, V59, P2263, DOI 10.1111/j.1532-5415.2011.03726.x; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Fitzgerald SP, 2010, J AM MED DIR ASSOC, V11, P475, DOI 10.1016/j.jamda.2010.05.008; Flannery C, 2012, DIABETES, V61, P2711, DOI 10.2337/db12-0206; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gerstein HC, 2014, LANCET, V384, P1936, DOI 10.1016/S0140-6736(14)60611-5; Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858; Gerstein HC, 2011, NEW ENGL J MED, V364, P818, DOI 10.1056/NEJMoa1006524; Gibbons RJ, 2003, CIRCULATION, V107, P2979, DOI 10.1161/01.CIR.0000063682.20730.A5; Godolphin William, 2009, Healthc Q, V12 Spec No Patient, pe186; Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352; Gregg EW, 2012, DIABETES CARE, V35, P1252, DOI 10.2337/dc11-1162; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Haupt A, 2009, DIABETOLOGIA, V52, P457, DOI 10.1007/s00125-008-1250-2; Hayward RA, 2015, NEW ENGL J MED, V372, P2197, DOI 10.1056/NEJMoa1414266; Hemmingsen Bianca, 2014, CMAJ Open, V2, pE162, DOI 10.9778/cmajo.20130073; Hemmingsen B, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008143.pub2; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Huang ES, 2014, JAMA INTERN MED, V174, P251, DOI 10.1001/jamainternmed.2013.12956; Ihm SH, 2006, DIABETES, V55, P1361, DOI 10.2337/db05-1333; Imamura F, 2013, AM J EPIDEMIOL, V177, P1418, DOI 10.1093/aje/kws440; Inzucchi SE, 2012, DIABETOLOGIA, V55, P1577, DOI 10.1007/s00125-012-2534-0; Inzucchi SE, 2014, JAMA-J AM MED ASSOC, V312, P2668, DOI 10.1001/jama.2014.15298; Iozzo P, 1999, J CLIN ENDOCR METAB, V84, P863, DOI 10.1210/jc.84.3.863; Ismail-Beigi F, 2010, LANCET, V376, P419, DOI 10.1016/S0140-6736(10)60576-4; Johnell K, 2007, DRUG SAFETY, V30, P911, DOI 10.2165/00002018-200730100-00009; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kirkman MS, 2012, J AM GERIATR SOC, V60, P2342, DOI 10.1111/jgs.12035; Kojima G, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.07.019; Lakey WC, 2013, DIABETOLOGIA, V56, P1226, DOI 10.1007/s00125-013-2890-4; Management of Diabetes Mellitus Guideline UpdateWorking Group, 2010, VA DOD CLIN PRACT GU; Mannucci E, 2009, NUTR METAB CARDIOVAS, V19, P604, DOI 10.1016/j.numecd.2009.03.021; Marcum ZA, 2012, J AM GERIATR SOC, V60, P34, DOI 10.1111/j.1532-5415.2011.03772.x; Mayo Clinic Shared Decision Making National Resource Center, 2014, SHAR DEC MAK PHIL; Miller ME, 2010, BMJ-BRIT MED J, V340, pb5444; Miller ME, 2014, DIABETES CARE, V37, P634, DOI 10.2337/dc13-1545; Mullan RJ, 2009, ARCH INTERN MED, V169, P1560, DOI 10.1001/archinternmed.2009.293; Munshi MN, 2013, J AM GERIATR SOC, V61, P535, DOI 10.1111/jgs.12167; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Punthakee Z, 2012, DIABETES CARE, V35, P787, DOI 10.2337/dc11-1855; Ray KK, 2009, LANCET, V373, P1765, DOI 10.1016/S0140-6736(09)60697-8; Riddle MC, 2015, DIABETES CARE, V38, P22, DOI 10.2337/dc14-1329; Sacks DB, 2014, JAMA-J AM MED ASSOC, V311, P2271, DOI 10.1001/jama.2014.6342; Sacks DB, 2012, DIABETES CARE, V35, P2674, DOI 10.2337/dc12-1348; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shorr RI, 1997, ARCH INTERN MED, V157, P1681, DOI 10.1001/archinte.157.15.1681; Sinclair A, 2013, J AM MED DIR ASSOC, V14, P777, DOI 10.1016/j.jamda.2013.09.001; Sinclair AJ, 2011, DIABETES METAB, V37, pS27, DOI 10.1016/S1262-3636(11)70962-4; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Stoehr GP, 2008, AM J GERIATR PHARMAC, V6, P255, DOI 10.1016/j.amjopharm.2008.11.001; Szoke E, 2008, DIABETES CARE, V31, P539, DOI 10.2337/dc07-1443; Timbie JW, 2010, HEALTH SERV RES, V45, P437, DOI 10.1111/j.1475-6773.2009.01075.x; Turnbull FM, 2009, DIABETOLOGIA, V52, P2288, DOI 10.1007/s00125-009-1470-0; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vijan S, 2005, J GEN INTERN MED, V20, P479, DOI 10.1111/j.1525-1497.2005.0117.x; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Vijan S, 2014, JAMA INTERN MED, V174, P1227, DOI 10.1001/jamainternmed.2014.2894; Yaffe K, 2013, JAMA INTERN MED, V173, P1300, DOI 10.1001/jamainternmed.2013.6176; Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720; Zoungas S, 2014, NEW ENGL J MED, V371, P1392, DOI 10.1056/NEJMoa1407963; Zoungas S, 2010, NEW ENGL J MED, V363, P1410, DOI 10.1056/NEJMoa1003795	84	144	154	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2016	315	10					1034	1045		10.1001/jama.2016.0299	http://dx.doi.org/10.1001/jama.2016.0299			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF7LW	26954412	Green Accepted			2023-01-03	WOS:000371540200016
J	Tasaniyananda, N; Chaisri, U; Tungtrongchitr, A; Chaicumpa, W; Sookrung, N				Tasaniyananda, Natt; Chaisri, Urai; Tungtrongchitr, Anchalee; Chaicumpa, Wanpen; Sookrung, Nitat			Mouse Model of Cat Allergic Rhinitis and Intranasal Liposome-Adjuvanted Refined Fel d 1 Vaccine	PLOS ONE			English	Article							GRASS-POLLEN IMMUNOTHERAPY; NECROSIS-FACTOR-ALPHA; D-I; MONOCLONAL-ANTIBODIES; CELL RESPONSES; MESSENGER-RNA; NASAL-MUCOSA; TGF-BETA; IMMUNITY; TOLERANCE	Cats (Felis domesticus) are rich source of airborne allergens that prevailed in the environment and sensitized a number of people to allergy. In this study, a mouse model of allergic rhinitis caused by the cat allergens was developed for the first time and the model was used for testing therapeutic efficacy of a novel intranasal liposome-entrapped vaccines made of native Fel d 1 (major cat allergen) in comparison with the vaccine made of crude cat hair extract (cCE). BALB/c mice were sensitized with cCE mixed with alum intraperitoneally and intranasally. The allergic mice were treated with eight doses of either liposome (L)-entrapped native Fel d 1 (L-nFD1), L-cCE), or placebo on every alternate day. Vaccine efficacy evaluation was performed one day after provoking the treated mice with aerosolic cCE. All allergenized mice developed histological features of allergic rhinitis with rises of serum specific-IgE and Th2 cytokine gene expression. Serum IgE and intranasal mucus production of allergic mice reduced significantly after vaccination in comparison with the placebo mice. The vaccines also caused a shift of the Th2 response (reduction of Th2 cytokine expressions) towards the non-pathogenic responses: Th1 (down-regulation of the Th1 suppressive cytokine gene, IL-35) and Treg (up-regulation of IL-10 and TGF-beta). In conclusions, a mouse model of allergic rhinitis to cat allergens was successfully developed. The intranasal, liposome-adjuvanted vaccines, especially the refined single allergen formulation, assuaged the allergic manifestations in the modeled mice. The prototype vaccine is worthwhile testing further for clinical use in the pet allergic patients.	[Tasaniyananda, Natt] Mahidol Univ, Grad Program Immunol, Dept Immunol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand; [Tasaniyananda, Natt; Tungtrongchitr, Anchalee; Chaicumpa, Wanpen] Mahidol Univ, Dept Parasitol, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; [Chaisri, Urai] Mahidol Univ, Dept Trop Pathol, Fac Trop Med, Bangkok 10400, Thailand; [Sookrung, Nitat] Mahidol Univ, Dept Res & Dev, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand	Mahidol University; Mahidol University; Mahidol University; Mahidol University	Sookrung, N (corresponding author), Mahidol Univ, Dept Res & Dev, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand.	nitat.soo@mahidol.ac.th			National Research University (NRU) Project of the Office of Higher Education Commission, Ministry of Education, Thailand; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; NSTDA Chair Professor grant; National Science and Technology Development Agency (NSTDA); MRG grant of the Thailand Research Fund	National Research University (NRU) Project of the Office of Higher Education Commission, Ministry of Education, Thailand; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; NSTDA Chair Professor grant; National Science and Technology Development Agency (NSTDA); MRG grant of the Thailand Research Fund	This work was co-supported by grants from the National Research University (NRU) Project of the Office of Higher Education Commission, Ministry of Education, Thailand; the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; the NSTDA Chair Professor grant, the National Science and Technology Development Agency (NSTDA); and the MRG grant of the Thailand Research Fund to Nitat Sookrung.	Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5; Astry B, 2015, CYTOKINE, V74, P54, DOI 10.1016/j.cyto.2014.11.020; Badiee A, 2009, EXP PARASITOL, V121, P362, DOI 10.1016/j.exppara.2008.12.015; Ball T, 2009, ALLERGY, V64, P569, DOI 10.1111/j.1398-9995.2008.01910.x; Baraniuk J N, 2001, Curr Allergy Asthma Rep, V1, P207, DOI 10.1007/s11882-001-0007-5; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Boeuf P, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-5; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Brewer JM, 1998, J IMMUNOL, V161, P4000; Brimnes J, 2007, CLIN EXP ALLERGY, V37, P488, DOI 10.1111/j.1365-2222.2006.02624.x; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Bunnag C, 2009, ASIAN PAC J ALLERGY, V27, P79; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Cohn L, 1999, J IMMUNOL, V162, P6178; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; Czarneski J, 2004, LEUKEMIA, V18, P597, DOI 10.1038/sj.leu.2403244; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; Desmedt M, 1998, J IMMUNOL, V160, P5300; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebmeyer J, 2010, OTOL NEUROTOL, V31, P42, DOI 10.1097/MAO.0b013e3181b4e3e3; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Galli SJ, 2011, NAT IMMUNOL, V12, P1035, DOI 10.1038/ni.2109; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; Grundstrom J, 2012, INT ARCH ALLERGY IMM, V157, P136, DOI 10.1159/000327546; Henriksen-Lacey M, 2010, J CONTROL RELEASE, V145, P102, DOI 10.1016/j.jconrel.2010.03.027; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Ishikawa Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-42; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lehmann J, 2001, J IMMUNOL, V167, P5304, DOI 10.4049/jimmunol.167.9.5304; MAGGI E, 1992, J IMMUNOL, V148, P2142; Martinez-Gomez JM, 2009, INT ARCH ALLERGY IMM, V150, P59, DOI 10.1159/000210381; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Meechan P, 2013, INT ARCH ALLERGY IMM, V161, P351, DOI 10.1159/000348314; Mo JH, 2011, ALLERGY, V66, P279, DOI 10.1111/j.1398-9995.2010.02476.x; MONTE PD, 1989, J IMMUNOL, V142, P1437; Neimert-Andersson T, 2008, ALLERGY, V63, P518, DOI 10.1111/j.1398-9995.2008.01644.x; Olivieri M, 2000, J INVEST ALLERG CLIN, V10, P300; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Phipatanakul W, 2001, Curr Allergy Asthma Rep, V1, P461, DOI 10.1007/s11882-001-0034-2; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; Ryang YS, 2007, PARASITOL RES, V101, P1103, DOI 10.1007/s00436-007-0591-y; Saarne T, 2011, ALLERGY, V66, P255, DOI 10.1111/j.1398-9995.2010.02468.x; Samsom JN, 2005, J IMMUNOL, V174, P5279, DOI 10.4049/jimmunol.174.9.5279; Schuetze N, 2005, INT IMMUNOL, V17, P649, DOI 10.1093/intimm/dxh247; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Sookrung N, 2008, ASIAN PAC J ALLERGY, V26, P143; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vangasseri DP, 2006, MOL MEMBR BIOL, V23, P385, DOI 10.1080/09687860600790537; Wang M, 2013, CLIN EXP ALLERGY, V43, P956, DOI 10.1111/cea.12123; Williams Jesse W, 2012, J Allergy (Cairo), V2012, P236075, DOI 10.1155/2012/236075; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483	59	17	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0150463	10.1371/journal.pone.0150463	http://dx.doi.org/10.1371/journal.pone.0150463			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26954254	Green Published, Green Submitted, gold			2023-01-03	WOS:000371991300029
J	Song, HZ; Zheng, ZH; Wu, JA; Lai, J; Chu, Q; Zheng, XD				Song, Haizhao; Zheng, Zihuan; Wu, Jianan; Lai, Jia; Chu, Qiang; Zheng, Xiaodong			White Pitaya (Hylocereus undatus) Juice Attenuates Insulin Resistance and Hepatic Steatosis in Diet-Induced Obese Mice	PLOS ONE			English	Article							FATTY LIVER-DISEASE; METABOLIC SYNDROME; RED; POLYRHIZUS; MECHANISMS; INCREASES; FGF-21	Insulin resistance and hepatic steatosis are the most common complications of obesity. Pitaya is an important source of phytochemicals such as polyphenols, flavonoid and vitamin C which are related to its antioxidant activity. The present study was conducted to evaluate the influence of white pitaya juice (WPJ) on obesity-related metabolic disorders (e.g. insulin resistance and hepatic steatosis) in high-fat diet-fed mice. Forty-eight male C57BL/6J mice were assigned into four groups and fed low-fat diet with free access to water or WPJ, or fed high-fat diet with free access to water or WPJ for 14 weeks. Our results showed that administration of WPJ improved high-fat diet-induced insulin resistance, hepatic steatosis and adipose hypertrophy, but it exerted no influence on body weight gain in mice. Hepatic gene expression analysis indicated that WPJ supplement not only changed the expression profile of genes involved in lipid and cholesterol metabolism (Srebp1, HMGCoR, Cpt1b, HL, Insig1 and Insig2) but also significantly increased the expression levels of FGF21-related genes (Klb, FGFR2, Egr1 and cFos). In conclusion, WPJ protected from diet-induced hepatic steatosis and insulin resistance, which was associated with the improved FGF21 resistance and lipid metabolism.	[Song, Haizhao; Zheng, Zihuan; Wu, Jianan; Lai, Jia; Chu, Qiang; Zheng, Xiaodong] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou, Zhejiang, Peoples R China; [Song, Haizhao; Zheng, Xiaodong] Zhejiang Univ, Fuli Inst Food Sci, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Zheng, XD (corresponding author), Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou, Zhejiang, Peoples R China.; Zheng, XD (corresponding author), Zhejiang Univ, Fuli Inst Food Sci, Hangzhou 310003, Zhejiang, Peoples R China.	xdzhengzju@yahoo.com	Wu, Jianan/I-1666-2017	Wu, Jianan/0000-0002-6513-4769; Chu, Qiang/0000-0003-3075-3444	National Key Technology R&D Program of China [2012BAD33B08]; Zhejiang Provincial Natural Science Foundation of China [Z14C200006]; Foundation of Fuli Institute of Food Science, Zhejiang University [KY201301]	National Key Technology R&D Program of China(National Key Technology R&D Program); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Foundation of Fuli Institute of Food Science, Zhejiang University	This work was supported by National Key Technology R&D Program of China (Grant No. 2012BAD33B08, http://program.most.gov.cn/, received by XDZ), Zhejiang Provincial Natural Science Foundation of China (Grant No. Z14C200006, http://www.zjnsf.gov.cn/, received by XDZ) and the Foundation of Fuli Institute of Food Science, Zhejiang University (Grant No. KY201301, http://fifs.zju.edu.cn/content/detail.php?sid=3&cid=642, received by XDZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, BORNEO SCI; Auinger A, 2013, BRIT J NUTR, V109, P810, DOI 10.1017/S0007114512002656; Balkau B, 2005, LANCET, V366, P1921, DOI 10.1016/S0140-6736(05)67777-X; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Beaton MD, 2012, CAN J GASTROENTEROL, V26, P353, DOI 10.1155/2012/725468; Brennan AM, 2006, NAT CLIN PRACT ENDOC, V2, P318, DOI 10.1038/ncpendmet0196; Bugianesi E, 2005, DIABETOLOGIA, V48, P634, DOI 10.1007/s00125-005-1682-x; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Espin JC, 2007, PHYTOCHEMISTRY, V68, P2986, DOI 10.1016/j.phytochem.2007.09.014; Chang JJ, 2013, J AGR FOOD CHEM, V61, P6069, DOI 10.1021/jf401171k; Charlton M, 2004, CLIN GASTROENTEROL H, V2, P1048, DOI 10.1016/S1542-3565(04)00440-9; Chavez AO, 2009, DIABETES CARE, V32, P1542, DOI 10.2337/dc09-0684; Cuevas-Ramos D, 2012, CURR OPIN PEDIATR, V24, P523, DOI 10.1097/MOP.0b013e3283557d22; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; Dembinska-Kiec A, 2008, BRIT J NUTR, V99, pES109, DOI 10.1017/S000711450896579X; Diez JJ, 2003, EUR J ENDOCRINOL, V148, P293, DOI 10.1530/eje.0.1480293; Doria A, 2008, CELL METAB, V8, P186, DOI 10.1016/j.cmet.2008.08.006; Esquivel P, 2007, Z NATURFORSCH C, V62, P636; FOLCH J, 1957, J BIOL CHEM, V226, P497; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; He JA, 2010, ANNU REV FOOD SCI T, V1, P163, DOI 10.1146/annurev.food.080708.100754; Hossain P, 2007, NEW ENGL J MED, V356, P213, DOI 10.1056/NEJMp068177; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kruszynska YT, 1996, J INVEST MED, V44, P413; Leclercq IA, 2007, J HEPATOL, V47, P142, DOI 10.1016/j.jhep.2007.04.002; Liu RH, 2003, AM J CLIN NUTR, V78, p517S, DOI 10.1093/ajcn/78.3.517S; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Meda A, 2005, FOOD CHEM, V91, P571, DOI 10.1016/j.foodchem.2004.10.006; Munir KM, 2013, AM J PHYSIOL-ENDOC M, V305, pE679, DOI 10.1152/ajpendo.00377.2013; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Omidizadeh A, 2014, RSC ADV, V4, P62978, DOI 10.1039/c4ra10789f; Ramli NS, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-189; Ruzlan N, 2008, ANTIOXIDANT STUDY PU; Seymour EM, 2008, J MED FOOD, V11, P252, DOI 10.1089/jmf.2007.658; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Suh DH, 2014, J AGR FOOD CHEM, V62, P8764, DOI 10.1021/jf5020704; Timmers S, 2013, ANN NY ACAD SCI, V1290, P83, DOI 10.1111/nyas.12185; Walley AJ, 2009, NAT REV GENET, V10, P431, DOI 10.1038/nrg2594; Wybraniec S, 2002, J AGR FOOD CHEM, V50, P6086, DOI 10.1021/jf020145k; Xu J, 2009, DIABETES, V58, P250, DOI 10.2337/db08-0392; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yusof RM, 2009, ANN NUTR METAB, V55, P92; Zhang X, 2008, DIABETES, V57, P1246, DOI 10.2337/db07-1476	45	35	38	1	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0149670	10.1371/journal.pone.0149670	http://dx.doi.org/10.1371/journal.pone.0149670			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2LW	26914024	Green Published, Green Submitted, gold			2023-01-03	WOS:000371175700024
J	Wallace, D; Cooper, NR; Paulmann, S; Fitzgerald, PB; Russo, R				Wallace, Denise; Cooper, Nicholas R.; Paulmann, Silke; Fitzgerald, Paul B.; Russo, Riccardo			Perceived Comfort and Blinding Efficacy in Randomised Sham-Controlled Transcranial Direct Current Stimulation (tDCS) Trials at 2 mA in Young and Older Healthy Adults	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; HUMAN MOTOR CORTEX; MINI-MENTAL-STATE; ELECTRICAL-STIMULATION; WORKING-MEMORY; DC STIMULATION; PERCEPTION; SAFETY; EXCITABILITY; ELECTRODES	Background tDCS studies typically find that: lowest levels of comfort occur at stimulation-onset; young adult participants experience less comfort than older participants; and participants' blinding seems effective at low current strengths. At 2 mA conflicting results have been reported, questioning the effectiveness of blinding in sham-controlled paradigms using higher current strengths. Investigator blinding is rarely reported. Objective Using a protocol with 30 min of 2 mA stimulation we sought to: (a) investigate the level of perceived comfort in young and older adults, ranging in age from 19 to 29 years and 63 to 76 years, respectively; (b) test investigator and participant blinding; (c) assess comfort over a longer stimulation duration; (d) add to the literature on protocols using 2 mA current strength. Methods A two-session experiment was conducted where sham and active stimulation were administered to the frontal cortex at the F8/FP1 sites in a within-subjects manner. Levels of perceived comfort were measured, using a visual analogue scale, at the start and end of stimulation in young and older adults. Post-stimulation, participants and investigators judged whether or not active stimulation was used. Results Comfort scores were lower at stimulation onset in both age groups. Older adults reported: (i) more comfort than young participants overall; (ii) comparable levels of comfort in sham and active stimulation; (iii) significantly more comfort than the young participants during active stimulation. Stimulation mode was correctly identified above chance in the second of the two sessions; 65% of all participants correctly identified the stimulation mode, resulting in a statistical trend. Similarly, the experimenter correctly identified stimulation mode significantly above chance, with 62% of all investigator judgements correct across 120 judgements. Conclusions Using 2 mA current strength over 30 minutes, tDCS stimulation comfort is lower at stimulation onset in young and older adults and, overall, lower for young participants. Investigators and participants may be able to identify active stimulation at above chance levels, although accuracy never exceeded 65% for either participants or the experimenter. Further research into blinding efficacy is recommended.	[Wallace, Denise; Cooper, Nicholas R.; Paulmann, Silke; Russo, Riccardo] Univ Essex, Dept Psychol, Colchester CO4 3SQ, Essex, England; [Wallace, Denise; Cooper, Nicholas R.; Paulmann, Silke; Russo, Riccardo] Univ Essex, Ctr Brain Sci, Colchester CO4 3SQ, Essex, England; [Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia; [Fitzgerald, Paul B.] Monash Univ, Alfred, Melbourne, Vic 3004, Australia	University of Essex; University of Essex; Monash University; Monash University	Wallace, D; Russo, R (corresponding author), Univ Essex, Dept Psychol, Colchester CO4 3SQ, Essex, England.; Wallace, D; Russo, R (corresponding author), Univ Essex, Ctr Brain Sci, Colchester CO4 3SQ, Essex, England.	dwallace@essex.ac.uk; rrusso@essex.ac.uk	Fitzgerald, Paul B/A-1225-2008	Fitzgerald, Paul B/0000-0003-4217-8096; , Riccardo Russo/0000-0002-5946-8914; Paulmann, Silke/0000-0003-4148-3806	University of Essex Ageing and Assisted Living Seedcorn fund	University of Essex Ageing and Assisted Living Seedcorn fund	A grant awarded to Silke Paulmann and Riccardo Russo by the University of Essex Ageing and Assisted Living Seedcorn fund fully supported this project. There was no additional external funding received for this study.	Ambrus GG, 2012, BRAIN STIMUL, V5, P499, DOI 10.1016/j.brs.2011.12.001; Ambrus GG, 2010, CLIN NEUROPHYSIOL, V121, P1908, DOI 10.1016/j.clinph.2010.04.020; Bashir S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00111; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Berger VW, 2012, J CLIN EPIDEMIOL, V65, P1236, DOI 10.1016/j.jclinepi.2012.04.016; Bikson M, 2009, CLIN NEUROPHYSIOL, V120, P1033, DOI 10.1016/j.clinph.2009.03.018; BINDMAN LJ, 1962, NATURE, V196, P584, DOI 10.1038/196584a0; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Davis NJ, 2013, EUR J NEUROSCI, V38, P2973, DOI 10.1111/ejn.12307; Dundas JE, 2007, CLIN NEUROPHYSIOL, V118, P1166, DOI 10.1016/j.clinph.2007.01.010; Fertonani A, 2015, CLIN NEUROPHYSIOL, V126, P2181, DOI 10.1016/j.clinph.2015.03.015; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Heft MW, 2014, AGE, V36, P1, DOI 10.1007/s11357-013-9536-9; Hoy KE, 2014, SCHIZOPHR RES, V155, P96, DOI 10.1016/j.schres.2014.03.006; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Kemp J, 2014, CLIN NEUROPHYSIOL, V125, P602, DOI 10.1016/j.clinph.2013.08.020; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Liew SL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00378; Lovibond S.H., 1995, MANUAL DEPRESSION AN, V2; Meng ZQ, 2014, J PSYCHIATR RES, V54, P19, DOI 10.1016/j.jpsychires.2014.03.007; Minhas P, 2011, CLIN NEUROPHYSIOL, V122, P637, DOI 10.1016/j.clinph.2010.09.023; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Monti A, 2013, J NEUROL NEUROSUR PS, V84, P832, DOI 10.1136/jnnp-2012-302825; neuroConn GmbH, 2012, NEUROCONN PROGR DIR; Ngernyam N, 2015, CLIN NEUROPHYSIOL, V126, P382, DOI 10.1016/j.clinph.2014.05.034; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Palm U, 2013, BRAIN STIMUL, V6, P690, DOI 10.1016/j.brs.2013.01.005; Peron J, 2011, PROG NEURO-PSYCHOPH, V35, P987, DOI 10.1016/j.pnpbp.2011.01.019; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Richmond L, 2014, J COGNITIVE NEUROSCI, P1; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; San-Juan D, 2015, BRAIN STIMUL, V8, P455, DOI 10.1016/j.brs.2015.01.001; Shiozawa P, 2014, INT J NEUROPSYCHOPH, V17, P1443, DOI 10.1017/S1461145714000418; SMITH L, 1989, CUTIS, V43, P414; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Turi Z, 2014, BRAIN STIMUL, V7, P460, DOI 10.1016/j.brs.2014.01.059; Ulam F, 2015, CLIN NEUROPHYSIOL, V126, P486, DOI 10.1016/j.clinph.2014.05.015; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	47	51	51	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149703	10.1371/journal.pone.0149703	http://dx.doi.org/10.1371/journal.pone.0149703			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26900961	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000371276100131
J	Choi, HJ; Chung, TW; Park, MJ; Lee, KS; Yoon, Y; Kim, HS; Lee, JH; Kwon, SM; Lee, SO; Kim, KJ; Baek, JH; Ha, KT				Choi, Hee-Jung; Chung, Tae-Wook; Park, Mi-Ju; Lee, Kyu Sup; Yoon, Youngjin; Kim, Hyung Sik; Lee, Jun Hee; Kwon, Sang-Mo; Lee, Syng-Ook; Kim, Keuk-Jun; Baek, Jin-Ho; Ha, Ki-Tae			Paeonia lactiflora Enhances the Adhesion of Trophoblast to the Endometrium via Induction of Leukemia Inhibitory Factor Expression	PLOS ONE			English	Article							EMBRYONIC IMPLANTATION DYSFUNCTION; CHINESE HERBAL MEDICINE; UNEXPLAINED INFERTILITY; PREVENTS IMPLANTATION; UTERINE RECEPTIVITY; MENSTRUAL-CYCLE; CELL-ADHESION; FACTOR LIF; KAPPA-B; PAEONIFLORIN	In the present study, we investigated the role of Paeonia lactiflora Pall. extract on embryo implantation in vitro and in vivo. A polysaccharides depleted-water extract of P. lactiflora (PL-PP) increased LIF expression in human endometrial Ishikawa cells at non-cytotoxic doses. PL-PP significantly increased the adhesion of the human trophectoderm-derived JAr spheroids to endometrial Ishikawa cells. PL-PP-induced LIF expression was decreased in the presence of a p38 kinase inhibitor SB203580 and an MEK/ERK inhibitor U0126. Furthermore, endometrial LIF knockdown by shRNA reduced the expression of integrins beta 3 and beta 5 and adhesion of JAr spheroids to Ishikawa cells. In vivo administration of PL-PP restored the implantation of mouse blastocysts in a mifepristone-induced implantation failure mice model. Our results demonstrate that PL-PP increases LIF expression via the p38 and MEK/ERK pathways and favors trophoblast adhesion to endometrial cells.	[Choi, Hee-Jung; Chung, Tae-Wook; Park, Mi-Ju; Ha, Ki-Tae] Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, Gyeongsangnam D, South Korea; [Choi, Hee-Jung; Chung, Tae-Wook; Park, Mi-Ju; Ha, Ki-Tae] Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Yangsan, Gyeongsangnam D, South Korea; [Lee, Kyu Sup] Pusan Natl Univ Hosp, Dept Obstet & Gynecol, Pusan, South Korea; [Yoon, Youngjin] Pusan Natl Univ, Sch Korean Med, Dept Korean Obstet & Gynecol, Pusan 609735, South Korea; [Kim, Hyung Sik] Sungkyunkwan Univ, Sch Pharm, Mol Toxicol Lab, Suwon, Gyeonggi Do, South Korea; [Lee, Jun Hee; Kwon, Sang-Mo] Pusan Natl Univ, Sch Med, Med Res Inst, Lab Vasc Med & Stem Cell Biol,Dept Physiol, Yangsan, Gyeongsangnam D, South Korea; [Lee, Syng-Ook] Keimyung Univ, Dept Food Sci & Technol, Daegu, South Korea; [Kim, Keuk-Jun] TaeKyeung Univ, Dept Clin Pathol, Gyongsan, South Korea; [Baek, Jin-Ho] Daechubatbaek Korean Med Clin, Gyeongju, Gyeongsangbuk D, South Korea	Pusan National University; Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University; Sungkyunkwan University (SKKU); Pusan National University; Pusan National University Hospital; Keimyung University	Ha, KT (corresponding author), Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, Gyeongsangnam D, South Korea.; Ha, KT (corresponding author), Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Yangsan, Gyeongsangnam D, South Korea.	hagis@pusan.ac.kr		Chung, Tae-Wook/0000-0001-5243-5020; Lee, Syng-Ook/0000-0002-8958-8634	Traditional Korean Medicine R&D Project, Ministry of Health Welfare [HI13C0502]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MISP), Korea Government [2014R1A5A20009936]	Traditional Korean Medicine R&D Project, Ministry of Health Welfare; National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MISP), Korea Government	This study was supported by a grant of the Traditional Korean Medicine R&D Project, Ministry of Health & Welfare (Grant no. HI13C0502), and by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning (MISP), Korea Government (Grant no. 2014R1A5A20009936).	Agca C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.323; Aghajanova L, 2010, CURR OPIN OBSTET GYN, V22, P213, DOI 10.1097/GCO.0b013e32833848e5; ARICI A, 1995, J CLIN ENDOCR METAB, V80, P1908, DOI 10.1210/jc.80.6.1908; Aschenbach LC, 2013, CONTRACEPTION, V87, P813, DOI 10.1016/j.contraception.2012.09.032; Brown JK, 2012, MOL HUM REPROD, V18, P111, DOI 10.1093/molehr/gar068; Cakmak H, 2011, HUM REPROD UPDATE, V17, P242, DOI 10.1093/humupd/dmq037; Castelbaum AJ, 1997, J CLIN ENDOCR METAB, V82, P136, DOI 10.1210/jc.82.1.136; Catalano RD, 2005, P NATL ACAD SCI USA, V102, P8585, DOI 10.1073/pnas.0502343102; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; da Costa SV, 2010, LEUKEMIA RES, V34, P507, DOI 10.1016/j.leukres.2009.10.012; Danielsson KG, 1997, HUM REPROD, V12, P1293; Diedrich K, 2007, HUM REPROD UPDATE, V13, P365, DOI 10.1093/humupd/dmm011; Dimitriadis E, 2010, PLACENTA, V31, pS99, DOI 10.1016/j.placenta.2009.12.027; Fan ZY, 2004, CYTOKINE, V28, P17, DOI 10.1016/j.cyto.2004.06.003; Gao D., 1997, ENCY CHINESE MED; Gao WN, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/678390; Giudice LC, 1999, HUM REPROD, V14, P3, DOI 10.1093/humrep/14.suppl_2.3; Gui J, 2012, AM J REPROD IMMUNOL, V67, P383, DOI 10.1111/j.1600-0897.2011.01097.x; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; He DY, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00010; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Jia W, 2006, PHYTOTHER RES, V20, P819, DOI 10.1002/ptr.1905; Koot YEM, 2013, CURR OPIN OBSTET GYN, V25, P274, DOI 10.1097/GCO.0b013e3283630d94; Laird SM, 2000, MOL HUM REPROD, V6, P34, DOI 10.1093/molehr/6.1.34; Lalitkumar PGL, 2007, HUM REPROD, V22, P3031, DOI 10.1093/humrep/dem297; Lee B, 2008, ARCH PHARM RES, V31, P445, DOI 10.1007/s12272-001-1177-6; Lessey BA, 1998, HUM REPROD, V13, P247, DOI 10.1093/humrep/13.suppl_3.247; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Li QX, 2002, J BIOL CHEM, V277, P46447, DOI 10.1074/jbc.M203555200; Lian F, 2013, J ALTERN COMPLEM MED, V19, P353, DOI 10.1089/acm.2011.0410; Liu DF, 2006, CLIN EXP PHARMACOL P, V33, P332, DOI 10.1111/j.1440-1681.2006.04371.x; Macklon NS, 2006, ENDOCR REV, V27, P170, DOI 10.1210/er.2005-0015; Mao QQ, 2012, PHARM BIOL, V50, P72, DOI 10.3109/13880209.2011.602696; Menkhorst E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019665; Poncelet C, 2002, ACTA OBSTET GYN SCAN, V81, P195, DOI 10.1034/j.1600-0412.2002.810302.x; Ried K, 2011, COMPLEMENT THER MED, V19, P319, DOI 10.1016/j.ctim.2011.09.003; Robertson SA, 2010, J REPROD IMMUNOL, V85, P51, DOI 10.1016/j.jri.2010.01.008; ROBLERO LS, 1987, CONTRACEPTION, V36, P549, DOI 10.1016/0010-7824(87)90007-2; Steck T, 2004, EUR J OBSTET GYN R B, V112, P69, DOI 10.1016/S0301-2115(03)00315-4; Tabibzadeh SRGJDALCGS, 2004, ENDOMETRIUM; Terakawa J, 2011, J REPROD DEVELOP, V57, P700, DOI 10.1262/jrd.11-048H; THIE M, 1995, EUR J CELL BIOL, V66, P180; TOMODA M, 1993, BIOL PHARM BULL, V16, P1207, DOI 10.1248/bpb.16.1207; Tong HB, 2014, CARBOHYD POLYM, V105, P20, DOI 10.1016/j.carbpol.2014.01.039; Vogiagis D, 1996, J ENDOCRINOL, V148, P95, DOI 10.1677/joe.0.1480095; White CA, 2007, P NATL ACAD SCI USA, V104, P19357, DOI 10.1073/pnas.0710110104; Wu M, 2013, CYTOKINE, V62, P334, DOI 10.1016/j.cyto.2013.03.002; Yu N, 2011, J ETHNOPHARMACOL, V137, P389, DOI 10.1016/j.jep.2011.05.037; Zhang MM, 2008, J HUAZHONG U SCI-MED, V28, P65, DOI 10.1007/s11596-008-0116-7; Zheng YQ, 2007, INFLAMM RES, V56, P182, DOI 10.1007/s00011-006-6002-5	50	17	17	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0148232	10.1371/journal.pone.0148232	http://dx.doi.org/10.1371/journal.pone.0148232			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26839969	Green Published, gold, Green Submitted			2023-01-03	WOS:000369550200104
J	Delaney, M; Wendel, S; Bercovitz, RS; Cid, J; Cohn, C; Dunbar, NM; Apelseth, TO; Popovsky, M; Stanworth, SJ; Tinmouth, A; De Watering, LV; Waters, JH; Yazer, M; Ziman, A				Delaney, Meghan; Wendel, Silvano; Bercovitz, Rachel S.; Cid, Joan; Cohn, Claudia; Dunbar, Nancy M.; Apelseth, Torunn O.; Popovsky, Mark; Stanworth, Simon J.; Tinmouth, Alan; De Watering, Leo Van; Waters, Jonathan H.; Yazer, Mark; Ziman, Alyssa		Biomed Excellence Safer Transfusio	Transfusion reactions: prevention, diagnosis, and treatment	LANCET			English	Review							SICKLE-CELL-DISEASE; ACUTE LUNG INJURY; VERSUS-HOST-DISEASE; CONVERTING ENZYME-INHIBITORS; HYPERKALEMIC CARDIAC-ARREST; POSTTRANSFUSION PURPURA; CIRCULATORY OVERLOAD; MASSIVE TRANSFUSION; BLOOD-TRANSFUSION; NECROTIZING ENTEROCOLITIS	Blood transfusion is one of the most common procedures in patients in hospital so it is imperative that clinicians are knowledgeable about appropriate blood product administration, as well as the signs, symptoms, and management of transfusion reactions. In this Review, we, an international panel, provide a synopsis of the pathophysiology, treatment, and management of each diagnostic category of transfusion reaction using evidence-based recommendations whenever available.	[Delaney, Meghan] Bloodworks NW, Seattle, WA 98115 USA; [Delaney, Meghan] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Wendel, Silvano] Hosp Sirio Libanes Blood Bank, Sao Paulo, Brazil; [Bercovitz, Rachel S.] BloodCtr Wisconsin, Milwaukee, WI USA; [Cid, Joan] UB, Dept Hemotherapy & Hemostasis, CDB, IDIBAPS, Barcelona, Spain; [Cohn, Claudia] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Dunbar, Nancy M.] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA; [Dunbar, Nancy M.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA; [Apelseth, Torunn O.] Haukeland Hosp, Lab Clin Biochem, Bergen, Norway; [Apelseth, Torunn O.] Haukeland Hosp, Dept Immunol & Transfus Med, Bergen, Norway; [Popovsky, Mark] Haemonetics Corp, Braintree, MA USA; [Stanworth, Simon J.] John Radcliffe Hosp, NHS Blood & Transplant Oxford Univ Hosp NHS Trust, Oxford, England; [Stanworth, Simon J.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Tinmouth, Alan] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Tinmouth, Alan] Univ Ottawa, Dept Lab Med & Pathol, Ottawa, ON, Canada; [Tinmouth, Alan] Univ Ottawa, Ctr Transfus Res, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [De Watering, Leo Van] Sanquin, Ctr Clin Transfus Res, Amsterdam, Netherlands; [Waters, Jonathan H.] Univ Pittsburgh, Dept Anesthesiol & Bioengn, Pittsburgh, PA USA; [Waters, Jonathan H.] McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Yazer, Mark] Univ Pittsburgh, Dept Pathol, Div Transfus Med, Inst Transfus Med, Pittsburgh, PA USA; [Ziman, Alyssa] Univ Calif Los Angeles, David Geffen Sch Med, Div Transfus Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	University of Washington; University of Washington Seattle; Hospital Sirio Libanes; Versiti Blood Center of Wisconsin; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College; Dartmouth College; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Institute for Transfusion Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Delaney, M (corresponding author), Bloodworks NW, Seattle, WA 98115 USA.	meghand@bloodworksnw.org	Ziman, Alyssa/N-9598-2019; Wendel, S/AAQ-9048-2020; Selogie, Eileen A/L-3628-2016; Cid, Joan/F-7778-2016; Dunbar, Nancy M/D-8883-2011	Cid, Joan/0000-0001-5445-4508; Dunbar, Nancy M./0000-0001-8601-5438; Ziman, Alyssa/0000-0002-1814-9319; Bercovitz, Rachel/0000-0002-6399-1249				Amsler L, 2015, HAEMOVIGILANCE ANN R; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; Andrzejewski C, 2013, TRANSFUSION, V53, P3037, DOI 10.1111/trf.12454; Andrzejewski C, 2012, TRANSFUSION, V52, P2310, DOI 10.1111/j.1537-2995.2012.03595.x; Arnold DM, 2004, TRANSFUSION, V44, P1361, DOI 10.1111/j.0041-1132.2004.04057.x; Bolton-Maggs PHB, 2014, TRANSFUSION MED, V24, P197, DOI 10.1111/tme.12142; Bolton-Maggs PHB, 2014, 2013 ANN SHOT REPORT; BOYAN CP, 1964, ANN SURG, V160, P282, DOI 10.1097/00000658-196408000-00016; Callum JL, 2014, TRANSFUSION, V54, P2344, DOI 10.1111/trf.12802; CDC, 2014, NHSN BIOV COMP HEM M; Chou ST, 2013, BLOOD, V122, P1062, DOI 10.1182/blood-2013-03-490623; Cohn CS, 2014, TRANSFUSION, V54, P1927, DOI 10.1111/trf.12597; Cyr M, 2001, TRANSFUSION, V41, P136, DOI 10.1046/j.1537-2995.2001.41010136.x; Darabi K, 2005, TRANSFUSION, V45, P1930, DOI 10.1111/j.1537-2995.2005.00608.x; de Montalembert M, 2011, HAEMATOL-HEMATOL J, V96, P801, DOI 10.3324/haematol.2010.038307; Delaney M, 2013, PEDIATR CRIT CARE ME, V14, pE263, DOI 10.1097/PCC.0b013e31828a70c5; Delaney M, 2013, TRANSFUSION, V53, P771, DOI 10.1111/j.1537-2995.2012.03789.x; DIAMOND WJ, 1980, ANN INTERN MED, V93, P231, DOI 10.7326/0003-4819-93-2-231; Doria C, 2008, LIVER TRANSPLANT, V14, P684, DOI 10.1002/lt.21425; Dzik W H, 1988, Transfus Med Rev, V2, P76, DOI 10.1016/S0887-7963(88)70035-8; Eder AF, 2011, TRANSFUSION, V51, P1662, DOI 10.1111/j.1537-2995.2011.03083.x; El-Dib M, 2011, J PERINATOL, V31, P183, DOI 10.1038/jp.2010.157; Elliott Malcolm, 2012, Br J Nurs, V21, P621; Ezidiegwu CN, 2004, ARCH PATHOL LAB MED, V128, P991; Figueroa PI, 2006, AM J CLIN PATHOL, V126, P422, DOI 10.1309/C6U7VP87GC030WMG; FREDLUND H, 1989, EUR J HAEMATOL, V43, P259; FRIEDLANDER M, 1989, CAN J ANAESTH, V36, P460, DOI 10.1007/BF03005348; Fung MK, 2014, TECHNICAL MANUAL, V18th; Funk MB, 2011, TRANSFUS MED HEMOTH, V38, P266, DOI 10.1159/000330372; Garratty G, 2012, TRANSFUSION MED, V22, P77, DOI 10.1111/j.1365-3148.2012.01151.x; Gonzalez Corina E, 2005, Curr Hematol Rep, V4, P154; Goodnough LT, 2009, TRANSFUSION, V49, P1321, DOI 10.1111/j.1537-2995.2009.02157.x; Gupta S, 2015, TRANSFUSION, V55, P623, DOI 10.1111/trf.12876; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; Harm SK, 2014, AM J CLIN PATHOL, V141, P256, DOI 10.1309/AJCP47QAAXTOZEKJ; Harvey AR, 2015, TRANSFUSION, V55, P709, DOI 10.1111/trf.12918; Heddle N M, 1999, Curr Opin Hematol, V6, P420, DOI 10.1097/00062752-199911000-00012; Heddle NM, 2002, TRANSFUSION, V42, P556, DOI 10.1046/j.1537-2995.2002.00094.x; Hirayama F, 2013, BRIT J HAEMATOL, V160, P434, DOI 10.1111/bjh.12150; Inaba S, 2000, TRANSFUSION, V40, P1469, DOI 10.1046/j.1537-2995.2000.40121469.x; Jacobs MR, 2011, TRANSFUSION, V51, P2573, DOI 10.1111/j.1537-2995.2011.03308.x; KALISH RI, 1987, VOX SANG, V53, P169, DOI 10.1111/j.1423-0410.1987.tb04943.x; Kalra A, 2012, AM J THER, V19, pE90, DOI 10.1097/MJT.0b013e3181e4ddb2; Katus MC, 2014, VOX SANG, V107, P103, DOI 10.1111/vox.12146; Kennedy LD, 2008, TRANSFUSION, V48, P2285, DOI 10.1111/j.1537-2995.2008.01858.x; Kenton Alexander B, 2005, J Perinatol, V25, P173, DOI 10.1038/sj.jp.7211237; Kirpalani H, 2012, SEMIN PERINATOL, V36, P269, DOI 10.1053/j.semperi.2012.04.007; KOHAN AI, 1994, VOX SANG, V67, P195, DOI 10.1111/j.1423-0410.1994.tb01659.x; Koshy R, 2009, Immunohematology, V25, P44; Lafeuillade B, 2015, TRANSFUSION, V55, P636, DOI 10.1111/trf.12883; LaSalle-Williams M, 2011, TRANSFUSION, V51, P1732, DOI 10.1111/j.1537-2995.2010.03045.x; Lee AC, 2014, TRANSFUSION, V54, P244, DOI 10.1111/trf.12192; Leslie Kate, 2003, Best Pract Res Clin Anaesthesiol, V17, P485, DOI 10.1016/S1521-6896(03)00049-1; Lieberman L, 2013, TRANSFUS MED REV, V27, P206, DOI 10.1016/j.tmrv.2013.07.002; Lin L, 2004, TRANSFUSION, V44, P1496, DOI 10.1111/j.1537-2995.2004.04125.x; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Marschner S, 2010, TRANSFUSION, V50, P2489, DOI 10.1111/j.1537-2995.2010.02714.x; Marti-Carvajal AJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007539.pub2; MCCULLOUGH J, 1972, ANESTH ANAL CURR RES, V51, P102; Meikle A, 2000, CAN J ANAESTH, V47, P792, DOI 10.1007/BF03019483; Menis M, 2015, TRANSFUSION, V55, P284, DOI 10.1111/trf.12782; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; Moola S, 2011, INT J EVID-BASED HEA, V9, P337, DOI 10.1111/j.1744-1609.2011.00227.x; Moreau ME, 2007, TRANSFUSION, V47, P410, DOI 10.1111/j.1537-2995.2007.01097.x; MUELLERECKHARDT C, 1988, BLUT, V57, P163, DOI 10.1007/BF00319544; Murphy WG, 2011, TRANSFUS APHER SCI, V45, P69, DOI 10.1016/j.transci.2011.06.005; Narick C, 2012, TRANSFUSION, V52, P160, DOI 10.1111/j.1537-2995.2011.03247.x; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Noizat-Pirenne F, 2015, VOX SANG, V108, P262, DOI 10.1111/vox.12217; Noizat-Pirenne F, 2013, CR BIOL, V336, P152, DOI 10.1016/j.crvi.2012.09.011; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OLINGER GN, 1976, J THORAC CARDIOV SUR, V72, P503; OWEN HG, 1994, TRANSFUSION, V34, P891, DOI 10.1046/j.1537-2995.1994.341095026976.x; Pagano MB, 2015, TRANSFUSION, V55, P1668, DOI 10.1111/trf.13047; Pfuntner A, 2011, FREQUENT PROCEDURES; Piccin A, 2015, TRANSFUSION, V55, P1223, DOI 10.1111/trf.12965; Pujani M, 2014, BLOOD TRANSFUS-ITALY, V12, pS100, DOI 10.2450/2012.0154-12; Riley W, 2012, TRANSFUSION, V52, P1957, DOI 10.1111/j.1537-2995.2011.03539.x; Robillard P, 2011, TRANSFUSION, V51, P1405, DOI 10.1111/j.1537-2995.2010.03001.x; ROSSE WF, 1990, BLOOD, V76, P1431; Ruhl H, 2009, TRANSFUS MED REV, V23, P62, DOI 10.1016/j.tmrv.2008.09.006; RUNGE JW, 1992, ANN EMERG MED, V21, P237, DOI 10.1016/S0196-0644(05)80881-9; Sanders RP, 2005, BRIT J HAEMATOL, V130, P781, DOI 10.1111/j.1365-2141.2005.05670.x; Sandler SG, 2015, TRANSFUSION, V55, P199, DOI 10.1111/trf.12796; Sayah DM, 2012, CRIT CARE CLIN, V28, P363, DOI 10.1016/j.ccc.2012.04.001; Schonewille H, 2000, TRANSFUSION, V40, P1127, DOI 10.1046/j.1537-2995.2000.40091127.x; Schwickerath V, 2010, TRANSFUSION, V50, P1465, DOI 10.1111/j.1537-2995.2010.02629.x; SEAGER OA, 1974, JAMA-J AM MED ASSOC, V229, P790, DOI 10.1001/jama.229.7.790; Sesok-Pizzini D, 2014, TRANSFUSION, V54, P4, DOI 10.1111/trf.12470; Shaz BH, 2014, BLOOD, V123, P3374, DOI 10.1182/blood-2014-04-565473; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Silliman CC, 2014, BLOOD, V123, P3488, DOI 10.1182/blood-2013-10-532424; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Strauss RG, 2010, TRANSFUSION, V50, P1862, DOI 10.1111/j.1537-2995.2010.02789.x; STRAUTZ RL, 1989, AM J EMERG MED, V7, P162, DOI 10.1016/0735-6757(89)90129-0; Sweeney JD, 1998, TRANSFUSION, V38, P410, DOI 10.1046/j.1537-2995.1998.38498257382.x; Takahashi TA, 1995, TRANSFUSION, V35, P967, DOI 10.1046/j.1537-2995.1995.351196110903.x; Talano JAM, 2003, PEDIATRICS, V111, pE661, DOI 10.1542/peds.111.6.e661; Tinegate H, 2012, BRIT J HAEMATOL, V159, P143, DOI 10.1111/bjh.12017; Tobian AAR, 2011, TRANSFUSION, V51, P1676, DOI 10.1111/j.1537-2995.2010.03008.x; Tormey CA, 2013, ARCH PATHOL LAB MED, V137, P861, DOI 10.5858/arpa.2012-0154-CR; Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; Treleaven J, 2011, BRIT J HAEMATOL, V152, P35, DOI 10.1111/j.1365-2141.2010.08444.x; Uhlmann EJ, 2014, TRANSFUSION, V54, P384, DOI 10.1111/trf.12258; Unni N, 2014, TRANSFUSION, V54, P98, DOI 10.1111/trf.12251; VAMVAKAS EC, 1995, TRANSFUSION, V35, P26, DOI 10.1046/j.1537-2995.1995.35195090655.x; Van der Linden P, 2012, ACTA CLIN BELG, V67, P201, DOI 10.2143/ACB.67.3.2062656; Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x; Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7; Weinstock C, 2015, TRANSFUSION, V55, P605, DOI 10.1111/trf.12882; Weiskopf RB, 2005, TRANSFUSION, V45, P1295, DOI 10.1111/j.1537-2995.2005.00220.x; Whitaker BI, 2011, HHSP23320110008TC; Williamson LM, 2007, TRANSFUSION, V47, P1455, DOI 10.1111/j.1537-2995.2007.01281.x; WIN N, 1995, VOX SANG, V69, P138, DOI 10.1111/j.1423-0410.1995.tb01685.x; Win N, 2008, TRANSFUSION, V48, P1231, DOI 10.1111/j.1537-2995.2008.01693.x; Win N, 2010, TRANSFUS MED REV, V24, P64, DOI 10.1016/j.tmrv.2009.09.006; Winters JL, 2010, TRANSFUSION, V50, P1444, DOI 10.1111/j.1537-2995.2010.02609.x; Zavizion B, 2004, VOX SANG, V87, P143, DOI 10.1111/j.1423-0410.2004.00556.x	119	199	207	2	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2016	388	10061					2825	2836		10.1016/S0140-6736(15)01313-6	http://dx.doi.org/10.1016/S0140-6736(15)01313-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE5FB	27083327				2023-01-03	WOS:000389629800033
J	Rodriguez, CA; Agudelo, M; Aguilar, YA; Zuluaga, AF; Vesga, O				Rodriguez, Carlos A.; Agudelo, Maria; Aguilar, Yudy A.; Zuluaga, Andres F.; Vesga, Omar			Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam	PLOS ONE			English	Article							IN-VITRO; BETA-LACTAMASE; ANTIMICROBIAL RESISTANCE; STAPHYLOCOCCUS-AUREUS; VANCOMYCIN PRODUCTS; STREPTOCOCCUS-PNEUMONIAE; MULTIDRUG-RESISTANT; ANIMAL-MODELS; SELECTION; INFECTIONS	Previous studies have demonstrated that pharmaceutical equivalence and pharmacokinetic equivalence of generic antibiotics are necessary but not sufficient conditions to guarantee therapeutic equivalence (better called pharmacodynamic equivalence). In addition, there is scientific evidence suggesting a direct link between pharmacodynamic nonequivalence of generic vancomycin and promotion of resistance in Staphylococcus aureus. To find out if even subtle deviations from the expected pharmacodynamic behavior with respect to the innovator could favor resistance, we studied a generic product of piperacillin-tazobactam characterized by pharmaceutical and pharmacokinetic equivalence but a faulty fit of Hill's E-max sigmoid model that could be interpreted as pharmacodynamic nonequivalence. We determined the impact in vivo of this generic product on the resistance of a mixed Escherichia coli population composed of similar to 99% susceptible cells (ATCC 35218 strain) and a similar to 1% isogenic resistant subpopulation that overproduces TEM-1 beta-lactamase. After only 24 hours of treatment in the neutropenic murine thigh infection model, the generic amplified the resistant subpopulation up to 20-times compared with the innovator, following an inverted-U dose-response relationship. These findings highlight the critical role of therapeutic nonequivalence of generic antibiotics as a key factor contributing to the global problem of bacterial resistance.	[Rodriguez, Carlos A.; Agudelo, Maria; Aguilar, Yudy A.; Zuluaga, Andres F.; Vesga, Omar] Univ Antioquia, Fac Med, GRIPE Grp Invest Problemas Enfermedades Infeccios, Medellin, Colombia; [Agudelo, Maria; Vesga, Omar] Hosp Univ San Vicente Fdn, Infect Dis Unit, Medellin, Colombia	Universidad de Antioquia	Vesga, O (corresponding author), Univ Antioquia, Fac Med, GRIPE Grp Invest Problemas Enfermedades Infeccios, Medellin, Colombia.; Vesga, O (corresponding author), Hosp Univ San Vicente Fdn, Infect Dis Unit, Medellin, Colombia.	omar.vesga@udea.edu.co	Rodriguez, Carlos A./P-8324-2019; Zuluaga, Andres F./K-7366-2016	Rodriguez, Carlos A./0000-0002-4042-4313; Zuluaga, Andres F./0000-0001-5656-4153; Vesga, Omar/0000-0002-4308-7930	University of Antioquia (Estrategia de Sostenibilidad); Sistema General de Regalias de Colombia, Gobernacion de Antioquia [BPIN: 2013000100183]; Rodrigo Vesga Meneses Scientific Foundation	University of Antioquia (Estrategia de Sostenibilidad); Sistema General de Regalias de Colombia, Gobernacion de Antioquia; Rodrigo Vesga Meneses Scientific Foundation	This project was financed by the University of Antioquia (Estrategia de Sostenibilidad 2013-2014) (OV), Sistema General de Regalias de Colombia, Gobernacion de Antioquia (BPIN: 2013000100183) (AFZ), and Rodrigo Vesga Meneses Scientific Foundation, a non-profit foundation supporting research at GRIPE (OV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This project was financed by the University of Antioquia (Estrategia de Sostenibilidad 2013-2014), Sistema General de Regalias de Colombia, Gobernacion de Antioquia (BPIN: 2013000100183) and Rodrigo Vesga Meneses Scientific Foundation, a non-profit foundation supporting research at GRIPE.	Agudelo M, 2014, ANTIMICROB AGENTS CH, V58, P1005, DOI 10.1128/AAC.00350-13; Agudelo M, 2015, INT J ANTIMICROB AG, V45, P161, DOI 10.1016/j.ijantimicag.2014.10.014; Allen M.P., 1997, UNDERSTANDING REGRES; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; [Anonymous], 2014, BET LACT CLASS AM AC; Baquero F, 1997, TRENDS ECOL EVOL, V12, P482, DOI 10.1016/S0169-5347(97)01223-8; Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P1, DOI 10.1007/978-1-4419-9485-1; Cafini F, 2008, MICROB DRUG RESIST, V14, P13, DOI 10.1089/mdr.2008.0783; Chollet R, 2004, ANTIMICROB AGENTS CH, V48, P3621, DOI 10.1128/AAC.48.9.3621-3624.2004; Firsov AA, 2015, ANTIMICROB AGENTS CH, V59, P1014, DOI 10.1128/AAC.04214-14; Glantz Stanton, 2001, PRIMER APPL REGRESSI; Gnanaprakazam A, 2008, United States patent, Patent No. 7417143; GOUSSARD S, 1991, GENE, V102, P71, DOI 10.1016/0378-1119(91)90540-R; Goussard S, 1999, ANTIMICROB AGENTS CH, V43, P367, DOI 10.1128/AAC.43.2.367; GraphPad, 2014, GRAPHPAD STAT GUID; Howden BP, 2010, CLIN MICROBIOL REV, V23, P99, DOI 10.1128/CMR.00042-09; Huttner A, 2013, ANTIMICROB RESIST IN, V2, DOI 10.1186/2047-2994-2-31; IMS-IHI, 2013, GLOB US MED OUTL 201; Jones RN, 2008, DIAGN MICR INFEC DIS, V61, P76, DOI 10.1016/j.diagmicrobio.2007.12.010; Pallares CJ, 2014, BIOMEDICA, V34, P148, DOI [10.7705/biomedica.v34i0.1646, 10.1590/S0120-41572014000500017]; Karaiskos I, 2014, EXPERT OPIN PHARMACO, V15, P1351, DOI 10.1517/14656566.2014.914172; Lai J, 2013, United States patent, Patent No. 8476425; Lee C, 2006, J BIOTECHNOL, V123, P273, DOI 10.1016/j.jbiotec.2005.11.014; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; Louie A, 2015, ANTIMICROB AGENTS CH, V59, P622, DOI 10.1128/AAC.03710-14; Mabilat Claude, 1993, P553; Mastoraki E, 2008, J INFECTION, V56, P35, DOI 10.1016/j.jinf.2007.09.011; Michael CA, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00145; Moet GJ, 2009, DIAGN MICR INFEC DIS, V65, P319, DOI 10.1016/j.diagmicrobio.2009.06.012; Mouton JW, 2013, ANTIMICROB RESIST IN, V2, DOI 10.1186/2047-2994-2-32; N. I. S. T. Weighted Standard Deviation, 1996, DATAPLOT REF MAN; Negri MC, 2000, ANTIMICROB AGENTS CH, V44, P2485, DOI 10.1128/AAC.44.9.2485-2491.2000; Nelson EC, 1999, ANTIMICROB AGENTS CH, V43, P957, DOI 10.1128/AAC.43.4.957; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Odenholt I, 2003, ANTIMICROB AGENTS CH, V47, P518, DOI 10.1128/AAC.47.2.518-523.2003; Olofsson SK, 2007, J ANTIMICROB CHEMOTH, V60, P795, DOI 10.1093/jac/dkm265; Rawlings J.O., 1998, APPL REGRESSION ANAL, DOI 10.1007/b98890; Reddy NB., 2012, PHARM LETT, V4, P674; REGUERA JA, 1991, J ANTIMICROB CHEMOTH, V27, P569, DOI 10.1093/jac/27.5.569; Review on Antimicrobial Resistance, 2014, REV ANTIMICROB RESIS; Rodriguez CA, 2014, 54 INT C ANT AG CHEM; Rodriguez CA, 2015, ANTIMICROB AGENTS CH, V59, P233, DOI 10.1128/AAC.02352-13; Rodriguez CA, 2015, ANTIMICROB AGENTS CH, V59, P53, DOI 10.1128/AAC.03633-14; Rodriguez CA, 2012, ANTIMICROB AGENTS CH, V56, P243, DOI 10.1128/AAC.05129-11; Rodriguez CA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-153; Rodriguez CA, 2009, J INFECTION, V59, P277, DOI 10.1016/j.jinf.2009.08.005; Rodríguez Carlos Andrés, 2005, Biomed., V25, P575; Ruijter JM, 2014, MICROCHIM ACTA, V181, P1689, DOI 10.1007/s00604-013-1155-8; Sevillano D, 2006, J ANTIMICROB CHEMOTH, V58, P794, DOI 10.1093/jac/dkl307; SORGEL F, 1993, J ANTIMICROB CHEMOTH, V31, P39, DOI 10.1093/jac/31.suppl_A.39; Srivastava S, 2011, J INFECT DIS, V204, P1951, DOI 10.1093/infdis/jir658; Tattevin P, 2013, ANTIMICROB AGENTS CH, V57, P1157, DOI 10.1128/AAC.01669-12; TOMOEDA M, 1974, J BACTERIOL, V120, P1158, DOI 10.1128/JB.120.3.1158-1163.1974; TOOMER CA, 1991, J MED CHEM, V34, P1944, DOI 10.1021/jm00111a003; Trickes G, 1998, United States patent, Patent No. 5763603; VanScoy B, 2013, ANTIMICROB AGENTS CH, V57, P5924, DOI 10.1128/AAC.00656-13; Vesga O, 2010, ANTIMICROB AGENTS CH, V54, P3271, DOI 10.1128/AAC.01044-09; VIJVERBERG WPM, 1987, OXFORD B ECON STAT, V49, P417; Welage L S, 2001, J Am Pharm Assoc (Wash), V41, P856; Wu PJ, 1995, J ANTIMICROB CHEMOTH, V36, P927, DOI 10.1093/jac/36.6.927; You YQ, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00284; Zuluaga AF, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-55; Zuluaga AF, 2014, CLIN INFECT DIS, V59, P459, DOI 10.1093/cid/ciu306; Zuluaga AF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010744	64	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2016	11	5							e0155806	10.1371/journal.pone.0155806	http://dx.doi.org/10.1371/journal.pone.0155806			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3ZU	27191163	Green Published, Green Submitted, gold			2023-01-03	WOS:000376286100098
J	Yu, T; Zhang, QW; Zheng, TY; Shi, HS; Liu, Y; Feng, SJ; Hao, MQ; Ye, L; Wu, XQ; Yang, C				Yu, Ting; Zhang, Qiongwen; Zheng, Tianying; Shi, Huashan; Liu, Yang; Feng, Shijian; Hao, Meiqin; Ye, Lei; Wu, Xueqian; Yang, Cheng			The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures	PLOS ONE			English	Article							DOSE CONFORMAL RADIOTHERAPY; 2ND PRIMARY CANCERS; COMPARING 68 GY; PROGNOSTIC-FACTORS; ACUTE TOXICITY; TRIAL; IMRT; IMPACT; TERM; COMPLICATIONS	Background and Purpose Intensity modulated radiation therapy (IMRT) can deliver higher doses with less damage of healthy tissues compared with three-dimensional radiation therapy (3DCRT). However, for the scenarios with better clinical outcomes for IMRT than 3DCRT in prostate cancer, the results remain ambiguous. We performed a meta-analysis to assess whether IMRT can provide better clinical outcomes in comparison with 3DCRT in patients diagnosed with prostate cancer. Materials and Methods We conducted a meta-analysis of 23 studies (n = 9556) comparing the clinical outcomes, including gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, biochemical controland overall survival (OS). Results IMRT was significantly associated with decreased 2-4 grade acute GI toxicity [risk ratio (RR) = 0.59 (95% confidence interval (CI), 0.44, 0.78)], late GI toxicity [RR = 0.54, 95% CI (0.38, 0.78)], late rectal bleeding [RR = 0.48, 95% CI (0.27, 0.85)], and achieved better biochemical control[RR = 1.17, 95% CI (1.08, 1.27)] in comparison with 3DCRT. IMRT and 3DCRT remain the same in regard of grade 2-4 acute rectal toxicity [RR = 1.03, 95% CI (0.45, 2.36)], late GU toxicity [RR = 1.03, 95% CI (0.82, 1.30)] and overall survival [RR = 1.07, 95% CI (0.96, 1.19)], while IMRT slightly increased the morbidity of grade 2-4 acute GU toxicity [RR = 1.08, 95% CI (1.00, 1.17)]. Conclusions Although some bias cannot be ignored, IMRT appears to be a better choice for the treatment of prostate cancer when compared with 3DCRT.	[Yu, Ting; Zhang, Qiongwen; Zheng, Tianying; Shi, Huashan; Liu, Yang; Feng, Shijian; Hao, Meiqin; Ye, Lei; Wu, Xueqian; Yang, Cheng] Sichuan Univ, West China Med Sch, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China; [Yu, Ting; Zhang, Qiongwen; Zheng, Tianying; Shi, Huashan; Liu, Yang; Feng, Shijian; Hao, Meiqin; Ye, Lei; Wu, Xueqian; Yang, Cheng] Sichuan Univ, West China Med Sch, West China Hosp, Ctr Canc, Chengdu 610064, Sichuan, Peoples R China; [Zhang, Qiongwen; Shi, Huashan] Sichuan Univ, West China Med Sch, West China Hosp, Dept Head & Neck Oncol, Chengdu 610064, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Shi, HS (corresponding author), Sichuan Univ, West China Med Sch, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.; Shi, HS (corresponding author), Sichuan Univ, West China Med Sch, West China Hosp, Ctr Canc, Chengdu 610064, Sichuan, Peoples R China.; Shi, HS (corresponding author), Sichuan Univ, West China Med Sch, West China Hosp, Dept Head & Neck Oncol, Chengdu 610064, Sichuan, Peoples R China.	hx_natlife@163.com		Shi, Hua-shan/0000-0002-9958-9892; Zhang, Qiongwen/0000-0003-2033-6663	National Natural Science Foundation of China [81300320]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The data analysis was funded by the National Natural Science Foundation of China, number: 81300320, http://www.nsfc.gov.cn/.	Ailleres N, 2004, Cancer Radiother, V8, P59, DOI 10.1016/j.canrad.2003.10.007; Alongi F, 2009, RADIOTHER ONCOL, V93, P207, DOI 10.1016/j.radonc.2009.08.042; Ashman JB, 2005, INT J RADIAT ONCOL, V63, P765, DOI 10.1016/j.ijrobp.2005.02.050; Bauman G, 2012, Clin Oncol (R Coll Radiol), V24, P461, DOI 10.1016/j.clon.2012.05.002; Beckendorf V, 2011, INT J RADIAT ONCOL, V80, P1056, DOI 10.1016/j.ijrobp.2010.03.049; Bednarz B, 2010, MED PHYS, V37, P1987, DOI 10.1118/1.3367012; Budaus L, 2012, EUR UROL, V61, P112, DOI 10.1016/j.eururo.2011.09.027; Cahlon O, 2008, INT J RADIAT ONCOL, V71, P330, DOI 10.1016/j.ijrobp.2007.10.004; Cho JH, 2009, J KOREAN MED SCI, V24, P894, DOI 10.3346/jkms.2009.24.5.894; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; Crook J, 2013, SEMIN RADIAT ONCOL, V23, P165, DOI 10.1016/j.semradonc.2013.01.002; Damast S, 2012, HEAD NECK-J SCI SPEC, V34, P900, DOI 10.1002/hed.21677; Daskivich TJ, 2011, CANCER-AM CANCER SOC, V117, P2058, DOI 10.1002/cncr.25751; Dearnaley DP, 2007, LANCET ONCOL, V8, P475, DOI 10.1016/S1470-2045(07)70143-2; Dearnaley DP, 2007, RADIOTHER ONCOL, V83, P31, DOI 10.1016/j.radonc.2007.02.014; Dearnaley DP, 1999, LANCET, V353, P267, DOI 10.1016/S0140-6736(98)05180-0; Dolezel M, 2015, STRAHLENTHER ONKOL, V191, P338, DOI 10.1007/s00066-014-0806-y; Dolezel M, 2010, STRAHLENTHER ONKOL, V186, P197, DOI 10.1007/s00066-010-2065-x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fiveash JB, 2000, INT J RADIAT ONCOL, V47, P335, DOI 10.1016/S0360-3016(00)00441-7; Forsythe K, 2012, INT J RADIAT ONCOL, V83, P630, DOI 10.1016/j.ijrobp.2011.06.2013; Goenka A, 2011, EUR UROL, V60, P1142, DOI 10.1016/j.eururo.2011.08.006; Haas GP, 2007, JNCI-J NATL CANCER I, V99, P1484, DOI 10.1093/jnci/djm153; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Hanks GE, 2000, ANN MED, V32, P57, DOI 10.3109/07853890008995911; Hummel S, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14470; Jackson A, 2001, INT J RADIAT ONCOL, V49, P685, DOI 10.1016/S0360-3016(00)01414-0; Jani AB, 2003, LANCET, V361, P1045, DOI 10.1016/S0140-6736(03)12833-4; Jani AB, 2007, TECHNOL CANCER RES T, V6, P11, DOI 10.1177/153303460700600102; Kim H, 2014, RADIAT ONCOL J, V32, P187, DOI 10.3857/roj.2014.32.3.187; Kramer Karen M, 2005, Clin Prostate Cancer, V4, P15, DOI 10.3816/CGC.2005.n.007; Kuban DA, 2008, INT J RADIAT ONCOL, V70, P67, DOI 10.1016/j.ijrobp.2007.06.054; Kupelian PA, 2002, INT J RADIAT ONCOL, V53, P904, DOI 10.1016/S0360-3016(02)02836-5; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; Lee N, 2007, HEAD NECK-J SCI SPEC, V29, P387, DOI 10.1002/hed.20332; Livi L, 2007, Actas Urol Esp, V31, P611; Marta GN, 2014, RADIOTHER ONCOL, V110, P9, DOI 10.1016/j.radonc.2013.11.010; Matzinger O, 2009, EJC SUPPL, V7, P151, DOI 10.1016/S1359-6349(09)70517-8; Merglen A, 2007, ARCH INTERN MED, V167, P1944, DOI 10.1001/archinte.167.18.1944; Michalski JM, 2010, INT J RADIAT ONCOL, V76, pS123, DOI 10.1016/j.ijrobp.2009.03.078; Michalski JM, 2005, INT J RADIAT ONCOL, V62, P706, DOI 10.1016/j.ijrobp.2004.11.028; Michalski JM, 2003, INT J RADIAT ONCOL, V56, P192, DOI 10.1016/S0360-3016(03)00072-5; Murray L, 2014, RADIOTHER ONCOL, V110, P213, DOI 10.1016/j.radonc.2013.12.012; Odrazka K, 2010, INT J UROL, V17, P784, DOI 10.1111/j.1442-2042.2010.02592.x; Ohri N, 2012, CAN J UROL, V19, P6373; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Peeters STH, 2006, J CLIN ONCOL, V24, P1990, DOI 10.1200/JCO.2005.05.2530; Peeters STK, 2005, INT J RADIAT ONCOL, V61, P1019, DOI 10.1016/j.ijrobp.2004.07.715; Penson David F, 2003, Curr Urol Rep, V4, P185, DOI 10.1007/s11934-003-0068-1; Phan J, 2009, CANCER-AM CANCER SOC, V115, P1827, DOI 10.1002/cncr.24223; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Ratnayake G, 2014, J MED IMAG RADIAT ON, V58, P503, DOI 10.1111/1754-9485.12153; Roach M, 2004, UROL CLIN N AM, V31, P353, DOI 10.1016/j.ucl.2004.02.001; Ruben JD, 2008, INT J RADIAT ONCOL, V70, P1530, DOI 10.1016/j.ijrobp.2007.08.046; RUBIN P, 1995, RADIOTHER ONCOL, V35, P5; Schneider U, 2006, STRAHLENTHER ONKOL, V182, P647, DOI 10.1007/s00066-006-1534-8; Sharma NK, 2007, INT J RADIAT ONCOL, V69, pS10, DOI 10.1016/j.ijrobp.2007.07.019; Shu HKG, 2001, UROLOGY, V57, P102, DOI 10.1016/S0090-4295(00)00890-6; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Someya M, 2015, J RADIAT RES, V56, P122, DOI 10.1093/jrr/rru080; Staffurth J, 2010, CLIN ONCOL-UK, V22, P643, DOI 10.1016/j.clon.2010.06.013; Sveistrup J, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-44; Treutwein M, 2008, NOWOTWORY, V58, P154; Troeller A, 2015, INT J RADIAT ONCOL, V91, P435, DOI 10.1016/j.ijrobp.2014.09.046; Van de Werf E, 2009, RADIOTHER ONCOL, V93, P137, DOI 10.1016/j.radonc.2009.07.007; Viani GA, 2009, INT J RADIAT ONCOL, V74, P1405, DOI 10.1016/j.ijrobp.2008.10.091; Vora SA, 2007, INT J RADIAT ONCOL, V68, P1053, DOI 10.1016/j.ijrobp.2007.01.043; Wong WW, 2009, CANCER-AM CANCER SOC, V115, P5596, DOI 10.1002/cncr.24558; Wortel RC, 2015, INT J RADIAT ONCOL, V91, P737, DOI 10.1016/j.ijrobp.2014.12.017; Zelefsky MJ, 2008, EUR UROL, V53, P1172, DOI 10.1016/j.eururo.2007.12.030; Zelefsky MJ, 2008, INT J RADIAT ONCOL, V70, P1124, DOI 10.1016/j.ijrobp.2007.11.044; Zelefsky MJ, 2000, RADIOTHER ONCOL, V55, P241, DOI 10.1016/S0167-8140(99)00100-0; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; Zietman AL, 2008, JAMA-J AM MED ASSOC, V299, P899	74	40	40	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0154499	10.1371/journal.pone.0154499	http://dx.doi.org/10.1371/journal.pone.0154499			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171271	Green Published, Green Submitted, gold			2023-01-03	WOS:000376588600142
J	Weill, A; Dalichampt, M; Raguideau, F; Ricordeau, P; Blotiere, PO; Rudant, J; Alla, F; Zureik, M				Weill, Alain; Dalichampt, Marie; Raguideau, Fanny; Ricordeau, Philippe; Blotiere, Pierre-Olivier; Rudant, Jeremie; Alla, Francois; Zureik, Mahmoud			Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOEMBOLISM; YOUNG-WOMEN; DROSPIRENONE; THROMBOSIS; HEALTH; USERS	OBJECTIVE To assess the risk of pulmonary embolism, ischaemic stroke, and myocardial infarction associated with combined oral contraceptives according to dose of oestrogen (ethinylestradiol) and progestogen. DESIGN Observational cohort study. SETTING Data from the French national health insurance database linked with data from the French national hospital discharge database. PARTICIPANTS 4 945 088 women aged 15-49 years, living in France, with at least one reimbursement for oral contraceptives and no previous hospital admission for cancer, pulmonary embolism, ischaemic stroke, or myocardial infarction, between July 2010 and September 2012. MAIN OUTCOME MEASURES Relative and absolute risks of first pulmonary embolism, ischaemic stroke, and myocardial infarction. RESULTS The cohort generated 5 443 916 women years of oral contraceptive use, and 3253 events were observed: 1800 pulmonary embolisms (33 per 100 000 women years), 1046 ischaemic strokes (19 per 100 000 women years), and 407 myocardial infarctions (7 per 100 000 women years). After adjustment for progestogen and risk factors, the relative risks for women using low dose oestrogen (20 mu g v 30-40 mu g) were 0.75 (95% confidence interval 0.67 to 0.85) for pulmonary embolism, 0.82 (0.70 to 0.96) for ischaemic stroke, and 0.56 (0.39 to 0.79) for myocardial infarction. After adjustment for oestrogen dose and risk factors, desogestrel and gestodene were associated with statistically significantly higher relative risks for pulmonary embolism (2.16, 1.93 to 2.41 and 1.63, 1.34 to 1.97, respectively) compared with levonorgestrel. Levonorgestrel combined with 20 mu g oestrogen was associated with a statistically significantly lower risk than levonorgestrel with 30-40 mu g oestrogen for each of the three serious adverse events. CONCLUSIONS For the same dose of oestrogen, desogestrel and gestodene were associated with statistically significantly higher risks of pulmonary embolism but not arterial thromboembolism compared with levonorgestrel. For the same type of progestogen, an oestrogen dose of 20 mu g versus 30-40 mu g was associated with lower risks of pulmonary embolism, ischaemic stroke, and myocardial infarction.	[Weill, Alain; Dalichampt, Marie; Ricordeau, Philippe; Blotiere, Pierre-Olivier; Rudant, Jeremie; Alla, Francois] French Natl Hlth Insurance, Dept Studies Publ Hlth, F-75986 Paris 20, France; [Raguideau, Fanny; Zureik, Mahmoud] French Natl Agcy Med & Hlth Prod Safety, St Denis, Reunion, France		Weill, A (corresponding author), French Natl Hlth Insurance, Dept Studies Publ Hlth, F-75986 Paris 20, France.	alain.weill@cnamts.fr	Blotière, Pierre-Olivier/AAH-2024-2021; alla, francois/D-2295-2014; Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217; Weill, Alain/0000-0001-8687-9092; alla, francois/0000-0002-5793-7190	French National Health Insurance Fund (CNAMTS); French National Agency for Medicines and Health Products Safety (ANSM)	French National Health Insurance Fund (CNAMTS); French National Agency for Medicines and Health Products Safety (ANSM)	This research was funded by the French National Health Insurance Fund (CNAMTS) and the French National Agency for Medicines and Health Products Safety (ANSM). AW, MD, PB, JR, PR, and FA are employees of the French National Health Insurance Fund, MZ and FR of the French National Agency for Medicines and Health Products Safety. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers.	Aboa-Eboule C, 2013, J NEUROL, V260, P605, DOI 10.1007/s00415-012-6686-0; Bajos N, 2012, POPUL SOC PARIS, P492; Bitzer J, 2013, J FAM PLAN REPROD H, V39, P156, DOI 10.1136/jfprhc-2013-100624; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Casez P, 2010, J CLIN EPIDEMIOL, V63, P790, DOI 10.1016/j.jclinepi.2009.09.002; Dinger J, 2010, J FAM PLAN REPROD H, V36, P123, DOI 10.1783/147118910791749416; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Dunn N, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3164; Dunn NR, 2001, CONTRACEPTION, V63, P65, DOI 10.1016/S0010-7824(01)00172-X; Earth Policy Institute from U.N. Population Division, 2011, WORLD CONTRACEPTIVE; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Food and Drug Administration Office of Surveillance and Epidemiology, COMBINED HORMONAL CO; French Ministry of Labour. Employment and Health, 2011, OFFICIAL BULLETIN; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Gronich N, 2011, CAN MED ASSOC J, V183, pE1319, DOI 10.1503/cmaj.110463; Haute Autorite de Sante, 2012, CORRECT USE OF MEDIC; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lidegaard O, 2002, CONTRACEPTION, V65, P197, DOI 10.1016/S0010-7824(01)00306-7; Lidegaard Ojvind, 2011, BMJ, V343, pd6423, DOI 10.1136/bmj.d6423; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; Lidegaard Ojvind, 2009, BMJ, V339, pb2890, DOI 10.1136/bmj.b2890; Margolis KL, 2007, FERTIL STERIL, V88, P310, DOI 10.1016/j.fertnstert.2006.11.206; Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; Parkin L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2139; Poulter NR, 1999, LANCET, V354, P301, DOI 10.1016/S0140-6736(99)01013-2; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33; Rosenberg L, 2001, ARCH INTERN MED, V161, P1065, DOI 10.1001/archinte.161.8.1065; Sidney S, 1998, CIRCULATION, V98, P1058, DOI 10.1161/01.CIR.98.11.1058; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Stegeman BH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5298; Suissa S, 2000, HUM REPROD, V15, P817, DOI 10.1093/humrep/15.4.817; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; Tricotel A, 2015, J THROMB HAEMOST, V13, P1576, DOI 10.1111/jth.13053; Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005; van Hylckama Vlieg A, 2009, BMJ, V339, pb2921, DOI 10.1136/bmj.b2921; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; Vinogradova Y, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2135; Zhang G, 2014, SE ASIAN J TROP MED, V45, P736	46	97	98	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2016	353								i2002	10.1136/bmj.i2002	http://dx.doi.org/10.1136/bmj.i2002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6FP	27164970	Green Published, hybrid			2023-01-03	WOS:000376446300001
J	Bivona, TG; Doebele, RC				Bivona, Trever G.; Doebele, Robert C.			A framework for understanding and targeting residual disease in oncogene-driven solid cancers	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; RANDOMIZED PHASE-II; ACQUIRED-RESISTANCE; COMBINED BRAF; COLORECTAL-CANCER; MEK INHIBITION; RAF INHIBITORS; FEEDBACK ACTIVATION; DRUG-RESISTANCE; EGFR	Molecular targeted therapy has the potential to dramatically improve survival in patients with cancer. However, complete and durable responses to targeted therapy are rare in individuals with advanced-stage solid cancers. Even the most effective targeted therapies generally do not induce a complete tumor response, resulting in residual disease and tumor progression that limits patient survival. We discuss the emerging need to more fully understand the molecular basis of residual disease as a prelude to designing therapeutic strategies to minimize or eliminate residual disease so that we can move from temporary to chronic control of disease, or a cure, for patients with advanced-stage solid cancers. Ultimately, we propose a shift from the current reactive paradigm of analyzing and treating acquired drug resistance to a pre-emptive paradigm of defining the mechanisms that result in residual disease, to target and limit this disease reservoir.	[Bivona, Trever G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Bivona, Trever G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Bivona, Trever G.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Doebele, Robert C.] Univ Colorado, Dept Med & Med Oncol, Anschutz Med Campus, Aurora, CO USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus	Bivona, TG (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA USA.; Bivona, TG (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Bivona, TG (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	trever.bivona@ucsf.edu	Doebele, Robert C./I-8230-2019	Doebele, Robert C./0000-0001-6728-6857	US National Institutes of Health Director's Office and Common Fund [DP2-CA174497]; National Cancer Institute [R01-CA169338]; HHMI Collaborative Innovation Award Program; Searle Scholars Program; Pew Charitable Trust; Addario Lung Cancer Foundation; V Foundation for Cancer Research; University of Colorado Lung Cancer SPORE; NATIONAL CANCER INSTITUTE [P50CA058187, R01CA169338, R01CA193935, DP2CA174497] Funding Source: NIH RePORTER	US National Institutes of Health Director's Office and Common Fund(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); HHMI Collaborative Innovation Award Program; Searle Scholars Program; Pew Charitable Trust; Addario Lung Cancer Foundation; V Foundation for Cancer Research; University of Colorado Lung Cancer SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	T.G.B. acknowledges funding support from the US National Institutes of Health Director's Office and Common Fund (New Innovators Award DP2-CA174497), the National Cancer Institute (R01-CA169338), the HHMI Collaborative Innovation Award Program, the Searle Scholars Program, the Pew Charitable Trust, and the Addario Lung Cancer Foundation. R.C.D. acknowledges funding support from the V Foundation for Cancer Research and the University of Colorado Lung Cancer SPORE.	Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915; Behbehani GK, 2015, CANCER DISCOV, V5, P988, DOI 10.1158/2159-8290.CD-15-0298; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012; Blumenthal GM, 2015, J CLIN ONCOL, V33, P1008, DOI 10.1200/JCO.2014.59.0489; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747; Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005; Charakidis M, 2014, TRANSL LUNG CANCER R, V3, P395, DOI 10.3978/j.issn.2218-6751.2014.09.03; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Condeelis J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003848; Coombs C.C., 2015, NAT REV CLIN ONCOL; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; De Silva N, 2015, BRIT J CANCER, V113, P1305, DOI 10.1038/bjc.2015.342; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Gingras I, 2015, CURR OPIN ONCOL, V27, P560, DOI 10.1097/CCO.0000000000000223; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Hurvitz SA, 2015, LANCET ONCOL, V16, P816, DOI 10.1016/S1470-2045(15)00051-0; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janne PA, 2014, J THORAC ONCOL, V9, P316, DOI 10.1097/JTO.0000000000000088; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Johnson ML, 2015, J CLIN ONCOL, V33, P1666, DOI 10.1200/JCO.2014.59.7328; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li XN, 2014, NAT MED, V20, P769, DOI 10.1038/nm.3585; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lin NU, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0276-z; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Piotrowska Z, 2015, CANCER DISCOV, V5, P713, DOI 10.1158/2159-8290.CD-15-0399; Planchard D., 2011, ASCO ANN M AM SOC CL, V8006; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Price KA, 2010, J THORAC ONCOL, V5, P1623, DOI 10.1097/JTO.0b013e3181ec1531; Riely GJ, 2007, CLIN CANCER RES, V13, P5150, DOI 10.1158/1078-0432.CCR-07-0560; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Sawyers Charles L, 2012, Trans Am Clin Climatol Assoc, V123, P114; Sawyers Charles L, 2009, Clin Adv Hematol Oncol, V7, P588; Sawyers CL, 2009, NAT MED, V15, P1158, DOI 10.1038/nm1009-1158; Schwaederle M, 2015, MOL CANCER THER, V14, P1488, DOI 10.1158/1535-7163.MCT-14-1061; Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Spigel D.R., 2011, ASCO ANN M AM SOC CL, V7505; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Szmulewitz RZ, 2014, J CLIN PHARMACOL, V54, P375, DOI 10.1002/jcph.277; Thompson Craig B, 2009, Clin Adv Hematol Oncol, V7, P819; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Varmus H, 2010, NEW ENGL J MED, V362, P2028, DOI 10.1056/NEJMe0911933; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Witta SE, 2012, J CLIN ONCOL, V30, P2248, DOI 10.1200/JCO.2011.38.9411; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	84	104	106	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2016	22	5					472	478		10.1038/nm.4091	http://dx.doi.org/10.1038/nm.4091			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DL3DI	27149220	Green Accepted			2023-01-03	WOS:000375514000009
J	Engvall, G; Angstrom-Brannstrom, C; Mullaney, T; Nilsson, K; Wickart-Johansson, G; Svard, AM; Nyholm, T; Lindh, J; Lindh, V				Engvall, Gunn; Angstrom-Brannstrom, Charlotte; Mullaney, Tara; Nilsson, Kristina; Wickart-Johansson, Gun; Svard, Anna-Maja; Nyholm, Tufve; Lindh, Jack; Lindh, Viveca			It Is Tough and Tiring but It Works-Children's Experiences of Undergoing Radiotherapy	PLOS ONE			English	Article							CHILDHOOD	Approximately 300 children ages 0 to 18 are diagnosed with cancer in Sweden every year, and 80 to 90 of them undergo radiotherapy treatment. The aim was to describe children's experiences of preparing for and undergoing radiotherapy, and furthermore to describe children's suggestions for improvement. Thirteen children between the ages of 5 and 15 with various cancer diagnoses were interviewed. Data was analyzed using qualitative content analysis. The findings revealed five categories: positive and negative experiences with hospital stays and practical arrangements; age-appropriate information, communication, and guidance to various degrees; struggle with emotions; use of distraction and other suitable coping strategies; and children's suggestions for improvement during radiotherapy. An overarching theme emerged: "It is tough and tiring but it works". Some key areas were: explanatory visits, the need for information and communication, being afraid, discomfort and suffering, the need for media distraction, dealing with emotions, and the need for support. A systematic, family-centered preparation program could possible help families prepare and individualized distraction during radiotherapy could contribute to reducing distress. Further studies with interventions could clarify successful programs.	[Engvall, Gunn] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Engvall, Gunn] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [Angstrom-Brannstrom, Charlotte; Lindh, Viveca] Umea Univ, Dept Nursing, Umea, Sweden; [Mullaney, Tara] Umea Univ, Umea Inst Design, Umea, Sweden; [Nilsson, Kristina] Univ Uppsala Hosp, Dept Oncol Radiol & Clin Immunol, Sect Oncol, Uppsala, Sweden; [Wickart-Johansson, Gun] Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden; [Svard, Anna-Maja; Nyholm, Tufve; Lindh, Jack] Umea Univ, Dept Radiat Sci, Umea, Sweden	Uppsala University; Uppsala University; Umea University; Umea University; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital; Umea University	Engvall, G (corresponding author), Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.; Engvall, G (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.	gunn.engvall@kbh.uu.se	Nyholm, Tufve/I-1402-2019	Nyholm, Tufve/0000-0002-8971-9788; Engvall, Gunn/0000-0002-5225-9650	Swedish Childhood Cancer Foundation [PR 2013-0025]	Swedish Childhood Cancer Foundation(European Commission)	Funding provided by grant number PR 2013-0025, The Swedish Childhood Cancer Foundation, URL: http://www.barncancerfonden.se. TN received the funding.	Angstroem-Braennstroem, 2014, J PEDIATR ONCOL NURS, V31, P135, DOI 10.1177/1043454214521693; Aringstrom-Brannstrom C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141086; Bjork Maria, 2006, J Pediatr Oncol Nurs, V23, P210, DOI 10.1177/1043454206289737; Bucholtz J D, 1994, Oncol Nurs Forum, V21, P987; Carter B, 2013, RES NURS HEALTH, V36, P95, DOI 10.1002/nur.21517; Compas BE, 2009, NEW DIR CHILD ADOLES, V124, P87, DOI 10.1002/cd.245; Filin A, 2009, J PEDIATR ONCOL NURS, V26, P81, DOI 10.1177/1043454208328766; Fortier MA, 2011, BRIT J ANAESTH, V106, P713, DOI 10.1093/bja/aer010; Goske MJ, 2013, RADIOGRAPHY, V19, P283, DOI 10.1016/j.radi.2013.04.003; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Gustafsson G, CHILDHOOD CANC INCID; Harrison TM, 2010, J PEDIATR NURS, V25, P335, DOI 10.1016/j.pedn.2009.01.006; Harvey-Lloyd JM, 2013, RADIOGRAPHY, V19, P285, DOI 10.1016/j.radi.2013.07.010; Hildenbrand AK, 2011, J PEDIATR ONCOL NURS, V28, P344, DOI 10.1177/1043454211430823; McGovern SL, 2012, CURR ONCOL REP, V14, P320, DOI 10.1007/s11912-012-0235-y; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Pimm P, 1997, RADIOGRAPHY, V3, P27, DOI [10.1016/S1078-8174(97)80022-3, DOI 10.1016/S1078-8174(97)80022-3]; Scott Linda, 2002, Eur J Oncol Nurs, V6, P15, DOI 10.1054/ejon.2001.0162; Shrimpton BJM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001666; Soanes L, 2009, EUR J ONCOL NURS, V13, P255, DOI 10.1016/j.ejon.2009.03.009; Stackhouse C, 2013, RADIOGRAPHY, V19, P302, DOI 10.1016/j.radi.2013.08.004; Tornqvist E, 2015, J CHILD HEALTH CARE, V19, P359, DOI 10.1177/1367493513518374; Trier-Bieniek A, 2012, QUAL RES, V12, P630, DOI 10.1177/1468794112439005; Woodman H, 2013, RADIOGRAPHY, V19, P311, DOI 10.1016/j.radi.2013.08.006	24	11	11	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0153029	10.1371/journal.pone.0153029	http://dx.doi.org/10.1371/journal.pone.0153029			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27055258	Green Published, gold, Green Submitted			2023-01-03	WOS:000373608000066
J	Lee, YK; Hwang, SY; Shin, TG; Jo, IJ; Suh, GY; Jeon, K				Lee, Young Kun; Hwang, Sung Yeon; Shin, Tae Gun; Jo, Ik Joon; Suh, Gee Young; Jeon, Kyeongman			Prognostic Value of Lactate and Central Venous Oxygen Saturation after Early Resuscitation in Sepsis Patients	PLOS ONE			English	Article							GOAL-DIRECTED RESUSCITATION; SEPTIC SHOCK; CRITICALLY-ILL; MANAGEMENT; CLEARANCE; THERAPY; BUNDLE	The objective of this study was to evaluate the prognostic value of static and dynamic variables of central venous oxygen saturation (ScvO(2)) and lactate in patients with severe sepsis or septic shock who underwent early quantitative resuscitation. We also investigated whether ScvO(2) measured after initial resuscitation could provide additive prognostic value to that of lactate. We analyzed the sepsis registry for patients presenting to the emergency department and included patients with simultaneous measurements of lactate and ScvO(2) at the time of presentation (H0) and 6 hours (H6) after resuscitation. The primary outcome was 28-day mortality and multivariable logistic analysis was used to adjust for confounders. A total of 363 patients were included, and the overall 28-day mortality was 18%. The area under the receiver operator characteristic curve for predicting 28-day mortality was as follows: lactate (H6), 0.81; lactate (H0), 0.73; relative lactate change, 0.67; ScvO(2) (H6), 0.65; relative ScvO(2) change 0.59; ScvO(2) (H0), 0.58. Patients with lactate normalization showed significantly lower 28-day mortality compared to patients without lactate normalization (3% vs. 28%, P<0.01). However, in those who achieved ScvO(2) (H6) >= 70%, there was a significant difference in 28-mortality only in patients without lactate normalization (21% vs. 39%, P<0.01) but no difference in those with lactate normalization (4% vs. 3%, P = 0.71). Inmultivariable analysis, lactate normalization was significantly associated with 28-daymortality (adjusted odds ratio [OR] for 28-day mortality, 0.20; 95% confidence interval [CI], 0.07-0.54; P <0.01), but ScvO(2) (H6) >= 70% showed only a marginal association (the adjusted OR for 28-day mortality, 0.51; 95% CI, 0.26-1.01; P = 0.05). ScvO(2) (H6) >= 70% was associated with 28-day mortality only in cases without lactate normalization in subgroup analysis (adjusted OR 0.37, 95% CI, 0.18-0.79; P = 0.01). Six-hour lactate was the strongest predictor of 28-day mortality in patients with severe sepsis or septic shock. Six-hour ScvO(2) provided additional prognostic value only in cases where lactate values were not normalized after resuscitation.	[Lee, Young Kun; Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea; [Lee, Young Kun; Hwang, Sung Yeon; Shin, Tae Gun; Jo, Ik Joon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Emergency Med, Seoul, South Korea; [Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea.; Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea.	kjeon@skku.edu	Shin, Tae Gun/GSD-5866-2022; Suh, Gee Young/O-3676-2019; Jeon, Kyeongman/F-5963-2019	Suh, Gee Young/0000-0001-5473-1712; Jeon, Kyeongman/0000-0002-4822-1772	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI14C0743]; Samsung Medical Center	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; Samsung Medical Center(Samsung)	This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C0743). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, Samsung Medical Center provided support in the form of salaries for all of authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; [Anonymous], 2014, NEW ENGL J MED, DOI DOI 10.1056/NEJMoa1401602; [Anonymous], IMPACT TIMELY ANTIBI; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Hernandez G, 2012, CURR OPIN CRIT CARE, V18, P280, DOI 10.1097/MCC.0b013e3283532c08; Hernandez G, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.09.007; Hwang SY, 2014, SHOCK, V42, P205, DOI 10.1097/SHK.0000000000000205; Jeon K, 2012, SHOCK, V37, P463, DOI 10.1097/SHK.0b013e31824c31d1; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Joshi R, 2014, J EMERG MED, V47, P493, DOI 10.1016/j.jemermed.2014.06.016; Kang MJ, 2012, SHOCK, V38, P474, DOI 10.1097/SHK.0b013e31826eea2b; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Levraut J, 2003, CRIT CARE MED, V31, P705, DOI 10.1097/01.CCM.0000045561.85810.45; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Nguyen HB, 2004, CRIT CARE MED, V32, P1637, DOI 10.1097/01.CCM.0000132904.35713.A7; Park HY, 2012, CRIT CARE, V16, DOI 10.1186/cc10601; Park JH, 2014, LUNG, V192, P435, DOI 10.1007/s00408-014-9564-y; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Puskarich MA, 2013, CHEST, V143, P1548, DOI 10.1378/chest.12-0878; Puskarich MA, 2012, ACAD EMERG MED, V19, P252, DOI 10.1111/j.1553-2712.2012.01292.x; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rivers EP, 2011, CHEST, V140, P1408, DOI 10.1378/chest.11-2563; Shin TG, 2013, CRIT CARE, V17, DOI 10.1186/cc13047; Song YH, 2012, SHOCK, V38, P249, DOI 10.1097/SHK.0b013e3182613e33; Suetrong B, 2016, CHEST, V149, P252, DOI 10.1378/chest.15-1703; Vincent JL, 2014, CLIN EXP EMERG MED, V1, P3, DOI 10.15441/ceem.14.005; Vincent JL, 2013, NEW ENGL J MED, V369, P1726, DOI 10.1056/NEJMra1208943	29	15	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0153305	10.1371/journal.pone.0153305	http://dx.doi.org/10.1371/journal.pone.0153305			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27054713	Green Published, gold			2023-01-03	WOS:000373608000117
J	Jones, CHD; Ward, A; Hodkinson, PW; Reid, SJ; Wallis, LA; Harrison, S; Argent, AC				Jones, Caroline H. D.; Ward, Alison; Hodkinson, Peter W.; Reid, Stephen J.; Wallis, Lee A.; Harrison, Sian; Argent, Andrew C.			Caregivers' Experiences of Pathways to Care for Seriously Ill Children in Cape Town, South Africa: A Qualitative Investigation	PLOS ONE			English	Article							HEALTH-CARE; MORTALITY; TRIAGE; MOTHERS	Purpose Understanding caregivers' experiences of care can identify barriers to timely and good quality care, and support the improvement of services. We aimed to explore caregivers' experiences and perceptions of pathways to care, from first access through various levels of health service, for seriously ill and injured children in Cape Town, South Africa, in order to identify areas for improvement. Methods Semi-structured, qualitative interviews were conducted with primary caregivers of children who were admitted to paediatric intensive care or died in the health system prior to intensive care admission. Interviews explored caregivers' experiences from when their child first became ill, through each level of health care to paediatric intensive care or death. A maximum variation sample of transcripts was purposively sampled from a larger cohort study based on demographic characteristics, child diagnosis, and outcome at 30 days; and analysed using the method of constant comparison. Results Of the 282 caregivers who were interviewed in the larger cohort study, 45 interviews were included in this qualitative analysis. Some caregivers employed 'tactics' to gain quicker access to care, including bypassing lower levels of care, and negotiating or demanding to see a healthcare professional ahead of other patients. It was sometimes unclear how to access emergency care within facilities; and non-medical personnel informally judged illness severity and helped or hindered quicker access. Caregivers commonly misconceived ambulances to be slow to arrive, and were concerned when ambulance transfers were seemingly not prioritised by illness severity. Communication was often good, but some caregivers experienced language difficulties and/or criticism. Conclusions Interventions to improve child health care could be based on: reorganising the reception of seriously ill children and making the emergency route within healthcare facilities clear; promoting caregivers' use of ambulances and prioritising transfers according to illness severity; addressing language barriers, and emphasising the importance of effective communication to healthcare providers.	[Jones, Caroline H. D.; Ward, Alison; Harrison, Sian] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Hodkinson, Peter W.; Wallis, Lee A.] Univ Cape Town, Div Emergency Med, ZA-7925 Cape Town, South Africa; [Reid, Stephen J.] Univ Cape Town, Primary Hlth Care Directorate, ZA-7925 Cape Town, South Africa; [Argent, Andrew C.] Univ Cape Town, Dept Paediat, ZA-7925 Cape Town, South Africa	University of Oxford; University of Cape Town; University of Cape Town; University of Cape Town	Ward, A (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.	alison.ward@phc.ox.ac.uk	Reid, Stephen/AAY-6101-2020; Hodkinson, PW W/N-3122-2018; Argent, Andrew/J-1605-2019	Hodkinson, PW W/0000-0002-0376-7982; Argent, Andrew/0000-0001-9333-2036; Wallis, Lee/0000-0003-2711-3139; Reid, Steve/0000-0003-2826-2304	Wellcome Trust [WT091107MA]	Wellcome Trust(Wellcome TrustEuropean Commission)	The study was funded by the Wellcome Trust (WT091107MA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argent AC, 2009, SOUTH AFR J CRIT CAR, V25, P4; Bhutta ZA, 2013, LANCET, V381, P1417, DOI 10.1016/S0140-6736(13)60648-0; Bradshaw D., 2014, RAPID MORTALITY SURV; Brockerhoff M, 2000, B WORLD HEALTH ORGAN, V78, P30; Buys H, 2013, SAMJ S AFR MED J, V103, P161, DOI [10.7196/samj.6020, 10.7196/SAMJ.6020]; Chopra M, 2009, LANCET, V374, P835, DOI 10.1016/S0140-6736(09)61123-5; Harris B, 2011, J PUBLIC HEALTH POL, V32, pS102, DOI 10.1057/jphp.2011.35; Herxheimer A, 2000, LANCET, V355, P1540, DOI 10.1016/S0140-6736(00)02174-7; Kahabuka C, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-315; Kahabuka C, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-158; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Kissoon N, 2011, PEDIATR CRIT CARE ME, V12, P73, DOI 10.1097/PCC.0b013e3181ce74ef; Kissoon N, 2011, PEDIATR CRIT CARE ME, V12, P494, DOI 10.1097/PCC.0b013e318207096c; Krug A, 2008, S AFR MED J, V94, P202; Molyneux E, 2006, B WORLD HEALTH ORGAN, V84, P314, DOI 10.2471/BLT.04.019505; Molyneux EM, 2013, SAMJ S AFR MED J, V103, P158, DOI [10.7196/SAMJ.6531, 10.7196/samj.6531]; Molyneux E, 2009, T ROY SOC TROP MED H, V103, P11, DOI 10.1016/j.trstmh.2008.07.002; Neill SJ, 2013, INT J NURS STUD, V50, P757, DOI 10.1016/j.ijnurstu.2011.11.007; Samuelsen H, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-67; Schneider H, 2002, HEALTH POLICY PLANN, V17, P32, DOI 10.1093/heapol/17.1.32; Schneider H, 2010, J HEALTH SERV RES PO, V15, P137, DOI 10.1258/jhsrp.2010.008174; Scribante J, 2008, SAMJ, V97, P1323; Sobo EJ, 2006, HEALTH SERV RES, V41, P148, DOI 10.1111/j.1475-6773.2005.00455.x; Statistics South Africa, 2011, CENS 2011 MUN REP W; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Thandrayen K, 2010, S AFR J CHILD HEALTH, V4, P73; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Twomey M, 2013, SAMJ S AFR MED J, V103, P304, DOI 10.7196/SAMJ.6877; Wallis LA, 2008, S AFR MED J, V96, P53; Watermeyer J, 2012, EVAL HEALTH PROF, V35, P360, DOI 10.1177/0163278712445472; Ziebland S, 2014, J HEALTH SERV RES PO; Ziebland S., 2013, UNDERSTANDING USING, P39, DOI [10.1093/acprof:oso/9780199665372.001.0001, DOI 10.1093/ACPROF:OSO/9780199665372.001.0001]; Ziebland S, 2013, UNDERSTANDING USING	33	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2016	11	3							e0151606	10.1371/journal.pone.0151606	http://dx.doi.org/10.1371/journal.pone.0151606			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH9LB	27027499	Green Published, Green Submitted, gold			2023-01-03	WOS:000373116500028
J	Niimi, M; Hashimoto, K; Kakuda, W; Miyano, S; Momosaki, R; Ishima, T; Abo, M				Niimi, Masachika; Hashimoto, Kenji; Kakuda, Wataru; Miyano, Satoshi; Momosaki, Ryo; Ishima, Tamaki; Abo, Masahiro			Role of Brain-Derived Neurotrophic Factor in Beneficial Effects of Repetitive Transcranial Magnetic Stimulation for Upper Limb Hemiparesis after Stroke	PLOS ONE			English	Article							MOTOR RECOVERY; BDNF; POLYMORPHISM; ASSOCIATION; MECHANISMS; PROBDNF	Background Repetitive transcranial magnetic stimulation (rTMS) can improve upper limb hemiparesis after stroke but the mechanism underlying its efficacy remains elusive. rTMS seems to alter brain-derived neurotrophic factor (BDNF) and such effect is influenced by BDNF gene polymorphism. Objectives To investigate the molecular effects of rTMS on serum levels of BDNF, its precursor proBDNF and matrix metalloproteinase-9 (MMP-9) in poststroke patients with upper limb hemiparesis. Methods Poststroke patients with upper limb hemiparesis were studied. Sixty-two patients underwent rehabilitation plus rTMS combination therapy and 33 patients underwent rehabilitation monotherapy without rTMS for 14 days at our hospital. One Hz rTMS was applied over the motor representation of the first dorsal interosseous muscle on the non-lesional hemisphere. Fugl-Meyer Assessment and Wolf Motor Function (WMFT) were used to evaluate motor function on the affected upper limb before and after intervention. Blood samples were collected for analysis of BDNF polymorphism and measurement of BDNF, proBDNF and MMP-9 levels. Results Two-week combination therapy increased BDNF and MMP-9 serum levels, but not serum proBDNF. Serum BDNF and MMP-9 levels did not correlate with motor function improvement, though baseline serum proBDNF levels correlated negatively and significantly with improvement in WMFT (rho = -0.422, p = 0.002). The outcome of rTMS therapy was not altered by BDNF gene polymorphism. Conclusions The combination therapy of rehabilitation plus low-frequency rTMS seems to improve motor function in the affected limb, by activating BDNF processing. BDNF and its precursor proBDNF could be potentially suitable biomarkers for poststroke motor recovery.	[Niimi, Masachika; Kakuda, Wataru; Momosaki, Ryo; Abo, Masahiro] Jikei Univ, Sch Med, Dept Rehabil Med, Tokyo, Japan; [Hashimoto, Kenji; Ishima, Tamaki] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba, Japan; [Miyano, Satoshi] Tokyo Gen Hosp, Dept Rehabil Med, Tokyo, Japan	Jikei University; Chiba University	Abo, M (corresponding author), Jikei Univ, Sch Med, Dept Rehabil Med, Tokyo, Japan.	abo@jikei.ac.jp	Momosaki, Ryo/H-6486-2018; Hashimoto, Kenji/I-5800-2015	Momosaki, Ryo/0000-0003-3274-3952; Hashimoto, Kenji/0000-0002-8892-0439; Abo, Masahiro/0000-0001-6701-4974				Abo M, 2014, INT J STROKE, V9, P607, DOI 10.1111/ijs.12100; Castren E, 2014, Handb Exp Pharmacol, V220, P461, DOI 10.1007/978-3-642-45106-5_17; Chang WH, 2014, BRAIN STIMUL, V7, P553, DOI 10.1016/j.brs.2014.03.008; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003; Hashimoto K, 2015, EUR ARCH PSY CLIN N, V265, P83, DOI 10.1007/s00406-014-0557-x; Hashimoto K, 2014, BRIT J PSYCHIAT, V205, P410, DOI 10.1192/bjp.205.5.410; Hashimoto K, 2014, JAMA NEUROL, V71, P653, DOI 10.1001/jamaneurol.2013.6414; Hashimoto K, 2013, PROG NEUROBIOL, V100, P15, DOI 10.1016/j.pneurobio.2012.09.001; Hashimoto K, 2010, PSYCHIAT CLIN NEUROS, V64, P341, DOI 10.1111/j.1440-1819.2010.02113.x; Itoh K, 2005, AM J MED GENET B, V132B, P70, DOI 10.1002/ajmg.b.30097; Itoh K, 2004, AM J MED GENET B, V124B, P61, DOI 10.1002/ajmg.b.20078; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Levin R, 2015, J PSYCHIATR RES, V61, P188, DOI 10.1016/j.jpsychires.2014.12.007; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Ludemann-Podubecka J, 2015, PROG BRAIN RES, V218, P281, DOI 10.1016/bs.pbr.2014.12.001; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; Mirowska-Guzel D, 2013, NEUROREHABILITATION, V32, P573, DOI 10.3233/NRE-130879; Muller-Dahlhaus F, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00050; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Sodersten K, 2014, J AFFECT DISORDERS, V160, P1, DOI 10.1016/j.jad.2014.01.009; Takeuchi N, 2005, STROKE, V36, P2681, DOI 10.1161/01.STR.0000189658.51972.34; VILLARDITA C, 1985, CORTEX, V21, P627, DOI 10.1016/S0010-9452(58)80010-6; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; Ward NS, 2004, ARCH NEUROL-CHICAGO, V61, P1844, DOI 10.1001/archneur.61.12.1844; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Yoshida T., 2012, OPEN CLIN CHEM J, V5, P7, DOI [10.2174/1874241601205010007, DOI 10.2174/1874241601205010007]; Yoshida T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042676; Yukimasa T, 2006, PHARMACOPSYCHIATRY, V39, P52, DOI 10.1055/s-2006-931542; Zanardini R, 2006, J AFFECT DISORDERS, V91, P83, DOI 10.1016/j.jad.2005.12.029	33	32	39	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2016	11	3							e0152241	10.1371/journal.pone.0152241	http://dx.doi.org/10.1371/journal.pone.0152241			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3QJ	27007747	Green Published, Green Submitted, gold			2023-01-03	WOS:000372701200116
J	Silva, VTDE; Costalonga, EC; Oliveira, APL; Hung, J; Caires, RA; Hajjar, LA; Fukushima, JT; Soares, CM; Bezerra, JS; Oikawa, L; Yu, L; Burdmann, EA				da Costa e Silva, Veronica Torres; Costalonga, Elerson C.; Leandro Oliveira, Ana Paula; Hung, James; Caires, Renato Antunes; Hajjar, Ludhmila Abrahao; Fukushima, Julia T.; Soares, Cilene Muniz; Bezerra, Juliana Silva; Oikawa, Luciane; Yu, Luis; Burdmann, Emmanuel A.			Evaluation of Intermittent Hemodialysis in Critically Ill Cancer Patients with Acute Kidney Injury Using Single-Pass Batch Equipment	PLOS ONE			English	Article							LOW-EFFICIENCY DIALYSIS; RENAL REPLACEMENT THERAPY; INTENSIVE-CARE; OUTCOMES; FAILURE; TEMPERATURE; PREDICTORS; ADMISSION; EFFICACY; TESTS	Background Data on renal replacement therapy (RRT) in cancer patients with acute kidney injury (AKI) in the intensive care unit (ICU) is scarce. The aim of this study was to assess the safety and the adequacy of intermittent hemodialysis (IHD) in critically ill cancer patients with AKI. Methods and Findings In this observational prospective cohort study, 149 ICU cancer patients with AKI were treated with 448 single-pass batch IHD procedures and evaluated from June 2010 to June 2012. Primary outcomes were IHD complications (hypotension and clotting) and adequacy. A multiple logistic regression was performed in order to identify factors associated with IHD complications (hypotension and clotting). Patients were 62.2 +/- 14.3 years old, 86.6% had a solid cancer, sepsis was the main AKI cause (51%) and in-hospital mortality was 59.7%. RRT session time was 240 (180-300) min, blood/dialysate flow was 250 (200-300) mL/min and UF was 1000 (0-2000) ml. Hypotension occurred in 25% of the sessions. Independent risk factors (RF) for hypotension were dialysate conductivity (each ms/cm, OR 0.81, CI 0.69-0.95), initial mean arterial pressure (each 10 mmHg, OR 0.49, CI 0.40-0.61) and SOFA score (OR 1.16, CI 1.03-1.30). Clotting and malfunctioning catheters (MC) occurred in 23.8% and 29.2% of the procedures, respectively. Independent RF for clotting were heparin use (OR 0.57, CI 0.33-0.99), MC (OR 3.59, CI 2.24-5.77) and RRT system pressure increase over 25% (OR 2.15, CI 1.61-4.17). Post RRT blood tests were urea 71 (49-104) mg/dL, creatinine 2.71 (2.10-3.8) mg/dL, bicarbonate 24.1 (22.5-25.5) mEq/L and K 3.8 (3.5-4.1) mEq/L. Conclusion IHD for critically ill patients with cancer and AKI offered acceptable hemodynamic stability and provided adequate metabolic control.	[da Costa e Silva, Veronica Torres; Costalonga, Elerson C.; Leandro Oliveira, Ana Paula; Hung, James; Caires, Renato Antunes; Soares, Cilene Muniz; Bezerra, Juliana Silva; Oikawa, Luciane] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo State Canc Inst, Sao Paulo, SP, Brazil; [Hajjar, Ludhmila Abrahao; Fukushima, Julia T.] Univ Sao Paulo, Sch Med Sch, Intens Care Unit Dept, Sao Paulo State Canc Inst, Sao Paulo, SP, Brazil; [Yu, Luis; Burdmann, Emmanuel A.] Univ Sao Paulo, Sch Med, Div Nephrol, LIM 12, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Burdmann, EA (corresponding author), Univ Sao Paulo, Sch Med, Div Nephrol, LIM 12, Sao Paulo, Brazil.	burdmann@usp.br	Burdmann, Emmanuel/B-7023-2009; Burdmann, Emmanuel/AAY-1966-2020	Burdmann, Emmanuel/0000-0002-7644-8579; Yu, Luis/0000-0001-9102-0063; Abrahao Hajjar, Ludhmila/0000-0001-5645-2055; Torres Costa e Silva, Veronica/0000-0001-8211-018X				Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5; Benoit DD, 2005, NEPHROL DIAL TRANSPL, V20, P552, DOI 10.1093/ndt/gfh637; Berbece AN, 2006, KIDNEY INT, V70, P963, DOI 10.1038/sj.ki.5001700; Darmon M, 2006, CRIT CARE, V10, DOI 10.1186/cc4907; Darmon M, 2007, INTENS CARE MED, V33, P765, DOI 10.1007/s00134-007-0579-1; DAUGIRDAS JT, 1994, AM J KIDNEY DIS, V23, P33, DOI 10.1016/S0272-6386(12)80809-2; Dhondt A, 2010, ARTIF ORGANS, V34, P1132, DOI 10.1111/j.1525-1594.2009.00981.x; Eloot S, 2007, NEPHROL DIAL TRANSPL, V22, P2962, DOI 10.1093/ndt/gfm356; Falanga A, 2015, THROMB RES, V135, pS8, DOI 10.1016/S0049-3848(15)50432-5; Falanga A, 2014, CURR OPIN HEMATOL, V21, P423, DOI 10.1097/MOH.0000000000000072; Fassbinder W, 2003, KIDNEY BLOOD PRESS R, V26, P96, DOI 10.1159/000070990; Fiaccadori E, 2007, NEPHROL DIAL TRANSPL, V22, P529, DOI 10.1093/ndt/gfl627; Fiaccadori E, 2013, CLIN J AM SOC NEPHRO, V8, P1670, DOI 10.2215/CJN.00510113; Fieghen HE, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-32; Hajjar LA, 2011, CLINICS, V66, P2037, DOI 10.1590/S1807-59322011001200007; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer DW, 1997, STAT MED, V16, P965; Koyner JL, 2014, AM J KIDNEY DIS, V64, P394, DOI 10.1053/j.ajkd.2014.03.018; Lameire N, 2008, CURR OPIN CRIT CARE, V14, P635, DOI 10.1097/MCC.0b013e32830ef70b; Lecuyer L, 2007, CRIT CARE MED, V35, P808, DOI 10.1097/01.CCM.0000256846.27192.7A; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P785, DOI 10.1093/ndt/gfh102; Lombardi R, 2014, NEPHROL DIAL TRANSPL, V29, P1369, DOI 10.1093/ndt/gfu078; Maccariello E, 2011, NEPHROL DIAL TRANSPL, V26, P537, DOI 10.1093/ndt/gfq441; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Park MR, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.07.006; Pertosa G, 2000, KIDNEY INT, V58, pS104, DOI 10.1046/j.1523-1755.2000.07613.x; Ponce D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081697; Ruka W, 2001, ANN ONCOL, V12, P1423, DOI 10.1023/A:1012527006566; Salahudeen AK, 2009, CLIN J AM SOC NEPHRO, V4, P1338, DOI 10.2215/CJN.02130309; Schortgen F, 2000, AM J RESP CRIT CARE, V162, P197, DOI 10.1164/ajrccm.162.1.9907098; Schwenger V, 2012, CRIT CARE, V16, DOI 10.1186/cc11445; Seruga B, 2008, NAT REV CANCER, V8, P887, DOI 10.1038/nrc2507; Soares M, 2006, J CLIN ONCOL, V24, P4003, DOI 10.1200/JCO.2006.05.7869; Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e; Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	38	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0149706	10.1371/journal.pone.0149706	http://dx.doi.org/10.1371/journal.pone.0149706			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938932	Green Published, gold			2023-01-03	WOS:000371735200033
J	Loy, BA; Shkedy, CI; Powell, AC; Happe, LE; Royalty, JA; Miao, MT; Smith, GL; Long, JW; Gupta, AK				Loy, Bryan A.; Shkedy, Clive I.; Powell, Adam C.; Happe, Laura E.; Royalty, Julie A.; Miao, Michael T.; Smith, Gary L.; Long, James W.; Gupta, Amit K.			Do Case Rates Affect Physicians' Clinical Practice in Radiation Oncology?: An Observational Study	PLOS ONE			English	Article							CANCER CARE; DRUGS	Case rate payments combined with utilization monitoring may have the potential to improve the quality of care by reducing over and under-treatment. Thus, a national managed care organization introduced case rate payments at one multi-site radiation oncology provider while maintaining only fee-for-service payments at others. This study examined whether the introduction of the payment method had an effect on radiation fractions administered when compared to clinical guidelines. The number of fractions of radiation therapy delivered to patients with bone metastases, breast, lung, prostate, and skin cancer was assessed for concordance with clinical guidelines. The proportion of guideline-based care ascertained from the payer's claims database was compared before (2011) and after (2013) the payment method introduction using relative risks (RR). After the introduction of case rates, there were no significant changes in guideline-based care in breast, lung, and skin cancer; however, patients with bone metastases and prostate cancer were significantly more likely to have received guideline-based care (RR = 2.0 and 1.1, respectively, p<0.05). For the aggregate of all cancers, the under-treatment rate significantly declined (p = 0.008) from 4% to 0% after the introduction of case rate payments, while the over-treatment rate remained steady at 9%, with no significant change (p = 0.20). These findings suggest that the introduction of case rate payments did not adversely affect the rate of guideline-based care at the provider examined. Additional research is needed to isolate the effect of the payment model and assess implications in other populations.	[Loy, Bryan A.; Happe, Laura E.; Royalty, Julie A.; Miao, Michael T.; Long, James W.] Humana Inc, Louisville, KY USA; [Shkedy, Clive I.; Powell, Adam C.; Smith, Gary L.; Gupta, Amit K.] HealthHelp LLC, Houston, TX USA	Humana Inc.	Powell, AC (corresponding author), HealthHelp LLC, Houston, TX USA.	powellad@healthhelp.com		Powell, Adam/0000-0001-6519-3120	HealthHelp LLC; Humana Inc.	HealthHelp LLC; Humana Inc.	The authors received no specific funding for this work. This study was completed by Humana, Inc. and HealthHelp, LLC, and authors worked on it as a part of their duties for their respective organization. HealthHelp LLC and Humana Inc. provided support in the form of paid employment or consulting fees for all the authors. (Humana: BL, LH, JR, MM, and JL. HealthHelp: CS, AP, GS, and AG.). The specific roles of these authors are articulated in the 'author contributions' section. This research represents the findings of a quality improvement project conducted by the funding organizations, which were both actively involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. URL of HealthHelp: www.healthhelp.com; URL of Humana: www.humana.com.	[Anonymous], REL RISK CALC VERS 1; [Anonymous], 2015, NCCN CLIN GUID ONC S; Bekelman JE, 2014, JAMA-J AM MED ASSOC, V312, P2542, DOI 10.1001/jama.2014.16616; Colla CH, 2012, J ONCOL PRACT, V8, DOI 10.1200/JOP.2012.000539; Cutler DM, 2012, NEW ENGL J MED, V366, P1075, DOI 10.1056/NEJMp1113361; Falit BP, 2014, INT J RADIAT ONCOL, V89, P950, DOI 10.1016/j.ijrobp.2014.04.023; Feinberg B, 2014, AM J MANAG CARE, V20, P303; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563; Jagsi R, 2014, INT J RADIAT ONCOL, V90, P1001, DOI 10.1016/j.ijrobp.2014.09.032; Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026; Medicare Program, 2012, FED REGISTER, V77, P68910; National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; NCCN, 2020, ANT; Newcomer LN, 2014, J ONCOL PRACT, V10, P322, DOI 10.1200/JOP.2014.001488; Smith BD, 2011, INT J RADIAT ONCOL, V81, P59, DOI 10.1016/j.ijrobp.2010.04.042	15	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0149449	10.1371/journal.pone.0149449	http://dx.doi.org/10.1371/journal.pone.0149449			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26870963	Green Submitted, Green Published, gold			2023-01-03	WOS:000370054100158
J	Anderson, K; Burford, O; Emmerton, L				Anderson, Kevin; Burford, Oksana; Emmerton, Lynne			Mobile Health Apps to Facilitate Self-Care: A Qualitative Study of User Experiences	PLOS ONE			English	Article							TECHNOLOGY ACCEPTANCE; YOUNG-PEOPLE; MANAGEMENT; ASTHMA; LITERACY; INTERVENTION; PROTOCOL; PROGRAM; MODEL; RISK	Objective Consumers are living longer, creating more pressure on the health system and increasing their requirement for self-care of chronic conditions. Despite rapidly-increasing numbers of mobile health applications ('apps') for consumers' self-care, there is a paucity of research into consumer engagement with electronic self-monitoring. This paper presents a qualitative exploration of how health consumers use apps for health monitoring, their perceived benefits from use of health apps, and suggestions for improvement of health apps. Materials and Methods 'Health app' was defined as any commercially-available health or fitness app with capacity for self-monitoring. English-speaking consumers aged 18 years and older using any health app for self-monitoring were recruited for interview from the metropolitan area of Perth, Australia. The semi-structured interview guide comprised questions based on the Technology Acceptance Model, Health Information Technology Acceptance Model, and the Mobile Application Rating Scale, and is the only study to do so. These models also facilitated deductive thematic analysis of interview transcripts. Implicit and explicit responses not aligned to these models were analyzed inductively. Results Twenty-two consumers (15 female, seven male) participated, 13 of whom were aged 26-35 years. Eighteen participants reported on apps used on iPhones. Apps were used to monitor diabetes, asthma, depression, celiac disease, blood pressure, chronic migraine, pain management, menstrual cycle irregularity, and fitness. Most were used approximately weekly for several minutes per session, and prior to meeting initial milestones, with significantly decreased usage thereafter. Deductive and inductive thematic analysis reduced the data to four dominant themes: engagement in use of the app; technical functionality of the app; ease of use and design features; and management of consumers' data. Conclusions The semi-structured interviews provided insight into usage, benefits and challenges of health monitoring using apps. Understanding the range of consumer experiences and expectations can inform design of health apps to encourage persistence in self-monitoring.	[Anderson, Kevin; Burford, Oksana; Emmerton, Lynne] Curtin Univ, Sch Pharm, Perth, WA 6845, Australia	Curtin University	Emmerton, L (corresponding author), Curtin Univ, Sch Pharm, Perth, WA 6845, Australia.	lynne.emmerton@curtin.edu.au		Anderson, Kevin/0000-0001-7324-491X				Anderson K, 2016, AUST HEALTH REV, V40, P591, DOI 10.1071/AH15162; Android, 2016, LAUNCH CHECKL; Antezana G, 2015, JMIR RES PROTOC, V4, DOI 10.2196/resprot.4098; Apple, 2015, APP STOR REV GUID; Baker DW, 1998, J GEN INTERN MED, V13, P791, DOI 10.1046/j.1525-1497.1998.00242.x; Baker DW, 2002, AM J PUBLIC HEALTH, V92, P1278, DOI 10.2105/AJPH.92.8.1278; BECKER MH, 1978, PUBLIC HEALTH REP, V93, P268; Blodt S, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-490; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Briz-Ponce L, 2015, J MED SYST, V39, DOI 10.1007/s10916-015-0352-x; Burt R. S., 2005, BROKERAGE CLOSURE IN; Chiang LC, 2004, J ASTHMA, V41, P205, DOI 10.1081/JAS-120026078; Cho J, 2014, AM J HEALTH BEHAV, V38, P860, DOI 10.5993/AJHB.38.6.8; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Cooper S, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0546-4; Cormier DJ, 2006, J CARDIOPULM REHABIL, V26, P250, DOI [10.1097/00008483-200607000-00015, DOI 10.1097/00008483-200607000-00015]; DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008; Doherty G, 2010, INTERACT COMPUT, V22, P243, DOI 10.1016/j.intcom.2010.02.006; Dolan B, 2014, RISE SEEMINGLY SERIO; Dumas RA, 2014, HLTH APP COMPLETELY; Elias Pierre, 2013, Med 2 0, V2, pe1, DOI 10.2196/med20.2014; Eyles H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-950; Fereday J, 2006, INT J QUAL METH, P5, DOI [DOI 10.1177/160940690600500107, 10.1177/160940690600500107]; Finkelstein EA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099572; Fishbein M, 2007, PREDICTION CHANGE HL; Gill PS, 2012, RISK MANAG HEALTHC P, V5, P105, DOI 10.2147/RMHP.S34813; Green J, 2009, QUALITATIVE METHODS; Green L, 2014, PRECEDE PROCEED MODE; Hasford J, 2010, ALLERGY, V65, P347, DOI 10.1111/j.1398-9995.2009.02161.x; Haug S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1140; Hebly P, 2012, THESIS ERASMUS U ROT; Hesse-Biber S. N., 2010, PRACTICE QUALITATIVE; Holden RJ, 2010, J BIOMED INFORM, V43, P159, DOI 10.1016/j.jbi.2009.07.002; Holman H, 2004, PUBLIC HEALTH REP, V119, P239, DOI 10.1016/j.phr.2004.04.002; Host T, 2014, HLTH MARKET VALIDATI; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jeon E, 2015, HEALTHC INFORM RES, V21, P10, DOI 10.4258/hir.2015.21.1.10; Jin BS, 2010, COMPUT IND, V61, P350, DOI 10.1016/j.compind.2009.12.006; Kenny R, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.4370; Kim J, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2143; Kirwan M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2588; Korhonen I, 2003, IEEE ENG MED BIOL, V22, P66, DOI 10.1109/MEMB.2003.1213628; Krebs P, 2015, JMIR MHEALTH UHEALTH, V3, P107, DOI 10.2196/mhealth.4924; Licskai CJ, 2013, CAN RESPIR J, V20, P301, DOI 10.1155/2013/906710; Lister C, 2014, JMIR SERIOUS GAMES, V2, P51, DOI 10.2196/games.3413; Liu WT, 2011, EUR RESPIR J, V37, P310, DOI 10.1183/09031936.00000810; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; MADDEN TJ, 1992, PERS SOC PSYCHOL B, V18, P3, DOI 10.1177/0146167292181001; Miller KM, 2013, DIABETES CARE, V36, P2009, DOI 10.2337/dc12-1770; Morrison LG, 2014, J MED INTERNET RES, V16, P43, DOI 10.2196/jmir.3579; Nilges P, 2007, SCHMERZ, V21, P57, DOI 10.1007/s00482-006-0508-1; OptumHealth, 2010, OPTUMHEALTH DEB OPTU; Pan D, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3956; Pandey A, 2013, J CANCER EDUC, V28, P138, DOI 10.1007/s13187-012-0446-9; Phillips D.N., 2000, POSTPOSITIVISM ED RE; Proudfoot J, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-312; Radcliffe C, 2003, MED EDUC, V37, P32, DOI 10.1046/j.1365-2923.2003.01405.x; Ryan D, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1756; Scheibe Madlen, 2015, Med 2 0, V4, pe1, DOI 10.2196/med20.3912; Stoyanov SR, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3422; Thomas O., 2014, APPLES HLTH APP IS E; Underwood B, 2015, BR DENT J, V219, P7; Velsor-Friedrich Barbara, 2005, J Pediatr Health Care, V19, P163, DOI 10.1016/j.pedhc.2004.12.002; Wiederhold BK, 2013, CYBERPSYCH BEH SOC N, V16, P411, DOI 10.1089/cyber.2013.1520; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Yarbrough AK, 2007, MED CARE RES REV, V64, P650, DOI 10.1177/1077558707305942; Zichermann G., 2011, GAMIFICATION DESIGN	69	147	148	7	109	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2016	11	5							e0156164	10.1371/journal.pone.0156164	http://dx.doi.org/10.1371/journal.pone.0156164			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DN2FT	27214203	Green Published, gold, Green Submitted			2023-01-03	WOS:000376880200064
J	Leesombun, A; Boonmasawai, S; Shimoda, N; Nishikawa, Y				Leesombun, Arpron; Boonmasawai, Sookruetai; Shimoda, Naomi; Nishikawa, Yoshifumi			Effects of Extracts from Thai Piperaceae Plants against Infection with Toxoplasma gondii	PLOS ONE			English	Article							EURYCOMA-LONGIFOLIA JACK; IN-VITRO; ANTIMALARIAL ACTIVITIES; BETLE; PARASITE; PROTEIN; ROOT; VIVO; L.	Herbal medicines and natural herb extracts are widely used as alternative treatments for various parasitic diseases, and such extracts may also have potential to decrease the side effects of the standard regimen drugs used to treat toxoplasmosis (sulfadiazine-pyrimethamine combination). We evaluated how effective the Thai piperaceae plants Piper betle, P. nigrum and P. sarmentosum are against Toxoplasma gondii infection in vitro and in vivo. Individually, we extracted the piperaceae plants with ethanol, passed them through a rotary evaporator and then lyophilized them to obtain crude extracts for each one. The in vitro study indicated that the P. betle extract was the most effective extract at inhibiting parasite growth in HFF cells (IC50 on RH-GFP: 23.2 mu g/mL, IC50 on PLK-GFP: 21.4 mu g/mL). Further-more, treatment of experimental mice with the P. betle extract for 7 days after infection with 1,000 tachyzoites of the T. gondii PLK strain increased their survival (survival rates: 100% in 400 mg/kg-treated, 83.3% in 100 mg/kg-treated, 33.3% in 25 mg/kg-treated, 33.3% in untreated mice). Furthermore, treatment with 400 mg/kg of the P. betle extract resulted in 100% mouse survival following infection with 100,000 tachyzoites. The present study shows that P. betle extract has the potential to act as a medical plant for the treatment of toxoplasmosis.	[Leesombun, Arpron; Shimoda, Naomi; Nishikawa, Yoshifumi] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan; [Boonmasawai, Sookruetai] Mahidol Univ, Fac Vet Sci, Dept Preclin & Appl Anim Sci, 999 Phutthamonthon Sai 4 Rd Salaya, Phutthamonthon Nakhonpat 73170, Thailand	Obihiro University of Agriculture & Veterinary Medicine; Mahidol University	Nishikawa, Y (corresponding author), Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.	nisikawa@obihiro.ac.jp						Al-Adhroey AH, 2011, MOLECULES, V16, P107, DOI 10.3390/molecules16010107; Al-Zanbagi NA, 2009, J FAM COMMUNITY MED, V16, P59; Ali I, 2010, ANN CLIN MICROB ANTI, V9, DOI 10.1186/1476-0711-9-7; Arambewela LSR, 2005, J ETHNOPHARMACOL, V102, P239, DOI 10.1016/j.jep.2005.06.016; Atjanasuppat K, 2009, J ETHNOPHARMACOL, V123, P475, DOI 10.1016/j.jep.2009.03.010; Bagatela BS, 2013, NAT PROD RES, V27, P2202, DOI 10.1080/14786419.2013.821123; Bhalerao S. A., 2013, J PHARMACOGNOSY PHYT, V1, P10; Carroll RW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013124; Chaveerach A., 2006, Ethnobotany Research and Applications, V4, P223; Choochote Wej, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P33, DOI 10.1590/S0036-46652006000100007; de Oliveira TC, 2009, EXP PARASITOL, V122, P233, DOI 10.1016/j.exppara.2009.04.010; Dwivedi V., 2014, J PHARMACOGN PHYTOCH, V93, P9398; El-Zawawy Lobna A., 2008, Journal of the Egyptian Society of Parasitology, V38, P185; Elsheikha HM, 2008, PUBLIC HEALTH, V122, P335, DOI 10.1016/j.puhe.2007.08.009; EVANS PH, 1984, J AGR FOOD CHEM, V32, P1254, DOI 10.1021/jf00126a011; Fazal Farhan, 2014, Chin J Integr Med; Furtado JM, 2011, J GLOB INFECT DIS, V3, P281, DOI 10.4103/0974-777X.83536; Hermes G, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-48; Jain V, 2015, STRUCTURE, V23, P819, DOI 10.1016/j.str.2015.02.011; Kavitha N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-91; Khanam Zakia, 2015, Journal of King Saud University Science, V27, P23, DOI 10.1016/j.jksus.2014.04.006; Koch A, 2005, J ETHNOPHARMACOL, V101, P95, DOI 10.1016/j.jep.2005.03.011; Maisuthisakul P, 2007, FOOD CHEM, V100, P1409, DOI 10.1016/j.foodchem.2005.11.032; McLeod R., 2014, CURR PEDIAT REP, V2, P166; Misra P, 2009, J MED MICROBIOL, V58, P1058, DOI 10.1099/jmm.0.009290-0; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Montoya JG, 2008, CLIN INFECT DIS, V47, P554, DOI 10.1086/590149; Nagamune K, 2007, EUKARYOT CELL, V6, P2147, DOI 10.1128/EC.00262-07; Nishikawa Y, 2003, INT J PARASITOL, V33, P1525, DOI 10.1016/S0020-7519(03)00204-2; Nishikawa Y, 2008, PARASITOL INT, V57, P219, DOI 10.1016/j.parint.2007.10.004; Pillai S, 2012, APCBEE PROC, V2, P92, DOI 10.1016/j.apcbee.2012.06.017; Rekha VPB, 2014, AM J ETHNOMED, V1, P276; Ruangnoo S., 2012, Journal of the Medical Association of Thailand, V95, P127; Saeij JPJ, 2005, INFECT IMMUN, V73, P695, DOI 10.1128/IAI.73.2.695-702.2005; SCHOONDERMARKVANDEVEN E, 1995, ANTIMICROB AGENTS CH, V39, P763, DOI 10.1128/AAC.39.3.763; Scott Ian M., 2008, Phytochemistry Reviews, V7, P65, DOI 10.1007/s11101-006-9058-5; Sepulveda-Arias Juan C, 2014, Recent Pat Antiinfect Drug Discov, V9, P186; Sudmoon R, 2012, J MED PLANTS RES, V6, P1168, DOI DOI 10.5897/JMPR11.807; Suthanurak M., 2010, THAI PHARM, V32, P160; Tanaka S, 2013, INFECT IMMUN, V81, P3609, DOI 10.1128/IAI.00439-13; Thiengsusuk A, 2013, PARASITOL RES, V112, P1475, DOI 10.1007/s00436-013-3294-6; Weiss LM, 2009, INT J PARASITOL, V39, P895, DOI 10.1016/j.ijpara.2009.02.004; Youn HJ, 2003, VET PARASITOL, V116, P7, DOI 10.1016/S0304-4017(03)00154-7	43	25	26	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2016	11	5							e0156116	10.1371/journal.pone.0156116	http://dx.doi.org/10.1371/journal.pone.0156116			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2FT	27213575	gold, Green Published, Green Submitted			2023-01-03	WOS:000376880200058
J	Giacco, D; Priebe, S				Giacco, Domenico; Priebe, Stefan			Suicidality and Hostility following Involuntary Hospital Treatment	PLOS ONE			English	Article							MENTAL-HEALTH; UNEMPLOYMENT; INPATIENT	Background Psychiatric patients showing risk to themselves or others can be involuntarily hospitalised. No data is available on whether following hospitalisation there is a reduction in psychopathological indicators of risk such as suicidality and hostility. This study aimed to assess changes in suicidality and hostility levels following involuntary admission and their patient-level predictors. Methods A pooled analysis of studies on involuntary treatment, including 11 countries and 2790 patients was carried out. Suicidality and hostility were measured by the Brief Psychiatric Rating Scale. Results 2790 patients were included; 2129 followed-up after one month and 1864 after three months. 387 (13.9%) patients showed at least moderate suicidality when involuntarily admitted, 107 (5.0%) after one month and 97 (5.2%) after three months. Moderate or higher hostility was found in 1287 (46.1%) patients after admission, 307 (14.5%) after one month, and 172 (9.2%) after three months. Twenty-three (1.2%) patients showed suicidality, and 53 (2.8%) patients hostility at all time-points. Predictors of suicidality three months after admission were: suicidality at baseline, not having a diagnosis of psychotic disorder and being unemployed. Predictors of hostility were: hostility at baseline, not having a psychotic disorder, living alone, and having been hospitalized previously. Conclusions After involuntary hospital admission, the number of patients with significant levels of suicidality and hostility decreases substantially over time, and very few patients show consistently moderate or higher levels of these symptoms. In patients with psychotic disorders these symptoms are more likely to improve. Social factors such as unemployment and isolation could hamper suicidality and hostility reduction and may be targeted in interventions to reduce risk in involuntarily admitted patients.	[Giacco, Domenico; Priebe, Stefan] Queen Mary Univ London, WHO Collaborat Ctr Mental Hlth Serv Dev, Unit Social & Community Psychiat, London, England	University of London; Queen Mary University London	Giacco, D (corresponding author), Queen Mary Univ London, WHO Collaborat Ctr Mental Hlth Serv Dev, Unit Social & Community Psychiat, London, England.	d.giacco@qmul.ac.uk		Giacco, Domenico/0000-0001-7809-8800	Department of Health UK [0230072]; European Commission [QLG4-CT-2002-01036]	Department of Health UK; European Commission(European CommissionEuropean Commission Joint Research Centre)	The Department of Health UK (commission no. 0230072), and the European Commission (contract no. QLG4-CT-2002-01036) supported data collection for the analysed studies. The presented data analysis from those studies received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.	American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Appelbaum PS, 1997, J AM ACAD PSYCHIATRY, V25, P135; Beauchamp T. L., 2013, PRINCIPLES BIOMEDICA, V7; Blakely TA, 2003, J EPIDEMIOL COMMUN H, V57, P594, DOI 10.1136/jech.57.8.594; Blettner M, 1999, INT J EPIDEMIOL, V28, P1, DOI 10.1093/ije/28.1.1; CHODOFF P, 1984, AM J PSYCHIAT, V141, P384; Etter JF, 2000, INT J EPIDEMIOL, V29, P43, DOI 10.1093/ije/29.1.43; Fiorillo A, 2011, EUR PSYCHIAT, V26, P201, DOI 10.1016/j.eurpsy.2010.01.013; Fleischhacker WW, 2014, J CLIN PSYCHIAT, V75, pE184, DOI 10.4088/JCP.13m08563; Giacco D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050119; Giner L, 2014, J CLIN PSYCHIAT, V75, pE191, DOI 10.4088/JCP.13m08524; Janofsky JS, 2009, J AM ACAD PSYCHIATRY, V37, P15; Kallert TW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028191; Kan CK, 2007, SOC PSYCH PSYCH EPID, V42, P208, DOI 10.1007/s00127-006-0153-0; Katsakou C, 2006, ACTA PSYCHIAT SCAND, V114, P232, DOI 10.1111/j.1600-0447.2006.00823.x; Lipsedge M, 1995, Qual Health Care, V4, P122, DOI 10.1136/qshc.4.2.122; Lukoff D, 1986, SCHIZOPHRENIA B, V12, P594, DOI DOI 10.1093/SCHBUL/12.4.578; Madsen T, 2013, J CLIN PSYCHIAT, V74, pE1190, DOI 10.4088/JCP.13m08656; Marshall M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004026.pub2; Milner A, 2014, PSYCHOL MED, V44, P909, DOI 10.1017/S0033291713001621; Oquendo MA, 2004, AM J PSYCHIAT, V161, P1433, DOI 10.1176/appi.ajp.161.8.1433; Priebe S, 2011, EUR ARCH PSY CLIN N, V261, P377, DOI 10.1007/s00406-010-0179-x; Priebe S, 2009, BRIT J PSYCHIAT, V194, P49, DOI 10.1192/bjp.bp.108.052266; Salize HJ, 2005, CURR OPIN PSYCHIATR, V18, P576, DOI 10.1097/01.yco.0000179501.69053.d3; Spivak B, 2003, J CLIN PSYCHIAT, V64, P755, DOI 10.4088/JCP.v64n0703; Steele MM, 2007, CAN J PSYCHIAT, V52, p35S; World Health Organization, 1993, THE ICD 10 CLASSIFIC; Zivin K, 2009, AM J MANAG CARE, V15, P105	28	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0154458	10.1371/journal.pone.0154458	http://dx.doi.org/10.1371/journal.pone.0154458			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DM8CQ	27171229	Green Published, gold			2023-01-03	WOS:000376588600135
J	Horst, K; Eschbach, D; Pfeifer, R; Relja, B; Sassen, M; Steinfeldt, T; Wulf, H; Vogt, N; Frink, M; Ruchholtz, S; Pape, HC; Hildebrand, F				Horst, K.; Eschbach, D.; Pfeifer, R.; Relja, B.; Sassen, M.; Steinfeldt, T.; Wulf, H.; Vogt, N.; Frink, M.; Ruchholtz, S.; Pape, H. C.; Hildebrand, F.			Long-Term Effects of Induced Hypothermia on Local and Systemic Inflammation - Results from a Porcine Long-Term Trauma Model	PLOS ONE			English	Article							MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; GENE-EXPRESSION; CARDIAC-ARREST; PROFOUND HYPOTHERMIA; ENDOTHELIAL-CELLS; LETHAL HEMORRHAGE; CLINICAL-PRACTICE; IMMUNE-SYSTEM; BRAIN-INJURY	Background Hypothermia has been discussed as playing a role in improving the early phase of systemic inflammation. However, information on the impact of hypothermia on the local inflammatory response is sparse. We therefore investigated the kinetics of local and systemic inflammation in the late posttraumatic phase after induction of hypothermia in an established porcine long-term model of combined trauma. Materials & Methods Male pigs (35 +/- 5kg) were mechanically ventilated and monitored over the study period of 48 h. Combined trauma included tibia fracture, lung contusion, liver laceration and pressure-controlled hemorrhagic shock (MAP < 30 +/- 5 mmHg for 90 min). After resuscitation, hypothermia (33 degrees C) was induced for a period of 12 h (HT-T group) with subsequent rewarming over a period of 10 h. The NT-T group was kept normothermic. Systemic and local (fracture hematoma) cytokine levels (IL-6, -8, -10) and alarmins (HMGB1, HSP70) were measured via ELISA. Results Severe signs of shock as well as systemic and local increases of pro-inflammatory mediators were observed in both trauma groups. In general the local increase of pro-and anti-inflammatory mediator levels was significantly higher and prolonged compared to systemic concentrations. Induction of hypothermia resulted in a significantly prolonged elevation of both systemic and local HMGB1 levels at 48 h compared to the NT-T group. Correspondingly, local IL-6 levels demonstrated a significantly prolonged increase in the HT-T group at 48 h. Conclusion A prolonged inflammatory response might reduce the well-described protective effects on organ and immune function observed in the early phase after hypothermia induction. Furthermore, local immune response also seems to be affected. Future studies should aim to investigate the use of therapeutic hypothermia at different degrees and duration of application.	[Horst, K.; Pfeifer, R.; Pape, H. C.; Hildebrand, F.] Univ Hosp Aachen, Dept Orthoped Trauma, Pauwelsstr 30, D-52074 Aachen, Germany; [Horst, K.; Pape, H. C.; Hildebrand, F.] Univ Hosp Aachen, Harald Tscherne Res Lab, Pauwelsstr 30, D-52074 Aachen, Germany; [Eschbach, D.; Frink, M.; Ruchholtz, S.] Univ Hosp Marburg, Dept Hand Traumatol & Reconstruct Surg, Marburg, Germany; [Relja, B.] Goethe Univ Frankfurt, Dept Trauma Hand & Reconstruct Surg, D-60054 Frankfurt, Germany; [Sassen, M.; Steinfeldt, T.; Wulf, H.] Univ Hosp Marburg, Dept Anesthesiol, Marburg, Germany; [Vogt, N.] Univ Hosp Giessen, Dept Neurosurg, Giessen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University Hospital of Giessen & Marburg; Goethe University Frankfurt; University Hospital of Giessen & Marburg; University Hospital of Giessen & Marburg	Horst, K (corresponding author), Univ Hosp Aachen, Dept Orthoped Trauma, Pauwelsstr 30, D-52074 Aachen, Germany.; Horst, K (corresponding author), Univ Hosp Aachen, Harald Tscherne Res Lab, Pauwelsstr 30, D-52074 Aachen, Germany.	khorst@ukaachen.de	Relja, Borna/B-6642-2016; Hildebrand, Frank/J-3176-2017	Relja, Borna/0000-0002-5625-8823; Pape, Hans-Christoph/0000-0002-2059-4980	AO-Trauma, Germany	AO-Trauma, Germany	The article was proofread by Proof-Reading-Service.com, Devonshire Business Centre, Works Road, Letchworth Garden City, SG6 1GJ, United Kingdom. We would like to thank Jan Goloup, Nick Lippitz, Christin Buttner, and Johanna Miller for their support in conducting the experiments. We also thank Katharina Eisoldt, Andreas Gockel, and Petra Ewers for their substantial commitment during the entire investigation. This research project is supported by AO-Trauma, Germany.	Alam HB, 2010, J TRAUMA, V68, P1084, DOI 10.1097/TA.0b013e3181d76bd1; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446; Bisschops LLA, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0546-5; Bisschops LLA, 2012, CRIT CARE MED, V40, P1136, DOI 10.1097/CCM.0b013e3182377050; Chen CW, 2014, NEUROL RES, V36, P897, DOI 10.1179/1743132814Y.0000000374; Chen Z, 2005, RESUSCITATION, V66, P209, DOI 10.1016/j.resuscitation.2005.01.021; Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Currie HN, 2014, CYTOKINE, V66, P112, DOI 10.1016/j.cyto.2014.01.001; De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Drapalova J, 2014, CRYOBIOLOGY, V68, P269, DOI 10.1016/j.cryobiol.2014.02.007; Dresner-Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013; Eschbach D, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0162-0; Fantus Richard J, 2015, Bull Am Coll Surg, V100, P61; Flohe SB, 2008, INNATE IMMUN-LONDON, V14, P333, DOI 10.1177/1753425908100016; Frohlich M, 2014, J TRAUMA ACUTE CARE, V76, P1425, DOI 10.1097/TA.0000000000000224; George ME, 2010, J TRAUMA, V68, P662, DOI 10.1097/TA.0b013e3181d3cbc0; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hauser CJ, 1997, J TRAUMA, V42, P895, DOI 10.1097/00005373-199705000-00021; Hayashi S, 2005, ACT NEUR S, V95, P269; Heiner DE, 2006, J ORTHOP TRAUMA, V20, P27, DOI 10.1097/01.bot.0000184143.90448.aa; Hildebrand F, 2005, CYTOKINE, V31, P382, DOI 10.1016/j.cyto.2005.06.008; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Hildebrand F, 2014, INTENS CARE MED EXP, V2, DOI 10.1186/2197-425X-2-16; Hoff P, 2013, CELL MOL IMMUNOL, V10, P151, DOI 10.1038/cmi.2012.56; Horst K, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/126060; Huet O, 2007, ACTA ANAESTH SCAND, V51, P1211, DOI 10.1111/j.1399-6576.2007.01419.x; Kolar P, 2011, CLIN ORTHOP RELAT R, V469, P3118, DOI 10.1007/s11999-011-1865-3; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Liu DW, 2006, EUR J ORAL SCI, V114, P42, DOI 10.1111/j.1600-0722.2006.00283.x; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luchette F, 2010, J TRAUMA, V69, P530; Manganelli V, 2010, CRIT CARE, V14, DOI 10.1186/cc9316; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Metsemakers WJ, 2015, INJURY, V46, P740, DOI 10.1016/j.injury.2014.12.018; Moffatt SE, 2013, EMERG MED J, V30, P989, DOI 10.1136/emermed-2012-201883; Mohr J, 2013, J TRAUMA ACUTE CARE, V74, P1014, DOI 10.1097/TA.0b013e3182826edd; Mommsen P, 2013, INJURY, V44, P86, DOI 10.1016/j.injury.2011.10.013; Morita Y, 2009, CYTOKINE, V47, P48, DOI 10.1016/j.cyto.2009.04.004; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Recknagel S, 2011, J ORTHOP RES, V29, P734, DOI 10.1002/jor.21299; Ruchholtz S, 2013, CHIRURG, V84, P730, DOI 10.1007/s00104-013-2474-3; Sasaki H, 2000, J IMMUNOL, V165, P3626, DOI 10.4049/jimmunol.165.7.3626; Schmidt-Bleek K, 2014, J TISSUE ENG REGEN M, V8, P120, DOI 10.1002/term.1505; Schmidt-Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441-011-1205-7; Schmidt-Bleek K, 2009, J ORTHOP RES, V27, P1147, DOI 10.1002/jor.20901; Shin HI, 2004, ENDOCRINOLOGY, V145, P1376, DOI 10.1210/en.2003-0839; Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872; So HY, 2010, KOREAN J ANESTHESIOL, V59, P299, DOI 10.4097/kjae.2010.59.5.299; Song H, 2008, CLIN EXP IMMUNOL, V152, P311, DOI 10.1111/j.1365-2249.2008.03643.x; Soreide K, 2014, INJURY, V45, P647, DOI 10.1016/j.injury.2012.12.027; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086-200009000-00033; Taniguchi N, 2007, MOL CELL BIOL, V27, P5650, DOI 10.1128/MCB.00130-07; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185; Vaagenes P, 2003, RESUSCITATION, V58, P103, DOI 10.1016/S0300-9572(03)00102-3; vanderPoll T, 1997, J INFECT DIS, V176, P439, DOI 10.1086/514062; Venjakob AJ, 2013, J ORTHOP RES, V31, P1820, DOI 10.1002/jor.22417; Weuster M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/829195; Wu XR, 2003, CRIT CARE MED, V31, P195, DOI 10.1097/00003246-200301000-00030	67	16	16	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2016	11	5							e0154788	10.1371/journal.pone.0154788	http://dx.doi.org/10.1371/journal.pone.0154788			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KR	27144532	Green Published, gold			2023-01-03	WOS:000375676400071
J	Moreau, P; Masszi, T; Grzasko, N; Bahlis, NJ; Hansson, M; Pour, L; Sandhu, I; Ganly, P; Baker, BW; Jackson, SR; Stoppa, AM; Simpson, DR; Gimsing, P; Palumbo, A; Garderet, L; Cavo, M; Kumar, S; Touzeau, C; Buadi, FK; Laubach, JP; Berg, DT; Lin, J; Di Bacco, A; Hui, AM; van de Velde, H; Richardson, PG				Moreau, P.; Masszi, T.; Grzasko, N.; Bahlis, N. J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B. W.; Jackson, S. R.; Stoppa, A. -M.; Simpson, D. R.; Gimsing, P.; Palumbo, A.; Garderet, L.; Cavo, M.; Kumar, S.; Touzeau, C.; Buadi, F. K.; Laubach, J. P.; Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A. -M.; van de Velde, H.; Richardson, P. G.		TOURMALINE-MM1 Study Grp	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEASOME INHIBITOR MLN9708; QUALITY-OF-LIFE; RANDOMIZED PHASE-3; ANTITUMOR-ACTIVITY; BORTEZOMIB; THALIDOMIDE; THERAPY; TRANSPLANTATION; CARFILZOMIB; SUPERIORITY	BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group). The primary end point was progression-free survival. RESULTS Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a median follow-up of 14.7 months (median progression-free survival, 20.6 months vs. 14.7 months; hazard ratio for disease progression or death in the ixazomib group, 0.74; P=0.01); a benefit with respect to progression-free survival was observed with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic abnormalities. The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39%. The median time to response was 1.1 months in the ixazomib group and 1.9 months in the placebo group, and the corresponding median duration of response was 20.5 months and 15.0 months. At a median follow-up of approximately 23 months, the median overall survival has not been reached in either study group, and follow-up is ongoing. The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were the rates of death during the study period (4% and 6%, respectively); adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, respectively. Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, respectively) than in the placebo group (5% and 4% of the patients, respectively). Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did gastrointestinal adverse events, which were predominantly low grade. The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group). Patient-reported quality of life was similar in the two study groups. CONCLUSIONS The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited.	[Moreau, P.; Touzeau, C.] Univ Hosp Hotel Dieu, F-44093 Nantes 01, France; [Stoppa, A. -M.] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France; [Garderet, L.] Hosp St Antoine, Dept Hematol & Cell Therapy, Paris, France; [Masszi, T.] Semmelweis Univ, Dept Internal Med 3, St Istvan & St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, H-1085 Budapest, Hungary; [Grzasko, N.] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland; [Grzasko, N.] St Johns Canc Ctr, Lublin, Poland; [Bahlis, N. J.] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada; [Sandhu, I.] Univ Alberta, Dept Med, Div Hematol, Edmonton, AB, Canada; [Hansson, M.] Lund Univ, Dept Hematol, Skane Univ Hosp, Lund, Sweden; [Pour, L.] Univ Hosp Brno, Hematol & Oncol, Brno, Czech Republic; [Ganly, P.] Christchurch Hosp, Dept Haematol, Christchurch, New Zealand; [Baker, B. W.] Palmerston North Hosp, Dept Haematol, Palmerston North, Manawatu, New Zealand; [Jackson, S. R.] Middlemore Hosp, Dept Haematol, Auckland 6, New Zealand; [Simpson, D. R.] North Shore Hosp, Dept Haematol, Auckland, New Zealand; [Gimsing, P.] Univ Copenhagen Hosp, Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark; [Palumbo, A.] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy; [Cavo, M.] Univ Bologna, St Orsola Malpighi Univ Hosp, Sch Med, Seragnoli Inst Haematol, Bologna, Italy; [Kumar, S.; Buadi, F. K.] Mayo Clin, Div Hematol, Rochester, MN USA; [Laubach, J. P.; Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A. -M.; van de Velde, H.] Millennium Pharmaceut Inc, Cambridge, MA USA	Nantes Universite; CHU de Nantes; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Semmelweis University; Medical University of Lublin; University of Calgary; University of Alberta; Lund University; Skane University Hospital; University Hospital Brno; Christchurch Hospital New Zealand; Rigshospitalet; University of Copenhagen; University of Turin; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Mayo Clinic; Harvard University; Dana-Farber Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Moreau, P (corresponding author), Univ Hosp Hotel Dieu, F-44093 Nantes 01, France.	philippe.moreau@chu-nantes.fr	Hajek, Roman/I-6639-2017; CAVO, MICHELE/AAK-8274-2020; Ganly, Peter/B-8355-2008; Greil, Richard F/C-7673-2017; Blimark, Cecilie Hveding/AAZ-6423-2021; Kumar, Shaji K/A-9853-2008; Kim, Kihyun/D-5175-2013	Hajek, Roman/0000-0001-6955-6267; CAVO, MICHELE/0000-0003-4514-3227; Greil, Richard F/0000-0002-4462-3694; Blimark, Cecilie Hveding/0000-0003-3297-6019; Kumar, Shaji K/0000-0001-5392-9284; moreau, philippe/0000-0003-1780-8746; Touzeau, Cyrille/0000-0003-0275-2575; Ganly, Peter/0000-0003-0335-2063; nahi, hareth/0000-0003-4711-5094; Kim, Kihyun/0000-0002-5878-8895; Grzasko, Norbert/0000-0001-7727-4307; Hari, Parameswaran/0000-0002-8800-297X; sandhu, irwindeep/0000-0001-9407-6265; Masszi, Tamas/0000-0003-2322-9863	Millennium Pharmaceuticals	Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd)	Funded by Millennium Pharmaceuticals; TOURMALINE-MM1 ClinicalTrials.gov number, NCT01564537.	Anderson KC, 2011, CLIN CANCER RES, V17, P1225, DOI 10.1158/1078-0432.CCR-10-3366; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Cavo M, 2010, LANCET, V376, P2075, DOI 10.1016/S0140-6736(10)61424-9; Center for Drug Evaluation and Research, 2009, GUID IND PAT REP OUT; Chauhan D, 2011, CLIN CANCER RES, V17, P5311, DOI 10.1158/1078-0432.CCR-11-0476; Chng WJ, 2014, LEUKEMIA, V28, P269, DOI 10.1038/leu.2013.247; Durie B, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.25.25; Garderet L, 2012, J CLIN ONCOL, V30, P2475, DOI 10.1200/JCO.2011.37.4918; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kumar SK, 2014, LANCET ONCOL, V15, P1503, DOI 10.1016/S1470-2045(14)71125-8; Kumar SK, 2014, BLOOD, V124, P1047, DOI 10.1182/blood-2014-01-548941; Kupperman E, 2010, CANCER RES, V70, P1970, DOI 10.1158/0008-5472.CAN-09-2766; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Laubach J, 2016, LEUKEMIA, V30, P1005, DOI 10.1038/leu.2015.356; Lee EC, 2011, CLIN CANCER RES, V17, P7313, DOI 10.1158/1078-0432.CCR-11-0636; Lonial S, 2005, BLOOD, V106, P3777, DOI 10.1182/blood-2005-03-1173; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Lonial S, 2011, CLIN CANCER RES, V17, P1264, DOI 10.1158/1078-0432.CCR-10-1805; Manier S, 2015, BLOOD, V126; Millennium Pharmaceuticals, 2015, NINLARO IX CAPS OR U; Moreau P, 2011, LANCET ONCOL, V12, P431, DOI 10.1016/S1470-2045(11)70081-X; Osborne TR, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-496; Osborne TR, 2012, EUR J HAEMATOL, V89, P437, DOI 10.1111/ejh.12012; Palumbo A, 2014, J CLIN ONCOL, V32, P634, DOI 10.1200/JCO.2013.52.0023; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Richardson PG, 2012, LEUKEMIA, V26, P595, DOI 10.1038/leu.2011.346; Richardson PG, 2014, BLOOD, V124, P1038, DOI 10.1182/blood-2014-01-548826; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; Rosinol L, 2012, BLOOD, V120, P1589, DOI 10.1182/blood-2012-02-408922; Ross FM, 2012, HAEMATOL-HEMATOL J, V97, P1272, DOI 10.3324/haematol.2011.056176; Siegel D, 2013, HAEMATOLOGICA, V98, P1753, DOI 10.3324/haematol.2013.089334; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321	33	695	722	2	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	2016	374	17					1621	1634		10.1056/NEJMoa1516282	http://dx.doi.org/10.1056/NEJMoa1516282			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK3UR	27119237	Green Published, Bronze			2023-01-03	WOS:000374843400006
J	Buckner, JC; Shaw, EG; Pugh, SL; Chakravarti, A; Gilbert, MR; Barger, GR; Coons, S; Ricci, P; Bullard, D; Brown, PD; Stelzer, K; Brachman, D; Suh, JH; Schultz, CJ; Bahary, JP; Fisher, BJ; Kim, H; Murtha, AD; Bell, EH; Won, M; Mehta, MP; Curran, WJ				Buckner, Jan C.; Shaw, Edward G.; Pugh, Stephanie L.; Chakravarti, Arnab; Gilbert, Mark R.; Barger, Geoffrey R.; Coons, Stephen; Ricci, Peter; Bullard, Dennis; Brown, Paul D.; Stelzer, Keith; Brachman, David; Suh, John H.; Schultz, Christopher J.; Bahary, Jean-Paul; Fisher, Barbara J.; Kim, Harold; Murtha, Albert D.; Bell, Erica H.; Won, Minhee; Mehta, Minesh P.; Curran, Walter J., Jr.			Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; TERM-FOLLOW-UP; ANAPLASTIC OLIGODENDROGLIOMA; RECURRENT GLIOMA; CHEMOTHERAPY; LOMUSTINE; RADIOTHERAPY; THERAPY; CANCER	BACKGROUND Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. We now report the long-term results. METHODS We included patients with grade 2 astrocytoma, oligoastrocytoma, or oligodendroglioma who were younger than 40 years of age and had undergone subtotal resection or biopsy or who were 40 years of age or older and had undergone biopsy or resection of any of the tumor. Patients were stratified according to age, histologic findings, Karnofsky performance-status score, and presence or absence of contrast enhancement on pre-operative images. Patients were randomly assigned to radiation therapy alone or to radiation therapy followed by six cycles of combination chemotherapy. RESULTS A total of 251 eligible patients were enrolled from 1998 through 2002. The median follow-up was 11.9 years; 55% of the patients died. Patients who received radiation therapy plus chemotherapy had longer median overall survival than did those who received radiation therapy alone (13.3 vs. 7.8 years; hazard ratio for death, 0.59; P = 0.003). The rate of progression-free survival at 10 years was 51% in the group that received radiation therapy plus chemotherapy versus 21% in the group that received radiation therapy alone; the corresponding rates of overall survival at 10 years were 60% and 40%. A Cox model identified receipt of radiation therapy plus chemotherapy and histologic findings of oligodendroglioma as favorable prognostic variables for both progression-free and overall survival. CONCLUSIONS In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 years of age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than among those who received radiation therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00003375.)	[Buckner, Jan C.] Mayo Clin, 200 First St SW, Rochester, MN 55905 USA; [Shaw, Edward G.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Bullard, Dennis] Triangle Neurosurg, Raleigh, NC USA; [Pugh, Stephanie L.; Won, Minhee] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA; [Chakravarti, Arnab; Bell, Erica H.] Ohio State Univ, Columbus, OH 43210 USA; [Suh, John H.] Cleveland Clin, Cleveland, OH 44106 USA; [Gilbert, Mark R.; Brown, Paul D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Barger, Geoffrey R.; Kim, Harold] Wayne State Univ, Detroit, MI USA; [Coons, Stephen] Barrow Neurol Inst, Phoenix, AZ USA; [Brachman, David] Arizona Oncol Serv Fdn, Phoenix, AZ USA; [Ricci, Peter] Radiol Imaging Associates, Englewood, CO USA; [Stelzer, Keith] Mid Columbia Med Ctr, The Dalles, OR USA; [Schultz, Christopher J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Bahary, Jean-Paul] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Fisher, Barbara J.] London Reg Canc Program, London, ON, Canada; [Murtha, Albert D.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Mehta, Minesh P.] Univ Maryland, Baltimore, MD 21201 USA; [Curran, Walter J., Jr.] Emory Univ, Atlanta, GA 30322 USA	Mayo Clinic; Wake Forest University; Wake Forest Baptist Medical Center; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; University of Texas System; UTMD Anderson Cancer Center; Wayne State University; Barrow Neurological Institute; Medical College of Wisconsin; Universite de Montreal; Western University (University of Western Ontario); University of Alberta; University System of Maryland; University of Maryland Baltimore; Emory University	Buckner, JC (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	buckner.jan@mayo.edu	Buckner, Jan/AAE-6388-2019; Mehta, Minesh P./AAB-8915-2019; Gilbert, Mark R/J-7494-2016	Mehta, Minesh P./0000-0002-4812-5713; Gilbert, Mark R/0000-0003-2556-9722	Radiation Therapy Oncology Group [U10 CA21661]; Community Clinical Oncology Program grant from the National Cancer Institute [U10 CA37422]; North Central Cancer Treatment Group [U10 CA25224]; Ohio State University Comprehensive Cancer Center [R01CA108633, 1RC2CA148190, 1R01CA169368]; Cancer Therapy Evaluation Program of the National Cancer Institute [NRG-BN-TS002]; NATIONAL CANCER INSTITUTE [U10CA037422, U10CA180868, U10CA025224, UG1CA189867, U10CA180822, U10CA021661, R01CA169368, R01CA108633, RC2CA148190, R01CA140314, P30CA022453, R01CA188228, U10CA180835, U10CA180850] Funding Source: NIH RePORTER	Radiation Therapy Oncology Group; Community Clinical Oncology Program grant from the National Cancer Institute; North Central Cancer Treatment Group; Ohio State University Comprehensive Cancer Center; Cancer Therapy Evaluation Program of the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by a Radiation Therapy Oncology Group grant (U10 CA21661) and a Community Clinical Oncology Program grant (U10 CA37422) from the National Cancer Institute, a grant (U10 CA25224) from the North Central Cancer Treatment Group, grants (R01CA108633, to Dr. Chakravarti; 1RC2CA148190, to Drs. Chakravarti and Curran; and 1R01CA169368, to Dr. Chakravarti) from the Ohio State University Comprehensive Cancer Center, and a grant (NRG-BN-TS002, to Drs. Bell and Chakravarti) from the Cancer Therapy Evaluation Program of the National Cancer Institute.	Biemond-ter Stege EM, 2005, CANCER-AM CANCER SOC, V103, P802, DOI 10.1002/cncr.20828; BUCKNER JC, 1995, J NEUROSURG, V82, P430, DOI 10.3171/jns.1995.82.3.0430; Buckner JC, 2003, J CLIN ONCOL, V21, P251, DOI 10.1200/JCO.2003.06.023; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; COX DR, 1972, J R STAT SOC B, V34, P187; FU KK, 1995, INT J RADIAT ONCOL, V32, P577, DOI 10.1016/0360-3016(95)00080-I; Galanis E, 1998, J CLIN ONCOL, V16, P2953, DOI 10.1200/JCO.1998.16.9.2953; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klein JP, 2003, SURVIVAL ANAL TECHNI, V2nd, DOI DOI 10.1007/B97377; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mason WP, 1996, NEUROLOGY, V46, P203, DOI 10.1212/WNL.46.1.203; Prabhu RS, 2014, J CLIN ONCOL, V32, P535, DOI 10.1200/JCO.2013.53.1830; Shaw EG, 2012, J CLIN ONCOL, V30, P3065, DOI 10.1200/JCO.2011.35.8598; van den Bent MJ, 2013, J CLIN ONCOL, V31, P344, DOI 10.1200/JCO.2012.43.2229	16	568	578	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2016	374	14					1344	1355		10.1056/NEJMoa1500925	http://dx.doi.org/10.1056/NEJMoa1500925			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DI3UW	27050206	Green Accepted, Bronze			2023-01-03	WOS:000373425000008
J	Farley, TA				Farley, Thomas A.			When Is It Ethical to Withhold Prevention?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COST-EFFECTIVENESS ANALYSIS		[Farley, Thomas A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA		Farley, TA (corresponding author), Philadelphia Dept Publ Hlth, Philadelphia, PA USA.							Chambers JD, 2015, HEALTH POLICY, V119, P156, DOI 10.1016/j.healthpol.2014.11.012; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Fojo T, 2009, JNCI-J NATL CANCER I, V101, P1044, DOI 10.1093/jnci/djp177; Ong MK, 2005, AM J PUBLIC HEALTH, V95, P969, DOI 10.2105/AJPH.2004.040667; Xu X, 2015, AM J PREV MED, V48, P318, DOI 10.1016/j.amepre.2014.10.011	5	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2016	374	14					1303	1306		10.1056/NEJMp1516534	http://dx.doi.org/10.1056/NEJMp1516534			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DI3UW	27050204				2023-01-03	WOS:000373425000003
J	Fivez, T; Kerklaan, D; Mesotten, D; Verbruggen, S; Wouters, PJ; Vanhorebeek, I; Debaveye, Y; Vlasselaers, D; Desmet, L; Casaer, MP; Guerra, GG; Hanot, J; Joffe, A; Tibboel, D; Joosten, K; Van den Berghe, G				Fivez, Tom; Kerklaan, Dorian; Mesotten, Dieter; Verbruggen, Sascha; Wouters, Pieter J.; Vanhorebeek, Ilse; Debaveye, Yves; Vlasselaers, Dirk; Desmet, Lars; Casaer, Michael P.; Guerra, Gonzalo Garcia; Hanot, Jan; Joffe, Ari; Tibboel, Dick; Joosten, Koen; Van den Berghe, Greet			Early versus Late Parenteral Nutrition in Critically Ill Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS LIPID EMULSION; OPEN-HEART-SURGERY; CRITICAL ILLNESS; ENTERAL NUTRITION; ACID; PRETREATMENT; AUTOPHAGY; OUTCOMES; INFANTS	BACKGROUND Recent trials have questioned the benefit of early parenteral nutrition in adults. The effect of early parenteral nutrition on clinical outcomes in critically ill children is unclear. METHODS We conducted a multicenter, randomized, controlled trial involving 1440 critically ill children to investigate whether withholding parenteral nutrition for 1 week (i.e., providing late parenteral nutrition) in the pediatric intensive care unit (ICU) is clinically superior to providing early parenteral nutrition. Fluid loading was similar in the two groups. The two primary end points were new infection acquired during the ICU stay and the adjusted duration of ICU dependency, as assessed by the number of days in the ICU and as time to discharge alive from ICU. For the 723 patients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 hours after ICU admission, whereas for the 717 patients receiving late parenteral nutrition, parenteral nutrition was not provided until the morning of the 8th day in the ICU. In both groups, enteral nutrition was attempted early and intravenous micronutrients were provided. RESULTS Although mortality was similar in the two groups, the percentage of patients with a new infection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% confidence interval [CI], 0.35 to 0.66). The mean (+/- SE) duration of ICU stay was 6.5 +/- 0.4 days in the group receiving late parenteral nutrition, as compared with 9.2 +/- 0.8 days in the group receiving early parenteral nutrition; there was also a higher likelihood of an earlier live discharge from the ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23; 95% CI, 1.11 to 1.37). Late parenteral nutrition was associated with a shorter duration of mechanical ventilatory support than was early parenteral nutrition (P = 0.001), as well as a smaller proportion of patients receiving renal-replacement therapy (P = 0.04) and a shorter duration of hospital stay (P = 0.001). Late parenteral nutrition was also associated with lower plasma levels of.-glutamyltransferase and alkaline phosphatase than was early parenteral nutrition (P = 0.001 and P = 0.04, respectively), as well as higher levels of bilirubin (P = 0.004) and C-reactive protein (P = 0.006). CONCLUSIONS In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinically superior to providing early parenteral nutrition.	[Fivez, Tom; Mesotten, Dieter; Wouters, Pieter J.; Vanhorebeek, Ilse; Debaveye, Yves; Vlasselaers, Dirk; Desmet, Lars; Casaer, Michael P.; Hanot, Jan; Van den Berghe, Greet] KU Leuven Univ Hosp, Clin Div, Dept Cellular & Mol Med, Leuven, Belgium; [Fivez, Tom; Mesotten, Dieter; Wouters, Pieter J.; Vanhorebeek, Ilse; Debaveye, Yves; Vlasselaers, Dirk; Desmet, Lars; Casaer, Michael P.; Hanot, Jan; Van den Berghe, Greet] KU Leuven Univ Hosp, Lab Intens Care Med, Leuven, Belgium; [Kerklaan, Dorian; Verbruggen, Sascha; Tibboel, Dick; Joosten, Koen] Erasmus MC Sophia Childrens Hosp, Dept Pediat & Pediat Surg, Intens Care, Rotterdam, Netherlands; [Guerra, Gonzalo Garcia; Hanot, Jan; Joffe, Ari] Univ Alberta, Stollery Childrens Hosp, Dept Pediat, Intens Care Unit, Edmonton, AB, Canada	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Erasmus University Rotterdam; Erasmus MC; Stollery Children's Hospital; University of Alberta	Van den Berghe, G (corresponding author), KU Leuven Univ & Hosp, Intens Care Med, Herestr 49, B-3000 Louvain, Belgium.	greet.vandenberghe@kuleuven.be	Casaer, Michael/Y-7131-2019; Mesotten, Dieter/ABE-4176-2020; Verbruggen, Sascha/ABB-7745-2020	Casaer, Michael/0000-0002-7087-0795; Mesotten, Dieter/0000-0002-3258-4720; Verbruggen, Sascha/0000-0003-4866-9865; Van den Berghe, Greet/0000-0002-5320-1362; Vanhorebeek, Ilse/0000-0002-5261-5192	Flemish Agency for Innovation through Science and Technology [IWT-TBM110685]; Fund for Scientific Research Flanders; UZ Leuven Clinical Research Fund; Methusalem Program - Flemish Government through KU Leuven [METH/08/07, METH/14/06]; European Research Council under the European Union [321670]; Fonds NutsOhra; Erasmus MC Cost-Effectiveness Research Grant; Erasmus Trustfonds through Erasmus University Rotterdam; Nutricia	Flemish Agency for Innovation through Science and Technology; Fund for Scientific Research Flanders(FWO); UZ Leuven Clinical Research Fund; Methusalem Program - Flemish Government through KU Leuven; European Research Council under the European Union(European Research Council (ERC)); Fonds NutsOhra; Erasmus MC Cost-Effectiveness Research Grant; Erasmus Trustfonds through Erasmus University Rotterdam; Nutricia(Danone Nutricia)	Supported by a grant from the Flemish Agency for Innovation through Science and Technology (IWT-TBM110685, to Dr. Van den Berghe), a private donation by an anonymous Dutch family through the Leuven University Hospitals to Drs. Van den Berghe and Casaer, a senior clinical research fellowship from the Fund for Scientific Research Flanders to Dr. Mesotten, a postdoctoral fellowship from the UZ Leuven Clinical Research Fund to Dr. Casaer, a grant from the Methusalem Program funded by the Flemish Government (METH/08/07 and METH/14/06 through KU Leuven, to Dr. Van den Berghe), the European Research Council under the European Union's Seventh Framework Program ([FP7/2013-2018]/ERC Advanced Grant Agreement no 321670, to Dr. Van den Berghe), a grant from Fonds NutsOhra to Dr. Verbruggen, an Erasmus MC Cost-Effectiveness Research Grant to Dr. Verbruggen; and a grant from the Erasmus Trustfonds through Erasmus University Rotterdam to Dr. Verbruggen.; Dr. Verbruggen reports receiving lecture fees from Nutricia. No other potential conflict of interest relevant to this article was reported.	Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chaloupecky V, 1997, J THORAC CARDIOV SUR, V114, P1053, DOI 10.1016/S0022-5223(97)70019-9; Chaloupecky V., 1994, Cor et Vasa, V36, P26; de Betue CTI, 2015, CLIN NUTR, V34, P115, DOI 10.1016/j.clnu.2014.01.019; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Fivez T, 2015, CLIN NUTR; Fivez T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0728-8; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Hermans G, 2013, LANCET RESP MED, V1, P621, DOI 10.1016/S2213-2600(13)70183-8; Hulst JM, 2010, CLIN NUTR, V29, P106, DOI 10.1016/j.clnu.2009.07.006; Jenniskens M, 2016, INTENS CARE MED, V42, P16, DOI 10.1007/s00134-015-4054-0; Joffe A, 2009, COCHRANE DB SYST REV, V2; Kerklaan D, 2016, PEDIATR CRIT CARE ME, V17, P10, DOI 10.1097/PCC.0000000000000542; Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4; Larsen BMK, 2015, JPEN-PARENTER ENTER, V39, P171, DOI 10.1177/0148607113505326; Larsen BMK, 2012, CLIN NUTR, V31, P322, DOI 10.1016/j.clnu.2011.11.006; Lekmanov A. U., 2013, Anesteziologiya i Reanimatologiya, P49; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; McKinlay CJD, 2015, NEW ENGL J MED, V373, P1507, DOI 10.1056/NEJMoa1504909; Mehta N. M., 2008, Nutrition in pediatrics: basic science and clinical applications, P663; Mehta NM, 2012, CRIT CARE MED, V40, P2204, DOI 10.1097/CCM.0b013e31824e18a8; Mehta NM, 2010, JPEN-PARENTER ENTER, V34, P38, DOI 10.1177/0148607109348065; Mehta NM, 2009, JPEN-PARENTER ENTER, V33, P260, DOI 10.1177/0148607109333114; Mesotten D, 2012, JAMA-J AM MED ASSOC, V308, P1641, DOI 10.1001/jama.2012.12424; POLLACK MM, 1985, JPEN-PARENTER ENTER, V9, P309, DOI 10.1177/0148607185009003309; Skillman HE., 2015, PEDIAT CRITICAL CARE; Tin W, 2012, PEDIATRICS, V130, pE1497, DOI 10.1542/peds.2012-0776; Vanwijngaerden YM, 2014, HEPATOLOGY, V60, P202, DOI 10.1002/hep.26928; Vanwijngaerden YM, 2011, HEPATOLOGY, V54, P1741, DOI 10.1002/hep.24582; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; Ziegler TR, 2009, NEW ENGL J MED, V361, P1088, DOI 10.1056/NEJMct0806956	32	279	302	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2016	374	12					1111	1122		10.1056/NEJMoa1514762	http://dx.doi.org/10.1056/NEJMoa1514762			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH2AA	26975590	Bronze			2023-01-03	WOS:000372585100004
J	Iimura, K; Watanabe, N; Masunaga, K; Miyazaki, S; Hotta, H; Kim, H; Hisajima, T; Takahashi, H; Kasuya, Y				Iimura, Kaori; Watanabe, Nobuhiro; Masunaga, Koichi; Miyazaki, Shogo; Hotta, Harumi; Kim, Hunkyung; Hisajima, Tatsuya; Takahashi, Hidenori; Kasuya, Yutaka			Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial	PLOS ONE			English	Article							OVERACTIVE BLADDER SYNDROME; QUALITY-OF-LIFE; MICTURITION CONTRACTIONS; CUTANEOUS STIMULATION; SOLIFENACIN SUCCINATE; URINARY-INCONTINENCE; INHIBITION; REFLEX; SYMPTOMS; HEAT	Background Somatic afferent nerve stimuli are used for treating an overactive bladder (OAB), a major cause of nocturia in the elderly. Clinical evidence for this treatment is insufficient because of the lack of appropriate control stimuli. Recent studies on anesthetized animals show that gentle stimuli applied to perineal skin with a roller could inhibit micturition contractions depending on the roller's surface material. We examined the efficacy of gentle skin stimuli for treating nocturia. Methods The study was a cross-over, placebo-controlled, double-blind randomized clinical study using two rollers with different effects on micturition contractions. Participants were elderly women (79-89 years) with nocturia. Active (soft elastomer roller) or placebo (hard polystyrene roller) stimuli were applied to perineal skin by participants for 1 min at bedtime. A 3-day baseline assessment period was followed by 3-day stimulation and 4-day resting periods, after which the participants were subjected to other stimuli for another 3 days. The primary outcome was change in the frequency of nighttime urination, for which charts were maintained during each 3-day period. Results Twenty-four participants were randomized, of which 22 completed all study protocols. One participant discontinued treatment because of an adverse event (abdominal discomfort). In participants with OAB (n = 9), change from baseline in the mean frequency of urination per night during the active stimuli period (mean +/- standard deviation, -0.74 +/- 0.7 times) was significantly greater than that during placebo stimuli periods (-0.15 +/- 0.8 times [p < 0.05]). In contrast, this difference was not observed in participants without OAB (n = 13). Conclusions These results suggest that gentle perineal stimulation with an elastomer roller is effective for treating OAB-associated nocturia in elderly women. Here the limitation was a study period too short to assess changes in the quality of sleep and life.	[Iimura, Kaori; Miyazaki, Shogo; Hisajima, Tatsuya; Takahashi, Hidenori] Teikyo Heisei Univ, Grad Sch Hlth Sci, Tokyo, Japan; [Iimura, Kaori; Watanabe, Nobuhiro; Miyazaki, Shogo; Hotta, Harumi] Tokyo Metropolitan Inst Gerontol, Dept Auton Neurosci, Tokyo, Japan; [Masunaga, Koichi; Kasuya, Yutaka] Tokyo Metropolitan Geriatr Hosp, Dept Urol, Tokyo 173, Japan; [Miyazaki, Shogo; Hisajima, Tatsuya; Takahashi, Hidenori] Teikyo Heisei Univ, Fac Hlth Care, Dept Acupuncture & Moxibust, Tokyo, Japan; [Kim, Hunkyung] Tokyo Metropolitan Inst Gerontol, Dept Promot Prevent Musculoskeletal Aging, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology	Hotta, H (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Auton Neurosci, Tokyo, Japan.	hhotta@tmig.or.jp		Miyazaki, Shogo/0000-0001-7270-0725; Hotta, Harumi/0000-0002-4590-7162	Translational research fund in Tokyo Metropolitan Institute of Gerontology	Translational research fund in Tokyo Metropolitan Institute of Gerontology	This study was supported by Translational research fund in Tokyo Metropolitan Institute of Gerontology (http://www.tmig.or.jp/index.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham L, 2004, UROLOGY, V63, P481, DOI 10.1016/j.urology.2003.10.019; Abrams P, 2006, J UROLOGY, V175, P1063, DOI 10.1016/S0022-5347(05)00348-4; Bing MH, 2007, J UROLOGY, V178, P552, DOI 10.1016/j.juro.2007.03.141; Bosch JLHR, 2010, J UROLOGY, V184, P440, DOI 10.1016/j.juro.2010.04.011; But I, 2005, J UROLOGY, V173, P1644, DOI 10.1097/01.ju.0000157336.87781.32; Cardozo L, 2004, J UROLOGY, V172, P1919, DOI 10.1097/01.ju.0000140729.07840.16; Cevik C, 2013, ACUPUNCTURE ELECTRO, V38, P199, DOI 10.3727/036012913X13831832269298; Chapple CR, 2007, EUR UROL, V52, P1195, DOI 10.1016/j.eururo.2007.05.027; Chapple CR, 2005, EUR UROL, V48, P464, DOI 10.1016/j.eururo.2005.05.015; Chen FY, 2007, INT UROGYNECOL J, V18, P431, DOI 10.1007/s00192-006-0167-x; Coyne KS, 2003, BJU INT, V92, P948, DOI 10.1111/j.1464-410X.2003.04527.x; Guo ZF, 2014, CLIN INTERV AGING, V9, P851, DOI 10.2147/CIA.S61084; Herbison P, 2003, BMJ-BRIT MED J, V326, P841, DOI 10.1136/bmj.326.7394.841; Homma Y, 2006, UROLOGY, V68, P318, DOI 10.1016/j.urology.2006.02.042; Hotta H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135185; Hotta H, 2013, J PHYSIOL SCI, V63, pS63; Hotta H, 2012, AUTON NEUROSCI-BASIC, V167, P12, DOI 10.1016/j.autneu.2011.11.002; Hotta H, 2010, EUR J PAIN, V14, P806, DOI 10.1016/j.ejpain.2010.02.009; Iimura K, 2013, 62 ANN C JAP SOC AC, P142; Iimura K, 2014, AUTON NERV SYST, V51, P168; Kim H, 2011, GERIATR GERONTOL INT, V11, P452, DOI 10.1111/j.1447-0594.2011.00705.x; Kim H, 2011, ARCH GERONTOL GERIAT, V52, P99, DOI 10.1016/j.archger.2010.02.008; Kim Sun-Ouck, 2011, Int Neurourol J, V15, P82, DOI 10.5213/inj.2011.15.2.82; Nakagawa H, 2010, J UROLOGY, V184, P1413, DOI 10.1016/j.juro.2010.05.093; Paik SH, 2013, EXP THER MED, V6, P773, DOI 10.3892/etm.2013.1210; Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036; Portney L.G., 2000, FDN CLIN RES APPL PR, V3rd; SATO A, 1980, J AUTONOM NERV SYST, V1, P229, DOI 10.1016/0165-1838(80)90019-3; SATO A, 1992, NEUROSCI RES, V15, P189, DOI 10.1016/0168-0102(92)90004-V; Sato A, 1997, REV PHYSIOL BIOCH P, V130, P1, DOI 10.1007/BFb0046598; SATO A, 1975, BRAIN RES, V94, P465, DOI 10.1016/0006-8993(75)90229-2; SATO A, 1977, NEUROSCIENCE, V2, P111, DOI 10.1016/0306-4522(77)90072-0; Tikkinen KAO, 2010, EUR UROL, V57, P488, DOI 10.1016/j.eururo.2009.03.080; Tomita K, 2009, J JPN SOC ACUPUNCT M, V59, P116; van Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053; Watanabe N, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0001-x; Watanabe N, 2012, J PHYSIOL SCI, V62, P343, DOI 10.1007/s12576-012-0210-2; Weiss JP, 2013, J UROLOGY, V189, P1396, DOI 10.1016/j.juro.2012.11.067; Woock JP, 2008, AM J PHYSIOL-REG I, V294, pR1880, DOI 10.1152/ajpregu.00029.2008; Yamaguchi O, 2009, INT J UROL, V16, P126, DOI 10.1111/j.1442-2042.2008.02177.x	40	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2016	11	3							e0151726	10.1371/journal.pone.0151726	http://dx.doi.org/10.1371/journal.pone.0151726			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3OX	27003163	Green Published, gold, Green Submitted			2023-01-03	WOS:000372697400039
J	Branco, BHM; Fukuda, DH; Andreato, LV; Santos, JFD; Esteves, JVD; Franchini, E				Magnani Branco, Braulio Henrique; Fukuda, David Hideyoshi; Andreato, Leonardo Vidal; da Silva Santos, Jonatas Ferreira; Del Conti Esteves, Joao Victor; Franchini, Emerson			The Effects of Hyperbaric Oxygen Therapy on Post-Training Recovery in Jiu-Jitsu Athletes	PLOS ONE			English	Article							TESTOSTERONE	Objectives The present study aimed to evaluate the effects of using hyperbaric oxygen therapy during post-training recovery in jiu-jitsu athletes. Methods Eleven experienced Brazilian jiu-jitsu athletes were investigated during and following two training sessions of 1h30min. Using a cross-over design, the athletes were randomly assigned to passive recovery for 2 hours or to hyperbaric oxygen therapy (OHB) for the same duration. After a 7-day period, the interventions were reversed. Before, immediately after, post 2 hours and post 24 hours, blood samples were collected to examine hormone concentrations (cortisol and total testosterone) and cellular damage markers [creatine kinase (CK), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH)]. Moreover, the rating of perceived exertion (RPE) and recovery (RPR) scales were applied. Results Final lactate [La] values (control: 11.9 +/- 1.4 mmol/L, OHB: 10.2 +/- 1.4 mmol/L) and RPE [control: 14 (13-17 a.u.), OHB: 18 (17-20 a.u.)] were not significantly different following the training sessions. Furthermore, there was no difference between any time points for blood lactate and RPE in the two experimental conditions (P > 0.05). There was no effect of experimental conditions on cortisol (F-1,F-20 = 0.1, P = 0.793, eta(2) = 0.00, small), total testosterone (F-1,F-20 = 0.03, P = 0.877, eta(2) = 0.00, small), CK (F-1,F-20 = 0.1, P = 0.759, eta(2) = 0.01, small), AST (F-1,F-20 = 0.1, P = 0.761, eta(2) = 0.01, small), ALT (F-1,F-20 = 0.0, P = 0.845, eta(2) = 0.00, small) or LDH (F-1,F-20 = 0.7, P = 0.413, eta(2) = 0.03, small). However, there was a difference between the two experimental conditions in RPR with higher values at post 2 h and 24 h in OHB when compared to the control condition (P < 0.05). Conclusions Thus, it can be concluded that OHB exerts no influence on the recovery of hormonal status or cellular damage markers. Nonetheless, greater perceived recovery, potentially due to the placebo effect, was evident following the OHB condition.	[Magnani Branco, Braulio Henrique; da Silva Santos, Jonatas Ferreira; Franchini, Emerson] Univ Sao Paulo, Sports & Phys Educ Sch, Sao Paulo, Brazil; [Magnani Branco, Braulio Henrique; da Silva Santos, Jonatas Ferreira; Franchini, Emerson] Univ Sao Paulo, Combat Sports & Martial Arts Res Grp, Phys Educ & Sports Sch, Sao Paulo, Brazil; [Fukuda, David Hideyoshi] Univ Cent Florida, Orlando, FL 32816 USA; [Andreato, Leonardo Vidal] Santa Catarina State Univ, Florianopolis, SC, Brazil; [Del Conti Esteves, Joao Victor] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; State University System of Florida; University of Central Florida; Universidade do Estado de Santa Catarina; Universidade de Sao Paulo	Branco, BHM (corresponding author), Univ Sao Paulo, Sports & Phys Educ Sch, Sao Paulo, Brazil.; Branco, BHM (corresponding author), Univ Sao Paulo, Combat Sports & Martial Arts Res Grp, Phys Educ & Sports Sch, Sao Paulo, Brazil.	brauliomagnani@live.com	da Silva Santos, Jonatas Ferreira/O-6956-2019; Esteves, João Victor/N-7866-2015; Branco, Braulio/AAA-1747-2019; Franchini, Emerson/B-9119-2012; Fukuda, David/F-4507-2014; Magnani Branco, Braulio Henrique/B-8178-2017	da Silva Santos, Jonatas Ferreira/0000-0002-3309-4731; Esteves, João Victor/0000-0001-8274-000X; Franchini, Emerson/0000-0002-0769-8398; Fukuda, David/0000-0002-4299-7764; Magnani Branco, Braulio Henrique/0000-0002-4625-9128	Laboratory of Energy Determinants of Performance Sports (LADESP) of School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil	Laboratory of Energy Determinants of Performance Sports (LADESP) of School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil	Research was carried out with funds provided by the Laboratory of Energy Determinants of Performance Sports (LADESP) of School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreato LV, 2015, J STRENGTH COND RES, V29, P2015, DOI 10.1519/JSC.0000000000000819; Babul S, 2003, CLIN J SPORT MED, V13, P138, DOI 10.1097/00042752-200305000-00003; Babul S, 2000, SPORTS MED, V30, P395, DOI 10.2165/00007256-200030060-00002; Barata P, 2011, THER ADV MUSCULOSKEL, V3, P111, DOI 10.1177/1759720X11399172; Barnett A, 2006, SPORTS MED, V36, P781, DOI 10.2165/00007256-200636090-00005; Bennett MH, 2005, COCHRANE DB SYST REV, V19, P1; Bennett MH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004609.pub3; Bishop PA, 2015, INT J EXERC SCI, V3, P297; Bleakley C, 2003, BRIT J SPORT MED, V37, P72; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Broatch JR, 2014, MED SCI SPORT EXER, V46, P2139, DOI 10.1249/MSS.0000000000000348; Brownlee KK, 2005, J SPORT SCI MED, V4, P76; Cohen J., 2013, STAT POWER ANAL BEHA; Santos WOC, 2012, J HUM SPORT EXERC, V7, P629, DOI 10.4100/jhse.2012.73.03; Field A., 2005, METHODS; Hai-peng Z, 1994, PATHOPHYSIOLOGY, V1, P91; Hayes LD, 2015, SPORTS MED, V45, P713, DOI 10.1007/s40279-015-0306-y; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; Jones NB, 2012, STRENGTH COND J, V34, P60, DOI 10.1519/SSC.0b013e3182405476; Kim S., 2011, HEALTH-LONDON, V03, P432, DOI [DOI 10.4236/HEALTH.2011.37071, https://doi.org/10.4236/health.2011.37071]; Laurent CM, 2011, J STRENGTH COND RES, V25, P620, DOI 10.1519/JSC.0b013e3181c69ec6; Lund V, 1999, UNDERSEA HYPERBAR M, V26, P87; Mayer R, 2005, STRAHLENTHER ONKOL, V181, P113, DOI 10.1007/s00066-005-1277-y; Mortensen C.R., 2008, CURR ANAESTH CRIT CA, V19, P333, DOI DOI 10.1016/J.CACC.2008.07.007; Passavanti G, 2010, UROLOG J, V77, P52, DOI 10.1177/039156031007700109; Pinho Júnior E. A., 2014, Rev Andal Med Deporte, V7, P7; Reilly T, 2005, J SPORT SCI, V23, P619, DOI 10.1080/02640410400021302; Sheridan RL, 1999, J TRAUMA, V47, P426, DOI 10.1097/00005373-199908000-00045; Shimoda M, 2015, J STRENGTH COND RES, V29, P1648, DOI 10.1519/JSC.0000000000000809; Staples J, 1996, SPORTS MED, V22, P219, DOI 10.2165/00007256-199622040-00002; Tiidus PM, 2015, CURR REV MUSCULOSKE, V8, P162, DOI 10.1007/s12178-015-9261-3	31	18	20	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150517	10.1371/journal.pone.0150517	http://dx.doi.org/10.1371/journal.pone.0150517			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26959652	Green Published, Green Submitted, gold			2023-01-03	WOS:000371992300054
J	Yang, SN; Kong, WM; Hsue, CY; Fish, AF; Chen, YF; Guo, XH; Lou, QQ; Anderson, R				Yang, Shengnan; Kong, Weimin; Hsue, Cunyi; Fish, Anne F.; Chen, Yufeng; Guo, Xiaohui; Lou, Qingqing; Anderson, Robert			Knowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes	PLOS ONE			English	Article							IMPROVES GLYCEMIC CONTROL; FEEDBACK; HBA(1C); CARE; VALUES; HBA1C	This study was to identify current A1c understanding status among Chinese patients with type 2 diabetes, assess if knowledge of A1c affects their diabetes self-management and their glycemic control and recognize the factors influencing knowledge of A1c among patients with type 2 diabetes. A multi-center, cross-sectional survey was conducted between April and July 2010 in 50 medical centers in the Mainland China. Participants were recruited from inpatients and outpatients who were admitted to or visited those medical centers. The survey included core questions about their demographic characteristics, diabetes self-management behavior, and A1c knowledge. Overall, of 5957 patients, the percentage of patients with good understanding was 25.3%. In the multivariable logistic regression model, the variables related to the knowledge of A1c status are presented. We discovered that patients with longer diabetes duration (OR = 1.05; 95% CI = 1.04-1.06) and having received diabetes education (OR = 1.80; 95% CI = 1.49-2.17) were overrepresented in the good understanding of A1c group. In addition, compared to no education level, higher education level was statistically associated with good understanding of A1c (P<0.001). The percentage of patients with good understanding varied from region to region (P<0.001), with Eastern being highest (OR = 1.54; 95% CI = 1.32-1.80), followed by Central (OR = 1.25; 95% CI = 1.02-1.53), when referring to Western. Only a minority of patients with type 2 diabetes in China understood their A1c value. The patients who had a good understanding of their A1c demonstrated significantly better diabetes self-management behavior and had lower A1c levels than those who did not.	[Yang, Shengnan; Lou, Qingqing] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Jiangsu, Peoples R China; [Yang, Shengnan; Kong, Weimin; Chen, Yufeng] Nanjing Univ Chinese Med, Coll Nursing, Nanjing, Jiangsu, Peoples R China; [Yang, Shengnan; Lou, Qingqing] Jiangsu Prov Acad Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Hsue, Cunyi] Hangzhou 9 High Sch, Hangzhou, Zhejiang, Peoples R China; [Fish, Anne F.] Univ Missouri, Coll Nursing, ISP Fellowship Support Program, St Louis, MO 63121 USA; [Guo, Xiaohui] Peking Univ, Hosp 1, Dept Endocrinol, Beijing 100871, Peoples R China; [Anderson, Robert] Michigan Diabet Res & Training Ctr, Dept Med Educ & Senior Res Scientist, Ann Arbor, MI USA	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; University of Missouri System; University of Missouri Saint Louis; Peking University	Lou, QQ (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Jiangsu, Peoples R China.; Lou, QQ (corresponding author), Jiangsu Prov Acad Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.; Guo, XH (corresponding author), Peking Univ, Hosp 1, Dept Endocrinol, Beijing 100871, Peoples R China.	guoxh@medmail.com.cn; lqq188@yahoo.com						American Diabetes Association, 2003, DOCT PAT DIAL MAY HE; Beard E, 2010, PATIENT EDUC COUNS, V80, P227, DOI 10.1016/j.pec.2009.11.008; Beckles GLA, 1998, DIABETES CARE, V21, P1432, DOI 10.2337/diacare.21.9.1432; Cagliero E, 1999, DIABETES CARE, V22, P1785, DOI 10.2337/diacare.22.11.1785; Chapin RB, 2003, J GEN INTERN MED, V18, P120, DOI 10.1046/j.1525-1497.2003.20367.x; Chrvala CA, 2016, PATIENT EDUC COUNS, V99, P926, DOI 10.1016/j.pec.2015.11.003; DUNN SM, 1990, SOC SCI MED, V31, P1135, DOI 10.1016/0277-9536(90)90235-K; Gopalan A, 2014, J GEN INTERN MED, V29, P996, DOI 10.1007/s11606-014-2810-4; Guo XH, 2012, CHINESE MED J-PEKING, V125, P4175, DOI 10.3760/cma.j.issn.0366-6999.2012.23.003; He XW, 2011, CHINESE NURSING MANA, V11, P10; Heisler M, 2005, DIABETES CARE, V28, P816, DOI 10.2337/diacare.28.4.816; Hu QH, 2007, J NURSING, V14, P3; International Diabetes Federatoin, 2013, IDF DIAB ATL, P29; Iqbal N, 2008, ANN CLIN BIOCHEM, V45, P504, DOI 10.1258/acb.2008.008034; Kahn CR, 2005, JOSLINS DIABETES MEL, P587; Lafata JE, 2002, J GEN INTERN MED, V17, P521, DOI 10.1046/j.1525-1497.2002.10901.x; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; Lou QQ, 2011, PATIENT EDUC COUNS, V85, P336, DOI 10.1016/j.pec.2011.01.006; [莫永珍 Mo Yongzhen], 2012, [中华护理杂志, Chinese Journal of Nursing], V47, P141; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; Skeie S, 2001, CLIN CHEM, V47, P1212; Stolar M, 2010, AM J MED, V123, pS3, DOI 10.1016/j.amjmed.2009.12.004; Suzuki-Saito T, 2013, J DIABETES INVEST, V4, P206, DOI 10.1111/jdi.12002; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Wei H., 2008, J SW U NAT, V10, P56; Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118; Zhang Y, 2003, CHINESE J PUBLIC HLT, V19, P888	28	12	12	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150753	10.1371/journal.pone.0150753	http://dx.doi.org/10.1371/journal.pone.0150753			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DG3TF	26959422	Green Published, gold			2023-01-03	WOS:000371992300071
J	Vikmoen, O; Raastad, T; Seynnes, O; Bergstrom, K; Ellefsen, S; Ronnestad, BR				Vikmoen, Olav; Raastad, Truls; Seynnes, Olivier; Bergstrom, Kristoffer; Ellefsen, Stian; Ronnestad, Bent R.			Effects of Heavy Strength Training on Running Performance and Determinants of Running Performance in Female Endurance Athletes	PLOS ONE			English	Article							SKELETAL-MUSCLE ADAPTATIONS; LONG-DISTANCE RUNNERS; WHOLE-BODY VIBRATION; MECHANICAL-PROPERTIES; PATELLAR TENDON; CONCURRENT ENDURANCE; JUMP PERFORMANCE; OXYGEN-UPTAKE; ECONOMY; CYCLISTS	Purpose The purpose of the current study was to investigate the effects of adding strength training to normal endurance training on running performance and running economy in well-trained female athletes. We hypothesized that the added strength training would improve performance and running economy through altered stiffness of the muscle-tendon complex of leg extensors. Methods Nineteen female endurance athletes [maximal oxygen consumption (VO2max): 53 +/- 3 ml.kg(-1).min(-1), 5.8 h weekly endurance training] were randomly assigned to either normal endurance training (E, n = 8) or normal endurance training combined with strength training (E+S, n = 11). The strength training consisted of four leg exercises [3 x 4-10 repetition maximum (RM)], twice a week for 11 weeks. Muscle strength, 40 min all-out running distance, running performance determinants and patellar tendon stiffness were measured before and after the intervention. Results E + S increased 1RM in leg exercises (40 +/- 15%) and maximal jumping height in counter movement jump (6 +/- 6%) and squat jump (9 +/- 7%, p < 0.05). This was accompanied by increased muscle fiber cross sectional area of both fiber type I (13 +/- 7%) and fiber type II (31 +/- 20%) in m. vastus lateralis (p < 0.05), with no change in capillary density in m. vastus lateralis or the stiffness of the patellar tendon. Neither E + S nor E changed running economy, fractional utilization of VO2max or VO2max. There were also no change in running distance during a 40 min all-out running test in neither of the groups. Conclusion Adding heavy strength training to endurance training did not affect 40 min all-out running performance or running economy compared to endurance training only.	[Vikmoen, Olav; Ellefsen, Stian; Ronnestad, Bent R.] Lillehammer Univ Coll, Sect Sport Sci, Lillehammer, Norway; [Raastad, Truls; Seynnes, Olivier; Bergstrom, Kristoffer] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway	Inland Norway University of Applied Sciences; Norwegian School of Sport Sciences	Vikmoen, O (corresponding author), Lillehammer Univ Coll, Sect Sport Sci, Lillehammer, Norway.	olav.vikmoen@hil.no	Raastad, Truls/AFP-1474-2022	Raastad, Truls/0000-0002-2567-3004; Seynnes, Olivier/0000-0002-1289-246X; Ronnestad, Bent/0000-0002-6907-1347	Regional Science Fund-Innlandet of Norway [203961]	Regional Science Fund-Innlandet of Norway	This work was supported by grant 203961 from the Regional Science Fund-Innlandet of Norway. (http://www.regionaleforskningsfond.no/prognett-innlandet/Forside/1253953746925). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aagaard P, 2011, SCAND J MED SCI SPOR, V21, pE298, DOI 10.1111/j.1600-0838.2010.01283.x; Arampatzis A, 2006, J EXP BIOL, V209, P3345, DOI 10.1242/jeb.02340; Barnes KR, 2013, MED SCI SPORT EXER, V45, P2322, DOI 10.1249/MSS.0b013e31829af603; Bassett DR, 2000, MED SCI SPORT EXER, V32, P70, DOI 10.1097/00005768-200001000-00012; Bell GJ, 2000, EUR J APPL PHYSIOL, V81, P418, DOI 10.1007/s004210050063; Bertuzzi R, 2013, INT J SPORTS MED, V34, P917, DOI 10.1055/s-0033-1333748; BRODAL P, 1977, AM J PHYSIOL, V232, pH705, DOI 10.1152/ajpheart.1977.232.6.H705; COSTILL DL, 1976, MED SCI SPORT EXER, V8, P96; Damasceno MV, 2015, EUR J APPL PHYSIOL, V115, P1513, DOI 10.1007/s00421-015-3130-z; Ferrauti A, 2010, J STRENGTH COND RES, V24, P2770, DOI 10.1519/JSC.0b013e3181d64e9c; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Francesca PM, 2012, J STRENGTH COND RES, DOI [10.1519/JSC.0b013e3182794485, DOI 10.1519/JSC.0B013E3182794485]; Guglielmo LGA, 2009, INT J SPORTS MED, V30, P27, DOI 10.1055/s-2008-1038792; HATHER BM, 1991, ACTA PHYSIOL SCAND, V143, P177, DOI 10.1111/j.1748-1716.1991.tb09219.x; Helland C, 2013, BRIT J SPORT MED, V47, P862, DOI 10.1136/bjsports-2013-092275; Hickson RC, 1988, APPL PHYSL, V65, P2285; Hill DW, 1996, MED SCI SPORT EXER, V28, P114, DOI 10.1097/00005768-199601000-00022; Hoff J, 2003, FOOTBALL SOCCER NEW, P37; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; INGJER F, 1978, EUR J APPL PHYSIOL O, V38, P291, DOI 10.1007/BF00423112; Jeukendrup A E, 2000, J Sci Med Sport, V3, P414, DOI 10.1016/S1440-2440(00)80008-0; Johnston RE, 1997, J STRENGTH COND RES, V11, P224; Kelly CM, 2008, J STRENGTH COND RES, V22, P396, DOI 10.1519/JSC.0b013e318163534a; Kongsgaard M, 2007, ACTA PHYSIOL, V191, P111, DOI 10.1111/j.1748-1716.2007.01714.x; KRAEMER WJ, 1995, J APPL PHYSIOL, V78, P976, DOI 10.1152/jappl.1995.78.3.976; Kubo K, 2006, J APPL BIOMECH, V22, P112, DOI 10.1123/jab.22.2.112; Kubo K, 2006, EUR J APPL PHYSIOL, V96, P305, DOI 10.1007/s00421-005-0087-3; Kubo K, 2001, J APPL PHYSIOL, V91, P26, DOI 10.1152/jappl.2001.91.1.26; Magnusson SP, 2007, INT J EXP PATHOL, V88, P237, DOI 10.1111/j.1365-2613.2007.00551.x; Mikkola J, 2007, INT J SPORTS MED, V28, P602, DOI 10.1055/s-2007-964849; Millet GP, 2002, MED SCI SPORT EXER, V34, P1351, DOI 10.1097/00005768-200208000-00018; Noakes TD, 1990, J SPORT SCI, V8, P35, DOI 10.1080/02640419008732129; Paavolainen L, 1999, J APPL PHYSIOL, V86, P1527; Reeves ND, 2003, J PHYSIOL-LONDON, V548, P971, DOI 10.1113/jphysiol.2002.035576; Roberts TJ, 2011, J EXP BIOL, V214, P353, DOI 10.1242/jeb.038588; Ronnestad BR, 2010, EUR J APPL PHYSIOL, V110, P1269, DOI 10.1007/s00421-010-1622-4; Ronnestad BR, 2010, EUR J APPL PHYSIOL, V108, P965, DOI 10.1007/s00421-009-1307-z; Ronnestad BR, 2008, J STRENGTH COND RES, V22, P773, DOI 10.1519/JSC.0b013e31816a5e86; Roschel H, 2015, J STRENGTH COND RES, V29, P2215, DOI 10.1519/JSC.0000000000000857; Saunders PU, 2006, J STRENGTH COND RES, V20, P947; Sedano S, 2013, J STRENGTH COND RES, V27, P2433, DOI 10.1519/JSC.0b013e318280cc26; Seynnes OR, 2009, J APPL PHYSIOL, V107, P523, DOI 10.1152/japplphysiol.00213.2009; SJOGAARD G, 1984, INT J SPORTS MED, V5, P250, DOI 10.1055/s-2008-1025915; Spurrs RW, 2003, EUR J APPL PHYSIOL, V89, P1, DOI 10.1007/s00421-002-0741-y; Taipale RS, 2010, INT J SPORTS MED, V31, P468, DOI 10.1055/s-0029-1243639; Tricoli V, 2005, J STRENGTH COND RES, V19, P433; Vikmoen O, 2016, SCAND J MED SCI SPOR, V26, P384, DOI 10.1111/sms.12468; WILSON GJ, 1993, MED SCI SPORT EXER, V25, P1279	49	27	29	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0150799	10.1371/journal.pone.0150799	http://dx.doi.org/10.1371/journal.pone.0150799			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26953893	Green Published, Green Submitted, gold			2023-01-03	WOS:000371991300051
J	Gulland, A				Gulland, Anne			Seven day services: how are trusts doing against Keogh's clinical standards?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												agulland@bmj.com						*AC MED ROY COLL, 2012, 7 DAY CONS PRES CAR; *NHS ENGL, 2013, NHS SERV 7 DAYS WEEK	2	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 1	2016	352								i1258	10.1136/bmj.i1258	http://dx.doi.org/10.1136/bmj.i1258			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG0LJ	26931479				2023-01-03	WOS:000371756000013
J	Carroll, R; Metcalfe, C; Steeg, S; Davies, NM; Cooper, J; Kapur, N; Gunnell, D				Carroll, Robert; Metcalfe, Chris; Steeg, Sarah; Davies, Neil M.; Cooper, Jayne; Kapur, Nav; Gunnell, David			Psychosocial Assessment of Self-Harm Patients and Risk of Repeat Presentation: An Instrumental Variable Analysis Using Time of Hospital Presentation	PLOS ONE			English	Article							BIAS	Background Clinical guidelines have recommended psychosocial assessment of self-harm patients for years, yet estimates of its impact on the risk of repeat self-harm vary. Assessing the association of psychosocial assessment with risk of repeat self-harm is challenging due to the effects of confounding by indication. Methods We analysed data from a cohort study of 15,113 patients presenting to the emergency departments of three UK hospitals to investigate the association of psychosocial assessment with risk of repeat hospital presentation for self-harm. Time of day of hospital presentation was used as an instrument for psychosocial assessment, attempting to control for confounding by indication. Results Conventional regression analysis suggested psychosocial assessment was not associated with risk of repeat self-harm within 12 months (Risk Difference (RD) 0.00 95% confidence interval (95% CI) -0.01 to 0.02). In contrast, IV analysis suggested risk of repeat self-harm was reduced by 18% (RD -0.18, 95% CI -0.32 to -0.03) in those patients receiving a psychosocial assessment. However, the instrument of time of day did not remove all potential effects of confounding by indication, suggesting the IV effect estimate may be biased. Conclusions We found that psychosocial assessments reduce risk of repeat self-harm. This is in-line with other non-randomised studies based on populations in which allocation to assessment was less subject to confounding by indication. However, as our instrument did not fully balance important confounders across time of day, the IV effect estimate should be interpreted with caution.	[Carroll, Robert; Metcalfe, Chris; Davies, Neil M.; Gunnell, David] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Steeg, Sarah; Cooper, Jayne; Kapur, Nav] Univ Manchester, Ctr Suicide Prevent, Manchester, Lancs, England; [Kapur, Nav] Manchester Mental Hlth & Social Care Trust, Manchester, Lancs, England; [Davies, Neil M.] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol, Avon, England; [Gunnell, David] Univ Hosp Bristol NHS Fdn Trust, Natl Inst Hlth Res Collaborat Leadership Appl Hlt, Bristol, Avon, England	University of Bristol; University of Manchester; Open University - UK; University of Bristol; University of Bristol	Metcalfe, C (corresponding author), Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.	Chris.Metcalfe@Bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Kapur, Nav/0000-0002-3100-3234; Metcalfe, Chris/0000-0001-8318-8907; Davies, Neil/0000-0002-2460-0508; Steeg, Sarah/0000-0002-7935-1414	Department of Health (England) as part of the Multi-Centre Study of Self-harm; Manchester Mental Health and Social Care Trust; NIHR; Medical Research Council; University of Bristol [MC_UU_12013/9]; Economics and Social Research Council (ESRC) [ES/N000757/1]; MRC [MC_UU_12013/9, MC_UU_12013/1] Funding Source: UKRI; Medical Research Council [MC_UU_12013/1, MC_UU_12013/9] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10068, DRF-2012-05-189] Funding Source: researchfish	Department of Health (England) as part of the Multi-Centre Study of Self-harm; Manchester Mental Health and Social Care Trust; NIHR(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Bristol; Economics and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The MASH Project is funded by the Department of Health (England) as part of the Multi-Centre Study of Self-harm. NK is supported by Manchester Mental Health and Social Care Trust. RC was funded by a NIHR doctoral research fellowship. DG's time is supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West). The Integrative Epidemiology Unit is supported by the Medical Research Council and the University of Bristol [MC_UU_12013/9]. NMD is supported by the Economics and Social Research Council (ESRC) via a Future Research Leaders Fellowship (ES/N000757/1). The funders had no role in study design, the collection, analysis and interpretation of data, the writing of the report, and the decision to submit the paper for publication. The views and opinions expressed within this paper are those of the authors and do not necessarily reflect those of the NIHR, MRC, ESRC or the Department of Health.	Bennewith O, 2005, J AFFECT DISORDERS, V89, P91, DOI 10.1016/j.jad.2005.08.011; Bergen H, 2010, BRIT J PSYCHIAT, V197, P493, DOI 10.1192/bjp.bp.110.077651; Bickley H, 2013, MANCHEST SELF HARM P; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Brookhart M Alan, 2007, Int J Biostat, V3, P14; Burgess S, 2011, INT J EPIDEMIOL, V40, P755, DOI 10.1093/ije/dyr036; Cheung YB, 2007, AM J EPIDEMIOL, V166, P1337, DOI 10.1093/aje/kwm223; Clarke PS, 2012, J AM STAT ASSOC, V107, P1638, DOI 10.1080/01621459.2012.734171; Clarke PS, 2010, BIOSTATISTICS, V11, P756, DOI 10.1093/biostatistics/kxq024; Cooper J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003444; Davies NM, 2013, J CLIN EPIDEMIOL, V66, P1386, DOI 10.1016/j.jclinepi.2013.06.008; Greenland S, 2000, INT J EPIDEMIOL, V29, P1102, DOI 10.1093/oxfordjournals.ije.a019909; HAUSMAN JA, 1978, ECONOMETRICA, V46, P1251, DOI 10.2307/1913827; Hawton K, 2015, J AFFECT DISORDERS, V175, P147, DOI 10.1016/j.jad.2014.12.062; Ho V, 2000, HEALTH SERV RES, V34, P1499; Kapur N, 2005, BMJ-BRIT MED J, V330, P394, DOI 10.1136/bmj.38337.584225.82; Kapur N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070434; Kapur N, 2008, J AFFECT DISORDERS, V106, P285, DOI 10.1016/j.jad.2007.07.010; Larkin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084282; National Institute for Clinical Excellence, 2004, SELF HARM SHORT TERM; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17; O'Donnell HC, 2014, ACAD PEDIATR, V14, P84, DOI 10.1016/j.acap.2013.09.010; Royal College of Psychiatrists, 2004, ASS FOLL SELF HARM A; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934	26	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0149713	10.1371/journal.pone.0149713	http://dx.doi.org/10.1371/journal.pone.0149713			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3UU	26918579	Green Published, gold, Green Submitted			2023-01-03	WOS:000371274400039
J	Saleem, Z; Saeed, H; Ahmad, M; Yousaf, M; Hassan, HB; Javed, A; Anees, N; Maharjan, S				Saleem, Zikria; Saeed, Hamid; Ahmad, Mobasher; Yousaf, Mahrukh; Hassan, Hafsa Binte; Javed, Ayesha; Anees, Nida; Maharjan, Sonu			Antibiotic Self-Prescribing Trends, Experiences and Attitudes in Upper Respiratory Tract Infection among Pharmacy and Non-Pharmacy Students: A Study from Lahore	PLOS ONE			English	Article							NONMEDICAL UNIVERSITY-STUDENTS; MEDICAL-STUDENTS; PHYSICIANS; COUNTRIES; KARACHI; CARE	Pharmacists are the custodians of drugs; hence their education, training, behaviors and experiences would affect the future use of drugs at community and hospital pharmacies. Therefore, we aimed at evaluating the self-prescribing antibiotic trends, knowledge and attitudes among pharmacy and non-pharmacy students. We found that pharmacy students had higher risks of experiencing URIs related symptoms such as cough (RR; 1.7, p = 0.002), allergy (RR; 2.07, p = 0.03) and running nose (RR; 3.17, p<0.005), compared to non-pharmacy students-resulting in higher probabilities of selecting cough syrups (OR; 2.3, p<0.005), anti-histamines (OR; 1.8, p = 0.036) and anti-inflammatory/anti-pyretic (OR; 2.4, p<0.005) drugs. Likewise, bachelor's degree pupils (OR; 2, p = 0.045), urban area residents (OR; 2.44; p = 0.002) and pharmacy students (OR; 2.9, p<0.005) exhibited higher propensities of antibiotic self-use-notable classes include, b-lactams (45.9%) followed by macrolides (26.5%) and augmentin (28.94%), respectively. Surprisingly, pharmacy and non-pharmacy students had higher odds of using antibiotics in common cold (OR; 3.2, p<0.005) and pain (OR; 2.37, p = 0.015), respectively. Unlike non-pharmacy students, pharmacy students were likely to select alternative therapy, such as Joshanda (OR; 2.22, p = 0.011) and were well acquainted with antibiotic hazards, with 77% reduction in risk of antibiotics re-use. In conclusion, university students exhibited antibiotic self-prescribing trends in conditions that does not warrant their use, thus are irrational users. The pharmacy education confers very little benefit to rational self-prescribing practices among students, while non-pharmacy students are more vulnerable to repeated antibiotic usage. Thus, the educational and training modules should be designed for university students to disseminate targeted information regarding the potential hazards of antibiotic self-use and importance of consultation with qualified and registered medical doctor/pharmacist before starting with antibiotics.	[Saleem, Zikria; Saeed, Hamid; Ahmad, Mobasher; Yousaf, Mahrukh; Hassan, Hafsa Binte; Javed, Ayesha; Anees, Nida; Maharjan, Sonu] Univ Punjab, Clin Pharm Sect, Univ Coll Pharm, AllamaIqbal Campus, Lahore 54000, Pakistan	University of Punjab	Saeed, H (corresponding author), Univ Punjab, Clin Pharm Sect, Univ Coll Pharm, AllamaIqbal Campus, Lahore 54000, Pakistan.	hamid.pharmacy@pu.edu.pk	Saleem, Zikria/AAB-5786-2022	Saleem, Zikria/0000-0003-3202-6347				Abay SM, 2010, J YOUNG PHARM, V2, P306, DOI 10.4103/0975-1483.66798; Aljinovic-Vucic V, 2005, CROAT MED J, V46, P74; Appelbaum P, 1977, LANCET, V310, P995; Ashraf S, 2010, J PAK MED ASSOC, V60, P1015; Balbisi EA, 2005, AM J HEALTH-SYST PH, V62, P2508, DOI 10.2146/ajhp050007; Barden LS, 1998, CLIN PEDIATR, V37, P665, DOI 10.1177/000992289803701104; Benson V, 1994, VITAL HLTH STAT, V189, P1; Burak LJ, 2000, J AM COLL HEALTH, V49, P118, DOI 10.1080/07448480009596293; Choudhry AJ, 1997, MOTHER CHILD, V35, P84; Dabney D A, 2001, J Am Pharm Assoc (Wash), V41, P392; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Grimsmo A, 2001, SCAND J PRIM HEALTH, V19, P76; Gulliford M, 2009, J PUBLIC HEALTH-UK, V31, P512, DOI 10.1093/pubmed/fdp081; Hem E, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-16; James H, 2008, INT J CLIN PHARM TH, V46, P23; Jaruseviciene L, 2013, UPSALA J MED SCI, V118, P98, DOI 10.3109/03009734.2013.778925; Kafle K, 1993, SELF MEDICATION ITS; Mainous AG, 1998, ARCH FAM MED, V7, P45, DOI 10.1001/archfami.7.1.45; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; Mumtaz Y, 2011, J LIAQUAT UNIV MED H, V10, P102; Nalini G. K., 2010, British Journal of Medical Practitioners, V3, P325; Napolitano F, 2013, PUBLIC KNOWLEDGE ATT; Pandya RN, 2013, INT J BASIC CLINPHAR, V2, P275; Sawalha AF, 2008, RES SOC ADMIN PHARM, V4, P164, DOI 10.1016/j.sapharm.2007.04.004; Shah SJ, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-74; Sharif SI, 2012, AM J PHARMACOLTOXICO, V7, P135, DOI DOI 10.3844/AJPTSP.2012.135.140; Tomasi Elaine, 2007, Rev. bras. epidemiol., V10, P66; TOMSON G, 1986, LANCET, V2, P620; Van der Linden MW, 2004, 2 NATL STUDY DIS ACT; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609; Yamada K, 2015, PHARMACOTHERAPY, V5, P4; Zafar Syed Nabeel, 2008, J Pak Med Assoc, V58, P214; Zafar SN, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-162	34	30	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0149929	10.1371/journal.pone.0149929	http://dx.doi.org/10.1371/journal.pone.0149929			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3UU	26919465	Green Published, gold			2023-01-03	WOS:000371274400058
J	Bate, J; Schuman, A				Bate, Jonathan; Schuman, Andrew			Books do furnish a mind: the art and science of bibliotherapy	LANCET			English	Editorial Material									[Bate, Jonathan] Univ Oxford Worcester Coll, Oxford OX1 2HB, England; [Schuman, Andrew] Dr Kenyon & Partners, Oxford OX1 2NA, England	University of Oxford	Bate, J (corresponding author), Univ Oxford Worcester Coll, Oxford OX1 2HB, England.	provost@worc.ox.ac.uk	Bate, Jonathan/E-5181-2019	Bate, Jonathan/0000-0002-3894-8580				Cornett CE, 1980, ATLANTIC MONTHLY; Crothers Samuel McChord, 1916, ATLANTIC MONTHLY, P291; Jack SJ, 2008, SCHOOL PSYCHOL INT, V29, P161, DOI 10.1177/0143034308090058; Kelly R., 2014, BLACK RAINBOW WORDS; Latchem JM, 2014, AGING MENT HEALTH, V18, P731, DOI 10.1080/13607863.2013.875125	5	8	8	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	2016	387	10020					742	743		10.1016/S0140-6736(16)00337-8	http://dx.doi.org/10.1016/S0140-6736(16)00337-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DE1WU	26913308				2023-01-03	WOS:000370418000019
J	Hennegan, J; Montgomery, P				Hennegan, Julie; Montgomery, Paul			Do Menstrual Hygiene Management Interventions Improve Education and Psychosocial Outcomes for Women and Girls in Low and Middle Income Countries? A Systematic Review	PLOS ONE			English	Review							ADOLESCENT GIRLS; EXPERIENCES; HEALTH; SCHOOLGIRLS; SANITATION; PUBERTY; AGE	Background Unhygienic and ineffective menstrual hygiene management has been documented across low resource contexts and linked to negative consequences for women and girls. Objectives To summarise and critically appraise evidence for the effectiveness of menstruation management interventions in improving women and girls' education, work and psychosocial wellbeing in low and middle income countries. Methods Structured systematic searches were conducted in peer-reviewed and grey literature to identify studies evaluating education and resource provision interventions for menstruation management. Individual and cluster randomised controlled trials were eligible for inclusion, as were non-randomised controlled trials. Study characteristics, outcomes and risk of bias were extracted using a piloted form. Risk of bias was independently assessed by two researchers. Results Eight studies described in ten citations were eligible for inclusion. Studies were highly heterogeneous in design and context. Six included assessment of education-only interventions, and three provided assessment of the provision of different types of sanitary products (menstrual cups, disposable sanitary pads, and reusable sanitary pads). A moderate but non-significant standardised mean difference was found for the two studies assessing the impact of sanitary pad provision on school attendance: 0.49 (95% CI -0.13, 1.11). Included studies were heterogeneous with considerable risk of bias. Trials of education interventions reported positive impacts on menstrual knowledge and practices, however, many studies failed to assess other relevant outcomes. No trials assessed or reported harms. Conclusions There is insufficient evidence to establish the effectiveness of menstruation management interventions, although current results are promising. Eight trials have been conducted, but a high risk of bias was found and clinical heterogeneity precluded synthesis of most results. Whilst trials provided some indication of positive results, further research is needed to establish the role of menstruation hygiene management in education performance, employment and other psychosocial outcomes. This review provides a concise summary of present trials and highlights improvements for future work.	[Hennegan, Julie; Montgomery, Paul] Univ Oxford, Ctr Evidence Based Intervent, Oxford, England	University of Oxford	Hennegan, J (corresponding author), Univ Oxford, Ctr Evidence Based Intervent, Oxford, England.	julie.hennegan@spi.ox.ac.uk		Montgomery, Paul/0000-0001-8008-1370; Hennegan, Julie/0000-0003-2011-1595	Department of Social Policy & Intervention Centenary Scholarship; Fellowships Fund Inc. of Graduate Women Queensland; Green Templeton College Rosemary Stewart Scholarship; ESRC [ES/I034145/2] Funding Source: UKRI; Economic and Social Research Council [ES/I034145/2] Funding Source: researchfish	Department of Social Policy & Intervention Centenary Scholarship; Fellowships Fund Inc. of Graduate Women Queensland; Green Templeton College Rosemary Stewart Scholarship; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	JH's PhD is supported by a Department of Social Policy & Intervention Centenary Scholarship, a fellowship from the Fellowships Fund Inc. of Graduate Women Queensland and Green Templeton College Rosemary Stewart Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedian Z, 2011, J AM SCI, V7, P1; Abrahams N, 2006, TROP MED INT HEALTH, V11, P751, DOI 10.1111/j.1365-3156.2006.01600.x; Adams J, 2009, WATER SANITATION HYG; Adinma ED, 2009, AFR J REPROD HEALTH, V12, P74; Ali TS, 2010, J ADOLESCENCE, V33, P531, DOI 10.1016/j.adolescence.2009.05.013; Anderson SE, 2003, PEDIATRICS, V111, P844, DOI 10.1542/peds.111.4.844; Avasarala Atchuta Kameswararao, 2008, Indian J Community Med, V33, P246, DOI 10.4103/0970-0218.43231; Birdthistle I., 2011, WHAT IMPACT DOES PRO; BROOKSGUNN J, 1980, PSYCHOSOM MED, V42, P503, DOI 10.1097/00006842-198009000-00005; Business for Social Responsibility (BSR), 2012, HERPROJECT INV WOM B; Business for Social Responsibility (BSR), 2011, HERPROJECT HLTH EN R; Chothe V, 2014, HEALTH PROMOT PRACT, V15, P319, DOI 10.1177/1524839914525175; Crichton J, 2013, HEALTH CARE WOMEN IN, V34, P891, DOI 10.1080/07399332.2012.740112; Crofts T, 2012, J WATER SANIT HYG DE, V2, P50, DOI 10.2166/washdev.2012.067; Das P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130777; Dasgupta A, 2008, Indian J Community Med, V33, P77, DOI 10.4103/0970-0218.40872; Deo D. S., 2005, INDIAN J COMMUNITY M, V30, P33; Djalalinia S, 2012, INT J PREVENTIVE MED, V3, P622; Dolan CS, 2014, J INT DEV, V26, P643, DOI 10.1002/jid.2917; Effective Practice and Organisation of Care (EPOC) EPaOoC, 2013, EPOC RES REV AUTH; El-Gilany AH, 2005, REPROD HEALTH MATTER, V13, P147, DOI 10.1016/S0968-8080(05)26191-8; Fakhri M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-193; Fetohy Ebtisam M, 2007, J Egypt Public Health Assoc, V82, P105; Fisher Julie, 2006, WATER SANITATION HYG; Garg R, 2012, MATERN CHILD HLTH J, V16, P767, DOI 10.1007/s10995-011-0798-5; Grant M, 2013, COMP EDUC REV, V57, P260, DOI 10.1086/669121; Haver J, 2013, WASH IN SCHOOLS EMPO; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; House S., 2012, MENSTRUAL HYGIENE MA; Inter-agency Task Force on Gender and Water (GWTF), 2006, GEND WAT SAN POL BRI; Jasper C, 2012, INT J ENV RES PUB HE, V9, P2772, DOI 10.3390/ijerph9082772; Khanna A, 2005, J HEALTH MANAG, V7, P91, DOI 10.1177/097206340400700103; Kirk J., 2006, MENSTRUATION BODY AW, P1; Kumar A, 2011, SOC WORK PUBLIC HLTH, V26, P594, DOI 10.1080/19371918.2010.525144; Lloyd C. B., 2009, NEW LESSONS POWER ED; Mahon T., 2010, Gender and Development, V18, P99, DOI 10.1080/13552071003600083; Mbizvo MT, 1997, SOC SCI MED, V44, P573, DOI 10.1016/S0277-9536(96)00204-3; McMahon SA, 2011, BMC INT HEALTH HUM R, V11, DOI 10.1186/1472-698X-11-7; Ministry of Health & Family Welfare Government of India, 2012, 2 YEAR 2009 2011 ACH; Mmari K, 2015, AMERICAN JOURNAL OF, pe1; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Montgomery P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048274; Oster E, 2011, AM ECON J-APPL ECON, V3, P91, DOI 10.1257/app.3.1.91; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Pillitteri S.P., 2011, SCH MENSTRUAL HYGIEN; RevMan, 2012, REV MAN REVMAN COMP; Santina T, 2012, E MEDITERR HEALTH J, V18, P1; Sommer M., 2011, International Electronic Journal of Health Education, V14, P77; Sommer M, 2015, COMPARE, V45, P589, DOI 10.1080/03057925.2013.871399; Sommer M, 2013, AM J PUBLIC HEALTH, V103, P1556, DOI 10.2105/AJPH.2013.301374; Sommer M, 2010, J ADOLESCENCE, V33, P521, DOI 10.1016/j.adolescence.2009.03.008; Sommer M, 2009, CULT HEALTH SEX, V11, P383, DOI 10.1080/13691050902722372; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Tavallaee M, 2011, J OBSTET GYNAECOL RE, V37, P442, DOI 10.1111/j.1447-0756.2010.01362.x; Wilson EF, 2012, RES REPORT SCHARR RE, V27; Wilson E, 2014, DEV PRACT, V24, P63, DOI 10.1080/09614524.2014.867305; World Bank, 2014, COUNTR LEND GROUPS D	57	94	97	1	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0146985	10.1371/journal.pone.0146985	http://dx.doi.org/10.1371/journal.pone.0146985			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6PR	26862750	Green Published, gold			2023-01-03	WOS:000370046600016
J	Ibitoye, MO; Hamzaid, NA; Hasnan, N; Wahab, AKA; Davis, GM				Ibitoye, Morufu Olusola; Hamzaid, Nur Azah; Hasnan, Nazirah; Wahab, Ahmad Khairi Abdul; Davis, Glen M.			Strategies for Rapid Muscle Fatigue Reduction during FES Exercise in Individuals with Spinal Cord Injury: A Systematic Review	PLOS ONE			English	Review							FUNCTIONAL ELECTRICAL-STIMULATION; FEEDBACK-CONTROLLED STIMULATION; SKELETAL-MUSCLE; THENAR MUSCLES; CONTRACTILE PROPERTIES; PARALYZED QUADRICEPS; RANDOM MODULATION; FORCE; FREQUENCY; PATTERN	Background Rapid muscle fatigue during functional electrical stimulation (FES)-evoked muscle contractions in individuals with spinal cord injury (SCI) is a significant limitation to attaining health benefits of FES-exercise. Delaying the onset of muscle fatigue is often cited as an important goal linked to FES clinical efficacy. Although the basic concept of fatigue-resistance has a long history, recent advances in biomedical engineering, physiotherapy and clinical exercise science have achieved improved clinical benefits, especially for reducing muscle fatigue during FES-exercise. This review evaluated the methodological quality of strategies underlying muscle fatigue-resistance that have been used to optimize FES therapeutic approaches. The review also sought to synthesize the effectiveness of these strategies for persons with SCI in order to establish their functional impacts and clinical relevance. Methods Published scientific literature pertaining to the reduction of FES-induced muscle fatigue was identified through searches of the following databases: Science Direct, Medline, IEEE Xplore, SpringerLink, PubMed and Nature, from the earliest returned record until June 2015. Titles and abstracts were screened to obtain 35 studies that met the inclusion criteria for this systematic review. Results Following the evaluation of methodological quality (mean (SD), 50 (6) %) of the reviewed studies using the Downs and Black scale, the largest treatment effects reported to reduce muscle fatigue mainly investigated isometric contractions of limited functional and clinical relevance (n = 28). Some investigations (n = 13) lacked randomisation, while others were characterised by small sample sizes with low statistical power. Nevertheless, the clinical significance of emerging trends to improve fatigue-resistance during FES included (i) optimizing electrode positioning, (ii) fine-tuning of stimulation patterns and other FES parameters, (iii) adjustments to the mode and frequency of exercise training, and (iv) biofeedback-assisted FES-exercise to promote selective recruitment of fatigue-resistant motor units. Conclusion Although the need for further in-depth clinical trials (especially RCTs) was clearly warranted to establish external validity of outcomes, current evidence was sufficient to support the validity of certain techniques for rapid fatigue-reduction in order to promote FES therapy as an integral part of SCI rehabilitation. It is anticipated that this information will be valuable to clinicians and other allied health professionals administering FES as a treatment option in rehabilitation and aid the development of effective rehabilitation interventions.	[Ibitoye, Morufu Olusola; Hamzaid, Nur Azah; Wahab, Ahmad Khairi Abdul; Davis, Glen M.] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur, Malaysia; [Ibitoye, Morufu Olusola] Univ Ilorin, Fac Engn & Technol, Dept Biomed Engn, Ilorin, Nigeria; [Hasnan, Nazirah] Univ Malaya, Fac Med, Dept Rehabil Med, Kuala Lumpur, Malaysia; [Davis, Glen M.] Univ Sydney, Discipline Exercise & Sport Sci, Sci Fac Hlth Sci, Clin Exercise & Rehabil Unit, Sydney, NSW 2006, Australia	Universiti Malaya; University of Ilorin; Universiti Malaya; University of Sydney	Hamzaid, NA (corresponding author), Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur, Malaysia.	azah.hamzaid@um.edu.my	Ibitoye, Morufu Olusola/G-2021-2014; Hamzaid, Nur Azah/AAH-4122-2020; HAMZAID, NUR AZAH/B-9417-2010; Hasnan, Nazirah/M-5081-2017; Abdul Wahab, Assoc. Prof. Ir. Dr. Ahmad Khairi/B-8162-2010; HASNAN, NAZIRAH/B-9217-2010	Ibitoye, Morufu Olusola/0000-0001-8927-0653; Hamzaid, Nur Azah/0000-0002-4277-2813; HAMZAID, NUR AZAH/0000-0002-4277-2813; Hasnan, Nazirah/0000-0002-5775-428X; Abdul Wahab, Assoc. Prof. Ir. Dr. Ahmad Khairi/0000-0001-5900-8718; HASNAN, NAZIRAH/0000-0002-5775-428X	Ministry of Higher Education, Malaysia [UM.C/625/1/HIR/MOHE/ENG/39]	Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia)	This review was financially supported by the Ministry of Higher Education, Malaysia, hir.um.edu.my, under the grant number: UM.C/625/1/HIR/MOHE/ENG/39. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ama del- AJ, 2013, J AUTOM CONTROL, V21, P19, DOI DOI 10.2298/JAC1301019A; Bickel CS, 2011, EUR J APPL PHYSIOL, V111, P2399, DOI 10.1007/s00421-011-2128-4; Bickel CS, 2004, J REHABIL RES DEV, V41, P33, DOI 10.1682/JRRD.2004.01.0033; BINDERMACLEOD SA, 1993, PHYS THER, V73, P902, DOI 10.1093/ptj/73.12.902; Burnham R, 1997, SPINAL CORD, V35, P86, DOI 10.1038/sj.sc.3100364; Butler JE, 2004, MUSCLE NERVE, V29, P575, DOI 10.1002/mus.20002; Castro MJ, 1999, EUR J APPL PHYSIOL, V80, P373, DOI 10.1007/s004210050606; Chang YJ, 2011, NEUROREHAB NEURAL RE, V25, P423, DOI 10.1177/1545968310390224; Chou LW, 2008, ARCH PHYS MED REHAB, V89, P856, DOI 10.1016/j.apmr.2007.10.027; Chudyk AM, 2009, ARCH PHYS MED REHAB, V90, P246, DOI 10.1016/j.apmr.2008.06.036; Collins DF, 2007, EXERC SPORT SCI REV, V35, P102; Crameri RM, 2002, SCAND J MED SCI SPOR, V12, P316, DOI 10.1034/j.1600-0838.2002.20106.x; Decker MJ, 2010, J ELECTROMYOGR KINES, V20, P1163, DOI 10.1016/j.jelekin.2010.07.015; Deeks J J, 2003, Health Technol Assess, V7, piii; Deley G, 2015, MUSCLE NERVE, V52, P260, DOI 10.1002/mus.24530; Doucet Barbara M., 2012, Yale Journal of Biology and Medicine, V85, P201; Downey RJ, 2014, COMP INDUCED MUSCLE, DOI [10.1109/TNSRE.2014.2364735, DOI 10.1109/TNSRE.2014.2364735]; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Dudley-Javoroski S, 2011, ARCH PHYS MED REHAB, V92, P242, DOI 10.1016/j.apmr.2010.10.031; Eser PC, 2003, IEEE T NEUR SYS REH, V11, P236, DOI 10.1109/TNSRE.2003.817677; Finsterer J, 2013, AM J HOSP PALLIAT ME, P1; Fornusek C, 2004, J REHABIL MED, V36, P232, DOI 10.1080/16501970410029843; Fornusek C, 2014, SPINAL CORD, V52, P635, DOI 10.1038/sc.2014.85; Fouad K, 2012, EXP NEUROL, V235, P91, DOI 10.1016/j.expneurol.2011.02.009; Gerrits HL, 2002, MUSCLE NERVE, V25, P559, DOI 10.1002/mus.10071; Gerrits HL, 2000, SPINAL CORD, V38, P214, DOI 10.1038/sj.sc.3100974; Gobbo M, 2006, EUR J APPL PHYSIOL, V97, P9, DOI 10.1007/s00421-006-0134-8; Gobbo M, 2011, EUR J APPL PHYSIOL, V111, P2451, DOI 10.1007/s00421-011-2047-4; Gobbo M, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-17; Godfrey S, 2002, MUSCLE NERVE, V26, P122, DOI 10.1002/mus.10173; Gorgey AS, 2007, SPINAL CORD, V45, P304, DOI 10.1038/sj.sc.3101968; Gorgey AS, 2015, J SPINAL CORD MED, V0; Gorgey AS, 2014, J REHABIL RES DEV, V51, P1455, DOI 10.1682/JRRD.2014.02.0054; Graham GM, 2006, IEEE T NEUR SYS REH, V14, P38, DOI 10.1109/TNSRE.2006.870490; Graupe D, 2000, NEUROL RES, V22, P703; Griffin L, 2002, J NEUROPHYSIOL, V87, P2271, DOI 10.1152/jn.2002.87.5.2271; Hamzaid NA, 2009, TOP SPINAL CORD INJ, V14, P88; Hartkopp A, 2003, MUSCLE NERVE, V27, P72, DOI 10.1002/mus.10290; Hatsopoulos NG, 2009, ANNU REV NEUROSCI, V32, P249, DOI 10.1146/annurev.neuro.051508.135241; Hillegass EA, 1999, SPINAL CORD, V37, P251, DOI 10.1038/sj.sc.3100792; Hunter S, 1998, J GERONTOL A-BIOL, V53, pB204, DOI 10.1093/gerona/53A.3.B204; Ibitoye MO, 2014, SENSORS-BASEL, V14, P12598, DOI 10.3390/s140712598; Jacobs PL, 2002, ARCH PHYS MED REHAB, V83, P19, DOI 10.1053/apmr.2002.26829; Jaime RP, 2002, IEEE T NEUR SYS REH, V10, P239, DOI 10.1109/TNSRE.2002.806830; KARU ZZ, 1995, IEEE T BIO-MED ENG, V42, P809, DOI 10.1109/10.398642; Kebaetse MB, 2005, ARCH PHYS MED REHAB, V86, P2157, DOI 10.1016/j.apmr.2005.06.011; Kluger BM, 2013, NEUROLOGY, V80, P409, DOI 10.1212/WNL.0b013e31827f07be; Maffiuletti NA, 2014, EUR J APPL PHYSIOL, V114, P1197, DOI 10.1007/s00421-014-2849-2; Maffiuletti NA, 2010, EUR J APPL PHYSIOL, V110, P223, DOI 10.1007/s00421-010-1502-y; Mahoney E, 2007, J SPINAL CORD MED, V30, P458, DOI 10.1080/10790268.2007.11753510; Malesevic NM, 2010, MUSCLE NERVE, V42, P556, DOI 10.1002/mus.21736; Mizrahi J., 1997, CRITICAL REV PHYSICA, V9, P93; Mohr T, 1997, SPINAL CORD, V35, P1, DOI 10.1038/sj.sc.3100343; Nash MS, 2007, ARCH PHYS MED REHAB, V88, P228, DOI 10.1016/j.apmr.2006.11.012; Nguyen R, 2011, ARTIF ORGANS, V35, P1174, DOI 10.1111/j.1525-1594.2010.01195.x; Ojha HA, 2014, PHYS THER, V94, P14, DOI 10.2522/ptj.20130096; Opperman EA, 2010, SPINAL CORD, V48, P60, DOI 10.1038/sc.2009.86; PECKHAM PH, 1976, CLIN ORTHOP RELAT R, P326; Pelletier CA., 2013, CRITICAL REV PHYS RE, V25, P143, DOI [10.1615/CritRevPhysRehabilMed.2013008225, DOI 10.1615/CRITREVPHYSREHABILMED.2013008225]; Pelletier Chelsea A., 2009, Critical Reviews in Biomedical Engineering, V37, P139, DOI 10.1615/CritRevBiomedEng.v37.i1-2.40; Popovic LZ, 2009, IEEE ENG MED BIO, P6785, DOI 10.1109/IEMBS.2009.5333983; Ragnarsson KT, 2008, SPINAL CORD, V46, P255, DOI 10.1038/sj.sc.3102091; ROUND JM, 1993, J NEUROL SCI, V116, P207, DOI 10.1016/0022-510X(93)90327-U; Sabatier MJ, 2006, SPINAL CORD, V44, P227, DOI 10.1038/sj.sc.3101834; Sayenko DG, 2015, NEUROREHAB NEURAL RE, V29, P722, DOI 10.1177/1545968314565463; Scelsi R, 2001, BASIC APPL MYOL, V11, P75; Scott WB, 2007, MUSCLE NERVE, V35, P471, DOI 10.1002/mus.20717; Scott WB, 2005, MUSCLE NERVE, V31, P581, DOI 10.1002/mus.20300; Sharma N, 2009, IEEE T NEUR SYS REH, V17, P576, DOI 10.1109/TNSRE.2009.2023294; Shields RK, 2006, J APPL PHYSIOL, V101, P1312, DOI 10.1152/japplphysiol.00385.2006; Shields RK, 2006, J APPL PHYSIOL, V101, P556, DOI 10.1152/japplphysiol.00099.2006; Shields RK, 2006, J NEUROPHYSIOL, V95, P2380, DOI 10.1152/jn.01181.2005; Sinkjaer T, 2003, MED ENG PHYS, V25, P29, DOI 10.1016/S1350-4533(02)00178-9; Tanaka M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070949; Thomas CK, 2003, J NEUROPHYSIOL, V89, P2055, DOI 10.1152/jn.01002.2002; Thomas CK, 2002, MUSCLE NERVE, V25, P797, DOI 10.1002/mus.10111; Thrasher A, 2005, ARTIF ORGANS, V29, P453, DOI 10.1111/j.1525-1594.2005.29076.x	77	54	54	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0149024	10.1371/journal.pone.0149024	http://dx.doi.org/10.1371/journal.pone.0149024			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859296	Green Submitted, Green Published, gold			2023-01-03	WOS:000370038400120
J	Povsic, TJ; Zeiher, AM				Povsic, Thomas J.; Zeiher, Andreas M.			IxCELL-DCM: rejuvenation for cardiac regenerative therapy?	LANCET			English	Editorial Material							LEFT-VENTRICULAR FUNCTION; REFRACTORY ANGINA; HEART-FAILURE; CELL THERAPY; METAANALYSIS; TRIALS; DESIGN		[Povsic, Thomas J.] Duke Med, DCRI, Durham, NC 27708 USA; [Zeiher, Andreas M.] Goethe Univ Frankfurt, Dept Internal Med, D-60054 Frankfurt, Germany	Duke University; Goethe University Frankfurt	Povsic, TJ (corresponding author), Duke Med, DCRI, Durham, NC 27708 USA.	Thomas.povsic@duke.edu						Bartunek J, 2016, EUR J HEART FAIL, V18, P160, DOI 10.1002/ejhf.434; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Delewi R, 2013, HEART, V99, P225, DOI 10.1136/heartjnl-2012-302230; Felker GM, 2008, J CARD FAIL, V14, P368, DOI 10.1016/j.cardfail.2008.01.009; Jeevanantham V, 2012, CIRCULATION, V126, P551, DOI 10.1161/CIRCULATIONAHA.111.086074; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Losordo DW, 2011, CIRC RES, V109, P428, DOI 10.1161/CIRCRESAHA.111.245993; Patel AN, 2016, LANCET; Perin EC, 2012, JAMA-J AM MED ASSOC, V307, P1717, DOI 10.1001/jama.2012.418; Povsic TJ, 2013, AM HEART J, V165, P854, DOI 10.1016/j.ahj.2013.03.003	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2016	387	10036					2362	2363		10.1016/S0140-6736(16)30138-6	http://dx.doi.org/10.1016/S0140-6736(16)30138-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO1ST	27059889				2023-01-03	WOS:000377560100010
J	Alpern, JD; Song, J; Stauffer, WM				Alpern, Jonathan D.; Song, John; Stauffer, William M.			Essential Medicines in the United States - Why Access Is Diminishing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Alpern, Jonathan D.; Stauffer, William M.] Univ Minnesota, Div Infect Dis, Minneapolis, MN USA; [Song, John] Univ Minnesota, Ctr Bioeth, Minneapolis, MN USA; [Song, John] Univ Minnesota, Div Gen Internal Med, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Alpern, JD (corresponding author), Univ Minnesota, Div Infect Dis, Minneapolis, MN USA.							Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; Greene JA, 2016, JAMA-J AM MED ASSOC, V315, P461, DOI 10.1001/jama.2015.18720; World Health Organization, 2016, ESS MED HLTH PROD IN	3	24	25	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2016	374	20					1904	1907		10.1056/NEJMp1601559	http://dx.doi.org/10.1056/NEJMp1601559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DM1OX	27192669				2023-01-03	WOS:000376116600002
J	Fu, HY; Cheng, HQ; Cao, G; Zhang, XD; Tu, J; Sun, MJ; Mou, XZ; Shou, QY; Ke, YH				Fu, Huiying; Cheng, Hongqiang; Cao, Gang; Zhang, Xingde; Tu, Jue; Sun, Mingjiao; Mou, Xiaozhou; Shou, Qiyang; Ke, Yuehai			The Inhibition of Mast Cell Activation of Radix Paeoniae alba Extraction Identified by TCRP Based and Conventional Cell Function Assay Systems	PLOS ONE			English	Article							LIVER FIBROSIS; SENSOR ARRAYS; PAEONIFLORIN; DEGRANULATION; MICE; LACTIFLORA; PREDICTION; MEDICINE; LEUKEMIA; ROOT	Chinese herbs have long been used to treat allergic disease, but recently the development was greatly impeded by the lack of good methods to explore the mechanism of action. Here, we showed the effects of Chinese herb Radix Paeoniae alba were identified and characterized by a mast cell activation assay that involves electronic impedance readouts for dynamic monitoring of cellular responses to produce time-dependent cell responding profiles (TCRPs), and the anti-allergic activities were further confirmed with various conventional molecular and cell biology tools. We found Radix P. alba can dose-dependently inhibit TCPRs, and have anti-allergic function in vitro and in vivo. Radix P. alba suppressed mast cell degranulation not only inhibiting the translocation of granules to the plasma membrane, but also blocking membrane fusion and exocytosis; and that there may be other anti-allergic components in addition to paeoniflorin. Our results suggest that Radix P. alba regulated mast cell activation with multiple targets, and this approach is also suitable for discovering other mast cell degranulation-targeting Chinese herbs and their potential multi-target mechanisms.	[Fu, Huiying; Cheng, Hongqiang; Sun, Mingjiao; Mou, Xiaozhou; Ke, Yuehai] Zhejiang Univ, Sch Med, Dept Basic Med Sci, Program Mol Cell Biol, Hangzhou 310003, Zhejiang, Peoples R China; [Tu, Jue; Shou, Qiyang] Zhejiang Chinese Med Univ, Expt Anim Res Ctr, Hangzhou, Zhejiang, Peoples R China; [Fu, Huiying] Zhejiang Chinese Med Univ, Cent Lab, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China; [Cao, Gang] Zhejiang Chinese Med Univ, Res Ctr TCM Proc Technol, Hangzhou, Zhejiang, Peoples R China; [Zhang, Xingde] Nanjing Chinese Med Univ, Sch Pharm, Nanjing, Jiangsu, Peoples R China	Zhejiang University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Nanjing University of Chinese Medicine	Ke, YH (corresponding author), Zhejiang Univ, Sch Med, Dept Basic Med Sci, Program Mol Cell Biol, Hangzhou 310003, Zhejiang, Peoples R China.; Shou, QY (corresponding author), Zhejiang Chinese Med Univ, Expt Anim Res Ctr, Hangzhou, Zhejiang, Peoples R China.	sqy133@126.com; yke@zju.edu.cn	fu, huiying/GZG-2399-2022		National Natural Science Foundation of China [81573677, 81202918, 81001667]; Province Natural Science Foundation of Zhejiang [LY15H280006, LY13H280005]; Zhejiang Provincial TCM Sci-research Foundation Plan [2014ZQ013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Province Natural Science Foundation of Zhejiang; Zhejiang Provincial TCM Sci-research Foundation Plan	Funded by National Natural Science Foundation of China (Grant 81573677 to Q.Y.S., Grant 81202918 to G.C. and Grant 81001667 to H.Y.F.) http://www.nsfc.gov.cn/, Province Natural Science Foundation of Zhejiang (Grant LY15H280006 to Q.Y.S. and LY13H280005 to H.Y.F.) http://www.zjnsf.gov.cn/, and Zhejiang Provincial TCM Sci-research Foundation Plan (2014ZQ013 to H.Y.F.) http://zgj.zjtcm.net/.	Abassi YA, 2004, J IMMUNOL METHODS, V292, P195, DOI 10.1016/j.jim.2004.06.022; Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Atienza JM, 2005, J BIOMOL SCREEN, V10, P795, DOI 10.1177/1087057105279635; Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597; Chen XR, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-254; Chow Moses Sing Sum, 2010, Curr Drug Discov Technol, V7, P1; Dai Y, 2002, BIOL PHARM BULL, V25, P1175, DOI 10.1248/bpb.25.1175; Ehrman TM, 2010, BIOORGAN MED CHEM, V18, P2204, DOI 10.1016/j.bmc.2010.01.070; Fu HY, 2011, ANAL CHEM, V83, P6518, DOI 10.1021/ac201670e; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; He DY, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00010; Ke N, 2010, ANAL CHEM, V82, P6495, DOI 10.1021/ac1007877; Kim H, 2013, J ETHNOPHARMACOL, V149, P471, DOI 10.1016/j.jep.2013.06.055; Kim M, 2014, J ETHNOPHARMACOL, V154, P798, DOI 10.1016/j.jep.2014.05.005; Lee B, 2008, ARCH PHARM RES, V31, P445, DOI 10.1007/s12272-001-1177-6; Li JZ, 2013, INT J MOL MED, V31, P493, DOI 10.3892/ijmm.2012.1211; Li XY, 2010, PARASITOLOGY, V137, P1213, DOI 10.1017/S003118201000003X; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Nishida K, 2005, J CELL BIOL, V170, P115, DOI 10.1083/jcb.200501111; Nunomura S, 2010, FEBS LETT, V584, P1143, DOI 10.1016/j.febslet.2010.02.006; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PHANUPHAK P, 1974, J IMMUNOL, V112, P115; Rudich N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00134; Schmidt BM, 2007, NAT CHEM BIOL, V3, P360, DOI 10.1038/nchembio0707-360; Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363; Taketomi Y, 2007, J IMMUNOL, V178, P7042, DOI 10.4049/jimmunol.178.11.7042; Tsang IKY, 2007, NAT CLIN PRACT RHEUM, V3, P60, DOI 10.1038/ncprheum0406; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278; YAMAHARA J, 1982, J PHARMACOBIO-DYNAM, V5, P921; Yanase Y, 2011, IMMUNOL CELL BIOL, V89, P149, DOI 10.1038/icb.2010.67	33	6	7	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155930	10.1371/journal.pone.0155930	http://dx.doi.org/10.1371/journal.pone.0155930			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27195739	Green Submitted, gold, Green Published			2023-01-03	WOS:000376291100136
J	Pathan, SA; Mitra, B; Straney, LD; Afzal, MS; Anjum, S; Shukla, D; Morley, K; Al Hilli, SA; Al Rumaihi, K; Thomas, SH; Cameron, PA				Pathan, Sameer A.; Mitra, Biswadev; Straney, Lahn D.; Afzal, Muhammad Shuaib; Anjum, Shahzad; Shukla, Dharmesh; Morley, Kostantinos; Al Hilli, Shatha A.; Al Rumaihi, Khalid; Thomas, Stephen H.; Cameron, Peter A.			Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; SEVERE ACUTE PAIN; ANTIINFLAMMATORY DRUGS; 0.10 MG/KG; MORPHINE; DICLOFENAC; KETOROLAC; EFFICACY; ACETAMINOPHEN; UROLITHIASIS	Background The excruciating pain of patients with renal colic on presentation to the emergency department requires effective analgesia to be administered in the shortest possible time. Trials comparing intramuscular non-steroidal anti-inflammatory drugs with intravenous opioids or paracetamol have been inconclusive because of the challenges associated with concealment of randomisation, small sample size, differences in outcome measures, and inadequate masking of participants and assessors. We did this trial to develop definitive evidence regarding the choice of initial analgesia and route of administration in participants presenting with renal colic to the emergency department. Methods In this three-treatment group, double-blind, randomised controlled trial, adult participants (aged 18-65 years) presenting to the emergency department of an academic, tertiary care hospital in Qatar, with moderate to severe renal colic (Numerical pain Rating Scale >= 4) were recruited. With the use of computer-generated block randomisation (block sizes of six and nine), participants were assigned (1:1:1) to receive diclofenac (75 mg/3 mL intramuscular), morphine (0.1 mg/kg intravenous), or paracetamol (1 g/100 mL intravenous). Participants, clinicians, and trial personnel were masked to treatment assignment. The primary outcome was the proportion of participants achieving at least a 50% reduction in initial pain score at 30 min after analgesia, assessed by intention-to-treat analysis and per-protocol analysis, which included patients where a calculus in the urinary tract was detected with imaging. This trial is registered with ClinicalTrials.gov, number NCT02187614. Findings Between Aug 5, 2014, and March 15, 2015, we randomly assigned 1645 participants, of whom 1644 were included in the intention-to-treat analysis (547 in the diclofenac group, 548 in the paracetemol group, and 549 in the morphine group). Ureteric calculi were detected in 1316 patients, who were analysed as the per-protocol population (438 in the diclofenac group, 435 in the paracetemol group, and 443 in the morphine group). The primary outcome was achieved in 371 (68%) patients in the diclofenac group, 364 (66%) in the paracetamol group, and 335 (61%) in the morphine group in the intention-to-treat population. Compared to morphine, diclofenac was significantly more effective in achieving the primary outcome (odds ratio [OR] 1.35, 95% CI 1.05-1.73, p = 0.0187), whereas no difference was detected in the effectiveness of morphine compared with intravenous paracetamol (1.26, 0.99-1.62, p = 0.0629). In the per-protocol population, diclofenac (OR 1.49, 95% CI 1.13-1.97, p = 0.0046) and paracetamol (1.40, 1.06-1.85, p = 0.0166) were more effective than morphine in achieving the primary outcome. Acute adverse events in the morphine group occurred in 19 (3%) participants. Significantly lower numbers of adverse events were recorded in the diclofenac group (7 [1%] participants, OR 0.31, 95% CI 0.12-0.78, p = 0.0088) and paracetamol group (7 [1%] participants, 0.36, 0.15-0.87, p = 0.0175) than in the morphine group. During the 2 week follow-up, no additional adverse events were noted in any group. Interpretation Intramuscular non-steroidal anti-infl ammatory drugs off er the most effective sustained analgesia for renal colic in the emergency department and seem to have fewer side-effects.	[Pathan, Sameer A.; Afzal, Muhammad Shuaib; Anjum, Shahzad; Morley, Kostantinos; Thomas, Stephen H.; Cameron, Peter A.] Hamad Med Corp, Hamad Gen Hosp, Emergency Dept, Doha, Qatar; [Al Hilli, Shatha A.] Hamad Med Corp, Hamad Gen Hosp, Emergency Radiol Sect, Dept Radiol, Doha, Qatar; [Al Rumaihi, Khalid] Hamad Med Corp, Hamad Gen Hosp, Dept Urol, Doha, Qatar; [Pathan, Sameer A.; Mitra, Biswadev; Straney, Lahn D.; Cameron, Peter A.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Mitra, Biswadev; Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Mitra, Biswadev; Cameron, Peter A.] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Thomas, Stephen H.] Weill Cornell Med Coll Qatar, Doha, Qatar	Hamad Medical Corporation; Hamad General Hospital; Hamad Medical Corporation; Hamad General Hospital; Hamad Medical Corporation; Hamad General Hospital; Monash University; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Pathan, SA (corresponding author), POB 50107, Mesaieed, Qatar.	drsameer_pathan@live.com	Mitra, Biswadev/AAC-3724-2019	Mitra, Biswadev/0000-0002-0508-2450; Cameron, Peter/0000-0002-1443-557X; Thomas, Stephen/0000-0003-4153-3965; Sayed Abdelmoneim, Mohamed/0000-0001-5073-6532	Hamad Medical Corporation Medical Research Center, Doha, Qatar [IRGC-01-NI-045]	Hamad Medical Corporation Medical Research Center, Doha, Qatar	The trial was funded by Hamad Medical Corporation Medical Research Center, Doha, Qatar (grant number IRGC-01-NI-045). We thank all trial participants and the staff at HGH-ED for taking part in this trial. We especially thank Ramzi Mohammad, Kirti S Prabhu (Interim Translational Research Institute [iTRI]-HMC), Saleem Farook, Yogdutt Sharma, Dominic Jenkins, Warda Ali Alsaad, Aftab Azad, Mandar Marathe, Zain A Bhutta, Isma Qureshi, Furqan B Irfan, Galal Saleh Alessai, Hany H Ali Kamel, Mohammed A Majeed, Vajjalaravi Kumar, Syed Nabir, Salman Mirza, Andrew Frazer, Noor B Khial, Hani S Ali Aljazzazi, Mohamed Sayed Abdelmoneim, Hani Abdelaziz, Rajaa Ghallab Abdelhadi, Sathish Munirathinam, Sithik Ajees Khan, Sana Nadeem, Amjad Ali, Asmaa Abdul Hameed, Mohammed Yousuf Shariff, Muhammad Masood Khalid, Hamdy Nasser Awad Abdullah, Mujeed Ur Rehman, Mizanur Rahman, and Ramsha Tahir for their assistance with the conduct of the trial.	Afshar K, 2015, COCHRANE DB SYST REV, V6; Ahmad F, 2015, SAUDI J KIDNEY DIS T, V26, P386, DOI 10.4103/1319-2442.152557; [Anonymous], 2002, BMJ-BRIT MED J, V325, P1408; Ay MO, 2014, AM J THER, V21, P296, DOI 10.1097/MJT.0b013e318274db78; Azizkhani R, 2013, J RES MED SCI, V18, P772; Bektas F, 2009, ANN EMERG MED, V54, P568, DOI 10.1016/j.annemergmed.2009.06.501; Birnbaum A, 2007, ANN EMERG MED, V49, P445, DOI 10.1016/j.annemergmed.2006.06.030; Burton JH, 2008, EMERGENCY SEDATION AND PAIN MANAGEMENT, P1, DOI 10.1017/CBO9780511547225; Cohen E, 1998, EUR J CLIN PHARMACOL, V54, P455, DOI 10.1007/s002280050492; Davies EC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004439; Ducharme J, 2011, TINTINALLIS EMERGENC; Farsi D, 2013, ULUS TRAVMA ACIL CER, V19, P398, DOI 10.5505/tjtes.2013.86383; Fisang C, 2015, DTSCH ARZTEBL INT, V112, P83, DOI 10.3238/arztebl.2015.0083; Forrest JB, 2002, BRIT J ANAESTH, V88, P227, DOI 10.1093/bja/88.2.227; Ghani KR, 2014, J UROLOGY, V191, P90, DOI 10.1016/j.juro.2013.07.098; Grissa MH, 2011, AM J EMERG MED, V29, P203, DOI 10.1016/j.ajem.2009.09.019; Hindle A, 2003, BRIT MED J, V326, P502, DOI 10.1136/bmj.326.7387.502; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Holdgate A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004137.PUB2; Kaynar M, 2015, AM J EMERG MED, V33, P749, DOI 10.1016/j.ajem.2015.02.033; Keane Michael, 2007, ACUTE PAIN, V9, P87; LABRECQUE M, 1994, ARCH INTERN MED, V154, P1381, DOI 10.1001/archinte.154.12.1381; Larkin GL, 1999, AM J EMERG MED, V17, P6, DOI 10.1016/S0735-6757(99)90003-7; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Manjiani D, 2014, OCHSNER J, V14, P208; Masoumi K, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/571326; Pickard R, 2015, USE DRUG THERAPY MAN; Safdar B, 2006, ANN EMERG MED, V48, P173, DOI 10.1016/j.annemergmed.2006.03.013; Sakhaee K, 2012, J CLIN ENDOCR METAB, V97, P1847, DOI 10.1210/jc.2011-3492; Salameh S, 2011, OPEN EMERG MED J, V4, P9; Serinken M, 2012, EMERG MED J, V29, P902, DOI 10.1136/emermed-2011-200165; Stein A, 1996, AM J EMERG MED, V14, P385, DOI 10.1016/S0735-6757(96)90055-8; Strope SA, 2010, UROLOGY, V75, P543, DOI 10.1016/j.urology.2009.08.007; Thomas SH, 2013, INT SCHOLARLY RES NO, V2013, DOI [10.1155/2013/583132, DOI 10.1155/2013/583132]; Tramer MR, 1998, ACTA ANAESTH SCAND, V42, P71; Tuomilehto H, 2002, ACTA ANAESTH SCAND, V46, P184, DOI 10.1034/j.1399-6576.2002.460211.x; Tveita T, 2008, ACTA ANAESTH SCAND, V52, P920, DOI 10.1111/j.1399-6576.2008.01608.x	38	66	68	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2016	387	10032					1999	2007		10.1016/S0140-6736(16)00652-8	http://dx.doi.org/10.1016/S0140-6736(16)00652-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL8HJ	26993881				2023-01-03	WOS:000375881500028
J	McAuley, K; McAullay, D; Strobel, NA; Marriott, R; Atkinson, DN; Marley, JV; Stanley, FJ; Edmond, KM				McAuley, Kimberley; McAullay, Daniel; Strobel, Natalie A.; Marriott, Rhonda; Atkinson, David N.; Marley, Julia V.; Stanley, Fiona J.; Edmond, Karen M.			Hospital Utilisation in Indigenous and Non-Indigenous Infants under 12 Months of Age in Western Australia, Prospective Population Based Data Linkage Study	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT PRESENTATIONS; STRAIT ISLANDER PEOPLE; HEALTH-SERVICES; RETROSPECTIVE COHORT; IDENTIFICATION; PRACTITIONERS; ACCESSIBILITY; QUALITY; RECORDS	Background Indigenous infants (infants aged under 12 months) have the highest hospital admission and emergency department presentation risks in Australia. However, there have been no recent reports comparing hospital utilisation between Indigenous and non-Indigenous infants. Methods Our primary objective was to use a large prospective population-based linked dataset to assess the risk of all-cause hospital admission and emergency department presentation in Indigenous compared to non-Indigenous infants in Western Australia (WA). Secondary objectives were to assess the effect of socio-economic status (Index of Relative Socio-Economic Disadvantage [IRSD]) on hospital utilisation and to understand the causes of hospital utilisation. Findings There were 3,382 (5.4%) Indigenous and 59,583 (94.6%) non-Indigenous live births in WA from 1 January 2010 to 31 December 2011. Indigenous infants had a greater risk of hospital admission (adjusted odds ratio [aOR] 1.90, 95% confidence interval [95% CI] 1.77-2.04, p = <0.001) and emergency department presentation (aOR 2.15, 95% CI 1.98-2.33, p = <0.001) compared to non-Indigenous infants. Fifty nine percent (59.0%) of admissions in Indigenous children were classified as preventable compared to 31.2% of admissions in non-Indigenous infants (aOR 2.12, 95% CI 1.88-2.39). The risk of hospital admission in the most disadvantaged (IRSD 1) infants in the total cohort (35.7%) was similar to the risk in the least disadvantaged (IRSD 5) infants (30.6%) (aOR 1.04, 95% CI 0.96-1.13, p = 0.356). Interpretation WA Indigenous infants have much higher hospital utilisation than non Indigenous infants. WA health services should prioritise Indigenous infants regardless of their socio economic status or where they live.	[McAuley, Kimberley; McAullay, Daniel; Strobel, Natalie A.; Edmond, Karen M.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [McAullay, Daniel] Edith Cowan Univ, Ctr Indigenous Australian Educ & Res, Kurongkurl Katitjin, Perth, WA, Australia; [Marriott, Rhonda] Murdoch Univ, Sch Psychol & Exercise Sci, Perth, WA, Australia; [Atkinson, David N.; Marley, Julia V.] Univ Western Australia, Rural Clin Sch Western Australia, Broome, WA, Australia; [Stanley, Fiona J.] Telethon Kids Inst, Perth, WA, Australia	University of Western Australia; Edith Cowan University; Murdoch University; University of Western Australia; Telethon Kids Institute	McAuley, K (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia.	kimberley.mcauley@uwa.edu.au	Marley, Julia V/A-9515-2009; Strobel, Natalie A/O-9174-2014	Marley, Julia V/0000-0003-1014-4860; Strobel, Natalie A/0000-0002-2962-5704; Atkinson, David/0000-0001-7069-5555; McAullay, Daniel/0000-0002-0651-899X				AIHW, 2015, PER STAT SER, V31; AIHW, 2013, HLTH WELF EXP SER, V48; AIHW AIFS, 2013, CLOS GAP CLEAR ANN R; Australan Institute of Health and Welfare, 2012, PICT AUSTR CHILDR 20; Australian Institute of Health and Welfare (AIHW), 2011, HLTH WELF AUSTR AB T; Australian Institute of Health and Welfare (AIHW), 2015, HLTH SERV SER, V60; Bar-Zeev SJ, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-19; COAG, 2009, NAT INT STRAT CLOS G; Commonwealth Department of Health and Aged Care: Measuring remoteness: Accessibility/remoteness index of Australia (ARIA), 2001, INF RES BRANCH OCC P, V14; Costa N, 2008, HEALTH INF MANAG J, V37, P15, DOI 10.1177/183335830803700303; DoH, 2007, EM DEP DAT COLL DAT; Doh, 2013, NAT AB TORR STRAIT I; DoH, 2013, DAT QUAL MIDW NOT SY; DoH, 2010, AB MAT SERV SUPP UN; DoH, 2015, IND AUSTR HLTH PROGR; Downey F., 2007, VALIDATION STUDY W A; Duncan C, 2013, J PAEDIATR CHILD H, V49, pE448, DOI 10.1111/jpc.12225; Freeman T, 2014, AUST NZ J PUBL HEAL, V38, P355, DOI 10.1111/1753-6405.12231; Freeman T, 2011, AUST J PRIM HEALTH, V17, P355, DOI 10.1071/PY11033; Griew R, 2008, LINK PRIMARY HLTH CA; Gruen RL, 2006, LANCET, V368, P130, DOI 10.1016/S0140-6736(06)68812-0; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Joyce A, 2012, W AUSTR MOTHERS BABI; Kearns T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058231; Lawrence D, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-90; Li S. Q., 2011, HOSP ADMISSIONS NO T; Li SQ, 2007, INFANCY YOUNG ADULTH; Mnatzaganian G, 2012, J CLIN EPIDEMIOL, V65, P107, DOI 10.1016/j.jclinepi.2011.03.014; Moore HC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-703; Moorin RE, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-74; NHPA, 2015, HLTH COMM POT PREV H; Pink B, 2008, SOCIOECONOMIC INDEXE; SCRGSP, 2014, OV IND DIS KEY IND 2; Thomas DP, 2008, AUST HEALTH REV, V32, P648, DOI 10.1071/AH080648; Thompson SC, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-133; World Health Organization, 2015, INT STAT CLASS DIS R; Zhao YJ, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-466	38	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2016	11	4							e0154171	10.1371/journal.pone.0154171	http://dx.doi.org/10.1371/journal.pone.0154171			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5QZ	27120331	Green Published, gold			2023-01-03	WOS:000374976200048
J	Wu, MY; He, XY; Hu, CS				Wu, Ming-Yao; He, Xia-Yun; Hu, Chao-Su			Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; NODE METASTASIS; STAGE-III; PHASE-III; CANCER; SURVIVAL; OUTCOMES	Purpose To study tumor regression and failure patterns in T1-T2 non-metastatic nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT). Methods A retrospective analysis of 139 nasopharyngeal carcinoma patients treated with IMRT between January 2005 and December 2010 in our center was performed. According to the AJCC staging system, all primary lesions were attributed to T1 and T2. The prescription doses were 66 Gy at 30 fractions to gross tumor volume of the nasopharynx and the positive neck nodes, 60 Gy to high-risk clinical target volume and 54 Gy to low-risk clinical target volume. Patients staged III, IV A/B or II (lymph node measured 4 cm or more in diameter) received platinum-based chemotherapy. Results By the end of radiotherapy, 7.2% (10/139), 23.7% (33/139), and 9.4% (13/139) of patients had residual lesions in the nasopharynx, cervical lymph nodes and retropharyngeal lymph nodes, respectively. The majority of patients had complete remission within 6 months of radiotherapy completion. Five months after IMRT, three patients with residual tumors in the cervical lymph nodes underwent surgery. Among these patients, two patients had positive pathological findings, and one patient had negative findings. With a median follow-up of 59 months, the 5-year overall survival, local control, regional control and distant metastasis-free rates were 87.8%, 96.7%, 94.9% and 89.1%, respectively. Fifteen patients developed distant metastases, representing the primary failure pattern. Conclusions Most residual lesions that persisted after IMRT vanished completely in six months. Considering the potential damage to normal structures, clinicians should be cautious when considering the use of boost irradiation after radiotherapy. Distant metastasis was the primary cause of treatment failure, which was significantly higher in N2-3 patients than in N0-1. Additional studies to better understand distant metastases are needed.	[Wu, Ming-Yao; He, Xia-Yun; Hu, Chao-Su] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200433, Peoples R China; [Wu, Ming-Yao; He, Xia-Yun; Hu, Chao-Su] Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Fudan University	He, XY (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200433, Peoples R China.; He, XY (corresponding author), Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	donganlu270hao@gmail.com		Hu, Chaosu/0000-0002-6503-0951	Department of Radiation Oncology at the Fudan University Shanghai Cancer Center; Department of Radiation Oncology	Department of Radiation Oncology at the Fudan University Shanghai Cancer Center; Department of Radiation Oncology	This work was supported by the Department of Radiation Oncology at the Fudan University Shanghai Cancer Center. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge the support of Department of Radiation Oncology. The views expressed in this publication are those of the authors.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Chen J, 2014, INT J CLIN ONCOL, V19, P998, DOI 10.1007/s10147-013-0650-6; Chen Y, 2013, CANCER-AM CANCER SOC, V119, P2230, DOI 10.1002/cncr.28049; Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054; Han Lu, 2010, Chin J Cancer, V29, P145; Ho FCH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-98; Kwong DLW, 1999, CANCER, V85, P1446, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1446::AID-CNCR4>3.0.CO;2-3; Lee AWM, 2014, RADIOTHER ONCOL, V110, P377, DOI 10.1016/j.radonc.2014.02.003; Lee AWM, 2012, RADIOTHER ONCOL, V104, P272, DOI 10.1016/j.radonc.2012.08.001; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Li AC, 2015, ONCOTARGET, V6, P24511, DOI 10.18632/oncotarget.4312; Li WF, 2013, INT J RADIAT ONCOL, V86, P249, DOI 10.1016/j.ijrobp.2012.09.003; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Lin SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-39; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Sun XM, 2014, RADIOTHER ONCOL, V110, P398, DOI 10.1016/j.radonc.2013.10.020; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; Wang XS, 2014, ORAL ONCOL, V50, P1109, DOI 10.1016/j.oraloncology.2014.08.007; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; Xu TT, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001457; Yeh SA, 2005, INT J RADIAT ONCOL, V62, P672, DOI 10.1016/j.ijrobp.2004.11.002; Zhang N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-136	27	74	77	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2016	11	4							e0154501	10.1371/journal.pone.0154501	http://dx.doi.org/10.1371/journal.pone.0154501			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5QZ	27119991	Green Published, gold, Green Submitted			2023-01-03	WOS:000374976200085
J	Singla, S; Harjai, K; Katare, OP; Chhibber, S				Singla, Saloni; Harjai, Kusum; Katare, Om Prakash; Chhibber, Sanjay			Encapsulation of Bacteriophage in Liposome Accentuates Its Entry in to Macrophage and Shields It from Neutralizing Antibodies	PLOS ONE			English	Article							HUMAN EPITHELIAL-CELLS; KLEBSIELLA-PNEUMONIAE; BACTERIAL BIOFILMS; STAPHYLOCOCCUS-AUREUS; BRUCELLA-ABORTUS; PHAGE THERAPY; CIPROFLOXACIN; STREPTOMYCIN; DELIVERY; PENETRATION	Phage therapy has been a centre of attraction for biomedical scientists to treat infections caused by drug resistant strains. However, ability of phage to act only on extracellular bacteria and probability of interference by anti-phage antibodies in vivo is considered as a important limitation of bacteriophage therapy. To overcome these hurdles, liposome were used as delivery vehicle for phage in this study. Anti-phage antibodies were raised in mice and pooled serum was evaluated for its ability to neutralize free and liposome entrapped phage. Further, ability of phage and liposome-entrapped phage to enter mouse peritoneal macrophages and kill intracellular Klebsiella pneumoniae was compared. Also, an attempt to compare the efficacy of free phage and liposome entrapped phage, alone or in conjunction with amikacin in eradicating mature biofilm was made. The entrapment of phage in liposome provided 100% protection to phage from neutralizing antibody. On the contrary unentrapped phage got neutralized within 3 h of its interaction with antibody. Compared to the inability of free phage to enter macrophages, the liposome were able to deliver entrapped phage inside macrophages and cause 94.6% killing of intracellular K. pneumoniae. Liposome entrapped phage showed synergistic activity along with amikacin to eradicate mature biofilm of K. pneumoniae. Our study reinforces the growing interest in using phage therapy as a means of targeting multidrug resistant bacterial infections as liposome entrapment of phage makes them highly effective in vitro as well as in vivo by overcoming the majority of the hurdles related to clinical use of phage.	[Singla, Saloni; Harjai, Kusum; Chhibber, Sanjay] Panjab Univ, Dept Microbiol, Chandigarh 160014, India; [Katare, Om Prakash] Panjab Univ, Univ Inst Pharmaceut Sci, Chandigarh 160014, India	Panjab University; Panjab University	Chhibber, S (corresponding author), Panjab Univ, Dept Microbiol, Chandigarh 160014, India.	sanjaychhibber8@gmail.com						Adams MH, 1959, LYSOGENY BACTERIOPHA, P365; Ahmed K, 2002, J LIPOSOME RES, V12, P285, DOI 10.1081/LPR-120016195; Anderl JN, 2000, ANTIMICROB AGENTS CH, V44, P1818, DOI 10.1128/AAC.44.7.1818-1824.2000; Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5; ASHTEKAR D, 1991, J ANTIMICROB CHEMOTH, V28, P615, DOI 10.1093/jac/28.4.615; Beaulac C, 1998, J ANTIMICROB CHEMOTH, V41, P35, DOI 10.1093/jac/41.1.35; Bedi MS, 2009, WORLD J MICROB BIOT, V25, P1145, DOI 10.1007/s11274-009-9991-8; Bhatia A, 2004, J PHARM PHARM SCI, V7, P252; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Cairns BJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000253; Cano V, 2015, CELL MICROBIOL, V17, P1537, DOI 10.1111/cmi.12466; Capparelli R, 2007, ANTIMICROB AGENTS CH, V51, P2765, DOI 10.1128/AAC.01513-06; Cornelissen A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018597; DEES C, 1990, VET IMMUNOL IMMUNOP, V24, P135, DOI 10.1016/0165-2427(90)90016-L; Donlan RM, 2001, CLIN INFECT DIS, V33, P1387, DOI 10.1086/322972; Doolittle MM, 1996, J IND MICROBIOL, V16, P331, DOI 10.1007/BF01570111; Fodah RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107394; FOUNTAIN MW, 1985, J INFECT DIS, V152, P529, DOI 10.1093/infdis/152.3.529; Fumagalli O, 1997, INFECT IMMUN, V65, P4445, DOI 10.1128/IAI.65.11.4445-4451.1997; Hughes KA, 1998, MICROBIOL-UK, V144, P3039, DOI 10.1099/00221287-144-11-3039; Hughes KA, 1998, J APPL MICROBIOL, V85, P583, DOI 10.1046/j.1365-2672.1998.853541.x; Kaszuba M, 1997, COLLOID SURFACE B, V8, P321, DOI 10.1016/S0927-7765(97)00007-6; Kysela DT, 2007, J THEOR BIOL, V249, P411, DOI 10.1016/j.jtbi.2007.08.007; Lasic DD., 1997, LIPOSOMES GENE DELIV, P259; Lederberg J, 1996, P NATL ACAD SCI USA, V93, P3167, DOI 10.1073/pnas.93.8.3167; MACLEOD DL, 1988, CAN J VET RES, V52, P445; MAJUMDAR S, 1992, ANTIMICROB AGENTS CH, V36, P2808, DOI 10.1128/AAC.36.12.2808; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Oelschlaeger TA, 1997, INFECT IMMUN, V65, P2950, DOI 10.1128/IAI.65.7.2950-2958.1997; Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589; Rashel M, 2007, J INFECT DIS, V196, P1237, DOI 10.1086/521305; Sihorkar V, 2001, PHARM RES-DORDR, V18, P1247, DOI 10.1023/A:1013073508318; Singla S, 2015, J INFECT DIS, V212, P325, DOI 10.1093/infdis/jiv029; Stent G., 1963, MOL BIOL BACTERIAL V; STEVENSON M, 1983, ANTIMICROB AGENTS CH, V24, P742, DOI 10.1128/AAC.24.5.742; Tullio V, 2000, J ANTIMICROB CHEMOTH, V46, P241, DOI 10.1093/jac/46.2.241; Verma V, 2010, BIOFOULING, V26, P729, DOI 10.1080/08927014.2010.511196; Verma V, 2009, CURR MICROBIOL, V59, P274, DOI 10.1007/s00284-009-9430-y; Vitas AI, 1996, ANTIMICROB AGENTS CH, V40, P146, DOI 10.1128/AAC.40.1.146	39	61	65	2	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2016	11	4							e0153777	10.1371/journal.pone.0153777	http://dx.doi.org/10.1371/journal.pone.0153777			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK5QB	27115154	gold, Green Published, Green Submitted			2023-01-03	WOS:000374973600030
J	Wen, J; Yan, M; Liu, Y; Li, J; Xie, YM; Lu, YF; Kamata, M; Chen, ISY				Wen, Jing; Yan, Ming; Liu, Yang; Li, Jie; Xie, Yiming; Lu, Yunfeng; Kamata, Masakazu; Chen, Irvin S. Y.			Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BROADLY NEUTRALIZING ANTIBODIES; PROTON SPONGE; RICIN; INFECTION; IMMUNOTOXINS; PERSISTENCE; CHAIN; COMBINATION; RESERVOIRS	Anti-retroviral drugs suppress HIV-1 plasma viremia to undetectable levels; however, latent HIV-1 persists in reservoirs within HIV-1-infected patients. The silent provirus can be activated through the use of drugs, including protein kinase C activators and histone deacetylase inhibitors. This "shock" approach is then followed by "kill" of the producing cells either through direct HIV-1-induced cell death or natural immune mechanisms. However, these mechanisms are relatively slow and effectiveness is unclear. Here, we develop an approach to specifically target and kill cells that are activated early in the process of virus production. We utilize a novel nanocapsule technology whereby the ricin A chain is encapsulated in an inactive form within a polymer shell. Specificity for release of the ricin A toxin is conferred by peptide crosslinkers that are sensitive to cleavage by HIV-1 protease. By using well-established latent infection models, J-Lat and U1 cells, we demonstrate that only within an HIV-1-producing cell expressing functional HIV-1 protease will the nanocapsule release its ricin A cargo, shutting down viral and cellular protein synthesis, and ultimately leading to rapid death of the producer cell. Thus, we provide proof of principle for a novel technology to kill HIV-1-producing cells without effects on non-target cells.	[Wen, Jing; Yan, Ming; Xie, Yiming; Chen, Irvin S. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Kamata, Masakazu] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Liu, Yang; Li, Jie; Lu, Yunfeng] Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA USA; [Lu, Yunfeng] Univ Calif Los Angeles, CNSI, Los Angeles, CA USA; [Chen, Irvin S. Y.] UCLA AIDS Inst, Los Angeles, CA USA; [Yan, Ming] Calimmune Inc, Pasadena, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Chen, ISY (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.; Kamata, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.; Chen, ISY (corresponding author), UCLA AIDS Inst, Los Angeles, CA USA.	masa3k@ucla.edu; syuchen@mednet.ucla.edu	Wen, Jing/F-1949-2019; Li, Jie/I-5695-2015; KAMATA, MASAKAZU/E-7550-2017; Liu, Yang/AAY-7115-2020	Wen, Jing/0000-0002-6127-6276; Li, Jie/0000-0003-0189-2787; Liu, Yang/0000-0001-5752-5180; Kamata, Masakazu/0000-0003-0323-3742	U.S. National Institutes of Health (NIH) R21 grant [AI114433]; NIH [AI028697]; James B. Pendleton Charitable Trust; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI114433, P30AI028697] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) R21 grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James B. Pendleton Charitable Trust; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by U.S. National Institutes of Health (NIH) R21 grant (AI114433 to ISYC). p24 ELISA was performed in the CFAR Virology core laboratory supported by NIH grant (AI028697). MACSQuant Flow Cytometer and a part of Fortessa Cytometry system were supported by James B. Pendleton Charitable Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696; Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Archin NM, 2014, CURR OPIN INFECT DIS, V27, P29, DOI 10.1097/QCO.0000000000000026; Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Behr JP, 1997, CHIMIA, V51, P34; Berger EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000803; BLAKEY DC, 1986, CANC DRUG DEL, V3, P189, DOI 10.1089/cdd.1986.3.189; Blanco R, 2003, J BIOL CHEM, V278, P1086, DOI 10.1074/jbc.M205636200; Bosque A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002288; Bosque A, 2009, BLOOD, V113, P58, DOI 10.1182/blood-2008-07-168393; Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a; Casazza JP, 2013, J INFECT DIS, V207, P1829, DOI 10.1093/infdis/jit098; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2015, NAT IMMUNOL, V16, P584, DOI 10.1038/ni.3152; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; CUSHLEY W, 1984, TOXICON, V22, P265, DOI 10.1016/0041-0101(84)90027-8; Darcis G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005063; DAVEY RT, 1994, J INFECT DIS, V170, P1180, DOI 10.1093/infdis/170.5.1180; Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872; El-Nikhely N, 2007, PROTEIN J, V26, P481, DOI 10.1007/s10930-007-9088-x; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; FitzGerald DJ, 2011, CANCER RES, V71, P6300, DOI 10.1158/0008-5472.CAN-11-1374; Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Garcia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004682; Gu Z, 2009, NANO LETT, V9, P4533, DOI 10.1021/nl902935b; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043; JIMENEZ A, 1985, ANNU REV MICROBIOL, V39, P649, DOI 10.1146/annurev.mi.39.100185.003245; Johansson S, 2006, AIDS, V20, P1911, DOI 10.1097/01.aids.0000247111.58961.60; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Katlama C, 2013, LANCET, V381, P2109, DOI 10.1016/S0140-6736(13)60104-X; Kennedy PE, 2006, J LEUKOCYTE BIOL, V80, P1175, DOI 10.1189/jlb.0306139; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; Liang M, 2010, J GENE MED, V12, P255, DOI 10.1002/jgm.1440; Liu CY, 2015, ADV MATER, V27, P292, DOI 10.1002/adma.201403387; Martins LJ, 2015, AIDS RES HUM RETROVI; Nagata S, 2001, Tanpakushitsu Kakusan Koso, V46, P540; Nie Z, 2007, J VIROL, V81, P6947, DOI 10.1128/JVI.02798-06; Olesen R, 2015, J VIROL; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009; Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Pettit SC, 2002, J VIROL, V76, P10226, DOI 10.1128/JVI.76.20.10226-10233.2002; Pincus SH, 1996, ANTIVIR RES, V33, P1, DOI 10.1016/S0166-3542(96)00995-3; RAMACHANDRAN RV, 1994, J INFECT DIS, V170, P1009, DOI 10.1093/infdis/170.4.1009; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; Sanchez-Duffhues G, 2011, CURR DRUG TARGETS, V12, P348, DOI 10.2174/138945011794815266; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005; Sigal A, 2012, CELL HOST MICROBE, V12, P132, DOI 10.1016/j.chom.2012.07.005; Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347; Thrush GR, 1996, ANNU REV IMMUNOL, V14, P49, DOI 10.1146/annurev.immunol.14.1.49; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; UCKUN FM, 1989, BLOOD, V74, P2445; VALLERA DA, 1983, SCIENCE, V222, P512, DOI 10.1126/science.6353579; VANOOSTERHOUT YVJM, 1992, CANCER RES, V52, P5921; Ventoso I, 2001, P NATL ACAD SCI USA, V98, P12966, DOI 10.1073/pnas.231343498; Weber IT, 2009, VIRUSES-BASEL, V1, P1110, DOI 10.3390/v1031110; WELLNER RB, 1995, J TOXICOL-TOXIN REV, V14, P483, DOI 10.3109/15569549509016439; Wen J, 2011, ADV MATER, V23, P4549, DOI 10.1002/adma.201101771; Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200; Yan M, 2006, J AM CHEM SOC, V128, P11008, DOI 10.1021/ja064126t; Yan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127986; Yan M, 2012, J AM CHEM SOC, V134, P13542, DOI 10.1021/ja304649a; Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/nnano.2009.341, 10.1038/NNANO.2009.341]; Zhang P, 2015, P NATL ACAD SCI USA, V112, P12046, DOI 10.1073/pnas.1512465112	73	13	13	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2016	11	4							e0151572	10.1371/journal.pone.0151572	http://dx.doi.org/10.1371/journal.pone.0151572			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6IX	27049645	gold, Green Published			2023-01-03	WOS:000373603500009
J	Cai, KD; Luo, Q; Dai, ZW; Zhu, BX; Fei, JP; Xue, CP; Wu, D				Cai, Kedan; Luo, Qun; Dai, Zhiwei; Zhu, Beixia; Fei, Jinping; Xue, Congping; Wu, Dan			Hypomagnesemia Is Associated with Increased Mortality among Peritoneal Dialysis Patients	PLOS ONE			English	Article							LOW SERUM MAGNESIUM; CARDIOVASCULAR-DISEASE; CALCIUM; RISK; ATHEROSCLEROSIS; RECEPTOR; PROTEIN	Objective Hypomagnesemia has been associated with an increase in mortality among the general population as well as patients with chronic kidney disease or those on hemodialysis. However, this association has not been thoroughly studied in patients undergoing peritoneal dialysis. The aim of this study was to evaluate the association between serum magnesium concentrations and all-cause and cardiovascular mortalities in peritoneal dialysis patients. Methods This single-center retrospective study included 253 incident peritoneal dialysis patients enrolled between July 1, 2005 and December 31, 2014 and followed to June 30, 2015. Patient's demographic characteristics as well as clinical and laboratory measurements were collected. Results Of 253 patients evaluated, 36 patients (14.2%) suffered from hypomagnesemia. During a median follow-up of 29 months (range: 4-120 months), 60 patients (23.7%) died, and 35 (58.3%) of these deaths were attributed to cardiovascular causes. Low serum magnesium was positively associated with peritoneal dialysis duration (r = 0.303, p < 0.001) as well as serum concentrations of albumin (r = 0.220, p < 0.001), triglycerides (r = 0.160, p = 0.011), potassium (r = 0.156, p = 0.013), calcium(r = 0.299, p < 0.001) and phosphate (r = 0.191, p = 0.002). Patients in the hypomagnesemia group had a lower survival rate than those in the normal magnesium groups (p < 0.001). In a multivariate Cox proportional hazards regression analysis, serum magnesium was an independent negative predictor of all-cause mortality (hazard ratio [HR] = 0.075, p = 0.011) and cardiovascular mortality (HR = 0.003, p < 0.001), especially in female patients. However, in univariate and multivariate Cox analysis, Delta Mg(difference between 1-year magnesium and baseline magnesium) was not an independent predictor of all-cause mortality and cardiovascular mortality. Conclusion Hypomagnesemia was common among peritoneal dialysis patients and was independently associated with all-cause mortality and cardiovascular mortality.	[Cai, Kedan; Luo, Qun; Dai, Zhiwei; Zhu, Beixia; Fei, Jinping; Xue, Congping; Wu, Dan] Ningbo Univ, Sch Med, Ningbo Hosp 2, Dept Nephrol, Ningbo, Zhejiang, Peoples R China	Ningbo University	Luo, Q (corresponding author), Ningbo Univ, Sch Med, Ningbo Hosp 2, Dept Nephrol, Ningbo, Zhejiang, Peoples R China.	nbluoqun@163.com			Ningbo social-development fund [2015C50038]	Ningbo social-development fund	This work was supported by Ningbo social-development fund (2015C50038). Website: http://www.nbsti.gov.cn/gb/Project/ContentByXml.aspx? CID=00671&CID1=00441&CID2=00442&CID3=00448&CID4=00671&Info_ID=6612706f-2380-4261-b858-eee50c1698ea&Page=1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRANNAN PG, 1976, J CLIN INVEST, V57, P1412, DOI 10.1172/JCI108410; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Chiuve SE, 2011, AM J CLIN NUTR, V93, P253, DOI 10.3945/ajcn.110.002253; Cho Min Seok, 2002, Korean Journal of Internal Medicine, V17, P114; Dmitrieva NI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128870; EJAZ AA, 1995, PERITON DIALYSIS INT, V15, P61; Fein Paul, 2010, Adv Perit Dial, V26, P112; Fein Paula, 2014, Adv Perit Dial, V30, P90; FERMENT O, 1987, J ENDOCRINOL, V113, P117, DOI 10.1677/joe.0.1130117; Fouque D, 2011, KIDNEY INT, V80, P348, DOI 10.1038/ki.2011.118; Han SH, 2008, PERITON DIALYSIS INT, V28, pS21; Kanbay M, 2012, AM J NEPHROL, V36, P228, DOI 10.1159/000341868; Matias PJ, 2014, BLOOD PURIFICAT, V38, P244, DOI 10.1159/000366124; Navarro-Gonzalez JF, 2009, SEMIN DIALYSIS, V22, P37, DOI 10.1111/j.1525-139X.2008.00530.x; Qu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057720; Reffelmann T, 2011, ATHEROSCLEROSIS, V219, P280, DOI 10.1016/j.atherosclerosis.2011.05.038; ROSEN EU, 1970, J PEDIATR-US, V77, P709, DOI 10.1016/S0022-3476(70)80220-7; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Silva AP, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/308190; Stenvinkel P, 2001, PERITON DIALYSIS INT, V21, pS157; Suzuki K, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/231018; Tin A, 2015, KIDNEY INT, V87, P820, DOI 10.1038/ki.2014.331; Van Laecke S, 2013, AM J MED, V126, P825, DOI 10.1016/j.amjmed.2013.02.036; van Zuijdewijn CLMD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143104; Wang AYM, 2003, J AM SOC NEPHROL, V14, P159, DOI 10.1097/01.ASN.0000038685.95946.83; Ye HJ, 2013, PERITON DIALYSIS INT, V33, P450, DOI 10.3747/pdi.2012.00164; Zhang F, 2015, PERITON DIALYSIS INT, V35, P199, DOI 10.3747/pdi.2013.00164; Zhang W, 2012, ATHEROSCLEROSIS, V221, P587, DOI 10.1016/j.atherosclerosis.2012.01.034	30	35	39	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2016	11	3							e0152488	10.1371/journal.pone.0152488	http://dx.doi.org/10.1371/journal.pone.0152488			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9KB	27023783	gold, Green Published, Green Submitted			2023-01-03	WOS:000373113900064
J	Isetta, V; Montserrat, JM; Santano, R; Wimms, AJ; Ramanan, D; Woehrle, H; Navajas, D; Farre, R				Isetta, Valentina; Montserrat, Josep M.; Santano, Raquel; Wimms, Alison J.; Ramanan, Dinesh; Woehrle, Holger; Navajas, Daniel; Farre, Ramon			Novel Approach to Simulate Sleep Apnea Patients for Evaluating Positive Pressure Therapy Devices	PLOS ONE			English	Article							AIRWAY PRESSURE; GENDER-DIFFERENCES; CONSTANT; EFFICACY; EVENTS; ADULTS; BENCH; TRIAL; STAGE; CPAP	Bench testing is a useful method to characterize the response of different automatic positive airway pressure (APAP) devices under well-controlled conditions. However, previous models did not consider the diversity of obstructive sleep apnea (OSA) patients' characteristics and phenotypes. The objective of this proof-of-concept study was to design a new bench test for realistically simulating an OSA patient's night, and to implement a one-night example of a typical female phenotype for comparing responses to several currently-available APAP devices. We developed a novel approach aimed at replicating a typical night of sleep which includes different disturbed breathing events, disease severities, sleep/wake phases, body postures and respiratory artefacts. The simulated female OSA patient example that we implemented included periods of wake, light sleep and deep sleep with positional changes and was connected to ten different APAP devices. Flow and pressure readings were recorded; each device was tested twice. The new approach for simulating female OSA patients effectively combined a wide variety of disturbed breathing patterns to mimic the response of a predefined patient type. There were marked differences in response between devices; only three were able to overcome flow limitation to normalize breathing, and only five devices were associated with a residual apnea-hypopnea index of <5/h. In conclusion, bench tests can be designed to simulate specific patient characteristics, and typical stages of sleep, body position, and wake. Each APAP device behaved differently when exposed to this controlled model of a female OSA patient, and should lead to further understanding of OSA treatment.	[Isetta, Valentina; Santano, Raquel; Farre, Ramon] Univ Barcelona, Fac Med, Unitat Biofis & Bioengn, Barcelona 7, Spain; [Isetta, Valentina; Navajas, Daniel; Farre, Ramon] CIBERES, Madrid, Spain; [Montserrat, Josep M.] Hosp Clin Barcelona, Dept Pneumol, Sleep Lab, Barcelona, Spain; [Montserrat, Josep M.; Farre, Ramon] IDIBAPS, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Wimms, Alison J.; Ramanan, Dinesh; Woehrle, Holger] ResMed Sci Ctr, Munich, Germany; [Navajas, Daniel] IBEC, Inst Bioengn Catalonia, Barcelona, Spain	University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ResMed; Barcelona Institute of Science & Technology; Institut de Bioenginyeria de Catalunya; University of Barcelona	Farre, R (corresponding author), Univ Barcelona, Fac Med, Unitat Biofis & Bioengn, Barcelona 7, Spain.; Farre, R (corresponding author), CIBERES, Madrid, Spain.; Farre, R (corresponding author), IDIBAPS, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.	rfarre@ub.edu	Farre, Ramon/L-2664-2017; Navajas, Daniel/E-4233-2010	Farre, Ramon/0000-0002-9084-7824; Navajas, Daniel/0000-0001-7150-9363; MONTSERRAT, Josep Maria/0000-0003-3098-4605	ResMed Science Centre [307990]; Universitat de Barcelona [307990]; Ministerio de Economia y Competitividad [PI14/0004]; ResMed	ResMed Science Centre; Universitat de Barcelona; Ministerio de Economia y Competitividad(Spanish Government); ResMed	The work presented here has been partially supported by a research agreement (number 307990) between ResMed Science Centre and Universitat de Barcelona (PI: Ramon Farre). The work has been also partially funded by Ministerio de Economia y Competitividad (PI14/0004). There was no additional funding received for this study. ResMed Science Centre provided support in the form of salaries for authors AJW, DR, and HW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; Authors wish to thank Mr. Miguel Angel Rodriguez for his technical support. English language medical writing assistance was provided by Nicola Ryan, independent medical writer, funded by ResMed.	Ayas NT, 2004, SLEEP, V27, P249, DOI 10.1093/sleep/27.2.249; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Behbehani K, 1998, SLEEP; Brown LK, 2006, CHEST, V130, P312, DOI 10.1016/S0012-3692(15)51841-2; d'Ortho MP, 2000, CHEST, V118, P1010, DOI 10.1378/chest.118.4.1010; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Eiseman NA, 2012, J CLIN SLEEP MED, V8, P655, DOI 10.5664/jcsm.2258; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; Farre R, 2002, AM J RESP CRIT CARE, V166, P469, DOI 10.1164/rccm.2111050; Gibson GJ, 2005, BRIT MED BULL, V72, P49, DOI 10.1093/bmb/ldh044; Gozal D, 2015, CHEST; Isetta Valentina, 2015, ERJ Open Res, V1; Jayaraman G, 2011, SLEEP BREATH, V15, P781, DOI 10.1007/s11325-010-0436-2; Jordan AS, 2014, LANCET, V383, P736, DOI 10.1016/S0140-6736(13)60734-5; Levy P, 2015, NAT REV DIS PRI 0625, P15015; Marrone O, 2002, CHEST, V121, P759, DOI 10.1378/chest.121.3.759; Massie CA, 2003, AM J RESP CRIT CARE, V167, P20, DOI 10.1164/rccm.200201-022OC; Nolan GM, 2006, EUR RESPIR J, V28, P159, DOI 10.1183/09031936.06.00127205; Noseda A, 2004, CHEST, V126, P31, DOI 10.1378/chest.126.1.31; O'Connor C, 2000, AM J RESP CRIT CARE, V161, P1465, DOI 10.1164/ajrccm.161.5.9904121; Oksenberg A, 1999, CHEST, V116, P1000, DOI 10.1378/chest.116.4.1000; Penzel T, 2001, SLEEP, V24, P90, DOI 10.1093/sleep/24.1.90; Pevernagie DA, 2004, CHEST, V126, P25, DOI 10.1378/chest.126.1.25; Randerath Winfried J, 2003, Med Sci Monit, V9, pCR353; Rigau J, 2006, CHEST, V130, P350, DOI 10.1378/chest.130.2.350; Russell T, 2011, AM J MED, V124, P1123, DOI 10.1016/j.amjmed.2011.04.017; Series F, 2001, EUR RESPIR J, V18, P170, DOI 10.1183/09031936.01.98103501; Tan HL, 2013, NAT SCI SLEEP, V5, P109, DOI 10.2147/NSS.S51907; Teschler H, 2000, EUR RESPIR J, V15, P990, DOI 10.1034/j.1399-3003.2000.01503.x; Teschler H, 1996, AM J RESP CRIT CARE, V154, P734, DOI 10.1164/ajrccm.154.3.8810613; Valencia-Flores, 1992, J Sleep Res, V1, P51; Ware JC, 2000, SLEEP, V23, P165; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	34	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151530	10.1371/journal.pone.0151530	http://dx.doi.org/10.1371/journal.pone.0151530			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26978077	Green Published, gold, Green Submitted			2023-01-03	WOS:000372572800083
J	Abadjieva, D; Kistanova, E				Abadjieva, Desislava; Kistanova, Elena			Tribulus terrestris Alters the Expression of Growth Differentiation Factor 9 and Bone Morphogenetic Protein 15 in Rabbit Ovaries of Mothers and F-1 Female Offspring	PLOS ONE			English	Article							GENE-EXPRESSION; FOLLICULAR DEVELOPMENT; SYNERGISTIC ROLES; OOCYTE; MOUSE; EXTRACT; RAT; RECEPTOR; BMP15; GDF9	Although previous research has demonstrated the key role of the oocyte-derived factors, bone morphogenetic protein (BMP) 15 and growth differentiation factor (GDF) 9, in follicular development and ovulation, there is a lack of knowledge on the impact of external factors, which females are exposed to during folliculogenesis, on their expression. The present study investigated the effect of the aphrodisiac Tribulus terrestris on the GDF9 and BMP15 expression in the oocytes and cumulus cells at mRNA and protein levels during folliculogenesis in two generations of female rabbits. The experiment was conducted with 28 New Zealand rabbits. Only the diet of the experimental mothers group was supplemented with a dry extract of T. terrestris for the 45 days prior to insemination. The expression of BMP15 and GDF9 genes in the oocytes and cumulus cells of mothers and F1 female offspring was analyzed using real-time polymerase chain reaction (RT-PCR). The localization of the GDF9 and BMP15 proteins in the ovary tissues was determined by immunohistochemical analysis. The BMP15 and GDF9 transcripts were detected in the oocytes and cumulus cells of rabbits from all groups. T. terrestris caused a decrease in the BMP15 mRNA level in the oocytes and an increase in the cumulus cells. The GDF9 mRNA level increased significantly in both oocytes and cumulus cells. The downregulated expression of BMP15 in the treated mothers' oocytes was inherited in the F1 female offspring born to treated mothers. BMP15 and GDF9 show a clearly expressed sensitivity to the bioactive compounds of T. terrestris.	[Abadjieva, Desislava; Kistanova, Elena] Bulgarian Acad Sci, Inst Biol & Immunol Reprod, BU-1113 Sofia, Bulgaria	Bulgarian Academy of Sciences	Kistanova, E (corresponding author), Bulgarian Acad Sci, Inst Biol & Immunol Reprod, BU-1113 Sofia, Bulgaria.	kistanova@gmail.com	Kistanova, Elena K/J-3532-2016	Kistanova, Elena K/0000-0002-5239-1715	Seventh frame work program (FP7), ReProForce [GA245641]; FP7 Post-Grant Open Access Pilot	Seventh frame work program (FP7), ReProForce; FP7 Post-Grant Open Access Pilot	Funding provided by the Seventh frame work program (FP7), ReProForce, GA245641-EK, DA, and a FP7 Post-Grant Open Access Pilot "Support in charging of publication fee." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adaay M.H., 2012, J MAT ENV SCI, V3, P1153; Adaikan P. G., 2000, Annals Academy of Medicine Singapore, V29, P22; Adailkan P. G., 2001, AGING MALE, V4, P163, DOI DOI 10.1080/tam.4.3.163.169; Akram M, 2011, J MED PLANTS RES, V5, P3601; Brown GA, 2001, INT J VITAM NUTR RES, V71, P293, DOI 10.1024/0300-9831.71.5.293; Chhatre Saurabh, 2014, Pharmacogn Rev, V8, P45, DOI 10.4103/0973-7847.125530; Cordier AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063101; Daniel-Carlier N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060451; Daoud NM, 2012, ANIM REPROD SCI, V136, P121, DOI 10.1016/j.anireprosci.2012.09.011; Dehghan A, 2012, REPROD DOMEST ANIM, V47, pe12, DOI 10.1111/j.1439-0531.2011.01877.x; Demars J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003482; Di Pasquale E, 2004, AM J HUM GENET, V75, P106, DOI 10.1086/422103; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Eppig JJ, 2002, P NATL ACAD SCI USA, V99, P2890, DOI 10.1073/pnas.052658699; Esfandiari A, 2011, J ANIM VET ADV, V10, P883, DOI 10.3923/javaa.2011.883.886; Feeney A, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-48; Findlay JK, 2002, MOL CELL ENDOCRINOL, V191, P35, DOI 10.1016/S0303-7207(02)00053-9; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Gama CRB, 2014, CLIN MED INSIGHTS-WO, V7, P45, DOI 10.4137/CMWH.S17853; Gauthaman K, 2005, J ETHNOPHARMACOL, V96, P127, DOI 10.1016/j.jep.2004.08.030; Gauthaman K, 2002, LIFE SCI, V71, P1385, DOI 10.1016/S0024-3205(02)01858-1; Gueripel X, 2006, BIOL REPROD, V75, P836, DOI 10.1095/biolreprod.106.055574; Halvorson LM, 1999, REPROD ENDOCRINOLOGY, P81; Hamatani T, 2004, HUM MOL GENET, V13, P2263, DOI 10.1093/hmg/ddh241; Hosoe M, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-33; Huang Q, 2009, AM J PHYSIOL-ENDOC M, V296, pE1344, DOI 10.1152/ajpendo.90929.2008; Koncic MZ, 2013, CURR DRUG TARGETS, V14, P1079, DOI 10.2174/1389450111314090016; Kostova I., 2005, Phytochemistry Reviews, V4, P111, DOI 10.1007/s11101-005-2833-x; Liao WX, 2003, J BIOL CHEM, V278, P3713, DOI 10.1074/jbc.M210598200; Lieberman S, 1996, J CLIN ENDOCR METAB, V81, P850, DOI 10.1210/jc.81.2.850; Martino-Andrade AJ, 2010, J ETHNOPHARMACOL, V127, P165, DOI 10.1016/j.jep.2009.09.031; Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P653, DOI 10.1210/me.2003-0393; McMahon HE, 2008, ENDOCRINOLOGY, V149, P2807, DOI 10.1210/en.2007-1550; Nikolova M., 2010, Biotechnology in Animal Husbandry, V26, P259; Orisaka M, 2006, MOL ENDOCRINOL, V20, P2456, DOI 10.1210/me.2005-0357; Otsuka F, 2000, J BIOL CHEM, V275, P39523, DOI 10.1074/jbc.M007428200; Otsuka F, 2001, J BIOL CHEM, V276, P11387, DOI 10.1074/jbc.M010043200; Otsuka F, 2002, P NATL ACAD SCI USA, V99, P8060, DOI 10.1073/pnas.122066899; Otsuka F, 2011, MOL REPROD DEV, V78, P9, DOI 10.1002/mrd.21265; Paulini F, 2011, REPROD DOMEST ANIM, V46, P354, DOI 10.1111/j.1439-0531.2010.01739.x; Persani L, 2014, HUM REPROD UPDATE, V20, P869, DOI 10.1093/humupd/dmu036; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pisani LF, 2008, REPRODUCTION, V136, P303, DOI 10.1530/REP-07-0394; Qureshi Ahmed, 2014, Journal of Dietary Supplements, V11, P64, DOI 10.3109/19390211.2014.887602; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Sandeep PM, 2015, METAB SYNDR RELAT D, V13, P248, DOI 10.1089/met.2014.0136; Sharov AA, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-24; Stocco C, 2008, STEROIDS, V73, P473, DOI 10.1016/j.steroids.2008.01.017; Su YQ, 2004, DEV BIOL, V276, P64, DOI 10.1016/j.ydbio.2004.08.020; Sugiura K, 2010, MOL ENDOCRINOL, V24, P2303, DOI 10.1210/me.2010-0260; Sun WJ, 2002, NAT PROD LETT, V16, P243, DOI 10.1080/10575630290020541; Tabakova P., 2012, KIRKOUA SOFIA CLIN S; Teixeira FL, 2002, J CLIN ENDOCR METAB, V87, P1337, DOI 10.1210/jc.87.3.1337; Vitt UA, 2002, BIOL REPROD, V67, P473, DOI 10.1095/biolreprod67.2.473; Wu G, 1996, PHYTOCHEMISTRY, V42, P1677, DOI 10.1016/0031-9422(96)00182-3; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yeo CX, 2009, BIOL REPROD, V80, P1072, DOI 10.1095/biolreprod.108.073908; Yin Ping, 2008, Zoological Research, V29, P603, DOI 10.3724/SP.J.1141.2008.06603	59	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 29	2016	11	2							e0150400	10.1371/journal.pone.0150400	http://dx.doi.org/10.1371/journal.pone.0150400			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5WU	26928288	Green Published, gold			2023-01-03	WOS:000371424200041
J	Dondorp, AM; Iyer, SS; Schultz, MJ				Dondorp, Arjen M.; Iyer, Shivakumar S.; Schultz, Marcus J.			Critical Care in Resource-Restricted Settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Dondorp, Arjen M.; Schultz, Marcus J.] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; [Dondorp, Arjen M.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England; [Iyer, Shivakumar S.] Bharati Vidyapeeth Univ, Coll Med, Dept Intens Care, Pune, Maharashtra, India; [Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands	Mahidol University; University of Oxford; Bharati Vidyapeeth Deemed University; University of Amsterdam; Academic Medical Center Amsterdam	Dondorp, AM (corresponding author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	arjen@tropmedres.ac	Schultz, Marcus/AAB-6379-2021	Schultz, Marcus/0000-0003-3969-7792				Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Ashley EA, 2011, TROP MED INT HEALTH, V16, P1167, DOI 10.1111/j.1365-3156.2011.02822.x; Austin S, 2014, INTENS CARE MED, V40, P342, DOI 10.1007/s00134-013-3174-7; Divatia JV, 2015, INTENS CARE MED, V41, P1468, DOI 10.1007/s00134-014-3618-8; Kulkarni AP, 2013, INDIAN J CRIT CARE M, V17, P292, DOI 10.4103/0972-5229.120321; Neto AS, 2016, INTENS CARE MED, V42, P100, DOI 10.1007/s00134-015-4070-0; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385	7	39	39	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2016	315	8					753	754		10.1001/jama.2016.0976	http://dx.doi.org/10.1001/jama.2016.0976			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE5VH	26903331				2023-01-03	WOS:000370700500008
J	Matthay, MA; Liu, KD				Matthay, Michael A.; Liu, Kathleen D.			New Strategies for Effective Therapeutics in Critically Ill Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SEVERE SEPSIS; SEPTIC SHOCK; MORTALITY; TRIAL		[Matthay, Michael A.; Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm M-917, San Francisco, CA 94143 USA; [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Liu, Kathleen D.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Matthay, MA (corresponding author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm M-917, San Francisco, CA 94143 USA.; Matthay, MA (corresponding author), Univ Calif San Francisco, Dept Anesthesia, 505 Parnassus Ave,Rm M-917, San Francisco, CA 94143 USA.	michael.matthay@ucsf.edu		Liu, Kathleen/0000-0003-4891-8649				Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Janz DR, 2015, CRIT CARE MED, V43, P534, DOI 10.1097/CCM.0000000000000718; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Lee CR, 2015, NEW ENGL J MED, V373, P2183, DOI 10.1056/NEJMcibr1511280; Opal SM, 2014, CRIT CARE MED, V42, P1714, DOI 10.1097/CCM.0000000000000325; Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6	9	14	14	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2016	315	8					747	748		10.1001/jama.2016.0661	http://dx.doi.org/10.1001/jama.2016.0661			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE5VH	26903328				2023-01-03	WOS:000370700500005
J	Guo, RN; Zheng, HZ; Ou, CQ; Huang, LQ; Zhou, Y; Zhang, X; Liang, CK; Lin, JY; Zhong, HJ; Song, T; Luo, HM				Guo, Ru-ning; Zheng, Hui-zhen; Ou, Chun-quan; Huang, Li-qun; Zhou, Yong; Zhang, Xin; Liang, Can-kun; Lin, Jin-yan; Zhong, Hao-jie; Song, Tie; Luo, Hui-ming			Impact of Influenza on Outpatient Visits, Hospitalizations, and Deaths by Using a Time Series Poisson Generalized Additive Model	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; SEASONAL INFLUENZA; ECONOMIC BURDEN; MORTALITY; ILLNESS	Background The disease burden associated with influenza in developing tropical and subtropical countries is poorly understood owing to the lack of a comprehensive disease surveillance system and information-exchange mechanisms. The impact of influenza on outpatient visits, hospital admissions, and deaths has not been fully demonstrated to date in south China. Methods A time series Poisson generalized additive model was used to quantitatively assess influenza-like illness (ILI) and influenza disease burden by using influenza surveillance data in Zhuhai City from 2007 to 2009, combined with the outpatient, inpatient, and respiratory disease mortality data of the same period. Results The influenza activity in Zhuhai City demonstrated a typical subtropical seasonal pattern; however, each influenza virus subtype showed a specific transmission variation. The weekly ILI case number and virus isolation rate had a very close positive correlation (r = 0.774, P < 0.0001). The impact of ILI and influenza on weekly outpatient visits was statistically significant (P < 0.05). We determined that 10.7% of outpatient visits were associated with ILI and 1.88% were associated with influenza. ILI also had a significant influence on the hospitalization rates (P < 0.05), but mainly in populations < 25 years of age. No statistically significant effect of influenza on hospital admissions was found (P > 0.05). The impact of ILI on chronic obstructive pulmonary disease (COPD) was most significant (P < 0.05), with 33.1% of COPD-related deaths being attributable to ILI. The impact of influenza on the mortality rate requires further evaluation. Conclusions ILI is a feasible indicator of influenza activity. Both ILI and influenza have a large impact on outpatient visits. Although ILI affects the number of hospital admissions and deaths, we found no consistent influence of influenza, which requires further assessment.	[Guo, Ru-ning] Ctr Dis Control & Prevent Guangdong Prov, Publ Hlth Emergency Management Off, Guangzhou, Guangdong, Peoples R China; [Zheng, Hui-zhen] Ctr Dis Control & Prevent Guangdong Prov, Inst Immunizat Programs, Guangzhou, Guangdong, Peoples R China; [Ou, Chun-quan] Southern Med Univ, Sch Publ Hlth, Dept Biostat, Guangzhou, Guangdong, Peoples R China; [Huang, Li-qun; Zhou, Yong; Liang, Can-kun] Zhuhai Municipal Ctr Dis Control & Prevent, Zhuhai, Peoples R China; [Zhang, Xin] Ctr Dis Control & Prevent Guangdong Prov, Inst Pathogen Microorganisms, Guangzhou, Guangdong, Peoples R China; [Lin, Jin-yan; Song, Tie] Ctr Dis Control & Prevent Guangdong Prov, Guangzhou, Guangdong, Peoples R China; [Zhong, Hao-jie] Ctr Dis Control & Prevent Guangdong Prov, Inst Infect Dis Prevent & Control, Guangzhou, Guangdong, Peoples R China; [Luo, Hui-ming] Ctr Dis Control & Prevent, Beijing, Peoples R China	Southern Medical University - China; Chinese Center for Disease Control & Prevention	Zheng, HZ (corresponding author), Ctr Dis Control & Prevent Guangdong Prov, Inst Immunizat Programs, Guangzhou, Guangdong, Peoples R China.	zhz@cdcp.org.cn		Ou, Chun-Quan/0000-0001-6866-7213	World Health Organization [WP/2008/CHN/02/CSR/PE 15.01]; Medical Research Foundation of Guangdong Province, China [A2007079]	World Health Organization(World Health Organization); Medical Research Foundation of Guangdong Province, China	The work was supported by grants from the World Health Organization (WP/2008/CHN/02/CSR/PE 15.01), and Medical Research Foundation of Guangdong Province, China (project number: A2007079). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ai-ping D, 2008, S CHINA J PREVENTIVE, V34, P14; Bhuiyan MU, 2014, INFLUENZA OTHER RESP, V8, P406, DOI 10.1111/irv.12254; Burton C, 2014, PEDIATR INFECT DIS J, V33, P710, DOI 10.1097/INF.0000000000000272; Chaves SS, 2014, PEDIATR INFECT DIS J, V33, P912, DOI 10.1097/INF.0000000000000321; Chiu SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092914; Chow A, 2006, EMERG INFECT DIS, V12, P114, DOI 10.3201/eid1201.050826; Chowell G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-214; Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013; Dushoff J, 2006, AM J EPIDEMIOL, V163, P181, DOI 10.1093/aje/kwj024; Emukule GO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105543; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Guo RN, 2011, PUBLIC HEALTH, V125, P389, DOI 10.1016/j.puhe.2011.03.004; Guo RN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041403; Ortiz JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113903; Ortiz JR, 2014, CRIT CARE MED, V42, P2325, DOI 10.1097/CCM.0000000000000545; Ping H, 2004, CHINESE J DIS CONTRO, V8, P144; Shortridge K F, 1992, Semin Respir Infect, V7, P11; Silva ML, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-56; Thompson WW, 2009, AM J PUBLIC HEALTH, V99, pS225, DOI 10.2105/AJPH.2008.151944; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tsai Y, 2014, OCCUP MED-OXFORD, V64, P341, DOI 10.1093/occmed/kqu022; Wang DM, 2004, CHINESE J EPIDEMIOLO, V01; WHO, PRACT GUID DES COND; WISELKA M, 1994, BRIT MED J, V308, P1341, DOI 10.1136/bmj.308.6940.1341; Wong C M, 2012, Hong Kong Med J, V18 Suppl 2, P8; Wong CM, 2004, CLIN INFECT DIS, V39, P1611, DOI 10.1086/425315; Wu AP, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000882; Yang L, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-342; Yang L, 2011, VACCINE, V29, P8909, DOI 10.1016/j.vaccine.2011.09.071; Yu H, 2012, INFLUENZA OTHER RESP, V8, P53, DOI DOI 10.1111/IRV.12205	31	13	16	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2016	11	2							e0149468	10.1371/journal.pone.0149468	http://dx.doi.org/10.1371/journal.pone.0149468			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3DG	26894876	Green Submitted, Green Published, gold			2023-01-03	WOS:000371223400057
J	Tang, MF; Hammond, GR; Badcock, DR				Tang, Matthew F.; Hammond, Geoffrey R.; Badcock, David R.			Are Participants Aware of the Type and Intensity of Transcranial Direct Current Stimulation?	PLOS ONE			English	Article							MOTOR CORTEX; VISUAL PSYCHOPHYSICS; MAJOR DEPRESSION; DC STIMULATION; CLINICAL-TRIAL; TDCS; MODULATION; CONSOLIDATION; PERCEPTION; COMFORT	Transcranial direct current stimulation (tDCS) is commonly used to alter cortical excitability but no experimental study has yet determined whether human participants are able to distinguish between the different types (anodal, cathodal, and sham) of stimulation. If they can then they are not blind to experimental conditions. We determined whether participants could identify different types of stimulation (anodal, cathodal, and sham) and current strengths after experiencing the sensations of stimulation during current onset and offset (which are associated with the most intense sensations) in Experiment 1 and also with a prolonged period of stimulation in Experiment 2. We first familiarized participants with anodal, cathodal, and sham stimulation at both 1 and 2 mA over either primary motor or visual cortex while their sensitivity to small changes in visual stimuli was assessed. The different stimulation types were then applied for a short (Experiment 1) or extended (Experiment 2) period with participants indicating the type and strength of the stimulation on the basis of the evoked sensations. Participants were able to identify the intensity of stimulation with shorter, but not longer periods, of stimulation at better than chance levels but identification of the different stimulation types was at chance levels. This result suggests that even after exposing participants to stimulation, and ensuring they are fully aware of the existence of a sham condition, they are unable to identify the type of stimulation from transient changes in stimulation intensity or from more prolonged stimulation. Thus participants are able to identify intensity of stimulation but not the type of stimulation.	[Tang, Matthew F.; Hammond, Geoffrey R.; Badcock, David R.] Univ Western Australia, Sch Psychol, Crawley, WA, Australia; [Tang, Matthew F.] Univ Queensland, Queensland Brain Inst, St Lucia, Qld, Australia	University of Western Australia; University of Queensland	Tang, MF (corresponding author), Univ Western Australia, Sch Psychol, Crawley, WA, Australia.; Tang, MF (corresponding author), Univ Queensland, Queensland Brain Inst, St Lucia, Qld, Australia.	m.tang1@uq.edu.au	Badcock, David R/A-4913-2008; Tang, Matthew/E-6520-2016	Badcock, David R/0000-0002-4517-435X; Tang, Matthew/0000-0001-5858-5126	Australian Research Council [DP130102580, DP110104553]; University of Western Australia	Australian Research Council(Australian Research Council); University of Western Australia	This work was supported by Australian Research Council grants DP130102580 and DP110104553 to DRB. The University of Western Australia also provided a scholarship to MFT.	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Antal A, 2003, EXP BRAIN RES, V150, P375, DOI 10.1007/s00221-003-1459-8; Antal A, 2006, BRAIN RES BULL, V68, P459, DOI 10.1016/j.brainresbull.2005.10.006; Boggio PS, 2008, INT J NEUROPSYCHOPH, V11, P249, DOI 10.1017/S1461145707007833; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Brunoni AR, 2014, CLIN NEUROPHYSIOL, V125, P298, DOI 10.1016/j.clinph.2013.07.020; Cecere R, 2013, J NEUROSCI, V33, P6469, DOI 10.1523/JNEUROSCI.3431-12.2013; Dundas JE, 2007, CLIN NEUROPHYSIOL, V118, P1166, DOI 10.1016/j.clinph.2007.01.010; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Horvath JC, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00002; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528; Moos K, 2012, J NEUROSCI, V32, P16360, DOI 10.1523/JNEUROSCI.6233-11.2012; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Palm U, 2013, BRAIN STIMUL, V6, P690, DOI 10.1016/j.brs.2013.01.005; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Peters MAK, 2013, NEUROPSYCHOLOGIA, V51, P1234, DOI 10.1016/j.neuropsychologia.2013.03.013; Petrov Y, 2005, J NEUROSCI, V25, P8704, DOI 10.1523/JNEUROSCI.2871-05.2005; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; Spiegel DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036220; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Tang MF, 2013, J VISION, V13, DOI 10.1167/13.13.20; Tang MF, 2013, EUR J NEUROSCI, V38, P2802, DOI 10.1111/ejn.12280; TANG MF, 2015, J VISION, V15, DOI DOI 10.1167/15.13.4	31	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0148825	10.1371/journal.pone.0148825	http://dx.doi.org/10.1371/journal.pone.0148825			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6PR	26863314	Green Submitted, gold, Green Published			2023-01-03	WOS:000370046600111
J	van Leeuwen, N; Lingsma, HF; Vanrolleghem, AM; Sturkenboom, MCJM; van Doorn, PA; Steyerberg, EW; Jacobs, BC				van Leeuwen, Nikki; Lingsma, Hester F.; Vanrolleghem, Ann M.; Sturkenboom, Miriam C. J. M.; van Doorn, Pieter A.; Steyerberg, Ewout W.; Jacobs, Bart C.			Hospital Admissions, Transfers and Costs of Guillain-Barre Syndrome	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS	Background Guillain-Barre syndrome (GBS) has a highly variable clinical course, leading to frequent transfers within and between hospitals and high associated costs. We defined the current admissions, transfers and costs in relation to disease severity of GBS. Methods Dutch neurologists were requested to report patients diagnosed with GBS between November 2009 and November 2010. Information regarding clinical course and transfers was obtained via neurologists and general practitioners. Results 87 GBS patients were included with maximal GBS disability score of 1 or 2 (28%), 3 or 4 (53%), 5 (18%) and 6 (1%). Four mildly affected GBS patients were not hospital admitted. Of the 83 hospitalized patients 68 (82%) were initially admitted at a neurology department, 4 (5%) at an ICU, 4 (5%) at pediatrics, 4 (5%) at pediatrics neurology and 3 (4%) at internal medicine. Median hospital stay was 17 days (IQR 11-26 days, absolute range 1-133 days). Transfers between departments or hospitals occurred in 33 (40%) patients and 25 (30%) were transferred 2 times or more. From a cost-effectiveness perspective 21 (25%) of the admissions was suboptimal. Median costs for hospital admission of GBS patients were 15,060 Euro (IQR 11,226-23,683). Maximal GBS disability score was significantly correlated with total length of stay, number of transfers, ICU admission and costs. Conclusions Hospital admissions for GBS patients are highly heterogeneous, with frequent transfers and higher costs for those with more severe disease. Future research should aim to develop prediction models to early identify the most cost-effective allocation in individual patients.	[van Leeuwen, Nikki; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Vanrolleghem, Ann M.; Sturkenboom, Miriam C. J. M.] Erasmus MC, Dept Med Informat, POB 2040, NL-3000 CA Rotterdam, Netherlands; [van Doorn, Pieter A.; Jacobs, Bart C.] Erasmus MC, Dept Neurol, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Jacobs, Bart C.] Erasmus MC, Dept Immunol, POB 2040, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Leeuwen, N (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	n.vanleeuwen.1@erasmusmc.nl	Jacobs, Bart/ABE-2210-2021	Sturkenboom, Miriam/0000-0003-1360-2388				[Anonymous], HANDLEIDING KOSTENON; Barratt H, 2012, CRIT CARE, V16, DOI 10.1186/cc11662; de Wit Marie-Claire Y, 2011, Ned Tijdschr Geneeskd, V155, pA3808; Dieleman J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3908; Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285; Frenzen PD, 2008, NEUROLOGY, V71, P21, DOI 10.1212/01.wnl.0000316393.54258.d1; Havelaar AH, 2000, EPIDEMIOL INFECT, V125, P505, DOI 10.1017/S0950268800004933; Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; Hughes RAC, 2007, BRAIN, V130, P2245, DOI 10.1093/brain/awm004; Ligtenberg JJM, 2005, CRIT CARE, V9, pR446, DOI 10.1186/cc3749; Mehndiratta M M, 2001, J Assoc Physicians India, V49, P459; Nagpal S, 1999, J CLIN APHERESIS, V14, P107, DOI 10.1002/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3; Roodbol J, 2011, NEUROLOGY, V76, P807, DOI 10.1212/WNL.0b013e31820e7b62; Ruts L, 2005, NEUROLOGY, V65, P138, DOI 10.1212/01.wnl.0000167549.09664.b8; Ruts L, 2010, NEUROLOGY, V75, P1439, DOI 10.1212/WNL.0b013e3181f88345; Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003; Van Koningsveld R, 2001, NEUROLOGY, V56, P564, DOI 10.1212/WNL.56.4.564; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Walgaard C, 2011, NEUROLOGY, V76, P968, DOI 10.1212/WNL.0b013e3182104407; Walgaard C, 2010, ANN NEUROL, V67, P781, DOI 10.1002/ana.21976; Winters JL, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-101	22	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0143837	10.1371/journal.pone.0143837	http://dx.doi.org/10.1371/journal.pone.0143837			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859880	gold, Green Published, Green Submitted			2023-01-03	WOS:000370038400001
J	Muller, A; Eller, J; Albrecht, F; Prochnow, P; Kuhlmann, K; Bandow, JE; Slusarenko, AJ; Leichert, LIO				Mueller, Alexandra; Eller, Jakob; Albrecht, Frank; Prochnow, Pascal; Kuhlmann, Katja; Bandow, Julia Elisabeth; Slusarenko, Alan John; Leichert, Lars Ingo Ole			Allicin Induces Thiol Stress in Bacteria through S-Allylmercapto Modification of Protein Cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; HEAT-SHOCK RESPONSE; ESCHERICHIA-COLI; ANTIBACTERIAL PRINCIPLE; ISOCITRATE LYASE; MODE; IDENTIFICATION; THIOREDOXIN; ANTIOXIDANT; GLUTATHIONE	Allicin (diallyl thiosulfinate) from garlic is a highly potent natural antimicrobial substance. It inhibits growth of a variety of microorganisms, among them antibiotic-resistant strains. However, the precise mode of action of allicin is unknown. Here, we show that growth inhibition of Escherichia coli during allicin exposure coincides with a depletion of the glutathione pool and S-allylmercapto modification of proteins, resulting in overall decreased total sulfhydryl levels. This is accompanied by the induction of the oxidative and heat stress response. We identified and quantified the allicin-induced modification S-allylmercaptocysteine for a set of cytoplasmic proteins by using a combination of label-free mass spectrometry and differential isotope-coded affinity tag labeling of reduced and oxidized thiol residues. Activity of isocitrate lyase AceA, an S-allylmercapto-modified candidate protein, is largely inhibited by allicin treatment in vivo. Allicin-induced protein modifications trigger protein aggregation, which largely stabilizes RpoH and thereby induces the heat stress response. At sublethal concentrations, the heat stress response is crucial to overcome allicin stress. Our results indicate that the mode of action of allicin is a combination of a decrease of glutathione levels, unfolding stress, and inactivation of crucial metabolic enzymes through S-allylmercapto modification of cysteines.	[Mueller, Alexandra; Eller, Jakob; Leichert, Lars Ingo Ole] Ruhr Univ Bochum, Inst Biochem & Pathobiochem Microbial Biochem, D-44780 Bochum, Germany; [Prochnow, Pascal; Bandow, Julia Elisabeth] Ruhr Univ Bochum, Angew Mikrobiol, D-44780 Bochum, Germany; [Kuhlmann, Katja] Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany; [Albrecht, Frank; Slusarenko, Alan John] Rhein Westfal Tech Hsch Aachen Univ, Dept Plant Physiol, D-52056 Aachen, Germany	Ruhr University Bochum; Ruhr University Bochum; Ruhr University Bochum; RWTH Aachen University	Leichert, LIO (corresponding author), Ruhr Univ Bochum, Inst Biochem & Pathobiochem, Microbial Biochem, Univ Str 150, D-44780 Bochum, Germany.	lars.leichert@ruhr-uni-bochum.de	Slusarenko, Alan/AAD-2785-2020; Bandow, Julia/K-8854-2012; Leichert, Lars I./B-4762-2009	Bandow, Julia/0000-0003-4100-8829; Leichert, Lars I./0000-0002-5666-9681; Baumann, Alexandra/0000-0002-6527-5262	Deutsche Forschungsgemeinschaft under German Research Foundation [LE 2905/1-1, SPP1710]; European Research Council (ERC) under the European Union [281384-FuMe]; Ruhr University Research SchoolPLUS; Richtlinien zur Forderung des wissenschaftlichen Nachwuchses der Rheinisch-Westfalischen Technischen Hochschule Aachen (RFwN); Rheinisch-Westfalische Technische Hochschule Aachen (RWTH); German Federal state of North Rhine-Westphalia	Deutsche Forschungsgemeinschaft under German Research Foundation(German Research Foundation (DFG)); European Research Council (ERC) under the European Union(European Research Council (ERC)); Ruhr University Research SchoolPLUS; Richtlinien zur Forderung des wissenschaftlichen Nachwuchses der Rheinisch-Westfalischen Technischen Hochschule Aachen (RFwN); Rheinisch-Westfalische Technische Hochschule Aachen (RWTH); German Federal state of North Rhine-Westphalia	This work was supported in part by Deutsche Forschungsgemeinschaft Grant LE 2905/1-1 under Priority Program SPP1710 of the German Research Foundation and by the European Research Council (ERC) under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement 281384-FuMe (to L. I. O. L.). This manuscript was written in part during a paper writing retreat sponsored by the Ruhr University Research SchoolPLUS. The authors declare that they have no conflicts of interest with the contents of this article.; Supported by Richtlinien zur Forderung des wissenschaftlichen Nachwuchses der Rheinisch-Westfalischen Technischen Hochschule Aachen (RFwN) and Rheinisch-Westfalische Technische Hochschule Aachen (RWTH).; Supported by funding from the German Federal state of North Rhine-Westphalia "Translation innovativer Antibiotika aus NRW."	Albada HB, 2012, BEILSTEIN J ORG CHEM, V8, P1753, DOI 10.3762/bjoc.8.200; Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3; Appel E, 2010, ANTIMICROB AGENTS CH, V54, P898, DOI 10.1128/AAC.01267-09; Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Banerjee SK, 2003, PHYTOTHER RES, V17, P97, DOI 10.1002/ptr.1281; Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591; Cai Y, 2007, J ANTIBIOT, V60, P335, DOI 10.1038/ja.2007.45; Cavallito CJ, 1944, J AM CHEM SOC, V66, P1950, DOI 10.1021/ja01239a048; Cavallito CJ, 1944, J AM CHEM SOC, V66, P1952, DOI 10.1021/ja01239a049; Cavallo L, 2003, NUCLEIC ACIDS RES, V31, P3364, DOI 10.1093/nar/gkg601; CHELL RM, 1978, BIOCHEM J, V173, P165, DOI 10.1042/bj1730165; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Curtis H, 2004, PHYSIOL MOL PLANT P, V65, P79, DOI 10.1016/j.pmpp.2004.11.006; Cutler RR, 2004, BRIT J BIOMED SCI, V61, P71, DOI 10.1080/09674845.2004.11732646; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; ELLMORE GS, 1994, AM J BOT, V81, P89, DOI 10.2307/2445567; FELDBERG RS, 1988, ANTIMICROB AGENTS CH, V32, P1763, DOI 10.1128/AAC.32.12.1763; FREEMAN F, 1995, J AGR FOOD CHEM, V43, P2332, DOI 10.1021/jf00057a004; GHANNOUM MA, 1988, J GEN MICROBIOL, V134, P2917; Gruhlke MCH, 2010, FREE RADICAL BIO MED, V49, P1916, DOI 10.1016/j.freeradbiomed.2010.09.019; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; LANCASTER JE, 1981, PLANT SCI LETT, V22, P169, DOI 10.1016/0304-4211(81)90139-5; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Leichert LI, 2008, P NATL ACAD SCI USA, V105, P8197, DOI 10.1073/pnas.0707723105; Leichert LIO, 2003, J BACTERIOL, V185, P1967, DOI 10.1128/JB.185.6.1967-1975.2003; MIRELMAN D, 1987, J INFECT DIS, V156, P243, DOI 10.1093/infdis/156.1.243; Miron T, 2000, BBA-BIOMEMBRANES, V1463, P20, DOI 10.1016/S0005-2736(99)00174-1; Muller A, 2013, J BACTERIOL, V195, P2807, DOI 10.1128/JB.00127-13; Neidhardt F. C., 1996, ESCHERICHIA COLI SAL, P14; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Obrist M, 2005, J BACTERIOL, V187, P3807, DOI 10.1128/JB.187.11.3807-3813.2005; Rabinkov A, 2000, BBA-MOL CELL RES, V1499, P144, DOI 10.1016/S0167-4889(00)00119-1; Rabinkov A, 1998, BBA-GEN SUBJECTS, V1379, P233, DOI 10.1016/S0304-4165(97)00104-9; Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378; Rao R., 1949, P INDIAN ACAD SCI B, V29, P148; Rivlin RS, 2001, J NUTR, V131, p951S, DOI 10.1093/jn/131.3.951S; ROBERTSON AGS, 1995, BIOCHEM J, V305, P239, DOI 10.1042/bj3050239; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Stoll A., 2006, ADV ENZYMOLOGY RELAT, V11, P377; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Wallock-Richards D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112726; Wenzel M, 2013, ACS CHEM BIOL, V8, P1442, DOI 10.1021/cb4000844; Wenzel M, 2011, ANTIMICROB AGENTS CH, V55, P2590, DOI 10.1128/AAC.00078-11; WILLS ED, 1956, BIOCHEM J, V63, P514, DOI 10.1042/bj0630514; YAMADA Y, 1977, ANTIMICROB AGENTS CH, V11, P743, DOI 10.1128/AAC.11.4.743; Zhang H, 2009, PROTEINS, V76, P617, DOI 10.1002/prot.22375; Zhou JD, 2013, NUCLEIC ACIDS RES, V41, pD613, DOI 10.1093/nar/gks1235	53	79	83	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2016	291	22					11477	11490		10.1074/jbc.M115.702308	http://dx.doi.org/10.1074/jbc.M115.702308			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DN7NZ	27008862	Green Published, hybrid			2023-01-03	WOS:000377264800002
J	Stempel, DA; Raphiou, IH; Kral, KM; Yeakey, AM; Emmett, AH; Prazma, CM; Buaron, KS; Pascoe, SJ				Stempel, David A.; Raphiou, Ibrahim H.; Kral, Kenneth M.; Yeakey, Anne M.; Emmett, Amanda H.; Prazma, Charlene M.; Buaron, Kathleen S.; Pascoe, Steven J.		AUSTRI Investigators	Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDA	BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, >= 12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation. RESULTS Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P = 0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001). CONCLUSIONS Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group.	[Stempel, David A.; Raphiou, Ibrahim H.; Yeakey, Anne M.; Prazma, Charlene M.; Buaron, Kathleen S.; Pascoe, Steven J.] GlaxoSmith Kline, Resp Clin Dev, 5 Moore Dr,POB 13398,Res Triangle Pk, Durham, NC 27709 USA; [Kral, Kenneth M.; Emmett, Amanda H.] GlaxoSmith Kline, Res & Dev, Clin Platforms & Sci, Clin Stat, Durham, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline	Stempel, DA (corresponding author), GlaxoSmith Kline, Resp Clin Dev, 5 Moore Dr,POB 13398,Res Triangle Pk, Durham, NC 27709 USA.	david.a.stempel@gsk.com	Jahnz-Różyk, Karina/AAA-2560-2021; Zhebel, Vadym/Q-7058-2019; Shirinsky, Valery/I-5653-2018; Barbé, Ferran/A-5988-2010; Kryuchko, T. A./W-4506-2017; Upham, John/F-4420-2010; Panina, Svitlana/W-2900-2019; Arnedillo, Aurelio/AAK-7390-2020; Blazowski, Lukasz/AAO-9756-2020; Shpagina, Lyubov/Y-7864-2018; Esposito, Susanna/K-3475-2016	Jahnz-Różyk, Karina/0000-0002-3505-1858; Zhebel, Vadym/0000-0002-6542-9313; Shirinsky, Valery/0000-0002-4922-9303; Barbé, Ferran/0000-0002-2340-8928; Kryuchko, T. A./0000-0002-5034-4181; Upham, John/0000-0002-0017-3433; Panina, Svitlana/0000-0003-1080-7185; Arnedillo, Aurelio/0000-0002-2267-057X; Shpagina, Lyubov/0000-0003-0871-7551; Soler-Sempere, MariaJose/0000-0002-6607-2037; , iemoli/0000-0003-1510-9677; Valdes, Luis/0000-0003-2540-8013; Blazowski, Lukasz/0000-0002-6387-2768; Bozek, Andrzej/0000-0003-2263-2263; Antuni, Julio Daniel/0000-0002-9069-0855; Seddon, Paul/0000-0003-2136-958X; Comellas, Alejandro/0000-0003-1521-7520; Esposito, Susanna/0000-0003-4103-2837; Robinson, Paul/0000-0001-7397-105X; Ioachimescu, Octavian/0000-0001-9047-6894; Vukcevic, Miodrag/0000-0002-6218-3848; /0000-0002-8537-9165	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	Supported by GlaxoSmithKline.	[Anonymous], 2007, CYTEL E 5 USER MANUA; Bateman E, 2008, ANN INTERN MED, V149, P33, DOI 10.7326/0003-4819-149-1-200807010-00229; Bateman ED, 2014, THORAX, V69, P312, DOI 10.1136/thoraxjnl-2013-203600; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Cates CJ, 2008, COCHRANE DB SYST REV, V3; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; CRANE J, 1989, LANCET, V1, P917; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; *GINA, 2007, GLOB STRAT ASTHM MAN; Jennison C, 1999, GROUP SEQUENTIAL MET; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; McMahon AW, 2011, PEDIATRICS, V128, pE1147, DOI 10.1542/peds.2010-1720; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; National Institute of Health, 2007, GUID DIAGN MAN ASTHM; Nelson H, 2010, J ALLERGY CLIN IMMUN, V125, P390, DOI 10.1016/j.jaci.2009.11.036; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sadatsafavi M, 2014, THORAX, V69, P328, DOI 10.1136/thoraxjnl-2013-203998; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Salpeter SR, 2010, EXPERT OPIN DRUG SAF, V9, P407, DOI 10.1517/14740330903535852; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P570, DOI 10.1016/j.jaip.2014.05.002; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608	27	114	115	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2016	374	19					1822	1830		10.1056/NEJMoa1511049	http://dx.doi.org/10.1056/NEJMoa1511049			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL6JS	26949137	Green Published, Bronze			2023-01-03	WOS:000375746100005
J	Wise, J				Wise, Jacqui			Dilute apple juice is good alternative to electrolyte fluids for children with gastroenteritis, study finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Freedman SB, 2016, JAMA-J AM MED ASSOC, V315, P1966, DOI 10.1001/jama.2016.5352	1	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2016	353								i2479	10.1136/bmj.i2479	http://dx.doi.org/10.1136/bmj.i2479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL4AE	27143366				2023-01-03	WOS:000375574000012
J	Svensson, K; Albert, V; Cardel, B; Salatino, S; Handschin, C				Svensson, Kristoffer; Albert, Verena; Cardel, Bettina; Salatino, Silvia; Handschin, Christoph			Skeletal muscle PGC-1 alpha modulates systemic ketone body homeostasis and ameliorates diabetic hyperketonemia in mice	FASEB JOURNAL			English	Article						ketone body metabolism; diabetes; exercise; ketoacidosis; transcriptional regulation	TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; PROLIFERATOR-ACTIVATED RECEPTOR; ENERGY-METABOLISM; REGULATORY SITES; GENE-EXPRESSION; ERR-ALPHA; EXERCISE; RATS; KETOACIDOSIS; DISORDERS	Ketone bodies (KBs) are crucial energy substrates during states of low carbohydrate availability. However, an aberrant regulation of KB homeostasis can lead to complications such as diabetic ketoacidosis. Exercise and diabetes affect systemic KB homeostasis, but the regulation of KB metabolism is still enigmatic. In our study in mice with either knockout or overexpression of the peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1 alpha in skeletal muscle, PGC-1 alpha regulated ketolytic gene transcription in muscle. Furthermore, KB homeostasis of these mice was investigated during withholding of food, exercise, and ketogenic diet feeding, and after streptozotocin injection. In response to these ketogenic stimuli, modulation of PGC-1 alpha levels in muscle affected systemic KB homeostasis. Moreover, the data demonstrate that skeletal muscle PGC-1 alpha is necessary for the enhanced ketolytic capacity in response to exercise training and overexpression of PGC-1 alpha in muscle enhances systemic ketolytic capacity and is sufficient to ameliorate diabetic hyperketonemia in mice. In cultured myotubes, the transcription factor estrogen-related receptor-a was a partner of PGC-1 alpha In the regulation of ketolytic gene transcription. These results demonstrate a central role of skeletal muscle PGC-1 alpha in the transcriptional regulation of systemic ketolytic capacity.-Svensson, K., Albert, V., Cardel, B., Salatino, S., Handschin, C. Skeletal muscle PGC-1 alpha modulates systemic ketone body homeostasis and ameliorates diabetic hyperketonemia in mice. www.fasebj.org	[Svensson, Kristoffer; Albert, Verena; Cardel, Bettina; Salatino, Silvia; Handschin, Christoph] Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland	University of Basel	Handschin, C (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	christoph.handschin@unibas.ch	Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097; Salatino, Silvia/0000-0003-1286-3076	ERC [616830-MUSCLE_NET]; Swiss National Science Foundation, SystemsX.ch; Swiss Society for Research on Muscle Diseases (SSEM); Novartis Foundation for Medical-Biological Research; University of Basel; Biozentrum	ERC(European Research Council (ERC)European Commission); Swiss National Science Foundation, SystemsX.ch(Swiss National Science Foundation (SNSF)); Swiss Society for Research on Muscle Diseases (SSEM); Novartis Foundation for Medical-Biological Research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); University of Basel; Biozentrum	The authors thank Prof. A. Kralli (Scripps Research Institute, La Jolla, CA, USA) for the providing the shERR alpha adenovirus. This project was funded by ERC Consolidator Grant 616830-MUSCLE_NET, the Swiss National Science Foundation, SystemsX.ch, the Swiss Society for Research on Muscle Diseases (SSEM), the Novartis Foundation for Medical-Biological Research, the University of Basel, and the Biozentrum. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. K.S. and C.H. designed research and wrote the manuscript; K.S., V.A., B.C., and S.S. performed research and analyzed data. The authors declare no conflicts of interest.	ADAMS JH, 1988, J PHYSIOL-LONDON, V407, P453, DOI 10.1113/jphysiol.1988.sp017425; Arnold P, 2012, BIOINFORMATICS, V28, P487, DOI 10.1093/bioinformatics/btr695; Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662; Baresic M, 2014, MOL CELL BIOL, V34, P2996, DOI 10.1128/MCB.01710-13; Burgess SC, 2006, J BIOL CHEM, V281, P19000, DOI 10.1074/jbc.M600050200; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; Cotter DG, 2013, AM J PHYSIOL-HEART C, V304, pH1060, DOI 10.1152/ajpheart.00646.2012; Cotter DG, 2011, J BIOL CHEM, V286, P6902, DOI 10.1074/jbc.M110.192369; El Midaoui A, 2005, AM J PHYSIOL-ENDOC M, V288, pE748, DOI 10.1152/ajpendo.00515.2004; Geng TY, 2010, AM J PHYSIOL-CELL PH, V298, pC572, DOI 10.1152/ajpcell.00481.2009; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; JOHNSON RH, 1972, Q J EXP PHYSIOL CMS, V57, P73, DOI 10.1113/expphysiol.1972.sp002139; JOHNSON RH, 1969, LANCET, V2, P452; Kamel KS, 2015, NEW ENGL J MED, V372, P546, DOI 10.1056/NEJMra1207788; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; McNeill J. H, 1999, EXPT MODELS DIABETES; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OHMORI H, 1990, ENDOCRINOL JAPON, V37, P421; Pachkov M, 2013, NUCLEIC ACIDS RES, V41, pD214, DOI 10.1093/nar/gks1145; Perez-Schindler J, 2013, P NATL ACAD SCI USA, V110, P20314, DOI 10.1073/pnas.1312039110; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pugliese G, 2009, DIABETES-METAB RES, V25, pS11, DOI 10.1002/dmrr.982; Shafqat N, 2013, J INHERIT METAB DIS, V36, P983, DOI 10.1007/s10545-013-9589-z; Summermatter S, 2013, P NATL ACAD SCI USA, V110, P8738, DOI 10.1073/pnas.1212976110; Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005; Westerberg DP, 2013, AM FAM PHYSICIAN, V87, P337; WINDER WW, 1974, EUR J BIOCHEM, V47, P461, DOI 10.1111/j.1432-1033.1974.tb03713.x; Zhang Y, 2006, J BIOL CHEM, V281, P39897, DOI 10.1074/jbc.M608657200	32	25	25	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2016	30	5					1976	1986		10.1096/fj.201500128	http://dx.doi.org/10.1096/fj.201500128			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DK4HW	26849960	Green Accepted			2023-01-03	WOS:000374879400025
J	Gould, IM; Lawes, T				Gould, Ian M.; Lawes, Timothy			Antibiotic stewardship: prescribing social norms	LANCET			English	Editorial Material							RESISTANCE		[Gould, Ian M.] Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen, Scotland; [Lawes, Timothy] Royal Aberdeen Childrens Hosp, Aberdeen AB25 2ZN, Scotland	University of Aberdeen; University of Aberdeen	Lawes, T (corresponding author), Royal Aberdeen Childrens Hosp, Aberdeen AB25 2ZN, Scotland.	t.lawes@nhs.net		Lawes, Timothy/0000-0003-4393-245X				Cole A, 2014, BMJ-BRIT MED J, V349, P5238; Dar OA, 2016, LANCET, V387, P285, DOI 10.1016/S0140-6736(15)00520-6; Davey P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub3; Department of Health and Department for Environment Food and Rural Afairs, 2013, UK 5 YEAR ANT RES AM; European Centre for Disease prevention and Control, ANT CONS INT DAT ESA; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Hallsworth M, 2016, LANCET; Health Protection Scotland and Information Services Division, 2014, REP ANT US RES HUM 2; Lawes T, 2015, LANCET INFECT DIS, V15, P1438, DOI 10.1016/S1473-3099(15)00315-1; Molstad S, 2008, LANCET INFECT DIS, V8, P125, DOI 10.1016/S1473-3099(08)70017-3; Outterson K, 2010, CLIN INFECT DIS, V51, P751, DOI 10.1086/655955; Peterson LR, 2005, CLIN MICROBIOL INFEC, V11, P4, DOI 10.1111/j.1469-0691.2005.01238.x; Teillant A, 2015, LANCET INFECT DIS, V15, P1429, DOI 10.1016/S1473-3099(15)00270-4	13	11	11	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	2016	387	10029					1699	1701		10.1016/S0140-6736(16)00007-6	http://dx.doi.org/10.1016/S0140-6736(16)00007-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DJ9OD	26898851	hybrid			2023-01-03	WOS:000374541900006
J	Ailabouni, NJ; Nishtala, PS; Mangin, D; Tordoff, JM				Ailabouni, Nagham J.; Nishtala, Prasad S.; Mangin, Dee; Tordoff, June M.			Challenges and Enablers of Deprescribing: A General Practitioner Perspective	PLOS ONE			English	Article							PRIMARY-CARE; MULTIPLE CONDITIONS; OLDER-PEOPLE; MEDICATION; POLYPHARMACY; IMPACT; MULTIMORBIDITY; FEASIBILITY; GUIDELINES; BENEFITS	Aims Deprescribing is the process of reducing or discontinuing medicines that are unnecessary or deemed to be harmful. We aimed to investigate general practitioner (GP) perceived challenges to deprescribing in residential care and the possible enablers that support GPs to implement deprescribing. Methods A qualitative study was undertaken using semi-structured, face-to-face interviews from two cities in New Zealand and a purpose-developed pilot-tested interview schedule. Interviews were recorded with permission and transcribed verbatim. Transcripts were read and re-read and themes were identified with iterative building of a coding list until all data was accounted for. Interviews continued until saturation of ideas occurred. Analysis was carried out with the assistance of a Theoretical Domains Framework (TDF) and constant comparison techniques. Several themes were identified. Challenges and enablers of deprescribing were determined based on participants' answers. Results Ten GPs agreed to participate. Four themes were identified to define the issues around prescribing for older people, from the GPs' perspectives. Theme 1, the 'recognition of the problem', discusses the difficulties involved with prescribing for older people. Theme 2 outlines the identified behaviour change factors relevant to the problem. Deprescribing challenges were drawn from these factors and summarised in Theme 3 under three major headings; 'prescribing factors', 'social influences' and 'policy and processes'. Deprescribing enablers, based on the opinions and professional experience of GPs, were retrieved and summarised in Theme 4. Conclusion The process of deprescribing is laced with many challenges for GPs. The uncertainty of research evidence in older people and social factors such as specialists' and nurses' influences were among the major challenges identified. Deprescribing enablers encompassed support for GPs' awareness and knowledge, improvement of communication between multiple prescribers, adequate reimbursement and pharmacists being involved in the multidisciplinary team.	[Ailabouni, Nagham J.; Nishtala, Prasad S.; Tordoff, June M.] Univ Otago, Sch Pharm, Dunedin, New Zealand; [Mangin, Dee] McMaster Univ, David Braley Chair Family Med, Hamilton, ON, Canada; [Mangin, Dee] Univ Otago, Christchurch, New Zealand	University of Otago; McMaster University; University of Otago	Ailabouni, NJ (corresponding author), Univ Otago, Sch Pharm, Dunedin, New Zealand.	Nagham.ailabouni@otago.ac.nz	Nishtala, Prasad/B-6988-2012; Ailabouni, Nagham J/AAE-9720-2021	Nishtala, Prasad/0000-0002-4155-8540; Ailabouni, Nagham J/0000-0002-6732-745X; Tordoff, June/0000-0001-5571-7592; Mangin, Dee/0000-0003-2149-9376	New Zealand Lottery Health Research; New Zealand Pharmacy Education and Research Foundation (NZPERF)	New Zealand Lottery Health Research; New Zealand Pharmacy Education and Research Foundation (NZPERF)	New Zealand Lottery Health Research provided the scholarship for this PhD (http://www.communitymatters.govt.nz/Funding-and-grants-Lottery-grants-Lottery-Health-Research); and the New Zealand Pharmacy Education and Research Foundation (NZPERF) provided funding for the employment of a transcriber for the interviews in this study (http://www.psnz.org.nz/Category?Action=View&Category_id=155). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; Betteridge TM, 2012, INTERN MED J, V42, P208, DOI 10.1111/j.1445-5994.2011.02690.x; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Cumming RG, 2003, CNS DRUGS, V17, P825, DOI 10.2165/00023210-200317110-00004; Farrell B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122246; Fried TR, 2011, ARCH INTERN MED, V171, P75, DOI 10.1001/archinternmed.2010.318; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Gheewala PA, 2014, DRUG AGING, V31, P825, DOI 10.1007/s40266-014-0208-y; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Gnjidic D, 2012, CLIN GERIATR MED, V28, P237, DOI 10.1016/j.cger.2012.01.006; Guba E.G., 1994, HDB QUALITATIVE RES, P110; Herzog A, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0249-2; Lincoln YS, 1986, IS IT RIGOROUS TRUST; Luijks HD, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X652373; McLarin PE, 2015, CURR MED RES OPIN, V10, P1; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Ministry of Health, 2015, HEALTHCERT B INF SEC; Nishtala PS, 2009, DRUG AGING, V26, P677, DOI 10.2165/11316440-000000000-00000; Olazaran J, 2013, J AM MED DIR ASSOC, V14, P213, DOI 10.1016/j.jamda.2012.10.020; Reeve E, 2015, ANN PHARMACOTHER, V49, P29, DOI 10.1177/1060028014558290; Reeve E, 2014, MED J AUSTRALIA, V201, P386, DOI 10.5694/mja13.00200; Reeve E, 2014, INT J CLIN PHARM-NET, V36, P26, DOI 10.1007/s11096-013-9871-z; Schoen C, 2011, HEALTH AFFAIR, V30, P2437, DOI 10.1377/hlthaff.2011.0923; Schuling J, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-56; Scott IA, 2015, INTERN MED J, V45, P352, DOI 10.1111/imj.12693; Sinnott C, 2015, BRIT J GEN PRACT, V65, pE184, DOI 10.3399/bjgp15X684001; Sinnott C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003610; Sloane PD, 2004, ARCH INTERN MED, V164, P2031, DOI 10.1001/archinte.164.18.2031; Solomon J, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X636119; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458	31	104	105	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0151066	10.1371/journal.pone.0151066	http://dx.doi.org/10.1371/journal.pone.0151066			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27093289	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000374541200001
J	Garfield, S; Jheeta, S; Husson, F; Lloyd, J; Taylor, A; Boucher, C; Jacklin, A; Bischler, A; Norton, C; Hayles, R; Franklin, BD				Garfield, Sara; Jheeta, Seetal; Husson, Fran; Lloyd, Jill; Taylor, Alex; Boucher, Charles; Jacklin, Ann; Bischler, Anna; Norton, Christine; Hayles, Rob; Franklin, Bryony Dean			The Role of Hospital Inpatients in Supporting Medication Safety: A Qualitative Study	PLOS ONE			English	Article							PATIENT INVOLVEMENT; PRESCRIBING ERRORS	Background Inpatient medication errors are a significant concern. An approach not yet widely studied is to facilitate greater involvement of inpatients with their medication. At the same time, electronic prescribing is becoming increasingly prevalent in the hospital setting. In this study we aimed to explore hospital inpatients' involvement with medication safety-related behaviours, facilitators and barriers to this involvement, and the impact of electronic prescribing. Methods We conducted ethnographic observations and interviews in two UK hospital organisations, one with established electronic prescribing and one that changed from paper to electronic prescribing during our study. Researchers and lay volunteers observed nurses' medication administration rounds, pharmacists' ward rounds, doctor-led ward rounds and drug history taking. We also conducted interviews with healthcare professionals, patients and carers. Interviews were audio-recorded and transcribed. Observation notes and transcripts were coded thematically. Results Paper or electronic medication records were shown to patients in only 4 (2%) of 247 cases. However, where they were available during patient-healthcare professional interactions, healthcare professionals often viewed them in order to inform patients about their medicines and answer any questions. Interprofessional discussions about medicines seemed more likely to happen in front of the patient where paper or electronic drug charts were available near the bedside. Patients and carers had more access to paper-based drug charts than electronic equivalents. However, interviews and observations suggest there are potentially more significant factors that affect patient involvement with their inpatient medication. These include patient and healthcare professional beliefs concerning patient involvement, the way in which healthcare professionals operate as a team, and the underlying culture. Conclusion Patients appear to have more access to paper-based records than electronic equivalents. However, to develop interventions to increase patient involvement with medication safety behaviours, a wider range of factors needs to be considered.	[Garfield, Sara; Jheeta, Seetal; Husson, Fran; Lloyd, Jill; Taylor, Alex; Jacklin, Ann; Norton, Christine; Franklin, Bryony Dean] Imperial Coll Healthcare NHS Trust, Ctr Medicat Safety & Serv Qual, London, England; [Garfield, Sara; Franklin, Bryony Dean] UCL Sch Pharm, Res Dept Practice & Policy, BMA House,Tavistock Sq, London, England; [Bischler, Anna] Chelsea & Westminster Healthcare NHS Fdn Trust, Dept Pharm, London, England; [Norton, Christine] Kings Coll London, Fac Nursing & Midwifery, London WC2R 2LS, England; [Norton, Christine] Imperial Coll Healthcare NHS Trust, London, England; [Boucher, Charles] Patients Participat Grp, Walm Lane Surg, London, England; [Hayles, Rob] Meeting Minds, London, England; [Hayles, Rob] Collaborat Leadership Appl Healthcare Res Northwe, London, England	Imperial College London; University of London; University College London; University of London; King's College London; Imperial College London	Garfield, S (corresponding author), Imperial Coll Healthcare NHS Trust, Ctr Medicat Safety & Serv Qual, London, England.; Garfield, S (corresponding author), UCL Sch Pharm, Res Dept Practice & Policy, BMA House,Tavistock Sq, London, England.	sara.garfield@imperial.nhs.uk	Garfield, Sara/F-9941-2019	Garfield, Sara/0000-0002-9980-0520	Health Foundation [7205]	Health Foundation	This study was funded by The Health Foundation (Grant number 7205). The Health Foundation is an independent charity working to continuously improve the quality of healthcare in the UK (http://www.health.org.uk). The Health Foundation funded the roles of SG, AJ, BDF, AB, CN, FH, JL, AT, CB and RH. The Centre for Medication Safety and Service Quality is affiliated with the National Institute for Health Research Imperial Patient Safety Translational Research Centre and the National Institute for Healthcare Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with Public Health England (PHE). The views expressed are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, The PHE or the Department of Health. A member of the Health Foundation was on the patient and clinical engagement group, which met quarterly and provided general contextual information and advice to the research team. Neither the Health Foundation nor the National Institute for Health Research had any specific role in the design, data collection and analysis, decision to publish, or preparation of the manuscript.	Academy of Royal Medical Colleges, 2011, STAND DES HOSP IN PA; Ahmed Z, 2013, PLOS ONE, V8; [Anonymous], 2010, EQ EXC LIB NHS; Brock TP, 2007, AM J HEALTH-SYST PH, V64, P1541, DOI 10.2146/ajhp060444; Caldwell G., 2010, PHARM MANAGE, V26, P3; Cumbler E, 2010, J HOSP MED, V5, P83, DOI 10.1002/jhm.566; Davis RE, 2011, BMJ QUAL SAF, V20, P108, DOI 10.1136/bmjqs.2010.041871; Davis RE, 2012, J PATIENT SAF, V8, P182, DOI 10.1097/PTS.0b013e318267c4aa; de Lusignan S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006021; Entwistle VA, 2010, BMJ QUAL SAF, V19, P33; Fereday J, 2006, INT J QUAL METH, P5, DOI [DOI 10.1177/160940690600500107, 10.1177/160940690600500107]; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Franklin BD, 2011, POSTGRAD MED J, V87, P739, DOI 10.1136/pgmj.2011.117879; Garfield Sara, 2015, Res Involv Engagem, V1, P8, DOI 10.1186/s40900-015-0006-7; Hall J, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.032748; Hibbard JH, 2005, MED CARE RES REV, V62, P601, DOI 10.1177/1077558705279313; Lawton R, 2012, ROLE PATIENT CLIN SA; Lee Lisa, 2015, J Innov Health Inform, V22, P391, DOI 10.14236/jhi.v22i4.176; Manias E, 2015, HEALTH EXPECT, V18, P850, DOI 10.1111/hex.12057; McLeod M, 2015, PLOSONE IN PRESS MAR; McLeod MC, 2013, BMJ QUAL SAF, V22, P278, DOI 10.1136/bmjqs-2012-001330; Milne H, 2016, HEALTH EXPECT, V19, P602, DOI 10.1111/hex.12320; Mohsin-Shaikh S, 2014, INT J CLIN PHARM-NET, V36, P657, DOI 10.1007/s11096-014-9951-8; O'Grady K., 2006, BJHC&IM-British Journal of Healthcare Computing & Information Management, V23, P15; Schwappach D. L., 2010, QUAL SAF HEALTH CARE, V19, P9; Schwappach DLB, 2011, ANN ONCOL, V22, P424, DOI 10.1093/annonc/mdq346; Schwappach DLB, 2010, ONCOLOGIST, V15, P903, DOI 10.1634/theoncologist.2010-0117; Schwappach DLB, 2010, J CLIN ONCOL, V28, P2896, DOI 10.1200/JCO.2009.27.6626; Vincent C., 2010, PATIENT SAFETY, V2nd Ed.; Watt I, 2009, REV STRATEGIES PROMO; Westbrook JI, 2015, INT J QUAL HEALTH C, V27, P1, DOI 10.1093/intqhc/mzu098	31	19	19	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0153721	10.1371/journal.pone.0153721	http://dx.doi.org/10.1371/journal.pone.0153721			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27093438	Green Published, Green Submitted, gold			2023-01-03	WOS:000374541200042
J	Ribeiro, BG; Alves, AN; dos Santos, LAD; Cantero, TM; Fernandes, KPS; Dias, DD; Bernardes, N; De Angelis, K; Mesquita-Ferrari, RA				Ribeiro, Beatriz Guimaraes; Alves, Agnelo Neves; Dias dos Santos, Lucas Andreo; Cantero, Tatiane Matarazzo; Santos Fernandes, Kristianne Porta; Dias, Danielle da Silva; Bernardes, Nathalia; De Angelis, Katia; Mesquita-Ferrari, Raquel Agnelli			Red and Infrared Low-Level Laser Therapy Prior to Injury with or without Administration after Injury Modulate Oxidative Stress during the Muscle Repair Process	PLOS ONE			English	Article							TIBIALIS ANTERIOR MUSCLE; INTENSITY LIGHT THERAPY; SKELETAL-MUSCLE; MAMMALIAN-CELLS; EXPRESSION; FIBROSIS; DAMAGE; MODEL	Introduction Muscle injury is common among athletes and amateur practitioners of sports. Following an injury, the production of reactive oxygen species (ROS) occurs, which can harm healthy muscle fibers (secondary damage) and delay the repair process. Low-level laser therapy (LLLT) administered prior to or following an injury has demonstrated positive and protective effects on muscle repair, but the combination of both administration times together has not been clarified. Aim To evaluate the effect of LLLT (660 nm and 780 nm, 10 J/cm(2), 40 mW, 3.2 J) prior to injury with or without the administration after injury on oxidative stress during the muscle repair process. Methods Wistar rats were divided into following groups: control; muscle injury alone; LLLT 660 nm + injury; LLLT 780 nm + injury; LLLT 660 nm before and after injury; and LLLT 780 nm before and after injury. The rats were euthanized on days 1, 3 and 7 following cryoinjury of the tibialis anterior (TA) muscle, which was then removed for analysis. Results Lipid peroxidation decreased in the 660+injury group after one day. Moreover, red and infrared LLLT employed at both administration times induced a decrease in lipid peroxidation after seven days. CAT activity was altered by LLLT in all periods evaluated, with a decrease after one day in the 780+injury+780 group and after seven days in the 780+injury group as well as an increase in the 780+injury and 780+injury+780 groups after three days. Furthermore, increases in GPx and SOD activity were found after seven days in the 780+injury+780 group. Conclusion The administration of red and infrared laser therapy at different times positively modulates the activity of antioxidant enzymes and reduces stress markers during the muscle repair process.	[Ribeiro, Beatriz Guimaraes; Alves, Agnelo Neves; Cantero, Tatiane Matarazzo; Dias, Danielle da Silva; De Angelis, Katia; Mesquita-Ferrari, Raquel Agnelli] Univ Nove de Julho UNINOVE, Rehabil Dept, Sao Paulo, SP, Brazil; [Dias dos Santos, Lucas Andreo; Santos Fernandes, Kristianne Porta; Mesquita-Ferrari, Raquel Agnelli] Univ Nove de Julho UNINOVE, Biophoton Dept, Sao Paulo, SP, Brazil; [Bernardes, Nathalia] Univ Sao Paulo, Sch Med, Hypertens Unit, Heart Inst InCor, Sao Paulo, SP, Brazil; [De Angelis, Katia] Univ Nove de Julho UNINOVE, Dept Med, Sao Paulo, SP, Brazil	Universidade Nove de Julho; Universidade Nove de Julho; Universidade de Sao Paulo; Universidade Nove de Julho	Mesquita-Ferrari, RA (corresponding author), Univ Nove de Julho UNINOVE, Rehabil Dept, Sao Paulo, SP, Brazil.; Mesquita-Ferrari, RA (corresponding author), Univ Nove de Julho UNINOVE, Biophoton Dept, Sao Paulo, SP, Brazil.	raquel.mesquita@gmail.com	Andreo, Lucas/GQB-0944-2022; Ferrari, Raquel/I-4419-2016; Fernandes, Kristianne Porta Santos/I-4417-2016; DE ANGELIS, KATIA/I-6098-2016; da Silva Dias, Danielle/AAN-7618-2020; Alves, Agnelo N/C-2775-2013; Bernardes, Nathalia/L-7460-2015	Ferrari, Raquel/0000-0001-5142-9526; Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; DE ANGELIS, KATIA/0000-0002-3640-9049; da Silva Dias, Danielle/0000-0003-4152-0849; Alves, Agnelo N/0000-0003-2586-4377; Bernardes, Nathalia/0000-0001-9555-4134	UNINOVE; National Council for Scientific and Technological Development [305739/2014 RAMF, 303662/2012 RAMF]; Coordination for the Improvement of Higher Education Personnel [1510536 BGR]; Sao Paulo Research Foundation [2013/21540-3 ANA, 2014/12381-1 RAMF]	UNINOVE; National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by UNINOVE and the Brazilian fostering agencies: National Council for Scientific and Technological Development (www.cnpq.br; process numbers: 305739/2014 RAMF, 303662/2012 RAMF); Coordination for the Improvement of Higher Education Personnel (www.capes.gov.br; process number: 1510536 BGR); Sao Paulo Research Foundation (www.fapesp.br; process numbers: 2013/21540-3 ANA; 2014/12381-1 RAMF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida P, 2011, PHOTOCHEM PHOTOBIOL, V87, P1159, DOI DOI 10.1111/J.1751-1097.2011.00968.X; Alves AN, 2014, LASER MED SCI, V29, P813, DOI 10.1007/s10103-013-1428-9; Alves AN, 2014, AM J PHYS MED REHAB, V93, P1073, DOI 10.1097/PHM.0000000000000158; Assis L, 2013, LASER MED SCI, V28, P947, DOI 10.1007/s10103-012-1183-3; Assis L, 2012, LASER SURG MED, V44, P726, DOI 10.1002/lsm.22077; Baptista J, 2011, PHOTOMED LASER SURG, V29, P11, DOI 10.1089/pho.2009.2737; Barbieri Elena, 2012, J Signal Transduct, V2012, P982794, DOI 10.1155/2012/982794; Brunelli RM, 2014, LASER MED SCI, V29, P91, DOI 10.1007/s10103-013-1277-6; Conti FF, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-185; de Souza TOF, 2011, LASER MED SCI, V26, P803, DOI 10.1007/s10103-011-0951-9; Ferraresi Cleber, 2012, Photonics Lasers Med, V1, P267; FLECHA BG, 1991, FREE RADICAL BIO MED, V10, P93; Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4; Garg K, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00087; Gharaibeh B, 2012, BIRTH DEFECTS RES C, V96, P82, DOI 10.1002/bdrc.21005; Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b; Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x; Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359; Liu XG, 2009, PHOTOMED LASER SURG, V27, P863, DOI 10.1089/pho.2008.2443; Silveira PCL, 2013, LASER MED SCI, V28, P431, DOI 10.1007/s10103-012-1075-6; Luo L, 2013, LASER MED SCI, V28, P725, DOI 10.1007/s10103-012-1133-0; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; Mesquita-Ferrari RA, 2011, LASER MED SCI, V26, P335, DOI 10.1007/s10103-010-0850-5; Leal ECP, 2015, LASER MED SCI, V30, P925, DOI 10.1007/s10103-013-1465-4; Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040; Quinteiro H, 2015, MENOPAUSE, V22, P534, DOI [10.1097/GME.0000000000000344, 10.1097/gme.0000000000000344]; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Ribeiro BG, 2015, LASER SURG MED, DOI [10.1002/Ism.22381, DOI 10.1002/ISM.22381]; Rizzi CF, 2006, LASER SURG MED, V38, P704, DOI 10.1002/lsm.20371; Fernandes KPS, 2013, LASER MED SCI, V28, P1043, DOI 10.1007/s10103-012-1233-x; Schaur RJ, 2015, BIOMOLECULES, V5, P2247, DOI 10.3390/biom5042247; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Tafur J, 2010, PHOTOMED LASER SURG, V28, P23, DOI 10.1089/pho.2008.2373; Urish KL, 2009, MOL BIOL CELL, V20, P509, DOI 10.1091/mbc.E08-03-0274; Vatansever Fatma, 2012, Photonics Lasers Med, V1, P287	35	20	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0153618	10.1371/journal.pone.0153618	http://dx.doi.org/10.1371/journal.pone.0153618			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ6AH	27082964	Green Published, gold			2023-01-03	WOS:000374291800034
J	Bradley, SM; Liu, WH; Chan, PS; Nallamothu, BK; Grunwald, GK; Self, A; Sasson, C; Varosy, PD; Anderson, ML; Schneider, PM; Ho, PM				Bradley, Steven M.; Liu, Wenhui; Chan, Paul S.; Nallamothu, Brahmajee K.; Grunwald, Gary K.; Self, Alyssa; Sasson, Comilla; Varosy, Paul D.; Anderson, Monique L.; Schneider, Preston M.; Ho, P. Michael		Amer Heart Assoc Get Guidelines-Re	Defibrillation time intervals and outcomes of cardiac arrest in hospital: retrospective cohort study from Get With The Guidelines-Resuscitation registry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-ASSOCIATION GUIDELINES; BIPHASIC WAVE-FORM; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; CHEST COMPRESSIONS; COUNCIL GUIDELINES; CONTROLLED-TRIAL; SURVIVAL; IMPEDANCE; PROTOCOL	OBJECTIVE To describe temporal trends in the time interval between first and second attempts at defibrillation and the association between this time interval and outcomes in patients with persistent ventricular tachycardia or ventricular fibrillation (VT/VF) arrest in hospital. DESIGN Retrospective cohort study. SETTING 172 hospitals in the United States participating in the Get With The Guidelines-Resuscitation registry, 2004-12. PARTICIPANTS Adults who received a second defibrillation attempt for persistent VT/VF arrest within three minutes of a first attempt. INTERVENTIONS Second defibrillation attempts categorized as early (time interval of up to and including one minute between first and second defibrillation attempts) or deferred (time interval of more than one minute between first and second defibrillation attempts). MAIN OUTCOME MEASURE Survival to hospital discharge. RESULTS Among 2733 patients with persistent VT/VF after the first defibrillation attempt, 1121 (41%) received a deferred second attempt. Deferred second defibrillation for persistent VT/VF increased from 26% in 2004 to 57% in 2012 (P<0.001 for trend). Compared with early second defibrillation, unadjusted patient outcomes were significantly worse with deferred second defibrillation (57.4% v 62.5% for return of spontaneous circulation, 38.4% v 43.6% for survival to 24 hours, and 24.7% v 30.8% for survival to hospital discharge; P<0.01 for all comparisons). After risk adjustment, deferred second defibrillation was not associated with survival to hospital discharge (propensity weighting adjusted risk ratio 0.89, 95% confidence interval 0.78 to 1.01; P=0.08; hierarchical regression adjusted 0.92, 0.83 to 1.02; P=0.1). CONCLUSIONS Since 2004, the use of deferred second defibrillation for persistent VT/VF in hospital has doubled. Deferred second defibrillation was not associated with improved survival.	[Bradley, Steven M.; Liu, Wenhui; Grunwald, Gary K.; Varosy, Paul D.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, 1055 Clermont St 111B, Denver, CO 80220 USA; [Bradley, Steven M.; Self, Alyssa; Varosy, Paul D.; Schneider, Preston M.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA; [Bradley, Steven M.; Varosy, Paul D.; Schneider, Preston M.; Ho, P. Michael] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA; [Liu, Wenhui; Grunwald, Gary K.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA; [Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA; [Chan, Paul S.] Univ Missouri, Kansas City, MO 64110 USA; [Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA; [Sasson, Comilla] Amer Heart Assoc, Dallas, TX USA; [Anderson, Monique L.] Duke Clin Res Inst, Durham, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; University of Michigan System; University of Michigan; Duke University	Bradley, SM (corresponding author), VA Eastern Colorado Hlth Care Syst, Dept Vet Affairs, 1055 Clermont St 111B, Denver, CO 80220 USA.	Steven.Bradley@va.gov	Bradley, Steven/AID-7839-2022		VA Health Services Research and Development [HSRD-CDA2 10-199]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123980] Funding Source: NIH RePORTER	VA Health Services Research and Development(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research received no specific grant from any funding agency in the public, commercial, or not for profit sectors. SMB is supported by a career development award (HSR&D-CDA2 10-199) from VA Health Services Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; [Anonymous], 2000, CIRCULATION S, V102, pI90; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bobrow BJ, 2008, JAMA-J AM MED ASSOC, V299, P1158, DOI 10.1001/jama.299.10.1158; Cammarata G, 2006, RESUSCITATION, V69, P23, DOI 10.1016/j.resuscitation.2005.09.022; Chan PS, 2013, J AM COLL CARDIOL, V62, P601, DOI 10.1016/j.jacc.2013.05.051; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Eftestol T, 2002, CIRCULATION, V105, P2270, DOI 10.1161/01.CIR.0000016362.42586.FE; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Hinchey PR, 2010, ANN EMERG MED, V56, P348, DOI 10.1016/j.annemergmed.2010.01.036; Jost D, 2010, CIRCULATION, V121, P1614, DOI 10.1161/CIRCULATIONAHA.109.878389; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; Li F, 2013, STAT MED, V32, P3373, DOI 10.1002/sim.5786; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Mittal S, 1999, J AM COLL CARDIOL, V34, P1595, DOI 10.1016/S0735-1097(99)00363-0; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Morrison LJ, 2013, RESUSCITATION, V84, P1480, DOI 10.1016/j.resuscitation.2013.07.008; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Poole JE, 1997, J CARDIOVASC ELECTR, V8, P1373, DOI 10.1111/j.1540-8167.1997.tb01034.x; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; Schneider T, 2000, CIRCULATION, V102, P1780; Tang WC, 2006, CIRCULATION, V113, P2683, DOI 10.1161/CIRCULATIONAHA.105.592121; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; White RD, 2005, RESUSCITATION, V64, P63, DOI 10.1016/j.resuscitation.2004.06.021; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759	33	10	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2016	353								i1653	10.1136/bmj.i1653	http://dx.doi.org/10.1136/bmj.i1653			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ0LQ	27052620	hybrid, Green Published			2023-01-03	WOS:000373895500003
J	Wei, CQ; Ni, WT; Cai, XJ; Zhao, J; Cui, JC				Wei, Chuanqi; Ni, Wentao; Cai, Xuejiu; Zhao, Jin; Cui, Junchang			Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments	PLOS ONE			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE; ANTIBIOTIC COMBINATIONS; PHARMACOKINETICS; PHARMACODYNAMICS; GLYCYLCYCLINE; MONOTHERAPY	Background The optimal therapy for infections caused by Stenotrophomonas maltophilia (S. maltophilia) has not yet been established. The objective of our study was to evaluate the efficacy of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, polymyxin E, chloramphenicol, and ceftazidime against clinical isolated S. maltophilia strains by susceptibility testing and carried out time-kill experiments in potential antimicrobials. Methods The agar dilution method was used to test susceptibility of nine candidate antimicrobials, and time-killing experiments were carried out to evaluate the efficacy of SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, and ceftazidime both alone and in combinations at clinically relevant antimicrobial concentrations. Results The susceptibility to SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E, and ceftazidime were 93.8%, 95.0%, 83.8%, 80.0%, 76.3%, 76.3%, 37.5%, 22.5%, and 20.0% against 80 clinical consecutively isolated strains, respectively. Minocycline and tigecycline showed consistent active against 22 SXT-resistant strains. However, resistance rates were high in the remaining antimicrobial agents against SXT-resistant strains. In time-kill experiments, there were no synergisms in most drug combinations in time-kill experiments. SXT plus moxifloxacin displayed synergism when strains with low moxifloxacin MICs. Moxifloxacin plus Minocycline and moxifloxacin plus tigecycline displayed synergism in few strains. No antagonisms were found in these combinations. Overall, compared with single drug, the drug combinations demonstrated lower bacterial concentrations. Some combinations showed bactericidal activity. Conclusions In S. maltophilia infections, susceptibility testing suggests that minocycline and SXT may be considered first-line therapeutic choices while tigecycline, moxifloxacin, levofloxacin, and ticarcillin-clavulanate may serve as second-line choices. Ceftazidime, colistin, and chloramphenicol show poor active against S. maltophilia. However, monotherapy is inadequate in infection management, especially in case of immunocompromised patients. Combination therapy, especially SXT plus moxifloxacin, may benefit than monotherapy in inhibiting or killing S. maltophilia.	[Wei, Chuanqi; Ni, Wentao; Zhao, Jin; Cui, Junchang] Chinese Peoples Liberat Army Gen Hosp, Dept Resp Dis, Beijing 100853, Peoples R China; [Cai, Xuejiu] Chinese Peoples Liberat Army, Guangzhou Army Command, Guangzhou Gen Hosp, Dept Resp Dis, Guangzhou 510010, Guangdong, Peoples R China	Chinese People's Liberation Army General Hospital	Cui, JC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Resp Dis, Beijing 100853, Peoples R China.	guoguoyoumeng@163.com	Ni, Wentao/HDN-9973-2022	Zhao, Jin/0000-0001-6902-9408	National Natural Science Foundation of China [81371855]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81371855). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, M100S25 CLSI; Sanchez MB, 2015, ANTIMICROB AGENTS CH, V59, P4347, DOI 10.1128/AAC.00714-15; Brooke JS, 2012, CLIN MICROBIOL REV, V25, P2, DOI 10.1128/CMR.00019-11; Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57; Falagas ME, 2008, J ANTIMICROB CHEMOTH, V62, P889, DOI 10.1093/jac/dkn301; Giamarellos-Bourboulis EJ, 2002, ANTIMICROB AGENTS CH, V46, P3997, DOI 10.1128/AAC.46.12.3997-3999.2002; Hand E, 2016, J ANTIMICROB CHEMOTH; JUNG AC, 1994, ARCH INTERN MED, V154, P2402, DOI 10.1001/archinte.154.21.2402; LEROY A, 1984, ANTIMICROB AGENTS CH, V25, P638, DOI 10.1128/AAC.25.5.638; Levison ME, 2009, INFECT DIS CLIN N AM, V23, P791, DOI 10.1016/j.idc.2009.06.008; Looney WJ, 2009, LANCET INFECT DIS, V9, P312, DOI 10.1016/S1473-3099(09)70083-0; Meagher AK, 2005, DIAGN MICR INFEC DIS, V52, P165, DOI 10.1016/j.diagmicrobio.2005.05.006; Ni WT, 2015, INT J ANTIMICROB AG, V45, P8, DOI 10.1016/j.ijantimicag.2014.10.002; Noskin GA, 2005, CLIN INFECT DIS, V41, pS303, DOI 10.1086/431672; Pillai SK, 2005, ANTIBIOTICS LAB MED, V5, P365; POULOS CD, 1995, ANTIMICROB AGENTS CH, V39, P2220, DOI 10.1128/AAC.39.10.2220; Rodvold KA, 2001, PHARMACOTHERAPY, V21, p233S, DOI 10.1592/phco.21.16.233S.33992; Sader HS, 2014, INT J ANTIMICROB AG, V43, P328, DOI 10.1016/j.ijantimicag.2014.01.007; Sanford Jay P., SANFORD GUIDE ANTIMI, P86; Tangden T, 2014, ANTIMICROB AGENTS CH, V58, P1757, DOI 10.1128/AAC.00741-13; Wang YL, 2014, ANTIMICROB AGENTS CH, V58, P176, DOI 10.1128/AAC.01324-13; Wei CQ, 2015, INFECT DIS-NOR, V47, P846, DOI 10.3109/23744235.2015.1064542; Zelenitsky SA, 2005, DIAGN MICR INFEC DIS, V51, P39, DOI 10.1016/j.diagmicrobio.2004.09.002	23	38	39	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2016	11	3							e0152132	10.1371/journal.pone.0152132	http://dx.doi.org/10.1371/journal.pone.0152132			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3NW	26999818	Green Published, Green Submitted, gold			2023-01-03	WOS:000372694700103
J	Aziz, MH; Fakhar-e-Alam, M; Fatima, M; Shaheen, F; Iqbal, S; Atif, M; Talha, M; Ali, SM; Afzal, M; Majid, A; Al Harbi, TS; Ismail, M; Wang, ZMM; AlSalhi, MS; Alahmed, ZA				Aziz, Muhammad Hammad; Fakhar-e-Alam, M.; Fatima, Mahvish; Shaheen, Fozia; Iqbal, Seemab; Atif, M.; Talha, Muhammad; Ali, Syed Mansoor; Afzal, Muhammad; Majid, Abdul; Al Harbi, Thamir Shelih; Ismail, Muhammad; Wang, Zhiming M.; AlSalhi, M. S.; Alahmed, Z. A.			Photodynamic Effect of Ni Nanotubes on an HeLa Cell Line	PLOS ONE			English	Article							OXIDATIVE STRESS; NANOPARTICLES	Nickel nanomaterials are promising in the biomedical field, especially in cancer diagnostics and targeted therapy, due to their distinctive chemical and physical properties. In this experiment, the toxicity of nickel nanotubes (Ni NTs) were tested in an in vitro cervical cancer model (HeLa cell line) to optimize the parameters of photodynamic therapy (PDT) for their greatest effectiveness. Ni NTs were synthesized by electrodeposition. Morphological analysis and magnetic behavior were examined using a Scanning electron microscope (SEM), an energy dispersive X-ray analysis (EDAX) and a vibrating sample magnetometer (VSM) analysis. Phototoxic and cytotoxic effects of nanomaterials were studied using the Ni NTs alone as well as in conjugation with aminolevulinic acid (5-ALA); this was performed both in the dark and under laser exposure. Toxic effects on the HeLa cell model were evaluated by a neutral red assay (NRA) and by detection of intracellular reactive oxygen species (ROS) production. Furthermore, 10-200 nM of Ni NTs was prepared in solution form and applied to HeLa cells in 96-well plates. Maximum toxicity of Ni NTs complexed with 5-ALA was observed at 100 J/cm(2) and 200 nM. Up to 65-68% loss in cell viability was observed. Statistical analysis was performed on the experimental results to confirm the worth and clarity of results, with p-values = 0.003 and 0.000, respectively. Current results pave the way for a more rational strategy to overcome the problem of drug bioavailability in nanoparticulate targeted cancer therapy, which plays a dynamic role in clinical practice.	[Aziz, Muhammad Hammad; Majid, Abdul; Al Harbi, Thamir Shelih] Majmaah Univ, Coll Sci Zulfi, Dept Phys, Zulfi, Saudi Arabia; [Aziz, Muhammad Hammad] COMSATS Inst Informat & Technol, Dept Phys, Lahore, Pakistan; [Fakhar-e-Alam, M.; Wang, Zhiming M.] Univ Elect Sci & Technol China, Inst Fundamental & Frontier Sci, Chengdu 610054, Peoples R China; [Fakhar-e-Alam, M.; Iqbal, Seemab] GC Univ Faisalabad, Dept Phys, Faisalabad, Pakistan; [Fatima, Mahvish; Afzal, Muhammad] Islamia Univ Bahawalpur, Dept Phys, Bahawalpur, Pakistan; [Shaheen, Fozia] GC Univ Lahore, Dept Phys, Lahore, Pakistan; [Atif, M.; Ali, Syed Mansoor; AlSalhi, M. S.; Alahmed, Z. A.] King Saud Univ, Coll Sci, Dept Phys & Astron, Riyadh 11451, Saudi Arabia; [Atif, M.] Natl Inst Laser & Optron, Islamabad, Pakistan; [Talha, Muhammad] King Saud Univ, Sci Res, Riyadh 11421, Saudi Arabia; [Ismail, Muhammad] IBGE, 24 Mauve Area,G-9-1, Islamabad, Pakistan	Majmaah University; COMSATS University Islamabad (CUI); University of Electronic Science & Technology of China; Government College University Faisalabad; Islamia University of Bahawalpur; Government College University Lahore; University of Lahore; King Saud University; King Saud University	Aziz, MH (corresponding author), Majmaah Univ, Coll Sci Zulfi, Dept Phys, Zulfi, Saudi Arabia.; Aziz, MH (corresponding author), COMSATS Inst Informat & Technol, Dept Phys, Lahore, Pakistan.; Atif, M (corresponding author), King Saud Univ, Coll Sci, Dept Phys & Astron, Riyadh 11451, Saudi Arabia.; Atif, M (corresponding author), Natl Inst Laser & Optron, Islamabad, Pakistan.	m.hammad@mu.edu.sa; atifhull@gmail.com	Atif, Muhammad/Z-5682-2019; AlSalhi, Mohamad S/F-2217-2019; Alahmed, Zeyad A/F-1683-2013; alsalhi, mohamad/M-5013-2019; Majid, Abdul/G-5584-2016; Atif, Muhammad/C-4789-2013	Atif, Muhammad/0000-0002-7356-4275; AlSalhi, Mohamad S/0000-0002-4557-8821; Alahmed, Zeyad A/0000-0001-7304-8118; Majid, Abdul/0000-0001-8861-4354; Atif, Muhammad/0000-0002-7356-4275	Deanship of Scientific Research, Majmaah University [37-1-3]	Deanship of Scientific Research, Majmaah University	The authors acknowledge the support from Deanship of Scientific Research, Majmaah University under project No. 37-1-3.	Ahamed M, 2013, CHEMOSPHERE, V93, P2514, DOI 10.1016/j.chemosphere.2013.09.047; Ahamed M, 2008, TOXICOL APPL PHARM, V233, P404, DOI 10.1016/j.taap.2008.09.015; Ali SMU, 2012, INT J MED MED SCI, V2; Atif M, 2011, LASER PHYS, V21, P1235, DOI 10.1134/S1054660X11130020; Atif M, 2010, LASER PHYS LETT, V7, P757, DOI 10.1002/lapl.201010061; Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690; Chikazumi S., 1964, PHYSICS MAGNETISM, P130; Fakhar-e-Alam M, 2014, LASER PHYS LETT, V11, DOI 10.1088/1612-2011/11/2/025601; Fakhar-e-Alam M, 2011, LASER PHYS, V21, P1978, DOI 10.1134/S1054660X1119011X; Fakhar-e-Alam M., 2012, REV NANOSCI NANOTECH, V1, P40, DOI [10.1166/rnn.2012.1004, DOI 10.1166/RNN.2012.1004]; Fatima M, 2014, LASER PHYS, V24, DOI 10.1088/1054-660X/24/12/125602; Garland SM, 2012, CANCER EPIDEM BIOMAR, V21, P1414, DOI 10.1158/1055-9965.EPI-12-0164; Hossain MZ, 2011, INT J NANOMED, V6, P1475, DOI 10.2147/IJN.S21697; Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015; Lahiria D, 2010, ACTA BIOMATER; Li X, 2012, J NANOMATER, V2012, P9; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Panchompoo J, 2010, ELECTROANAL, V22, P912, DOI 10.1002/elan.200900547; Patil SS, 2016, ENVIRON TECHNOL INNO, V5, P10, DOI 10.1016/j.eti.2015.11.001; Prina-Mello Adriele, 2006, J Nanobiotechnology, V4, P9, DOI 10.1186/1477-3155-4-9; Tao FF, 2006, ADV MATER, V18, P2161, DOI 10.1002/adma.200600275; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Yu IJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/789312	25	7	7	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2016	11	3							e0150295	10.1371/journal.pone.0150295	http://dx.doi.org/10.1371/journal.pone.0150295			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1ZE	26990435	Green Published, gold, Green Submitted			2023-01-03	WOS:000372582800026
J	Matone, A; Scott-Boyer, MP; Carayol, J; Fazelzadeh, P; Lefebvre, G; Valsesia, A; Charon, C; Vervoort, J; Astrup, A; Saris, WHM; Morine, M; Hager, J				Matone, Alice; Scott-Boyer, Marie-Pier; Carayol, Jerome; Fazelzadeh, Parastoo; Lefebvre, Gregory; Valsesia, Armand; Charon, Celine; Vervoort, Jacques; Astrup, Arne; Saris, Wim H. M.; Morine, Melissa; Hager, Joerg			Network Analysis of Metabolite GWAS Hits: Implication of CPS1 and the Urea Cycle in Weight Maintenance	PLOS ONE			English	Article							GENE-EXPRESSION; RECEPTOR-ALPHA; POPULATION; RISK; INFORMATION; RESISTANCE; VARIANTS; BIOLOGY; PATHWAY; OBESE	Background and Scope Weight loss success is dependent on the ability to refrain from regaining the lost weight in time. This feature was shown to be largely variable among individuals, and these differences, with their underlying molecular processes, are diverse and not completely elucidated. Altered plasma metabolites concentration could partly explain weight loss maintenance mechanisms. In the present work, a systems biology approach has been applied to investigate the potential mechanisms involved in weight loss maintenance within the Diogenes weight-loss intervention study. Methods and Results A genome wide association study identified SNPs associated with plasma glycine levels within the CPS1 (Carbamoyl-Phosphate Synthase 1) gene (rs10206976, p-value = 4.709e-11 and rs12613336, p-value = 1.368e-08). Furthermore, gene expression in the adipose tissue showed that CPS1 expression levels were associated with successful weight maintenance and with several SNPs within CPS1 (cis-eQTL). In order to contextualize these results, a gene-metabolite interaction network of CPS1 and glycine has been built and analyzed, showing functional enrichment in genes involved in lipid metabolism and one carbon pool by folate pathways. Conclusions CPS1 is the rate-limiting enzyme for the urea cycle, catalyzing carbamoyl phosphate from ammonia and bicarbonate in the mitochondria. Glycine and CPS1 are connected through the one-carbon pool by the folate pathway and the urea cycle. Furthermore, glycine could be linked to metabolic health and insulin sensitivity through the betaine osmolyte. These considerations, and the results from the present study, highlight a possible role of CPS1 and related pathways in weight loss maintenance, suggesting that it might be partly genetically determined in humans.	[Matone, Alice; Scott-Boyer, Marie-Pier; Morine, Melissa] Univ Trento, Ctr Computat Syst Biol COSBI, Microsoft Res, Rovereto, Italy; [Carayol, Jerome; Lefebvre, Gregory; Valsesia, Armand; Hager, Joerg] Nestle Inst Hlth Sci SA, Lausanne, Switzerland; [Fazelzadeh, Parastoo; Vervoort, Jacques] Wageningen Univ, Nutr Metab & Genom Grp, NL-6700 AP Wageningen, Netherlands; [Charon, Celine] CEA, Genom Inst, Natl Genotyping Ctr, Evry, France; [Astrup, Arne] Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen, Denmark; [Saris, Wim H. M.] Maastricht Univ, Fac Med & Hlth Sci, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	University of Trento; Nestle SA; Wageningen University & Research; CEA; University of Copenhagen; Maastricht University	Hager, J (corresponding author), Nestle Inst Hlth Sci SA, Lausanne, Switzerland.	Jorg.Hager@rd.nestle.com	Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996; Scott-Boyer, Marie-Pier/0000-0003-2626-4584; Lefebvre, Greg/0000-0001-7519-2316; Matone, Alice/0000-0003-4530-908X; Carayol, Jerome/0000-0002-0049-0244; Valsesia, Armand/0000-0003-0746-9664	European Commission [FP6-2005-513946]	European Commission(European CommissionEuropean Commission Joint Research Centre)	The DIOGENES trial was funded by the European Commission, contract no. FP6-2005-513946. The funding source had no role in the study design, data collection, data analysis, data interpretation or writing of the report.	Abildso CG, 2014, J OBES, V2014, DOI 10.1155/2014/736080; Bales CW, 2013, J CARDIOPULM REHABIL, V33, P201, DOI 10.1097/HCR.0b013e318295019e; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Bolusani S, 2011, J BIOL CHEM, V286, P5166, DOI 10.1074/jbc.M110.196840; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; Corpeleijn E, 2009, OBES REV, V10, P178, DOI 10.1111/j.1467-789X.2008.00544.x; Craig SAS, 2004, AM J CLIN NUTR, V80, P539; Csardi G, 1695, IGRAPH SOFTWARE PACK; Demirkan A, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004835; Dixon JB, 2010, MOL CELL ENDOCRINOL, V316, P104, DOI 10.1016/j.mce.2009.07.008; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dulloo AG, 2007, INT J OBESITY, V31, P201, DOI 10.1038/sj.ijo.0803537; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Faro A, 2012, BRIEF BIOINFORM, V13, P61, DOI 10.1093/bib/bbr018; Fonville JM, 2010, ANAL CHEM, V82, P1811, DOI 10.1021/ac902443k; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Frame B, 2007, J PHARMACOKINET PHAR, V34, P753, DOI 10.1007/s10928-007-9067-z; Fredriksen A, 2007, HUM MUTAT, V28, P856, DOI 10.1002/humu.20522; Galgani J, 2008, INT J OBESITY, V32, pS109, DOI 10.1038/ijo.2008.246; Guanjie C, 2008, 68 SCI SESS AM DIAB; Hoaglin DC, 1986, PERFORMANCE SOME RES; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hunt MC, 2012, BBA-MOL BASIS DIS, V1822, P1397, DOI 10.1016/j.bbadis.2012.03.009; Hussey SE, 2013, MED SCI SPORT EXER, V45, P1069, DOI 10.1249/MSS.0b013e3182814917; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Khandhar A. P., 2013, 2013 International Workshop on Magnetic Particle Imaging (IWMPI), DOI 10.1109/IWMPI.2013.6528377; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Larsen Thomas Meinert, 2010, N Engl J Med, V363, P2102, DOI 10.1056/NEJMoa1007137; Lean MEJ, 2000, P NUTR SOC, V59, P331, DOI 10.1017/S0029665100000379; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liolitsa D, 2002, J NEUROL NEUROSUR PS, V73, P261, DOI 10.1136/jnnp.73.3.261; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI DOI 10.1093/BI0INF0RMATICS/BTV402; Matsuo T, 2014, METABOLISM, V63, P912, DOI 10.1016/j.metabol.2014.03.013; Merico D, 2009, NAT BIOTECHNOL, V27, P921, DOI 10.1038/nbt.1567; Neiberg RH, 2012, OBESITY, V20, P2048, DOI 10.1038/oby.2012.33; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Ng A, 2006, BRIEF BIOINFORM, V7, P318, DOI 10.1093/bib/bbl036; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Oliveri LM, 2012, BIOCHEM J, V442, P303, DOI 10.1042/BJ20111005; Purcell S, PLINK WHOLE GENOME D; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qiu J, 2007, BIOCHEM BIOPH RES CO, V352, P469, DOI 10.1016/j.bbrc.2006.11.049; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Sandhoff K, 2002, BIOCH LIPIDS LIPOPRO, P373; Saris WHM, 2005, NUTR BULL, V30, P188, DOI 10.1111/j.1467-3010.2005.00496.x; Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Soare A, 2014, DIABETES-METAB RES, V30, P41, DOI 10.1002/dmrr.2517; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Team R.C., 2021, R FOUN DATION STAT C; Torkamani A, 2008, GENOMICS, V92, P265, DOI 10.1016/j.ygeno.2008.07.011; Tumova E, 2013, J OBES, V2013, DOI 10.1155/2013/729515; Viguerie N, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002959; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Xie WJ, 2013, DIABETES, V62, P2141, DOI 10.2337/db12-0876; Yoon M, 2003, BRIT J PHARMACOL, V138, P1295, DOI 10.1038/sj.bjp.0705169; Zeisel SH, 2013, CLIN CHEM LAB MED, V51, P467, DOI 10.1515/cclm-2012-0518; Zhou JB, 2010, MED SCI MONITOR, V16, pBR179	62	10	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150495	10.1371/journal.pone.0150495	http://dx.doi.org/10.1371/journal.pone.0150495			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938218	Green Published, gold			2023-01-03	WOS:000371735200094
J	McGilvray, A				McGilvray, Annabel			Restoration project	NATURE			English	Editorial Material							FEMALE RHESUS-MONKEYS; COGNITIVE FUNCTION											Hao JD, 2006, J NEUROSCI, V26, P2571, DOI 10.1523/JNEUROSCI.3440-05.2006; Hara Y, 2011, J NEUROSCI, V31, P7737, DOI 10.1523/JNEUROSCI.0822-11.2011; Marschallinger J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9466; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357	5	6	6	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 3	2016	531	7592					S4	S5		10.1038/531S4a	http://dx.doi.org/10.1038/531S4a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2YW	26934524	Bronze			2023-01-03	WOS:000371211900002
J	Gartlehner, G; Gaynes, BN; Amick, HR; Asher, GN; Morgan, LC; Coker-Schwimmer, E; Forneris, C; Boland, E; Lux, LJ; Gaylord, S; Bann, C; Pierl, CB; Lohr, KN				Gartlehner, Gerald; Gaynes, Bradley N.; Amick, Halle R.; Asher, Gary N.; Morgan, Laura C.; Coker-Schwimmer, Emmanuel; Forneris, Catherine; Boland, Erin; Lux, Linda J.; Gaylord, Susan; Bann, Carla; Pierl, Christiane Barbara; Lohr, Kathleen N.			Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							ST-JOHNS-WORT; RANDOMIZED CONTROLLED-TRIAL; TO-MODERATE DEPRESSION; PRIMARY-CARE PATIENTS; ONCE-DAILY DOSAGE; DOUBLE-BLIND; COGNITIVE THERAPY; TREATING DEPRESSION; 2ND-GENERATION ANTIDEPRESSANTS; PSYCHODYNAMIC PSYCHOTHERAPY	Background: Primary care patients and clinicians may prefer options other than second-generation antidepressants for the treatment of major depressive disorder (MDD). The comparative benefits and harms of antidepressants and alternative treatments are unclear. P urpose: To compare the benefits and harms of second-generation antidepressants and psychological, complementary and alternative medicine (CAM), and exercise treatments as first- and second-step interventions for adults with acute MDD. Data Sources: English-, German-, and Italian-language studies from multiple electronic databases (January 1990 to September 2015); trial registries and gray-literature databases were used to identify unpublished research. Study Selection: Two investigators independently selected comparative randomized trials of at least 6 weeks' duration on health outcomes of adult outpatients; nonrandomized studies were eligible for harms. Data Extraction: Reviewers abstracted data on study design, participants, interventions, and outcomes; rated the risk of bias; and graded the strength of evidence. A senior reviewer confirmed data and ratings. Data Synthesis: 45 trials met inclusion criteria. On the basis of moderate-strength evidence, cognitive behavioral therapy (CBT) and antidepressants led to similar response rates (relative risk [RR], 0.90 [95% CI, 0.76 to 1.07]) and remission rates (RR, 0.98 [CI, 0.73 to 1.32]). In trials, antidepressants had higher risks for adverse events than most other treatment options; no information from nonrandomized studies was available. The evidence was too limited to make firm conclusions about differences in the benefits and harms of antidepressants compared with other treatment options as first-step therapies for acute MDD. For second-step therapies, different switching and augmentation strategies provided similar symptom relief. Limitation: High dropout rates, dosing inequalities, small sample sizes, and poor assessment of adverse events limit confidence in the evidence. Conclusion: Given their similar efficacy, CBT and antidepressants are both viable choices for initial treatment of MDD. Primary Funding Source: Agency for Healthcare Research and Quality.	[Morgan, Laura C.; Boland, Erin; Lux, Linda J.; Bann, Carla; Lohr, Kathleen N.] RTI Int, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Chapel Hill, NC USA; [Gartlehner, Gerald] Danube Univ, Dr Karl Dorrek Str 30, A-3500 Krems, Austria; [Gaynes, Bradley N.; Forneris, Catherine] Univ N Carolina, Dept Psychiat, 101 Manning Dr,CB 7160, Chapel Hill, NC 27599 USA; [Amick, Halle R.; Coker-Schwimmer, Emmanuel] Univ N Carolina, Sheps Ctr Hlth Serv Res, 725 Martin Luther King Jr Blvd, Chapel Hill, NC 27599 USA; [Asher, Gary N.] Univ N Carolina, Dept Family Med, 101 Manning Dr,CB 7160, Chapel Hill, NC 27599 USA; [Gaylord, Susan] Univ N Carolina, Dept Phys Med & Rehabil, 101 Manning Dr,CB 7160, Chapel Hill, NC 27599 USA; [Pierl, Christiane Barbara] Danube Univ, Dept Evidence Based Med & Clin Epidemiol, Dr Karl Dorrek Str 30, A-3500 Krems, Austria	Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; Danube University Krems; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Danube University Krems	Gartlehner, G (corresponding author), Danube Univ, Dr Karl Dorrek Str 30, A-3500 Krems, Austria.	gerald.gartlehner@donau-uni.ac.at	Lux, Linda/GPX-3639-2022; Gartlehner, Gerald/AAY-2801-2021	Gartlehner, Gerald/0000-0001-5531-3678; Lohr, Kathleen/0000-0002-3825-0713; Bann, Carla/0000-0001-9305-8305	Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; American Psychiatric Association, 2010, PRACT GUID TREATM PA, P152; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Barber JP, 2012, J CLIN PSYCHIAT, V73, P66, DOI 10.4088/JCP.11m06831; Bastos AG, 2013, J AFFECT DISORDERS, V151, P1066, DOI 10.1016/j.jad.2013.08.036; Behnke K, 2002, ADV THER, V19, P43, DOI 10.1007/BF02850017; Berkman ND, 2013, 2902007100561 U N CA; Bjerkenstedt L, 2005, EUR ARCH PSY CLIN N, V255, P40, DOI 10.1007/s00406-004-0532-z; Blom MBJ, 2007, PSYCHOTHER PSYCHOSOM, V76, P289, DOI 10.1159/000104705; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Brenner R, 2000, CLIN THER, V22, P411, DOI 10.1016/S0149-2918(00)89010-4; Chen JQ, 2014, NEURAL REGEN RES, V9, P213, DOI 10.4103/1673-5374.125353; Chen JA, 2011, J CLIN PSYCHIAT, V72, P1669, DOI 10.4088/JCP.10m06453; Cochrane Depression Anxiety and Neurosis Group, 2013, CCDAN TOP LIST INT T; Cooney GM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub6; Cuijpers P, 2008, J CLIN PSYCHIAT, V69, P1675, DOI 10.4088/JCP.v69n1102; David D, 2008, J CLIN PSYCHOL, V64, P728, DOI 10.1002/jclp.20487; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; De Berardis D, 2015, CNS NEUROL DISORD DR; Dekker JJM, 2008, J AFFECT DISORDERS, V109, P183, DOI 10.1016/j.jad.2007.10.015; Department of Veterans Affairs; Department of Defense, 2009, VA DOD CLIN PRACT GU, P199; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; Dimidjian S, 2006, J CONSULT CLIN PSYCH, V74, P658, DOI 10.1037/0022-006X.74.4.658; Fava M, 2005, J CLIN PSYCHOPHARM, V25, P441, DOI 10.1097/01.jcp.0000178416.60426.29; Fischer A, 2015, LANCET PSYCHIAT, V2, P217, DOI 10.1016/S2215-0366(14)00049-2; Frank E, 2011, PSYCHOL MED, V41, P151, DOI 10.1017/S0033291710000553; Gartlehner G, 2015, AHRQ PUBLICATION; Gartlehner G, 2011, ANN INTERN MED, V155, P772, DOI 10.7326/0003-4819-155-11-201112060-00009; Gastpar M, 2006, PHARMACOPSYCHIATRY, V39, P66, DOI 10.1055/s-2006-931544; Gastpar M, 2005, PHARMACOPSYCHIATRY, V38, P78, DOI 10.1055/s-2005-837807; Gaynes BN, 2011, COMP EFFECTIVENESS R; Gaynes BN, 2008, J GEN INTERN MED, V23, P551, DOI 10.1007/s11606-008-0522-3; Gertsik L, 2012, J CLIN PSYCHOPHARM, V32, P61, DOI 10.1097/JCP.0b013e31823f3b5f; Harrer G, 1999, ARZNEIMITTELFORSCH, V49, P289; Hegerl U, 2010, INT J NEUROPSYCHOPH, V13, P31, DOI 10.1017/S1461145709000224; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hoffman BM, 2008, MED SCI SPORT EXER, V40, P1344, DOI 10.1249/MSS.0b013e31816b877c; Huang Y, 2005, INT J CLIN ACUPUNCTU, V14, P7; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jazayeri S, 2008, AUST NZ J PSYCHIAT, V42, P192, DOI 10.1080/00048670701827275; Jorm AF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007142.pub2; Kennedy SH, 2007, AM J PSYCHIAT, V164, P778, DOI 10.1176/appi.ajp.164.5.778; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kronstrom K, 2009, DEPRESS ANXIETY, V26, P689, DOI 10.1002/da.20585; Lam RW, 2013, BRIT J PSYCHIAT, V203, P358, DOI 10.1192/bjp.bp.112.125237; Landenberger NA, 2002, PROQUEST INFORM LEAR; Le Noury J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4320; Lenox-Smith AJ, 2008, INT CLIN PSYCHOPHARM, V23, P113, DOI 10.1097/YIC.0b013e3282f424c2; Leykin Y, 2007, J CONSULT CLIN PSYCH, V75, P267, DOI 10.1037/0022-006X.75.2.267; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Maratos AS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004517.pub2; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; Menchetti M, 2014, BRIT J PSYCHIAT, V204, P144, DOI 10.1192/bjp.bp.112.122663; Miranda J, 2003, JAMA-J AM MED ASSOC, V290, P57, DOI 10.1001/jama.290.1.57; Mischoulon D, 2014, J CLIN PSYCHIAT, V75, P370, DOI 10.4088/JCP.13m08591; Mojtabai R, 2008, J CLIN PSYCHIAT, V69, P1064, DOI 10.4088/JCP.v69n0704; Moradveisi L, 2013, BRIT J PSYCHIAT, V202, P204, DOI 10.1192/bjp.bp.112.113696; Moreno RA, 2006, REV BRAS PSIQUIATR, V28, P29, DOI 10.1590/S1516-44462006000100007; Murri MB, 2015, BRIT J PSYCHIAT, V207, P235, DOI 10.1192/bjp.bp.114.150516; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Papakostas GI, 2007, NEUROPSYCHOBIOLOGY, V56, P132, DOI 10.1159/000115779; Papakostas GI, 2009, EUR NEUROPSYCHOPHARM, V19, P34, DOI 10.1016/j.euroneuro.2008.08.009; Qu SS, 2013, J PSYCHIATR RES, V47, P726, DOI 10.1016/j.jpsychires.2013.02.004; Raue PJ, 2009, PSYCHIAT SERV, V60, P337, DOI 10.1176/appi.ps.60.3.337; Rimer J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub5; Rucci P, 2011, DEPRESS ANXIETY, V28, P303, DOI 10.1002/da.20758; Rush AJ, 2006, NEW ENGL J MED, V354, P1231, DOI 10.1056/NEJMoa052963; Salminen JK, 2008, PSYCHOTHER PSYCHOSOM, V77, P351, DOI 10.1159/000151388; Sava FA, 2009, J CLIN PSYCHOL, V65, P36, DOI 10.1002/jclp.20550; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; Segal ZV, 2006, ARCH GEN PSYCHIAT, V63, P749, DOI 10.1001/archpsyc.63.7.749; Shamsaei F, 2008, HONG KONG J PSYCHIAT, V18, P76; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3; Song YQ, 2007, J AFFECT DISORDERS, V98, P253, DOI 10.1016/j.jad.2006.07.012; SOTSKY SM, 1991, AM J PSYCHIAT, V148, P997; Spielmans GI, 2011, J NERV MENT DIS, V199, P142, DOI 10.1097/NMD.0b013e31820caefb; Sun H, 2013, J ALTERN COMPLEM MED, V19, P733, DOI 10.1089/acm.2011.0637; Szegedi A, 2005, BMJ-BRIT MED J, V330, P503, DOI 10.1136/bmj.38356.655266.82; Thase ME, 2007, AM J PSYCHIAT, V164, P739, DOI 10.1176/appi.ajp.164.5.739; Trivedi MH, 2006, NEW ENGL J MED, V354, P1243, DOI 10.1056/NEJMoa052964; University of Pittsburgh Epidemiology Data Center, 2010, INV DEPR SYMPT IDS Q; van Gurp G, 2002, CAN FAM PHYSICIAN, V48, P905; Viswanathan M, 2012, ASSESSING RISK BIAS; Weitz ES, 2015, JAMA PSYCHIAT; West SL, 2010, 2902007100561 U N CA; Zhang WJ, 2009, J ALTERN COMPLEM MED, V15, P837, DOI 10.1089/acm.2008.0607; Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005; Zimmerman M, 2013, J AFFECT DISORDERS, V150, P384, DOI 10.1016/j.jad.2013.04.028	89	68	69	2	70	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	2016	164	5					331	+		10.7326/M15-1813	http://dx.doi.org/10.7326/M15-1813			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF3CC	26857743				2023-01-03	WOS:000371220300004
J	Gupt, A; Kaur, P; Kamraj, P; Murthy, BN				Gupt, Anadi; Kaur, Prabhdeep; Kamraj, P.; Murthy, B. N.			Out of Pocket Expenditure for Hospitalization among Below Poverty Line Households in District Solan, Himachal Pradesh, India, 2013	PLOS ONE			English	Article							HEALTH-INSURANCE; PROTECTION	Introduction Health insurance schemes, like Rashtriya Swasthya Bima Yojana (RSBY), should provide financial protection against catastrophic health costs by reducing out of pocket expenditure (OOPE) for hospitalizations. We estimated and compared the proportion and extent of OOPE among below poverty line (BPL) families beneficiaries and not beneficiaries by RSBY during hospitalizations in district Solan, H.P., India, 2013. Methods We conducted a cross sectional survey among hospitalized BPL families in the beneficiaries and non-beneficiaries groups. We compared proportion incurring OOPE and its extent during hospitalization, pre/post-hospitalization periods in different domains. Results Overall, proportion of non-beneficiaries who incurred OOPE was higher than the beneficiaries but it was not statistically significant (87.2% vs. 80.9%). The median overall OOPE was $39 (Rs 2567) in the non-beneficiaries group as compared to $11 (Rs 713) in the beneficiaries group (p<0.01). Median expenditure on in house and out house drugs and consumables was $23 (Rs 1500) in the non beneficiaries group as compared to nil in the beneficiaries group (p<0.01). Non-beneficiary status was significantly associated [OR: 2.4 (1.3-4.3)] with OOPE above median independently and also after adjusting for various covariates. Conclusion RSBY has decreased the extent of OOPE among the beneficiaries; however OOPE was incurred mainly due to purchase of drugs from outside the health facility. The treatment seeking behaviour in beneficiaries group has improved among comparatively older group with chronic conditions. RSBY has enabled beneficiaries to get more facilities such as drugs, consumables and diagnostics from the health facility.	[Gupt, Anadi; Kaur, Prabhdeep; Kamraj, P.; Murthy, B. N.] Govt Himachal Pradesh, Natl Hlth Mission, Block 6,SDA Complex, Shimla 171009, Himachal Prades, India		Gupt, A (corresponding author), Govt Himachal Pradesh, Natl Hlth Mission, Block 6,SDA Complex, Shimla 171009, Himachal Prades, India.	dranadigupt@yahoo.com	Kaur, Prabhdeep/AFO-2518-2022	Kaur, Prabhdeep/0000-0002-2605-3739	National Institute of Epidemiology	National Institute of Epidemiology	National Institute of Epidemiology partially funded this study. The rest of the funds were contributed by Dr. Anadi Gupt-first author.	Acharya A., 2012, IMPACT NATL HLTH INS; Berman P., 2010, Economic and Political Weekly, V45, P65; Bhojani U, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-990; Commission P, 2013, PRESS NOT POV EST 20 PRESS NOT POV EST 20; Devadasan N, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-43; Ekman Bjorn, 2007, Health Res Policy Syst, V5, P6, DOI 10.1186/1478-4505-5-6; Fan VY, 2012, INT J HEALTH CARE FI, V12, P189, DOI 10.1007/s10754-012-9110-5; Galarraga O, 2010, EUR J HEALTH ECON, V11, P437, DOI 10.1007/s10198-009-0180-3; Garg CC, 2009, HEALTH POLICY PLANN, V24, P116, DOI 10.1093/heapol/czn046; Ministry of Health and Family Welfare GoI, 2009, NAT HLTH ACC IND 200; Nguyen HTH, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-4; Ramani K V, 2006, J Health Organ Manag, V20, P560, DOI 10.1108/14777260610702307; Rao M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004471; Rashtriya Swasthya Bima Yojana Gol, ENR BEN 2014; Selvaraj Sakthivel, 2012, ECON POLIT WEEKLY, V47, P61; Sood N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5114; World Health Organization (WHO), 2014, MAK FAIR CHOIC PATH	17	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2016	11	2							e0149824	10.1371/journal.pone.0149824	http://dx.doi.org/10.1371/journal.pone.0149824			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3DG	26895419	Green Published, gold, Green Submitted			2023-01-03	WOS:000371223400084
J	Pringsheim, T; Kelly, M; Barbui, C				Pringsheim, Tamara; Kelly, Martina; Barbui, Corrado			10-MINUTE CONSULTATION Stopping antidepressants following depression	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PSYCHIATRY WFSBP GUIDELINES; BIOLOGICAL TREATMENT; WORLD FEDERATION; SOCIETIES		[Pringsheim, Tamara] Univ Calgary, Dept Clin Neurosci Psychiat & Community Hlth Sci, Calgary, AB, Canada; [Kelly, Martina] Univ Calgary, Dept Family Med, Calgary, AB, Canada; [Barbui, Corrado] Univ Verona, Sect Psychiat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy	University of Calgary; University of Calgary; University of Verona	Pringsheim, T (corresponding author), Mathison Ctr Mental Hlth Res & Educ, TRW Bldg,3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.	tmprings@ucalgary.ca	Pringsheim, Tamara/L-5955-2019	Pringsheim, Tamara/0000-0002-8229-8431; Kelly, Martina/0000-0002-8763-7092				Bauer M, 2015, WORLD J BIOL PSYCHIA, V16, P76, DOI 10.3109/15622975.2014.1001786; Bauer M, 2013, WORLD J BIOL PSYCHIA, V14, P334, DOI 10.3109/15622975.2013.804195; Dua T, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001122; Furukawa TA, 2007, CAN J PSYCHIAT, V52, P545, DOI 10.1177/070674370705200902; Kaymaz N, 2008, J CLIN PSYCHIAT, V69, P1423, DOI 10.4088/JCP.v69n0910; National Institute for Health and Care Excellence, 2009, DEPR AD REC MAN CLIN	6	1	1	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2016	352								i220	10.1136/bmj.i220	http://dx.doi.org/10.1136/bmj.i220			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE6FB	26891905				2023-01-03	WOS:000370728000004
J	Parikh, RB; Kakad, M; Bates, DW				Parikh, Ravi B.; Kakad, Meetali; Bates, David W.			Integrating Predictive Analytics Into High-Value Care The Dawn of Precision Delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH; RISK		[Parikh, Ravi B.; Kakad, Meetali; Bates, David W.] Brigham & Womens Hosp, Dept Med, 1620 Tremont St, Boston, MA 02120 USA; [Parikh, Ravi B.; Kakad, Meetali; Bates, David W.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bates, DW (corresponding author), Brigham & Womens Hosp, Dept Med, 1620 Tremont St, Boston, MA 02120 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					Amarasingham R, 2014, HEALTH AFFAIR, V33, P1148, DOI 10.1377/hlthaff.2014.0352; Amarasingham R, 2013, BMJ QUAL SAF, V22, P998, DOI 10.1136/bmjqs-2013-001901; Bates DW, 2014, HEALTH AFFAIR, V33, P1123, DOI 10.1377/hlthaff.2014.0041; Escobar GJ, 2014, PEDIATRICS, V133, P30, DOI 10.1542/peds.2013-1689; Fihn SD, 2014, HEALTH AFFAIR, V33, P1203, DOI 10.1377/hlthaff.2014.0054; Hines AL, 2006, CONDITIONS LARGEST N; Madan C. M., 2010, P UBICOMP 2010 12 AC, P291, DOI DOI 10.1145/1864349.1864394.URL; Nelson KM, 2014, JAMA INTERN MED, V174, P1350, DOI 10.1001/jamainternmed.2014.2488; Sniderman AD, 2015, JAMA-J AM MED ASSOC, V314, P25, DOI 10.1001/jama.2015.6177	9	93	94	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2016	315	7					651	652		10.1001/jama.2015.19417	http://dx.doi.org/10.1001/jama.2015.19417			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD8JB	26881365				2023-01-03	WOS:000370171500006
J	Roybal, KT; Rupp, LJ; Morsut, L; Walker, WJ; McNally, KA; Park, JS; Lim, WA				Roybal, Kole T.; Rupp, Levi J.; Morsut, Leonardo; Walker, Whitney J.; McNally, Krista A.; Park, Jason S.; Lim, Wendell A.			Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits	CELL			English	Article							CANCER; THERAPIES; TOOLS; ERBB2	T cells can be re-directed to kill cancer cells using chimeric antigen receptors (CARs) or T cell receptors (TCRs). This approach, however, is constrained by the rarity of tumor-specific single antigens. Targeting antigens also found on bystander tissues can cause life-threatening adverse effects. A powerful way to enhance ON-target activity of therapeutic T cells is to engineer them to require combinatorial antigens. Here, we engineer a combinatorially activated T cell circuit in which a synthetic Notch receptor for one antigen induces the expression of a CAR for a second antigen. These dual-receptor AND-gate T cells are only armed and activated in the presence of dual antigen tumor cells. These T cells show precise therapeutic discrimination in vivo-sparing single antigen "bystander'' tumors while efficiently clearing combinatorial antigen "disease'' tumors. This type of precision dual-receptor circuit opens the door to immune recognition of a wider range of tumors.	[Roybal, Kole T.; Rupp, Levi J.; Morsut, Leonardo; Walker, Whitney J.; McNally, Krista A.; Park, Jason S.; Lim, Wendell A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Roybal, Kole T.; Rupp, Levi J.; Morsut, Leonardo; Walker, Whitney J.; McNally, Krista A.; Park, Jason S.; Lim, Wendell A.] Univ Calif San Francisco, Ctr Syst & Synthet Biol, San Francisco, CA 94158 USA; [Roybal, Kole T.; Rupp, Levi J.; Morsut, Leonardo; Walker, Whitney J.; McNally, Krista A.; Park, Jason S.; Lim, Wendell A.] Howard Hughes Med Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.	wendell.lim@ucsf.edu			Jane Coffin Childs Memorial Fund Postdoctoral Fellowship [A121505]; Human Frontiers of Science Program Postdoctoral Fellowship; NIH [PN2 EY016546, P50GM081879, R01 GM055040, R01 CA196277]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA196277] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K99EB021030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055040, T32GM007618, P50GM081879] Funding Source: NIH RePORTER	Jane Coffin Childs Memorial Fund Postdoctoral Fellowship; Human Frontiers of Science Program Postdoctoral Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Scott Coyle and members of the Lim lab and Arthur Weiss and members of the Weiss lab for helpful discussions and comments on the manuscript. We also thank the Preclinical Therapeutics Core at UCSF for help with in vivo studies and Michael Milone and Carl June (University of Pennsylvania) for the CAR constructs. This work was supported by a Jane Coffin Childs Memorial Fund Postdoctoral Fellowship A121505 (K.T.R.), a Human Frontiers of Science Program Postdoctoral Fellowship (L.M.), and NIH grants PN2 EY016546, P50GM081879, R01 GM055040, and R01 CA196277, and the Howard Hughes Medical Institute (W.A.L.).	Barrett DM, 2014, CURR OPIN PEDIATR, V26, P43, DOI 10.1097/MOP.0000000000000043; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Dotti G, 2014, IMMUNOL REV, V257, P107, DOI 10.1111/imr.12131; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Fridy PC, 2014, NAT METHODS, V11, P1253, DOI [10.1038/NMETH.3170, 10.1038/nmeth.3170]; Gordon WR, 2015, DEV CELL, V33, P729, DOI 10.1016/j.devcel.2015.05.004; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Lienert F, 2014, NAT REV MOL CELL BIO, V15, P95, DOI 10.1038/nrm3738; Lim WA, 2010, NAT REV MOL CELL BIO, V11, P393, DOI 10.1038/nrm2904; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Rabinovich BA, 2008, P NATL ACAD SCI USA, V105, P14342, DOI 10.1073/pnas.0804105105; Sadelain M, 2009, CURR OPIN IMMUNOL, V21, P215, DOI 10.1016/j.coi.2009.02.009; Wilkie S, 2012, J CLIN IMMUNOL, V32, P1059, DOI 10.1007/s10875-012-9689-9	18	528	592	10	148	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2016	164	4					770	779		10.1016/j.cell.2016.01.011	http://dx.doi.org/10.1016/j.cell.2016.01.011			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DD5XN	26830879	Bronze, Green Accepted			2023-01-03	WOS:000369998300021
J	Yang, JF; Wang, Q; He, FF; Ding, YX; Sun, QY; Hua, TM; Xi, MM				Yang, Jinfang; Wang, Qian; He, Fenfen; Ding, Yanxia; Sun, Qingyan; Hua, Tianmiao; Xi, Minmin			Dietary Restriction Affects Neuronal Response Property and GABA Synthesis in the Primary Visual Cortex	PLOS ONE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; CALORIC RESTRICTION; NORADRENERGIC MODULATION; SYNAPTIC-TRANSMISSION; CORTICAL-CELLS; LIVE LONGER; BRAIN; INHIBITION; MECHANISMS; EXPRESSION	Previous studies have reported inconsistent effects of dietary restriction (DR) on cortical inhibition. To clarify this issue, we examined the response properties of neurons in the primary visual cortex (V1) of DR and control groups of cats using in vivo extracellular single-unit recording techniques, and assessed the synthesis of inhibitory neurotransmitter GABA in the V1 of cats from both groups using immunohistochemical and Western blot techniques. Our results showed that the response of V1 neurons to visual stimuli was significantly modified by DR, as indicated by an enhanced selectivity for stimulus orientations and motion directions, decreased visually-evoked response, lowered spontaneous activity and increased signal-to-noise ratio in DR cats relative to control cats. Further, it was shown that, accompanied with these changes of neuronal responsiveness, GABA immunoreactivity and the expression of a key GABA-synthesizing enzyme GAD67 in the V1 were significantly increased by DR. These results demonstrate that DR may retard brain aging by increasing the intracortical inhibition effect and improve the function of visual cortical neurons in visual information processing. This DR-induced elevation of cortical inhibition may favor the brain in modulating energy expenditure based on food availability.	[Yang, Jinfang; Wang, Qian; He, Fenfen; Ding, Yanxia; Sun, Qingyan; Hua, Tianmiao] Anhui Normal Univ, Coll Life Sci, Wuhu, Anhui, Peoples R China; [Xi, Minmin] Univ West Scotland, Sch Business, Glasgow, Lanark, Scotland	Anhui Normal University	Hua, TM (corresponding author), Anhui Normal Univ, Coll Life Sci, Wuhu, Anhui, Peoples R China.	tmhua@ahnu.edu.cn			National Natural Science Foundation of China [31171082]; Anhui Provincial Natural Science Foundation [070413138]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Anhui Provincial Natural Science Foundation(Natural Science Foundation of Anhui Province)	This research was supported by the National Natural Science Foundation of China (No. 31171082), Anhui Provincial Natural Science Foundation (No. 070413138), and Foundation of Anhui university scientific research innovation platform team (No. AT161805). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen K, 2015, CURR OPIN NEUROBIOL, V31, P81, DOI 10.1016/j.conb.2014.08.016; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P466, DOI 10.1113/jphysiol.1962.sp006990; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Buzsaki G, 2007, NEURON, V56, P771, DOI 10.1016/j.neuron.2007.11.008; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Caputi A, 2013, CURR OPIN NEUROBIOL, V23, P179, DOI 10.1016/j.conb.2013.01.021; Chantranupong L, 2015, CELL, V161, P67, DOI 10.1016/j.cell.2015.02.041; [陈翠云 Chen Cuiyun], 2014, [解剖学报, Acta Anatomica Sinica], V45, P304; Cheng CM, 2004, J NEUROSCI RES, V77, P270, DOI 10.1002/jnr.20144; Chiu CQ, 2013, SCIENCE, V340, P759, DOI 10.1126/science.1234274; Chung KW, 2013, EXP GERONTOL, V48, P1049, DOI 10.1016/j.exger.2012.11.007; Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; COLOMBO JP, 1992, ANN NUTR METAB, V36, P23, DOI 10.1159/000177695; Duan WZ, 2001, J MOL NEUROSCI, V16, P1, DOI 10.1385/JMN:16:1:1; Ego-Stengel V, 2002, NEUROSCIENCE, V111, P275, DOI 10.1016/S0306-4522(02)00011-8; Escanilla O, 2010, EUR J NEUROSCI, V32, P458, DOI 10.1111/j.1460-9568.2010.07297.x; Flores CE, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00327; Fontan-Lozano A, 2008, MOL NEUROBIOL, V38, P167, DOI 10.1007/s12035-008-8040-1; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Gribble KE, 2013, J GERONTOL A-BIOL, V68, P349, DOI 10.1093/gerona/gls170; Hasselmo ME, 1997, J NEUROPHYSIOL, V77, P3326, DOI 10.1152/jn.1997.77.6.3326; Henneberger C, 2005, NEUROSCIENCE, V135, P749, DOI 10.1016/j.neuroscience.2005.06.044; Hestrin S, 2011, NEURON, V71, P197, DOI 10.1016/j.neuron.2011.07.007; Hirata A, 2006, J NEUROSCI, V26, P4426, DOI 10.1523/JNEUROSCI.5298-05.2006; Hong YM, 2014, GENET MOL RES, V13, P6455, DOI 10.4238/2014.August.25.9; Hu B, 2000, BRAIN RES, V885, P87, DOI 10.1016/S0006-8993(00)02946-2; Hua TM, 2008, BRAIN RES BULL, V75, P119, DOI 10.1016/j.brainresbull.2007.08.001; Hua TM, 2010, CURR BIOL, V20, P887, DOI 10.1016/j.cub.2010.03.066; Hua TM, 2009, NEUROSCI LETT, V451, P25, DOI 10.1016/j.neulet.2008.12.041; Hua TM, 2006, NEUROBIOL AGING, V27, P155, DOI 10.1016/j.neurobiolaging.2004.11.012; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Ikeda MZ, 2015, J NEUROSCI, V35, P9356, DOI 10.1523/JNEUROSCI.4445-14.2015; Ingram DK, 2007, NEUROSCIENCE, V145, P1359, DOI 10.1016/j.neuroscience.2006.10.031; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kishi T, 2015, INT HEART J, V56, P110, DOI 10.1536/ihj.14-168; Kuhla A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068778; Kullmann DM, 2012, NEURON, V75, P951, DOI 10.1016/j.neuron.2012.07.030; Lennie P, 2003, CURR BIOL, V13, P493, DOI 10.1016/S0960-9822(03)00135-0; Leonhardt S, 1999, J NEUROENDOCRINOL, V11, P613; Levenson CW, 2007, NUTR REV, V65, P412, DOI [10.1301/nr.2007.sept.412-415, 10.1111/j.1753-4887.2007.tb00319.x]; Leventhal AG, 2003, SCIENCE, V300, P812, DOI 10.1126/science.1082874; Liang Z, 2010, NEUROBIOL AGING, V31, P863, DOI 10.1016/j.neurobiolaging.2008.06.013; Ling LL, 2005, NEUROSCIENCE, V132, P1103, DOI 10.1016/j.neuroscience.2004.12.043; Luebke JI, 2004, NEUROSCIENCE, V125, P277, DOI 10.1016/j.neuroscience.2004.01.035; Mair W, 2010, AGING CELL, V9, P916, DOI 10.1111/j.1474-9726.2010.00602.x; Matsumoto T, 2006, MOL CELL NEUROSCI, V31, P70, DOI 10.1016/j.mcn.2005.09.002; Mattson MP, 2002, MECH AGEING DEV, V123, P947, DOI 10.1016/S0047-6374(02)00032-5; McGinley MJ, 2015, NEURON, V87, P1143, DOI 10.1016/j.neuron.2015.09.012; Meneguello-Coutinho M, 2014, IMMUNOL INVEST, V43, P113, DOI 10.3109/08820139.2013.847456; Meng JJ, 2013, EXP BRAIN RES, V225, P377, DOI 10.1007/s00221-012-3378-z; Moncada R, 2016, OBES SURG, V26, P1549, DOI 10.1007/s11695-015-1919-9; Mower GD, 2001, DEV BRAIN RES, V126, P65, DOI 10.1016/S0165-3806(00)00139-5; Moxon KA, 2007, BRAIN RES, V1147, P105, DOI 10.1016/j.brainres.2007.02.006; Mu SH, 2016, NEUROCHEM RES, V41, P707, DOI 10.1007/s11064-015-1739-2; Murphy T, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/563160; Nayak P, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-4; Newton IG, 2005, NEUROBIOL AGING, V26, P683, DOI 10.1016/j.neurobiolaging.2004.06.005; Okada M, 2003, MOL BRAIN RES, V111, P175, DOI 10.1016/S0169-328X(03)00028-7; Paille V, 2013, J NEUROSCI, V33, P9353, DOI 10.1523/JNEUROSCI.5796-12.2013; Palizvan MR, 2004, NEUROSCIENCE, V126, P955, DOI 10.1016/j.neuroscience.2004.03.053; Pani G, 2015, SEMIN CELL DEV BIOL, V40, P106, DOI 10.1016/j.semcdb.2015.03.004; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Peng Qing-Song, 2011, Zoological Research, V32, P337, DOI 10.3724/SP.J.1141.2011.03337; Pezet S, 2002, MOL CELL NEUROSCI, V21, P51, DOI 10.1006/mcne.2002.1166; Pinto JGA, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00016; Ribaric S, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/741468; Rico B, 2002, NAT NEUROSCI, V5, P225, DOI 10.1038/nn808; Roth LW, 2012, MATURITAS, V71, P315, DOI 10.1016/j.maturitas.2011.12.017; Rudofsky G, 2011, HORM METAB RES, V43, P343, DOI 10.1055/s-0031-1271778; Sanchez-Huertas C, 2011, CEREB CORTEX, V21, P777, DOI 10.1093/cercor/bhq150; Schmolesky MT, 2000, NAT NEUROSCI, V3, P384, DOI 10.1038/73957; Seki K, 2011, J EXP NEUROSCI, V5, P9, DOI 10.4137/JEN.S6833; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P287, DOI 10.1113/jphysiol.1975.sp011055; Smyers ME, 2015, PHYSIOL BEHAV, V139, P303, DOI 10.1016/j.physbeh.2014.11.044; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Spolidoro M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1323; Tan N, 2016, HISTOPATHOLOGY, V68, P221, DOI 10.1111/his.12738; Thanos PK, 2008, SYNAPSE, V62, P50, DOI 10.1002/syn.20468; Tsutsumi A, 2011, BIOCHEM BIOPH RES CO, V404, P339, DOI 10.1016/j.bbrc.2010.11.120; Tucci P, 2012, AGING-US, V4, P525, DOI 10.18632/aging.100481; van de Lagemaat LN, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00394; Vaz SH, 2011, J BIOL CHEM, V286, P40464, DOI 10.1074/jbc.M111.232009; Vinck M, 2015, NEURON, V86, P740, DOI 10.1016/j.neuron.2015.03.028; Wang H, 2006, BRAIN RES, V1122, P93, DOI 10.1016/j.brainres.2006.09.010; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012; Xiang L, 2011, ANN NUTR METAB, V58, P42, DOI 10.1159/000323748; Yang Y, 2008, NEUROSCIENCE, V156, P748, DOI 10.1016/j.neuroscience.2008.08.007; Yoon H, 2008, BIOCHEM BIOPH RES CO, V371, P495, DOI 10.1016/j.bbrc.2008.04.102; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhang K, 2014, NEUROSCIENCE, V275, P238, DOI 10.1016/j.neuroscience.2014.06.020; Zhou Jun, 2011, Zoological Research, V32, P533, DOI 10.3724/SP.J.1141.2011.05533	95	10	10	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0149004	10.1371/journal.pone.0149004	http://dx.doi.org/10.1371/journal.pone.0149004			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6PR	26863207	Green Submitted, Green Published, gold			2023-01-03	WOS:000370046600137
J	Holter, JC; Ueland, T; Jenum, PA; Muller, F; Brunborg, C; Froland, SS; Aukrust, P; Husebye, E; Heggelund, L				Holter, Jan C.; Ueland, Thor; Jenum, Pal A.; Muller, Fredrik; Brunborg, Cathrine; Froland, Stig S.; Aukrust, Pal; Husebye, Einar; Heggelund, Lars			Risk Factors for Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study	PLOS ONE			English	Article							1-YEAR MORTALITY; IMMUNE-RESPONSE; PROGNOSIS; SURVIVAL; SEVERITY; PREDICTION; ETIOLOGY; OUTCOMES; MARKERS; ADULTS	Background Contributors to long-term mortality in patients with community-acquired pneumonia (CAP) remain unclear, with little attention paid to pneumonia etiology. We examined long-term survival, causes of death, and risk factors for long-term mortality in adult patients who had been hospitalized for CAP, with emphasis on demographic, clinical, laboratory, and microbiological characteristics. Methods Two hundred and sixty-seven consecutive patients admitted in 2008-2011 to a general hospital with CAP were prospectively recruited and followed up. Patients who died during hospital stay were excluded. Demographic, clinical, and laboratory data were collected within 48 hours of admission. Extensive microbiological work-up was performed to establish the etiology of CAP in 63% of patients. Mortality data were obtained from the Norwegian Cause of Death Registry. Cox regression models were used to identify independent risk factors for all-cause mortality. Results Of 259 hospital survivors of CAP (median age 66 years), 79 (30.5%) died over a median of 1,804 days (range 1-2,520 days). Cumulative 5-year survival rate was 72.9% (95% CI 67.4-78.4%). Standardized mortality ratio was 2.90 for men and 2.05 for women. The main causes of death were chronic obstructive pulmonary disease (COPD), vascular diseases, and malignancy. Independent risk factors for death were the following (hazard ratio, 95% CI): age (1.83 per decade, 1.47-2.28), cardiovascular disease (2.63, 1.61-4.32), COPD (2.09, 1.27-3.45), immunocompromization (1.98, 1.17-3.37), and low serum albumin level at admission (0.75 per 5g/L higher, 0.58-0.96), whereas active smoking was protective (0.32, 0.14-0.74); active smokers were younger than non-smokers (P < 0.001). Microbial etiology did not predict mortality. Conclusions Results largely confirm substantial comorbidity-related 5-year mortality after hospitalization for CAP and the impact of several well-known risk factors for death, and extend previous findings on the prognostic value of serum albumin level at hospital admission. Pneumonia etiology had no prognostic value, but this remains to be substantiated by further studies using extensive diagnostic microbiological methods in the identification of causative agents of CAP.	[Holter, Jan C.; Husebye, Einar; Heggelund, Lars] Vestre Viken Hlth Trust, Dept Internal Med, Drammen Hosp, Drammen, Norway; [Holter, Jan C.; Ueland, Thor; Froland, Stig S.; Aukrust, Pal] Univ Oslo, Rikshosp, Internal Med Res Inst, Oslo Univ Hosp, N-0027 Oslo, Norway; [Holter, Jan C.; Ueland, Thor; Jenum, Pal A.; Froland, Stig S.; Aukrust, Pal; Husebye, Einar; Heggelund, Lars] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Ueland, Thor; Aukrust, Pal] Univ Oslo, KG Jebsen Inflammatory Res Ctr, Oslo, Norway; [Jenum, Pal A.] Vestre Viken Hlth Trust, Dept Med Microbiol, Drammen Hosp, Drammen, Norway; [Muller, Fredrik] Univ Oslo, Rikshosp, Dept Microbiol, Oslo Univ Hosp, N-0027 Oslo, Norway; [Brunborg, Cathrine] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway; [Froland, Stig S.; Aukrust, Pal] Univ Oslo, Rikshosp, Sect Clin Immunol & Infect Dis, Oslo Univ Hosp, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; National Hospital Norway	Holter, JC (corresponding author), Vestre Viken Hlth Trust, Dept Internal Med, Drammen Hosp, Drammen, Norway.	jancho@mail.uio.no	Heggelund, Lars/GSN-0026-2022		Vestre Viken Health Trust	Vestre Viken Health Trust	This study was funded by Vestre Viken Health Trust. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamuz J, 2014, J INFECTION, V68, P534, DOI 10.1016/j.jinf.2014.02.006; Alan M, 2015, J INTERN MED, V278, P174, DOI 10.1111/joim.12341; Bordon J, 2010, CHEST, V138, P279, DOI 10.1378/chest.09-2702; Bruns AHW, 2011, CLIN MICROBIOL INFEC, V17, P763, DOI 10.1111/j.1469-0691.2010.03296.x; Bruns AHW, 2013, CLIN INFECT DIS, V57, P1370, DOI 10.1093/cid/cit507; Cangemi R, 2015, AM J CARDIOL, V116, P647, DOI 10.1016/j.amjcard.2015.05.028; Cecere LM, 2010, RESPIRATION, V79, P128, DOI 10.1159/000255764; Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229; de Roux A, 2006, CHEST, V129, P1219, DOI 10.1378/chest.129.5.1219; Eurich DT, 2015, AM J RESP CRIT CARE, V192, P597, DOI 10.1164/rccm.201501-0140OC; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Guertler C, 2011, EUR RESPIR J, V37, P1439, DOI 10.1183/09031936.00121510; HEDLUND JU, 1993, THORAX, V48, P785, DOI 10.1136/thx.48.8.785; Holter JC, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0803-5; Hosmer DW, 2013, WILEY SER PROBAB ST, P89; Johnstone J, 2008, MEDICINE, V87, P329, DOI 10.1097/MD.0b013e318190f444; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; Karhu J, 2011, ACTA ANAESTH SCAND, V55, P1254, DOI 10.1111/j.1399-6576.2011.02535.x; Katz MH., 2011, MULTIVARIABLE ANAL A; Kleinbaum DG., 1982, EPIDEMIOLOGIC RES PR; Koivula I, 1999, ARCH INTERN MED, V159, P1550, DOI 10.1001/archinte.159.14.1550; Koskela HO, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005715; Kruger S, 2010, AM J RESP CRIT CARE, V182, P1426, DOI 10.1164/rccm.201003-0415OC; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Lu TH, 2003, J EPIDEMIOL COMMUN H, V57, P470, DOI 10.1136/jech.57.6.470; Mortensen EM, 2012, SEMIN RESP CRIT CARE, V33, P319, DOI 10.1055/s-0032-1315644; Murugan R, 2010, KIDNEY INT, V77, P527, DOI 10.1038/ki.2009.502; Ramirez J, 2008, CLIN INFECT DIS, V47, P182, DOI 10.1086/589246; Restrepo MI, 2013, CURR OPIN INFECT DIS, V26, P151, DOI 10.1097/QCO.0b013e32835ebc6d; Sandvall B, 2013, CLIN INFECT DIS, V56, P1145, DOI 10.1093/cid/cis1207; Sington JD, 2002, J CLIN PATHOL, V55, P499, DOI 10.1136/jcp.55.7.499; Sligl WI, 2011, CHEST, V139, P88, DOI 10.1378/chest.10-1054; Sligl WI, 2010, CRIT CARE MED, V38, P2126, DOI 10.1097/CCM.0b013e3181eedaeb; Statistics Norway, STATBANK NORW DEATHS; Viasus D, 2013, EXPERT REV ANTI-INFE, V11, P917, DOI 10.1586/14787210.2013.825442; Viasus D, 2013, J INFECTION, V66, P415, DOI 10.1016/j.jinf.2012.12.007; Vincent JL, 2014, CRIT CARE, V18, DOI 10.1186/cc13991; Waterer GW, 2004, AM J RESP CRIT CARE, V169, P910, DOI 10.1164/rccm.200310-1448OC; Wesemann T, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0730-x; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x; Yende S, 2013, CHEST, V144, P1008, DOI 10.1378/chest.12-2818; Yende S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022847; Yende S, 2010, THORAX, V65, P870, DOI 10.1136/thx.2010.136317	45	43	45	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0148741	10.1371/journal.pone.0148741	http://dx.doi.org/10.1371/journal.pone.0148741			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26849359	Green Submitted, Green Published, gold			2023-01-03	WOS:000369554000165
J	Baharoglu, MI; Cordonnier, C; Salman, RAS; de Gans, K; Koopman, MM; Brand, A; Majoie, CB; Beenen, LF; Marquering, HA; Vermeulen, M; Nederkoorn, PJ; de Haan, RJ; Roos, YB				Baharoglu, M. Irem; Cordonnier, Charlotte; Salman, Rustam Al-Shahi; de Gans, Koen; Koopman, Maria M.; Brand, Anneke; Majoie, Charles B.; Beenen, Ludo F.; Marquering, Henk A.; Vermeulen, Marinus; Nederkoorn, Paul J.; de Haan, Rob J.; Roos, Yvo B.		PATCH Investigators	Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial	LANCET			English	Article							INTRACEREBRAL HEMORRHAGE; OXFORDSHIRE; COMMUNITY; GROWTH; AGENTS	Background Platelet transfusion after acute spontaneous primary intracerebral haemorrhage in people taking antiplatelet therapy might reduce death or dependence by reducing the extent of the haemorrhage. We aimed to investigate whether platelet transfusion with standard care, compared with standard care alone, reduced death or dependence after intracerebral haemorrhage associated with antiplatelet therapy use. Methods We did this multicentre, open-label, masked-endpoint, randomised trial at 60 hospitals in the Netherlands, UK, and France. We enrolled adults within 6 h of supratentorial intracerebral haemorrhage symptom onset if they had used antiplatelet therapy for at least 7 days beforehand and had a Glasgow Coma Scale score of at least 8. With use of a secure web-based system that concealed allocation and used biased coin randomisation, study collaborators randomly assigned participants (1: 1; stratified by hospital and type of antiplatelet therapy) to receive either standard care or standard care with platelet transfusion within 90 min of diagnostic brain imaging. Participants and local investigators giving interventions were not masked to treatment allocation, but allocation was concealed from outcome assessors and investigators analysing data. The primary outcome was shift towards death or dependence rated on the modified Rankin Scale (mRS) at 3 months, and analysed by ordinal logistic regression, adjusted for stratification variables and the Intracerebral Haemorrhage Score. The primary analysis was done in the intention-to-treat population and safety analyses were done in the intention-to-treat and as-treated populations. This trial is registered with the Netherlands Trial Register, number NTR1303, and is now closed. Findings Between Feb 4, 2009, and Oct 8, 2015, 41 sites enrolled 190 participants. 97 participants were randomly assigned to platelet transfusion and 93 to standard care. The odds of death or dependence at 3 months were higher in the platelet transfusion group than in the standard care group (adjusted common odds ratio 2.05, 95% CI 1.18-3.56; p = 0.0114). 40 (42%) participants who received platelet transfusion had a serious adverse event during their hospital stay, as did 28 (29%) who received standard care. 23 (24%) participants assigned to platelet transfusion and 16 (17%) assigned to standard care died during hospital stay. Interpretation Platelet transfusion seems inferior to standard care for people taking antiplatelet therapy before intracerebral haemorrhage. Platelet transfusion cannot be recommended for this indication in clinical practice.	[Baharoglu, M. Irem; Vermeulen, Marinus; Nederkoorn, Paul J.; Roos, Yvo B.] Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands; [Majoie, Charles B.; Beenen, Ludo F.; Marquering, Henk A.] Acad Med Ctr, Dept Radiol, NL-1100 DD Amsterdam, Netherlands; [Marquering, Henk A.] Acad Med Ctr, Dept Biomed Engn & Phys, NL-1100 DD Amsterdam, Netherlands; [de Haan, Rob J.] Acad Med Ctr, Clin Res Unit, NL-1100 DD Amsterdam, Netherlands; [Cordonnier, Charlotte] Univ Lille, Degenerat & Vasc Cognit Disorders, CHU Lille, Inserm,U1171,Dept Neurol, Lille, France; [Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [de Gans, Koen] Groene Hart Ziekenhuis, Dept Neurol, Gouda, Netherlands; [Koopman, Maria M.; Brand, Anneke] Sanquin Bloodbank, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; University of Edinburgh	Roos, YB (corresponding author), Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands.	y.b.roos@amc.uva.nl	Cordonnier, Charlotte/O-3258-2017; Roos, Yvo BWEM/B-9843-2013; Klijn, C.J.M./E-1700-2016; Beenen, Ludo F/AAA-3114-2021	Cordonnier, Charlotte/0000-0002-5697-6892; Klijn, C.J.M./0000-0002-8495-4578; Beenen, Ludo F/0000-0001-9204-1026; Marquering, Henk/0000-0002-1414-6313; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Touze, Emmanuel/0000-0002-7254-2162; El Tawil, Salwa/0000-0002-0473-8091; Timsit, Serge/0000-0003-0346-8576; Mazighi, Mikael/0000-0003-0911-8999; Bejot, Yannick/0000-0001-7848-7072	Netherlands Organisation for Health Research and Development (ZonMw) [170881002]; Sanquin Blood Bank in the Netherlands; French Ministry of Health (PHRC-N) [19-15]; Chest Heart and Stroke Scotland [Res10]; MRC [G108/613]; Academic Medical Centre, University of Amsterdam, in the Netherlands; Inserm, CHU Lille, Lille, in France [U1171]; University of Edinburgh, NHS Lothian Academic and Clinical Central Office for Research and Development (ACCORD) in Scotland;  [G1002605]; MRC [G1002605, G0900428] Funding Source: UKRI; Medical Research Council [G0900428, G1002605, G108/613] Funding Source: researchfish; Chest Heart and Stroke Scotland [Res10/A127] Funding Source: researchfish	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Sanquin Blood Bank in the Netherlands; French Ministry of Health (PHRC-N); Chest Heart and Stroke Scotland; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academic Medical Centre, University of Amsterdam, in the Netherlands; Inserm, CHU Lille, Lille, in France; University of Edinburgh, NHS Lothian Academic and Clinical Central Office for Research and Development (ACCORD) in Scotland; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chest Heart and Stroke Scotland	PATCH was funded by The Netherlands Organisation for Health Research and Development (ZonMw, 170881002) and Sanquin Blood Bank in the Netherlands; French Ministry of Health (PHRC-N, 2011, 19-15; to CC); and a Chest Heart and Stroke Scotland project grant (Reference Res10; to RA-SS)) and MRC clinician scientist (G108/613 to RA-SS) and senior clinical fellowships (G1002605 to RA-SS) in Scotland. PATCH was sponsored by Academic Medical Centre, University of Amsterdam, in the Netherlands; Inserm U1171, CHU Lille, Lille, in France; and The University of Edinburgh, NHS Lothian Academic and Clinical Central Office for Research and Development (ACCORD) in Scotland. PATCH received non-financial support from Strokavenir network and Etablissement Francais du Sang in France; and the UK National Institute for Health Research (NIHR) stroke research network, the Scottish Stroke Research Network, and the Scottish National Blood Transfusion Service clinical governance and safety committee in the UK. CC is a member of the Institut Universitaire de France. We are very grateful for the tireless dedication of the PATCH trial managers and research staff : Nadine Fleitour (Netherlands); Fanny Ben Oune, Thavarak Ouk, and Dominique Deplanque (France); and Bridget Colam, Robin Flaig, Katrina McCormick, Neshika Samarasekera, Aidan Hutchison, and Christine Lerpiniere (Scotland). We are grateful to all principal investigators and delegated physicians who included participants in all participating centres. We are indebted to the participants and their carers and families who consented to participate in PATCH.	BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Beshay JE, 2010, J NEUROSURG, V112, P307, DOI 10.3171/2009.7.JNS0982; Boers AM, 2014, AM J NEURORADIOL, V35, P2279, DOI 10.3174/ajnr.A4042; Charlton A, 2014, TRANSFUSION MED, V24, P213, DOI 10.1111/tme.12126; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; de Gans K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-19; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Fonville AF, 2013, STROKE, V44, P2729, DOI 10.1161/STROKEAHA.113.001493; Goel R, 2015, BLOOD, V125, P1470, DOI 10.1182/blood-2014-10-605493; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Kaufman RM, 2015, ANN INTERN MED, V162, P205, DOI 10.7326/M14-1589; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Kumar A, 2015, TRANSFUSION, V55, P1116, DOI 10.1111/trf.12943; Leong LB, 2015, J EMERG MED, V49, P561, DOI 10.1016/j.jemermed.2015.02.023; Lovelock CE, 2007, LANCET NEUROL, V6, P487, DOI 10.1016/S1474-4422(07)70107-2; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Salman RAS, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2586; Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831; Stolla M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00028; Suzuki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097328; Thompson BB, 2010, NEUROLOGY, V75, P1333, DOI 10.1212/WNL.0b013e3181f735e5; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x	30	371	386	1	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2016	387	10038					2605	2613		10.1016/S0140-6736(16)30392-0	http://dx.doi.org/10.1016/S0140-6736(16)30392-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP3JX	27178479	Green Accepted			2023-01-03	WOS:000378390500028
J	Abukres, SH; Hoti, K; Hughes, JD				Abukres, Salem Hasn; Hoti, Kreshnik; Hughes, Jeffery David			Avoiding Treatment Interruptions: What Role Do Australian Community Pharmacists Play?	PLOS ONE			English	Article							WESTERN-AUSTRALIA; GENERAL-PRACTICE; ATTITUDES; VIGNETTES; IMPACT; CHART; CARE	Objective To explore the reported practice of Australian community pharmacists when dealing with medication supply requests in absence of a valid prescription. Methods Self-administered questionnaire was posted to 1490 randomly selected community pharmacies across all Australian states and territories. This sample was estimated to be a 20% of all Australian community pharmacies. Results Three hundred eighty five pharmacists participated in the study (response rate achieved was 27.9% (there were 111 undelivered questionnaires). Respondents indicated that they were more likely to provide medications to regular customers without a valid prescription compared to non-regular customers (p<0.0001). However, supply was also influenced by the type of prescription and the medication requested. In the case of type of prescription (Standard, Authority or Private) this relates to the complexity/probability of obtaining a valid prescription from the prescriber at a later date (i.e. supply with an anticipated prescription). Decisions to supply and/or not supply related to medication type were more complex. For some cases, including medication with potential for abuse, the practice and/or the method of supply varied significantly according to age and gender of the pharmacist, and pharmacy location (p<0.05). Conclusions Although being a regular customer does not guarantee a supply, results of this study reinforce the importance for patients having a regular pharmacy, where pharmacists were more likely to continue medication supply in cases of patients presenting without a valid prescription. We would suggest, more flexible legislation should be implemented to allow pharmacists to continue supplying of medication when obtaining a prescription is not practical.	[Abukres, Salem Hasn; Hoti, Kreshnik; Hughes, Jeffery David] Curtin Univ, Sch Pharm, Perth, WA 6845, Australia; [Hoti, Kreshnik] Univ Prishtina, Fac Med, Dept Pharm, Prishtina, Kosovo, Serbia	Curtin University; Universiteti i Prishtines	Hoti, K (corresponding author), Curtin Univ, Sch Pharm, Perth, WA 6845, Australia.; Hoti, K (corresponding author), Univ Prishtina, Fac Med, Dept Pharm, Prishtina, Kosovo, Serbia.	kreshnik.hoti@uni-pr.edu	Hoti, Kreshnik/AAA-4562-2021					Abu-Omar SM, 2000, INT J PHARM PRACT, V8, P135, DOI DOI 10.1111/J.2042-7174.2000.TB00998.X; Abukres SH, 2015, PEERJ, V3, DOI 10.7717/peerj.924; Abukres SH, 2014, PATIENT PREFER ADHER, V8, P1143, DOI 10.2147/PPA.S66719; Australian Government Department of Health, 2014, SUPPL MED WHAT PHARM; Australian Government Department of Health, 2015, 2 PRESCR MED INF PBS; Australian Government Department of Health, 2015, PBS FREQ ASK QUEST; Australian Government Department of Health, 2015, PBS COP SAF NET AM 2; Australian Institute of Health and Welfare, 2016, RUR REM METR AR RRMA; Barbero-Gonzalez A, 2006, Aten Primaria, V37, P78, DOI 10.1157/13084485; Bessell T, IMPROVING AUSTR ACCE; Cates ME, 2005, ANN PHARMACOTHER, V39, P1450, DOI 10.1345/aph.1G009; Evans SC, 2015, INT J CLIN HLTH PSYC, V15, P160, DOI 10.1016/j.ijchp.2014.12.001; Garth B, 2014, AUST FAM PHYSICIAN, V43, P404; Hamrosi KK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-183; Health Workforce Australia, 2014, HLTH WORKF AUSTR PHA; Hoti K, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-25; Hoti Kreshnik, 2011, Int J Pharm Pract, V19, P5, DOI 10.1111/j.2042-7174.2010.00077.x; Hoti K, 2010, PHARM WORLD SCI, V32, P610, DOI 10.1007/s11096-010-9400-2; Hynd A, 2009, AUST NZ J PUBL HEAL, V33, P246, DOI 10.1111/j.1753-6405.2009.00383.x; Kahan M, 2011, CAN FAM PHYSICIAN, V57, pE448; Law Michael R, 2012, Can Pharm J (Ott), V145, P17, DOI 10.3821/1913-701X-145.1.17; Monheit B, 2010, AUST FAM PHYSICIAN, V39, P540; Morecroft C, 2014, EVALUATION ROLE COMM; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; Murray M, 2000, Fam Pract Manag, V7, P45; NHS Direct Wales, 2015, PHARM FREQ ASK QUEST; Ong AD, 2000, J APPL SOC PSYCHOL, V30, P1691, DOI 10.1111/j.1559-1816.2000.tb02462.x; Parliament of Victoria, 2014, INQ COMM PHARM VICT; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Puspitasari HP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113337; Rutten GMJ, 2006, J EVAL CLIN PRACT, V12, P491, DOI 10.1111/j.1365-2753.2006.00699.x; Sampson F, 2008, BRIT J GEN PRACT, V58, P641, DOI 10.3399/bjgp08X330780; Scott A, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-126; Sinnott SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064914; Smith JD, 2013, RURAL REMOTE HEALTH, V13; Starkweather J., 2011, MULTINOMIAL LOGISTIC; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481	37	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0154992	10.1371/journal.pone.0154992	http://dx.doi.org/10.1371/journal.pone.0154992			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27170997	Green Published, gold			2023-01-03	WOS:000376588600019
J	Wittenberg, E; Prosser, LA				Wittenberg, Eve; Prosser, Lisa A.			Health as a Family Affair	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPILLOVER		[Wittenberg, Eve] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA; [Prosser, Lisa A.] Univ Michigan, Dept Pediat & Communicable Dis, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA; [Prosser, Lisa A.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wittenberg, E (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA.							Bobinac A, 2011, MED DECIS MAKING, V31, P292, DOI 10.1177/0272989X10374212; National Alliance for Caregiving & AARP, 2015, CAR US 2015 REP; Perkins M, 2013, J GERONTOL B-PSYCHOL, V68, P504, DOI 10.1093/geronb/gbs084; Prosser LA, 2015, MED DECIS MAKING, V35, P81, DOI 10.1177/0272989X14541328; Wittenberg E, 2013, MED DECIS MAKING, V33, P235, DOI 10.1177/0272989X12464434	5	39	39	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2016	374	19					1804	1806		10.1056/NEJMp1604456	http://dx.doi.org/10.1056/NEJMp1604456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL6JS	27168430				2023-01-03	WOS:000375746100002
J	Chen, HY; Shen, ZJ; Chen, JD; Zhang, HW; Chen, XH				Chen, Hanyu; Shen, Zhengjie; Chen, Jiandong; Zhang, Haowen; Chen, Xiaohu			Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							MYOCARDIAL-INFARCTION; RISK; DEFINITION; PREVALENCE; MECHANISMS; PLATELETS; CHILDREN; DISEASE; STROKE	Objectives To assess the effectiveness and safety of Chinese herbal medicine (CHM) for the treatment of aspirin resistance (AR). Methods A comprehensive research of seven electronic databases was performed for comparative studies evaluating CHM for AR. Two authors independently extracted data and assessed the methodological quality of the included trials using the Cochrane risk of bias tool. Data wasere synthesized by using RevMan 5.3 software. (PROSPERO Registration #CRD42015020182) Results 18 randomized controlled trials (RCTs) involving 1,460 patients were included. 15 RCTs reported significant difference in the reduction of platelet aggregation rate (PAR) induced by adenosine diphosphate (ADP) (P < 0.05), and 11 reported significant effect of CHM plus aspirin to reduce PAR induced by arachidonic acid (AA) (P < 0.05) compared with aspirin 100mg/d treatment. The pooling data of 3 RCTs showed the thromboxane B-2 (TXB2) in patients with CHM plus aspirin versus aspirin were significantly reduced (Random Effect model (RE), Standard Deviation (SD) = -95.93, 95% Confidential Interval (CI)[-118.25,-73.61], P < 0.00001). Subgroup analysis showed that TXB2 (Fixed Effect model (FE), SD = -89.23, 95% CI[-121.96,-56.49], P < 0.00001) had significant difference in Tongxinluo capsule plus aspirin versus aspirin. 2 RCTs reported the clinical effective rate, and the meta-analysis result showed a significant difference in intervention and control group (FE, Relative Risk (RR) = 1.67, 95% CI[1.15, 2.42], P = 0.007 < 0.05). In 4 trials, CHM plus aspirin had better effects of reducing the reoccurrence of cerebral infarction than aspirin (FE, RR = 0.24, 95% CI [0.11, 0.49], P < 0.0001). And one trial showed that CHM plus aspirin could decrease the National Institutes of Health Stroke Scale (NHISS) score (P < 0.05) and increase the Barthel Index (BI) score (P < 0.05). 4 trials stated that there were no adverse effects occurred in intervention group, and analysis showed significant difference of CHM or CHM plus aspirin in reducing the occurrence of adverse events (FE, RR = 0.22, 95% CI[0.13, 0.39], P < 0.00001). 5 trials claimed that the CHM monotherapy and CHM adjunctive therapy for AR did not add the risk of bleeding (FE, RR = 0.50, 95% CI[0.20, 1.22], P = 0.13 > 0.05). Conclusions CHM may be effective and safe as an alternative and collaborative therapy for AR. However, the current evidence and potential promising findings should be interpreted with caution due to poor and varying methodological quality of included studies and the heterogeneity of interventions. Thus, further exploration of this strategy with adequately powered RCTs is warranted.	[Chen, Hanyu; Shen, Zhengjie; Zhang, Haowen] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China; [Chen, Hanyu; Chen, Jiandong; Zhang, Haowen; Chen, Xiaohu] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Cardiol, Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Shen, Zhengjie] Nanjing Univ Chinese Med, Translat Med Ctr, Key Lab Famous Doctors Proved Recipe Evaluat & Tr, State Adm Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Chen, XH (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Dept Cardiol, Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.	chenxhdoctor@126.com			National Natural Science Foundation of China [81273943]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	CXH received the funding from the National Natural Science Foundation of China (NO.81273943), available from http://isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list.	Bishopric NH, 2013, J AM COLL CARDIOL, V62, P1277, DOI 10.1016/j.jacc.2013.06.024; Chadha DS, 2014, CATHETER CARDIOVASC; Chai ZQ, 2008, PRACTICAL J MED PHAR, V04, P387; Cheng G, 2013, SHANXI MED J, V42, P1388; Eikelboom JW, 2002, CIRCULATION, V105, P1650, DOI 10.1161/01.CIR.0000013777.21160.07; Floyd CN, 2014, PHARMACOL THERAPEUT, V141, P69, DOI 10.1016/j.pharmthera.2013.08.005; Guo H Y, 2012, CHINESE J MODERN DRU, V6, P74; Hankey GJ, 2006, LANCET, V367, P606, DOI 10.1016/S0140-6736(06)68040-9; Harrison P, 2007, THROMB RES, V120, P323, DOI 10.1016/j.thromres.2006.11.012; Heistein LC, 2008, PEDIATR CARDIOL, V29, P285, DOI 10.1007/s00246-007-9098-7; Huang H.M., 2014, GUIDE CHINA MED, P19; Huang LF, 2014, THROMB RES, V133, P848, DOI 10.1016/j.thromres.2014.02.009; Hurlen M, 2000, THROMB RES, V99, P487, DOI 10.1016/S0049-3848(00)00277-2; Krasopoulos G, 2008, BMJ-BRIT MED J, V336, P195, DOI 10.1136/bmj.39430.529549.BE; Kuliczkowski W, 2009, EUR HEART J, V30, P426, DOI 10.1093/eurheartj/ehn562; Larsen SB, 2013, THROMB HAEMOSTASIS, V109, P920, DOI 10.1160/TH12-09-0666; Lee JJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-137; Liu AJ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/890950; Liu DF, 2015, J NINGXIA MED U, V29, P205; Liu HQ, 2008, J LIAONING U TRADITI, V10, P109; Liu L, 2014, THROMB RES, V134, P866, DOI 10.1016/j.thromres.2014.07.019; Liu Q. K., 2010, ZHEJIANG J TRADITION, V45, P320; Ma XJ, 2012, CHINESE J MISDIAGNOS, V12, P530; Maione F, 2015, FITOTERAPIA, V100, P174, DOI 10.1016/j.fitote.2014.11.024; Patrono C, 2003, J THROMB HAEMOST, V1, P1710, DOI 10.1046/j.1538-7836.2003.00284.x; Phankingthongkum Rewat, 2013, Journal of the Medical Association of Thailand, V96, pS146; Sirachainan N, 2015, THROMB RES, V135, P916, DOI 10.1016/j.thromres.2015.03.003; Song SJ, 2008, SHANDONG MED J, V48, P13; Su W, 2012, CHINA PHARM, V21, P26; Tu X P, 2013, J NINGXIA MED U, V35, P172; Wang J, 2012, CHINA MED HERALD, V9, P17; Wen Dan, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P585, DOI 10.3760/cma.j.issn.2095-4352.2014.08.013; Yi XY, 2013, INT J STROKE, V8, P535, DOI 10.1111/j.1747-4949.2012.00929.x; Yin Cheng-hua, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P380; Zhang HX, 2014, ARCH GERONTOL GERIAT, V59, P491, DOI 10.1016/j.archger.2014.04.005; Zhang JH, 2010, SENSOR LETT, V8, P16, DOI 10.1166/sl.2010.1194; Zhang K, 2013, J LIAONING U TCM, V15, P21; Zhang Lei, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P594; Zhang X, 2013, J INTERNAL MED CONCE, V8, P200; 吴同和, 2012, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V23, P1586	40	4	5	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154897	10.1371/journal.pone.0154897	http://dx.doi.org/10.1371/journal.pone.0154897			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	27153119	Green Published, Green Submitted, gold			2023-01-03	WOS:000375677000045
J	Buntrock, C; Ebert, DD; Lehr, D; Smit, F; Riper, H; Berking, M; Cuijpers, P				Buntrock, Claudia; Ebert, David Daniel; Lehr, Dirk; Smit, Filip; Riper, Heleen; Berking, Matthias; Cuijpers, Pim			Effect of a Web-Based Guided Self-help Intervention for Prevention of Major Depression in Adults With Subthreshold Depression A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE-BEHAVIOR THERAPY; PRIMARY-CARE; DSM-IV; DISORDER; VALIDATION; INTERVIEW; DISEASE; ANXIETY; BURDEN; ONSET	IMPORTANCE Evidence-based treatments for major depressive disorder (MDD) are not very successful in improving functional and health outcomes. Attention has increasingly been focused on the prevention of MDD. OBJECTIVE To evaluate the effectiveness of a web-based guided self-help intervention for the prevention of MDD. DESIGN, SETTING, AND PARTICIPANTS Two-group randomized clinical trial conducted between March 1, 2013, and March 4, 2015. Participants were recruited in Germany from the general population via a large statutory health insurance company (ie, insurance funded by joint employer-employee contributions). Participants included 406 self-selected adults with subthreshold depression (Centre for Epidemiologic Studies Depression Scale score >= 16, no current MDD according to Diagnostic and Statistical Manual of Mental Disorders [Fourth Edition, Text Revision] criteria). INTERVENTIONS All participants had unrestricted access to usual care (visits to the primary care clinician) and were randomized to either a web-based guided self-help intervention (cognitive-behavioral and problem-solving therapy supported by an online trainer; n = 202) or a web-based psychoeducation program (n = 204). MAIN OUTCOMES AND MEASURES The primary outcomewas time to onset of MDD in the intervention group relative to the control group over a 12-month follow-up period as assessed by blinded diagnostic raters using the telephone-administered Structured Clinical Interview for DSM-IV Axis Disorders at 6-and 12-month follow-up, covering the period to the previous assessment. RESULTS Among 406 randomized patients (mean age, 45 years; 73.9% women), 335 (82%) completed the telephone follow-up at 12 months. Fifty-five participants (27%) in the intervention group experienced MDD compared with 84 participants (41%) in the control group. Cox regression analyses controlling for baseline depressive symptom severity revealed a hazard ratio of 0.59 (95% CI, 0.42-0.82; P =.002) at 12-month follow-up. The number needed to treat to avoid 1 new case of MDD was 5.9 (95% CI, 3.9-14.6). CONCLUSIONS AND RELEVANCE Among patients with subthreshold depression, the use of a web-based guided self-help intervention compared with enhanced usual care reduced the incidence of MDD over 12 months. Further research is needed to understand whether the effects are generalizable to both first onset of depression and depression recurrence as well as efficacy without the use of an online trainer.	[Buntrock, Claudia; Ebert, David Daniel; Lehr, Dirk; Riper, Heleen; Berking, Matthias; Cuijpers, Pim] Leuphana Univ, Div Online Hlth Training, Innovat Incubator, Luneburg, Germany; [Buntrock, Claudia; Smit, Filip; Riper, Heleen; Cuijpers, Pim] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Dept Clin Psychol, Amsterdam, Netherlands; [Ebert, David Daniel; Berking, Matthias] Univ Erlangen Nurnberg, Dept Clin Psychol & Psychotherapy, D-91054 Erlangen, Germany; [Smit, Filip] Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Dept Publ Mental Hlth, Utrecht, Netherlands; [Smit, Filip] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Riper, Heleen] Univ Southern Denmark, Inst Telepsychiat, Odense, Denmark	Leuphana University Luneburg; Vrije Universiteit Amsterdam; University of Erlangen Nuremberg; Trimbos Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Southern Denmark	Buntrock, C (corresponding author), Vrije Univ Amsterdam, Dept Clin Psychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	buntrockclaudia@gmail.com	Cuijpers, Pim/G-1703-2013; Lehr, Dirk/AAN-2010-2020	Lehr, Dirk/0000-0002-5560-3605; Ebert, David Daniel/0000-0001-6820-0146	European Union (project EFRE) [CCI 2007DE161PR001]; BARMER GEK (German statutory health insurance company)	European Union (project EFRE); BARMER GEK (German statutory health insurance company)	The associated project of all authors was funded by the European Union (project EFRE: CCI 2OO7DE161PROO1) and the BARMER GEK (German statutory health insurance company).	Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Andrews G, 2004, BRIT J PSYCHIAT, V184, P526, DOI 10.1192/bjp.184.6.526; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Berle D, 2011, CLIN PSYCHOL PSYCHOT, V18, P339, DOI 10.1002/cpp.724; [Bundesarztekammer Bundesarztekammer. Bundesvereinigung K Fachgesellschaften AdWM], 2011, GERM S3 GUID NAT DIS; Buntrock C, 2015, PSYCHOTHER PSYCHOSOM, V84, P348, DOI 10.1159/000438673; Cookson J, 2006, INT CLIN PSYCHOPHARM, V21, P267, DOI 10.1097/00004850-200609000-00004; Crippa JAS, 2008, PERSPECT PSYCHIATR C, V44, P241, DOI 10.1111/j.1744-6163.2008.00183.x; Cuijpers P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-181; Dam EAV, 2007, J AFFECT DISORDERS, V97, P219, DOI 10.1016/j.jad.2006.06.020; de Jonge P, 2009, PSYCHOSOMATICS, V50, P227, DOI 10.1176/appi.psy.50.3.227; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; Ebert DD, 2015, J AFFECT DISORDERS, V176, P9, DOI 10.1016/j.jad.2015.01.056; Ferrari AJ, 2013, PSYCHOL MED, V43, P471, DOI 10.1017/S0033291712001511; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gilbody S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5627; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hagan R, 2004, BJOG-INT J OBSTET GY, V111, P641, DOI 10.1111/j.1471-0528.2004.00165.x; Hakkaart-van Roijen L, 2002, MANUAL TRIMBOS IMTA; Kessler RC, 2015, EPIDEMIOL PSYCH SCI, V24, P210, DOI 10.1017/S2045796015000189; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; KUPFER DJ, 1991, J CLIN PSYCHIAT, V52, P28; Lobbestael J, 2011, CLIN PSYCHOL PSYCHOT, V18, P75, DOI 10.1002/cpp.693; Lohse MJ, 2008, ARZNEIVERORDNUNGSREP, P775; LYKETSOS CG, 1994, INT J METHOD PSYCH, V4, P143; Mack S, 2014, INT J METH PSYCH RES, V23, P289, DOI 10.1002/mpr.1438; Manos RC, 2011, BEHAV THER, V42, P726, DOI 10.1016/j.beth.2011.04.004; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Newcombe RG, 1999, STAT MED, V18, P1293, DOI 10.1002/(SICI)1097-0258(19990530)18:10<1293::AID-SIM175>3.0.CO;2-7; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Otero P, 2015, PSYCHOL MED, V45, P1401, DOI 10.1017/S0033291714002505; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; StataCorp, 2013, STAT STAT SOFTW REL; van Zoonen K, 2014, INT J EPIDEMIOL, V43, P318, DOI 10.1093/ije/dyt175; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Willemse GRWM, 2004, BRIT J PSYCHIAT, V185, P416, DOI 10.1192/bjp.185.5.416; Zhang DX, 2014, J AFFECT DISORDERS, V169, P212, DOI 10.1016/j.jad.2014.08.015; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	42	147	149	1	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2016	315	17					1854	1863		10.1001/jama.2016.4326	http://dx.doi.org/10.1001/jama.2016.4326			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DK9XF	27139058	Bronze, Green Published			2023-01-03	WOS:000375284400014
J	Maiti, A; Bhattacharya, S				Maiti, Abhishek; Bhattacharya, Sreyasi			A patient with cancer and nail pigmentation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Maiti, Abhishek] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA; [Bhattacharya, Sreyasi] Pacific Cardiol Associates, Dept Cardiol, Fremont, CA USA	University of Texas System; University of Texas Health Science Center Houston	Maiti, A (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA.	abhishek.maiti@uth.tmc.edu						Braun RP, 2007, J AM ACAD DERMATOL, V56, P835, DOI 10.1016/j.jaad.2006.12.021; Gilbar Peter, 2009, J Oncol Pharm Pract, V15, P143, DOI 10.1177/1078155208100450; Lateur N, 2002, DERMATOL THER, V15, P131; Quinlan KE, 2005, J AM ACAD DERMATOL, V53, pS112, DOI 10.1016/j.jaad.2004.11.020	4	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2016	353								i2346	10.1136/bmj.i2346	http://dx.doi.org/10.1136/bmj.i2346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL4AE	27142474				2023-01-03	WOS:000375574000003
J	Iakovleva, I; Begum, A; Brannstrom, K; Wijsekera, A; Nilsson, L; Zhang, J; Andersson, PL; Sauer-Eriksson, AE; Olofsson, A				Iakovleva, Irina; Begum, Afshan; Brannstrom, Kristoffer; Wijsekera, Alexandra; Nilsson, Lina; Zhang, Jin; Andersson, Patrik L.; Sauer-Eriksson, A. Elisabeth; Olofsson, Anders			Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer	PLOS ONE			English	Article							BROMINATED FLAME RETARDANTS; AMYLOID FIBRIL FORMATION; THYROID-HORMONE-BINDING; INHIBITION PROPERTIES; NATIVE-STATE; POTENT; DIFLUNISAL; AMYLOIDOGENESIS; POLYNEUROPATHY; DISEASE	Amyloid formation of the human plasma protein transthyretin (TTR) is associated with several human disorders, including familial amyloidotic polyneuropathy (FAP) and senile systemic amyloidosis. Dissociation of TTR's native tetrameric assembly is the rate-limiting step in the conversion into amyloid, and this feature presents an avenue for intervention because binding of an appropriate ligand to the thyroxin hormone binding sites of TTR stabilizes the native tetrameric assembly and impairs conversion into amyloid. The desired features for an effective TTR stabilizer include high affinity for TTR, high selectivity in the presence of other proteins, no adverse side effects at the effective concentrations, and a long half-life in the body. In this study we show that the commonly used flame retardant tetrabromobisphenol A (TBBPA) efficiently stabilizes the tetrameric structure of TTR. The X-ray crystal structure shows TBBPA binding in the thyroxine binding pocket with bromines occupying two of the three halogen binding sites. Interestingly, TBBPA binds TTR with an extremely high selectivity in human plasma, and the effect is equal to the recently approved drug tafamidis and better than diflunisal, both of which have shown therapeutic effects against FAP. TBBPA consequently present an interesting scaffold for drug design. Its absorption, metabolism, and potential side-effects are discussed.	[Iakovleva, Irina; Brannstrom, Kristoffer; Wijsekera, Alexandra; Olofsson, Anders] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Begum, Afshan; Nilsson, Lina; Zhang, Jin; Andersson, Patrik L.; Sauer-Eriksson, A. Elisabeth] Umea Univ, Dept Chem, Umea, Sweden	Umea University; Umea University	Olofsson, A (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	anders.olofsson@umu.se	Brännström, Kristoffer/AAC-1204-2020	BEGUM, AFSHAN/0000-0001-5047-5168; Sauer-Eriksson, Elisabeth/0000-0003-0124-0199	Swedish Research Council; Parkinsofonden; Insamlingsstiftelsen at Umea University; Alzheimerfonden; Ahlen-stiftelsen; J.C. Kempes stiftelse; Hjarnfonden; O.E. och Edlas stiftelse; Torsten Soderbergs stiftelse; Vasterbottens Lans lasting (ALF-medel); Patientforeningen FAMY/AMYL; Medical Faculty of Umea University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Parkinsofonden; Insamlingsstiftelsen at Umea University; Alzheimerfonden; Ahlen-stiftelsen; J.C. Kempes stiftelse; Hjarnfonden; O.E. och Edlas stiftelse; Torsten Soderbergs stiftelse; Vasterbottens Lans lasting (ALF-medel); Patientforeningen FAMY/AMYL; Medical Faculty of Umea University	We thank the Swedish Research Council, Parkinsofonden, Insamlingsstiftelsen at Umea University, Alzheimerfonden, Ahlen-stiftelsen, J.C. Kempes stiftelse, Hjarnfonden, O.E. och Edlas stiftelse, Torsten Soderbergs stiftelse, Vasterbottens Lans lasting (ALF-medel), Patientforeningen FAMY/AMYL, and the Medical Faculty of Umea University for funding.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Adamski-Werner SL, 2004, J MED CHEM, V47, P355, DOI 10.1021/jm030347n; Addison RS, 2000, EUR J CLIN PHARMACOL, V56, P715, DOI 10.1007/s002280000211; Alhamadsheh MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002473; Almeida M. R., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P587, DOI 10.2174/156800705774322076; Alshehri B, 2015, J NEUROENDOCRINOL, V27, P303, DOI 10.1111/jne.12271; Arvidsson S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143456; Belluti F, 2014, EUR J MED CHEM, V78, P157, DOI 10.1016/j.ejmech.2014.03.042; Berk JL, 2013, JAMA-J AM MED ASSOC, V310, P2658, DOI 10.1001/jama.2013.283815; Bromine Science and Environmental Forum (BSEF), BSEF POST TBBPA; Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109; Carvalho A, 2015, LIVER TRANSPLANT, V21, P282, DOI 10.1002/lt.24058; Cheng SB, 2015, AM J REPROD IMMUNOL; CHENG SY, 1977, BIOCHEMISTRY-US, V16, P3707, DOI 10.1021/bi00635a031; Coelho T, 2013, J NEUROL, V260, P2802, DOI 10.1007/s00415-013-7051-7; Coelho T, 2012, NEUROLOGY, V79, P785, DOI 10.1212/WNL.0b013e3182661eb1; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Cope RB, 2015, TOXICOLOGY, V329, P49, DOI 10.1016/j.tox.2014.12.013; Cotrina EY, 2013, J MED CHEM, V56, P9110, DOI 10.1021/jm401061w; Cruz MW, 2015, NEUROL THER, V4, P61, DOI 10.1007/s40120-015-0031-3; de Wit CA, 2010, SCI TOTAL ENVIRON, V408, P2885, DOI 10.1016/j.scitotenv.2009.08.037; Dunnick JK, 2015, TOXICOL PATHOL, V43, P464, DOI 10.1177/0192623314557335; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; European Medicines Agency, 2011, VYND ASS REP EUR MED; Ferreira N, 2013, BBA-MOL BASIS DIS, V1832, P39, DOI 10.1016/j.bbadis.2012.10.007; Ferreira N, 2012, AMYLOID, V19, P39, DOI 10.3109/13506129.2012.668502; Ferreira N, 2011, FEBS LETT, V585, P2424, DOI 10.1016/j.febslet.2011.06.030; Fromme H, 2014, ENVIRON INT, V64, P61, DOI 10.1016/j.envint.2013.11.017; Gales L, 2005, BIOCHEM J, V388, P615, DOI 10.1042/BJ20042035; Gales L, 2008, BBA-PROTEINS PROTEOM, V1784, P512, DOI 10.1016/j.bbapap.2007.11.014; Gertz MA, 2015, J AM COLL CARDIOL, V66, P2451, DOI 10.1016/j.jacc.2015.09.075; Hamers T, 2006, TOXICOL SCI, V92, P157, DOI 10.1093/toxsci/kfj187; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Iakovleva I, 2015, J MED CHEM, V58, P6507, DOI 10.1021/acs.jmedchem.5b00544; Iakovleva I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128222; Jiang X, 2001, P NATL ACAD SCI USA, V98, P14943, DOI 10.1073/pnas.261419998; Johnson SM, 2009, J MED CHEM, V52, P1115, DOI 10.1021/jm801347s; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kalkunte SS, 2013, AM J PATHOL, V183, P1425, DOI 10.1016/j.ajpath.2013.07.022; Kang MJ, 2009, J TOXICOL ENV HEAL A, V72, P1439, DOI 10.1080/15287390903212907; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Knudsen GA, 2014, TOXICOL REP, V1, P214, DOI 10.1016/j.toxrep.2014.03.005; Lai DY, 2015, FOOD CHEM TOXICOL, V80, P206, DOI 10.1016/j.fct.2015.03.023; Lindhagen-Persson M, 2008, AMYLOID, V15, P240, DOI 10.1080/13506120802524916; Maetzler W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048042; Mairal T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004124; Manral P, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20140155; Marchesini GR, 2006, ANAL CHEM, V78, P1107, DOI 10.1021/ac051399i; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281; Meerts IATM, 2000, TOXICOL SCI, V56, P95, DOI 10.1093/toxsci/56.1.95; Miller SR, 2004, LAB INVEST, V84, P545, DOI 10.1038/labinvest.3700059; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Morais-de-Sa E, 2004, J BIOL CHEM, V279, P53483, DOI 10.1074/jbc.M408053200; Moreira L, 2015, AMYLOID, V22, P93, DOI 10.3109/13506129.2015.1007497; Mu YS, 2015, FEBS LETT, V589, P849, DOI 10.1016/j.febslet.2015.02.020; National Toxicology Program, 2014, 587 NTP; Nencetti S, 2013, CHEMMEDCHEM, V8, P1617, DOI 10.1002/cmdc.201300245; Nyholm JR, 2010, ENVIRON POLLUT, V158, P2235, DOI 10.1016/j.envpol.2010.02.010; Palaninathan SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006290; Patel KS, 2015, J INTERN MED, V278, P126, DOI 10.1111/joim.12383; Penchala SC, 2013, P NATL ACAD SCI USA, V110, P9992, DOI 10.1073/pnas.1300761110; Raghu P, 2002, ARCH BIOCHEM BIOPHYS, V400, P43, DOI 10.1006/abbi.2002.2779; Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101; Reixach N, 2006, BIOCHEM BIOPH RES CO, V348, P889, DOI 10.1016/j.bbrc.2006.07.109; Ruberg FL, 2012, CIRCULATION, V126, P1286, DOI 10.1161/CIRCULATIONAHA.111.078915; Sant'Anna RO, 2013, INT J MOL SCI, V14, P5284, DOI 10.3390/ijms14035284; Saraiva MJ, 2012, CURR MED CHEM, V19, P2304; Schauer UMD, 2006, TOXICOL SCI, V91, P49, DOI 10.1093/toxsci/kfj132; Sekijima Y, 2006, AMYLOID, V13, P236, DOI 10.1080/13506120600960882; Sorgjerd K, 2008, BIOCHEM BIOPH RES CO, V377, P1072, DOI 10.1016/j.bbrc.2008.10.121; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2002, AM J PATHOL, V161, P1935, DOI 10.1016/S0002-9440(10)64469-0; Suhr OB, 2015, TRANSPLANTATION; Sun FF, 2014, ENVIRON SCI TECHNOL, V48, P14291, DOI 10.1021/es503383h; Tojo K, 2006, NEUROSCI RES, V56, P441, DOI 10.1016/j.neures.2006.08.014; Trivella DBB, 2012, J STRUCT BIOL, V180, P143, DOI 10.1016/j.jsb.2012.07.008; Trivella DBB, 2011, J STRUCT BIOL, V173, P323, DOI 10.1016/j.jsb.2010.10.003; Vaidya B, 2014, DIAGNOSIS MANAGEMENT; Viberg H, 2011, TOXICOLOGY, V289, P59, DOI 10.1016/j.tox.2011.07.010; Vilaro M, 2015, ACS COMB SCI, V17, P32, DOI 10.1021/co5001234; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; Wilce JA, 2001, J BIOL CHEM, V276, P25997, DOI 10.1074/jbc.M101228200; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Yanagisawa A, 2015, MODERN PATHOL, V28, P201, DOI 10.1038/modpathol.2014.102; Yokoyama T, 2014, J MED CHEM, V57, P8928, DOI 10.1021/jm500997m	86	12	12	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2016	11	4							e0153529	10.1371/journal.pone.0153529	http://dx.doi.org/10.1371/journal.pone.0153529			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9NW	27093678	gold, Green Published, Green Submitted			2023-01-03	WOS:000374541200025
J	Torssander, J; Ahlbom, A; Modig, K				Torssander, Jenny; Ahlbom, Anders; Modig, Karin			Four Decades of Educational Inequalities in Hospitalization and Mortality among Older Swedes	PLOS ONE			English	Article							SOCIOECONOMIC INEQUALITIES; EUROPEAN COUNTRIES; LIFE EXPECTANCY; HEALTH; NORWAY	Background The inverse association between education and mortality has grown stronger the last decades in many countries. During the same period, gains in life expectancy have been concentrated to older ages; still, old-age mortality is seldom the focus of attention when analyzing trends in the education-mortality gradient. It is further unknown if increased educational inequalities in mortality are preceded by increased inequalities in morbidity of which hospitalization may be a proxy. Methods Using administrative population registers from 1971 and onwards, education-specific annual changes in the risk of death and hospital admission were estimated with complimentary log-log models. These risk changes were supplemented by estimations of the ages at which 25, 50, and 75% of the population had been hospitalized or died (after age 60). Results The mortality decline among older people increasingly benefitted the well-educated over the less well-educated. This inequality increase was larger for the younger old, and among men. Educational inequalities in the age of a first hospital admission generally followed the development of growing gaps, but at a slower pace than mortality and inequalities did not increase among the oldest individuals. Conclusions Education continues to be a significant predictor of health and longevity into old age. That the increase in educational inequalities is greater for mortality than for hospital admissions (our proxy of overall morbidity) may reflect that well-educated individuals gradually have obtained more possibilities or resources to survive a disease than less well-educated individuals have the last four decades.	[Torssander, Jenny] Stockholm Univ, Swedish Inst Social Res, S-10691 Stockholm, Sweden; [Ahlbom, Anders; Modig, Karin] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Stockholm University; Karolinska Institutet	Torssander, J (corresponding author), Stockholm Univ, Swedish Inst Social Res, S-10691 Stockholm, Sweden.	jenny.torssander@sofi.su.se	Modig, Karin/H-1542-2014	Modig, Karin/0000-0002-5151-4867	Swedish Research Council for Health, Working Life and Welfare [20140445, 2014-0231]	Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte))	Funding was received from the Swedish Research Council for Health, Working Life and Welfare (http://forte.se/en/), Grant numbers 20140445 (JT) and 2014-0231 (AA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison P.D., 2010, SURVIVAL ANAL USING; Bronnum-Hansen H, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-994; Bygren LO., 2001, J PUBLIC HLTH POLICY; Cutler DM, 2011, J HEALTH ECON, V30, P1174, DOI 10.1016/j.jhealeco.2011.06.009; Fors S., 2007, EUROPEAN J PUBLIC HL, V18, P138; Fritzell J, 2007, HLTH INEQUALITIES WE; Glied S., 2003, HLTH INEQUALITY ED M; Karampampa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099034; Karampampa K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003447; Kinge JM, 2015, AGE AGEING, V44, P1040, DOI 10.1093/ageing/afv128; Kunst AE, 2005, INT J EPIDEMIOL, V34, P295, DOI 10.1093/ije/dyh342; Lagergren M, 2016, SCAND J PUBLIC HEALT, V44, P55, DOI 10.1177/1403494815605195; Mackenbach JP, 2015, J EPIDEMIOL COMMUN H, V69, P207, DOI 10.1136/jech-2014-204319; Majer IM, 2011, J EPIDEMIOL COMMUN H, V65, P972, DOI 10.1136/jech.2010.111492; Meinow Bettina, 2006, Eur J Ageing, V3, P98, DOI 10.1007/s10433-006-0027-z; Montez JK, 2013, J HEALTH SOC BEHAV, V54, P165, DOI [10.1177/0022146513491066, 10.1177/0022146513481230]; National Board of Health and Welfare, 2009, FOLKH 2009; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Ostergren O, 2015, SCAND J PUBLIC HEALT, V43, P563, DOI 10.1177/1403494815585401; Shkolnikov VM, 2012, J EPIDEMIOL COMMUN H, V66, P372, DOI 10.1136/jech.2009.104786; Vaupel JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000128; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4	22	3	3	0	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152369	10.1371/journal.pone.0152369	http://dx.doi.org/10.1371/journal.pone.0152369			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27031107	Green Submitted, gold, Green Published			2023-01-03	WOS:000373121800063
J	Kaczmarek, MC; Ware, RS; Coulthard, MG; McEniery, J; Lambert, SB				Kaczmarek, Marlena C.; Ware, Robert S.; Coulthard, Mark G.; McEniery, Julie; Lambert, Stephen B.			Epidemiology of Australian Influenza-Related Paediatric Intensive Care Unit Admissions, 1997-2013	PLOS ONE			English	Article							HOSPITALIZED CHILDREN; CONFIRMED INFLUENZA; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; PREGNANT-WOMEN; VACCINE; BURDEN; STATES	Background Influenza virus predictably causes an annual epidemic resulting in a considerable burden of illness in Australia. Children are disproportionately affected and can experience severe illness and complications, which occasionally result in death. Methods We conducted a retrospective descriptive study using data collated in the Australian and New Zealand Paediatric Intensive Care (ANZPIC) Registry of influenza-related intensive care unit (ICU) admissions over a 17-year period (1997-2013, inclusive) in children < 16 years old. National laboratory-confirmed influenza notifications were used for comparison. Results Between 1997 and 2013, a total of 704 influenza-related ICU admissions were recorded, at a rate of 6.2 per 1,000 all-cause ICU admissions. Age at admission ranged from 0 days and 15.9 years (median = 2.1 years), with 135 (19.2%) aged < 6 months. Pneumonia/pneumonitis and bronchiolitis were the most common primary diagnoses among influenza-related admissions (21.9% and 13.6%, respectively). More than half of total cases (59.2%) were previously healthy (no co-morbidities recorded), and in the remainder, chronic lung disease (16.7%) and asthma (12.5%) were the most common co-morbidities recorded. Pathogen co-detection occurred in 24.7% of cases, most commonly with respiratory syncytial virus or a staphylococcal species. Median length of all ICU admissions was 3.2 days (range 2.0 hours-107.4 days) and 361 (51.3%) admissions required invasive respiratory support for a median duration of 4.3 days (range 0.2 hours-107.5 days). There were 27 deaths recorded, 14 (51.9%) in children without a recorded co-morbidity. Conclusion Influenza causes a substantial number of ICU admissions in Australian children each year with the majority occurring in previously healthy children.	[Kaczmarek, Marlena C.; Ware, Robert S.; Lambert, Stephen B.] Univ Queensland, Sch Med, Child Hlth Res Ctr, Brisbane, Qld, Australia; [Kaczmarek, Marlena C.; Ware, Robert S.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Kaczmarek, Marlena C.; Ware, Robert S.; Lambert, Stephen B.] Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Coulthard, Mark G.; McEniery, Julie] Lady Cilento Childrens Hosp, Paediat Intens Care Unit, Brisbane, Qld, Australia; [Coulthard, Mark G.] Univ Queensland, Sch Med, Acad Discipline Paediat & Child Hlth, Brisbane, Qld, Australia; [Lambert, Stephen B.] Queensland Hlth, Communicable Dis Unit, Brisbane, Qld, Australia	University of Queensland; University of Queensland; University of Queensland; Queensland Health	Kaczmarek, MC (corresponding author), Univ Queensland, Sch Med, Child Hlth Res Ctr, Brisbane, Qld, Australia.; Kaczmarek, MC (corresponding author), Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia.; Kaczmarek, MC (corresponding author), Queensland Childrens Med Res Inst, Brisbane, Qld, Australia.	m.kaczmarek@uq.edu.au	McEniery, Julie/M-8492-2015; Ware, Robert S./B-2024-2014; Coulthard, Mark G/AAT-7735-2021; Lambert, Stephen/N-7819-2019; Coulthard, Mark Graeme/E-9444-2010	McEniery, Julie/0000-0002-7136-8043; Ware, Robert S./0000-0002-6129-6736; Coulthard, Mark G/0000-0001-7400-5582; Lambert, Stephen/0000-0002-2709-193X; Coulthard, Mark Graeme/0000-0001-7400-5582; Kaczmarek, Marlena/0000-0002-5556-276X	Sidney Myer Health Scholarship; Australian Government National Health and Medical Research Council; Queensland Children's Hospital Foundation	Sidney Myer Health Scholarship; Australian Government National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Queensland Children's Hospital Foundation	The authors received no specific funding for this work. Ms Kaczmarek is the recipient of a Sidney Myer Health Scholarship and receives student support from the Queensland Children's Medical Research Institute and The University of Queensland School of Public Health. A/Prof Lambert is supported by an Early Career Fellowship from the Australian Government National Health and Medical Research Council and a people support grant from the Queensland Children's Hospital Foundation.	Alexander J, 2014, REPORT AUSTR NZ PAED; Australian Government Department of Health, 2014, PUBL SUMM DOC JUL 20; Australian Government Department of Health, 2013, AUSTR IMM HDB; Australian Government Department of Health, 2008, AUSTR NAT NOT DIS CA; Bagdure D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015173; Blyth CC, 2014, PEDIATRICS, V133, pE1218, DOI 10.1542/peds.2013-3707; Chiu SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092914; D'Onise K, 2008, MED J AUSTRALIA, V188, P510, DOI 10.5694/j.1326-5377.2008.tb01763.x; Daley AJ, 2000, J PAEDIATR CHILD H, V36, P332, DOI 10.1046/j.1440-1754.2000.00533.x; Dawood FS, 2014, J INFECT DIS, V209, P686, DOI 10.1093/infdis/jit473; Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012; Dixon GA, 2010, INFLUENZA OTHER RESP, V4, P231, DOI 10.1111/j.1750-2659.2010.00141.x; Ferdinands JM, 2014, J INFECT DIS, V210, P674, DOI 10.1093/infdis/jiu185; Flood EM, 2010, CLIN THER, V32, P1448, DOI 10.1016/j.clinthera.2010.06.020; Fraaij PLA, 2011, VACCINE, V29, P7524, DOI 10.1016/j.vaccine.2011.08.010; Grohskopf LA, 2015, MMWR-MORBID MORTAL W, V64, P818, DOI 10.1111/ajt.13505; Heininger U, 2013, PEDIATR INFECT DIS J, V32, P293, DOI 10.1097/INF.0b013e318279ce4b; Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687; Kaczmarek M, 2010, COMMUN DIS INTELL, V34, P8; Kaczmarek MC, 2013, MED J AUSTRALIA, V198, P624, DOI 10.5694/mja13.10044; Khandaker G, 2014, INFLU OTHER RESP VIR, V8, P636, DOI DOI 10.1111/IRV.12286; Lester-Smith D, 2009, COMMUN DIS INTELL, V33, P209; Li Z, 2013, PERINATAL STAT SERIE, V28; Lu AB, 2012, VACCINE, V30, P4055, DOI 10.1016/j.vaccine.2012.04.012; Maher L, 2013, VACCINE, V31, P5557, DOI 10.1016/j.vaccine.2013.08.081; Morris SK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000310; National Centre for Immunisation Research & Surveillance, 2014, SIGN EV INFL VACC PR; O'Grady KAF, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005676; Owen R, 2008, COMMUN DIS INTELL, V32, P208; Pebody R, 2015, EUROSURVEILLANCE, V20, P21025; PEBODY R, 2014, EURO SURVEILL, V19; Public Health England, 2015, NAT CHILDH FLU IMM P; Ruf BR, 2014, EUR J PEDIATR, V173, P265, DOI 10.1007/s00431-013-2023-6; Schrag SJ, 2006, PEDIATR INFECT DIS J, V25, P395, DOI 10.1097/01.inf.0000214988.81379.71; Slater A, 2003, INTENS CARE MED, V29, P271, DOI 10.1007/s00134-002-1600-3; Song XY, 2012, INFLUENZA OTHER RESP, V6, P25, DOI 10.1111/j.1750-2659.2011.00258.x; Streng A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-233; Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849	38	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2016	11	3							e0152305	10.1371/journal.pone.0152305	http://dx.doi.org/10.1371/journal.pone.0152305			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9KB	27023740	Green Published, gold, Green Submitted			2023-01-03	WOS:000373113900044
J	Amador-Licona, N; Diaz-Murillo, TA; Gabriel-Ortiz, G; Pacheco-Moises, FP; Pereyra-Nobara, TA; Guizar-Mendoza, JM; Barbosa-Sabanero, G; Orozco-Avina, G; Moreno-Martinez, SC; Luna-Montalban, R; Vazquez-Valls, E				Amador-Licona, Norma; Diaz-Murillo, Teresa A.; Gabriel-Ortiz, Genaro; Pacheco-Moises, Fermin P.; Pereyra-Nobara, Texar A.; Guizar-Mendoza, Juan M.; Barbosa-Sabanero, Gloria; Orozco-Avina, Gustavo; Moreno-Martinez, Sandra C.; Luna-Montalban, Rafael; Vazquez-Valls, Eduardo			Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial	PLOS ONE			English	Article							CORONARY-ARTERY-DISEASE; INDIVIDUAL ANTIRETROVIRAL DRUGS; FATTY-ACID SUPPLEMENTATION; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; INFECTED PATIENTS; FISH-OIL; RISK; INFLAMMATION; ASSOCIATION	HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups.	[Amador-Licona, Norma; Diaz-Murillo, Teresa A.; Pereyra-Nobara, Texar A.; Moreno-Martinez, Sandra C.; Luna-Montalban, Rafael] UMAE HE 1, Inst Mexicano Seguro Social, Dept Educ & Res, Mexico City, DF, Mexico; [Gabriel-Ortiz, Genaro; Vazquez-Valls, Eduardo] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Lab Oxidat Stress & Pathol, Guadalajara, Jalisco, Mexico; [Pacheco-Moises, Fermin P.] Univ Guadalajara, Dept Chem, Guadalajara 44430, Jalisco, Mexico; [Guizar-Mendoza, Juan M.] Univ DeLa Salle Bajio, Leon, Mexico; [Barbosa-Sabanero, Gloria] Univ Guanajuato, Dept Res, Leon, Mexico; [Orozco-Avina, Gustavo] Inst Res Inflammat, Guadalajara, Jalisco, Mexico	Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social; Universidad de Guadalajara; Universidad de Guanajuato	Amador-Licona, N (corresponding author), UMAE HE 1, Inst Mexicano Seguro Social, Dept Educ & Res, Mexico City, DF, Mexico.	licoamador@gmail.com	Amador-Licona, Norma/W-3881-2019	pacheco-moises, fermin/0000-0002-3769-5649; Vazquez-Valls, Eduardo/0000-0002-9639-5339; AMADOR, NORMA/0000-0003-1470-6883	Institute Mexicano del Seguro Social grant [FIS/IMSS/PROT/FRIO/12/019]	Institute Mexicano del Seguro Social grant	This research was funded by Institute Mexicano del Seguro Social grant number FIS/IMSS/PROT/FRIO/12/019.	Blum A, 2005, CLIN CARDIOL, V28, P149, DOI 10.1002/clc.4960280311; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Dalle-Donne I, 2008, ANTIOXID REDOX SIGN, V10, P445, DOI 10.1089/ars.2007.1716; Dangardt F, 2010, ATHEROSCLEROSIS, V212, P580, DOI 10.1016/j.atherosclerosis.2010.06.046; Das UN, 2005, MED SCI MONITOR, V11, pRA206; Din JN, 2004, BMJ-BRIT MED J, V328, P30, DOI 10.1136/bmj.328.7430.30; Ding X, 2012, JAIDS-J ACQ IMM DEF, V61, P441, DOI 10.1097/QAI.0b013e31826f993c; Doshi SN, 2001, CLIN SCI, V101, P629, DOI 10.1042/CS20010033; Du XL, 2006, J CLIN INVEST, V116, P1071, DOI 10.1172/JCI23354; FLAGG EW, 1993, BRIT J NUTR, V70, P797, DOI 10.1079/BJN19930175; Francisci D, 2009, AIDS, V23, P589, DOI 10.1097/QAD.0b013e328325a87c; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; FULBERT JC, 1992, PATHOL BIOL, V40, P66; Goodfellow J, 2000, J AM COLL CARDIOL, V35, P265, DOI 10.1016/S0735-1097(99)00548-3; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hakeem A, 2010, CURR ATHEROSCLER REP, V12, P119, DOI 10.1007/s11883-010-0089-4; HALLIWELL B, 1991, ARCH INTERN MED, V151, P29, DOI 10.1001/archinte.151.1.29; Harris W S, 1997, J Cardiovasc Risk, V4, P385, DOI 10.1097/00043798-199710000-00011; Hellerstein MK, 1996, J ACQ IMMUN DEF SYND, V11, P258, DOI 10.1097/00042560-199603010-00006; KOHN A, 1980, ARCH VIROL, V66, P301, DOI 10.1007/BF01320626; KREMER JM, 1990, ARTHRITIS RHEUM, V33, P810, DOI 10.1002/art.1780330607; Lang S, 2010, ARCH INTERN MED, V170, P1228, DOI 10.1001/archinternmed.2010.197; Li J, 2010, CLIN CARDIOL, V33, P222, DOI 10.1002/clc.20724; Lo J, 2010, AIDS, V24, P243, DOI 10.1097/QAD.0b013e328333ea9e; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; MEYDANI SN, 1991, J NUTR, V121, P547, DOI 10.1093/jn/121.4.547; Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726; Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365; Nettleton JA, 2005, J AM DIET ASSOC, V105, P428, DOI 10.1016/j.jada.2004.11.029; Okuda Y, 1997, BIOCHEM BIOPH RES CO, V232, P487, DOI 10.1006/bbrc.1997.6328; Oliveira JM, 2014, INT J STD AIDS, V25, P96, DOI 10.1177/0956462413513748; Omura M, 2001, FEBS LETT, V487, P361, DOI 10.1016/S0014-5793(00)02351-6; Pacher P, 2008, AM J PATHOL, V173, P2, DOI 10.2353/ajpath.2008.080019; Paranandi A, 2014, AIDS RES HUM RETROV, V30, P800, DOI [10.1089/aid.2014.0005, 10.1089/AID.2014.0005]; Park IW, 2001, BLOOD, V97, P352, DOI 10.1182/blood.V97.2.352; Pastore A, 2013, INT J MOL SCI, V14, P20845, DOI 10.3390/ijms141020845; Patel AA, 2015, AM J CARDIOVASC DRUG, V15, P81, DOI 10.1007/s40256-015-0105-8; REARDON MF, 1985, CIRCULATION, V71, P881, DOI 10.1161/01.CIR.71.5.881; Schiano V, 2008, CLIN NUTR, V27, P241, DOI 10.1016/j.clnu.2007.11.007; Stirban A, 2010, AM J CLIN NUTR, V91, P808, DOI 10.3945/ajcn.2009.28374; Tayyebi-Khosroshahi H, 2010, IRAN J KIDNEY DIS, V4, P322; Vassalle C, 2008, CLIN BIOCHEM, V41, P1162, DOI 10.1016/j.clinbiochem.2008.07.005; Wang LM, 2009, J LIPID RES, V50, P204, DOI 10.1194/jlr.M700505-JLR200; Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897	44	11	12	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2016	11	3							e0151637	10.1371/journal.pone.0151637	http://dx.doi.org/10.1371/journal.pone.0151637			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3TE	27015634	Green Published, Green Submitted, gold			2023-01-03	WOS:000372708900027
J	Holloway, KA; Rosella, L; Henry, D				Holloway, Kathleen Anne; Rosella, Laura; Henry, David			The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; INTEGRATED MANAGEMENT; BACTERIAL-RESISTANCE; CHILDHOOD ILLNESS; IMPROVE; COUNTRIES; EPIDEMIOLOGY; GUIDELINES; DRUG; CARE	Background Inappropriate overuse of antibiotics contributes to antimicrobial resistance (AMR), yet policy implementation to reduce inappropriate antibiotic use is poor in low and middle-income countries. Aims To determine whether public sector inappropriate antibiotic use is lower in countries reporting implementation of selected essential medicines policies. Materials and Methods Results from independently conducted antibiotic use surveys in countries that did, and did not report implementation of policies to reduce inappropriate antibiotic prescribing, were compared. Survey data on four validated indicators of inappropriate antibiotic use and 16 self-reported policy implementation variables from WHO databases were extracted. The average difference for indicators between countries reporting versus not reporting implementation of specific policies was calculated. For 16 selected policies we regressed the four antibiotic use variables on the numbers of policies the countries reported implementing. Results Data were available for 55 countries. Of 16 policies studied, four (having a national Ministry of Health unit on promoting rational use of medicines, a national drug information centre and provincial and hospital drugs and therapeutics committees) were associated with statistically significant reductions in antibiotic use of >= 20% in upper respiratory infection (URTI). A national strategy to contain antibiotic resistance was associated with a 30% reduction in use of antibiotics in acute diarrheal illness. Policies seemed to be associated with greater effects in antibiotic use for URTI and diarrhea compared with antibiotic use in all patients. There were negative correlations between the numbers of policies reported implemented and the percentage of acute diarrhoea cases treated with antibiotics (r = -0.484, p = 0.007) and the percentage of URTI cases treated with antibiotics (r = -0.472, p = 0.005). Major study limitations were the reliance on self-reported policy implementation data and antibiotic use data from linited surveys. Conclusions Selected essential medicines policies were associated with lower antibiotic use in low and middle income countries.	[Holloway, Kathleen Anne] WHO, Dept Hlth Syst Dev, Reg Off SouthEast Asia, New Delhi, India; [Rosella, Laura; Henry, David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada	World Health Organization; University of Toronto	Holloway, KA (corresponding author), WHO, Dept Hlth Syst Dev, Reg Off SouthEast Asia, New Delhi, India.	kaholloway54@gmail.com	Henry, David/AAU-4650-2020; Henry, David/L-3895-2017	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242	WHO Geneva	WHO Geneva(World Health Organization)	WHO Geneva funded collection of primary data on medicines policies and creation of the WHO medicines use database. However, WHO had no role in study design, data collection and analysis of secondary data on medicines policies and use, the decision to publish, nor preparation of the manuscript.	Bavestrello L, 2002, REV MED CHILE, V130, P1265; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; Francke AL, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-38; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Holloway KA, 2011, WHOBEMPMIE201122; Holloway KA, 2009, TROP MED INT HEALTH, V14, P1; Holloway KA, 2015, PAEDIATR INT CHILD H, V35, P5, DOI 10.1179/2046905514Y.0000000115; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Holloway Kathleen Anne, 2011, Expert Rev Clin Pharmacol, V4, P335, DOI 10.1586/ecp.11.14; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Institute of Medicine, 1998, MICROBIAL THREATS HL; Jaffer B., 2007, WHO NGO TECHN BRIEF; Levy SB, 2005, ADV DRUG DELIVER REV, V57, P1446, DOI 10.1016/j.addr.2005.04.001; Livermore DM, 2003, CLIN INFECT DIS, V36, pS11, DOI 10.1086/344654; Logez S, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-136; Lu CY, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-75; Molstad S, 2008, LANCET INFECT DIS, V8, P125, DOI 10.1016/S1473-3099(08)70017-3; Okeke IN, 2005, LANCET INFECT DIS, V5, P568, DOI 10.1016/S1473-3099(05)70217-6; Park S, 2005, HEALTH POLICY PLANN, V20, P302, DOI 10.1093/heapol/czi033; Parrino TA, 2005, PHARMACOTHERAPY, V25, P289, DOI 10.1592/phco.25.2.289.56951; Radyowijati A, 2003, SOC SCI MED, V57, P733, DOI 10.1016/S0277-9536(02)00422-7; Ratanawijitrasin S, 2001, SOC SCI MED, V53, P831, DOI 10.1016/S0277-9536(00)00390-7; Rowe AK, 2009, AM J PUBLIC HEALTH, V99, P837, DOI 10.2105/AJPH.2008.134411; Sabuncu E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000084; SCORE, 2004, RES SENS ISS EUR ROA; Shorr AF, 2007, PHARMACOECONOMICS, V25, P751, DOI 10.2165/00019053-200725090-00004; Sketris IS, 2009, J POPUL THER CLIN PH, V16, pE103; Teng C L, 2006, Med J Malaysia, V61, P323; Trap B, 2002, HEALTH POLICY PLANN, V17, P288, DOI 10.1093/heapol/17.3.288; Vang C, 2006, EUR J CLIN PHARMACOL, V62, P57, DOI 10.1007/s00228-005-0069-8; WHO, 2005, WHOPSM20051; WHO, 1985, RAT US DRUGS C EXP; WHO, 2001, WHOCSRDRS20012; World Health Organisation, 2002, WHO POL PERSP MED, V5; World Health Organization, 2015, A6820 WHO; World Health Organization, 2006, US IND MEAS COUNTR P; World Health Organization, 2007, WHOTCM20072; World Health Organization, 1993, INVESTIGATE DRUG USE; World Health Organization, 2009, MED US PRIM CAR DEV; World Health Organization, 2010, WHOEMPMPC20101	42	40	43	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2016	11	3							e0152020	10.1371/journal.pone.0152020	http://dx.doi.org/10.1371/journal.pone.0152020			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH3OX	27002977	gold, Green Published, Green Submitted			2023-01-03	WOS:000372697400066
J	Fujita, T; Nagayama, H; Sato, A; Yamamoto, Y; Yamane, K; Otsuki, K; Tsuchiya, K; Tozato, F				Fujita, Takaaki; Nagayama, Hirofumi; Sato, Atsushi; Yamamoto, Yuichi; Yamane, Kazuhiro; Otsuki, Koji; Tsuchiya, Kenji; Tozato, Fusae			Hierarchy of Dysfunction Related to Dressing Performance in Stroke Patients: A Path Analysis Study	PLOS ONE			English	Article							MUSCLE STRENGTH; BALANCE; DISABILITY; LIMB; IMPAIRMENTS; ABILITY; MOTOR	Previous reports indicated that various dysfunctions caused by stroke affect the level of independence in dressing. These dysfunctions can be hierarchical, and these effects on dressing performance can be complicated in stroke patients. However, there are no published reports focusing on the hierarchical structure of the relationships between the activities of daily living and balance function, motor and sensory functions of the affected lower limb, strength of the abdominal muscles and knee extension on the unaffected side, and visuospatial deficits. The purpose of this study was to elucidate the hierarchical and causal relationships between dressing performance and these dysfunctions in stroke patients. This retrospective study included 104 first-time stroke patients. The causal relationship between the dressing performance and age, time post stroke, balance function, motor and sensory functions of the affected lower limb, strength of the abdominal muscles and knee extension on the unaffected side, and visuospatial deficits were examined using path analysis. A hypothetical path model was created based on previous studies, and the goodness of fit between the data and model were verified. A modified path model was created that achieved an almost perfect fit to the data. Balance function and abdominal muscle strength have direct effects on dressing performance, with standardized direct effect estimates of 0.78 and 0.15, respectively. Age, motor and sensory functions of the affected lower limb, and strength of abdominal muscle and knee extension on the unaffected side have indirect effects on dressing by influencing balance function. Our results suggest that dressing performance depends strongly on balance function, and it is mainly influenced by the motor function of the affected lower limb.	[Fujita, Takaaki] Tohoku Fukushi Univ, Fac Hlth Sci, Dept Rehabil, Sendai, Miyagi, Japan; [Fujita, Takaaki; Tsuchiya, Kenji; Tozato, Fusae] Gunma Univ, Grad Sch Hlth Sci, Dept Rehabil Sci, Maebashi, Gunma, Japan; [Nagayama, Hirofumi] Kanagawa Univ Human Serv, Fac Hlth & Welf, Dept Rehabil, Yokosuka, Kanagawa, Japan; [Sato, Atsushi] Yachiyo Rehabil Coll, Dept Phys Therapy, Yachiyo, Chiba, Japan; [Yamamoto, Yuichi; Yamane, Kazuhiro; Otsuki, Koji] Northern Fukushima Med Ctr, Dept Rehabil, Date, Fukushima, Japan; [Tsuchiya, Kenji] Gunma Chuo Hosp, Japan Community Healthcare Org, Dept Rehabil, Maebashi, Gunma, Japan	Gunma University	Fujita, T (corresponding author), Tohoku Fukushi Univ, Fac Hlth Sci, Dept Rehabil, Sendai, Miyagi, Japan.; Fujita, T (corresponding author), Gunma Univ, Grad Sch Hlth Sci, Dept Rehabil Sci, Maebashi, Gunma, Japan.	t-fujita@tfu-mail.tfu.ac.jp	Nagayama, Hirofumi/AAF-1364-2020	Nagayama, Hirofumi/0000-0002-1763-1330; Fujita, Takaaki/0000-0002-9009-8325	Japan Society for the Promotion of Science [26893250]; Uniform Data System for Medical Rehabilitation (UDSMR)	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uniform Data System for Medical Rehabilitation (UDSMR)	This work was supported by the Japan Society for the Promotion of Science (grant Number 26893250), https://www.jsps.go.jp/english/index.html (TF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The use of the FIM (R) instrument to collect data for this research study was authorized and conducted in accordance with the term of a special purpose license granted to the licensee by the Uniform Data System for Medical Rehabilitation (UDSMR). Licensee has not been trained by UDSMR in the use of the FIM (R) instrument, and the patient data collected during the course of this research study has not been submitted to or processed by UDSMR. No implication is intended that such data has been or will be subjected to UDSMR's standard data processing procedures or that it is otherwise comparable to data processed by UDSMR.	[Anonymous], 1990, GUID UN DAT SET MED; [Anonymous], NIG J HLTH BIOMED SC; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG K, 1989, Physiotherapy Canada, V41, P304; Bohannon R., 1995, CLIN REHABIL, V9, P47, DOI DOI 10.1177/026921559500900107; Bonan IV, 2007, J NEUROL NEUROSUR PS, V78, P49, DOI 10.1136/jnnp.2006.087791; Chino N, 1994, JPN J REHABIL MED, V31, P119, DOI DOI 10.2490/JJRM1963.31.119; Domen K, 1995, JPN J REHABIL MED, V32, P113, DOI DOI 10.2490/jjrm1963.32.113; Edmans JA, 1990, BRIT J OCCUPATIONAL, V53, P139; Fricke J, 1993, AUST OCCUP THER J, V40, P7; Fujita T, AM J OCCUP IN PRESS, P70; Fujita T, 2015, J PHYS THER SCI, V27, P3771, DOI 10.1589/jpts.27.3771; Fujita T, 2015, J PHYS THER SCI, V27, P815, DOI 10.1589/jpts.27.815; Hodges PW, 1997, ERGONOMICS, V40, P1220, DOI 10.1080/001401397187469; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI 10.21427/D79B73; Karatas M, 2004, AM J PHYS MED REHAB, V83, P81, DOI 10.1097/01.PHM.0000107486.99756.C7; Lee H, 2015, J PHYS THER SCI, V27, P1, DOI 10.1589/jpts.27.1; Liao CF, 2015, J PHYS THER SCI, V27, P2201, DOI 10.1589/jpts.27.2201; Mercier L, 2001, STROKE, V32, P2602, DOI 10.1161/hs1101.098154; Nijboer TCW, 2014, NEUROREPORT, V25, P1381, DOI 10.1097/WNR.0000000000000277; Saito Y, 2012, SAGYOURYOUHOU, V31, P134; SEGAL ME, 1994, STROKE, V25, P2391, DOI 10.1161/01.STR.25.12.2391; Sonoda S, 1995, JPN J REHABIL MED, V32, P123; Tokuno CD, 2013, SCAND J MED SCI SPOR, V23, P349, DOI 10.1111/j.1600-0838.2011.01394.x; Tyson SF, 2013, TOP STROKE REHABIL, V20, P441, DOI 10.1310/tsr2005-441; Tyson SF, 2006, PHYS THER, V86, P30, DOI 10.1093/ptj/86.1.30; Usuda S, 1998, J PHYS THER SCI, V10, P53, DOI DOI 10.1589/jpts.10.53; WALKER MF, 1991, J NEUROL NEUROSUR PS, V54, P699, DOI 10.1136/jnnp.54.8.699; Wee SK, 2015, PHYS THER, V95, P1163, DOI 10.2522/ptj.20140487; Yanase Y, 2010, J JPN PHYS THER ASS, V37, P397	30	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0151162	10.1371/journal.pone.0151162	http://dx.doi.org/10.1371/journal.pone.0151162			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26954499	Green Published, gold			2023-01-03	WOS:000371991300091
J	Saha, MR; Dey, P; Begum, S; De, B; Chaudhuri, TK; De Sarker, D; Das, AP; Sen, A				Saha, Manas Ranjan; Dey, Priyankar; Begum, Sainiara; De, Bratati; Chaudhuri, Tapas Kr.; De Sarker, Dilip; Das, Abhaya Prasad; Sen, Arnab			Effect of Acacia catechu (L.f.) Willd. on Oxidative Stress with Possible Implications in Alleviating Selected Cognitive Disorders	PLOS ONE			English	Article							RADICAL SCAVENGING ACTIVITY; ANTIOXIDANT ACTIVITIES; BIOLOGICAL-ACTIVITIES; HYDROGEN-PEROXIDE; DEMENTIA; SUPEROXIDE; PREVALENCE; EXTRACTS; PEROXYNITRITE; PROTECTION	In human body, several categories of degenerative processes are largely determined by free radicals originating in cell. Free radicals are also known to have correlated with a variety of cognitive disorders (CDs) resulting in neuronal injury and eventually to death. Alzheimer's disease (AD) and Parkinson's disease (PD) are such kind of killer CDs that occur due to dysfunction of cholinergic and dopaminergic neurons. Plant parts of Ginkgo biloba, Bacopa monnieri etc. are being used for the treatment of cognitive disorders in several countries. The present study was aimed to explore the detailed antioxidant and anti-cholinesterase activity of Acaciacatechu leaf (ACL) over CDs. Gas chromatography-Mass spectroscopy (GC-MS) analysis and Nuclear Magnetic Resonance (NMR) were employed to identify the bioactive components present in ACL. Furthermore, the extract was evaluated to check the cytotoxic effects of ACL on normal cells. Amongst several antioxidant assays, DPPH assay, hydroxyl radical, nitric oxide radical and hypochlorous acid inhibitory activities were found to be greater in ACL than that of the respective standards while other assays exhibited a moderate or at per inhibitory activity with standards. Total phenolic and flavonoid content were also found to be present in decent amount. In addition, we found, a greater acetylcholinesterase (AChE) inhibitory activity of ACL when compared to other medicinally important plants, indicating its positive effect over CDs. Forty one bioactive components were explored through GC-MS. Of these, gallic acid, epicatechin, catechin, isoquercitrin etc. were found, which are potent antioxidant and a few of them have anti-neurodegenerative properties. Eventually, ACL was found to be nontoxic and safer to consume. Further studies with animal or human model however, would determine its efficacy as a potential anti-schizophrenic drug.	[Saha, Manas Ranjan; Sen, Arnab] Univ N Bengal, Dept Bot, Mol Cytogenet Lab, Siliguri 734013, India; [Dey, Priyankar; Chaudhuri, Tapas Kr.] Univ N Bengal, Dept Zool, Cellular Immunol Lab, Siliguri 734013, India; [Begum, Sainiara; De, Bratati] Univ Calcutta, Dept Bot, Phytochem & Pharmacognosy Res Lab, 35 Ballygunge Circular Rd, Kolkata 700019, India; [De Sarker, Dilip] Raiganj Univ, Dept Bot, Raiganj 733134, India; [Das, Abhaya Prasad] Univ N Bengal, Dept Bot, Taxon & Envioronmental Biol Lab, Siliguri 734013, India	University of North Bengal; University of North Bengal; University of Calcutta; University of North Bengal	Sen, A (corresponding author), Univ N Bengal, Dept Bot, Mol Cytogenet Lab, Siliguri 734013, India.	senarnab_nbu@hotmail.com	Dey, Priyankar/AAG-5125-2022; Dey, Priyankar/AFE-4921-2022; Das, A P/AGK-7697-2022	Dey, Priyankar/0000-0002-9513-425X; Dey, Priyankar/0000-0002-9513-425X; BEGUM, SAINIARA/0000-0001-6581-6869				Abrahim NN, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-220; [Anonymous], 1964, QUANTITATIVE ANAL DR, DOI DOI 10.1016/j.foodchem.2005.06.040; [Anonymous], 2013, GLOB J BOT SCI; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; ARUOMA OI, 1987, BIOCHEM J, V248, P973, DOI 10.1042/bj2480973; Bailly F, 2000, FEBS LETT, V486, P19, DOI 10.1016/S0014-5793(00)02234-1; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Berr C, 2005, EUR NEUROPSYCHOPHARM, V15, P463, DOI 10.1016/j.euroneuro.2005.04.003; Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643; Biradar S. M., 2012, Journal of Pharmacology and Toxicology, V7, P231; Brodal P., 2004, CENTRAL NERVOUS SYST; Chang ST, 2001, J AGR FOOD CHEM, V49, P3420, DOI 10.1021/jf0100907; Chattipakorn S, 2007, J ETHNOPHARMACOL, V110, P61, DOI 10.1016/j.jep.2006.09.007; Chaudhuri D, 2012, ASIAN J PHARM CLIN R, V5, P193, DOI DOI 10.1186/0717-6287-47-24; Chew YL, 2009, FOOD CHEM, V116, P13, DOI 10.1016/j.foodchem.2009.01.091; Chinta SJ, 2005, INT J BIOCHEM CELL B, V37, P942, DOI 10.1016/j.biocel.2004.09.009; Chirino Yolanda I., 2004, BMC Pharmacology, V4, P20, DOI 10.1186/1471-2210-4-20; Das A, 2002, PHARMACOL BIOCHEM BE, V73, P893, DOI 10.1016/S0091-3057(02)00940-1; DESESSO JM, 1994, TERATOLOGY, V49, P248, DOI 10.1002/tera.1420490404; Dey P, 2015, CYTOTECHNOLOGY, P1; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Fontana M, 2001, BIOCHEM PHARMACOL, V61, P1253, DOI 10.1016/S0006-2952(01)00565-2; Gandhi S, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/428010; Gimenez-Garzo C, 2015, ANTIOXID REDOX SIGN, V22, P871, DOI 10.1089/ars.2014.6240; Goyal AK, 2011, FUNCT PLANT BIOL, V38, P697, DOI 10.1071/FP11016; Haro-Vicente JF, 2006, FOOD CHEM, V98, P639, DOI 10.1016/j.foodchem.2005.06.040; Hou WC, 2005, J ETHNOPHARMACOL, V100, P216, DOI 10.1016/j.jep.2005.03.017; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8; Khare C.P., 2007, INDIAN MED PLANTS, V1, DOI [10.1007/978-0-387-70638-2_1383, DOI 10.1007/978-0-387-70638-2_1383, 10.1007/978-0-387-70638-2]; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; Kirtikar KR, 1975, INDIA MED PLANTS, V2; Kizil G, 2008, PHARM BIOL, V46, P231, DOI 10.1080/13880200701739363; Kulma A, 2007, PLANT SCI, V172, P433, DOI 10.1016/j.plantsci.2006.10.013; Kumar D. S., 2010, International Journal of PharmTech Research, V2, P2063; KUNCHANDY E, 1990, INT J PHARM, V58, P237, DOI 10.1016/0378-5173(90)90201-E; Lakshmi T., 2011, International Journal of Phytomedicine, V3, P579; Li Xingcui, 2010, Zhongguo Zhong Yao Za Zhi, V35, P1425; Long LH, 1999, BIOCHEM BIOPH RES CO, V262, P605, DOI 10.1006/bbrc.1999.1263; Mathew M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086804; Mohan S. C., 2012, Journal of Chemical and Pharmaceutical Research, V4, P197; Mukherjee PK, 2007, PHYTOTHER RES, V21, P1142, DOI 10.1002/ptr.2224; Mustafa RA, 2010, J FOOD SCI, V75, pC28, DOI 10.1111/j.1750-3841.2009.01401.x; OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307; Pereira DM, 2010, PHYTOMEDICINE, V17, P646, DOI 10.1016/j.phymed.2009.10.008; Peterhans E, 1997, J NUTR, V127, pS962, DOI 10.1093/jn/127.5.962S; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Ramakrishna H., 2012, ASIAN J PLANT SCI RE, V2, P30; Rathee JS, 2006, J AGR FOOD CHEM, V54, P9046, DOI 10.1021/jf061679e; Shyur L.-F., 2005, INT J APPL SCI ENG, V3, P195; Silverstein RM, 2005, PROTON NMR SPECTROME, P127; Singh R. P., 2004, J IND ACAD CLIN MED, V5, P218; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Sullivan RJ, 2000, BRIT J PSYCHIAT, V177, P174, DOI 10.1192/bjp.177.2.174; Sun J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032021; Tripathi AK, 2006, PHYTOCHEM ANALYSIS, V17, P394, DOI 10.1002/pca.936; Trivedi J K, 2006, Indian J Psychiatry, V48, P10, DOI 10.4103/0019-5545.31613; Valcic S, 2000, CHEM RES TOXICOL, V13, P801, DOI 10.1021/tx000080k; Vellosa J. C. R., 2011, Ecletica Quimica, V36, P7, DOI 10.1590/S0100-46702011000200001; Yen GC, 2002, FOOD CHEM, V79, P307, DOI 10.1016/S0308-8146(02)00145-0; Zhao CY, 2005, BBA-GEN SUBJECTS, V1723, P114, DOI 10.1016/j.bbagen.2005.02.004; Zia-Ul-Haq M, 2014, MOLECULES, V19, P10998, DOI 10.3390/molecules190810998; Zia-Ul-Haq M, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-23	65	26	26	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2016	11	3							e0150574	10.1371/journal.pone.0150574	http://dx.doi.org/10.1371/journal.pone.0150574			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SL	26949964	Green Submitted, Green Published, gold			2023-01-03	WOS:000371990100042
J	Fodor, T; Szanto, M; Abdul-Rahman, O; Nagy, L; Der, A; Kiss, B; Bai, P				Fodor, Tamas; Szanto, Magdolna; Abdul-Rahman, Omar; Nagy, Lilla; Der, Adam; Kiss, Borbala; Bai, Peter			Combined Treatment of MCF-7 Cells with AICAR and Methotrexate, Arrests Cell Cycle and Reverses Warburg Metabolism through AMP-Activated Protein Kinase (AMPK) and FOXO1	PLOS ONE			English	Article							CANCER; PGC-1-ALPHA; GLUCOSE; SIRT1; PROLIFERATION; COACTIVATORS; MITOCHONDRIA; HOMEOSTASIS; INHIBITION; GLYCOLYSIS	Cancer cells are characterized by metabolic alterations, namely, depressed mitochondrial oxidation, enhanced glycolysis and pentose phosphate shunt flux to support rapid cell growth, which is called the Warburg effect. In our study we assessed the metabolic consequences of a joint treatment of MCF-7 breast cancer cells with AICAR, an inducer of AMP-activated kinase (AMPK) jointly with methotrexate (MTX), a folate-analog antimetabolite that blunts de novo nucleotide synthesis. MCF7 cells, a model of breast cancer cells, were resistant to the individual application of AICAR or MTX, however combined treatment of AICAR and MTX reduced cell proliferation. Prolonged joint application of AICAR and MTX induced AMPK and consequently enhanced mitochondrial oxidation and reduced the rate of glycolysis. These metabolic changes suggest an anti-Warburg rearrangement of metabolism that led to the block of the G1/S and the G2/M transition slowing down cell cycle. The slowdown of cell proliferation was abolished when mitotropic transcription factors, PGC-1 alpha, PGC-1 beta or FOXO1 were silenced. In human breast cancers higher expression of AMPK alpha and FOXO1 extended survival. AICAR and MTX exerts similar additive antiproliferative effect on other breast cancer cell lines, such as SKBR and 4T1 cells, too. Our data not only underline the importance of Warburg metabolism in breast cancer cells but nominate the AICAR+MTX combination as a potential cytostatic regime blunting Warburg metabolism. Furthermore, we suggest the targeting of AMPK and FOXO1 to combat breast cancer.	[Fodor, Tamas; Szanto, Magdolna; Abdul-Rahman, Omar; Nagy, Lilla; Bai, Peter] Univ Debrecen, Dept Med Chem, Fac Med, H-4032 Debrecen, Hungary; [Der, Adam] Univ Debrecen, Sect Radiat Therapy, Dept Oncol, Fac Med, H-4032 Debrecen, Hungary; [Kiss, Borbala] Univ Debrecen, Fac Med, Dept Dermatol, H-4032 Debrecen, Hungary; [Szanto, Magdolna; Abdul-Rahman, Omar; Nagy, Lilla] MTA DE Cell Biol & Signaling Res Grp, H-4032 Debrecen, Hungary; [Bai, Peter] MTA DE Lendulet Lab Cellular Metab, H-4032 Debrecen, Hungary; [Bai, Peter] Univ Debrecen, Res Ctr Mol Med, H-4032 Debrecen, Hungary	University of Debrecen; University of Debrecen; University of Debrecen; University of Debrecen	Bai, P (corresponding author), Univ Debrecen, Dept Med Chem, Fac Med, H-4032 Debrecen, Hungary.; Bai, P (corresponding author), MTA DE Lendulet Lab Cellular Metab, H-4032 Debrecen, Hungary.; Bai, P (corresponding author), Univ Debrecen, Res Ctr Mol Med, H-4032 Debrecen, Hungary.	baip@med.unideb.hu		Szanto, Magdolna/0000-0002-7714-7065	Bolyai fellowship; Hungarian National, Research, Development and Innovation Office (NKFIH) [K108308, K105872, C120732, C129074]; Momentum fellowship of the Hungarian Academy of Sciences; University of Debrecen;  [TAMOP-4.2.2. A-11/1/KONV-2012-0025]	Bolyai fellowship(Hungarian Academy of Sciences); Hungarian National, Research, Development and Innovation Office (NKFIH); Momentum fellowship of the Hungarian Academy of Sciences; University of Debrecen; 	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The author(s) received no specific funding for this work. The authors acknowledge the technical assistance of Erzsebet Herbaly and Laszlo Gelenczei-Finta. This work was supported by a Bolyai fellowship to MS. Furthermore, by grants from The Hungarian National, Research, Development and Innovation Office (NKFIH (K108308, K105872, C120732, C129074)), TAMOP-4.2.2. A-11/1/KONV-2012-0025, the Momentum fellowship of the Hungarian Academy of Sciences and the University of Debrecen.	[Anonymous], 2014, NCCN CLIN GUID ONC; Ayyasamy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024792; Bai P, 2001, FREE RADICAL BIO MED, V31, P1616, DOI 10.1016/S0891-5849(01)00756-0; Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200; Bai P, 2015, TRENDS ENDOCRIN MET, V26, P75, DOI 10.1016/j.tem.2014.11.003; Bao Y, 2013, MOL CANCER RES, V11, P973, DOI 10.1158/1541-7786.MCR-12-0669-T; Beckers A, 2006, MOL CANCER THER, V5, P2211, DOI 10.1158/1535-7163.MCT-06-0001; Boratko A, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-99; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Colombo SL, 2011, P NATL ACAD SCI USA, V108, P21069, DOI 10.1073/pnas.1117500108; Ertel A, 2012, CELL CYCLE, V11, P253, DOI 10.4161/cc.11.2.19006; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017; Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662; Gonzalez-Angulo AM, 2012, CLIN CANCER RES, V18, P1109, DOI 10.1158/1078-0432.CCR-11-2762; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001; Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537; Isidoro A, 2005, CARCINOGENESIS, V26, P2095, DOI 10.1093/carcin/bgi188; Kim S, 2013, TUMOR BIOL, V34, P1699, DOI 10.1007/s13277-013-0707-1; Kroemer G, 2006, ONCOGENE, V25, P4630, DOI 10.1038/sj.onc.1209589; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lai L, 2008, GENE DEV, V22, P1948, DOI 10.1101/gad.1661708; Moncada S, 2012, BIOCHEM J, V446, P1, DOI 10.1042/BJ20120427; Mouradian M, 2015, MOL CARCINOGEN, V54, P810, DOI 10.1002/mc.22151; Nagy L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069420; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Suhane S, 2011, BIOCHEM BIOPH RES CO, V414, P73, DOI 10.1016/j.bbrc.2011.09.024; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Szanto M, 2011, CARDIOVASC RES, V92, P430, DOI 10.1093/cvr/cvr246; Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911; Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530; Yadav N, 2013, BBA-REV CANCER, V1836, P336, DOI 10.1016/j.bbcan.2013.10.002; Zhai XM, 2013, ONCOL REP, V30, P2983, DOI 10.3892/or.2013.2735	43	37	43	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0150232	10.1371/journal.pone.0150232	http://dx.doi.org/10.1371/journal.pone.0150232			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3UU	26919657	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000371274400107
J	Hartung, JC; Wilitzki, S; Thio-Lluch, M; te Pas, AB; Schmalisch, G; Roehr, CC				Hartung, Julia C.; Wilitzki, Silke; Thio-Lluch, Marta; te Pas, Arjan B.; Schmalisch, Gerd; Roehr, Charles C.			Reliability of Single-Use PEEP-Valves Attached to Self-Inflating Bags during Manual Ventilation of Neonates - An In Vitro Study	PLOS ONE			English	Article							END-EXPIRATORY PRESSURE; FUNCTIONAL RESIDUAL CAPACITY; PRETERM INFANTS; DELIVERY ROOM; RESUSCITATION; BIRTH; TRANSITION; MINUTES; DEVICES; LAMBS	Introduction International resuscitation guidelines suggest to use positive end-expiratory pressure (PEEP) during manual ventilation of neonates. Aim of our study was to test the reliability of self-inflating bags (SIB) with single-use PEEP valves regarding PEEP delivery and the effect of different peak inflation pressures (PIP) and ventilation rates (VR) on the delivered PEEP. Methods Ten new single-use PEEP valves from 5 manufacturers were tested by ventilating an intubated 1kg neonatal manikin containing a lung model with a SIB that was actuated by an electromechanical plunger device. Standard settings: PIP 20cmH(2)O, VR 60/min, flow 8L/min. PEEP settings of 5 and 10cmH(2)O were studied. A second test was conducted with settings of PIP 40cmH(2)O and VR 40/min. The delivered PEEP was measured by a respiratory function monitor (CO2SMO+). Results Valves from one manufacturer delivered no relevant PEEP and were excluded. The remaining valves showed a continuous decay of the delivered pressure during expiration. The median (25th and 75th percentile) delivered PEEP with standard settings was 3.4(2.7-3.8) cmH(2)O when set to 5cmH(2)O and 6.1(4.9-7.1) cmH(2)O when set to 10cmH(2)O. Increasing the PIP from 20 to 40 cmH2O led to a median (25th and 75th percentile) decrease in PEEP to 2.3 (1.8-2.7) cmH(2)O and 4.3(3.2-4.8) cmH(2)O; changing VR from 60 to 40/min led to a PEEP decrease to 2.8(2.1-3.3) cmH(2)O and 5.0(3.5-6.2) cmH(2)O for both PEEP settings. Conclusion Single-use PEEP valves do not reliably deliver the set PEEP. PIP and VR have an effect on the delivered PEEP. Operators should be aware of these limitations when manually ventilating neonates.	[Hartung, Julia C.; Wilitzki, Silke; Schmalisch, Gerd; Roehr, Charles C.] Charite, Med Ctr, Dept Neonatol, D-13353 Berlin, Germany; [Thio-Lluch, Marta] Royal Womens Hosp, Dept Neonatol, Parkville, Vic, Australia; [te Pas, Arjan B.] Leiden Univ, Med Ctr, Dept Neonatol, Leiden, Netherlands; [Roehr, Charles C.] Univ Oxford, John Radcliffe Hosp, Newborn Serv, Oxford OX3 9DU, England; [Roehr, Charles C.] Monash Univ, Hudson Inst Med Res, Ritchie Ctr, Melbourne, Vic 3004, Australia	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Oxford; Hudson Institute of Medical Research; Monash University	Roehr, CC (corresponding author), Charite, Med Ctr, Dept Neonatol, D-13353 Berlin, Germany.; Roehr, CC (corresponding author), Univ Oxford, John Radcliffe Hosp, Newborn Serv, Oxford OX3 9DU, England.; Roehr, CC (corresponding author), Monash Univ, Hudson Inst Med Res, Ritchie Ctr, Melbourne, Vic 3004, Australia.	charles.roehr@ouh.nhs.uk	pas, arjan te/AAA-9019-2020	pas, arjan te/0000-0001-7831-8797; Roehr, Charles Christoph/0000-0001-7965-4637				Barton SK, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00097; Bennett S, 2005, RESUSCITATION, V67, P113, DOI 10.1016/j.resuscitation.2005.02.016; Dinger J, 2001, J PERINAT MED, V29, P137, DOI 10.1515/JPM.2001.018; Ersdal HL, 2013, SEMIN FETAL NEONAT M, V18, P373, DOI 10.1016/j.siny.2013.07.001; Hartung JC, 2012, NEONATOLOGY, V102, P190, DOI 10.1159/000339325; Hartung JC, 2013, J PAEDIATR CHILD H, V49, P741, DOI 10.1111/jpc.12258; Hooper SB, 2015, PAEDIATR RESPIR REV, V16, P147, DOI 10.1016/j.prrv.2015.03.003; Kelm M, 2009, KLIN PADIATR, V221, P415, DOI 10.1055/s-0029-1233493; Michna J, 1999, AM J RESP CRIT CARE, V160, P634, DOI 10.1164/ajrccm.160.2.9902016; Morley CJ, 2010, J PAEDIATR CHILD H, V46, P51, DOI 10.1111/j.1440-1754.2009.01617.x; O'Donnell CPF, 2004, ACTA PAEDIATR, V93, P583, DOI 10.1111/j.1651-2227.2004.tb02981.x; Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276; Probyn ME, 2004, PEDIATR RES, V56, P198, DOI 10.1203/01.PDR.0000132752.94155.13; Roehr CC, 2010, EUR J MED RES, V15, P493, DOI 10.1186/2047-783X-15-11-493; Schmolzer GM, 2011, KLIN PADIATR, V223, P261, DOI 10.1055/s-0031-1275696; Schmolzer GM, 2008, J PEDIATR-US, V153, P741, DOI 10.1016/j.jpeds.2008.08.016; Siew ML, 2009, J APPL PHYSIOL, V106, P1487, DOI 10.1152/japplphysiol.91591.2008; Szyld E, 2014, J PEDIATR-US, V165, P234, DOI 10.1016/j.jpeds.2014.02.035; te Pas AB, 2009, PEDIATR RES, V65, P537, DOI 10.1203/PDR.0b013e31819da21b; Thallinger M, 2015, ARCH DIS CHILD-FETAL, DOI [10.1136/archdischild-2015-308754, DOI 10.1136/ARCHDISCHILD-2015-308754]; Vento M, 2015, PAEDIATR RESPIR REV, V16, P151, DOI 10.1016/j.prrv.2015.02.004; Vento M, 2010, CHINESE MED J-PEKING, V123, P2924, DOI 10.3760/cma.j.issn.0366-6999.2010.20.032; Vento M, 2009, NEONATOLOGY, V95, P286, DOI 10.1159/000178770; Wyckoff MH, 2014, SEMIN PERINATOL, V38, P12, DOI 10.1053/j.semperi.2013.07.003; Wyllie J, 2015, RESUSCITATION, V95, P249, DOI 10.1016/j.resuscitation.2015.07.029	25	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0150224	10.1371/journal.pone.0150224	http://dx.doi.org/10.1371/journal.pone.0150224			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2LW	26914209	gold, Green Published, Green Submitted			2023-01-03	WOS:000371175700064
J	Carlson, N; Hommel, K; Olesen, JB; Soja, AM; Vilsboll, T; Kamper, AL; Torp-Pedersen, C; Gislason, G				Carlson, Nicholas; Hommel, Kristine; Olesen, Jonas Bjerring; Soja, Anne-Merete; Vilsboll, Tina; Kamper, Anne-Lise; Torp-Pedersen, Christian; Gislason, Gunnar			Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide Study	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; CARDIAC-SURGERY; MORTALITY; POPULATION; OUTCOMES; REGISTRY; DISEASE; VALIDATION; MORBIDITY; VALIDITY	Introduction Dialysis-requiring acute kidney injury is a severe illness associated with poor prognosis. However, information pertaining to incidence rates and prevalence of risk factors remains limited in spite of increasing focus. We evaluate time trends of incidence rates and changing patterns in prevalence of comorbidities, concurrent medication, and other risk factors in nationwide retrospective cohort study. Materials and Methods All patients with dialysis-requiring acute kidney injury were identified between January 1st 2000 and December 31st 2012. By cross-referencing data from national administrative registries, the association of changing patterns in dialysis treatment, comorbidity, concurrent medication and demographics with incidence of dialysis-requiring acute kidney injury was evaluated. Results A total of 18,561 adult patients with dialysis-requiring AKI were identified between 2000 and 2012. Crude incidence rate of dialysis-requiring AKI increased from 143 per million (95% confidence interval, 137-144) in 2000 to 366 per million (357-375) in 2006, and remained stable hereafter. Notably, incidence of continuous veno-venous hemodialysis (CRRT) and use of acute renal replacement therapy in elderly >75 years increased substantially from 23 per million (20-26) and 328 per million (300-355) in 2000, to 213 per million (206-220) and 1124 per million (1076-1172) in 2012, respectively. Simultaneously, patient characteristics and demographics shifted towards increased age and comorbidity. Conclusions Although growth in crude incidence rate of dialysis-requiring AKI stabilized in 2006, continuous growth in use of CRRT, and acute renal replacement therapy of elderly patients >75 years, was observed. Our results indicate an underlying shift in clinical paradigm, as opposed to unadulterated growth in incidence of dialysis-requiring AKI.	[Carlson, Nicholas; Olesen, Jonas Bjerring; Gislason, Gunnar] Univ Copenhagen, Dept Cardiol, Gentofte Hosp, Gentofte, Denmark; [Carlson, Nicholas; Hommel, Kristine] Univ Copenhagen, Herlev Hosp, Dept Nephrol, DK-2730 Herlev, Denmark; [Soja, Anne-Merete] Univ Copenhagen, Hvidovre Hosp, Dept Cardiol, DK-2650 Hvidovre, Denmark; [Vilsboll, Tina] Univ Copenhagen, Gentofte Hosp, Ctr Diabet Res, Gentofte, Denmark; [Kamper, Anne-Lise] Univ Copenhagen, Rigshosp, Dept Nephrol, DK-2100 Copenhagen, Denmark; [Torp-Pedersen, Christian] Aalborg Univ, Inst Hlth Sci & Technol, Aalborg, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Aalborg University	Carlson, N (corresponding author), Univ Copenhagen, Dept Cardiol, Gentofte Hosp, Gentofte, Denmark.; Carlson, N (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Nephrol, DK-2730 Herlev, Denmark.	Nicholas.carlson@regionh.dk	Gislason, Gunnar/B-7561-2009; Vilsboll, Tina/I-6562-2016; Carlson, Nicholas/M-2666-2016	Gislason, Gunnar/0000-0002-0548-402X; Kamper, Anne-Lise/0000-0001-7523-6569; Carlson, Nicholas/0000-0002-4374-470X	Danish Heart Foundation; Danish Kidney Foundation; Department of Cardiology at Copenhagen University Hospital Gentofte; Department of Nephrology at Copenhagen University Hospital Herlev; Helen and Ejnar Bjoernows Foundation; Danish Society of Nephrology; Health Foundation; Novo Nordisk Foundation; Bristol-Myers Squibb; Boehringer Ingelheim; Lundbeck Foundation; Capital Region of Denmark; Novo Nordisk Fonden [NNF16OC0020224, NNF12OC1015904, NNF15OC0016230, NNF12OC1015957] Funding Source: researchfish	Danish Heart Foundation; Danish Kidney Foundation; Department of Cardiology at Copenhagen University Hospital Gentofte; Department of Nephrology at Copenhagen University Hospital Herlev; Helen and Ejnar Bjoernows Foundation; Danish Society of Nephrology; Health Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Bristol-Myers Squibb(Bristol-Myers Squibb); Boehringer Ingelheim(Boehringer Ingelheim); Lundbeck Foundation(Lundbeckfonden); Capital Region of Denmark; Novo Nordisk Fonden(Novo Nordisk Foundation)	NC: Grants received from The Danish Heart Foundation, The Danish Kidney Foundation, The Department of Cardiology at Copenhagen University Hospital Gentofte and the Department of Nephrology at Copenhagen University Hospital Herlev, Helen and Ejnar Bjoernows Foundation, The Danish Society of Nephrology and the Health Foundation. GG: Supported by an unrestricted clinical research scholarship from the Novo Nordisk Foundation. JO: Has received speaker fees and funding for research from Bristol-Myers Squibb and Boehringer Ingelheim, the Lundbeck Foundation, and The Capital Region of Denmark. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and no funding was specifically designated for this work.	Afshinnia F, 2009, RENAL FAILURE, V31, P647, DOI 10.3109/08860220903151401; Blichert-Hansen Linea, 2013, Clin Epidemiol, V5, P9, DOI 10.2147/CLEP.S37763; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Fagugli RM, 2014, J NEPHROL; Gammelager H, 2013, CRIT CARE, V17, DOI 10.1186/cc12824; Grams ME, 2014, CLIN J AM SOC NEPHRO, V9, P682, DOI 10.2215/CJN.07650713; Hamel MB, 2005, J AM GERIATR SOC, V53, P424, DOI 10.1111/j.1532-5415.2005.53159.x; Hommel K, 2010, NEPHROL DIAL TRANSPL, V25, P947, DOI 10.1093/ndt/gfp571; Hsu CY, 2008, KIDNEY INT, V74, P101, DOI 10.1038/ki.2008.107; Hsu CY, 2007, KIDNEY INT, V72, P208, DOI 10.1038/sj.ki.5002297; Hsu RK, 2013, CLIN J AM SOC NEPHRO, V8, P1476, DOI 10.2215/CJN.12611212; Hsu RK, 2013, J AM SOC NEPHROL, V24, P37, DOI 10.1681/ASN.2012080800; Johannesdottir Sigrun Alba, 2012, Clin Epidemiol, V4, P303, DOI 10.2147/CLEP.S37587; JURGENSEN HJ, 1986, METHOD INFORM MED, V25, P158; Karkouti K, 2009, CIRCULATION, V119, P495, DOI 10.1161/CIRCULATIONAHA.108.786913; Kearns B, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-49; Khera S, 2013, AM J CARDIOL, V112, P1279, DOI 10.1016/j.amjcard.2013.06.008; Kheterpal S, 2009, ANESTHESIOLOGY, V110, P505, DOI 10.1097/ALN.0b013e3181979440; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KIDNEY INT SUPP, V2, P1, DOI 10.1038/kisup.2012.1; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kolhe NV, 2015, KIDNEY INT, V88, P1161, DOI 10.1038/ki.2015.234; Lameire NH, 2013, LANCET, V382, P170, DOI 10.1016/S0140-6736(13)60647-9; Lenihan CR, 2013, ANN THORAC SURG, V95, P20, DOI 10.1016/j.athoracsur.2012.05.131; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lewington AJP, 2013, KIDNEY INT, V84, P457, DOI 10.1038/ki.2013.153; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Matuszkiewicz-Rowinska J, 2015, KIDNEY INT, V87, P1264, DOI 10.1038/ki.2015.61; O'Hare AM, 2012, AM J KIDNEY DIS, V59, P513, DOI 10.1053/j.ajkd.2011.11.044; Olesen Jonas Bjerring, 2011, BMJ, V342, pd124, DOI 10.1136/bmj.d124; Rodrigues FB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069998; Sakhuja A, 2015, AM J RESP CRIT CARE, V192, P951, DOI 10.1164/rccm.201502-0329OC; Siew ED, 2015, KIDNEY INT, V87, P46, DOI 10.1038/ki.2014.293; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Thakar CV, 2003, AM J KIDNEY DIS, V41, P742, DOI 10.1016/S0272-6386(03)00021-0; Thakar CV, 2013, INT J NEPHROL, V2013, DOI [10.1155/2013/827459, DOI 10.1155/2013/827459]; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83; Toft P, 2000, Ugeskr Laeger, V162, P2868; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073; Wald R, 2015, AM J KIDNEY DIS, V65, P870, DOI 10.1053/j.ajkd.2014.10.017; Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487; Wonnacott A, 2014, CLIN J AM SOC NEPHRO; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668	45	19	20	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2016	11	2							e0148809	10.1371/journal.pone.0148809	http://dx.doi.org/10.1371/journal.pone.0148809			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6PR	26863015	Green Published, gold			2023-01-03	WOS:000370046600108
J	Elorinne, AL; Alfthan, G; Erlund, I; Kivimaki, H; Paju, A; Salminen, I; Turpeinen, U; Voutilainen, S; Laakso, J				Elorinne, Anna-Liisa; Alfthan, Georg; Erlund, Iris; Kivimaki, Hanna; Paju, Annukka; Salminen, Irma; Turpeinen, Ursula; Voutilainen, Sari; Laakso, Juha			Food and Nutrient Intake and Nutritional Status of Finnish Vegans and Non-Vegetarians	PLOS ONE			English	Article							VITAMIN-D; SERUM 25-HYDROXYVITAMIN-D; DIETARY-INTAKE; IODINE STATUS; VEGETARIANS; SELENIUM; PLASMA; OMNIVORES	Background Vegetarian and vegan diets have become more popular among adolescents and young adults. However, few studies have investigated the nutritional status of vegans, who may be at risk of nutritional deficiencies. Objective To compare dietary intake and nutritional status of Finnish long-term vegans and non-vegetarians. Methods Dietary intake and supplement use were estimated using three-day dietary records. Nutritional status was assessed by measuring biomarkers in plasma, serum, and urine samples. Vegans' (n = 22) data was compared with those of sex-and age-matched non-vegetarians (n = 19). Results All vegans adhered strictly to their diet; however, individual variability was marked in food consumption and supplementation habits. Dietary intakes of key nutrients, vitamins B12 and D, were lower (P < 0.001) in vegans than in non-vegetarians. Nutritional biomarker measurements showed lower concentrations of serum 25-hydroxyvitamin D3 (25(OH) D3), iodine and selenium (corrected for multiple comparisons, P < 0.001), Vegans showed more favorable fatty acid profiles (P < 0.001) as well as much higher concentrations of polyphenols such as genistein and daidzein (P < 0.001). Eicosapentaenoic acid proportions in vegans were higher than expected. The median concentration of iodine in urine was below the recommended levels in both groups. Conclusions Long-term consumption of a vegan diet was associated with some favorable laboratory measures but also with lowered concentrations of key nutrients compared to reference values. This study highlights the need for nutritional guidance to vegans.	[Elorinne, Anna-Liisa] Univ Eastern Finland, Sch Appl Educ Sci & Teacher Educ, Savonlinna, Finland; [Alfthan, Georg; Erlund, Iris; Salminen, Irma] Natl Inst Hlth & Welf, Genom & Biomarkers Unit, Helsinki, Finland; [Kivimaki, Hanna; Voutilainen, Sari] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Paju, Annukka] Univ Helsinki, Cent Hosp, Dept Clin Chem & Hematol, Cent Hosp Lab, Helsinki, Finland; [Turpeinen, Ursula] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; [Laakso, Juha] Finnish Safety & Chem Agcy, Helsinki, Finland	University of Eastern Finland; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Elorinne, AL (corresponding author), Univ Eastern Finland, Sch Appl Educ Sci & Teacher Educ, Savonlinna, Finland.	Anna-Liisa.Elorinne@uef.fi	Erlund, Iris/AAA-4108-2019		Juho Vainio Foundation	Juho Vainio Foundation	This work was supported by The Juho Vainio Foundation (A-LE and JL). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfthan G, 2011, COMBATING MICRONUTRIENT DEFICIENCIES: FOOD-BASED APPROACHES, P312, DOI 10.1079/9781845937140.0312; Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692; Chan J, 2009, AM J CLIN NUTR, V89, pS1686, DOI 10.3945/ajcn.2009.26736X; Craig WJ, 2009, J AM DIET ASSOC, V109, P1266, DOI 10.1016/j.jada.2009.05.027; Crowe FL, 2011, PUBLIC HEALTH NUTR, V14, P340, DOI 10.1017/S1368980010002454; Elmadfa I, 2009, AM J CLIN NUTR, V89, pS1693, DOI 10.3945/ajcn.2009.26736Y; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fraser GE, 2009, AM J CLIN NUTR, V89, pS1607, DOI 10.3945/ajcn.2009.26736K; GARDINER PHE, 1995, J TRACE ELEM MED BIO, V9, P74, DOI 10.1016/S0946-672X(11)80014-3; Haddad EH, 1999, AM J CLIN NUTR, V70, p586S, DOI 10.1093/ajcn/70.3.586s; Hakala P, 1996, FOOD CHEM, V57, P71, DOI 10.1016/0308-8146(96)00077-5; HERBERT V, 1988, AM J CLIN NUTR, V48, P852, DOI 10.1093/ajcn/48.3.852; Ho-Pham LT, 2012, EUR J CLIN NUTR, V66, P75, DOI 10.1038/ejcn.2011.131; JACOBSON BE, 1988, CLIN CHEM, V34, P709; KADRABOVA J, 1995, BIOL TRACE ELEM RES, V50, P13, DOI 10.1007/BF02789145; Kilkkinen A, 2006, AM J EPIDEMIOL, V163, P687, DOI 10.1093/aje/kwj080; Knoll N, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-141; Kornsteiner M, 2008, ANN NUTR METAB, V52, P37, DOI 10.1159/000118629; Kosonen H, 2005, SOZ PRAVENTIV MED, V50, P142, DOI 10.1007/s00038-005-3167-6; Krajcovicova-Kudlackova M, 2003, ANN NUTR METAB, V47, P183, DOI 10.1159/000070483; KTL-National Public Health Institute, 2008, PUBL NAT PUBL HLTH I; LAMBERG-ALLARDT C, 1993, AM J CLIN NUTR, V58, P684, DOI 10.1093/ajcn/58.5.684; Larsson CL, 2001, PUBLIC HEALTH NUTR, V4, P1005, DOI 10.1079/PHN2001167; Larsson CL, 2002, AM J CLIN NUTR, V76, P100; Leung AM, 2011, J CLIN ENDOCR METAB, V96, pE1303, DOI 10.1210/jc.2011-0256; Miettinen ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100235; National Nutrition Council, FINN NUTR REC 2014; Obersby D, 2013, BRIT J NUTR, V109, P785, DOI 10.1017/S000711451200520X; Ohashi T, 2000, CLIN CHEM, V46, P529; Outila TA, 2000, J AM DIET ASSOC, V100, P434, DOI 10.1016/S0002-8223(00)00134-6; Paturi M, FINRAVINTO 2007 TUTK; RAUMA AL, 1994, NUTR RES, V14, P1789, DOI 10.1016/S0271-5317(05)80715-8; Rauma AL, 2000, NUTRITION, V16, P111, DOI 10.1016/S0899-9007(99)00267-1; RAUMA AL, 1995, J NUTR, V125, P2511; Sanders TAB, 2009, PROSTAG LEUKOTR ESS, V81, P137, DOI 10.1016/j.plefa.2009.05.013; Soderholm PP, 2012, NUTR METAB CARDIOVAS, V22, P575, DOI 10.1016/j.numecd.2010.09.011; STOFFEL W, 1958, P SOC EXP BIOL MED, V99, P238; Vinnari M, 2009, PUBLIC HEALTH NUTR, V12, P481, DOI 10.1017/S1368980008002486; Virtanen JK, 2011, EUR J NUTR, V50, P305, DOI 10.1007/s00394-010-0138-3	39	117	126	3	110	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0148235	10.1371/journal.pone.0148235	http://dx.doi.org/10.1371/journal.pone.0148235			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840251	Green Published, gold, Green Submitted			2023-01-03	WOS:000369550200106
J	Wang, CC; Schmid, CH; Iversen, MD; Harvey, WF; Fielding, RA; Driban, JB; Price, LL; Wong, JB; Reid, KF; Rones, R; McAlindon, T				Wang, Chenchen; Schmid, Christopher H.; Iversen, Maura D.; Harvey, William F.; Fielding, Roger A.; Driban, Jeffrey B.; Price, Lori Lyn; Wong, John B.; Reid, Kieran F.; Rones, Ramel; McAlindon, Timothy			Comparative Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIALS; PAIN; FIBROMYALGIA; ARTHRITIS; OUTCOMES; HIP; INTERVENTIONS; RELIABILITY; DISABILITY	Background: Few remedies effectively treat long-term pain and disability from knee osteoarthritis. Studies suggest that Tai Chi alleviates symptoms, but no trials have directly compared Tai Chi with standard therapies for osteoarthritis. Objective: To compare Tai Chi with standard physical therapy for patients with knee osteoarthritis. Design: Randomized, 52-week, single-blind comparative effectiveness trial. (ClinicalTrials.gov:NCT01258985) Setting: An urban tertiary care academic hospital. Patients: 204 participants with symptomatic knee osteoarthritis (mean age, 60 years; 70% women; 53% white). Intervention: Tai Chi (2 times per week for 12 weeks) or standard physical therapy (2 times per week for 6 weeks, followed by 6 weeks of monitored home exercise). Measurements: The primary outcome was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at 12 weeks. Secondary outcomes included physical function, depression, medication use, and quality of life. Results: At 12 weeks, the WOMAC score was substantially reduced in both groups (Tai Chi, 167 points [ 95% CI, 145 to 190 points]; physical therapy, 143 points [ CI, 119 to 167 points]). The between-group difference was not significant (24 points [ CI, - 10 to 58 points]). Both groups also showed similar clinically significant improvement in most secondary outcomes, and the benefits were maintained up to 52 weeks. Of note, the Tai Chi group had significantly greater improvements in depression and the physical component of quality of life. The benefit of Tai Chi was consistent across instructors. No serious adverse events occurred. Limitation: Patients were aware of their treatment group assignment, and the generalizability of the findings to other settings remains undetermined. Conclusion: Tai Chi produced beneficial effects similar to those of a standard course of physical therapy in the treatment of knee osteoarthritis.	[Wang, Chenchen] Tufts Med Ctr, 800 Washington St,Box 406, Boston, MA 02111 USA; [Wang, Chenchen] Tufts Univ, Sch Med, 800 Washington St,Box 406, Boston, MA 02111 USA; Tufts Univ, Boston, MA 02111 USA; Northeastern Univ, Boston, MA 02115 USA; Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA; Ctr Mind Body Therapies, Boston, MA USA; Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA; [Schmid, Christopher H.] Brown Univ, Sch Publ Hlth, Ctr Evidence Based Med, 121 South Main St,Box G-S121-8, Providence, RI 02912 USA; [Iversen, Maura D.] Northeastern Univ, Dept Phys Therapy Movement & Rehabil Sci, 360 Huntington Ave,Room 301c, Boston, MA 02115 USA; [Harvey, William F.; Driban, Jeffrey B.; McAlindon, Timothy] Tufts Univ, Sch Med, Tufts Med Ctr, Div Rheumatol, Box 406, Boston, MA 02111 USA; [Fielding, Roger A.; Reid, Kieran F.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Exercise Physiol & Sarcopenia Lab, 711 Washington St, Boston, MA 02111 USA; [Price, Lori Lyn] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Box 063, Boston, MA 02111 USA; [Wong, John B.] Tufts Med Ctr, Dept Med, Ctr Clin Decis Making, Box 302, Boston, MA 02111 USA; [Rones, Ramel] RR Prod, 17 Parker St, Lexington, MA 02421 USA	Tufts Medical Center; Tufts University; Tufts University; Northeastern University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Brown University; Brown University; Northeastern University; Tufts Medical Center; Tufts University; Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts Medical Center	Wang, CC (corresponding author), Tufts Med Ctr, 800 Washington St,Box 406, Boston, MA 02111 USA.; Wang, CC (corresponding author), Tufts Univ, Sch Med, 800 Washington St,Box 406, Boston, MA 02111 USA.	cwang2@tuftsmedicalcenter.org	Schmid, Christopher H./J-2398-2014; Driban, Jeffrey/H-3486-2019	Schmid, Christopher H./0000-0002-0855-5313; Driban, Jeffrey/0000-0001-6098-4273; Wong, John/0000-0003-4203-9010	National Center for Complementary and Integrative Health of the National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD065688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000073, UL1TR001064] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT005521] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT007323] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health of the National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Center for Complementary and Integrative Health of the National Institutes of Health.	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; [Anonymous], 2012, R LANG ENV STAT COMP; Axford J, 2008, J PSYCHOSOM RES, V64, P461, DOI 10.1016/j.jpsychores.2007.11.009; Baker KR, 2001, J RHEUMATOL, V28, P1655; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Bellamy N, 1997, J RHEUMATOL, V24, P799; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Blagojevic M, 2010, OSTEOARTHR CARTILAGE, V18, P24, DOI 10.1016/j.joca.2009.08.010; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hall MC, 2006, ANN RHEUM DIS, V65, P865, DOI 10.1136/ard.2005.043653; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; Iversen MD, 2012, AM J NURS, V112, pS32, DOI 10.1097/01.NAJ.0000412649.02926.35; Jamtvedt G, 2008, PHYS THER, V88, P123, DOI 10.2522/ptj.20070043; King S, 1999, J RHEUMATOL, V26, P2233; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Morgan N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100903; Motyl JM, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-166; Murphy L, 2008, ARTHRIT RHEUM-ARTHR, V59, P1207, DOI 10.1002/art.24021; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Pham T, 2003, J RHEUMATOL, V30, P1648; Phillips K, 2011, BEST PRACT RES CL RH, V25, P141, DOI 10.1016/j.berh.2011.02.005; Resnick B, 2000, J GERONTOL B-PSYCHOL, V55, pS352, DOI 10.1093/geronb/55.6.S352; Slemenda C, 1997, ANN INTERN MED, V127, P97, DOI 10.7326/0003-4819-127-2-199707150-00001; Smalley WE, 1996, GASTROENTEROL CLIN N, V25, P373, DOI 10.1016/S0889-8553(05)70253-3; Sports China, 1983, SIMPL TAIJ; Tubach F, 2005, ANN RHEUM DIS, V64, P34, DOI 10.1136/ard.2004.023028; Wang C, 2005, RHEUMATOLOGY, V44, P685, DOI 10.1093/rheumatology/keh572; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang CC, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-333; Wang CC, 2012, CURR RHEUMATOL REP, V14, P598, DOI 10.1007/s11926-012-0294-y; Wang CC, 2011, RHEUM DIS CLIN N AM, V37, P19, DOI 10.1016/j.rdc.2010.11.002; Wang CC, 2010, NEW ENGL J MED, V363, P2266; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Ware JE., 1994, SF 36 PHYS MENTAL HL; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; Yan JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061672	40	84	91	1	66	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 19	2016	165	2					77	+		10.7326/M15-2143	http://dx.doi.org/10.7326/M15-2143			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS2GY	27183035	Green Accepted			2023-01-03	WOS:000380583100014
J	Ribrag, V; Koscielny, S; Bosq, J; Leguay, T; Casasnovas, O; Fornecker, LM; Recher, C; Ghesquieres, H; Morschhauser, F; Girault, S; Le Gouill, S; Ojeda-Uribe, M; Mariette, C; Cornillon, J; Cartron, G; Verge, V; Chassagne-Clement, C; Dombret, H; Coiffier, B; Lamy, T; Tilly, H; Salles, G				Ribrag, Vincent; Koscielny, Serge; Bosq, Jacques; Leguay, Thibaut; Casasnovas, Olivier; Fornecker, Luc-Mathieu; Recher, Christian; Ghesquieres, Herve; Morschhauser, Franck; Girault, Stephane; Le Gouill, Steven; Ojeda-Uribe, Mario; Mariette, Clara; Cornillon, Jerome; Cartron, Guillaume; Verge, Veronique; Chassagne-Clement, Catherine; Dombret, Herve; Coiffier, Bertrand; Lamy, Thierry; Tilly, Herve; Salles, Gilles			Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial	LANCET			English	Article							CLEAVED-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; CODOX-M/IVAC; MULTIAGENT CHEMOTHERAPY; PLUS RITUXIMAB; SURVIVAL RATE; CHILDREN; LEUKEMIA; ADOLESCENTS; THERAPY	Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm studies suggest that addition of rituximab to these regimens could improve patient outcomes. Our objective was to test this possibility in a randomised trial. Methods In this randomised, controlled, open-label, phase 3 trial, we recruited patients older than 18 years with untreated HIV-negative Burkitt's lymphoma (including Burkitt's leukaemia) from 45 haematological centres in France. Exclusion criteria were contraindications to any drug included in the chemotherapy regimens, any serious comorbidity, poor renal (creatinine concentration >150 mu mol/L) or hepatic (cirrhosis or previous hepatitis B or C) function, pregnancy, and any history of cancer except for non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma. Patients were stratified into two groups based on disease extension (absence [group B] or presence [group C] of bone marrow or central nervous system involvement). Patients were further stratified in group C according to age (<40 years, 40-60 years, and >60 years) and central nervous system involvement. Participants were randomly assigned in each group to either intravenous rituximab injections and chemotherapy (lymphome malin B [LMB]) or chemotherapy alone by the Groupe d'Etude des Lymphomes de l'Adulte datacentre. Randomisation was stratified by treatment group and centre using computer-assisted permuted-block randomisation (block size of four; allocation ratio 1: 1). We gave rituximab (375 mg/m(2)) on day 1 and day 6 during the first two courses of chemotherapy (total of four infusions). The primary endpoint is 3 year event-free survival (EFS). We analysed all patients who had data available according to their originally assigned group. This trial is registered with ClinicalTrials.gov, number NCT00180882. Results Between Oct 14, 2004, and Sept 7, 2010, we randomly allocated 260 patients to rituximab or no rituximab (group B 124 patients [64 no rituximab; 60 rituximab]; group C 136 patients [66 no rituximab; 70 rituximab]). With a median follow-up of 38 months (IQR 24-59), patients in the rituximab group achieved better 3 year EFS (75% [95% CI 66-82]) than did those in the no rituximab group (62% [53-70]; log-rank p stratified by treatment group= 0.024). The hazard ratio estimated with a Cox model stratified by treatment group, assuming proportionality, was 0.59 for EFS (95% CI 0.38-0.94; p= 0.025). Adverse events did not differ between the two treatment groups. The most common adverse events were infectious (grade 3-4 in 137 [17%] treatment cycles in the rituximab group vs 115 [15%] in the no rituximab group) and haematological (mean duration of grade 4 neutropenia of 3.31 days per cycle [95% CI 3.01-3.61] vs 3.38 days per cycle [3.05-3.70]) events. Interpretation Addition of rituximab to a short intensive chemotherapy programme improves EFS in adults with Burkitt's leukaemia or lymphoma.	[Ribrag, Vincent] Univ Paris Saclay, Dept Med, Gustave Roussy, F-94805 Villejuif, France; [Koscielny, Serge] Univ Paris Saclay, Biostat & Epidemiol Unit, Gustave Roussy, F-94805 Villejuif, France; [Bosq, Jacques] Univ Paris Saclay, Dept Biopathol, Morphol Unit, Gustave Roussy, F-94805 Villejuif, France; [Verge, Veronique] Univ Paris Saclay, Haematol Unit, Gustave Roussy, F-94805 Villejuif, France; [Koscielny, Serge] Univ Paris 11, Inst Natl Sante & Rech Med, Ctr Res Epidemiol & Populat Hlth, U1018, Villejuif, France; [Leguay, Thibaut] Ctr Hosp Univ Bordeaux, Serv Hematol Clin & Therapie Cellulaire, Bordeaux, France; [Casasnovas, Olivier] Ctr Hosp Univ Dijon, Serv Hematol Clin, Dijon, France; [Fornecker, Luc-Mathieu] Univ Strasbourg, Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France; [Recher, Christian] Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France; [Ghesquieres, Herve] Univ Lyon 1, Ctr Leon Berard, Oncohematol, F-69365 Lyon, France; [Morschhauser, Franck] Univ Lille, Unite Grp Rech Formes Injectables & Technol Assoc, Serv Malad Sang, Lille, France; [Girault, Stephane] Ctr Hosp Univ Limoges, Hematol Clin & Therapie Cellulaire, Limoges, France; [Le Gouill, Steven] Nantes Univ Hosp, Nantes Inst Natl Sante & Rech Med, Ctr Invest Clin 004,Equipe 10, Inst Natl Sante & Rech Med,Dept Hematol,Unite Mix, Nantes, France; [Ojeda-Uribe, Mario] Hop Emile Muller, Dept Hematol, Ctr Competences Thrombot Microangiopathies, Mulhouse, France; [Ojeda-Uribe, Mario] Hop Emile Muller, Cellular Therapy Unit, Ctr Competences Thrombot Microangiopathies, Mulhouse, France; [Mariette, Clara] Grenoble Univ Hosp, Dept Haematol, Grenoble, France; [Cornillon, Jerome] Inst Canc Lucien Neuwirth, Dept Hematol, Saint Priest En Jarez, France; [Cartron, Guillaume] Ctr Hosp Univ Montpellier, Dept Hematol, Ctr Natl Rech Sci, Unite Mixte Rech 5235, Montpellier, France; [Chassagne-Clement, Catherine] Ctr Leon Berard, Dept Biopathol, F-69373 Lyon, France; [Dombret, Herve] Ctr Hosp Univ Paris, Serv Hematol Clin, Grp Hosp St Louis, Lariboisiere, Fernand Widal, France; [Dombret, Herve] Hop St Louis, Paris, France; [Coiffier, Bertrand] Hosp Civils Lyon, Hematol Clin, Ctr Hosp Lyon Sud, Pierre Benite, France; [Lamy, Thierry] Rennes Univ Hosp, Dept Clin Hematol, Rennes, France; [Lamy, Thierry] Univ Rennes 1, Inst Natl Sante & Rech, Unite Mixte Rech 917, Rennes Dept Clin Invest,Rennes Univ Hosp,Fac Med, Rennes, France; [Tilly, Herve] Univ Rouen, Ctr Henri Becquerel, Rouen, France; [Salles, Gilles] Univ Lyon 1, Hosp Civils Lyon, Pierre Benite, France	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Bordeaux; CHU Dijon Bourgogne; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Universite de Lille - ISITE; Universite de Lille; CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut de Cancerologie de la Loire; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CHU de Montpellier; UNICANCER; Centre Leon Berard; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; CHU Rennes; Universite de Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; UNICANCER; Centre Henri Becquerel; Universite de Rouen Normandie; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ribrag, V (corresponding author), Univ Paris Saclay, Dept Med, Gustave Roussy, F-94805 Villejuif, France.	vincent.ribrag@gustaveroussy.fr	Salles, Gilles/Z-2336-2019	Salles, Gilles/0000-0002-9541-8666; Cartron, Guillaume/0000-0003-0659-9635; le gouill, steven/0000-0001-9840-2128; Ojeda-Uribe, Mario/0000-0001-6881-6055; Casasnovas, Rene-Olivier/0000-0002-1156-8983	Roche	Roche(Roche Holding)	HT, OC, SLG, GS, and FM have received personal fees from Roche, and OC, GS, and HD have received grants from Roche. All other authors declare no competing interests.	Barnes JA, 2011, ANN ONCOL, V22, P1859, DOI 10.1093/annonc/mdq677; Bishop PC, 2000, CANCER INVEST, V18, P574, DOI 10.3109/07357900009012197; Cairo MS, 2007, BLOOD, V109, P2736, DOI 10.1182/blood-2006-07-036665; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Corazzelli G, 2012, BRIT J HAEMATOL, V156, P234, DOI 10.1111/j.1365-2141.2011.08947.x; Divine M, 2005, ANN ONCOL, V16, P1928, DOI 10.1093/annonc/mdi403; Divine M, 1996, J CLIN ONCOL, V14, P240, DOI 10.1200/JCO.1996.14.1.240; Dunleavy K, 2013, NEW ENGL J MED, V369, P1915, DOI 10.1056/NEJMoa1308392; Goldman S, 2014, BRIT J HAEMATOL, V167, P394, DOI 10.1111/bjh.13040; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Intermesoli T, 2013, HAEMATOLOGICA, V98, P1718, DOI 10.3324/haematol.2013.086827; JOST LM, 1995, ANN ONCOL, V6, P445, DOI 10.1093/oxfordjournals.annonc.a059214; Lee EJ, 2001, J CLIN ONCOL, V19, P4014, DOI 10.1200/JCO.2001.19.20.4014; LONGO DL, 1994, J CLIN ONCOL, V12, P2153, DOI 10.1200/JCO.1994.12.10.2153; Machin D, 1997, SAMPLE SIZE TABLES C, P251; Magrath I, 1996, J CLIN ONCOL, V14, P925, DOI 10.1200/JCO.1996.14.3.925; Mead GM, 2002, ANN ONCOL, V13, P1264, DOI 10.1093/annonc/mdf253; Mead GM, 2008, BLOOD, V112, P2248, DOI 10.1182/blood-2008-03-145128; MURPHY SB, 1980, SEMIN ONCOL, V7, P332; PATTE C, 1991, J CLIN ONCOL, V9, P123, DOI 10.1200/JCO.1991.9.1.123; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; Patte C, 2001, BLOOD, V97, P3370, DOI 10.1182/blood.V97.11.3370; Patte C, 2007, BLOOD, V109, P2773, DOI 10.1182/blood-2006-07-036673; Rizzieri DA, 2014, BRIT J HAEMATOL, V165, P102, DOI 10.1111/bjh.12736; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Thomas DA, 2006, CANCER-AM CANCER SOC, V106, P1569, DOI 10.1002/cncr.21776; Thomas DA, 1999, J CLIN ONCOL, V17, P2461, DOI 10.1200/JCO.1999.17.8.2461; Todeschini G, 2012, AM J HEMATOL, V87, P22, DOI 10.1002/ajh.22189; Wasterlid T, 2013, ANN ONCOL, V24, P1879, DOI 10.1093/annonc/mdt058	31	117	122	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2016	387	10036					2402	2411		10.1016/S0140-6736(15)01317-3	http://dx.doi.org/10.1016/S0140-6736(15)01317-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO1ST	27080498				2023-01-03	WOS:000377560100033
J	Cardona, AF; Rojas, L; Wills, B; Arrieta, O; Carranza, H; Vargas, C; Otero, J; Cuello, M; Corrales, L; Martin, C; Ortiz, C; Franco, S; Rosell, R				Felipe Cardona, Andres; Rojas, Leonardo; Wills, Beatriz; Arrieta, Oscar; Carranza, Hernan; Vargas, Carlos; Otero, Jorge; Cuello, Mauricio; Corrales, Luis; Martin, Claudio; Ortiz, Carlos; Franco, Sandra; Rosell, Rafael		CLICaP	Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression	PLOS ONE			English	Article							RANDOMIZED PHASE-III; PEMETREXED PLUS CARBOPLATIN; OPEN-LABEL; 1ST-LINE TREATMENT; CHEMOTHERAPY; BEVACIZUMAB; CISPLATIN; PACLITAXEL; GEMCITABINE; SURVIVAL	Objective To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Methods A cohort of 144 patients were administered pemetrexed (500 mg/m(2)), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. Results One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1-32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9-10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2-32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6-12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. Conclusion Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors.	[Felipe Cardona, Andres; Wills, Beatriz; Carranza, Hernan; Vargas, Carlos; Otero, Jorge; Ortiz, Carlos; Franco, Sandra] Inst Oncol, Thorac Oncol Unit, Clin & Translat Oncol Grp, Clin Country, Bogota, Colombia; [Felipe Cardona, Andres; Rojas, Leonardo; Wills, Beatriz; Carranza, Hernan; Vargas, Carlos; Otero, Jorge] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia; [Rojas, Leonardo] Hosp Univ San Ignacio, Dept Clin Oncol, Ctr Javeriano Oncol, Bogota, Colombia; [Arrieta, Oscar] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City, DF, Mexico; [Cuello, Mauricio] Hosp Clin UdeLAR, Dept Clin Oncol, Montevideo, Uruguay; [Corrales, Luis] Hosp San Juan Dios, Dept Clin Oncol, San Jose, Costa Rica; [Martin, Claudio] Alexander Fleming Inst, Thorac Oncol Unit, Buenos Aires, DF, Argentina; [Rosell, Rafael] Hosp Badalona Germans Trias & Pujol, Dept Oncol, Catalan Inst Oncol, Barcelona, Spain	Clinica del Country - Unidad Medica; Hospital Universitario San Ignacio; Instituto Nacional de Cancerologia (INCAN); Catalan Institute of Oncology; Hospital Germans Trias i Pujol	Cardona, AF (corresponding author), Inst Oncol, Thorac Oncol Unit, Clin & Translat Oncol Grp, Clin Country, Bogota, Colombia.; Cardona, AF (corresponding author), Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia.	andres.cardona@clinicadelcountry.com	Arrieta, Oscar/ABH-6022-2020	Arrieta, Oscar/0000-0002-1164-3779	Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant [017-2014]	Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant	This work was supported by the Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant 017-2014.	Adjei Alex A, 2003, Expert Rev Anticancer Ther, V3, P145, DOI 10.1586/14737140.3.2.145; Azzoli CG, 2011, J CLIN ONCOL, V29, P3825, DOI 10.1200/JCO.2010.34.2774; Barlesi F, 2014, ANN ONCOL, V25, P1044, DOI 10.1093/annonc/mdu098; Barlesi F, 2013, J CLIN ONCOL, V31, P3004, DOI 10.1200/JCO.2012.42.3749; Brodowicz T, 2012, ANN ONCOL, V23, P1223, DOI 10.1093/annonc/mdr381; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Cancer IARC, 2012, GLOBOCAN 2012 EST CA; Ceppi P, 2006, CANCER-AM CANCER SOC, V107, P1589, DOI 10.1002/cncr.22208; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Gandara DR, 2012, CLIN LUNG CANCER, V13, P321, DOI 10.1016/j.cllc.2012.05.004; Howlader N, 2014, CANCER-AM CANCER SOC, V120, P3771, DOI 10.1002/cncr.29059; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Liu Y, 2013, CANCER CHEMOTH PHARM, V72, P1125, DOI 10.1007/s00280-013-2299-2; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Ozasa H, 2010, CANCER SCI, V101, P161, DOI 10.1111/j.1349-7006.2009.01358.x; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Patel JD, 2013, J CLIN ONCOL, V31, P4349, DOI 10.1200/JCO.2012.47.9626; Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3; Pickl M, 2012, NEW BIOTECHNOL, V29, P651, DOI 10.1016/j.nbt.2012.03.008; Reck M, 2010, ANN ONCOL, V21, P1804, DOI 10.1093/annonc/mdq020; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rossi A, 2009, LUNG CANCER, V66, P141, DOI 10.1016/j.lungcan.2009.06.006; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Scrump DC DK CR, 2011, CANC PRINCIPLES PRAC; Sun JM, 2015, J CLIN ONCOL, V33, P2450, DOI 10.1200/JCO.2014.59.9324; Wang L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-205; Wen S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1524-2; Wu MF, 2010, J THORAC ONCOL, V5, P1143, DOI 10.1097/JTO.0b013e3181e0b954; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yang TY, 2013, MOL CARCINOGEN, V52, P183, DOI 10.1002/mc.21842; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zinner RG, 2015, J THORAC ONCOL, V10, P134, DOI 10.1097/JTO.0000000000000366	38	8	8	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2016	11	5							e0154293	10.1371/journal.pone.0154293	http://dx.doi.org/10.1371/journal.pone.0154293			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3ZU	27191954	Green Submitted, Green Published, gold			2023-01-03	WOS:000376286100015
J	White, S; Kuper, H; Itimu-Phiri, A; Holm, R; Biran, A				White, Sian; Kuper, Hannah; Itimu-Phiri, Ambumulire; Holm, Rochelle; Biran, Adam			A Qualitative Study of Barriers to Accessing Water, Sanitation and Hygiene for Disabled People in Malawi	PLOS ONE			English	Article							DISABILITIES; ISSUES	Globally, millions of people lack access to improved water, sanitation and hygiene (WASH). Disabled people, disadvantaged both physically and socially, are likely to be among those facing the greatest inequities in WASH access. This study explores the WASH priorities of disabled people and uses the social model of disability and the World Health Organization's International Classification of Functioning, Disability and Health (ICF) framework to look at the relationships between impairments, contextual factors and barriers to WASH access. 36 disabled people and 15 carers from urban and rural Malawi were purposively selected through key informants. The study employed a range of qualitative methods including interviews, emotion mapping, free-listing of priorities, ranking, photo voice, observation and WASH demonstrations. A thematic analysis was conducted using nVivo 10. WASH access affected all participants and comprised almost a third of the challenges of daily living identified by disabled people. Participants reported 50 barriers which related to water and sanitation access, personal and hand hygiene, social attitudes and participation in WASH programs. No two individuals reported facing the same set of barriers. This study found that being female, being from an urban area and having limited wealth and education were likely to increase the number and intensity of the barriers faced by an individual. The social model proved useful for classifying the majority of barriers. However, this model was weaker when applied to individuals who were more seriously disabled by their body function. This study found that body function limitations such as incontinence, pain and an inability to communicate WASH needs are in and of themselves significant barriers to adequate WASH access. Understanding these access barriers is important for the WASH sector at a time when there is a global push for equitable access.	[White, Sian; Biran, Adam] Univ London London Sch Hyg & Trop Med, Dept Dis Control, Keppel St, London WC1E 7HT, England; [Kuper, Hannah] Univ London London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, Keppel St, London WC1E 7HT, England; [Itimu-Phiri, Ambumulire] Mzuzu Univ, Dept Educ & Teaching Studies, Private Bag 201,Karonga Rd, Mzuzu 2, Malawi; [Holm, Rochelle] Mzuzu Univ, Ctr Excellence Water & Sanitat, Private Bag 201,Karonga Rd, Mzuzu 2, Malawi	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	White, S (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Dis Control, Keppel St, London WC1E 7HT, England.	sian.white@lshtm.ac.uk			Australian Aid (Australian Government Department of Foreign Affairs and Trade)) through the Australian Development Research Awards Scheme under an award entitled 'Disability and its impact on safe hygiene and sanitation' [66469]; Malawian Ministry for Gender, Social Welfare and Disability; Federation of Disability Organisations in Malawi (FEDOMA)	Australian Aid (Australian Government Department of Foreign Affairs and Trade)) through the Australian Development Research Awards Scheme under an award entitled 'Disability and its impact on safe hygiene and sanitation'; Malawian Ministry for Gender, Social Welfare and Disability; Federation of Disability Organisations in Malawi (FEDOMA)	This research has been funded by Australian Aid (Australian Government Department of Foreign Affairs and Trade)) through the Australian Development Research Awards Scheme under an award entitled 'Disability and its impact on safe hygiene and sanitation' (Grant number 66469). The views expressed in this publication are those of the authors and not necessarily those of the Commonwealth of Australia. The Commonwealth of Australia accepts no responsibility for any loss, damage or injury resulting from reliance on any of the information or views contained in this publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to acknowledge the support of the Malawian Ministry for Gender, Social Welfare and Disability and the Federation of Disability Organisations in Malawi (FEDOMA) for their support throughout this research. We would like to recognise the contributions of Lizzie Shaba, Fiskani Ndhlovu Msutu, Overstone Kondowe, Juma Mkandawire and Hermes Tebulo who assisted with data collection and transcription. Lisa Danquah, Hazel Jones and Maria Zuurmond shared their existing data collection tools with us and made useful contributions to the development of the tools used in this study. We would particularly like to thank the disabled participants and their carers who took time to share their personal experiences with us as part of this research. Lastly we would like to thank Brian Reed and an anonymous reviewer for their comments which improved the overall strength of this paper.	Altman B. M., ANN EPIDEMIOLOGY, V24, P2; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Groce N, 2011, J WATER HEALTH, V9, P617, DOI 10.2166/wh.2011.198; Hayes N., 2013, DOING QUALITATIVE AN, P93; Jones H., 2002, WATER SUPPLY SANITAT; Jones H., 2005, WHY SHOULD WATER SAN; Jones H., 2003, WATER SUPPLY SANITAT; Jones H., 2014, COMPENDIUM ACCESSIBL; Jones H.E., 2005, WHY SHOULD WATER SAN; Llewellyn A, 2000, DISABIL SOC, V15, P157, DOI 10.1080/09687590025829; MacLeod M, 2014, J WATER HEALTH, V12, P885, DOI 10.2166/wh.2014.009; Moe Christine L., 2006, Journal of Water and Health, V4, P41; Norman W. R., 2010, WATER SANITATION DIS; OHCHR, 2011, HUM RIGHTS OLD PERS; Rheingans R, 2006, Glob Public Health, V1, P31, DOI 10.1080/17441690500443139; Rheingans R, 2014, TROP MED INT HEALTH, V19, P2, DOI 10.1111/tmi.12220; SDJS-UN, 2015, 2030 AG SUST DEV; Shakespeare T., 2013, DISABILITY STUDIES R; Sloper P., 2007, PRIORITIES PERCEPTIO; Tesfu M., 2006, WATER SANITATION ACC; UPIAS, 1975, FUND PRINC DIS; Washington Group on Disability Statistics, 2010, REC SHORT SET QUEST; WEDC, 2012, ACC AUD WAT SAN FAC; White S., 2015, PHOTOGRAPHING UNSPOK; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WHO/UNICEF JMP, 2012, JMP WORK GROUP EQ NO; Wilbur J, 2014, FRONTIERS CLTS ISSUE; World Health Organization (WHO), 2002, COMMON LANGUAGE FUNC	28	45	45	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0155043	10.1371/journal.pone.0155043	http://dx.doi.org/10.1371/journal.pone.0155043			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171520	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000376588600006
J	Wyer, P				Wyer, Peter			Review: Mechanical and manual CPR do not differ for survival or neurologic outcome in out-of-hospital cardiac arrest	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Wyer, Peter] Columbia Univ, Med Ctr, New York, NY USA	Columbia University	Wyer, P (corresponding author), Columbia Univ, Med Ctr, New York, NY USA.							Bobrow BJ, 2009, ANN EMERG MED, V54, P656, DOI 10.1016/j.annemergmed.2009.06.011; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; Lewis RJ, 2006, JAMA-J AM MED ASSOC, V295, P2661, DOI 10.1001/jama.295.22.2661; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729	4	0	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2016	164	8					JC46	JC46		10.7326/ACPJC-2016-164-8-046	http://dx.doi.org/10.7326/ACPJC-2016-164-8-046			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ5OH	27089096				2023-01-03	WOS:000374257900008
J	Little, A; Elliott, B; Conneller, C; Pomstra, D; Evans, AA; Fitton, LC; Holland, A; Davis, R; Kershaw, R; O'Connor, S; O'Connor, T; Sparrow, T; Wilson, AS; Jordan, P; Collins, MJ; Colonese, AC; Craig, OE; Knight, R; Lucquin, AJA; Taylor, B; Milner, N				Little, Aimee; Elliott, Benjamin; Conneller, Chantal; Pomstra, Diederik; Evans, Adrian A.; Fitton, Laura C.; Holland, Andrew; Davis, Robert; Kershaw, Rachel; O'Connor, Sonia; O'Connor, Terry; Sparrow, Thomas; Wilson, Andrew S.; Jordan, Peter; Collins, Matthew J.; Colonese, Andre Carlo; Craig, Oliver E.; Knight, Rebecca; Lucquin, Alexandre J. A.; Taylor, Barry; Milner, Nicky			Technological Analysis of the World's Earliest Shamanic Costume: A Multi-Scalar, Experimental Study of a Red Deer Headdress from the Early Holocene Site of Star Carr, North Yorkshire, UK	PLOS ONE			English	Article							PRODUCTS; POTTERY; BURIAL	Shamanic belief systems represent the first form of religious practice visible within the global archaeological record. Here we report on the earliest known evidence of shamanic costume: modified red deer crania headdresses from the Early Holocene site of Star Carr (c. 11 kya). More than 90% of the examples from prehistoric Europe come from this one site, establishing it as a place of outstanding shamanistic/cosmological significance. Our work, involving a programme of experimental replication, analysis of macroscopic traces, organic residue analysis and 3D image acquisition, metrology and visualisation, represents the first attempt to understand the manufacturing processes used to create these artefacts. The results produced were unexpected-rather than being carefully crafted objects, elements of their production can only be described as expedient.	[Little, Aimee; Elliott, Benjamin; Fitton, Laura C.; Davis, Robert; O'Connor, Terry; Collins, Matthew J.; Colonese, Andre Carlo; Craig, Oliver E.; Knight, Rebecca; Lucquin, Alexandre J. A.] Univ York, Dept Archaeol, BioArCh, York YO10 5DD, N Yorkshire, England; [Conneller, Chantal] Univ Manchester, Sch Arts Languages & Cultures, Manchester, Lancs, England; [Pomstra, Diederik] Leiden Univ, Fac Archaeol, Leiden, Netherlands; [Evans, Adrian A.; Holland, Andrew; Kershaw, Rachel; O'Connor, Sonia; Sparrow, Thomas; Wilson, Andrew S.] Univ Bradford, Sch Archaeol Sci, Bradford BD7 1DP, W Yorkshire, England; [Jordan, Peter] Univ Groningen, Arctic Ctr, Groningen, Netherlands; [Taylor, Barry] Dept Hist & Archaeol, Chester, Cheshire, England; [Fitton, Laura C.] Hull York Med Sch, York, N Yorkshire, England	University of York - UK; University of Manchester; Leiden University; Leiden University - Excl LUMC; University of Bradford; University of Groningen; University of Hull; University of York - UK	Little, A (corresponding author), Univ York, Dept Archaeol, BioArCh, York YO10 5DD, N Yorkshire, England.	aimee.little@york.ac.uk	Colonese, Andre Carlo/AAA-9266-2020; Jordan, Peter/HDO-4721-2022; Evans, Adrian/ABE-2632-2020; Lucquin, Alexandre/K-9045-2017	Colonese, Andre Carlo/0000-0002-0279-6634; Jordan, Peter/0000-0002-2837-3920; Evans, Adrian/0000-0003-3612-7372; wilson, andrew/0000-0003-1346-937X; Holland, Andrew/0000-0003-0554-822X; Elliott, Benjamin/0000-0002-2456-1983; Lucquin, Alexandre/0000-0003-4892-6323	European Research Council [283938]; English Heritage [6793, 6796]; Arts and Humanities Research Council [AH/L00688X/1]; Vale of Pickering Research Trust; AHRC [AH/K006169/1, AH/J007935/1, AH/L00688X/1] Funding Source: UKRI; Arts and Humanities Research Council [AH/K006169/1, AH/J007935/1] Funding Source: researchfish	European Research Council(European Research Council (ERC)European Commission); English Heritage; Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); Vale of Pickering Research Trust; AHRC(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC))	European Research Council funded the POSTGLACIAL Project, No. 283938. NM received the funding. English Heritage funded part of this research, grant numbers 6793 and 6796. NM received the funding. The funders supported the excavation of the site of Star Carr which led to the discovery of the headdress, its analysis, and the preparation of this manuscript. The Arts and Humanities Research Council funded the 'Fragmented Heritage' Research Project (AH/L00688X/1), under which aspects of the acquisition and metrology of 3D data presented by this research took place. ASW and AAE received this funding.; We thank the landowners, English Heritage and Natural England for allowing excavations on the site and the support from the Vale of Pickering Research Trust. Further thanks to the British Deer Society for providing the deer skull. This manuscript benefited from the anonymous reviewers' comments, to who we are grateful.	Bevan L, 2003, PEOPLING MESOLITHIC, V1157, P35; Chatterton R., 2003, PEOPLING MESOLITHIC, P69; Clark G., 1954, EXCAVATIONS STAR CAR; Conneller, 2011, ARCHAEOLOGY MAT SUBS; Conneller C., 2004, ARCHAEOL DIALOG, V11, P37, DOI DOI 10.1017/S1380203804001357; Conneller C, 2003, P PREHIST SOC, V65, P85; Craig OE, 2007, ARCHAEOMETRY, V49, P135, DOI 10.1111/j.1475-4754.2007.00292.x; Craig OE, 2012, RAPID COMMUN MASS SP, V26, P2359, DOI 10.1002/rcm.6349; Driscoll-Engelstad B, 2005, ARCTIC ANTHROPOL, V42, P33, DOI 10.1353/arc.2011.0010; Du Bois C., 1936, AM ARCHAEOLOGY ETHNO, V36, P1; Elliott B., 2010, P PREHIST SOC, V76, P75, DOI DOI 10.1017/S0079497X00000451; Gifford E., 1936, AM ARCHAEOLOGY ETHNO, V36, P247; Grant J., 2008, ARCHAEOLOGY COURSEBO; Grosman L, 2008, P NATL ACAD SCI USA, V105, P17665, DOI 10.1073/pnas.0806030105; Hansel FA, 2004, TETRAHEDRON LETT, V45, P2999, DOI 10.1016/j.tetlet.2004.01.111; Heyne FG, 1999, ASIAN FOLKLORE STUD, V58, P377, DOI 10.2307/1179101; Jordan P., 2003, MAT CULTURE SACRED L; Lane P, 2004, HUNTER GATHERERS HIS; Lawson John, 1967, NEW VOYAGE CAROLINA; Milo RG, 1998, J ARCHAEOL SCI, V25, P99, DOI 10.1006/jasc.1997.0233; Moyne de Morgues L., 1875, NARRATIVE LE MOYNE A; Oliva M., 2005, PALAEOLITHIC MESOLIT, P11; PENTIKAINEN Juha, 1996, SHAMANISM NO ECOLOGY; Pernet H., 2006, RITUAL MASKS DECEPTI; Porr M, 2006, INT J OSTEOARCHAEOL, V16, P395, DOI 10.1002/oa.839; Regert M, 2003, MEAS SCI TECHNOL, V14, P1620, DOI 10.1088/0957-0233/14/9/313; Schmidt Robert, 2000, ARCHAEOLOGIES SEXUAL, P220; Smart Ninian, 1989, WORLDS RELIG OLD TRA; Strachey W., 1953, HIST TRAVEL VIRINGIA; Vitebsky P, 2005, REINDEER PEOPLE LIVI; Vitebsky P., 2006, REINDEER PEOPLE LIVI; Wetmore R., 1975, 1 LAND N CAROLINA IN; Zvelebil M., 1993, ARCHAEOLOGICAL REV C, V12, P51	33	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2016	11	4							e0152136	10.1371/journal.pone.0152136	http://dx.doi.org/10.1371/journal.pone.0152136			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	DJ3UC	27073850	Green Published, Green Accepted, gold			2023-01-03	WOS:000374131200016
J	Herout, S; Mandorfer, M; Breitenecker, F; Reiberger, T; Grabmeier-Pfistershammer, K; Rieger, A; Aichelburg, MC				Herout, Sandra; Mandorfer, Mattias; Breitenecker, Florian; Reiberger, Thomas; Grabmeier-Pfistershammer, Katharina; Rieger, Armin; Aichelburg, Maximilian C.			Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria	PLOS ONE			English	Article							TRANSMISSION; DNA	Background It is unclear whether antiretroviral therapy (ART) should be initiated during acute HIV infection. Most recent data provides evidence of benefits of early ART. Methods We retrospectively compared the clinical and immunological course of individuals with acute HIV infection, who received ART within 3 months (group A) or not (group B) after diagnosis. Results Among the 84 individuals with acute HIV infection, 57 (68%) received ART within 3 months (A) whereas 27 (32%) did not receive ART within 3 months (B), respectively. Clinical progression to CDC stadium B or C within 5 years after the diagnosis of HIV was less common in (A) when compared to (B) (P = 0.002). After twelve months, both the mean increase in CD4+ T cell count and the mean decrease in viral load was more pronounced in (A), when compared to (B) (225 vs. 87 cells/mu l; P = 0.002 and -4.19 vs. -1.14 log10 copies/mL; P<0.001). Twenty-four months after diagnosis the mean increase from baseline of CD4+ T cells was still higher in group A compared to group B (251 vs. 67 cells/mu l, P = 0.004). Conclusions Initiation of ART during acute HIV infection is associated with a lower probability of clinical progression to more advanced CDC stages and significant immunological benefits.	[Herout, Sandra; Breitenecker, Florian; Grabmeier-Pfistershammer, Katharina; Rieger, Armin; Aichelburg, Maximilian C.] Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis DIAID, Vienna, Austria; [Mandorfer, Mattias; Reiberger, Thomas] Med Univ Vienna, Vienna HIV & Liver Study Grp, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Aichelburg, MC (corresponding author), Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis DIAID, Vienna, Austria.	maximilian.aichelburg@meduniwien.ac.at	Mandorfer, Mattias/H-7603-2019; Reiberger, Thomas/H-7613-2019	Mandorfer, Mattias/0000-0003-2330-0017; Reiberger, Thomas/0000-0002-4590-3583; Grabmeier-Pfistershammer, Katharina/0000-0003-0665-5414; Osorio, Sandra/0000-0002-6651-3197				[Anonymous], 2015, GUID CLIN MAN TREATM, P7; Austrian HIV Cohort Study (AHIVCOS), 2014, 26 AHIVCOS STUDIA UN; Braun DL, 2015, CLIN INFECT DIS, V61, P1013, DOI 10.1093/cid/civ398; Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088; Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001; Casari S, 2012, J Prev Med Hyg, V53, P190; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; de Luna J.R.G., 2014, J AIDS HIV RES, V5, P285; Delwart E, 2002, AIDS, V16, P189, DOI 10.1097/00002030-200201250-00007; Fidler S, 2013, NEW ENGL J MED, V368, P207, DOI 10.1056/NEJMoa1110039; Gianella S, 2011, ANTIVIR THER, V16, P535, DOI 10.3851/IMP1776; Grijsen ML, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001196; Hogan CM, 2012, J INFECT DIS, V205, P87, DOI 10.1093/infdis/jir699; Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311; Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; Mocroft A, 2000, J ACQ IMMUN DEF SYND, V24, P475, DOI 10.1097/00126334-200008150-00013; Ngo-Giang-Huong N, 2001, AIDS, V15, P665, DOI 10.1097/00002030-200104130-00001; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI [10.1172/JCI200421540, 10.1172/JCI21540]; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777; von Wyl V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027463; Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006	27	25	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2016	11	4							e0152910	10.1371/journal.pone.0152910	http://dx.doi.org/10.1371/journal.pone.0152910			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ0KH	27065239	gold, Green Submitted, Green Published			2023-01-03	WOS:000373891000024
J	Infante, J; Rosalen, PL; Lazarini, JG; Franchin, M; de Alencar, SM				Infante, Juliana; Rosalen, Pedro Luiz; Lazarini, Josy Goldoni; Franchin, Marcelo; de Alencar, Severino Matias			Antioxidant and Anti-Inflammatory Activities of Unexplored Brazilian Native Fruits	PLOS ONE			English	Article							NEUTROPHILS; CAPACITIES	Brazilian native fruits are unmatched in their variety, but a poorly explored resource for the development of food and pharmaceutical products. The aim of this study was to evaluate the phenolic composition as well as the antioxidant and anti-inflammatory activities of the extracts of leaves, seeds, and pulp of four Brazilian native fruits (Eugenia leitonii, Eugenia involucrata, Eugenia brasiliensis, and Eugenia myrcianthes). GC-MS analyses of the ethanolic extracts showed the presence of epicatechin and gallic acid as the major compounds in these fruits. Antioxidant activity was measured using synthetic DPPH free-radical scavenging, beta-carotene bleaching assay, and reactive oxygen species (ROO center dot, O-2 center dot(-), and HOCl). The fruit extracts also exhibited antioxidant effect against biologically relevant radicals such as peroxyl, superoxide, and hypochlorous acid. In general, the pulps were the fruit fractions that exhibited the lowest antioxidant activities, whereas the leaves showed the highest ones. The anti-inflammatory activity was assessed in an in vivo model using the carrageenan-induced neutrophil migration assay, which evaluates the inflammatory response in the acute phase. The pulp, seeds, and leaves of these fruits reduced the neutrophil influx by 40% to 64%. Based on these results, we suggest that the anti-inflammatory activity of these native fruits is related to the modulation of neutrophil migration, through the inhibition of cytokines, chemokines, and adhesion molecules, as well as to the antioxidant action of their ethanolic extracts in scavenging the free-radicals released by neutrophils. Therefore, these native fruits can be useful to produce food additives and functional foods.	[Infante, Juliana; de Alencar, Severino Matias] Univ Sao Paulo, Dept Agrifood Ind Food & Nutr, Luiz de Queiroz Coll Agr, Padua Dias Ave,POB 9, BR-13418900 Piracicaba, SP, Brazil; [Rosalen, Pedro Luiz; Lazarini, Josy Goldoni; Franchin, Marcelo] Univ Estadual Campinas, Dept Physiol Sci, Piracicaba Dent Sch, 901 Limeira Ave, BR-13414903 Piracicaba, SP, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas	de Alencar, SM (corresponding author), Univ Sao Paulo, Dept Agrifood Ind Food & Nutr, Luiz de Queiroz Coll Agr, Padua Dias Ave,POB 9, BR-13418900 Piracicaba, SP, Brazil.	smalencar@usp.br	Rosalen, Pedro Luiz/I-3718-2012; Alencar, Severino Matias/B-7743-2012; Franchin, Marcelo/M-7636-2017; Lazarini, Josy Goldoni/L-3477-2016	Rosalen, Pedro Luiz/0000-0003-0812-4027; Alencar, Severino Matias/0000-0002-6637-7973; Franchin, Marcelo/0000-0001-5613-2756; Lazarini, Josy Goldoni/0000-0002-3498-8243	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2013/13190-2, 2014/50235-7]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Grant number: 2013/13190-2 - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - JI; and Grant number: 2014/50235-7 - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - SMA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argyropoulou A, 2013, NAT PROD REP, V30, P1412, DOI 10.1039/c3np70031c; Delfanian M, 2015, FOOD SCI NUTR, V3, P613, DOI [10.1002/fsn3.320, 10.1002/fsn3.201]; Denny C, 2014, J FUNCT FOODS, V8, P292, DOI 10.1016/j.jff.2014.03.016; Edreva A, 2005, AGR ECOSYST ENVIRON, V106, P119, DOI 10.1016/j.agee.2004.10.022; Emmons CL, 1999, J AGR FOOD CHEM, V47, P4894, DOI 10.1021/jf990530i; Folmer F, 2014, PHYTOCHEM REV, V13, P295, DOI 10.1007/s11101-013-9319-z; Food and Agriculture Organization of the United Nations, 2009, FEED WORLD 2050 HIGH; Fraga CG, 2011, FREE RADICAL BIO MED, V51, P813, DOI 10.1016/j.freeradbiomed.2011.06.002; Rodriguez-Roque MJ, 2016, FOOD FUNCT, V7, P380, DOI [10.1039/C5FO01060H, 10.1039/c5fo01060h]; JOLY C.A., 2011, REV USP, V89, P114; Locatelli C, 2013, EUR J MED CHEM, V60, P233, DOI 10.1016/j.ejmech.2012.10.056; Ma MM, 2015, INFLAMMATION, V38, P1669, DOI 10.1007/s10753-015-0144-y; Marinovic MP, 2015, TOXICOL IN VITRO, V29, P1766, DOI 10.1016/j.tiv.2015.07.014; Massarioli AP, 2013, J FOOD AGRIC ENVIRON, V11, P288; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Melo PS, 2015, FOOD CHEM, V181, P160, DOI 10.1016/j.foodchem.2015.02.087; Nemeth T, 2012, IMMUNOL LETT, V143, P9, DOI 10.1016/j.imlet.2012.01.013; Oldoni TLC, 2011, SEP PURIF TECHNOL, V77, P208, DOI 10.1016/j.seppur.2010.12.007; Patthamakanokporn O, 2008, J FOOD COMPOS ANAL, V21, P241, DOI 10.1016/j.jfca.2007.10.002; Sadik CD, 2012, J LEUKOCYTE BIOL, V91, P207, DOI 10.1189/jlb.0811402; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Tiveron AP, 2012, INT J MOL SCI, V13, P8943, DOI 10.3390/ijms13078943; Wang SY, 2011, INT J FOOD SCI TECH, V46, P2482, DOI 10.1111/j.1365-2621.2011.02771.x; Wang SY, 2000, J AGR FOOD CHEM, V48, P140, DOI 10.1021/jf9908345; Wong SH, 2004, ARCH IMMUNOL THER EX, V52, P379; Wu XL, 2004, J AGR FOOD CHEM, V52, P4026, DOI 10.1021/jf049696w	26	52	54	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2016	11	4							e0152974	10.1371/journal.pone.0152974	http://dx.doi.org/10.1371/journal.pone.0152974			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6IX	27050817	Green Published, Green Submitted, gold			2023-01-03	WOS:000373603500074
J	Xu, R; Zhang, GD; Mai, JH; Deng, XY; Segura-Ibarra, V; Wu, SH; Shen, JL; Liu, HR; Hu, ZH; Chen, LX; Huang, Y; Koay, E; Huang, Y; Liu, J; Ensor, JE; Blanco, E; Liu, XW; Ferrari, M; Shen, HF				Xu, Rong; Zhang, Guodong; Mai, Junhua; Deng, Xiaoyong; Segura-Ibarra, Victor; Wu, Suhong; Shen, Jianliang; Liu, Haoran; Hu, Zhenhua; Chen, Lingxiao; Huang, Yi; Koay, Eugene; Huang, Yu; Liu, Jun; Ensor, Joe E.; Blanco, Elvin; Liu, Xuewu; Ferrari, Mauro; Shen, Haifa			An injectable nanoparticle generator enhances delivery of cancer therapeutics	NATURE BIOTECHNOLOGY			English	Article							PEGYLATED LIPOSOMAL DOXORUBICIN; BREAST-CANCER; MULTIDRUG-RESISTANCE; METASTASIS; PH; VASCULATURE; PARTICLES; THERAPY; DESIGN; FUSION	The efficacy of cancer drugs is often limited because only a small fraction of the administered dose accumulates in tumors. Here we report an injectable nanoparticle generator (iNPG) that overcomes multiple biological barriers to cancer drug delivery. The iNPG is a discoidal micrometer-sized particle that can be loaded with chemotherapeutics. We conjugate doxorubicin to poly(l-glutamic acid) by means of a pH-sensitive cleavable linker, and load the polymeric drug (pDox) into iNPG to assemble iNPG-pDox. Once released from iNPG, pDox spontaneously forms nanometer-sized particles in aqueous solution. Intravenously injected iNPG-pDox accumulates at tumors due to natural tropism and enhanced vascular dynamics and releases pDox nanoparticles that are internalized by tumor cells. Intracellularly, pDox nanoparticles are transported to the perinuclear region and cleaved into Dox, thereby avoiding excretion by drug efflux pumps. Compared to its individual components or current therapeutic formulations, iNPG-pDox shows enhanced efficacy in MDA-MB-231 and 4T1 mouse models of metastatic breast cancer, including functional cures in 40-50% of treated mice.	[Xu, Rong; Zhang, Guodong; Mai, Junhua; Deng, Xiaoyong; Segura-Ibarra, Victor; Wu, Suhong; Shen, Jianliang; Liu, Haoran; Hu, Zhenhua; Chen, Lingxiao; Huang, Yi; Koay, Eugene; Huang, Yu; Blanco, Elvin; Liu, Xuewu; Ferrari, Mauro; Shen, Haifa] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA; [Xu, Rong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pharmacol, Wuhan 430074, Peoples R China; [Koay, Eugene] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA; [Liu, Jun] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Ensor, Joe E.] Houston Methodist Canc Ctr, Houston, TX USA; [Ferrari, Mauro] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Shen, Haifa] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA; [Deng, Xiaoyong] Shanghai Univ, Inst Nanochem & Nanobiol, Shanghai, Peoples R China; [Huang, Yu] Univ S Dakota, Dept Biomed Engn, Sioux Falls, SD USA	The Methodist Hospital System; The Methodist Hospital - Houston; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; Cornell University; Shanghai University; University of South Dakota	Ferrari, M; Shen, HF (corresponding author), Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA.; Ferrari, M (corresponding author), Weill Cornell Med Coll, Dept Med, New York, NY USA.; Shen, HF (corresponding author), Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA.	mferrari@HoustonMethodist.org; hshen@HoustonMethodist.org	Segura, Victor/AAS-5236-2021; Deng, Xiaoyong/A-5682-2012; Liu, Haoran/L-2057-2019	Deng, Xiaoyong/0000-0001-6967-7050; Ensor, Joe/0000-0003-3533-4388; Mai, Junhua/0000-0001-8374-4352	Department of Defense grants [W81XWH-09-1-0212, W81XWH-12-1-0414]; National Institute of Health grants NIH [U54CA143837, U54CA151668, 1R01CA193880-01A1]; Welch Foundation grant [AU-1714]; National Natural Science Foundation of China [81301314]; NATIONAL CANCER INSTITUTE [R01CA193880, U54CA143837, U54CA151668] Funding Source: NIH RePORTER	Department of Defense grants(United States Department of Defense); National Institute of Health grants NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation grant(The Welch Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	M.F. is grateful for the Ernest Cockrell Jr. Distinguished Endowed Chair in the Department of Nanomedicine at the Houston Methodist Research Institute. The authors acknowledge financial support from Department of Defense grants W81XWH-09-1-0212 and W81XWH-12-1-0414, National Institute of Health grants NIH U54CA143837, U54CA151668 (M.F.) and 1R01CA193880-01A1 (H.S.), Welch Foundation grant AU-1714 (J.L.), and National Natural Science Foundation of China 81301314 (R.X.). The authors thank the Nanofabrication Core of the Houston Methodist Research Institute for porous silicon microparticle fabrication and surface chemical modification. We acknowledge J. Gu for AFM analysis, D. Kirui for intravital microscopy, and H.H. Hoang for manuscript proofreading and editing.	Alhareth K, 2012, J CHROMATOGR B, V887, P128, DOI 10.1016/j.jchromb.2012.01.025; Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Decuzzi P, 2010, J CONTROL RELEASE, V141, P320, DOI 10.1016/j.jconrel.2009.10.014; Decuzzi P, 2009, PHARM RES-DORD, V26, P235, DOI 10.1007/s11095-008-9697-x; Demaurex N, 2002, NEWS PHYSIOL SCI, V17, P1; Ferrari M, 2010, TRENDS BIOTECHNOL, V28, P181, DOI 10.1016/j.tibtech.2009.12.007; Fojo T, 2007, ANN ONCOL, V18, pV3, DOI 10.1093/annonc/mdm172; Godin B, 2012, ADV FUNCT MATER, V22, P4225, DOI 10.1002/adfm.201200869; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Lesniak A, 2013, J AM CHEM SOC, V135, P1438, DOI 10.1021/ja309812z; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lien MY, 2014, ANTICANCER RES, V34, P7319; Lu X, 2009, P NATL ACAD SCI USA, V106, P9385, DOI 10.1073/pnas.0900108106; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Maeda H, 2015, ADV DRUG DELIVER REV, V91, P3, DOI 10.1016/j.addr.2015.01.002; McConnell KI, 2014, J CONTROL RELEASE, V194, P113, DOI 10.1016/j.jconrel.2014.08.020; Michor F, 2011, NAT REV CANCER, V11, P657, DOI 10.1038/nrc3092; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moghimi SM, 1998, ADV DRUG DELIVER REV, V32, P45, DOI 10.1016/S0169-409X(97)00131-2; Padilla-Parra S, 2012, P NATL ACAD SCI USA, V109, P17627, DOI 10.1073/pnas.1211714109; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Shen HF, 2012, ADV HEALTHC MATER, V1, P84, DOI 10.1002/adhm.201100005; Tasciotti E, 2008, NAT NANOTECHNOL, V3, P151, DOI 10.1038/nnano.2008.34; van de Ven AL, 2012, J CONTROL RELEASE, V158, P148, DOI 10.1016/j.jconrel.2011.10.021; Verma S, 2008, CANCER TREAT REV, V34, P391, DOI 10.1016/j.ctrv.2008.01.008; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919	30	214	217	11	438	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2016	34	4					414	+		10.1038/nbt.3506	http://dx.doi.org/10.1038/nbt.3506			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	DI6NL	26974511	Green Accepted			2023-01-03	WOS:000373616100022
J	Gonzalez, PN; Gasperowicz, M; Barbeito-Andres, J; Klenin, N; Cross, JC; Hallgrimsson, B				Gonzalez, Paula N.; Gasperowicz, Malgorzata; Barbeito-Andres, Jimena; Klenin, Natasha; Cross, James C.; Hallgrimsson, Benedikt			Chronic Protein Restriction in Mice Impacts Placental Function and Maternal Body Weight before Fetal Growth	PLOS ONE			English	Article							RESOURCE-ALLOCATION; FOOD RESTRICTION; GESTATIONAL-AGE; GENE-EXPRESSION; SKULL; PHENOTYPE; NUTRITION; PREGNANCY; MODEL; RATS	Mechanisms of resource allocation are essential for maternal and fetal survival, particularly when the availability of nutrients is limited. We investigated the responses of feto-placental development to maternal chronic protein malnutrition to test the hypothesis that maternal low protein diet produces differential growth restriction of placental and fetal tissues, and adaptive changes in the placenta that may mitigate impacts on fetal growth. C57BL/6J female mice were fed either a low-protein diet (6% protein) or control isocaloric diet (20% protein). On embryonic days E10.5, 17.5 and 18.5 tissue samples were prepared for morphometric, histological and quantitative RT-PCR analyses, which included markers of trophoblast cell subtypes. Potential endocrine adaptations were assessed by the expression of Prolactin-related hormone genes. In the low protein group, placenta weight was significantly lower at E10.5, followed by reduction of maternal weight at E17.5, while the fetuses became significantly lighter no earlier than at E18.5. Fetal head at E18.5 in the low protein group, though smaller than controls, was larger than expected for body size. The relative size and shape of the cranial vault and the flexion of the cranial base was affected by E17.5 and more severely by E18.5. The junctional zone, a placenta layer rich in endocrine and energy storing glycogen cells, was smaller in low protein placentas as well as the expression of Pcdh12, a marker of glycogen trophoblast cells. Placental hormone gene Prl3a1 was altered in response to low protein diet: expression was elevated at E17.5 when fetuses were still growing normally, but dropped sharply by E18.5 in parallel with the slowing of fetal growth. This model suggests that nutrients are preferentially allocated to sustain fetal and brain growth and suggests the placenta as a nutrient sensor in early gestation with a role in mitigating impacts of poor maternal nutrition on fetal growth.	[Gonzalez, Paula N.; Barbeito-Andres, Jimena] CCT CONICET, Inst Genet Vet, La Plata, Buenos Aires, Argentina; [Gonzalez, Paula N.; Barbeito-Andres, Jimena] UNLP, Ciencias Nat & Museo, La Plata, Buenos Aires, Argentina; [Gasperowicz, Malgorzata; Cross, James C.] Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada; [Gasperowicz, Malgorzata; Cross, James C.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Klenin, Natasha; Cross, James C.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Hallgrimsson, Benedikt] Univ Calgary, Dept Cell Biol & Anat, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Hallgrimsson, Benedikt] Univ Calgary, McCaig Inst Bone & Joint Health, Calgary, AB, Canada	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; Museo La Plata; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Cross, JC (corresponding author), Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada.; Cross, JC (corresponding author), Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada.; Cross, JC (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.; Hallgrimsson, B (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada.; Hallgrimsson, B (corresponding author), Univ Calgary, McCaig Inst Bone & Joint Health, Calgary, AB, Canada.	jcross@ucalgary.ca; bhallgri@ucalgary.ca	Hallgrimsson, Benedikt/A-9616-2008; Cross, James/F-4814-2011; Cross, James/AAU-2973-2020	Hallgrimsson, Benedikt/0000-0002-7192-9103; Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378	Canadian Institutes of Health Research [37776]; National Institute of Health [1R01DE021708, 1R01DE01963]; Natural Sciences and Engineering Research Council of Canada [238992-12]; Agencia Nacional de Promocion Cientifica y Tecnologica [PICT2014-1810]; COnsejo Nacional de Investigaciones Cientificas y Tecnicas [11220120100603]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021708] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Agencia Nacional de Promocion Cientifica y Tecnologica(ANPCyT); COnsejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the Canadian Institutes of Health Research 37776 to JC, National Institute of Health 1R01DE021708 and 1R01DE01963 to BH, Natural Sciences and Engineering Research Council of Canada 238992-12 to BH, Agencia Nacional de Promocion Cientifica y Tecnologica PICT2014-1810 to PG, COnsejo Nacional de Investigaciones Cientificas y Tecnicas 11220120100603 to PG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baisden B, 2007, PLACENTA, V28, P1082, DOI 10.1016/j.placenta.2007.04.002; Baker J, 2010, AM J HUM BIOL, V22, P206, DOI 10.1002/ajhb.20979; Barbeito-Andres J., 2016, REV ARGENTINA ANTROP, V18, P1; Barker DJP, 2011, PLACENTA HUMAN DEV P, P5; Bookstein F.L., 1997, MORPHOMETRIC TOOLS L, V2nd ed.; BRASEL JA, 1972, ARCH DIS CHILD, V47, P479, DOI 10.1136/adc.47.254.479; Burton GJ, 2012, PLACENTA, V33, pS23, DOI 10.1016/j.placenta.2011.11.013; Cahill LS, 2014, J CEREBR BLOOD F MET, V34, P1082, DOI 10.1038/jcbfm.2014.62; Chen PY, 2013, PHYSIOL GENOMICS, V45, P565, DOI 10.1152/physiolgenomics.00034.2013; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Coan PM, 2011, J PHYSIOL-LONDON, V589, P3659, DOI 10.1113/jphysiol.2011.208629; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Coan PM, 2006, DEV DYNAM, V235, P3280, DOI 10.1002/dvdy.20981; Collins SL, 2013, ULTRASOUND MED BIOL, V39, P253, DOI 10.1016/j.ultrasmedbio.2012.09.003; Cross JC, 2006, NUTR REV, V64, pS12, DOI 10.1301/nr.may.S12-S18; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Damodaram M, 2010, PLACENTA, V31, P491, DOI 10.1016/j.placenta.2010.03.001; Dilworth MR, 2011, PLACENTA, V32, P914, DOI 10.1016/j.placenta.2011.08.007; Dressino V, 1997, AM J PHYS ANTHROPOL, V102, P545, DOI 10.1002/(SICI)1096-8644(199704)102:4<545::AID-AJPA8>3.0.CO;2-Q; EDELSTONE DI, 1980, AM J PHYSIOL, V238, pH656, DOI 10.1152/ajpheart.1980.238.5.H656; Elia M, 2012, NUTRITION, V28, P477, DOI 10.1016/j.nut.2011.11.009; Fernandez-Twinn DS, 2003, BRIT J NUTR, V90, P815, DOI 10.1079/BJN2003967; Fowden AL, 2012, PLACENTA, V33, pE11, DOI 10.1016/j.placenta.2012.05.002; Fowden AL, 2009, J PHYSIOL-LONDON, V587, P3459, DOI 10.1113/jphysiol.2009.173013; Gao H, 2013, FRONT BIOSCI ELITE E, V4, P1434; Gasperowicz M, 2013, DEV BIOL, V382, P1, DOI 10.1016/j.ydbio.2013.08.005; Gheorghe CP, 2009, PLACENTA, V30, P411, DOI 10.1016/j.placenta.2009.03.002; Gonzalez PN, 2014, AM J PHYS ANTHROPOL, V154, P544, DOI 10.1002/ajpa.22545; Gonzalez PN, 2013, EVOL DEV, V15, P133, DOI 10.1111/ede.12025; Gonzalez PN, 2011, J ANAT, V218, P243, DOI 10.1111/j.1469-7580.2010.01326.x; Gonzalez PN, 2011, J EXP ZOOL PART B, V316B, P547, DOI 10.1002/jez.b.21430; Gutierrez-Marcos JF, 2012, PLACENTA, V33, pE3, DOI 10.1016/j.placenta.2012.08.006; Hallgrimsson B, 2007, EVOL DEV, V9, P76, DOI 10.1111/j.1525-142X.2006.00139.x; Hallgrimsson B, 2009, EVOL BIOL, V36, P355, DOI 10.1007/s11692-009-9076-5; Jansson N, 2006, J PHYSIOL-LONDON, V576, P935, DOI 10.1113/jphysiol.2003.550004; King JC, 2000, AM J CLIN NUTR, V71, p1218S, DOI 10.1093/ajcn/71.5.1218s; Knox K, 2011, PLACENTA, V32, P811, DOI 10.1016/j.placenta.2011.08.013; Knox K, 2008, GENOME RES, V18, P695, DOI 10.1101/gr.071407.107; KRAMER MS, 1989, PEDIATRICS, V84, P717; Lieberman DE, 2008, J ANAT, V212, P720, DOI 10.1111/j.1469-7580.2008.00900.x; Malandro MS, 1996, AM J PHYSIOL-CELL PH, V271, pC295, DOI 10.1152/ajpcell.1996.271.1.C295; Metscher BD, 2009, DEV DYNAM, V238, P632, DOI 10.1002/dvdy.21857; Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X; Morrison JL, 2008, CLIN EXP PHARMACOL P, V35, P730, DOI 10.1111/j.1440-1681.2008.04975.x; Mu JW, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477-7827-6-34; Newbern D, 2011, CURR OPIN ENDOCRINOL, V18, P409, DOI 10.1097/MED.0b013e32834c800d; Prada JA, 1998, EUR J CLIN NUTR, V52, pS21; Proctor LK, 2009, ULTRASOUND OBST GYN, V34, P274, DOI 10.1002/uog.7308; PUCCIARELLI HM, 1987, AM J PHYS ANTHROPOL, V72, P67, DOI 10.1002/ajpa.1330720109; Rawn SM, 2008, ANNU REV CELL DEV BI, V24, P159, DOI 10.1146/annurev.cellbio.24.110707.175418; Rebelato HJ, 2013, J MOL HISTOL, V44, P629, DOI 10.1007/s10735-013-9522-7; Reichling TD, 2000, J NUTR, V130, P2326, DOI 10.1093/jn/130.9.2326; Romo Agustin, 2009, Pediatr Endocrinol Rev, V6 Suppl 3, P332; Roza SJ, 2008, AM J EPIDEMIOL, V168, P1145, DOI 10.1093/aje/kwn233; Rutland CS, 2007, PLACENTA, V28, P734, DOI 10.1016/j.placenta.2006.07.001; Salam RA, 2014, CURR OPIN CLIN NUTR, V17, P249, DOI 10.1097/MCO.0000000000000051; Schell LM, 2007, AM J HUM BIOL, V19, P606, DOI 10.1002/ajhb.20669; Schonfeldt HC, 2012, BRIT J NUTR, V108, pS69, DOI 10.1017/S0007114512002553; Schulz LC, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103218; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Simmons DG, 2007, DEV BIOL, V304, P567, DOI 10.1016/j.ydbio.2007.01.009; Simmons DG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-352; Strakovsky RS, 2010, J NUTR, V140, P2116, DOI 10.3945/jn.110.127803; Thompson JMD, 2007, BJOG-INT J OBSTET GY, V114, P715, DOI 10.1111/j.1471-0528.2007.01327.x; Tunster SJ, 2010, MOL CELL BIOL, V30, P295, DOI 10.1128/MCB.00662-09; Vaughan OR, 2012, REPROD FERT DEVELOP, V24, P80, DOI 10.1071/RD11909; Wallace JM, 2013, PLACENTA, V34, P269, DOI 10.1016/j.placenta.2012.12.007; Watson ED, 2005, PHYSIOLOGY, V20, P180, DOI 10.1152/physiol.00001.2005; Wedegartner U, 2006, RADIOLOGY, V238, P872, DOI 10.1148/radiol.2383042213; Wiley DF, 2005, IEEE VISUALIZATION 2005, PROCEEDINGS, P431; Willmore KE, 2006, EVOL DEV, V8, P550, DOI 10.1111/j.1525-142X.2006.00127.x; Wong MD, 2013, PLOS ONE, V13; Wong MD, 2012, DEVELOPMENT, V139, P3248, DOI 10.1242/dev.082016; Young NM, 2007, ANAT REC, V290, P123, DOI 10.1002/ar.20415; Zelditch ML, 2004, EVOL DEV, V6, P194, DOI 10.1111/j.1525-142X.2004.04025.x	75	37	39	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2016	11	3							e0152227	10.1371/journal.pone.0152227	http://dx.doi.org/10.1371/journal.pone.0152227			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH5EH	27018791	Green Published, Green Submitted, gold			2023-01-03	WOS:000372807800033
J	Honda, H; Kobayashi, Y; Onuma, S; Shibagaki, K; Yuza, T; Hirao, K; Yamamoto, T; Tomosugi, N; Shibata, T				Honda, Hirokazu; Kobayashi, Yasuna; Onuma, Shoko; Shibagaki, Keigo; Yuza, Toshitaka; Hirao, Keiichi; Yamamoto, Toshinori; Tomosugi, Naohisa; Shibata, Takanori			Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis	PLOS ONE			English	Article							HEPCIDIN	Background We aimed to identify associations between erythroferrone (ERFE), a regulator of hepcidin 25, and biomarkers of erythropoiesis and iron metabolism. We also aimed to determine the effects of erythropoiesis-stimulating agents (ESA), continuous erythropoietin receptor activator (CERA) and darbepoetin-a (DA) on ERFE production in patients on hemodialysis (HD). Methods Blood samples were obtained from 59 patients before HD sessions on day 0 (baseline). Twenty patients who were injected with either CERA (N = 10) or DA (N = 10) at the end of the dialysis week (day 0), who had ferritin >= 100 ng/mL and/or transferrin saturation >= 20%, and hemoglobin > 9 g/dL were selected from among the 59 patients. Blood was sampled serially before HD sessions on days 3, 5, 7 from patients on DA and on the same days plus day 14 from those on CERA. Results Levels of ERFE correlated inversely with those of hepcidin 25 and ferritin, and positively with those of soluble transferrin receptor. The hepcidin 25: ERFE ratio and hepcidin 25 levels positively correlated with ferritin levels. Levels of ERFE significantly increased from day 3 of treatment with DA and CERA and decreased by days 7 and 14, respectively. Erythropoiesis-stimulating agents concomitantly decreased levels of hepcidin 25 as those of ERFE increased. Conclusion We identified a novel association between ESA and ERFE in patients on HD. Both DA and CERA increased levels of ERFE that regulated hepcidin 25 and led to iron mobilization from body stores during erythropoiesis.	[Honda, Hirokazu] Showa Univ, Koto Toyusu Hosp, Dept Med, Div Nephrol, Tokyo, Japan; [Kobayashi, Yasuna; Yamamoto, Toshinori] Showa Univ, Sch Pharm, Dept Pharmacotherapeut, Div Clin Pharm, Tokyo, Japan; [Onuma, Shoko; Shibata, Takanori] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo 142, Japan; [Shibagaki, Keigo; Yuza, Toshitaka] Shibagaki Dialysis Clin Jiyugaoka, Tokyo, Japan; [Hirao, Keiichi] Shibagaki Dialysis Clin Togoshi, Tokyo, Japan; [Tomosugi, Naohisa] Kanazawa Med Univ, Aging Res Unit, Dept Adv Med, Med Res Inst, Kanazawa, Ishikawa, Japan	Showa University; Showa University; Showa University; Kanazawa Medical University	Honda, H (corresponding author), Showa Univ, Koto Toyusu Hosp, Dept Med, Div Nephrol, Tokyo, Japan.	hondah@med.showa-u.ac.jp			Kidney Foundation, Japan [JKFB 13-18, JKFB 15-11]; Private University High Technology Research Center Project from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Ministry of Education, Culture, Sports, Science and Technology (MEXT)	Kidney Foundation, Japan(Kidney Foundation, Japan); Private University High Technology Research Center Project from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The Kidney Foundation, Japan provided funding to HH (Grant No. JKFB 13-18). This study was supported in part by Grants-in-Aid from the Private University High Technology Research Center Project's matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) The Kidney Foundation, Japan provided funding to HH (Grant No. JKFB 13-18, JKFB from the Private University High Technology Research Center Project's matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The Kidney Foundation, Japan provided funding to H.H. (Grant No. JKFB 13-18, JKFB 15-11). This study was supported in part by Grants-in-Aid from a matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) for the Private University High Technology Research Center Project.	Ciniselli CM, 2015, EXPERT REV PROTEOMIC, V12, DOI 10.1586/14789450.2015.1099436; Kakimoto-Shino M, 2014, THER APHER DIAL, V18, P421, DOI 10.1111/1744-9987.12161; Kautz L, 2014, BLOOD, V124, P479, DOI 10.1182/blood-2014-05-516252; Kautz L, 2014, NAT GENET, V46, P678, DOI 10.1038/ng.2996; Kuragano T, 2010, AM J NEPHROL, V31, P534, DOI 10.1159/000312381; Lankhorst CE, 2010, BLOOD REV, V24, P39, DOI 10.1016/j.blre.2009.09.001; Morikami Y, 2014, THER APHER DIAL, V18, P414, DOI 10.1111/1744-9987.12164; Onuma S, 2015, THER APHER DIAL, V19, P582, DOI 10.1111/1744-9987.12322; Seldin MM, 2012, J BIOL CHEM, V287, P11968, DOI 10.1074/jbc.M111.336834; Shoji S, 2013, EUR J HAEMATOL, V90, P237, DOI 10.1111/ejh.12067; Tessitore N, 2010, NEPHROL DIAL TRANSPL, V25, P3996, DOI 10.1093/ndt/gfq321; Tomosugi N, 2006, BLOOD, V108, P1381, DOI 10.1182/blood-2005-10-4043; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; van der Weerd NC, 2013, NEPHROL DIAL TRANSPL, V28, P3062, DOI 10.1093/ndt/gfs488; van der Weerd NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039783; Zumbrennen-Bullough K, 2014, NEPHROL DIAL TRANSPL, V29, P263, DOI 10.1093/ndt/gft443	16	39	42	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0151601	10.1371/journal.pone.0151601	http://dx.doi.org/10.1371/journal.pone.0151601			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1VK	26978524	Green Published, Green Submitted, gold			2023-01-03	WOS:000372572800093
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Resuscitation orders and reality	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION					davidoliver372@googlemail.com						Etheridge Z, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2640; Murray K., 2012, GUARDIAN; Resuscitation Council, 2016, CONS EM CAR TREATM P; Sokol DK, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i26; Tresch DD, 1998, EMERG MED CLIN N AM, V16, P649, DOI 10.1016/S0733-8627(05)70023-7; van Gijn MS, 2014, AGE AGEING, V43, P456, DOI 10.1093/ageing/afu035; Varney M., 2015, LEIGH DAY       0821	7	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2016	352								i1494	10.1136/bmj.i1494	http://dx.doi.org/10.1136/bmj.i1494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH1ZT	26980294	Green Published, hybrid			2023-01-03	WOS:000372584400020
J	Garguilo, M; Lejaille, M; Vaugier, I; Orlikowski, D; Terzi, N; Lofaso, F; Prigent, H				Garguilo, Marine; Lejaille, Michele; Vaugier, Isabelle; Orlikowski, David; Terzi, Nicolas; Lofaso, Frederic; Prigent, Helene			Noninvasive Mechanical Ventilation Improves Breathing-Swallowing Interaction of Ventilator Dependent Neuromuscular Patients: A Prospective Crossover Study	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; OBSTRUCTIVE PULMONARY-DISEASE; PENETRATION-ASPIRATION SCALE; SUBGLOTTIC AIR-PRESSURE; FEEDING PROBLEMS; BOLUS VOLUME; COORDINATION; RESPIRATION; TRACHEOSTOMY; DISORDERS	Background Respiratory involvement in neuromuscular disorders may contribute to impaired breathing-swallowing interactions, swallowing disorders and malnutrition. We investigated whether the use of non-invasive ventilation (NIV) controlled by the patient could improve swallowing performances in a population of neuromuscular patients requiring daytime NIV. Methods Ten neuromuscular patients with severe respiratory failure requiring extensive NIV use were studied while swallowing without and with NIV (while ventilated with a modified ventilator allowing the patient to withhold ventilation as desired). Breathing-swallowing interactions were investigated by chin electromyography, cervical piezoelectric sensor, nasal flow recording and inductive plethysmography. Two water-bolus sizes (5 and 10ml) and a textured yogurt bolus were tested in a random order. Results NIV use significantly improved swallowing fragmentation (defined as the number of respiratory interruption of the swallowing of a single bolus) (p = 0.003) and breathing-swallowing synchronization (with a significant increase of swallows followed by an expiration) (p <0.0001). Patient exhibited piecemeal swallowing which was not influenced by NIV use (p = 0.07). NIV use also significantly reduced dyspnea during swallowing (p = 0.04) while preserving swallowing comfort, regardless of bolus type. Conclusion The use of patient controlled NIV improves swallowing parameters in patients with severe neuromuscular respiratory failure requiring daytime NIV, without impairing swallowing comfort.	[Garguilo, Marine; Lejaille, Michele; Orlikowski, David; Lofaso, Frederic; Prigent, Helene] Univ Versailles St Quentin En Yvelines, UMR1179, Versailles, France; [Lejaille, Michele; Vaugier, Isabelle; Orlikowski, David] Hop Raymond Poincare, AP HP, CIC INSERM 1429, Garches, France; [Orlikowski, David] Hop Raymond Poincare, AP HP, Home Ventilat Unit, Dept Intens Care, Garches, France; [Terzi, Nicolas] CHRU Caen, Dept Intens Care, Caen, France; [Terzi, Nicolas] Univ Caen, INSERM U1075, F-14032 Caen, France; [Lofaso, Frederic; Prigent, Helene] Hop Raymond Poincare, AP HP, Dept Physiol, Garches, France	UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; CHU de Caen NORMANDIE; Universite de Caen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Prigent, H (corresponding author), Univ Versailles St Quentin En Yvelines, UMR1179, Versailles, France.; Prigent, H (corresponding author), Hop Raymond Poincare, AP HP, Dept Physiol, Garches, France.	helene.prigent@rpc.aphp.fr	orlikowski, david/R-2162-2019; TERZI, Nicolas/AAD-4348-2019; PRIGENT, HELENE/S-7445-2018; Lofaso, Frédéric/R-6100-2018	TERZI, Nicolas/0000-0003-4036-6245; 	Fondation Garches; Axa fund for research; Association d'Entraide des Polios et Handicapes (ADEP assistance, 2 Rue BenoitMalon, Suresnes, France); Association Francaise contre les Myopathies	Fondation Garches; Axa fund for research(AXA Research Fund); Association d'Entraide des Polios et Handicapes (ADEP assistance, 2 Rue BenoitMalon, Suresnes, France); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	Marine Garguilo received a PhD grant from the Fondation Garches and the Axa fund for research. The study was sponsored by the Association d'Entraide des Polios et Handicapes (ADEP assistance, 2 Rue BenoitMalon, Suresnes, France) and received funding from the Association Francaise contre les Myopathies. ResMed provided the ventilator prototype. Sponsors and funders did not have any role on study design, collection, management, analysis, and interpretation of data; writing of the report.	Cedborg AIH, 2009, EXP PHYSIOL, V94, P459, DOI 10.1113/expphysiol.2008.045724; Eibling DE, 1996, ANN OTO RHINOL LARYN, V105, P253, DOI 10.1177/000348949610500401; Ertekin C, 1998, ELECTROMYOGR MOTOR C, V109, P331, DOI 10.1016/S0924-980X(98)00027-7; Ertekin C, 2001, ARCH PHYS MED REHAB, V82, P1255, DOI 10.1053/apmr.2001.25156; Finder JD, 2004, AM J RESP CRIT CARE, V170, P456, DOI 10.1164/rccm.200307-885ST; Gross RD, 2006, LARYNGOSCOPE, V116, P753, DOI 10.1097/01.mlg.0000205168.39446.12; Gross RD, 2003, J APPL PHYSIOL, V95, P2211, DOI 10.1152/japplphysiol.00316.2003; Gross RD, 2012, DYSPHAGIA; Gross RD, 2009, AM J RESP CRIT CARE, V179, P559, DOI 10.1164/rccm.200807-1139OC; Kijima M, 1999, AM J RESP CRIT CARE, V159, P1898, DOI 10.1164/ajrccm.159.6.9811092; Klahn MS, 1999, DYSPHAGIA, V14, P131, DOI 10.1007/PL00009594; Kohler M, 2009, J NEUROL NEUROSUR PS, V80, P320, DOI 10.1136/jnnp.2007.141721; Langmore Susan E, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P485, DOI 10.1097/00020840-200312000-00014; Lanini B, 2001, CHEST, V120, P402, DOI 10.1378/chest.120.2.402; Logemann JA, 1998, HEAD NECK-J SCI SPEC, V20, P52; Martigne L, 2010, CLIN NUTR, V29, P60, DOI 10.1016/j.clnu.2009.06.009; Martin Bonnie J. W., 1993, Dysphagia, V8, P11, DOI 10.1007/BF01351472; Martin-Harris B, 2005, ARCH OTOLARYNGOL, V131, P762, DOI 10.1001/archotol.131.9.762; Messina S, 2008, NEUROMUSCULAR DISORD, V18, P389, DOI 10.1016/j.nmd.2008.02.008; Misuri G, 2000, CHEST, V117, P447, DOI 10.1378/chest.117.2.447; Mizuno T, 2012, BRAIN DEV-JPN, V34, P756, DOI 10.1016/j.braindev.2011.11.012; Nishino T, 1998, AM J RESP CRIT CARE, V157, P815, DOI 10.1164/ajrccm.157.3.9707158; Pane M, 2006, EUR J PAEDIATR NEURO, V10, P231, DOI 10.1016/j.ejpn.2006.08.008; Pellegrini N, 2004, NEUROMUSCULAR DISORD, V14, P297, DOI 10.1016/j.nmd.2004.02.005; PREIKSAITIS HG, 1992, AM J PHYSIOL, V263, pR624, DOI 10.1152/ajpregu.1992.263.3.R624; Robbins J, 1999, DYSPHAGIA, V14, P228, DOI 10.1007/PL00009610; Rosenbek JC, 1996, DYSPHAGIA, V11, P93, DOI 10.1007/BF00417897; SHAKER R, 1992, AM J PHYSIOL, V263, pG750, DOI 10.1152/ajpgi.1992.263.5.G750; Stachler RJ, 1996, LARYNGOSCOPE, V106, P231, DOI 10.1097/00005537-199602000-00024; Terzi N, 2007, AM J RESP CRIT CARE, V175, P269, DOI 10.1164/rccm.200608-1067OC; Terzi N, 2014, CRIT CARE MED, V42, P565, DOI 10.1097/CCM.0b013e3182a66b4a; Terzi N, 2010, NEUROMUSCULAR DISORD, V20, P493, DOI 10.1016/j.nmd.2010.05.009; Toussaint M, 2006, EUR RESPIR J, V28, P549, DOI 10.1183/09031936.06.00004906; WILLIG TN, 1994, ARCH PHYS MED REHAB, V75, P1175, DOI 10.1016/0003-9993(94)90001-9; WILLIG TN, 1995, SEMIN NEUROL, V15, P18, DOI 10.1055/s-2008-1041002	35	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0148673	10.1371/journal.pone.0148673	http://dx.doi.org/10.1371/journal.pone.0148673			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938617	Green Submitted, Green Published, gold			2023-01-03	WOS:000371735200009
J	Manson, JE; Kaunitz, AM				Manson, Joann E.; Kaunitz, Andrew M.			Menopause Management - Getting Clinical Care Back on Track	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HORMONE-THERAPY		[Manson, Joann E.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA; [Kaunitz, Andrew M.] Univ Florida, Coll Med, Gainesville, FL 32611 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University System of Florida; University of Florida	Manson, JE (corresponding author), Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA.		Kaunitz, Andrew/AAL-8448-2020					Gass MLS, 2015, MENOPAUSE, V22, P1276, DOI 10.1097/GME.0000000000000553; Hsieh E, 2013, J WOMENS HEALTH, V22, P667, DOI 10.1089/jwh.2013.4264; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Santen RJ, 2014, J WOMENS HEALTH, V23, P281, DOI 10.1089/jwh.2014.4746; Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015-2236	5	121	127	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	2016	374	9					803	806		10.1056/NEJMp1514242	http://dx.doi.org/10.1056/NEJMp1514242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF2FT	26962899				2023-01-03	WOS:000371158400002
J	Patel, RM; Knezevic, A; Shenvi, N; Hinkes, M; Keene, S; Roback, JD; Easley, KA; Josephson, CD				Patel, Ravi M.; Knezevic, Andrea; Shenvi, Neeta; Hinkes, Michael; Keene, Sarah; Roback, John D.; Easley, Kirk A.; Josephson, Cassandra D.			Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight Infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREMATURE-INFANTS; FEEDING PRACTICES; TRIAL; RISK; NEED	IMPORTANCE Data regarding the contribution of red blood cell (RBC) transfusion and anemia to necrotizing enterocolitis (NEC) are conflicting. These associations have not been prospectively evaluated, accounting for repeated, time-varying exposures. OBJECTIVE To determine the relationship between RBC transfusion, severe anemia, and NEC. DESIGN, SETTING, AND PARTICIPANTS In a secondary, prospective, multicenter observational cohort study from January 2010 to February 2014, very low-birth-weight (VLBW, <= 1500 g) infants, within 5 days of birth, were enrolled at 3 level III neonatal intensive care units in Atlanta, Georgia. Two hospitals were academically affiliated and lwas a community hospital. Infants received follow-up until 90 days, hospital discharge, transfer to a non-study-affiliated hospital, or death (whichever came first). Multivariable competing-risks Cox regression was used, including adjustment for birth weight, center, breastfeeding, illness severity, and duration of initial antibiotic treatment, to evaluate the association between RBC transfu on, severe anemia, and NEC. EXPOSURES The primary exposure was RBC transfusion. The secondary exposure was severe anemia, defined a priori as a hemoglobin level of 8 g/dL or less. Both exposures were evaluated as time-varying covariates at weekly intervals. MAIN OUTCOMES AND MEASURES Necrotizing enterocolitis, defined as Bell stage 2 or greater by preplanned adjudication. Mortality was evaluated as a competing risk. RESULTS Of 600 VLBW infants enrolled, 598 were evaluated. Forty-four (7.4%) infants developed NEC. Thirty-two (5.4%) infants died (all cause). Fifty-three percent of infants (319) received a total of 1430 RBC transfusion exposures. The unadjusted cumulative incidence of NEC at week 8 among RBC transfusion-exposed infants was 9.9% (95% CI, 6.9%-14.2%) vs 4.6% (95% CI, 2.6%-8.0%) among those who were unexposed. In multivariable analysis, RBC transfusion in a given week was not significantly related to the rate of NEC (adjusted cause-specific hazard ratio, 0.44 [95% CI, 0.17-1.12]; P = .09). Based on evaluation of 4565 longitudinal measurements of hemoglobin (median, 7 per infant), the rate of NEC was significantly increased among VLBW infants with severe anemia in a given week compared with those who did not have severe anemia (adjusted cause-specific hazard ratio, 5.99 [95% CI, 2.00-18.0]; P = .001). CONCLUSIONS AND RELEVANCE Among VLBW infants, severe anemia, but not RBC transfusion, was associated with an increased risk of NEC. Further studies are needed to evaluate whether preventing severe anemia is more important than minimizing RBC transfusion.	[Patel, Ravi M.; Keene, Sarah; Josephson, Cassandra D.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Patel, Ravi M.; Keene, Sarah; Josephson, Cassandra D.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Knezevic, Andrea; Shenvi, Neeta; Easley, Kirk A.] Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA USA; [Hinkes, Michael] Northside Hosp, Dept Neonatol, Atlanta, GA USA; [Roback, John D.; Josephson, Cassandra D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Roback, John D.; Josephson, Cassandra D.] Emory Univ, Sch Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322 USA	Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Rollins School Public Health; Emory University; Emory University	Patel, RM (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, 2015 Uppergate Dr NE,Third Flr, Atlanta, GA 30322 USA.	rmpatel@emory.edu	Patel, Ravi/B-7218-2011; Josephson, Cassandra/AFS-2243-2022; Easley, Kirk A/K-6910-2015	Patel, Ravi/0000-0002-7444-5550; Easley, Kirk A/0000-0003-4419-2617; Knezevic, Andrea/0000-0002-0741-2150	National Institutes of Health; National Heart, Lung, and Blood Institute [P01 HL086773]; National Center for Advancing Translational Sciences [UL1 TR000454, KL2 TR000455]; Emory Children's Center for Clinical and Translational Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454, KL2TR000455] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046925, P01HL086773] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Emory Children's Center for Clinical and Translational Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health. The National Heart, Lung, and Blood Institute provided funding for the parent study under award number P01 HL086773. The National Center for Advancing Translational Sciences provided support for this study and for Dr Patel under award numbers UL1 TR000454 and KL2 TR000455. Dr Patel reports receipt of research support from the Emory Children's Center for Clinical and Translational Research.	AlFaleh K, 2014, J Neonatal Perinatal Med, V7, P193, DOI 10.3233/NPM-14814048; Allison P.E., 2010, SURVIVAL ANAL USING, Vsecond; Bell EF, 2005, PEDIATRICS, V115, P1685, DOI 10.1542/peds.2004-1884; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Blackstone EH, 2001, J THORAC CARDIOV SUR, V122, P430, DOI 10.1067/mtc.2001.117536; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; DeRienzo C, 2014, EARLY HUM DEV, V90, P237, DOI 10.1016/j.earlhumdev.2014.02.003; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Josephson CD, 2014, JAMA PEDIATR, V168, P1054, DOI 10.1001/jamapediatrics.2014.1360; Josephson CD, 2011, TRANSFUS MED REV, V25, P125, DOI 10.1016/j.tmrv.2010.11.004; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Kirpalani H, 2012, SEMIN PERINATOL, V36, P269, DOI 10.1053/j.semperi.2012.04.007; Klein HG, 2015, JAMA-J AM MED ASSOC, V314, P1557, DOI 10.1001/jama.2015.10890; Lin PW, 2006, LANCET, V368, P1271, DOI 10.1016/S0140-6736(06)69525-1; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Patel RM, 2015, NEW ENGL J MED, V372, P331, DOI 10.1056/NEJMoa1403489; Ramani M, 2013, CLIN PERINATOL, V40, P1, DOI 10.1016/j.clp.2012.12.001; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; Sharma R, 2014, J PERINATOL, V34, P858, DOI 10.1038/jp.2014.59; Singh R, 2011, J PERINATOL, V31, P176, DOI 10.1038/jp.2010.145; Sood BG, 2016, J MATERN-FETAL NEO M, V29, P737, DOI 10.3109/14767058.2015.1016422; Strauss RG, 1997, AM J CLIN PATHOL, V107, pS57; Wallenstein MB, 2014, J PEDIATR-US, V165, P678, DOI 10.1016/j.jpeds.2014.06.012	26	156	169	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2016	315	9					889	897		10.1001/jama.2016.1204	http://dx.doi.org/10.1001/jama.2016.1204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DF1DB	26934258	Green Accepted, Bronze			2023-01-03	WOS:000371077500019
J	Stason, WB; Ritter, GA; Martin, T; Prottas, J; Tompkins, C; Shepard, DS				Stason, William B.; Ritter, Grant A.; Martin, Timothy; Prottas, Jeffrey; Tompkins, Christopher; Shepard, Donald S.			Effects of Expanded Coverage for Chiropractic Services on Medicare Costs in a CMS Demonstration	PLOS ONE			English	Article							MANIPULATIVE THERAPY; PUBLIC-HEALTH; CARE; UPDATE; PAIN	Background Moderately convincing evidence supports the benefits of chiropractic manipulations for low back pain. Its effectiveness in other applications is less well documented, and its cost-effectiveness is not known. These questions led the Centers for Medicaid and Medicare Services (CMS) to conduct a two-year demonstration of expanded Medicare coverage for chiropractic services in the treatment of beneficiaries with neuromusculoskeletal (NMS) conditions affecting the back, limbs, neck, or head. Methods The demonstration was conducted in 2005-2007 in selected counties of Illinois, Iowa, and Virginia and the entire states of Maine and New Mexico. Medicare claims were compiled for the preceding year and two demonstration years for the demonstration areas and matched comparison areas. The impact of the demonstration was analyzed through multivariate regression analysis with a difference-in-difference framework. Results Expanded coverage increased Medicare expenditures by $ 50 million or 28.5% in users of chiropractic services and by $ 114 million or 10.4% in all patients treated for NMS conditions in demonstration areas during the two-year period. Results varied widely among demonstration areas ranging from increased costs per user of $ 485 in Northern Illinois and Chicago counties to decreases in costs per user of $ 59 in New Mexico and $ 178 in Scott County, Iowa. Conclusion The demonstration did not assess possible decreases in costs to other insurers, out-of-pocket payments by patients, the need for and costs of pain medications, or longer term clinical benefits such as avoidance of orthopedic surgical procedures beyond the two-year period of the demonstration. It is possible that other payers or beneficiaries saved money during the demonstration while costs to Medicare were increased.	[Stason, William B.; Ritter, Grant A.; Martin, Timothy; Prottas, Jeffrey; Tompkins, Christopher; Shepard, Donald S.] Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, MS 035, Waltham, MA 02254 USA	Brandeis University	Shepard, DS (corresponding author), Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, MS 035, Waltham, MA 02254 USA.	shepard@brandeis.edu			Centers for Medicare & Medicaid Services [500-00-0031/TO 007]	Centers for Medicare & Medicaid Services	This work was supported by the Centers for Medicare & Medicaid Services to Brandeis University (www.cms.gov) contract number 500-00-0031/TO 007. The funders approved the study design and analysis in the underlying report (Stason et al., 2010, reference 2) but had no role in the decision to publish or preparation of this manuscript.	Biondi DM, 2005, HEADACHE, V45, P738, DOI 10.1111/j.1526-4610.2005.05141.x; Bronfort G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001878.PUB2; Cooper RA, 2003, MILBANK Q, V81, P107, DOI 10.1111/1468-0009.00040; DeVocht JW, 2006, CLIN ORTHOP RELAT R, P243, DOI 10.1097/01.blo.0000203460.89887.8d; Ernst E, 2006, J ROY SOC MED, V99, P192, DOI 10.1258/jrsm.99.4.192; Ernst E, 2008, J PAIN SYMPTOM MANAG, V35, P544, DOI 10.1016/j.jpainsymman.2007.07.004; French HP, 2011, MANUAL THER, V16, P109, DOI 10.1016/j.math.2010.10.011; Gaumer G, 2006, J MANIP PHYSIOL THER, V29, P455, DOI 10.1016/j.jmpt.2006.06.013; Hahne AJ, 2010, SPINE, V35, pE488, DOI 10.1097/BRS.0b013e3181cc3f56; Haynes MJ, 2012, INT J CLIN PRACT, V66, P940, DOI 10.1111/j.1742-1241.2012.03004.x; Herd CR, 2008, J MAN MANIP THER, V16, P225, DOI 10.1179/106698108790818288; Jansen MJ, 2011, J PHYSIOTHER, V57, P11, DOI 10.1016/S1836-9553(11)70002-9; Johnson C, 2008, J MANIP PHYSIOL THER, V31, P397, DOI 10.1016/j.jmpt.2008.07.001; Johnson C, 2012, J MANIP PHYSIOL THER, V35, P493, DOI 10.1016/j.jmpt.2012.09.001; Keating Jr JC, 2004, CHIROPRACTIC HSTORY; Leboeuf-Yde Charlotte, 2008, Chiropr Osteopat, V16, P3, DOI 10.1186/1746-1340-16-3; Leininger B, 2011, PHYS MED REH CLIN N, V22, P105, DOI 10.1016/j.pmr.2010.11.002; Lin CWC, 2011, EUR SPINE J, V20, P1024, DOI 10.1007/s00586-010-1676-3; Meeker WC, 2002, ANN INTERN MED, V136, P216, DOI 10.7326/0003-4819-136-3-200202050-00010; Mootz RD, 1997, CHIROPRACTIC IN THE; National Board of Chiropractic Examiners (NBCE), 2014, ABOUT CHIROPRACTIC 2; Nelson Craig F, 2005, Chiropr Osteopat, V13, P9, DOI 10.1186/1746-1340-13-9; Posadzki P, 2011, NEW ZEAL MED J, V124, P55; Pribicevic M, 2010, J MANIP PHYSIOL THER, V33, P679, DOI 10.1016/j.jmpt.2010.08.019; Rubinstein SM, 2013, SPINE, V38, pE158, DOI 10.1097/BRS.0b013e31827dd89d; Short R., 2010, THE CHIROPRACTIC DEM; Stapleton DC, 2005, MEDICARE CHIROPRACTI; Stason WB, 2010, FINAL REPORT; Weeks WB, 2013, J MANIP PHYSIOL THER, V36, P468, DOI 10.1016/j.jmpt.2013.07.003; Whedon James M, 2013, J Chiropr Humanit, V20, P9, DOI 10.1016/j.echu.2013.07.001; Whedon JM, 2012, J MANIP PHYSIOL THER, V35, P101, DOI 10.1016/j.jmpt.2011.12.004; Whedon JM, 2010, TOPICS IN INTEGRATIV, V1	32	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 29	2016	11	2							e0147959	10.1371/journal.pone.0147959	http://dx.doi.org/10.1371/journal.pone.0147959			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5WU	26928221	gold, Green Submitted, Green Published			2023-01-03	WOS:000371424200001
J	Tasker, RC; Menon, DK				Tasker, Robert C.; Menon, David K.			Critical Care and the Brain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; INJURY; OUTCOMES; FAILURE		[Tasker, Robert C.] Boston Childrens Hosp, Dept Anesthesia Perioperat & Pain Med, Div Crit Care Med, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Menon, David K.] Univ Cambridge, Sch Clin, Div Anaesthesia, Cambridge, England; [Menon, David K.] Addenbrookes Hosp, Cambridge, England	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tasker, RC (corresponding author), Boston Childrens Hosp, Div Crit Care Med, Bader 621,300 Longwood Ave, Boston, MA 02115 USA.	robert.tasker@childrens.harvard.edu	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113	National Institute for Health Research [NF-SI-0512-10090] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399; Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727; Miller CM, 2015, NEUROCRIT CARE S2, V23, P1; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Riech S, 2015, CRIT CARE MED, V43, pE386, DOI 10.1097/CCM.0000000000001150; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090	8	21	22	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2016	315	8					749	750		10.1001/jama.2016.0701	http://dx.doi.org/10.1001/jama.2016.0701			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE5VH	26903329				2023-01-03	WOS:000370700500006
J	Soriano-Maldonado, A; Klokker, L; Bartholdy, C; Bandak, E; Ellegaard, K; Bliddal, H; Henriksen, M				Soriano-Maldonado, Alberto; Klokker, Louise; Bartholdy, Cecilie; Bandak, Elisabeth; Ellegaard, Karen; Bliddal, Henning; Henriksen, Marius			Intra-Articular Corticosteroids in Addition to Exercise for Reducing Pain Sensitivity in Knee Osteoarthritis: Exploratory Outcome from a Randomized Controlled Trial	PLOS ONE			English	Article							THERAPY	Objective To assess the effects of one intra-articular corticosteroid injection two weeks prior to an exercise-based intervention program for reducing pain sensitivity in patients with knee osteoarthritis (OA). Design Randomized, masked, parallel, placebo-controlled trial involving 100 participants with clinical and radiographic knee OA that were randomized to one intra-articular injection on the knee with either 1 ml of 40 mg/ml methylprednisolone (corticosteroid) dissolved in 4 ml lidocaine (10 mg/ml) or 1 ml isotonic saline (placebo) mixed with 4 ml lidocaine (10 mg/ml). Two weeks after the injections all participants undertook a 12-week supervised exercise program. Main outcomes were changes from baseline in pressure-pain sensitivity (pressurepain threshold [PPT] and temporal summation [TS]) assessed using cuff pressure algometry on the calf. These were exploratory outcomes from a randomized controlled trial. Results A total of 100 patients were randomized to receive either corticosteroid (n = 50) or placebo (n = 50); 45 and 44, respectively, completed the trial. Four participants had missing values for PPT and one for TS at baseline; thus modified intention-to-treat populations were analyzed. The mean group difference in changes from baseline at week 14 was 0.6 kPa (95% CI: -1.7 to 2.8; P = 0.626) for PPT and 384 mmxsec (95% CI: -2980 to 3750; P = 0.821) for TS. Conclusions These results suggest that adding intra-articular corticosteroid injection 2 weeks prior to an exercise program does not provide additional benefits compared to placebo in reducing pain sensitivity in patients with knee OA.	[Soriano-Maldonado, Alberto] Univ Granada, Fac Sport Sci, Dept Phys Educ & Sport, Granada, Spain; [Klokker, Louise; Bartholdy, Cecilie; Bandak, Elisabeth; Ellegaard, Karen; Bliddal, Henning; Henriksen, Marius] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Parker Inst, Frederiksberg, Denmark; [Bartholdy, Cecilie; Henriksen, Marius] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Phys & Occupat Therapy, Frederiksberg, Denmark	University of Granada; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital	Henriksen, M (corresponding author), Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Parker Inst, Frederiksberg, Denmark.; Henriksen, M (corresponding author), Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Phys & Occupat Therapy, Frederiksberg, Denmark.	marius.henriksen@regionh.dk	Soriano-Maldonado, Alberto/I-6379-2015; Henriksen, Marius/ABD-7887-2020; Bartholdy, Cecilie/AAJ-5496-2020; Bliddal, Henning/AAB-3168-2019	Soriano-Maldonado, Alberto/0000-0002-4626-420X; Henriksen, Marius/0000-0003-1091-2962; Bartholdy, Cecilie/0000-0001-5700-385X; Bliddal, Henning/0000-0002-7951-1668	Danish Council for Independent Research, Medical Science [10093704]; Oak Foundation; Association of Danish Physiotherapists; Lundbeck Foundation; Capital Region of Denmark; Spanish Ministry of Education, Culture and Sport [FPU12/00963]	Danish Council for Independent Research, Medical Science(Det Frie Forskningsrad (DFF)); Oak Foundation; Association of Danish Physiotherapists; Lundbeck Foundation(Lundbeckfonden); Capital Region of Denmark; Spanish Ministry of Education, Culture and Sport(Spanish Government)	This study was supported by grant 10093704 from the Danish Council for Independent Research, Medical Science and by the Oak Foundation, Association of Danish Physiotherapists, Lundbeck Foundation, and Capital Region of Denmark. AS-M was supported by the Spanish Ministry of Education, Culture and Sport (FPU12/00963). The funding sources had no role in the study design, data collection and analysis, interpretation or reporting of this work, or the decision to submit the work for publication. All authors are independent of the funding sources.	Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003; Arroll B, 2004, BMJ-BRIT MED J, V328, P869, DOI 10.1136/bmj.38039.573970.7C; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Finan PH, 2013, ARTHRITIS RHEUM-US, V65, P363, DOI 10.1002/art.34646; Fingleton C, 2015, OSTEOARTHR CARTILAGE, V23, P1043, DOI 10.1016/j.joca.2015.02.163; Henriksen M, 2015, JAMA INTERN MED, V175, P923, DOI 10.1001/jamainternmed.2015.0461; Henriksen M, 2014, ARTHRIT CARE RES, V66, P1836, DOI 10.1002/acr.22375; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Jorgensen TS, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/710490; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Polianskis R, 2001, EUR J PAIN, V5, P267, DOI 10.1053/eujp.2001.0245; Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477-7525-1-64; Sharif B, 2015, OSTEOARTHR CARTILAGE, V23, P1654, DOI 10.1016/j.joca.2015.05.029; Suokas AK, 2012, OSTEOARTHR CARTILAGE, V20, P1075, DOI 10.1016/j.joca.2012.06.009	14	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0149168	10.1371/journal.pone.0149168	http://dx.doi.org/10.1371/journal.pone.0149168			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26871954	Green Published, Green Submitted, gold			2023-01-03	WOS:000370054100117
J	Nuti, SV; Qin, L; Rumsfeld, JS; Ross, JS; Masoudi, FA; Normand, SLT; Murugiah, K; Bernheim, SM; Suter, LG; Krumholz, HM				Nuti, Sudhakar V.; Qin, Li; Rumsfeld, John S.; Ross, Joseph S.; Masoudi, Frederick A.; Normand, Sharon-Lise T.; Murugiah, Karthik; Bernheim, Susannah M.; Suter, Lisa G.; Krumholz, Harlan M.			Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE-SYSTEM; QUALITY-OF-CARE; 30-DAY MORTALITY; MEDICAL-CENTERS; PERFORMANCE; OUTCOMES; VA; ENROLLEES	IMPORTANCE Little contemporary information is available about comparative performance between Veterans Affairs (VA) and non-VA hospitals, particularly related to mortality and readmission rates, 2 important outcomes of care. OBJECTIVE To assess and compare mortality and readmission rates among men in VA and non-VA hospitals. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis involving male Medicare fee-for service beneficiaries aged 65 years or older hospitalized between 2010 and 2013 in VA and non-VA acute care hospitals for acute myocardial infarction (AMI), heart failure (HF), or pneumonia using the Medicare Standard Analytic Files and Enrollment Database together with VA administrative claims data. To avoid confounding geographic effects with health care system effects, we studied VA and non-VA hospitals within the same metropolitan statistical area (MSA). EXPOSURES Hospitalization in a VA or non-VA hospital in MSAs that contained at least 1 VA and non-VA hospital. MAIN OUTCOMES AND MEASURES For each condition, 30-day risk-standardized mortality rates and risk-standardized readmission rates for VA and non-VA hospitals. Mean aggregated within-MSA differences in mortality and readmission rates were also assessed. RESULTS We studied 104 VA and 1513 non-VA hospitals, with each condition-outcome analysis cohort for VA and non-VA hospitals containing at least 7900 patients (men; >= 65 years), in 92 MSAs. Mortality rates were lower in VA hospitals than non-VA hospitals for AMI (13.5% vs 13.7%, P = .02; -0.2 percentage-point difference) and HF (11.4% vs 11.9%, P = .008; -0.5 percentage-point difference), but higher for pneumonia (12.6% vs 12.2%, P = .045; 0.4 percentage-point difference). In contrast, readmission rates were higher in VA hospitals for all 3 conditions (AMI, 17.8% vs 17.2%, 0.6 percentage-point difference; HF, 24.7% vs 23.5%, 1.2 percentage-point difference; pneumonia, 19.4% vs 18.7%, 0.7 percentage-point difference, all P < .001). In within-MSA comparisons, VA hospitals had lower mortality rates for AMI (percentage-point difference, -0.22; 95% CI, -0.40 to -0.04) and HF (-0.63; 95% CI, -0.95 to -0.31), and mortality rates for pneumonia were not significantly different (-0.03; 95% CI, -0.46 to 0.40); however, VA hospitals had higher readmission rates for AMI (0.62; 95% CI, 0.48 to 0.75), HF (0.97; 95% CI, 0.59 to 1.34), or pneumonia (0.66; 95% CI, 0.41 to 0.91). CONCLUSIONS AND RELEVANCE Among older men with AMI, HF, or pneumonia, hospitalization at VA hospitals, compared with hospitalization at non-VA hospitals, was associated with lower 30-day risk-standardized all-cause mortality rates for AMI and HF, and higher 30-day risk-standardized all-cause readmission rates for all 3 conditions, both nationally and within similar geographic areas, although absolute differences between these outcomes at VA and non-VA hospitals were small.	[Nuti, Sudhakar V.; Qin, Li; Ross, Joseph S.; Murugiah, Karthik; Bernheim, Susannah M.; Suter, Lisa G.; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Qin, Li; Ross, Joseph S.; Suter, Lisa G.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, Clin Scholars Program,Robert Wood Johnson Fdn, New Haven, CT USA; [Qin, Li; Ross, Joseph S.; Suter, Lisa G.; Krumholz, Harlan M.] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT USA; [Qin, Li; Ross, Joseph S.; Suter, Lisa G.; Krumholz, Harlan M.] Yale Univ, Sch Med, Rheumatol Sect, Dept Internal Med, New Haven, CT USA; [Rumsfeld, John S.] VA Eastern Colorado Healthcare Syst, Denver, CO USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Masoudi, Frederick A.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Normand, Sharon-Lise T.] Harvard Univ, Dept Biostat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Suter, Lisa G.] Vet Affairs Med Ctr, West Haven, CT USA	Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; Yale University; Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, One Church St,Ste 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020; Masoudi, Frederick/Q-7467-2019	Murugiah, Karthik/0000-0001-7932-382X; Normand, Sharon-Lise/0000-0001-7027-4769; Ross, Joseph/0000-0002-9218-3320	National Institute on Aging [K08 AG032886]; American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute [U01 HL105270-05]; VA Connecticut Healthcare System; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG032886] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); VA Connecticut Healthcare System(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Ross is supported by grant K08 AG032886 from the National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. Dr Krumholz is supported by grant U01 HL105270-05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. Dr Suter is partially supported by the VA Connecticut Healthcare System.	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; American Hospital Association, 2014, AHA DAT DIR; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Borrero S, 2006, J GEN INTERN MED, V21, pS54, DOI 10.1111/j.1525-1497.2006.00375.x; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Centers for Medicare & Medicaid Services, DEN FIL; Fihn SD, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-44; Gerhardt Geoffrey, 2013, Medicare Medicaid Res Rev, V3, DOI 10.5600/mmrr.003.02.b01; HOLLOWAY JJ, 1990, HEALTH SERV RES, V25, P213; Institute of Medicine (US) Committee on the Future of Rural Health Care, 2005, QUAL COLL FUT RUR HL; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Jones LG, 2015, CIRC-HEART FAIL, V8, P17, DOI 10.1161/CIRCHEARTFAILURE.114.001300; Kazis LE, 1999, AM J MED QUAL, V14, P28, DOI 10.1177/106286069901400105; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Keyhani S, 2012, CIRC-CARDIOVASC QUAL, V5, P508, DOI 10.1161/CIRCOUTCOMES.111.962936; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Landrum MB, 2004, HEALTH SERV RES, V39, P1773, DOI 10.1111/j.1475-6773.2004.00317.x; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; National Center for Veterans Analysis and Statistics, 2014, UT; Payne SMC, 2005, J AMBUL CARE MANAG, V28, P125, DOI 10.1097/00004479-200504000-00004; QualityNet, MEAS METH REP READM; Rogers William H, 2004, J Ambul Care Manage, V27, P249; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Ross JS, 2010, MED CARE, V48, P652, DOI 10.1097/MLR.0b013e3181dbe35d; Selim AJ, 2006, MED CARE, V44, P359, DOI 10.1097/01.mlr.0000204119.27597.f1; Trivedi AN, 2011, MED CARE, V49, P560, DOI 10.1097/MLR.0b013e31820fb0f6; Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575; US Census Bureau, 2015, POP EST METR MICR ST; US Department of Labor Office of Workers' Compensation Programs, 2011, GEOGR PRACT COST IND; US Department of Veterans Affairs, VA HOSP HOM H2H IN; US Department of Veterans Affairs, HEART FAIL PROV NETW; Weeks WB, 2002, J RURAL HEALTH, V18, P298, DOI 10.1111/j.1748-0361.2002.tb00890.x; Weeks WB, 2008, MED CARE, V46, P863, DOI 10.1097/MLR.0b013e31817d92e1; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694	38	68	70	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2016	315	6					582	592		10.1001/jama.2016.0278	http://dx.doi.org/10.1001/jama.2016.0278			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD0UJ	26864412	Bronze, Green Accepted			2023-01-03	WOS:000369635200017
J	Hummler, HD; Banke, K; Wolfson, MR; Buonocore, G; Ebsen, M; Bernhard, W; Tsikas, D; Fuchs, H				Hummler, Helmut D.; Banke, Katharina; Wolfson, Marla R.; Buonocore, Giuseppe; Ebsen, Michael; Bernhard, Wolfgang; Tsikas, Dimitrios; Fuchs, Hans			The Effects of Lung Protective Ventilation or Hypercapnic Acidosis on Gas Exchange and Lung Injury in Surfactant Deficient Rabbits	PLOS ONE			English	Article							OXIDATION PROTEIN PRODUCTS; PARTIAL LIQUID VENTILATION; PERMISSIVE HYPERCAPNIA; THERAPEUTIC HYPERCAPNIA; MECHANICAL VENTILATION; PULMONARY; BIRTH; INFLAMMATION; MORTALITY; VOLUME	Background Permissive hypercapnia has been shown to reduce lung injury in subjects with surfactant deficiency. Experimental studies suggest that hypercapnic acidosis by itself rather than decreased tidal volume may be a key protective factor. Objectives To study the differential effects of a lung protective ventilatory strategy or hypercapnic acidosis on gas exchange, hemodynamics and lung injury in an animal model of surfactant deficiency. Methods 30 anesthetized, surfactant-depleted rabbits were mechanically ventilated (FiO(2) = 0.8, PEEP = 7cmH(2)O) and randomized into three groups: Normoventilation-Normocapnia (NN)-group: tidal volume (Vt) = 7.5 ml/kg, target PaCO2 = 40 mmHg; Normoventilation-Hypercapnia (NH)-group: Vt = 7.5 ml/kg, target PaCO2 = 80 mmHg by increasing FiCO(2); and a Hypoventilation-Hypercapnia (HH)-group: Vt = 4.5 ml/kg, target PaCO2 = 80 mmHg. Plasma lactate and interleukin (IL)-8 were measured every 2 h. Animals were sacrificed after 6 h to perform bronchoalveolar lavage (BAL), to measure lung wet-to-dry weight, lung tissue IL-8, and to obtain lung histology. Results PaO2 was significantly higher in the HH-group compared to the NN-group (p<0.05), with values of the NH-group between the HH- and NN-groups. Other markers of lung injury (wet-dry-weight, BAL-Protein, histology-score, plasma-IL-8 and lung tissue IL-8) resulted in significantly lower values for the HH-group compared to the NN-group and trends for the NH-group towards lower values compared to the NN-group. Lactate was significantly lower in both hypercapnia groups compared to the NN-group. Conclusion Whereas hypercapnic acidosis may have some beneficial effects, a significant effect on lung injury and systemic inflammatory response is dependent upon a lower tidal volume rather than resultant arterial CO2 tensions and pH alone.	[Hummler, Helmut D.; Banke, Katharina; Fuchs, Hans] Univ Ulm, Dept Pediat, Childrens Hosp, Div Neonatol & Pediat Crit Care, D-89070 Ulm, Germany; [Wolfson, Marla R.] CENTRe Collaborat Environm & Neonatal Therapeut R, Dept Physiol, Philadelphia, PA USA; [Wolfson, Marla R.] CENTRe Collaborat Environm & Neonatal Therapeut R, Dept Med, Philadelphia, PA USA; [Wolfson, Marla R.] CENTRe Collaborat Environm & Neonatal Therapeut R, Dept Pediat, Philadelphia, PA USA; [Wolfson, Marla R.] Temple Lung Ctr, Philadelphia, PA USA; [Wolfson, Marla R.] Temple Univ, Sch Med, Ctr Inflammat Translat & Clin Lung Res, Philadelphia, PA 19122 USA; [Buonocore, Giuseppe] Univ Hosp Siena, Dept Mol & Dev Med, Pediat Neonatol Unit, Siena, Italy; [Ebsen, Michael] Staedt Krankenhaus Kiel, Med Versorgungszentrum, Inst Pathol, Kiel, Germany; [Bernhard, Wolfgang] Univ Tubingen, Childrens Hosp, Dept Neonatol, Tubingen, Germany; [Tsikas, Dimitrios] Hannover Med Sch, Ctr Pharmacol & Toxicol, Hannover, Germany	Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University Hospital of Siena; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Hannover Medical School	Hummler, HD (corresponding author), Univ Ulm, Dept Pediat, Childrens Hosp, Div Neonatol & Pediat Crit Care, D-89070 Ulm, Germany.	helmut.hummler@uni-ulm.de	Hummler, Helmut/AAN-7297-2021; Bernhard, Wolfgang/AAT-1393-2021; Buonocore, Giuseppe/U-3873-2019	Buonocore, Giuseppe/0000-0002-7921-7485; Bernhard, Wolfgang/0000-0003-0307-223X	Department of Defense/Office of Naval Research [N000141210597, N000141210810]	Department of Defense/Office of Naval Research(Office of Naval ResearchUnited States Department of Defense)	Work performed in this study was supported in part by the Department of Defense/Office of Naval Research N000141210597 and N000141210810 (MRW).	Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Bernhard W, 2007, PEDIATR PULM, V42, P794, DOI 10.1002/ppul.20657; Broccard AF, 2001, AM J RESP CRIT CARE, V164, P802, DOI 10.1164/ajrccm.164.5.2007060; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buonocore G, 2000, PEDIATR RES, V47, P221, DOI 10.1203/00006450-200002000-00012; Carlo WA, 2002, J PEDIATR-US, V141, P370, DOI 10.1067/mpd.2002.127507; Clark RH, 2001, J PEDIATR-US, V139, P478, DOI 10.1067/mpd.2001.118201; COATES AL, 1991, PEDIATR PULM, V11, P350, DOI 10.1002/ppul.1950110413; Contreras M, 2012, CRIT CARE MED, V40, P2622, DOI 10.1097/CCM.0b013e318258f8b4; Doerr CH, 2005, AM J RESP CRIT CARE, V171, P1371, DOI 10.1164/rccm.200309-1223OC; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Feihl F, 2000, AM J RESP CRIT CARE, V162, P209, DOI 10.1164/ajrccm.162.1.9907119; Fritz KI, 2005, PEDIATR RES, V57, P299, DOI 10.1203/01.PDR.0000148718.47137.9B; Fuchs H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023816; Haitsma JJ, 2000, INTENS CARE MED, V26, P1515, DOI 10.1007/s001340000648; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HOOD VL, 1988, AM J PHYSIOL, V255, pF479, DOI 10.1152/ajprenal.1988.255.3.F479; Hood VL, 1998, NEW ENGL J MED, V339, P819, DOI 10.1056/NEJM199809173391207; Hummler HD, 2001, PEDIATR RES, V49, P572, DOI 10.1203/00006450-200104000-00021; Kantores C, 2006, AM J PHYSIOL-LUNG C, V291, pL912, DOI 10.1152/ajplung.00480.2005; LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P2287, DOI 10.1164/ajrccm.162.6.2003066; Lee WL, 2001, SEMIN RESP CRIT CARE, V22, P269, DOI 10.1055/s-2001-15784; Mariani G, 1999, PEDIATRICS, V104, P1082, DOI 10.1542/peds.104.5.1082; Masood A, 2009, AM J PHYSIOL-LUNG C, V297, pL920, DOI 10.1152/ajplung.00139.2009; NETO GS, 1992, PEDIATR PULM, V12, P146, DOI 10.1002/ppul.1950120304; Paffetti P, 2006, BIOL TRACE ELEM RES, V112, P221, DOI 10.1385/BTER:112:3:221; Rai S, 2004, PEDIATR RES, V55, P42, DOI 10.1203/01.PDR.0000098502.72182.55; Raith M, 2012, J APPL PHYSIOL, V112, P1317, DOI 10.1152/japplphysiol.00887.2011; Sinclair SE, 2002, AM J RESP CRIT CARE, V166, P403, DOI 10.1164/rccm.200112-117OC; STEINHART CR, 1983, AM J PHYSIOL, V244, pH46, DOI 10.1152/ajpheart.1983.244.1.H46; Strand M, 2003, PEDIATR RES, V53, P468, DOI 10.1203/01.PDR.0000049463.76133.8F; Subramanian Siva, 2011, Matern Child Health J, V15 Suppl 1, pS17, DOI 10.1007/s10995-011-0863-0; Takeshita K, 2003, AM J RESP CELL MOL, V29, P124, DOI 10.1165/rcmb.2002-0126OC; Thome UH, 2001, CRIT CARE MED, V29, P1175, DOI 10.1097/00003246-200106000-00018; Thome UH, 2006, BIOL NEONATE, V90, P218, DOI 10.1159/000092723; Thome UH, 2015, LANCET RESP MED, V3, P534, DOI 10.1016/S2213-2600(15)00204-0; Tomimatsu T, 2006, PEDIATR RES, V60, P711, DOI 10.1203/01.pdr.0000246308.37154.ce; Tsikas D, 2003, J CHROMATOGR B, V794, P237, DOI 10.1016/S1570-0232(03)00457-4; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Witko-Sarsat V, 1998, J IMMUNOL, V161, P2524; Wolthuis EK, 2008, ANESTHESIOLOGY, V108, P46, DOI 10.1097/01.anes.0000296068.80921.10; Yamamoto Y, 2001, J APPL PHYSIOL, V91, P1121, DOI 10.1152/jappl.2001.91.3.1121	44	11	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0147807	10.1371/journal.pone.0147807	http://dx.doi.org/10.1371/journal.pone.0147807			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840779	gold, Green Published, Green Submitted			2023-01-03	WOS:000369550200061
J	Lin, LZ; Guo, LL; Zhang, WX; Cai, XB; Chen, DF; Wan, XJ				Lin, Lizhou; Guo, Lili; Zhang, Weixing; Cai, Xiaobo; Chen, Dafan; Wan, Xinjian			Novel Silicone-Coated I-125 Seeds for the Treatment of Extrahepatic Cholangiocarcinoma	PLOS ONE			English	Article							MALIGNANT BILIARY OBSTRUCTION; BRUSH CYTOLOGY; METALLIC STENT; CANCER; MANAGEMENT; PATTERNS; QUALITY; GEL	I-125 seeds coated with titanium are considered a safe and effective interstitial brachytherapy for tumors, while the cost of I-125 seeds is a major problem for the patients implanting lots of seeds. The aim of this paper was to develop a novel silicone coating for I-125 seeds with a lower cost. In order to show the radionuclide utilization ratio, the silicone was coated onto the seeds using the electro-spinning method and the radioactivity was evaluated, then the anti-tumor efficacy of silicone I-125 seeds was compared with titanium I-125 seeds. The seeds were divided into four groups: A (control), B (pure silicone), C (silicone I-125), D (titanium I-125) at 2 Gy or 4 Gy. Their anti-tumour activity and mechanism were assessed in vitro and in vivo using a human extrahepatic cholangiocarcinoma cell line FRH-0201 and tumor-bearing BALB/c nude mice. The silicone I-125 seeds showed higher radioactivity; the rate of cell apoptosis in vitro and the histopathology in vivo demonstrated that the silicone I-125 seeds shared similar anti-tumor efficacy with the titanium I-125 seeds for the treatment of extrahepatic cholangiocarcinoma, while they have a much lower cost.	[Lin, Lizhou; Guo, Lili; Zhang, Weixing; Cai, Xiaobo; Chen, Dafan; Wan, Xinjian] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Gastroenterol, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University	Wan, XJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Gastroenterol, Shanghai 200080, Peoples R China.	wanxj_sh@163.com		Wan, Xinjian/0000-0002-4201-633X	Doctoral Fund of Education Administration for New Teacher [070162]	Doctoral Fund of Education Administration for New Teacher	This work was supported by Doctoral Fund of Education Administration for New Teacher (project code: 070162). The funding receiver was Xinjian Wan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen Y, 2012, CANCER BIOTHER RADIO, V27, P317, DOI 10.1089/cbr.2011.0999; Chun HJ, 2010, J GASTROEN HEPATOL, V25, P234, DOI 10.1111/j.1440-1746.2009.06152.x; Daramwar PP, 2012, ANALYST, V137, P4564, DOI 10.1039/c2an35575b; Davila Jessica A., 2002, American Journal of Gastroenterology, V97, P3199; de Groen PC, 1999, NEW ENGL J MED, V341, P1368, DOI 10.1056/NEJM199910283411807; Fanelli F, 2008, EUR RADIOL, V18, P911, DOI 10.1007/s00330-008-0852-x; Fung LCT, 1996, PERITON DIALYSIS INT, V16, P398; Han YH, 2006, ABDOM IMAGING, V31, P433, DOI 10.1007/s00261-005-8017-8; Hejna M, 1998, EUR J CANCER, V34, P977, DOI 10.1016/S0959-8049(97)10166-6; Kawada N, 2011, J GASTROEN HEPATOL, V26, P1247, DOI 10.1111/j.1440-1746.2011.06725.x; Khan SA, 2002, J HEPATOL, V37, P806, DOI 10.1016/S0168-8278(02)00297-0; Khan SA, 2012, GUT, V61, P1657, DOI 10.1136/gutjnl-2011-301748; Kim HS, 2002, GASTROINTEST ENDOSC, V55, P359, DOI 10.1067/mge.2002.121603; Kumar R, 2004, J GASTROEN HEPATOL, V19, P994, DOI 10.1111/j.1440-1746.2004.03415.x; Li G, 2013, BIOMATERIALS, V34, P9451, DOI 10.1016/j.biomaterials.2013.08.055; Liu Y, 2009, GASTROINTEST ENDOSC, V69, P1067, DOI 10.1016/j.gie.2008.08.033; Luman W, 1997, EUR J GASTROEN HEPAT, V9, P481, DOI 10.1097/00042737-199705000-00013; Ma JX, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-35; Miura Y, 2001, J Hepatobiliary Pancreat Surg, V8, P113, DOI 10.1007/s005340170032; Mulhonen V, 2009, ACTA BIOMATER, V5, P785, DOI 10.1016/j.actbio.2008.08.023; Naitoh I, 2009, J GASTROEN HEPATOL, V24, P552, DOI 10.1111/j.1440-1746.2008.05750.x; Ortner MA, 2004, PHOTODIAGN PHOTODYN, V1, P85, DOI 10.1016/S1572-1000(04)00013-4; Park SW, 2004, HEPATO-GASTROENTEROL, V51, P1612; Radin S, 2001, J BIOMED MATER RES, V57, P313, DOI 10.1002/1097-4636(200111)57:2<313::AID-JBM1173>3.0.CO;2-E; Rumalla A, 2001, MAYO CLIN PROC, V76, P29, DOI 10.4065/76.1.29; Shinchi H, 2000, J SURG ONCOL, V75, P89, DOI 10.1002/1096-9098(200010)75:2<89::AID-JSO3>3.3.CO;2-M; Shinohara ET, 2009, INT J RADIAT ONCOL, V74, P1191, DOI 10.1016/j.ijrobp.2008.09.017; Takahashi Yutaka, 2006, Radiat Med, V24, P675, DOI 10.1007/s11604-006-0088-0; Trombetta MG, 2008, BRACHYTHERAPY, V7, P50, DOI 10.1016/j.brachy.2007.11.003; Wang JJ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-88; Wang ZM, 2010, EUR RADIOL, V20, P1786, DOI 10.1007/s00330-009-1703-0	31	5	5	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0147701	10.1371/journal.pone.0147701	http://dx.doi.org/10.1371/journal.pone.0147701			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840346	Green Published, Green Submitted, gold			2023-01-03	WOS:000369550200055
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: Technology isn't enough	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Hunt J., 2015, PATIENT POWER THREAT	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	2016	352								i620	10.1136/bmj.i620	http://dx.doi.org/10.1136/bmj.i620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD2QD	26831338	Bronze, Green Published			2023-01-03	WOS:000369766400016
J	Prochazka, A				Prochazka, Arthur			Targeted stimulation of the spinal cord to restore locomotor activity	NATURE MEDICINE			English	Editorial Material							FUNCTIONAL WALKING	A new study has located 'hot spots' in the rat spinal cord that are associated with leg flexion and extension in rats. Electrical stimulation applied in an alternating pattern between these hot spots facilitated locomotion after the hindlimbs were paralyzed as a result of spinal cord injury (SCI).	[Prochazka, Arthur] Univ Alberta, Sch Mol & Syst Med, Edmonton, AB, Canada	University of Alberta	Prochazka, A (corresponding author), Univ Alberta, Sch Mol & Syst Med, Edmonton, AB, Canada.	arthur.prochazka@ualberta.ca						Carhart MR, 2004, IEEE T NEUR SYS REH, V12, P32, DOI 10.1109/TNSRE.2003.822763; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Furlan J.C., 2014, EPIDEMIOLOGY TRAUMAT, P1; Gan LS, 2007, IEEE T BIO-MED ENG, V54, P509, DOI 10.1109/TBME.2006.886664; GRANAT MH, 1993, J BIOMED ENG, V15, P51, DOI 10.1016/0141-5425(93)90093-E; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Herman R, 2002, SPINAL CORD, V40, P65, DOI 10.1038/sj.sc.3101263; Prochazka A., 2015, OXFORD TXB CLIN NEUR, P374; Prochazka A, 2007, INTEGR COMP BIOL, V47, P474, DOI 10.1093/icb/icm065; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Yakovenko S, 2002, J NEUROPHYSIOL, V87, P1542, DOI 10.1152/jn.00479.2001	12	7	7	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2016	22	2					125	126		10.1038/nm.4043	http://dx.doi.org/10.1038/nm.4043			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DC8JX	26845403				2023-01-03	WOS:000369466800003
J	Kmietowicz, Z				Kmietowicz, Zosia			Patient care worsens as NHS deficits persist	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Appleby J, 2016, 19 KINGS FUND; Iacobucci G, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6430; O'Dowd A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1444	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2016	353								i2866	10.1136/bmj.i2866	http://dx.doi.org/10.1136/bmj.i2866			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GD	27198695				2023-01-03	WOS:000376447700023
J	Yeh, GY; Chan, CW; Wayne, PM; Conboy, L				Yeh, Gloria Y.; Chan, Caroline W.; Wayne, Peter M.; Conboy, Lisa			The Impact of Tai Chi Exercise on Self-Efficacy, Social Support, and Empowerment in Heart Failure: Insights from a Qualitative Sub-Study from a Randomized Controlled Trial	PLOS ONE			English	Article							PERCEIVED CONTROL; OF-LIFE; WOMEN; PROPRIOCEPTION; MECHANISMS; ADHERENCE; MEDICINE; OUTCOMES; ANKLE	Objective To qualitatively explore perceived physical and psychosocial effects and overall patient experience associated with a 12-week tai chi (TC) intervention and an education group in a clinical trial of patients with chronic heart failure (HF). Subjects and Methods We randomized 100 patients with chronic systolic HF (NYHA Class 1-3, ejection fraction <= 40%) to a 12-week group TC program or an education control. At 12-weeks, semistructured interviews were conducted on a random subset (n = 32; n = 17 in TC, n = 15 in control), audiorecorded and transcribed verbatim. Two independent reviewers extracted information using grounded-theory methods for emergent themes. We explored similarities and differences in themes/sub-themes between the groups, and examined qualitative association with changes from baseline to post-intervention in previously reported quantitative measures (e.g., Minnesota Living with HF, Cardiac Exercise Self Efficacy and Profile of Mood States). Results The mean age (+/-SD) of participants was 68+/-9 years, baseline ejection fraction 29+/-7%, and median New York Heart Association class 2 HF. We idenitifed themes related to the patient's experience of illness, perceptions of self, and relationship to others. Specific psychosocial and physical benefits were described. Common themes emerged from both groups including: social support and self-efficacy related to activity/exercise and diet. The tai chi group, however, also exhibited a more global empowerment and perceived control. Additional themes in TC included mindfulness/self-awareness, decreased stress reactivity, and renewed social role. These themes mirrored improvements in previously reported quantitative measures (quality-of-life, self-efficacy, and mood) in TC compared to control. Patients in TC also reported physical benefits (e.g., decreased pain, improved energy, endurance, flexibility). Conclusion Positive themes emerged from both groups, although there were qualitative differences in concepts of self-efficacy and perceived control between groups. Those in tai chi reported not only self efficacy and social support, but overall empowerment with additional gains such as internal locus of control, self-awareness and stress management. Future studies of mind-body exercise might further examine perceived control, self-efficacy, and locus-of-control as potential mediators of effect.	[Yeh, Gloria Y.; Chan, Caroline W.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Wayne, Peter M.] Harvard Univ, Sch Med, Osher Ctr Integrat Med, Boston, MA USA; [Wayne, Peter M.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA; [Conboy, Lisa] New England Sch Acupuncture, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Yeh, GY (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.	gyeh@hms.harvard.edu	Conboy, Lisa/ABC-5173-2021	Conboy, Lisa/0000-0003-2218-7841	National Institutes of Health National Center for Complementary and Integrative Health [R01 AT002454]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT002454] Funding Source: NIH RePORTER	National Institutes of Health National Center for Complementary and Integrative Health; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	The Original RCT was funded by National Institutes of Health National Center for Complementary and Integrative Health(formerly National Center for Complementary and Alternative Medicine) R01 AT002454.	ANDERSON RM, 1995, DIABETES CARE, V18, P412, DOI 10.2337/diacare.18.3.412; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Banerjee T, 2014, J CARDIOVASC NURS, V29, P227, DOI 10.1097/JCN.0b013e31828b2b23; Barbour KA, 2008, HEART FAIL REV, V13, P81, DOI 10.1007/s10741-007-9054-x; Barez M, 2009, J BEHAV MED, V32, P187, DOI 10.1007/s10865-008-9180-5; Calfee CS, 2006, CHEST, V130, P1312, DOI 10.1378/chest.130.5.1312; Charmanz K., 2006, CONSTRUCTING GROUNDE; Corbin J., 1998, BASICS QUALITATIVE R; Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775; Davies EJ, 2010, EUR J HEART FAIL, V12, P706, DOI 10.1093/eurjhf/hfq056; Davies P, 2014, COCHRANE DB SYST REV, V6; Du HY, 2012, J CLIN NURS, V21, P301, DOI 10.1111/j.1365-2702.2011.03983.x; Farb N, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00763; Fischer M, 2014, MENOPAUSE, V21, P1181, DOI [10.1097/gme.0000000000000257, 10.1097/GME.0000000000000257]; Foley G, 2015, HEALTH SERV RES, V50, P1195, DOI 10.1111/1475-6773.12275; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Heo S, 2015, EUR J CARDIOVASC NUR, V14, P137, DOI 10.1177/1474515113519931; Jindal V, 2013, MOL NEUROBIOL, V48, P186, DOI 10.1007/s12035-013-8416-8; Kerr CE, 2008, EXP BRAIN RES, V188, P317, DOI 10.1007/s00221-008-1409-6; Li F, 2001, Prev Sci, V2, P229, DOI 10.1023/A:1013614200329; Lincoln YS., 1985, NATURALISTIC INQUIRY, DOI 10.1016/0147-1767(85)90062-8; Maeda U, 2013, INT J BEHAV MED, V20, P88, DOI 10.1007/s12529-011-9215-0; Maxwell JA, 2005, QUALITATIVE RES DESI, P105; Miles M.B., 1994, QUALITATIVE DATA ANA; Moser DK, 2007, PSYCHOSOM MED, V69, P10, DOI 10.1097/01.psy.0000245868.43447.d8; Moser DK, 2009, NURS RES, V58, P42, DOI 10.1097/NNR.0b013e3181900ca0; MOSER DK, 1995, HEART LUNG, V24, P273, DOI 10.1016/S0147-9563(05)80070-6; Nugent LE, 2015, J CLIN NURS, V24, P2201, DOI 10.1111/jocn.12878; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Rodwell CM, 1996, J ADV NURS, V23, P305, DOI 10.1111/j.1365-2648.1996.tb02672.x; Rydlewska A, 2013, PATIENT PREFER ADHER, V7, P337, DOI 10.2147/PPA.S41863; Sandelowski M, 2000, RES NURS HEALTH, V23, P246, DOI 10.1002/1098-240X(200006)23:3<246::AID-NUR9>3.0.CO;2-H; Schmalzl L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00205; Taylor AG, 2010, EXPLORE-NY, V6, P29, DOI 10.1016/j.explore.2009.10.004; Taylor-Piliae RE, 2006, J ADV NURS, V54, P313, DOI 10.1111/j.1365-2648.2006.03809.x; Verhoef MJ, 2002, J ALTERN COMPLEM MED, V8, P275, DOI 10.1089/10755530260127961; WALLSTON KA, 1987, CURR PSYCHOL RES REV, V6, P5, DOI 10.1007/BF02686633; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; Woodgate J, 2008, J HEALTH PSYCHOL, V13, P366, DOI 10.1177/1359105307088141; Xu D, 2004, BRIT J SPORT MED, V38, P50, DOI 10.1136/bjsm.2002.003335; Yang Yang, 2011, J Aging Res, V2011, P650210, DOI 10.4061/2011/650210; Yeh GY, 2011, ARCH INTERN MED, V171, P750, DOI 10.1001/archinternmed.2011.150; Yeh GY, 2009, J CARDIOPULM REHABIL, V29, P152, DOI 10.1097/HCR.0b013e3181a33379; Yu DSF, 2008, J ADV NURS, V61, P474, DOI 10.1111/j.1365-2648.2007.04553.x; Zhang C, 2015, RES SPORTS MED, V23, P102, DOI 10.1080/15438627.2014.915835; Zheng GH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117360	47	45	47	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2016	11	5							e0154678	10.1371/journal.pone.0154678	http://dx.doi.org/10.1371/journal.pone.0154678			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DM8CX	27177041	Green Published, gold, Green Submitted			2023-01-03	WOS:000376589400067
J	Isaac, S; Saini, B; Chaar, BB				Isaac, Sami; Saini, Bandana; Chaar, Betty B.			The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives	PLOS ONE			English	Article							OPIOID SUBSTITUTION TREATMENT; NEW-ZEALAND DOCTORS; MEDICAL MARIJUANA; PRESCRIBE CANNABIS; PRIMARY-CARE; PHYSICIANS; ATTITUDES; IMPLEMENTATION; VICTORIA; PAIN	Background Medicinal cannabis has recently attracted much media attention in Australia and across the world. With the exception of a few countries, cannabinoids remain illegal-known for their adverse effects rather than their medicinal application and therapeutic benefit. However, there is mounting evidence demonstrating the therapeutic benefits of cannabis in alleviating neuropathic pain, improving multiple sclerosis spasticity, reducing chemotherapy induced nausea and vomiting, and many other chronic conditions. Many are calling for the legalisation of medicinal cannabis including consumers, physicians and politicians. Pharmacists are the gatekeepers of medicines and future administrators/dispensers of cannabis to the public, however very little has been heard about pharmacists' perspectives. Therefore the aim of this study was to explore pharmacists' views about medicinal cannabis; its legalisation and supply in pharmacy. Methods Semi-structured interviews with 34 registered pharmacists in Australia were conducted. All interviews were audio-recorded, transcribed ad verbatim and thematically analysed using the NVivo software. Results Emergent themes included stigma, legislation, safety and collaboration. Overall the majority of pharmacists felt national legalisation of a standardised form of cannabis would be suitable, and indicated various factors and strategies to manage its supply. The majority of participants felt that the most suitable setting would be via a community pharmacy setting due to the importance of accessibility for patients. Discussion This study explored views of practicing pharmacists, revealing a number of previously undocumented views and barriers about medicinal cannabis from a supply perspective. There were several ethical and professional issues raised for consideration. These findings highlight the important role that pharmacists hold in the supply of medicinal cannabis. Additionally, this study identified important factors, which will help shape future policies for the successful implementation of medicinal cannabis in healthcare. We recommend that these views and strategies be incorporated in the development of policies and legislations.	[Isaac, Sami; Saini, Bandana; Chaar, Betty B.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	University of Sydney	Chaar, BB (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	betty.chaar@sydney.edu.au	Isaac, Sami/ABG-1695-2020	Isaac, Sami/0000-0002-9870-6129; Chaar, Betty/0000-0001-8757-9403	Australian pharmacists	Australian pharmacists	The researchers wish to thank the Australian pharmacists who participated in the study.	Aamir T, 2015, J PRIM HEALTH CARE, V7, P160, DOI 10.1071/HC15160; Australian Government Department of Health, 2015, POIS STAND 2015; Australian Institute of Health and Welfare, 2015, BULLETIN, V128; Bammer G, 2009, AUST NZ J PUBL HEAL, V33, P34, DOI 10.1111/j.1753-6405.2009.00335.x; Bardet JD, 2015, RES SOC ADMIN PHARM, V11, P602, DOI 10.1016/j.sapharm.2014.12.003; Belackova V., 2015, MED CANNABIS AUSTR F; Bressler T, 2016, NURSE EDUC PRACT, V16, P144, DOI 10.1016/j.nepr.2015.07.004; Caulkins J.P., 2012, MARIJUANA LEGALIZATI, V1st; Chaar BB, 2013, DRUG ALCOHOL REV, V32, P426, DOI 10.1111/dar.12032; Charuvastra A, 2005, J ADDICT DIS, V24, P87, DOI 10.1300/J069v24n03_07; Commonwealth of Australia, 2010, NAT NEEDL SYR PROGR; Cummins P, 2015, MED CANNABIS REPORT; Ebert T, 2015, ISR MED ASSOC J, V17, P437; European Medicines Agency, 2010, EMA 655072 2010 ANN; European Medicines Agency, 2012, EMA4803312012; European Medicines Agency, 2011, EMA COMP 924925 2011; Fichera GP, 2009, MED LAV, V100, P97; Fleming GF, 2001, PHARM WORLD SCI, V23, P13, DOI 10.1023/A:1011239812477; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Hardy PA, 2015, J PRIM HEALTH CARE, V7, P158, DOI 10.1071/HC15158; Kondrad E, 2013, J AM BOARD FAM MED, V26, P52, DOI 10.3122/jabfm.2013.01.120089; Limentani AE, 1999, J MED ETHICS, V25, P394, DOI 10.1136/jme.25.5.394; Lintzeris Nicholas, 2002, Subst Abus, V23, P245, DOI 10.1023/A:1021102301285; Merrill JO, 2005, J GEN INTERN MED, V20, P344, DOI 10.1111/j.1525-1497.2005.04028.x; Murphy J, 2015, GOVT SUPPORT ALLOW C; Okie S, 2005, NEW ENGL J MED, V353, P648, DOI 10.1056/NEJMp058165; Rauwendall E, 2013, NSW PARLIAMENT UNPUB, P1; Reiman AE, 2008, HEALTH SOC CARE COMM, V16, P31, DOI 10.1111/j.1365-2524.2007.00722.x; Russo EB, 2007, CHEM BIODIVERS, V4, P1614, DOI 10.1002/cbdv.200790144; Rychert M, 2015, NEW ZEAL MED J, V128, P69; Samitca S, 2007, EUR ADDICT RES, V13, P50, DOI 10.1159/000095815; Smith MY, 2009, J AM PHARM ASSOC, V49, P599, DOI 10.1331/JAPhA.2009.08028; The Australian National Council on Drugs, 2014, MED US CANN BACKGR I; Thompson MS, 2013, QUANT METH EDUC BEHA, P163; US Department of Health and Human-Services, 2015, FDA MAR QUEST ANSW U; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Winstock AR, 2010, ADDICTION, V105, P335, DOI 10.1111/j.1360-0443.2009.02774.x; Ziemianski D, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0335-0	38	14	14	2	73	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0155113	10.1371/journal.pone.0155113	http://dx.doi.org/10.1371/journal.pone.0155113			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171490	gold, Green Submitted, Green Published			2023-01-03	WOS:000376588600147
J	Souday, V; Koning, NJ; Perez, B; Grelon, F; Mercat, A; Boer, C; Seegers, V; Radermacher, P; Asfar, P				Souday, Vincent; Koning, Nick J.; Perez, Bruno; Grelon, Fabien; Mercat, Alain; Boer, Christa; Seegers, Valerie; Radermacher, Peter; Asfar, Pierre			Enriched Air Nitrox Breathing Reduces Venous Gas Bubbles after Simulated SCUBA Diving: A Double-Blind Cross-Over Randomized Trial	PLOS ONE			English	Article							NEUTROPHIL ACTIVATION; BODY-FAT; DECOMPRESSION; DIVES; MICROPARTICLES; EMBOLI	Objective To test the hypothesis whether enriched air nitrox (EAN) breathing during simulated diving reduces decompression stress when compared to compressed air breathing as assessed by intravascular bubble formation after decompression. Methods Human volunteers underwent a first simulated dive breathing compressed air to include subjects prone to post-decompression venous gas bubbling. Twelve subjects prone to bubbling underwent a double-blind, randomized, cross-over trial including one simulated dive breathing compressed air, and one dive breathing EAN (36% O-2) in a hyperbaric chamber, with identical diving profiles (28 msw for 55 minutes). Intravascular bubble formation was assessed after decompression using pulmonary artery pulsed Doppler. Results Twelve subjects showing high bubble production were included for the cross-over trial, and all completed the experimental protocol. In the randomized protocol, EAN significantly reduced the bubble score at all time points (cumulative bubble scores: 1 [0-3.5] vs. 8 [4.5-10]; P < 0.001). Three decompression incidents, all presenting as cutaneous itching, occurred in the air versus zero in the EAN group (P = 0.217). Weak correlations were observed between bubble scores and age or body mass index, respectively. Conclusion EAN breathing markedly reduces venous gas bubble emboli after decompression in volunteers selected for susceptibility for intravascular bubble formation. When using similar diving profiles and avoiding oxygen toxicity limits, EAN increases safety of diving as compared to compressed air breathing.	[Souday, Vincent; Koning, Nick J.; Perez, Bruno; Grelon, Fabien; Mercat, Alain; Asfar, Pierre] Univ Hosp, Dept Med Intens Care & Hyperbar Med, Angers, France; [Koning, Nick J.; Asfar, Pierre] Univ Hosp, CNRS UMR 6214, INSERM U1083, Angers, France; [Seegers, Valerie] SFR Pole Sante, Interact Cellulaires & Applicat Therapeut & DRCI, Angers, France; [Seegers, Valerie] Univ Hosp, Angers, France; [Koning, Nick J.; Boer, Christa] Vrije Univ Amsterdam, Dept Anesthesiol, Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands; [Radermacher, Peter] Univ Ulm Klinikum, Inst Anasthesiol Pathophysiol & Verfahrensentwick, Ulm, Germany	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Vrije Universiteit Amsterdam; Ulm University	Asfar, P (corresponding author), Univ Hosp, Dept Med Intens Care & Hyperbar Med, Angers, France.; Asfar, P (corresponding author), Univ Hosp, CNRS UMR 6214, INSERM U1083, Angers, France.	piasfar@chu-angers.fr	Mercat, Alain/AFU-4426-2022	Grelon, Fabien/0000-0002-2606-9933; Boer, Christa/0000-0002-7781-6951				[Anonymous], 1994, NONLINEAR WORLD; Beasley TM, 2009, J MOD APPL STAT METH, V8, P16, DOI 10.22237/jmasm/1241136180; Blatteau JE, 2012, EUR J APPL PHYSIOL, V112, P2257, DOI 10.1007/s00421-011-2195-6; Brubakk AO, 2005, J PHYSIOL-LONDON, V566, P901, DOI 10.1113/jphysiol.2005.089862; Brubakk AO, 2001, UNDERSEA HYPERBAR M, V28, P131; Cameron BA, 2007, AVIAT SPACE ENVIR MD, V78, P493; Carturan D, 2002, J APPL PHYSIOL, V93, P1349, DOI 10.1152/japplphysiol.00723.1999; DONALD K W, 1947, Br Med J, V1, ppassim; Durnin J. V., 1969, J PHYSL, V200, P105; Eatock B., 1984, UNDERSEA BIOMED RES, V11, P326; Eftedal O, 1997, UNDERSEA HYPERBAR M, V24, P293; Eftedal OS, 2007, UNDERSEA HYPERBAR M, V34, P99; Harris RJD, 2003, UNDERSEA HYPERBAR M, V30, P285; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Levett DZH, 2008, POSTGRAD MED J, V84, P571, DOI 10.1136/pgmj.2008.068320; Mollerlokken A, 2011, DIVING HYPERB MED, V41, P124; Nishi R. Y., 2003, BENNETT ELLIOTTS PHY, P501; Pollock NW, 2007, ANN DIVING REPORT; Schellart NAM, 2013, J APPL PHYSIOL, V114, P602, DOI 10.1152/japplphysiol.00949.2012; Schellart NAM, 2012, AVIAT SPACE ENVIR MD, V83, P951, DOI 10.3357/ASEM.3189.2012; Spencer MP, 1974, N0001473C0094 I ENV; Thom SR, 2015, J APPL PHYSIOL, V119, P427, DOI 10.1152/japplphysiol.00380.2015; Thom SR, 2013, J APPL PHYSIOL, V114, P1396, DOI 10.1152/japplphysiol.00106.2013; Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9; Zanchi J, 2014, INT J SPORTS MED, V35, P465, DOI 10.1055/s-0033-1334968	25	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2016	11	5							e0154761	10.1371/journal.pone.0154761	http://dx.doi.org/10.1371/journal.pone.0154761			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8BN	27163253	Green Published, gold			2023-01-03	WOS:000376585700018
J	Fleming-Dutra, KE; Hersh, AL; Shapiro, DJ; Bartoces, M; Enns, EA; File, TM; Finkelstein, JA; Gerber, JS; Hyun, DY; Linder, JA; Lynfield, R; Margolis, DJ; May, LS; Merenstein, D; Metlay, JP; Newland, JG; Piccirillo, JF; Roberts, RM; Sanchez, GV; Suda, KJ; Thomas, A; Woo, TM; Zetts, RM; Hicks, LA				Fleming-Dutra, Katherine E.; Hersh, Adam L.; Shapiro, Daniel J.; Bartoces, Monina; Enns, Eva A.; File, Thomas M., Jr.; Finkelstein, Jonathan A.; Gerber, Jeffrey S.; Hyun, David Y.; Linder, Jeffrey A.; Lynfield, Ruth; Margolis, David J.; May, Larissa S.; Merenstein, Daniel; Metlay, Joshua P.; Newland, Jason G.; Piccirillo, Jay F.; Roberts, Rebecca M.; Sanchez, Guillermo V.; Suda, Katie J.; Thomas, Ann; Woo, Teri Moser; Zetts, Rachel M.; Hicks, Lauri A.			Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINE; RESPIRATORY-TRACT INFECTIONS; MANAGEMENT; DIAGNOSIS; TRENDS; PRINCIPLES; CHILDREN; UPDATE	IMPORTANCE The National Action Plan for Combating Antibiotic-Resistant Bacteria set a goal of reducing inappropriate outpatient antibiotic use by 50% by 2020, but the extent of inappropriate outpatient antibiotic use is unknown. OBJECTIVE To estimate the rates of outpatient oral antibiotic prescribing by age and diagnosis, and the estimated portions of antibiotic use that may be inappropriate in adults and children in the United States. DESIGN, SETTING, AND PARTICIPANTS Using the 2010-2011 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, annual numbers and population-adjusted rates with 95% confidence intervals of ambulatory visits with oral antibiotic prescriptions by age, region, and diagnosis in the United States were estimated. EXPOSURES Ambulatory care visits. MAIN OUTCOMES AND MEASURES Based on national guidelines and regional variation in prescribing, diagnosis-specific prevalence and rates of total and appropriate antibiotic prescriptions were determined. These rates were combined to calculate an estimate of the appropriate annual rate of antibiotic prescriptions per 1000 population. RESULTS Of the 184 032 sampled visits, 12.6% of visits (95% CI, 12.0%-13.3%) resulted in antibiotic prescriptions. Sinusitis was the single diagnosis associated with the most antibiotic prescriptions per 1000 population (56 antibiotic prescriptions [95% CI, 48-64]), followed by suppurative otitis media (47 antibiotic prescriptions [95% CI, 41-54]), and pharyngitis (43 antibiotic prescriptions [95% CI, 38-49]). Collectively, acute respiratory conditions per 1000 population led to 221 antibiotic prescriptions (95% CI, 198-245) annually, but only 111 antibiotic prescriptions were estimated to be appropriate for these conditions. Per 1000 population, among all conditions and ages combined in 2010-2011, an estimated 506 antibiotic prescriptions (95% CI, 458-554) were written annually, and, of these, 353 antibiotic prescriptions were estimated to be appropriate antibiotic prescriptions. CONCLUSIONS AND RELEVANCE In the United States in 2010-2011, there was an estimated annual antibiotic prescription rate per 1000 population of 506, but only an estimated 353 antibiotic prescriptions were likely appropriate, supporting the need for establishing a goal for outpatient antibiotic stewardship.	[Fleming-Dutra, Katherine E.; Bartoces, Monina; Roberts, Rebecca M.; Sanchez, Guillermo V.; Hicks, Lauri A.] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA; [Hersh, Adam L.] Univ Utah, Pediat Infect Dis, Salt Lake City, UT USA; [Shapiro, Daniel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Enns, Eva A.] Univ Minnesota, Div Hlth Policy & Management, Minneapolis, MN USA; [File, Thomas M., Jr.] Summa Hlth Syst, Akron, OH USA; [File, Thomas M., Jr.] Northeast Ohio Med Univ, Akron, OH USA; [Finkelstein, Jonathan A.] Boston Childrens Hosp, Boston, MA USA; [Finkelstein, Jonathan A.; Linder, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA USA; [Gerber, Jeffrey S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Gerber, Jeffrey S.; Margolis, David J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Hyun, David Y.; Zetts, Rachel M.] Pew Charitable Trusts, Washington, DC USA; [Linder, Jeffrey A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA; [May, Larissa S.] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA; [Merenstein, Daniel] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA; [Metlay, Joshua P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA; [Newland, Jason G.] Washington Univ, Sch Med, Div Pediat Infect Dis, St Louis, MO USA; [Piccirillo, Jay F.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; [Suda, Katie J.] Univ Illinois, Dept Vet Affairs, Chicago, IL USA; [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA; [Woo, Teri Moser] Pacific Lutheran Univ, Tacoma, WA 98447 USA	Centers for Disease Control & Prevention - USA; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; Summa Health System; Northeast Ohio Medical University (NEOMED); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Brigham & Women's Hospital; Minnesota Department of Health (MHD); University of California System; University of California Davis; Georgetown University; Harvard University; Massachusetts General Hospital; Washington University (WUSTL); Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Pacific Lutheran University	Fleming-Dutra, KE (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA.	ftu2@cdc.gov	Gerber, Jeffrey/GYD-3567-2022; Linder, Jeffrey/AAF-3424-2021	Gerber, Jeffrey/0000-0002-3076-3186; Linder, Jeffrey/0000-0003-2217-184X	Pew Charitable Trusts	Pew Charitable Trusts	This project was made possible through a partnership with the Centers for Disease Control and Prevention (CDC) Foundation. Support for this project was provided by Pew Charitable Trusts.	Anonymous, 2008, Morbidity and Mortality Weekly Report, V57, P1148; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Centers for Disease Control and Prevention, 2013, ANT RES THREATS US; Centers for Disease Control and Prevention, AMB HLTH CAR DAT; Centers for Disease Control and Prevention, GET SMART KNOW ANT W; Chow AW, 2012, CLIN INFECT DIS, V54, pE72, DOI [10.1093/cid/cis370, 10.1093/cid/cir1043]; Drekonja DM, 2015, INFECT CONT HOSP EP, V36, P142, DOI 10.1017/ice.2014.41; European Centre for Disease Prevention and Control, ANN EP REP 2014 ANT; Fine AM, 2012, ARCH INTERN MED, V172, P847, DOI 10.1001/archinternmed.2012.950; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Gerber JS, 2013, PEDIATRICS, V131, P677, DOI 10.1542/peds.2012-2500; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Groth A, 2011, INT J PEDIATR OTORHI, V75, P1496, DOI 10.1016/j.ijporl.2011.08.015; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Healthy People, 2020, IMM INF DIS; Hersh AL, 2013, PEDIATRICS, V132, P1146, DOI 10.1542/peds.2013-3260; Hicks LA, 2015, CLIN INFECT DIS, V60, P1308, DOI 10.1093/cid/civ076; Hing E, NONRESPONSE BIAS EST; Irwin RS, 2006, CHEST, V129, p1S, DOI 10.1378/chest.129.1_suppl.1S; Kronman MP, 2014, PEDIATRICS, V134, pE956, DOI 10.1542/peds.2014-0605; Levri K, 2011, EIS C APR 28 ATL GA; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; Linder JA, 2008, CLIN INFECT DIS, V47, P744, DOI 10.1086/591149; Metlay JP, 2015, CLIN INFECT DIS, V60, P1317, DOI 10.1093/cid/civ081; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; NCQA. HEDIS, 2016, HEDIS 2016; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599815572097; Rosenfeld RM, 2004, PEDIATRICS, V113, P1412, DOI 10.1542/peds.113.5.1412; Shaikh N, 2010, PEDIATRICS, V126, pE557, DOI 10.1542/peds.2009-2648; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Shulman ST, 2012, CLIN INFECT DIS, V55, P1279, DOI 10.1093/cid/cis847; Snow V, 2001, ANN INTERN MED, V134, P487, DOI 10.7326/0003-4819-134-6-200103200-00014; Suda KJ, 2014, ANTIMICROB AGENTS CH, V58, P2763, DOI 10.1128/AAC.02239-13; Swedres-Svarm Reports, 2014, SWEDR SVARM REP; The White House, NAT ACT PLAN COMB AN; US Census Bureau Population Division Vintage, 2010, VINT 2010 SPEC TAB V; Vaz LE, 2014, PEDIATRICS, V133, P375, DOI 10.1542/peds.2013-2903; Wald ER, 2013, PEDIATRICS, V132, pE262, DOI 10.1542/peds.2013-1071	39	943	955	7	81	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2016	315	17					1864	1873		10.1001/jama.2016.4151	http://dx.doi.org/10.1001/jama.2016.4151			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK9XF	27139059	Bronze			2023-01-03	WOS:000375284400015
J	Zhou, R; Kuang, Y; Zhou, J; Du, XW; Li, J; Shi, JF; Haburcak, R; Xu, B				Zhou, Rong; Kuang, Yi; Zhou, Jie; Du, Xuewen; Li, Jie; Shi, Junfeng; Haburcak, Richard; Xu, Bing			Nanonets Collect Cancer Secretome from Pericellular Space	PLOS ONE			English	Article							PROTEIN IDENTIFICATION DATA; CELL-LINES; TUMOR MICROENVIRONMENT; INTERSTITIAL FLUID; SMALL MOLECULES; HYDROGELATION; MECHANISMS; PROTEOMICS; PEPTIDES; EXOSOMES	Identifying novel cancer biomarkers is important for early cancer detection as it can reduce mortality rates. The cancer secretome, the collection of all macromolecules secreted by a tumor cell, alters its composition compared to normal tissue, and this change plays an important role in the observation of cancer progression. The collection and accurate analysis of cancer secretomes could lead to the discovery of novel biomarkers, thus improving outcomes of cancer treatment. We unexpectedly discovered that enzyme-instructed self-assembly (EISA) of a D-peptide hydrogelator results in nanonets/hydrogel around cancer cells that overexpress ectophosphatases. Here we show that these nanonets are able to rapidly collect proteins in the pericellular space (i.e., near the surface) of cancer cells. Because the secretory substances are at their highest concentration near the cell surface, the use of pericellular nanonets to collect the cancer secretome maximizes the yield and quality of samples, reduces pre-analytical variations, and allows the dynamic profiling of secretome samples. Thus, this new approach has great potential in identifying the heterotypic signaling in tumor microenvironments thereby improving the understanding of tumor microenvironments and accelerating the discovery of potential biomarkers in cancer biology. Data are available via ProteomeXchange with identifier PXD003924.	[Zhou, Rong; Kuang, Yi; Zhou, Jie; Du, Xuewen; Li, Jie; Shi, Junfeng; Haburcak, Richard; Xu, Bing] Brandeis Univ, Dept Chem, Waltham, MA 02254 USA	Brandeis University	Xu, B (corresponding author), Brandeis Univ, Dept Chem, Waltham, MA 02254 USA.	bxu@brandeis.edu	Li, Jie/ABD-8476-2021; XU, Bing/A-7828-2008	XU, Bing/0000-0002-4639-387X; Kuang, Yi/0000-0003-3643-2684; Haburcak, Richard/0000-0002-6591-8918	National Institutes of Health [R01CA142746]; Kenneth Rainin Foundation; National Science Foundation [DMR-1420382]; NATIONAL CANCER INSTITUTE [R01CA142746] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kenneth Rainin Foundation; National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is partially supported by National Institutes of Health (R01CA142746), Kenneth Rainin Foundation, and a National Science Foundation grant (DMR-1420382). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Cancer Society, 2013, CANC FACTS FIG 2013; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Barsnes H, 2009, NAT BIOTECHNOL, V27, P598, DOI 10.1038/nbt0709-598; Bendtsen JD, 2004, PROTEIN ENG DES SEL, V17, P349, DOI 10.1093/protein/gzh037; BERNHARD A, 1953, SCIENCE, V118, P114, DOI 10.1126/science.118.3056.114; Bobrie A, 2012, CANCER RES, V72, P4920, DOI 10.1158/0008-5472.CAN-12-0925; Bradshaw RA, 2006, MOL CELL PROTEOMICS, V5, P787, DOI 10.1074/mcp.E600005-MCP200; Brown KJ, 2013, BBA-PROTEINS PROTEOM, V1834, P2454, DOI 10.1016/j.bbapap.2013.04.007; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; ESTEBAN C, 1991, INT J CANCER, V49, P425, DOI 10.1002/ijc.2910490320; Gao Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2040; Gromov P, 2013, BBA-PROTEINS PROTEOM, V1834, P2259, DOI 10.1016/j.bbapap.2013.01.013; Haslene-Hox H, 2013, BBA-PROTEINS PROTEOM, V1834, P2336, DOI 10.1016/j.bbapap.2013.01.028; Iguchi Haruhisa, 2010, Commun Integr Biol, V3, P478, DOI 10.4161/cib.3.5.12693; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Iwata M, 2014, STEM CELLS DEV, V23, P729, DOI 10.1089/scd.2013.0300; Jeffries GDM, 2007, NANO LETT, V7, P415, DOI 10.1021/nl0626784; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kuang Y, 2014, ANGEW CHEM IN PRESS, V53; Lei M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107746; Li JY, 2013, J AM CHEM SOC, V135, P542, DOI 10.1021/ja310019x; Lin QF, 2013, BBA-PROTEINS PROTEOM, V1834, P2360, DOI 10.1016/j.bbapap.2013.01.030; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009; Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989; Mbeunkui F, 2006, J PROTEOME RES, V5, P899, DOI 10.1021/pr050375p; McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Polacek M, 2010, J ORTHOP RES, V28, P1040, DOI 10.1002/jor.21067; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997; Shin SJ, 2013, P NATL ACAD SCI USA, V110, P19414, DOI 10.1073/pnas.1309720110; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870; Tan HY, 2008, OPT COMMUN, V281, P3013, DOI 10.1016/j.optcom.2008.01.012; TANAKA T, 1967, J BIOCHEM-TOKYO, V62, P71, DOI 10.1093/oxfordjournals.jbchem.a128639; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wang XW, 1998, LIFE SCI, V64, P17, DOI 10.1016/S0024-3205(98)00529-3; Whitaker RD, 2011, J BIOL CHEM, V286, P21623, DOI 10.1074/jbc.M111.239897; Wu CC, 2010, MOL CELL PROTEOMICS, V9, P1100, DOI 10.1074/mcp.M900398-MCP200; Xue H, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-52; Yang Z, 2008, ACCOUNTS CHEM RES, V41, P315, DOI 10.1021/ar7001914; Yang Z, 2007, ANGEW CHEM INT EDIT, V46, P8216, DOI 10.1002/anie.200701697; Yang ZM, 2007, ADV MATER, V19, P3152, DOI 10.1002/adma.200701971; Yang ZM, 2006, J AM CHEM SOC, V128, P3038, DOI 10.1021/ja057412y; Yang ZM, 2004, ADV MATER, V16, P1440, DOI 10.1002/adma.200400340; Zhou J, 2014, J AM CHEM S IN PRESS	49	4	4	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2016	11	4							e0154126	10.1371/journal.pone.0154126	http://dx.doi.org/10.1371/journal.pone.0154126			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK4OR	27100780	Green Submitted, Green Published, gold			2023-01-03	WOS:000374898500151
J	Hawkes, N				Hawkes, Nigel			Education team finalists	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2016	353								i2057	10.1136/bmj.i2057	http://dx.doi.org/10.1136/bmj.i2057			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ7EV	27084409				2023-01-03	WOS:000374375600001
J	Weidner, C; Rousseau, M; Plauth, A; Wowro, SJ; Fischer, C; Abdel-Aziz, H; Sauer, S				Weidner, Christopher; Rousseau, Morten; Plauth, Annabell; Wowro, Sylvia J.; Fischer, Cornelius; Abdel-Aziz, Heba; Sauer, Sascha			Iberis amara Extract Induces Intracellular Formation of Reactive Oxygen Species and Inhibits Colon Cancer	PLOS ONE			English	Article							ANTIINFLAMMATORY PROPERTIES; STW-5 IBEROGAST(R); PLANT POLYPHENOLS; ANTIOXIDANTS; THERAPY; HEALTH; CELLS; PROLIFERATION; CHEMOTHERAPY; ANTICANCER	Massively increasing global incidences of colorectal cancer require efficient treatment and prevention strategies. Here, we report unexpected anticancerogenic effects of hydroethanolic Iberis amara extract (IAE), which is known as a widely used phytomedical product for treating gastrointestinal complaints. IAE significantly inhibited the proliferation of HT-29 and T84 colon carcinoma cells with an inhibitory concentration (IC50) of 6 and 9 mu g/ml, respectively, and further generated inhibitory effects in PC-3 prostate and MCF7 breast cancer cells. Inhibition of proliferation in HT-29 cells was associated with a G2/M phase cell cycle arrest including reduced expression of various regulatory marker proteins. Notably, in HT-29 cells IAE further induced apoptosis by intracellular formation of reactive oxygen species (ROS). Consistent with predictions derived from our in vitro experiments, bidaily oral gavage of 50 mg/kg of IAE over 4 weeks resulted in significant inhibition of tumor growth in a mouse HT-29 tumor xenograft model. Taken together, Iberis amara extracts could become useful alternatives for preventing and treating the progression of colon cancer.	[Weidner, Christopher; Rousseau, Morten; Plauth, Annabell; Wowro, Sylvia J.; Fischer, Cornelius; Sauer, Sascha] Max Planck Inst Mol Genet, Otto Warburg Lab, Ihnestr 73, D-14195 Berlin, Germany; [Abdel-Aziz, Heba] Steigerwald Arzneimittelwerk GmbH, Dept Sci, Darmstadt, Germany; [Sauer, Sascha] Univ Wurzburg, CU Syst Med, D-97070 Wurzburg, Germany	Max Planck Society; Bayer AG; Steigerwald Pharmaceutical Factory GmbH; University of Wurzburg	Sauer, S (corresponding author), Max Planck Inst Mol Genet, Otto Warburg Lab, Ihnestr 73, D-14195 Berlin, Germany.; Sauer, S (corresponding author), Univ Wurzburg, CU Syst Med, D-97070 Wurzburg, Germany.	sauer@molgen.mpg.de		Wowro, Sylvia/0000-0003-1728-9210; Plauth, Annabell/0000-0002-4521-1368	German Ministry for Education and Research (BMBF) [0315082, 01EA1303]; Steigerwald Arzneimittelwerk GmbH	German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Steigerwald Arzneimittelwerk GmbH	This work was supported by the German Ministry for Education and Research (BMBF, grant numbers 0315082, 01EA1303). Author HAA was supported by Steigerwald Arzneimittelwerk GmbH in the form of salary. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammon HPT, 2006, PHYTOMEDICINE, V13, P67, DOI 10.1016/j.phymed.2006.08.004; Bonaterra GA, 2013, PHYTOMEDICINE, V20, P691, DOI 10.1016/j.phymed.2013.02.011; Bouayed J, 2010, OXID MED CELL LONGEV, V3, P228, DOI 10.4161/oxim.3.4.12858; Braun Michael S, 2011, Ther Adv Med Oncol, V3, P43, DOI 10.1177/1758834010388342; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Forester SC, 2011, MOL NUTR FOOD RES, V55, P844, DOI 10.1002/mnfr.201000641; Fuhr L, 2015, J NAT PROD, V78, P1160, DOI 10.1021/np500747y; Germann I, 2006, PHYTOMEDICINE, V13, P45, DOI 10.1016/j.phymed.2006.03.018; Halliwell B, 2008, ARCH BIOCHEM BIOPHYS, V476, P107, DOI 10.1016/j.abb.2008.01.028; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hayes JD, 2008, EUR J NUTR, V47, P73, DOI 10.1007/s00394-008-2009-8; Hoensch Harald P, 2005, Int J Gastrointest Cancer, V35, P187, DOI 10.1385/IJGC:35:3:187; Khan HY, 2012, CURR DRUG TARGETS, V13, P1738; Ko JSK, 2013, CURR PHARM DESIGN, V19, P48, DOI 10.2174/13816128130109; Kong YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103760; Kroll U, 2006, PHYTOMEDICINE, V13, P12, DOI 10.1016/j.phymed.2006.03.016; Mitchison TJ, 2012, MOL BIOL CELL, V23, P1, DOI 10.1091/mbc.E10-04-0335; Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044; Ristow M, 2009, P NATL ACAD SCI USA, V106, P8665, DOI 10.1073/pnas.0903485106; Schempp H, 2006, PHYTOMEDICINE, V13, P36, DOI 10.1016/j.phymed.2006.03.017; Shekhar MPV, 2011, CURR CANCER DRUG TAR, V11, P613; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Weidner C, 2015, PHYTOMEDICINE, V22, P262, DOI 10.1016/j.phymed.2014.12.008; Weidner C, 2014, MOL NUTR FOOD RES, V58, P903, DOI 10.1002/mnfr.201300477; Weidner C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080335; Yang Y, 2013, CURR MED CHEM, V20, P3677, DOI 10.2174/0929867311320999165	28	17	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2016	11	4							e0152398	10.1371/journal.pone.0152398	http://dx.doi.org/10.1371/journal.pone.0152398			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6IX	27050665	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000373603500037
J	Cao, DD; Xu, HL; He, AB; Xu, XM; Ge, W				Cao Dedong; Xu Huilin; He Anbing; Xu Ximing; Ge Wei			The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; PLATINUM-BASED CHEMOTHERAPY; THERAPY; HERBS	Objective To evaluate the effect of ShenQi FuZheng Injection (SFI) on cellular immunity and clinical efficacy in patients with advanced non small cell lung cancer(NSCLC) when combined with chemotherapy. Methods Electronic databases including EMBASE, PUBMED, the conference proceedings of the American Society of Clinical Oncology (ASCO), Cochrane, Chinese National Knowledge Infrastructure (CNKI), and Chinese BiologicalMedical disc(CBM) were searched, until July, 2015. The randomized controlled clinical studies reporting results of efficacy and immune function were collected according to the inclusion criteria. Cochrane handbook 5.1.0 was applied to assess the quality of included trials and Revman 5 software was used for data analysis. Results Fifteen studies including 1006 cases of advanced NSCLC were included based on the inclusion criteria. The results ofmeta-analysis showed that there were significant differences in percentages of CD3 + cells (SMD = 13.48; 95% CI: 8.11-18.85; p<0.01), CD4+ cells (SMD = 10.78; 95% CI, 6.38-15.18; p<0.01), NK [ WMD = 8.59, 95% CI(3.97, 13.21), p = 0.003], and ratio of CD4+/ CD8+ (SMD = 0.32; 95%: 0.28-0.36; p<0.01) between SFI combination group and control group, whereas the difference was not significant in CD8+ (SMD = -1.44; 95% CI, -4.53-1.65; p = 0.36). Funnel plot, Begg's rank correlation test and Egger's linear regression analysis indicated that there was significant publication bias across studies. Conclusion SFI is effective to improve the efficacy of chemotherpay and function of cellular immunity in NSCLC patients, however, high quality RCTs are needed to further confirm the findings.	[Cao Dedong; Xu Ximing; Ge Wei] Wuhan Univ, Dept Oncol, RenMin Hosp, Wuhan 430072, Peoples R China; [Xu Huilin; He Anbing] Fifth Hosp Wuhan, Dept Oncol, Wuhan, Peoples R China	Wuhan University	Ge, W (corresponding author), Wuhan Univ, Dept Oncol, RenMin Hosp, Wuhan 430072, Peoples R China.	gewei514@126.com	xu, huilin/HHZ-3153-2022					Caihong L, 2014, THESIS, V2014, P1; Chen S, 2010, LUNG CANCER, V68, P137, DOI 10.1016/j.lungcan.2009.11.008; Chen XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059314; Ding C. J., 2012, GANSU J TRADITIONAL, V25, P7; Dong J, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-137; Dugoua JJ, 2010, LUNG CANCER-TARGETS, V1, P85; Gopalakrishnan S, 2013, J Family Med Prim Care, V2, P9, DOI 10.4103/2249-4863.109934; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jiang HJ, 2015, J CANCER RES THER, V11, pC101, DOI 10.4103/0973-1482.163855; Jing W, 2013, GUIDE CHINA MED, V11, P503; Karachaliou N, 2015, CANCER BIOL MED, V12, P79, DOI 10.7497/j.issn.2095-3941.2015.0029; Kohlhapp FJ, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0063-3; Lee JW, 2015, EUR J INTEGR MED, V7, P577, DOI 10.1016/j.eujim.2015.08.005; Li G, 2004, J MED FORUM, V25, P29; Li J, 2015, CHIN J INTEGR MED, V21, P71, DOI 10.1007/s11655-014-1768-8; Li K, 2015, J CANCER RES CLIN, V141, P1249, DOI 10.1007/s00432-014-1867-0; Li SG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057604; Li XM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003641; Li YL, 2015, INT J CLIN EXP MED, V8, P7816; Lijuan N, 2015, INT J RESP, V35, P192; Lili Z, 2009, TREATING ADV NONSMAL; Lortet-Tieulent J, 2014, LUNG CANCER, V84, P13, DOI 10.1016/j.lungcan.2014.01.009; MAN A, 2012, SHANDONG MED J, V52, P60; McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392; Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019; Qiao SL, 2012, CHINA PRAC MED, V7, P25; Qiguang L, 2011, JIANGXI J TRADITIONA, V42, P44; Ren J. S., 2015, MODERN J INTEGRATED, V24, P1286; Ren L., 2014, CHINESE J CLIN ONCOL, V21, P463; She J, 2013, CHEST, V143, P1117, DOI 10.1378/chest.11-2948; Tao Z, 2009, CANC RES CLIN, P706; Wang JX, 2014, J ETHNOPHARMACOL, V155, P405, DOI 10.1016/j.jep.2014.05.038; Wang JX, 2012, J ETHNOPHARMACOL, V139, P788, DOI 10.1016/j.jep.2011.12.019; Yangfan L, 2011, CHINA MODERN MED, V18, P83; Yin JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038150; Ying J, 2005, CHINA PHARM, V16, P772; Yiyu S, 2007, J EMERGENCY TRADITIO, V16, P776; Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141	38	12	17	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2016	11	3							e0152270	10.1371/journal.pone.0152270	http://dx.doi.org/10.1371/journal.pone.0152270			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3TE	27015629	Green Submitted, Green Published, gold			2023-01-03	WOS:000372708900049
J	Baime, MJ				Baime, Michael J.			In chronic nonspecific neck pain, adding Alexander Technique lessons or acupuncture to usual care reduced pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Baime, Michael J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Baime, MJ (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.							Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2	1	3	3	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	2016	164	6					JC29	JC29		10.7326/ACPJC-2016-164-6-029	http://dx.doi.org/10.7326/ACPJC-2016-164-6-029			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG6PG	26974729				2023-01-03	WOS:000372207200004
J	Knight, J; Perkovic, V				Knight, John; Perkovic, Vlado			The Affordable Dialysis Prize steams ahead	LANCET			English	Editorial Material							KIDNEY		[Knight, John; Perkovic, Vlado] George Inst Global Hlth, Sydney, NSW 2000, Australia	George Institute for Global Health; University of Sydney	Perkovic, V (corresponding author), George Inst Global Hlth, Sydney, NSW 2000, Australia.	VPerkovic@georgeinstitute.org.au	Perkovic, Vlado/AAY-1933-2021					Karopadi AN, 2013, NEPHROL DIAL TRANSPL, V28, P2553, DOI 10.1093/ndt/gft214; Kolff WJ, 1944, ACTA MED SCAND, V117, P121; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9	3	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	2016	387	10023					1040	1040		10.1016/S0140-6736(16)00657-7	http://dx.doi.org/10.1016/S0140-6736(16)00657-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DG0SD	26970720				2023-01-03	WOS:000371775000010
J	Gopal, S; Fedoriw, Y; Kaimila, B; Montgomery, ND; Kasonkanji, E; Moses, A; Nyasosela, R; Mzumara, S; Varela, C; Chikasema, M; Makwakwa, V; Itimu, S; Tomoka, T; Kamiza, S; Dhungel, BM; Chimzimu, F; Kampani, C; Krysiak, R; Richards, KL; Shea, TC; Liomba, NG				Gopal, Satish; Fedoriw, Yuri; Kaimila, Bongani; Montgomery, Nathan D.; Kasonkanji, Edwards; Moses, Agnes; Nyasosela, Richard; Mzumara, Suzgo; Varela, Carlos; Chikasema, Maria; Makwakwa, Victor; Itimu, Salama; Tomoka, Tamiwe; Kamiza, Steve; Dhungel, Bal M.; Chimzimu, Fred; Kampani, Coxcilly; Krysiak, Robert; Richards, Kristy L.; Shea, Thomas C.; Liomba, N. George			CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi	PLOS ONE			English	Article							B-CELL LYMPHOMA; RITUXIMAB; CANCER; RADIOTHERAPY; AFRICA; TRENDS; EPOCH	There are no prospective studies of aggressive non-Hodgkin lymphoma (NHL) treated with CHOP in sub-Saharan Africa. We enrolled adults with aggressive NHL in Malawi between June 2013 and May 2015. Chemotherapy and supportive care were standardized, and HIV + patients received antiretroviral therapy (ART). Thirty-seven of 58 patients (64%) were HIV +. Median age was 47 years (IQR 39-56), and 35 (60%) were male. Thirty-five patients (60%) had stage III/IV, 43 (74%) B symptoms, and 28 (48%) performance status >= 2. B-cell NHL predominated among HIV+ patients, and all T-cell NHL occurred among HIV-individuals. Thirty-one HIV+ patients (84%) were on ART for a median 9.9 months (IQR 1.1-31.7) before NHL diagnosis, median CD4 was 121 cells/mu L (IQR 61-244), and 43% had suppressed HIV RNA. HIV+ patients received a similar number of CHOP cycles compared to HIV-patients, but more frequently developed grade 3/4 neutropenia (84% vs 31%, p = 0.001), resulting in modestly lower cyclophosphamide and doxorubicin doses with longer intervals between cycles. Twelve-month overall survival (OS) was 45% (95% CI 31-57%). T-cell NHL (HR 3.90, p = 0.017), hemoglobin (HR 0.82 per g/dL, p = 0.017), albumin (HR 0.57 per g/dL, p = 0.019), and IPI (HR 2.02 per unit, p<0.001) were associated with mortality. HIV was not associated with mortality, and findings were similar among patients with diffuse large B-cell lymphoma. Twenty-three deaths were from NHL (12 HIV+, 11 HIV-), and 12 from CHOP (9 HIV+, 3 HIV-). CHOP can be safe, effective, and feasible for aggressive NHL in Malawi with and without HIV.	[Gopal, Satish; Kaimila, Bongani; Kasonkanji, Edwards; Moses, Agnes; Chikasema, Maria; Makwakwa, Victor; Itimu, Salama; Chimzimu, Fred; Kampani, Coxcilly; Krysiak, Robert; Liomba, N. George] UNC Project Malawi, Lilongwe, Malawi; [Gopal, Satish; Fedoriw, Yuri; Shea, Thomas C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Fedoriw, Yuri; Montgomery, Nathan D.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Gopal, Satish; Moses, Agnes; Mzumara, Suzgo; Varela, Carlos; Tomoka, Tamiwe; Kamiza, Steve] Univ Malawi, Coll Med, Blantyre, Malawi; [Nyasosela, Richard; Mzumara, Suzgo; Varela, Carlos; Dhungel, Bal M.] Kamuzu Cent Hosp, Lilongwe, Malawi; [Richards, Kristy L.] Weill Cornell Med Coll, Ithaca, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Malawi; Cornell University	Gopal, S (corresponding author), UNC Project Malawi, Lilongwe, Malawi.; Gopal, S (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Gopal, S (corresponding author), Univ Malawi, Coll Med, Blantyre, Malawi.	gopal@med.unc.edu		Montgomery, Nathan/0000-0003-1765-6623; Dhungel, Bal Mukunda/0000-0003-3132-9370	National Institutes of Health [K01TW009488, R21CA180815, U54CA190152]; Medical Education Partnership Initiative [U2GPS001965]; Lineberger Comprehensive Cancer Center [P30CA016086]; AIDS Malignancy Consortium [U01CA121947]; leadership of Kamuzu Central Hospital; UNC Project-Malawi; Lineberger Comprehensive Cancer Center; FOGARTY INTERNATIONAL CENTER [K01TW009488] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U54CA190152, P30CA016086, R21CA180815, U01CA121947] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Education Partnership Initiative; Lineberger Comprehensive Cancer Center; AIDS Malignancy Consortium; leadership of Kamuzu Central Hospital; UNC Project-Malawi; Lineberger Comprehensive Cancer Center; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (K01TW009488, R21CA180815, and U54CA190152) (S.G.), the Medical Education Partnership Initiative (U2GPS001965) (S.K.), as well as the Lineberger Comprehensive Cancer Center (P30CA016086) and AIDS Malignancy Consortium (U01CA121947). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We especially wish to thank patients and their families for participating despite extraordinarily challenging circumstances, which reflects their deep commitment to improving cancer care in Malawi. We also wish to acknowledge Wiza Kumwenda for developing the study database, and Charles Mabedi, Melanie Sion, Jared Gallaher, Carol Shores, and Anthony Charles for assistance obtaining biopsy specimens. We additionally acknowledge leadership of Kamuzu Central Hospital (Jonathan Ngoma), UNC Project-Malawi (Irving Hoffman, Innocent Mofolo, Mina Hosseinipour, Francis Martinson), and Lineberger Comprehensive Cancer Center (Shelley Earp, Ned Sharpless, Lisa Carey, Blossom Damania, Dirk Dittmer) for their support of this study.	Abdel-Wahab M, 2013, LANCET ONCOL, V14, pE168, DOI 10.1016/S1470-2045(12)70532-6; Adesina A, 2013, LANCET ONCOL, V14, pE152, DOI 10.1016/S1470-2045(12)70598-3; Bateganya MH, 2011, JAIDS-J ACQ IMM DEF, V56, P312, DOI 10.1097/QAI.0b013e31820c011a; Brinkhof MWG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014149; Chokunonga E, 2013, INT J CANCER, V133, P721, DOI 10.1002/ijc.28063; Coghill AE, 2013, AIDS, V27, P2933, DOI 10.1097/01.aids.0000433236.55937.cb; Davies A, 2014, LANCET ONCOL, V15, P343, DOI 10.1016/S1470-2045(14)70005-1; de Witt P, 2013, JAIDS-J ACQ IMM DEF, V64, P66, DOI 10.1097/QAI.0b013e3182a03e9b; Dunleavy K, 2013, NEW ENGL J MED, V369, P1915, DOI 10.1056/NEJMoa1308392; Dunleavy K, 2012, BLOOD, V119, P3245, DOI 10.1182/blood-2011-08-373738; Dunleavy K, 2010, BLOOD, V115, P3017, DOI 10.1182/blood-2009-11-253039; Egger M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000390; Ferlay J., 2013, IARC CANCERBASE, V11; Gopal S, 2013, JNCI-J NATL CANCER I, V105, P1221, DOI 10.1093/jnci/djt158; Gopal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070361; Gopal S, 2012, BLOOD, V119, P5078, DOI 10.1182/blood-2012-02-387092; Hentrich M, 2012, J CLIN ONCOL, V30, P4117, DOI 10.1200/JCO.2012.41.8137; Montoto S, 2012, J CLIN ONCOL, V30, P4111, DOI 10.1200/JCO.2011.41.4193; Mwanda WO, 2009, J CLIN ONCOL, V27, P3480, DOI 10.1200/JCO.2008.18.7641; Naresh KN, 2011, BRIT J HAEMATOL, V154, P696, DOI 10.1111/j.1365-2141.2011.08772.x; Orem Jackson, 2012, Clin Epidemiol, V4, P339, DOI 10.2147/CLEP.S35671; Parkin DM, 2010, INT J CANCER, V126, P1187, DOI 10.1002/ijc.24838; Persky DO, 2008, J CLIN ONCOL, V26, P2258, DOI 10.1200/JCO.2007.13.6929; Phan Jack, 2010, J Clin Oncol, V28, P4170, DOI 10.1200/JCO.2009.27.3441; Roy PS, 2013, INDIAN J MED PAEDIAT, V34, P292, DOI 10.4103/0971-5851.125248; Sparano JA, 2010, BLOOD, V115, P3008, DOI 10.1182/blood-2009-08-231613; UNAIDS, MAL PROGR REP 2013; United Nations Statistics Division, MAL COUNTR PROF	29	27	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2016	11	3							e0150445	10.1371/journal.pone.0150445	http://dx.doi.org/10.1371/journal.pone.0150445			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0AN	26934054	Green Published, gold, Green Submitted			2023-01-03	WOS:000371724200092
J	Van Holle, V; Van Cauwenberg, J; Gheysen, F; Van Dyck, D; Deforche, B; Van de Weghe, N; De Bourdeaudhuij, I				Van Holle, Veerle; Van Cauwenberg, Jelle; Gheysen, Freja; Van Dyck, Delfien; Deforche, Benedicte; Van de Weghe, Nico; De Bourdeaudhuij, Ilse			The Association between Belgian Older Adults' Physical Functioning and Physical Activity: What Is the Moderating Role of the Physical Environment?	PLOS ONE			English	Article							NEIGHBORHOOD WALKABILITY; BUILT ENVIRONMENT; COMPUTER-SCIENCE; WALKING; PEOPLE; PERFORMANCE; ATTRIBUTES; DECLINES; VALIDITY; MOBILITY	Background Better physical functioning in the elderly may be associated with higher physical activity levels. Since older adults spend a substantial part of the day in their residential neighborhood, the neighborhood physical environment may moderate associations between functioning and older adults' physical activity. The present study investigated the moderating role of the objective and perceived physical environment on associations between Belgian older adults' physical functioning and transport walking, recreational walking, and moderate-to-vigorous physical activity. Methods Data from 438 older adults were included. Objective physical functioning was assessed using the Short Physical Performance Battery. Potential moderators included objective neighborhood walkability and perceptions of land use mix diversity, access to recreational facilities, access to services, street connectivity, physical barriers for walking, aesthetics, crime-related safety, traffic speeding-related safety, and walking infrastructure. Transport and recreational walking were self-reported, moderate-to-vigorous physical activity was assessed through accelerometers. Multi-level regression analyses were conducted using MLwiN to examine two-way interactions between functioning and the environment on both walking outcomes. Based on a previous study where environment x neighborhood income associations were found for Belgian older adults' moderate-to-vigorous physical activity, three-way functioning x environment x income interactions were examined for moderate-to-vigorous physical activity. Results Objectively-measured walkability moderated the association between functioning and transport walking; this positive association was only present in high-walkable neighborhoods. Moreover, a three-way interaction was observed for moderate-to-vigorous physical activity. Only in high-income, high-walkable neighborhoods, there was a positive association between functioning and moderate-to-vigorous physical activity. No functioning x walkability interactions were observed for recreational walking, and none of the perceived environmental variables moderated the positive association between physical functioning and the physical activity outcomes. Conclusions For older adults with better physical functioning, living in a high-walkable neighborhood could be beneficial to engage in more transport walking. Living in high-income, high-walkable neighborhoods and having better functioning might also be beneficial for more engagement in moderate-to-vigorous physical activity. This might suggest a protective role of neighborhood walkability for preventing declining physical functioning and consequently decreasing physical activity levels in older adults. However, given the cross-sectional design of the present study, this suggestion needs to be confirmed through longitudinal assessment investigating over-time changes in the observed associations.	[Van Holle, Veerle; Gheysen, Freja; Van Dyck, Delfien; De Bourdeaudhuij, Ilse] Univ Ghent, Dept Movement & Sport Sci, B-9000 Ghent, Belgium; [Van Cauwenberg, Jelle; Deforche, Benedicte] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium; [Van Cauwenberg, Jelle; Deforche, Benedicte] Vrije Univ Brussel, Dept Human Biometry & Biomech, Brussels, Belgium; [Van de Weghe, Nico] Univ Ghent, Dept Geog, B-9000 Ghent, Belgium; [Van Holle, Veerle; Van Cauwenberg, Jelle; Van Dyck, Delfien] Res Fdn Flanders FWO, Brussels, Belgium	Ghent University; Ghent University; Vrije Universiteit Brussel; Ghent University	Van Dyck, D (corresponding author), Univ Ghent, Dept Movement & Sport Sci, B-9000 Ghent, Belgium.; Van Dyck, D (corresponding author), Res Fdn Flanders FWO, Brussels, Belgium.	delfien.vandyck@ugent.be	Van de Weghe, Nico/N-4214-2019; Van de Weghe, Nico/B-7680-2011; Van Dyck, Delfien/AAO-8981-2020; De+Bourdeaudhuij, Ilse/AAC-5528-2019	Van de Weghe, Nico/0000-0002-5327-4000; Van de Weghe, Nico/0000-0002-5327-4000; De+Bourdeaudhuij, Ilse/0000-0001-9969-7597; Van Cauwenberg, Jelle/0000-0003-1292-6241; Van Dyck, Delfien/0000-0003-1783-9075	Fund for Scientific Research Flanders (FWO) [11O3115N, 11N0313N, WO12/PDO/158]	Fund for Scientific Research Flanders (FWO)(FWO)	VVH, JVC and DVD were supported by a grant from the Fund for Scientific Research Flanders (FWO; www.fwo.be). Grant numbers: VVH: 11O3115N, JVC: 11N0313N, DVD: WO12/PDO/158.	Adams MA, 2014, INT J HEALTH GEOGR, V13, DOI 10.1186/1476-072X-13-43; Berke EM, 2007, AM J PUBLIC HEALTH, V97, P486, DOI 10.2105/AJPH.2006.085837; Bruce DG, 2002, J AM GERIATR SOC, V50, P84, DOI 10.1046/j.1532-5415.2002.50012.x; Cain K.L., 2011, ACCELEROMETER DATA C; Van Cauwenberg J, 2011, HEALTH PLACE, V17, P458, DOI 10.1016/j.healthplace.2010.11.010; Cerin E, 2013, PREV MED, V56, P86, DOI 10.1016/j.ypmed.2012.10.024; Cerin E, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-84; Choi L, 2012, MED SCI SPORT EXER, V44, P2009, DOI 10.1249/MSS.0b013e318258cb36; Copeland JL, 2009, J AGING PHYS ACTIV, V17, P17, DOI 10.1123/japa.17.1.17; Giehl MWC, 2012, REV SAUDE PUBL, V46, P516, DOI 10.1590/S0034-89102012000300014; da Costa EM, 2012, ARCH PUBLIC HEALTH, V70, DOI 10.1186/0778-7367-70-1; Daly M, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01044; Denkinger MD, 2015, AM J GERIAT PSYCHIAT, V23, P72, DOI 10.1016/j.jagp.2014.03.002; Devereux K, 2005, AUST J PHYSIOTHER, V51, P102, DOI 10.1016/S0004-9514(05)70038-6; Ferreira FR, 2010, J URBAN HEALTH, V87, P54, DOI 10.1007/s11524-009-9406-z; Forsyth A, 2009, TRANSPORT RES D-TR E, V14, P42, DOI 10.1016/j.trd.2008.10.003; Frank LD, 2010, BRIT J SPORT MED, V44, P924, DOI 10.1136/bjsm.2009.058701; Frank L, 2010, J PHYS ACT HEALTH, V7, pS82, DOI 10.1123/jpah.7.s1.s82; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Frontera WR, 2000, AM J PHYSIOL-CELL PH, V279, pC611, DOI 10.1152/ajpcell.2000.279.3.C611; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hall KS, 2010, HEALTH EDUC RES, V25, P478, DOI 10.1093/her/cyq019; King AC, 2011, SOC SCI MED, V73, P1525, DOI 10.1016/j.socscimed.2011.08.032; Kirkendall DT, 1998, AM J SPORT MED, V26, P598, DOI 10.1177/03635465980260042401; Kremers SPJ, 2006, INT J BEHAV NUTR PHY, V3, DOI 10.1186/1479-5868-3-9; Lim K, 2005, PREV MED, V40, P33, DOI 10.1016/j.ypmed.2004.04.046; Manini TM, 2009, BRIT J SPORT MED, V43, P28, DOI 10.1136/bjsm.2008.053736; Matthews C.E., 2002, PHYS ACTIVITY ASSESS, P107; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; MELANSON EL, 1995, MED SCI SPORT EXER, V27, P934; Milanovic Z, 2013, CLIN INTERV AGING, V8, DOI 10.2147/CIA.S44112; Morie M, 2010, J AM GERIATR SOC, V58, P1727, DOI 10.1111/j.1532-5415.2010.03012.x; Murtagh EM, 2010, CURR OPIN CARDIOL, V25, P490, DOI 10.1097/HCO.0b013e32833ce972; National Institute of Statistics-Belgium, 2014, FOD EC KMO MIDD EN; NEWMAN PWG, 1991, TRANSPORT REV, V11, P249, DOI 10.1080/01441649108716787; Peace S., 2007, AGEING SOC, P209; Prince F, 1997, GAIT POSTURE, V5, P128, DOI 10.1016/S0966-6362(97)01118-1; Pruitt LA, 2008, J AGING PHYS ACTIV, V16, P416, DOI 10.1123/japa.16.4.416; Rasinaho M, 2007, J AGING PHYS ACTIV, V15, P90, DOI 10.1123/japa.15.1.90; Rimmer James H, 2005, Phys Med Rehabil Clin N Am, V16, P41, DOI 10.1016/j.pmr.2004.06.013; Rockwood K, 2004, J GERONTOL A-BIOL, V59, P1310, DOI 10.1093/gerona/59.12.1310; Sahlqvist S, 2012, PREV MED, V55, P206, DOI 10.1016/j.ypmed.2012.06.028; Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100; Satariano WA, 2010, AM J PREV MED, V38, P419, DOI 10.1016/j.amepre.2009.12.031; Shigematsu R, 2009, MED SCI SPORT EXER, V41, P314, DOI 10.1249/MSS.0b013e318185496c; Shimura H, 2014, J PHYS ACT HEALTH, V11, P1078, DOI 10.1123/jpah.2012-0244; Shimura H, 2012, J PHYS ACT HEALTH, V9, P1004, DOI 10.1123/jpah.9.7.1004; SIEGEL PZ, 1995, AM J PUBLIC HEALTH, V85, P706, DOI 10.2105/AJPH.85.5.706; Stathi A, 2012, J AGING PHYS ACTIV, V20, P148, DOI 10.1123/japa.20.2.148; Thompson CW, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2012-091718; Twisk J, 2006, APPL MULTILEVEL ANAL, DOI [10.1017/CBO9780511610806, DOI 10.1017/CBO9780511610806]; United Nations, 2013, WORLD POP AG AG 2013, P114, DOI ST/ESA/SER.A/348; Van Cauwenberg J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-142; Van Dyck D, 2015, J SPORT MED PHYS FIT, V55, P776; Van Dyck D, 2010, PREV MED, V50, pS74, DOI 10.1016/j.ypmed.2009.07.027; Van Holle V, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1785-3; Van Holle V, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0110-3; Wahl HW, 2004, ANNU REV GERONTOL GE, V23, P1; Wang L, 2002, J AM GERIATR SOC, V50, P1525, DOI 10.1046/j.1532-5415.2002.50408.x; Yorston LC, 2012, J AM GERIATR SOC, V60, P719, DOI 10.1111/j.1532-5415.2012.03906.x	60	34	34	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148398	10.1371/journal.pone.0148398	http://dx.doi.org/10.1371/journal.pone.0148398			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6SI	26872017	Green Published, Green Submitted, gold			2023-01-03	WOS:000370054100028
J	do Prado, C; Guinsburg, R; de Almeida, MFB; Mascaretti, RS; Vale, LA; Haddad, LB; Rebello, CM				do Prado, Cristiane; Guinsburg, Ruth; Branco de Almeida, Maria Fernanda; Mascaretti, Renata Suman; Vale, Luciana Assis; Haddad, Luciana Branco; Rebello, Celso Moura			Manual Ventilation and Sustained Lung Inflation in an Experimental Model: Influence of Equipment Type and Operator's Training	PLOS ONE			English	Article							FUNCTIONAL RESIDUAL CAPACITY; END-EXPIRATORY PRESSURE; T-PIECE RESUSCITATOR; NEONATAL RESUSCITATION; TIDAL VOLUME; PRETERM INFANTS; MASK VENTILATION; AIRWAY PRESSURE; BIRTH; DEVICES	Aim To compare the influence of devices for manual ventilation and individual experience on the applied respiratory mechanics and sustained lung inflation. Methods A total of 114 instructors and non-instructors from the Neonatal Resuscitation Program of the Brazilian Society of Pediatrics participated in this study. Participants ventilated an intubated manikin. To evaluate respiratory mechanics and sustained lung inflation parameters, a direct comparison was made between the self-inflating bag and the T-shaped resuscitator (T-piece), followed by an analysis of the effectiveness of the equipment according to the participants' education and training. Results A difference between equipment types was observed for the tidal volume, with a median (interquartile range) of 28.5 mL (12.6) for the self-inflating bag and 20.1 mL (8.4) for the T-piece in the instructor group and 31.6 mL (14) for the self-inflating bag and 22.3 mL (8.8) for the T-piece in the non-instructor group. Higher inspiratory time values were observed with the T-piece in both groups of professionals, with no significant difference between them. The operator's ability to maintain the target pressure over the 10 seconds of sustained lung inflation was evaluated using the area under the pressure-time curve and was 1.7-fold higher with the use of the T-piece. Inspiratory pressure and mean airway pressure applied during sustained lung inflation were greater with the self-inflating bag, as evaluated between the beginning and the end of the procedure. Conclusion The T-piece resulted in lower tidal volume and higher inspiratory time values, irrespective of the operator's experience, and increased the ease of performing the sustained lung inflation maneuver, as demonstrated by the maintenance of target pressure for the desired period and a higher mean airway pressure than that obtained using the self-inflating bag.	[do Prado, Cristiane; Rebello, Celso Moura] Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, SP, Brazil; [Guinsburg, Ruth; Branco de Almeida, Maria Fernanda] Brazilian Soc Pediat, Neonatal Resuscitat Program, Sao Paulo, SP, Brazil; [Mascaretti, Renata Suman] Hosp Vila Santa Catarina, Dept Pediat, Sao Paulo, SP, Brazil; [do Prado, Cristiane; Vale, Luciana Assis; Haddad, Luciana Branco; Rebello, Celso Moura] Hosp Israelita Albert Einstein, Dept Pediat, Sao Paulo, SP, Brazil; [Guinsburg, Ruth; Branco de Almeida, Maria Fernanda] Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert Einstein; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	do Prado, C (corresponding author), Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, SP, Brazil.; do Prado, C (corresponding author), Hosp Israelita Albert Einstein, Dept Pediat, Sao Paulo, SP, Brazil.	crisprado@einstein.br	Guinsburg, Ruth/F-1984-2013; Rebello, Celso M/E-9400-2013	Guinsburg, Ruth/0000-0003-1967-9861; Rebello, Celso/0000-0002-4637-6295	Brazilian Society of Pediatrics	Brazilian Society of Pediatrics	The authors gratefully acknowledge Dr. Eduardo da Silva Vaz, Chair of the Brazilian Society of Pediatrics for his generous support.	Attar Mohammad Ali, 2002, Semin Neonatol, V7, P353, DOI 10.1053/siny.2002.0129; Bennett S, 2005, RESUSCITATION, V67, P113, DOI 10.1016/j.resuscitation.2005.02.016; Dawson JA, 2011, J PAEDIATR CHILD H, V47, P698, DOI 10.1111/j.1440-1754.2011.02036.x; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Ersdal HL, 2012, RESUSCITATION, V83, P869, DOI 10.1016/j.resuscitation.2011.12.011; Hawkes CP, 2012, RESUSCITATION, V83, P797, DOI 10.1016/j.resuscitation.2011.12.020; Hillman NH, 2012, PEDIATR RES, V72, P593, DOI 10.1038/pr.2012.135; Hussey SG, 2004, ARCH DIS CHILD-FETAL, V89, pF490, DOI 10.1136/adc.2003.047712; Jobe AH, 2008, NEONATOLOGY, V94, P190, DOI 10.1159/000143721; Klingenberg C, 2011, NEONATOLOGY, V100, P78, DOI 10.1159/000322983; Lista G, 2015, PEDIATRICS, V135, pE457, DOI 10.1542/peds.2014-1692; McHale S, 2008, RESUSCITATION, V79, P230, DOI 10.1016/j.resuscitation.2008.06.024; Murthy V, 2012, ARCH DIS CHILD-FETAL, V97, pF249, DOI 10.1136/archdischild-2011-300117; O'Donnell CPF, 2012, CLIN PERINATOL, V39, P857, DOI 10.1016/j.clp.2012.09.010; O'Reilly M, 2013, CRIT CARE RES PRACT, V2013, P1; Oddie S, 2005, RESUSCITATION, V67, P109, DOI 10.1016/j.resuscitation.2005.05.004; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Polglase GR, 2008, PEDIATR RES, V64, P517, DOI 10.1203/PDR.0b013e3181841363; Polglase GR, 2009, PEDIATR RES, V65, P67, DOI 10.1203/PDR.0b013e318189487e; Roehr CC, 2010, AM J PERINAT, V27, P753, DOI 10.1055/s-0030-1254236; Roehr CC, 2010, RESUSCITATION, V81, P202, DOI 10.1016/j.resuscitation.2009.10.008; Schmolzer GM, 2010, ARCH DIS CHILD-FETAL, V95, pF393, DOI 10.1136/adc.2009.174003; Szyld E, 2014, J PEDIATR-US, V165, P234, DOI 10.1016/j.jpeds.2014.02.035; te Pas AB, 2009, PEDIATR RES, V66, P295, DOI 10.1203/PDR.0b013e3181b1bca4; te Pas AB, 2009, PEDIATR RES, V65, P537, DOI 10.1203/PDR.0b013e31819da21b; Thio M, 2014, ARCH DIS CHILD-FETAL, V99, pF274, DOI 10.1136/archdischild-2013-305239	26	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148475	10.1371/journal.pone.0148475	http://dx.doi.org/10.1371/journal.pone.0148475			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859896	gold, Green Published, Green Submitted			2023-01-03	WOS:000370038400046
J	Gill, TM; Pahor, M; Guralnik, JM; McDermott, MM; King, AC; Buford, TW; Strotmeyer, ES; Nelson, ME; Sink, KM; Demons, JL; Kashaf, SS; Walkup, MP; Miller, ME				Gill, Thomas M.; Pahor, Marco; Guralnik, Jack M.; McDermott, Mary M.; King, Abby C.; Buford, Thomas W.; Strotmeyer, Elsa S.; Nelson, Miriam E.; Sink, Kaycee M.; Demons, Jamehl L.; Kashaf, Susan S.; Walkup, Michael P.; Miller, Michael E.		LIFE Study Investigators	Effect of structured physical activity on prevention of serious fall injuries in adults aged 70-89: randomized clinical trial (LIFE Study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OLDER-ADULTS; STYLE INTERVENTIONS; HEALTH-EDUCATION; INDEPENDENCE; EXERCISE; ELDERS; RISK; PERFORMANCE; DISABILITY; OUTCOMES	OBJECTIVE To test whether a long term, structured physical activity program compared with a health education program reduces the risk of serious fall injuries among sedentary older people with functional limitations. DESIGN Multicenter, single blinded randomized trial (Lifestyle Interventions and Independence for Elders (LIFE) study). SETTING Eight centers across the United States between February 2010 and December 2013. PARTICIPANTS 1635 sedentary adults aged 70-89 years with functional limitations, defined as a short physical performance battery score <= 9, but who were able to walk 400 m. INTERVENTIONS A permuted block algorithm stratified by field center and sex was used to allocate interventions. Participants were randomized to a structured, moderate intensity physical activity program (n=818) conducted in a center (twice a week) and at home (3-4 times a week) that included aerobic, strength, flexibility, and balance training activities, or to a health education program (n=817) consisting of workshops on topics relevant to older people and upper extremity stretching exercises. MAIN OUTCOME MEASURES Serious fall injuries, defined as a fall that resulted in a clinical, non-vertebral fracture or that led to a hospital admission for another serious injury, was a prespecified secondary outcome in the LIFE Study. Outcomes were assessed every six months for up to 42 months by staff masked to intervention assignment. All participants were included in the analysis. RESULTS Over a median follow-up of 2.6 years, a serious fall injury was experienced by 75 (9.2%) participants in the physical activity group and 84 (10.3%) in the health education group (hazard ratio 0.90, 95% confidence interval 0.66 to 1.23; P=0.52). These results were consistent across several subgroups, including sex. However, in analyses that were not prespecified, sex specific differences were observed for rates of all serious fall injuries (rate ratio 0.54, 95% confidence interval 0.31 to 0.95 in men; 1.07, 0.75 to 1.53 in women; P=0.043 for interaction), fall related fractures (0.47, 0.25 to 0.86 in men; 1.12, 0.77 to 1.64 in women; P=0.017 for interaction), and fall related hospital admissions (0.41, 0.19 to 0.89 in men; 1.10, 0.65 to 1.88 in women; P=0.039 for interaction). CONCLUSIONS In this trial, which was underpowered to detect small, but possibly important reductions in serious fall injuries, a structured physical activity program compared with a health education program did not reduce the risk of serious fall injuries among sedentary older people with functional limitations. These null results were accompanied by suggestive evidence that the physical activity program may reduce the rate of fall related fractures and hospital admissions in men.	[Gill, Thomas M.; Kashaf, Susan S.] Yale Univ, Sch Med, Dept Med, Adler Geriatr Ctr, 874 Howard Ave, New Haven, CT 06510 USA; [Pahor, Marco; Buford, Thomas W.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA; [Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [King, Abby C.] Stanford Sch Med, Dept Hlth Res, Stanford, CA USA; [King, Abby C.] Stanford Sch Med, Dept Policy & Med, Stanford, CA USA; [Strotmeyer, Elsa S.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Nelson, Miriam E.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA; [Sink, Kaycee M.; Demons, Jamehl L.] Wake Forest Sch Med, Dept Med, Winston Salem, NC USA; [Walkup, Michael P.; Miller, Michael E.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA	Yale University; State University System of Florida; University of Florida; University System of Maryland; University of Maryland Baltimore; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tufts University; Wake Forest University; Wake Forest University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dept Med, Adler Geriatr Ctr, 874 Howard Ave, New Haven, CT 06510 USA.	thomas.gill@yale.edu	Buford, Thomas W/B-1111-2011; King, Abby/AAD-5257-2021; Gill, Thomas M./H-7043-2019; Sink, Kaycee/AAY-5920-2020	Buford, Thomas W/0000-0002-9541-4358; Gill, Thomas M./0000-0002-6450-0368; Kaplan, Robert/0000-0003-4837-5330; Strotmeyer, Elsa/0000-0002-4093-6036; Handberg, Eileen/0000-0002-7805-9577; Sink, Kaycee/0000-0001-9608-3856; King, Abby/0000-0002-7949-8811	National Institutes of Health (NIH) [U01AG22376]; National Institute on Aging; National Heart, Lung, and Blood Institute [U01AG022376]; Intramural Research Program; Claude D Pepper Older Americans Independence Centers at the University of Florida [P30AG028740]; Wake Forest University [P30AG21332]; Tufts University [P30AG031679]; University of Pittsburgh [P30AG024827]; Yale University [P30AG021342, UL1TR000142]; NIH/NCATS CTSA at Stanford University [UL1RR025744]; University of Florida [U54RR025208]; Boston Rehabilitation Outcomes Center [R24HD065688]; National Institute on Aging [K07AG3587]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD065688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142, UL1TR001427, UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024827, P30AG021342, U01AG022376, P30AG031679, K07AG043587, P30AG021332, P30AG028740] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural Research Program; Claude D Pepper Older Americans Independence Centers at the University of Florida; Wake Forest University; Tufts University; University of Pittsburgh(University of Pittsburgh); Yale University; NIH/NCATS CTSA at Stanford University; University of Florida(University of Florida); Boston Rehabilitation Outcomes Center; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by cooperative agreement U01AG22376 from the National Institutes of Health (NIH) and National Institute on Aging; supplement U01AG022376 from the National Heart, Lung, and Blood Institute; and sponsorship in part from the Intramural Research Program. The research is partially supported by the Claude D Pepper Older Americans Independence Centers at the University of Florida (P30AG028740), Wake Forest University (P30AG21332), Tufts University (P30AG031679), University of Pittsburgh (P30AG024827), and Yale University (P30AG021342), and the NIH/NCATS CTSA at Stanford University (UL1RR025744), University of Florida (U54RR025208) and Yale University (UL1TR000142). Tufts University is also supported by the Boston Rehabilitation Outcomes Center (R24HD065688). LIFE investigators are also partially supported by the following: TMG is the recipient of an academic leadership award (K07AG3587) from the National Institute on Aging.	Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; cdc, 2021, CTR DIS CONTROL PREV; Centers for Disease Control and Prevention, 2015, COST FALLS OLD AD; Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P225; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Fielding RA, 2011, J GERONTOL A-BIOL, V66, P1226, DOI 10.1093/gerona/glr123; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Ganz DA, 2005, J AM GERIATR SOC, V53, P2190, DOI 10.1111/j.1532-5415.2005.00509.x; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Groessl EJ, 2016, J GERONTOL A; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; KING MB, 1995, J AM GERIATR SOC, V43, P1146, DOI 10.1111/j.1532-5415.1995.tb07017.x; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Marsh AP, 2013, J GERONTOL A-BIOL, V68, P1549, DOI 10.1093/gerona/glt064; Matthews CE, 2005, MED SCI SPORT EXER, V37, pS512, DOI 10.1249/01.mss.0000185659.11982.3d; Moye LA, 2010, MULTIPLE ANALYSES IN; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Quach L, 2013, J GERONTOL A-BIOL, V68, P1575, DOI 10.1093/gerona/glt084; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Sink KM, 2015, JAMA-J AM MED ASSOC, V314, P781, DOI 10.1001/jama.2015.9617; Srikanth V, 2009, STROKE, V40, P175, DOI 10.1161/STROKEAHA.108.524355; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tinetti ME, 1998, J GERONTOL A-BIOL, V53, pM112, DOI 10.1093/gerona/53A.2.M112; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806	29	51	53	0	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2016	352								i245	10.1136/bmj.i245	http://dx.doi.org/10.1136/bmj.i245			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DD2QN	26842425	hybrid, Green Published			2023-01-03	WOS:000369767400002
J	Shaw, C; Nitsch, D; Lee, J; Fogarty, D; Sharpe, CC				Shaw, Catriona; Nitsch, Dorothea; Lee, Jasmine; Fogarty, Damian; Sharpe, Claire C.			Impact of an Early Invasive Strategy versus Conservative Strategy for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome in Patients with Chronic Kidney Disease: A Systematic Review	PLOS ONE			English	Article							REAL-WORLD-DATA; MYOCARDIAL-INFARCTION; RENAL-FUNCTION; ANGIOGRAPHY; MANAGEMENT; REVASCULARIZATION; OUTCOMES; THERAPIES; TRIALS	Background Clinical practice guidelines support an early invasive approach after NSTE-ACS in patients with chronic kidney disease (CKD). There is no direct randomised controlled trial evidence in the CKD population, and whether the benefit of an early invasive approach is maintained across the spectrum of severity of CKD remains controversial. Methods We conducted a systematic review to evaluate the association between an early invasive approach and all-cause mortality in patients with CKD. We searched MEDLINE and EMBASE (1990-May 2015) and article reference lists. Data describing study design, participants, invasive management strategies, renal function, all-cause mortality and risk of bias were extracted. Results 3,861 potentially relevant studies were identified. Ten studies, representing data on 147,908 individuals with NSTE-ACS met the inclusion criteria. Qualitative heterogeneity in the definitions of early invasive approach, comparison groups and renal dysfunction existed. Meta-analysis of the RCT derived and observational data were generally supportive of an early invasive approach in CKD (RR0.76 (95% CI 0.49-1.17) and RR0.50 (95% CI 0.42-0.59) respectively). Meta-analysis of the observational studies demonstrated a large degree of heterogeneity (I-2 79%) driven in part by study size and heterogeneity across various kidney function levels. Conclusions The observational data support that an early invasive approach after NSTE-ACS confers a survival benefit in those with early-moderate CKD. Local opportunities for quality improvement should be sought. Those with severe CKD and the dialysis population are high risk and under-studied. Novel and inclusive approaches for CKD and dialysis patients in cardiovascular clinical trials are needed.	[Shaw, Catriona] Southmead Hosp, UK Renal Registry, London, England; [Shaw, Catriona; Sharpe, Claire C.] Kings Coll London, Dept Renal Med, London WC2R 2LS, England; [Nitsch, Dorothea] London Sch Hyg & Trop Med, London WC1, England; [Lee, Jasmine] Guys & St Thomas NHS Fdn Trust, Dept Renal Med, London, England; [Fogarty, Damian] Belfast Hlth & Social Care Trust, Dept Renal Med, Belfast, Antrim, North Ireland	Southmead Hospital; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust	Shaw, C (corresponding author), Southmead Hosp, UK Renal Registry, London, England.; Shaw, C (corresponding author), Kings Coll London, Dept Renal Med, London WC2R 2LS, England.	catriona.shaw@nhs.net	Sharpe, Claire/B-5619-2015	Sharpe, Claire/0000-0003-1704-8492; Nitsch, Dorothea/0000-0001-5767-248X	UK Renal Registry; Medical Research Council [MR/J006742/1] Funding Source: researchfish	UK Renal Registry; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has contributed to Dr C Shaw's PhD which is funded by the UK Renal Registry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinina SA, 2011, TERAPEVT ARKH, V83, P20; Altahan RY, 2011, CARDIOLOGY, V119, P224, DOI 10.1159/000332588; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Bhatt DL, 2004, JAMA-J AM MED ASSOC, V292, P2096, DOI 10.1001/jama.292.17.2096; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Charytan DM, 2009, CLIN J AM SOC NEPHRO, V4, P1032, DOI 10.2215/CJN.05551008; Chertow GM, 2004, J AM SOC NEPHROL, V15, P2462, DOI 10.1097/01.ASN.0000135969.33773.0B; Chu CY, 2013, NEPHRON CLIN PRACT, V124, P38, DOI 10.1159/000355008; Coca SG, 2006, JAMA-J AM MED ASSOC, V296, P1377, DOI 10.1001/jama.296.11.1377; D'Errigo P, 2010, ACTA CARDIOL, V65, P645, DOI 10.1080/AC.65.6.2059861; de Winter RJ, 2005, NEW ENGL J MED, V353, P1095, DOI 10.1056/NEJMoa044259; Fox CS, 2010, CIRCULATION, V121, P357, DOI 10.1161/CIRCULATIONAHA.109.865352; Goldenberg I, 2010, ARCH INTERN MED, V170, P888, DOI 10.1001/archinternmed.2010.95; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Imai T, 2000, Nihon Ronen Igakkai Zasshi, V37, P272; James MT, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4151; James MT, 2011, CIRCULATION, V123, P409, DOI 10.1161/CIRCULATIONAHA.110.970160; Jneid H, 2012, CIRCULATION, V126, P875, DOI 10.1161/CIR.0b013e318256f1e0; Lin TH, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-66; Ozen N, 2010, TURK KARDIYOL DERN A, V38, P393; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Rothman KJ, 2008, MODERN EPIDEMIOLOGY, V3rd, P106; Shaw C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099925; Spacek R, 2002, EUR HEART J, V23, P230, DOI 10.1053/euhj.2001.2735; Szummer K, 2009, CIRCULATION, V120, P851, DOI 10.1161/CIRCULATIONAHA.108.838169; Wallentin L, 1999, LANCET, V354, P708; Wong JA, 2009, EUR HEART J, V30, P549, DOI 10.1093/eurheartj/ehp014; Yang RQ, 2014, EXP CLIN CARDIOL, V20, P145	28	19	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0153478	10.1371/journal.pone.0153478	http://dx.doi.org/10.1371/journal.pone.0153478			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27195786	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000376291100005
J	Sambol, NC; Tappero, JW; Arinaitwe, E; Parikh, S				Sambol, Nancy C.; Tappero, Jordan W.; Arinaitwe, Emmanuel; Parikh, Sunil			Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; DIHYDROARTEMISININ-PIPERAQUINE; POPULATION PHARMACOKINETICS; ARTEMISININ RESISTANCE; SULFADOXINE-PYRIMETHAMINE; THERAPEUTIC RESPONSE; UGANDAN CHILDREN; CLINICAL-TRIAL; DOUBLE-BLIND; PHARMACODYNAMICS	Background The combination of short-acting dihydroartemisinin and long-acting piperaquine (DP) is among the first-line therapies for the treatment of uncomplicated Plasmodium falciparum malaria. Population pharmacokinetic models of piperaquine (PQ) based on data from acute treatment of young children can be used to predict exposure profiles of piperaquine under different DP chemoprevention regimens. The purpose of our study was to make such predictions in young children. Methods Based on a prior population pharmacokinetic model of PQ in young Ugandan children, we simulated capillary plasma concentration-time profiles (including their vloading dose improves early exposure, thereby reducing the risk of breakthrough infections at the initiation of chemoprevention. Conclusions Once weekly chemoprevention of DP predicts favourable exposures with respect to both trough and peak concentrations. These predictions need to be verified, as well as safety evaluated, in field-based clinical studies of young children. Simulations based on prior knowledge provide a systematic information-driven approach to evaluate candidate DP chemopreventive regimens for future trial designs.ariability) of candidate chemoprevention regimens for a reference population of 1-2 year olds weighing at least 11 kg. Candidate regimens that were tested included monthly administration of standard therapeutic doses, bimonthly dosing, and weekly dosing (with and without a loading dose). Results Once daily doses of 320 mg for three days (960 mg total) at the beginning of each month are predicted to achieve an average steady-state trough capillary piperaquine concentration of 35 ng/mL, with 60% achieving a level of 30 ng/mL or higher. In contrast, weekly dosing of 320 mg (i.e., 33% higher amount per month) is predicted to approximately double the average steady-state trough concentration, increase the percent of children predicted to achieve 30 ng/mL or higher (94%), while at the same time lowering peak concentrations. Exposure at steady-state, reached at approximately 3 months of multiple dosing, is expected to be approximately 2-fold higher than exposure following initial dosing, due to accumulation. A loading dose improves early exposure, thereby reducing the risk of breakthrough infections at the initiation of chemoprevention. Conclusions Once weekly chemoprevention of DP predicts favourable exposures with respect to both trough and peak concentrations. These predictions need to be verified, as well as safety evaluated, in field- based clinical studies of young children. Simulations based on prior knowledge provide a systematic information- driven approach to evaluate candidate DP chemopreventive regimens for future trial designs.	[Sambol, Nancy C.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Tappero, Jordan W.] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Atlanta, GA USA; [Arinaitwe, Emmanuel] Makerere Univ, Sch Med, Kampala, Uganda; [Parikh, Sunil] Yale Univ, Sch Publ Hlth, New Haven, CT USA	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; Makerere University; Yale University	Parikh, S (corresponding author), Yale Univ, Sch Publ Hlth, New Haven, CT USA.	sunil.parikh@yale.edu			National Institutes of Health [5R01HD068174]; President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention [U62P024421]; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) [U62PS024421] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by funding by the National Institutes of Health (Parikh and Aweeka [grant number #5R01HD068174]). This research has also been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention under the terms of U62P024421. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achan J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001564; Agency EM, EUR DIH PIP PHOSPH E; Amaratunga C, 2016, LANCET INFECT DIS, V16, P357, DOI 10.1016/S1473-3099(15)00487-9; Arinaitwe E, 2009, CLIN INFECT DIS, V49, P1629, DOI 10.1086/647946; Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981; Barnes KI, 2008, TRENDS PARASITOL, V24, P127, DOI 10.1016/j.pt.2007.11.008; Bauer R.J., 2009, NONMEM USERS GUIDE; Bergstrand M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3005311; Bigira V, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001689; Blesius A, 2006, CLIN PHARMACOKINET, V45, P95, DOI 10.2165/00003088-200645010-00007; Bojang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011225; Checchi F, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-59; Cisse B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007164; Conrad MD, 2014, J INFECT DIS, V210, P344, DOI 10.1093/infdis/jiu141; Creek DJ, 2013, J INFECT DIS, V207, P1646, DOI 10.1093/infdis/jit078; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Eckhoff P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044950; Ezzet F, 1998, BRIT J CLIN PHARMACO, V46, P553, DOI 10.1046/j.1365-2125.1998.00830.x; Flexner C, 2010, CLIN INFECT DIS, V50, P1041, DOI 10.1086/651118; Gordi T, 2005, BRIT J CLIN PHARMACO, V60, P594, DOI 10.1111/j.1365-2125.2005.02508.x; Hayes DJ, 2015, B WORLD HEALTH ORGAN, V93, P74, DOI 10.2471/BLT.14.139113; Hietala SF, 2010, ANTIMICROB AGENTS CH, V54, P4780, DOI 10.1128/AAC.00252-10; Johnston GL, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003025; Kamya MR, 2014, AIDS, V28, P2701, DOI 10.1097/QAD.0000000000000497; Kay K, 2015, ANTIMICROB AGENTS CH, V59, P6419, DOI 10.1128/AAC.00482-15; Kay K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003151; Klein K, 2012, J PHARM PHARMACOL, V64, P1603, DOI 10.1111/j.2042-7158.2012.01554.x; Kloprogge F, 2015, BRIT J CLIN PHARMACO, V80, P642, DOI 10.1111/bcp.12660; Leang R, 2015, ANTIMICROB AGENTS CH, V59, P4719, DOI 10.1128/AAC.00835-15; Lwin KM, 2012, ANTIMICROB AGENTS CH, V56, P1571, DOI 10.1128/AAC.05877-11; Manning J, 2014, ANTIMICROB AGENTS CH, V58, P6056, DOI 10.1128/AAC.02667-14; McGready R, 2012, BRIT J CLIN PHARMACO, V73, P467, DOI 10.1111/j.1365-2125.2011.04103.x; Nankabirwa J, 2014, TROP MED INT HEALTH, V19, P1294, DOI 10.1111/tmi.12374; Nankabirwa J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013438; Patel K, 2013, ANTIMICROB AGENTS CH, V57, P508, DOI [10.1128/AAC.01463-12, 10.1128/AA]; Price RN, 2007, ANTIMICROB AGENTS CH, V51, P4090, DOI 10.1128/AAC.00486-07; Sambol NC, 2015, CLIN PHARMACOL THER, V98, P87, DOI 10.1002/cpt.104; Saunders DL, 2014, NEW ENGL J MED, V371, P484, DOI 10.1056/NEJMc1403007; Sundell K, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0908-8; Takala-Harrison S, 2015, J INFECT DIS, V211, P670, DOI 10.1093/infdis/jiu491; Tarning J, 2012, CLIN PHARMACOL THER, V91, P497, DOI 10.1038/clpt.2011.254; Tarning J, 2012, ANTIMICROB AGENTS CH, V56, P1997, DOI 10.1128/AAC.05756-11; White NJ, 2013, ANTIMICROB AGENTS CH, V57, P5792, DOI 10.1128/AAC.00287-13; WHO, 2010, GUID TREATM MAL, V2nd; WHO, 2015, GUID TREATM MAL, VThird; World Health Organization, 2013, SEAS MAL CHEM SULF P; Zaloumis S, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-303; Zongo I, 2015, ANTIMICROB AGENTS CH, V59, P4387, DOI 10.1128/AAC.04923-14	48	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2016	11	5							e0154623	10.1371/journal.pone.0154623	http://dx.doi.org/10.1371/journal.pone.0154623			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3XH	27182702	Green Published, gold			2023-01-03	WOS:000376279500005
J	Singh, SP; Anderson, B; Liabo, K; Ganeshamoorthy, T				Singh, Swaran P.; Anderson, Beth; Liabo, Kristin; Ganeshamoorthy, Thines		Guideline Committee	Supporting young people in their transition to adults' services: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Singh, Swaran P.] Univ Warwick, Warwick, England; [Singh, Swaran P.] Birmingham & Solihull Mental Hlth Fdn Trust, Birmingham, W Midlands, England; [Singh, Swaran P.] Forward Thinking Birmingham, Birmingham, W Midlands, England; [Anderson, Beth] Social Care Inst Excellence, London SW1Y 5BP, England; [Ganeshamoorthy, Thines] Univ Exeter, Sch Med, Peninsula Collaborat Leadership Appl Hlth Res Pen, Exeter, Devon, England; [Guideline Committee] Royal Coll Paediat & Child Hlth, London, England	University of Warwick; University of Exeter	Anderson, B (corresponding author), Social Care Inst Excellence, London SW1Y 5BP, England.	Beth.Anderson@scie.org.uk	Ganeshamoorthy, Thines/AAV-1333-2021	Ganeshamoorthy, Thines/0000-0003-2558-1502; Anderson, Beth/0000-0001-5613-6722				Beresford B, 2009, TRANS AD SERV DIS YO; Clarke S, 2011, J INTEGR CARE, V19, P30, DOI 10.1108/14769011111176734; Department of Health, 2006, TRANS GETT RIGHT YOU; National Institute for Health and Care Excellence, 2016, TRANS CHILDR AD SERV; National Institute for Health and Care Excellence, 2004, DEV NICE GUID MAN; Singh SP, 2010, BRIT J PSYCHIAT, V197, P305, DOI 10.1192/bjp.bp.109.075135; Watson AR, 2005, PEDIATR NEPHROL, V20, P113, DOI 10.1007/s00467-004-1763-y	7	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	2016	353								i2225	10.1136/bmj.i2225	http://dx.doi.org/10.1136/bmj.i2225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6FR	27170336				2023-01-03	WOS:000376446500002
J	Gerth, HU; Pohlen, M; Gorlich, D; Tholking, G; Kropff, M; Berdel, WE; Pavenstadt, H; Brand, M; Kumpers, P				Gerth, Hans U.; Pohlen, Michele; Goerlich, Dennis; Thoelking, Gerold; Kropff, Martin; Berdel, Wolfgang E.; Pavenstaedt, Hermann; Brand, Marcus; Kuempers, Philipp			Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; FREE LIGHT-CHAINS; HEMODIALYSIS; FAILURE; CHEMOTHERAPY; THERAPY; REVERSIBILITY; NEPHROPATHY; IMPROVEMENT; IMPAIRMENT	Background High-cut-off hemodialysis (HCO-HD) can effectively reduce high concentrations of circulating serum free light chains (sFLC) in patients with dialysis-dependent acute kidney injury (AKI) due to multiple myeloma (MM). Therefore, the aim of this study was to analyze renal recovery in a retrospective single-center cohort of dialysis-dependent MM patients treated with either conventional HD (conv. HD) or HCO-HD. Methods and Results The final cohort consisted of 59 patients treated with HCO-HD (n = 42) or conv. HD (n = 17). A sustained sFLC response was detected in a significantly higher proportion of HCO-HD patients (83.3%) compared with conv. HD patients (29.4%; p = 0.007). The median duration of sFLC required to reach values < 1000 mg/l was 14.5 days in the HCO-HD group and 36 days in the conv. HD group. The corresponding rates of renal recovery were 64.3% and 29.4%, respectively (chi-squared test, p = 0.014). Multivariate regression and decision tree analysis (recursive partitioning) revealed HCO-HD (adjusted odds ratio [OR] 6.1 [95% confidence interval (CI) 1.5-24.5], p = 0.011) and low initial uric acid values (adjusted OR 1.3 [95% CI 1.0-1.7], p = 0.045) as independent and paramount variables associated with a favorable renal outcome. Conclusions In summary, the results from this retrospective case-control study suggest in addition to novel agent-based chemotherapy a benefit of HCO-HD in sFLC removal and renal outcome in dialysis-dependent AKI secondary to MM. This finding was especially pertinent in patients with low initial uric acid values, resulting in a promising renal recovery rate of 71.9%. Further prospective studies are warranted.	[Gerth, Hans U.; Thoelking, Gerold; Pavenstaedt, Hermann; Brand, Marcus; Kuempers, Philipp] Univ Hosp Muenster, Dept Med D, Div Gen Internal Med Nephrol & Rheumatol, Munster, Germany; [Pohlen, Michele; Kropff, Martin; Berdel, Wolfgang E.] Univ Hosp Muenster, Dept Med Hematol & Oncol A, Munster, Germany; [Goerlich, Dennis] Univ Hosp Muenster, Inst Biostat & Clin Res, Munster, Germany	University of Munster; University of Munster; University of Munster	Gerth, HU (corresponding author), Univ Hosp Muenster, Dept Med D, Div Gen Internal Med Nephrol & Rheumatol, Munster, Germany.	ulrich.gerth@ukmuenster.de	Görlich, Dennis/C-8950-2012	Görlich, Dennis/0000-0002-2574-9419				Dimopoulos MA, 2014, ANN ONCOL, V25, P195, DOI 10.1093/annonc/mdt483; Dimopoulos MA, 2013, LEUKEMIA, V27, P423, DOI 10.1038/leu.2012.182; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Haynes RJ, 2010, NEPHROL DIAL TRANSPL, V25, P419, DOI 10.1093/ndt/gfp488; Heyne N, 2012, ANN HEMATOL, V91, P729, DOI 10.1007/s00277-011-1383-0; Hutchison CA, 2007, J AM SOC NEPHROL, V18, P886, DOI 10.1681/ASN.2006080821; Hutchison CA, 2012, NEPHROL DIAL TRANSPL, V27, P3823, DOI 10.1093/ndt/gfr773; Hutchison CA, 2011, J AM SOC NEPHROL, V22, P1129, DOI 10.1681/ASN.2010080857; Hutchison CA, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-55; Hutchison CA, 2009, CLIN J AM SOC NEPHRO, V4, P745, DOI 10.2215/CJN.04590908; Jorres A, 2013, NEPHROL DIAL TRANSPL, V28, P2940, DOI 10.1093/ndt/gft297; Joung KW, 2014, J CARDIOTHOR VASC AN, V28, P1440, DOI 10.1053/j.jvca.2014.04.020; Khan R, 2015, LEUKEMIA, V29, P1195, DOI 10.1038/leu.2015.15; Knudsen LM, 2000, EUR J HAEMATOL, V65, P175, DOI 10.1034/j.1600-0609.2000.90221.x; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Levey AS, 2010, AM J KIDNEY DIS, V55, P622, DOI 10.1053/j.ajkd.2010.02.337; Ludwig H, 2010, J CLIN ONCOL, V28, P4635, DOI 10.1200/JCO.2010.28.1238; Murphy PT, 2014, BRIT J HAEMATOL, V165, P890, DOI 10.1111/bjh.12818; Najafi I, 2008, J NEPHROL, V21, P776; Otomo K, 2015, CLIN EXP NEPHROL; Peters NO, 2011, HEMODIAL INT, V15, P538, DOI 10.1111/j.1542-4758.2011.00587.x; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Tsakiris DJ, 2010, NEPHROL DIAL TRANSPL, V25, P1200, DOI 10.1093/ndt/gfp679; Yadav P, 2015, EUR J HAEMATOL; Zannetti BA, 2015, AM J HEMATOL, V90, P647, DOI 10.1002/ajh.24035	26	15	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154993	10.1371/journal.pone.0154993	http://dx.doi.org/10.1371/journal.pone.0154993			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	27152520	gold, Green Submitted, Green Published			2023-01-03	WOS:000375677000057
J	Goligher, EC; Ferguson, ND; Brochard, LJ				Goligher, Ewan C.; Ferguson, Niall D.; Brochard, Laurent J.			Clinical challenges in mechanical ventilation	LANCET			English	Article							RESPIRATORY-DISTRESS-SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION; END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; NONINVASIVE VENTILATION; ACUTE EXACERBATIONS; PULMONARY-EDEMA; RECRUITMENT MANEUVERS; ESOPHAGEAL PRESSURE; DIAPHRAGM THICKNESS	Mechanical ventilation supports gas exchange and alleviates the work of breathing when the respiratory muscles are overwhelmed by an acute pulmonary or systemic insult. Although mechanical ventilation is not generally considered a treatment for acute respiratory failure per se, ventilator management warrants close attention because inappropriate ventilation can result in injury to the lungs or respiratory muscles and worsen morbidity and mortality. Key clinical challenges include averting intubation in patients with respiratory failure with non-invasive techniques for respiratory support; delivering lung-protective ventilation to prevent ventilator-induced lung injury; maintaining adequate gas exchange in severely hypoxaemic patients; avoiding the development of ventilator-induced diaphragm dysfunction; and diagnosing and treating the many pathophysiological mechanisms that impair liberation from mechanical ventilation. Personalisation of mechanical ventilation based on individual physiological characteristics and responses to therapy can further improve outcomes.	[Goligher, Ewan C.; Ferguson, Niall D.; Brochard, Laurent J.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Goligher, Ewan C.; Ferguson, Niall D.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Goligher, Ewan C.; Ferguson, Niall D.] Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada; [Goligher, Ewan C.; Ferguson, Niall D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Brochard, Laurent J.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1T8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Brochard, LJ (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1T8, Canada.	brochardl@smh.ca	Ferguson, Niall/D-7619-2019	Ferguson, Niall/0000-0002-6213-5264; Goligher, Ewan/0000-0002-0990-6701	Covidien; Philips; Fisher-Paykel; Maquet; General Electric	Covidien; Philips; Fisher-Paykel; Maquet; General Electric(General Electric)	LJB reports receiving support in the form of grants and equipment from Covidien, Philips, Fisher-Paykel, Maquet, and General Electric. ECG and NDF declare no competing interests.	Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55; Adler D, 2014, AM J RESP CRIT CARE, V190, P347, DOI 10.1164/rccm.201404-0655LE; Akoumianaki E, 2014, AM J RESP CRIT CARE, V189, P520, DOI 10.1164/rccm.201312-2193CI; Akoumianaki E, 2013, CHEST, V143, P927, DOI 10.1378/chest.12-1817; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; ASHBAUGH DG, 1967, LANCET, V2, P319; BAKER A B, 1971, Medical History, V15, P336; Barbaro RP, 2015, AM J RESP CRIT CARE, V191, P894, DOI 10.1164/rccm.201409-1634OC; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Beitler JR, 2014, INTENS CARE MED, V40, P332, DOI 10.1007/s00134-013-3194-3; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bellani G, 2014, CURR OPIN CRIT CARE, V20, P352, DOI 10.1097/MCC.0000000000000089; Blanch L, 2015, INTENS CARE MED, V41, P633, DOI 10.1007/s00134-015-3692-6; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379; Carteaux G, 2013, CRIT CARE MED, V41, P2125, DOI 10.1097/CCM.0b013e31828a42e5; Chandra D, 2012, AM J RESP CRIT CARE, V185, P152, DOI 10.1164/rccm.201106-1094OC; CHENEY FW, 1980, ANESTHESIOLOGY, V52, P496, DOI 10.1097/00000542-198006000-00009; Chiumello D, 2015, AM J RESP CRIT CARE, DOI [10.1164/rccm.201507-1413OC, DOI 10.1164/RCCM.201507-14130C]; Chiumello D, 2008, AM J RESP CRIT CARE, V178, P346, DOI 10.1164/rccm.200710-1589OC; Chiumello D, 2014, CRIT CARE MED, V42, P252, DOI 10.1097/CCM.0b013e3182a6384f; Combes A, 2014, AM J RESP CRIT CARE, V190, P488, DOI 10.1164/rccm.201404-0630CP; DANTZKER DR, 1980, CHEST, V77, P636, DOI 10.1378/chest.77.5.636; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; Del Sorbo L, 2014, LANCET RESP MED, V2, P154, DOI 10.1016/S2213-2600(13)70197-8; Demoule A, 2004, BRIT J ANAESTH, V93, P295, DOI 10.1093/bja/aeh185; Dessap AM, 2016, INTENS CARE MED, V42, P862, DOI 10.1007/s00134-015-4141-2; Dessap AM, 2012, AM J RESP CRIT CARE, V186, P1256, DOI 10.1164/rccm.201205-0939OC; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Ebihara S, 2002, AM J RESP CRIT CARE, V165, P221, DOI 10.1164/ajrccm.165.2.2108041; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2016, INTENS CARE MED, V42, P663, DOI 10.1007/s00134-015-4200-8; Gea JQ, 2009, ARCH BRONCONEUMOL, V45, P68, DOI 10.1016/j.arbres.2008.04.003; Girou E, 2000, JAMA-J AM MED ASSOC, V284, P2361, DOI 10.1001/jama.284.18.2361; Goligher EC, 2015, AM J RESP CRIT CARE, V192, P1416, DOI 10.1164/rccm.201410-1832CP; Goligher EC, 2015, AM J RESP CRIT CARE, V192, P1080, DOI 10.1164/rccm.201503-0620OC; Goligher EC, 2015, INTENS CARE MED, V41, P642, DOI 10.1007/s00134-015-3687-3; Goligher EC, 2014, AM J RESP CRIT CARE, V190, P70, DOI 10.1164/rccm.201404-0688OC; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Hernandez G, 2016, JAMA-J AM MED ASSOC, V315, P1354, DOI 10.1001/jama.2016.2711; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hooijman PE, 2015, AM J RESP CRIT CARE, V191, P1126, DOI 10.1164/rccm.201412-2214OC; Ibsen B, 1966, Int Anesthesiol Clin, V4, P277, DOI 10.1097/00004311-196622000-00003; Jaber S, 2016, JAMA-J AM MED ASSOC, V315, P1345, DOI 10.1001/jama.2016.2706; Jiang TX, 1998, AM J RESP CRIT CARE, V157, P736, DOI 10.1164/ajrccm.157.3.9707056; Jubran A, 2013, JAMA-J AM MED ASSOC, V309, P671, DOI 10.1001/jama.2013.159; Jubran A, 2010, INTENS CARE MED, V36, P828, DOI 10.1007/s00134-010-1842-4; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kavanagh BP, 2005, INTENS CARE MED, V31, P1161, DOI 10.1007/s00134-005-2729-7; LEMAIRE F, 1988, ANESTHESIOLOGY, V69, P171, DOI 10.1097/00000542-198808000-00004; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Lorusso R, 2016, ANN THORAC SURG, V101, P919, DOI 10.1016/j.athoracsur.2015.08.014; Maggiore SM, 2014, AM J RESP CRIT CARE, V190, P282, DOI 10.1164/rccm.201402-0364OC; Martin AD, 2011, CRIT CARE, V15, DOI 10.1186/cc10081; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Matamis D, 2013, INTENS CARE MED, V39, P801, DOI 10.1007/s00134-013-2823-1; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; Mekontso-Dessap A, 2006, INTENS CARE MED, V32, P1529, DOI 10.1007/s00134-006-0339-7; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Miller DR, 2010, THORAX, V65, P938, DOI 10.1136/thx.2009.134411; NASH G, 1967, NEW ENGL J MED, V276, P368, DOI 10.1056/NEJM196702162760702; Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Perren A, 2013, INTENS CARE MED, V39, P1885, DOI 10.1007/s00134-013-3014-9; Pham T, 2013, AM J RESP CRIT CARE, V187, P276, DOI 10.1164/rccm.201205-0815OC; Piastra M, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.08.006; Poulton EP, 1936, LANCET, V2, P981; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; RUTLEDGE FS, 1988, J APPL PHYSIOL, V64, P1908, DOI 10.1152/jappl.1988.64.5.1908; Slutsky AS, 2015, AM J RESP CRIT CARE, V191, P1106, DOI 10.1164/rccm.201503-0421PP; Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Sud S, 2014, CAN MED ASSOC J, V186, pE381, DOI 10.1503/cmaj.140081; Supinski GS, 2013, CRIT CARE, V17, DOI 10.1186/cc12792; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Thille AW, 2013, AM J RESP CRIT CARE, V187, P1294, DOI 10.1164/rccm.201208-1523CI; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Vassilakopoulos T, 1998, AM J RESP CRIT CARE, V158, P378, DOI 10.1164/ajrccm.158.2.9710084; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101; Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC; Yoshida T, 2013, CRIT CARE MED, V41, P536, DOI 10.1097/CCM.0b013e3182711972; Zanella A, 2015, AM J RESP CRIT CARE, V192, P719, DOI 10.1164/rccm.201502-0289OC; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	100	65	80	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2016	387	10030					1856	1866		10.1016/S0140-6736(16)30176-3	http://dx.doi.org/10.1016/S0140-6736(16)30176-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK6SS	27203509				2023-01-03	WOS:000375056100034
J	Fitzpatrick, KE; Gray, R; Quigley, MA				Fitzpatrick, Kate E.; Gray, Ron; Quigley, Maria A.			Women's Longitudinal Patterns of Smoking during the Pre-Conception, Pregnancy and Postnatal Period: Evidence from the UK Infant Feeding Survey	PLOS ONE			English	Article							MODEL-SELECTION; CESSATION; RELAPSE; COHORT; EPIDEMIOLOGY; PREVALENCE; CRITERION; OUTCOMES	Background An understanding of women's longitudinal patterns of smoking during the pre-conception, pregnancy and postnatal period and the factors associated with these patterns could help better inform smoking cessation services and interventions. Methods Latent class analysis (LCA) was used to empirically identify women's smoking patterns in a sample of 10,768 mothers from the 2010 UK Infant Feeding Survey. Multinomial logistic regression was used to identify characteristics associated with these patterns. Results LCA identified five distinct smoking patterns during the pre-conception, pregnancy and postnatal period: "non-smokers" (74.1% of women); "pregnancy-inspired quitters" (10.2%); "persistent smokers" (10.1%); "temporary quitters" (4.4%); and postnatal quitters (1.1%). Smoking patterns varied markedly according to socio-demographic variables and parity. After adjusting for these variables, mothers who lived during pregnancy with a partner who smoked were more likely to be temporary quitters (aOR 2.64, 95% CI 1.74-3.99) or persistent smokers (aOR 3.32, 95% CI 2.34-4.72) than pregnancy-inspired quitters. Mothers who lived during pregnancy with someone else other than a partner who smoked were more likely to be persistent smokers (aOR 2.34, 95% CI 1.38-3.97) or postnatal quitters (aOR 2.97, 95% CI 1.078.24) than pregnancy-inspired quitters. Mothers given information on how their partner could stop smoking if they lived during pregnancy with a smoking partner were less likely to be persistent smokers (aOR 0.42, 95% CI 0.27-0.65) than pregnancy-inspired quitters. Conclusion Health professionals should ask about smoking at every opportunity, and refer women who self-report as current smokers to an evidence based smoking cessation service.	[Fitzpatrick, Kate E.; Gray, Ron; Quigley, Maria A.] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Policy Res Unit Maternal Hlth & Care, Oxford, England	University of Oxford	Quigley, MA (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Policy Res Unit Maternal Hlth & Care, Oxford, England.	maria.quigley@npeu.ox.ac.uk		Quigley, Maria/0000-0002-8058-6181	Policy Research Programme in the Department of Health	Policy Research Programme in the Department of Health	This paper reports on an independent study which is funded by the Policy Research Programme in the Department of Health. The views expressed are not necessarily those of the Department.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Celeux G, 1996, J CLASSIF, V13, P195, DOI 10.1007/BF01246098; Chamberlain C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub4; Cnattingius S, 2004, NICOTINE TOB RES, V6, pS125, DOI 10.1080/14622200410001669187; Colman GJ, 2003, AM J PREV MED, V24, P29, DOI 10.1016/S0749-3797(02)00574-3; Flemming K, 2015, J ADV NURS, V71, P1210, DOI 10.1111/jan.12580; Gray R, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3754; Harmer C, 2013, NICOTINE TOB RES, V15, P904, DOI 10.1093/ntr/nts221; Hauge LJ, 2013, NICOTINE TOB RES, V15, P428, DOI 10.1093/ntr/nts147; Health and Social Care Information Centre, 2014, STAT WOM SMOK STAT T, V4; Health and Social Care Information Centre, 2012, STAT WOM SMOK STAT T; Hemsing N, 2009, NICE RAPID REV; Kahn RS, 2002, AM J PUBLIC HEALTH, V92, P1801, DOI 10.2105/AJPH.92.11.1801; Lanza ST, 2014, CA STATA PLUGIN USER; Lu Y, 2001, HEALTH PROMOT INT, V16, P355, DOI 10.1093/heapro/16.4.355; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Mai SK, 2007, HLTH CONS SMOK REP S, V2, P30; McAndrew F., 2012, INFANT FEEDING SURVE; Mumford EA, 2014, MATERN CHILD HLTH J, V18, P810, DOI 10.1007/s10995-013-1305-y; Munafo M, 2008, NICOTINE TOB RES, V10, P1609, DOI 10.1080/14622200802412895; Murphy DJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h297; Myers K., 2009, RAPID REV INTERVENTI; National Institute for Health & Clinical Excellence, 2010, NICE PUBL HLTH GUID; Prady SL, 2012, MATERN CHILD HLTH J, V16, P1364, DOI 10.1007/s10995-011-0899-1; Raisanen S, 2014, J EPIDEMIOL COMMUN H, V68, P159, DOI 10.1136/jech-2013-202991; *ROYAL COLL PHYS, 1992, SMOK YOUNG REP WORK; Royal College of Physicians, 2010, PASS SMOK CHILDR; Salihu HM, 2007, EARLY HUM DEV, V83, P713, DOI 10.1016/j.earlhumdev.2007.08.002; Schneider S, 2008, EUR J CONTRACEP REPR, V13, P138, DOI 10.1080/13625180802027993; Schneider S, 2010, DRUG ALCOHOL REV, V29, P81, DOI 10.1111/j.1465-3362.2009.00098.x; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; SCLOVE SL, 1987, PSYCHOMETRIKA, V52, P333, DOI 10.1007/BF02294360; Shipton D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4347; Solomon LJ, 2007, DRUG ALCOHOL DEPEN, V90, P224, DOI 10.1016/j.drugalcdep.2007.03.012	35	25	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2016	11	4							e0153447	10.1371/journal.pone.0153447	http://dx.doi.org/10.1371/journal.pone.0153447			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DK5OX	27111661	gold, Green Published, Green Submitted			2023-01-03	WOS:000374970600014
J	Latronico, T; Depalo, N; Valente, G; Fanizza, E; Laquintana, V; Denora, N; Fasano, A; Striccoli, M; Colella, M; Agostiano, A; Curri, ML; Liuzzi, GM				Latronico, Tiziana; Depalo, Nicoletta; Valente, Gianpiero; Fanizza, Elisabetta; Laquintana, Valentino; Denora, Nunzio; Fasano, Anna; Striccoli, Marinella; Colella, Matilde; Agostiano, Angela; Curri, M. Lucia; Liuzzi, Grazia Maria			Cytotoxicity Study on Luminescent Nanocrystals Containing Phospholipid Micelles in Primary Cultures of Rat Astrocytes	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; QUANTUM DOTS; CELL-CULTURES; IN-VITRO; NANOPARTICLES; APOPTOSIS; NEURONS; CDSE; SURVIVAL; DELIVERY	Luminescent colloidal nanocrystals (NCs) are emerging as a new tool in neuroscience field, representing superior optical probes for cellular imaging and medical diagnosis of neurological disorders with respect to organic fluorophores. However, only a limited number of studies have, so far, explored NC applications in primary neurons, glia and related cells. Indeed astrocytes, as resident cells in the central nervous system (CNS), play an important pathogenic role in several neurodegenerative and neuroinflammatory diseases, therefore enhanced imaging tools for their thorough investigation are strongly amenable. Here, a comprehensive and systematic study on the in vitro toxicological effect of core-shell type luminescent CdSe@ZnS NCs incorporated in polyethylene glycol (PEG) terminated phospholipid micelles on primary cultures of rat astrocytes was carried out. Cytotoxicity response of empty micelles based on PEG modified phospholipids was compared to that of their NC containing counterpart, in order to investigate the effect on cell viability of both inorganic NCs and micelles protecting NC surface. Furthermore, since the surface charge and chemistry influence cell interaction and toxicity, effect of two different functional groups terminating PEG-modified phospholipid micelles, namely amine and carboxyl group, respectively, was evaluated against bare micelles, showing that carboxyl group was less toxic. The ability of PEG-lipid micelles to be internalized into the cells was qualitatively and quantitatively assessed by fluorescence microscopy and photoluminescence (PL) assay. The results of the experiments clearly demonstrate that, once incorporated into the micelles, a low, not toxic, concentration of NCs is sufficient to be distinctly detected within cells. The overall study provides essential indications to define the optimal experimental conditions to effectively and profitably use the proposed luminescent colloidal NCs as optical probe for future in vivo experiments.	[Latronico, Tiziana; Fasano, Anna; Colella, Matilde; Liuzzi, Grazia Maria] Univ Bari Aldo Moro, Dipartimento Biosci Biotecnol & Biofarmaceut, Bari, Italy; [Depalo, Nicoletta; Valente, Gianpiero; Striccoli, Marinella; Agostiano, Angela; Curri, M. Lucia] CNR, Ist Proc Chim Fis, I-70126 Bari, Italy; [Depalo, Nicoletta; Valente, Gianpiero; Striccoli, Marinella; Agostiano, Angela; Curri, M. Lucia] Univ Bari, Dipartimento Chim, Bari, Italy; [Valente, Gianpiero; Fanizza, Elisabetta; Agostiano, Angela] Univ Bari Aldo Moro, Dipartimento Chim, Bari, Italy; [Laquintana, Valentino; Denora, Nunzio] Univ Bari Aldo Moro, Dipartimento Farm Sci Farmaco, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Istituto per i Processi Chimico-Fisici (IPCF-CNR); Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Curri, ML (corresponding author), CNR, Ist Proc Chim Fis, I-70126 Bari, Italy.; Curri, ML (corresponding author), Univ Bari, Dipartimento Chim, Bari, Italy.	lucia.curri@ba.ipcf.cnr.it	Curri, Maria Lucia/C-5360-2009; Depalo, Nicoletta/AAD-9489-2020; Colella, Matilde/G-9246-2011; Striccoli, Marinella/C-5456-2009; Liuzzi, Grazia Maria/GVR-7164-2022; agostiano, angela/E-2579-2015; DENORA, Nunzio/J-6881-2018	Colella, Matilde/0000-0002-9584-7030; Striccoli, Marinella/0000-0002-5366-691X; Liuzzi, Grazia Maria/0000-0001-5692-9335; agostiano, angela/0000-0003-1938-9944; DENORA, Nunzio/0000-0002-7756-7828; Valente, Gianpiero/0000-0002-6721-4180; Latronico, Tiziana/0000-0001-6971-5416	PRIN [2010C4R8M8]; PON R&C MAAT-Molecular Nanotechnology for Health and Environment [PON02 00563 3316357]; FIRB Futuro in Ricerca [RBFR122HFZ]; Nanomax-integrable sensors for pathological biomarkers diagnosis (N-CHEM); National and Sens&Micro LAB (POFESR)	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); PON R&C MAAT-Molecular Nanotechnology for Health and Environment; FIRB Futuro in Ricerca(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Nanomax-integrable sensors for pathological biomarkers diagnosis (N-CHEM); National and Sens&Micro LAB (POFESR)	This work was supported by PRIN 2010-2011 (2010C4R8M8), PON R&C 2007-2013 MAAT-Molecular Nanotechnology for Health and Environment (Project number: PON02 00563 3316357), FIRB Futuro in Ricerca (RBFR122HFZ), Nanomax-integrable sensors for pathological biomarkers diagnosis (N-CHEM), National and Sens&Micro LAB (POFESR 2007-2013) projects.	Al-Ali A, 2015, TOXICOL RES-UK, V4, P623, DOI 10.1039/c4tx00175c; Arizono Misa, 2014, Curr Protoc Neurosci, V66, DOI 10.1002/0471142301.ns0221s66; Calvo P, 2002, EUR J NEUROSCI, V15, P1317, DOI 10.1046/j.1460-9568.2002.01967.x; Cardone A, 2012, BBA-BIOMEMBRANES, V1818, P2808, DOI 10.1016/j.bbamem.2012.06.011; Chan WH, 2006, TOXICOL LETT, V167, P191, DOI 10.1016/j.toxlet.2006.09.007; Chen N, 2012, BIOMATERIALS, V33, P1238, DOI 10.1016/j.biomaterials.2011.10.070; Damalakiene L, 2013, INT J NANOMED, V8, P555, DOI 10.2147/IJN.S39658; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Denora N, 2013, J CONTROL RELEASE, V172, P1111, DOI 10.1016/j.jconrel.2013.09.024; Depalo N, 2008, J COLLOID INTERF SCI, V325, P558, DOI 10.1016/j.jcis.2008.06.018; Depalo N, 2011, LANGMUIR, V27, P6962, DOI 10.1021/la200822b; Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334; Fanizza E, 2010, LANGMUIR, V26, P14294, DOI 10.1021/la1023339; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Gerbino A, 2012, CELL CALCIUM, V51, P393, DOI 10.1016/j.ceca.2012.01.002; Giancaspero TA, 2013, J BIOL CHEM, V288, P29069, DOI 10.1074/jbc.M113.500066; Gobe G, 2010, TOXICOL LETT, V198, P49, DOI 10.1016/j.toxlet.2010.04.013; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m; Kondoh M, 2002, TOXICOLOGY, V170, P111, DOI 10.1016/S0300-483X(01)00536-4; Latronico T, 2013, TOXICOL SCI, V135, P218, DOI 10.1093/toxsci/kft146; Latronico T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049656; Li KG, 2009, TOXICOL IN VITRO, V23, P1007, DOI 10.1016/j.tiv.2009.06.020; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Maysinger D, 2007, NANO LETT, V7, P2513, DOI 10.1021/nl071611t; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagy A, 2011, CHEM RES TOXICOL, V24, P2176, DOI 10.1021/tx2003195; Ni DL, 2014, ACS NANO, V8, P1231, DOI 10.1021/nn406197c; Pathak S, 2006, J NEUROSCI, V26, P1893, DOI 10.1523/JNEUROSCI.3847-05.2006; Pinkernelle J, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-32; Rivet CJ, 2012, CHEM RES TOXICOL, V25, P153, DOI 10.1021/tx200369s; Romoser A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022079; Shilo M, 2014, NANOSCALE, V6, P2146, DOI 10.1039/c3nr04878k; Singh A V, 2012, THERANOSTIC IMPLICAT; Srikanth M, 2012, NAT REV NEUROL, V8, P307, DOI 10.1038/nrneurol.2012.76; Walters R, 2012, ASN NEURO, V4, DOI 10.1042/AN20120042; Wang J, 2012, ACS NANO, V6, P5018, DOI 10.1021/nn300571c; Wang J, 2012, J CONTROL RELEASE, V160, P637, DOI 10.1016/j.jconrel.2012.02.021; Xu G, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00140; Yan L, 2013, CHEM-ASIAN J, V8, P2342, DOI 10.1002/asia.201300542; Yong KT, 2010, INTEGR BIOL-UK, V2, P121, DOI 10.1039/b916663g; Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k; Zhao YL, 2015, TOXICOL RES-UK, V4, P399, DOI 10.1039/c4tx00207e	44	17	17	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2016	11	4							e0153451	10.1371/journal.pone.0153451	http://dx.doi.org/10.1371/journal.pone.0153451			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9OU	27097043	Green Submitted, Green Published, gold			2023-01-03	WOS:000374543600035
J	Liao, TL; Lin, CH; Chen, YM; Chang, CL; Chen, HH; Chen, DY				Liao, Tsai-Ling; Lin, Ching-Heng; Chen, Yi-Ming; Chang, Chia-Li; Chen, Hsin-Hua; Chen, Der-Yuan			Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR ANTAGONISTS; INFECTION; MYCOBACTERIAL; RITUXIMAB; REACTIVATION; MULTICENTER; COMORBIDITY; INHIBITORS; DISEASES	Increasing evidence indicates an increased risk of tuberculosis (TB) for rheumatoid arthritis (RA) patients receiving biologic therapy, and the effectiveness of isoniazid prophylaxis (INHP) in TB prevention. We aimed to examine 1) the incidence rate (IR) and risk factors for TB among RA patients receiving different therapies; 2) INHP effectiveness for TB prevention; 3) mortality rates after TB diagnosis in patients receiving different therapies. This retrospective study was conducted using a nationwide database: 168,720 non-RA subjects and a total of 42,180 RA patients including 36,162 csDMARDs-exposed, 3,577 etanercept-exposed, 1,678 adalimumab-exposed and 763 rituximab-exposed patients. TB risk was 2.7-fold higher in RA cohort compared with non-RA group, with an adjusted hazard ratio (aHR) of 2.58. Advanced age, male, the use of corticosteroids >= 5mg/day, and the presence of diabetes mellitus (DM), chronic obstructive pulmonary disease and chronic kidney disease were risk factors for developing TB. Using csDMARDs-exposed group as reference, aHR of TB was the highest with adalimumab treatment (1.52), followed by etanercept (1.16), and the lowest with rituximab (0.08). INHP could effectively reduce TB risk in biologics-exposed patients. Mortality rates after TB diagnosis were higher in RA patients, particularly the elderly and those with DM, with lower rates in adalimumab-exposed patients compared with csDMARDs-exposed patients. In conclusion, TB risk was increased in patients receiving TNF-alpha inhibitors, but the risk associated with rituximab therapy was relatively low. With the effectiveness of INHP shown in the prevention of biologics-associated TB, stricter implementation of INHP should be beneficial. The mortality from biologics-associated TB may be efficiently reduced through increased awareness.	[Liao, Tsai-Ling; Lin, Ching-Heng; Chen, Yi-Ming; Chang, Chia-Li; Chen, Hsin-Hua; Chen, Der-Yuan] Taichung Vet Gen Hosp, Dept Med Educ & Res, Taichung, Taiwan; [Liao, Tsai-Ling; Chen, Yi-Ming; Chen, Der-Yuan] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; [Liao, Tsai-Ling; Chen, Yi-Ming; Chen, Der-Yuan] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung 40227, Taiwan; [Lin, Ching-Heng] Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan; [Chen, Yi-Ming; Chen, Hsin-Hua; Chen, Der-Yuan] Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taipei, Taiwan; [Chen, Yi-Ming; Chen, Hsin-Hua; Chen, Der-Yuan] Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan; [Chen, Der-Yuan] Chung Shan Med Univ, Inst Microbiol & Immunol, Taichung, Taiwan	Taichung Veterans General Hospital; National Chung Hsing University; National Chung Hsing University; National Taipei University of Nursing & Health Science (NTUNHS); Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chung Shan Medical University	Chen, DY (corresponding author), Taichung Vet Gen Hosp, Dept Med Educ & Res, Taichung, Taiwan.; Chen, DY (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.; Chen, DY (corresponding author), Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung 40227, Taiwan.; Chen, DY (corresponding author), Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taipei, Taiwan.; Chen, DY (corresponding author), Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan.; Chen, DY (corresponding author), Chung Shan Med Univ, Inst Microbiol & Immunol, Taichung, Taiwan.	dychen@vghtc.gov.tw	Chen, Yi-Ming/AAV-3806-2021	Chen, Yi-Ming/0000-0001-7593-3065	Taichung Veterans General Hospital, Taiwan [TCVGH-NHRI10307]	Taichung Veterans General Hospital, Taiwan	This study was supported in part by grants from Taichung Veterans General Hospital, Taiwan (TCVGH-NHRI10307) [http://www.vghtc.gov.tw]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arkema EV, 2015, ANN RHEUM DIS, V74, P1212, DOI 10.1136/annrheumdis-2013-204960; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Askling J, 2005, ARTHRITIS RHEUM-US, V52, P1986, DOI 10.1002/art.21137; Brassard P, 2009, ARTHRIT RHEUM-ARTHR, V61, P300, DOI 10.1002/art.24476; Brode SK, 2014, CHEST, V146, P563, DOI 10.1378/chest.13-2058; Carmona L, 2005, ARTHRITIS RHEUM-US, V52, P1766, DOI 10.1002/art.21043; Centers for Disease Control R. O. C. (Taiwan), 2013, TAIW TUB CONTR REP 2; Chen DY, 2012, ANN RHEUM DIS, V71, P231, DOI 10.1136/annrheumdis-2011-200489; Chen YM, 2013, RHEUMATOLOGY, V52, P697, DOI 10.1093/rheumatology/kes365; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2294, DOI 10.1002/art.10529; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Dougados M, 2014, ANN RHEUM DIS, V73, P62, DOI 10.1136/annrheumdis-2013-204223; Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Gomez-Reino JJ, 2003, ARTHRITIS RHEUM-US, V48, P2122, DOI 10.1002/art.11137; Gomez-Reino JJ, 2007, ARTHRIT RHEUM-ARTHR, V57, P756, DOI 10.1002/art.22768; Gupta A, 2012, IMMUNOBIOLOGY, V217, P363, DOI 10.1016/j.imbio.2011.07.008; Jick SS, 2006, ARTHRIT RHEUM-ARTHR, V55, P19, DOI 10.1002/art.21705; Jou RW, 2009, EMERG INFECT DIS, V15, P1525, DOI 10.3201/eid1509.081336; Kourbeti IS, 2014, CLIN INFECT DIS, V58, P1649, DOI 10.1093/cid/ciu185; Ledingham J, 2005, RHEUMATOLOGY, V44, P157, DOI 10.1093/rheumatology/keh464; Lee CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037978; Lee H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119260; Lee JH, 2014, KOREAN J INTERN MED, V29, P76, DOI 10.3904/kjim.2014.29.1.76; Liao TL, 2015, EMERG INFECT DIS, V21, P1387, DOI 10.3201/eid2108.141846; Lin CH, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-5; Lobue P, 2010, RESPIROLOGY, V15, P603, DOI 10.1111/j.1440-1843.2010.01751.x; Maglione PJ, 2007, J IMMUNOL, V178, P7222, DOI 10.4049/jimmunol.178.11.7222; Marais BJ, 2013, LANCET INFECT DIS, V13, P436, DOI 10.1016/S1473-3099(13)70015-X; Navarra SV, 2014, INT J RHEUM DIS, V17, P291, DOI 10.1111/1756-185X.12188; Reed GW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058044; Schluger NW, 2002, CHEST, V121, P1733, DOI 10.1378/chest.121.6.1733; Tubach F, 2009, ARTHRITIS RHEUM-US, V60, P1884, DOI 10.1002/art.24632; van Vollenhoven RF, 2013, ANN RHEUM DIS, V72, P1496, DOI 10.1136/annrheumdis-2012-201956; WHO, 2009, GLOBAL TUBERCULOSIS; WHO, 2014, GLOB TUB REP 2014; Winthrop KL, 2013, ANN RHEUM DIS, V72, P37, DOI 10.1136/annrheumdis-2011-200690; Winthrop KL, 2008, CLIN INFECT DIS, V46, P1738, DOI 10.1086/587989; Winthrop KL, 2013, NAT REV RHEUMATOL, V9, P524, DOI 10.1038/nrrheum.2013.82; Yamada T, 2006, ANN RHEUM DIS, V65, P1661, DOI 10.1136/ard.2005.047274; Yeh JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110922; Zellweger JP, 2015, AM J RESP CRIT CARE	45	29	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2016	11	4							e0153217	10.1371/journal.pone.0153217	http://dx.doi.org/10.1371/journal.pone.0153217			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ0KH	27064275	gold, Green Submitted, Green Published			2023-01-03	WOS:000373891000037
J	Zhang, LH; Li, J; Li, X; Nasir, K; Zhang, HB; Wu, YJ; Hu, S; Wang, Q; Downing, NS; Desai, NR; Masoudi, FA; Spertus, JA; Krumholz, HM; Jiang, LX				Zhang, Lihua; Li, Jing; Li, Xi; Nasir, Khurram; Zhang, Haibo; Wu, Yongjian; Hu, Shuang; Wang, Qing; Downing, Nicholas S.; Desai, Nihar R.; Masoudi, Frederick A.; Spertus, John A.; Krumholz, Harlan M.; Jiang, Lixin		China PEACE Collaborative Grp	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011	PLOS ONE			English	Article							ACUTE CORONARY SYNDROMES; ASSOCIATION TASK-FORCE; ST-ELEVATION; WRITING COMMITTEE; AMERICAN-COLLEGE; CARDIOVASCULAR ANGIOGRAPHY; PULMONARY REHABILITATION; EMERGENCY PHYSICIANS; GENDER-DIFFERENCES; PATTERNS	Background Statin therapy is among the most effective treatments to improve short-and long-term mortality after acute myocardial infarction. The use of statin, and the intensity of their use, has not been described in acute myocardial infarction patients in China, a country with a rapidly growing burden of cardiovascular disease. Methods and Results Using a nationally representative sample of patients with acute myocardial infarction admitted to 162 Chinese hospitals in 2001, 2006 and 2011, we identified 14,958 patients eligible for statin therapy to determine rates of statin use and the intensity of statin therapy, defined as those statin regimens with expected low-density lipoprotein cholesterol lowering of at least 40%, to identify factors associated with the use of statin therapy. Statin use among hospitalized patients with acute myocardial infarction increased from 27.9% in 2001 to 72.5% in 2006, and 88.8% in 2011 (P<0.001 for trend). Regional variation in statin use correspondingly decreased over time. Among treated patients, those receiving intensive statin therapy increased from 1.0% in 2001 to 24.2% in 2006 to 57.2% in 2011(P<0.001 for trend). Patients without low-density lipoprotein cholesterol measured were less likely to be treated with statin or to receive intensive therapy. Conclusions The use of statin therapy has dramatically increased over the past decade in Chinese patients with acute myocardial infarction. However, half of patients still did not receive intensive statin therapy in 2011. Given that guidelines strongly endorse intensive statin therapy for acute myocardial infarction patients, initiatives promoting the use of statin therapy, with attention to treatment intensity, would support further improvements in practice.	[Zhang, Lihua; Li, Jing; Li, Xi; Zhang, Haibo; Wu, Yongjian; Hu, Shuang; Wang, Qing; Jiang, Lixin] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis,Fuwai Hosp, Beijing 100730, Peoples R China; [Zhang, Lihua; Li, Jing; Li, Xi; Zhang, Haibo; Wu, Yongjian; Hu, Shuang; Wang, Qing; Jiang, Lixin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Nasir, Khurram] Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes, Miami, FL USA; [Nasir, Khurram; Krumholz, Harlan M.] Baptist Hlth South Florida, Miami Cardiac & Vasc Inst, Miami, FL USA; [Downing, Nicholas S.; Desai, Nihar R.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Anschutz Med Campus, Aurora, CO USA; [Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Baptist Cardiac & Vascular Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Yale University; Yale University; Yale University	Jiang, LX (corresponding author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis,Fuwai Hosp, Beijing 100730, Peoples R China.; Jiang, LX (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	jiangl@fwoxford.org	Spertus, John/ABD-3075-2021; , Harlan/AAI-2875-2020; Masoudi, Frederick/Q-7467-2019	Li, Xi/0000-0003-2249-688X; Wu, Yongjian/0000-0002-5590-8396	Research Special Fund for Public Welfare Industry of Health from National Health and Family Planning Commission of China [201202025]; National Heart, Lung, and Blood Institute [U01 HL105270-03]; Chinese government; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER	Research Special Fund for Public Welfare Industry of Health from National Health and Family Planning Commission of China; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Chinese government; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This project was partly supported by the Research Special Fund for Public Welfare Industry of Health (201202025) from National Health and Family Planning Commission of China. Dr. Krumholz are supported by grant U01 HL105270-03 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We appreciate the multiple contributions made by study teams at the China Oxford Centre for International Health Research and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the realms of study design and operations, particularly the data collection by the China PEACE Collaborative Group of Yi Pi, Jiamin Liu, Wuhanbilige Hundei, Xue Du, Wenchi Guan, Xin Zheng, and Yuanlin Guo. We are grateful for the support provided by the Chinese government.	Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Anonymous, 2007, Zhonghua Xinxueguanbing Zazhi, V35, P295; Anonymous, 2007, Zhonghua Xinxueguanbing Zazhi, V35, P390; Armitage J, 2010, LANCET, V376, P1658, DOI 10.1016/S0140-6736(10)60310-8; Arnold SV, 2014, CIRCULATION, V129, P1303, DOI 10.1161/CIRCULATIONAHA.113.003589; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Buettner C, 2008, J GEN INTERN MED, V23, P1182, DOI 10.1007/s11606-008-0636-7; Cannon CP, 2013, J AM COLL CARDIOL, V61, P992, DOI 10.1016/j.jacc.2012.10.005; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cao Q, 2012, INT J HEALTH SERV, V42, P177, DOI 10.2190/HS.42.2.b; China Society of Cardiology of Chinese Medical Association, 2010, Zhonghua Xin Xue Guan Bing Za Zhi, V38, P675; Chong PH, 2002, ANN PHARMACOTHER, V36, P1907, DOI 10.1345/aph.1C116; Dallongevillle J, 2010, HEART, V96, P1744, DOI 10.1136/hrt.2010.196170; Dharmarajan K, 2013, CIRC-CARDIOVASC QUAL, V6, P732, DOI 10.1161/CIRCOUTCOMES.113.000441; Elbarouni B, 2012, AM J CARDIOL, V109, P1418, DOI 10.1016/j.amjcard.2012.01.352; Ferrieres J, 2009, ATHEROSCLEROSIS, V204, P491, DOI 10.1016/j.atherosclerosis.2008.09.031; Guan F, 2010, CHINESE MED J-PEKING, V123, P884, DOI 10.3760/cma.j.issn.0366-6999.2010.07.022; Haynes R, 2013, EUR HEART J, V34, P1279, DOI 10.1093/eurheartj/eht055; Hulten E, 2006, ARCH INTERN MED, V166, P1814, DOI 10.1001/archinte.166.17.1814; Jacobs AK, 2007, CIRCULATION, V116, P217, DOI 10.1161/CIRCULATIONAHA.107.184043; Ko DT, 2005, AM HEART J, V150, P419, DOI 10.1016/j.ahj.2004.09.057; Krumholz HM, 2008, J AM COLL CARDIOL, V52, P2046, DOI 10.1016/j.jacc.2008.10.012; Larsen AI, 2014, AM J CARDIOL, V113, P1273, DOI 10.1016/j.amjcard.2014.01.401; Lee KH, 2011, J AM COLL CARDIOL, V58, P1664, DOI 10.1016/j.jacc.2011.05.057; Lenderink T, 2006, EUR HEART J, V27, P1799, DOI 10.1093/eurheartj/ehl125; Li J, 2015, LANCET, V385, P441, DOI 10.1016/S0140-6736(14)60921-1; Li X, 2012, CHINESE MED J-PEKING, V125, P1703, DOI 10.3760/cma.j.issn.0366-6999.2012.10.005; Liao JK, 2007, AM J CARDIOL, V99, P410, DOI 10.1016/j.amjcard.2006.08.051; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; Ministry of Labour and Social Security, 2004, ESS DRUG CAT NAT BAS; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shiu JR, 2012, AM J CARDIOL, V109, P1, DOI 10.1016/j.amjcard.2011.07.064; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; The World Bank, HLTH HARM LIF CHIN S; Vale N, 2011, COCHRANE DB SYST REV, V6; Victor BM, 2014, AM J CARDIOL, V113, P1611, DOI 10.1016/j.amjcard.2014.02.018; Wang C, 2013, CHEST, V143, P524, DOI 10.1378/chest.12-1839	37	49	53	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2016	11	4							e0150806	10.1371/journal.pone.0150806	http://dx.doi.org/10.1371/journal.pone.0150806			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6JK	27058862	gold, Green Published, Green Submitted			2023-01-03	WOS:000373604800001
J	Adamo, A; Beingessner, RL; Behnam, M; Chen, J; Jamison, TF; Jensen, KF; Monbaliu, JCM; Myerson, AS; Revalor, EM; Snead, DR; Stelzer, T; Weeranoppanant, N; Wong, SY; Zhang, P				Adamo, Andrea; Beingessner, Rachel L.; Behnam, Mohsen; Chen, Jie; Jamison, Timothy F.; Jensen, Klavs F.; Monbaliu, Jean-Christophe M.; Myerson, Allan S.; Revalor, Eve M.; Snead, David R.; Stelzer, Torsten; Weeranoppanant, Nopphon; Wong, Shin Yee; Zhang, Ping			On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system	SCIENCE			English	Article							CONTINUOUS MANUFACTURING SYMPOSIUM; FINAL DOSAGE FORMATION; WORK-UP; INGREDIENTS; CHEMISTRY; BATCH; TOOL	Pharmaceutical manufacturing typically uses batch processing at multiple locations. Disadvantages of this approach include long production times and the potential for supply chain disruptions. As a preliminary demonstration of an alternative approach, we report here the continuous-flow synthesis and formulation of active pharmaceutical ingredients in a compact, reconfigurable manufacturing platform. Continuous end-to-end synthesis in the refrigerator-sized [1.0 meter (width) x 0.7 meter (length) x 1.8 meter (height)] system produces sufficient quantities per day to supply hundreds to thousands of oral or topical liquid doses of diphenhydramine hydrochloride, lidocaine hydrochloride, diazepam, and fluoxetine hydrochloride that meet U.S. Pharmacopeia standards. Underlying this flexible plug-and-play approach are substantial enabling advances in continuous-flow synthesis, complex multistep sequence telescoping, reaction engineering equipment, and real-time formulation.	[Adamo, Andrea; Behnam, Mohsen; Chen, Jie; Jensen, Klavs F.; Monbaliu, Jean-Christophe M.; Myerson, Allan S.; Revalor, Eve M.; Stelzer, Torsten; Weeranoppanant, Nopphon; Wong, Shin Yee] MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Beingessner, Rachel L.; Jamison, Timothy F.; Snead, David R.; Zhang, Ping] MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Monbaliu, Jean-Christophe M.] Univ Liege, Dept Chem, Allee Six Aout 13, B-4000 Liege, Sart Tilman, Belgium; [Revalor, Eve M.] Univ Melbourne, Dept Chem & Biomol Engn, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia; [Snead, David R.] Georgia Pacific Chem, 2883 Miller Rd, Decatur, GA 30312 USA; [Stelzer, Torsten] Univ Puerto Rico, Dept Pharmaceut Sci, Med Sci Campus, San Juan, PR 00936 USA; [Wong, Shin Yee] Singapore Inst Technol, Chem Engn & Food Technol Cluster, 10 Dover Dr, Singapore 138683, Singapore; [Zhang, Ping] Novartis Inst Biomed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Liege; University of Melbourne; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Singapore Institute of Technology; Novartis	Jensen, KF; Myerson, AS (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Jamison, TF (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tfj@mit.edu; kfjensen@mit.edu; myerson@mit.edu	Weeranoppanant, Nopphon/AAE-6770-2021; Jensen, Klavs F/F-2462-2012	Weeranoppanant, Nopphon/0000-0002-5379-4954; Jensen, Klavs F/0000-0001-7192-580X; Snead, David/0000-0003-1239-533X; Monbaliu, Jean-Christophe/0000-0001-6916-8846	Defense Advanced Research Project Agency (DARPA); Space and Naval Warfare Systems Center Pacific (SSC Pacific) [N66001-II-C-4147]	Defense Advanced Research Project Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Space and Naval Warfare Systems Center Pacific (SSC Pacific)	Authors are listed in alphabetical order. We thank A. Clayton for elements of the system design, S. H. Harrison for the LabVIEW programming downstream, and A. T. Carlson for assistance with the design of the downstream units. We also thank L. M. Heckman and J. M. Noss for assistance with development of chemistry. This work was supported by the Defense Advanced Research Project Agency (DARPA) and Space and Naval Warfare Systems Center Pacific (SSC Pacific) under Contract no. N66001-II-C-4147. We thank E. Choi, D. T. McQuade, J. Lewin, and G. Ling for their advice and support. The data reported in this paper are available in the article or in the supplementary materials. A. A. is founder of Zaiput Flow Technologies. T.F.J. is a cofounder of Snapdragon Chemistry, Inc., and a scientific adviser for Zaiput Flow Technologies, Continuus Pharmaceuticals, Paraza Pharmaceuticals, and Asymchem. K.F.J. is a scientific adviser for Snapdragon Chemistry, Inc. A.S.M. is a scientific adviser to GenSyn Technologies, Blues Spark Technologies, Continuus Pharmaceuticals, and Goddard Laboratories. MIT has filed a patent on behalf of A. A., M.B., T.F.J., K.F.J., J.C., A.S.M., J.-C.M.M., E.M.R., D.R.S., T.S., N.W., S.Y.W., and P.Z.	Adamo A, 2013, IND ENG CHEM RES, V52, P10802, DOI 10.1021/ie401180t; Ahmed-Omer B, 2011, ORG BIOMOL CHEM, V9, P3854, DOI 10.1039/c0ob00906g; Badman C, 2015, J PHARM SCI-US, V104, P779, DOI 10.1002/jps.24246; Baumann M, 2015, BEILSTEIN J ORG CHEM, V11, P1194, DOI 10.3762/bjoc.11.134; Baxendale IR, 2015, J PHARM SCI-US, V104, P781, DOI 10.1002/jps.24252; Byrn S, 2015, J PHARM SCI-US, V104, P792, DOI 10.1002/jps.24247; Carter CF, 2010, ORG PROCESS RES DEV, V14, P393, DOI 10.1021/op900305v; Correia CA, 2015, ANGEW CHEM INT EDIT, V54, P4945, DOI 10.1002/anie.201411728; Ende D. J. am, 2011, CHEM ENG PHARM IND; Food and Drug Administration, 2013, FDA PERSP CONT MAN; Food and Drug Administration, 2013, STRAT PLAN PREV MIT; Ghislieri D, 2015, ANGEW CHEM INT EDIT, V54, P678, DOI 10.1002/anie.201409765; Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318; Hartman RL, 2011, ANGEW CHEM INT EDIT, V50, P7502, DOI 10.1002/anie.201004637; Hartman RL, 2010, ORG PROCESS RES DEV, V14, P1347, DOI 10.1021/op100154d; Heider PL, 2014, ORG PROCESS RES DEV, V18, P402, DOI 10.1021/op400294z; Hessel V, 2009, CHEM ENG TECHNOL, V32, P1655, DOI 10.1002/ceat.200900474; Hopkin MD, 2013, ORG BIOMOL CHEM, V11, P1822, DOI 10.1039/c2ob27002a; Ingham RJ, 2015, ANGEW CHEM INT EDIT, V54, P144, DOI 10.1002/anie.201409356; Lee SL, 2015, J PHARM INNOV, V10, P191, DOI 10.1007/s12247-015-9215-8; Levesque F, 2012, ANGEW CHEM INT EDIT, V51, P1706, DOI 10.1002/anie.201107446; Loefgren N. M., 1948, U. S. Patent, Patent No. [2,441,498, 244149811]; Malet-Sanz L, 2012, J MED CHEM, V55, P4062, DOI 10.1021/jm2006029; Mascia S, 2013, ANGEW CHEM INT EDIT, V52, P12359, DOI 10.1002/anie.201305429; Murray PRD, 2013, ORG PROCESS RES DEV, V17, P1192, DOI 10.1021/op4001548; Reilly TJ, 1999, J CHEM EDUC, V76, P1557, DOI 10.1021/ed076p1557; Rieveschl G., 1947, US Pat., Patent No. [2,421,714A, 2421714, 2 421 714]; Schaber SD, 2011, IND ENG CHEM RES, V50, P10083, DOI 10.1021/ie2006752; Service RF, 2015, SCIENCE, V347, P1190, DOI 10.1126/science.347.6227.1190; SUGASAWA T, 1979, J HETEROCYCLIC CHEM, V16, P445, DOI 10.1002/jhet.5570160306; USP (U. S. Pharmacopeia), 2014, USP MONOGRAPH, V34, P2597; USP (U. S. Pharmacopeia), 2014, USP MONOGRAPH, V37, P3035; USP (U. S. Pharmacopeia), 2014, USP MONOGRAPH, V37, P2580; USP (U. S. Pharmacopeia), 2014, USP MONOGRAPH, V37, P3552; Viviano M, 2011, ORG PROCESS RES DEV, V15, P858, DOI 10.1021/op2001047; Webb D, 2010, CHEM SCI, V1, P675, DOI 10.1039/c0sc00381f; Wong SY, 2013, ORG PROCESS RES DEV, V17, P684, DOI 10.1021/op400011s; Zhang P, 2014, ORG PROCESS RES DEV, V18, P1567, DOI 10.1021/op500166n	38	575	599	38	521	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2016	352	6281					61	67		10.1126/science.aaf1337	http://dx.doi.org/10.1126/science.aaf1337			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH8JP	27034366				2023-01-03	WOS:000373039600034
J	De Jong, A; Deras, P; Martinez, O; Latry, P; Jaber, S; Capdevila, X; Charbit, J				De Jong, Audrey; Deras, Pauline; Martinez, Orianne; Latry, Pascal; Jaber, Samir; Capdevila, Xavier; Charbit, Jonathan			Relationship between Obesity and Massive Transfusion Needs in Trauma Patients, and Validation of TASH Score in Obese Population: A Retrospective Study on 910 Trauma Patients	PLOS ONE			English	Article							LIFE-THREATENING HEMORRHAGE; DIFFICULT INTUBATION; MORBID-OBESITY; MAJOR TRAUMA; MORTALITY; RISK; CARE; PROBABILITY; PREDICTION; OUTCOMES	Background Prediction of massive transfusion (MT) is challenging in management of trauma patients. However, MT and its prediction were poorly studied in obese patients. The main objective was to assess the relationship between obesity and MT needs in trauma patients. The secondary objectives were to validate the Trauma Associated Severe Hemorrhage (TASH) score in predicting MT in obese patients and to use a grey zone approach to optimize its ability to predict MT. Methods and Findings An observational retrospective study was conducted in a Level I Regional Trauma Center Trauma in obese and non-obese patients. MT was defined as >= 10U of packed red blood cells in the first 24h and obesity as a BMI >= 30kg/m(2). Between January 2008 and December 2012, 119 obese and 791 non-obese trauma patients were included. The rate of MT was 10% (94/910) in the whole population. The MT rate tended to be higher in obese patients than in non-obese patients: 15% (18/119, 95% CI 9-23%) versus 10% (76/791, 95% CI 8-12%), OR, 1.68 [95% CI 0.97-2.92], p = 0.07. After adjusting for Injury Severity Score (ISS), obesity was significantly associated with MT rate (OR, 1.79[95% CI 1.00-3.21], p = 0.049). The TASH score was higher in the obese group than in the non-obese group: 7(4-11) versus 5(2-10)(p<0.001). The area under the ROC curves of the TASH score in predicting MT was very high and comparable between the obese and non-obese groups: 0.93 (95% CI, 0.89. 0.98) and 0.94 (95% CI, 0.92. 0.96), respectively (p = 0.80). The grey zone ranged respectively from 10 to 13 and from 9 to 12 in obese and non obese patients, and allowed separating patients at low, intermediate or high risk of MT using the TASH score. Conclusions Obesity was associated with a higher rate of MT in trauma patients. The predictive performance of the TASH score and the grey zones were robust and comparable between obese and non-obese patients.	[De Jong, Audrey; Deras, Pauline; Martinez, Orianne; Capdevila, Xavier; Charbit, Jonathan] Lapeyronie Univ Hosp, Trauma Intens Care & Crit Care Unit, Montpellier, France; [De Jong, Audrey; Jaber, Samir] St Eloi Univ Hosp, Intens Care Unit, Montpellier, France; [De Jong, Audrey; Jaber, Samir] St Eloi Univ Hosp, Dept Anesthesiol, Montpellier, France; [De Jong, Audrey; Latry, Pascal; Jaber, Samir] INSERM U1046 Montpellier, Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	De Jong, A (corresponding author), Lapeyronie Univ Hosp, Trauma Intens Care & Crit Care Unit, Montpellier, France.; De Jong, A (corresponding author), St Eloi Univ Hosp, Intens Care Unit, Montpellier, France.; De Jong, A (corresponding author), St Eloi Univ Hosp, Dept Anesthesiol, Montpellier, France.; De Jong, A (corresponding author), INSERM U1046 Montpellier, Montpellier, France.	a-de_jong@chu-montpellier.fr	De Jong, Audrey/AAA-8553-2020; De Jong, Audrey/N-6406-2018	De Jong, Audrey/0000-0002-3413-2752; capdevila, xavier/0000-0002-9791-8779				Akinnusi ME, 2008, CRIT CARE MED, V36, P151, DOI 10.1097/01.CCM.0000297885.60037.6E; Berghofer A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-200; Bowditch MG, 1999, ANN ROY COLL SURG, V81, P198; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brockamp T, 2012, CRIT CARE, V16, DOI 10.1186/cc11432; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Brown CVR, 2005, J TRAUMA, V59, P1048, DOI 10.1097/01.ta.0000189047.65630.c5; Brusasco C, 2009, OBES SURG, V19, P1365, DOI 10.1007/s11695-009-9902-y; Cannesson M, 2011, ANESTHESIOLOGY, V115, P231, DOI 10.1097/ALN.0b013e318225b80a; Charbit J, 2014, INJURY, V45, P88, DOI 10.1016/j.injury.2012.05.018; Charbit J, 2013, AM J EMERG MED, V31, P130, DOI 10.1016/j.ajem.2012.06.024; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; De Jong A, 2015, BRIT J ANAESTH, V114, P297, DOI 10.1093/bja/aeu373; De Jong A, 2013, CHEST, V143, P1554, DOI 10.1378/chest.12-2115; De Jong A, 2013, AM J RESP CRIT CARE, V187, P832, DOI 10.1164/rccm.201210-1851OC; De Jong A, 2012, CHEST, V141, P1637, DOI 10.1378/chest.11-3302; Ditillo M, 2014, J TRAUMA ACUTE CARE, V76, P176, DOI 10.1097/TA.0b013e3182ab0d7c; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P109, DOI 10.1016/0895-4356(90)90064-V; Gaarder C, 2009, J TRAUMA, V67, P323, DOI 10.1097/TA.0b013e3181a4ed27; Glance LG, 2014, ANN SURG, V259, P576, DOI 10.1097/SLA.0000000000000330; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; Jiang C, 2015, CRIT CARE MED, V43, pE241, DOI 10.1097/CCM.0000000000000999; Kornezos I, 2010, EUR RADIOL, V20, P234, DOI 10.1007/s00330-009-1516-1; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Maegele M, 2011, VOX SANG, V100, P231, DOI 10.1111/j.1423-0410.2010.01387.x; MAXWELL MH, 1982, LANCET, V2, P33; Mitra B, 2012, VOX SANG, V102, P324, DOI 10.1111/j.1423-0410.2011.01564.x; Nelson J, 2012, CRIT CARE, V16, DOI 10.1186/cc11334; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; O'Brien JM, 2012, CRIT CARE MED, V40, P1456, DOI 10.1097/CCM.0b013e31823e9a80; Ogura T, 2014, J TRAUMA ACUTE CARE, V76, P1243, DOI 10.1097/TA.0000000000000200; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Pickkers P, 2013, CRIT CARE MED, V41, P1878, DOI 10.1097/CCM.0b013e31828a2aa1; Rainer TH, 2011, RESUSCITATION, V82, P724, DOI 10.1016/j.resuscitation.2011.02.016; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Riou B, 2001, ANESTHESIOLOGY, V95, P56, DOI 10.1097/00000542-200107000-00014; SNAPINN SM, 1986, BIOMETRICS, V42, P583, DOI 10.2307/2531208; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Xiang LS, 2012, AM J PHYSIOL-HEART C, V302, pH340, DOI 10.1152/ajpheart.00439.2011; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf	49	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0152109	10.1371/journal.pone.0152109	http://dx.doi.org/10.1371/journal.pone.0152109			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3SV	27010445	Green Submitted, Green Published, gold			2023-01-03	WOS:000372708000090
J	Kwak, J; Strasser, E; Luzynski, K; Thoss, M; Penn, DJ				Kwak, Jae; Strasser, Eva; Luzynski, Ken; Thoss, Michaela; Penn, Dustin J.			Are MUPs a Toxic Waste Disposal System?	PLOS ONE			English	Article							MAJOR URINARY PROTEINS; PHEROMONE BINDING; VOLATILE LIGANDS; MULTIPLE ROLES; HOUSE MOUSE; LIPOCALINS; 2,4-DI-TERT-BUTYLPHENOL; TOXICOKINETICS; MICE; RAT	Male house mice produce large quantities of major urinary proteins (MUPs), which function to bind and transport volatile pheromones, though they may also function as scavengers that bind and excrete toxic compounds ('toxic waste hypothesis'). In this study, we demonstrate the presence of an industrial chemical, 2,4-di-tert-butylphenol (DTBP), in the urine of wild-derived house mice (Mus musculus musculus). Addition of guanidine hydrochloride to male and female urine resulted in an increased release of DTBP. This increase was only observed in the high molecular weight fractions (HMWF; > 3 kDa) separated from male or female urine, suggesting that the increased release of DTBP was likely due to the denaturation of MUPs and the subsequent release of MUP-bound DTBP. Furthermore, when DTBP was added to a HMWF isolated from male urine, an increase in 2-sec-butyl-4,5-dihydrothiazole (SBT), the major ligand of MUPs and a male-specific pheromone, was observed, indicating that DTBP was bound to MUPs and displaced SBT. These results suggest that DTBP is a MUP ligand. Moreover, we found evidence for competitive ligand binding between DTBP and SBT, suggesting that males potentially face a tradeoff between eliminating toxic wastes versus transporting pheromones. Our findings support the hypothesis that MUPs bind and eliminate toxic wastes, which may provide the most important fitness benefits of excreting large quantities of these proteins.	[Kwak, Jae] Univ Vet Med Vienna, Dept Integrat Biol & Evolut, Res Inst Wildlife Ecol, Vienna, Austria; [Strasser, Eva; Luzynski, Ken; Thoss, Michaela; Penn, Dustin J.] Univ Vet Med Vienna, Konrad Lorenz Inst Ethol, Dept Integrat Biol & Evolut, Vienna, Austria	University of Veterinary Medicine Vienna; University of Veterinary Medicine Vienna	Kwak, J (corresponding author), Univ Vet Med Vienna, Dept Integrat Biol & Evolut, Res Inst Wildlife Ecol, Vienna, Austria.	jaekwak@hotmail.com	Kwak, Jae/E-5781-2011	Kwak, Jae/0000-0003-4216-2019	Austrian Science Fund [FWF: P24711-B21]; Austrian Science Fund (FWF) [P 24711] Funding Source: researchfish	Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This work was funded by a grant from the Austrian Science Fund https://www.fwf.ac.at (FWF: P24711-B21) to D.J. Penn. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BACCHINI A, 1992, EXPERIENTIA, V48, P419, DOI 10.1007/BF01923448; Beynon RJ, 2003, BIOCHEM SOC T, V31, P142, DOI 10.1042/bst0310142; Choi SJ, 2013, J MED FOOD, V16, P977, DOI 10.1089/jmf.2012.2739; Flower DR, 1996, BIOCHEM J, V318, P1; Hagemeyer P, 2011, J CHEM ECOL, V37, P687, DOI 10.1007/s10886-011-9971-y; Hakk H, 2009, TOXICOL APPL PHARM, V241, P119, DOI 10.1016/j.taap.2009.08.009; Hurst JL, 2004, BIOESSAYS, V26, P1288, DOI 10.1002/bies.20147; Hurst JL, 1998, ANIM BEHAV, V55, P1289, DOI 10.1006/anbe.1997.0650; Kwak J, 2013, PHYSIOL BEHAV, V120, P211, DOI 10.1016/j.physbeh.2013.08.011; Kwak J, 2012, PHYSIOL BEHAV, V107, P112, DOI 10.1016/j.physbeh.2012.06.008; Kwak J, 2011, CHEM SENSES, V36, P443, DOI 10.1093/chemse/bjr015; LARSEN GL, 1990, XENOBIOTICA, V20, P1343, DOI 10.3109/00498259009046632; Logan DW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003280; Novotny MV, 1999, P ROY SOC B-BIOL SCI, V266, P2017, DOI 10.1098/rspb.1999.0880; Phelan MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108415; Roberts SA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-75; Robertson D, 1998, J CHEM ECOL, V24, P1127, DOI 10.1023/A:1022434300449; Sharrow SD, 2002, PROTEIN SCI, V11, P2247, DOI 10.1110/ps.0204202; Spitzer M, 2014, NAT METHODS, V11, P121, DOI 10.1038/nmeth.2811; Staskal DF, 2006, TOXICOL SCI, V94, P28, DOI 10.1093/toxsci/kfl091; Staskal DF, 2005, TOXICOL SCI, V83, P215, DOI 10.1093/toxsci/kfi018; Stopkova R, 2014, BIOCHEM SOC T, V42, P893, DOI 10.1042/BST20140053; Stopkova R, 2009, FOLIA ZOOL, V58, P29; TELFORD IR, 1962, AM J ANAT, V110, P29, DOI 10.1002/aja.1001100104; Thoss M, 2015, FRONT ECOL EVOL, V3, DOI 10.3389/fevo.2015.00071; Timm DE, 2001, PROTEIN SCI, V10, P997, DOI 10.1110/ps.52201; Yoon MA, 2006, BIOL PHARM BULL, V29, P735, DOI 10.1248/bpb.29.735	27	13	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2016	11	3							e0151474	10.1371/journal.pone.0151474	http://dx.doi.org/10.1371/journal.pone.0151474			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SC	26966901	Green Submitted, gold, Green Published			2023-01-03	WOS:000371989200057
J	Liu, JH; Liu, M; Zheng, B; Yao, ZP; Xia, J				Liu, Jiahui; Liu, Miao; Zheng, Bo; Yao, Zhongping; Xia, Jiang			Affinity Enhancement by Ligand Clustering Effect Inspired by Peptide Dendrimers-Shank PDZ Proteins Interactions	PLOS ONE			English	Article							MASS-SPECTROMETRY; POSTSYNAPTIC DENSITY; STRUCTURAL BASIS; COMPLEXES; DOMAINS; ORGANIZATION; BINDING	High-affinity binders are desirable tools to probe the function that specific protein-protein interactions play in cell. In the process of seeking a general strategy to design high-affinity binders, we found a clue from the beta PIX (p21-activated kinase interacting exchange factor)-Shank PDZ interaction in synaptic assembly:three PDZ-binding sites are clustered by a parallel coiled-coil trimer but bind to Shank PDZ protein with 1:1 stoichiometry (1 trimer/1 PDZ). Inspired by this architecture, we proposed that peptide dendrimer, mimicking the ligand clustering in beta PIX, will also show enhanced binding affinity, yet with 1:1 stoichiometry. This postulation has been proven here, as we synthesized a set of monomeric, dimeric and trimeric peptides and measured their binding affinity and stoichiometry with Shank PDZ domains by isothermal titration calorimetry, native mass spectrometry and surface plasmon resonance. This affinity enhancement, best explained by proximity effect, will be useful to guide the design of high-affinity blockers for protein-protein interactions.	[Liu, Jiahui; Liu, Miao; Xia, Jiang] Chinese Univ Hong Kong, Dept Chem, Ctr Novel Biomat, Shatin, Hong Kong, Peoples R China; [Zheng, Bo; Yao, Zhongping] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China	Chinese University of Hong Kong; Hong Kong Polytechnic University	Xia, J (corresponding author), Chinese Univ Hong Kong, Dept Chem, Ctr Novel Biomat, Shatin, Hong Kong, Peoples R China.	jiangxia@cuhk.edu.hk	Xia, Jiang/AAT-2366-2020; CHEN, Huanwen/B-1794-2008; Yao, Zhongping/K-2117-2014	Yao, Zhongping/0000-0003-3555-9632; Xia, Jiang/0000-0001-8112-7625	Research Grants Council [CUHK 404812, 403711, 404413, AoE/M-09/12]	Research Grants Council(Hong Kong Research Grants Council)	This work was supported by the Research Grants Council, Early Career Scheme grant CUHK 404812 (website: http://www.ugc.edu.hk/eng/rgc/fund/grants.htm#a), the Research Grants Council, General Research Fund grants 403711 and 404413 (website: http://www.ugc.edu.hk/eng/rgc/fund/grants.htm#b), and the Research Grants Council, Areas of Excellence Scheme, AoE/M-09/12 (website: http://www.ugc.edu.hk/eng/ugc/activity/aoes/aoes.htm). Prof. Xia received all the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Feng W, 2009, NAT REV NEUROSCI, V10, P87, DOI 10.1038/nrn2540; Gopalakrishnan M, 2005, BIOPHYS J, V89, P3686, DOI 10.1529/biophysj.105.065300; Grassme H, 2002, J BIOL CHEM, V277, P30289, DOI 10.1074/jbc.M200494200; Heck AJR, 2004, MASS SPECTROM REV, V23, P368, DOI 10.1002/mas.10081; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; Im YJ, 2010, J MOL BIOL, V397, P457, DOI 10.1016/j.jmb.2010.01.048; Jiang YH, 2013, NEURON, V78, P8, DOI 10.1016/j.neuron.2013.03.016; Kitov PI, 2003, J AM CHEM SOC, V125, P16271, DOI 10.1021/ja038223n; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Lorenzen Kristina, 2010, Curr Protoc Protein Sci, VChapter 17, DOI 10.1002/0471140864.ps1712s62; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Pieters RJ, 2009, ORG BIOMOL CHEM, V7, P2013, DOI 10.1039/b901828j; RAO C, 1994, J AM CHEM SOC, V116, P6975, DOI 10.1021/ja00094a078; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Saupe J, 2011, CHEMMEDCHEM, V6, P1411, DOI 10.1002/cmdc.201100094; Schlenker O, 2009, J MOL BIOL, V386, P280, DOI 10.1016/j.jmb.2008.12.050; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Tomas S, 2010, NAT CHEM, V2, P1077, DOI 10.1038/NCHEM.892; van Baal I, 2005, ANGEW CHEM INT EDIT, V44, P5052, DOI 10.1002/anie.200500635; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Wang CK, 2010, PROTEIN CELL, V1, P737, DOI 10.1007/s13238-010-0099-6; Xia J, 2005, BIOCHEMISTRY-US, V44, P4442, DOI 10.1021/bi047747c; Ye F, 2013, BIOCHEM J, V455, P1, DOI 10.1042/BJ20130783	25	6	8	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0149580	10.1371/journal.pone.0149580	http://dx.doi.org/10.1371/journal.pone.0149580			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3UU	26918521	Green Published, gold, Green Submitted			2023-01-03	WOS:000371274400025
J	Choi, BH; Ro, H; Jung, ES; Kim, AJ; Chang, JH; Lee, HH; Chung, W; Jung, JY				Choi, Byoung Ho; Ro, Han; Jung, Eul Sik; Kim, Ae Jin; Chang, Jae Hyun; Lee, Hyun Hee; Chung, Wookyung; Jung, Ji Yong			Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients	PLOS ONE			English	Article							GLYCATION END-PRODUCT; SOLUBLE RECEPTOR; VASCULAR CALCIFICATION; PLASMA S100A12; SERUM S100A12; ALL-CAUSE; RAGE; MORTALITY; DISEASE; SRAGE	Vascular calcification is an important factor associated with mortality in dialysis patients. Recently, soluble receptor for advanced glycation end product (sRAGE) and extracellular RAGE binding protein S100A12 (EN-RAGE) have been reported to be involved in the process of vascular calcification. Therefore, we investigated whether sRAGE and S100A12 are useful indicators of progression of abdominal aortic calcification in hemodialysis (HD) patients. We analyzed annual changes in vascular calcification score (VCS) for up to 4 years, compared to clinical and biological parameters in 149 HD patients. VCS was assessed annually using plain X-ray images of the lateral lumbar spine. The progression group was defined as patients with an increase in VCS more than 1 point each year on average during the observation period. Time-averaged concentrations were also evaluated to examine the association between biological parameters and changes in VCS. The patients had a mean age of 58.59 +/- 12.93 years; 53.7% were male, and 45% were diabetic. The VCS increased in 55 patients; the mean increase was 1.60 +/- 2.91 points. In a stepwise multivariate logistic analysis, we found that higher levels of S100A12 were significantly associated with progression of VCS (odds ratio [OR], 2.622; 95% confidence interval [CI], 1.371-5.016; P = 0.004). The relationship between sRAGE and VCS was not statistically significant (OR, 0.644; 95% CI, 0.302-1.374; P = 0.255). Our findings suggest that serum levels of S100A12 are associated with progression of abdominal aortic calcification in HD patients, independent of sRAGE level.	[Choi, Byoung Ho; Ro, Han; Jung, Eul Sik; Kim, Ae Jin; Chang, Jae Hyun; Lee, Hyun Hee; Chung, Wookyung; Jung, Ji Yong] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Nephrol, Incheon, South Korea; [Ro, Han; Chang, Jae Hyun; Lee, Hyun Hee; Chung, Wookyung; Jung, Ji Yong] Gachon Univ, Sch Med, Incheon, South Korea	Gachon University; Gachon University	Jung, JY (corresponding author), Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Nephrol, Incheon, South Korea.; Jung, JY (corresponding author), Gachon Univ, Sch Med, Incheon, South Korea.	jyjung@gachon.ac.kr		Jung, Eul Sik/0000-0003-3898-4693				Bowman MAH, 2011, ARTERIOSCL THROM VAS, V31, P337, DOI 10.1161/ATVBAHA.110.217745; Foley RN, 1998, J NEPHROL, V11, P239; Gawdzik J, 2011, AM J NEPHROL, V33, P250, DOI 10.1159/000324693; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Heller F, 2011, CLIN J AM SOC NEPHRO, V6, P2347, DOI 10.2215/CJN.02490311; Humpert PM, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-9; Isoyama N, 2015, NEPHROL DIAL TRANSPL, V30, P84, DOI 10.1093/ndt/gfu259; Kauppila LI, 1997, ATHEROSCLEROSIS, V132, P245, DOI 10.1016/S0021-9150(97)00106-8; Kierdorf K, 2013, J LEUKOCYTE BIOL, V94, P55, DOI 10.1189/jlb.1012519; Kim AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147255; Kim HS, 2013, NEPHROLOGY, V18, P777, DOI 10.1111/nep.12166; Kim JK, 2012, ATHEROSCLEROSIS, V220, P208, DOI 10.1016/j.atherosclerosis.2011.07.115; Kimura K, 1999, KIDNEY INT, V56, pS238, DOI 10.1046/j.1523-1755.1999.07163.x; Lindholm B, 2015, AM J NEPHROL, V42, P1, DOI 10.1159/000438873; Lindsey JB, 2009, DIABETES VASC DIS RE, V6, P7, DOI 10.3132/dvdr.2009.002; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; McCormick MM, 2005, J BIOL CHEM, V280, P41521, DOI 10.1074/jbc.M509442200; Morrow DA, 2008, AM HEART J, V155, P49, DOI 10.1016/j.ahj.2007.08.018; Nakashima A, 2010, CLIN J AM SOC NEPHRO, V5, P2213, DOI 10.2215/CJN.03360410; NasrAllah MM, 2012, INT UROL NEPHROL, V44, P1201, DOI 10.1007/s11255-011-0067-y; New SEP, 2013, CIRC RES, V113, P72, DOI 10.1161/CIRCRESAHA.113.301036; Oesterle A, 2015, ARTERIOSCL THROM VAS, V35, P2496, DOI 10.1161/ATVBAHA.115.302072; Okuno S, 2007, AM J KIDNEY DIS, V49, P417, DOI 10.1053/j.ajkd.2006.12.017; Saran R, 2015, AM J KIDNEY DIS, V66, pS1, DOI 10.1053/j.ajkd.2015.05.001; Schlieper G, 2016, NEPHROL DIAL TRANSPL, V31, P31, DOI 10.1093/ndt/gfv111; Shiotsu Y, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-16; Shiotsu Y, 2011, NEPHRON EXTRA, V1, P242, DOI 10.1159/000335198; Shiotsu Y, 2011, CLIN J AM SOC NEPHRO, V6, P718, DOI 10.2215/CJN.08310910; Towler DA, 2011, ARTERIOSCL THROM VAS, V31, P237, DOI 10.1161/ATVBAHA.110.220038; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wang YN, 2015, AM J NEPHROL, V42, P4, DOI 10.1159/000438869; Wilson PWF, 2001, CIRCULATION, V103, P1529, DOI 10.1161/01.cir.103.11.1529; Yan L, 2013, ATHEROSCLEROSIS, V228, P69, DOI 10.1016/j.atherosclerosis.2013.02.023	33	8	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0150145	10.1371/journal.pone.0150145	http://dx.doi.org/10.1371/journal.pone.0150145			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2LW	26914918	gold, Green Submitted, Green Published			2023-01-03	WOS:000371175700056
J	Wang, CH; Shi, CX; Rou, KM; Zhao, Y; Cao, XB; Luo, W; Liu, EW; Wu, ZY				Wang, Changhe; Shi, Cynthia X.; Rou, Keming; Zhao, Yan; Cao, Xiaobin; Luo, Wei; Liu, Enwu; Wu, Zunyou			Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment Program	PLOS ONE			English	Article							HEPATITIS-C VIRUS; GLOBAL EPIDEMIOLOGY; TREATMENT CLINICS; INJECT DRUGS; INFECTION; HIV; PEOPLE; IMPACT; KNOWLEDGE; SHANGHAI	Background Hepatitis C virus (HCV) is the most common viral infection among injecting drug users worldwide. We aimed to assess HCV antibody prevalence and associated risk factors among clients in the Chinese national methadone maintenance treatment (MMT) program. Methods Data from 296,209 clients who enrolled in the national MMT program between March 2004 and December 2012 were analyzed to assess HCV antibody prevalence, associated risk factors, and geographical distribution. Results Anti-HCV screening was positive for 54.6% of clients upon MMT entry between 2004 and 2012. HCV antibody prevalence at entry declined from 66.8% in 2005 to 45.9% in 2012. The most significant predictors of HCV seropositivity were injecting drug use (adjusted odds ratio [AOR]: 8.34, 95% confidence interval [CI]: 8.17-8.52, p<0.0001) and a history of drug use >= 9 years (AOR: 2.01, 95% CI: 1.96-2.06, p<0.0001). Being female, of Uyghur or Zhuang ethnicity, and unmarried were identified as demographic risk factors (all p-values<0.0001). Of the 28 provincial-level divisions included in the study, we found that 5 divisions had HCV antibody prevalence above 70% and 20 divisions above 50%. The HCV screening rate within 6 months after MMT entry greatly increased from 30.4% in 2004 to 93.1% in 2012. Conclusions The current HCV antibody prevalence remains alarmingly high among MMT clients throughout most provincial-level divisions in China, particularly among injecting drug users and females. A comprehensive prevention strategy is needed to control the HCV epidemic among MMT clients in China.	[Wang, Changhe; Shi, Cynthia X.; Rou, Keming; Zhao, Yan; Cao, Xiaobin; Luo, Wei; Liu, Enwu; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention	Wu, ZY (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.	wuzy@263.net	Liu, Enwu/AGC-4748-2022	Liu, Enwu/0000-0003-2580-3523	China National Health and Family Planning Commission [131-14-000-105-01]; US NIH Fogarty International Center and National Institute on Drug Abuse [U2RTW06918]	China National Health and Family Planning Commission; US NIH Fogarty International Center and National Institute on Drug Abuse	This work was supported by funding from China National Health and Family Planning Commission (Grant # 131-14-000-105-01), and by US NIH Fogarty International Center and National Institute on Drug Abuse (Grant# U2RTW06918). Funding organizations had no role in the design of this study, in the collection, analysis, or interpretation of data, or in the final decision to submit the manuscript for publication.	Aceijas C, 2007, INT J DRUG POLICY, V18, P352, DOI 10.1016/j.drugpo.2007.04.004; Bao YP, 2009, INT J STD AIDS, V20, P399, DOI 10.1258/ijsa.2008.008362; Bao YP, 2012, AM J DRUG ALCOHOL AB, V38, P140, DOI 10.3109/00952990.2011.643984; Broers B, 1998, AIDS, V12, P2059, DOI 10.1097/00002030-199815000-00018; Chen Ang, 2009, Zhonghua Liu Xing Bing Xue Za Zhi, V30, P1230; Chen Yuan-sheng, 2011, Zhonghua Liu Xing Bing Xue Za Zhi, V32, P888; Crofts N, 1997, ADDICTION, V92, P999, DOI 10.1111/j.1360-0443.1997.tb02979.x; Crofts N, 2001, AUSTR PERSPECTIVE; Cui Y, 2013, J GASTROEN HEPATOL, V28, P7, DOI 10.1111/jgh.12220; Du J, 2012, AM J DRUG ALCOHOL AB, V38, P228, DOI 10.3109/00952990.2011.643974; Fuller CM, 2001, PUBLIC HEALTH REP, V116, P136, DOI 10.1093/phr/116.S1.136; Hagan H, 2011, J INFECT DIS, V204, P74, DOI 10.1093/infdis/jir196; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Hser Y, 2012, J PUBLIC HEALTH-UK, V34, P24, DOI 10.1093/pubmed/fdr098; Kulsudjarit K, 2004, ANN NY ACAD SCI, V1025, P446, DOI 10.1196/annals.1316.055; Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x; Lee KCK, 2008, J CLIN VIROL, V41, P297, DOI 10.1016/j.jcv.2007.09.013; Li L, 2012, ADDICT BEHAV, V37, P264, DOI 10.1016/j.addbeh.2011.11.004; Lu J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008467; Lu L, 2005, J MED VIROL, V75, P538, DOI 10.1002/jmv.20307; Mao YR, 2010, INT J EPIDEMIOL, V39, pII79, DOI 10.1093/ije/dyq213; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Maxwell S, 2002, HEROIN ADDICT REL CL, V4, P5; McCarthy JJ, 2001, J ADDICT DIS, V20, P19, DOI 10.1300/J069v20n01_03; Metzger David S, 2010, Curr HIV/AIDS Rep, V7, P220, DOI 10.1007/s11904-010-0059-z; Ministry of Health People's Republic of China Joint United Nations Programme on HIV/AIDS World Health Organization, 2011, 2011 EST HIV AIDS EP; Murray JM, 2003, INT J EPIDEMIOL, V32, P708, DOI 10.1093/ije/dyg102; National Center for AIDS/STD Control and Prevention/China CDC, 2013, ANN REP IMPL NAT HIV; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; Novick DM, 2000, MT SINAI J MED, V67, P437; Rao HY, 2012, J VIRAL HEPATITIS, V19, P173, DOI 10.1111/j.1365-2893.2011.01497.x; Rosen HR, 2011, NEW ENGL J MED, V364, P2429, DOI 10.1056/NEJMcp1006613; Ruan YH, 2007, AIDS, V21, pS39, DOI 10.1097/01.aids.0000304695.54884.4f; Scheinmann R, 2007, DRUG ALCOHOL DEPEN, V89, P1, DOI 10.1016/j.drugalcdep.2006.11.014; Shah DP, 2012, J MED VIROL, V84, P235, DOI 10.1002/jmv.22271; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Sun Y, 2007, OCCUPATION HLTH, V23, P881; Treloar C, 2012, DRUG ALCOHOL REV, V31, P918, DOI 10.1111/j.1465-3362.2012.00468.x; Turner KME, 2011, ADDICTION, V106, P1978, DOI 10.1111/j.1360-0443.2011.03515.x; Vlahov D, 2004, J URBAN HEALTH, V81, P14, DOI 10.1093/jurban/jth083; Wiessing L, 2011, EURO SURVEILL, V16; Xia X, 2008, PUBLIC HEALTH, V122, P990, DOI 10.1016/j.puhe.2008.01.014; Xia YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066787; Yin WY, 2010, INT J EPIDEMIOL, V39, pII29, DOI 10.1093/ije/dyq210; Zhuang X, 2012, DRUG ALCOHOL DEPEN, V126, P286, DOI 10.1016/j.drugalcdep.2012.05.028; Zhuang X, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-130	46	9	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2016	11	2							e0147922	10.1371/journal.pone.0147922	http://dx.doi.org/10.1371/journal.pone.0147922			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF2HK	26906025	Green Published, gold, Green Submitted			2023-01-03	WOS:000371163000003
J	Huang, CY; Hsu, CW; Chuang, CR; Lee, CC				Huang, Chih-Yuan; Hsu, Chia-Wen; Chuang, Chi-Rou; Lee, Ching-Chih			Pre-Dialysis Visits to a Nephrology Department and Major Cardiovascular Events in Patients Undergoing Dialysis	PLOS ONE			English	Article							INSURANCE RESEARCH DATABASE; CHRONIC KIDNEY-DISEASE; PRE-ESRD CARE; INITIATION; MORTALITY; SURVIVAL; TAIWAN; HEMODIALYSIS; VALIDATION; COHORT	Background and Objectives Pre-dialysis care by a nephrology out-patient department (OPD) may affect the outcomes of patients who ultimately undergo maintenance dialysis. This study examined the effect of pre-dialysis care by a nephrology OPD on the incidence of one-year major cardiovascular events after initiation of dialysis. Design, Setting Participants, & Measurements The study consisted of Taiwanese patients with chronic kidney disease (CKD) who commenced dialysis from 2006 to 2008. The number of nephrology OPD visits during the critical care period (within 6 months of initiation of dialysis) and the early care period (6-36 months before initiation of dialysis) were analyzed. The primary outcome measure was one-year major cardiovascular events. Results A total of 1191 CKD patients who initiated dialysis from 2006 to 2008 were included. Binary logistic regression showed that patients with. 3 visits during the critical care period and those with. 11 visits during the early care period had fewer composite major cardiovascular events than those with 0 visits. Patients with early referral are less likely to experience composite major cardiovascular events than those with late referral, with aOR 0.574 (95% CI = 0.43-0.77, P<0.001). Patients with both. 3 visits during critical care period and. 11 visits during early care period were less likely to experience composite major cardiovascular events (aOR = 0.25, 95% CI = 0.16-0.39, P < 0.001). Conclusions Patients with adequate pre-dialysis nephrology OPD visits, not just early referral, may had fewer one-year composite major cardiovascular events after initiation of dialysis. This information may be important to medical care providers and public health policy makers in their efforts to improve the well-being of CKD patients.	[Huang, Chih-Yuan] Ditmanson Med Fdn, Chia Yi Christian Hosp, Dept Internal Med, Div Nephrol, Chiayi, Taiwan; [Hsu, Chia-Wen] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med Res, Chiayi, Taiwan; [Chuang, Chi-Rou] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Obstet & Gynecol, Chiayi, Taiwan; [Lee, Ching-Chih] Kaohsiung Vet Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg, Kaohsiung, Taiwan; [Lee, Ching-Chih] Natl Def Med Ctr, Sch Med, Taipei, Taiwan	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Kaohsiung Veterans General Hospital; National Defense Medical Center	Chuang, CR (corresponding author), Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Obstet & Gynecol, Chiayi, Taiwan.; Lee, CC (corresponding author), Kaohsiung Vet Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg, Kaohsiung, Taiwan.; Lee, CC (corresponding author), Natl Def Med Ctr, Sch Med, Taipei, Taiwan.	alexleelab@hotmail.com; hematcd@hotmail.com	Huang, Chih Yuan/G-5328-2015	Huang, Chih Yuan/0000-0002-7253-6301				Agrawal V, 2009, CLIN J AM SOC NEPHRO, V4, P323, DOI 10.2215/CJN.03510708; Avron J, 2002, ARCH INTERN MED, V162, P2002; Boulware LE, 2006, AM J KIDNEY DIS, V48, P192, DOI 10.1053/j.ajkd.2006.04.073; Buck J, 2007, NEPHROL DIAL TRANSPL, V22, P3240, DOI 10.1093/ndt/gfm387; Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; de Jager DJ, 2011, NEPHROL DIAL TRANSPL, V26, P652, DOI 10.1093/ndt/gfq438; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Hasegawa T, 2009, CLIN J AM SOC NEPHRO, V4, P595, DOI 10.2215/CJN.03540708; Heatley SA, 2009, PERITON DIALYSIS INT, V29, pS128; Hommel K, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-108; Inaguma D, 2011, CLIN EXP NEPHROL, V15, P738, DOI 10.1007/s10157-011-0472-7; Jungers P, 2001, NEPHROL DIAL TRANSPL, V16, P2357, DOI 10.1093/ndt/16.12.2357; KDIGO-group, 2013, KIDNEY INT S, V3, P112; Khan SS, 2005, KIDNEY INT, V67, P1038, DOI 10.1111/j.1523-1755.2005.00168.x; Kip KE, 2008, J AM COLL CARDIOL, V51, P701, DOI 10.1016/j.jacc.2007.10.034; McClellan WM, 2009, J AM SOC NEPHROL, V20, P1078, DOI 10.1681/ASN.2008060624; Mendelssohn DC, 2011, NEPHROL DIAL TRANSPL, V26, P2959, DOI 10.1093/ndt/gfq843; Roderick P, 2002, NEPHROL DIAL TRANSPL, V17, P1252, DOI 10.1093/ndt/17.7.1252; Singhal R, 2014, KIDNEY INT, V86, P399, DOI 10.1038/ki.2014.16; Smart NA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007333.pub2; Stack AG, 2003, AM J KIDNEY DIS, V41, P310, DOI 10.1053/ajkd.2003.50038; Wen CP, 2008, LANCET, V371, P2173, DOI 10.1016/S0140-6736(08)60952-6	23	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0147508	10.1371/journal.pone.0147508	http://dx.doi.org/10.1371/journal.pone.0147508			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26900915	Green Submitted, gold, Green Published			2023-01-03	WOS:000371276100010
J	Thurston, A				Thurston, Andrew			The Unreasonable Patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Thurston, Andrew] Univ Pittsburgh, Med Ctr, Mercy Hosp, Sect Palliat Care & Med Eth, Pittsburgh, PA USA; [Thurston, Andrew] UPMC Palliat & Support Inst, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Thurston, A (corresponding author), Univ Pittsburgh, Med Ctr, Mercy Hosp, Sect Palliat Care & Med Eth, Pittsburgh, PA USA.; Thurston, A (corresponding author), UPMC Palliat & Support Inst, Pittsburgh, PA USA.	thurstonal@upmc.edu						Back AL, 2015, JAMA ONCOL, V1, P18, DOI 10.1001/jamaoncol.2014.185; Gogineni K, 2015, JAMA ONCOL, V1, P33, DOI 10.1001/jamaoncol.2014.197	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2016	315	7					657	658		10.1001/jama.2015.17059	http://dx.doi.org/10.1001/jama.2015.17059			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD8JB	26881366				2023-01-03	WOS:000370171500009
J	Cebey-Lopez, M; Pardo-Seco, J; Gomez-Carballa, A; Martinon-Torres, N; Martinon-Sanchez, JM; Justicia-Grande, A; Rivero-Calle, I; Pinnock, E; Salas, A; Fink, C; Martinon-Torres, F				Cebey-Lopez, Miriam; Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Martinon-Torres, Nazareth; Maria Martinon-Sanchez, Jose; Justicia-Grande, Antonio; Rivero-Calle, Irene; Pinnock, Elli; Salas, Antonio; Fink, Colin; Martinon-Torres, Federico		GENDRES Network	Bacteremia in Children Hospitalized with Respiratory Syncytial Virus Infection	PLOS ONE			English	Article							BACTERIAL-INFECTION; FEBRILE INFANTS; INFLUENZA-VIRUS; ANTIBIOTIC USE; RISK	Background The risk of bacteremia is considered low in children with acute bronchiolitis. However the rate of occult bacteremia in infants with RSV infection is not well established. The aim was to determine the actual rate and predictive factors of bacteremia in children admitted to hospital due to confirmed RSV acute respiratory illness (ARI), using both conventional culture and molecular techniques. Methods A prospective multicenter study (GENDRES-network) was conducted between 2011-2013 in children under the age of two admitted to hospital because of an ARI. Among those RSV-positive, bacterial presence in blood was assessed using PCR for Meningococcus, Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, in addition to conventional cultures. Results 66 children with positive RSV respiratory illness were included. In 10.6% patients, bacterial presence was detected: H. influenzae (n = 4) and S. pneumoniae (n = 2). In those patients with bacteremia, there was a previous suspicion of bacterial superinfection and had received empirical antibiotic treatment 6 out of 7 (85.7%) patients. There were significant differences in terms of severity between children with positive bacterial PCR and those with negative results: PICU admission (100% vs. 50%, P-value = 0.015); respiratory support necessity (100% vs. 18.6%, P-value < 0.001); Wood-Downes score (mean = 8.7 vs. 4.8 points, P-value < 0.001); GENVIP scale (mean = 17 vs. 10.1, P-value < 0.001); and length of hospitalization (mean = 12.1 vs. 7.5 days, P-value = 0.007). Conclusion Bacteremia is not frequent in infants hospitalized with RSV respiratory infection, however, it should be considered in the most severe cases.	[Cebey-Lopez, Miriam; Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Martinon-Torres, Nazareth; Maria Martinon-Sanchez, Jose; Justicia-Grande, Antonio; Rivero-Calle, Irene; Salas, Antonio; Martinon-Torres, Federico] Hosp Clin Univ, Grp Invest Genet Vacunas Infecc & Pediat GENVIP W, Galicia, Spain; [Cebey-Lopez, Miriam; Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Martinon-Torres, Nazareth; Maria Martinon-Sanchez, Jose; Justicia-Grande, Antonio; Rivero-Calle, Irene; Salas, Antonio; Martinon-Torres, Federico] Univ Santiago de Compostela, Galicia, Spain; [Cebey-Lopez, Miriam; Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Martinon-Torres, Nazareth; Maria Martinon-Sanchez, Jose; Justicia-Grande, Antonio; Rivero-Calle, Irene; Martinon-Torres, Federico] Hosp Clin Univ Santiago, Dept Pediat, Translat Pediat & Infect Dis Sect, Santiago De Compostela, Galicia, Spain; [Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Salas, Antonio] Univ Santiago de Compostela, Fac Med, Unidade Xenet, Dept Anat Patolox & Ciencias Forenses, Galicia, Spain; [Pardo-Seco, Jacobo; Gomez-Carballa, Alberto; Salas, Antonio] Univ Santiago de Compostela, Fac Med, Inst Ciencias Forenses, GMX, Galicia, Spain; [Pinnock, Elli; Fink, Colin] Univ Warwick, Micropathol Ltd, Coventry CV4 7AL, W Midlands, England	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; University of Warwick	Martinon-Torres, F (corresponding author), Hosp Clin Univ, Grp Invest Genet Vacunas Infecc & Pediat GENVIP W, Galicia, Spain.; Martinon-Torres, F (corresponding author), Univ Santiago de Compostela, Galicia, Spain.; Martinon-Torres, F (corresponding author), Hosp Clin Univ Santiago, Dept Pediat, Translat Pediat & Infect Dis Sect, Santiago De Compostela, Galicia, Spain.	federico.martinon.torres@sergas.es	Martinon-Torres, Federico/E-4982-2016; Gómez-Carballa, Alberto/I-4610-2014; Cebey, Miriam/K-9347-2014; Salas, Antonio/E-3977-2012; Salas, Antonio/U-2029-2019; rivero, irene/ABC-9006-2020; Pardo-Seco, Jacobo J/G-3752-2016	Martinon-Torres, Federico/0000-0002-9023-581X; Gómez-Carballa, Alberto/0000-0003-0927-1272; Cebey, Miriam/0000-0003-0599-7519; Salas, Antonio/0000-0002-2336-702X; Salas, Antonio/0000-0002-2336-702X; Pardo-Seco, Jacobo J/0000-0002-8059-8908; Rivero Calle, Irene/0000-0002-3678-9264; Justicia Grande, Antonio/0000-0002-0410-3328	Spanish Government [PI10/00540 y PI13/02382]; Regional Galician funds (Promotion of Research Project) [10 PXIB 918 184 PR]; Ministerio de Ciencia e Innovacion [SAF2011-26983]; Plan Galego IDT, Xunta de Galicia [EM 2012/045]; Instituto de Investigacion Sanitaria de Santiago de Compostela; Instituto Carlos III (Intensificacion de la actividad investigadora); European Union [279185]	Spanish Government(Spanish GovernmentEuropean Commission); Regional Galician funds (Promotion of Research Project); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Plan Galego IDT, Xunta de Galicia; Instituto de Investigacion Sanitaria de Santiago de Compostela; Instituto Carlos III (Intensificacion de la actividad investigadora)(Instituto de Salud Carlos III); European Union(European Commission)	This work was supported by the Spanish Government (Research Program Health Research Fund (FIS; PI10/00540 y PI13/02382) National Plan I + D + I and FEDER funds) and Regional Galician funds (Promotion of Research Project 10 PXIB 918 184 PR) (FMT), and Ministerio de Ciencia e Innovacion (SAF2011-26983) and the Plan Galego IDT, Xunta de Galicia (EM 2012/045) (AS). MC's research activities had been supported by grants from Instituto de Investigacion Sanitaria de Santiago de Compostela. FMT's research activities have been supported by grants from Instituto Carlos III (Intensificacion de la actividad investigadora). Investigators received funding from the European Union's Seventh Framework Program under ECGA no. 279185 (EUCLIDS) during the production of this paper.	Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Bloomfield P, 2004, ARCH DIS CHILD, V89, P363, DOI 10.1136/adc.2003.035105; Cebey-Lopez M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136526; Farley R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005189.pub4; Fitzgerald DA, 2004, MED J AUSTRALIA, V180, P399, DOI 10.5694/j.1326-5377.2004.tb05993.x; Greenes DS, 1999, PEDIATR INFECT DIS J, V18, P258, DOI 10.1097/00006454-199903000-00010; Hall C, 2009, TXB PEDIAT INFECT DI, P2462; HALL CB, 1988, J PEDIATR-US, V113, P266; Hishiki H, 2011, J INFECT CHEMOTHER, V17, P87, DOI 10.1007/s10156-010-0097-x; Jansen AGSC, 2008, EPIDEMIOL INFECT, V136, P1448, DOI 10.1017/S0950268807000271; Jartti T, 2013, PAEDIATR RESPIR REV, V14, P38, DOI 10.1016/j.prrv.2012.04.002; Justicia-Grande A, 2015, 33 ANN M EUR SOC PAE; Levine DA, 2004, PEDIATRICS, V113, P1728, DOI 10.1542/peds.113.6.1728; Luginbuhl LM, 2008, PEDIATRICS, V122, P947, DOI 10.1542/peds.2007-3206; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; Melendez E, 2003, PEDIATR INFECT DIS J, V22, P1053, DOI 10.1097/01.inf.0000101296.68993.4d; Randolph AG, 2004, PEDIATR INFECT DIS J, V23, P990, DOI 10.1097/01.inf.0000143647.88873.66; Sacco RE, 2014, VET PATHOL, V51, P427, DOI 10.1177/0300985813501341; Schrenzel J, 2007, INT J ANTIMICROB AG, V30, pS2, DOI 10.1016/j.ijantimicag.2007.06.030; Thibeault R, 2007, J CLIN VIROL, V39, P169, DOI 10.1016/j.jcv.2007.04.013; Thorburn K, 2006, THORAX, V61, P611, DOI 10.1136/thx.2005.048397; Titus MO, 2003, PEDIATRICS, V112, P282, DOI 10.1542/peds.112.2.282; Weinberger DM, 2013, EMERG INFECT DIS, V19, P1084, DOI 10.3201/eid1907.121625	23	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0146599	10.1371/journal.pone.0146599	http://dx.doi.org/10.1371/journal.pone.0146599			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26872131	gold, Green Published, Green Submitted			2023-01-03	WOS:000370054100002
J	Mezzenga, E; D'Errico, V; Sarnelli, A; Strigari, L; Menghi, E; Marcocci, F; Bianchini, D; Benassi, M				Mezzenga, Emilio; D'Errico, Vincenzo; Sarnelli, Anna; Strigari, Lidia; Menghi, Enrico; Marcocci, Francesco; Bianchini, David; Benassi, Marcello			Preliminary Retrospective Analysis of Daily Tomotherapy Output Constancy Checks Using Statistical Process Control	PLOS ONE			English	Article							CONTROL CHARTS; BREAST-CANCER; QA; RADIOTHERAPY	The purpose of this study was to retrospectively evaluate the results from a Helical TomoTherapy Hi-Art treatment system relating to quality controls based on daily static and dynamic output checks using statistical process control methods. Individual value X-charts, exponentially weighted moving average charts, and process capability and acceptability indices were used to monitor the treatment system performance. Daily output values measured from January 2014 to January 2015 were considered. The results obtained showed that, although the process was in control, there was an out-of-control situation in the principal maintenance intervention for the treatment system. In particular, process capability indices showed a decreasing percentage of points in control which was, however, acceptable according to AAPM TG148 guidelines. Our findings underline the importance of restricting the acceptable range of daily output checks and suggest a future line of investigation for a detailed process control of daily output checks for the Helical TomoTherapy Hi-Art treatment system.	[Mezzenga, Emilio; D'Errico, Vincenzo; Sarnelli, Anna; Menghi, Enrico; Marcocci, Francesco; Bianchini, David; Benassi, Marcello] IRCCS, Dept Med Phys, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, FC, Italy; [Strigari, Lidia] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Rome, Italy	IRCCS Meldola (IRST); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Mezzenga, E (corresponding author), IRCCS, Dept Med Phys, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, FC, Italy.	emilio.mezzenga@irst.emr.it	Sarnelli, Anna/V-4284-2018; Bianchini, David/K-7205-2016; Strigari, Lidia/B-9352-2017; Strigari, Lidia/J-3541-2012; Mezzenga, Emilio/Q-1018-2018	Sarnelli, Anna/0000-0001-5986-3845; Bianchini, David/0000-0001-5927-7483; Strigari, Lidia/0000-0003-4293-2298; Mezzenga, Emilio/0000-0002-0150-7757				Abbas N, 2011, QUAL RELIAB ENG INT, V27, P821, DOI 10.1002/qre.1175; Breen SL, 2008, MED PHYS, V35, P4417, DOI 10.1118/1.2975144; Carey R.G., 2003, IMPROVING HEALTHCARE; CHAMP CW, 1987, TECHNOMETRICS, V29, P393, DOI 10.2307/1269449; Cisar P, 2011, ACTA POLYTECH HUNG, V8, P73; DAVIS RB, 1988, J QUAL TECHNOL, V20, P260, DOI 10.1080/00224065.1988.11979118; Dettmer H. W., 1997, GOLDRATTS THEORY CON; Gerard K, 2009, MED PHYS, V36, P1275, DOI 10.1118/1.3089793; Holli K, 1999, INT J RADIAT ONCOL, V44, P827, DOI 10.1016/S0360-3016(99)00078-4; KANE VE, 1986, J QUAL TECHNOL, V18, P41, DOI 10.1080/00224065.1986.11978984; Kelly DL, 1999, USE CONTROL CHARTS H; Langen KM, 2010, MED PHYS, V37, P4817, DOI 10.1118/1.3462971; Montgomery DC, 2009, INTRO STAT QUALITY C, P179; Nornadiah MR, 2011, J STAT MODELING ANAL, V2, P13, DOI DOI 10.1515/BILE-2015-0008; Palaniswaamy G, 2012, MED PHYS, V39, P7560, DOI 10.1118/1.4768161; Pawlicki T, 2008, RADIOTHER ONCOL, V89, P330, DOI 10.1016/j.radonc.2008.07.002; Pitkanen MA, 2001, ACTA ONCOL, V40, P50; RYAN T, 2000, STAT METHODS QUALITY; Sanghangthum T, 2013, J APPL CLIN MED PHYS, V14, P147, DOI 10.1120/jacmp.v14i1.4032; Wheeler DJ, 1992, UNDERSTANDING STAT P, V2nd; Woodall WH, 2000, J QUAL TECHNOL, V32, P341	21	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0147936	10.1371/journal.pone.0147936	http://dx.doi.org/10.1371/journal.pone.0147936			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26848962	Green Published, gold, Green Submitted			2023-01-03	WOS:000369554000029
J	Sterlinski, M; Sokal, A; Lenarczyk, R; Van Heuverswyn, F; Rinaldi, CA; Vanderheyden, M; Khalameizer, V; Francis, D; Heynens, J; Stegemann, B; Cornelussen, R				Sterlinski, Maciej; Sokal, Adam; Lenarczyk, Radoslaw; Van Heuverswyn, Frederic; Rinaldi, C. Aldo; Vanderheyden, Marc; Khalameizer, Vladimir; Francis, Darrel; Heynens, Joeri; Stegemann, Berthold; Cornelussen, Richard			In Heart Failure Patients with Left Bundle Branch Block Single Lead MultiSpot Left Ventricular Pacing Does Not Improve Acute Hemodynamic Response To Conventional Biventricular Pacing. A Multicenter Prospective, Interventional, Non-Randomized Study	PLOS ONE			English	Article							CARDIAC RESYNCHRONIZATION THERAPY; CORONARY-SINUS LEAD; QUADRIPOLAR LEAD; FOLLOW-UP; OPTIMIZATION; SITE; DELAY; STIMULATION; INSIGHTS; ACTIVATION	Introduction Recent efforts to increase CRT response by multiSPOT pacing (MSP) from multiple bipols on the same left ventricular lead are still inconclusive. Aim The Left Ventricular (LV) MultiSPOTpacing for CRT (iSPOT) study compared the acute hemodynamic response of MSP pacing by using 3 electrodes on a quadripolar lead compared with conventional biventricular pacing (BiV). Methods Patients with left bundle branch block (LBBB) underwent an acute hemodynamic study to determine the %change in LV+dP/dtmax from baseline atrial pacing compared to the following configurations: BiV pacing with the LV lead in a one of lateral veins, while pacing from the distal, mid, or proximal electrode and all 3 electrodes together (i.e. MSP). All measurements were repeated 4 times at 5 different atrioventricular delays. We also measured QRS-width and individual Q-LV durations. Results Protocol was completed in 24 patients, all with LBBB (QRS width 171 +/- 20 ms) and 58% ischemic aetiology. The percentage change in LV+ dP/dtmax for MSP pacing was 31.0 +/- 3.3% (Mean +/- SE), which was not significantly superior to any BiV pacing configuration: 28.9 +/- 3.2% (LV-distal), 28.3 +/- 2.7% (LV-mid), and 29.5 +/- 3.0% (LV-prox), respectively. Correlation between LV+ dP/dtmax and either QRS-width or Q-LV ratio was poor. Conclusions In patients with LBBB MultiSPOT LV pacing demonstrated comparable improvement in contractility to best conventional BiV pacing. Optimization of atrioventricular delay is important for the best performance for both BiV and MultiSPOT pacing configurations.	[Sterlinski, Maciej] Inst Cardiol, Dept Coronary Artery Dis 2, Warsaw, Poland; [Sokal, Adam; Lenarczyk, Radoslaw] Silesian Ctr Heart Dis, Dept Cardiol Congenital Heart Dis & Electrotherap, Zabrze, Poland; [Van Heuverswyn, Frederic] Ghent Univ Hosp, Ctr Heart, Ghent, Belgium; [Rinaldi, C. Aldo] Guys & St Thomas NHS Trust, St Thomas Hosp, London, England; [Vanderheyden, Marc] Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium; [Khalameizer, Vladimir] Barzilai Govt Hosp, Cardiac Electrophysiol Unit, Ashqelon, Israel; [Francis, Darrel] Imperial Coll Healthcare NHS Trust, Fac Med, London, England; [Heynens, Joeri; Stegemann, Berthold; Cornelussen, Richard] Medtronic, Bakken Res Ctr, Maastricht, Netherlands	Institute of Cardiology - Poland; Silesian Center for Heart Diseases; Ghent University; Ghent University Hospital; Guy's & St Thomas' NHS Foundation Trust; Ben Gurion University; Barzilai Medical Center; Imperial College London; Medtronic; Medtronic Bakken Research Center B.V.	Sterlinski, M (corresponding author), Inst Cardiol, Dept Coronary Artery Dis 2, Warsaw, Poland.	msterlinski@poczta.onet.pl	Sterliński, Maciej/AAJ-9064-2021; Lenarczyk, Radosław/D-1827-2013; Stegemann, Berthold/HHR-8812-2022; Rinaldi, Claudia/GSD-6821-2022	Lenarczyk, Radosław/0000-0002-4680-6734; Cornelussen, Richard/0000-0002-6504-3314; Rinaldi, christopher/0000-0002-3930-1957; Stegemann, Berthold/0000-0003-2841-8022; IT, AcademicLabs/0000-0002-8307-2215	Medtronic, Inc.; Bakken Research Center (BRC), Maastricht, The Netherlands, USA; Bakken Research Center, Medtronic Maastricht, The Netherlands	Medtronic, Inc.(Medtronic); Bakken Research Center (BRC), Maastricht, The Netherlands, USA; Bakken Research Center, Medtronic Maastricht, The Netherlands	Funding for this research was provided by Medtronic, Inc., Bakken Research Center (BRC), Maastricht, The Netherlands, USA. BRC's clinical department ran the multi-center clinical trial that was used to develop this manuscript. Medtronic provided the statistician and database management for the execution of the trial. Medtronic facilitated the advisory panel in the development of the trial and provided guidance for the manuscript preparation and submission process. Medtronic will also assist with any publication fees incurred. The funder had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to acknowledge the help of Barbel Maus (Medtronic, Inc.) for statistical evaluation. This study was sponsored by Bakken Research Center, Medtronic Maastricht, The Netherlands.	Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 2011, CIRC J, V75, P521, DOI 10.1253/circj.CJ-10-1268; Bogaard MD, 2011, EUR J HEART FAIL, V13, P1126, DOI 10.1093/eurjhf/hfr094; Bordachar P, 2010, J CARD FAIL, V16, P709, DOI 10.1016/j.cardfail.2010.04.010; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Ginks MR, 2012, CIRC-ARRHYTHMIA ELEC, V5, P889, DOI 10.1161/CIRCEP.111.967505; Ginks MR, 2012, EUROPACE, V14, P373, DOI 10.1093/europace/eur336; Gold MR, 2013, HEART RHYTHM, V10, P988, DOI 10.1016/j.hrthm.2013.03.009; Gottlieb C, 2014, HEART RHYTHM, V11, P402, DOI 10.1016/j.hrthm.2013.12.015; Leclercq C, 2008, J AM COLL CARDIOL, V51, P1455, DOI 10.1016/j.jacc.2007.11.074; Martin DO, 2012, HEART RHYTHM, V9, P1807, DOI 10.1016/j.hrthm.2012.07.009; Merchant FM, 2010, HEART RHYTHM, V7, P639, DOI 10.1016/j.hrthm.2010.01.035; Molhoek SG, 2004, PACE, V27, P308, DOI 10.1111/j.1540-8159.2004.00433.x; Niederer SA, 2012, PACE, V35, P204, DOI 10.1111/j.1540-8159.2011.03243.x; Pabari PA, 2011, HEART FAIL REV, V16, P277, DOI 10.1007/s10741-010-9203-5; Padeletti L, 2008, AM J CARDIOL, V102, P1687, DOI 10.1016/j.amjcard.2008.08.016; Pappone C, 2015, HEART RHYTHM, V12, P1250, DOI 10.1016/j.hrthm.2015.02.008; Pappone C, 2014, HEART RHYTHM, V11, P394, DOI 10.1016/j.hrthm.2013.11.023; Ploux S, 2014, HEART RHYTHM, V11, P119, DOI 10.1016/j.hrthm.2013.10.018; Rinaldi CA, 2014, J INTERV CARD ELECTR, V40, P75, DOI 10.1007/s10840-014-9891-1; Rinaldi CA, 2013, J CARD FAIL, V19, P731, DOI 10.1016/j.cardfail.2013.10.003; Rinaldi CA, 2015, EUROPACE, V17, P7, DOI 10.1093/europace/euu197; Rossillo A, 2004, J CARDIOVASC ELECTR, V15, P1120, DOI 10.1046/j.1540-8167.2004.04089.x; Shetty AK, 2014, EUROPACE, V16, P873, DOI 10.1093/europace/eut420; Shetty AK, 2013, PACE, V36, pe48, DOI 10.1111/j.1540-8159.2011.03267.x; Shetty AK, 2012, PACE, V35, P196, DOI 10.1111/j.1540-8159.2011.03268.x; Sohal M, 2015, HEART RHYTHM, V12, P2449, DOI 10.1016/j.hrthm.2015.07.012; Thibault B, 2013, EUROPACE, V15, P984, DOI 10.1093/europace/eus435; van Deursen CJM, 2015, J CARDIOVASC TRANSL, V8, P128, DOI 10.1007/s12265-015-9615-7; van Gelder BM, 2015, PACE, V38, P558, DOI 10.1111/pace.12606; Whinnett ZI, 2006, HEART, V92, P1628, DOI 10.1136/hrt.2005.080721; Whinnett ZI, 2013, INT J CARDIOL, V168, P2228, DOI 10.1016/j.ijcard.2013.01.216; Zanon F, 2015, HEART RHYTHM, V12, P975, DOI 10.1016/j.hrthm.2015.01.034	33	19	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2016	11	4							e0154024	10.1371/journal.pone.0154024	http://dx.doi.org/10.1371/journal.pone.0154024			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK8XE	27124724	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000375211700041
J	Hallsworth, M; Chadborn, T; Sallis, A; Sanders, M; Berry, D; Greaves, F; Clements, L; Davies, SC				Hallsworth, Michael; Chadborn, Tim; Sallis, Anna; Sanders, Michael; Berry, Daniel; Greaves, Felix; Clements, Lara; Davies, Sally C.			Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial	LANCET			English	Article							INTERVENTIONS; RESISTANCE	Background Unnecessary antibiotic prescribing contributes to antimicrobial resistance. In this trial, we aimed to reduce unnecessary prescriptions of antibiotics by general practitioners (GPs) in England. Methods In this randomised, 2 x 2 factorial trial, publicly available databases were used to identify GP practices whose prescribing rate for antibiotics was in the top 20% for their National Health Service (NHS) Local Area Team. Eligible practices were randomly assigned (1: 1) into two groups by computer-generated allocation sequence, stratified by NHS Local Area Team. Participants, but not investigators, were blinded to group assignment. On Sept 29, 2014, every GP in the feedback intervention group was sent a letter from England's Chief Medical Officer and a leaflet on antibiotics for use with patients. The letter stated that the practice was prescribing antibiotics at a higher rate than 80% of practices in its NHS Local Area Team. GPs in the control group received no communication. The sample was re-randomised into two groups, and in December, 2014, GP practices were either sent patient-focused information that promoted reduced use of antibiotics or received no communication. The primary outcome measure was the rate of antibiotic items dispensed per 1000 weighted population, controlling for past prescribing. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN32349954, and has been completed. Findings Between Sept 8 and Sept 26, 2014, we recruited and assigned 1581 GP practices to feedback intervention (n=791) or control (n=790) groups. Letters were sent to 3227 GPs in the intervention group. Between October, 2014, and March, 2015, the rate of antibiotic items dispensed per 1000 population was 126.98 (95% CI 125.68-128.27) in the feedback intervention group and 131.25 (130.33-132.16) in the control group, a difference of 4.27 (3.3%; incidence rate ratio [IRR] 0.967 [95% CI 0.957-0.977]; p<0.0001), representing an estimated 73 406 fewer antibiotic items dispensed. In December, 2014, GP practices were re-assigned to patient-focused intervention (n=777) or control (n=804) groups. The patient-focused intervention did not significantly affect the primary outcome measure between December, 2014, and March, 2015 (antibiotic items dispensed per 1000 population: 135.00 [95% CI 133.77-136.22] in the patient-focused intervention group and 133.98 [133.06-134.90] in the control group; IRR for difference between groups 1.01, 95% CI 1.00-1.02; p=0.105). Interpretation Social norm feedback from a high-profile messenger can substantially reduce antibiotic prescribing at low cost and at national scale; this outcome makes it a worthwhile addition to antimicrobial stewardship programmes. Copyright (C) Hallsworth et al. Open Access article distributed under the terms of CC BY-NC-ND.	[Hallsworth, Michael; Sanders, Michael] Behav Insights Team, 33 Greycoat St, London SW1P 2QF, England; [Chadborn, Tim; Sallis, Anna; Greaves, Felix; Clements, Lara] Publ Hlth England, London, England; [Berry, Daniel; Davies, Sally C.] Dept Hlth, London SE1 6TE, England; [Hallsworth, Michael] Univ London Imperial Coll Sci Technol & Med, London, England; [Sanders, Michael] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Public Health England; Imperial College London; Harvard University	Hallsworth, M (corresponding author), Behav Insights Team, 33 Greycoat St, London SW1P 2QF, England.	michael.hallsworth@behaviouralinsights.co.uk	Greaves, Felix/AAL-5891-2021; Greaves, Felix/A-1324-2012	Greaves, Felix/0000-0001-9393-3122; Greaves, Felix/0000-0001-9393-3122	Public Health England; National Institute for Health Research [ACF-2009-21-030] Funding Source: researchfish	Public Health England; National Institute for Health Research(National Institute for Health Research (NIHR))	Public Health England.	Arnold SR, 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003539.PUB2; Arroll B, 2005, RESP MED, V99, P255, DOI 10.1016/j.rmed.2004.11.004; Brinol P, 2009, EUR REV SOC PSYCHOL, V20, P49, DOI 10.1080/10463280802643640; Coenen S, 2006, BRIT J GEN PRACT, V56, P183; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Davies SC, 2013, LANCET, V381, P1606, DOI 10.1016/S0140-6736(13)60604-2; Drekonja DM, 2015, INFECT CONT HOSP EP, V36, P142, DOI 10.1017/ice.2014.41; Goldstein NJ, 2008, J CONSUM RES, V35, P472, DOI 10.1086/586910; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Hawker JI, 2014, J ANTIMICROB CHEMOTH, V69, P3423, DOI 10.1093/jac/dku291; Health and Social Care Information Centre, 2013, PRESCR GP PRACT; Health and Social Care Information Centre, 2015, PRESCR DISP COMM ENG; HM Government, 2014, UK 5 YEAR ANT RES AM; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Kazdin A. E., 2013, BEHAV MODIFICATION A; Lay P, 1997, CAMBRIDGE HDB PSYCHO, P331; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Naughton C, 2009, J EVAL CLIN PRACT, V15, P807, DOI 10.1111/j.1365-2753.2008.01099.x; NHS Business Services Authority, 2015, AM DRUG TAR APR 2 3A; Pinder R., 2015, BEHAV CHANGE ANTIBIO; Public Health England, 2014, MAN INF GUID PRIM CA; Public Health England, ENGL SURV PROGR ANT; Ranji SR, 2008, MED CARE, V46, P847, DOI 10.1097/MLR.0b013e318178eabd; The National Institute for Health and Care Excellence, 2015, SELF LIM RESP TRACT; Tonkin-Crine S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h3413; van der Velden AW, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659268; Wang J., 2014, USE DESCRIPTIVE NORM; Wang KY, 2009, BRIT J GEN PRACT, V59, P724, DOI 10.3399/bjgp09X472593; World Health Organization, 2014, ANTIMICROBIAL RESIST	30	232	232	2	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	2016	387	10029					1743	1752		10.1016/S0140-6736(16)00215-4	http://dx.doi.org/10.1016/S0140-6736(16)00215-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ9OD	26898856	hybrid, Green Published			2023-01-03	WOS:000374541900027
J	Najafian, B; Tondel, C; Svarstad, E; Sokolovkiy, A; Smith, K; Mauer, M				Najafian, Behzad; Tondel, Camilla; Svarstad, Einar; Sokolovkiy, Alexey; Smith, Kelly; Mauer, Michael			One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease	PLOS ONE			English	Article							LYSOSOMAL STORAGE DISORDERS; AGALSIDASE-BETA THERAPY; FOOT PROCESS EFFACEMENT; CHOLESTEROL ACCUMULATION; ALPHA-GALACTOSIDASE; ALBUMIN FILTRATION; MEMBRANE REPAIR; LAMELLAR BODIES; EXOCYTOSIS; RAT	Fabry nephropathy is associated with progressive accumulation of globotriaosylceramide (GL3) in podocytes. Reducing this GL3 burden may reduce podocyte injury. Sensitive methods to quantify podocyte GL3 content may determine whether a given strategy can benefit podocytes in Fabry disease. We developed an unbiased electron microscopic stereological method to estimate the average volume of podocytes and their GL3 inclusions in 6 paired pre- and post-enzyme replacement therapy (ERT) biopsies from 5 men with Fabry disease. Podocyte GL3 content was regularly reduced (average 73%) after 11-12 months of ERT. This was not detectable using a semi-quantitative approach. Parallel to GL3 reduction, podocytes became remarkably smaller (average 63%). These reductions in podocyte GL3 content or size were not significantly correlated with changes in foot process width (FPW). However, FPWafter ERT was significantly correlated with the magnitude of the decrease in podocyte GL3 content from baseline to 11-12 months of ERT. Also podocytes exocytosed GL3 inclusions, a phenomenon correlated with their reduction in their GL3 content. Demonstrable after11-12 months, reduction in podocyte GL3 content allows for early assessment of treatment efficacy and shorter clinical trials in Fabry disease.	[Najafian, Behzad; Sokolovkiy, Alexey; Smith, Kelly] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Tondel, Camilla; Svarstad, Einar] Univ Bergen, Dept Clin Med, Bergen, Norway; [Tondel, Camilla] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway; [Svarstad, Einar] Haukeland Hosp, Dept Med, N-5021 Bergen, Norway; [Mauer, Michael] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Mauer, Michael] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA	University of Washington; University of Washington Seattle; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Najafian, B (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	najafian@uw.edu	Mauer, Michael/ABD-5415-2020	Najafian, Behzad/0000-0002-0904-6721	National Institutes of Health Lysosomal Disease Network, NCATS Rare Diseases Clinical Research Network (RDCRN) [U54NS065768]; Genzyme (a Sanofi company); NCATS; National Institute of Neurological Disorders and Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS065768] Funding Source: NIH RePORTER	National Institutes of Health Lysosomal Disease Network, NCATS Rare Diseases Clinical Research Network (RDCRN); Genzyme (a Sanofi company)(Sanofi-AventisGenzyme Corporation); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by a grant (MM) from the National Institutes of Health Lysosomal Disease Network [(U54NS065768), a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded through a collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)], no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and by an investigator initiated grant from Genzyme (a Sanofi company) to MM. Genzyme provided five paired biopsies with associated clinical information, but had no role in study design, research data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank Ms. Frida Meiers and Karen Zaruba for electron microscopy studies and Ms. Cathy Bagne for research coordination. This work was supported by a grant from the National Institutes of Health Lysosomal Disease Network [(U54NS065768), a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded through a collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)] and by an investigator initiated grant from Genzyme (a Sanofi company). Sanofi Genzyme provided the biopsy material and corresponding clinical data for 5 cases from the Fabrazyme (R) phase III clinical trial.	Arantes RME, 2006, J NEUROSCI, V26, P4630, DOI 10.1523/JNEUROSCI.0009-06.2006; Banikazemi M, 2007, ANN INTERN MED, V146, P77, DOI 10.7326/0003-4819-146-2-200701160-00148; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78; Cao Y, 2006, J BIOL CHEM, V281, P20483, DOI 10.1074/jbc.M602180200; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Deegens JKJ, 2008, KIDNEY INT, V74, P1568, DOI 10.1038/ki.2008.413; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; ELLIS EN, 1987, KIDNEY INT, V32, P736, DOI 10.1038/ki.1987.268; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Fogo AB, 2010, NEPHROL DIAL TRANSPL, V25, P2168, DOI 10.1093/ndt/gfp528; Fraldi A, 2010, EMBO J, V29, P3607, DOI 10.1038/emboj.2010.237; Fukuda T, 2006, ANN NEUROL, V59, P700, DOI 10.1002/ana.20807; Gerasimenko JV, 2001, CURR BIOL, V11, pR971, DOI 10.1016/S0960-9822(01)00577-2; Germain DP, 2007, J AM SOC NEPHROL, V18, P1547, DOI 10.1681/ASN.2006080816; GUBLER MC, 1978, KIDNEY INT, V13, P223, DOI 10.1038/ki.1978.32; GUNDERSEN HJG, 1985, J MICROSC-OXFORD, V138, P127, DOI 10.1111/j.1365-2818.1985.tb02607.x; Hodgin JB, 2015, J AM SOC NEPHROL; Kinugasa S, 2010, MED MOL MORPHOL, V43, P218, DOI 10.1007/s00795-010-0500-9; Kukic I, 2014, J CELL SCI, V127, P3094, DOI 10.1242/jcs.145318; Lee SH, 2015, APOPTOSIS, V20, P1056, DOI 10.1007/s10495-015-1134-0; LESAGE GD, 1993, GASTROENTEROLOGY, V105, P889, DOI 10.1016/0016-5085(93)90909-V; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052; MacDermot KD, 2001, J MED GENET, V38, P750, DOI 10.1136/jmg.38.11.750; Mauer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112188; Medina DL, 2011, DEV CELL, V21, P421, DOI 10.1016/j.devcel.2011.07.016; Miklavc P, 2009, ANN NY ACAD SCI, V1152, P43, DOI 10.1111/j.1749-6632.2008.03989.x; Najafian B, 2013, PEDIATR NEPHROL, V28, P679, DOI 10.1007/s00467-012-2222-9; Najafian B, 2011, KIDNEY INT, V79, P663, DOI 10.1038/ki.2010.484; Ogasawara R, 2009, CELL TISSUE RES, V335, P397, DOI 10.1007/s00441-008-0717-2; Patel V, 2015, HEART, V101, P961, DOI 10.1136/heartjnl-2014-306782; Pena K, 2015, CELL CALCIUM, V57, P257, DOI 10.1016/j.ceca.2015.01.005; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; REHDER V, 1992, NEUROSCIENCE, V51, P565, DOI 10.1016/0306-4522(92)90296-E; Schiffmann R, 2006, VIRCHOWS ARCH, V448, P337, DOI 10.1007/s00428-005-0089-x; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Sever S, 2007, J CLIN INVEST, V117, P2095, DOI 10.1172/JCI32022; Sheppard MN, 2010, CARDIOVASC PATHOL, V19, P293, DOI 10.1016/j.carpath.2009.05.003; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; TAPPER H, 1990, BIOCHEM J, V272, P407, DOI 10.1042/bj2720407; Thurberg BL, 2002, KIDNEY INT, V62, P1933, DOI 10.1046/j.1523-1755.2002.00675.x; Tondel C, 2008, AM J KIDNEY DIS, V51, P767, DOI 10.1053/j.ajkd.2007.12.032; Tondel C, 2013, J AM SOC NEPHROL, V24, P137, DOI 10.1681/ASN.2012030316; van den Berg JG, 2004, KIDNEY INT, V66, P1901, DOI 10.1111/j.1523-1755.2004.00964.x; Warnock DG, 2012, NEPHROL DIAL TRANSPL, V27, P1042, DOI 10.1093/ndt/gfr420; Weibel E, 1979, PRACTICAL METHODS BI, P9; Wiggins JE, 2005, J AM SOC NEPHROL, V16, P2953, DOI 10.1681/ASN.2005050488; Wiggins RC, 2007, KIDNEY INT, V71, P1205, DOI 10.1038/sj.ki.5002222	50	27	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0152812	10.1371/journal.pone.0152812	http://dx.doi.org/10.1371/journal.pone.0152812			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ6AH	27081853	Green Published, gold			2023-01-03	WOS:000374291800009
J	Dimov, LF; Franciosi, AC; Campos, ACP; Brunoni, AR; Pagano, RL				Dimov, Luiz Fabio; Franciosi, Adriano Cardozo; Pinheiro Campos, Ana Carolina; Brunoni, Andre Russowsky; Pagano, Rosana Lima			Top-Down Effect of Direct Current Stimulation on the Nociceptive Response of Rats	PLOS ONE			English	Article							MOTOR CORTEX STIMULATION; C-FOS EXPRESSION; MIDBRAIN PERIAQUEDUCTAL GRAY; TRANSCRANIAL DC-STIMULATION; CENTRAL-NERVOUS-SYSTEM; IMMEDIATE-EARLY GENES; SPINAL-CORD-INJURY; DORSAL-HORN; NEUROPATHIC PAIN; HIGH-DEFINITION	Transcranial direct current stimulation (tDCS) is an emerging, noninvasive technique of neurostimulation for treating pain. However, the mechanisms and pathways involved in its analgesic effects are poorly understood. Therefore, we investigated the effects of direct current stimulation (DCS) on thermal and mechanical nociceptive thresholds and on the activation of the midbrain periaqueductal gray (PAG) and the dorsal horn of the spinal cord (DHSC) in rats; these central nervous system areas are associated with pain processing. Male Wistar rats underwent cathodal DCS of the motor cortex and, while still under stimulation, were evaluated using tail-flick and paw pressure nociceptive tests. Sham stimulation and naive rats were used as controls. We used a randomized design; the assays were not blinded to the experimenter. Immunoreactivity of the early growth response gene 1 (Egr-1), which is a marker of neuronal activation, was evaluated in the PAG and DHSC, and enkephalin immunoreactivity was evaluated in the DHSC. DCS did not change the thermal nociceptive threshold; however, it increased the mechanical nociceptive threshold of both hind paws compared with that of controls, characterizing a topographical effect. DCS decreased the Egr-1 labeling in the PAG and DHSC as well as the immunoreactivity of spinal enkephalin. Altogether, the data suggest that DCS disinhibits the midbrain descending analgesic pathway, consequently inhibiting spinal nociceptive neurons and causing an increase in the nociceptive threshold. This study reinforces the idea that the motor cortex participates in the neurocircuitry that is involved in analgesia and further clarifies the mechanisms of action of tDCS in pain treatment.	[Dimov, Luiz Fabio; Franciosi, Adriano Cardozo; Pinheiro Campos, Ana Carolina; Pagano, Rosana Lima] Hosp Sirio Libanes, Lab Neuromodulat & Expt Pain, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, SP, Brazil; [Brunoni, Andre Russowsky] Univ Sao Paulo, Fac Med, SIN, Dept & Inst Psychiat,Lab Neurosci LIM27, Rua Doutor Ovidio Pires Campos 785, BR-05403000 Sao Paulo, SP, Brazil; [Brunoni, Andre Russowsky] Univ Sao Paulo, Ctr Clin & Epidemiol Res, Univ Hosp, Ave Prof Lineu Prestes 2565,Ext 3, BR-05508000 Sao Paulo, SP, Brazil; [Brunoni, Andre Russowsky] Univ Sao Paulo, Interdisciplinary Ctr Appl Neuromodulat CINA, Univ Hosp, Ave Prof Lineu Prestes 2565,Ext 3, BR-05508000 Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Pagano, RL (corresponding author), Hosp Sirio Libanes, Lab Neuromodulat & Expt Pain, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, SP, Brazil.	rosana.lpagano@hsl.org.br	Franciosi, Adriano C/R-3102-2016; Campos, Ana Carolina Pinheiro/AAD-7760-2019; , Ap/AAB-2985-2019; Dimov, Luiz Fabio/AAS-2616-2020; Pagano, Rosana Lima/I-1088-2013; Brunoni, Andre R./H-8394-2012	Franciosi, Adriano C/0000-0001-7172-539X; Campos, Ana Carolina Pinheiro/0000-0003-2901-5823; , Ap/0000-0002-5351-6575; Brunoni, Andre R./0000-0002-6310-3571; Dimov, Luiz Fabio/0000-0002-7264-3000	Hospital Sirio Libanes; Sao Paulo State Foundation (FAPESP); FAPESP [11/21631-3, 09/50772-4, 12/20911-5]; NARSAD Young Investigator from the Brain & Behavior Research Foundation [20493]; Brazilian National Council for Scientific and Technological Development (CNPq) [303197, 470904]	Hospital Sirio Libanes; Sao Paulo State Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NARSAD Young Investigator from the Brain & Behavior Research Foundation(NARSAD); Brazilian National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This research was supported by the Hospital Sirio Libanes and Sao Paulo State Foundation (FAPESP). LFD, RLP and ARB were funded by FAPESP (11/21631-3, 09/50772-4 and 12/20911-5, respectively). ARB is supported by NARSAD Young Investigator from the Brain & Behavior Research Foundation (Grant Number 20493) and Brazilian National Council for Scientific and Technological Development (CNPq, Grant Numbers 303197 and 470904). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BASBAUM AI, 1991, NEW ENGL J MED, V325, P1168, DOI 10.1056/NEJM199110173251610; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; Beaudry H, 2011, J NEUROSCI, V31, P13068, DOI 10.1523/JNEUROSCI.1817-11.2011; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BEHBEHANI MM, 1995, PROG NEUROBIOL, V46, P575, DOI 10.1016/0301-0082(95)00009-K; Benarroch EE, 2012, NEUROLOGY, V78, P210, DOI 10.1212/WNL.0b013e31823fcdee; BENNETT GJ, 1982, BRAIN RES, V240, P162, DOI 10.1016/0006-8993(82)90656-4; Benninger DH, 2010, J NEUROL NEUROSUR PS, V81, P1105, DOI 10.1136/jnnp.2009.202556; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Bolognini N, 2015, J PAIN, V16, P657, DOI 10.1016/j.jpain.2015.03.013; Bowman BR, 2015, AUTON NEUROSCI-BASIC, V193, P84, DOI 10.1016/j.autneu.2015.08.006; Brunoni AR, 2014, EXPERT REV MED DEVIC, V11, P383, DOI 10.1586/17434440.2014.911082; Brunoni AR, 2011, REV NEUROSCIENCE, V22, P471, DOI 10.1515/RNS.2011.042; BURITOVA J, 1995, BRAIN RES, V674, P211, DOI 10.1016/0006-8993(95)00009-F; Buritova J, 2003, EUR J PAIN, V7, P241, DOI 10.1016/S1090-3801(02)00122-2; CANAVERO S, 1995, J NEUROSURG, V83, P1117; Castillo-Saavedra L, 2016, J PAIN, V17, P14, DOI 10.1016/j.jpain.2015.09.009; Chapman V, 1996, J NEUROPHYSIOL, V76, P1817, DOI 10.1152/jn.1996.76.3.1817; Chen WL, 2008, NEUROPHARMACOLOGY, V54, P944, DOI 10.1016/j.neuropharm.2008.02.002; Cioato SG, 2015, BRAIN STIMUL; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DaSilva AF, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00089; DaSilva AF, 2012, HEADACHE, V52, P1283, DOI 10.1111/j.1526-4610.2012.02141.x; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; Di Lazzaro V, 2008, BRAIN STIMUL, V1, P345, DOI 10.1016/j.brs.2008.07.004; DICKENSON AH, 1983, EXP BRAIN RES, V49, P174, DOI 10.1007/BF00238577; DosSantos MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102350; DosSantos Marcos Fabio, 2012, Front Psychiatry, V3, P93, DOI 10.3389/fpsyt.2012.00093; Fagerlund AJ, 2015, PAIN, V156, P62, DOI 10.1016/j.pain.0000000000000006; Ferrucci R, 2014, NEUROREHABILITATION, V34, P121, DOI 10.3233/NRE-131019; Foerster BR, 2015, ARTHRITIS RHEUMATOL, V67, P576, DOI 10.1002/art.38945; Fonoff ET, 2009, BEHAV BRAIN RES, V202, P138, DOI 10.1016/j.bbr.2009.03.018; Fonoff ET, 2009, BEHAV BRAIN RES, V196, P63, DOI 10.1016/j.bbr.2008.07.027; Franca NRM, 2013, BEHAV BRAIN RES, V250, P211, DOI 10.1016/j.bbr.2013.05.019; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; George A, 2000, PAIN, V88, P267, DOI 10.1016/S0304-3959(00)00333-X; Giuliani A, 2004, INT J TISSUE REACT, V26, P29; GOGAS KR, 1991, NEUROSCIENCE, V42, P617, DOI 10.1016/0306-4522(91)90031-I; Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361-9230(97)00277-3; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HERDEGEN T, 1990, NEUROSCI LETT, V120, P21, DOI 10.1016/0304-3940(90)90158-6; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Hiscock JJ, 2001, J NEUROSCI RES, V66, P1094, DOI 10.1002/jnr.1252.abs; HOKFELT T, 1977, NEUROSCI LETT, V5, P25, DOI 10.1016/0304-3940(77)90160-4; HOKFELT T, 1979, NEUROSCI LETT, V14, P55, DOI 10.1016/0304-3940(79)95343-6; Holsheimer J, 2007, ACTA NEUROCHIR SUPPL, V97, P57; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Keay KA, 2002, EXP PHYSIOL, V87, P275, DOI 10.1113/eph8702355; Kuo MF, 2007, J NEUROSCI, V27, P14442, DOI 10.1523/JNEUROSCI.4104-07.2007; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; LANTERIMINET M, 1993, NEUROSCIENCE, V55, P737, DOI 10.1016/0306-4522(93)90439-M; Laste G, 2012, EXP BRAIN RES, V221, P75, DOI 10.1007/s00221-012-3149-x; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2006, EPILEPSIA, V47, P1216, DOI 10.1111/j.1528-1167.2006.00539.x; Lima MC, 2008, NEUROLOGY, V2329, P37; Liu RJ, 1999, BRAIN RES, V830, P183, DOI 10.1016/S0006-8993(99)01293-7; Ma JY, 2001, LIFE SCI, V69, P969, DOI 10.1016/S0024-3205(01)01191-2; Maarrawi J, 2007, PAIN, V127, P183, DOI 10.1016/j.pain.2006.10.013; Maarrawi J, 2013, PAIN, V154, P2563, DOI 10.1016/j.pain.2013.07.042; Marques PR, 2016, PROG NEURO-PSYCHOPH, V64, P44, DOI 10.1016/j.pnpbp.2015.06.016; Mehta S, 2015, SPINAL CORD, V53, P780, DOI 10.1038/sc.2015.118; Mielke D, 2013, NEUROL RES, V35, P1029, DOI 10.1179/1743132813Y.0000000248; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; Nekhendzy V, 2004, ANESTH ANALG, V98, P730, DOI 10.1213/01.ANE.0000096007.12845.70; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; Nitsche MA, 2004, CEREB CORTEX, V14, P1240, DOI 10.1093/cercor/bhh085; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002; Pagano RL, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.08.003; Paxinos G, RAT BRAIN STEREOTAXI, V6th; POHL M, 1994, J NEUROCHEM, V63, P1226; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Reidler JS, 2012, J PAIN, V13, P450, DOI 10.1016/j.jpain.2012.01.005; RUDA MA, 1982, SCIENCE, V215, P1523, DOI 10.1126/science.6121374; RUDA MA, 1986, PROG BRAIN RES, V66, P219, DOI 10.1016/S0079-6123(08)64606-3; SENBA E, 1982, J COMP NEUROL, V208, P54, DOI 10.1002/cne.902080105; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Shiozawa P, 2014, INT J NEUROPSYCHOPH, V17, P1539, DOI 10.1017/S1461145714000807; Sohn MK, 2013, ANN REHABIL MED-ARM, V37, P759, DOI 10.5535/arm.2013.37.6.759; Song BB, 2007, BRAIN RES, V1158, P57, DOI 10.1016/j.brainres.2007.05.006; Soyguder Z, 2005, BRAIN RES, V1033, P202, DOI 10.1016/j.brainres.2004.11.044; Adachi LNS, 2015, EXP BRAIN RES, V233, P1377, DOI 10.1007/s00221-015-4212-1; Adachi LNS, 2012, BRAIN RES, V1489, P17, DOI 10.1016/j.brainres.2012.10.009; Szakacs R, 2003, BRAIN RES BULL, V59, P485, DOI 10.1016/S0361-9230(02)00965-6; Tao YX, 1997, NEUROSCI LETT, V221, P105, DOI 10.1016/S0304-3940(96)13300-0; Terney D, 2008, J PAIN SYMPTOM MANAG, V36, P79, DOI 10.1016/j.jpainsymman.2007.08.014; Vaseghi B, 2015, EUR J NEUROSCI, V42, P2426, DOI 10.1111/ejn.13043; Vaseghi B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123873; Villamar MF, 2013, J PAIN, V14, P371, DOI 10.1016/j.jpain.2012.12.007; Wachter D, 2011, EXP NEUROL, V227, P322, DOI 10.1016/j.expneurol.2010.12.005; Wassermann EM, 2005, TRENDS COGN SCI, V9, P503, DOI 10.1016/j.tics.2005.09.001; Zaghi Soroush, 2009, J Pain Manag, V2, P339; Zhang Y, 2015, J CLIN INVEST, V125, P3782, DOI 10.1172/JCI81156; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	111	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2016	11	4							e0153506	10.1371/journal.pone.0153506	http://dx.doi.org/10.1371/journal.pone.0153506			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ0NI	27071073	gold, Green Published, Green Submitted			2023-01-03	WOS:000373900700074
J	Silva, LMG; da Silva, CAA; da Silva, A; Vieira, RP; Mesquita-Ferrari, RA; Cogo, JC; Zamuner, SR				Goncalves Silva, Luciana Miato; Alves da Silva, Camila Aparecida; da Silva, Aline; Vieira, Rodolfo Paula; Mesquita-Ferrari, Raquel Agnelli; Cogo, Jose Carlos; Zamuner, Stella Regina			Photobiomodulation Protects and Promotes Differentiation of C2C12 Myoblast Cells Exposed to Snake Venom	PLOS ONE			English	Article							LEVEL LASER THERAPY; MUSCLE HEALING-PROCESS; SKELETAL-MUSCLE; PHOSPHOLIPASES A(2); SAO-PAULO; IRRADIATION; INFLAMMATION; ANTIVENOMS; MECHANISM; PROTEINS	Background Snakebites is a neglected disease and in Brazil is considered a serious health problem, with the majority of the snakebites caused by the genus Bothrops. Antivenom therapy and other first-aid treatments do not reverse local myonecrose which is the main sequel caused by the envenomation. Several studies have shown the effectiveness of low level laser (LLL) therapy in reducing local myonecrosis induced by Bothropic venoms, however the mechanism involved in this effect is unknown. In this in vitro study, we aimed to analyze the effect of LLL irradiation against cytotoxicity induced by Bothrops jararacussu venom on myoblast C2C12 cells. Methodology C2C12 were utilized as a model target and were incubated with B. jararacussu venom (12.5 mu g/mL) and immediately irradiated with LLL at wavelength of red 685 nm or infrared 830 nm with energy density of 2.0, 4.6 and 7.0 J/cm(2). Effects of LLL on cellular responses of venom-induced cytotoxicity were examined, including cell viability, measurement of cell damage and intra and extracellular ATP levels, expression of myogenic regulatory factors, as well as cellular differentiation. Results In non-irradiated cells, the venom caused a decrease in cell viability and a massive release of LDH and CK levels indicating myonecrosis. Infrared and red laser at all energy densities were able to considerably decrease venom-induced cytotoxicity. Laser irradiation induced myoblasts to differentiate into myotubes and this effect was accompanied by up regulation of MyoD and specially myogenin. Moreover, LLL was able to reduce the extracellular while increased the intracellular ATP content after venom exposure. In addition, no difference in the intensity of cytotoxicity was shown by non-irradiated and irradiated venom. Conclusion LLL irradiation caused a protective effect on C2C12 cells against the cytotoxicity caused by B. jararacussu venom and promotes differentiation of these cells by up regulation of myogenic factors. A modulatory effect of ATP synthesis may be suggested as a possible mechanism mediating cytoprotection observed under laser irradiation.	[Goncalves Silva, Luciana Miato; Alves da Silva, Camila Aparecida; da Silva, Aline; Vieira, Rodolfo Paula; Zamuner, Stella Regina] Univ Nove de Julho UNINOVE, Posgrad Program Med, Sao Paulo, SP, Brazil; [Mesquita-Ferrari, Raquel Agnelli] Univ Nove de Julho UNINOVE, Posgrad Program Biophoton, Sao Paulo, SP, Brazil; [Cogo, Jose Carlos] Univ Vale Paraiba, UNIVAP, Inst Res & Dev, Sao Jose Dos Campos, SP, Brazil	Universidade Nove de Julho; Universidade Nove de Julho; Universidade do Vale do Paraiba	Zamuner, SR (corresponding author), Univ Nove de Julho UNINOVE, Posgrad Program Med, Sao Paulo, SP, Brazil.	stella.rz@uninove.br	de Paula Vieira, Rodolfo/E-9315-2011; Ferrari, Raquel/I-4419-2016; Fernandes, Kristianne Porta Santos/I-4417-2016; Zamuner, Stella R/C-3132-2012; Zamuner, Stella Regina/AAA-8106-2019	de Paula Vieira, Rodolfo/0000-0001-6379-1143; Ferrari, Raquel/0000-0001-5142-9526; Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; Zamuner, Stella R/0000-0002-4694-7617; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/04660-0, 2011/14376-6]; FAPESP [2011/04660-0, 2011/14376-6, 2012/15165-2]; CNPq-PQ [449948/2014-0]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq-PQ(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The authors acknowledge the financial support from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), 2011/04660-0 and 2011/14376-6. CMS is recipient of FAPESP M.Sc. fellowship (Grant no 2011/04660-0), RPV is recipient of FAPESP grant process: 2012/15165-2 and SRZ is recipient of CNPq-PQ grant Process: 449948/2014-0 and FAPESP 2011/14376-6. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41; Barbosa AM, 2010, J VENOM ANIM TOXINS, V16, P470, DOI 10.1590/S1678-91992010000300014; Barbosa AM, 2008, TOXICON, V51, P1236, DOI 10.1016/j.toxicon.2008.02.007; Barbosa AM, 2009, PHOTOMED LASER SURG, V27, P591, DOI 10.1089/pho.2008.2296; Barretto SR, 2013, J PHOTOCH PHOTOBIO B, V129, P135, DOI 10.1016/j.jphotobiol.2013.10.002; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Brunelli RM, 2014, LASER MED SCI, V29, P91, DOI 10.1007/s10103-013-1277-6; Burattini S, 2004, EUR J HISTOCHEM, V48, P223; Bustillo S, 2012, TOXICON, V59, P338, DOI 10.1016/j.toxicon.2011.11.007; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; CARDOSO JLC, 1993, Q J MED, V86, P315; Cintra-Francischinelli M, 2010, P NATL ACAD SCI USA, V107, P14140, DOI 10.1073/pnas.1009128107; da Silva CJ, 2003, TOXICON, V41, P251, DOI 10.1016/S0041-0101(02)00287-8; de Araujo CEN, 2007, J PHOTOCH PHOTOBIO B, V86, P87, DOI 10.1016/j.jphotobiol.2006.08.006; de Sousa EA, 2013, PHOTOCH PHOTOBIO SCI, V12, P1895, DOI 10.1039/c3pp50036e; Doin-Silva R, 2009, PHOTOCHEM PHOTOBIOL, V85, P63, DOI 10.1111/j.1751-1097.2008.00397.x; dos Santos JI, 2011, PROTEINS, V79, P61, DOI 10.1002/prot.22858; Dourado DM, 2003, LASER SURG MED, V33, P352, DOI 10.1002/lsm.10237; Dourado DM, 2011, PHOTOCHEM PHOTOBIOL, V87, P418, DOI 10.1111/j.1751-1097.2010.00878.x; Fernandes CAH, 2014, BBA-PROTEINS PROTEOM, V1844, P2265, DOI 10.1016/j.bbapap.2014.09.015; Ferraz MC, 2014, MOLECULES, V19, P5790, DOI 10.3390/molecules19055790; Gutierrez JM, 2003, TOXICON, V42, P915, DOI 10.1016/j.toxicon.2003.11.005; Hawkins D, 2005, ANN NY ACAD SCI, V1056, P486, DOI 10.1196/annals.1352.040; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Idzko M, 2013, ALLERGY, V68, P472, DOI 10.1111/all.12119; KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3; Lomonte B, 1999, TOXICON, V37, P145, DOI 10.1016/S0041-0101(98)00171-8; Milani R, 1997, QJM-MON J ASSOC PHYS, V90, P323, DOI 10.1093/qjmed/90.5.323; Mora-Obando D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109846; Nadur-Andrade N, 2014, PHOTOCH PHOTOBIO SCI, V13, P1561, DOI 10.1039/c4pp00111g; Nadur-Andrade N, 2014, PHOTOCHEM PHOTOBIOL, V90, P207, DOI 10.1111/php.12189; Nadur-Andrade N, 2012, LASER MED SCI, V27, P65, DOI 10.1007/s10103-011-0914-1; Nakano J, 2009, EXP PHYSIOL, V94, P1005, DOI 10.1113/expphysiol.2009.047738; Neto HS, 2004, TOXICON, V44, P847, DOI 10.1016/j.toxicon.2004.08.007; Peplow PV, 2010, PHOTOMED LASER SURG, V28, pS3, DOI 10.1089/pho.2010.2771; Rangel J, 2011, CELL BIOCHEM FUNCT, V29, P365, DOI 10.1002/cbf.1758; Rodrigues NC, 2013, J REHABIL RES DEV, V50, P985, DOI 10.1682/JRRD.2012.08.0147; Segura A, 2010, TOXICON, V56, P980, DOI 10.1016/j.toxicon.2010.07.001; Shefer G, 2003, BBA-MOL CELL RES, V1593, P131, DOI 10.1016/S0167-4889(02)00350-6; Silva CAA, 2012, CLIN EXP MED LETT, V53, P7; Souza L.G., 2011, CLIN EXP MED LETT, V52, P97; Vomero VU, 2009, TOXICON, V54, P361, DOI 10.1016/j.toxicon.2009.04.006; Yen YP, 2010, ENVIRON HEALTH PERSP, V118, P949, DOI 10.1289/ehp.0901525; Yin H, 2013, PHYSIOL REV, V93, P23, DOI 10.1152/physrev.00043.2011; Zamuner SR, 2004, TOXICON, V44, P259, DOI 10.1016/j.toxicon.2004.05.029	45	20	20	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2016	11	4							e0152890	10.1371/journal.pone.0152890	http://dx.doi.org/10.1371/journal.pone.0152890			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6JK	27058357	Green Published, gold, Green Submitted			2023-01-03	WOS:000373604800014
J	Blankenstein, T				Blankenstein, Thomas			Receptor combinations hone T-cell therapy	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-THERAPY; ANTIGENS; AFFINITY; MELANOMA		[Blankenstein, Thomas] Max Delbruck Ctr Mol Med, Berlin, Germany; [Blankenstein, Thomas] Charite Campus Buch, Inst Immunol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blankenstein, T (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.; Blankenstein, T (corresponding author), Charite Campus Buch, Inst Immunol, Berlin, Germany.	tblanke@mdc-berlin.de						Blankenstein T, 2015, CURR OPIN IMMUNOL, V33, P112, DOI 10.1016/j.coi.2015.02.005; Gross G, 2016, ANNU REV PHARMACOL, V56, P59, DOI 10.1146/annurev-pharmtox-010814-124844; Hinrichs CS, 2013, NAT BIOTECHNOL, V31, P999, DOI 10.1038/nbt.2725; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Leisegang M, 2016, J CLIN INVEST, V126, P854, DOI 10.1172/JCI83465; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Obenaus M, 2015, NAT BIOTECHNOL, V33, P402, DOI 10.1038/nbt.3147; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Wilkie S, 2012, J CLIN IMMUNOL, V32, P1059, DOI 10.1007/s10875-012-9689-9	10	2	2	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2016	34	4					389	391		10.1038/nbt.3539	http://dx.doi.org/10.1038/nbt.3539			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	DI6NL	27054992				2023-01-03	WOS:000373616100017
J	Wang, B; Franklin, JM; Eddings, W; Landon, J; Kesselheim, AS				Wang, Bo; Franklin, Jessica M.; Eddings, Wesley; Landon, Joan; Kesselheim, Aaron S.			Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis	PLOS ONE			English	Article							OPEN-LABEL; RISK; ADOLESCENTS; MEDICATIONS; OLANZAPINE; MONOTHERAPY; QUETIAPINE; DISORDER; COHORT	Background Following Food and Drug Administration (FDA) approval, many drugs are prescribed for non-FDA-approved ("off-label") uses. If substantial evidence supports the efficacy and safety of off-label indications, manufacturers can pursue formal FDA approval through supplemental new drug applications (sNDAs). We evaluated the effect of FDA determinations on pediatric sNDAs for antipsychotic drugs on prescribing of these products in children. Methods Retrospective, segmented time-series analysis using new prescription claims during 20032012 for three atypical antipsychotics (olanzapine, quetiapine, ziprasidone). FDA approved the sNDAs for pediatric use of olanzapine and quetiapine in December 2009, but did not approve the sNDA for pediatric use of ziprasidone. Results During the months before FDA approval of its pediatric sNDA, new prescriptions of olanzapine decreased for both children and adults. After FDA approval, the increase in prescribing trends was similar for both age groups (P = 0.47 for schizophrenia and bipolar disorder; P = 0.37 for other indications). Comparable decreases in use of quetiapine were observed between pediatrics and adults following FDA approval of its pediatric sNDA (P = 0.88; P = 0.63). Prescribing of ziprasidone decreased similarly for pediatric and adult patients after FDA non-approval of its pediatric sNDA (P = 0.61; P = 0.79). Conclusions The FDA's sNDA determinations relating to use of antipsychotics in children did not result in changes in use that favored the approved sNDAs and disfavored the unapproved sNDA. Improved communication may help translate the agency's expert judgments to clinical practice.	[Wang, Bo; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA; [Wang, Bo; Franklin, Jessica M.; Eddings, Wesley; Landon, Joan; Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA; [Franklin, Jessica M.; Eddings, Wesley; Landon, Joan] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA.; Kesselheim, AS (corresponding author), Harvard Univ, Sch Med, Boston, MA USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666	Harvard Program in Therapeutic Science; Laura and John Arnold Foundation	Harvard Program in Therapeutic Science; Laura and John Arnold Foundation	Dr. Kesselheim's work is supported by the Harvard Program in Therapeutic Science and the Laura and John Arnold Foundation. The funders had no role in the conception, writing, or review of the manuscript.	Advisory meeting minutes: US Food and Drug Administration, 2009, SUMM MIN PSYCH DRUGS; Agency for Healthcare Research and Quality, 2011, OFF LAB US AT ANT UP; Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; Barnett MS, 2004, J CHILD ADOL PSYCHOP, V14, P471, DOI 10.1089/cap.2004.14.471; Barry CL, 2012, J MENT HEALTH POLICY, V15, P119; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Czaja AS, 2012, PHARMACOEPIDEM DR S, V21, P997, DOI 10.1002/pds.3312; Department of Health and Human Services and US Food and Drug Administration, FDA TRANSP IN IMPR T; Department of Health and Human Services and US Food and Drug Administration, FOOD DRUG ADM TRANSP; DiMasi JA, 2013, CLIN THER, V35, P808, DOI 10.1016/j.clinthera.2013.04.004; Dusetzina SB, 2012, MED CARE, V50, P466, DOI 10.1097/MLR.0b013e318245a160; Eli Lilly and Company, 2009, FDA APPR LILL ZYPR 2; Eng PM, 2005, PHARMACOEPIDEM DR S, V14, pS1; Findling RL, 2002, J CLIN PSYCHIAT, V63, P27; Food and Drug Administration, CLIN REV UNPUB; Frazier JA, 2001, J CHILD ADOL PSYCHOP, V11, P239, DOI 10.1089/10445460152595568; Gill SS, 2005, BMJ-BRIT MED J, V330, P445, DOI 10.1136/bmj.38330.470486.8F; Harris G., 2009, NY TIMES; Justice Department Press Release, 2022, JUST DEP INV LEADS S; Kemner C, 2002, J CLIN PSYCHOPHARM, V22, P455, DOI 10.1097/00004714-200210000-00003; Kesselheim AS, 2014, ANN INTERN MED, V161, P96, DOI 10.7326/M13-2381; Kesselheim AS, 2011, HEALTH AFFAIR, V30, P2318, DOI 10.1377/hlthaff.2011.0370; Lambert BL, 2006, AM J EPIDEMIOL, V164, P672, DOI 10.1093/aje/kwj289; Mack Alicia, 2003, J Manag Care Pharm, V9, P559; McIntyre RS, 2008, ARCH PEDIAT ADOL MED, V162, P929, DOI 10.1001/archpedi.162.10.929; Penfold RB, 2010, PEDIATRICS, V125, P475, DOI 10.1542/peds.2009-1288; Tarkan Laurie, 2008, NY TIMES; U.S. Department of Justice, 2010, PHARM GIANT ASTRAZEN; US Department of Justice, 2009, EL LILL COMP AGR PAY; US Food and Drug Administration, DRUG RES CHILDR; Vitiello B, 2009, EUR NEUROPSYCHOPHARM, V19, P629, DOI 10.1016/j.euroneuro.2009.04.008; Wang B, 2014, JAMA INTERN MED, V174, P1938, DOI 10.1001/jamainternmed.2014.5266; Wang PS, 2005, NEW ENGL J MED, V353, P2335, DOI 10.1056/NEJMoa052827; Wilson D., 2010, 520 MILLION ASTRAZEN; World Health Organization, PROM SAF MED CHILDR	35	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152195	10.1371/journal.pone.0152195	http://dx.doi.org/10.1371/journal.pone.0152195			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27032095	Green Submitted, Green Published, gold			2023-01-03	WOS:000373121800041
J	Overdyk, FJ; Dowling, O; Marino, J; Qiu, JJ; Chien, HL; Erslon, M; Morrison, N; Harrison, B; Dahan, A; Gan, TJ				Overdyk, Frank J.; Dowling, Oonagh; Marino, Joseph; Qiu, Jiejing; Chien, Hung-Lun; Erslon, Mary; Morrison, Neil; Harrison, Brooke; Dahan, Albert; Gan, Tong J.			Association of Opioids and Sedatives with Increased Risk of In-Hospital Cardiopulmonary Arrest from an Administrative Database	PLOS ONE			English	Article							CARDIAC-ARREST; ADVERSE EVENTS; RESUSCITATION; SURVIVAL; SYSTEM; TRENDS; IMPACT; GUIDELINES; HYPOXEMIA; MORTALITY	Background While opioid use confers a known risk for respiratory depression, the incremental risk of in-hospital cardiopulmonary arrest, respiratory arrest, or cardiopulmonary resuscitation (CPRA) has not been studied. Our aim was to investigate the prevalence, outcomes, and risk profile of in-hospital CPRA for patients receiving opioids and medications with central nervous system sedating side effects (sedatives). Methods A retrospective analysis of adult inpatient discharges from 2008-2012 reported in the Premier Database. Patients were grouped into four mutually exclusive categories: (1) opioids and sedatives, (2) opioids only, (3) sedatives only, and (4) neither opioids nor sedatives. Results Among 21,276,691 inpatient discharges, 53% received opioids with or without sedatives. A total of 96,554 patients suffered CPRA (0.92 per 1000 hospital bed-days). Patients who received opioids and sedatives had an adjusted odds ratio for CPRA of 3.47 (95% CI: 3.40-3.54; p<0.0001) compared with patients not receiving opioids or sedatives. Opioids alone and sedatives alone were associated with a 1.81-fold and a 1.82-fold (p<0.0001 for both) increase in the odds of CPRA, respectively. In opioid patients, locations of CPRA were intensive care (54%), general care floor (25%), and stepdown units (15%). Only 42% of patients survived CPRA and only 22% were discharged home. Opioid patients with CPRA had mean increased hospital lengths of stay of 7.57 days and mean increased total hospital costs of $27,569. Conclusions Opioids and sedatives are independent and additive risk factors for in-hospital CPRA. The impact of opioid sparing analgesia, reduced sedative use, and better monitoring on CPRA incidence deserves further study.	[Overdyk, Frank J.; Marino, Joseph] Hofstra North Shore LIJ Sch Med, Dept Anesthesiol, New Hyde Pk, NY USA; [Overdyk, Frank J.; Marino, Joseph] North Amer Partners Anesthesia, Melville, NY USA; [Dowling, Oonagh] Hofstra North Shore LIJ Sch Med, Dept Med, Hempstead, NY USA; [Qiu, Jiejing; Chien, Hung-Lun] Covidien Healthcare Econ & Outcomes Res, Mansfield, MA USA; [Erslon, Mary] Covidien Resp & Monitoring Solut, Boulder, CO USA; [Morrison, Neil] Harrier Consultancy, Lancaster, England; [Harrison, Brooke] Boulder Med Writing, Boulder, CO USA; [Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, Leiden, Netherlands; [Gan, Tong J.] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	Hofstra University; Northwell Health; Hofstra University; Northwell Health; Covidien; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Overdyk, FJ (corresponding author), Hofstra North Shore LIJ Sch Med, Dept Anesthesiol, New Hyde Pk, NY USA.; Overdyk, FJ (corresponding author), North Amer Partners Anesthesia, Melville, NY USA.	overdykf@icloud.com	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945	Covidien Healthcare Economics and Outcome Research; Covidien; Boulder Medical Writing	Covidien Healthcare Economics and Outcome Research; Covidien; Boulder Medical Writing	This analysis was supported by Covidien Healthcare Economics and Outcome Research. JQ, HLC, and ME are Covidien employees. The funder, Covidien, provided support in the form of salaries for authors JQ, HLC, and ME, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. FJO and JM are employed by North American Partners in Anesthesia. NM is employed by Harrier Consultancy. BH is employed by Boulder Medical Writing. North American Partners in Anesthesia, Harrier Consultancy, and Boulder Medical Writing provided support in the form of salaries for authors FJO, JM, NM, and BH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Chan PS, 2008, JAMA-J AM MED ASSOC, V300, P2506, DOI 10.1001/jama.2008.715; Chan PS, 2010, ARCH INTERN MED, V170, P18, DOI 10.1001/archinternmed.2009.424; Chan PS, 2009, JAMA-J AM MED ASSOC, V302, P1195, DOI 10.1001/jama.2009.1340; Chen J, 2009, RESUSCITATION, V80, P35, DOI 10.1016/j.resuscitation.2008.10.009; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Davies EC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004439; DeVita MA, 2006, CRIT CARE MED, V34, P2463, DOI 10.1097/01.CCM.0000235743.38172.6E; Ebell MH, 2013, JAMA INTERN MED, V173, P1872, DOI 10.1001/jamainternmed.2013.10037; Ehlenbach WJ, 2009, NEW ENGL J MED, V361, P22, DOI 10.1056/NEJMoa0810245; Galhotra S, 2007, QUAL SAF HEALTH CARE, V16, P260, DOI 10.1136/qshc.2007.022210; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Giummarra MJ, 2014, PAIN MED; Herzig SJ, 2014, J HOSP MED, V9, P73, DOI 10.1002/jhm.2102; Hillman K, 2005, LANCET, V365, P2091; Hillman KM, 2001, INTERN MED J, V31, P343, DOI 10.1046/j.1445-5994.2001.00077.x; Howington JA, 2012, CHEST, V141, P429, DOI 10.1378/chest.10-3013; Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008; Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027; KOHN LT, 1999, TO ERR IS HUMAN BUIL; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; Lindenauer PK, 2014, JAMA INTERN MED, V174, P1982, DOI 10.1001/jamainternmed.2014.5430; Lindenauer PK, 2005, NEW ENGL J MED, V353, P349, DOI 10.1056/NEJMoa041895; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Morrison LJ, 2013, CIRCULATION, V127, P1538, DOI 10.1161/CIR.0b013e31828b2770; Oderda GM, 2007, ANN PHARMACOTHER, V41, P400, DOI 10.1345/aph.1H386; Oderda Gary M, 2013, J Pain Palliat Care Pharmacother, V27, P62, DOI 10.3109/15360288.2012.751956; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Reed K, 2011, HEALTHGRADES PATIENT; Sandroni C, 2007, INTENS CARE MED, V33, P237, DOI 10.1007/s00134-006-0326-z; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Sun Z, 2015, ANESTH ANALG, V121, P709, DOI 10.1213/ANE.0000000000000836; Taenzer AH, 2010, ANESTHESIOLOGY, V112, P282, DOI 10.1097/ALN.0b013e3181ca7a9b; The Joint Commission, 2012, SENTINEL EVENT ALERT; Zerzan JT, 2006, MED CARE, V44, P1005, DOI 10.1097/01.mlr.0000228025.04535.25	37	52	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0150214	10.1371/journal.pone.0150214	http://dx.doi.org/10.1371/journal.pone.0150214			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2LW	26913753	Green Published, Green Submitted, gold			2023-01-03	WOS:000371175700061
J	Wang, XJ; Tang, T; Farid, M; Quek, R; Tao, M; Lim, ST; Wee, HL; Chan, A				Wang, Xiao Jun; Tang, Tiffany; Farid, Mohamad; Quek, Richard; Tao, Miriam; Lim, Soon Thye; Wee, Hwee Lin; Chan, Alexandre			Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy	PLOS ONE			English	Article							ELDERLY-PATIENTS; SECONDARY PROPHYLAXIS; AGGRESSIVE LYMPHOMA; UNITED-STATES; SOLID TUMOR; FILGRASTIM; CANCER; RISK	Objective This study aims to compare the cost-effectiveness of various strategies of myeloid growth factor prophylaxis for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma in Singapore who are undergoing R-CHOP chemotherapy with curative intent. Methods A Markov model was created to compare seven prophylaxis strategies: 1) primary prophylaxis (PP) with nivestim (biosimilar filgrastim) throughout all cycles of chemotherapy; 2) PP with nivestim during the first two cycles of chemotherapy; 3) secondary prophylaxis (SP) with nivestim; 4) PP with pegfilgrastim throughout all cycles of chemotherapy; 5) PP with pegfilgrastim during the first two cycles of chemotherapy; 6) SP with pegfilgrastim; and 7) no prophylaxis (NP). The perspective of a hospital was taken and cost-effectiveness was expressed as the cost per episode of FN avoided over six cycles of chemotherapy. A probabilistic sensitivity analysis was conducted. Results Strategies 3, 6, and 7 were dominated in the base case analysis by strategy 5. The costs associated with strategies 2, 5, 1, and 4 were US$3,813, US$4,056, US$4,545, and US $5,331, respectively. The incremental cost-effectiveness ratios for strategy 5 vs. strategy 2, strategy 1 vs. strategy 5, and strategy 4 vs. strategy 1 were US$13,532, US$22,565, and US$30,452, respectively, per episode of FN avoided. Strategy 2 has the highest probability to be cost-effective (ranged from 48% to 60%) when the willingness to pay (WTP) threshold is lower than US$10,000 per FN episode prevented. Conclusion In Singapore, routine PP with granulocyte colony-stimulating factor (nivestim or pegfilgrastim) is cost-effective for reducing the risk of FN in patients receiving R-CHOP.	[Wang, Xiao Jun; Wee, Hwee Lin; Chan, Alexandre] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore; [Wang, Xiao Jun; Chan, Alexandre] Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore; [Tang, Tiffany; Farid, Mohamad; Quek, Richard; Tao, Miriam; Lim, Soon Thye] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore	National University of Singapore; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Chan, A (corresponding author), Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore.; Chan, A (corresponding author), Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore.	phaac@nus.edu.sg	Wee, Hwee Lin/D-4126-2012; Chan, Alexandre/D-5035-2016	Wee, Hwee Lin/0000-0002-7150-1801; Chan, Alexandre/0000-0003-4391-4219				Aapro Matti, 2012, J Oncol Pharm Pract, V18, P171, DOI 10.1177/1078155211407367; Aarts MJ, 2013, J CLIN ONCOL, V31, P4283, DOI 10.1200/JCO.2012.48.3644; Chan A, 2014, SUPPORT CARE CANCER, V22, P1105, DOI 10.1007/s00520-013-2067-1; Chan A, 2011, ASIA-PAC J CLIN ONCO, V7, P75, DOI 10.1111/j.1743-7563.2010.01355.x; Chan KKW, 2012, J CLIN ONCOL, V30, P1064, DOI 10.1200/JCO.2011.36.8647; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Department of Statistics Singapore, CONS PRIC IND; Gascon P, 2013, SUPPORT CARE CANCER, V21, P2925, DOI 10.1007/s00520-013-1911-7; Henry D, 2014, SEMIN ONCOL, V41, pS13, DOI 10.1053/j.seminoncol.2014.03.009; Hill Gregory, 2014, J Med Econ, V17, P32, DOI 10.3111/13696998.2013.844160; Kamioner D, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-547; Lathia N, 2013, JNCI-J NATL CANCER I, V105, P1078, DOI 10.1093/jnci/djt182; Lyman G, 2009, CURR MED RES OPIN, V25, P401, DOI 10.1185/03007990802636817 ; Lyman GH, 2003, LEUKEMIA LYMPHOMA, V44, P2069, DOI 10.1080/1042819031000119262; Michels SL, 2012, PHARMACOECONOMICS, V30, P809, DOI 10.2165/11592980-000000000-00000; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; NCCN, CLIN PRACT GUID ONC; Osby E, 2003, BLOOD, V101, P3840, DOI 10.1182/blood-2002-10-3238; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Szende A, 2007, EQ 5D VALUE SETS INV, P63; The World Bank, PPP CONV FACT GDP; Waller CF, 2010, ONKOLOGIE, V33, P504, DOI 10.1159/000319693; Wang XJ, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-434; Wang XJ, 2015, PSYCHOMETRIC PROPERT; Wong M, 2012, ANN ACAD MED SINGAP, V41, P287	25	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148901	10.1371/journal.pone.0148901	http://dx.doi.org/10.1371/journal.pone.0148901			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26871584	gold, Green Published			2023-01-03	WOS:000370054100070
J	Ventrella, E; Adamski, Z; Chudzinska, E; Miadowicz-Kobielska, M; Marciniak, P; Buyukguzel, E; Buyukguzel, K; Erdem, M; Falabella, P; Scrano, L; Bufo, SA				Ventrella, Emanuela; Adamski, Zbigniew; Chudzinska, Ewa; Miadowicz-Kobielska, Mariola; Marciniak, Pawel; Buyukguzel, Ender; Buyukguzel, Kemal; Erdem, Meltem; Falabella, Patrizia; Scrano, Laura; Bufo, Sabino Aurelio			Solanum tuberosum and Lycopersicon esculentum Leaf Extracts and Single Metabolites Affect Development and Reproduction of Drosophila melanogaster	PLOS ONE			English	Article							PLANT DEFENSE; POTATO GLYCOALKALOIDS; TOMATO GLYCOALKALOIDS; SECONDARY METABOLITES; ALPHA-SOLANINE; TOXICITY; RESISTANCE; ALKALOIDS; DIPTERA; LARVAE	Glycoalkaloids are secondary metabolites commonly found in Solanaceae plants. They have anti-bacterial, anti-fungal and insecticidal activities. In the present study we examine the effects of potato and tomato leaf extracts and their main components, the glycoalkaloids a-solanine, a-chaconine and a-tomatine, on development and reproduction of Drosophila melanogaster wild-type flies at different stages. Parental generation was exposed to five different concentrations of tested substances. The effects were examined also on the next, non-exposed generation. In the first (exposed) generation, addition of each extract reduced the number of organisms reaching the pupal and imaginal stages. Parent insects exposed to extracts and metabolites individually applied showed faster development. However, the effect was weaker in case of single metabolites than in case of exposure to extracts. An increase of developmental rate was also observed in the next, non-exposed generation. The imagoes of both generations exposed to extracts and pure metabolites showed some anomalies in body size and malformations, such as deformed wings and abdomens, smaller black abdominal zone. Our results further support the current idea that Solanaceae can be an impressive source of molecules, which could efficaciously be used in crop protection, as natural extract or in formulation of single pure metabolites in sustainable agriculture.	[Ventrella, Emanuela; Falabella, Patrizia; Bufo, Sabino Aurelio] Univ Basilicata, Dept Sci, I-85100 Potenza, Italy; [Adamski, Zbigniew] Adam Mickiewicz Univ, Electron & Confocal Microscope Lab, Poznan, Poland; [Adamski, Zbigniew; Marciniak, Pawel] Adam Mickiewicz Univ, Dept Anim Physiol & Dev Biol, Poznan, Poland; [Chudzinska, Ewa; Miadowicz-Kobielska, Mariola] Adam Mickiewicz Univ, Dept Genet, Poznan, Poland; [Buyukguzel, Ender] Bulent Ecevit Univ, Dept Mol Biol & Genet, Zonguldak, Turkey; [Buyukguzel, Kemal] Bulent Ecevit Univ, Fac Arts & Sci, Dept Biol, Zonguldak, Turkey; [Erdem, Meltem] Bulent Ecevit Univ, Ahmet Erdogan Vocat Sch Hlth, Zonguldak, Turkey; [Scrano, Laura] Univ Basilicata, Dept European & Mediterranean Cultures, Matera, Italy	Italfarmaco; University of Basilicata; Adam Mickiewicz University; Adam Mickiewicz University; Adam Mickiewicz University; Bulent Ecevit University; Bulent Ecevit University; Bulent Ecevit University; University of Basilicata	Bufo, SA (corresponding author), Univ Basilicata, Dept Sci, I-85100 Potenza, Italy.	sabino.bufo@unibas.it	Marciniak, Pawel/GVU-4616-2022; Marciniak, Pawel/G-7455-2012; Buyukguzel, Kemal/AAH-8750-2019; Marciniak, Pawel/P-1410-2019; Bufo, Sabino A./D-5212-2016	Marciniak, Pawel/0000-0002-4790-001X; Marciniak, Pawel/0000-0002-4790-001X; Buyukguzel, Kemal/0000-0002-9589-9383; Bufo, Sabino A./0000-0002-0857-2367; Adamski, Zbigniew/0000-0002-8696-3785; chudzinska, ewa/0000-0002-4576-4763; Buyukguzel, Kemal/0000-0002-6959-8480; Scrano, Laura/0000-0002-3716-2666				Abolaji A, 2013, ARCH BASIC APPL MED, V1, P33; Adamski Z, 2005, J APPL ENTOMOL, V129, P526, DOI 10.1111/j.1439-0418.2005.01001.x; Adamski Zbigniew, 2005, Journal of Biological Research (Thessaloniki), V3, P15; Adamski Z, 2014, ARCH INSECT BIOCHEM, V87, P26, DOI 10.1002/arch.21177; Adamski Zbigniew, 2012, P169; Adamski Z, 2009, J TOXICOL ENV HEAL A, V72, P1132, DOI 10.1080/15287390903091749; Adamski Z, 2009, PESTIC BIOCHEM PHYS, V94, P73, DOI 10.1016/j.pestbp.2009.04.005; BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/j.1469-8137.1994.tb02968.x; Bidlack W. R., 2000, PHYTOCHEMICALS BIOAC; Buyukguzel E, 2013, ARCH INSECT BIOCHEM, V83, P15, DOI 10.1002/arch.21089; Cataldi TRI, 2005, RAPID COMMUN MASS SP, V19, P3103, DOI 10.1002/rcm.2176; CHAN HT, 1985, J ECON ENTOMOL, V78, P305, DOI 10.1093/jee/78.2.305; Chowanski S, 2016, TOXINS, V8, DOI 10.3390/toxins8030060; Corio C, 2013, BIOL J LINN SOC, V109, P342, DOI 10.1111/bij.12036; Croteau R., 2000, BIOCH MOL BIOL PLANT, P1250, DOI DOI 10.1201/B11003-3; Duffey SS, 1996, ARCH INSECT BIOCHEM, V32, P3, DOI 10.1002/(SICI)1520-6327(1996)32:1&lt;3::AID-ARCH2&gt;3.0.CO;2-1; Fogleman JC, 2000, CHEM-BIOL INTERACT, V125, P93, DOI 10.1016/S0009-2797(99)00161-1; Fragoyiannis DA, 1998, ENTOMOL EXP APPL, V88, P59, DOI 10.1023/A:1003231621662; Friedman M, 2002, J AGR FOOD CHEM, V50, P5751, DOI 10.1021/jf020560c; Friedman M, 1997, CRIT REV PLANT SCI, V16, P55, DOI 10.1080/713608144; Gut L, 2002, FRUIT CROP ECOLOGY M, P34; Humphrey A.J., 2006, PLANT SECONDARY META, P46; Johnson T, 1999, CRC EDMOBOTANY DES R; Ke Li-Xia, 2009, Acta Ecologica Sinica, V29, P182; KIRCHER HW, 1967, J INSECT PHYSIOL, V13, P1869, DOI 10.1016/0022-1910(67)90023-6; KIRK D, 1975, HUMANGENETIK, V26, P105; Marciniak P, 2010, B ENVIRON CONTAM TOX, V84, P153, DOI 10.1007/s00128-009-9921-3; Milner SE, 2011, J AGR FOOD CHEM, V59, P3454, DOI 10.1021/jf200439q; Nenaah G, 2011, J PEST SCI, V84, P77, DOI 10.1007/s10340-010-0329-y; Nenaah GE, 2011, J STORED PROD RES, V47, P185, DOI 10.1016/j.jspr.2010.11.003; Newman MC, 2003, FUNDAMENTALS ECOTOXI; Ong C, 2015, NANOTOXICOLOGY, V9, P396, DOI 10.3109/17435390.2014.940405; Osbourn AE, 1996, PLANT CELL, V8, P1821, DOI 10.1105/tpc.8.10.1821; Ozkan Ferbal, 1997, Turkish Journal of Zoology, V21, P309; Panacek A, 2011, ENVIRON SCI TECHNOL, V45, P4974, DOI 10.1021/es104216b; Rattan RS, 2010, CROP PROT, V29, P913, DOI 10.1016/j.cropro.2010.05.008; Sanford LL, 1996, AM POTATO J, V73, P79, DOI 10.1007/BF02854762; SECOY DM, 1983, ECON BOT, V37, P28, DOI 10.1007/BF02859304; Ventrella E, 2015, INSECT SCI, V22, P251, DOI 10.1111/1744-7917.12110; War AR, 2012, PLANT SIGNAL BEHAV, V7, P1306, DOI 10.4161/psb.21663; Weissenberg M, 1998, PHYTOCHEMISTRY, V47, P203, DOI 10.1016/S0031-9422(97)00565-7; Wittstock U, 2002, CURR OPIN PLANT BIOL, V5, P300, DOI 10.1016/S1369-5266(02)00264-9	42	23	23	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2016	11	5							e0155958	10.1371/journal.pone.0155958	http://dx.doi.org/10.1371/journal.pone.0155958			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2FT	27213896	Green Published, gold, Green Submitted			2023-01-03	WOS:000376880200038
J	Tseng, CY; Lin, CH; Wu, LY; Wang, JS; Chung, MC; Chang, JF; Chao, MW				Tseng, Chia-Yi; Lin, Chin-Hung; Wu, Lung-Yuan; Wang, Jhih-Syuan; Chung, Meng-Chi; Chang, Jing-Fen; Chao, Ming-Wei			Potential Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin	PLOS ONE			English	Article							MORUS-ALBA L.; PRENYLATED FLAVONOIDS; CLINICAL-FEATURES; RISK-FACTORS; CIK CELLS; APOPTOSIS; CHEMOTHERAPY; DIAGNOSIS; ANTITUMOR; ASBESTOS	Traditional lung cancer treatments involve chemical or radiation therapies after surgical tumor removal; however, these procedures often kill normal cells as well. Recent studies indicate that chemotherapies, when combined with Traditional Chinese Medicines, may offer a new way to treat cancer. In vitro tests measuring the induction of autophagy and/or apoptosis were used to examine the cytotoxicity of SBPE, commonly used for lung inflammation on A549 cell line. The results indicated that intercellular levels of p62 and Atg12 were increased, LC3-I was cleaved into LC3-II, and autophagy was induced with SBPE only. After 24 hours, the apoptotic mechanism was induced. If the Cisplatin was added after cells reached the autophagy state, we observed synergistic effects of the two could achieve sufficient death of lung cancer cells. Therefore, the Cisplatin dosage used to induce apoptosis could be reduced by half, and the amount of time needed to achieve the inhibitory concentration of 50% was also half that of the original. In addition to inducing autophagy within a shortened period of time, the SBPE and chemotherapy drug combination therapy was able to achieve the objective of rapid low-dosage cancer cell elimination. Besides, SBPE was applied with Gemcitabine or Paclitaxel, and found that the combination treatment indeed achieve improved lung cancer cell killing effects. However, SBPE may also be less toxic to normal cells.	[Tseng, Chia-Yi] Chung Yuan Christian Univ, Coll Engn, Dept Biomed Engn, Taoyuan, Taiwan; [Lin, Chin-Hung; Wang, Jhih-Syuan; Chung, Meng-Chi; Chang, Jing-Fen; Chao, Ming-Wei] Chung Yuan Christian Univ, Coll Sci, Dept Biosci Technol, Taoyuan, Taiwan; [Wu, Lung-Yuan] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan	Chung Yuan Christian University; Chung Yuan Christian University; I Shou University	Chao, MW (corresponding author), Chung Yuan Christian Univ, Coll Sci, Dept Biosci Technol, Taoyuan, Taiwan.	chao@cycu.edu.tw			Ministry of Science and Technology in Taiwan [NSC-102-2320-B-033-001-MY3]	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grant from Ministry of Science and Technology (NSC-102-2320-B-033-001-MY3) in Taiwan.	Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S; Amarasena IU, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006849.pub2; [Anonymous], 2015, CANC REGISTRY ANN RE; [Anonymous], 2002, SMALL CELL LUNG CANC; Bjerager M, 2006, BRIT J GEN PRACT, V56, P863; Chen PN, 2006, CANCER LETT, V235, P248, DOI 10.1016/j.canlet.2005.04.033; Cheng XH, 2014, ONCOTARGETS THER, V7, P1689, DOI 10.2147/OTT.S66502; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; Cui Qing-Li, 2013, Zhongguo Zhong Yao Za Zhi, V38, P3549; Dasari R, 2015, EUR J MED CHEM, V103, P226, DOI 10.1016/j.ejmech.2015.08.047; El-Beshbishy HA, 2006, LIFE SCI, V78, P2724, DOI 10.1016/j.lfs.2005.10.010; Feng L, 2013, MOLECULES, V18, P9966, DOI 10.3390/molecules18089966; Gao YT, 1996, LUNG CANCER-J IASLC, V14, pS39, DOI 10.1016/S0169-5002(96)90209-3; Gustavsson P, 2002, AM J EPIDEMIOL, V155, P1016, DOI 10.1093/aje/155.11.1016; Hamilton W, 2005, THORAX, V60, P1059, DOI 10.1136/thx.2005.045880; Hauptmann M, 2002, AM J IND MED, V41, P89, DOI 10.1002/ajim.10020; Honnorat J, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-22; Hui KM, 2012, EXPERT OPIN BIOL TH, V12, P659, DOI 10.1517/14712598.2012.676037; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V83, P1; Iyengar P, 2002, SURG ONCOL, V11, P167, DOI 10.1016/S0960-7404(02)00047-6; Jagetia GC, 2007, J CLIN IMMUNOL, V27, P19, DOI 10.1007/s10875-006-9066-7; Kao ST, 2001, LIFE SCI, V69, P1485, DOI 10.1016/S0024-3205(01)01226-7; Kim BH, 2003, ARCH PHARM RES, V26, P306, DOI 10.1007/BF02976960; Ko YC, 2000, AM J EPIDEMIOL, V151, P140, DOI 10.1093/oxfordjournals.aje.a010181; Langer CJ, 2010, J CLIN ONCOL, V28, P5311, DOI 10.1200/JCO.2010.28.8126; Lee HJ, 2012, ARCH PHARM RES, V35, P163, DOI 10.1007/s12272-012-0118-7; Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001; Lim SL, 2015, AM J CANCER RES, V5, P289; Maneeton B, 2014, ONCOTARGETS THER, V7, P815, DOI 10.2147/OTT.S60000; McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392; Minna J., 2008, LIBR J, V133, P96; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Pohlabeln H, 2002, OCCUP ENVIRON MED, V59, P410, DOI 10.1136/oem.59.6.410; Presutti D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143333; Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019; Ramalingam S, 2008, ONCOLOGIST, V13, P5, DOI 10.1634/theoncologist.13-S1-5; Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4; Santabarbara G, 2016, EXPERT OPIN PHARMACO, V17, P561, DOI 10.1517/14656566.2016.1122757; Sekine T, 1998, STP PHARMA SCI, V8, P249; Services USDoHaH, 2006, PUBL REP SURG GEN; Shibata Y, 2007, ATHEROSCLEROSIS, V193, P20, DOI 10.1016/j.atherosclerosis.2006.08.011; Sohn HY, 2004, PHYTOMEDICINE, V11, P666, DOI 10.1016/j.phymed.2003.09.005; Spaans JN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00190; Spiro SG, 2005, AM J RESP CRIT CARE, V172, P523, DOI 10.1164/rccm.200504-531OE; Tamaki T, 2003, J INT MED RES, V31, P6, DOI 10.1177/147323000303100102; Tseng TH, 2010, TETRAHEDRON, V66, P1335, DOI 10.1016/j.tet.2009.12.002; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; VCV, 1999, DICT VIETN MED PLANT; Wang CZ, 2015, AM J CHINESE MED, V43, P1351, DOI 10.1142/S0192415X15500767; Wang TJ, 1996, LUNG CANCER-J IASLC, V14, pS93, DOI 10.1016/S0169-5002(96)90214-7; Wang XM, 2014, CELL IMMUNOL, V287, P18, DOI 10.1016/j.cellimm.2013.11.009; Wang X, 2015, INT IMMUNOPHARMACOL, V29, P701, DOI 10.1016/j.intimp.2015.09.006; Xiong F, 2014, INTEGR CANCER THER, V13, P152, DOI 10.1177/1534735413503544; Yang P, 2005, CHEST, V128, P452, DOI 10.1378/chest.128.1.452; Yang Song, 2015, Asian Pac J Cancer Prev, V16, P5963; YANO H, 1994, CANCER RES, V54, P448; Zarogoulidis K, 2013, J THORAC DIS, V5, pS389, DOI 10.3978/j.issn.2072-1439.2013.07.10; Zhang XT, 2011, MOLECULES, V16, P9505, DOI 10.3390/molecules16119505; Zheng CH, 2015, INT J CLIN EXP MED, V8, P14527; Zong Yu-ying, 2007, Zhongguo Zhong Yao Za Zhi, V32, P1038	61	14	20	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2016	11	5							e0155469	10.1371/journal.pone.0155469	http://dx.doi.org/10.1371/journal.pone.0155469			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CQ	27171432	Green Submitted, Green Published, gold			2023-01-03	WOS:000376588600103
J	Sharma, S; Chowdhury, A; Tang, LL; Willes, L; Glynn, B; Quan, SF				Sharma, Sunil; Chowdhury, Anindita; Tang, Lili; Willes, Leslee; Glynn, Brian; Quan, Stuart F.			Hospitalized Patients at High Risk for Obstructive Sleep Apnea Have More Rapid Response System Events and Intervention Is Associated with Reduced Events	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; OUTCOMES; MORTALITY; PREVALENCE	Background Rapid response system (RRS) is a safety tool designed for early detection and intervention of a deteriorating patient on the general floor in the hospital. Obstructive sleep apnea (OSA) has been associated with significant cardiovascular complications. We hypothesized that patients with high-risk of OSA have higher rate of RRS events and intervention with positive airway pressure therapy in these patients can mitigate the RRS events. Methods As part of a clinical pathway, during a 15 month period, patients with BMI >= 30 kg/m(2) in select medical services were screened with a validated sleep questionnaire. Patients were characterized as high or low risk based on the screening questionnaire. RRS rates were compared between the groups. Subsequently the impact of PAP therapy on RRS events was evaluated. Results Out of the 2,590 patients screened, 1,973 (76%) were identified as high-risk. RRS rates calculated per 1,000 admissions, were 43.60 in the High-Risk OSA group versus 25.91 in the Low-Risk OSA Group. The PAP therapy compliant group had significantly reduced RRS event rates compared to non-compliant group and group with no PAP therapy (16.99 vs. 53.40 vs. 56.21) (p < 0.01). Conclusion In a large cohort of patients at a tertiary care hospital, we show an association of increased rate of RRS events in high-risk OSA patients and reduction of the risk with PAP intervention in the compliant group.	[Sharma, Sunil; Chowdhury, Anindita; Tang, Lili; Glynn, Brian] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Quan, Stuart F.] Harvard Univ, Sch Med, Boston, MA USA; [Quan, Stuart F.] Univ Arizona, Coll Med, Tucson, AZ USA; [Willes, Leslee] Willes Consulting Grp Inc, Encinitas, CA USA	Jefferson University; Harvard University; Harvard Medical School; University of Arizona	Sharma, S (corresponding author), Thomas Jefferson Univ, Philadelphia, PA 19107 USA.	Sunil.Sharma@jefferson.edu	Quan, Stuart/J-5026-2019	Quan, Stuart/0000-0002-9474-7679	RESMED corp.	RESMED corp.	Dr. Sunil Sharma has an unrestricted research grant from RESMED corp. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boynton Grace, 2013, J Sleep Disord Treat Care, V2, DOI 10.4172/2325-9639.1000121; Chan PS, 2010, ARCH INTERN MED, V170, P18, DOI 10.1001/archinternmed.2009.424; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DeVita MA, 2006, CRIT CARE MED, V34, P2463, DOI 10.1097/01.CCM.0000235743.38172.6E; Floras JS, 2014, J CARDIOL, V63, P3, DOI 10.1016/j.jjcc.2013.08.009; Gami AS, 2013, J AM COLL CARDIOL, V62, P610, DOI 10.1016/j.jacc.2013.04.080; Goring K, 2008, J CLIN SLEEP MED, V4, P105; Jean RE, 2015, J CRIT CARE, V30, P778, DOI 10.1016/j.jcrc.2015.03.016; Jennum P, 2015, NAT SCI SLEEP, V7, P43, DOI 10.2147/NSS.S75166; Lindenauer PK, 2014, CHEST, V145, P1032, DOI 10.1378/chest.13-1544; Lyons PG, 2015, J HOSP MED, V10, P592, DOI 10.1002/jhm.2404; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Nagappa M, 2015, ANESTH ANALG, V120, P1013, DOI 10.1213/ANE.0000000000000634; Proczko MA, 2014, J ANESTH, V28, P891, DOI 10.1007/s00540-014-1848-0; Sharma S, 2015, J CLIN SLEEP MED, V11, P717, DOI 10.5664/jcsm.4842; Sharma S, 2012, CLIN CARDIOL, V35, P641, DOI 10.1002/clc.22057; Silva GE, 2011, J CLIN SLEEP MED, V7, P468, DOI 10.5664/JCSM.1308; Spurr KF, 2008, SLEEP BREATH, V12, P229, DOI 10.1007/s11325-007-0166-2; Venkateshiah SB, 2012, CHEST, V141, P1337, DOI 10.1378/chest.11-2591; Winters BD, 2013, ANN INTERN MED, V158, P417, DOI 10.7326/0003-4819-158-5-201303051-00009; Yuan XD, 2015, SLEEP BREATH, V19, P911, DOI 10.1007/s11325-014-1091-9	22	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2016	11	5							e0153790	10.1371/journal.pone.0153790	http://dx.doi.org/10.1371/journal.pone.0153790			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM8CD	27168330	Green Published, gold			2023-01-03	WOS:000376587300048
J	Lee, J; Machin, M; Russell, KE; Pavlidis, S; Zhu, J; Barnes, PJ; Chung, KF; Adcock, IM; Durham, AL				Lee, Jin; Machin, Matthew; Russell, Kirsty E.; Pavlidis, Stelios; Zhu, Jie; Barnes, Peter J.; Chung, Kian F.; Adcock, Ian M.; Durham, Andrew L.			Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD	FASEB JOURNAL			English	Article						DUSP1; ERK; fluticasone propionate; LABA	OBSTRUCTIVE PULMONARY-DISEASE; DUAL-SPECIFICITY PHOSPHATASES; AIRWAY GENE-EXPRESSION; MAP KINASE; INHALED FLUTICASONE; LUNG-FUNCTION; GLUCOCORTICOIDS; EXACERBATIONS; TRANSCRIPTION; INFLAMMATION	We investigated changes in gene expression that occur in chronic obstructive pulmonary disease (COPD) after corticosteroid treatment and sought to identify the mechanisms that regulate these changes. Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). Gene expression was measured by microarray and was confirmed by real-time reverse transcription-quantitative PCR (RT-qPCR). The effect of FP on IgG expression and B-cell proliferation in the presence of oxidative stress was also studied. FP/SM significantly increased the expression of 180 genes while repressing 343 genes. The top 5 down-regulated genes were associated with immunoglobulin production, whereas the immunomodulatory FK506 binding protein (FK506BP) was up-regulated. Genes including IL6, IL8, and TBET-encoding TBX21 were unaffected. FP reduced IgG protein and mRNA expression and proliferation of human B cells through the dephosphorylation of ERK1/2 via increased DUSP1 (dual-specificity protein phosphatase 1) expression. Consistent with in vivo data, oxidative stress did not prevent FP-induced suppression of IgG expression in human B cells in vitro. Changes in expression were validated by RT-qPCR and by gene set enrichment analysis in distinct COPD cohorts. FP may reduce the adaptive immune response in COPD and may be more effective in patients with an increased B-cell/antibody response indicated by high autoantibody titers.-Lee, J., Machin, M., Russell, K. E., Pavlidis, S., Zhu, J., Barnes, P. J., Chung, K. F., Adcock, I. M., Durham, A. L. Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD. www.fasebj.org	[Lee, Jin; Machin, Matthew; Russell, Kirsty E.; Zhu, Jie; Barnes, Peter J.; Chung, Kian F.; Adcock, Ian M.; Durham, Andrew L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England; [Pavlidis, Stelios] Janssen Res & Dev, High Wycombe, Bucks, England	Imperial College London; Johnson & Johnson	Durham, AL (corresponding author), Natl Heart & Lung Inst, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	a.durham@imperial.ac.uk	Adcock, Ian/L-3217-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Adcock, Ian/0000-0003-2101-8843; Machin, Matthew/0000-0002-9692-4552; Durham, Andrew/0000-0003-2372-4688; Barnes, Peter/0000-0002-5122-4018	Medical Research Council [G1001367/1]; Wellcome Trust [093080/Z/10/Z]; Interuniversity Attraction Poles Program Belgian State-Belgian Science Policy Project [P7/30]; National Institute for Health Research Respiratory Disease Biomedical Research Unit; Royal Brompton National Health Service (NHS) Foundation Trust; Imperial College London; GSK; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Interuniversity Attraction Poles Program Belgian State-Belgian Science Policy Project; National Institute for Health Research Respiratory Disease Biomedical Research Unit; Royal Brompton National Health Service (NHS) Foundation Trust; Imperial College London(General Electric); GSK(GlaxoSmithKline); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The microarray data was carried out with the help of A. McLaren, B. P. Hayes, and C. Clayton at GlaxoSmithKline (GSK), and bronchial biopsy samples were obtained with the help of A. Torrego. I.M.A. is supported by the Medical Research Council (G1001367/1) and the Wellcome Trust (093080/Z/10/Z). I.M.A. is a member of Interuniversity Attraction Poles Program Belgian State-Belgian Science Policy Project P7/30. Research by I.M.A., P.J.B., K.F.C., and A.L.D. is supported in part by the National Institute for Health Research Respiratory Disease Biomedical Research Unit, Royal Brompton National Health Service (NHS) Foundation Trust, and Imperial College London. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. This work was funded by the Wellcome Trust (093080/Z/10/Z) and an unrestricted research grant from GSK. The sponsors had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	Ayroldi E, 2012, FASEB J, V26, P4805, DOI 10.1096/fj.12-216382; Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC; Barnes PJ, 2013, CURR MED CHEM, V20, P1531; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley P, 2004, EUR RESPIR J, V24, P206; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Christenson SA, 2015, AM J RESP CRIT CARE, V191, P758, DOI 10.1164/rccm.201408-1458OC; CUPPS TR, 1985, J CLIN INVEST, V75, P754, DOI 10.1172/JCI111757; Duncan SR, 2010, AM J RESP CRIT CARE, V181, P4, DOI 10.1164/rccm.200910-1488ED; Durham AL, 2013, FASEB J, V27, P2367, DOI 10.1096/fj.12-217083; Fokkens WJ, 1999, ALLERGY, V54, P158, DOI 10.1034/j.1398-9995.1999.00747.x; Ford PA, 2010, CHEST, V137, P1338, DOI 10.1378/chest.09-2363; Georas Steve N, 2004, Proc Am Thorac Soc, V1, P215, DOI 10.1513/pats.200402-004MS; Gold MR, 2008, IMMUNITY, V28, P488, DOI 10.1016/j.immuni.2008.03.008; Gosman MME, 2006, EUR RESPIR J, V27, P60, DOI 10.1183/09031936.06.00007005; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hakim A, 2012, DRUGS, V72, P1299, DOI 10.2165/11634350-000000000-00000; Haque R, 2013, J ALLERGY CLIN IMMUN, V132, P1166, DOI 10.1016/j.jaci.2013.07.038; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K., 2001, FASEB Journal, V15, P1110; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kaur M, 2008, MOL PHARMACOL, V73, P203, DOI 10.1124/mol.107.040121; Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2; Kirkham PA, 2011, AM J RESP CRIT CARE, V184, P796, DOI 10.1164/rccm.201010-1605OC; Lapperre TS, 2009, ANN INTERN MED, V151, P517, DOI 10.7326/0003-4819-151-8-200910200-00004; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maas A. K., 2010, F1000 MED REP, V2, P2; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Magnussen H, 2014, NEW ENGL J MED, V371, P1285, DOI 10.1056/NEJMoa1407154; Maneechotesuwan K, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000076; Mercado N, 2011, J PHARMACOL EXP THER, V337, P465, DOI 10.1124/jpet.110.175950; National Institute for Health and Care Excellence (NICE), 2019, CHRON OBSTR PULM DIS; Nunez B, 2011, AM J RESP CRIT CARE, V183, P1025, DOI 10.1164/rccm.201001-0029OC; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reth M, 2014, ADV IMMUNOL, V122, P129, DOI 10.1016/B978-0-12-800267-4.00004-3; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; Statistical Solutions, POW SAMPL SIZ CALC; Steiling K, 2013, AM J RESP CRIT CARE, V187, P933, DOI 10.1164/rccm.201208-1449OC; Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44; van den Berge M, 2014, THORAX, V69, P14, DOI 10.1136/thoraxjnl-2012-202878; Wedzicha JA, 2012, EUR RESPIR J, V40, P1545, DOI 10.1183/09031936.00048912; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; ZON LI, 1991, J BIOL CHEM, V266, P22948	54	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2016	30	5					2014	2026		10.1096/fj.201500135	http://dx.doi.org/10.1096/fj.201500135			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DK4HW	26887440	Green Submitted			2023-01-03	WOS:000374879400028
J	Cerritelli, S; Hirschberg, S; Hill, R; Balthasar, N; Pickering, AE				Cerritelli, Serena; Hirschberg, Stefan; Hill, Rob; Balthasar, Nina; Pickering, Anthony E.			Activation of Brainstem Pro-opiomelanocortin Neurons Produces Opioidergic Analgesia, Bradycardia and Bradypnoea	PLOS ONE			English	Article							NUCLEUS-TRACTUS-SOLITARIUS; VAGUS NERVE-STIMULATION; CARDIAC VAGAL NEURONS; STRESS-INDUCED ANALGESIA; BETA-ENDORPHIN; RETICULARIS-VENTRALIS; AFFERENT MODULATION; MEDULLA-OBLONGATA; POMC NEURONS; IN-VIVO	Opioids are widely used medicinally as analgesics and abused for hedonic effects, actions that are each complicated by substantial risks such as cardiorespiratory depression. These drugs mimic peptides such as beta-endorphin, which has a key role in endogenous analgesia. The beta-endorphin in the central nervous system originates from pro-opiomelanocortin (POMC) neurons in the arcuate nucleus and nucleus of the solitary tract (NTS). Relatively little is known about the NTSPOMC neurons but their position within the sensory nucleus of the vagus led us to test the hypothesis that they play a role in modulation of cardiorespiratory and nociceptive control. The NTSPOMC neurons were targeted using viral vectors in a POMC-Cre mouse line to express either opto-genetic (channelrhodopsin-2) or chemo-genetic (Pharmacologically Selective Actuator Modules). Opto-genetic activation of the NTSPOMC neurons in the working heart brainstem preparation (n = 21) evoked a reliable, titratable and time-locked respiratory inhibition (120% increase in inter-breath interval) with a bradycardia (125 +/- 26 beats per minute) and augmented respiratory sinus arrhythmia (58% increase). Chemo-genetic activation of NTSPOMC neurons in vivo was anti-nociceptive in the tail flick assay (latency increased by 126 +/- 65%, p<0.001; n = 8). All effects of NTSPOMC activation were blocked by systemic naloxone (opioid antagonist) but not by SHU9119 (melanocortin receptor antagonist). The NTSPOMC neurons were found to project to key brainstem structures involved in cardiorespiratory control (nucleus ambiguus and ventral respiratory group) and endogenous analgesia (periaqueductal gray and midline raphe). Thus the NTSPOMC neurons may be capable of tuning behaviour by an opioidergic modulation of nociceptive, respiratory and cardiac control.	[Cerritelli, Serena; Hirschberg, Stefan; Hill, Rob; Balthasar, Nina; Pickering, Anthony E.] Univ Bristol, Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg, Bristol BS8 1TD, Avon, England; [Pickering, Anthony E.] Univ Hosp Bristol, Dept Anaesthesia, Bristol BS2 8HW, Avon, England	University of Bristol; University of Bristol	Pickering, AE (corresponding author), Univ Bristol, Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg, Bristol BS8 1TD, Avon, England.; Pickering, AE (corresponding author), Univ Hosp Bristol, Dept Anaesthesia, Bristol BS2 8HW, Avon, England.	Tony.Pickering@bristol.ac.uk	Core, Vector/CAF-4832-2022; Pickering, Anthony E/A-9929-2011	Hirschberg, Stefan/0000-0002-4297-9224; Hill, Rob/0000-0003-3859-8506; Pickering, Anthony/0000-0003-0345-0456	Wellcome Trust [gr088373]; Medical Research Council	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Wellcome Trust, gr088373, AEP; http://www.wellcome.ac.uk/ and Medical Research Council, in vivo PhD studentship, SC; http://www.mrc.ac.uk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AICHER SA, 1990, PAIN, V42, P103, DOI 10.1016/0304-3959(90)91096-2; Anseloni VCZ, 2005, NEUROSCIENCE, V133, P231, DOI 10.1016/j.neuroscience.2005.01.055; Aponte Y, 2011, NAT NEUROSCI, V14, P351, DOI 10.1038/nn.2739; Appleyard SM, 2003, ENDOCRINOLOGY, V144, P1753, DOI 10.1210/en.2002-221096; Appleyard SM, 2005, J NEUROSCI, V25, P3578, DOI 10.1523/JNEUROSCI.4177-04.2005; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; Barraco IRA, 1994, NUCL SOLITARY TRACT; Benarroch EE, 2012, NEUROLOGY, V79, P807, DOI 10.1212/WNL.0b013e3182662098; Bicknell AB, 2008, J NEUROENDOCRINOL, V20, P692, DOI 10.1111/j.1365-2826.2008.01709.x; BIEGER D, 1987, J COMP NEUROL, V262, P546, DOI 10.1002/cne.902620408; Bohotin C, 2003, PAIN, V101, P3, DOI 10.1016/S0304-3959(02)00301-9; Boscan P, 2002, EXP PHYSIOL, V87, P259, DOI 10.1113/eph8702353; BRONSTEIN DM, 1992, BRAIN RES, V587, P269, DOI 10.1016/0006-8993(92)91007-2; Busch V, 2013, BRAIN STIMUL, V6, P202, DOI 10.1016/j.brs.2012.04.006; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; Cardin JA, 2010, NAT PROTOC, V5, P247, DOI 10.1038/nprot.2009.228; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; COX BM, 1976, P NATL ACAD SCI USA, V73, P1821, DOI 10.1073/pnas.73.6.1821; DUM J, 1984, PHARMACOL BIOCHEM BE, V21, P259, DOI 10.1016/0091-3057(84)90224-7; Dutschmann M, 2009, PHILOS T R SOC B, V364, P2611, DOI 10.1098/rstb.2009.0076; FANG FG, 1989, BRAIN RES, V501, P116, DOI 10.1016/0006-8993(89)91033-0; Farmer D, 2015, FASEB J, V29; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Frank JG, 2009, J NEUROPHYSIOL, V101, P1755, DOI 10.1152/jn.91134.2008; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Harrison D, 2012, PEDIATRICS, V130, P918, DOI 10.1542/peds.2011-3848; Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; Howorth PW, 2009, J COMP NEUROL, V512, P141, DOI 10.1002/cne.21879; Irnaten M, 2003, NEUROSCIENCE, V116, P573, DOI 10.1016/S0306-4522(02)00657-7; IZZO PN, 1993, J COMP NEUROL, V327, P572, DOI 10.1002/cne.903270408; JOSEPH SA, 1983, NEUROSCI LETT, V38, P221, DOI 10.1016/0304-3940(83)90372-5; Kirchner A, 2000, NEUROLOGY, V55, P1167, DOI 10.1212/WNL.55.8.1167; Kirchner A, 2006, EUR J PAIN, V10, P449, DOI 10.1016/j.ejpain.2005.06.005; Lalley PM, 2014, J PHYSIOL-LONDON, V592, P1163, DOI 10.1113/jphysiol.2013.258830; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; LEVINE JD, 1980, BRAIN RES, V201, P129, DOI 10.1016/0006-8993(80)90780-5; LEWIS JW, 1987, BRAIN RES, V424, P65, DOI 10.1016/0006-8993(87)91193-0; Magnus CJ, 2011, SCIENCE, V333, P1292, DOI 10.1126/science.1206606; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Mason P, 2009, ANN NY ACAD SCI, V1170, P399, DOI 10.1111/j.1749-6632.2009.04368.x; Meister B, 2006, EUR J NEUROSCI, V24, P2731, DOI 10.1111/j.1460-9568.2006.05157.x; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Mogil JS, 2000, NEUROSCIENCE, V101, P709, DOI 10.1016/S0306-4522(00)00422-X; Montandon G, 2014, J PHYSIOL-LONDON, V592, P1159, DOI 10.1113/jphysiol.2013.261974; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; MORGAN MM, 1989, BRAIN RES, V486, P175, DOI 10.1016/0006-8993(89)91291-2; Mountjoy KG, 2010, ADV EXP MED BIOL, V681, P29, DOI 10.1007/978-1-4419-6354-3_3; Opland D, 2013, MOL METAB, V2, P423, DOI 10.1016/j.molmet.2013.07.008; PALKOVITS M, 1987, BRAIN RES, V436, P323, DOI 10.1016/0006-8993(87)91676-3; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Prkic I, 2012, J NEUROPHYSIOL, V108, P2430, DOI 10.1152/jn.00185.2012; RANDICH A, 1988, J NEUROSCI, V8, P4675; RANDICH A, 1992, BRAIN RES REV, V17, P77, DOI 10.1016/0165-0173(92)90009-B; REN K, 1988, BRAIN RES, V446, P285, DOI 10.1016/0006-8993(88)90887-6; Richardson J, 2013, J NEUROSCI, V33, P13286, DOI 10.1523/JNEUROSCI.0780-13.2013; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SCHWARTZBERG DG, 1983, BRAIN RES, V276, P351, DOI 10.1016/0006-8993(83)90746-1; Stannard CF, 2013, OPIOIDS BRIEF HIST O, P1; SUH HH, 1990, J PHARMACOL EXP THER, V253, P981; Sutton AK, 2014, J NEUROSCI, V34, P15306, DOI 10.1523/JNEUROSCI.0226-14.2014; TSENG LF, 1992, EUR J PHARMACOL, V214, P59, DOI 10.1016/0014-2999(92)90096-M; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; Venkatesan P, 2003, J NEUROPHYSIOL, V90, P1581, DOI 10.1152/jn.01117.2002; Wan S, 2008, J NEUROSCI, V28, P4957, DOI 10.1523/JNEUROSCI.5398-07.2008; Wang DQ, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00040; WATSON SJ, 1978, NATURE, V275, P226, DOI 10.1038/275226a0; Yang YL, 2011, CELL, V146, P991, DOI 10.1016/j.cell.2011.07.039; Zhan C, 2013, J NEUROSCI, V33, P3624, DOI 10.1523/JNEUROSCI.2742-12.2013; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936	74	24	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2016	11	4							e0153187	10.1371/journal.pone.0153187	http://dx.doi.org/10.1371/journal.pone.0153187			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ3UH	27077912	Green Published, Green Submitted, gold			2023-01-03	WOS:000374131700026
J	Hawkes, N				Hawkes, Nigel			THE BMJ AWARDS 2016 Palliative care team	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2016	353								i1991	10.1136/bmj.i1991	http://dx.doi.org/10.1136/bmj.i1991			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ0LV	27059532				2023-01-03	WOS:000373896100004
J	Beutler, E; Beltrami, FG; Boutellier, U; Spengler, CM				Beutler, Eveline; Beltrami, Fernando G.; Boutellier, Urs; Spengler, Christina M.			Effect of Regular Yoga Practice on Respiratory Regulation and Exercise Performance	PLOS ONE			English	Article							VENTILATORY RESPONSE; CHEMOREFLEX RESPONSE; TRAINED MALES; BAROREFLEX; PRESSURES; CAPACITY; HYPOXIA; VALUES; SLOPE; CYCLE	Yoga alters spontaneous respiratory regulation and reduces hypoxic and hypercapnic ventilatory responses. Since a lower ventilatory response is associated with an improved endurance capacity during whole-body exercise, we tested whether yogic subjects (YOGA) show an increased endurance capacity compared to matched non-yogic individuals (CON) with similar physical activity levels. Resting ventilation, the ventilatory response to hypercapnia, passive leg movement and exercise, as well as endurance performance were assessed. YOGA (n = 9), compared to CONTROL (n = 6), had a higher tidal volume at rest (0.7 +/- 0.2 vs. 0.5 +/- 0.1 l, p = 0.034) and a reduced ventilatory response to hypercapnia (33 +/- 15 vs. 47 +/- 15 l.min(-1), p = 0.048). A YOGA subgroup (n = 6) with maximal performance similar to CONTROL showed a blunted ventilatory response to passive cycling (11 +/- 2 vs. 14 +/- 2 l.min(-1), p = 0.039) and a tendency towards lower exercise ventilation (33 +/- 2 vs. 36 +/- 3 l.min(-1), p = 0.094) while cycling endurance (YOGA: 17.3 +/- 3.3; CON: 19.6 +/- 8.5 min, p = 0.276) did not differ. Thus, yoga practice was not associated with improved exercise capacity nor with significant changes in exercise ventilation despite a significantly different respiratory regulation at rest and in response to hypercapnia and passive leg movement.	[Beutler, Eveline; Beltrami, Fernando G.; Boutellier, Urs; Spengler, Christina M.] ETH, Inst Human Movement Sci, Exercise Physiol Lab, Winterthurerstr 190, CH-8057 Zurich, Switzerland; [Boutellier, Urs; Spengler, Christina M.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Winterthurerstr 190, CH-8057 Zurich, Switzerland	ETH Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Spengler, CM (corresponding author), ETH, Inst Human Movement Sci, Exercise Physiol Lab, Winterthurerstr 190, CH-8057 Zurich, Switzerland.; Spengler, CM (corresponding author), Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christina.spengler@hest.ethz.ch	Spengler, Christina M./E-9776-2012	Spengler, Christina M./0000-0002-4598-3595				Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; BALASUBRAMANIAN B, 1991, Indian Journal of Physiology and Pharmacology, V35, P281; Bernardi L, 1998, LANCET, V351, P1308, DOI 10.1016/S0140-6736(97)10341-5; Bernardi L, 2001, J HYPERTENS, V19, P2221, DOI 10.1097/00004872-200112000-00016; Bernardi L, 2007, EUR J APPL PHYSIOL, V99, P511, DOI 10.1007/s00421-006-0373-8; Birkel DA, 2000, ALTERN THER HEALTH M, V6, P55; Bowman AJ, 1997, EUR J CLIN INVEST, V27, P443, DOI 10.1046/j.1365-2362.1997.1340681.x; BYRNEQUINN E, 1971, J APPL PHYSIOL, V30, P91, DOI 10.1152/jappl.1971.30.1.91; Calbet JAL, 2006, RESP PHYSIOL NEUROBI, V151, P132, DOI 10.1016/j.resp.2006.01.014; Clark AL, 1997, HEART, V77, P138, DOI 10.1136/hrt.77.2.138; Evans JA, 2009, RESP CARE, V54, P1348; FLUME PA, 1994, RESP PHYSIOL, V95, P53, DOI 10.1016/0034-5687(94)90047-7; Flume PA, 1996, RESP PHYSIOL, V103, P221, DOI 10.1016/0034-5687(95)00094-1; FOWLER WS, 1954, J APPL PHYSIOL, V6, P539, DOI 10.1152/jappl.1954.6.9.539; GOPAL K S, 1973, Indian Journal of Physiology and Pharmacology, V17, P273; Guenette JA, 2006, APPL PHYSIOL NUTR ME, V31, P159, DOI 10.1139/H05-016; Hagins Marshall, 2007, BMC Complement Altern Med, V7, P40, DOI 10.1186/1472-6882-7-40; Harms CA, 2008, MED SCI SPORT EXER, V40, P664, DOI 10.1249/MSS.0b013e3181621325; Harver A, 2000, CHEST, V118, P679, DOI 10.1378/chest.118.3.679; Ingle L, 2007, INT J CARDIOL, V118, P350, DOI 10.1016/j.ijcard.2006.07.105; JOSHI L N, 1992, Indian Journal of Physiology and Pharmacology, V36, P105; Joshi M, 2009, J ALTERN COMPLEM MED, V15, P281, DOI 10.1089/acm.2008.0250; Lansing RW, 2000, AM J RESP CRIT CARE, V162, P1690, DOI 10.1164/ajrccm.162.5.9907096; LEVINE BD, 1992, MED SCI SPORT EXER, V24, P769; LORINC Z, 1991, AM J PHYSIOL, V261, pR747, DOI 10.1152/ajpregu.1991.261.3.R747; MAKWANA K, 1988, Indian Journal of Physiology and Pharmacology, V32, P202; MCCONNELL AK, 1992, J GERONTOL, V47, pB137, DOI 10.1093/geronj/47.4.B137; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miyamura M, 2002, JPN J PHYSIOL, V52, P313, DOI 10.2464/jilm.52.313; Ohtake PJ, 1998, MED SCI SPORT EXER, V30, P17, DOI 10.1097/00005768-199801000-00004; Oosthuyse T, 2010, SPORTS MED, V40, P207, DOI 10.2165/11317090-000000000-00000; Ozkaplan A, 2005, EUR J APPL PHYSIOL, V95, P52, DOI 10.1007/s00421-005-1399-z; Pomidori L, 2009, J CARDIOPULM REHABIL, V29, P133, DOI 10.1097/HCR.0b013e31819a0227; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Raju P S, 1986, Indian J Physiol Pharmacol, V30, P121; Raju P S, 1997, J Altern Complement Med, V3, P291, DOI 10.1089/acm.1997.3.291; RAJU PS, 1994, INDIAN J MED RES, V100, P81; Ray U. S., 2001, Indian Journal of Physiology and Pharmacology, V45, P37; Ray US, 2001, INDIAN J MED RES, V114, P215; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; Sarang PS, 2006, APPL PSYCHOPHYS BIOF, V31, P143, DOI 10.1007/s10484-006-9012-8; Spengler CM, 2000, J PHYSIOL-LONDON, V526, P683, DOI 10.1111/j.1469-7793.2000.00683.x; Spicuzza L, 2000, LANCET, V356, P1495, DOI 10.1016/S0140-6736(00)02881-6; STANESCU DC, 1981, J APPL PHYSIOL, V51, P1625, DOI 10.1152/jappl.1981.51.6.1625; Tatsumi K, 1997, J APPL PHYSIOL, V83, P1706, DOI 10.1152/jappl.1997.83.5.1706; Telles S, 1993, Indian J Med Sci, V47, P235; Tran M D, 2001, Prev Cardiol, V4, P165, DOI 10.1111/j.1520-037X.2001.00542.x; ULDRY C, 1995, THORAX, V50, P371, DOI 10.1136/thx.50.4.371; Verges S, 2008, RESP PHYSIOL NEUROBI, V161, P16, DOI 10.1016/j.resp.2007.11.004; Villien F, 2005, RESP PHYSIOL NEUROBI, V146, P85, DOI 10.1016/j.resp.2004.11.010; WHITE DP, 1983, J APPL PHYSIOL, V54, P874, DOI 10.1152/jappl.1983.54.4.874; WHITE DP, 1985, J APPL PHYSIOL, V59, P1452, DOI 10.1152/jappl.1985.59.5.1452; Wilkie SS, 2015, J APPL PHYSIOL, V118, P255, DOI 10.1152/japplphysiol.00400.2014; WILSON SH, 1984, THORAX, V39, P535, DOI 10.1136/thx.39.7.535; Yadav Raj Kumar, 2001, Indian Journal of Physiology and Pharmacology, V45, P493	55	10	10	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2016	11	4							e0153159	10.1371/journal.pone.0153159	http://dx.doi.org/10.1371/journal.pone.0153159			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DI6KO	27055287	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000373608000090
J	Casarett, D				Casarett, David			The Science of Choosing Wisely - Overcoming the Therapeutic Illusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Casarett, David] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Casarett, D (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.							CHERKIN DC, 1995, SPINE, V20, P1, DOI 10.1097/00007632-199501000-00001; JENKINS HM, 1965, PSYCHOL MONOGR, V79, P1, DOI 10.1037/h0093874; LANGER EJ, 1975, J PERS SOC PSYCHOL, V32, P311, DOI 10.1037/0022-3514.32.2.311; Schroen AT, 2000, CHEST, V118, P129, DOI 10.1378/chest.118.1.129; THOMAS KB, 1978, BRIT MED J, V1, P1327, DOI 10.1136/bmj.1.6123.1327	5	81	82	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2016	374	13					1203	1205		10.1056/NEJMp1516803	http://dx.doi.org/10.1056/NEJMp1516803			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DH8ZM	27028909				2023-01-03	WOS:000373085500002
J	MacInnes, JJ; Dickerson, KC; Chen, NK; Adcock, RA				MacInnes, Jeff J.; Dickerson, Kathryn C.; Chen, Nan-kuei; Adcock, R. Alison			Cognitive Neurostimulation: Learning to Volitionally Sustain Ventral Tegmental Area Activation	NEURON			English	Article							NUCLEUS-ACCUMBENS; SELF-REGULATION; DOPAMINE; REWARD; FMRI; MODULATION; MEMORY; NEUROFEEDBACK; UNCERTAINTY; MECHANISMS	Activation of the ventral tegmental area (VTA) and mesolimbic networks is essential to motivation, performance, and learning. Humans routinely attempt to motivate themselves, with unclear efficacy or impact on VTA networks. Using fMRI, we found untrained participants' motivational strategies failed to consistently activate VTA. After real-time VTA neuro-feedback training, however, participants volitionally induced VTA activation without external aids, relative to baseline, Pre-test, and control groups. VTA self-activation was accompanied by increased mesolimbic network connectivity. Among two comparison groups (no neurofeedback, false neurofeedback) and an alternate neurofeedback group (nucleus accumbens), none sustained activation in target regions of interest nor increased VTA functional connectivity. The results comprise two novel demonstrations: learning and generalization after VTA neurofeedback training and the ability to sustain VTA activation without external reward or reward cues. These findings suggest theoretical alignment of ideas about motivation and midbrain physiology and the potential for generalizable interventions to improve performance and learning.	[MacInnes, Jeff J.; Dickerson, Kathryn C.; Adcock, R. Alison] Duke Univ, Ctr Cognit Neurosci, Durham, NC 27708 USA; [MacInnes, Jeff J.; Dickerson, Kathryn C.; Adcock, R. Alison] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; [Chen, Nan-kuei] Duke Univ, Brain Imaging & Anal Ctr, Durham, NC 27710 USA; [Chen, Nan-kuei] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; [Adcock, R. Alison] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA; [Adcock, R. Alison] Duke Univ, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Adcock, RA (corresponding author), Duke Univ, Ctr Cognit Neurosci, Durham, NC 27708 USA.; Adcock, RA (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.; Adcock, RA (corresponding author), Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA.; Adcock, RA (corresponding author), Duke Univ, Dept Neurobiol, Durham, NC 27710 USA.	alison.adcock@duke.edu	Adcock, R Alison/AAX-6649-2020; Chen, Nan-Kuei/E-7791-2016	Adcock, R Alison/0000-0002-7859-5484; Chen, Nan-Kuei/0000-0001-6564-4219	NIMH BRAINS [MH9743]; NIMH [MH100764]; Alfred P. Sloan Foundation; Esther A. & Joseph Klingenstein Fund; Dana Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH100764, R01MH094743] Funding Source: NIH RePORTER	NIMH BRAINS; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Esther A. & Joseph Klingenstein Fund(Klingenstein Philanthropies); Dana Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank C. Petty and J. Voyvodic for valuable technical support; D. Paulsen, R.M. Carter, E. Sumner, C. Coutlee, S. Floresco, S. Kollins, S. Madlon-Kay, M. Scult, T. Strauman, V. Murty, L. Davachi, S. Hakimi, and K. Dzirasa for comments and suggestions; and staff at the Brain Imaging and Analysis Center for MR imaging support. Supported by a NIMH BRAINS award (MH9743) to R.A.A. and a NIMH F32 (MH100764) to K.C.D. Additional support is provided by the Alfred P. Sloan Foundation, the Esther A. & Joseph Klingenstein Fund, and the Dana Foundation.	Adcock RA, 2006, NEURON, V50, P507, DOI 10.1016/j.neuron.2006.03.036; Alcaro A, 2007, BRAIN RES REV, V56, P283, DOI 10.1016/j.brainresrev.2007.07.014; Ballard IC, 2011, J NEUROSCI, V31, P10340, DOI 10.1523/JNEUROSCI.0895-11.2011; Beierholm U, 2013, NEUROPSYCHOPHARMACOL, V38, P1495, DOI 10.1038/npp.2013.48; Botvinick MM, 2009, COGN AFFECT BEHAV NE, V9, P16, DOI 10.3758/CABN.9.1.16; Braver TS, 2014, COGN AFFECT BEHAV NE, V14, P443, DOI 10.3758/s13415-014-0300-0; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022; Brooks JCW, 2008, NEUROIMAGE, V39, P680, DOI 10.1016/j.neuroimage.2007.09.018; Callan DE, 2008, HUM BRAIN MAPP, V29, P237, DOI 10.1002/hbm.20383; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; Dayana P, 2008, CURR OPIN NEUROBIOL, V18, P185, DOI 10.1016/j.conb.2008.08.003; Decharms RC, 2007, TRENDS COGN SCI, V11, P473, DOI 10.1016/j.tics.2007.08.014; Duncan K, 2014, J NEUROSCI, V34, P11188, DOI 10.1523/JNEUROSCI.0521-14.2014; Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349; Goldman-Rakic P S, 1998, Adv Pharmacol, V42, P707; Goto Y, 2007, NEUROPHARMACOLOGY, V53, P583, DOI 10.1016/j.neuropharm.2007.07.007; Greer SM, 2014, NEUROIMAGE, V96, P237, DOI 10.1016/j.neuroimage.2014.03.073; Hall J, 2001, EUR J NEUROSCI, V13, P1984, DOI 10.1046/j.0953-816x.2001.01577.x; Harvey AK, 2008, J MAGN RESON IMAGING, V28, P1337, DOI 10.1002/jmri.21623; HOLM S, 1979, SCAND J STAT, V6, P65; Howe MW, 2013, NATURE, V500, P575, DOI 10.1038/nature12475; Huettel SA, 2009, FUNCTIONAL MAGNETIC; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; James William, 1950, PRINCIPLES PSYCHOL, V2; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Lee W, 2013, SOC COGN AFFECT NEUR, V8, P538, DOI 10.1093/scan/nss029; Lee W, 2012, NEUROSCI RES, V73, P68, DOI 10.1016/j.neures.2012.02.010; Leotti LA, 2011, PSYCHOL SCI, V22, P1310, DOI 10.1177/0956797611417005; Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002; Lisman J, 2011, TRENDS NEUROSCI, V34, P536, DOI 10.1016/j.tins.2011.07.006; Lou HC, 2011, J VISION, V11, DOI 10.1167/11.2.15; Maia TV, 2011, NAT NEUROSCI, V14, P154, DOI 10.1038/nn.2723; Marder E, 2012, NEURON, V76, P1, DOI 10.1016/j.neuron.2012.09.010; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Murayama K, 2010, P NATL ACAD SCI USA, V107, P20911, DOI 10.1073/pnas.1013305107; Murty VP, 2014, NEUROIMAGE, V100, P580, DOI 10.1016/j.neuroimage.2014.06.047; NISHINO H, 1987, BRAIN RES, V413, P302, DOI 10.1016/0006-8993(87)91021-3; Niv Y, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-6; Niv Y, 2007, PSYCHOPHARMACOLOGY, V191, P507, DOI 10.1007/s00213-006-0502-4; Pessoa L, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00017; PHILLIPSON OT, 1985, NEUROSCIENCE, V16, P275, DOI 10.1016/0306-4522(85)90002-8; Plato, 1991, REPUBLIC PLATO; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004; Salamone JD, 2012, NEURON, V76, P470, DOI 10.1016/j.neuron.2012.10.021; Schott BH, 2008, J NEUROSCI, V28, P14311, DOI 10.1523/JNEUROSCI.2058-08.2008; Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722; Shibata K, 2011, SCIENCE, V334, P1413, DOI 10.1126/science.1212003; Shohamy D, 2010, TRENDS COGN SCI, V14, P464, DOI 10.1016/j.tics.2010.08.002; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Stuber GD, 2005, NEUROPSYCHOPHARMACOL, V30, P853, DOI 10.1038/sj.npp.1300619; Sulzer J, 2013, NEUROIMAGE, V83, P817, DOI 10.1016/j.neuroimage.2013.05.115; Takahashi YK, 2011, NAT NEUROSCI, V14, P1590, DOI 10.1038/nn.2957; Treadway MT, 2012, J NEUROSCI, V32, P6170, DOI 10.1523/JNEUROSCI.6459-11.2012; Tricomi EM, 2004, NEURON, V41, P281, DOI 10.1016/S0896-6273(03)00848-1; Volkow ND, 2011, MOL PSYCHIATR, V16, P1147, DOI 10.1038/mp.2010.97; Volkow ND, 2009, JAMA-J AM MED ASSOC, V302, P1084, DOI 10.1001/jama.2009.1308; Voyvodic JT, 1999, NEUROIMAGE, V10, P91, DOI 10.1006/nimg.1999.0457; Weiskopf N, 2004, J PHYSIOL-PARIS, V98, P357, DOI 10.1016/j.jphysparis.2005.09.019; Wimmer GE, 2012, EUR J NEUROSCI, V35, P1092, DOI 10.1111/j.1460-9568.2012.08017.x; Wittmann BC, 2005, NEURON, V45, P459, DOI 10.1016/j.neuron.2005.01.010; Wolosin SM, 2012, J COGNITIVE NEUROSCI, V24, P1532, DOI 10.1162/jocn_a_00237	63	48	48	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAR 16	2016	89	6					1331	1342		10.1016/j.neuron.2016.02.002	http://dx.doi.org/10.1016/j.neuron.2016.02.002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DI5UI	26948894	Green Accepted, Bronze			2023-01-03	WOS:000373565600020
J	McGrail, K; Lavergne, R; Lewis, S				McGrail, Kimberlyn; Lavergne, Ruth; Lewis, Steven			The chronic disease explosion: artificial bang or empirical whimper?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PREVALENCE		[McGrail, Kimberlyn] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada; [Lavergne, Ruth] McGill Univ, Montreal, PQ H3A 2T5, Canada; [Lewis, Steven] Access Consulting Saskatoon, Saskatoon, SK, Canada; [Lewis, Steven] Simon Fraser Univ Burnaby, Burnaby, BC, Canada	University of British Columbia; McGill University; Simon Fraser University	McGrail, K (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada.	kim.mcgrail@ubc.ca		Lewis, Steven/0000-0002-4247-674X				Anderson G., 2010, CHRONIC CARE MAKING; Barnett ML, 2012, ARCH INTERN MED, V172, P163, DOI 10.1001/archinternmed.2011.722; British Columbia Ministry of Health, 2013, MEDICAL SERVICES PLA; British Columbia Ministry of Health, 2013, HOSP SEP EXTR HOSP C; British Columbia Ministry of Health, 2012, CONS FIL CENS GEOD; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Cavers WJR, 2010, CAN FAM PHYSICIAN, V56, P1318; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fortin M, 2012, ANN FAM MED, V10, P142, DOI 10.1370/afm.1337; Gilbert Welch H., 2011, OVERDIAGNOSED; Harding Center for Risk Literacy, RISKS BEN PROST CANC; Huber Machteld, 2011, BMJ, V343, pd4163, DOI 10.1136/bmj.d4163; Jayaraman G., 2013, COMP COMM INF ICCCI, P1; Kaplan RM, 2007, ANNU REV PUBL HEALTH, V28, P321, DOI 10.1146/annurev.publhealth.28.021406.144141; Lix L, 2006, DEFINING VALIDATING; Macdonald H, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1163; Manuel Douglas G, 2014, CMAJ Open, V2, pE94, DOI 10.9778/cmajo.2012-0015; May C, 2005, CHRONIC ILLN, V1, P15, DOI 10.1179/174239505X19581; May C, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2803; Statistics Canada, 2005, PROF HLTH IND ANN ES; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4	21	13	13	0	61	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2016	352								i1312	10.1136/bmj.i1312	http://dx.doi.org/10.1136/bmj.i1312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH1ZT	26980185				2023-01-03	WOS:000372584400005
J	Altemimi, A; Watson, DG; Choudhary, R; Dasari, MR; Lightfoot, DA				Altemimi, Ammar; Watson, Dennis G.; Choudhary, Ruplal; Dasari, Mallika R.; Lightfoot, David A.			Ultrasound Assisted Extraction of Phenolic Compounds from Peaches and Pumpkins	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; OPTIMIZATION; L.; FLAVONOIDS; POLYSACCHARIDES; CAROTENOIDS; CAPACITIES; CULTIVARS	The ultrasound-assisted extraction (UAE) method was used to optimize the extraction of phenolic compounds from pumpkins and peaches. The response surface methodology (RSM) was used to study the effects of three independent variables each with three treatments. They included extraction temperatures (30, 40 and 50 degrees C), ultrasonic power levels (30, 50 and 70%) and extraction times (10, 20 and 30min). The optimal conditions for extractions of total phenolics from pumpkins were inferred to be a temperature of 41.45 degrees C, a power of 44.60% and a time of 25.67min. However, an extraction temperature of 40.99 degrees C, power of 56.01% and time of 25.71min was optimal for recovery of free radical scavenging activity (measured by 1, 1-diphenyl-2-picrylhydrazyl (DPPH) reduction). The optimal conditions for peach extracts were an extraction temperature of 41.53 degrees C, power of 43.99% and time of 27.86 min for total phenolics. However, an extraction temperature of 41.60 degrees C, power of 44.88% and time of 27.49 min was optimal for free radical scavenging activity (judged by from DPPH reduction). Further, the UAE processes were significantly better than solvent extractions without ultrasound. By electron microscopy it was concluded that ultrasonic processing caused damage in cells for all treated samples (pumpkin, peach). However, the FTIR spectra did not show any significant changes in chemical structures caused by either ultrasonic processing or solvent extraction.	[Altemimi, Ammar; Watson, Dennis G.; Choudhary, Ruplal; Lightfoot, David A.] So Illinois Univ, Dept Plant Soil & Agr Syst, Carbondale, IL 62901 USA; [Altemimi, Ammar] Univ Basrah, Coll Agr, Dept Food Sci & Biotechnol, Basrah, Basrah Province, Iraq; [Dasari, Mallika R.] So Illinois Univ, Dept Chem & Biochem, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; University of Basrah; Southern Illinois University System; Southern Illinois University	Lightfoot, DA (corresponding author), So Illinois Univ, Dept Plant Soil & Agr Syst, Carbondale, IL 62901 USA.	ga4082@siu.edu	Altemimi, B./D-7342-2017	Altemimi, B./0000-0001-7750-5988; Lightfoot, David/0000-0002-5725-4381	Government of Iraq; Higher Committee for Education Development in Iraq (HCED)	Government of Iraq; Higher Committee for Education Development in Iraq (HCED)	This work was funded by Government of Iraq to AA.; The authors like to thank the Higher Committee for Education Development in Iraq (HCED) for the financial support to achieve this work. Also, the authors are thankful to Dr. Alan Walters for providing pumpkin and peach samples. We also are grateful to Dr. Rebecca Atkinson and Dr. John Haddock for providing some of the equipment and facilities used in this study. The OECD is thanked for a 2012 Visiting Fellow Award to DAL to visit CRAG at UAB, Catalunia, Spain.	Altemimi A, 2015, MOLECULES, V20, P6611, DOI 10.3390/molecules20046611; Altemimi A, 2015, CHEM CENT J, V9, DOI 10.1186/s13065-015-0113-4; Altemimi A, 2015, ULTRASON SONOCHEM, V24, P247, DOI 10.1016/j.ultsonch.2014.10.023; Atrooz Omar M, 2009, Pak J Biol Sci, V12, P1063, DOI 10.3923/pjbs.2009.1063.1068; Ben-Amotz A, 1998, FOOD CHEM, V62, P515, DOI 10.1016/S0308-8146(97)00196-9; Braca A, 2002, J ETHNOPHARMACOL, V79, P379, DOI 10.1016/S0378-8741(01)00413-5; CHANG SS, 1977, J FOOD SCI, V42, P1102, DOI 10.1111/j.1365-2621.1977.tb12676.x; Chemat F, 2011, ULTRASON SONOCHEM, V18, P813, DOI 10.1016/j.ultsonch.2010.11.023; Dong JN, 2010, ULTRASON SONOCHEM, V17, P61, DOI 10.1016/j.ultsonch.2009.05.006; El-Shemy HA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/801501; Escribano-Bailon MT, 2002, METHODS IN POLYPHENOL ANALYSIS, P1; Firuzi O, 2011, CURR MED CHEM, V18, P3871, DOI 10.2174/092986711803414368; Ghasemzadeh A, 2015, MOLECULES, V20, P10822, DOI 10.3390/molecules200610822; Gil MI, 2002, J AGR FOOD CHEM, V50, P4976, DOI 10.1021/jf020136b; Hossain MB, 2012, ULTRASON SONOCHEM, V19, P582, DOI 10.1016/j.ultsonch.2011.11.001; Jerman T, 2010, FOOD CHEM, V123, P175, DOI 10.1016/j.foodchem.2010.04.006; Kikuchi T., 2011, Journal of Physics: Conference Series, V279, DOI 10.1088/1742-6596/279/1/012012; Kurz C, 2008, FOOD CHEM, V106, P421, DOI 10.1016/j.foodchem.2007.05.078; Liu BG, 2013, TROP J PHARM RES, V12, P1045, DOI 10.4314/tjpr.v12i6.27; Ma YQ, 2008, J AGR FOOD CHEM, V56, P5682, DOI 10.1021/jf072474o; Muniz-Marquez DB, 2013, ULTRASON SONOCHEM, V20, P1149, DOI 10.1016/j.ultsonch.2013.02.008; Murkovic M, 2002, J FOOD COMPOS ANAL, V15, P633, DOI 10.1006/jfca.2002.1052; Nassr-Allah AA, 2009, J MED PLANTS RES, V3, P799; Ozsoy N, 2008, FOOD CHEM, V110, P571, DOI 10.1016/j.foodchem.2008.02.037; Pan GY, 2012, ULTRASON SONOCHEM, V19, P486, DOI 10.1016/j.ultsonch.2011.11.006; Prasad KN, 2011, FOOD CHEM, V128, P1121, DOI 10.1016/j.foodchem.2011.03.105; Qu CL, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-160; Raso J, 1999, ULTRASON SONOCHEM, V5, P157, DOI 10.1016/S1350-4177(98)00042-X; Singleton V. L., 1965, AM J ENOL VITICULT, V16; Song W, 2010, J AGR FOOD CHEM, V58, P6621, DOI 10.1021/jf9035832; Toma M, 2001, ULTRASON SONOCHEM, V8, P137, DOI 10.1016/S1350-4177(00)00033-X; Versari A, 2002, FOOD CHEM, V76, P181, DOI 10.1016/S0308-8146(01)00261-8; Vilkhu K, 2008, INNOV FOOD SCI EMERG, V9, P161, DOI 10.1016/j.ifset.2007.04.014; Wu JY, 2001, ULTRASON SONOCHEM, V8, P347, DOI 10.1016/S1350-4177(01)00066-9; Xanthopoulou MN, 2009, FOOD RES INT, V42, P641, DOI 10.1016/j.foodres.2009.02.003; Yang ZD, 2010, INNOV FOOD SCI EMERG, V11, P470, DOI 10.1016/j.ifset.2010.03.003; Zahin M., 2009, INT J PHARM PHARM SC, V1, P88, DOI DOI 10.1371/J0URNAL.P0NE.0028499; Zhong K, 2010, INT J BIOL MACROMOL, V47, P356, DOI 10.1016/j.ijbiomac.2010.05.022	38	85	87	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2016	11	2							e0148758	10.1371/journal.pone.0148758	http://dx.doi.org/10.1371/journal.pone.0148758			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3BJ	26885655	gold, Green Published, Green Submitted			2023-01-03	WOS:000371218400048
J	Kaasboll, OJ; Moe, IT; Ahmed, MS; Stang, E; Hagelin, EMV; Attramadal, H				Kaasboll, Ole Jorgen; Moe, Ingvild Tronstad; Ahmed, Mohammad Shakil; Stang, Espen; Hagelin, Else Marie Valbjorn; Attramadal, Havard			CTGF/CCN2 Postconditioning Increases Tolerance of Murine Hearts towards Ischemia-Reperfusion Injury	PLOS ONE			English	Article							TISSUE-GROWTH-FACTOR; PERCUTANEOUS CORONARY INTERVENTION; FIBROBLAST PROLIFERATION; CARDIAC-HYPERTROPHY; CCN FAMILY; PROTECTION; PROTEINS; DYSFUNCTION; ACTIVATION; MECHANISMS	Background and Purpose Previous studies of ischemia-reperfusion injury (IRI) in hearts from mice with cardiacrestricted overexpression of CCN2 have shown that CCN2 increases tolerance towards IRI. The objectives of this study were to investigate to what extent post-ischemic administration of recombinant human CCN2 (rhCCN2) would limit infarct size and improve functional recovery and what signaling pathways are involved. Experimental Approach Isolated mice hearts were perfused ad modum Langendorff, subjected to no-flow, global ischemia, and subsequently, exposed to mammalian cell derived, full-length (38-40kDa) rhCCN2 (250 nM) or vehicle during the first 15 min of a 60 min reperfusion period. Key Results Post-ischemic administration of rhCCN2 resulted in attenuation of infarct size from 58 +/- 4% to 34 +/- 2% (p < 0.001) which was abrogated by concomitant administration of the PI3 kinase inhibitor LY294002 (45 +/- 3% vs. 50 +/- 3%, ns). In congruence with reduction of infarct size rhCCN2 also improved recovery of left ventricular developed pressure (p < 0.05). Western blot analyses of extracts of ex vivo-perfused murine hearts also revealed that rhCCN2 evoked concentration-dependent increase of cardiac phospho-GSK3 beta (serine-9) contents. Conclusions and Implications We demonstrate that post-ischemic administration of rhCCN2 increases the tolerance of ex vivo-perfused murine hearts to IRI. Mechanistically, this postconditioning effect of rhCCN2 appeared to be mediated by activation of the reperfusion injury salvage kinase pathway as demonstrated by sensitivity to PI3 kinase inhibition and increased CCN2-induced phosphorylation of GSK3 beta (Ser - 9). Thus, the rationale for testing rhCCN2-mediated post-ischemic conditioning of the heart in more complex models is established.	[Kaasboll, Ole Jorgen; Moe, Ingvild Tronstad; Ahmed, Mohammad Shakil; Hagelin, Else Marie Valbjorn; Attramadal, Havard] Oslo Univ Hosp, Inst Surg Res, Oslo, Norway; [Kaasboll, Ole Jorgen; Moe, Ingvild Tronstad; Ahmed, Mohammad Shakil; Hagelin, Else Marie Valbjorn; Attramadal, Havard] Univ Oslo, Oslo, Norway; [Kaasboll, Ole Jorgen; Moe, Ingvild Tronstad; Ahmed, Mohammad Shakil; Hagelin, Else Marie Valbjorn; Attramadal, Havard] Univ Oslo, Ctr Heart Failure Res, Oslo, Norway; [Stang, Espen] Oslo Univ Hosp, Dept Pathol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo	Attramadal, H (corresponding author), Oslo Univ Hosp, Inst Surg Res, Oslo, Norway.; Attramadal, H (corresponding author), Univ Oslo, Oslo, Norway.; Attramadal, H (corresponding author), Univ Oslo, Ctr Heart Failure Res, Oslo, Norway.	havard.attramadal@medisin.uio.no		Attramadal, Havard/0000-0001-9506-0687	South Eastern Norway Regional Health Authority [OUS30334_HSO2010, OUS39315_HSO2011006]; Norwegian Council on Cardiovascular Disease [2010.ST.068, 2011.DR.100]	South Eastern Norway Regional Health Authority; Norwegian Council on Cardiovascular Disease	This study was supported by grants from The South Eastern Norway Regional Health Authority (http://www.helse-sorost.no/omoss_/english_/) - grant no. OUS30334_HSO2010 (HA) and grant no. OUS39315_HSO2011006 (HA) and grants from the Norwegian Council on Cardiovascular Disease (http://www.nasjonalforeningen.no/no/Hjerte/Hjerteforskning/Forskningsprosjekter/) - grant no. 2010.ST.068 (HA; fellowship to OJK) and grant no. 2011.DR.100 (HA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Accornero F, 2015, MOL CELL BIOL, V35, P2154, DOI 10.1128/MCB.00199-15; Ahmed MS, 2011, AM J PHYSIOL-HEART C, V300, pH1291, DOI 10.1152/ajpheart.00604.2010; Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Bohr W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0016000; Chen CC, 2007, EMBO J, V26, P1257, DOI 10.1038/sj.emboj.7601596; Crean JK, 2006, FASEB J, V20, P1712, DOI 10.1096/fj.05-5010fje; Durgan DJ, 2010, CIRC RES, V106, P546, DOI 10.1161/CIRCRESAHA.109.209346; Frangogiannis NG, 2012, PHYSIOL REV, V92, P635, DOI 10.1152/physrev.00008.2011; Gravning J, 2013, INT J CARDIOL, V168, P2049, DOI 10.1016/j.ijcard.2013.01.165; Gravning J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052120; Grotendorst GR, 2005, FASEB J, V19, P729, DOI 10.1096/fj.04-3217com; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874; Hausenloy DJ, 2010, BASIC RES CARDIOL, V105, P677, DOI 10.1007/s00395-010-0121-4; Hausenloy DJ, 2005, AM J PHYSIOL-HEART C, V288, pH971, DOI 10.1152/ajpheart.00374.2004; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; Hausenloy DJ, 2011, NAT REV CARDIOL; Ibanez B, 2013, CIRCULATION, V128, P1495, DOI 10.1161/CIRCULATIONAHA.113.003653; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Jun JI, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8386; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KLONER RA, 1974, AM J PATHOL, V74, P399; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Maeda A, 2009, J BIOCHEM, V145, P207, DOI 10.1093/jb/mvn159; Moe IT, 2013, J CELL COMMUN SIGNAL, V7, P31, DOI 10.1007/s12079-012-0183-1; Moran AE, 2014, CIRCULATION, V129, P1483, DOI 10.1161/CIRCULATIONAHA.113.004042; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nishida T, 2011, ENDOCRINOLOGY, V152, P4232, DOI 10.1210/en.2011-0234; O'Connell Timothy D, 2007, Methods Mol Biol, V357, P271; Panek AN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006743; Pizarro G, 2014, J AM COLL CARDIOL, V63, P2356, DOI 10.1016/j.jacc.2014.03.014; Pride YB, 2010, AM J CARDIOL, V106, P635, DOI 10.1016/j.amjcard.2010.04.012; Reichelt ME, 2009, EXP PHYSIOL, V94, P54, DOI 10.1113/expphysiol.2008.043554; Spoon DB, 2014, CIRCULATION, V129, P1286, DOI 10.1161/CIRCULATIONAHA.113.006518; Staat P, 2005, CIRCULATION, V112, P2143, DOI 10.1161/CIRCULATIONAHA.105.558122; Sutherland FJ, 2003, CLIN EXP PHARMACOL P, V30, P867, DOI 10.1046/j.1440-1681.2003.03925.x; Szabo Z, 2014, HYPERTENSION, V63, P1235, DOI 10.1161/HYPERTENSIONAHA.114.03279; Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe; Wang QD, 2001, ACTA PHYSIOL SCAND, V171, P123, DOI 10.1046/j.1365-201x.2001.00788.x; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Weir RAP, 2006, AM J CARDIOL, V97, p13F, DOI 10.1016/j.amjcard.2006.03.005; Yellon D.M., 2007, NEW ENGL J MED, V357, P1121, DOI [DOI 10.1056/NEJMRA071667, 10.1056/NEJMra071667]; Yoon PO, 2010, J MOL CELL CARDIOL, V49, P294, DOI 10.1016/j.yjmcc.2010.04.010	49	6	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0149000	10.1371/journal.pone.0149000	http://dx.doi.org/10.1371/journal.pone.0149000			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26872261	Green Published, gold, Green Submitted			2023-01-03	WOS:000370054100084
J	Pozzi, C; Cuomo, A; Spadoni, I; Magni, E; Silvola, A; Conte, A; Sigismund, S; Ravenda, PS; Bonaldi, T; Zampino, MG; Cancelliere, C; Di Fiore, PP; Bardelli, A; Penna, G; Rescigno, M				Pozzi, Chiara; Cuomo, Alessandro; Spadoni, Ilaria; Magni, Elena; Silvola, Alessio; Conte, Alexia; Sigismund, Sara; Ravenda, Paola Simona; Bonaldi, Tiziana; Zampino, Maria Giulia; Cancelliere, Carlotta; Di Fiore, Pier Paolo; Bardelli, Alberto; Penna, Giuseppe; Rescigno, Maria			The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death	NATURE MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; 1ST-LINE TREATMENT; BRAF MUTATION; CALRETICULIN EXPOSURE; ENDOPLASMIC-RETICULUM; PLUS IRINOTECAN; POOLED ANALYSIS; COLON-CANCER; KRAS; EFFICACY	Cetuximab is a monoclonal antibody that is effective in the treatment of metastatic colorectal cancer (mCRC). Cetuximab blocks epidermal growth factor receptor (EGFR)-ligand interaction and inhibits downstream RAS-ERK activation. However, only some activating mutations in RAS affect cetuximab efficacy, and it is not clear what else mediates treatment success. Here we hypothesized that cetuximab induces immunogenic cell death (ICD) that activates a potent antitumor response. We found that cetuximab, in combination with chemotherapy, fostered ICD in CRC cells, which we measured via the endoplasmic reticulum (ER) stress response and an increase in phagocytosis by dendritic cells. ICD induction depended on the mutational status of the EGFR signaling pathway and on the inhibition of the splicing of X-box binding protein 1 (XBP1), an unfolded protein response (UPR) mediator. We confirmed the enhanced immunogenicity elicited by cetuximab in a mouse model of human EGFR-expressing CRC. Overall, we demonstrate a new, immune-related mechanism of action of cetuximab that may help to tailor personalized medicine.	[Pozzi, Chiara; Cuomo, Alessandro; Spadoni, Ilaria; Silvola, Alessio; Bonaldi, Tiziana; Di Fiore, Pier Paolo; Penna, Giuseppe; Rescigno, Maria] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Magni, Elena; Ravenda, Paola Simona; Zampino, Maria Giulia] European Inst Oncol, Div Med Oncol, Unit Gastrointestinal & Neuroendocrine Tumors, Milan, Italy; [Conte, Alexia; Sigismund, Sara; Di Fiore, Pier Paolo; Bardelli, Alberto] Fdn Ist FIRC Fdn Italiana Ric Canc Oncol Mol, IFOM, Milan, Italy; [Cancelliere, Carlotta] FPO, IRCCS, Candiolo Canc Inst, Candiolo, Italy; [Di Fiore, Pier Paolo; Rescigno, Maria] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Bardelli, Alberto] Univ Turin, Dept Oncol, Turin, Italy	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; IRCCS Fondazione del Piemonte per l'Oncologia; University of Milan; University of Turin	Rescigno, M (corresponding author), European Inst Oncol, Dept Expt Oncol, Milan, Italy.; Rescigno, M (corresponding author), Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.	maria.rescigno@ieo.eu	Sigismund, Sara/H-3687-2017; Zampino, Maria Giulia/AAQ-4795-2020; Penna, Giuseppe/AAB-8784-2019; Di Fiore, Pier Paolo/K-2130-2012; Spadoni, Ilaria/K-1054-2018; Pozzi, Chiara/K-4481-2018; Ravenda, Paola Simona/AAC-2048-2019; cuomo, alessandro/AAB-7372-2019; Rescigno, Maria/J-9704-2012; BARDELLI, Alberto/J-9721-2018; Bonaldi, Tiziana/K-5075-2016	Sigismund, Sara/0000-0002-1396-4453; Zampino, Maria Giulia/0000-0001-5142-1778; Penna, Giuseppe/0000-0003-3534-7090; Di Fiore, Pier Paolo/0000-0002-2252-0950; Pozzi, Chiara/0000-0003-2153-6130; Rescigno, Maria/0000-0002-6464-509X; BARDELLI, Alberto/0000-0003-1647-5070; Spadoni, Ilaria/0000-0002-1067-0695; Cuomo, Alessandro/0000-0002-9778-7190; Bonaldi, Tiziana/0000-0003-3556-1265	Italian Association for Cancer Research (AIRC) [IG11863]; Italian Ministry of Health [RF-2011-02348920]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	This work has been funded by grants of the Italian Association for Cancer Research (AIRC) (IG11863 to M.R.) and the Italian Ministry of Health (Ricerca finalizzata) (RF-2011-02348920 to M.R.). We thank S. Chiocca for editing the manuscript.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Elias JE, 2010, METHODS MOL BIOL, V604, P55, DOI 10.1007/978-1-60761-444-9_5; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Garrido G, 2011, J IMMUNOL, V187, P4954, DOI 10.4049/jimmunol.1003477; Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606; Kato H, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00093; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Kishiki T, 2014, ONCOL REP, V32, P57, DOI 10.3892/or.2014.3179; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Licitra L, 2013, EUR J CANCER, V49, P1161, DOI 10.1016/j.ejca.2012.11.018; Modest DP, 2012, ONCOLOGY-BASEL, V83, P241, DOI 10.1159/000339534; Obeid M, 2008, J IMMUNOL, V181, P2533, DOI 10.4049/jimmunol.181.4.2533; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Peeters M, 2012, CANCER TREAT REV, V38, P397, DOI 10.1016/j.ctrv.2011.08.002; Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054; Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961; Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rimoldi M, 2005, BLOOD, V106, P2818, DOI 10.1182/blood-2004-11-4321; Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619; Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sigismund S, 2013, EMBO J, V32, P2140, DOI 10.1038/emboj.2013.149; Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Tyanova S, 2014, METHODS MOL BIOL, V1188, P351, DOI 10.1007/978-1-4939-1142-4_24; Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27878, 10.4161/onci.27048]; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	40	158	159	1	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2016	22	6					624	+		10.1038/nm.4078	http://dx.doi.org/10.1038/nm.4078			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DO0NQ	27135741				2023-01-03	WOS:000377476000019
J	Denman, M				Denman, Michael			Review: Exercise therapy reduces fatigue in chronic fatigue syndrome	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Denman, Michael] Univ London Imperial Coll Sci Technol & Med, London, England	Imperial College London	Denman, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.							Smith MEB, 2015, ANN INTERN MED, V162, P841, DOI 10.7326/M15-0114	1	3	3	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2016	164	10					JC55	JC55		10.7326/ACPJC-2016-164-10-055	http://dx.doi.org/10.7326/ACPJC-2016-164-10-055			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL8GF	27182921				2023-01-03	WOS:000375878500006
J	Nunan, D				Nunan, David			Doctors should be able to prescribe exercise like a drug	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHYSICAL-ACTIVITY		[Nunan, David] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	University of Oxford	Nunan, D (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.	david.nunan@phc.ox.ac.uk		Barrett, Kevin/0000-0002-0785-1815				Abell B, 2015, CIRC-CARDIOVASC QUAL, V8, P187, DOI 10.1161/CIRCOUTCOMES.114.001381; Academy of Medical Royal Colleges, 2015, EX MIR CUR; Bailey V, 2012, NHSS ROLE PUBLICS HL; Bull F, 2003, LANCET, V361, P258, DOI 10.1016/S0140-6736(03)12290-8; Department of Health, 2008, HIGH QUALITY CARE AL; Hebert ET, 2012, BRIT J SPORT MED, V46, P625, DOI 10.1136/bjsports-2011-090734; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Josephson RA, 2016, EXERCISE PRESCRIPTIO; Kohl Harold W 3rd, 2012, Lancet, V380, P294, DOI 10.1016/S0140-6736(12)60898-8; National Institute for Health and Care Excellence, 2014, PHYS ACT EX REF SCHE; Nunan D, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-56; Royal College of Physicians, 2015, EX FOR LIF	12	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 5	2016	353								i2468	10.1136/bmj.i2468	http://dx.doi.org/10.1136/bmj.i2468			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL4AS	27149982	Green Published			2023-01-03	WOS:000375575600003
J	Ayiasi, RM; Kolsteren, P; Batwala, V; Criel, B; Orach, CG				Ayiasi, Richard Mangwi; Kolsteren, Patrick; Batwala, Vincent; Criel, Bart; Orach, Christopher Garimoi			Effect of Village Health Team Home Visits and Mobile Phone Consultations on Maternal and Newborn Care Practices in Masindi and Kiryandongo, Uganda: A Community-Intervention Trial	PLOS ONE			English	Article							NEONATAL-MORTALITY; BANGLADESH; PREVENT; WORKERS; PACKAGE; DEATHS; IMPACT	Introduction The World Health Organisation recommends home visits conducted by Community Health Workers (in Uganda known as Village Health Teams-VHTs) in order to improve maternal and newborn health. This study measured the effect of home visits combined with mobile phone consultations on maternal and newborn care practices. Method In a community intervention trial design 16 health centres in Masindi and Kiryandongo districts, Uganda were randomly and equally allocated to one of two arms: control and intervention arms. Eight control health centres received the usual maternal and newborn educational messages offered by professional health workers and eight intervention health centres that received an intervention package for maternal care and essential newborn care practices. In the intervention arm VHTs made two prenatal and one postnatal home visit to households. VHTs were provided with mobile phones to enable them make regular telephone consultations with health workers at the health centre serving the catchment area. The primary outcome was health facility delivery. Other outcomes included antenatal attendances, birth preparedness, cord and thermal care and breastfeeding practices. Analysis was by intention-to-treat. Results A total of 1385 pregnant women were analysed: 758 and 627 in the control and intervention arms respectively. Significant post-intervention differences were: delivery place [adjusted Odds Ratio aOR: 17.94(95% CI: 6.26-51.37); p< 0.001], cord care [aOR: 3.05(95% CI: 1.81-5.12); p< 0.001] thermal care [aOR: 7.58(95% CI: 2.52-22.82); p< 0.001], and timely care-seeking for newborn illness [aOR: 4.93(95% CI: 1.59-15.31); p = 0.006]. Conclusion VHTs can have an effect in promoting proper cord and thermal care for the newborn and improve timely care-seeking for health facility delivery and newborn illness, because they could answer questions and refer patients correctly. However, VHTs should be supported by professional health workers through the use of mobile phones.	[Ayiasi, Richard Mangwi; Orach, Christopher Garimoi] Makerere Univ, Sch Publ Hlth, Coll Hlth Sci, POB 7072, Kampala, Uganda; [Batwala, Vincent] Mbarara Univ Sci & Technol, POB 1410, Mbarara, Uganda; [Kolsteren, Patrick; Criel, Bart] Inst Trop Med, Natl Str 150, B-2000 Antwerp, Belgium	Makerere University; Mbarara University of Science & Technology; Institute of Tropical Medicine (ITM)	Ayiasi, RM (corresponding author), Makerere Univ, Sch Publ Hlth, Coll Hlth Sci, POB 7072, Kampala, Uganda.	mangwirichard@gmail.com	Urzua, Andrea Silva/AAS-7284-2020		Directorate General for Development Cooperation (DGDC) of Belgium	Directorate General for Development Cooperation (DGDC) of Belgium	Directorate General for Development Cooperation (DGDC) of Belgium. The funders had no role in the study design, data management and manuscript writing.	Alshurafa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049163; Ayiasi MR, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-176; Ayiasi RM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1939-3; Ayiasi RM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-114; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Braun R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065772; De Amici D, 2000, CONTROL CLIN TRIALS, V21, P103, DOI 10.1016/S0197-2456(99)00054-9; DHO, 2010, MAS DISTR ANN PLAN B; Gogia S, 2010, B WORLD HEALTH ORGAN, V88, P658, DOI 10.2471/BLT.09.069369; Government of Uganda, 2010, VHT VILL HLTH TEAM H; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Kirkwood BR, 2013, LANCET, V381, P2184, DOI 10.1016/S0140-6736(13)60095-1; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Kumar V, 2010, SEMIN PERINATOL, V34, P446, DOI 10.1053/j.semperi.2010.09.006; Lawn J, 2006, AFRICAS NEWBORNS COU; Lawn JE, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.27363; Ministry of Health, 2010, VHT VILL HLTH TEAM S; Nalwadda CK, 2013, TROP MED INT HEALTH, V18, P898, DOI 10.1111/tmi.12106; Owais A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-239; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Thorpe KE, 2009, CAN MED ASSOC J, V180, pE47, DOI 10.1503/cmaj.090523; Tomlinson M, 2014, TROP MED INT HEALTH, V19, P256, DOI 10.1111/tmi.12257; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; UDHS and ICF, 2012, UG DEM HLTH SURV 201; Uganda Bureau of Statistics, 2014, 2014 STAT ABSTR; UGANDA BUREAU OF STATISTICS AND BANK OF UGANDA, 2008, UGANDA WORKERSREMITT; UNICEF, 2014, COMM CHILD SURV PROM; UNICEF, 2009, STATE WORLDS CHILDRE; Waiswa P, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.24584; Waiswa P, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-9; WHO ICM, 2014, TRENDS MAT MORT 1990; WHO/UNICEF, 2009, HOM VIS NEWB CHILD S; World Health Organization, 2015, GLOB STRAT WOM CHILD; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	36	25	25	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2016	11	4							e0153051	10.1371/journal.pone.0153051	http://dx.doi.org/10.1371/journal.pone.0153051			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK4OR	27101379	Green Published, gold			2023-01-03	WOS:000374898500024
J	Califf, RM; Woodcock, J; Ostroff, S				Califf, Robert M.; Woodcock, Janet; Ostroff, Stephen			A Proactive Response to Prescription Opioid Abuse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									[Califf, Robert M.; Woodcock, Janet; Ostroff, Stephen] Food & Drug Adm, Silver Spring, MD USA	US Food & Drug Administration (FDA)	Califf, RM (corresponding author), Food & Drug Adm, Silver Spring, MD USA.				Amgen; Bayer Healthcare; BMEB Services; Bristol-Myers Squibb; Janssen; Medscape/Heart.org; Merck; Novartis; Regado; Roche; Astra-Zeneca; Genentech; GlaxoSmithKline; Heart.org/Daiichi-Sankyo; Kowa; Servier; Bayer Pharma; CV Sight; DSI-Lilly; Gambro; Gilead Sciences; Heart.org/Bayer; Pfizer; Regeneron; Medicines Company; Nile; Parkview; Amylin; Eli Lilly; Schering-Plough Research Institute; Scios	Amgen(Amgen); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); BMEB Services(Pharmatest Services); Bristol-Myers Squibb(Bristol-Myers Squibb); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Medscape/Heart.org; Merck(Merck & Company); Novartis(Novartis); Regado; Roche(Roche Holding); Astra-Zeneca(AstraZeneca); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Heart.org/Daiichi-Sankyo; Kowa; Servier(Servier); Bayer Pharma; CV Sight; DSI-Lilly(Eli Lilly); Gambro; Gilead Sciences(Gilead Sciences); Heart.org/Bayer; Pfizer(Pfizer); Regeneron(Regeneron); Medicines Company; Nile; Parkview; Amylin; Eli Lilly(Eli Lilly); Schering-Plough Research Institute(Merck & Company); Scios	Dr. Califf reports receiving consulting fees from Amgen, Bayer Healthcare, BMEB Services, Bristol-Myers Squibb, Janssen, Medscape/Heart.org, Merck, Novartis, Regado, Roche, Astra-Zeneca, Genentech, GlaxoSmithKline, Heart.org/Daiichi-Sankyo, Kowa, Servier, Bayer Pharma, CV Sight, DSI-Lilly, Gambro, Gilead Sciences, Heart.org/Bayer, Pfizer, Regeneron, the Medicines Company, Nile, and Parkview; receiving grant support from Amylin, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, the Schering-Plough Research Institute, Scios, and Parkview; and holding equity in Nitrox/N30 Pharma and Portola, all prior to March 1, 2015. No other potential conflict of interest relevant to this article was reported.	Centers for Disease Control and Prevention, 2014, VIT SIGNS OP PAINK P; Department of Health and Human Services, 2015, HHS TAK STRONG STEPS; Executive Office of the President of the United States, 2011, EP RESP AM PRESCR DR; Federal Register Notice, FED REG NOTICE PROPO; Food and Drug Administration, 2014, FDA APPR NEW HAND HE; Food and Drug Administration, 2015, FDA MOV QUICKL APPR; Food and Drug Administration, RISK EV MIT STRAT RE; Food and Drug Administration, 2015, GUID IND AB OP EV LA; Office of National Drug Control Policy, NAT DRUG CONTR STRAT; Office of the Surgeon General, 2011, NAT PREV STRAT AM PL; WISQARS, 2020, WISQARS WEB BAS INJ	11	169	172	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	2016	374	15					1480	1485		10.1056/NEJMsr1601307	http://dx.doi.org/10.1056/NEJMsr1601307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ3TD	26845291	Bronze			2023-01-03	WOS:000374128400013
J	Yang, X; Jiang, L; Jia, YG; Hu, Y; Xu, Q; Xu, X; Huang, H				Yang, Xin; Jiang, Ling; Jia, Yigang; Hu, Yi; Xu, Qing; Xu, Xian; Huang, He			Counteraction of Trehalose on N,N-Dimethylformamide-Induced Candida rugosa Lipase Denaturation: Spectroscopic Insight and Molecular Dynamic Simulation	PLOS ONE			English	Article							INDUCED PROTEIN DENATURATION; BIODIESEL PRODUCTION; INTERNAL-FRICTION; STABILITY; BIOCATALYSIS; ACCUMULATION; SOLVENTS; WATER; PH	Candida rugosa lipase (CRL) has been widely used as a biocatalyst for non-aqueous synthesis in biotechnological applications, which, however, often suffers significant loss of activity in organic solvent. Experimental results show that trehalose could actively counteract the organic-solvent-induced protein denaturation, while the molecular mechanisms still don't unclear. Herein, CRL was used as a model enzyme to explore the effects of trehalose on the retention of enzymatic activity upon incubation in N,N-dimethylformamide (DMF). Results showed that both catalytic activity and conformation changes of CRL influenced by DMF solvent were inhibited by trehalose in a dose-dependent fashion. The simulations further indicated that the CRL protein unfolded in binary DMF solution, but retained the native state in the ternary DMF/trehalose system. Trehalose as the second osmolyte added into binary DMF solution decreased DMF-CRL hydrogen bonds efficiently, whereas increased the intermolecular hydrogen bondings between DMF and trehalose. Thus, the origin of its denaturing effects of DMF on protein is thought to be due to the preferential exclusion of trehalose as well as the intermolecular hydrogen bondings between trehalose and DMF. These findings suggest that trehalose protect the CRL protein from DMF-induced unfolding via both indirect and direct interactions.	[Yang, Xin; Hu, Yi; Xu, Qing; Xu, Xian] Nanjing Tech Univ, Coll Biotechnol & Pharmaceut Engn, Nanjing 210009, Peoples R China; [Jiang, Ling; Jia, Yigang] Nanjing Tech Univ, Coll Food Sci & Light Ind, Nanjing 210009, Peoples R China; [Huang, He] Nanjing Tech Univ, Coll Pharmaceut Sci, Nanjing 210009, Peoples R China	Nanjing Tech University; Nanjing Tech University; Nanjing Tech University	Jiang, L (corresponding author), Nanjing Tech Univ, Coll Food Sci & Light Ind, Nanjing 210009, Peoples R China.; Huang, H (corresponding author), Nanjing Tech Univ, Coll Pharmaceut Sci, Nanjing 210009, Peoples R China.	jinagling@njtech.edu.cn; biotech@njtech.edu.cn			National Science Foundation; National Basic Research Program of China; National High Technology Research and Development Program of China; Natural Science Foundation of Jiangsu Province; Six Talent Peaks Project in Jiangsu Province	National Science Foundation(National Science Foundation (NSF)); National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Six Talent Peaks Project in Jiangsu Province	The authors are grateful for the support of the National Science Foundation, National Basic Research Program of China, the National High Technology Research and Development Program of China, the Natural Science Foundation of Jiangsu Province, and the Six Talent Peaks Project in Jiangsu Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azizi A, 2011, INT J BIOL MACROMOL, V49, P652, DOI 10.1016/j.ijbiomac.2011.06.025; Benaroudj N, 2001, J BIOL CHEM, V276, P24261, DOI 10.1074/jbc.M101487200; Borgia A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2204; Bornscheuer UT, 2012, NATURE, V485, P185, DOI 10.1038/nature11117; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Colombo G, 2002, J BIOTECHNOL, V96, P23, DOI 10.1016/S0168-1656(02)00034-2; De Los Rios P, 2012, NAT CHEM BIOL, V8, P226, DOI 10.1038/nchembio.791; DePaz RA, 2002, ENZYME MICROB TECH, V31, P765, DOI 10.1016/S0141-0229(02)00173-4; Eisenmenger MJ, 2009, ENZYME MICROB TECH, V45, P331, DOI 10.1016/j.enzmictec.2009.08.001; Gangadhara, 2009, J AM OIL CHEM SOC, V86, P773, DOI 10.1007/s11746-009-1408-1; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; Haque I, 2006, BIOPHYS CHEM, V119, P224, DOI 10.1016/j.bpc.2005.09.016; He F, 2011, PHARM RES-DORDR, V28, P1552, DOI 10.1007/s11095-011-0388-7; Hu Y, 2013, CHINESE J CATAL, V34, P1608, DOI 10.1016/S1872-2067(12)60628-7; Jain NK, 2009, PROTEIN SCI, V18, P24, DOI 10.1002/pro.3; Jia R, 2013, ACS CATAL, V3, P1976, DOI 10.1021/cs400404f; Jiang L, 2015, GREEN CHEM, V17, P250, DOI 10.1039/c4gc01256a; Kaushik JK, 2003, J BIOL CHEM, V278, P26458, DOI 10.1074/jbc.M300815200; Klibanov AM, 2001, NATURE, V409, P241, DOI 10.1038/35051719; Korman TP, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-70; Lei Y, 2003, J PHYS CHEM A, V107, P1574, DOI 10.1021/jp026638+; Lerbret A, 2007, J PHYS CHEM B, V111, P9410, DOI 10.1021/jp071946z; Li XJ, 2015, IND ENG CHEM RES, V54, P8072, DOI 10.1021/acs.iecr.5b01881; Liu FF, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3453713; Lousa D, 2013, PHYS CHEM CHEM PHYS, V15, P13723, DOI 10.1039/c3cp51761f; Majtan T, 2008, J BIOL CHEM, V283, P34588, DOI 10.1074/jbc.M805928200; Mattos C, 2001, CURR OPIN STRUC BIOL, V11, P761, DOI 10.1016/S0959-440X(01)00278-0; Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090; Pace C N, 1986, Methods Enzymol, V131, P266; Paul S, 2015, J PHYS CHEM B, V119, P10975, DOI 10.1021/acs.jpcb.5b01457; Pazhang M, 2006, J BIOTECHNOL, V127, P45, DOI 10.1016/j.jbiotec.2006.05.017; Reetz MT, 2010, CHEM COMMUN, V46, P8657, DOI 10.1039/c0cc02657c; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Secundo F, 2004, BIOTECHNOL BIOENG, V86, P236, DOI 10.1002/bit.20034; Shu ZY, 2010, J MOL CATAL B-ENZYM, V62, P1, DOI 10.1016/j.molcatb.2009.09.003; Singh R, 2005, J BIOL CHEM, V280, P11035, DOI 10.1074/jbc.M410716200; Stergiou PY, 2013, BIOTECHNOL ADV, V31, P1846, DOI 10.1016/j.biotechadv.2013.08.006; Tan TW, 2010, BIOTECHNOL ADV, V28, P628, DOI 10.1016/j.biotechadv.2010.05.012; Villeneuve P, 2000, J MOL CATAL B-ENZYM, V9, P113, DOI 10.1016/S1381-1177(99)00107-1; Wang PM, 2014, BIORESOURCE TECHNOL, V152, P371, DOI 10.1016/j.biortech.2013.11.033; Wensley BG, 2012, P NATL ACAD SCI USA, V109, P17795, DOI 10.1073/pnas.1201793109; Yang J, 2013, BIOCHEM ENG J, V70, P46, DOI 10.1016/j.bej.2012.09.016; Yang X, 2015, BIORESOURCES BIOPROC, V2, P1; Zhang N, 2014, BIOCHEM ENG J, V91, P231, DOI 10.1016/j.bej.2014.08.019; Zhang N, 2012, J PHYS CHEM B, V116, P7040, DOI 10.1021/jp300171h	46	7	7	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2016	11	3							e0152275	10.1371/journal.pone.0152275	http://dx.doi.org/10.1371/journal.pone.0152275			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH9NC	27031946	Green Published, Green Submitted, gold			2023-01-03	WOS:000373121800049
J	Xu, HF; Liu, BY; Wu, JN; Du, RS; Liu, XX; Yu, JN; Liu, ZS				Xu, Huanfang; Liu, Baoyan; Wu, Jiani; Du, Ruosang; Liu, Xiaoxu; Yu, Jinna; Liu, Zhishun			A Pilot Randomized Placebo Controlled Trial of Electroacupuncture for Women with Pure Stress Urinary Incontinence	PLOS ONE			English	Article							QUALITY-OF-LIFE; SURGICAL-TREATMENT; MUSCLE; IMPACT; STIMULATION; BIOFEEDBACK; MANAGEMENT; SYMPTOMS; ICIQ	Background Acupuncture is a potential conservative therapy for women with stress urinary incontinence (SUI). There is limited evidence to support its effectiveness due to the poor quality of existing studies. Methods We performed a pilot randomized, controlled trial to preliminarily assess the efficacy of electroacupuncture (EA) in women with pure SUI. A total of 80 women with pure SUI were randomly assigned to receive EA with deep needling at BL33 and BL35 (n = 40) or sham EA with non-penetrating needling at sham acupoints (n = 40) three sessions per week for 6 weeks. The women were followed for 24 weeks. The primary outcome was the change from baseline in the amount of urine leakage measured by a 1-hour pad test after 6 weeks. The secondary outcomes included the 72-hour incontinence episode frequency (IEF), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score, and patient self-evaluation of therapeutic effect. Adverse events (AEs) were monitored throughout the trial. Results The median decrease from baseline of urine leakage measured by the 1-hour pad test was 2.5 g [interquartile range (IQR): 1.80-14.6 in the EA group, which was greater than the median decrease of 0.05 g (IQR: -2.80-+0.50) in the sham EA group after 6 weeks (p<0.01). The differences between groups in the decrease from baseline of 72-hour IEF became statistically significant at week 30 with a median decrease of 3.25 g (IQR: 1.25-5.69) in the EA group, and a median decrease of 1.00 g (IQR: -0.69-+2.88) in the sham EA group (p = 0.01). The participants in the EA group showed greater decreases in ICIQ-SF score and higher ratings in the help they received from the treatment than those in the sham EA group at weeks 6,18 and 30 (all p < 0.05). No obvious AEs were observed in either group. Conclusion EA may effectively and safely relieve urinary incontinence symptoms and improve quality of life in women with pure SUI. EA demonstrated more than a placebo effect. Since this is a pilot study, results should be interpreted with caution.	[Xu, Huanfang; Liu, Baoyan; Wu, Jiani; Du, Ruosang; Liu, Xiaoxu; Yu, Jinna; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture & Moxibust, Beijing, Peoples R China; [Liu, Xiaoxu] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Beijing University of Chinese Medicine	Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture & Moxibust, Beijing, Peoples R China.	liuzhishun@aliyun.com			Ministry of Science and Technology of the People's Republic of China [2012BAI24B01]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China)	This work was funded by Grant numbers: 2012BAI24B01; Funder' website: http://www.most.gov.cn; Funding institution: Ministry of Science and Technology of the People's Republic of China. ZL received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams P, 1988, Scand J Urol Nephrol Suppl, V114, P5; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Abrams P, 2017, INCONTINENCE 6 INT C; Aksac B, 2003, GYNECOL OBSTET INVES, V56, P23, DOI 10.1159/000072327; Ammi M, 2014, INT UROGYNECOL J, V25, P1065, DOI 10.1007/s00192-014-2359-0; [Anonymous], 2013, URINARY INCONTINENCE; Avery K, 2004, NEUROUROL URODYNAM, V23, P322, DOI 10.1002/nau.20041; Bi W, 2007, CHINESE ARCH TRADITI, V25, P1284; Bo K, 2013, NEUROUROL URODYNAM, V32, P215, DOI 10.1002/nau.22292; Chene G, 2013, EUR J OBSTET GYN R B, V170, P275, DOI 10.1016/j.ejogrb.2013.06.011; Gras S, 2014, J UROLOGY, V192, P850, DOI 10.1016/j.juro.2014.04.005; Hirakawa T, 2013, INT UROGYNECOL J, V24, P1347, DOI 10.1007/s00192-012-2012-8; Horng SS, 2013, NEUROUROL URODYNAM, V32, P371, DOI 10.1002/nau.22302; Huang L, 2008, NEUROUROL URODYNAM, V27, P522, DOI 10.1002/nau.20546; Hui Kathleen K S, 2007, BMC Complement Altern Med, V7, P33, DOI 10.1186/1472-6882-7-33; Kim JH, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-254; Lalos O, 2001, J ADV NURS, V33, P316, DOI 10.1046/j.1365-2648.2001.01667.x; Liebergall-Wischnitzer M, 2009, J WOMENS HEALTH, V18, P377, DOI 10.1089/jwh.2008.0950; Lin Alex Tong-Long, 2008, BMC Urol, V8, P2, DOI 10.1186/1471-2490-8-2; Liu BY, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000200; Lucas MG, 2013, ACTAS UROL ESP, V37, P199, DOI 10.1016/j.acuro.2012.12.001; MacPherson H, 2001, Acupunct Med, V19, P93; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; Markland AD, 2011, J UROLOGY, V186, P589, DOI 10.1016/j.juro.2011.03.114; Mo Q, 2013, BEIJING J TRADIT CHI, V32, P434; Noblett K, 2014, NEUROUROLOGY URODYNA; Olausson H, 2010, NEUROSCI BIOBEHAV R, V34, P185, DOI 10.1016/j.neubiorev.2008.09.011; Pacific WROftW, 2008, WHO STAND AC POINT L; Sari D, 2009, J WOUND OSTOMY CONT, V36, P429, DOI 10.1097/WON.0b013e3181aaf539; Sjostrom M, 2013, BJU INT, V112, P362, DOI 10.1111/j.1464-410X.2012.11713.x; Smither Anna R, 2007, BMC Urol, V7, P2, DOI 10.1186/1471-2490-7-2; STAMEY TA, 1980, ANN SURG, V192, P465, DOI 10.1097/00000658-198010000-00005; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Sun MJ, 2008, TAIWAN J OBSTET GYNE, V47, P175, DOI 10.1016/S1028-4559(08)60076-5; Swithinbank LV, 1999, WORLD J UROL, V17, P225, DOI 10.1007/s003450050137; Wang Y, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009408.pub2; Wood LN, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4531; Xue CCL, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-169; Yalcin I, 2010, NEUROUROL URODYNAM, V29, P344, DOI 10.1002/nau.20744; Yin CS, 2005, AM J CHINESE MED, V33, P729, DOI 10.1142/S0192415X05003284; Yoshimura N, 2012, INT J UROL, V19, P524, DOI 10.1111/j.1442-2042.2012.02976.x; Zhao Lin, 2013, Zhongguo Zhen Jiu, V33, P1088; Zhu L, 2009, MENOPAUSE, V16, P831, DOI 10.1097/gme.0b013e3181967b5d	43	19	21	4	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150821	10.1371/journal.pone.0150821	http://dx.doi.org/10.1371/journal.pone.0150821			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26960195	Green Submitted, Green Published, gold			2023-01-03	WOS:000371992300076
J	Hellwig, K; Chen, LH; Stancyzk, FZ; Langer-Gould, AM				Hellwig, Kerstin; Chen, Lie H.; Stancyzk, Frank Z.; Langer-Gould, Annette M.			Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility	PLOS ONE			English	Article							CYTOKINE SECRETION; SCLEROSIS PATIENTS; RISK; PREGNANCY	Background The incidence of multiple sclerosis (MS) is rising in women. Objective To determine whether the use of combined oral contraceptives (COCs) are associated with MS risk and whether this varies by progestin content. Methods We conducted a nested case-control study of females ages 14-48 years with incident MS or clinically isolated syndrome (CIS) 2008-2011 from the membership of Kaiser Permanente Southern California. Controls were matched on age, race/ethnicity and membership characteristics. COC use up to ten years prior to symptom onset was obtained from the complete electronic health record. Results We identified 400 women with incident MS/CIS and 3904 matched controls. Forty-percent of cases and 32% of controls had used COCs prior to symptom onset. The use of COCs was associated with a slightly increased risk of MS/CIS (adjusted OR = 1.52, 95% CI = 1.21-1.91; p< 0.001). This risk did not vary by duration of COC use. The association varied by progestin content being more pronounced for levenorgestrol (adjusted OR = 1.75, 95% CI = 1.29-2.37; p< 0.001) than norethindrone (adjusted OR = 1.57, 95% CI = 1.16-2.12; p = 0.003) and absent for the newest progestin, drospirenone (p = 0.95). Conclusions Our findings should be interpreted cautiously. While the use of some combination oral contraceptives may contribute to the rising incidence of MS in women, an unmeasured confounder associated with the modern woman's lifestyle is a more likely explanation for this weak association.	[Hellwig, Kerstin] St Josef Univ Hosp, Neuroimmunol Ward, Bochum, Germany; [Hellwig, Kerstin] St Josef Univ Hosp, Outpatient Clin, Bochum, Germany; [Hellwig, Kerstin; Chen, Lie H.; Langer-Gould, Annette M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA; [Stancyzk, Frank Z.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Langer-Gould, Annette M.] Kaiser Permanente So Calif, Los Angeles Med Ctr, Dept Neurol, Los Angeles, CA USA	Ruhr University Bochum; Ruhr University Bochum; University of Hamburg; University Medical Center Hamburg-Eppendorf; Kaiser Permanente; University of Southern California; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Langer-Gould, AM (corresponding author), Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.; Langer-Gould, AM (corresponding author), Kaiser Permanente So Calif, Los Angeles Med Ctr, Dept Neurol, Los Angeles, CA USA.	Annette.M.Langer-Gould@kp.org			Kaiser Permanente Direct Community Benefit Funds; National Institute of Neurological Disorders and Stroke [1R01NS075308]; National Institute of Neurological Disorders and Stroke (NINDS) [1R01NS075308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075308] Funding Source: NIH RePORTER	Kaiser Permanente Direct Community Benefit Funds; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by Kaiser Permanente Direct Community Benefit Funds and National Institute of Neurological Disorders and Stroke 1R01NS075308. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by the Kaiser Permanente Direct Community Benefit Funds and the National Institute of Neurological Disorders and Stroke (NINDS, 1R01NS075308 PI: Langer-Gould)	Alonso A, 2005, ARCH NEUROL-CHICAGO, V62, P1362, DOI 10.1001/archneur.62.9.1362; Barnes G, 2002, NEUROLOGY, V59, P499, DOI 10.1212/wnl.59.4.499; Correale J, 1998, J IMMUNOL, V161, P3365; Gava G, 2014, FERTIL STERIL, V102, P116, DOI 10.1016/j.fertnstert.2014.03.054; Gilmore W, 1997, J IMMUNOL, V158, P446; GODET PG, 1995, GUT, V37, P668, DOI 10.1136/gut.37.5.668; Hedstrom AK, 2014, MULT SCLER J, V20, P406, DOI 10.1177/1352458513498126; Hernan MA, 2000, NEUROLOGY, V55, P848, DOI 10.1212/WNL.55.6.848; Holmqvist P, 2010, FERTIL STERIL, V94, P2835, DOI 10.1016/j.fertnstert.2010.06.045; Holmqvist P, 2009, EUR J CONTRACEP REPR, V14, P365, DOI 10.3109/13625180903137329; Khalili H, 2013, GUT, V62, P1153, DOI 10.1136/gutjnl-2012-302362; Koch-Henriksen N, 2010, LANCET NEUROL, V9, P520, DOI 10.1016/S1474-4422(10)70064-8; Koebnick Corinna, 2012, Perm J, V16, P37; Langer-Gould A, 2011, NEUROLOGY, V77, P1143, DOI 10.1212/WNL.0b013e31822facdd; Langer-Gould A, 2010, MULT SCLER J, V16, P855, DOI 10.1177/1352458510369146; Langer-Gould A, 2013, NEUROLOGY, V80, P1734, DOI 10.1212/WNL.0b013e3182918cc2; Langer-Gould A, 2013, NEUROLOGY, V80, P548, DOI 10.1212/WNL.0b013e31828154f3; McKay KA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/817238; Ngo ST, 2014, FRONTIERS NEUROENDOC; Palacios N, 2011, ANN EPIDEMIOL, V21, P536, DOI 10.1016/j.annepidem.2011.03.001; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Ponsonby AL, 2012, NEUROLOGY, V78, P867, DOI 10.1212/WNL.0b013e31824c4648; Sena A, 2012, J NEUROL SCI, V317, P47, DOI 10.1016/j.jns.2012.02.033; Suissa S, 1997, CONTRACEPTION, V56, P141, DOI 10.1016/S0010-7824(97)00119-4; Thorogood M, 1998, BRIT J OBSTET GYNAEC, V105, P1296, DOI 10.1111/j.1471-0528.1998.tb10008.x; VILLARDMACKINTOSH L, 1993, CONTRACEPTION, V47, P161, DOI 10.1016/0010-7824(93)90088-O; WEINSHENKER BG, 1989, NEUROLOGY, V39, P1438, DOI 10.1212/WNL.39.11.1438	27	30	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2016	11	3							e0149094	10.1371/journal.pone.0149094	http://dx.doi.org/10.1371/journal.pone.0149094			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SL	26950301	Green Published, gold, Green Submitted			2023-01-03	WOS:000371990100009
J	Kanthack, TFD; Guillot, A; Altimari, LR; Nagy, SN; Collet, C; Di Rienzo, F				Dias Kanthack, Thiago Ferreira; Guillot, Aymeric; Altimari, Leandro Ricardo; Nunez Nagy, Susana; Collet, Christian; Di Rienzo, Franck			Selective Efficacy of Static and Dynamic Imagery in Different States of Physical Fatigue	PLOS ONE			English	Article							MOTOR IMAGERY; MENTAL PRACTICE; EXERCISE; PERFORMANCE; CHALLENGE; ACCURACY; EXERTION; STROKE; SPEED	There is compelling evidence that motor imagery contributes to improved motor performance, and recent work showed that dynamic motor imagery (dMI) might provide additional benefits by comparison with traditional MI practice. However, the efficacy of motor imagery in different states of physical fatigue remains largely unknown, especially as imagery accuracy may be hampered by the physical fatigue states elicited by training. We investigated the effect of static motor imagery (sMI) and dMI on free-throw accuracy in 10 high-level basketball athletes, both in a non -fatigued state (Experiment 1) and immediately after an incremental running test completed until exhaustion (20m shuttle run-test Experiment 2). We collected perceived exhaustion and heart rate to quantify the subjective experience of fatigue and energy expenditure. We found that dMI brought better shooting performance than sMI, except when athletes were physically exhausted. These findings shed light on the conditions eliciting optimal use of sMI and dMI. In particular, considering that the current physical state affects body representation, performing dMI under fatigue may result in mismatches between actual and predicted body states.	[Dias Kanthack, Thiago Ferreira; Guillot, Aymeric; Collet, Christian; Di Rienzo, Franck] Univ Lyon 1, LIBM, F-69622 Villeurbanne, France; [Dias Kanthack, Thiago Ferreira; Altimari, Leandro Ricardo] Univ Estadual Londrina, Grp Pesquisa Sistema Neuromuscular & Exercicio, Londrina, Parana, Brazil; [Dias Kanthack, Thiago Ferreira] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil; [Guillot, Aymeric] Inst Univ France, Paris, France; [Nunez Nagy, Susana] Univ Alcala de Henares, Unidad Fisioterapia, Madrid, Spain	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universidade Estadual de Londrina; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Institut Universitaire de France; Universidad de Alcala	Di Rienzo, F (corresponding author), Univ Lyon 1, LIBM, F-69622 Villeurbanne, France.	franck.di-rienzo@univ-lyon1.fr	Ferreira Dias Kanthack, Thiago/N-8419-2017	Ferreira Dias Kanthack, Thiago/0000-0002-8725-9044	CAPES Foundation, Ministry of Education of Brazil; CAPES foundation	CAPES Foundation, Ministry of Education of Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CAPES foundation(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by CAPES Foundation, Ministry of Education of Brazil, http://capes.academia.edu/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank CAPES foundation for the financial support on this project.	Baguley T., 2012, SERIOUS STATS GUIDE; Bates D., 2020, LME4 LINEAR MIXED EF; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Callow N., 2006, Journal of Imagery Research in Sport and Physical Activity, V1, P2, DOI 10.2202/1932-0191.1001; Coelho CJ, 2012, J EXP PSYCHOL LEARN, V38, P1759, DOI 10.1037/a0028065; Collet C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00415; Collet C, 2011, EXERC SPORT SCI REV, V39, P85, DOI 10.1097/JES.0b013e31820ac5e0; Csataljay G., 2009, INT J PERF ANAL SPOR, V34, P552, DOI [10.1080/24748668.2009.11868464, DOI 10.1080/24748668.2009.11868464]; Cumming J., 2013, MOVEMENT SPORT SCI, V82, P69, DOI [10.1051/sm/2013098, DOI 10.1051/SM/2013098, 10.3917/sm.082.0069, DOI 10.3917/SM.082.0069]; Debarnot U, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00280; Demougeot L, 2011, J NEUROSCI, V31, P10712, DOI 10.1523/JNEUROSCI.6032-10.2011; Di Rienzo F, 2014, NEUROPSYCHOL REV, V24, P116, DOI 10.1007/s11065-014-9257-6; Di Rienzo F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047207; Dijkerman HC, 2004, CLIN REHABIL, V18, P538, DOI 10.1191/0269215504cr769oa; Doud AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026322; Driediger M, 2006, J SPORT SCI, V24, P261, DOI 10.1080/02640410500128221; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; Edelman BJ, 2016, IEEE T BIO-MED ENG, V63, P4, DOI 10.1109/TBME.2015.2467312; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Fusco A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00760; Gibson AS, 2004, BRIT J SPORT MED, V38, P797, DOI 10.1136/bjsm.2003.009852; Guillot A, 2005, EUR J APPL PHYSIOL, V95, P186, DOI 10.1007/s00421-005-1400-x; Guillot A, 2005, BIOL SPORT, V22, P215; Guillot A., 2008, INT REV SPORT EXER P, V1, P31, DOI [10.1080/17509840701823139, DOI 10.1080/17509840701823139]; Guillot A, 2013, J SPORT SCI MED, V12, P332; Guillot A, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-8; Guillot A, 2012, INT REV SPORT EXER P, V5, P3, DOI 10.1080/1750984X.2011.623787; Guillot A, 2012, PSYCHOL SPORT EXERC, V13, P533, DOI 10.1016/j.psychsport.2012.03.002; He B, 2015, P IEEE, V103, P907, DOI [10.1109/JPROC.2015.2407272, 10.1109/jproc.2015.2407272]; HOLM S, 1979, SCAND J STAT, V6, P65; Holmes PS, 2001, J APPL SPORT PSYCHOL, V13, P60, DOI 10.1080/10413200109339004; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Jackson PL, 2001, ARCH PHYS MED REHAB, V82, P1133, DOI 10.1053/apmr.2001.24286; Kanekar N, 2008, CLIN NEUROPHYSIOL, V119, P2304, DOI 10.1016/j.clinph.2008.06.015; Kanthack Thiago Ferreira Dias, 2014, Rev. bras. cineantropom. desempenho hum., V16, P47, DOI 10.5007/1980-0037.2014v16n1p47; Lacey J, 1980, SPECIFIC ROLE HEART, P495; LaFleur K, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/4/046003; LAMIRAND M, 1994, PERCEPT MOTOR SKILL, V78, P1229, DOI 10.2466/pms.1994.78.3c.1229; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Leger LA, 1988, J SPORT SCI, V6, P93, DOI 10.1080/02640418808729800; Louis M, 2008, J MOTOR BEHAV, V40, P117, DOI 10.3200/JMBR.40.2.117-132; MacIntyre TE, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00104; Martin K, 2015, EUR J APPL PHYSIOL, V115, P715, DOI 10.1007/s00421-014-3052-1; Maruff P, 2000, NEUROPSYCHOLOGIA, V38, P1251, DOI 10.1016/S0028-3932(00)00031-2; Olsson CJ, 2010, SCAND J MED SCI SPOR, V20, P711, DOI 10.1111/j.1600-0838.2010.01101.x; Peynircioglu ZF, 2000, J GEN PSYCHOL, V127, P145, DOI 10.1080/00221300009598574; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; Post P. G., 2010, J IMAGERY RES SPORT, V5; R Core Team, 2021, R LANG ENV STAT COMP; Rozand V, 2015, NEUROSCIENCE, V297, P219, DOI 10.1016/j.neuroscience.2015.03.066; Rozand V, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00755; Schuster C, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-75; Utter AC, 2004, MED SCI SPORT EXER, V36, P1776, DOI 10.1249/01.MSS.0000142310.97274.94; Vogt S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00807; Williams SE, 2012, EUR J SPORT SCI, V12, P499, DOI 10.1080/17461391.2011.630102; Williams SE, 2010, J SPORT EXERCISE PSY, V32, P339, DOI 10.1123/jsep.32.3.339; Winter B., 2013, ARXIV13085499; Wrisberg C. A., 1989, SPORT PSYCHOL, V2, P95, DOI DOI 10.1123/TSP.3.2.95; Yuan H, 2010, NEUROIMAGE, V49, P2596, DOI 10.1016/j.neuroimage.2009.10.028	59	13	13	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0149654	10.1371/journal.pone.0149654	http://dx.doi.org/10.1371/journal.pone.0149654			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF5ZW	26930279	gold, Green Published, Green Submitted			2023-01-03	WOS:000371434500037
J	Song, T; Li, N; Zarepisheh, M; Li, YB; Gautier, Q; Zhou, LH; Mell, L; Jiang, S; Cervino, L				Song, Ting; Li, Nan; Zarepisheh, Masoud; Li, Yongbao; Gautier, Quentin; Zhou, Linghong; Mell, Loren; Jiang, Steve; Cervino, Laura			An Automated Treatment Plan Quality Control Tool for Intensity-Modulated Radiation Therapy Using a Voxel-Weighting Factor-Based Re-Optimization Algorithm	PLOS ONE			English	Article							CONFORMAL RADIOTHERAPY; IMRT; PROSTATE; REGISTRATION	Intensity-modulated radiation therapy (IMRT) currently plays an important role in radiotherapy, but its treatment plan quality can vary significantly among institutions and planners. Treatment plan quality control (QC) is a necessary component for individual clinics to ensure that patients receive treatments with high therapeutic gain ratios. The voxel-weighting factor-based plan re-optimization mechanism has been proved able to explore a larger Pareto surface (solution domain) and therefore increase the possibility of finding an optimal treatment plan. In this study, we incorporated additional modules into an in-house developed voxel weighting factor-based re-optimization algorithm, which was enhanced as a highly automated and accurate IMRT plan QC tool (TPS-QC tool). After importing an underassessment plan, the TPS-QC tool was able to generate a QC report within 2 minutes. This QC report contains the plan quality determination as well as information supporting the determination. Finally, the IMRT plan quality can be controlled by approving quality-passed plans and replacing quality-failed plans using the TPS-QC tool. The feasibility and accuracy of the proposed TPS-QC tool were evaluated using 25 clinically approved cervical cancer patient IMRT plans and 5 manually created poor-quality IMRT plans. The results showed high consistency between the QC report quality determinations and the actual plan quality. In the 25 clinically approved cases that the TPS-QC tool identified as passed, a greater difference could be observed for dosimetric endpoints for organs at risk (OAR) than for planning target volume (PTV), implying that better dose sparing could be achieved in OAR than in PTV. In addition, the dose-volume histogram (DVH) curves of the TPS-QC tool re-optimized plans satisfied the dosimetric criteria more frequently than did the under-assessment plans. In addition, the criteria for unsatisfied dosimetric endpoints in the 5 poor-quality plans could typically be satisfied when the TPS-QC tool generated re-optimized plans without sacrificing other dosimetric endpoints. In addition to its feasibility and accuracy, the proposed TPS-QC tool is also user-friendly and easy to operate, both of which are necessary characteristics for clinical use.	[Song, Ting; Zhou, Linghong] Southern Med Univ, Dept Biomed Engn, Guangzhou, Guangdong, Peoples R China; [Li, Nan; Zarepisheh, Masoud; Gautier, Quentin; Mell, Loren; Cervino, Laura] Univ Calif San Diego, Ctr Adv Radiotherapy Technol, La Jolla, CA 92093 USA; [Li, Nan; Zarepisheh, Masoud; Gautier, Quentin; Mell, Loren; Cervino, Laura] Univ Calif San Diego, Dept Radiat Oncol, La Jolla, CA 92093 USA; [Song, Ting; Li, Yongbao; Jiang, Steve] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA	Southern Medical University - China; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhou, LH (corresponding author), Southern Med Univ, Dept Biomed Engn, Guangzhou, Guangdong, Peoples R China.; Cervino, L (corresponding author), Univ Calif San Diego, Ctr Adv Radiotherapy Technol, La Jolla, CA 92093 USA.; Cervino, L (corresponding author), Univ Calif San Diego, Dept Radiat Oncol, La Jolla, CA 92093 USA.; Jiang, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.	smart@smu.edu.au; Steve.Jiang@UTSouthwestern.edu; lcervino@ucsd.edu	Jiang, Steve/GRO-3951-2022	Cervino, Laura/0000-0001-6479-6990	National Natural Science Foundation of China [30970866]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China (http://www.nsfc.gov.cn/), No. 30970866 (receiver: LZ).	Alber M, 2001, PHYS MED BIOL, V46, P3229, DOI 10.1088/0031-9155/46/12/311; Bohsung J, 2005, RADIOTHER ONCOL, V76, P354, DOI 10.1016/j.radonc.2005.08.003; Chung HT, 2008, INT J RADIAT ONCOL, V71, P1167, DOI 10.1016/j.ijrobp.2007.11.040; Cotrutz C, 2003, MED PHYS, V30, P544, DOI 10.1118/1.1556610; Cotrutz C, 2002, PHYS MED BIOL, V47, P1659, DOI 10.1088/0031-9155/47/10/304; Fredriksson A, 2012, PHYS MED BIOL, V57, P7799, DOI 10.1088/0031-9155/57/23/7799; Gu X, 2011, INT J RADIAT ONCOL, V81, pS803, DOI 10.1016/j.ijrobp.2011.06.1409; Gu XJ, 2011, PHYS MED BIOL, V56, P3337, DOI 10.1088/0031-9155/56/11/010; Gu XJ, 2010, PHYS MED BIOL, V55, P207, DOI 10.1088/0031-9155/55/1/012; Halabi T, 2006, PHYS MED BIOL, V51, P3809, DOI 10.1088/0031-9155/51/15/014; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Hunt MA, 2006, INT J RADIAT ONCOL, V66, P296, DOI 10.1016/j.ijrobp.2006.05.028; Jia X, 2011, PHYS MED BIOL, V56, P6205, DOI 10.1088/0031-9155/56/19/004; Li N, 2013, PHYS MED BIOL, V58, P8725, DOI 10.1088/0031-9155/58/24/8725; Lu RZ, 2007, PHYS MED BIOL, V52, P849, DOI 10.1088/0031-9155/52/3/022; Men CH, 2010, MED PHYS, V37, P5787, DOI 10.1118/1.3491675; Men CH, 2010, PHYS MED BIOL, V55, P4309, DOI 10.1088/0031-9155/55/15/008; Moore KL, 2012, SEMIN RADIAT ONCOL, V22, P62, DOI 10.1016/j.semradonc.2011.09.005; Mutic S, 2003, MED PHYS, V30, P2762, DOI 10.1118/1.1609271; Petit SF, 2012, RADIOTHER ONCOL, V102, P38, DOI 10.1016/j.radonc.2011.05.025; Sveistrup J, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-44; Teh B S, 1999, Oncologist, V4, P433; Teh BS, 2001, INT J RADIAT ONCOL, V49, P465, DOI 10.1016/S0360-3016(00)01474-7; Vlachaki MT, 2005, MED DOSIM, V30, P69, DOI 10.1016/j.meddos.2005.01.002; Williams MJ, 2007, AUSTRALAS RADIOL, V51, P472, DOI 10.1111/j.1440-1673.2007.01873.x; Wu BB, 2009, MED PHYS, V36, P5497, DOI 10.1118/1.3253464; Wu C, 2003, PHYS MED BIOL, V48, P2479, DOI 10.1088/0031-9155/48/15/315; Wu QW, 2000, MED PHYS, V27, P701, DOI 10.1118/1.598932; Young R, 2000, RADIOLOGY MANAGEMENT, V23, P3; Young R, 2000, RADIOL MANAG, V23, P20; Young R, 2000, RADIOLOGY MANAGEMENT, V23, P8; Young R, 2000, RADIOLOGY MANAGEMENT, V23, P30; Yuan LL, 2012, MED PHYS, V39, P6868, DOI 10.1118/1.4757927; Zarepisheh M, 2012, ARXIV12107006; Zarepisheh M, 2014, MED PHYS, V41, DOI 10.1118/1.4875700; Zelefsky MJ, 2001, J UROLOGY, V166, P876, DOI 10.1016/S0022-5347(05)65855-7; Zhen X, 2012, PHYS MED BIOL, V57, P6807, DOI 10.1088/0031-9155/57/21/6807	37	8	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0149273	10.1371/journal.pone.0149273	http://dx.doi.org/10.1371/journal.pone.0149273			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF5ZW	26930204	Green Published, Green Submitted, gold			2023-01-03	WOS:000371434500022
J	Eriksson, H; Milberg, A; Hjelm, K; Friedrichsen, M				Eriksson, Helene; Milberg, Anna; Hjelm, Katarina; Friedrichsen, Maria			End of Life Care for Patients Dying of Stroke: A Comparative Registry Study of Stroke and Cancer	PLOS ONE			English	Article							PALLIATIVE CARE; TEAM; PROFESSIONALS; PREFERENCES; DEMENTIA; FAMILY; DEATH; NEEDS; PAIN	Background Although stroke is a significant public health challenge and the need for palliative care has been emphasized for these patients, there is limited data on end-of-life care for patients dying from stroke. Objective To study the end-of-life care during the last week of life for patients who had died of stroke in terms of registered symptom, symptom management, and communication, in comparison with patients who had died of cancer. Design This study is a retrospective, comparative registry study. Methods A retrospective comparative registry study was performed using data from a Swedish national quality register for end-of-life care based on WHO's definition of Palliative care. Data from 1626 patients who had died of stroke were compared with data from 1626 patients who had died of cancer. Binary logistic analyses were used to calculate odds ratios, with 95% CI. Results Compared to patients who was dying of cancer, the patients who was dying of stroke had a significantly higher prevalence of having death rattles registered, but a significantly lower prevalence of, nausea, confusion, dyspnea, anxiety, and pain. In addition, the stroke group had significantly lower odds ratios for health care staff not to know whether all these six symptoms were present or not. Patients who was dying of stroke had significantly lower odds ratio of having informative communication from a physician about the transition to end-of-life care and of their family members being offered bereavement follow-up. Conclusions The results indicate on differences in end-of-life care between patients dying of stroke and those dying from cancer. To improve the end-of-life care in clinical practice and ensure it has consistent quality, irrespective of diagnosis, education and implementation of palliative care principles are necessary.	[Eriksson, Helene; Milberg, Anna; Hjelm, Katarina; Friedrichsen, Maria] Linkoping Univ, Dept Social & Welf Studies, Norrkoping, Sweden; [Milberg, Anna; Friedrichsen, Maria] Vrinnevi Hosp, Palliat Educ & Res Ctr, Norrkoping, Sweden; [Milberg, Anna; Friedrichsen, Maria] Vrinnevi Hosp, Dept Adv Home Care, Norrkoping, Sweden	Linkoping University	Eriksson, H (corresponding author), Linkoping Univ, Dept Social & Welf Studies, Norrkoping, Sweden.	Helene.m.eriksson@liu.se			Stroke Riksforbund [2012-00185]; Stahls stiftelse [4813101041]; Forss [479071]	Stroke Riksforbund; Stahls stiftelse; Forss	This work was supported by Stroke Riksforbund (number: 2012-00185) 30 000SEK Stahls stiftelse (number: 4813101041) 200 000 SEK Forss (number: 479071) 150 000 SEK (Helene Eriksson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADDINGTONHALL J, 1995, STROKE, V26, P2242, DOI 10.1161/01.STR.26.12.2242; Bito Seiji, 2007, BMC Med Ethics, V8, P7, DOI 10.1186/1472-6939-8-7; Bruera E, 2013, PALLIATIVE MED, V27, P939, DOI 10.1177/0269216313477177; Burton CR, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-22; Creutzfeldt CJ, 2015, STROKE, V46, P2714, DOI 10.1161/STROKEAHA.115.008224; Creutzfeldt CJ, 2012, STROKE, V43, P3405, DOI 10.1161/STROKEAHA.112.673376; de Boer ME, 2015, PALLIATIVE MED, V29, P451, DOI 10.1177/0269216314563427; Epstein RM, 2010, HEALTH AFFAIR, V29, P1489, DOI 10.1377/hlthaff.2009.0888; Eriksson H, 2014, J NEUROSCI NURS, V46, P162, DOI 10.1097/JNN.0000000000000049; Helvig E, 2015, VASC HEALTH RISK MAN, V11, P507, DOI 10.2147/VHRM.S85814; Henoch I, 2016, SCAND J CARING SCI, V30, P5, DOI 10.1111/scs.12253; Holloway RG, 2014, STROKE, V45, P1887, DOI 10.1161/STR.0000000000000015; Kehl KA, 2013, AM J HOSP PALLIAT ME, V30, P601, DOI 10.1177/1049909112468222; Liljehult J, 2015, ACTA NEUROL SCAND; Lindblom AK, 2012, J NURS MANAGE, V20, P206, DOI 10.1111/j.1365-2834.2011.01376.x; Lundstrom S, 2012, PALLIATIVE MED, V26, P313, DOI 10.1177/0269216311414758; Martinsson L, 2011, ACTA ONCOL, V50, P642, DOI 10.3109/0284186X.2011.554434; Mazzocato C, 2010, EUR J NEUROL, V17, P73, DOI 10.1111/j.1468-1331.2009.02744.x; Meleis A.I., 2011, THEORETICAL NURSING; Monacelli F, 2013, CLIN TER, V164, pE23, DOI 10.7417/CT.2013.1516; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Norrving Bo, 2007, Int J Stroke, V2, P139, DOI 10.1111/j.1747-4949.2007.00109.x; Ntlholang O, 2015, IRISH J MED SCI; Payne S, 2010, PALLIATIVE MED, V24, P146, DOI 10.1177/0269216309350252; Rejno A, 2013, BMC NURS, V12, DOI 10.1186/1472-6955-12-13; Rejno A, 2012, NURS ETHICS, V19, P642, DOI 10.1177/0969733011412099; Roberts SE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131836; San Luis COV, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-21; The National Board of Health and Welfare, 2014, BRYTP; Thomas RL, 2014, MED J AUSTRALIA, V201, P452, DOI 10.5694/mja14.00623; van der Steen JT, 2015, J PAIN SYMPTOM MANAG, V50, P659, DOI 10.1016/j.jpainsymman.2015.05.015; Weil J, 2015, PALLIATIVE MED, V29, P293, DOI 10.1177/0269216314560801; World Health Organization, WHO DEF PALL CAR 201	33	22	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2016	11	2							e0147694	10.1371/journal.pone.0147694	http://dx.doi.org/10.1371/journal.pone.0147694			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PF	26845149	Green Submitted, gold, Green Published			2023-01-03	WOS:000369552800013
J	McDonald, A; Glusman, G; Price, ND				McDonald, Aniel; Glusman, Gustavo; Price, Nathan D.			Personalized nutrition through big data	NATURE BIOTECHNOLOGY			English	Editorial Material									[McDonald, Aniel; Glusman, Gustavo; Price, Nathan D.] Inst Syst Biol, Seattle, WA USA	Institute for Systems Biology (ISB)	Price, ND (corresponding author), Inst Syst Biol, Seattle, WA USA.	nprice@systemsbiology.org		Price, Nathan/0000-0002-4157-0267; Glusman, Gustavo/0000-0001-8060-5955				Ausiello D, 2015, BIG DATA, V3, P203, DOI 10.1089/big.2015.0016; Dodd H, 2011, AM J CLIN NUTR, V94, P992, DOI 10.3945/ajcn.111.012138; Hood L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008665; Olle B, 2013, NAT BIOTECHNOL, V31, P309, DOI 10.1038/nbt.2548; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	8	13	15	1	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2016	34	2					152	154		10.1038/nbt.3476	http://dx.doi.org/10.1038/nbt.3476			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	DD0OK	26849520				2023-01-03	WOS:000369619100016
J	Wares, JR; Lawson, B; Shemin, D; D'Agata, EMC				Wares, Joanna R.; Lawson, Barry; Shemin, Douglas; D'Agata, Erika M. C.			Evaluating Infection Prevention Strategies in Out-Patient Dialysis Units Using Agent-Based Modeling	PLOS ONE			English	Article							VANCOMYCIN-RESISTANT ENTEROCOCCI; CHRONIC-HEMODIALYSIS; ANTIMICROBIAL USE; GASTROINTESTINAL COLONIZATION; TRANSMISSION DYNAMICS; IMPACT; ENTEROBACTERIACEAE; PROGRAMS; BACTERIA	Patients receiving chronic hemodialysis (CHD) are among the most vulnerable to infections caused by multidrug-resistant organisms (MDRO), which are associated with high rates of morbidity and mortality. Current guidelines to reduce transmission of MDRO in the outpatient dialysis unit are targeted at patients considered to be high-risk for transmitting these organisms: those with infected skin wounds not contained by a dressing, or those with fecal incontinence or uncontrolled diarrhea. Here, we hypothesize that targeting patients receiving antimicrobial treatment would more effectively reduce transmission and acquisition of MDRO. We also hypothesize that environmental contamination plays a role in the dissemination of MDRO in the dialysis unit. To address our hypotheses, we built an agent-based model to simulate different treatment strategies in a dialysis unit. Our results suggest that reducing antimicrobial treatment, either by reducing the number of patients receiving treatment or by reducing the duration of the treatment, markedly reduces overall colonization rates and also the levels of environmental contamination in the dialysis unit. Our results also suggest that improving the environmental decontamination efficacy between patient dialysis treatments is an effective method for reducing colonization and contamination rates. These findings have important implications for the development and implementation of future infection prevention strategies.	[Wares, Joanna R.; Lawson, Barry] Univ Richmond, Dept Math & Comp Sci, Richmond, VA 23173 USA; [Shemin, Douglas] Brown Univ, Rhode Isl Hosp, Div Nephrol, Providence, RI 02903 USA; [D'Agata, Erika M. C.] Brown Univ, Rhode Isl Hosp, Div Infect Dis, Providence, RI 02903 USA	University of Richmond; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Wares, JR (corresponding author), Univ Richmond, Dept Math & Comp Sci, Richmond, VA 23173 USA.	jwares@richmond.edu			Agency of Healthcare Research and Quality [R18HS021666]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS021666] Funding Source: NIH RePORTER	Agency of Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Support for this project was provided by the Agency of Healthcare Research and Quality grant R18HS021666 (EMCD).	Austin DJ, 1999, P NATL ACAD SCI USA, V96, P6908, DOI 10.1073/pnas.96.12.6908; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; Cheng VCC, 2008, J HOSP INFECT, V70, P27, DOI 10.1016/j.jhin.2008.05.019; D'Agata EMC, 2002, J INFECT DIS, V185, P766, DOI 10.1086/339293; D'Agata EMC, 2001, CLIN INFECT DIS, V32, P23, DOI 10.1086/317549; D'Agata EMC, 2002, CLIN INFECT DIS, V34, P167, DOI 10.1086/338234; D'Agata EMC, 2013, SEMIN DIALYSIS, V26, P457, DOI 10.1111/sdi.12090; D'Agata EMC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030170; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014; Grabsch EA, 2006, INFECT CONT HOSP EP, V27, P287, DOI 10.1086/503174; Hotchkiss JR, 2007, CLIN J AM SOC NEPHRO, V2, P1176, DOI 10.2215/CJN.00130107; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Pop-Vicas A, 2008, CLIN J AM SOC NEPHRO, V3, P752, DOI 10.2215/CJN.04651107; Savard P, 2014, CLIN MICROBIOL INFEC, V20, P854, DOI 10.1111/1469-0691.12748; Schwaber MJ, 2006, ANTIMICROB AGENTS CH, V50, P1257, DOI 10.1128/AAC.50.4.1257-1262.2006; Snyder GM, 2013, INFECT CONT HOSP EP, V34, P349, DOI 10.1086/669869; Snyder GM, 2012, CURR OPIN NEPHROL HY, V21, P211, DOI 10.1097/MNH.0b013e328350089b	18	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0153820	10.1371/journal.pone.0153820	http://dx.doi.org/10.1371/journal.pone.0153820			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27195984	Green Published, gold, Green Submitted			2023-01-03	WOS:000376291100007
J	Klement, RJ; Champ, CE; Otto, C; Kammerer, U				Klement, Rainer J.; Champ, Colin E.; Otto, Christoph; Kaemmerer, Ulrike			Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis	PLOS ONE			English	Article							CARBOHYDRATE RESTRICTION; PROSTATE-CANCER; TUMOR-GROWTH; KETONE-BODIES; CALORIC RESTRICTION; MOUSE; THERAPY; GLUCOSE; MODEL	Background Currently ketogenic diets (KDs) are hyped as an anti-tumor intervention aimed at exploiting the metabolic abnormalities of cancer cells. However, while data in humans is sparse, translation of murine tumor models to the clinic is further hampered by small sample sizes, heterogeneous settings and mixed results concerning tumor growth retardation. The aim was therefore to synthesize the evidence for a growth inhibiting effect of KDs when used as a monotherapy in mice. Methods We conducted a Bayesian random effects meta-analysis on all studies assessing the survival (defined as the time to reach a pre-defined endpoint such as tumor volume) of mice on an unrestricted KD compared to a high carbohydrate standard diet (SD). For 12 studies meeting the inclusion criteria either a mean survival time ratio (MR) or hazard ratio (HR) between the KD and SD groups could be obtained. The posterior estimates for the MR and HR averaged over four priors on the between-study heterogeneity tau(2) were MR = 0.85 (95% highest posterior density interval (HPDI) = [0.73, 0.97]) and HR = 0.55 (95% HPDI = [0.26, 0.87]), indicating a significant overall benefit of the KD in terms of prolonged mean survival times and reduced hazard rate. All studies that used a brain tumor model also chose a late starting point for the KD (at least one day after tumor initiation) which accounted for 26% of the heterogeneity. In this subgroup the KD was less effective (MR = 0.89, 95% HPDI = [0.76, 1.04]). Conclusions There was an overall tumor growth delaying effect of unrestricted KDs in mice. Future experiments should aim at differentiating the effects of KD timing versus tumor location, since external evidence is currently consistent with an influence of both of these factors.	[Klement, Rainer J.] Leopoldina Hosp Schweinfurt, Dept Radiotherapy & Radiat Oncol, Schweinfurt, Germany; [Champ, Colin E.] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA; [Otto, Christoph] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Wurzburg, Germany; [Kaemmerer, Ulrike] Univ Hosp Wurzburg, Dept Obstet & Gynaecol, Wurzburg, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wurzburg; University of Wurzburg	Klement, RJ (corresponding author), Leopoldina Hosp Schweinfurt, Dept Radiotherapy & Radiat Oncol, Schweinfurt, Germany.	rainer_klement@gmx.de	Champ, Colin/AAA-6842-2019; Klement, Rainer J/H-3484-2019	Champ, Colin/0000-0002-1879-7463; Klement, Rainer J/0000-0003-1401-4270				Abdelwahab MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036197; Allen BG, 2013, CLIN CANCER RES, V19, P3905, DOI 10.1158/1078-0432.CCR-12-0287; Altman DG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d2090; Borghjid S, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-69; CAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397, DOI 10.1016/S0300-595X(76)80028-X; Caso J, 2013, PROSTATE, V73, P449, DOI 10.1002/pros.22586; Dang MT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133633; Fontana L, 2013, ONCOTARGET, V4, P2451, DOI 10.18632/oncotarget.1586; Freedland SJ, 2008, PROSTATE, V68, P11, DOI 10.1002/pros.20683; Gluschnaider U, 2014, CANC RES; Hao Guang-Wei, 2015, Asian Pac J Cancer Prev, V16, P2061; Healy ME, 2015, J HEPATOL, V62, P599, DOI 10.1016/j.jhep.2014.10.024; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Ho VW, 2011, CANCER RES, V71, P4484, DOI 10.1158/0008-5472.CAN-10-3973; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Hursting SD, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-10; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; Kim HS, 2012, BJU INT, V110, P1062, DOI 10.1111/j.1464-410X.2012.10971.x; Klement RJ, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.2; Klement RJ, 2014, TRENDS MOL MED, V20, P471, DOI 10.1016/j.molmed.2014.07.001; Klement RJ, 2013, ONCOLOGIST, V18, P1056, DOI 10.1634/theoncologist.2013-0032; Lai M, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.30; Lamming DW, 2015, ONCOTARGET, V6, P31233, DOI 10.18632/oncotarget.5180; Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lin BQ, 2013, LUNG CANCER, V79, P111, DOI 10.1016/j.lungcan.2012.11.001; Lv MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115147; Mahoney LB, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476-511X-5-13; Martuscello RT, 2015, CLIN CANC RES; Masko EM, 2010, CANCER PREV RES, V3, P1124, DOI 10.1158/1940-6207.CAPR-10-0071; Maurer GD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-315; Mavropoulos JC, 2009, CANCER PREV RES, V2, P557, DOI 10.1158/1940-6207.CAPR-08-0188; Meidenbauer JJ, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0009-2; Moreschi C, 1909, Z IMMUNITATSFORSCH, V2, P651; Morscher RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129802; Otto C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-122; Peterman MG, 1925, J AMER MED ASSOC, V84, P1979, DOI 10.1001/jama.1925.02660520007003; Poff AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127407; Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522; Rieger J, 2014, INT J ONCOL, V44, P1843, DOI 10.3892/ijo.2014.2382; Schwartz K, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0129-1; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Shukla SK, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-18; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; Spruance SL, 2004, ANTIMICROB AGENTS CH, V48, P2787, DOI 10.1128/AAC.48.8.2787-2792.2004; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Sutton AJ, 2001, STAT METHODS MED RES, V10, P277, DOI 10.1191/096228001678227794; Van Alstyne EVN, 1913, J MED RES, V29, P217; Woolf EC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130357; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5; Zhuang YX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108444	52	70	71	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2016	11	5							e0155050	10.1371/journal.pone.0155050	http://dx.doi.org/10.1371/journal.pone.0155050			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM7YQ	27159218	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000376576700035
J	Yang, H; Chen, YH; Hsieh, TF; Chuang, SY; Wu, MJ				Yang, Hsun; Chen, Yi-Hsin; Hsieh, Teng-Fu; Chuang, Shiun-Yang; Wu, Ming-Ju			Prediction of Mortality in Incident Hemodialysis Patients: A Validation and Comparison of CHADS2, CHA2DS2, and CCI Scores	PLOS ONE			English	Article							CHARLSON COMORBIDITY INDEX; STAGE RENAL-DISEASE; ATRIAL-FIBRILLATION; CLINICAL CHARACTERISTICS; DIALYSIS OUTCOMES; ANEMIA MANAGEMENT; PRACTICE PATTERNS; SURVIVAL; RISK; MORBIDITY	Background The CHADS2 and CHA2DS2 scores are usually applied for stroke prediction in atrial fibrillation patients, and the Charlson comorbidity index (CCI) is a commonly used scale for assessing morbidity. The role in assessing mortality with score system in hemodialysis is not clear and comparisons are lacking. We aimed at evaluating CHADS2, CHA2DS2, and CCI scores to predict mortality in incident hemodialysis patients. Methods Using data from the Nation Health Insurance system of Taiwan (NHIRD) from 1 January 2005 to 31 December 2009, individuals >= 20 y/o who began hemodialysis identified by procedure code and receiving dialysis for >3 months were included for our study. Renal transplantation patients after dialysis or PD patients were excluded. We calculated the CHADS2, CHA2DS2, and CCI score according to the ICD-9 code and categorized the patients into three groups in each system: 0-1, 2-3, over 4. A total of 3046 incident hemodialysis patients enrolled from NHIRD were examined for an association between the separate scoring systems (CHADS2, CHA2DS2, and CCI score) and mortality. Results CHADS2 and CHA2DS2 scores revealed good predictive value for total mortality (CHADS2 AUC = 0.805; CHA2DS2 AUC = 0.790). However, the CCI score did not reveal a similarly satisfying result (AUC = 0.576). Conclusions Our results show that CHADS2 and CHA2DS2 scores can be applied for mortality prediction in incident hemodialysis patients.	[Yang, Hsun; Chen, Yi-Hsin] Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Hosp, Dept Nephrol, Taichung, Taiwan; [Hsieh, Teng-Fu] Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Hosp, Dept Urol, Taichung, Taiwan; [Hsieh, Teng-Fu; Chuang, Shiun-Yang] Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Gen Hosp, Dept Med Res, Taichung, Taiwan; [Wu, Ming-Ju] Taichung Vet Gen Hosp, Div Nephrol, Dept Internal Med, Taichung, Taiwan; [Chen, Yi-Hsin] Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan; [Chen, Yi-Hsin] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Wu, Ming-Ju] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan; [Wu, Ming-Ju] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan	Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Tzu Chi University; Chung Shan Medical University; China Medical University Taiwan	Chen, YH (corresponding author), Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Hosp, Dept Nephrol, Taichung, Taiwan.; Chen, YH (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan.; Chen, YH (corresponding author), Tzu Chi Univ, Sch Med, Hualien, Taiwan.	nephp06@gmail.com						Abbott Kevin C, 2003, BMC Nephrol, V4, P1, DOI 10.1186/1471-2369-4-1; Andresdottir G, 2015, KIDNEY INT, V87, P417, DOI 10.1038/ki.2014.206; Boriani G, 2011, STROKE, V42, P1768, DOI 10.1161/STROKEAHA.110.609297; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Brookhart MA, 2010, JAMA-J AM MED ASSOC, V303, P857, DOI 10.1001/jama.2010.206; Camm AJ, 2012, EUR HEART J, V33; Chae JW, 2011, NEPHRON CLIN PRACT, V117, pC379, DOI 10.1159/000321525; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collins AJ, 2010, AM J KIDNEY DIS, V55, pVI, DOI 10.1053/j.ajkd.2009.10.009; Ethier J, 2007, AM J KIDNEY DIS, V50, P602, DOI 10.1053/j.ajkd.2007.07.007; Fabbian F, 2000, CLIN NEPHROL, V54, P234; Gangji AS, 2006, THROMB RES, V118, P423, DOI 10.1016/j.thromres.2005.03.029; Genovesi S, 2005, AM J KIDNEY DIS, V46, P897, DOI 10.1053/j.ajkd.2005.07.044; Genovesi S, 2008, AM J KIDNEY DIS, V51, P255, DOI 10.1053/j.ajkd.2007.10.034; Genovesi S, 2014, J NEPHROL, V27, P187, DOI 10.1007/s40620-013-0030-3; Gomez Alwyn T, 2015, Can J Kidney Health Dis, V2, P34, DOI 10.1186/s40697-015-0068-3; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; Holden RM, 2008, CLIN J AM SOC NEPHRO, V3, P105, DOI 10.2215/CJN.01810407; INNES A, 1992, NEPHROL DIAL TRANSPL, V7, P467; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kaw D, 2006, SEMIN DIALYSIS, V19, P317, DOI 10.1111/j.1525-139X.2006.00179.x; KHAN IH, 1995, AM J KIDNEY DIS, V25, P276, DOI 10.1016/0272-6386(95)90009-8; Limdi NA, 2009, J AM SOC NEPHROL, V20, P912, DOI 10.1681/ASN.2008070802; Lip GYH, 2010, STROKE, V41, P2731, DOI 10.1161/STROKEAHA.110.590257; Miskulin DC, 2003, AM J KIDNEY DIS, V41, P149, DOI 10.1053/ajkd.2003.50034; Myers OB, 2010, J AM SOC NEPHROL, V21, P1970, DOI 10.1681/ASN.2010010125; Ng YY, 2013, NEPHROL DIAL TRANSPL, V28, P1005, DOI 10.1093/ndt/gfs512; Perini AP, 2014, EUROPACE, V16, P71, DOI 10.1093/europace/eut190; Puymirat E, 2012, JAMA-J AM MED ASSOC, V308, P998, DOI 10.1001/2012.jama.11348; Rattanasompattikul M, 2012, INT UROL NEPHROL, V44, P1813, DOI 10.1007/s11255-011-0085-9; Ruwald MH, 2013, CLIN CARDIOL, V36, P262, DOI 10.1002/clc.22102; Shafi T, 2010, AM J KIDNEY DIS, V56, P348, DOI 10.1053/j.ajkd.2010.03.020; Soucie JM, 1996, J AM SOC NEPHROL, V7, P2169; van Manen JG, 2007, NEPHROL DIAL TRANSPL, V22, P187, DOI 10.1093/ndt/gfl502; Wakasugi M, 2014, CLIN EXP NEPHROL, V18, P662, DOI 10.1007/s10157-013-0885-6; Wang YF, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/138653; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; Wu SC, 2004, TAIWAN J PUBLIC HLTH, V23, P419; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406; Zavascki AP, 2007, J CLIN EPIDEMIOL, V60, P867, DOI 10.1016/j.jclinepi.2006.11.004; Zhang Y, 2010, JAMA-J AM MED ASSOC, V304, P41, DOI 10.1001/jama.2010.889	42	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2016	11	5							e0154627	10.1371/journal.pone.0154627	http://dx.doi.org/10.1371/journal.pone.0154627			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KV	27148867	gold, Green Published, Green Submitted			2023-01-03	WOS:000375676800043
J	Yang, W; Bai, YB; Xiong, Y; Zhang, J; Chen, SK; Zheng, XJ; Meng, XB; Li, LY; Wang, J; Xu, CG; Yan, CS; Wang, LJ; Chang, CCY; Chang, TY; Zhang, T; Zhou, PH; Song, BL; Liu, WL; Sun, SC; Liu, XL; Li, BL; Xu, CQ				Yang, Wei; Bai, Yibing; Xiong, Ying; Zhang, Jin; Chen, Shuokai; Zheng, Xiaojun; Meng, Xiangbo; Li, Lunyi; Wang, Jing; Xu, Chenguang; Yan, Chengsong; Wang, Lijuan; Chang, Catharine C. Y.; Chang, Ta-Yuan; Zhang, Ti; Zhou, Penghui; Song, Bao-Liang; Liu, Wanli; Sun, Shao-Cong; Liu, Xiaolong; Li, Bo-liang; Xu, Chenqi			Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism	NATURE			English	Article							THYMOCYTE POSITIVE SELECTION; CANCER-IMMUNOTHERAPY; ACYL-COENZYME; IMMUNOLOGICAL SYNAPSE; IMMUNE MODULATION; MEMBRANE-BINDING; ACAT INHIBITORS; RECEPTOR; ACTIVATION; DOMAIN	CD8(+) T cells have a central role in antitumour immunity, but their activity is suppressed in the tumour microenvironment(1-4). Reactivating the cytotoxicity of CD8(+) T cells is of great clinical interest in cancer immunotherapy. Here we report a new mechanism by which the antitumour response of mouse CD8(+) T cells can be potentiated by modulating cholesterol metabolism. Inhibiting cholesterol esterification in T cells by genetic ablation or pharmacological inhibition of ACAT1, a key cholesterol esterification enzyme(5), led to potentiated effector function and enhanced proliferation of CD8(+) but not CD4(+) T cells. This is due to the increase in the plasma membrane cholesterol level of CD8(+) T cells, which causes enhanced T-cell receptor clustering and signalling as well as more efficient formation of the immunological synapse. ACAT1-deficient CD8(+) T cells were better than wildtype CD8(+) T cells at controlling melanoma growth and metastasis in mice. We used the ACAT inhibitor avasimibe, which was previously tested in clinical trials for treating atherosclerosis and showed a good human safety profile(6,7), to treat melanoma in mice and observed a good antitumour effect. A combined therapy of avasimibe plus an anti-PD-1 antibody showed better efficacy than monotherapies in controlling tumour progression. ACAT1, an established target for atherosclerosis, is therefore also a potential target for cancer immunotherapy.	[Yang, Wei; Bai, Yibing; Zhang, Jin; Chen, Shuokai; Meng, Xiangbo; Li, Lunyi; Yan, Chengsong; Xu, Chenqi] Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol,Natl Ctr Prot Sci Shanghai, Shanghai Sci Res Ctr,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; [Xiong, Ying; Wang, Lijuan; Li, Bo-liang] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Ctr Excellence Mol Cell Sci, State Key Lab Mol Biol,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; [Zheng, Xiaojun] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China; [Wang, Jing; Xu, Chenguang; Liu, Wanli] Tsinghua Univ, Collaborat Innovat Ctr Infect Dis, Sch Life Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China; [Chang, Catharine C. Y.; Chang, Ta-Yuan] Geisel Sch Med Dartmouth, Dept Biochem, Hanover, NH USA; [Zhang, Ti] Second Mil Med Univ, ChangZheng Hosp, Rheumatol & Immunol Dept, Shanghai 200433, Peoples R China; [Zhou, Penghui] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Song, Bao-Liang] Wuhan Univ, Coll Life Sci, Wuhan 430072, Hubei Province, Peoples R China; [Sun, Shao-Cong] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; [Liu, Xiaolong] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Ctr Excellence Mol Cell Sci, State Key Lab Cell Biol,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; [Xu, Chenqi] ShanghaiTech Univ, Sch Life Sci & Technol, 100 Haike Rd, Shanghai 201210, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Tsinghua University; Dartmouth College; Naval Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Wuhan University; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; ShanghaiTech University	Xu, CQ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol,Natl Ctr Prot Sci Shanghai, Shanghai Sci Res Ctr,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.; Li, BL (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Ctr Excellence Mol Cell Sci, State Key Lab Mol Biol,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.; Xu, CQ (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, 100 Haike Rd, Shanghai 201210, Peoples R China.	blli@sibcb.ac.cn; cqxu@sibcb.ac.cn	liu, wanli/H-5690-2011	liu, wanli/0000-0003-2624-6802; Xu, Chenqi/0000-0002-4968-6782; Song, Bao-Liang/0000-0002-6397-5935; Yang, Wei/0000-0001-9438-7215; li, bo liang/0000-0002-7123-5638; Wang, Jing/0000-0003-1140-6690; Bai, Yibing/0000-0002-2944-5367	NSFC [31370860, 31425009, 31530022, 31271377, 31400745]; CAS [XDB08020100, KSCX2-EW-J-11]; China Postdoctoral Science Foundation [2014M561533, 2014T70440]; NIH [HL 60306]; MOST [2011CB910901, 2012CB910804]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER	NSFC(National Natural Science Foundation of China (NSFC)); CAS(Chinese Academy of Sciences); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MOST; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Q. Leng for providing L. monocytogenes, F.-J. Nan for providing K604, and Y. Jiang for some preliminary experiments. We thank H. Gu and D. Li for careful reading of the manuscript. Imaging work was performed at the National Center for Protein Science Shanghai. Chenqi Xu is funded by MOST (2011CB910901 and 2012CB910804), NSFC grants (31370860, 31425009 and 31530022), and CAS grants (Strategic Priority Research Program XDB08020100; KSCX2-EW-J-11). B.L. is funded by MOST (2011CB910901) and NSFC grant 31271377. W.Y. is funded by NSFC grant (31400745) and China Postdoctoral Science Foundation (2014M561533 and 2014T70440). T.-Y.C. and C.C.Y.C. are funded by NIH grant HL 60306.	Beal AM, 2009, IMMUNITY, V31, P632, DOI 10.1016/j.immuni.2009.09.004; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; Cao YH, 2011, EMBO J, V30, P2083, DOI 10.1038/emboj.2011.116; Cenedella RJ, 2009, LIPIDS, V44, P477, DOI 10.1007/s11745-009-3305-7; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Das A, 2013, P NATL ACAD SCI USA, V110, P10580, DOI 10.1073/pnas.1309273110; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Gagnon E, 2012, J EXP MED, V209, P2423, DOI 10.1084/jem.20120790; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Guo ZY, 2005, J BIOL CHEM, V280, P37814, DOI 10.1074/jbc.M508384200; Huttunen HJ, 2008, NEURODEGENER DIS, V5, P212, DOI 10.1159/000113705; Ikenoya M, 2007, ATHEROSCLEROSIS, V191, P290, DOI 10.1016/j.atherosclerosis.2006.05.048; Jenkins MR, 2009, IMMUNITY, V31, P621, DOI 10.1016/j.immuni.2009.08.024; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Leon C, 2005, PHARM RES-DORDR, V22, P1578, DOI 10.1007/s11095-005-6306-0; Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832; Liu WL, 2010, J IMMUNOL, V184, P1977, DOI 10.4049/jimmunol.0902334; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Molnar E, 2012, J BIOL CHEM, V287, P42664, DOI 10.1074/jbc.M112.386045; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Pal P, 2013, MINI-REV MED CHEM, V13, P1195, DOI 10.2174/1389557511313080007; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rossy J, 2013, NAT IMMUNOL, V14, P82, DOI 10.1038/ni.2488; Santori FR, 2002, IMMUNITY, V17, P131, DOI 10.1016/S1074-7613(02)00361-8; Schamel WWA, 2005, J EXP MED, V202, P493, DOI 10.1084/jem.20042155; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi XS, 2013, NATURE, V493, P111, DOI 10.1038/nature11699; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Xu CQ, 2008, CELL, V135, P702, DOI 10.1016/j.cell.2008.09.044; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877; Zech T, 2009, EMBO J, V28, P466, DOI 10.1038/emboj.2009.6	38	366	386	31	349	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2016	531	7596					651	+		10.1038/nature17412	http://dx.doi.org/10.1038/nature17412			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH8EX	26982734	Green Accepted			2023-01-03	WOS:000373027400041
J	Ortega, R; Canelli, RJ; Quillen, K; Mustafa, W; Kotova, F				Ortega, Rafael; Canelli, Robert J.; Quillen, Karen; Mustafa, Wissam; Kotova, Faina			Transfusion of Red Cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ortega, Rafael; Canelli, Robert J.; Mustafa, Wissam; Kotova, Faina] Boston Med Ctr, Dept Anesthesiol, Boston, MA USA; [Quillen, Karen] Boston Med Ctr, Dept Pathol & Lab Med, Boston, MA USA	Boston Medical Center; Boston Medical Center	Ortega, R (corresponding author), Boston Univ, Med Ctr, Dept Anesthesiol, 88 E Newton St, Boston, MA 02118 USA.	rafael.ortega@bmc.org							0	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2016	374	11							e12	10.1056/NEJMvcm1504413	http://dx.doi.org/10.1056/NEJMvcm1504413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG4TR	26981950				2023-01-03	WOS:000372066100011
J	Bryce, A; Hay, AD; Lane, IF; Thornton, HV; Wootton, M; Costelloe, C				Bryce, Ashley; Hay, Alastair D.; Lane, Isabel F.; Thornton, Hannah V.; Wootton, Mandy; Costelloe, Ceire			Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTIMICROBIAL RESISTANCE; MOLECULAR EPIDEMIOLOGY; OUTPATIENT CHILDREN; RISK-FACTORS; UROPATHOGENS; PATTERNS; SUSCEPTIBILITY; PATHOGENS; SENSITIVITY; AGE	OBJECTIVES To systematically review studies investigating the prevalence of antibiotic resistance in urinary tract infections caused by Escherichia coli in children and, when appropriate, to meta-analyse the relation between previous antibiotics prescribed in primary care and resistance. DESIGN AND DATA ANALYSIS Systematic review and meta-analysis. Pooled percentage prevalence of resistance to the most commonly used antibiotics in children in primary care, stratified by the OECD (Organisation for Economic Co-operation and Development) status of the study country. Random effects meta-analysis was used to quantify the association between previous exposure to antibiotics in primary care and resistance. DATA SOURCES Observational and experimental studies identified through Medline, Embase, Cochrane, and ISI Web of Knowledge databases, searched for articles published up to October 2015. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Studies were eligible if they investigated and reported resistance in community acquired urinary tract infection in children and young people aged 0-17. Electronic searches with MeSH terms and text words identified 3115 papers. Two independent reviewers assessed study quality and performed data extraction. RESULTS 58 observational studies investigated 77 783 E coli isolates in urine. In studies from OECD countries, the pooled prevalence of resistance was 53.4% (95% confidence interval 46.0% to 60.8%) for ampicillin, 23.6% (13.9% to 32.3%) for trimethoprim, 8.2% (7.9% to 9.6%) for co-amoxiclav, and 2.1% (0.8 to 4.4%) for ciprofloxacin; nitrofurantoin was the lowest at 1.3% (0.8% to 1.7%). Resistance in studies in countries outside the OECD was significantly higher: 79.8% (73.0% to 87.7%) for ampicillin, 60.3% (40.9% to 79.0%) for co-amoxiclav, 26.8% (11.1% to 43.0%) for ciprofloxacin, and 17.0% (9.8% to 24.2%) for nitrofurantoin. There was evidence that bacterial isolates from the urinary tract from individual children who had received previous prescriptions for antibiotics in primary care were more likely to be resistant to antibiotics, and this increased risk could persist for up to six months (odds ratio 13.23, 95% confidence interval 7.84 to 22.31). CONCLUSIONS Prevalence of resistance to commonly prescribed antibiotics in primary care in children with urinary tract infections caused by E coli is high, particularly in countries outside the OECD, where one possible explanation is the availability of antibiotics over the counter. This could render some antibiotics ineffective as first line treatments for urinary tract infection. Routine use of antibiotics in primary care contributes to antimicrobial resistance in children, which can persist for up to six months after treatment.	[Bryce, Ashley; Hay, Alastair D.; Lane, Isabel F.; Thornton, Hannah V.] Univ Bristol, Sch Social & Community Med, NIHR Sch Primary Care Res, Ctr Acad Primary Care, Bristol BS8 2PS, Avon, England; [Wootton, Mandy] Univ Wales Hosp, Publ Hlth Wales Microbiol Cardiff, Specialist Antimicrobial Chemotherapy Unit, Cardiff CF14 4XW, S Glam, Wales; [Costelloe, Ceire] Univ London Imperial Coll Sci Technol & Med, NIHR Hlth Protect Res Unit Healthcare Associated, London W12 0NN, England	University of Bristol; Cardiff University; Imperial College London	Bryce, A (corresponding author), Univ Bristol, Sch Social & Community Med, NIHR Sch Primary Care Res, Ctr Acad Primary Care, Bristol BS8 2PS, Avon, England.	ashley.bryce@bristol.ac.uk	Hay, Alastair/L-1818-2019	Hammond, Ashley/0000-0002-6657-1514; Hay, Alastair/0000-0003-3012-375X; Thornton, Hannah/0000-0003-0899-4102	National Institute for Health Research School for Primary Care Research (NIHR-SPCR); NIHR [NIHR RP-R2-12-012]; National Institute for Health Research [CDF-2009-02-10, NIHR-RP-02-12-012, SPCR-089, CDF-2016-09-015, SPCR-054] Funding Source: researchfish	National Institute for Health Research School for Primary Care Research (NIHR-SPCR); NIHR(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	AB was supported to conduct this study through a doctoral fellowship from the National Institute for Health Research School for Primary Care Research (NIHR-SPCR). ADH is supported by a NIHR research professorship (NIHR RP-R2-12-012). The views expressed in this publication are those of the authors and not necessarily those of the NIHR. The funder had no role in the study design; data collection, data analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Adjei O, 2004, INT J ANTIMICROB AG, V24, pS32, DOI 10.1016/j.ijantimicag.2004.02.007; Afsharpaiman S., 2012, J COMPREHENSIVE PEDI, V3, P16, DOI [10.5812/jcp.7078, DOI 10.5812/JCP.7078]; Akinyandenu O, 2014, J SCI INNOV RES, V3, P251; Al-Mardeni RI, 2009, SAUDI J KIDNEY DIS T, V20, P135; Al-Saif MA, 2012, SAUDI MED J, V33, P565; Allen UD, 1999, CAN MED ASSOC J, V160, P1436; AlMugeiren MM, 1996, CLIN THER, V18, P295, DOI 10.1016/S0149-2918(96)80010-5; Alshara M., 2011, Jordan Medical Journal, V45, P44; Anatoliotaki M, 2007, SCAND J INFECT DIS, V39, P671, DOI 10.1080/00365540701199899; [Anonymous], 2009, SPECIAL EUROBAROMETE, V338; [Anonymous], 2014, SUSC; ASHKENAZI S, 1991, PEDIATR INFECT DIS J, V10, P742, DOI 10.1097/00006454-199110000-00005; Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104; Bean David C, 2008, Ann Clin Microbiol Antimicrob, V7, P13, DOI 10.1186/1476-0711-7-13; Bin Abdulhak AA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-538; Borsari AG, 2008, CLIN THER, V30, P2090, DOI 10.1016/j.clinthera.2008.11.002; Brown B J, 2003, West Afr J Med, V22, P110; Bryce A, 2011, J INFECTION, V63, pE61, DOI 10.1016/j.jinf.2011.04.112; Burman WJ, 2003, AM J MED, V115, P358, DOI 10.1016/S0002-9343(03)00372-3; Car J, 2006, BMJ-BRIT MED J, V332, P94, DOI 10.1136/bmj.332.7533.94; Caracciolo Alessandra, 2011, Ital J Pediatr, V37, P3, DOI 10.1186/1824-7288-37-3; Centre for Disease Dynamics Economics and Policy (CDDEP), 2010, RES MAP; Chen CJ, 2014, CLIN MICROBIOL INFEC, V20, P605, DOI 10.1111/1469-0691.12705; Cizman M, 2004, INT J ANTIMICROB AG, V24, P199, DOI 10.1016/j.ijantimicag.2004.03.016; Conway PH, 2007, JAMA-J AM MED ASSOC, V298, P179, DOI 10.1001/jama.298.2.179; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Cullen IM, 2013, IRISH J MED SCI, V182, P81, DOI 10.1007/s11845-012-0834-5; Donkor ES, 2012, INT J ENV RES PUB HE, V9, P3519, DOI 10.3390/ijerph9103519; Duffy MA, 2013, BRIT J GEN PRACT, V63, pE238, DOI 10.3399/bjgp13X665198; Edlin RS, 2013, J UROLOGY, V190, P222, DOI 10.1016/j.juro.2013.01.069; European Centre for Disease Prevention and Control network, 2014, ANT RES INT DAT EARS; Falagas ME, 2008, MED SCI MONITOR, V14, pCR75; Farrell DJ, 2003, J INFECTION, V46, P94, DOI 10.1053/jinf.2002.1091; Farshad S, 2010, IRAN RED CRESCENT ME, V12, P33; Farshad S, 2012, ARCH IRAN MED, V15, P312, DOI 012155/AIM.0013; Farshad S, 2011, AFR J MICROBIOL RES, V5, P4476, DOI 10.5897/AJMR11.285; Fredrick F., 2013, African Journal of Microbiology Research, V7, P1029; Fritzsche M, 2005, EUR J CLIN MICROBIOL, V24, P233, DOI 10.1007/s10096-005-1301-2; Gallegos J, 2013, REV CHIL INFECTOL, V30, P474, DOI 10.4067/S0716-10182013000500002; Gaspari RJ, 2005, INT J ANTIMICROB AG, V26, P267, DOI 10.1016/j.ijantimicag.2005.07.009; Gaspari RJ, 2006, MICROB DRUG RESIST, V12, P126, DOI 10.1089/mdr.2006.12.126; Goldraich NP, 2002, PEDIATR NEPHROL, V17, P173, DOI 10.1007/s00467-001-0808-8; GRUNEBERG RN, 1976, J MED MICROBIOL, V9, P233, DOI 10.1099/00222615-9-2-233; Guner SN, 2012, TURK PEDIATR ARSIVI, V47, P107, DOI 10.4274/tpa.721; Guneysel O, 2009, J EMERG MED, V36, P338, DOI 10.1016/j.jemermed.2007.08.068; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hawkey PM, 2009, J ANTIMICROB CHEMOTH, V64, P3, DOI 10.1093/jac/dkp256; HELIN I, 1986, SCAND J INFECT DIS, V18, P447, DOI 10.3109/00365548609032362; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; Holten KB, 2000, AM FAM PHYSICIAN, V62, P611; Ipek IO, 2011, SE ASIAN J TROP MED, V42, P355; Ismaili K, 2011, PEDIATR INFECT DIS J, V30, P371, DOI 10.1097/INF.0b013e318204dcf3; Karlowsky JA, 2002, ANTIMICROB AGENTS CH, V46, P2540, DOI 10.1128/AAC.46.8.2540-2545.2002; Ladhani S, 2003, ARCH DIS CHILD, V88, P444, DOI 10.1136/adc.88.5.444; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Majeed A, 1999, BRIT J GEN PRACT, V49, P735; Mandal J, 2012, INDIAN J MED RES, V136, P842; Mantadakis E, 2011, INT UROL NEPHROL, V43, P549, DOI 10.1007/s11255-010-9768-x; McGregor JC, 2014, J PEDIATR NURS, V29, P152, DOI 10.1016/j.pedn.2013.09.001; McLoughlin TG, 2003, ACAD EMERG MED, V10, P347, DOI 10.1111/j.1553-2712.2003.tb01347.x; Guidoni EBM, 2008, BRAZ J INFECT DIS, V12, P321, DOI 10.1590/S1413-86702008000400013; Mehr SS, 2004, J PAEDIATR CHILD H, V40, P48, DOI 10.1111/j.1440-1754.2004.00290.x; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Muoneke VU, 2012, ANN MED HEALTH SCI R, V2, P29, DOI 10.4103/2141-9248.96933; Narchi H, 2008, J CHEMOTHERAPY, V20, P472, DOI 10.1179/joc.2008.20.4.472; Paschke AA, 2010, PEDIATRICS, V125, P664, DOI 10.1542/peds.2009-1527; Planta MB, 2007, J AM BOARD FAM MED, V20, P533, DOI 10.3122/jabfm.2007.06.070019; Pourakbari B, 2012, BRAZ J MICROBIOL, V43, P766, DOI 10.1590/S1517-83822012000200041; Prelog M, 2008, PEDIATR NEPHROL, V23, P597, DOI 10.1007/s00467-007-0701-1; Price E, 2010, J ANTIMICROB CHEMOTH, V65, P836, DOI 10.1093/jac/dkq045; Rai G K, 2008, Nepal Med Coll J, V10, P86; Ready D, 2004, ANTIMICROB AGENTS CH, V48, P2883, DOI 10.1128/AAC.48.8.2883-2887.2004; Sanchez GV, 2014, J ANTIMICROB CHEMOTH, V69, P3259, DOI 10.1093/jac/dku282; Sedighi I, 2014, IRAN J MICROBIOL, V6, P387; Senel S, 2010, MED PRIN PRACT, V19, P359, DOI 10.1159/000316373; Sharan R, 2013, INDIAN PEDIATR, V50, P707, DOI 10.1007/s13312-013-0195-9; Sharef SW, 2015, J INFECT PUBLIC HEAL, V8, P458, DOI 10.1016/j.jiph.2015.01.005; Sharma A, 2011, Nepal Med Coll J, V13, P24; Sommet A, 2004, J ANTIMICROB CHEMOTH, V54, P524, DOI 10.1093/jac/dkh342; Swerkersson S, 2014, EUR J PEDIATR, V173, P1075, DOI 10.1007/s00431-014-2289-3; Topaloglu R, 2010, PEDIATR NEPHROL, V25, P919, DOI 10.1007/s00467-009-1431-3; Turgut F, 2008, INT UROL NEPHROL, V40, P453, DOI 10.1007/s11255-008-9445-5; Turnidge J, 2005, LANCET, V365, P548; Uwaezuoke J. C., 2006, Journal of Applied Sciences and Environmental Management, V10, P103; Valavi E, 2013, JUNDISHAPUR J MICROB, V6, DOI 10.5812/jjm.4958; Wachter DA, 1999, TROP MED INT HEALTH, V4, P782, DOI 10.1046/j.1365-3156.1999.00476.x; WHO, 2014, GLOBAL REPORT SURVEI, DOI 10.1007/s13312-014-0374-3; World Health Organization (WHO), 2015, ANT RES DRAFT GLOB A; Wu JH, 2012, PEDIATR NEONATOL, V53, P283, DOI 10.1016/j.pedneo.2012.08.003; Yildirim M, 2010, TURK KLIN TIP BILIM, V30, P533, DOI 10.5336/medsci.2008-9024; Yolbas I, 2013, EUR REV MED PHARMACO, V17, P971; Zhanel GG, 2005, INT J ANTIMICROB AG, V26, P380, DOI 10.1016/j.ijantimicag.2005.08.003	94	85	93	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2016	352								i939	10.1136/bmj.i939	http://dx.doi.org/10.1136/bmj.i939			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH1ZT	26980184	Green Published, hybrid			2023-01-03	WOS:000372584400029
J	Pisesky, A; Benchimol, EI; Wong, CA; Hui, C; Crowe, M; Belair, MA; Pojsupap, S; Karnauchow, T; O'Hearn, K; Yasseen, AS; McNally, JD				Pisesky, Andrea; Benchimol, Eric I.; Wong, Coralie A.; Hui, Charles; Crowe, Megan; Belair, Marc-Andre; Pojsupap, Supichaya; Karnauchow, Tim; O'Hearn, Katie; Yasseen, Abdool S., III; McNally, James D.			Incidence of Hospitalization for Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A Population-Based Study Using Validated Health Administrative Data	PLOS ONE			English	Article							BRONCHIOLITIS HOSPITALIZATIONS; YOUNG-CHILDREN; UNITED-STATES; DISEASE; BURDEN; EPIDEMIOLOGY; INFANTS; CODES	Importance RSV is a common illness among young children that causes significant morbidity and health care costs. Objective Routinely collected health administrative data can be used to track disease incidence, explore risk factors and conduct health services research. Due to potential for misclassification bias, the accuracy of data-elements should be validated prior to use. The objectives of this study were to validate an algorithm to accurately identify pediatric cases of hospitalized respiratory syncytial virus (RSV) from within Ontario's health administrative data, estimate annual incidence of hospitalization due to RSV and report the prevalence of major risk factors within hospitalized patients. Study Design and Setting A retrospective chart review was performed to establish a reference-standard cohort of children from the Ottawa region admitted to the Children's Hospital of Eastern Ontario (CHEO) for RSV-related disease in 2010 and 2011. Chart review data was linked to Ontario's administrative data and used to evaluate the diagnostic accuracy of algorithms of RSV-related ICD-10 codes within provincial hospitalization and emergency department databases. Age-and sex-standardized incidence was calculated over time, with trends in incidence assessed using Poisson regression. Results From a total of 1411 admissions, chart review identified 327 children hospitalized for laboratory confirmed RSV-related disease. Following linkage to administrative data and restriction to first admissions, there were 289 RSV patients in the reference-standard cohort. The best algorithm, based on hospitalization data, resulted in sensitivity 97.9%(95% CI: 95.5-99.2%), specificity 99.6%(95% CI: 98.2-99.8%), PPV 96.9% (95% CI: 94.2-98.6%), NPV 99.4% (95% CI: 99.4-99.9%). Incidence of hospitalized RSV in Ontario from 2005-2012 was 10.2 per 1000 children under 1 year and 4.8 per 1000 children aged 1 to 3 years. During the surveillance period, there was no identifiable increasing or decreasing linear trend in the incidence of hospitalized RSV, hospital length of stay and PICU admission rates. Among the Ontario RSV cohort, 16.3% had one or more major risk factors, with a decreasing trend observed over time. Conclusion Children hospitalized for RSV-related disease can be accurately identified within population-based health administrative data. RSV is a major public health concern and incidence has not changed over time, suggesting a lack of progress in prevention.	[Pisesky, Andrea; Benchimol, Eric I.; Hui, Charles; Pojsupap, Supichaya; Karnauchow, Tim; McNally, James D.] Univ Ottawa, Dept Pediat, Childrens Hosp Eastern Ontario, Ottawa, ON K1N 6N5, Canada; [Benchimol, Eric I.; O'Hearn, Katie; Yasseen, Abdool S., III; McNally, James D.] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada; [Benchimol, Eric I.; Crowe, Megan] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada; [Benchimol, Eric I.; Wong, Coralie A.; Belair, Marc-Andre] Inst Clin Evaluat Sci ICES uOttawa, Ottawa, ON, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	McNally, JD (corresponding author), Univ Ottawa, Dept Pediat, Childrens Hosp Eastern Ontario, Ottawa, ON K1N 6N5, Canada.; McNally, JD (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.	dmcnally@cheo.on.ca	Benchimol, Eric Ian/A-7711-2010	Benchimol, Eric Ian/0000-0001-8855-3598; Yasseen, Abdool S./0000-0001-9814-9249	Institute for Clinical Evaluative Sciences (ICES Ottawa); CHEO RI Cost centre [9715]	Institute for Clinical Evaluative Sciences (ICES Ottawa); CHEO RI Cost centre	Financial support was provided by a grant awarded through the Institute for Clinical Evaluative Sciences (ICES Ottawa) called the ICES Research Grant. This grant was received by JM and EIB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The CHEO RI Cost centre number was 9715 (no other grant number provided). URL: http://www.ices.on.ca/Research/Grants?year=2014&page=6.	[Anonymous], 2003, PEDIATR INFECT DIS J; Benchimol EI, 2014, J CLIN EPIDEMIOL, V67, P887, DOI 10.1016/j.jclinepi.2014.02.019; Benchimol EI, 2011, J CLIN EPIDEMIOL, V64, P821, DOI 10.1016/j.jclinepi.2010.10.006; Ducharme R, 2013, J PEDIATR-US, V163, P1073, DOI 10.1016/j.jpeds.2013.05.034; Fisher WH, 2010, PSYCHIAT SERV, V61, P546, DOI 10.1176/ps.2010.61.6.546; Gil-Prieto R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000831; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48; Hsu VP, 2005, PEDIATRICS, V115, P78, DOI 10.1542/peds.2004-0860; Law BJ, 2004, PEDIATR INFECT DIS J, V23, P806, DOI 10.1097/01.inf.0000137568.71589.bd; Luo G, 2014, INT J MED INFORM, V83, P691, DOI 10.1016/j.ijmedinf.2014.07.005; McGuiness CB, 2014, PEDIATR INFECT DIS J, V33, P589, DOI [10.1097/INF.0000000000000257, DOI 10.1097/INF.0000000000000257]; Moth G, 2007, ACTA PAEDIATR, V96, P1470, DOI 10.1111/j.1651-2227.2007.00460.x; Murray J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089186; Nair H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S30; Paes BA, 2011, CAN RESPIR J, V18, pE10, DOI 10.1155/2011/493056; Pelletier AJ, 2006, PEDIATRICS, V118, P2418, DOI 10.1542/peds.2006-1193; Ranmuthugala G, 2011, COMMUN DIS INTELL, V35, P177; Schwartz KL, 2015, HUM VACC IMMUNOTHER, V11, P1840, DOI 10.1080/21645515.2015.1043499; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Shiff NJ, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-236; Simoes EAF, 2003, PEDIATR INFECT DIS J, V22, pS13, DOI 10.1097/00006454-200302001-00003; Stang P, 2001, ARCH PEDIAT ADOL MED, V155, P95, DOI 10.1001/archpedi.155.1.95; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; To T, 2006, PEDIAT ALLERG IMM-UK, V17, P69, DOI 10.1111/j.1399-3038.2005.00346.x; Welke KF, 2008, CARDIOL YOUNG, V18, P137, DOI 10.1017/S1047951108002837; Williams CL, 2013, VACCINE, V31, pK28, DOI 10.1016/j.vaccine.2013.03.078; Williams DJ, 2013, JAMA PEDIATR, V167, P851, DOI 10.1001/jamapediatrics.2013.186	30	38	38	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150416	10.1371/journal.pone.0150416	http://dx.doi.org/10.1371/journal.pone.0150416			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26958849	Green Submitted, gold, Green Published			2023-01-03	WOS:000371992300050
J	Worrell, CM; Wiegand, RE; Davis, SM; Odero, KO; Blackstock, A; Cuellar, VM; Njenga, SM; Montgomery, JM; Roy, SL; Fox, LM				Worrell, Caitlin M.; Wiegand, Ryan E.; Davis, Stephanie M.; Odero, Kennedy O.; Blackstock, Anna; Cuellar, Victoria M.; Njenga, Sammy M.; Montgomery, Joel M.; Roy, Sharon L.; Fox, LeAnne M.			A Cross-Sectional Study of Water, Sanitation, and Hygiene-Related Risk Factors for Soil-Transmitted Helminth Infection in Urban School- and Preschool-Aged Children in Kibera, Nairobi	PLOS ONE			English	Article							DRINKING-WATER; HEALTH; SLUM; PREVALENCE; HOOKWORM; DIARRHEA; CONTAMINATION; EPIDEMIOLOGY; REINFECTION; COINFECTION	Soil-transmitted helminth (STH) infections affect persons living in areas with poor water, sanitation, and hygiene (WASH). Preschool-aged children (PSAC) and school-aged children (SAC) are disproportionately affected by STH infections. We aimed to identify WASH factors associated with STH infection among PSAC and SAC in Kibera, Kenya. In 2012, households containing a PSAC or SAC were randomly selected from those enrolled in the International Emerging Infections Program, a population-based surveillance system. We administered a household questionnaire, conducted environmental assessments for WASH, and tested three stools from each child for STH eggs using the Kato-Katz method. WASH factors were evaluated for associations with STH infection using univariable and multivariable Poisson regression. Any-STH prevalence was 40.8% among 201 PSAC and 40.0% among 475 SAC enrolled. Using the Joint Monitoring Programme water and sanitation classifications, 1.5% of households reported piped water on premises versus 98.5% another improved water source; 1.3% reported improved sanitation facilities, while 81.7% used shared sanitation facilities, 13.9% had unimproved facilities, and 3.1% reported no facilities (open defecation). On univariable analysis, STH infection was significantly associated with a household toilet located off-premises (prevalence ratio (PR) = 1.33; p = 0.047), while always treating water (PR = 0.81; p = 0.04), covering drinking water containers (PR = 0.75; p = 0.02), using clean towels during hand drying (PR = 0.58; p < 0.01), having finished household floor material (PR = 0.76; p < 0.01), having electricity (PR = 0.70; p < 0.01), and increasing household elevation in 10-meter increments (PR = 0.89; p < 0.01) were protective against STH infection. On multivariable analysis, usually versus always treating water was associated with increased STH prevalence (adjusted prevalence ratio (aPR) = 1.52; p < 0.01), while having finished household floor material (aPR = 0.76; p = 0.03), reported child deworming in the last year (aPR = 0.76; p < 0.01), and 10-meter household elevation increases (aPR = 0.89; p < 0.01) were protective against infection. The intersection between WASH and STH infection is complex; site-specific WASH interventions should be considered to sustain the gains made by deworming activities.	[Worrell, Caitlin M.; Wiegand, Ryan E.; Davis, Stephanie M.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA; [Odero, Kennedy O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya; [Blackstock, Anna; Cuellar, Victoria M.; Roy, Sharon L.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA; [Njenga, Sammy M.] Kenya Govt Med Res Ctr, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya; [Montgomery, Joel M.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Nairobi, Kenya	Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute	Worrell, CM (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.	cworrell@cdc.gov		Worrell, Caitlin/0000-0003-0229-6565; Njenga, Sammy/0000-0001-6309-476X; Wiegand, Ryan/0000-0002-9486-1850	U.S. Agency for International Development (USAID); Centers for Disease Control and Prevention [OG11-12021]	U.S. Agency for International Development (USAID)(United States Agency for International Development (USAID)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding for this study was obtained from the U.S. Agency for International Development (USAID) though an inter-agency agreement with the Centers for Disease Control and Prevention (No. OG11-12021). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akullian A, 2015, ENV TRANSMISSION TYP; Albonico M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000126; [Anonymous], 2010, INS IND WOM EXP SLUM; [Anonymous], 2004, J STAT SOFTW, DOI DOI 10.18637/JSS.V009.I05; Arnold BF, 2007, AM J TROP MED HYG, V76, P354, DOI 10.4269/ajtmh.2007.76.354; Balen J, 2011, INT J PARASITOL, V41, P1165, DOI 10.1016/j.ijpara.2011.07.006; Basualdo Juan A., 2007, Rev. Inst. Med. trop. S. Paulo, V49, P251, DOI 10.1590/S0036-46652007000400011; Breiman RF, 2011, J HEALTH POPUL NUTR, V29, P123; Brocklehurst C, 2005, ROGUES NO MORE WATER; Brooker S, 1999, T ROY SOC TROP MED H, V93, P240, DOI 10.1016/S0035-9203(99)90007-X; Centers for Disease Control and Prevention, 2013, SHOW ME SCI WHY WASH; Chammartin F, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-152; Clasen T, 2007, BMJ-BRIT MED J, V334, P782, DOI 10.1136/bmj.39118.489931.BE; Clemens J, 1996, PEDIATR INFECT DIS J, V15, P1113, DOI 10.1097/00006454-199612000-00012; COATES D, 1987, EPIDEMIOL INFECT, V99, P265, DOI 10.1017/S095026880006773X; Crompton DWT, 2002, ANNU REV NUTR, V22, P35, DOI 10.1146/annurev.nutr.22.120501.134539; Crow B, 2010, WATER INT, V35, P733, DOI 10.1080/02508060.2010.533344; Davis SM, 2014, AM J TROP MED HYG, V91, P1002, DOI 10.4269/ajtmh.14-0060; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Feikin DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016085; Feikin DR, 2010, INT J EPIDEMIOL, V39, P450, DOI 10.1093/ije/dyp374; Fink G, 2014, DEMOGRAPHY, V51, P1175, DOI 10.1007/s13524-014-0302-0; FORRESTER JE, 1990, T ROY SOC TROP MED H, V84, P272, DOI 10.1016/0035-9203(90)90284-L; Freeman MC, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002439; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Furst T, 2012, LANCET INFECT DIS, V12, P210, DOI 10.1016/S1473-3099(11)70294-8; GRYSEELS B, 1985, TROP GEOGR MED, V37, P129; Hall A, 1998, WORLD HLTH ORG; Halpenny CM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002070; HAN AM, 1989, TROP GEOGR MED, V41, P138; Harris JR, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003590; Heinss U., 1998, SOLIDS SEPARATION PO; HENDRICKSON AE, 1964, BRIT J STATIST PSYCH, V17, P65, DOI 10.1111/j.2044-8317.1964.tb00244.x; Huang CR, 2012, MAYO CLIN PROC, V87, P791, DOI 10.1016/j.mayocp.2012.02.019; Jia TW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001621; Jonnalagadda Padmaja R., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P789; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kenya National Bureau of Statistics, 2010, KEN DEM HLTH SURV 20; KHAIRY AEM, 1982, J HYG-CAMBRIDGE, V88, P57, DOI 10.1017/S0022172400069898; Kunii O, 2002, PUBLIC HEALTH, V116, P68, DOI 10.1038/sj.ph.1900828; Luby SP, 2007, TROP MED INT HEALTH, V12, P765, DOI 10.1111/j.1365-3156.2007.01847.x; Magalhaes RJS, 2011, P NATL ACAD SCI USA, V108, P20084, DOI 10.1073/pnas.1106784108; MAHALANABIS D, 1976, AM J CLIN NUTR, V29, P1372, DOI 10.1093/ajcn/29.12.1372; Matheron G., 1963, ECON GEOL, V58, P1246, DOI DOI 10.2113/GSECONGEO.58.8.1246; MINTZ ED, 1995, JAMA-J AM MED ASSOC, V273, P948, DOI 10.1001/jama.273.12.948; Moore SR, 2001, INT J EPIDEMIOL, V30, P1457, DOI 10.1093/ije/30.6.1457; Morel, 2005, UNDERSTANDING SMALL; Mumtaz Shadma, 2009, JPMA Journal of the Pakistan Medical Association, V59, P216; Palit A, 2012, WATER SCI TECHNOL, V66, P299, DOI 10.2166/wst.2012.177; Patrick DR, 1997, EPIDEMIOL INFECT, V119, P319, DOI 10.1017/S0950268897008261; Person B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074370; Pullan RL, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000713; Pullan RL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000352; ROBERTSON LJ, 1992, T ROY SOC TROP MED H, V86, P654, DOI 10.1016/0035-9203(92)90176-D; SPRUNT K, 1973, PEDIATRICS, V52, P264; Stephenson LS, 2000, PARASITOLOGY, V121, pS73, DOI 10.1017/S0031182000006867; Stephenson LS, 2000, PARASITOLOGY, V121, pS23, DOI 10.1017/S0031182000006491; Stoltzfus RJ, 1997, J NUTR, V127, P1099, DOI 10.1093/jn/127.6.1099; Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389; Strunz EC, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001620; Suchdev PS, 2014, AM J TROP MED HYG, V90, P299, DOI 10.4269/ajtmh.13-0560; Taylor JH, 2000, J APPL MICROBIOL, V89, P910, DOI 10.1046/j.1365-2672.2000.01122.x; Todd ECD, 2010, J FOOD PROTECT, V73, P1937, DOI 10.4315/0362-028X-73.10.1937; Tumwebaze IK, 2013, INT J ENVIRON HEAL R, V23, P191, DOI 10.1080/09603123.2012.713095; *UN DEV PROGR, 2006, HUM DEV REP 2006 SCA; United Nations Human Settlement Program, 2003, GLOBAL REPORT HUMAN; United Nations Human Settlements Programme, 2006, STAT WORLDS CIT 2006; Walson JL, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000644; Watkins WE, 1997, PSYCHOL BULL, V121, P171, DOI 10.1037/0033-2909.121.2.171; WHO, 2011, HELMINTH CONTROL IN SCHOOL-AGE CHILDREN: A GUIDE FOR MANAGERS OF CONTROL PROGRAMMES, SECOND EDITION, P1; WHO/UNICEF, 2006, COR QUEST DRINK WAT; World Health Organization, 2012, SOIL TRANSM HELM EL; World Health Organization and United Nations Children's Fund Joint Monitoring Programme for Water Supply and Sanitation (JMP), 2008, PROGR DRINK WAT SAN; Ziegelbauer K, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001162	74	36	36	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2016	11	3							e0150744	10.1371/journal.pone.0150744	http://dx.doi.org/10.1371/journal.pone.0150744			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SL	26950552	Green Published, Green Submitted, gold			2023-01-03	WOS:000371990100056
J	Potter, K; Flicker, L; Page, A; Etherton-Beer, C				Potter, Kathleen; Flicker, Leon; Page, Amy; Etherton-Beer, Christopher			Deprescribing in Frail Older People: A Randomised Controlled Trial	PLOS ONE			English	Article							RESIDENTIAL AGED-CARE; POTENTIALLY INAPPROPRIATE MEDICATIONS; DRUG BURDEN INDEX; HEART-FAILURE; CONSENSUS PANEL; ELDERLY-PEOPLE; UNITED-STATES; POLYPHARMACY; AUSTRALIANS; MEDICINES	Objectives Deprescribing has been proposed as a way to reduce polypharmacy in frail older people. We aimed to reduce the number of medicines consumed by people living in residential aged care facilities (RACF). Secondary objectives were to explore the effect of deprescribing on survival, falls, fractures, hospital admissions, cognitive, physical, and bowel function, quality of life, and sleep. Methods Ninety-five people aged over 65 years living in four RACF in rural mid-west Western Australia were randomised in an open study. The intervention group (n = 47) received a deprescribing intervention, the planned cessation of non-beneficial medicines. The control group (n = 48) received usual care. Participants were monitored for twelve months from randomisation. Primary outcome was change in the mean number of unique regular medicines. All outcomes were assessed at baseline, six, and twelve months. Results Study participants had a mean age of 84.3 +/- 6.9 years and 52% were female. Intervention group participants consumed 9.6 +/- 5.0 and control group participants consumed 9.5 +/- 3.6 unique regular medicines at baseline. Of the 348 medicines targeted for deprescribing (7.4 +/- 3.8 per person, 78% of regular medicines), 207 medicines (4.4 +/- 3.4 per person, 59% of targeted medicines) were successfully discontinued. The mean change in number of regular medicines at 12 months was -1.9 +/- 4.1 in intervention group participants and +0.1 +/- 3.5 in control group participants (estimated difference 2.0 +/- 0.9, 95% CI 0.08, 3.8, p = 0.04). Twelve intervention participants and 19 control participants died within 12 months of randomisation (26% versus 40% mortality, p = 0.16, HR 0.60, 95% CI 0.30 to 1.22) There were no significant differences between groups in other secondary outcomes. The main limitations of this study were the open design and small participant numbers. Conclusions Deprescribing reduced the number of regular medicines consumed by frail older people living in residential care with no significant adverse effects on survival or other clinical outcomes.	[Potter, Kathleen; Flicker, Leon; Page, Amy; Etherton-Beer, Christopher] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Flicker, Leon; Etherton-Beer, Christopher] Royal Perth Hosp, Dept Geriatr Med, Perth, WA 6001, Australia; [Potter, Kathleen; Flicker, Leon; Etherton-Beer, Christopher] Univ Western Australia, Western Australian Ctr Hlth & Ageing, Perth, WA 6009, Australia	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia	Potter, K (corresponding author), Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.; Potter, K (corresponding author), Univ Western Australia, Western Australian Ctr Hlth & Ageing, Perth, WA 6009, Australia.	Kathleen.Potter@uwa.edu.au	Etherton-Beer, Christopher/B-2714-2014; Flicker, Leon/AAE-1530-2022; Page, Amy/F-9424-2013	Etherton-Beer, Christopher/0000-0001-5148-0188; Flicker, Leon/0000-0002-3650-0475; Page, Amy/0000-0002-2084-8469; Potter, Kathleen/0000-0001-7806-8708	National Health and Medical Research Council of Australia [APP1016241]; Royal Australian College of General Practitioners; Mason Foundation; Dementia Collaborative Research Centre	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Royal Australian College of General Practitioners; Mason Foundation; Dementia Collaborative Research Centre	This study was funded by the National Health and Medical Research Council of Australia (http://www.nhmrc.gov.au) through a post-doctoral training fellowship for KP (APP1016241). Additional funding was provided by the Royal Australian College of General Practitioners (http://www.racgp.org.au), The Mason Foundation (http://www.eqt.com.au/notfor-profit-organisations/confirmed-2015-programs/eqtmedical-programs.aspx), and the Dementia Collaborative Research Centre (www.dementiaresearch.org.au). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON K, 2014, BMJ OPEN, P4; [Anonymous], 2015, AUSTR MED HDB; Barat I, 2001, BRIT J CLIN PHARMACO, V51, P615, DOI 10.1046/j.0306-5251.2001.01401.x; Basger BJ, 2008, DRUG AGING, V25, P777, DOI 10.2165/00002512-200825090-00004; Beswick A, 2008, LIT REV; Bradley MC, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-72; Bugeja G, 1997, BRIT MED J, V315, P1059, DOI 10.1136/bmj.315.7115.1059; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147; Cherubini A, 2011, ARCH INTERN MED, V171, P550, DOI 10.1001/archinternmed.2011.31; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dalleur O, 2014, DRUG AGING, V31, P291, DOI 10.1007/s40266-014-0157-5; Derry S, 2000, RISK GASTROINTESTINA, P1183; Elliott Rohan A., 2014, Journal of Pharmacy Practice and Research, V44, P258, DOI 10.1002/jppr.1041; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher PF, 2011, CLIN PHARM THERAPEUT; Garfinkel D, 2007, ISR MED ASSOC J, V9, P430; Garfinkel D, 2015, THER ADV DRUG SAF, V6, P212, DOI 10.1177/2042098615613984; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Gnjidic D, 2012, NEW ENGL J MED, V366, P859, DOI 10.1056/NEJMc1114768; Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920; Hilmer SN, 2009, AM J MED, V122, P1142, DOI 10.1016/j.amjmed.2009.02.021; Holland R, 2008, BRIT J CLIN PHARMACO, V65, P303, DOI 10.1111/j.1365-2125.2007.03071.x; Iyer S, 2008, DRUG AGING, V25, P1021, DOI 10.2165/0002512-200825120-00004; Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kaur S, 2009, DRUG AGING, V26, P1013, DOI 10.2165/11318890-000000000-00000; Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2; Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; Morgan TK, 2012, MED J AUSTRALIA, V196, P50, DOI 10.5694/mja11.10698; Palagyi A, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0181-x; Pitkala KH, 2014, J AM MED DIR ASSOC, V15, P892, DOI 10.1016/j.jamda.2014.04.002; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; Reeve E, 2013, DRUG AGING, V30, P793, DOI 10.1007/s40266-013-0106-8; Roughead Elizabeth E., 2008, Journal of Pharmacy Practice and Research, V38, P14; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Somers M, 2010, AUST FAM PHYSICIAN, V39, P413; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson NM, 2011, J AM GERIATR SOC, V59, P875, DOI 10.1111/j.1532-5415.2011.03386.x; Woodward MC, 2003, J PHARM PRACTICE RES, V33	46	117	122	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2016	11	3							e0149984	10.1371/journal.pone.0149984	http://dx.doi.org/10.1371/journal.pone.0149984			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0FG	26942907	Green Submitted, Green Published, gold			2023-01-03	WOS:000371739400009
J	Engelmann, F; Rivera, A; Park, B; Messerle-Forbes, M; Jensen, JT; Messaoudi, I				Engelmann, Flora; Rivera, Andrea; Park, Byung; Messerle-Forbes, Marci; Jensen, Jeffrey T.; Messaoudi, Ilhem			Impact of Estrogen Therapy on Lymphocyte Homeostasis and the Response to Seasonal Influenza Vaccine in Post-Menopausal Women	PLOS ONE			English	Article							HORMONE REPLACEMENT THERAPY; SYSTEMIC ANTIBODY-RESPONSES; BLOOD MONONUCLEAR-CELLS; TUMOR-NECROSIS-FACTOR; T-CELLS; TNF-ALPHA; IMMUNE-RESPONSES; IFN-GAMMA; RECEPTOR; INTERLEUKIN-6	It is widely recognized that changes in levels of ovarian steroids modulate severity of autoimmune disease and immune function in young adult women. These observations suggest that the loss of ovarian steroids associated with menopause could affect the age-related decline in immune function, known as immune senescence. Therefore, in this study, we determined the impact of menopause and estrogen therapy (ET) on lymphocyte subset frequency as well as the immune response to seasonal influenza vaccine in three different groups: 1) young adult women (regular menstrual cycles, not on hormonal contraception); 2) post-menopausal (at least 2 years) women who are not receiving any form of hormone therapy (HT) and 3) post-menopausal hysterectomized women receiving ET. Although the numbers of circulating CD4 and CD20 B cells were reduced in the post-menopausal group receiving ET, we also detected a better preservation of naive B cells, decreased CD4 T cell inflammatory cytokine production, and slightly lower circulating levels of the pro-inflammatory cytokine IL-6. Following vaccination, young adult women generated more robust antibody and T cell responses than both post-menopausal groups. Despite similar vaccine responses between the two post-menopausal groups, we observed a direct correlation between plasma 17 beta estradiol (E2) levels and fold increase in IgG titers within the ET group. These findings suggest that ET affects immune homeostasis and that higher plasma E2 levels may enhance humoral responses in post-menopausal women.	[Engelmann, Flora; Rivera, Andrea; Messaoudi, Ilhem] Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA; [Park, Byung] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA; [Messerle-Forbes, Marci; Jensen, Jeffrey T.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; [Jensen, Jeffrey T.; Messaoudi, Ilhem] Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR USA; [Messaoudi, Ilhem] Oregon Natl Primate Res Ctr, Div Pathobiol & Immunol, Beaverton, OR USA	University of California System; University of California Riverside; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center	Messaoudi, I (corresponding author), Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA.; Messaoudi, I (corresponding author), Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR USA.; Messaoudi, I (corresponding author), Oregon Natl Primate Res Ctr, Div Pathobiol & Immunol, Beaverton, OR USA.	messaoud@ucr.edu	Jensen, Jeffrey T/C-7421-2014	Jensen, Jeffrey T/0000-0002-4733-1224	Center for Gender Differences at OHSU; Leadership in Aging Research Fellowship from the Brookdale Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD085809] Funding Source: NIH RePORTER	Center for Gender Differences at OHSU; Leadership in Aging Research Fellowship from the Brookdale Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by a grant from the Center for Gender Differences at OHSU, and a Leadership in Aging Research Fellowship from the Brookdale Foundation.	Agematsu K, 2000, HISTOL HISTOPATHOL, V15, P573, DOI 10.14670/HH-15.573; Al-Harthi L, 2001, AIDS, V15, P1535, DOI 10.1097/00002030-200108170-00011; Al-Harthi L, 2000, J INTERF CYTOK RES, V20, P719, DOI 10.1089/10799900050116426; Angstwurm MWA, 1997, CYTOKINE, V9, P370, DOI 10.1006/cyto.1996.0178; Baeten JM, 2001, AM J OBSTET GYNECOL, V185, P380, DOI 10.1067/mob.2001.115862; Baeza I, 2010, J NEUROIMMUNOL, V219, P90, DOI 10.1016/j.jneuroim.2009.12.008; Baeza I, 2011, BIOGERONTOLOGY, V12, P227, DOI 10.1007/s10522-010-9317-0; Bluming AZ, 2009, CANCER J, V15, P93, DOI 10.1097/PPO.0b013e31819e332a; Brooks-Asplund EM, 2002, CYTOKINE, V19, P193, DOI 10.1006/cyto.2002.1963; Butts CL, 2007, INT IMMUNOL, V19, P287, DOI 10.1093/intimm/dxl145; Calder AE, 2011, NEUROIMMUNOMODULAT, V18, P281, DOI 10.1159/000329496; Calippe B, 2010, J IMMUNOL, V185, P1169, DOI 10.4049/jimmunol.0902383; CARLSTEN H, 1992, CELL IMMUNOL, V144, P190, DOI 10.1016/0008-8749(92)90236-I; Carroll ML, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-184; CLEMENTS ML, 1986, J CLIN MICROBIOL, V23, P66, DOI 10.1128/JCM.23.1.66-72.1986; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055; Deguchi K, 2001, MENOPAUSE, V8, P266, DOI 10.1097/00042192-200107000-00008; Delpy L, 2005, J IMMUNOL, V175, P5050, DOI 10.4049/jimmunol.175.8.5050; Effros Rita B, 2005, Discov Med, V5, P293; Engelmann F, 2010, AGE DORDR; Evans MJ, 1997, CLIN IMMUNOL IMMUNOP, V82, P258, DOI 10.1006/clin.1996.4300; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Franklin RD, 1999, J REPROD IMMUNOL, V42, P93, DOI 10.1016/S0165-0378(98)00086-2; Gameiro Catia, 2010, Front Biosci (Elite Ed), V2, P1299; Gameiro CM, 2010, MATURITAS, V67, P316, DOI 10.1016/j.maturitas.2010.08.003; GIGLIO T, 1994, LIFE SCI, V54, P1305, DOI 10.1016/0024-3205(94)00508-7; Giuliani N, 2001, EXP GERONTOL, V36, P547, DOI 10.1016/S0531-5565(00)00220-5; Hsu HC, 2006, MECH AGEING DEV, V127, P231, DOI 10.1016/j.mad.2005.10.001; Hughes GC, 2008, J IMMUNOL, V180, P2029, DOI 10.4049/jimmunol.180.4.2029; Jansen R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-33; Jentes ES, 2011, LANCET INFECT DIS, V11, P622, DOI 10.1016/S1473-3099(11)70147-5; Kanda N, 1999, J ALLERGY CLIN IMMUN, V103, P282, DOI 10.1016/S0091-6749(99)70503-8; Karpuzoglu E, 2009, CLIN REV ALLERG IMMU, V40, P16; Kaushic C, 2003, J VIROL, V77, P4558, DOI 10.1128/JVI.77.8.4558-4565.2003; Khan D, 2010, EUR J IMMUNOL, V40, P2549, DOI 10.1002/eji.201040303; Kim WU, 2010, CLIN EXP IMMUNOL, V161, P453, DOI 10.1111/j.1365-2249.2010.04194.x; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Kovats S, 2010, SEX HORMONES AND IMMUNITY TO INFECTION, P53, DOI 10.1007/978-3-642-02155-8_3; Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566; Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009; Kumru S, 2004, J REPROD IMMUNOL, V63, P31, DOI 10.1016/j.jri.2004.02.001; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; McElhaney JE, 2009, CURR OPIN IMMUNOL, V21, P418, DOI 10.1016/j.coi.2009.05.023; McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333; McNerlan SE, 2002, EXP GERONTOL, V37, P227, DOI 10.1016/S0531-5565(01)00188-7; Nguyen DC, 2011, VACCINE, V29, P2515, DOI 10.1016/j.vaccine.2011.01.080; PAAVONEN T, 1981, J EXP MED, V154, P1935, DOI 10.1084/jem.154.6.1935; Pennock JW, 2009, VACCINE, V27, P5830, DOI 10.1016/j.vaccine.2009.07.052; Polanczyk MJ, 2006, J NEUROSCI RES, V84, P370, DOI 10.1002/jnr.20881; Porter VR, 2001, EXP GERONTOL, V36, P311, DOI 10.1016/S0531-5565(00)00195-9; Rider V, 2001, J RHEUMATOL, V28, P2644; Salem Mohamed Labib, 2004, Current Drug Targets - Inflammation and Allergy, V3, P97, DOI 10.2174/1568010043483944; Sandmand M, 2003, GERONTOLOGY, V49, P155, DOI 10.1159/000069174; Saucedo R, 2002, GYNECOL OBSTET INVES, V53, P114, DOI 10.1159/000053005; Stopinska-Gluszak U, 2006, J REPROD IMMUNOL, V69, P65, DOI 10.1016/j.jri.2005.07.006; Suenaga R, 1998, J RHEUMATOL, V25, P1305; Vasto S, 2009, MECH AGEING DEV, V130, P40, DOI 10.1016/j.mad.2008.06.003; Verthelyi D, 2000, IMMUNOLOGY, V100, P384, DOI 10.1046/j.1365-2567.2000.00047.x; Verthelyi DI, 1998, CELL IMMUNOL, V189, P125, DOI 10.1006/cimm.1998.1372; Vural P, 2006, PHARMACOL RES, V53, P367, DOI 10.1016/j.phrs.2006.01.005; Vural P, 2006, PHARMACOL RES, V54, P298, DOI 10.1016/j.phrs.2006.06.006; Wagner Wolfgang M, 2004, Biogerontology, V5, P63, DOI 10.1023/B:BGEN.0000017832.57617.66; Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432-2277.2009.00927.x; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Yasui T, 2007, MATURITAS, V56, P396, DOI 10.1016/j.maturitas.2006.11.002; Zanni F, 2003, EXP GERONTOL, V38, P981, DOI 10.1016/S0531-5565(03)00160-8	68	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0149045	10.1371/journal.pone.0149045	http://dx.doi.org/10.1371/journal.pone.0149045			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6MN	26859566	Green Published, Green Submitted, gold			2023-01-03	WOS:000370038400123
J	Graves, N; Page, K; Martin, E; Brain, D; Hall, L; Campbell, M; Fulop, N; Jimmeison, N; White, K; Paterson, D; Barnett, AG				Graves, Nicholas; Page, Katie; Martin, Elizabeth; Brain, David; Hall, Lisa; Campbell, Megan; Fulop, Naomi; Jimmeison, Nerina; White, Katherine; Paterson, David; Barnett, Adrian G.			Cost-Effectiveness of a National Initiative to Improve Hand Hygiene Compliance Using the Outcome of Healthcare Associated Staphylococcus aureus Bacteraemia	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; LENGTH-OF-STAY; DECISION-MAKING; SAVE-LIVES; INDICATOR; ECONOMICS; EFFICACY; PROGRAM; RATES	Background The objective is to estimate the incremental cost-effectiveness of the Australian National Hand Hygiene Inititiave implemented between 2009 and 2012 using healthcare associated Staphylococcus aureus bacteraemia as the outcome. Baseline comparators are the eight existing state and territory hand hygiene programmes. The setting is the Australian public healthcare system and 1,294,656 admissions from the 50 largest Australian hospitals are included. Methods The design is a cost-effectiveness modelling study using a before and after quasi-experimental design. The primary outcome is cost per life year saved from reduced cases of healthcare associated Staphylococcus aureus bacteraemia, with cost estimated by the annual on-going maintenance costs less the costs saved from fewer infections. Data were harvested from existing sources or were collected prospectively and the time horizon for the model was 12 months, 2011-2012. Findings No useable pre-implementation Staphylococcus aureus bacteraemia data were made available from the 11 study hospitals in Victoria or the single hospital in Northern Territory leaving 38 hospitals among six states and territories available for cost-effectiveness analyses. Total annual costs increased by $2,851,475 for a return of 96 years of life giving an incremental cost-effectiveness ratio (ICER) of $29,700 per life year gained. Probabilistic sensitivity analysis revealed a 100% chance the initiative was cost effective in the Australian Capital Territory and Queensland, with ICERs of $1,030 and $8,988 respectively. There was an 81% chance it was cost effective in New South Wales with an ICER of $33,353, a 26% chance for South Australia with an ICER of $64,729 and a 1% chance for Tasmania and Western Australia. The 12 hospitals in Victoria and the Northern Territory incur annual on-going maintenance costs of $1.51M; no information was available to describe cost savings or health benefits. Conclusions The Australian National Hand Hygiene Initiative was cost-effective against an Australian threshold of $42,000 per life year gained. The return on investment varied among the states and territories of Australia.	[Graves, Nicholas; Page, Katie; Martin, Elizabeth; Brain, David; Hall, Lisa; Campbell, Megan; White, Katherine; Barnett, Adrian G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Fulop, Naomi] UCL, Dept Appl Hlth Res, London, England; [Jimmeison, Nerina] Queensland Univ Technol, Sch Management, Brisbane, Qld 4001, Australia; [Jimmeison, Nerina] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia	Queensland University of Technology (QUT); University of London; University College London; Queensland University of Technology (QUT); University of Queensland	Graves, N (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.	n.graves@qut.edu.au	Hall, Lisa/H-6322-2012; Page, Katie/H-4283-2019; Barnett, Adrian/I-9850-2012; Martin, Elizabeth/O-3573-2019	Page, Katie/0000-0001-9183-9175; Barnett, Adrian/0000-0001-6339-0374; Martin, Elizabeth/0000-0003-0252-8303; White, Katherine/0000-0002-0345-4724; Graves, Nicholas/0000-0002-5559-3267; Jimmieson, Nerina/0000-0003-4901-7949; Paterson, David/0000-0003-2079-4437; Fulop, Naomi/0000-0001-5306-6140; Campbell, Megan/0000-0002-6056-6140; Brain, David/0000-0002-6612-348X	National Health and Medical Research Council [553081]; Australian Commission on Safety and Quality in Health Care; Hand Hygiene Australia; Centre for Healthcare Related Infection Surveillance and Prevention, Communicable Diseases Branch, Queensland Health	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Commission on Safety and Quality in Health Care; Hand Hygiene Australia; Centre for Healthcare Related Infection Surveillance and Prevention, Communicable Diseases Branch, Queensland Health	Financial support for this study was provided by a National Health and Medical Research Council Partnership grant (number 553081) with financial and in-kind support from Australian Commission on Safety and Quality in Health Care, Hand Hygiene Australia, and jurisdictional health departments. Representatives of the Australian Commission on Safety and Quality in Health Care attended research governance meetings to provide feedback on the progress of the project, but the design and conduct is the sole responsibility of the investigators awarded the grant. The funders had no veto on study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The Centre for Healthcare Related Infection Surveillance and Prevention, Communicable Diseases Branch, Queensland Health, supports the salaries of NG & DP. We are grateful to all the infection control practitioners who took their time to answer the costing survey and provide other information about the implementation of the National Hand Hygiene Initiative. All authors have no relationships with companies that might have an interest in the submitted work; their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and they have no non-financial interests that may be relevant to the submitted work.	ACSQHC, 2012, SURV HEALTHC ASS INF; Allegranzi B, GLOBAL IMPLEMENTATIO, P1474; Australian Comission on Safety and Quality in Health Care, 2013, IMPL GUID SURV STAPH; Australian Institute of Health and Welfare, 2013, HLTH SERV SER, V50; Australian Institute of Health and Welfare, 2010, AUSTR HLTH SER, V12; Australian Institute of Health and Welfare, 2013, HLTH SERV SER, V53; Australian Institute of Health and Welfare (AIHW), 2012, LIF EXP; Azim S, 2014, MED J AUSTRALIA, V200, P534, DOI 10.5694/mja13.11203; Barnett A. G., 2014, Healthcare Infection, V19, P128, DOI 10.1071/HI14033; Barnett AG, 2014, INFECT CONT HOSP EP, V35, P1029, DOI 10.1086/677160; Barnett AG, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003587; Barnett AG, 2011, VALUE HEALTH, V14, P381, DOI 10.1016/j.jval.2010.09.008; Beyersmann J, 2006, INFECT CONT HOSP EP, V27, P493, DOI 10.1086/503375; Brown C.A., 2006, BMC MED RES METHODOL, V6, P54, DOI DOI 10.1186/1471-2288-6-54; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Collignon PJ, 2006, MED J AUSTRALIA, V184, P404, DOI 10.5694/j.1326-5377.2006.tb00291.x; Collignon Pj, STAPHYLOCOCCUS AUREU; Dick AW, DECADE INVESTMENT IN, P1527; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; George B HA, 2001, PHARMACOECONOMICS; Gould DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005186.pub3; Graves N, 2004, EMERG INFECT DIS, V10, P561, DOI 10.3201/eid1004.020754; Graves N, 2007, INFECT CONT HOSP EP, V28, P178, DOI 10.1086/510787; Graves N, 2013, INFECT CONT HOSP EP, V34, P424, DOI 10.1086/669862; Graves N, 2010, CLIN INFECT DIS, V50, P1017, DOI 10.1086/651110; Grayson ML, 2008, MED J AUSTRALIA, V188, P633, DOI 10.5694/j.1326-5377.2008.tb01820.x; Grayson ML, 2009, MED J AUSTRALIA, V191, P420, DOI 10.5694/j.1326-5377.2009.tb02873.x; Hand Hygiene Australia, 2014, NAT DAT; Harris AD, 2004, CLIN INFECT DIS, V38, P1586, DOI 10.1086/420936; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Johnson PDR, 2005, MED J AUSTRALIA, V183, P509, DOI 10.5694/j.1326-5377.2005.tb07151.x; Kallen AJ, 2010, JAMA-J AM MED ASSOC, V304, P641, DOI 10.1001/jama.2010.1115; Kohn LT, 1999, ERR IS HUMAN BUILDIN; Lawes T, 2015, LANCET INFECT DIS, V15, P1438, DOI 10.1016/S1473-3099(15)00315-1; Lawes T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006596; Lawes TG, 2012, CLIN INFECT DIS, V55, P1027, DOI 10.1093/cid/cis602; Luangasanatip N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3728; McLaws ML, 2009, MED J AUSTRALIA, V191, pS26; Naikoba S, 2001, EFFECTIVENESS INTERV; National Institute for Health and Clinical Excellence, GUID METH TECHN APPR; Page K, 2014, J HOSP INFECT, V88, P141, DOI 10.1016/j.jhin.2014.06.005; Page K, 2013, J HOSP INFECT, V84, P200, DOI 10.1016/j.jhin.2013.03.006; Page K, J HOSP INFE IN PRESS; Pantle AC, 2009, MED J AUSTRALIA, V191, pS8; Perencevich EN, 2007, INFECT CONT HOSP EP, V28, P1121, DOI 10.1086/521852; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Playford EG, 2012, MED J AUSTRALIA, V197, P29, DOI 10.5694/mja12.10677; Rechner IJ, 2005, ANAESTH INTENS CARE, V33, P477, DOI 10.1177/0310057X0503300409; Reichardt C, 2013, J HOSP INFECT, V83, pS11, DOI 10.1016/S0195-6701(13)60004-3; Russo PL, 2015, AM J INFECT CONTROL, V43, P773, DOI 10.1016/j.ajic.2015.02.029; Sax H, 2007, J HOSP INFECT, V67, P9, DOI 10.1016/j.jhin.2007.06.004; Schweizer ML, SEARCHING OPTIMAL HA, P1537; Srigley JA, 2014, BMJ QUAL SAF, V23, P974, DOI 10.1136/bmjqs-2014-003080; Stewardson AJ, 2014, INFECT CONT HOSP EP, V35, P1294, DOI 10.1086/678063; Stone SP, EVALUATION NATL CLEA, P1756; van Hal SJ, 2012, CLIN MICROBIOL REV, V25, P362, DOI 10.1128/CMR.05022-11; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	58	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2016	11	2							e0148190	10.1371/journal.pone.0148190	http://dx.doi.org/10.1371/journal.pone.0148190			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6MN	26859688	gold, Green Published			2023-01-03	WOS:000370038400025
J	Yalon, M; Tuval-Kochen, L; Castel, D; Moshe, I; Mazal, I; Cohen, O; Avivi, C; Rosenblatt, K; Aviel-Ronen, S; Schiby, G; Yahalom, J; Amariglio, N; Pfeffer, R; Lawrence, Y; Toren, A; Rechavi, G; Paglin, S				Yalon, Michal; Tuval-Kochen, Liron; Castel, David; Moshe, Itai; Mazal, Inbal; Cohen, Osher; Avivi, Camila; Rosenblatt, Kineret; Aviel-Ronen, Sarit; Schiby, Ginette; Yahalom, Joachim; Amariglio, Ninette; Pfeffer, Raphael; Lawrence, Yaacov; Toren, Amos; Rechavi, Gideon; Paglin, Shoshana			Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITOR; RECOMBINATION DNA-REPAIR; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; MECHANISMS; THERAPY; PATHWAY; TUMOR; 6-THIOGUANINE; THIOREDOXIN	Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance to these drugs and thus expand the array of cancers that could benefit from them. We show that human cancer cell lines which respond poorly to ABT-888 (a PARPi), become sensitive to it when co-treated with vorinostat (a histone deacetylase inhibitor (HDACi)). Vorinostat also sensitized PARPis insensitive cancer cell lines to 6-thioguanine (6-TG)-a drug that targets PARPis sensitive cells. The sensitizing effect of vorinostat was associated with increased phosphorylation of eukaryotic initiation factor (eIF) 2 alpha which in and of itself increases the sensitivity of cancer cells to ABT-888. Importantly, these drug combinations did not affect survival of normal fibroblasts and breast cells, and significantly increased the inhibition of xenograft tumor growth relative to each drug alone, without affecting the mice weight or their liver and kidney function. Our results show that combination of vorinostat and ABT-888 could potentially prove useful for treatment of cancer with innate resistance to PARPis due to active HRR machinery, while the combination of vorinostat and 6-TG could potentially overcome innate or acquired resistance to PARPis due to secondary or reversal BRCA mutations, to decreased PARP-1 level or to increased expression of multiple drug resistant proteins. Importantly, drugs which increase phosphorylation of eIF2 alpha may mimic the sensitizing effect of vorinostat on cellular response to PARPis or to 6-TG, without activating all of its downstream effectors.	[Yalon, Michal; Moshe, Itai; Toren, Amos] Safra Childrens Hosp, Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, IL-52621 Ramat Gan, Israel; [Yalon, Michal; Tuval-Kochen, Liron; Mazal, Inbal; Amariglio, Ninette; Pfeffer, Raphael; Lawrence, Yaacov; Toren, Amos; Rechavi, Gideon; Paglin, Shoshana] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Ramat Gan, Israel; [Tuval-Kochen, Liron] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Castel, David] Chaim Sheba Med Ctr, Neufeld Cardiac Res Inst, IL-52621 Ramat Gan, Israel; [Cohen, Osher] Chaim Sheba Med Ctr, Dept Surg, IL-52621 Ramat Gan, Israel; [Avivi, Camila; Rosenblatt, Kineret; Aviel-Ronen, Sarit; Schiby, Ginette] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Ramat Gan, Israel; [Yahalom, Joachim] Mem Sloan Kettering, Dept Radiat Oncol, New York, NY 10021 USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Memorial Sloan Kettering Cancer Center	Paglin, S (corresponding author), Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Ramat Gan, Israel.	shoshana.paglin@sheba.health.gov.il	lawrence, yaacov richard/AFP-1121-2022	lawrence, yaacov richard/0000-0002-9959-2485	 [PCIG10-GA-2011-303795]		http://ec.europa.eu/research/mariecurieactions/ Grant # PCIG10-GA-2011-303795. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aktas BH, 2013, ONCOTARGET, V4, P1606, DOI 10.18632/oncotarget.1186; Brem R, 2012, CANCER RES, V72, P4787, DOI 10.1158/0008-5472.CAN-12-1278; Bunting SF, 2012, MOL CELL, V46, P125, DOI 10.1016/j.molcel.2012.02.015; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Chao OS, 2014, MOL CANCER RES, V12, P1755, DOI 10.1158/1541-7786.MCR-14-0173; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Gaymes TJ, 2009, HAEMATOL-HEMATOL J, V94, P638, DOI 10.3324/haematol.2008.001933; Gottesfeld JM, 2013, J NEUROCHEM, V126, P147, DOI 10.1111/jnc.12302; Ha K, 2014, ONCOTARGET, V5, P5637, DOI 10.18632/oncotarget.2154; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Issaeva N, 2010, CANCER RES, V70, P6268, DOI 10.1158/0008-5472.CAN-09-3416; Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292; Konstantinopoulos PA, 2014, GYNECOL ONCOL, V133, P599, DOI 10.1016/j.ygyno.2014.03.007; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Min W, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3993; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Rodriguez-Enfedaque A, 2012, BBA-MOL CELL RES, V1823, P1343, DOI 10.1016/j.bbamcr.2012.05.013; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Shibata H, 2011, CANCER SCI, V102, P1882, DOI 10.1111/j.1349-7006.2011.02016.x; Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499; Tuval-Kochen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077260; Wang W, 2010, BIOCHEM PHARMACOL, V80, P316, DOI 10.1016/j.bcp.2010.04.008; Wang YZ, 2010, CURR DRUG METAB, V11, P507, DOI 10.2174/138920010791636149; Werthmoller N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.129; Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72; Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103; Xu WS, 2005, CANCER RES, V65, P7832, DOI 10.1158/0008-5472.CAN-04-4608; Zhang G, 2008, CLIN CANCER RES, V14, P5385, DOI 10.1158/1078-0432.CCR-08-0469; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; Zheng QL, 2014, TUMOR BIOL, V35, P6255, DOI 10.1007/s13277-014-1789-0; ZIMM S, 1988, J CLIN ONCOL, V6, P696, DOI 10.1200/JCO.1988.6.4.696; Zimmerman M, 2014, TRENDS CELL BIOL, V24, P108, DOI 10.1016/j.tcb.2013.09.003	40	15	16	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155711	10.1371/journal.pone.0155711	http://dx.doi.org/10.1371/journal.pone.0155711			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27196668	Green Published, gold			2023-01-03	WOS:000376291100088
J	Chen, JLY; Choi, EPH; Wan, EYF; Chan, AKC; Tsang, JPY; Chan, KHY; Lo, WK; Lui, SL; Chu, WL; Lam, CLK				Chen, Julie Y.; Choi, Edmond P. H.; Wan, Eric Y. F.; Chan, Anca K. C.; Tsang, Joyce P. Y.; Chan, Karina H. Y.; Lo, W. K.; Lui, S. L.; Chu, W. L.; Lam, Cindy L. K.			Validation of the Disease-Specific Components of the Kidney Disease Quality of Life-36 (KDQOL-36) in Chinese Patients Undergoing Maintenance Dialysis	PLOS ONE			English	Article							OF-LIFE; HEALTH SURVEY; SHORT-FORM; HEMODIALYSIS; VERSION; SYMPTOMS; VALIDITY; OUTCOMES; IMPACT	Aim The aim of this study was to evaluate the validity, reliability and sensitivity of the disease-specific items of the Kidney Disease Quality of Life-36 (KDQOL-36) in Chinese patients undergoing maintenance dialysis. Methods The content validity was assessed by content validity index (CVI) in ten subjects. 356 subjects were recruited for pilot psychometric testing. The internal construct validity was assessed by corrected item-subscale total correlation. Confirmatory factor analysis (CFA) was used to confirm the factor structure. The convergent validity was assessed by Pearson's correlation test between the disease specific subscale scores and SF-12 version 2 Health Survey (SF-12 v2) scores. The reliability was assessed by the internal consistency (Cronbach's Alpha coefficient) and 2-week test-retest reliability (intraclass correlation coefficient (ICC)). The sensitivity was determined by performing known group comparisons by independent t-test. Results The CVI on clarity and relevance was >= 0.9 for all items. Corrected item-total correlation scores were >= 0.4 for all, except an item related to problems with access site. CFA confirmed the 3-factor structure of the disease-specific component of the KDQOL-36. The correlation coefficients between the disease-specific domain scores and the SF-12 v2 physical and mental component summary scores ranged from 0.328 to 0.492. The reliability was good (Cronbach's alpha coefficients ranged from 0.810 to 0.931, ICC ranged from 0.792 to 0.924). Only the effect subscale was sensitive in detecting differences in HRQOL between haemodialysis and peritoneal dialysis patients, with effect size = 0.68. Conclusion The disease-specific items of the KDQOL-36 are a valid, reliable and sensitive measure to assess the health-related quality of life of Chinese patients on maintenance dialysis.	[Chen, Julie Y.; Wan, Eric Y. F.; Chan, Anca K. C.; Tsang, Joyce P. Y.; Chan, Karina H. Y.; Lam, Cindy L. K.] Univ Hong Kong, Dept Family Med & Primary Care, Ap Lei Chau Clin, 3-F,161 Main St, Ap Lei Chau, Hong Kong, Peoples R China; [Choi, Edmond P. H.] Univ Hong Kong, Sch Nursing, 4-F,William MW Mong Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China; [Lo, W. K.; Lui, S. L.] Univ Hong Kong, Dept Med, Pokfulam, Hong Kong, Peoples R China; [Chu, W. L.] Tung Wah Hosp, Renal Unit, Sheung Wan, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Chen, JLY (corresponding author), Univ Hong Kong, Dept Family Med & Primary Care, Ap Lei Chau Clin, 3-F,161 Main St, Ap Lei Chau, Hong Kong, Peoples R China.	juliechen@hku.hk	Choi, Edmond/HDN-8462-2022; Choi, Edmond/H-4187-2019; Chen, Julie Yun/C-4226-2009	Choi, Edmond/0000-0001-9062-3540; Chen, Julie Yun/0000-0002-7444-6182	University of Hong Kong [201409176109]	University of Hong Kong(University of Hong Kong)	The study was supported by Small Project Funding, the University of Hong Kong (201409176109).	Chen JY, 2015, NEPHROLOGY; Chin WY, 2016, FAM PRACT, V33, P61, DOI 10.1093/fampra/cmv090; Chin WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135131; Choi EPH, 2014, PATIENT, V7, P403, DOI 10.1007/s40271-014-0062-3; Choi EPH, 2014, QUAL LIFE RES, V23, P2723, DOI 10.1007/s11136-014-0725-5; Choi EP, 2015, SUPPORT CARE CANCER, P1; Ekelund ML, 2010, PATIENT EDUC COUNS, V81, P30, DOI 10.1016/j.pec.2009.10.025; Fisher R, 1998, J CLIN NURS, V7, P553, DOI 10.1046/j.1365-2702.1998.00189.x; Hagren B, 2001, J ADV NURS, V34, P196, DOI 10.1046/j.1365-2648.2001.01745.x; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Hays RD, 1997, KIDNEY DIS QUALITY L; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Joshi VD, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-36; Kline P., 2000, HDB PSYCHOL TESTING, V2nd; Kline P., 2015, HDB TEST CONSTRUCTIO; Kwong V-K, 2015, KIDNEY DIS; Lam CLK, 2010, HONG KONG PRACTITION, V32, P77; Lam ETP, 2013, J EVAL CLIN PRACT, V19, P200, DOI 10.1111/j.1365-2753.2011.01800.x; Leidy NK, 2008, PHARMACOECONOMICS, V26, P363, DOI 10.2165/00019053-200826050-00002; Leung CB, 2015, KIDNEY INT SUPPL, V5, P33, DOI 10.1038/kisup.2015.7; LYNN MR, 1986, NURS RES, V35, P382; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; Matas AJ, 2002, CLIN TRANSPLANT, V16, P113, DOI 10.1034/j.1399-0012.2002.1o126.x; Noshad H, 2009, SINGAP MED J, V50, P185; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Ricardo AC, 2013, ETHNIC DIS, V23, P202; Tao XJ, 2014, BMC NEPHROL, V15, DOI [10.1186/1471-2369-15-115, 10.1186/1471-2369-15-199]; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Thaweethamcharoen T, 2013, Value Health Reg Issues, V2, P98, DOI 10.1016/j.vhri.2013.02.011; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Wan EYF, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0308-3; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P945, DOI 10.1016/S0895-4356(98)00085-7; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Ware John E., 2002, SF 12V2TM SCORE VERS; White Y, 1999, J ADV NURS, V30, P1312, DOI 10.1046/j.1365-2648.1999.01236.x; Yang F, 2013, PATIENT, V6, P135, DOI 10.1007/s40271-013-0015-2	37	18	20	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2016	11	5							e0155188	10.1371/journal.pone.0155188	http://dx.doi.org/10.1371/journal.pone.0155188			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DL5KV	27148742	Green Submitted, Green Published, gold			2023-01-03	WOS:000375676800122
J	Munoz, R; Borobia, AM; Quintana, M; Martinez, A; Ramirez, E; Munoz, M; Frias, J; Carcas, AJ				Munoz, Ral; Borobia, Alberto M.; Quintana, Manuel; Martinez, Ana; Ramirez, Elena; Munoz, Mario; Frias, Jesus; Carcas, Antonio J.			Outcomes and Costs of Poisoned Patients Admitted to an Adult Emergency Department of a Spanish Tertiary Hospital: Evaluation through a Toxicovigilance Program	PLOS ONE			English	Article							TRENDS; REPETITION; MORTALITY; STAY	The Abstract Toxicovigilance is the active process of identifying and evaluating the toxic risks existing in a community, and evaluating the measures taken to reduce or eliminate them. Objective Through a validated toxicovigilance program (SAT-HULP) we examined the characteristics of acute poisoning cases (APC) attended in the Emergency Department (ED) of La Paz Hospital (Madrid, Spain) and assessed their economic impact on the health system. Material and Methods The active poisoning surveillance system performs a daily search for cases in the hospital's computerized case records. Found cases are entered into a database for recording of type of poisoning episode, reasons for exposure, causative agent, signs and symptoms and treatment. We carried out a cross-sectional epidemiological study with analytical projection, based on an impact study on cost per survivor. The data for the costs attributable to cases of APC observed at HULP (outpatients and inpatients) was obtained from the based on the information provided by the diagnosis-related groups (DRG) through the corresponding hospital discharge reports (available through SAT-HULP). Results During the first 30 month of SAT-HULP operation we found a total of 3,195 APC, a cumulative incidence rate of 1.75% of patients attended in the ED. The mean (SD) patient age was 40.9 (17.8) years and 51.2% were men. Drug abuse accounted for 47.5% of the cases. Suicide attempt was the second most frequent category (38.1%) and other causes accounted for 14.5% of APC. The total cost of hospital care for our hospital rose to (sic)1,825,263.24 (approximately (sic)730,105.30/year) resulting in a permanent occupation of 4 beds/year. Conclusions SAT-HULP constitutes a validated toxicovigilance tool, which continuously integrates available data in real-time and helps health services manage APC data flexibly, including the consumption of resources from the health system.	[Munoz, Ral; Borobia, Alberto M.; Ramirez, Elena; Munoz, Mario; Frias, Jesus; Carcas, Antonio J.] Univ Autonoma Madrid, Clin Pharmacol Deparment, Hosp Univ La Paz, IdiPaz,Sch Med, Madrid, Spain; [Borobia, Alberto M.; Quintana, Manuel; Martinez, Ana] Univ Autonoma Madrid, Dept Accid & Emergency, Hosp Univ La Paz, Crit Care Dept,Sch Med,IdiPaz, Madrid, Spain; [Munoz, Ral; Borobia, Alberto M.; Quintana, Manuel; Martinez, Ana; Munoz, Mario; Frias, Jesus; Carcas, Antonio J.] Hosp Univ La Paz, Clin Toxicol Unit, Madrid, Spain	Autonomous University of Madrid; Hospital Universitario La Paz; Autonomous University of Madrid; Hospital Universitario La Paz; Hospital Universitario La Paz	Munoz, R; Carcas, AJ (corresponding author), Univ Autonoma Madrid, Clin Pharmacol Deparment, Hosp Univ La Paz, IdiPaz,Sch Med, Madrid, Spain.; Munoz, R; Carcas, AJ (corresponding author), Hosp Univ La Paz, Clin Toxicol Unit, Madrid, Spain.	rmunozromo@gmail.com; antonio.carcas@uam.es	Quintana-Diaz, Manuel/AAE-2265-2022; Ramírez, Elena/AGX-8858-2022; Ramírez, Elena/S-5600-2018; Carcas, Antonio J/E-1149-2012; Quintana-Díaz, Manuel/M-2313-2017; Borobia, Alberto M./H-6887-2013	Quintana-Diaz, Manuel/0000-0003-4852-4148; Ramírez, Elena/0000-0002-4052-8876; Ramírez, Elena/0000-0002-4052-8876; Carcas, Antonio J/0000-0003-1823-4174; Quintana-Díaz, Manuel/0000-0003-4852-4148; Borobia, Alberto M./0000-0002-8584-3263				Abad-Santos F, 2000, THER DRUG MONIT, V22, P163, DOI 10.1097/00007691-200004000-00004; [Anonymous], 2009, INF AN 2009; [Anonymous], 2009, B OFICIAL COMUNIDAD, V215, P15; Barrientos R, 1996, REV CALIDAD ASISTENC, V11, P37; Barrientos R, 2003, MED INTENSIVA, V27, P391; Buehler W, 2004, MMWR-MORBID MORTAL W, V53, P1; Putze GB, 2008, EMERGENCIAS, V20, P15; Camidge DR, 2003, BRIT J CLIN PHARMACO, V56, P613, DOI 10.1046/j.1365-2125.2003.01910.x; Carlsten A, 1996, ACTA PSYCHIAT SCAND, V94, P94, DOI 10.1111/j.1600-0447.1996.tb09831.x; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; Ferrer A, 2000, MED CLIN-BARCELONA, V115, P238, DOI 10.1016/S0025-7753(00)71518-1; Friedman LS, 2014, CLIN TOXICOL, V52, P198, DOI 10.3109/15563650.2014.892125; Andres MCG, 2011, EMERGENCIAS, V23, P193; Hawton K, 1997, DRUG ALCOHOL REV, V16, P123, DOI 10.1080/09595239700186411; Heyerdahl F, 2009, BRIT J PSYCHIAT, V194, P73, DOI 10.1192/bjp.bp.107.048322; Hoyt BT, 1999, ACAD EMERG MED, V6, P851, DOI 10.1111/j.1553-2712.1999.tb01220.x; Hu YH, 2010, J CHIN MED ASSOC, V73, P78, DOI 10.1016/S1726-4901(10)70006-X; Johnsson E, 1997, ACTA PSYCHIAT SCAND, V96, P362, DOI 10.1111/j.1600-0447.1997.tb09930.x; Kapur N, 1999, BRIT J GEN PRACT, V49, P733; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; Krajewski AK, 2015, CLIN TOXICOL, V53, P433, DOI 10.3109/15563650.2015.1030677; Librero J, 1999, J CLIN EPIDEMIOL, V52, P171, DOI 10.1016/S0895-4356(98)00160-7; Liisanantti JH, 2011, J CRIT CARE, V26, P160, DOI 10.1016/j.jcrc.2010.08.009; Litovitz T, 1998, DRUG SAFETY, V18, P9, DOI 10.2165/00002018-199818010-00002; McKenzie MS, 2007, PHARMACOEPIDEM DR S, V16, P513, DOI 10.1002/pds.1355; Moran JL, 2008, CRIT CARE MED, V36, P46, DOI 10.1097/01.CCM.0000295313.08084.58; Munoz R, 2013, EMERGENCIAS, V25, P423; Okumura Y, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001857; Okumura Y, 2012, GEN HOSP PSYCHIAT, V34, P681, DOI 10.1016/j.genhosppsych.2012.07.009; Prescott K, 2009, BRIT J CLIN PHARMACO, V68, P260, DOI 10.1111/j.1365-2125.2009.03458.x; Rafnsson SB, 2007, HUM EXP TOXICOL, V26, P49, DOI 10.1177/0960327107071855; Ruse M, 2000, ANN EMERG MED, V35, P512, DOI 10.1016/S0196-0644(00)70016-3; Satar S, 2005, ADV THER, V22, P137, DOI 10.1007/BF02849884; Strassels SA, 2009, J MANAGE CARE PHARM, V15, P556, DOI 10.18553/jmcp.2009.15.7.556; Townsend E, 2001, SOC PSYCH PSYCH EPID, V36, P228, DOI 10.1007/s001270170053; Watson AW, 2005, TOXICOL APPL PHARM, V207, pS604; Watson WA, 2005, AM J EMERG MED, V23, P589, DOI 10.1016/j.ajem.2005.05.001; White AM, 2011, J STUD ALCOHOL DRUGS, V72, P774, DOI 10.15288/jsad.2011.72.774; World Health Organisation, 2011, POIS PREV MAN 2011; Wu AHB, 2010, CLIN PHARMACOL THER, V88, P295, DOI 10.1038/clpt.2010.45; Yang ChM, 2006, HEALTH SERV RES, V125, P1	41	10	10	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2016	11	4							e0152876	10.1371/journal.pone.0152876	http://dx.doi.org/10.1371/journal.pone.0152876			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DK4OR	27100460	Green Submitted, gold, Green Published			2023-01-03	WOS:000374898500017
J	El-Mallawany, NK; Kamiyango, W; Slone, JS; Villiera, J; Kovarik, CL; Cox, CM; Dittmer, DP; Ahmed, S; Schutze, GE; Scheurer, ME; Kazembe, PN; Mehta, PS				El-Mallawany, Nader Kim; Kamiyango, William; Slone, Jeremy S.; Villiera, Jimmy; Kovarik, Carrie L.; Cox, Carrie M.; Dittmer, Dirk P.; Ahmed, Saeed; Schutze, Gordon E.; Scheurer, Michael E.; Kazembe, Peter N.; Mehta, Parth S.			Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study	PLOS ONE			English	Article							MULTICENTRIC CASTLEMAN DISEASE; MOTHER-TO-CHILD; HUMAN-HERPESVIRUS-8 INFECTION; UGANDAN CHILDREN; HERPESVIRUS KSHV; ENDEMIC REGION; TRANSMISSION; CANCER; AIDS; SEROPREVALENCE	Kaposi sarcoma (KS) is the most common HIV-associated malignancy in children and adolescents in Africa. Pediatric KS is distinct from adult disease. We evaluated the clinical characteristics associated with long-term outcomes. We performed a retrospective observational analysis of 70 HIV-infected children and adolescents with KS less than 18 years of age diagnosed between 8/2010 and 6/2013 in Lilongwe, Malawi. Local first-line treatment included bleomycin and vincristine plus nevirapine-based highly active anti-retroviral therapy (HAART). Median age was 8.6 years (range 1.7-17.9); there were 35 females (50%). Most common sites of presentation were: lymph node (74%), skin (59%), subcutaneous nodules (33%), oral (27%), woody edema (24%), and visceral (16%). Eighteen (26%) presented with lymphadenopathy only. Severe CD4 suppression occurred in 28%. At time of KS diagnosis, 49% were already on HAART. Overall, 28% presented with a platelet count < 100 x 10(9)/L and 37% with hemoglobin < 8 g/dL. The 2-year event-free (EFS) and overall survival (OS) were 46% and 58% respectively (median follow-up 29 months, range 15-50). Multivariable analysis of risk of death and failure to achieve EFS demonstrated that visceral disease (odds ratios [OR] 19.08 and 11.61, 95% CI 2.22-163.90 and 1.60-83.95 respectively) and presenting with more than 20 skin/oral lesions (OR 9.57 and 22.90, 95% CI 1.01-90.99 and 1.00-524.13 respectively) were independent risk factors for both. Woody edema was associated with failure to achieve EFS (OR 7.80, 95% CI 1.84-33.08) but not death. Univariable analysis revealed that lymph node involvement was favorable for EFS (OR 0.28, 95% CI 0.08-0.99), while T-1 TIS staging criteria, presence of cytopenias, and severe immune suppression were not associated with increased mortality. Long-term complete remission is achievable in pediatric KS, however outcomes vary according to clinical presentation. Based on clinical heterogeneity, treatment according to risk-stratification is necessary to improve overall outcomes.	[El-Mallawany, Nader Kim] New York Med Coll, Dept Pediat, Div Hematol Oncol & Hematopoiet Stem Cell Transpl, Valhalla, NY 10595 USA; [El-Mallawany, Nader Kim; Slone, Jeremy S.; Scheurer, Michael E.; Mehta, Parth S.] Baylor Coll Med, Dept Pediat, Sect Hematol & Oncol, Houston, TX 77030 USA; [Kamiyango, William; Villiera, Jimmy; Ahmed, Saeed; Kazembe, Peter N.] Baylor Coll Med Childrens Fdn Malawi, Lilongwe, Malawi; [Slone, Jeremy S.; Scheurer, Michael E.; Mehta, Parth S.] Texas Childrens Canc Ctr, Houston, TX USA; [Slone, Jeremy S.; Scheurer, Michael E.; Mehta, Parth S.] Texas Childrens Hematol Ctr, Houston, TX USA; [Kovarik, Carrie L.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; [Cox, Carrie M.] Loyola Univ Chicago, Stritch Sch Med, Dept Pediat, Maywood, IL USA; [Dittmer, Dirk P.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Ahmed, Saeed; Schutze, Gordon E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	New York Medical College; Baylor College of Medicine; Texas Children's Cancer Center; University of Pennsylvania; Loyola University Chicago; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine	El-Mallawany, NK (corresponding author), New York Med Coll, Dept Pediat, Div Hematol Oncol & Hematopoiet Stem Cell Transpl, Valhalla, NY 10595 USA.; El-Mallawany, NK (corresponding author), Baylor Coll Med, Dept Pediat, Sect Hematol & Oncol, Houston, TX 77030 USA.	nader.el-mallawany@bcm.edu	Dittmer, Dirk/AAH-3535-2021; Dittmer, Dirk/GPW-7423-2022; Slone, Jeremy S./AAW-5762-2021	Dittmer, Dirk/0000-0003-4968-5656; Slone, Jeremy S./0000-0002-0700-7104; Kovarik, Carrie/0000-0002-3258-3605; Scheurer, Michael/0000-0002-8379-6088; El-Mallawany, Nader/0000-0001-6115-1046	United States Agency for International Development through the Tingathe Program [674-A-00-10-00093-00]; ConocoPhillips; public health service [CA019014, CA190152, CA192744]; NATIONAL CANCER INSTITUTE [P30CA016086, P01CA019014, U54CA190152, R01CA163217, R21CA192744] Funding Source: NIH RePORTER	United States Agency for International Development through the Tingathe Program(United States Agency for International Development (USAID)); ConocoPhillips; public health service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Financial support for the pediatric HIV-associated malignancy and oncology program was provided by a grant from the United States Agency for International Development through the Tingathe Program via cooperative agreement number 674-A-00-10-00093-00 and philanthropic contributions to purchase chemotherapy from ConocoPhillips. The Kamuzu Central Hospital pathology laboratory and Kaposi sarcoma research at the University of North Carolina Project-Malawi are supported by public health service grants CA019014, CA190152, and CA192744. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreoni M, 2002, JAMA-J AM MED ASSOC, V287, P1295, DOI 10.1001/jama.287.10.1295; Anglemyer A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000034.pub2; [Anonymous], 2009, WHO CHILD GROWTH STA; Arkin LM, 2009, PEDIATR INFECT DIS J, V28, P426, DOI 10.1097/INF.0b013e318193ee21; Biggar RJ, 2000, JAMA-J AM MED ASSOC, V284, P205, DOI 10.1001/jama.284.2.205; Bourboulia D, 1998, JAMA-J AM MED ASSOC, V280, P31, DOI 10.1001/jama.280.1.31-a; Caselli D, 2000, J CLIN ONCOL, V18, P3854, DOI 10.1200/JCO.2000.18.22.3854; Chagaluka G, 2014, EUR J CANCER, V50, P1472, DOI 10.1016/j.ejca.2014.02.019; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chatlynne LG, 1999, SEMIN CANCER BIOL, V9, P175, DOI 10.1006/scbi.1998.0089; Cox CM, 2013, PEDIATR BLOOD CANCER, V60, P1274, DOI 10.1002/pbc.24516; DeSantis Stacia M., 2002, International Journal of Infectious Diseases, V6, P266, DOI 10.1016/S1201-9712(02)90159-1; Dollard SC, 2010, INT J CANCER, V127, P2395, DOI 10.1002/ijc.25235; Dow DE, 2014, J PEDIATR INFECT DIS, V3, P66, DOI 10.1093/jpids/pit051; Evans JA, 1997, ARCH DIS CHILD, V76, P330, DOI 10.1136/adc.76.4.330; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Gantt S, 2010, PEDIATR BLOOD CANCER, V54, P670, DOI 10.1002/pbc.22369; Gopal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070361; Granovsky MO, 1998, J CLIN ONCOL, V16, P1729, DOI 10.1200/JCO.1998.16.5.1729; Herce ME, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19929; Hosseinipour MC, 2014, MBIO, V5, DOI 10.1128/mBio.01633-14; Kasolo FC, 2007, J MED VIROL, V79, P1555, DOI 10.1002/jmv.20952; Kest H, 2005, PEDIATR INFECT DIS J, V24, P237, DOI 10.1097/01.inf.0000154324.59426.8d; Krown SE, 1997, J CLIN ONCOL, V15, P3085, DOI 10.1200/JCO.1997.15.9.3085; KROWN SE, 1989, J CLIN ONCOL, V7, P1201, DOI 10.1200/JCO.1989.7.9.1201; Martro E, 2004, J MED VIROL, V72, P126, DOI 10.1002/jmv.10548; Mayama S, 1998, INT J CANCER, V77, P817, DOI 10.1002/(SICI)1097-0215(19980911)77:6&lt;817::AID-IJC2&gt;3.0.CO;2-X; Mbulaiteye SM, 2003, J INFECT DIS, V187, P1780, DOI 10.1086/374973; Olsen SJ, 1998, AIDS, V12, P1921, DOI 10.1097/00002030-199814000-00024; OLWENY CLM, 1976, BRIT J CANCER, V33, P555, DOI 10.1038/bjc.1976.88; Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010; Pfeiffer RM, 2010, ANN EPIDEMIOL, V20, P958, DOI 10.1016/j.annepidem.2010.07.098; Plancoulaine S, 2000, LANCET, V356, P1062, DOI 10.1016/S0140-6736(00)02729-X; Polizzotto MN, 2013, BLOOD, V122, P4189, DOI 10.1182/blood-2013-08-519959; Polizzotto MN, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00073; Pollock BH, 2003, JAMA-J AM MED ASSOC, V289, P2393, DOI 10.1001/jama.289.18.2393; Reddy-Holdcraft S, 2014, AIDS, V28, P800, DOI 10.1097/QAD.0000000000000157; Rohner E, 2016, INT J CANCER, V138, P45, DOI 10.1002/ijc.29687; Sarmati Loredana, 2004, Herpes, V11, P50; SLAVIN G, 1970, J PATHOL, V100, P187, DOI 10.1002/path.1711000307; Stefan DC, 2011, PEDIATR BLOOD CANCER, V56, P392, DOI 10.1002/pbc.22903; Tobin NH, 2013, IMMUNOL REV, V254, P143, DOI 10.1111/imr.12074; Tweya H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-183; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Vaz P, 2011, PEDIATR INFECT DIS J, V30, P891, DOI 10.1097/INF.0b013e318228fb04; Venkataraman G, 2013, AM J CLIN PATHOL, V139, P651, DOI 10.1309/AJCPKGF7U8AWQBVG	46	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0153335	10.1371/journal.pone.0153335	http://dx.doi.org/10.1371/journal.pone.0153335			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ6AH	27082863	gold, Green Published, Green Submitted			2023-01-03	WOS:000374291800015
J	Zhang, YH; Chen, SR; Laumet, G; Chen, H; Pan, HL				Zhang, Yuhao; Chen, Shao-Rui; Laumet, Geoffroy; Chen, Hong; Pan, Hui-Lin			Nerve Injury Diminishes Opioid Analgesia through Lysine Methyltransferase-mediated Transcriptional Repression of mu-Opioid Receptors in Primary Sensory Neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; ROOT GANGLION NEURONS; NEUROPATHIC PAIN; SPINAL-CORD; HISTONE METHYLATION; SUBSTANTIA-GELATINOSA; IDIOPATHIC FORMS; G9A; GENE; CHROMATIN	The mu-opioid receptor (MOR, encoded by Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain. Nerve injury causes down-regulation of MORs in the dorsal root ganglion (DRG) and diminishes the opioid effect on neuropathic pain. However, the epigenetic mechanisms underlying the diminished MOR expression caused by nerve injury are not clear. G9a (encoded by Ehmt2), a histone 3 at lysine 9 methyltransferase, is a key chromatin regulator responsible for gene silencing. In this study, we determined the role of G9a in diminished MOR expression and opioid analgesic effects in animal models of neuropathic pain. We found that nerve injury in rats induced a long-lasting reduction in the expression level of MORs in the DRG but not in the spinal cord. Nerve injury consistently increased the enrichment of the G9a product histone 3 at lysine 9 dimethylation in the promoter of Oprm1 in the DRG. G9a inhibition or siRNA knockdown fully reversed MOR expression in the injured DRG and potentiated the morphine effect on pain hypersensitivity induced by nerve injury. In mice lacking Ehmt2 in DRG neurons, nerve injury failed to reduce the expression level of MORs and the morphine effect. In addition, G9a inhibition or Ehmt2 knockout in DRG neurons normalized nerve injury-induced reduction in the inhibitory effect of the opioid on synaptic glutamate release from primary afferent nerves. Our findings indicate that G9a contributes critically to transcriptional repression of MORs in primary sensory neurons in neuropathic pain. G9a inhibitors may be used to enhance the opioid analgesic effect in the treatment of chronic neuropathic pain.	[Zhang, Yuhao; Chen, Shao-Rui; Laumet, Geoffroy; Chen, Hong; Pan, Hui-Lin] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Ctr Neurosci & Pain Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Pan, HL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Ctr Neurosci & Pain Res, Houston, TX 77030 USA.; Pan, HL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Unit 110, 1515 Holcombe Blvd, Houston, TX 77030 USA.	huilinpan@mdanderson.org	Laumet, Geoffroy/O-7480-2019; Zhang, Yuhao/HHN-6356-2022	Pan, Hui-Lin/0000-0001-8444-3770	National Institutes of Health [DE022015, NS073935]; N. G. and Helen T. Hawkins Endowment; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073935] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); N. G. and Helen T. Hawkins Endowment; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the National Institutes of Health (DE022015 and NS073935) and by the N. G. and Helen T. Hawkins Endowment (to H. L. P.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen SR, 2014, J PHARMACOL EXP THER, V350, P301, DOI 10.1124/jpet.114.215855; Chen SR, 2009, J NEUROCHEM, V110, P352, DOI 10.1111/j.1471-4159.2009.06138.x; Chen SR, 2006, BRAIN RES, V1081, P119, DOI 10.1016/j.brainres.2006.01.053; Chen SR, 2006, J NEUROPHYSIOL, V95, P3086, DOI 10.1152/jn.01343.2005; Chen SR, 2002, J NEUROPHYSIOL, V87, P2726, DOI 10.1152/jn.2002.87.6.2726; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Hasegawa H, 2007, J NEUROSCI, V27, P14404, DOI 10.1523/JNEUROSCI.4908-07.2007; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jose CC, 2014, P NATL ACAD SCI USA, V111, P14631, DOI 10.1073/pnas.1406923111; Kohno T, 1999, J PHYSIOL-LONDON, V518, P803, DOI 10.1111/j.1469-7793.1999.0803p.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; Laedermann CJ, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-19; Laumet G, 2015, NAT NEUROSCI, V18, P1746, DOI 10.1038/nn.4165; Li DP, 2002, J PHYSIOL-LONDON, V543, P807, DOI 10.1113/jphysiol.2002.020644; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; OSSIPOV MH, 1995, NEUROSCI LETT, V199, P87, DOI 10.1016/0304-3940(95)12022-V; Pan HL, 2003, J NEUROSCI, V23, P2911; Pan YZ, 2004, J NEUROPHYSIOL, V91, P2413, DOI 10.1152/jn.01242.2003; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rashid MH, 2004, J PHARMACOL EXP THER, V309, P380, DOI 10.1124/jpet.103.060582; Riccio A, 2010, NAT NEUROSCI, V13, P1330, DOI 10.1038/nn.2671; Ringel AE, 2015, P NATL ACAD SCI USA, V112, pE5461, DOI 10.1073/pnas.1508449112; Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Sanna MD, 2015, PAIN, V156, P1265, DOI 10.1097/j.pain.0000000000000164; Santos SFA, 2007, J PHYSIOL-LONDON, V581, P241, DOI 10.1113/jphysiol.2006.126912; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Uchida H, 2015, J PHARMACOL SCI, V128, P208, DOI 10.1016/j.jphs.2015.07.040; Uchida H, 2010, J NEUROSCI, V30, P4806, DOI 10.1523/JNEUROSCI.5541-09.2010; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; Zhang X, 1998, NEUROSCIENCE, V82, P223; Zhang YH, 2015, J BIOL CHEM, V290, P14647, DOI 10.1074/jbc.M115.650218; Zhao YL, 2012, J BIOL CHEM, V287, P25073, DOI 10.1074/jbc.M112.378737; Zhou HY, 2010, J NEUROSCI, V30, P4460, DOI 10.1523/JNEUROSCI.5857-09.2010; Zhou XL, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-51	49	36	41	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2016	291	16					8475	8485		10.1074/jbc.M115.711812	http://dx.doi.org/10.1074/jbc.M115.711812			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DK2VT	26917724	hybrid, Green Published			2023-01-03	WOS:000374773200014
J	Ferrell, PB; Diggins, KE; Polikowsky, HG; Mohan, SR; Seegmiller, AC; Irish, JM				Ferrell, Paul Brent, Jr.; Diggins, Kirsten Elizabeth; Polikowsky, Hannah Grace; Mohan, Sanjay Ram; Seegmiller, Adam C.; Irish, Jonathan Michael			High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy	PLOS ONE			English	Article							PERIPHERAL-BLOOD; HEMATOLYMPHOID NEOPLASIA; MASS CYTOMETRY; FLOW-CYTOMETRY; STEM-CELLS; CLEARANCE; HETEROGENEITY; EXPRESSION; PREDICTS; IMMUNOPHENOTYPE	The plasticity of AML drives poor clinical outcomes and confounds its longitudinal detection. However, the immediate impact of treatment on the leukemic and non-leukemic cells of the bone marrow and blood remains relatively understudied. Here, we conducted a pilot study of high dimensional longitudinal monitoring of immunophenotype in AML. To characterize changes in cell phenotype before, during, and immediately after induction treatment, we developed a 27-antibody panel for mass cytometry focused on surface diagnostic markers and applied it to 46 samples of blood or bone marrow tissue collected over time from 5 AML patients. Central goals were to determine whether changes in AML phenotype would be captured effectively by cytomic tools and to implement methods for describing the evolving phenotypes of AML cell subsets. Mass cytometry data were analyzed using established computational techniques. Within this pilot study, longitudinal immune monitoring with mass cytometry revealed fundamental changes in leukemia phenotypes that occurred over time during and after induction in the refractory disease setting. Persisting AML blasts became more phenotypically distinct from stem and progenitor cells due to expression of novel marker patterns that differed from pre-treatment AML cells and from all cell types observed in healthy bone marrow. This pilot study of single cell immune monitoring in AML represents a powerful tool for precision characterization and targeting of resistant disease.	[Ferrell, Paul Brent, Jr.; Mohan, Sanjay Ram] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA; [Diggins, Kirsten Elizabeth; Polikowsky, Hannah Grace; Irish, Jonathan Michael] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Seegmiller, Adam C.; Irish, Jonathan Michael] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Irish, JM (corresponding author), Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.; Irish, JM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.	jonathan.irish@vanderbilt.edu	Irish, Jonathan M/E-1180-2013	Irish, Jonathan M/0000-0001-9428-8866	NIH/NCI [K12 CA090625, R25 CA136440-04, R00 CA143231-03]; Vanderbilt-Ingram Cancer Center (VICC) NIH/NCI [P30 CA68485]; VICC Hematology Helping Hands award; NATIONAL CANCER INSTITUTE [R25CA136440, K12CA090625, R00CA143231, P30CA068485] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt-Ingram Cancer Center (VICC) NIH/NCI; VICC Hematology Helping Hands award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH/NCI K12 CA090625 (PBF), NIH/NCI R25 CA136440-04 (KED), NIH/NCI R00 CA143231-03 (JMI), Vanderbilt-Ingram Cancer Center (VICC) NIH/NCI P30 CA68485 (JMI), and a VICC Hematology Helping Hands award (JMI, PBF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Arellano M, 2012, CANCER-AM CANCER SOC, V118, P5278, DOI 10.1002/cncr.27494; Baer MR, 2001, BLOOD, V97, P3574, DOI 10.1182/blood.V97.11.3574; Becher B, 2014, NAT IMMUNOL, V15, P1181, DOI 10.1038/ni.3006; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Diggins KE, 2015, METHODS, V82, P55, DOI 10.1016/j.ymeth.2015.05.008; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Elliott MA, 2007, BLOOD, V110, P4172, DOI 10.1182/blood-2007-07-104091; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Gianfaldoni G, 2006, BRIT J HAEMATOL, V134, P54, DOI 10.1111/j.1365-2141.2006.06100.x; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Irish JM, 2006, NAT REV CANCER, V6, P146, DOI 10.1038/nrc1804; Irish JM, 2014, NATURE IMMUNOLOGY; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Krutzik PO, 2004, CLIN IMMUNOL, V110, P206, DOI 10.1016/j.clim.2003.11.009; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Mason KD, 2006, BLOOD REV, V20, P71, DOI 10.1016/j.blre.2005.08.002; McCarthy N, 2013, NAT REV CANCER, V13, P439, DOI 10.1038/nrc3549; National Cancer Institute, 2013, SURV EP END RES SEER; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Nicholas KJ, 2016, CYTOM PART A, V89A, P271, DOI 10.1002/cyto.a.22799; Ornatsky OI, 2008, ANAL CHEM, V80, P2539, DOI 10.1021/ac702128m; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Shekhar K, 2014, P NATL ACAD SCI USA, V111, P202, DOI 10.1073/pnas.1321405111; Spoo AC, 2007, BLOOD, V109, P786, DOI 10.1182/blood-2006-05-024844; Stein EM, 2012, INT J HEMATOL, V96, P164, DOI 10.1007/s12185-012-1121-y; Stetler-Stevenson M, 2007, CYTOM PART B-CLIN CY, V72B, pS3, DOI 10.1002/cyto.b.20362; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Dongen JJM, 2012, LEUKEMIA, V26, P1899, DOI 10.1038/leu.2012.121; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; Wood BL, 2007, CYTOM PART B-CLIN CY, V72B, pS14, DOI 10.1002/cyto.b.20363	39	31	31	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2016	11	4							e0153207	10.1371/journal.pone.0153207	http://dx.doi.org/10.1371/journal.pone.0153207			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ3UC	27074138	Green Published, gold			2023-01-03	WOS:000374131200060
J	Prioreschi, A; Makda, MA; Tikly, M; McVeigh, JA				Prioreschi, Alessandra; Makda, Mohamed A.; Tikly, Mohammed; McVeigh, Joanne A.			In Patients with Established RA, Positive Effects of a Randomised Three Month WBV Therapy Intervention on Functional Ability, Bone Mineral Density and Fatigue Are Sustained for up to Six Months	PLOS ONE			English	Article							WHOLE-BODY VIBRATION; RHEUMATOID-ARTHRITIS; MUSCLE STRENGTH; MUSCULAR STRENGTH; EXERCISE; EFFICACY; IMPROVES; FRACTURE; PREVENTION; DISEASE	Functional ability is often impaired for people with rheumatoid arthritis (RA), rendering these patients highly sedentary. Additionally, patients with RA often take medication known to negatively affect bone mass. Thus improving functional ability and bone health in this group of patients is important. The aim of this study was to investigate the effects of whole body vibration (WBV) therapy in patients with stable, established RA. Thirty one females with RA were randomly assigned to a control group (CON, n = 15) who continued with their normal activities or a WBV group (n = 16) who underwent a three month WBV therapy intervention, consisting of 15 minutes of intermittent vibration, performed twice per week. Patients were assessed at baseline, three months, and three months post intervention for functional ability using the modified Health Assessment Questionnaire; for RA disease activity using the Clinical Disease Activity Index, for quality of life using self-report fatigue and pain scores; for physical activity profiles using accelerometry, and for BMD and body composition using DXA. Patients in both groups were matched for all variables at baseline. After the intervention period, functional ability was significantly improved in the WBV group (1.22(0.19) to 0.92(0.19), p = 0.02). Hip BMD was significantly reduced in the CON group (0.97(0.05) to 0.84(0.05) g.cm(-2), p = 0.01), while no decreases were seen in the WBV group (1.01(0.05) to 0.94(0.05) g.cm(-2), p = 0.50). Despite no change in RA disease activity in either group at either follow up, fatigue levels were improved in the WBV group (4.4(0.63) to 1.1(0.65), yet remained unchanged in the CON group at both follow ups (p = 0.01). Ten minute bouts of light to moderate physical activity were significantly reduced in the CON group after the intervention (2.8(0.61) to 1.8(0.64) bouts per day, p = 0.01), and were preserved in the WBV group (3.1(0.59) to 3.0(0.61) bouts per day, p = 0.70). Intermittent WBV shows promise for sustained improvements in functional ability, for attenuating loss of bone mass at the hip, as well as for decreasing fatigue in patients with established RA.	[Prioreschi, Alessandra; McVeigh, Joanne A.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Exercise Physiol Lab, Johannesburg, South Africa; [Prioreschi, Alessandra] Univ Witwatersrand, MRC Wits Dev Pathways Hlth Res Unit, Dept Paediat, Johannesburg, South Africa; [Makda, Mohamed A.; Tikly, Mohammed] Univ Witwatersrand, Dept Med, Chris Hani Baragwanath Acad Hosp, Div Rheumatol, ZA-2001 Johannesburg, South Africa	University of Witwatersrand; University of Witwatersrand; University of Witwatersrand	Prioreschi, A (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Exercise Physiol Lab, Johannesburg, South Africa.; Prioreschi, A (corresponding author), Univ Witwatersrand, MRC Wits Dev Pathways Hlth Res Unit, Dept Paediat, Johannesburg, South Africa.	alessandraprioreschi@gmail.com	McVeigh, Joanne/C-9363-2016; Taiar, Redha/Q-6769-2016	McVeigh, Joanne/0000-0002-2446-3814; Taiar, Redha/0000-0002-0227-3884; Prioreschi, Alessandra/0000-0002-6913-0706	Connective Tissues Research Grant; National Research Foundation Innovation Award; Carnegie Large Research Grant; Directorate For Engineering [1130289] Funding Source: National Science Foundation; Directorate For Geosciences [1313747] Funding Source: National Science Foundation; Division Of Environmental Biology [1021840] Funding Source: National Science Foundation	Connective Tissues Research Grant; National Research Foundation Innovation Award; Carnegie Large Research Grant; Directorate For Engineering(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Environmental Biology(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This work was supported by: Connective Tissues Research Grant (AP); National Research Foundation Innovation Award (AP); and Carnegie Large Research Grant (JAM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alentorn-Geli E, 2008, J ALTERN COMPLEM MED, V14, P975, DOI 10.1089/acm.2008.0050; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baillet A, 2010, ARTHRIT CARE RES, V62, P984, DOI 10.1002/acr.20146; Bainbridge KE, 2002, AM J EPIDEMIOL, V156, P410, DOI 10.1093/aje/kwf049; Beck BR, 2015, CURR OSTEOPOROS REP, V13, P381, DOI 10.1007/s11914-015-0294-8; Bemben DA, 2010, BONE, V47, P650, DOI 10.1016/j.bone.2010.06.019; Bredella MA, 2011, BONE, V48, P748, DOI 10.1016/j.bone.2010.12.011; Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14; Cairns AP, 2009, RHEUMATOL INT, V30, P147, DOI 10.1007/s00296-009-1090-5; Cardinale M, 2005, BRIT J SPORT MED, V39, P585, DOI 10.1136/bjsm.2005.016857; Cooney Jennifer K, 2011, J Aging Res, V2011, P681640, DOI 10.4061/2011/681640; da Rocha OM., 2009, REV BRAS REUMATOL, V49, P288, DOI [10.1590/S0482-50042009000300010, DOI 10.1590/S0482-50042009000300010]; De Zepetnek JO, 2009, J REHABIL RES DEV, V46, P529, DOI DOI 10.1682/JRRD.2008.09.0136; Deodhar AA, 1996, BRIT J RHEUMATOL, V35, P309; El Maghraoui A, 2008, QJM-INT J MED, V101, P605, DOI 10.1093/qjmed/hcn022; Ellingson LD, 2012, MED SCI SPORT EXER, V44, P1401, DOI 10.1249/MSS.0b013e318248f648; Figueiredo CP, 2014, OSTEOPOROSIS INT, V25, P589, DOI 10.1007/s00198-013-2455-x; Hakkinen A, 2004, ANN RHEUM DIS, V63, P910, DOI 10.1136/ard.2003.013003; Healy GN, 2011, EUR HEART J, V32, P590, DOI 10.1093/eurheartj/ehq451; Kinder J, 2013, J PAEDIAT NURS, V27, P127; Klareskog L, 2009, LANCET, V373, P659, DOI 10.1016/S0140-6736(09)60008-8; LAAN RFJM, 1993, ANN RHEUM DIS, V52, P21, DOI 10.1136/ard.52.1.21; Leslie WD, 2007, ARCH INTERN MED, V167, P1641, DOI 10.1001/archinte.167.15.1641; Looker A. C., 2012, VITAL HLTH STAT, V11, P1; Maddalozzo G, 2009, INT J OBESITY, V32, P1348; McMeeken J, 1999, Physiother Res Int, V4, P55; Metsios GS, 2008, RHEUMATOLOGY, V47, P239, DOI 10.1093/rheumatology/kem260; Milanese C, 2013, INT J MED SCI, V10, P307, DOI 10.7150/ijms.5161; Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239; Pang MYC, 2010, WORLD J ORTHOP, V1, P20, DOI 10.5312/wjo.v1.i1.20; Park YG, 2013, ANN REHABIL MED-ARM, V37, P505, DOI 10.5535/arm.2013.37.4.505; Pate RR, 2008, EXERC SPORT SCI REV, V36, P173, DOI 10.1097/JES.0b013e3181877d1a; Premaor MO, 2011, J CLIN ENDOCR METAB, V96, P2414, DOI 10.1210/jc.2011-0076; Prioreschi A, 2012, INT J SPORTS MED, V33, P593, DOI 10.1055/s-0032-1301886; Prioreschi A, 2013, RHEUMATOLOGY, V53, P1; Prioreschi A, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-403; REDELMEIER DA, 1993, ARCH INTERN MED, V153, P1337, DOI 10.1001/archinte.153.11.1337; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; Rodriguez-Miguelez P, 2015, MECH AGEING DEV, V150, P12, DOI 10.1016/j.mad.2015.08.002; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; Sanderson T, 2010, ARTHRIT CARE RES, V62, P647, DOI 10.1002/acr.20151; Sanudo B, 2010, CLIN EXP RHEUMATOL, V28, pS40; Schneider M, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-54; Tapp LR, 2014, CLIN INTERV AGING, V9, P63, DOI 10.2147/CIA.S30048; Tremblay MS, 2010, APPL PHYSIOL NUTR ME, V35, P725, DOI 10.1139/H10-079; Tudor-Locke C, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110332; Tudor-Locke C, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-60; Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756-3282(98)00118-5; Turner CH, 2005, BRIT J SPORT MED, V39, P188, DOI 10.1136/bjsm.2004.016923; Uzer G, 2013, J BIOMECH, V46, P2296, DOI 10.1016/j.jbiomech.2013.06.008; Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245; Wysocki A, 2011, REV ANN INTERNAL MED, P155; Zhou Y, 2015, BONE, V71, P17, DOI 10.1016/j.bone.2014.09.026	53	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2016	11	4							e0153470	10.1371/journal.pone.0153470	http://dx.doi.org/10.1371/journal.pone.0153470			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ3UC	27073832	Green Submitted, Green Published, gold			2023-01-03	WOS:000374131200097
J	Zitvogel, L; Ayyoub, M; Routy, B; Kroemer, G				Zitvogel, Laurence; Ayyoub, Maha; Routy, Bertrand; Kroemer, Guido			Microbiome and Anticancer Immunosurveillance	CELL			English	Review							REGULATORY T-CELLS; INFLAMMATORY-BOWEL-DISEASE; ANTIGEN-PRESENTING CELLS; NATURAL-KILLER-CELLS; GUT MICROBIOTA; IMMUNE-SYSTEM; INTESTINAL MICROBIOTA; EPITHELIAL BARRIERS; ANTITUMOR IMMUNITY; AUTOIMMUNE-DISEASE	Anticancer immune responses can be considered a desirable form of autoimmunity that may be profoundly shaped by the microbiome. Here, we discuss evidence for the microbiome's influence on anti-tumor immunosurveillance, including those that are indirect and can act at a distance, and we put forward hypotheses regarding mechanisms of how these effects are implemented. These may involve cross-reactivity between microbial and tumor antigens shaping T cell repertoires and/or microbial products stimulating pattern recognition receptors that influence the type and intensity of immune responses. Understanding how the microbiome impacts natural cancer immunosurveillance as well as treatment-induced immune responses will pave the way for more effective therapies and prophylactics.	[Zitvogel, Laurence; Ayyoub, Maha; Routy, Bertrand] INSERM, Equipe Labellisee Ligue Natl Canc, U1015, Gustave Roussy Canc Campus, F-95800 Villejuif, France; [Zitvogel, Laurence; Ayyoub, Maha; Routy, Bertrand] Univ Paris 11, F-94270 Le Kremlin Bicetre, France; [Zitvogel, Laurence; Ayyoub, Maha; Routy, Bertrand] Ctr Clin Invest Biotherapies Canc, F-95800 Villejuif, France; [Kroemer, Guido] Ctr Rech Cordeliers, Equipe Labellise Ligue Canc 11, F-75006 Paris, France; [Kroemer, Guido] Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, F-95800 Villejuif, France; [Kroemer, Guido] INSERM, U1138, F-75006 Paris, France; [Kroemer, Guido] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France; [Kroemer, Guido] Univ Paris 06, F-75006 Paris, France; [Kroemer, Guido] Hop Europe Georges Pompidou, AP HP, Pole Biol, F-75015 Paris, France; [Kroemer, Guido] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital	Zitvogel, L (corresponding author), INSERM, Equipe Labellisee Ligue Natl Canc, U1015, Gustave Roussy Canc Campus, F-95800 Villejuif, France.; Zitvogel, L (corresponding author), Univ Paris 11, F-94270 Le Kremlin Bicetre, France.; Zitvogel, L (corresponding author), Ctr Clin Invest Biotherapies Canc, F-95800 Villejuif, France.; Kroemer, G (corresponding author), Ctr Rech Cordeliers, Equipe Labellise Ligue Canc 11, F-75006 Paris, France.; Kroemer, G (corresponding author), Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, F-95800 Villejuif, France.; Kroemer, G (corresponding author), INSERM, U1138, F-75006 Paris, France.; Kroemer, G (corresponding author), Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France.; Kroemer, G (corresponding author), Univ Paris 06, F-75006 Paris, France.; Kroemer, G (corresponding author), Hop Europe Georges Pompidou, AP HP, Pole Biol, F-75015 Paris, France.; Kroemer, G (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden.	laurence.zitvogel@gustaveroussy.fr; kroemer@orange.fr	Ayyoub, Maha/A-2074-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	Ayyoub, Maha/0000-0003-2022-0898; KROEMER, Guido/0000-0002-9334-4405; ZITVOGEL, laurence/0000-0003-1596-0998	Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR)-Projets blancs; ANR; ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LeDucq Foundation; LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); Cancer Research Institute (CRI); Ludwig Institute for Cancer Research (LICR)	Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); ANR(French National Research Agency (ANR)); ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)); LeDucq Foundation(Leducq Foundation); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); Cancer Research Institute (CRI); Ludwig Institute for Cancer Research (LICR)	L.Z. and G.K. are supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LeDucq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). M.A. is supported by the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research (LICR).	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bindels LB, 2012, BRIT J CANCER, V107, P1337, DOI 10.1038/bjc.2012.409; Boursi B, 2015, EUR J CANCER, V51, P2655, DOI 10.1016/j.ejca.2015.08.015; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Burgener A, 2015, CURR OPIN IMMUNOL, V36, P22, DOI 10.1016/j.coi.2015.06.004; Burrows MP, 2015, P NATL ACAD SCI USA, V112, P9973, DOI 10.1073/pnas.1508740112; Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335; Cheng M, 2014, CANCER RES, V74, P4030, DOI 10.1158/0008-5472.CAN-13-2462; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Deshmukh US, 2011, J AUTOIMMUN, V37, P254, DOI 10.1016/j.jaut.2011.07.002; Dominianni C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124599; Dutoit V, 2002, J EXP MED, V196, P207, DOI 10.1084/jem.20020242; Floreani A., 2015, CLIN REV ALLERGY IMM; Friedman GD, 2006, CANCER EPIDEM BIOMAR, V15, P2102, DOI 10.1158/1055-9965.EPI-06-0401; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gagliani N, 2014, CELL, V157, P776, DOI 10.1016/j.cell.2014.03.006; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Green SI, 2015, INFECT IMMUN, V83, P3243, DOI 10.1128/IAI.00684-15; Greig SL, 2015, DRUGS, V75, P1687, DOI 10.1007/s40265-015-0462-2; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; Hand TW, 2012, SCIENCE, V337, P1553, DOI 10.1126/science.1220961; Harkiolaki M, 2009, IMMUNITY, V30, P348, DOI 10.1016/j.immuni.2009.01.009; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Honda K, 2012, ANNU REV IMMUNOL, V30, P759, DOI 10.1146/annurev-immunol-020711-074937; Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Jacquelot N, 2016, J CLIN INVEST, V126, P921, DOI 10.1172/JCI80071; Kiselyov A, 2015, BBA CLIN, V4, P27, DOI 10.1016/j.bbacli.2015.06.002; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; KROEMER G, 1993, ADV IMMUNOL, V53, P157, DOI 10.1016/S0065-2776(08)60500-3; Kroemer G, 2015, NAT MED, V21, P1128, DOI 10.1038/nm.3944; Kunisawa J, 2008, TRENDS IMMUNOL, V29, P505, DOI 10.1016/j.it.2008.07.008; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; LIN RS, 1995, J HEPATOL, V22, P165, DOI 10.1016/0168-8278(95)80424-2; Lochner M, 2011, J IMMUNOL, V186, P1531, DOI 10.4049/jimmunol.1001723; Longman RS, 2015, CURR OPIN RHEUMATOL, V27, P381, DOI 10.1097/BOR.0000000000000190; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135; Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006; Martin FPJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100153; Matsumura S, 2002, HEPATOLOGY, V35, P14, DOI 10.1053/jhep.2002.30280; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Meier C, 2007, NAT CLIN PRACT RHEUM, V3, P667, DOI 10.1038/ncprheum0625; Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377; Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279; Morton AM, 2014, P NATL ACAD SCI USA, V111, P6696, DOI 10.1073/pnas.1405634111; O'Keefe SJD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7342; Oikonomopoulou K, 2013, CLIN CANCER RES, V19, P2834, DOI 10.1158/1078-0432.CCR-12-3661; Parodi S, 2013, INT J CANCER, V133, P1892, DOI 10.1002/ijc.28205; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Perez-Chanona E, 2016, CURR OPIN IMMUNOL, V39, P75, DOI 10.1016/j.coi.2016.01.003; Raffin C, 2013, J IMMUNOL, V191, P4619, DOI 10.4049/jimmunol.1301378; Rojo D, 2015, SCI REP-UK, V5, DOI 10.1038/srep08310; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosadi F, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv105; Rossini A, 2006, CANCER RES, V66, P6219, DOI 10.1158/0008-5472.CAN-05-4592; Rubio-Godoy V, 2002, J IMMUNOL, V169, P5696, DOI 10.4049/jimmunol.169.10.5696; Ruff WE, 2015, TRENDS MOL MED, V21, P233, DOI 10.1016/j.molmed.2015.02.006; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009; Saito K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145788; Sanchez B, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00594; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sigmundsdottir H, 2008, NAT IMMUNOL, V9, P981, DOI 10.1038/ni.f.208; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974; Souza DG, 2004, J IMMUNOL, V173, P4137, DOI 10.4049/jimmunol.173.6.4137; Spadoni I, 2015, SCIENCE, V350, P830, DOI 10.1126/science.aad0135; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021; Szymula A, 2014, CLIN IMMUNOL, V152, P1, DOI 10.1016/j.clim.2014.02.004; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Tomura M, 2008, P NATL ACAD SCI USA, V105, P10871, DOI 10.1073/pnas.0802278105; Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Vujanovic L, 2007, CLIN CANCER RES, V13, P6796, DOI 10.1158/1078-0432.CCR-07-1909; Wheeler R, 2014, CELL MICROBIOL, V16, P1014, DOI 10.1111/cmi.12304; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Wilson HL, 2015, MOL IMMUNOL, V66, P22, DOI 10.1016/j.molimm.2014.09.004; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Xu XF, 2015, MICROBIOL RES, V171, P97, DOI 10.1016/j.micres.2014.11.002; Yang Y, 2014, NATURE, V510, P152, DOI 10.1038/nature13279; Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599; Yurkovetskiy LA, 2015, CELL HOST MICROBE, V17, P548, DOI 10.1016/j.chom.2015.04.010; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014	107	250	267	1	112	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 7	2016	165	2					276	287		10.1016/j.cell.2016.03.001	http://dx.doi.org/10.1016/j.cell.2016.03.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DJ3RJ	27058662	Bronze			2023-01-03	WOS:000374123000008
J	Li, KJ; Yu, Y; Sun, S; Liu, Y; Garg, S; Kaul, SC; Lei, ZF; Gao, R; Wadhwa, R; Zhang, ZY				Li, Kejuan; Yu, Yue; Sun, Shuang; Liu, Ye; Garg, Sukant; Kaul, Sunil C.; Lei, Zhongfang; Gao, Ran; Wadhwa, Renu; Zhang, Zhenya			Functional Characterisation of Anticancer Activity in the Aqueous Extract of Helicteres angustifolia L. Roots	PLOS ONE			English	Article							CANCER-CELLS; LEAF EXTRACT; HNRNP-K; TUMOR; IDENTIFICATION; CONSTITUENTS; ASHWAGANDHA; DERIVATIVES; INDUCTION; APOPTOSIS	Helicteres angustifolia L. is a shrub that forms a common ingredient of several cancer treatment recipes in traditional medicine system both in China and Laos. In order to investigate molecular mechanisms of its anticancer activity, we prepared aqueous extract of Helicteres angustifolia L. Roots (AQHAR) and performed several in vitro assays using human normal fibroblasts (TIG-3) and osteosarcoma (U2OS). We found that AQHAR caused growth arrest/apoptosis of U2OS cells in a dose-dependent manner. It showed no cytotoxicity to TIG-3 cells at doses up to 50 mu g/ml. Biochemical, imaging and cell cycle analyses revealed that it induces ROS signaling and DNA damage response selectively in cancer cells. The latter showed upregulation of p53, p21 and downregulation of Cyclin B1 and phospho-Rb. Furthermore, AQHAR-induced apoptosis was mediated by increase in pro-apoptotic proteins including cleaved PARP, caspases and Bax. Anti-apoptotic protein Bcl-2 showed decrease in AQHAR-treated U2OS cells. In vivo xenograft tumor assays in nude mice revealed dose-dependent suppression of tumor growth and lung metastasis with no toxicity to the animals suggesting that AQHAR could be a potent and safe natural drug for cancer treatment.	[Li, Kejuan; Yu, Yue; Sun, Shuang; Liu, Ye; Lei, Zhongfang; Zhang, Zhenya] Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan; [Li, Kejuan; Yu, Yue; Garg, Sukant; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, Drug Discovery & Assets Innovat Lab, DAILAB, Cent 5-41,1-1-1 Higashi, Tsukuba, Ibaraki 3058565, Japan; [Garg, Sukant; Wadhwa, Renu] Univ Tsukuba, Sch Integrat & Global Majors, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan; [Gao, Ran] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100021, Peoples R China	University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS	Zhang, ZY (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.; Wadhwa, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Drug Discovery & Assets Innovat Lab, DAILAB, Cent 5-41,1-1-1 Higashi, Tsukuba, Ibaraki 3058565, Japan.; Wadhwa, R (corresponding author), Univ Tsukuba, Sch Integrat & Global Majors, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.	renu-wadhwa@aist.go.jp; zhang.zhenya.fu@u.tsukuba.ac.jp	Yu, Yue/AAM-9329-2020; Lei, Zhongfang/V-8241-2019; Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; Lei, Zhongfang/B-3611-2014	Yu, Yue/0000-0002-7620-6078; Lei, Zhongfang/0000-0002-0479-6179; Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; Gao, Ran/0000-0001-8712-429X; Liu, Ye/0000-0002-4845-6643	Institute of Laboratory Animal Science, CAMSPUMC [DWS201402]; National Institute of Advanced Industrial Science & Technology (AIST) Special Research Fund	Institute of Laboratory Animal Science, CAMSPUMC; National Institute of Advanced Industrial Science & Technology (AIST) Special Research Fund	The study was supported by grants from the Institute of Laboratory Animal Science, CAMS&PUMC (DWS201402) to RG and National Institute of Advanced Industrial Science & Technology (AIST) Special Research Fund to SCK and RW.	Achliya GS, 2004, J ETHNOPHARMACOL, V90, P229, DOI 10.1016/j.jep.2003.09.037; CHEN CM, 1990, PHYTOCHEMISTRY, V29, P980, DOI 10.1016/0031-9422(90)80061-K; Chen WL, 2006, PHYTOCHEMISTRY, V67, P1041, DOI 10.1016/j.phytochem.2006.03.005; Chen ZT, 2006, CHEM PHARM BULL, V54, P1605, DOI 10.1248/cpb.54.1605; CHEN ZT, 1994, HETEROCYCLES, V38, P1399, DOI 10.3987/COM-94-6710; Chiu NY, 1995, ILLUSTRATED MED PLAN, V1, P104; Collins A, 2003, CANCER LETT, V189, P49, DOI 10.1016/S0304-3835(02)00502-5; Ding HM, 2009, NUTR CANCER, V61, P348, DOI 10.1080/01635580802567158; Duangmano S, 2012, J ONCOL, V2012, DOI 10.1155/2012/601682; Duangmano S, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-185; Efferth T, 2007, CURR MED CHEM, V14, P2024; Gao R, 2013, J BIOL CHEM, V288, P15046, DOI 10.1074/jbc.M113.466136; Inoue A, 2007, P NATL ACAD SCI USA, V104, P8983, DOI 10.1073/pnas.0607595104; Jiangsu New Medical College (JNMC), 1986, DICT CHIN HERB MED, P178; Kavitha K., 2006, Indian Journal of Pharmacology, V38, P185; Li D, 2007, J PHARMACOL SCI, V103, P56, DOI 10.1254/jphs.FPJ06016X; Li KJ, 2016, J TAIWAN INST CHEM E, V61, P75, DOI 10.1016/j.jtice.2015.12.022; Li KJ, 2015, J ETHNOPHARMACOL, V172, P61, DOI 10.1016/j.jep.2015.06.007; Navarro J, 1997, FREE RADICAL BIO MED, V22, P1203, DOI 10.1016/S0891-5849(96)00554-0; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Pan MH, 2008, CHEM BIODIVERS, V5, P565, DOI 10.1002/cbdv.200890053; Piccirillo S, 2009, J BIOL CHEM, V284, P27721, DOI 10.1074/jbc.M109.014837; Ryu J, 2014, J BIOL CHEM, V289, P24832, DOI 10.1074/jbc.M114.565929; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978-1-61779-998-3_40; Sreelatha S, 2011, FOOD CHEM TOXICOL, V49, P1270, DOI 10.1016/j.fct.2011.03.006; Stewart BS, WORLD CANCER REPORT, V9283204298; Vojnovic B, 2003, HIGH SENSITIVITY HIG; Wadhwa R, 2006, INT J CANCER, V118, P2973, DOI 10.1002/ijc.21773; Wadhwa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077189; Wang GC, 2012, FITOTERAPIA, V83, P1643, DOI 10.1016/j.fitote.2012.09.016; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Yoo JY, 2010, J GENE MED, V12, P586, DOI 10.1002/jgm.1471	35	14	15	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0152017	10.1371/journal.pone.0152017	http://dx.doi.org/10.1371/journal.pone.0152017			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3SV	27010955	Green Submitted, Green Published, gold			2023-01-03	WOS:000372708000071
J	Song, J; Tanida, M; Shibamoto, T; Zhang, T; Wang, MF; Kuda, Y; Kurata, Y				Song, Jie; Tanida, Mamoru; Shibamoto, Toshishige; Zhang, Tao; Wang, Mofei; Kuda, Yuhichi; Kurata, Yasutaka			The Role of Lumbar Sympathetic Nerves in Regulation of Blood Flow to Skeletal Muscle during Anaphylactic Hypotension in Anesthetized Rats	PLOS ONE			English	Article							NITRIC-OXIDE; VASOCONSTRICTION; SHOCK; ANTAGONISTS; INHIBITION; MECHANISMS; RESPONSES; SYSTEM	During hypovolemic shock, skeletal muscle blood flow could be redistributed to vital organs via vasoconstriction in part evoked by activation of the innervating sympathetic nerve activity. However, it is not well known whether this mechanism operates during anaphylactic shock. We determined the femoral artery blood flow (FBF) and lumbar sympathetic nerve activity (LSNA) mainly regulating the hindquater muscle blood flow during anaphylactic hypotension in anesthetized rats. Anesthetized Sprague-Dawley rats were randomly allocated to the following groups (n = 7/group): (1) non-sensitized, (2) anaphylaxis, (3) anaphylaxis-lumbar sympathectomy (LS) and (4) anaphylaxis-sinoaortic denervation (SAD) groups. Anaphylaxis was induced by an intravenous injection of the ovalbumin antigen to the sensitized rats. The systemic arterial pressure (SAP), heart rate (HR), central venous pressure (CVP), FBF and LSNA were continuously measured. In the anaphylaxis group, LSNA and HR increased, while SAP and FBF decreased after antigen injection. In the anaphylaxis-SAD group, LSNA did not significantly change during the early phase, but the responses of SAP and FBF were similar to those in the anaphylaxis group. In the anaphylaxis-LS group, both FBF and SAP decreased similarly to the anaphylaxis group during anaphylactic hypotension. These results indicated that LSNA increased via baroreceptor reflex, but this sympathoexcitation or LS did not affect antigen-induced decreases in FBF or SAP. Lumbar sympathetic nerves are not involved in regulation of the blood flow to the hindlimb or systemic blood pressure during anaphylactic hypotension in anesthetized rats.	[Song, Jie; Tanida, Mamoru; Shibamoto, Toshishige; Zhang, Tao; Wang, Mofei; Kuda, Yuhichi; Kurata, Yasutaka] Kanazawa Med Univ, Dept Physiol 2, Uchinada, Ishikawa 9200293, Japan; [Song, Jie] China Japan Friendship Hosp, Dept Anesthesiol, Beijing 100029, Peoples R China; [Zhang, Tao] China Med Univ, Affiliated Hosp 4, Dept Colorectal & Hernia Surg, Shenyang 110032, Peoples R China; [Wang, Mofei] China Med Univ, Affiliated Hosp 4, Dept Diabet Surg, Shenyang 110032, Peoples R China	Kanazawa Medical University; China-Japan Friendship Hospital; China Medical University; China Medical University	Tanida, M; Shibamoto, T (corresponding author), Kanazawa Med Univ, Dept Physiol 2, Uchinada, Ishikawa 9200293, Japan.	mtanida@kanazawa-med.ac.jp; shibamo@kanazawa-med.ac.jp			Kanazawa Medical University [S2013-1]; Mishima Kaiun Memorial Foundation [11]; Takeda Science Foundation; Grants-in-Aid for Scientific Research [16K09767] Funding Source: KAKEN	Kanazawa Medical University; Mishima Kaiun Memorial Foundation(Mishima Kaiun Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study is supported by grants from Grant for Promoted Research from Kanazawa Medical University (MT, S2013-1, http://www.kanazawa-med.ac.jp/kenkyu/publication.html), from Mishima Kaiun Memorial Foundation (MT, No11, http://www.mishima-kaiun.or.jp/assist/2147.html) and from Takeda Science Foundation (MT, http://www.takeda-sci.or.jp/business/doc/2013_list.pdf). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1990, EUROPEAN RESPIRATORY; BARON R, 1988, J COMP NEUROL, V275, P460, DOI 10.1002/cne.902750310; BAYORH MA, 1985, PROSTA LEUKOTR MED, V17, P229, DOI 10.1016/0262-1746(85)90110-6; BRANTIGAN JW, 1974, J APPL PHYSIOL, V37, P117, DOI 10.1152/jappl.1974.37.1.117; Coney AM, 2003, J PHYSIOL-LONDON, V549, P613, DOI 10.1113/jphysiol.2003.042267; Dewachter P, 2005, ANESTHESIOLOGY, V103, P40, DOI 10.1097/00000542-200507000-00010; Hui YQ, 2004, CIRCULATION, V110, P3360, DOI 10.1161/01.CIR.0000147775.50954.AA; Jendzjowsky NG, 2013, J APPL PHYSIOL, V115, P97, DOI 10.1152/japplphysiol.00250.2013; KAPIN MA, 1985, AM J PHYSIOL, V249, pH430, DOI 10.1152/ajpheart.1985.249.2.H430; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; MATHISON R, 1992, BRIT J PHARMACOL, V106, P263, DOI 10.1111/j.1476-5381.1992.tb14326.x; Miki K, 2004, J PHYSIOL-LONDON, V557, P261, DOI 10.1113/jphysiol.2003.055525; MITSUHATA H, 1995, J CLIN IMMUNOL, V15, P277, DOI 10.1007/BF01541317; Moreira TS, 2011, BRAZ J MED BIOL RES, V44, P883, DOI 10.1590/S0100-879X2011000900009; OFFNER B, 1994, J APPL PHYSIOL, V77, P173, DOI 10.1152/jappl.1994.77.1.173; Potas JR, 2004, AUTON NEUROSCI-BASIC, V112, P25, DOI 10.1016/j.autneu.2004.03.004; Shibamoto T, 2005, AM J PHYSIOL-HEART C, V289, pH1436, DOI 10.1152/ajpheart.00368.2005; SMEDEGARD G, 1979, ACTA PHYSIOL SCAND, V106, P191, DOI 10.1111/j.1748-1716.1979.tb06389.x; Sun LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113945; Thomas GD, 1998, J PHYSIOL-LONDON, V506, P817, DOI 10.1111/j.1469-7793.1998.817bv.x; VATNER SF, 1974, J CLIN INVEST, V54, P225, DOI 10.1172/JCI107757; Wang MF, 2015, EXP LUNG RES, V41, P324, DOI 10.3109/01902148.2015.1032448; Wang M, 2014, EUR J PHARMACOL, V731, P38, DOI 10.1016/j.ejphar.2014.03.012; Wang MF, 2013, AM J PHYSIOL-REG I, V305, pR900, DOI 10.1152/ajpregu.00120.2013; Zhang W, 2013, IN VIVO, V27, P485; Zhang W, 2012, AM J PHYSIOL-REG I, V302, pR1191, DOI 10.1152/ajpregu.00695.2011; Zhang W, 2011, ANESTHESIOLOGY, V114, P614, DOI 10.1097/ALN.0b013e31820b8d34	27	6	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2016	11	3							e0150882	10.1371/journal.pone.0150882	http://dx.doi.org/10.1371/journal.pone.0150882			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3NW	26998924	Green Published, gold, Green Submitted			2023-01-03	WOS:000372694700017
J	Reddy, M; Rilstone, S; Cooper, P; Oliver, NS				Reddy, Monika; Rilstone, Sian; Cooper, Philippa; Oliver, Nick S.			Type 1 diabetes in adults: supporting self management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; CONTROLLED CLINICAL-TRIAL; AWARENESS TRAINING BGAT; BLOOD-GLUCOSE PROFILES; EDUCATION-PROGRAM; METABOLIC-CONTROL; GLYCEMIC CONTROL; GLYCOSYLATED HEMOGLOBIN; TELEMEDICINE SYSTEM; SEVERE HYPOGLYCEMIA		[Reddy, Monika; Oliver, Nick S.] Univ London Imperial Coll Sci Technol & Med, Dept Diabet Endocrinol & Metab, St Marys Hosp Campus, London W2 1PG, England; [Reddy, Monika; Rilstone, Sian; Oliver, Nick S.] Imperial Healthcare NHS Trust, Diabet & Endocrinol, London, England	Imperial College London	Oliver, NS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Diabet Endocrinol & Metab, St Marys Hosp Campus, London W2 1PG, England.; Oliver, NS (corresponding author), Imperial Healthcare NHS Trust, Diabet & Endocrinol, London, England.	nick.oliver@imperial.ac.uk	Oliver, Nick S/G-9109-2016	Oliver, Nick S/0000-0003-3525-3633				Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746; Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069; [Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; CALLEPASCUAL AL, 1988, DIABETES METAB, V14, P629; Charpentier G, 2011, DIABETES CARE, V34, P533, DOI 10.2337/dc10-1259; CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517; Cox DJ, 2004, INT J BEHAV MED, V11, P212, DOI 10.1207/s15327558ijbm1104_4; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; DEWEERDT I, 1991, DIABETIC MED, V8, P338; Dyson PA, 2011, DIABETIC MED, V28, P1282, DOI [10.1111/j.1464-5491.2011.03371.x, 10.1111/dme.13603]; Evert AB, 2013, DIABETES CARE, V36, P3821, DOI 10.2337/dc13-2042; Gadsby R, 2013, DIABETIC MED, V30, P799, DOI 10.1111/dme.12182; Galassetti P, 2013, COMPR PHYSIOL, V3, P1309, DOI 10.1002/cphy.c110040; George JT, 2008, DIABETIC MED, V25, P1447, DOI 10.1111/j.1464-5491.2008.02607.x; GOLD AE, 1994, DIABETES CARE, V17, P697, DOI 10.2337/diacare.17.7.697; Group TNA, 2014, 1 HLTH SOC CAR INF C, V1, P28; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; Hermanns N, 2007, DIABETES-METAB RES, V23, P528, DOI 10.1002/dmrr.710; Hermanns N, 2013, DIABETES RES CLIN PR, V102, P149, DOI 10.1016/j.diabres.2013.10.009; ISO, 2013, ISO 15197; KORHONEN T, 1983, DIABETES CARE, V6, P256, DOI 10.2337/diacare.6.3.256; Kovatchev BP, 2000, METHOD ENZYMOL, V321, P410; Laffel LMB, 2006, DIABETIC MED, V23, P278, DOI 10.1111/j.1464-5491.2005.01771.x; Laurenzi A, 2011, DIABETES CARE, V34, P823, DOI 10.2337/dc10-1490; Lawton J, 2014, DIABETES CARE, V37, P109, DOI 10.2337/dc13-1154; Laxminarayan S, 2015, DIABETES TECHNOL THE, V17, P860, DOI 10.1089/dia.2015.0118; LENNON GM, 1990, DIABETIC MED, V7, P825, DOI 10.1111/j.1464-5491.1990.tb01500.x; Mann JI, 2004, NUTR METAB CARDIOVAS, V14, P373, DOI 10.1016/S0939-4753(04)80028-0; MCCULLOCH DK, 1985, DIABETOLOGIA, V28, P208, DOI 10.1007/BF00282234; McTavish L, 2015, DIABETIC MED, V32, P1143, DOI 10.1111/dme.12730; Miller KM, 2013, DIABETES CARE, V36, P2009, DOI 10.2337/dc12-1770; Monami M, 2009, DIABETES OBES METAB, V11, P372, DOI 10.1111/j.1463-1326.2008.00976.x; National Institute for Health and Care Excellence, 2015, TYP 1 DIAB AD DIAGN, P612; Nutrition SACo, 2015, CARB HLTH; Pickup JC, 2012, NAT REV ENDOCRINOL, V8, P425, DOI 10.1038/nrendo.2012.28; Rossi MCE, 2010, DIABETES CARE, V33, P109, DOI 10.2337/dc09-1327; Rossi MCE, 2009, DIABETES TECHNOL THE, V11, P19, DOI 10.1089/dia.2008.0020; Rossi MC, 2013, DIABETES TECHNOL THE, V15, P670, DOI 10.1089/dia.2013.0021; Scavone G, 2010, DIABETIC MED, V27, P477, DOI 10.1111/j.1464-5491.2010.02963.x; Schachinger H, 2005, J BEHAV MED, V28, P587, DOI 10.1007/s10865-005-9026-3; Schmidt S, 2012, DIABETES CARE, V35, P984, DOI 10.2337/dc11-2044; Service F John, 2007, Endocr Pract, V13, P350; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Skeie Svein, 2009, J Diabetes Sci Technol, V3, P83; Snoek FJ, 2008, DIABETIC MED, V25, P1337, DOI 10.1111/j.1464-5491.2008.02595.x; Snow R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003583; Sovik O, 1999, DIABETES CARE, V22, pB40; Speight J, 2007, DIABETIC MED, V24, P95; TERENT A, 1985, ACTA MED SCAND, V217, P47; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Trento M, 2005, NUTR METAB CARDIOVAS, V15, P293, DOI 10.1016/j.numecd.2004.12.005; Trento M, 2011, J ENDOCRINOL INVEST, V34, P101, DOI [10.3275/7027, 10.1007/BF03347038]; Vervoort G, 1996, DIABETIC MED, V13, P794; Wei N, 2014, DIABETES CARE, V37, P1048, DOI 10.2337/dc13-2173; Ziegler R, 2013, DIABETES CARE, V36, P3613, DOI 10.2337/dc13-0251	55	29	32	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 10	2016	352								i998	10.1136/bmj.i998	http://dx.doi.org/10.1136/bmj.i998			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG4NP	26965473	Green Published			2023-01-03	WOS:000372049200002
J	Bellani, G; Laffey, JG; Pham, T; Fan, E; Brochard, L; Esteban, A; Gattinoni, L; van Haren, F; Larsson, A; McAuley, DF; Ranieri, M; Rubenfeld, G; Thompson, BT; Wrigge, H; Slutsky, AS; Pesenti, A				Bellani, Giacomo; Laffey, John G.; Pham, Tai; Fan, Eddy; Brochard, Laurent; Esteban, Andres; Gattinoni, Luciano; van Haren, Frank; Larsson, Anders; McAuley, Daniel F.; Ranieri, Marco; Rubenfeld, Gordon; Thompson, B. Taylor; Wrigge, Hermann; Slutsky, Arthur S.; Pesenti, Antonio		LUNG SAFE Investigators & ESICM	Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LUNG INJURY; VENTILATION; UNDERRECOGNITION; PRESSURE; UNDERUSE	IMPORTANCE Limited information exists about the epidemiology, recognition, management, and outcomes of patients with the acute respiratory distress syndrome (ARDS). OBJECTIVES To evaluate intensive care unit (ICU) incidence and outcome of ARDS and to assess clinician recognition, ventilation management, and use of adjuncts-for example prone positioning-in routine clinical practice for patients fulfilling the ARDS Berlin Definition. DESIGN, SETTING, AND PARTICIPANTS The Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) was an international, multicenter, prospective cohort study of patients undergoing invasive or noninvasive ventilation, conducted during 4 consecutive weeks in the winter of 2014 in a convenience sample of 459 ICUs from 50 countries across 5 continents. EXPOSURES Acute respiratory distress syndrome. MAIN OUTCOMES AND MEASURES The primary outcome was ICU incidence of ARDS. Secondary outcomes included assessment of clinician recognition of ARDS, the application of ventilatory management, the use of adjunctive interventions in routine clinical practice, and clinical outcomes from ARDS. RESULTS Of 29 144 patients admitted to participating ICUs, 3022 (10.4%) fulfilled ARDS criteria. Of these, 2377 patients developed ARDS in the first 48 hours and whose respiratory failure was managed with invasive mechanical ventilation. The period prevalence of mild ARDS was 30.0%(95% CI, 28.2%-31.9%); of moderate ARDS, 46.6%(95% CI, 44.5%-48.6%); and of severe ARDS, 23.4%(95% CI, 21.7%-25.2%). ARDS represented 0.42 cases per ICU bed over 4 weeks and represented 10.4%(95% CI, 10.0%-10.7%) of ICU admissions and 23.4% of patients requiring mechanical ventilation. Clinical recognition of ARDS ranged from 51.3% (95% CI, 47.5%-55.0%) in mild to 78.5%(95% CI, 74.8%-81.8%) in severe ARDS. Less than two-thirds of patients with ARDS received a tidal volume 8 of mL/kg or less of predicted body weight. Plateau pressure was measured in 40.1%(95% CI, 38.2-42.1), whereas 82.6%(95% CI, 81.0%-84.1%) received a positive end-expository pressure (PEEP) of less than 12 cm H2O. Prone positioning was used in 16.3%(95% CI, 13.7%-19.2%) of patients with severe ARDS. Clinician recognition of ARDS was associated with higher PEEP, greater use of neuromuscular blockade, and prone positioning. Hospital mortality was 34.9%(95% CI, 31.4%-38.5%) for those with mild, 40.3%(95% CI, 37.4%-43.3%) for those with moderate, and 46.1%(95% CI, 41.9%-50.4%) for those with severe ARDS. CONCLUSIONS AND RELEVANCE Among ICUs in 50 countries, the period prevalence of ARDS was 10.4% of ICU admissions. This syndrome appeared to be underrecognized and undertreated and associated with a high mortality rate. These findings indicate the potential for improvement in the management of patients with ARDS.	[Bellani, Giacomo] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy; [Bellani, Giacomo] San Gerardo Hosp, Dept Emergency & Intens Care, Monza, Italy; [Laffey, John G.] St Michaels Hosp, Dept Anesthesia & Crit Care Med, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Laffey, John G.] Univ Toronto, Dept Anesthesia, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Laffey, John G.] Univ Toronto, Dept Physiol, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Laffey, John G.; Fan, Eddy; Brochard, Laurent; Esteban, Andres; Rubenfeld, Gordon; Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Pham, Tai] Grp Hosp Hop Univ Est Parisien, Hop Tenon, AP HP, Unite Reanimat Med Chirurgicale,Pole Thorax Voies, Paris, France; [Pham, Tai] Univ Paris Diderot, Sorbonne Paris Cite, ECSTRA Team, UMR 1153,Inserm, Paris, France; [Pham, Tai] Univ Paris Est Creteil, UMR 915, INSERM, Creteil, France; [Fan, Eddy] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Fan, Eddy] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Fan, Eddy] Univ Toronto, Inst Hlth Policy Management & Evaluat, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Brochard, Laurent] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Esteban, Andres] Hosp Univ Getafe, CIBER Enfermedades Respiratorias, Madrid, Spain; [Gattinoni, Luciano; Pesenti, Antonio] Univ Milan, Ist Anestesia & Rianimaz, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, Milan, Italy; [van Haren, Frank] Canberra Hosp, Intens Care Unit, Canberra, ACT, Australia; [van Haren, Frank] Australian Natl Univ, Canberra, ACT, Australia; [Larsson, Anders] Uppsala Univ, Sect Anesthesiol & Intens Care, Dept Surg Sci, Uppsala, Sweden; [McAuley, Daniel F.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Reg Intens Care Unit, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland; [Ranieri, Marco] Policlin Umberto 1, SAPIENZA Univ ROMA, Dipartimento Anestesia & Rianimaz, Viale Policlin 155, I-00161 Rome, Italy; [Rubenfeld, Gordon] Sunnybrook Hlth Sci Ctr, Program Trauma Emergency & Crit Care, Toronto, ON M4N 3M5, Canada; [Thompson, B. Taylor] Harvard Univ, Sch Med, Div Pulm, Boston, MA USA; [Thompson, B. Taylor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Crit Care Unit,Dept Med, Boston, MA USA; [Wrigge, Hermann] Univ Leipzig, Dept Anesthesiol & Intens Care Med, Liebigstr 20, D-04103 Leipzig, Germany; [Slutsky, Arthur S.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada	University of Milano-Bicocca; San Gerardo Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitario de Getafe; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Australian National University; Canberra Hospital; Australian National University; Uppsala University; Queens University Belfast; Sapienza University Rome; University Hospital Sapienza Rome; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Leipzig University; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Laffey, JG (corresponding author), Univ Toronto, Dept Anesthesia, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Laffey, JG (corresponding author), Univ Toronto, Dept Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Laffey, JG (corresponding author), Univ Toronto, Dept Crit Care Med, Keenan Res Ctr Biomed Sci, St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	laffeyj@smh.ca	Laake, Jon Henrik/L-3224-2019; Martinez, Felipe/ABF-5868-2021; Grigoryev, Evgeny/A-2321-2017; Chiche, Jean-Daniel/P-5220-2017; Cortegiani, Andrea/H-4902-2016; Battle, Ceri/AAK-5856-2021; Simon, Philipp/AAL-5318-2021; Frendl, Gyorgy/AAE-5345-2020; Volta, Carlo A/G-5981-2012; Rylander, Christian/AAV-3713-2020; Colombo, Riccardo/AAK-9081-2020; Occhipinti, Giovanna/K-7307-2016; erbabacan, safak emre/D-4940-2019; Meybohm, Patrick/K-4066-2017; Slutsky, Arthur/M-3325-2019; Roux, Damien/L-3671-2014; Rialp, Gemma/I-3353-2016; Ulatan, Jeffrey/AAM-5560-2020; CORNECI, DAN/ABG-1803-2021; Máca, Jan/E-4868-2017; Pesenti, Antonio/H-7483-2012; Reske, Andreas W/E-8141-2010; Berger-Estilita, Joana/AAB-4497-2021; Mehta, Sangeeta/C-4623-2015; Szakmany, Tamas/I-5546-2019; Conti, Sara/J-4891-2019; Tomescu, Dana/J-9941-2013; POTA, VINCENZO/C-4837-2013; Cinnella, Gilda/O-2987-2016; Albaiceta, Guillermo/AAU-5069-2020; Brown, Samuel M/E-6846-2015; Ferguson, Niall/D-7619-2019; Biondi, Rodrigo S/H-5212-2016; Unal, Necmettin/AAH-6241-2019; jochmans, sebastien/Y-3897-2019; Ranieri, Marco/AFX-8152-2022; Wrigge, Hermann/AAJ-8985-2021; Van Haren, Frank/G-1335-2015; Roux, Damien/C-5618-2014; TERZI, Nicolas/AAD-4348-2019; HASHEMIAN, SEYED MOHAMMAD REZA/C-1224-2018; Gritsan, Alexey/M-4261-2014; Spadaro, Savino/K-9070-2016	Laake, Jon Henrik/0000-0001-6157-5359; Martinez, Felipe/0000-0002-9857-8403; Grigoryev, Evgeny/0000-0001-8370-3083; Chiche, Jean-Daniel/0000-0002-6433-6254; Cortegiani, Andrea/0000-0003-1416-9993; Battle, Ceri/0000-0002-7503-1931; Frendl, Gyorgy/0000-0001-8918-8553; Volta, Carlo A/0000-0003-3533-6121; Rylander, Christian/0000-0002-4534-7150; Colombo, Riccardo/0000-0002-9616-803X; Occhipinti, Giovanna/0000-0003-3507-0036; erbabacan, safak emre/0000-0001-9314-9178; Meybohm, Patrick/0000-0002-2666-8696; Roux, Damien/0000-0002-6103-6416; Rialp, Gemma/0000-0003-3614-3639; Ulatan, Jeffrey/0000-0002-3756-0568; CORNECI, DAN/0000-0002-1170-0614; Máca, Jan/0000-0002-9771-0468; Pesenti, Antonio/0000-0003-2593-729X; Reske, Andreas W/0000-0002-2759-0245; Berger-Estilita, Joana/0000-0002-8695-4264; Szakmany, Tamas/0000-0003-3632-8844; Conti, Sara/0000-0002-5774-3740; Tomescu, Dana/0000-0001-9673-5754; POTA, VINCENZO/0000-0001-9999-3388; Cinnella, Gilda/0000-0001-9864-2893; Albaiceta, Guillermo/0000-0002-9276-3253; Brown, Samuel M/0000-0003-1206-6261; Ferguson, Niall/0000-0002-6213-5264; Biondi, Rodrigo S/0000-0002-9242-6062; Unal, Necmettin/0000-0002-9440-7893; jochmans, sebastien/0000-0002-7111-4107; Wrigge, Hermann/0000-0002-9035-6822; Van Haren, Frank/0000-0001-8037-4229; Roux, Damien/0000-0002-6103-6416; TERZI, Nicolas/0000-0003-4036-6245; Whitehead, Christina/0000-0003-4561-7082; Barros, Nelson/0000-0001-7919-2591; Nichol, Alistair/0000-0002-4689-1238; Hormis, Anil/0000-0001-5510-7639; Grelon, Fabien/0000-0002-2606-9933; Gattinoni, Luciano/0000-0001-5380-2494; Aguirre-Bermeo, Hernan/0000-0001-7205-7020; Bihari, Shailesh/0000-0001-7553-8620; HASHEMIAN, SEYED MOHAMMAD REZA/0000-0002-0768-9168; Knowles, Serena/0000-0002-5028-3825; Kulkarni, Shreedhar/0000-0002-9521-8461; Tainter, Christopher/0000-0002-9639-2795; Al-Dorzi, Hasan M/0000-0002-3772-8949; de Prost, Nicolas/0000-0002-4833-4320; Gritsan, Alexey/0000-0002-0500-2887; Schultz, Marcus/0000-0003-3969-7792; Harrois, Anatole/0000-0002-5098-4656; Grigoriev, Evgeny/0000-0002-3898-0740; foti, giuseppe/0000-0002-8698-2046; DANIN, Pierre-Eric/0000-0003-4234-7726; Kakar, Vivek/0000-0001-6353-3283; Laffey, John/0000-0002-1246-9573; FOLLIN, Arnaud/0000-0002-6496-3135; Aneman, Anders/0000-0003-2096-5304; PHAM, Tai/0000-0002-4373-0711; McAuley, Daniel/0000-0002-3283-1947; Banner-Goodspeed, Valerie/0000-0002-7644-2521; Kander, Thomas/0000-0002-5404-2981; Lanspa, Michael/0000-0003-0968-4755; Humphreys, Sally/0000-0002-4397-6404; MONTINI, Luca/0000-0003-4602-5134; Holzgraefe, Bernhard/0000-0002-5654-7764; carteaux, guillaume/0000-0003-1175-8821; Protti, Alessandro/0000-0002-0172-6079; Chelly, Jonathan/0000-0002-8198-1239; de Haro, Candelaria/0000-0002-2668-1030; herbrecht, jean-etienne/0000-0002-6415-5330; Gomez Brey, Aroa/0000-0002-1223-1186; Hedlund, Lars/0000-0002-0403-8749; Breen, Dorothy/0000-0001-5010-4017; Plotnikow, Gustavo A./0000-0003-0115-870X; Nitta, Kenichi/0000-0002-9906-5861; Michel, Philippe/0000-0003-2392-7186; Spadaro, Savino/0000-0001-5027-5318	European Society of Intensive Care Medicine (ESICM), Brussels, Belgium; St Michael's Hospital, Toronto, Canada; University of Milan-Bicocca, Monza, Italy	European Society of Intensive Care Medicine (ESICM), Brussels, Belgium; St Michael's Hospital, Toronto, Canada; University of Milan-Bicocca, Monza, Italy	This work was funded and supported by the European Society of Intensive Care Medicine (ESICM), Brussels, Belgium, by St Michael's Hospital, Toronto, Canada, and by the University of Milan-Bicocca, Monza, Italy.	Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Choi WI, 2014, J CRIT CARE, V29, P797, DOI 10.1016/j.jcrc.2014.05.017; Ferguson ND, 2005, CRIT CARE MED, V33, P2228, DOI 10.1097/01.CCM.0000181529.08630.49; Force ADT, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Frohlich S, 2013, J CRIT CARE, V28, P663, DOI 10.1016/j.jcrc.2013.05.012; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Harrell Frank E., 2001, REGRESSION MODELING; Herasevich V, 2009, INTENS CARE MED, V35, P1018, DOI 10.1007/s00134-009-1460-1; Hernu R, 2013, INTENS CARE MED, V39, P2161, DOI 10.1007/s00134-013-3122-6; Irish Critical Care Trials Group, 2008, CRIT CARE, V12, pR30; Kalhan R, 2006, CRIT CARE MED, V34, P300, DOI 10.1097/01.CCM.0000198328.83571.4A; Li GX, 2011, AM J RESP CRIT CARE, V183, P59, DOI 10.1164/rccm.201003-0436OC; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; Mikkelsen ME, 2008, RESP CARE, V53, P455; Needham DM, 2015, AM J RESP CRIT CARE, V191, P177, DOI 10.1164/rccm.201409-1598OC; Ortiz JR, 2014, CRIT CARE MED, V42, P2325, DOI 10.1097/CCM.0000000000000545; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2004, INTENS CARE MED, V30, P4, DOI 10.1007/s00134-003-2081-8; Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	27	2386	2609	13	206	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2016	315	8					788	800		10.1001/jama.2016.0291	http://dx.doi.org/10.1001/jama.2016.0291			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE5VH	26903337	Bronze, Green Published			2023-01-03	WOS:000370700500014
J	Vilaca, M; Aragao, I; Cardoso, T; Dias, C; Cabral-Campello, G				Vilaca, Marta; Aragao, Irene; Cardoso, Teresa; Dias, Claudia; Cabral-Campello, Gloria			The Role of Noninvasive Ventilation in Patients with "Do Not Intubate" Order in the Emergency Setting	PLOS ONE			English	Article							ACUTE RESPIRATORY-FAILURE; POSITIVE-PRESSURE VENTILATION; MECHANICAL VENTILATION; PALLIATIVE USE; CARE; PREDICTORS	Background Noninvasive ventilation (NIV) is being used increasingly in patients who have a "do not intubate" (DNI) order. However, the impact of NIV on the clinical and health-related quality of life (HRQOL) in the emergency setting is not known, nor is its effectiveness for relieving symptoms in end-of-life care. Objective The aim of this prospective study was to determine the outcome and HRQOL impact of regular use of NIV outcomes on patients with a DNI order who were admitted to the emergency room department (ED). METHODS: Eligible for participation were DNI-status patients who receive NIV for acute or acute-on-chronic respiratory failure when admitted to the ED of a tertiary care, university-affiliated, 600-bed hospital between January 2014 and December 2014. Patients were divided into 2 groups: (1) those whose DNI order related to a decision to withhold therapy and (2) those for whom any treatment, including NIV, was provided for symptom relief only. HRQOL was evaluated only in group 1, using the 12-item Short Form Health Survey (SF-12). Long-term outcome was evaluated 90 days after hospital discharge by means of a telephone interview. Results During the study period 1727 patients were admitted to the ED, 243 were submitted to NIV and 70 (29%) were included in the study. Twenty-nine (41%) of the 70 enrollees received NIV for symptom relief only (group2). Active cancer [7% vs 35%, p = 0,004] and neuromuscular diseases [0% vs. 17%] were more prevalent in this group. NIV was stopped in 59% of the patients in group 2 due to lake of clinical benefit. The in-hospital mortality rate was 37% for group 1 and 86% for group 2 0,001). Among patients who were discharged from hospital, 23% of the group 1 and all patients in group 2 died within 90 days. Relative to baseline, no significant decline in HRQOL occurred in group 1 by 90 days postdischarge. Conclusion The survival rate was 49% among DNI-status patients for whom NIV was used as a treatment in ED, and these patients did not experience a decline in HRQOL throughout the study. NIV did not provide significant relief of symptoms in more than half the patients who receive it for that purpose.	[Vilaca, Marta] Univ Porto, MIM, ICBAS, Oporto, Portugal; [Aragao, Irene; Cardoso, Teresa; Cabral-Campello, Gloria] Oporto Hosp Ctr, Intens Care Unit UCIP, Oporto, Portugal; [Dias, Claudia] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Oporto, Portugal; [Dias, Claudia] Univ Porto, Fac Med, Informat Sci & Decis Hlth Dept CIDES, Oporto, Portugal	Universidade do Porto; Universidade do Porto; Universidade do Porto	Vilaca, M (corresponding author), Univ Porto, MIM, ICBAS, Oporto, Portugal.	martarnvilaca@gmail.com	Dias, Claudia Camila/N-7130-2014	Dias, Claudia Camila/0000-0001-9356-3272; Aragao, Irene/0000-0001-5750-2739	Discipline of Initiation to Clinical Investigation (Disciplina de Iniciacao a Investigacao Clinica) of Instituto de Ciencias Biomedicas Abel Salazar; ASSUCIP (Associacao dos Amigos da Unidade de Cuidados Intensivos Polivalente, Hospital de Santo Antonio, Porto, Portugal)	Discipline of Initiation to Clinical Investigation (Disciplina de Iniciacao a Investigacao Clinica) of Instituto de Ciencias Biomedicas Abel Salazar; ASSUCIP (Associacao dos Amigos da Unidade de Cuidados Intensivos Polivalente, Hospital de Santo Antonio, Porto, Portugal)	Supported, in part, by grants from the Discipline of Initiation to Clinical Investigation (Disciplina de Iniciacao a Investigacao Clinica) of Instituto de Ciencias Biomedicas Abel Salazar and in part by ASSUCIP (Associacao dos Amigos da Unidade de Cuidados Intensivos Polivalente, Hospital de Santo Antonio, Porto, Portugal).	Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Azoulay E, 2014, INTENS CARE MED, V40, P305, DOI 10.1007/s00134-014-3217-8; Azoulay E, 2013, INTENS CARE MED, V39, P292, DOI 10.1007/s00134-012-2746-2; Azoulay E, 2011, INTENS CARE MED, V37, P1250, DOI 10.1007/s00134-011-2263-8; Baudouin S, 2002, THORAX, V57, P192; Brochard L, 2014, SEMIN RESP CRIT CARE, V35, P492, DOI 10.1055/s-0034-1383863; Cabrini L, 2012, RESP CARE, V57, P704, DOI 10.4187/respcare.01474; Chiumello D, 2009, RESP CARE, V54, P1302; Curtis JR, 2007, CRIT CARE MED, V35, P932, DOI 10.1097/01.CCM.0000256725.73993.74; Fiorino S, 2015, INTERN MED J, V45, P527, DOI 10.1111/imj.12726; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hill NS, 2009, RESP CARE, V54, P62; L'Her E, 2004, INTENS CARE MED, V30, P882, DOI 10.1007/s00134-004-2183-y; Nava S, 2009, MINERVA ANESTESIOL, V75, P31; Nava S, 2013, LANCET ONCOL, V14, P219, DOI 10.1016/S1470-2045(13)70009-3; Phua J, 2005, INTENS CARE MED, V31, P533, DOI 10.1007/s00134-005-2582-8; Quill CM, 2014, J PALLIAT MED, V17, P657, DOI 10.1089/jpm.2014.0010; Scarpazza P, 2011, INT J CHRONIC OBSTR, V6, P253, DOI 10.2147/COPD.S18501; Scarpazza Paolo, 2008, Int J Chron Obstruct Pulmon Dis, V3, P797; Schnell D, 2014, INTENS CARE MED, V40, P582, DOI 10.1007/s00134-014-3222-y; Schortgen F, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-5; Shreves Ashley, 2013, Emerg Med Pract, V15, P1; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Squadrone E, 2004, INTENS CARE MED, V30, P1303, DOI 10.1007/s00134-004-2320-7; Thille AW, 2013, CRIT CARE, V17, DOI 10.1186/cc13103	25	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149649	10.1371/journal.pone.0149649	http://dx.doi.org/10.1371/journal.pone.0149649			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901060	Green Published, Green Submitted, gold			2023-01-03	WOS:000371276100121
J	Dear, AE				Dear, Anthony E.			Epigenetic Modulators and the New Immunotherapies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER		[Dear, Anthony E.] Monash Univ, Dept Med, Eastern Hlth Clin Sch, Eastern Clin Res Unit,Translat Res Div, Melbourne, Vic, Australia	Monash University	Dear, AE (corresponding author), Monash Univ, Dept Med, Eastern Hlth Clin Sch, Eastern Clin Res Unit,Translat Res Div, Melbourne, Vic, Australia.							Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Sathyanarayanan V, 2015, MOL ONCOL	5	36	41	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	2016	374	7					684	686		10.1056/NEJMcibr1514673	http://dx.doi.org/10.1056/NEJMcibr1514673			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD9ER	26886527				2023-01-03	WOS:000370229000016
J	Yang, LP; Sun, GX; Guo, Y; Hou, ZF; Chen, S				Yang, Lanping; Sun, Guoxiang; Guo, Yong; Hou, Zhifei; Chen, Shuai			Holistic Evaluation of Quality Consistency of Ixeris sonchifolia (Bunge) Hance Injectables by Quantitative Fingerprinting in Combination with Antioxidant Activity and Chemometric Methods	PLOS ONE			English	Article							CHROMATOGRAPHIC FINGERPRINTS; PILL; IDENTIFICATION; ASSAY; TOOL	A widely used herbal medicine, Ixeris sonchifolia (Bge.) Hance Injectable (ISHI) was investigated for quality consistency. Characteristic fingerprints of 23 batches of the ISHI samples were generated at five wavelengths and evaluated by the systematic quantitative fingerprint method (SQFM) as well as simultaneous analysis of the content of seven marker compounds. Chemometric methods, i.e., support vector machine (SVM) and principal component analysis (PCA) were performed to assist in fingerprint evaluation of the ISHI samples. Qualitative classification of the ISHI samples by SVM was consistent with PCA, and in agreement with the quantitative evaluation by SQFM. In addition, the antioxidant activities of the ISHI samples were determined by both the off-line and on-line DPPH (2, 2-diphenyl-1- picryldrazyl) radical scavenging assays. A fingerprint-efficacy relationship linking the chemical components and in vitro antioxidant activity was established and validated using the partial least squares (PLS) and orthogonal projection to latent structures (OPLS) models; and the online DPPH assay further revealed those components that had position contribution to the total antioxidant activity. Therefore, the combined use of the chemometric methods, quantitative fingerprint evaluation by SQFM, and multiple marker compound analysis in conjunction with the assay of antioxidant activity provides a powerful and holistic approach to evaluate quality consistency of herbal medicines and their preparations.	[Yang, Lanping; Sun, Guoxiang; Hou, Zhifei; Chen, Shuai] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China; [Guo, Yong] Fairleigh Dickinson Univ, Sch Pharm, Florham Pk, NJ 07932 USA	Shenyang Pharmaceutical University; Fairleigh Dickinson University	Sun, GX (corresponding author), Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China.	gxswmwys@163.com		Guo, Yong/0000-0003-0488-3093				Alaerts G, 2014, J PHARMACEUT BIOMED, V95, P34, DOI 10.1016/j.jpba.2014.02.006; Babbar N, 2014, J FOOD SCI TECH MYS, V51, P2568, DOI 10.1007/s13197-012-0754-4; Benzi G, 1997, PHARMACOL RES, V35, P355, DOI 10.1006/phrs.1997.0132; Bhandari P, 2010, INDIAN J EXP BIOL, V48, P323; Chang YX, 2008, J CHROMATOGR A, V1208, P76, DOI 10.1016/j.chroma.2008.08.054; [陈春光 Chen Chunguang], 2012, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V28, P196; China Drug Administration Bureau of, 2000, CHIN TRAD PAT MED, V22, P671; Custers D, 2014, TALANTA, V123, P78, DOI 10.1016/j.talanta.2014.01.020; Ding XP, 2009, J CHROMATOGR A, V1216, P2204, DOI 10.1016/j.chroma.2008.08.115; European Medicines Agency, 2010, GUID DECL HERB SUBST; Food and Drug Administration, 2004, GUID IND BOT DRUG PR; Ghandi M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003711; Ibrahim FA, 2014, ACTA CHIM SLOV, V61, P11; Information Office of the State Council of the People's Republic of China, 2008, STAT QUO DRUG SUP CH; Li ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067451; Liang J, 2013, J CHROMATOGR A, V1294, P58, DOI 10.1016/j.chroma.2013.04.016; [刘睿 Liu Rui], 2013, [中草药, Chinese Traditional and Herbal Drugs], V44, P2542; Liu Ying, 2013, Zhongguo Zhong Yao Za Zhi, V38, P2675; Pomerantsev AL, 2014, J CHEMOMETR, V28, P429, DOI 10.1002/cem.2506; Prevc T, 2013, TALANTA, V109, P13, DOI 10.1016/j.talanta.2013.03.046; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; Shi PY, 2011, PHYTOCHEM ANALYSIS, V22, P66, DOI 10.1002/pca.1253; Sun Guo-xiang, 2009, Yaoxue Xuebao, V44, P401; Sun GX, 2013, ANN TRANSL MED, V1, DOI 10.3978/j.issn.2305-5839.2013.03.03; Sun GX, 2014, ANAL METHODS-UK, V6, P838, DOI 10.1039/c3ay41670d; Sun GX, 2009, CHIN J CHROMATOGR, V27, P318; Tistaert C, 2011, ANAL CHIM ACTA, V690, P148, DOI 10.1016/j.aca.2011.02.023; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; WHO, 1991, GUIDELINES ASSESSMEN; Wu JH, 2008, J AGR FOOD CHEM, V56, P328, DOI 10.1021/jf072314c; Yin L, 2013, J CHROMATOGR B, V931, P12, DOI 10.1016/j.jchromb.2013.04.039; Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057928; Zhang WZ, 2008, J ASIAN NAT PROD RES, V10, P1087, DOI 10.1080/10286020802361180; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhang YC, 2013, CHEM BIODIVERS, V10, P1373, DOI 10.1002/cbdv.201100234; Zhu JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087462	36	17	17	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0148878	10.1371/journal.pone.0148878	http://dx.doi.org/10.1371/journal.pone.0148878			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD6SI	26872364	Green Submitted, Green Published, gold			2023-01-03	WOS:000370054100067
J	Talbert, EE; Smuder, AJ; Kwon, OS; Sollanek, KJ; Wiggs, MP; Powers, SK				Talbert, Erin E.; Smuder, Ashley J.; Kwon, Oh Sung; Sollanek, Kurt J.; Wiggs, Michael P.; Powers, Scott K.			Blockage of the Ryanodine Receptor via Azumolene Does Not Prevent Mechanical Ventilation-Induced Diaphragm Atrophy	PLOS ONE			English	Article							CALCIUM-RELEASE CHANNELS; SKELETAL-MUSCLE; SOLEUS MUSCLE; CONTRACTILE PROPERTIES; DISUSE ATROPHY; DYSFUNCTION; CA2+; WEAKNESS; RATS; MITOCHONDRIA	Mechanical ventilation (MV) is a life-saving intervention for patients in respiratory failure. However, prolonged MV causes the rapid development of diaphragm muscle atrophy, and diaphragmatic weakness may contribute to difficult weaning from MV. Therefore, developing a therapeutic countermeasure to protect against MV-induced diaphragmatic atrophy is important. MV-induced diaphragm atrophy is due, at least in part, to increased production of reactive oxygen species (ROS) from diaphragm mitochondria and the activation of key muscle proteases (i.e., calpain and caspase-3). In this regard, leakage of calcium through the ryanodine receptor (RyR1) in diaphragm muscle fibers during MV could result in increased mitochondrial ROS emission, protease activation, and diaphragm atrophy. Therefore, these experiments tested the hypothesis that a pharmacological blockade of the RyR1 in diaphragm fibers with azumolene (AZ) would prevent MV-induced increases in mitochondrial ROS production, protease activation, and diaphragmatic atrophy. Adult female Sprague-Dawley rats underwent 12 hours of full-support MV while receiving either AZ or vehicle. At the end of the experiment, mitochondrial ROS emission, protease activation, and fiber cross-sectional area were determined in diaphragm muscle fibers. Decreases in muscle force production following MV indicate that the diaphragm took up a sufficient quantity of AZ to block calcium release through the RyR1. However, our findings reveal that AZ treatment did not prevent the MV-induced increase in mitochondrial ROS emission or protease activation in the diaphragm. Importantly, AZ treatment did not prevent MV-induced diaphragm fiber atrophy. Thus, pharmacological inhibition of the RyR1 in diaphragm muscle fibers is not sufficient to prevent MV-induced diaphragm atrophy.	[Talbert, Erin E.; Smuder, Ashley J.; Kwon, Oh Sung; Sollanek, Kurt J.; Wiggs, Michael P.; Powers, Scott K.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA; [Kwon, Oh Sung] George E Wahlen Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA; [Kwon, Oh Sung] Univ Utah, Dept Internal Med, Div Geriatr, Salt Lake City, UT 84112 USA; [Sollanek, Kurt J.] Sonoma State Univ, Dept Kinesiol, Rohnert Pk, CA 94928 USA; [Wiggs, Michael P.] Univ Texas Tyler, Dept Hlth & Kinesiol, Tyler, TX 75799 USA	State University System of Florida; University of Florida; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; California State University System; Sonoma State University; University of Texas System; University of Texas at Tyler	Talbert, EE (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.; Talbert, EE (corresponding author), Ohio State Univ, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA.	erin.talbert@osumc.edu	Kwon, Oh Sung/AAL-4116-2021; Talbert, Erin/AAM-5535-2020	Talbert, Erin/0000-0003-4587-0950	American Heart Association [11PRE6520001]; National Institutes of Health [R01 HL087839, R21 AR064956]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR064956] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	These experiments were supported by American Heart Association (www.heart.org) Predoctoral Fellowship 11PRE6520001 to EETand National Institutes of Health (www.nih.gov) R01 HL087839 and R21 AR064956 to SKP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson EJ, 2006, AM J PHYSIOL-CELL PH, V290, pC844, DOI 10.1152/ajpcell.00402.2005; Andersson DC, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-9; Andersson DC, 2011, CELL METAB, V14, P196, DOI 10.1016/j.cmet.2011.05.014; Bellinger AM, 2009, NAT MED, V15, P325, DOI 10.1038/nm.1916; Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Feissner RF, 2009, FRONT BIOSCI-LANDMRK, V14, P1197, DOI 10.2741/3303; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Fischer DR, 2001, SHOCK, V15, P200, DOI 10.1097/00024382-200115030-00007; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; Gellerich FN, 2008, J BIOL CHEM, V283, P30715, DOI 10.1074/jbc.M709555200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC; Ingalls CP, 1999, J APPL PHYSIOL, V87, P386, DOI 10.1152/jappl.1999.87.1.386; Kachaeva EV, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/493618; Kandarian SC, 2002, EXERC SPORT SCI REV, V30, P111, DOI 10.1097/00003677-200207000-00004; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; LEBOURDELLES G, 1994, AM J RESP CRIT CARE, V149, P1539, DOI 10.1164/ajrccm.149.6.8004310; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; LESLIE GC, 1989, BRIT J PHARMACOL, V97, P1151, DOI 10.1111/j.1476-5381.1989.tb12573.x; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Min K, 2015, J PHYSIOL-LONDON, V593, P2017, DOI 10.1113/jphysiol.2014.286518; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Nelson WB, 2012, CRIT CARE MED; Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003; Picard M, 2012, AM J RESPIR CRIT CAR; Powers SK, 2013, AM J PHYSIOL-REG I, V305, pR464, DOI 10.1152/ajpregu.00231.2013; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Schaffer S. W., 2007, MITOCHONDRIA DYNAMIC; SEGAL SS, 1986, AM J PHYSIOL, V250, pC474, DOI 10.1152/ajpcell.1986.250.3.C474; Shanely RA, 2002, AM J RESP CRIT CARE, V166, P1369, DOI 10.1164/rccm.200202-088OC; Smuder AJ, 2012, CRIT CARE MED, V40, P927, DOI 10.1097/CCM.0b013e3182374a84; Smuder AJ, 2012, J APPL PHYSIOL, V112, P501, DOI 10.1152/japplphysiol.01086.2011; Sudo RT, 2008, BASIC CLIN PHARMACOL, V102, P308, DOI 10.1111/j.1742-7843.2007.00156.x; Trouillet JL, 2009, J THORAC CARDIOV SUR, V138, P948, DOI 10.1016/j.jtcvs.2009.05.034; Wehrens XHT, 2005, P NATL ACAD SCI USA, V102, P9607, DOI 10.1073/pnas.0500353102; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; Zhang YF, 2005, J PHARMACOL EXP THER, V314, P94, DOI 10.1124/jpet.105.084046	42	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0148161	10.1371/journal.pone.0148161	http://dx.doi.org/10.1371/journal.pone.0148161			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26849371	gold, Green Published			2023-01-03	WOS:000369554000045
J	Homaira, N; Luby, SP; Hossain, K; Islam, K; Ahmed, M; Rahman, M; Rahman, Z; Paul, RC; Bhuiyan, MU; Brooks, WA; Sohel, BM; Banik, KC; Widdowson, MA; Willby, M; Rahman, M; Bresee, J; Ramirez, KS; Azziz-Baumgartner, E				Homaira, Nusrat; Luby, Stephen P.; Hossain, Kamal; Islam, Kariul; Ahmed, Makhdum; Rahman, Mustafizur; Rahman, Ziaur; Paul, Repon C.; Bhuiyan, Mejbah Uddin; Brooks, W. Abdullah; Sohel, Badrul Munir; Banik, Kajal Chandra; Widdowson, Marc-Alain; Willby, Melisa; Rahman, Mahmudur; Bresee, Joseph; Ramirez, Katharine-Sturm; Azziz-Baumgartner, Eduardo			Respiratory Viruses Associated Hospitalization among Children Aged < 5 Years in Bangladesh: 2010-2014	PLOS ONE			English	Article							SYNCYTIAL VIRUS; CHILDHOOD DEATHS; INFLUENZA; INFECTIONS; PNEUMONIA; COST; IMMUNIZATION; PROPHYLAXIS; RHINOVIRUS; RISK	Background We combined hospital-based surveillance and health utilization survey data to estimate the incidence of respiratory viral infections associated hospitalization among children aged <5 years in Bangladesh. Methods Surveillance physicians collected respiratory specimens from children aged <5 years hospitalized with respiratory illness and residing in the primary hospital catchment areas. We tested respiratory specimens for respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, influenza, adenovirus and rhinoviruses using rRT-PCR. During 2013, we conducted a health utilization survey in the primary catchment areas of the hospitals to determine the proportion of all hospitalizations for respiratory illness among children aged <5 years at the surveillance hospitals during the preceding 12 months. We estimated the respiratory virus-specific incidence of hospitalization by dividing the estimated number of hospitalized children with a laboratory confirmed infection with a respiratory virus by the population aged <5 years of the catchment areas and adjusted for the proportion of children who were hospitalized at the surveillance hospitals. Results We estimated that the annual incidence per 1000 children (95% CI) of all cause associated respiratory hospitalization was 11.5 (10-12). The incidences per 1000 children (95% CI) per year for respiratory syncytial virus, parainfluenza, adenovirus, human metapneumovirus and influenza infections were 3(2-3), 0.5(0.4-0.8), 0.4 (0.3-0.6), 0.4 (0.3-0.6), and 0.4 (0.3-0.6) respectively. The incidences per 1000 children (95%CI) of rhinovirus-associated infections among hospitalized children were 5 (3-7), 2 (1-3), 1 (0.6-2), and 3 (2-4) in 2010, 2011, 2012 and 2013, respectively. Conclusion Our data suggest that respiratory viruses are associated with a substantial burden of hospitalization in children aged <5 years in Bangladesh.	[Homaira, Nusrat; Luby, Stephen P.; Hossain, Kamal; Islam, Kariul; Ahmed, Makhdum; Rahman, Mustafizur; Rahman, Ziaur; Paul, Repon C.; Bhuiyan, Mejbah Uddin; Brooks, W. Abdullah; Sohel, Badrul Munir; Banik, Kajal Chandra; Ramirez, Katharine-Sturm; Azziz-Baumgartner, Eduardo] Icddr B, Dhaka, Bangladesh; [Luby, Stephen P.; Widdowson, Marc-Alain; Willby, Melisa; Bresee, Joseph; Ramirez, Katharine-Sturm; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Atlanta, GA USA; [Brooks, W. Abdullah] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ, Baltimore, MD USA; [Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Homaira, N (corresponding author), Icddr B, Dhaka, Bangladesh.	nhomaira@icddrb.org	Bhuiyan, Mejbah/ABG-4827-2020; Islam/AAO-8937-2020; Ahmed, Makhdum/D-2615-2012; Brooks, W. Abdullah/AAD-3876-2021; Bhuiyan, Mejbah/AAY-1238-2020; Homaira, Nusrat/U-4526-2019	Ahmed, Makhdum/0000-0002-0772-8710; Brooks, W. Abdullah/0000-0001-9871-5546; Bhuiyan, Mejbah/0000-0002-8274-6265; Homaira, Nusrat/0000-0003-3341-7964; Islam, Mdkariul/0000-0003-4085-7159; Luby, Stephen/0000-0001-5385-899X	Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta [1U01CI000628-01, 1U01CI000628-04]; US CDC [1U01CI000628-04]; National Center for Preparedness, Detection, and Control of Infectious Diseases [U01CI000628] Funding Source: NIH RePORTER	Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta; US CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Preparedness, Detection, and Control of Infectious Diseases(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was funded by the Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta under the co-operative agreement numbers 1U01CI000628-01 and 1U01CI000628-04. Co-authors SPL, MAW, MW, JB, KSR and EAB who work for the funding body were also involved in designing and analyzing of the study.; icddr,b is grateful for the commitment of CDC to its research efforts. US CDC gave financial support for this study (cooperative agreement 1U01CI000628-04). The authors would like to thank all the study participants and the surveillance hospitals for their contribution in the study. We gratefully acknowledge the relentless effort of the field staff involved in data collection and compilation. We also acknowledge the contribution of Dean D. Erdman for the design of the primers and probes for the laboratory testing of the study. We are also very grateful to Diana DiazGranados for her help with editing of the manuscript.	Ahmed SM, 2000, SOC SCI MED, V51, P361, DOI 10.1016/S0277-9536(99)00461-X; Alonso WJ, 2012, PEDIATR INFECT DIS J, V31, pE9, DOI 10.1097/INF.0b013e31823883be; Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; AUSINA V, 1988, EUR J CLIN MICROBIOL, V7, P343, DOI 10.1007/BF01962334; Banerjee S, 2007, J CLIN VIROL, V38, P70, DOI 10.1016/j.jcv.2006.07.003; Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; Centers for Disease Control and Prevention (CDC), 2009, PROTOCOL OF REALTIME; Clara W, 2012, B WORLD HEALTH ORGAN, V90, P756, DOI 10.2471/BLT.11.098202; Connor E, 1997, PEDIATRICS, V99, P93; Englund JA, 2003, VACCINE, V21, P3460, DOI 10.1016/S0264-410X(03)00351-7; Feikin DR, 2012, B WORLD HEALTH ORGAN, V90, P256, DOI 10.2471/BLT.11.094326; Fry AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015098; Gurley ES, 2010, CLIN INFECT DIS, V50, P1084, DOI 10.1086/651265; Saborio GG, 2014, EMERG INFECT DIS, V20, P878, DOI 10.3201/eid2005.131775; Halder AK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008145; Haque F, 2012, INT J INFECT DIS, V16, pE866, DOI 10.1016/j.ijid.2012.07.016; Hasan K, 2006, SCAND J INFECT DIS, V38, P690, DOI 10.1080/00365540600606473; Haynes LM, 2013, J INFECT DIS, V208, pS177, DOI 10.1093/infdis/jit512; Henrickson Kelly J, 1998, Semin Pediatr Infect Dis, V9, P217, DOI 10.1016/S1045-1870(98)80035-6; Homaira N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032056; Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10; Jartti T, 2008, PEDIATR INFECT DIS J, V27, P1103, DOI 10.1097/INF.0b013e31817e695d; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3675; Joffe S, 1999, PEDIATRICS, V104, P419, DOI 10.1542/peds.104.3.419; KORPPI M, 1993, EUR J PEDIATR, V152, P24, DOI 10.1007/BF02072512; Miller EK, 2013, J CLIN VIROL, V57, P291, DOI 10.1016/j.jcv.2013.04.015; Mitra S, 2004, BANGLADESH DEMOGRAPH; Montes A, 2005, VACCINE, V23, P4302, DOI 10.1016/j.vaccine.2005.04.006; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Nasreen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089978; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; OEHLERT GW, 1992, AM STAT, V46, P27, DOI 10.2307/2684406; Peng D, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-155; Poehling KA, 2011, AM J OBSTET GYNECOL, V204, pS141, DOI 10.1016/j.ajog.2011.02.042; Powell LA, 2007, CONDOR, V109, P949, DOI 10.1650/0010-5422(2007)109[949:AVODPU]2.0.CO;2; Rabie T, 2006, TROP MED INT HEALTH, V11, P258, DOI 10.1111/j.1365-3156.2006.01568.x; Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Singeton RJ, 2010, J MED VIROL, V82, P1282, DOI 10.1002/jmv.21790; Smyth A, 2002, BRIT MED BULL, V61, P247, DOI 10.1093/bmb/61.1.247; van Benten I, 2003, PEDIAT ALLERG IMM-UK, V14, P363, DOI 10.1034/j.1399-3038.2003.00064.x; WALKER TA, 1994, PEDIATR CLIN N AM, V41, P1365; WANG D, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI DOI 10.1099/vir.0.82282-0; Warren-Gash C., 2012, INFLUENZA OTHER RESP, DOI 10.111/Irv.12015; Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x; Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157; Weinberg GA, 2013, J CLIN VIROL, V57, P254, DOI 10.1016/j.jcv.2013.03.016; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	50	18	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0147982	10.1371/journal.pone.0147982	http://dx.doi.org/10.1371/journal.pone.0147982			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840782	Green Published, gold, Green Submitted			2023-01-03	WOS:000369550200074
J	Piccirillo, JF				Piccirillo, Jay F.			Transcranial Magnetic Stimulation for Chronic Tinnitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Piccirillo, Jay F.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 660 Euclid Ave,CB 8115, St Louis, MO 63110 USA	Washington University (WUSTL)	Piccirillo, JF (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 660 Euclid Ave,CB 8115, St Louis, MO 63110 USA.	piccirilloj@ent.wustl.edu						Folmer RL, 2015, JAMA OTOLARYNGOL, V141, P716, DOI 10.1001/jamaoto.2015.1219; Husain FT, 2014, HEARING RES, V307, P153, DOI 10.1016/j.heares.2013.07.010; Meng ZL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007946.pub2; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Pichora-Fuller MK, 2013, COMP EFFECTIVENESS R, V122; Plewnia C, 2003, ANN NEUROL, V53, P263, DOI 10.1002/ana.10468; Shargorodsky J, 2010, AM J MED, V123, P711, DOI 10.1016/j.amjmed.2010.02.015; Tunkel DE, 2014, OTOLARYNG HEAD NECK, V151, pS1, DOI 10.1177/0194599814545325; Wilson MB, 2015, OTOLARYNG HEAD NECK, V152, P897, DOI 10.1177/0194599815569692	9	2	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2016	315	5					506	507		10.1001/jama.2016.0075	http://dx.doi.org/10.1001/jama.2016.0075			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC2LZ	26836733				2023-01-03	WOS:000369049500020
J	Jensen, K				Jensen, Kimberley			John Mark Hinton OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																		HINTON JM, PUBLICATION LIST	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2016	353								i2773	10.1136/bmj.i2773	http://dx.doi.org/10.1136/bmj.i2773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6GI	27207614				2023-01-03	WOS:000376448200004
J	Tovey, ER; Liu-Brennan, D; Garden, FL; Oliver, BG; Perzanowski, MS; Marks, GB				Tovey, Euan R.; Liu-Brennan, Damien; Garden, Frances L.; Oliver, Brian G.; Perzanowski, Matthew S.; Marks, Guy B.			Time-Based Measurement of Personal Mite Allergen Bioaerosol Exposure over 24 Hour Periods	PLOS ONE			English	Article							LAMINAR AIR-FLOW; CAT ALLERGEN; ASTHMA; PERFORMANCE; CLASSROOMS; CHILDHOOD; COCKROACH; CHILDREN; SAMPLER; AEROSOL	Allergic diseases such as asthma and rhinitis are common in many countries. Globally the most common allergen associated with symptoms is produced by house dust mites. Although the bed has often been cited as the main site of exposure to mite allergens, surprisingly this has not yet been directly established by measurement due to a lack of suitable methods. Here we report on the development of novel methods to determine the pattern of personal exposure to mite allergen bioaerosols over 24-hour periods and applied this in a small field study using 10 normal adults. Air was sampled using a miniature time-based air-sampler of in-house design located close to the breathing zone of the participants, co-located with a miniature time-lapse camera. Airborne particles, drawn into the sampler at 2L/min via a narrow slot, were impacted onto the peripheral surface of a disk mounted on the hour-hand of either a 12 or 24 hour clock motor. The impaction surface was either an electret cloth, or an adhesive film; both novel for these purposes. Following a review of the time-lapse images, disks were post-hoc cut into subsamples corresponding to eight predetermined categories of indoor or outdoor location, extracted and analysed for mite allergen Der p 1 by an amplified ELISA. Allergen was detected in 57.2% of the total of 353 subsamples collected during 20 days of sampling. Exposure patterns varied over time. Higher concentrations of airborne mite allergen were typically measured in samples collected from domestic locations in the day and evening. Indoor domestic Der p 1 exposures accounted for 59.5% of total exposure, whereas total in-bed-asleep exposure, which varied 80 fold between individuals, accounted overall for 9.85% of total exposure, suggesting beds are not often the main site of exposure. This study establishes the feasibility of novel methods for determining the time-geography of personal exposure to many bioaerosols and identifies new areas for future technical development and clinical applications.	[Tovey, Euan R.; Liu-Brennan, Damien; Garden, Frances L.; Oliver, Brian G.; Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Garden, Frances L.] Univ New S Wales, South Western Sydney Clin Sch, Liverpool, NSW, Australia; [Garden, Frances L.; Marks, Guy B.] Univ New S Wales, Ingham Inst Appl Med Res, Liverpool, NSW, Australia; [Oliver, Brian G.] Univ Technol Sydney, Sch Life Sci, Broadway, NSW, Australia; [Perzanowski, Matthew S.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA	University of Sydney; Woolcock Institute of Medical Research; University of New South Wales Sydney; Ingham Institute for Applied Medical Research; University of New South Wales Sydney; University of Technology Sydney; Columbia University	Tovey, ER (corresponding author), Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia.	euan.tovey@sydney.edu.au	Oliver, Brian/E-7939-2010; Marks, Guy B./F-5058-2013; Tovey, Euan R/G-8604-2017	Oliver, Brian/0000-0002-7122-9262; Marks, Guy B./0000-0002-8976-8053; Tovey, Euan R/0000-0002-1802-7266; Garden, Frances/0000-0003-1653-3031	Asthma Foundation of New South Wales, Australia; Angior Family Foundation, Australia; Bridging Grant support; Lucy Falkiner Fellowship from the University of Sydney; National Health and Medical Research Council, Australia; NIH; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER	Asthma Foundation of New South Wales, Australia; Angior Family Foundation, Australia; Bridging Grant support; Lucy Falkiner Fellowship from the University of Sydney; National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank the Asthma Foundation of New South Wales, Australia, the Angior Family Foundation, Australia, Bridging Grant support and the Lucy Falkiner Fellowship from the University of Sydney for funding. The principal author was supported by a fellowship from the National Health and Medical Research Council, Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the multiple organisations described in the Funding Statement for their support in addition to colleagues and friends who collected samples over the 24 hour periods. Some of the ideas for this arose from discussions with Dr Ginger Chew in the NIH-funded Rapid Allergenic Particle Identification (RAPID) Project.	Bhangar S, 2014, INDOOR AIR, V24, P604, DOI 10.1111/ina.12111; Boyle RJ, 2012, THORAX, V67, P215, DOI 10.1136/thoraxjnl-2011-200665; De Lucca S, 1999, J ALLERGY CLIN IMMUN, V103, P174, DOI 10.1016/S0091-6749(99)70543-9; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; Doekes G, 2014, J ALLERGY CLIN IMMUN, V133, pAB187, DOI 10.1016/j.jaci.2013.12.669; Glasgow NJ, 2011, ARCH DIS CHILD, V96, P541, DOI 10.1136/adc.2010.189696; Gore R, 2011, CLIN EXP ALLERGY, V41, P1848; Gore RB, 2015, INDOOR AIR, V25, P36, DOI 10.1111/ina.12122; Gotzsche PC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001187.pub3; Graham JAH, 2000, ANN ALLERG ASTHMA IM, V84, P599, DOI 10.1016/S1081-1206(10)62410-6; Karlsson AS, 2004, J ALLERGY CLIN IMMUN, V113, P1172, DOI 10.1016/j.jaci.2003.12.590; Klimek L, 2015, ALLERGOLOGIE, V38, P70, DOI 10.5414/ALX01741; Krieger J, 2010, PEDIAT ALLER IMM PUL, V23, P139, DOI 10.1089/ped.2010.0022; Lau JY, 2006, J ALLERGY CLIN IMMUN, V117, pS30, DOI 10.1016/j.jaci.2005.12.125; Lau JY, 2005, J ALLERGY CLIN IMMUN, V115, pS94, DOI [10.1016/j.jaci.2004.12.390, DOI 10.1016/J.JACI.2004.12.390]; Lee SJ, 2005, J AEROSOL SCI, V36, P881, DOI 10.1016/j.jaerosci.2004.11.006; Liden G, 2009, ANN OCCUP HYG, V53, P99, DOI 10.1093/annhyg/mep001; LUNDGREN DALE A., 1967, J AIR POLLUT CONTR ASS, V17, P225; MARPLE VA, 1976, ATMOS ENVIRON, V10, P891, DOI 10.1016/0004-6981(76)90144-X; Montoya LD, 2005, J AEROSOL SCI, V36, P735, DOI 10.1016/j.jaerosci.2004.11.004; Morawska L, 2013, INDOOR AIR, V23, P462, DOI 10.1111/ina.12044; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Pawankar R., 2013, WAO WHITE BOOK ALLER; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Raja S, 2010, ENVIRON INT, V36, P8, DOI 10.1016/j.envint.2009.09.001; Rengasamy S, 2009, ANN OCCUP HYG, V53, P117, DOI 10.1093/annhyg/men086; Sakaguchi M, 1995, AEROBIOLOGIA, V11, P265, DOI 10.1007/BF02447207; SCHUMACHER MJ, 1988, J ALLERGY CLIN IMMUN, V82, P608, DOI 10.1016/0091-6749(88)90972-4; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Spilak MP, 2014, BUILD ENVIRON, V81, P60, DOI 10.1016/j.buildenv.2014.06.010; TAKAHASHI Y, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb00692.x; Tian Y, 2014, INDOOR AIR, V24, P592, DOI 10.1111/ina.12107; Tovey E, 2000, J ALLERGY CLIN IMMUN, V105, pS228, DOI 10.1016/S0091-6749(00)91104-7; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Tovey Euan, 2008, V138, P227, DOI 10.1007/978-1-59745-366-0_19; Tovey ER, 2015, J ALLERGY CLIN IMMUN, V135, P663, DOI 10.1016/j.jaci.2014.10.020; Tovey ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069900; Tovey ER, 2011, J ALLERGY CLIN IMMUN, V128, P723, DOI 10.1016/j.jaci.2011.07.009; Xu Y, 2010, BUILD ENVIRON, V45, P330, DOI 10.1016/j.buildenv.2009.06.010	41	30	30	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2016	11	5							e0153414	10.1371/journal.pone.0153414	http://dx.doi.org/10.1371/journal.pone.0153414			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3ZU	27192200	Green Published, Green Submitted, gold			2023-01-03	WOS:000376286100007
J	Zhou, RW; Zhou, RS; Zhuang, JX; Zong, ZC; Zhang, XH; Liu, DP; Bazaka, K; Ostrikov, K				Zhou, Renwu; Zhou, Rusen; Zhuang, Jinxing; Zong, Zichao; Zhang, Xianhui; Liu, Dongping; Bazaka, Kateryna; Ostrikov, Kostya			Interaction of Atmospheric-Pressure Air Microplasmas with Amino Acids as Fundamental Processes in Aqueous Solution	PLOS ONE			English	Article							OXIDATION; CHROMATOGRAPHY; DECOMPOSITION; INACTIVATION; SUPEROXIDE; REACTIVITY; PROTEINS; PLASMA	Plasma medicine is a relatively new field that investigates potential applications of cold atmospheric-pressure plasmas in bioengineering, such as for bacterial inactivation and degradation of organic molecules in water. In order to enunciate mechanisms of bacterial inactivation at molecular or atomic levels, we investigated the interaction of atmospheric-pressure air microplasmas with amino acids in aqueous solution by using high-resolution mass spectrometry (HRMS). Results show that the oxidation effect of plasma-induced species on the side chains of the amino acids can be categorized into four types, namely hydroxylation, nitration, dehydrogenation and dimerization. In addition, relative activities of amino acids resulting from plasma treatment come in descending order as follows: sulfurcontaining carbon-chain amino acids > aromatic amino acids > five-membered ring amino acids > basic carbon-chain amino acids. Since amino acids are building blocks of proteins vital to the growth and reproduction of bacteria, these results provide an insight into the mechanism of bacterial inactivation by plasma.	[Zhou, Renwu; Zong, Zichao; Liu, Dongping] Dalian Nationalities Univ, Liaoning Key Lab Optoelect Films & Mat, Sch Phys & Mat Engn, Dalian 116600, Peoples R China; [Zhou, Renwu; Bazaka, Kateryna; Ostrikov, Kostya] Queensland Univ Technol, Sch Chem Phys & Mech Engn, Brisbane, Qld 4000, Australia; [Zhou, Renwu; Zhuang, Jinxing; Zhang, Xianhui; Liu, Dongping] Xiamen Univ, Fujian Key Lab Plasma & Magnet Resonance, Sch Phys & Mech & Elect Engn, Xiamen 361005, Peoples R China; [Zhou, Rusen] Xiamen Univ, Dept Chem & Biochem Engn, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China; [Zhuang, Jinxing] Univ Int Business & Econ, Sch Informat Technol & Management, Beijing 10000, Peoples R China; [Zhou, Renwu; Bazaka, Kateryna; Ostrikov, Kostya] CSIRO, CSIRO QUT Joint Sustainable Mat & Devices Lab, POB 218, Lindfield, NSW 2070, Australia	Dalian Minzu University; Queensland University of Technology (QUT); Xiamen University; Xiamen University; University of International Business & Economics; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Queensland University of Technology (QUT)	Liu, DP (corresponding author), Dalian Nationalities Univ, Liaoning Key Lab Optoelect Films & Mat, Sch Phys & Mat Engn, Dalian 116600, Peoples R China.; Liu, DP (corresponding author), Xiamen Univ, Fujian Key Lab Plasma & Magnet Resonance, Sch Phys & Mech & Elect Engn, Xiamen 361005, Peoples R China.	dongping.liu@dlnu.edu.cn	Zhou, Renwu/AAM-1148-2020; Zhou, Rusen/AAX-5134-2021; Zhou, Renwu/AAZ-7174-2021	Zhou, Renwu/0000-0003-1773-7095; Zhou, Rusen/0000-0002-0762-7792; Ostrikov, Kostya (Ken)/0000-0001-8672-9297				Arjunan KP, 2011, PLASMA PROCESS POLYM, V8, P1154, DOI 10.1002/ppap.201100078; Bibinov NK, 2001, J PHYS D APPL PHYS, V34, P1819, DOI 10.1088/0022-3727/34/12/309; BIELSKI BHJ, 1991, INT J RADIAT BIOL, V59, P291, DOI 10.1080/09553009114550301; Boreen AL, 2008, ENVIRON SCI TECHNOL, V42, P5492, DOI 10.1021/es800185d; Bruggeman P, 2008, PLASMA SOURCES SCI T, V17, DOI 10.1088/0963-0252/17/2/025012; Chen C, 2014, PLASMA CHEM PLASMA P, V34, P403, DOI 10.1007/s11090-014-9545-1; Davies M.J., 1997, RADICAL MEDIATED PRO; Deng XT, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2410219; Fonseca C, 2009, J MASS SPECTROM, V44, P681, DOI 10.1002/jms.1543; HUGLI TE, 1972, J BIOL CHEM, V247, P2828; Ikawa S, 2010, PLASMA PROCESS POLYM, V7, P33, DOI 10.1002/ppap.200900090; Jablonowski H, 2015, CLIN PLASMA MED, V3, P42, DOI 10.1016/j.cpme.2015.11.003; Ke ZG, 2013, PLASMA PROCESS POLYM, V10, P181, DOI 10.1002/ppap.201200047; Ke ZG, 2010, NUCL INSTRUM METH B, V268, P2729, DOI 10.1016/j.nimb.2010.06.017; KHAN K, 1991, CLIN NUTR, V10, P186, DOI 10.1016/0261-5614(91)90037-D; Kong MG, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115012; Liu DX, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/30/305205; Liu DX, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3592775; Lu X, 2016, PHYS REP, V630, P1, DOI 10.1016/j.physrep.2016.03.003; Lu X, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3258071; Lukes P, 2014, PLASMA SOURCES SCI T, V23, DOI 10.1088/0963-0252/23/1/015019; Morfill GE, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115011; Moussa D, 2005, EUR PHYS J-APPL PHYS, V29, P189, DOI [10.1051/epjap:2004211, 10.1051/epjap.2004211]; Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564; Plewa JM, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/4/043027; PRYOR WA, 1984, J AM CHEM SOC, V106, P7094, DOI 10.1021/ja00335a038; Schneider S, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/29/295201; Sehested K, 1998, J PHYS CHEM A, V102, P2667, DOI 10.1021/jp9721053; SEHESTED K, 1991, ENVIRON SCI TECHNOL, V25, P1589, DOI 10.1021/es00021a010; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; Takai E, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4861842; Takenaka K, 2015, JPN J APPL PHYS, V54, DOI 10.7567/JJAP.54.01AF04; Takenaka K, 2013, J PHYS CONF SER, V441, DOI 10.1088/1742-6596/441/1/012001; Tunc O, 2009, J HAZARD MATER, V163, P187, DOI 10.1016/j.jhazmat.2008.06.078; von Gunten U, 2003, WATER RES, V37, P1469, DOI 10.1016/S0043-1354(02)00458-X; Walsh JL, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3052857; Weinstock IA, 2008, INORG CHEM, V47, P404, DOI 10.1021/ic701885q; Xu GH, 2007, CHEM REV, V107, P3514, DOI 10.1021/cr0682047; Yan X, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3212739; Zhang H, 2015, SCI REP-UK, V5, DOI 10.1038/srep10031; Zhang XH, 2016, PLASMA PROCESS POLYM, V13, P429, DOI 10.1002/ppap.201500088; Zhang XH, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4863204; Zhao SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073665; Zhao TL, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/34/345201; Zhou RW, 2016, CHINESE PHYS B, V25, DOI 10.1088/1674-1056/25/4/045202; Zhou RW, 2015, CHINESE PHYS B, V24, DOI 10.1088/1674-1056/24/8/085201; Zhou RW, 2015, APPL ENVIRON MICROB, V81, P5257, DOI 10.1128/AEM.01287-15	47	47	48	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2016	11	5							e0155584	10.1371/journal.pone.0155584	http://dx.doi.org/10.1371/journal.pone.0155584			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM3XH	27183129	Green Published, gold			2023-01-03	WOS:000376279500050
J	Hurley, R				Hurley, Richard			ILLICIT DRUG POLICY Consider legalising drugs despite UN treaties, says influential commission	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rhurley@bmj.com						Caulkins JP, LONG RUN TRENDS INCA; Commission on Narcotic Drugs, 2016, PREP SPEC SESS GEN A; UNAIDS (Joint United Nations Programme on HIV/AIDS), 2015, PUBL HLTH RIGHTS APP; UNGASS, 2016, CONTR STAK; UNGASS, 2016, CONTR UN ENT; United Nations General Assembly, 1998, 20 SPEC SESS WORLD D; United Nations Office on Drugs and Crime, WORLD DRUG REP 2014; United Nations Office on Drugs and Crime, 1971, CONV PSYCH SUBST; United Nations Office on Drugs and Crime, 1988, UN CONV ILL TRAFF NA; United Nations Office on Drugs and Crime, 1961, SINGL CONV NARC DRUG	10	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2016	353								i2474	10.1136/bmj.i2474	http://dx.doi.org/10.1136/bmj.i2474			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2RY	27130078				2023-01-03	WOS:000375484100019
J	Murakami, S; Verdonschot, RG; Kakimoto, N; Sumida, I; Fujiwara, M; Ogawa, K; Furukawa, S				Murakami, Shumei; Verdonschot, Rinus G.; Kakimoto, Naoya; Sumida, Iori; Fujiwara, Masateru; Ogawa, Kazuhiko; Furukawa, Souhei			Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer	PLOS ONE			English	Article							RATE INTERSTITIAL BRACHYTHERAPY; STAGE-I; CARCINOMA; OSTEORADIONECROSIS; RADIOTHERAPY; RECOMMENDATIONS; OPTIMIZATION; HEAD	Purpose To point out the advantages and drawbacks of high-dose rate brachytherapy in the treatment of mobile tongue cancer and indicate the clinical importance of modular lead-lined spacers when applying this technique to patients. Methods First, all basic steps to construct the modular spacer are shown. Second, we simulate and evaluate the dose rate reduction for a wide range of spacer configurations. Results With increasing distance to the source absorbed doses dropped considerably. Significantly more shielding was obtained when lead was added to the spacer and this effect was most pronounced on shorter (i.e. more clinically relevant) distances to the source. Conclusions The modular spacer represents an important addition to the planning and treatment stages of mobile tongue cancer using HDR-ISBT.	[Murakami, Shumei; Verdonschot, Rinus G.; Kakimoto, Naoya; Sumida, Iori; Furukawa, Souhei] Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Radiol, Suita, Osaka, Japan; [Murakami, Shumei; Kakimoto, Naoya; Sumida, Iori; Fujiwara, Masateru; Ogawa, Kazuhiko] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita, Osaka, Japan	Osaka University; Osaka University	Verdonschot, RG (corresponding author), Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Radiol, Suita, Osaka, Japan.	rinusverdonschot@gmail.com						Barrett JF, 2004, RADIOGRAPHICS, V24, P1679, DOI 10.1148/rg.246045065; Berger M., 1998, NIST STANDARD REFERE, V8, P87, DOI DOI 10.18434/T48G6X; Delacroix D, 1998, RADIAT PROT DOSIM, P112; Edmundson GK, 1990, BRACHYTHERAPY HDR LD, P184; FUJITA M, 1993, ORAL SURG ORAL MED O, V76, P797, DOI 10.1016/0030-4220(93)90054-8; Fujita M, 1996, INT J RADIAT ONCOL, V34, P333, DOI 10.1016/0360-3016(95)02066-7; FUJITA M, 1994, ORAL SURG ORAL MED O, V77, P589, DOI 10.1016/0030-4220(94)90316-6; Goethals P-E, 2014, OPPORTUNITIES BRACHY; Goineau A, 2015, BRACHYTHERAPY, V14, P71, DOI 10.1016/j.brachy.2014.09.011; Hubbell JH, 1975, PHYS CHEM REF DATA, V4, P471; Japan Radioisotope Association, 2011, RAD POCK DAT BOOK, V11; Kakimoto N, 2006, ANTICANCER RES, V26, P3933; Katimoto N, 2003, RADIOTHER ONCOL, V68, P123, DOI 10.1016/S0167-8140(03)00055-0; Kato H., 2014, JAPANESE J RADIOLOGI, V70, P1181; Kudoh T, 2010, ORAL SURG ORAL MED O, V109, pE102, DOI 10.1016/j.tripleo.2009.10.019; Lachance B, 2002, INT J RADIAT ONCOL, V54, P86, DOI 10.1016/S0360-3016(02)02897-3; Lau HY, 1996, RADIOTHER ONCOL, V39, P15, DOI 10.1016/0167-8140(95)01686-4; Leung TW, 1997, INT J RADIAT ONCOL, V39, P1113, DOI 10.1016/S0360-3016(97)00376-3; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Mazeron JJ, 2009, RADIOTHER ONCOL, V91, P150, DOI 10.1016/j.radonc.2009.01.005; MAZERON JJ, 1990, INT J RADIAT ONCOL, V19, P1369, DOI 10.1016/0360-3016(90)90346-L; Miura M, 1998, INT J RADIAT ONCOL, V41, P763, DOI 10.1016/S0360-3016(98)00118-7; NATH R, 1995, MED PHYS, V22, P209, DOI 10.1118/1.597458; Obinata K, 2003, ORAL SURG ORAL MED O, V95, P246, DOI 10.1067/moe.2003.94; Oota S, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-21; Petersen PE, 2009, ORAL ONCOL, V45, P454, DOI 10.1016/j.oraloncology.2008.05.023; Peterson DE, 2010, SUPPORT CARE CANCER, V18, P1089, DOI 10.1007/s00520-010-0898-6; Reuther T, 2003, INT J ORAL MAX SURG, V32, P289, DOI 10.1054/ijom.2002.0332; Rivard MJ, 2004, MED PHYS, V31, P633, DOI 10.1118/1.1646040; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sumida I, 2006, INT J RADIAT ONCOL, V64, P643, DOI 10.1016/j.ijrobp.2005.09.008; Tsai CJ, 2013, INT J RADIAT ONCOL, V85, P415, DOI 10.1016/j.ijrobp.2012.05.032; Umeda M, 2000, ORAL SURG ORAL MED O, V90, P667, DOI 10.1067/moe.2000.110087; WENDT CD, 1990, INT J RADIAT ONCOL, V18, P1287, DOI 10.1016/0360-3016(90)90299-Y; Williamson JF, 2002, MED PHYS, V29, P2404, DOI 10.1118/1.1509443; Yoshimura R, 2012, INT J RADIAT ONCOL, V83, P1198, DOI 10.1016/j.ijrobp.2011.09.018	36	8	10	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2016	11	4							e0154226	10.1371/journal.pone.0154226	http://dx.doi.org/10.1371/journal.pone.0154226			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK8XM	27128434	Green Published, gold, Green Submitted			2023-01-03	WOS:000375212600023
J	Chen, JH				Chen, Jonathan H.			The Patient You Least Want to See	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Chen, Jonathan H.] Stanford Univ, Dept Med, Div Gen Med Disciplines, Stanford, CA 94305 USA	Stanford University	Chen, JH (corresponding author), Stanford Univ, Dept Med, Div Gen Med Disciplines, Stanford, CA 94305 USA.	jonc101@stanford.edu		Chen, Jonathan H./0000-0002-4387-8740	NIEHS NIH HHS [K01 ES026837] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chen JH, 2016, JAMA INTERN MED, V176, P259, DOI 10.1001/jamainternmed.2015.6662; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; National Center on Addiction and Substance Abuse at Columbia University, 2012, ADD MED CLOS GAP SCI	4	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2016	315	16					1701	1702		10.1001/jama.2016.0221	http://dx.doi.org/10.1001/jama.2016.0221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK2QK	27115373	Green Accepted			2023-01-03	WOS:000374759300013
J	Dupervil, B; Grosse, S; Burnett, A; Parker, C				Dupervil, Brandi; Grosse, Scott; Burnett, Arthur; Parker, Christopher			Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010	PLOS ONE			English	Article							MANAGEMENT; HEMOLYSIS	People with sickle cell disease (SCD) suffer from numerous acute complications that can result in multiple hospitalizations and emergency department (ED) and outpatient care visits. Priapism, a prolonged unwanted erection of the penis not due to sexual stimulation, is a serious complication among males with SCD. Variations in estimates of prevalence make it difficult to accurately assess the burden of this complication of SCD. We analyzed data from the Nationwide Emergency Department Sample (NEDS), a product of the Healthcare Cost and Utilization Project, for the years 2006 through 2010 to measure the numbers of ED visits and to examine patterns of subsequent hospitalizations associated with priapism among male patients with SCD. We find that among ED visits associated with males with SCD, those prompted by priapism are more likely to result in hospitalization than are those associated with pain.	[Dupervil, Brandi; Grosse, Scott; Parker, Christopher] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA; [Burnett, Arthur] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Medicine	Dupervil, B (corresponding author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.	inm4@cdc.gov	Dupervil, Brandi/AAR-1471-2021	Grosse, Scott/0000-0003-1078-6855				Addis G, 2007, CHRONIC ILLN, V3, P145, DOI 10.1177/1742395307081505; Adeyoju AB, 2002, BJU INT, V90, P898, DOI 10.1046/j.1464-410X.2002.03022.x; Ashley-Koch A, 2000, AM J EPIDEMIOL, V151, P839; Boulet SL, 2010, AM J PREV MED, V38, pS528, DOI 10.1016/j.amepre.2010.01.003; Broderick GA, 2010, J SEX MED, V7, P476, DOI 10.1111/j.1743-6109.2009.01625.x; Burnett AL, 2013, J SEX MED, V10, P180, DOI 10.1111/j.1743-6109.2012.02707.x; Burnett AL, 2011, UROL CLIN N AM, V38, P185, DOI 10.1016/j.ucl.2011.02.005; Chrouser KL, 2011, AM J SURG, V201, P468, DOI 10.1016/j.amjsurg.2010.03.017; Crane G, 2011, ANEMIA, V2011, DOI 10.1155/2011/297364; Diggs LW, 1934, SOUTH MED J, V27, P839; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Kato GJ, 2007, BLOOD REV, V21, P37, DOI 10.1016/j.blre.2006.07.001; KULMALA RV, 1995, SCAND J UROL NEPHROL, V29, P93, DOI 10.3109/00365599509180545; National Heart Lung and Blood Institute, 2009, SICKL CELL AN WHO IS; Nolan VG, 2005, BLOOD, V106, P3264, DOI 10.1182/blood-2005-04-1594; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; Reeves S, 2014, ACAD PEDIATR, V14, pS61, DOI 10.1016/j.acap.2014.02.008; Roghmann F, 2013, J UROLOGY, V190, P1275, DOI 10.1016/j.juro.2013.03.118; Stein DM, 2013, J SEX MED, V10, P2418, DOI 10.1111/jsm.12251; Wolfson JA, 2011, PEDIATR BLOOD CANCER, V56, P413, DOI 10.1002/pbc.22792	20	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2016	11	4							e0153257	10.1371/journal.pone.0153257	http://dx.doi.org/10.1371/journal.pone.0153257			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ3UH	27078839	Green Published, gold			2023-01-03	WOS:000374131700031
J	Rodriguez-Prat, A; Monforte-Royo, C; Porta-Sales, J; Escribano, X; Balaguer, A				Rodriguez-Prat, Andrea; Monforte-Royo, Cristina; Porta-Sales, Josep; Escribano, Xavier; Balaguer, Albert			Patient Perspectives of Dignity, Autonomy and Control at the End of Life: Systematic Review and Meta-Ethnography	PLOS ONE			English	Article							PALLIATIVE CARE; OF-LIFE; TERMINALLY-ILL; ASSISTED SUICIDE; CANCER-PATIENTS; CHRONIC ILLNESS; DEATH; MODEL; EUTHANASIA; INVENTORY	Background Research in the end-of-life context has explored the sense of dignity experienced by patients with advanced disease, examining the factors associated with it. Whereas certain perspectives regard dignity as an intrinsic quality, independent of external factors, in the clinical setting it is generally equated with the person's sense of autonomy and control, and it appears to be related to patients' quality of life. This study aims to explore the relationship between perceived dignity, autonomy and sense of control in patients at the end of life. Methods We conducted a systematic review and meta-ethnography using reciprocal translation and line-of-argument synthesis. The search strategy used MeSH terms in combination with free-text searching of the Pubmed, Web of Science, CINAHL, PsycINFO and Cochrane databases, from their inception until 2015. This identified 186 articles, after excluding duplicates. The inclusion criterion was primary qualitative studies in which dignity, autonomy and control at the end of life were explored. Studies were evaluated using the CASP guidelines. Results Twenty-one studies recording the experiences of 400 participants were identified. Three themes emerged: a) dignity mediated by the loss of functionality, linked to the loss of control; b) dignity as identity; and c) autonomy as a determining factor of perceived dignity, understood as the desire for control over the dying process and the desire for self-determination. We propose an explanatory model which highlights that those patients with an intrinsic sense of dignity maintained a positive view of themselves in the face of their illness. Conclusion This synthesis illustrates how dignity and autonomy are intertwined and can be perceived as a multidimensional concept, one that is close to the notion of personal identity. The ability to regard dignity as an intrinsic quality has a positive impact on patients, and the design of care strategies should take this into account.	[Rodriguez-Prat, Andrea; Escribano, Xavier] Univ Int Catalunya, Fac Humanities, Barcelona, Spain; [Monforte-Royo, Cristina] Univ Int Catalunya, Dept Nursing, Sch Med & Hlth Sci, Barcelona, Spain; [Porta-Sales, Josep] Inst Catala Oncol, Palliat Care Serv, Barcelona, Spain; [Porta-Sales, Josep; Balaguer, Albert] Univ Int Catalunya, Sch Med & Hlth Sci, Barcelona, Spain	Universitat Internacional de Catalunya (UIC); Universitat Internacional de Catalunya (UIC); Catalan Institute of Oncology; Universitat Internacional de Catalunya (UIC)	Balaguer, A (corresponding author), Univ Int Catalunya, Sch Med & Hlth Sci, Barcelona, Spain.	abalaguer@uic.es	Balaguer, Albert/B-3530-2011; rodriguez, andrea/GRO-4054-2022; Monforte-Royo, Cristina/B-5016-2013; Rodriguez, Andrea/C-9725-2014; Balaguer, Albert/AAG-8678-2020	Balaguer, Albert/0000-0002-5222-8635; Monforte-Royo, Cristina/0000-0001-8334-4623; Rodriguez, Andrea/0000-0001-6382-243X; Balaguer, Albert/0000-0002-5222-8635	Junior Faculty programme grant; L'Obra Social "La Caixa"; Instituto de Salud Carlos III [PI14/00263]; Asociacion Espanola Contra el Cancer (aecc)- Catalunya contra el Cancer - Barcelona	Junior Faculty programme grant; L'Obra Social "La Caixa"(La Caixa Foundation); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Asociacion Espanola Contra el Cancer (aecc)- Catalunya contra el Cancer - Barcelona	This study was supported by: the Junior Faculty programme grant, cofinanced by L'Obra Social "La Caixa" (AR): http://www.uic.es/en/studies/grants/becas-junior-faculty; the Instituto de Salud Carlos III (grant number: PI14/00263) (CMR JPS AB): http://www.eng.isciii.es/ISCIII/es/general/index.shtml; Asociacion Espanola Contra el Cancer (aecc)- Catalunya contra el Cancer - Barcelona (CMR JPS AB): https://www.aecc.es/Nosotros/Dondeestamos/Barcelona/Paginas/home.aspx; WeCare Chair: End-of-life care at the Universitat Internacional de Catalunya and ALTIMA (AR CMR JPS AB): http://www.wecare.uic.es/home/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-45; Ashcroft RE, 2005, J MED ETHICS, V31, P679, DOI 10.1136/jme.2004.011130; Aujoulat I, 2008, SOC SCI MED, V66, P1228, DOI 10.1016/j.socscimed.2007.11.034; Bolmsjo I, 2000, J PALLIAT CARE, V16, P20, DOI 10.1177/082585970001600204; Brown Hilary, 2011, Br J Community Nurs, V16, P238; CASP, 1999, CRIT APPR SKILLS PRO; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Chapple A, 2006, J MED ETHICS, V32, P706, DOI 10.1136/jme.2006.015883; Charmaz K, 1995, SOCIOL QUART, V36, P657, DOI 10.1111/j.1533-8525.1995.tb00459.x; Charmaz K, 1983, Sociol Health Illn, V5, P168, DOI 10.1111/1467-9566.ep10491512; Chochinov HM, 2008, J PAIN SYMPTOM MANAG, V36, P559, DOI 10.1016/j.jpainsymman.2007.12.018; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2002, LANCET, V360, P2026, DOI 10.1016/S0140-6736(02)12022-8; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Coyle N, 2004, ONCOL NURS FORUM, V31, P699, DOI 10.1188/04.ONF.699-709; Dixon-Woods Mary, 2007, J Health Serv Res Policy, V12, P42, DOI 10.1258/135581907779497486; Enes SPD, 2003, PALLIATIVE MED, V17, P263, DOI 10.1191/0269216303pm699oa; Franklin LL, 2006, NURS ETHICS, V13, P130, DOI 10.1191/0969733006ne851oa; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Ganzini Linda, 2003, J Palliat Med, V6, P381, DOI 10.1089/109662103322144691; Guo QH, 2014, PALLIATIVE MED, V28, P931, DOI 10.1177/0269216314528399; Hack TF, 2004, PSYCHO-ONCOL, V13, P700, DOI 10.1002/pon.786; Hall Sue, 2009, BMC Palliat Care, V8, P5, DOI 10.1186/1472-684X-8-5; Ho AHY, 2013, DEATH STUD, V37, P953, DOI 10.1080/07481187.2012.703078; Ho AHY, 2013, AGE AGEING, V42, P455, DOI 10.1093/ageing/aft003; Jacelon CS, 2003, QUAL HEALTH RES, V13, P543, DOI 10.1177/1049732302250762; Jacobson N, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-3; Johnson PRS, 1998, THEOR MED BIOETH, V19, P337, DOI 10.1023/A:1009951813110; Kade W J, 2000, Ann Intern Med, V132, P504; Kleinman A., 1988, ILLNESS NARRATIVES; Lavery JV, 2001, LANCET, V358, P362, DOI 10.1016/S0140-6736(01)05555-6; Leung D, 2007, INT J PALLIAT NURS, V13, P170, DOI 10.12968/ijpn.2007.13.4.23487; Li HC, 2014, J ADV NURS, V70, P2920, DOI 10.1111/jan.12455; Mak YYW, 2005, PALLIATIVE MED, V19, P343, DOI 10.1191/0269216305pm1019oa; Mesler MA, 2000, DEATH STUD, V24, P135, DOI 10.1080/074811800200612; Monforte-Royo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037117; Nissim R, 2009, SOC SCI MED, V69, P165, DOI 10.1016/j.socscimed.2009.04.021; Noblit G, 1988, META ETHNOGRAPHY SIN; Nordenfelt L, 2004, HEALTH CARE ANAL, V12, P69, DOI 10.1023/B:HCAN.0000041183.78435.4b; Ostlund U, 2012, EUR J ONCOL NURS, V16, P353, DOI 10.1016/j.ejon.2011.07.010; Paterson BL, 2001, J NURS SCHOLARSHIP, V33, P21, DOI 10.1111/j.1547-5069.2001.00021.x; Pearlman RA, 2005, J GEN INTERN MED, V20, P234, DOI 10.1111/j.1525-1497.2005.40225.x; Periyakoil VS, 2013, J AM GERIATR SOC, V61, P440, DOI 10.1111/jgs.12145; Pleschberger S, 2007, AGE AGEING, V36, P197, DOI 10.1093/ageing/afl152; Pullman D, 2004, J PALLIAT CARE, V20, P171, DOI 10.1177/082585970402000309; Pullman D, 1996, Health Law J, V4, P197; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Sandelowski M, 2003, RES NURS HEALTH, V26, P153, DOI 10.1002/nur.10072; Sandelowski M, 2007, RES NURS HEALTH, V30, P99, DOI 10.1002/nur.20176; Street AF, 2001, J PALLIAT CARE, V17, P93, DOI 10.1177/082585970101700205; Sulmasy DP, 2013, MED HEALTH CARE PHIL, V16, P937, DOI 10.1007/s11019-012-9400-1; Vehling S, 2014, PSYCHO-ONCOLOGY, V23, P283, DOI 10.1002/pon.3417; Volker DL, 2004, ONCOL NURS FORUM, V31, P954, DOI 10.1188/04.ONF.954-960; Volker DL, 2004, ONCOL NURS FORUM, V31, P945, DOI 10.1188/04.ONF.945-953; Walsh Ken, 2002, Int J Nurs Pract, V8, P143, DOI 10.1046/j.1440-172X.2002.00355.x	55	77	77	1	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0151435	10.1371/journal.pone.0151435	http://dx.doi.org/10.1371/journal.pone.0151435			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH3SV	27010323	Green Published, gold, Green Submitted			2023-01-03	WOS:000372708000028
J	Samadder, NJ; Neklason, DW; Boucher, KM; Byrne, KR; Kanth, P; Samowitz, W; Jones, D; Tavtigian, SV; Done, MW; Berry, T; Jasperson, K; Pappas, L; Smith, L; Sample, D; Davis, R; Topham, MK; Lynch, P; Strait, E; McKinnon, W; Burt, RW; Kuwada, SK				Samadder, N. Jewel; Neklason, Deborah W.; Boucher, Kenneth M.; Byrne, Kathryn R.; Kanth, Priyanka; Samowitz, Wade; Jones, David; Tavtigian, Sean V.; Done, Michelle W.; Berry, Therese; Jasperson, Kory; Pappas, Lisa; Smith, Laurel; Sample, Danielle; Davis, Rian; Topham, Matthew K.; Lynch, Patrick; Strait, Elena; McKinnon, Wendy; Burt, Randall W.; Kuwada, Scott K.			Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL LUNG-CANCER; LONG-TERM TREATMENT; CYCLOOXYGENASE-2 INHIBITOR; CELECOXIB; RISK; COLI; CHEMOPREVENTION; METAANALYSIS; EXPRESSION; PREVENTION	IMPORTANCE Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal neoplasia is difficult and chemoprevention has not been successful. OBJECTIVE To evaluate the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in patients with FAP. DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized, placebo-controlled trial, enrolling 92 participants with FAP, conducted from July 2010 through June 2014 at Huntsman Cancer Institute in Salt Lake City, Utah. INTERVENTIONS Participants with FAP were randomized to sulindac (150mg) twice daily and erlotinib (75mg) daily (n = 46) vs placebo (n = 46) for 6 months. MAIN OUTCOMES AND MEASURES The total number and diameter of polyps in the proximal duodenum were mapped at baseline and 6 months. The primary outcome was change in total polyp burden at 6 months. Polyp burden was calculated as the sum of the diameters of polyps. The secondary outcomes were change in total duodenal polyp count, change in duodenal polyp burden or count stratified by genotype and initial polyp burden, and percentage of change from baseline in duodenal polyp burden. RESULTS Ninety-two participants (mean age, 41 years [range, 24-55]; women, 56 [61%]) were randomized when the trial was stopped by the external data and safety monitoring board because the second preplanned interim analysis met the prespecified stopping rule for superiority. Grade 1 and 2 adverse events were more common in the sulindac-erlotinib group, with an acne-like rash observed in 87% of participants receiving treatment and 20% of participants receiving placebo (P <.001). Only 2 participants experienced grade 3 adverse events. [GRAPHICS] . CONCLUSIONS AND RELEVANCE Among participants with FAP, the use of sulindac and erlotinib compared with placebo resulted in a lower duodenal polyp burden after 6 months. Adverse events may limit the use of these medications at the doses used in this study. Further research is necessary to evaluate these preliminary findings in a larger study population with longer follow-up to determine whether the observed effects will result in improved clinical outcomes.	[Samadder, N. Jewel; Neklason, Deborah W.; Boucher, Kenneth M.; Samowitz, Wade; Jones, David; Tavtigian, Sean V.; Done, Michelle W.; Berry, Therese; Jasperson, Kory; Pappas, Lisa; Smith, Laurel; Sample, Danielle; Davis, Rian; Topham, Matthew K.; Burt, Randall W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Samadder, N. Jewel; Byrne, Kathryn R.; Kanth, Priyanka; Burt, Randall W.] Univ Utah, Dept Med Gastroenterol, Salt Lake City, UT USA; [Neklason, Deborah W.; Jones, David; Tavtigian, Sean V.; Topham, Matthew K.; Burt, Randall W.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; [Neklason, Deborah W.] Univ Utah, Dept Med Genet Epidemiol, Salt Lake City, UT USA; [Boucher, Kenneth M.] Univ Utah, Dept Med Epidemiol, Salt Lake City, UT USA; [Samowitz, Wade] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Topham, Matthew K.] Univ Utah, Dept Med Pulm, Salt Lake City, UT USA; [Lynch, Patrick] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA; [Strait, Elena] Penrose Community Hosp, Colorado Springs, CO USA; [McKinnon, Wendy] Univ Vermont, Ctr Canc, Burlington, VT 05405 USA; [Kuwada, Scott K.] Univ Hawaii, Dept Med, Honolulu, HI 96822 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Texas System; UTMD Anderson Cancer Center; University of Vermont; University of Hawaii System	Neklason, DW (corresponding author), Univ Utah, Huntsman Canc Inst, High Risk Canc Res Program, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	deb.neklason@hci.utah.edu	Kanth, Priyanka/HJA-2102-2022		National Cancer Institute [P01-CA073992]; Huntsman Cancer Institute Cancer Center Support Grant [NCI P30CA042014]; Huntsman Cancer Foundation; American College of Gastroenterology; National Institutes of Health National Center for Advancing Translational Sciences [1ULTR001067]; NATIONAL CANCER INSTITUTE [P30CA042014, P01CA073992] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001067] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Huntsman Cancer Institute Cancer Center Support Grant; Huntsman Cancer Foundation; American College of Gastroenterology(General Electric); National Institutes of Health National Center for Advancing Translational Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This project was funded by provided by grant P01-CA073992 from the National Cancer Institute (Drs Burt and Tavtigian); the Huntsman Cancer Institute Cancer Center Support Grant (NCI P30CA042014), as well as by the Huntsman Cancer Foundation; by a junior faculty career development award from the American College of Gastroenterology (Dr Samadder); and by grant 1ULTR001067 from the National Institutes of Health National Center for Advancing Translational Sciences.	[Anonymous], 2008, SUL PACK INS; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Biasco G, 2004, GUT, V53, P1547; Bulow S, 2004, GUT, V53, P381, DOI 10.1136/gut.2003.027771; Bulow S, 2003, GUT, V52, P742, DOI 10.1136/gut.52.5.742; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Conio M, 2001, GASTROINTEST ENDOSC, V53, P265, DOI 10.1067/mge.2000.108721; Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890; DEBINSKI HS, 1995, LANCET, V345, P855, DOI 10.1016/S0140-6736(95)92989-4; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; Gibbons DC, 2011, FAM CANCER, V10, P11, DOI 10.1007/s10689-010-9394-x; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Heiskanen I, 1999, ENDOSCOPY, V31, P412; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Lynch PM, 2010, AM J GASTROENTEROL, V105, P1437, DOI 10.1038/ajg.2009.758; Lynch TJ, 2009, J THORAC ONCOL, V4, P1002, DOI 10.1097/JTO.0b013e3181aba89f; Marks JL, 2008, J THORAC ONCOL, V3, P111, DOI 10.1097/JTO.0b013e318160c607; MORTON DG, 1993, BRIT J SURG, V80, P255, DOI 10.1002/bjs.1800800249; NIV Y, 1994, GASTROENTEROLOGY, V107, P854, DOI 10.1016/0016-5085(94)90136-8; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857; Qi WX, 2015, J CHEMOTHERAPY, V27, P40, DOI 10.1179/1973947814Y.0000000189; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Shi L, 2014, LUNG CANCER, V83, P231, DOI 10.1016/j.lungcan.2013.11.016; Sos ML, 2008, J THORAC ONCOL, V3, P170, DOI 10.1097/JTO.0b013e3181622c05; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; THORSON AG, 1994, LANCET, V343, P180, DOI 10.1016/S0140-6736(94)90974-1; Tonelli F, 2000, J SURG ONCOL, V74, P15, DOI 10.1002/1096-9098(200005)74:1<15::AID-JSO4>3.0.CO;2-Z; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Woodcock J., WITHDRAWAL APPROVAL	34	84	88	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2016	315	12					1266	1275		10.1001/jama.2016.2522	http://dx.doi.org/10.1001/jama.2016.2522			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH0YQ	27002448	Green Accepted, Bronze			2023-01-03	WOS:000372511100013
J	Lim, HD; Kim, MH; Lee, CY; Namgung, U				Lim, Hee-Don; Kim, Min-Hee; Lee, Chan-Yong; Namgung, Uk			Anti-Inflammatory Effects of Acupuncture Stimulation via the Vagus Nerve	PLOS ONE			English	Article							SYSTEMIC INFLAMMATORY RESPONSE; SOLITARY TRACT; BRAIN-STEM; ENDOTOXEMIA; NUCLEUS; NEURONS; PATHWAY; ELECTROACUPUNCTURE; ACTIVATION; RECEPTORS	Although acupuncture therapy is widely used in traditional Asian medicine for the treatment of diverse internal organ disorders, its underlying biological mechanisms are largely unknown. Here, we investigated the functional involvement of acupuncture stimulation (AS) in the regulation of inflammatory responses. TNF-alpha production in mouse serum, which was induced by lipopolysaccharide (LPS) administration, was decreased by manual acupuncture (MAC) at the zusanli acupoint (stomach36, ST36). In the spleen, TNF-alpha mRNA and protein levels were also downregulated by MAC and were recovered by using a splenic neurectomy and a vagotomy. c-Fos, which was induced in the nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus nerve (DMV) by LPS and electroacupuncture (EAC), was further increased by focal administration of the AMPA receptor blocker CNQX and the purinergic receptor antagonist PPADS. TNF-alpha levels in the spleen were decreased by CNQX and PPADS treatments, implying the involvement of inhibitory neuronal activity in the DVC. In unanesthetized animals, both MAC and EAC generated c-Fos induction in the DVC neurons. However, MAC, but not EAC, was effective in decreasing splenic TNF-alpha production. These results suggest that the therapeutic effects of acupuncture may be mediated through vagal modulation of inflammatory responses in internal organs.	[Lim, Hee-Don; Kim, Min-Hee; Namgung, Uk] Daejeon Univ, Dept Oriental Med, Daejeon, South Korea; [Lee, Chan-Yong] Daejeon Univ, Dept Microbiol & Biotechnol, Daejeon, South Korea	Daejeon University; Daejeon University	Namgung, U (corresponding author), Daejeon Univ, Dept Oriental Med, Daejeon, South Korea.	unamgung@dju.kr			Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2013056735]; Ministry of Education [2013011219]	Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Ministry of Education	This work was supported by grants from the Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013056735) and by the Ministry of Education (2013011219), URL: www.nrf.re.kr. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from the Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013056735) and by the Ministry of Education (2013011219).	Andersson U, 2012, J EXP MED, V209, P1057, DOI 10.1084/jem.20120571; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bratton BO, 2012, EXP PHYSIOL, V97, P1180, DOI 10.1113/expphysiol.2011.061531; Buijs RM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003152; Burnstock G, 2014, SCIENCE, V346, pS23; Cailotto C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087785; Cano G, 2001, J COMP NEUROL, V439, P1, DOI 10.1002/cne.1331; Chang IA, 2013, J ACUPUNCT MERIDIAN, V6, P89, DOI 10.1016/j.jams.2012.12.004; Chang IA, 2012, FASEB J, V26, P2401, DOI 10.1096/fj.11-199018; Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Guyenet PG, 2006, NAT REV NEUROSCI, V7, P335, DOI 10.1038/nrn1902; Hermann GE, 2008, NEUROSCIENTIST, V14, P53, DOI 10.1177/1073858407305725; Illes P, 2012, NEUROSCIENTIST, V18, P422, DOI 10.1177/1073858411418524; Iwa M, 2006, AM J PHYSIOL-GASTR L, V290, pG285, DOI 10.1152/ajpgi.00068.2005; Janig W, 2006, INTEGRATIVE ACTION OF THE AUTONOMIC NERVOUS SYSTEM: NEUROBIOLOGY OF HOMEOSTASIS, P1; Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892; Kim MH, 2012, J ACUPUNCT MERIDIAN, V5, P148, DOI [10.1016/j.jams.2012.05.002, 10.1016/j.jams.2012.05.002/]; Kim SY, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1086; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Leake R., 1999, INTEGR MED, V1, P107; LUX G, 1994, GUT, V35, P1026, DOI 10.1136/gut.35.8.1026; Martelli D, 2014, AUTON NEUROSCI-BASIC, V182, P65, DOI 10.1016/j.autneu.2013.12.007; McDougal DH, 2011, J NEUROSCI, V31, P14037, DOI 10.1523/JNEUROSCI.2855-11.2011; MENETREY D, 1987, J COMP NEUROL, V255, P439, DOI 10.1002/cne.902550310; Nishijo K, 1997, NEUROSCI LETT, V227, P165, DOI 10.1016/S0304-3940(97)00337-6; Noguchi E, 2010, AUTON NEUROSCI-BASIC, V156, P15, DOI 10.1016/j.autneu.2010.06.010; Pavlov VA, 2006, P NATL ACAD SCI USA, V103, P5219, DOI 10.1073/pnas.0600506103; Potts JT, 2006, EXP PHYSIOL, V91, P59, DOI 10.1113/expphysiol.2005.032227; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Taniguchi T, 2005, MINI-REV MED CHEM, V5, P241, DOI 10.2174/1389557053175407; Toney GM, 2000, J APPL PHYSIOL, V88, P2062, DOI 10.1152/jappl.2000.88.6.2062; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Travagli RA, 2006, ANNU REV PHYSIOL, V68, P279, DOI 10.1146/annurev.physiol.68.040504.094635; Xu GY, 2009, NEUROGASTROENT MOTIL, V21, DOI 10.1111/j.1365-2982.2009.01354.x; Yang FL, 2007, SHOCK, V28, P309, DOI 10.1097/shk.0b013e31803dd04d; Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007; Zagon A, 2001, EUR J NEUROSCI, V13, P781, DOI 10.1046/j.0953-816x.2000.01445.x	41	76	89	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2016	11	3							e0151882	10.1371/journal.pone.0151882	http://dx.doi.org/10.1371/journal.pone.0151882			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1ZE	26991319	Green Published, gold, Green Submitted			2023-01-03	WOS:000372582800113
J	Teymoortash, A; Pfestroff, A; Wittig, A; Franke, N; Hoch, S; Harnisch, S; Schade-Brittinger, C; Hoeffken, H; Engenhart-Cabillic, R; Brugger, M; Strauch, K				Teymoortash, Afshin; Pfestroff, Andreas; Wittig, Andrea; Franke, Nora; Hoch, Stephan; Harnisch, Susanne; Schade-Brittinger, Carmen; Hoeffken, Helmut; Engenhart-Cabillic, Rita; Brugger, Markus; Strauch, Konstantin			Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial	PLOS ONE			English	Article							RADIATION-INDUCED XEROSTOMIA; SALIVARY HYPOFUNCTION; PAROTID-GLAND; MANAGEMENT; RECEPTOR; TESTS; FLOW	This prospective, randomized, placebo-controlled, double-blinded phase I clinical trial investigates safety and efficacy of botulinum toxin (BoNT) to preserve gland function after radiotherapy in patients with head and neck cancer. Twelve patients with advanced head and neck cancer were injected with BoNT into the submandibular glands prior to primary radiochemotherapy. Six patients received BoNT/A and 6 patients BoNT/A and B, half of each subgroup into their left and the other half into their right gland. As an internal control, sodium chloride was injected into the respective contralateral gland (placebo). For the evaluation of the salivary gland function, technetium pertechnetate salivary gland scintigraphy was performed before and after the end of radiotherapy. BoNT/A and B were well tolerated. Analysis of the scintigraphic data revealed no statistically significant difference between BoNT and placebo regarding the scintigraphic uptake difference (pBoNT/A = 0.84 and pBoNT/A-B = 0.56 for BoNT/A vs. placebo and BoNT/A-B vs. placebo, respectively). We also found no significant difference in treatment between BoNT and placebo in terms of salivary excretion fraction (pBoNT/A = 0.44; pBoNT/A-B = 0.44). This study demonstrates that BoNT can be safely combined with radiochemotherapy. Dosing and timing of BoNT injection should be further investigated for efficacy analysis.	[Teymoortash, Afshin; Franke, Nora; Hoch, Stephan] Univ Marburg, Dept Otolaryngol Head & Neck Surg, Marburg, Germany; [Pfestroff, Andreas; Hoeffken, Helmut] Univ Marburg, Dept Nucl Med, Marburg, Germany; [Wittig, Andrea; Engenhart-Cabillic, Rita] Univ Marburg, Dept Radiotherapy & Radiooncol, Marburg, Germany; [Harnisch, Susanne; Schade-Brittinger, Carmen] Univ Marburg, Ctr Clin Trials, Marburg, Germany; [Brugger, Markus; Strauch, Konstantin] Univ Munich, Inst Med Informat Biometry & Epidemiol, Chair Genet Epidemiol, Munich, Germany; [Brugger, Markus; Strauch, Konstantin] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany; [Strauch, Konstantin] Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Philipps University Marburg	Teymoortash, A (corresponding author), Univ Marburg, Dept Otolaryngol Head & Neck Surg, Marburg, Germany.	teymoort@med.uni-marburg.de			Von-Behring-Rontgen Foundation, Marburg, Germany [57-0011]; Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ	Von-Behring-Rontgen Foundation, Marburg, Germany; Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ	This study was financially supported by the Von-Behring-Rontgen Foundation, Marburg, Germany, Grant No. 57-0011. Furthermore, this work was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ.	ABOK K, 1984, VIRCHOWS ARCH B, V45, P443, DOI 10.1007/BF02889885; Bansal M, 2004, QUAL LIFE RES, V13, P481, DOI 10.1023/B:QURE.0000018491.80646.bc; Baujat B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002026.pub2; Cannon DM, 2008, INT J RADIAT ONCOL, V70, P660, DOI 10.1016/j.ijrobp.2007.09.018; Coppes RP, 2001, BRIT J CANCER, V85, P1055, DOI 10.1054/bjoc.2001.2038; Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302; Dirix P, 2010, LANCET ONCOL, V11, P85, DOI 10.1016/S1470-2045(09)70231-1; Ellies M, 2002, LARYNGOSCOPE, V112, P82, DOI 10.1097/00005537-200201000-00015; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Hothorn T, 2008, J STAT SOFTW, V28, P1; Jahn R, 2006, SCIENCE, V312, P540, DOI 10.1126/science.1127236; Jankovic J, 2004, J NEUROL NEUROSUR PS, V75, P951, DOI 10.1136/jnnp.2003.034702; Lipp A, 2003, NEUROLOGY, V61, P1279, DOI 10.1212/WNL.61.9.1279; Lovelace TL, 2014, OR SURG OR MED OR PA, V117, P595, DOI 10.1016/j.oooo.2014.01.229; Nagler RM, 2003, IN VIVO, V17, P369; Pfestroff A, 2010, IN VIVO, V24, P681; R Core Team, 2012, R LANG ENV STAT COMP; Senn S, 2006, STAT MED, V25, P4334, DOI 10.1002/sim.2682; Shiboski CH, 2007, ORAL SURG ORAL MED O, V103, pS66, DOI 10.1016/j.tripleo.2006.11.013; Teymoortash A, 2007, BRIT J PHARMACOL, V152, P161, DOI 10.1038/sj.bjp.0707375; Teymoortash A, 2009, ORAL ONCOL, V45, P737, DOI 10.1016/j.oraloncology.2008.11.014; VALDEZ IH, 1993, INT J RADIAT ONCOL, V25, P41, DOI 10.1016/0360-3016(93)90143-J; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Vissink A, 2010, INT J RADIAT ONCOL, V78, P983, DOI 10.1016/j.ijrobp.2010.06.052; Wei L, 2001, DRUG INF J, V35, P1201, DOI 10.1177/009286150103500417; Welz H, 2009, ONCOLOGY-BASEL, V76, P405, DOI 10.1159/000215927	26	8	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2016	11	3							e0151316	10.1371/journal.pone.0151316	http://dx.doi.org/10.1371/journal.pone.0151316			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH1ZE	26991494	Green Published, Green Submitted, gold			2023-01-03	WOS:000372582800055
J	Wu, MS; Chen, KH; Chen, IF; Huang, SK; Tzeng, PC; Yeh, ML; Lee, FP; Lin, JG; Chen, C				Wu, Ming-Shun; Chen, Kee-Hsin; Chen, I-Fan; Huang, Shihping Kevin; Tzeng, Pei-Chuan; Yeh, Mei-Ling; Lee, Fei-Peng; Lin, Jaung-Geng; Chen, Chiehfeng			The Efficacy of Acupuncture in Post-Operative Pain Management: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							ELECTRICAL NERVE-STIMULATION; ANALGESIC REQUIREMENT; ELECTROACUPUNCTURE; ACUPOINT; SURGERY; COMPLICATIONS; RELIEF	Background Postoperative pain resulting from surgical trauma is a significant challenge for healthcare providers. Opioid analgesics are commonly used to treat postoperative pain; however, these drugs are associated with a number of undesirable side effects. Objective This systematic review and meta-analysis evaluated the effectiveness of acupuncture and acupuncture-related techniques in treating postoperative pain. Data Source MEDLINE, Cochrane Library, and EMBASE databases were searched until Sep 30, 2014. Study Eligibility Criteria Randomized controlled trials of adult subjects (>= 18 years) who had undergone surgery and who had received acupuncture, electroacupuncture, or acupoint electrical stimulation for managing acute post-operative pain were included. Results We found that patients treated with acupuncture or related techniques had less pain and used less opioid analgesics on Day 1 after surgery compared with those treated with control (P < 0.001). Sensitivity analysis using the leave-one-out approach indicated the findings are reliable and are not dependent on any one study. In addition, no publication bias was detected. Subgroup analysis indicated that conventional acupuncture and transcutaneous electric acupoint stimulation (TEAS) were associated with less postoperative pain one day following surgery than control treatment, while electroacupuncture was similar to control (P = 0.116). TEAS was associated with significantly greater reduction in opioid analgesic use on Day 1 post surgery than control (P < 0.001); however conventional acupuncture and electroacupuncture showed no benefit in reducing opioid analgesic use compared with control (P >= 0.142). Conclusion Our findings indicate that certain modes of acupuncture improved postoperative pain on the first day after surgery and reduced opioid use. Our findings support the use of acupuncture as adjuvant therapy in treating postoperative pain.	[Wu, Ming-Shun] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan; [Wu, Ming-Shun] Taipei Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med,Coll Med, Taipei, Taiwan; [Chen, Kee-Hsin] Taipei Med Univ, Wan Fang Hosp, Dept Nursing, Taipei, Taiwan; [Chen, Kee-Hsin; Chen, Chiehfeng] Taipei Med Univ, Sch Nursing, Coll Nursing, Taipei, Taiwan; [Chen, Kee-Hsin; Chen, Chiehfeng] Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan; [Chen, I-Fan; Huang, Shihping Kevin] Natl Chiao Tung Univ, Inst Management Technol, Hsinchu, Taiwan; [Tzeng, Pei-Chuan; Chen, Chiehfeng] Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, Taipei, Taiwan; [Yeh, Mei-Ling] Natl Taipei Univ Nursing & Hlth Sci, Grad Inst Integrat Tradit Chinese Med Western Nur, Taipei, Taiwan; [Lee, Fei-Peng; Chen, Chiehfeng] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Lee, Fei-Peng] Taipei Med Univ, Shuang Ho Hosp, Dept Otolaryngol, New Taipei, Taiwan; [Lin, Jaung-Geng] China Med Univ, Sch Chinese Med Acupuncture Sci, Taichung, Taiwan; [Chen, Chiehfeng] Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, Taipei, Taiwan	Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; National Yang Ming Chiao Tung University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Taipei University of Nursing & Health Science (NTUNHS); Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; China Medical University Taiwan; Taipei Medical University	Chen, C (corresponding author), Taipei Med Univ, Sch Nursing, Coll Nursing, Taipei, Taiwan.; Chen, C (corresponding author), Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan.; Chen, C (corresponding author), Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, Taipei, Taiwan.; Chen, C (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.; Chen, C (corresponding author), Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, Taipei, Taiwan.; Chen, C (corresponding author), Taipei Med Univ, Wan Fang Hosp, Div Plast Surg, Dept Surg, Taipei, Taiwan.	chiehfeng@sina.com	Chen, Kee-Hsin/W-3576-2019	Chen, Kee-Hsin/0000-0001-9772-482X; Chen, Chiehfeng/0000-0002-1595-6553; Fei-Peng, Lee/0000-0002-6788-4336	Taipei Medical University - Wan Fang Hospital [103WF-EVA-18]	Taipei Medical University - Wan Fang Hospital	This work was supported by Taipei Medical University - Wan Fang Hospital under the Grant No. 103WF-EVA-18.	Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028; Chen SP, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/609594; Chiu JH, 1999, DIS COLON RECTUM, V42, P180, DOI 10.1007/BF02237124; Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601; de Leon-Casasola O, 2014, POSTGRAD MED, V126, P42, DOI 10.3810/pgm.2014.07.2782; Erthal V, 2013, LASER MED SCI, V28, P1345, DOI 10.1007/s10103-012-1260-7; Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Hartrick Craig T, 2003, Pain Pract, V3, P310; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; HINES R, 1992, ANESTH ANALG, V74, P503; Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015; Lan F, 2012, MINERVA ANESTESIOL, V78, P887; Langenbach MR, 2012, COLORECTAL DIS, V14, pE486, DOI 10.1111/j.1463-1318.2012.02984.x; Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0; Mayor D, 2013, ACUPUNCT MED, V31, P409, DOI 10.1136/acupmed-2013-010324; Sim Chin-Keng, 2002, Acupunct Med, V20, P56; Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029; WANG JQ, 1992, INT J NEUROSCI, V65, P117, DOI 10.3109/00207459209003283; Wang RR, 2000, AM J CHINESE MED, V28, P25, DOI 10.1142/S0192415X00000052; Ward U, 2013, CLIN NURS RES, V22, P130, DOI 10.1177/1054773812454136; Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064; Yamashita H, 1999, J ALTERN COMPLEM MED, V5, P229, DOI 10.1089/acm.1999.5.229; Yeh ML, 2011, INT J NURS STUD, V48, P703, DOI 10.1016/j.ijnurstu.2010.10.009	29	118	127	4	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2016	11	3							e0150367	10.1371/journal.pone.0150367	http://dx.doi.org/10.1371/journal.pone.0150367			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TF	26959661	Green Published, gold, Green Submitted			2023-01-03	WOS:000371992300045
J	Onda, Y; Nishimura, R; Morimoto, A; Sano, H; Utsunomiya, K; Tajima, N				Onda, Yoshiko; Nishimura, Rimei; Morimoto, Aya; Sano, Hironari; Utsunomiya, Kazunori; Tajima, Naoko		Diabet Epidemiology Res Int DERI M	Age at Transition from Pediatric to Adult Care Has No Relationship with Mortality for Childhood-Onset Type 1 Diabetes in Japan: Diabetes Epidemiology Research International (DERI) Mortality Study	PLOS ONE			English	Article							YOUNG-ADULTS; GLYCEMIC CONTROL; FOLLOW-UP; ADOLESCENCE; TRENDS	Objective To follow up Japanese patients with type 1 diabetes for a maximum of 40 years to examine when they transitioned from pediatric care to adult care and to explore whether the attending physician, i.e., pediatrician or internist, was associated with prognosis. Methods Participants consisted of 1,299 patients who had been diagnosed as having type 1 diabetes at less than 15 years old between 1965 and 1979 identified through two nationwide surveys. Patients were classified as having received either pediatric care or adult care at the age of 15 and 30, and were compared for differences in mortality associated with the attending physician. Results The attending physicians were confirmed for a total of 1,093 patients at the age of 15. Of these patients, 43.8% and 40.3% received pediatric care and adult care, respectively. Of the 569 patients receiving pediatric care, 74.2%, 56.6%, 53.4%, and 51.3% continued with pediatric care at 20, 30, 40, and 50 years old, respectively. The attending physicians (pediatrician or internist) at the age of 15 and 30 had no significant impact on their survival (P = 0.892, 0.411, respectively). Conclusions More than half of the patients who had received pediatric care at the age of 15 continued to receive pediatric care even after the age of 30, suggesting that their transition was far from smooth, while the attending physician at the age of both 15 and 30 was not a prognostic factor for mortality. Thus, the timing for transition to adult care in these patients has no relationship with mortality in Japan.	[Onda, Yoshiko; Nishimura, Rimei; Sano, Hironari; Utsunomiya, Kazunori] Jikei Univ, Dept Internal Med, Div Diabet Metab & Endocrinol, Sch Med, Tokyo, Japan; [Nishimura, Rimei] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Morimoto, Aya] Morimoto Hosp, Dept Internal Med, Tokyo, Japan; [Tajima, Naoko] Jikei Univ, Sch Med, Tokyo, Japan	Jikei University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jikei University	Onda, Y (corresponding author), Jikei Univ, Dept Internal Med, Div Diabet Metab & Endocrinol, Sch Med, Tokyo, Japan.	morohoshy@gmail.com			National Institutes of Health [DK-35905]; Ministry of Health, Labor and Welfare [H10-Kodomo-022]; Ministry of Education, Culture, Sports, Science and Technology, Japan [Wakate-B 14770186, 16790328, 22790573]; Jikei Graduate School of Medicine, Tokyo, Japan; COSTCO Japan Diabetes Foundation; Japan Child and Family Research Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Jikei Graduate School of Medicine, Tokyo, Japan; COSTCO Japan Diabetes Foundation; Japan Child and Family Research Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by a research grant from the National Institutes of Health (DK-35905), a grant from the Japan Child and Family Research Institute, Ministry of Health, Labor and Welfare (H10-Kodomo-022), a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Wakate-B 14770186, 16790328, 22790573), a research grant from Jikei Graduate School of Medicine, Tokyo, Japan, and a grant from COSTCO Japan Diabetes Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Acad Pediat, 2011, PEDIATRICS, V128, P182, DOI 10.1542/peds.2011-0969; AMIEL SA, 1986, NEW ENGL J MED, V315, P215, DOI 10.1056/NEJM198607243150402; [Anonymous], 1995, Am J Epidemiol, V142, P612; [Anonymous], 2014, SUCC APPR MAN PED AD; [Anonymous], 2014, TRANS PED AD CAR TOO; Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011; Bryden KS, 2003, DIABETES CARE, V26, P1052, DOI 10.2337/diacare.26.4.1052; Bryden KS, 2001, DIABETES CARE, V24, P1536, DOI 10.2337/diacare.24.9.1536; CROW EL, 1959, BIOMETRIKA, V46, P441, DOI 10.1093/biomet/46.3-4.441; Garvey KC, 2012, DIABETES CARE, V35, P1716, DOI 10.2337/dc11-2434; Harjutsalo V, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5364; International Diabetes Fedeartion, 2013, INT DIAB FED DIABETE; Jacobson AM, 1997, J PEDIATR-US, V131, P727, DOI 10.1016/S0022-3476(97)70101-X; Jorgensen ME, 2013, DIABETOLOGIA, V56, P2401, DOI 10.1007/s00125-013-3025-7; LAPORTE RE, 1991, DIABETES CARE, V14, P49; Lotstein DS, 2013, PEDIATRICS, V131, pE1062, DOI 10.1542/peds.2012-1450; Luyckx K, 2009, DIABETES CARE, V32, P797, DOI 10.2337/dc08-1990; MIKI E, 1972, Journal of the Japan Diabetes Society, V15, P38; Morimoto A, 2013, DIABETOLOGIA, V56, P2171, DOI 10.1007/s00125-013-3001-2; Nakhla M, 2008, J PEDIATR ENDOCR MET, V21, P507; ORCHARD TJ, 1991, DIABETES CARE, V14, P55; Peters A, 2011, DIABETES CARE, V34, P2477, DOI 10.2337/dc11-1723; Petitti DB, 2009, J PEDIATR-US, V155, P668, DOI 10.1016/j.jpeds.2009.05.025; Tanae A, 1980, JUVENILE ONSET TYPE; Van Walleghem N, 2008, DIABETES CARE, V31, P1529, DOI 10.2337/dc07-2247; Wills CJ, 2003, BRIT MED J, V327, P260, DOI 10.1136/bmj.327.7409.260; Wolpert HA, 2001, DIABETES CARE, V24, P1513, DOI 10.2337/diacare.24.9.1513	27	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150720	10.1371/journal.pone.0150720	http://dx.doi.org/10.1371/journal.pone.0150720			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26937952	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000371735200136
J	Teik, DOL; Lee, XSA; Lim, CJ; Low, CM; Muslima, M; Aquili, L				Teik, Derek Ong Lai; Lee, Xiao Shiang; Lim, Chu Jian; Low, Chia Mei; Muslima, Mariyam; Aquili, Luca			Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial	PLOS ONE			English	Article							ACUTE PSYCHOLOGICAL STRESS; ENERGY RESOURCE DEPLETION; BLOOD-PRESSURE REACTIVITY; ERROR-RELATED NEGATIVITY; PANAX-GINSENG; GENDER-DIFFERENCES; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; GLUCOSE-TOLERANCE; IMPROVES GLUCOSE	Background There is some evidence to suggest that ginseng and Ginkgo biloba can improve cognitive performance, however, very little is known about the mechanisms associated with such improvement. Here, we tested whether cardiovascular reactivity to a task is associated with cognitive improvement. Methodology/Principal findings Using a double-blind, placebo controlled, crossover design, participants (N = 24) received two doses of Panax Ginseng (500, 1000 mg) or Ginkgo Biloba (120, 240 mg) (N = 24), and underwent a series of cognitive tests while systolic, diastolic, and heart rate readings were taken. Ginkgo Biloba improved aspects of executive functioning (Stroop and Berg tasks) in females but not in males. Ginseng had no effect on cognition. Ginkgo biloba in females reversed the initial (i.e. placebo) increase in cardiovascular reactivity (systolic and diastolic readings increased compared to baseline) to cognitive tasks. This effect (reversal) was most notable after those tasks (Stroop and Iowa) that elicited the greatest cardiovascular reactivity during placebo. In males, although ginkgo also decreased cardiovascular readings, it did so from an initial (placebo) blunted response (i.e. decrease or no change from baseline) to cognitive tasks. Ginseng, on the contrary, increased cardiovascular readings compared to placebo. Conclusions/Significance These results suggest that cardiovascular reactivity may be a mechanism by which ginkgo but not ginseng, in females is associated with certain forms of cognitive improvement.	[Lee, Xiao Shiang; Lim, Chu Jian; Low, Chia Mei; Muslima, Mariyam; Aquili, Luca] Sunway Univ, Dept Psychol, Bandar Sunway, Malaysia; [Teik, Derek Ong Lai] Sunway Univ, Dept Mkt, Bandar Sunway, Malaysia; [Aquili, Luca] Dept Psychol, METU Northern Cyprus Campus, Kalkanli, Turkey	Sunway University; Sunway University	Aquili, L (corresponding author), Sunway Univ, Dept Psychol, Bandar Sunway, Malaysia.; Aquili, L (corresponding author), Dept Psychol, METU Northern Cyprus Campus, Kalkanli, Turkey.	aluca@metu.edu.tr	Ong, Derek/ABA-2009-2021; Aquili, Luca/GMX-1519-2022	Ong, Derek/0000-0002-5899-9975; 				ABEL JL, 1991, J PSYCHOSOM RES, V35, P365, DOI 10.1016/0022-3999(91)90091-2; ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; Alexander JK, 2007, J COGNITIVE NEUROSCI, V19, P468, DOI 10.1162/jocn.2007.19.3.468; Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025; Allen MT, 2011, INT J PSYCHOPHYSIOL, V81, P209, DOI 10.1016/j.ijpsycho.2011.06.013; Arab L, 2011, J ALZHEIMERS DIS, V27, P553, DOI 10.3233/JAD-2011-110431; Bang H, 2014, J MED FOOD, V17, P128, DOI 10.1089/jmf.2013.2889; Batterink L, 2010, NEUROIMAGE, V52, P1696, DOI 10.1016/j.neuroimage.2010.05.059; Beck A, 2009, BIOL PSYCHIAT, V66, P734, DOI 10.1016/j.biopsych.2009.04.035; Bibbey A, 2013, INT J PSYCHOPHYSIOL, V90, P28, DOI 10.1016/j.ijpsycho.2012.10.018; Botvinick MM, 2009, PSYCHOL RES-PSYCH FO, V73, P835, DOI 10.1007/s00426-008-0197-8; Brenner SL, 2011, PSYCHOPHYSIOLOGY, V48, P1587, DOI 10.1111/j.1469-8986.2011.01230.x; Brevers D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00665; Brinkmann K, 2009, INT J PSYCHOPHYSIOL, V74, P250, DOI 10.1016/j.ijpsycho.2009.09.009; Brown JP, 2009, HEALTH PSYCHOL, V28, P641, DOI 10.1037/a0015215; Cohen J., 2013, STAT POWER ANAL BEHA; Crowell SE, 2006, J ABNORM PSYCHOL, V115, P174, DOI 10.1037/0021-843X.115.1.174; DANGELO L, 1986, J ETHNOPHARMACOL, V16, P15, DOI 10.1016/0378-8741(86)90063-2; Daughters SB, 2013, J ABNORM CHILD PSYCH, V41, P749, DOI 10.1007/s10802-013-9713-4; Dias Natália Martins, 2012, Psychol. Neurosci., V5, P63, DOI 10.3922/j.psns.2012.1.09; Eimer M, 2014, TRENDS COGN SCI, V18, P526, DOI 10.1016/j.tics.2014.05.005; Elsabagh S, 2005, PSYCHOPHARMACOLOGY, V179, P437, DOI 10.1007/s00213-005-2206-6; Elsabagh S, 2005, J PSYCHOPHARMACOL, V19, P173, DOI 10.1177/0269881105049038; Gibson EL, 2002, NUTR RES REV, V15, P169, DOI 10.1079/NRR200131; Ginty AT, 2013, INT J PSYCHOPHYSIOL, V90, P90, DOI 10.1016/j.ijpsycho.2013.06.008; Ginty AT, 2013, PSYCHOPHYSIOLOGY, V50, P219, DOI 10.1111/psyp.12017; Ginty AT, 2012, PSYCHONEUROENDOCRINO, V37, P715, DOI 10.1016/j.psyneuen.2011.09.004; Ginty AT, 2012, PSYCHOPHYSIOLOGY, V49, P391, DOI 10.1111/j.1469-8986.2011.01316.x; Ginty AT, 2011, INT J PSYCHOPHYSIOL, V82, P167, DOI 10.1016/j.ijpsycho.2011.08.004; Ginty AT, 2011, PSYCHOPHYSIOLOGY, V48, P1022, DOI 10.1111/j.1469-8986.2010.01164.x; Good M, 2014, SOC COGN AFFECT NEUR, V25; Graybeal C, 2012, NEUROSCIENCE, V211, P28, DOI 10.1016/j.neuroscience.2012.02.042; HANCOCK PA, 1989, HUM FACTORS, V31, P519; Hansen AL, 2004, EUR J APPL PHYSIOL, V93, P263, DOI 10.1007/s00421-004-1208-0; Hansen AL, 2003, INT J PSYCHOPHYSIOL, V48, P263, DOI 10.1016/S0167-8760(03)00073-4; Hartley DE, 2003, PHARMACOL BIOCHEM BE, V75, P711, DOI 10.1016/S0091-3057(03)00123-0; Heaney JLJ, 2011, INT J PSYCHOPHYSIOL, V79, P323, DOI 10.1016/j.ijpsycho.2010.11.010; Hirsh JB, 2010, PSYCHOPHYSIOLOGY, V47, P192, DOI 10.1111/j.1469-8986.2009.00877.x; Iannaccone R, 2015, NEUROIMAGE, V105, P395, DOI 10.1016/j.neuroimage.2014.10.028; Jezova D, 2002, J PHYSIOL PHARMACOL, V53, P337; Karlen W, 2010, C P IEEE ENG MED BIO, V602; Kennedy DO, 2007, HUM PSYCHOPHARM CLIN, V22, P199, DOI 10.1002/hup.837; Kennedy DO, 2007, HUM PSYCHOPHARM CLIN, V22, P559, DOI 10.1002/hup.885; Kennedy DO, 2003, PHARMACOL BIOCHEM BE, V75, P701, DOI 10.1016/S0091-3057(03)00120-5; Kennedy DO, 2002, PHYSIOL BEHAV, V75, P739, DOI 10.1016/S0031-9384(02)00665-0; Kennedy DO, 2000, PSYCHOPHARMACOLOGY, V151, P416, DOI 10.1007/s002130000501; Killgore WDS, 2008, INT J NEUROSCI, V118, P1547, DOI 10.1080/00207450802323970; Kim J, 2008, PHARMACOL BIOCHEM BE, V90, P517, DOI 10.1016/j.pbb.2008.03.033; Kim Y, 2010, NUTR RES PRACT, V4, P270, DOI 10.4162/nrp.2010.4.4.270; Lee SH, 2012, BIOMOL THER, V20, P482, DOI 10.4062/biomolther.2012.20.5.482; Lighthall NR, 2012, SOC COGN AFFECT NEUR, V7, P476, DOI 10.1093/scan/nsr026; Ma SW, 2008, DIABETES OBES METAB, V10, P1125, DOI 10.1111/j.1463-1326.2008.00858.x; Minkley N, 2012, INT J PSYCHOPHYSIOL, V86, P245, DOI 10.1016/j.ijpsycho.2012.09.015; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Morsel AM, 2014, BIPOLAR DISORD, V16, P820, DOI 10.1111/bdi.12256; Moulton PL, 2001, PHYSIOL BEHAV, V73, P659, DOI 10.1016/S0031-9384(01)00510-8; Mueller RT, 2013, PSYCHOL EXPT BUILDIN; Mueller ST, 2014, J NEUROSCI METH, V222, P250, DOI 10.1016/j.jneumeth.2013.10.024; Nathan PJ, 2002, HUM PSYCHOPHARM CLIN, V17, P45, DOI 10.1002/hup.353; Newberg AB, 2010, J ALZHEIMERS DIS, V20, P517, DOI 10.3233/JAD-2010-1391; Ohira H, 2011, NEUROSCIENCE, V193, P193, DOI 10.1016/j.neuroscience.2011.07.014; Pang EW, 2014, TRANSL PSYCHIAT, V5, P63; Phillips AC, 2005, PSYCHOSOM MED, V67, P384, DOI 10.1097/01.psy.0000160464.63264.5d; Phillips AC, 2013, INT J PSYCHOPHYSIOL, V90, P1, DOI 10.1016/j.ijpsycho.2013.02.002; Phillips AC, 2011, PSYCHOPHYSIOLOGY, V48, P142, DOI 10.1111/j.1469-8986.2010.01045.x; Phillips AC, 2009, INT J PSYCHOPHYSIOL, V73, P273, DOI 10.1016/j.ijpsycho.2009.04.005; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Plessow F, 2011, J COGNITIVE NEUROSCI, V23, P3218, DOI 10.1162/jocn_a_00024; Polich J, 2001, HUM PSYCHOPHARM CLIN, V16, P409, DOI 10.1002/hup.308; Qi LW, 2011, CURR DRUG METAB, V12, P818, DOI 10.2174/138920011797470128; Reay JL, 2006, BRIT J NUTR, V96, P639, DOI 10.1079/BJN20061904; Reay JL, 2005, J PSYCHOPHARMACOL, V19, P357, DOI 10.1177/0269881105053286; Reay JL, 2006, J PSYCHOPHARMACOL, V20, P771, DOI 10.1177/0269881106061516; Reay JL, 2009, BRIT J NUTR, V101, P1673, DOI 10.1017/S0007114508123418; Reckelhoff JF, 2001, HYPERTENSION, V37, P1199, DOI 10.1161/01.HYP.37.5.1199; Richter M, 2006, INT J PSYCHOPHYSIOL, V61, P216, DOI 10.1016/j.ijpsycho.2005.10.003; Santos RF, 2003, PHARMACOPSYCHIATRY, V36, P127; Scholey AB, 2002, HUM PSYCHOPHARM CLIN, V17, P35, DOI 10.1002/hup.352; Scholey AB, 2001, PHYSIOL BEHAV, V73, P585, DOI 10.1016/S0031-9384(01)00476-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Sorensen H, 1996, CURR THER RES CLIN E, V57, P959, DOI 10.1016/S0011-393X(96)80114-7; Stough C, 2001, INT J NEUROPSYCHOPH, V4, P131, DOI 10.1017/S1461145701002292; SUBHAN Z, 1984, INT J CLIN PHARM RES, V4, P89; Sunram-Lea S. I., 2005, Current Topics in Nutraceutical Research, V3, P65; SWAN GE, 1993, HEALTH PSYCHOL, V12, P451, DOI 10.1037/0278-6133.12.6.451; Teper R, 2013, SOC COGN AFFECT NEUR, V8, P85, DOI 10.1093/scan/nss045; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Tops M, 2006, PSYCHONEUROENDOCRINO, V31, P847, DOI 10.1016/j.psyneuen.2006.04.001; Tops M, 2010, COGN AFFECT BEHAV NE, V10, P441, DOI 10.3758/CABN.10.4.441; van 't Ent D, 2014, J NEUROSCI METH, V229, P97, DOI 10.1016/j.jneumeth.2014.04.013; Verney SP, 2004, INT J PSYCHOPHYSIOL, V52, P23, DOI 10.1016/j.ijpsycho.2003.12.003; Vuksan V, 2000, DIABETES, V49, pA95; Vuksan V, 2008, NUTR METAB CARDIOVAS, V18, P46, DOI 10.1016/j.numecd.2006.04.003; Waldstein SR, 2005, NEUROLOGY, V64, P1746, DOI 10.1212/01.WNL.0000161851.01243.62; Wan HHH, 2003, J HUM HYPERTENS, V17, P581, DOI 10.1038/sj.jhh.1001585; Wong SW, 2007, NEUROIMAGE, V35, P698, DOI 10.1016/j.neuroimage.2006.12.027; Wright RA, 2003, PSYCHOPHYSIOLOGY, V40, P98, DOI 10.1111/1469-8986.00010; Wright RA, 2002, PSYCHOPHYSIOLOGY, V39, P182, DOI 10.1017/S0048577201392089; Yin HH, 2008, EUR J NEUROSCI, V28, P1437, DOI 10.1111/j.1460-9568.2008.06422.x	100	18	18	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2016	11	3							e0150447	10.1371/journal.pone.0150447	http://dx.doi.org/10.1371/journal.pone.0150447			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0EB	26938637	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000371735200085
J	Nagayama, H; Tomori, K; Ohno, K; Takahashi, K; Ogahara, K; Sawada, T; Uezu, S; Nagatani, R; Yamauchi, K				Nagayama, Hirofumi; Tomori, Kounosuke; Ohno, Kanta; Takahashi, Kayoko; Ogahara, Kakuya; Sawada, Tatsunori; Uezu, Sei; Nagatani, Ryutaro; Yamauchi, Keita			Effectiveness and Cost-Effectiveness of Occupation-Based Occupational Therapy Using the Aid for Decision Making in Occupation Choice (ADOC) for Older Residents: Pilot Cluster Randomized Controlled Trial	PLOS ONE			English	Article							NONPARAMETRIC BAYESIAN METHOD; SF-36 HEALTH SURVEY; PREFERENCE DATA; LIFE; VALIDITY; PURPOSE; RISK	Background Care-home residents are mostly inactive, have little interaction with staff, and are dependent on staff to engage in daily occupations. We recently developed an iPad application called the Aid for Decision-making in Occupation Choice (ADOC) to promote shared decision-making in activities and occupation-based goal setting by choosing from illustrations describing daily activities. This study aimed to evaluate if interventions based on occupation-based goal setting using the ADOC could focus on meaningful activities to improve quality of life and independent activities of daily living, with greater cost-effectiveness than an impairment-based approach as well as to evaluate the feasibility of conducting a large cluster, randomized controlled trial. Method In this single (assessor)-blind pilot cluster randomized controlled trial, the intervention group (ADOC group) received occupational therapy based on occupation-based goal setting using the ADOC, and the interventions were focused on meaningful occupations. The control group underwent an impairment-based approach focused on restoring capacities, without goal setting tools. In both groups, the 20-minute individualized intervention sessions were conducted twice a week for 4 months. Main Outcome Measures Short Form-36 (SF-36) score, SF-6D utility score, quality adjusted life years (QALY), Barthel Index, and total care cost. Results We randomized and analyzed 12 facilities (44 participants, 18.5% drop-out rate), with 6 facilities each allocated to the ADOC (n = 23) and control (n = 21) groups. After the 4-month intervention, the ADOC group had a significantly greater change in the BI score, with improved scores (P = 0.027, 95% CI 0.41 to 6.87, intracluster correlation coefficient = 0.14). No other outcome was significantly different. The incremental cost-effectiveness ratio, calculated using the change in BI score, was $63.1. Conclusion The results suggest that occupational therapy using the ADOC for older residents might be effective and cost-effective. We also found that conducting an RCT in the occupational therapy setting is feasible.	[Nagayama, Hirofumi; Tomori, Kounosuke; Ogahara, Kakuya; Nagatani, Ryutaro] Kanagawa Univ Human Serv, Dept Occupat Therapy, Yokosuka, Kanagawa, Japan; [Ohno, Kanta] Kanagawa Univ Human Serv, Grad Course Hlth & Social, Yokosuka, Kanagawa, Japan; [Takahashi, Kayoko] Kitasato Univ, Dept Occupat Therapy, Sch Allied Hlth, Sagamihara, Kanagawa, Japan; [Sawada, Tatsunori] IMS Itabashi Rehabil Hosp, Tokyo, Japan; [Uezu, Sei] Naha City Ajya Complex Welf Facil, Naha City, Okinawa, Japan; [Nagayama, Hirofumi; Yamauchi, Keita] Keio Univ, Grad Sch Hlth Management, Yokohama, Kanagawa, Japan	Kitasato University; Keio University	Nagayama, H (corresponding author), Kanagawa Univ Human Serv, Dept Occupat Therapy, Yokosuka, Kanagawa, Japan.; Nagayama, H (corresponding author), Keio Univ, Grad Sch Hlth Management, Yokohama, Kanagawa, Japan.	hirofuminagayama@gmail.com	Tomori, Kounosuke/AAN-3565-2020; Nagayama, Hirofumi/AAF-1364-2020	Nagayama, Hirofumi/0000-0002-1763-1330; Tomori, Kounosuke/0000-0003-0695-4385	Japanese Association of Occupational Therapists [2012-03]; Japanese Association of Occupational Therapists;  [24790510]	Japanese Association of Occupational Therapists; Japanese Association of Occupational Therapists; 	This research was supported by the challenge research subsidy program from the Japanese Association of Occupational Therapists (No. 2012-03) and a Grant-in-Aid for Young Scientists (B; Grant Number 24790510).; The authors thank all of the occupational therapists (Kida Y, Oniki N, Nomura J, Ikejiri N, Kinjyo A, Iida S, Hosaka K, Muguruma R, Nakamura M, Hatsushika M, Uechi Y, Takenishi I, Sugawara A) that participated in this study. We would like to thank Editage (www.editage.jp) for English language editing. Finally, we would like to thank the Japanese Association of Occupational Therapists and Grant-in-Aid for Young Scientists (B; Grant Number 24790510) for the grants that made it possible to complete this study.	Boyle PA, 2010, AM J GERIAT PSYCHIAT, V18, P1093, DOI 10.1097/JGP.0b013e3181d6c259; Boyle PA, 2009, PSYCHOSOM MED, V71, P574, DOI 10.1097/PSY.0b013e3181a5a7c0; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Fisher AG, 2009, OCCUPATIONAL THERAPY; Fisher AG, 2013, SCAND J OCCUP THER, V20, P162, DOI 10.3109/11038128.2012.754492; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1045, DOI 10.1016/S0895-4356(98)00096-1; Giraudeau B, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000065; Holthe Torhild, 2007, Scand J Occup Ther, V14, P96, DOI 10.1080/11038120600963796; Hooker S.A., 2014, J HLTH PSYCHOL; Kharroubi SA, 2005, J R STAT SOC C-APPL, V54, P879, DOI 10.1111/j.1467-9876.2005.00511.x; Kharroubi SA, 2007, J HEALTH ECON, V26, P597, DOI 10.1016/j.jhealeco.2006.09.002; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Law M., 2014, CANADIAN OCCUPATIONA, VAnniversary; Law M.C., 2005, MEASURING OCCUPATION; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; MAHONEY F I, 1965, Md State Med J, V14, P61; Ministry of Health Labour and Welfare, 2014, GEN COND CAR SERV FA; Murray D.M., 1998, DESIGN ANAL GROUP RA; Nagayama H, 2015, OCCUP THER INT; Polatajko HJ, 2012, CAN J OCCUP THER, V79, P259, DOI 10.2182/cjot.2012.79.5.1; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; Sackley C, 2006, INT J THER REHABIL, V13, P370, DOI 10.12968/ijtr.2006.13.8.370; Sackley CM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-52; Sackley CM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3123; Saito Y, 2013, JPN J OCCUP THER, V32, P55; Saito Y, 2012, JPN J OCCUP THER, V31, P22; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Toba K, 2014, GERIATR GERONTOL INT, V14, P206, DOI 10.1111/ggi.12080; Tomori K, 2013, DISABIL REHABIL ASSI; Tomori K, 2013, DISABIL REHABIL, V35, P113, DOI 10.3109/09638288.2012.689919; Tomori K, 2012, OCCUP THER INT, V19, P88, DOI 10.1002/oti.325; Weinstein MC, 1996, COST EFFECTIVENESS H, V55; World Federation of Occupational Therapists, 2010, WORLD FED OCC THER S; World Health Organisation, 2001, ICF INT CLASFUNCT; ZIKA S, 1992, BRIT J PSYCHOL, V83, P133, DOI 10.1111/j.2044-8295.1992.tb02429.x	36	18	18	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2016	11	3							e0150374	10.1371/journal.pone.0150374	http://dx.doi.org/10.1371/journal.pone.0150374			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF5ZW	26930191	Green Submitted, gold, Green Published			2023-01-03	WOS:000371434500134
J	Kim, SY; Sim, S; Park, B; Kim, JH; Choi, HG				Kim, So Young; Sim, Songyong; Park, Bumjung; Kim, Jin-Hwan; Choi, Hyo Geun			High-Fat and Low-Carbohydrate Diets Are Associated with Allergic Rhinitis But Not Asthma or Atopic Dermatitis in Children	PLOS ONE			English	Article							NONDIGESTIBLE OLIGOSACCHARIDES; CHILDHOOD ASTHMA; PREVALENCE; ACIDS; RISK; SENSITIZATION; LACTATION; HABITS; HEALTH; MICE	Background Numerous studies have suggested that nutritional intake is related to allergic diseases. Although conflicting results exist, fat intake is often associated with allergic diseases. We investigated the relationship between allergic diseases and nutritional intake after adjusting for various demographic and socioeconomic factors in a large, representative sample of Korean children. Methods A total of 3,040 participants, aged 4 to 13 years old, were enrolled in the present study from the Korean National Health and Nutrition Examination Survey (KNHANES), 2010-2012. Nutritional intake data, including total calories, protein, fat, carbohydrate, vitamin A, vitamin C, thiamine, riboflavin, and niacin, were retrieved from the survey using the complete 24-hour recall method. The associations between each nutritional factor and allergic rhinitis/asthma/atopic dermatitis were analyzed using simple and multiple logistic regression analyses with complex sampling. Age, sex, body mass index (BMI), number of household members, income level, and region of residence were adjusted for as covariates. Results Of the participants, 22.1%, 6.0%, and 15.5% suffered from allergic rhinitis, asthma, and atopic dermatitis, respectively. Allergic rhinitis was significantly correlated with high-fat and low-carbohydrate diets. The adjusted odds ratio (AOR) was 1.25 (95% CIs = 1.06-1.46, P = 0.007) for fat intake, denoting a 10% increase. Carbohydrate intake (10% increase) was negatively related to allergic rhinitis with an AOR of 0.84 (95% CIs = 0.74-0.95, P = 0.004). No other significant relationships were found between the retrieved nutritional factors and either asthma or atopic dermatitis. Conclusion Allergic rhinitis was related to high-fat and low-carbohydrate diets. Although the underlying mechanisms and causal relationships remain elusive, the present study provides reliable evidence regarding the associations between nutritional factors and allergic rhinitis by considering numerous factors within a large and representative population.	[Kim, So Young] Seoul Natl Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea; [Kim, So Young] CHA Univ, Dept Otorhinolaryngol Head & Neck Surg, CHA Bundang Med Ctr, Seoul, South Korea; [Sim, Songyong; Choi, Hyo Geun] Hallym Univ, Dept Stat, Chunchon, South Korea; [Park, Bumjung] Hallym Univ, Sacred Heart Hosp, Dept Otorhinolaryngol Head & Neck Surg, Anyang, South Korea; [Kim, Jin-Hwan] Hallym Univ, Sacred Heart Hosp, Dept Otolaryngol Head & Neck Surg, Anyang, South Korea	Seoul National University (SNU); Seoul National University Hospital; Pochon Cha University; Hallym University; Hallym University; Hallym University	Choi, HG (corresponding author), Hallym Univ, Dept Stat, Chunchon, South Korea.	pupen@naver.com	Choi, Hyo Geun/K-4461-2019	Choi, Hyo Geun/0000-0003-1655-9549	Hallym University Sacred Heart Hospital [HURF-2014-58]; National Research Foundation (NRF) of Korea [NRF-2015R1D1A1A01060860]	Hallym University Sacred Heart Hospital; National Research Foundation (NRF) of Korea(National Research Foundation of Korea)	This work was supported by a Research Grant funded by Hallym University Sacred Heart Hospital (HURF-2014-58). This work was supported, in part, by a research grant (NRF-2015R1D1A1A01060860) funded by the National Research Foundation (NRF) of Korea.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; [Anonymous], 2014, GLOB ATL ALL; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Centers for Disease Control and Prevention, 2015, AB CHILD TEEN BMI, V5, P15; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Hogenkamp A, 2015, J NUTR, V145, P996, DOI 10.3945/jn.115.210401; Hogenkamp A, 2015, J NUTR, V145, P640, DOI 10.3945/jn.114.197707; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Institute RRD, 2006, FOOD COMP TABL; Kim BK, 2016, ALLERGOL INT, V65, P186, DOI 10.1016/j.alit.2015.11.002; KOLETZKO B, 1992, ACTA PAEDIATR, V81, P302, DOI 10.1111/j.1651-2227.1992.tb12230.x; Lumia M, 2012, ACTA PAEDIATR, V101, pe337, DOI 10.1111/j.1651-2227.2012.02718.x; Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001; MANKU MS, 1984, BRIT J DERMATOL, V110, P643, DOI 10.1111/j.1365-2133.1984.tb04698.x; Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Nwaru BI, 2014, J ALLERGY CLIN IMMUN, V133, P1084, DOI 10.1016/j.jaci.2013.12.1069; Okada Y, 2016, ALLERGOL INT, V65, P37, DOI 10.1016/j.alit.2015.06.010; Precht D, 1995, NAHRUNG, V39, P343, DOI 10.1002/food.19950390503; Raj D, 2014, IMMUNOL ALLERGY CLIN, V34, P753, DOI 10.1016/j.iac.2014.07.001; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; Seo JH, 2013, ALLERGY ASTHMA IMMUN, V5, P81, DOI 10.4168/aair.2013.5.2.81; Soh JY, 2015, ASIA PAC ALLERGY, V5, P17, DOI 10.5415/apallergy.2015.5.1.17; Tamay Z, 2014, ALLERGOL INT, V63, P553, DOI 10.2332/allergolint.13-OA-0661; Tamay Z, 2013, INT J PEDIATR OTORHI, V77, P1416, DOI 10.1016/j.ijporl.2013.05.014; The Korean Nutrition Society, 2010, DIET REF INT KOR 201; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Wollenberg A, 2013, ALLERGY, V68, P1509, DOI 10.1111/all.12324; Zhang Y, 2014, ALLERGY ASTHMA IMMUN, V6, P105, DOI 10.4168/aair.2014.6.2.105	33	11	13	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0150202	10.1371/journal.pone.0150202	http://dx.doi.org/10.1371/journal.pone.0150202			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3UU	26919190	gold, Green Published, Green Submitted			2023-01-03	WOS:000371274400103
J	Rooney, C; Geh, C; Williams, V; Heuckmann, JM; Menon, R; Schneider, P; Al-Kadhimi, K; Dymond, M; Smith, NR; Baker, D; French, T; Smith, PD; Harrington, EA; Barrett, JC; Kilgour, E				Rooney, Claire; Geh, Catherine; Williams, Victoria; Heuckmann, Johannes M.; Menon, Roopika; Schneider, Petra; Al-Kadhimi, Katherine; Dymond, Michael; Smith, Neil R.; Baker, Dawn; French, Tim; Smith, Paul D.; Harrington, Elizabeth A.; Barrett, J. Carl; Kilgour, Elaine			Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon	PLOS ONE			English	Article							CELL LUNG-CANCER; HUMAN BREAST-CANCER; MESSENGER-RNA; EXPRESSION; SENSITIVITY; SURVIVAL	FGFR1 amplification occurs in similar to 20% of sqNSCLC and trials with FGFR inhibitors have selected FGFR1 amplified patients by FISH. Lung cancer cell lines were profiled for sensitivity to AZD4547, a potent, selective inhibitor of FGFRs 1-3. Sensitivity to FGFR inhibition was associated with but not wholly predicted by increased FGFR1 gene copy number. Additional biomarker assays evaluating expression of FGFRs and correlation between amplification and expression in clinical tissues are therefore warranted. We validated nanoString for mRNA expression analysis of 194 genes, including FGFRs, from clinical tumour tissue. In a panel of sqNSCLC tumours 14.4% (13/90) were FGFR1 amplified by FISH. Although mean FGFR1 expression was significantly higher in amplified samples, there was significant overlap in the range of expression levels between the amplified and non-amplified cohorts with several non-amplified samples expressing FGFR1 to levels equivalent to amplified samples. Statistical analysis revealed increased expression of FGFR1 neighboring genes on the 8p12 amplicon (BAG4, LSM1 and WHSC1L1) in FGFR1 amplified tumours, suggesting a broad rather than focal amplicon and raises the potential for codependencies. High resolution aCGH analysis of pre-clinical and clinical samples supported the presence of a broad and heterogeneous amplicon around the FGFR1 locus. In conclusion, the range of FGFR1 expression levels in both FGFR1 amplified and non-amplified NSCLC tissues, together with the breadth and intra-patient heterogeneity of the 8p amplicon highlights the need for gene expression analysis of clinical samples to inform the understanding of determinants of response to FGFR inhibitors. In this respect the nanoString platform provides an attractive option for RNA analysis of FFPE clinical samples.	[Rooney, Claire; Geh, Catherine; Al-Kadhimi, Katherine; Smith, Neil R.; Baker, Dawn; Smith, Paul D.; Harrington, Elizabeth A.; Kilgour, Elaine] AstraZeneca, Oncol Innovat Med, Alderley Pk, Macclesfield, Cheshire, England; [Williams, Victoria; French, Tim] AstraZeneca, Personalised Healthcare & Biomarkers Innovat Med, Alderley Pk, Cambridge, England; [Heuckmann, Johannes M.; Menon, Roopika; Schneider, Petra] Blackfield AG, Cologne, Germany; [Dymond, Michael] AstraZeneca, Discovery Sci Innovat Med, Alderley Pk, Macclesfield, Cheshire, England; [Barrett, J. Carl] AstraZeneca Oncol Innovat Med, Gatehouse Pk, Waltham, MA USA; [Heuckmann, Johannes M.; Menon, Roopika; Schneider, Petra] NEO New Oncol AG, Cologne, Germany	AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca	Rooney, C (corresponding author), AstraZeneca, Oncol Innovat Med, Alderley Pk, Macclesfield, Cheshire, England.	claire.rooney@astrazeneca.com						Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Goke F, 2015, CLIN CANCER RES, V21, P4356, DOI 10.1158/1078-0432.CCR-14-3357; Kilgour E, 2014, J CLIN ONCOL S; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kohler LH, 2012, VIRCHOWS ARCH, V461, P49, DOI 10.1007/s00428-012-1250-y; Kotani H, 2016, ONCOGENE, V35, P3587, DOI 10.1038/onc.2015.426; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; Malkov Vladislav A, 2009, BMC Res Notes, V2, P80, DOI 10.1186/1756-0500-2-80; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Reis PP, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-46; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wolf J, P 103 M AM ASS CANC; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694	26	17	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2016	11	2							e0149628	10.1371/journal.pone.0149628	http://dx.doi.org/10.1371/journal.pone.0149628			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF2HK	26905262	Green Published, gold, Green Submitted			2023-01-03	WOS:000371163000018
J	Lam, C; Kang, JH; Lin, HY; Huang, HC; Wu, CC; Chen, PL				Lam, Carlos; Kang, Jiunn-Horng; Lin, Hsiao-Yu; Huang, Hung-Chang; Wu, Chia-Chieh; Chen, Ping-Ling			First Fall-Related Injuries Requiring Hospitalization Increase the Risk of Recurrent Injurious Falls: A Nationwide Cohort Study in Taiwan	PLOS ONE			English	Article							INSURANCE RESEARCH DATABASE; DWELLING OLDER-PEOPLE; HEALTH INSURANCE; FOLLOW-UP; POPULATION; MEN; VALIDATION; DIAGNOSIS; WOMEN; URBANIZATION	Objectives Recurrent falls not only have risk factors different from those of single falls but also have less favorable outcomes. The aim of our study was to determine the association between the injury characteristics of a first fall and the likelihood of recurrent injurious falls in a cohort of hospitalized patients. Methods We designed a nationwide retrospective cohort study and selected hospitalized patients who had injurious falls between 2001 and 2010. Cox proportional hazards models were used to estimate the hazard ratios (HRs) of recurrent injurious falls requiring hospitalization in the following year on the basis of the patients' demographic characteristics, comorbidities, and the characteristics of injuries from the first injurious fall requiring hospitalization. Results Among the 504 512 patients hospitalized for injurious falls, 19 442 experienced recurrent injurious falls requiring hospitalization. The 1-year incidence of recurrent injurious falls requiring hospitalization was 3.85%. The incidence density was the highest within the 3-month period after the first injurious fall. The risk of recurrent injurious falls among patients aged 40 to 64, 65 to 74, and >= 75 years increased progressively (HR: 2.11, 95% confidence interval [CI]: 1.90-2.34; HR: 2.80, 95% CI: 2.51-3.11; and HR: 3.80, 95% CI: 3.42-4.23, respectively). The length of hospitalization (LOH) >= 15 or >= 31 days (HR: 1.39, 95% CI: 1.30-1.48; and HR: 1.59, 95% CI: 1.43-1.77, respectively) and injury to the head (HR: 1.59, 95% CI: 1.53-1.65) or spine (HR: 1.66, 95% CI: 1.59-1.74) were also found to be major risk factors. Conclusions Our findings show that the LOH and head and spine injuries are associated with an increased risk of recurrent injurious falls leading to hospitalization. The risk of recurrent injurious falls requiring hospitalization increased significantly among adults older than 40 years. We suggest further research on the effects of injury characteristics associated with the first injurious fall requiring hospitalization and resultant anatomical damages on the risk of recurrent injurious falls requiring hospitalization. High-risk patients should receive tailored rehabilitation addressing their respective injuries within 3 months after hospital discharge.	[Lam, Carlos; Wu, Chia-Chieh] Taipei Med Univ, Wan Fang Hosp, Emergency Dept, Dept Emergency & Crit Care Med, Taipei, Taiwan; [Lam, Carlos; Chen, Ping-Ling] Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth & Nutr, Taipei, Taiwan; [Lam, Carlos] Taipei Med Univ, Dept Emergency Med, Coll Med, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei, Taiwan; [Lin, Hsiao-Yu] Taipei Med Univ Hosp, Dept Urol, Taipei, Taiwan; [Huang, Hung-Chang] Taipei Med Univ Hosp, Div Acute Care Surg & Traumatol, Dept Surg, Taipei, Taiwan	Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital	Chen, PL (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth & Nutr, Taipei, Taiwan.	plchen@tmu.edu.tw		Lam, Carlos/0000-0002-8051-7485	Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan [E1020766]; Wan Fang Hospital, Taipei Medical University [103-wf-eva-26]	Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan; Wan Fang Hospital, Taipei Medical University	This research was supported by grants from the Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan (grant number E1020766). PLC received the funding (the funder's website: http://www.hpa.gov.tw/Bhpnet/Web/Index/Index.aspx); and grants from the Wan Fang Hospital, Taipei Medical University (grant number 103-wf-eva-26). CL received the funding (the funder's website: http://www.wanfang.gov.tw/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Geriatrics Society British Geriatrics Society, 2010, AGS BGS CLIN PRACT G; Askari M, 2013, DRUG AGING, V30, P845, DOI 10.1007/s40266-013-0110-z; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Center JR, 2007, JAMA-J AM MED ASSOC, V297, P387, DOI 10.1001/jama.297.4.387; Chen CS, 2008, EUR J OBSTET GYN R B, V141, P104, DOI 10.1016/j.ejogrb.2008.07.016; Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chien WC, 2013, INT J INJ CONTROL SA, V20, P50, DOI 10.1080/17457300.2012.674042; de Vries OJ, 2013, OSTEOPOROSIS INT, V24, P2397, DOI 10.1007/s00198-013-2303-z; Deandrea S, 2010, EPIDEMIOLOGY, V21, P658, DOI 10.1097/EDE.0b013e3181e89905; Donald IP, 1999, AGE AGEING, V28, P121, DOI 10.1093/ageing/28.2.121; Gassmann KG, 2009, Z GERONTOL GERIATR, V42, P3, DOI 10.1007/s00391-008-0506-2; Hanlon JT, 2009, J GERONTOL A-BIOL, V64, P492, DOI 10.1093/gerona/gln043; Hoang PD, 2014, ARCH PHYS MED REHAB, V95, P480, DOI 10.1016/j.apmr.2013.09.017; Huang YL, 2013, J OCCUP SAF HLTH, V21, P38; Kanjwal K, 2015, J CARDIOVASC MED, V16, P75, DOI 10.2459/01.JCM.0000446386.01100.35; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Ku YC, 2013, INT J GERONTOL, V7, P80, DOI 10.1016/j.ijge.2012.07.004; Lin CC, 2005, J FORMOS MED ASSOC, V104, P157; Lin MR, 2014, OSTEOPOROSIS INT, V25, P863, DOI 10.1007/s00198-013-2549-5; Lin YJ, 2011, HEALTH POLICY, V103, P236, DOI 10.1016/j.healthpol.2011.08.007; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; LUUKINEN H, 1995, PUBLIC HEALTH, V109, P57, DOI 10.1016/S0033-3506(95)80076-X; Matinolli M, 2011, ACTA NEUROL SCAND, V123, P193, DOI 10.1111/j.1600-0404.2010.01386.x; Muraki S, 2013, BONE, V52, P516, DOI 10.1016/j.bone.2012.10.020; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Newgard CD, 2010, ACAD EMERG MED, V17, P142, DOI 10.1111/j.1553-2712.2009.00647.x; Okubo Y, 2015, ARCH GERONTOL GERIAT, V60, P45, DOI 10.1016/j.archger.2014.10.008; Pijpers E, 2012, AGE AGEING, V41, P358, DOI 10.1093/ageing/afr145; Pluijm SMF, 2006, OSTEOPOROSIS INT, V17, P417, DOI 10.1007/s00198-005-0002-0; Rossat A, 2010, J NUTR HEALTH AGING, V14, P787, DOI 10.1007/s12603-010-0089-7; Spector WD, 2012, MED CARE, V50, P863, DOI 10.1097/MLR.0b013e31825f2840; Spice CL, 2009, AGE AGEING, V38, P33, DOI 10.1093/ageing/afn192; Stel VS, 2003, J AM GERIATR SOC, V51, P1356, DOI 10.1046/j.1532-5415.2003.51452.x; Talbot LA, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-86; Tamburella F, 2013, EUR J PHYS REHAB MED, V49, P353; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; van Nieuwenhuizen RC, 2010, AM J EMERG MED, V28, P994, DOI 10.1016/j.ajem.2009.06.003; Wu TY, 2013, PREV MED, V57, P511, DOI 10.1016/j.ypmed.2013.07.012; Yoo IY, 2011, J GERONTOL NURS, V37, P28, DOI 10.3928/00989134-20110503-01	40	14	14	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149887	10.1371/journal.pone.0149887	http://dx.doi.org/10.1371/journal.pone.0149887			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3VL	26900917	Green Published, gold			2023-01-03	WOS:000371276100175
J	Fotschki, B; Juskiewicz, J; Jurgonski, A; Kolodziejczyk, K; Milala, J; Kosmala, M; Zdunczyk, Z				Fotschki, Bartosz; Juskiewicz, Jerzy; Jurgonski, Adam; Kolodziejczyk, Krzysztof; Milala, Joanna; Kosmala, Monika; Zdunczyk, Zenon			Anthocyanins in Strawberry Polyphenolic Extract Enhance the Beneficial Effects of Diets with Fructooligosaccharides in the Rat Cecal Environment	PLOS ONE			English	Article							CHAIN FATTY-ACIDS; ELLAGIC ACID; PHENOLIC-COMPOUNDS; HUMAN HEALTH; ELLAGITANNINS; PROANTHOCYANIDINS; BIOAVAILABILITY; METABOLITES; CONSUMPTION; COMPONENTS	The administration of fructooligosaccharides (FOS) beneficially modulates gastrointestinal functions and may enhance the metabolism of polyphenols. However, different polyphenolic components in the diet may have different influences on the activities of the digestive enzymes and microbiota in the gastrointestinal tract. Therefore, a 4-week study of fortyeight male Wistar rats was conducted to investigate the physiological response of the rat cecal environment to diets without and with FOS that contained two different strawberry polyphenolic extracts, specifically EP (polyphenolic profile 60, 35, 5, and 0% ellagitannins, proanthocyanidins, flavonols, anthocyanins, respectively) and EPA (polyphenolic profile: 50, 35, 6, and 9%, respectively). When combined with FOS, both extracts beneficially enhanced the acidification of the cecal digesta (P <= 0.05 vs the groups without extracts), but the dietary combination of EPA and FOS elicited the greatest reduction in putrefactive short-chain fatty acid production and the lowest fecal beta-glucuronidase activity in the cecum (P <= 0.05 vs group EP). Moreover, the addition of dietary FOS elevated the metabolism of the examined strawberry extracts in the cecum and thereby increased the concentrations of the metabolites in the cecal digesta and urine (P <= 0.05 vs the group with cellulose). Overall, both strawberry extracts modulated the effects of FOS in the gastrointestinal tract; however, the combination with EPA extract that contained anthocyanins exhibited greater beneficial effects in the lower gut environment than the EP extract.	[Fotschki, Bartosz; Juskiewicz, Jerzy; Jurgonski, Adam; Zdunczyk, Zenon] Polish Acad Sci, Inst Anim Reprod & Food Res, Div Food Sci, Olsztyn, Poland; [Kolodziejczyk, Krzysztof; Milala, Joanna; Kosmala, Monika] Lodz Univ Technol, Inst Food Technol & Anal, Lodz, Poland	Polish Academy of Sciences; Institute of Animal Reproduction & Food Research of the Polish Academy of Sciences; Lodz University of Technology	Fotschki, B (corresponding author), Polish Acad Sci, Inst Anim Reprod & Food Res, Div Food Sci, Olsztyn, Poland.	b.fotschki@pan.olsztyn.pl	Kołodziejczyk, Krzysztof/M-2951-2018; Kosmala, Monika/AAB-3395-2019; FOTSCHKI, Bartosz/Q-4275-2019; Zduńczyk, Zenon/H-7272-2017; Milala, Joanna/AAZ-6460-2021; Fotschki, Bartosz/H-7172-2017; Jurgonski, Adam/A-5864-2009; Juśkiewicz, Jerzy/H-7193-2017	Kołodziejczyk, Krzysztof/0000-0003-3817-5140; Kosmala, Monika/0000-0002-9018-3028; Zduńczyk, Zenon/0000-0002-0640-7552; Milala, Joanna/0000-0002-4732-1907; Fotschki, Bartosz/0000-0002-9727-7481; Jurgonski, Adam/0000-0003-3524-3259; Juśkiewicz, Jerzy/0000-0003-0068-5970	National Science Centre of Poland [DEC-2012/05/B/NZ9/03402]	National Science Centre of Poland(National Science Centre, Poland)	This study was financially supported by the National Science Centre of Poland (Grant DEC-2012/05/B/NZ9/03402), https://www.ncn.gov.pl/?language=en. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaby K, 2012, FOOD CHEM, V132, P86, DOI 10.1016/j.foodchem.2011.10.037; AOAC, 2007, OFFICIAL METHODS ANA, V18th; Asgar MA, 2013, INT J FOOD PROP, V16, P91, DOI 10.1080/10942912.2011.595864; Aviram M, 2004, CLIN NUTR, V23, P423, DOI 10.1016/j.clnu.2003.10.002; Beecher GR, 2004, PHARM BIOL, V42, P2, DOI 10.3109/13880200490893474; Blade C, 2010, MOL NUTR FOOD RES, V54, P37, DOI 10.1002/mnfr.200900476; Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9]; DANIEL EM, 1991, J NAT PROD, V54, P946, DOI 10.1021/np50076a004; Duda-Chodak A, 2015, EUR J NUTR, V54, P325, DOI 10.1007/s00394-015-0852-y; Duncan SH, 2002, APPL ENVIRON MICROB, V68, P5186, DOI 10.1128/AEM.68.10.5186-5190.2002; Espin J. C., 2013, EVID-BASED COMPL ALT, V2013, P1; Fernandes I, 2014, J FUNCT FOODS, V7, P54, DOI 10.1016/j.jff.2013.05.010; Fotschki B, 2014, POL J FOOD NUTR SCI, V64, P193, DOI 10.2478/pjfns-2013-0001; Fotschki B, 2014, J AGR FOOD CHEM, V62, P5871, DOI 10.1021/jf405612a; Gimenez-Bastida JA, 2012, MOL NUTR FOOD RES, V56, P784, DOI 10.1002/mnfr.201100677; Jakobsdottir G, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/202534; Jurgonski A, 2008, J ANIM FEED SCI, V17, P88, DOI 10.22358/jafs/66473/2008; Jurgonski A, 2013, NUTRITION, V29, P898, DOI 10.1016/j.nut.2012.11.006; Juskiewicz J, 2011, BRIT J NUTR, V105, P710, DOI 10.1017/S0007114510004344; Juskiewicz J, 2011, NUTRITION, V27, P351, DOI 10.1016/j.nut.2010.02.002; Kennedy JA, 2001, J AGR FOOD CHEM, V49, P1740, DOI 10.1021/jf001030o; Klewicka E, 2009, EUR FOOD RES TECHNOL, V229, P153, DOI 10.1007/s00217-009-1036-x; Kosmala M, 2015, J AGR FOOD CHEM, V63, P2989, DOI 10.1021/acs.jafc.5b00648; Kosmala M, 2014, EUR J NUTR, V53, P521, DOI 10.1007/s00394-013-0557-z; Landete JM, 2011, FOOD RES INT, V44, P1150, DOI 10.1016/j.foodres.2011.04.027; Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.jnutbio.2005.09.004; Lhoste EF, 2001, J SCI FOOD AGR, V81, P1397, DOI 10.1002/jsfa.957; McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926; Nile SH, 2014, NUTRITION, V30, P134, DOI 10.1016/j.nut.2013.04.007; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reeves PG, 1997, J NUTR, V127, pS838; Roberfroid MB, 2005, BRIT J NUTR, V93, pS13, DOI 10.1079/BJN20041350; Seeram NP, 2004, CLIN CHIM ACTA, V348, P63, DOI 10.1016/j.cccn.2004.04.029; Sojka M, 2013, EUR FOOD RES TECHNOL, V237, P995, DOI 10.1007/s00217-013-2070-2; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; VISEK WJ, 1978, AM J CLIN NUTR, V31, pS216, DOI 10.1093/ajcn/31.10.S216; Zdunczyk Z, 2006, NUTRITION, V22, P898, DOI 10.1016/j.nut.2006.05.010	37	37	37	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2016	11	2							e0149081	10.1371/journal.pone.0149081	http://dx.doi.org/10.1371/journal.pone.0149081			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3BP	26882456	Green Submitted, gold, Green Published			2023-01-03	WOS:000371219000044
J	Deshpande, D; Kethireddy, S; Janero, DR; Amiji, MM				Deshpande, Dipti; Kethireddy, Sravani; Janero, David R.; Amiji, Mansoor M.			Therapeutic Efficacy of an omega-3-Fatty Acid-Containing 17-beta Estradiol Nano-Delivery System against Experimental Atherosclerosis	PLOS ONE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MUSCLE-CELL PHENOTYPES; EXPRESSION IN-VIVO; CARDIOVASCULAR-DISEASE; DIETARY FLAXSEED; NANOEMULSION SYSTEM; NITRIC-OXIDE; ESTROGEN; PREVENTION; 17-BETA-ESTRADIOL	Atherosclerosis and its consequences remain prevalent clinical challenges throughout the world. Initiation and progression of atherosclerosis involves a complex, dynamic interplay among inflammation, hyperlipidemia, and endothelial dysfunction. A multicomponent treatment approach targeted for delivery within diseased vessels could prove beneficial in treating atherosclerosis. This study was undertaken to evaluate the multimodal effects of a novel omega-3-fatty acid-rich, 17-beta-estradiol (17-beta E)-loaded, CREKA-peptide-modified nanoemulsion system on experimental atherosclerosis. In vitro treatment of cultured human aortic endothelial cells (ECs) with the 17-beta E-loaded, CREKA-peptide-modified nanoemulsion system increased cellular nitrate/ nitrite, indicating improved nitric oxide formation. In vivo, systemic administration of this nanoemulsion system to apolipoprotein-E knock out (ApoE(-/-)) mice fed a high-fat diet significantly improved multiple parameters related to the etiology and development of occlusive atherosclerotic vasculopathy: lesion area, circulating plasma lipid levels, and expression of aortic-wall inflammatory markers. These salutary effects were attributed selectively to the 17-beta E and/or omega-3 polyunsaturated fatty acid components of the nano-delivery system. At therapeutic doses, the 17-beta E-loaded, CREKA-peptide modified nanoemulsion system appeared to be biocompatible in that it elicited no apparent adverse/toxic effects, as indexed by body weight, plasma alanine aminotransferase/aspartate aminotransferase levels, and liver and kidney histopathology. The study demonstrates the therapeutic potential of a novel, 17-beta E-loaded, CREKA-peptide-modified nanoemulsion system against atherosclerosis in a multimodal fashion by reducing lesion size, lowering the levels of circulating plasma lipids and decreasing the gene expression of inflammatory markers associated with the disease.	[Deshpande, Dipti; Kethireddy, Sravani; Janero, David R.; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Janero, David R.] Northeastern Univ, Ctr Drug Discovery, Sch Pharm, Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Amiji, Mansoor M.] King Abdulaziz Univ, Fac Pharm, Jeddah 21413, Saudi Arabia	Northeastern University; Northeastern University; King Abdulaziz University	Amiji, MM (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Bouve Coll Hlth Sci, Boston, MA 02115 USA.; Amiji, MM (corresponding author), King Abdulaziz Univ, Fac Pharm, Jeddah 21413, Saudi Arabia.	m.amiji@neu.edu	kethireddy, sravani/J-8511-2019; Amiji, Mansoor M/AAK-1531-2020; Deshpande, Dipti/L-2523-2019	Amiji, Mansoor M/0000-0001-6170-881X; 				Barton M, 2013, CURR OPIN LIPIDOL, V24, P214, DOI 10.1097/MOL.0b013e3283613a94; Bassett CMC, 2009, APPL PHYSIOL NUTR ME, V34, P965, DOI 10.1139/H09-087; Binsalamah ZM, 2012, EXPERT REV CARDIOVAS, V10, P805, DOI [10.1586/erc.12.41, 10.1586/ERC.12.41]; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Brown WV, 2011, J CLIN LIPIDOL, V5, P424, DOI 10.1016/j.jacl.2011.09.006; Casula M, 2013, ATHEROSCLEROSIS SUPP, V14, P243, DOI 10.1016/S1567-5688(13)70005-9; Daly C, 2003, MICROCIRCULATION, V10, P247, DOI 10.1038/sj.mn.7800190; Deshpande D, 2014, J CONTROL RELEASE, V180, P117, DOI 10.1016/j.jconrel.2014.02.009; Deshpande D, 2013, NANOMED-NANOTECHNOL, V9, P885, DOI 10.1016/j.nano.2013.02.007; Deshpande DD, 2011, EXPERT OPIN BIOL TH, V11, P1637, DOI 10.1517/14712598.2011.625007; Dimitrow PP, 2009, MINI-REV MED CHEM, V9, P1030, DOI 10.2174/138955709788922638; Duckles SP, 2010, PFLUG ARCH EUR J PHY, V459, P841, DOI 10.1007/s00424-010-0797-1; Dupasquier CMC, 2006, AM J PHYSIOL-HEART C, V291, pH2987, DOI 10.1152/ajpheart.01179.2005; Dupasquier CMC, 2007, AM J PHYSIOL-HEART C, V293, pH2394, DOI 10.1152/ajpheart.01104.2006; Durst R, 2009, GENET TEST MOL BIOMA, V13, P583, DOI 10.1089/gtmb.2009.0048; Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2; Francis AA, 2013, AM J PHYSIOL-HEART C, V304, pH1743, DOI 10.1152/ajpheart.00606.2012; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Godin B, 2010, TRENDS PHARMACOL SCI, V31, P199, DOI 10.1016/j.tips.2010.01.003; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hamzah J, 2011, P NATL ACAD SCI USA, V108, P7154, DOI 10.1073/pnas.1104540108; Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100; Hastings NE, 2007, AM J PHYSIOL-CELL PH, V293, pC1824, DOI 10.1152/ajpcell.00385.2007; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; Janero DR, 2014, EXPERT OPIN PHARMACO, V15, P5, DOI 10.1517/14656566.2014.852538; Jawien J, 2012, CURR PHARM BIOTECHNO, V13, P2435, DOI 10.2174/1389201011208062435; Jayagopal A, 2010, CURR ATHEROSCLER REP, V12, P209, DOI 10.1007/s11883-010-0106-7; Jin RC, 2010, J BLOOD MED, V1, P147; Kaul S, 2004, J AM COLL CARDIOL, V43, P461, DOI 10.1016/j.jacc.2003.11.010; Kim KH, 2014, MOL CELL ENDOCRINOL, V389, P65, DOI 10.1016/j.mce.2014.02.001; Kitagawa K, 2002, ATHEROSCLEROSIS, V160, P305, DOI 10.1016/S0021-9150(01)00587-1; Knowlton AA, 2012, PHARMACOL THERAPEUT, V135, P54, DOI 10.1016/j.pharmthera.2012.03.007; Komesaroff PA, 2001, HYPERTENSION, V38, P1011, DOI 10.1161/hy1101.095006; Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972; Ley K, 2001, J CLIN INVEST, V107, P1209, DOI 10.1172/JCI13005; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009; Madigan M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00174; Makinen PI, 2013, CURR OPIN LIPIDOL, V24, P116, DOI 10.1097/MOL.0b013e32835da13c; Meng J, 2012, CURR DRUG METAB, V13, P1123, DOI 10.2174/138920012802850056; Meyer MR, 2006, HYPERTENSION, V47, P1019, DOI 10.1161/01.HYP.0000223064.62762.0b; Miller VM, 2008, PHARMACOL REV, V60, P210, DOI 10.1124/pr.107.08002; Mozaffarian D, 2011, J AM COLL CARDIOL, V58, P2047, DOI 10.1016/j.jacc.2011.06.063; Napoli C, 2006, NITRIC OXIDE-BIOL CH, V15, P265, DOI 10.1016/j.niox.2006.03.011; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Orr AW, 2010, J VASC RES, V47, P168, DOI 10.1159/000250095; Palmieri D, 2014, ANGIOLOGY, V65, P17, DOI 10.1177/0003319713477909; Pervin S, 1998, ARTERIOSCL THROM VAS, V18, P1575, DOI 10.1161/01.ATV.18.10.1575; Poudyal H, 2011, PROG LIPID RES, V50, P372, DOI 10.1016/j.plipres.2011.06.003; Psarros C, 2012, NANOMED-NANOTECHNOL, V8, pS59, DOI 10.1016/j.nano.2012.05.006; Rizos EC, 2013, EUR J PHARMACOL, V706, P1, DOI 10.1016/j.ejphar.2013.02.050; Rodriguez-Leyva D, 2010, CAN J CARDIOL, V26, P489, DOI 10.1016/S0828-282X(10)70455-4; Ryu SK, 2009, J CARDIOVASC TRANSL, V2, P240, DOI 10.1007/s12265-009-9105-x; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Silvestre-Roig C, 2014, CIRC RES, V114, P214, DOI 10.1161/CIRCRESAHA.114.302355; Takahashi Kiyoshi, 2002, Medical Electron Microscopy, V35, P179, DOI 10.1007/s007950200023; Valenzuela P, 2012, NANOMED-NANOTECHNOL, V8, pS83, DOI 10.1016/j.nano.2012.05.008; Volcik KA, 2009, CLIN CHEM, V55, P1076, DOI 10.1373/clinchem.2008.119487; Wu HZ, 2009, CIRCULATION, V119, P2708, DOI 10.1161/CIRCULATIONAHA.108.823740; Xu SP, 2014, REDOX BIOL, V2, P642, DOI 10.1016/j.redox.2014.04.004; Yeap BB, 2014, J AM MED DIR ASSOC, V15, P326, DOI 10.1016/j.jamda.2013.12.004; Yu SS, 2011, WIRES NANOMED NANOBI, V3, P620, DOI 10.1002/wnan.158	62	11	11	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2016	11	2							e0147337	10.1371/journal.pone.0147337	http://dx.doi.org/10.1371/journal.pone.0147337			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9OF	26840601	Green Published, gold, Green Submitted			2023-01-03	WOS:000369550200033
J	Wise, J				Wise, Jacqui			Yoga may improve asthma symptoms, Cochrane review finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Yang ZY, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010346.pub2	1	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2016	353								i2462	10.1136/bmj.i2462	http://dx.doi.org/10.1136/bmj.i2462			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL2RY	27129481				2023-01-03	WOS:000375484100014
J	Wise, J				Wise, Jacqui			Weekend admission to psychiatric hospital is not linked to increased risk of death	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Patel R, 2016, BRIT J PSYCHIAT, V209, P29, DOI 10.1192/bjp.bp.115.180307; Rimmer A, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5624; Ruiz M, 2015, BMJ QUAL SAF, V24, P492, DOI 10.1136/bmjqs-2014-003467	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	2016	353								i2342	10.1136/bmj.i2342	http://dx.doi.org/10.1136/bmj.i2342			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DL2RF	27114473				2023-01-03	WOS:000375482000005
J	Mulsow, K; Enzlein, T; Delebinski, C; Jaeger, S; Seifert, G; Melzig, MF				Mulsow, Katharina; Enzlein, Thomas; Delebinski, Catharina; Jaeger, Sebastian; Seifert, Georg; Melzig, Matthias F.			Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells	PLOS ONE			English	Article							VISCUM-ALBUM L; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VITRO; INTRACELLULAR-TRANSPORT; MEMBRANE INTERACTIONS; HUMAN MONOCYTES; OLEANOLIC ACID; EXTRACT; APOPTOSIS; RICIN	Complementary treatment possibilities for the therapy of cancer are increasing in demand due to the severe side effects of the standard cytostatics used in the first-line therapy. A common approach as a complementary treatment is the use of aqueous extracts of Viscum album L. (Santalaceace). The therapeutic activity of these extracts is attributed to Mistletoe lectins which are Ribosome-inactivating proteins type II. Besides these main constituents the extract of Viscum album L. comprises also a mixture of lipophilic ingredients like triterpene acids of the oleanane, lupane and ursane type. However, these constituents are not contained in commercially available aqueous extracts due to their high lipophilicity and insolubility in aqueous extraction media. To understand the impact of the extract ingredients in cancer therapy, the intracellular uptake of the mistletoe lectin I (ML) by cultured tumor cells was investigated in relation to the mistletoe triterpene acids, mainly oleanolic acid. Firstly, these hydrophobic triterpene acids were solubilized using cyclodextrins ("TT" extract). Afterwards, the uptake of either single compounds (isolated ML and the aqueous "viscum" extract) or in combination with the TT extract (ML+TT, viscumTT), was analyzed. The uptake of ML was studied in THP-1-, HL-60-, 143B- and Ewing TC-71-cells and determined after 30, 60 and 120 minutes by an enzyme linked immunosorbent assay which quantifies the A-chain of the hololectin. It could be shown that the intracellular uptake after 120 minutes amounted to 20% in all cell lines after incubation with viscumTT. The studies further revealed that the uptake in THP-1-, HL-60- and Ewing TC-71-cells was independent of the addition of TT extract. Interestingly, the uptake of ML by 143B-cells could only be measured after addition of triterpenes pointing to resistance to mistletoe lectin.	[Mulsow, Katharina; Melzig, Matthias F.] Free Univ Berlin, Dept Pharmaceut Biol, Inst Pharm, Berlin, Germany; [Enzlein, Thomas] Mannheim Univ Appl Sci, Dept Biotechnol, Mannheim, Germany; [Delebinski, Catharina; Seifert, Georg] Charite, Dept Paediat, Div Oncol Haematol, Otto Heubner Ctr Paediat & Adolescent Med OHC, D-13353 Berlin, Germany; [Jaeger, Sebastian] Birken AG, Niefern Oeschelbronn, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Melzig, MF (corresponding author), Free Univ Berlin, Dept Pharmaceut Biol, Inst Pharm, Berlin, Germany.	melzig@zedat.fu-berlin.de	Enzlein, Thomas/AFQ-4152-2022	Enzlein, Thomas/0000-0003-1789-4090; Delebinski, Catharina/0000-0003-2527-4385	Birken AG	Birken AG	Birken AG provided support in the form of salaries for authors SJ, respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of the author is articulated in the 'author contributions' section.	Broniatowski M, 2014, BBA-BIOMEMBRANES, V1838, P2530, DOI 10.1016/j.bbamem.2014.05.027; Buessing A., 1996, APOPTOSIS, V1, P25; Delebinski CI, 2012, CELL PROLIFERAT, V45, P176, DOI 10.1111/j.1365-2184.2011.00801.x; Delebinski CI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133892; Edlund U, 2000, ARZNEIMITTEL-FORSCH, V50, P645; Elsasser-Beile U, 2000, J CLIN LAB ANAL, V14, P255, DOI 10.1002/1098-2825(20001212)14:6<255::AID-JCLA1>3.0.CO;2-J; FRANZ H, 1986, ONCOLOGY, V43, P23, DOI 10.1159/000226417; FRANZ H, 1981, BIOCHEM J, V195, P481, DOI 10.1042/bj1950481; Fulda S, 2000, MED PEDIATR ONCOL, V35, P616, DOI 10.1002/1096-911X(20001201)35:6<616::AID-MPO27>3.0.CO;2-N; Han SK, 1997, LIPIDS, V32, P769, DOI 10.1007/s11745-997-0098-9; Huber R, 2005, EUR J MED RES, V10, P411; Jager S, 2007, PLANTA MED, V73, P157, DOI 10.1055/s-2007-967106; JAGGY C, 1995, ARZNEIMITTEL-FORSCH, V45-2, P905; JUNG ML, 1990, CANCER LETT, V51, P103, DOI 10.1016/0304-3835(90)90044-X; Laszczyk M, 2006, PLANTA MED, V72, P1389, DOI 10.1055/s-2006-951723; Laszczyk MN, 2009, PLANTA MED, V75, P1549, DOI 10.1055/s-0029-1186102; Lenartz D, 2000, ANTICANCER RES, V20, P2073; Li R, 2009, AAPS PHARMSCITECH, V10, P1137, DOI 10.1208/s12249-009-9317-z; Llorente A, 1998, FEBS LETT, V431, P200, DOI 10.1016/S0014-5793(98)00754-6; Manojlovic V, 2008, COLLOID SURFACE B, V64, P284, DOI 10.1016/j.colsurfb.2008.02.001; Marvibaigi M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/785479; Moisenovich M, 2003, ARZNEIMITTEL-FORSCH, V53, P470; Moisenovich M, 2002, EUR J CELL BIOL, V81, P529, DOI 10.1078/0171-9335-00263; MUSIELSKI H, 1996, GRUNDLAGEN MISTELTHE, P95; Muthing J, 2004, BIOCHEMISTRY-US, V43, P2996, DOI 10.1021/bi0301892; OLSNES S, 1982, J BIOL CHEM, V257, P13263; Pohl P, 1998, BBA-BIOMEMBRANES, V1371, P11, DOI 10.1016/S0005-2736(98)00024-8; Prades J, 2011, BBA-BIOMEMBRANES, V1808, P752, DOI 10.1016/j.bbamem.2010.12.007; Rather MA, 2013, PHYTOMEDICINE, V21, P1, DOI 10.1016/j.phymed.2013.07.015; RibereauGayon G, 1996, CANCER LETT, V109, P33, DOI 10.1016/S0304-3835(96)04401-1; Robert Koch Institute, 2015, HLTH IN GERM; Rostock M, 2005, ANTICANCER RES, V25, P1969; Safayhi H, 1997, PLANTA MED, V63, P487, DOI 10.1055/s-2006-957748; Sairafianpour M, 2003, PLANTA MED, V69, P846, DOI 10.1055/s-2003-43212; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; Schaller G, 1996, PHYTOTHER RES, V10, P473, DOI 10.1002/(SICI)1099-1573(199609)10:6&lt;473::AID-PTR879&gt;3.0.CO;2-Q; Seifert G, 2008, CANCER LETT, V264, P218, DOI 10.1016/j.canlet.2008.01.036; Struh CM, 2012, PHYTOTHER RES, V26, P1507, DOI 10.1002/ptr.4604; Struh CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062168; Thies A, 2008, BRIT J CANCER, V98, P106, DOI 10.1038/sj.bjc.6604106; Tonevitsky AG, 2003, BIOCHEMISTRY-MOSCOW+, V68, P275, DOI 10.1023/A:1023050132342; Tsuchiya H, 2015, MOLECULES, V20, P18923, DOI 10.3390/molecules201018923; Urech K, 2005, J PHARM PHARMACOL, V57, P101, DOI 10.1211/0022357055083; Valentiner U, 2002, TOXICOLOGY, V171, P187, DOI 10.1016/S0300-483X(01)00581-9; Vervecken W, 2000, INT J BIOCHEM CELL B, V32, P317, DOI 10.1016/S1357-2725(99)00135-1; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060; Zhang WS, 2014, J CANCER RES THER, V10, P14, DOI 10.4103/0973-1482.139746; ZISKA P, 1981, EXPERIENTIA, V37, P219, DOI 10.1007/BF01991618	49	12	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2016	11	4							e0153825	10.1371/journal.pone.0153825	http://dx.doi.org/10.1371/journal.pone.0153825			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9IK	27088729	Green Published, Green Submitted, gold			2023-01-03	WOS:000374527000052
J	Lenzer, J				Lenzer, Jeanne			MATERNAL AND CHILD HEALTH How Cuba eliminated mother-to-child transmission of HIV and syphilis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jlenzer@bmj.com						Matthews T J, 2015, Natl Vital Stat Rep, V64, P1; OMS, 2014, PREV TRANSM MAT SIF; Roig Álvarez Tania, 2013, Rev. Bras. Saude Mater. Infant., V13, P111, DOI 10.1590/S1519-38292013000200004	3	2	3	5	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2016	352								i1619	10.1136/bmj.i1619	http://dx.doi.org/10.1136/bmj.i1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH8LI	27000051				2023-01-03	WOS:000373044300008
J	Stern, WM; Desikan, M; Hoad, D; Jaffer, F; Strigaro, G; Sander, JW; Rothwell, JC; Sisodiya, SM				Stern, William M.; Desikan, Mahalekshmi; Hoad, Damon; Jaffer, Fatima; Strigaro, Gionata; Sander, Josemir W.; Rothwell, John C.; Sisodiya, Sanjay M.			Spontaneously Fluctuating Motor Cortex Excitability in Alternating Hemiplegia of Childhood: A Transcranial Magnetic Stimulation Study	PLOS ONE			English	Article							DE-NOVO MUTATIONS; CLINICAL-MANIFESTATIONS; ATP1A3; ATPASE; MECHANISMS; POTASSIUM; ALPHA	Background Alternating hemiplegia of childhood is a very rare and serious neurodevelopmental syndrome; its genetic basis has recently been established. Its characteristic features include typically-unprovoked episodes of hemiplegia and other transient or more persistent neurological abnormalities. Methods We used transcranial magnetic stimulation to assess the effect of the condition on motor cortex neurophysiology both during and between attacks of hemiplegia. Nine people with alternating hemiplegia of childhood were recruited; eight were successfully tested using transcranial magnetic stimulation to study motor cortex excitability, using single and paired pulse paradigms. For comparison, data from ten people with epilepsy but not alternating hemiplegia, and ten healthy controls, were used. Results YOne person with alternating hemiplegia tested during the onset of a hemiplegic attack showed progressively diminishing motor cortex excitability until no response could be evoked; a second person tested during a prolonged bilateral hemiplegic attack showed unusually low excitability. Three people tested between attacks showed asymptomatic variation in cortical excitability, not seen in controls. Paired pulse paradigms, which probe intracortical inhibitory and excitatory circuits, gave results similar to controls. Conclusions We report symptomatic and asymptomatic fluctuations in motor cortex excitability in people with alternating hemiplegia of childhood, not seen in controls. We propose that such fluctuations underlie hemiplegic attacks, and speculate that the asymptomatic fluctuation we detected may be useful as a biomarker for disease activity.	[Stern, William M.; Sander, Josemir W.; Sisodiya, Sanjay M.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, NIHR Univ Coll London Hosp Biomed Res Ctr, London WC1N 3BG, England; [Stern, William M.; Sander, Josemir W.; Sisodiya, Sanjay M.] Epilepsy Soc, Gerrards Cross SL9 0RJ, Bucks, England; [Desikan, Mahalekshmi; Hoad, Damon; Rothwell, John C.] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England; [Jaffer, Fatima] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England; [Strigaro, Gionata] Univ Piemonte Orientale, Neurol Sect, Dept Translat Med, Novara, Italy; [Sander, Josemir W.] Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of London; University College London; University of Eastern Piedmont Amedeo Avogadro	Sisodiya, SM (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, NIHR Univ Coll London Hosp Biomed Res Ctr, London WC1N 3BG, England.; Sisodiya, SM (corresponding author), Epilepsy Soc, Gerrards Cross SL9 0RJ, Bucks, England.	s.sisodiya@ucl.ac.uk	Sander, Josemir W/C-1576-2008	Sander, Josemir W/0000-0001-6041-9661; Jaffer, Fatima/0000-0001-6336-2752	Epilepsy Society (UK); Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme; Marvin Weil Epilepsy Research Fund	Epilepsy Society (UK); Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme(National Institute for Health Research (NIHR)); Marvin Weil Epilepsy Research Fund	The study was funded by Epilepsy Society (UK) and undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. JWS is supported by the Marvin Weil Epilepsy Research Fund.	Abbruzzese G, 1996, EXP BRAIN RES, V111, P465; AMINIAN A, 1993, ANN NEUROL, V33, P43, DOI 10.1002/ana.410330108; Bauer PR, 2014, INT J NEURAL SYST, V24, DOI 10.1142/S0129065714300010; Boroojerdi B, 2001, CLIN NEUROPHYSIOL, V112, P931, DOI 10.1016/S1388-2457(01)00523-5; Bottger P, 2011, J COMP NEUROL, V519, P376, DOI 10.1002/cne.22524; BOURGEOIS M, 1993, J PEDIATR-US, V122, P673, DOI 10.1016/S0022-3476(06)80003-X; Cantello R, 2002, BRAIN RES REV, V38, P309, DOI 10.1016/S0165-0173(01)00158-8; Dobretsov M, 2005, FRONT BIOSCI-LANDMRK, V10, P2373, DOI 10.2741/1704; Edwards IJ, 2013, J NEUROSCI, V33, P9913, DOI 10.1523/JNEUROSCI.5584-12.2013; Heinzen EL, 2014, LANCET NEUROL, V13, P503, DOI 10.1016/S1474-4422(14)70011-0; Heinzen EL, 2012, NAT GENET, V44, P1030, DOI 10.1038/ng.2358; Hoei-Hansen CE, 2014, EUR J PAEDIATR NEURO, V18, P50, DOI 10.1016/j.ejpn.2013.08.007; Hunanyan AS, 2015, EPILEPSIA, V56, P82, DOI 10.1111/epi.12878; Ishii A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056120; Jaffer F, 2015, BRAIN; Kale N, 2014, NEUROLOGY S, V82, pP4191; Kirshenbaum GS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060141; Koenderink JB, 2003, J BIOL CHEM, V278, P51213, DOI 10.1074/jbc.M306384200; Li M, 2015, NEUROBIOL DIS; Malcolm MP, 2006, CLIN NEUROPHYSIOL, V117, P1037, DOI 10.1016/j.clinph.2006.02.005; Mikati MA, 2000, PEDIATR NEUROL, V23, P134, DOI 10.1016/S0887-8994(00)00157-0; Neville BGR, 2007, DEV MED CHILD NEUROL, V49, P777, DOI 10.1111/j.1469-8749.2007.00777.x; Ogawa H, 2009, P NATL ACAD SCI USA, V106, P13742, DOI 10.1073/pnas.0907054106; Panagiotakaki E, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0335-5; Panagiotakaki E, 2010, BRAIN, V133, P3598, DOI 10.1093/brain/awq295; Rosewich H, 2012, LANCET NEUROL, V11, P764, DOI 10.1016/S1474-4422(12)70182-5; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rothwell JC, 2009, J PHYSIOL-LONDON, V587, P11, DOI 10.1113/jphysiol.2008.162461; Sasaki M, 2014, NEUROLOGY, V82, P482, DOI 10.1212/WNL.0000000000000102; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Viollet L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127045; Vollono C, 2014, EUR J NEUROL OF 0717; Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X; World Health Organization, 1992, ICD 10 CLASS MENT BE; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; ZUPANC ML, 1991, PEDIATR NEUROL, V7, P35, DOI 10.1016/0887-8994(91)90103-R	36	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2016	11	3							e0151667	10.1371/journal.pone.0151667	http://dx.doi.org/10.1371/journal.pone.0151667			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3NW	26999520	Green Published, gold, Green Submitted			2023-01-03	WOS:000372694700053
J	Fancourt, D; Perkins, R; Ascenso, S; Carvalho, LA; Steptoe, A; Williamon, A				Fancourt, Daisy; Perkins, Rosie; Ascenso, Sara; Carvalho, Livia A.; Steptoe, Andrew; Williamon, Aaron			Effects of Group Drumming Interventions on Anxiety, Depression, Social Resilience and Inflammatory Immune Response among Mental Health Service Users	PLOS ONE			English	Article							MUSIC-THERAPY; CYTOKINES; SUPPORT; SCALE; METAANALYSIS; MECHANISMS; DISEASE; STRESS; TH1	Growing numbers of mental health organizations are developing community music-making interventions for service users; however, to date there has been little research into their efficacy or mechanisms of effect. This study was an exploratory examination of whether 10 weeks of group drumming could improve depression, anxiety and social resilience among service users compared with a non-music control group (with participants allocated to group by geographical location.) Significant improvements were found in the drumming group but not the control group: by week 6 there were decreases in depression (-2.14 SE 0.50 CI -3.16 to -1.11) and increases in social resilience (7.69 SE 2.00 CI 3.60 to 11.78), and by week 10 these had further improved (depression: -3.41 SE 0.62 CI -4.68 to -2.15; social resilience: 10.59 SE 1.78 CI 6.94 to 14.24) alongside significant improvements in anxiety (-2.21 SE 0.50 CI -3.24 to -1.19) and mental wellbeing (6.14 SE 0.92 CI 4.25 to 8.04). All significant changes were maintained at 3 months follow-up. Furthermore, it is now recognised that many mental health conditions are characterised by underlying inflammatory immune responses. Consequently, participants in the drumming group also provided saliva samples to test for cortisol and the cytokines interleukin (IL) 4, IL6, IL17, tumour necrosis factor alpha (TNF alpha), and monocyte chemoattractant protein (MCP) 1. Across the 10 weeks there was a shift away from a pro-inflammatory towards an anti-inflammatory immune profile. Consequently, this study demonstrates the psychological benefits of group drumming and also suggests underlying biological effects, supporting its therapeutic potential for mental health.	[Fancourt, Daisy; Perkins, Rosie; Ascenso, Sara; Williamon, Aaron] Royal Coll Mus, Ctr Performance Sci, Prince Consort Rd, London SW7 2BS, England; [Fancourt, Daisy; Perkins, Rosie; Williamon, Aaron] Univ London Imperial Coll Sci Technol & Med, Fac Med, South Kensington Campus, London SW7 2AZ, England; [Fancourt, Daisy; Carvalho, Livia A.; Steptoe, Andrew] UCL, Dept Epidemiol & Publ Hlth, Psychobiol Grp, 1-19 Torrington Pl, London WC1E 7HB, England	Royal College of Music - UK; Imperial College London; University of London; University College London	Williamon, A (corresponding author), Royal Coll Mus, Ctr Performance Sci, Prince Consort Rd, London SW7 2BS, England.; Williamon, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, South Kensington Campus, London SW7 2AZ, England.	aaron.williamon@rcm.ac.uk	Steptoe, Andrew/Y-2440-2019; Carvalho, Livia/Y-1032-2019; Williamon, Aaron/C-5796-2013	Carvalho, Livia/0000-0001-8862-0148; Williamon, Aaron/0000-0002-1713-6161; Fancourt, Daisy/0000-0002-6952-334X; Ascenso, Sara/0000-0002-6896-1719; Perkins, Rosie/0000-0002-8917-7974	UK's Arts and Humanities Research Council [AH/K003364/1]; CW +; Society for Education, Music and Psychology Research (SEMPRE); Maurice-Marks Foundation; British Heart Foundation; Arts and Humanities Research Council [AH/K003364/1] Funding Source: researchfish	UK's Arts and Humanities Research Council; CW +; Society for Education, Music and Psychology Research (SEMPRE); Maurice-Marks Foundation; British Heart Foundation(British Heart Foundation); Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC))	This research was carried out as part of 'Creative Practice as Mutual Recovery', a Connected Communities project funded by the UK's Arts and Humanities Research Council (grant ref. AH/K003364/1). It was also supported by grants from CW + and an Arnold Bentley New Initiatives Award from the Society for Education, Music and Psychology Research (SEMPRE). DF is supported by the Maurice-Marks Foundation, and AS and LAC are supported by the British Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARON RS, 1990, J PERS SOC PSYCHOL, V59, P344, DOI 10.1037/0022-3514.59.2.344; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bosch JA, 2014, MONOGR ORAL SCI, V24, P99, DOI 10.1159/000358864; Byrne ML, 2013, BRAIN BEHAV IMMUN, V34, P164, DOI 10.1016/j.bbi.2013.08.010; Choi P, 1998, CLIN EXP IMMUNOL, V113, P317; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Coulton S, 2015, BRIT J PSYCHIAT, V207, P250, DOI 10.1192/bjp.bp.113.129908; Dahl J, 2014, PSYCHONEUROENDOCRINO, V45, P77, DOI 10.1016/j.psyneuen.2014.03.019; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dunbar RIM, 2003, ANNU REV ANTHROPOL, V32, P163, DOI 10.1146/annurev.anthro.32.061002.093158; Erkkila J, 2011, BRIT J PSYCHIAT, V199, P132, DOI 10.1192/bjp.bp.110.085431; Fagundes CP, 2012, ANNU REV GERONTOL GE, V32, P29, DOI 10.1891/0198-8794.32.29; Fancourt D, 2016, PSYCHOTHER PSYCHOSOM, V85, P53, DOI 10.1159/000431257; Fancourt D, 2014, BRAIN BEHAV IMMUN, V36, P15, DOI 10.1016/j.bbi.2013.10.014; Hickey MJ, 1997, J IMMUNOL, V158, P3391; Hicks K, 2014, MED ANTHROPOL Q, V28, P440, DOI 10.1111/maq.12102; Huron D, 2001, ANN NY ACAD SCI, V930, P43, DOI 10.1111/j.1749-6632.2001.tb05724.x; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Knell J, ARTS FUNDING, P27; Kohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611; Kubera N, 2001, J CLIN PSYCHOPHARM, V21, P199, DOI 10.1097/00004714-200104000-00012; Maes M, 1999, ADV EXP MED BIOL, V461, P25; Mindell J., 2012, HLTH SURVEY ENGLAND; Myint AM, 2005, J AFFECT DISORDERS, V88, P167, DOI 10.1016/j.jad.2005.07.008; O'Leary K, 2015, J HLTH PSYCHOL; Rosenkranz MA, 2013, BRAIN BEHAV IMMUN, V27, P174, DOI 10.1016/j.bbi.2012.10.013; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302; Slavish DC, 2015, BRAIN BEHAV IMMUN, V44, P253, DOI 10.1016/j.bbi.2014.08.008; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Song C, 2009, PHARMACOPSYCHIATRY, V42, P182, DOI 10.1055/s-0029-1202263; Talwar N, 2006, BRIT J PSYCHIAT, V189, P405, DOI 10.1192/bjp.bp.105.015073; Tarr B, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01096; Tennant R, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-63; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WALK A, 1928, J MENT SCI, V74, P521; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Williamson S, 2012, NURS RES PRACT, V2012, DOI 10.1155/2012/246178; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	41	73	73	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2016	11	3							e0151136	10.1371/journal.pone.0151136	http://dx.doi.org/10.1371/journal.pone.0151136			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH1UO	26974430	gold, Green Published, Green Submitted			2023-01-03	WOS:000372570600050
J	Chen, YZ; Huang, YK; Qin, DD; Liu, WC; Song, C; Lou, KY; Wang, W; Gao, F				Chen, Yanzuo; Huang, Yukun; Qin, Dongdong; Liu, Wenchao; Song, Chao; Lou, Kaiyan; Wang, Wei; Gao, Feng			beta-Cyclodextrin-Based Inclusion Complexation Bridged Biodegradable Self-Assembly Macromolecular Micelle for the Delivery of Paclitaxel	PLOS ONE			English	Article							DRUG-DELIVERY; POLYMERIC MICELLES; TARGETED DELIVERY; CO-DELIVERY; NANOPARTICLES; TUMOR; NANOCARRIERS; STABILITY; LIPOSOMES; SYSTEMS	In this study, a novel adamantanamine-paclitaxel (AD-PTX) incorporated oligochitosan-carboxymethyl-beta-cyclodextrin (CSO-g-CM-beta-CD) self-assembly macromolecular (CSO-gCM-beta-CD@AD-PTX) micelle was successfully prepared in water through sonication. The formed molecules were characterized by Fourier transform infrared spectroscopy, proton nuclear magnetic resonance (NMR) spectroscopy, two-dimensional NMR, elemental analysis, and liquid chromatography-mass spectrometry, while the correspondent micelles were characterized by dynamic light scattering and transmission electron microscopy. We showed that the macromolecular micelle contained a spherical core-shell structure with a diameter of 197.1 +/- 3.3 nm and zeta potential of -19.1 +/- 4.3 mV. The CSO-g-CM-beta-CD@AD-PTX micelle exhibited a high drug-loading efficacy up to 31.3%, as well as a critical micelle concentration of 3.4 x 10(-7) M, which indicated good stability. Additionally, the in vitro release profile of the CSO-g-CM-beta-CD@AD-PTX micelle demonstrated a long-term release pattern, 63.1% of AD-PTX was released from the micelle during a 30-day period. Moreover, the CSO-g-CM-beta-CD@AD-PTX micelle displayed cytotoxicity at a sub-mu M scale similar to PTX in U87 MG cells, and CSO-g-CM-beta-CD exhibited a good safety profile by not manifesting significant toxicity at concentrations up to 100 mu M. These results indicated that beta-CD-based inclusion complexation resulting in biodegradable self-assembled macromolecular micelles can be utilized as nanocarrier, and may provide a promising platform for drug delivery in the future medical applications.	[Chen, Yanzuo; Huang, Yukun; Qin, Dongdong; Liu, Wenchao; Gao, Feng] E China Univ Sci & Technol, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China; [Chen, Yanzuo; Gao, Feng] E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut, Shanghai 200237, Peoples R China; [Song, Chao; Lou, Kaiyan; Wang, Wei; Gao, Feng] E China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China; [Song, Chao; Lou, Kaiyan] E China Univ Sci & Technol, Shanghai Key Lab Chem Biol, Shanghai 200237, Peoples R China; [Song, Chao; Lou, Kaiyan] E China Univ Sci & Technol, State Key Lab Bioengn Reactor, Shanghai 200237, Peoples R China; [Wang, Wei] Univ New Mexico, Dept Chem & Chem Biol, Albuquerque, NM 87131 USA	East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; University of New Mexico	Gao, F (corresponding author), E China Univ Sci & Technol, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China.; Gao, F (corresponding author), E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut, Shanghai 200237, Peoples R China.; Lou, KY; Gao, F (corresponding author), E China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China.	kylou@ecust.edu.cn; fgao@ecust.edu.cn			Fundamental Research Funds for the Central Universities [WY1213013, 22A201514055]; National Natural Science Foundation of China [81503021]; School of Pharmacy, Fudan University & the Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education [SDD2014-2]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); School of Pharmacy, Fudan University & the Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education	This work was supported by Fundamental Research Funds for the Central Universities (WY1213013 ECUST) KL study design (http://en.moe.gov.cn/), Fundamental Research Funds for the Central Universities(22A201514055 ECUST) YC data collection and analysis (http://en.moe.gov.cn/), National Natural Science Foundation of China (81503021) YC decision to publish (http://www.nsfc.gov.cn/publish/portal1/), School of Pharmacy, Fudan University & the Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education (SDD2014-2) YC preparation of the manuscript (http://smartdds.fudan.edu.cn/).	Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Bae YH, 2008, J CONTROL RELEASE, V131, P2, DOI 10.1016/j.jconrel.2008.06.015; Chen G, 2011, CHEM SOC REV, V40, P2254, DOI 10.1039/c0cs00153h; Chen YZ, 2015, CHINESE CHEM LETT, V26, P909, DOI 10.1016/j.cclet.2015.05.044; Chen YZ, 2015, INT J PHARMACEUT, V488, P44, DOI 10.1016/j.ijpharm.2015.04.048; Fukushima K, 2008, BIOMACROMOLECULES, V9, P3051, DOI 10.1021/bm800526k; Furusaki E, 1996, CARBOHYD POLYM, V29, P29, DOI 10.1016/0144-8617(95)00133-6; Gao HJ, 2014, BIOMACROMOLECULES, V15, P3634, DOI 10.1021/bm5009348; Gao SS, 2012, INT J PHARMACEUT, V427, P410, DOI 10.1016/j.ijpharm.2012.01.054; Gregoriadis G, 1995, TRENDS BIOTECHNOL, V13, P527, DOI 10.1016/S0167-7799(00)89017-4; Hu QD, 2014, ACCOUNTS CHEM RES, V47, P2017, DOI 10.1021/ar500055s; Hu QL, 2012, BIOMATERIALS, V33, P6580, DOI 10.1016/j.biomaterials.2012.05.060; Jones MC, 1999, EUR J PHARM BIOPHARM, V48, P101, DOI 10.1016/S0939-6411(99)00039-9; Kataoka K, 2012, ADV DRUG DELIVER REV, V64, P37, DOI 10.1016/j.addr.2012.09.013; Li JF, 2015, BIOCONJUGATE CHEM, V26, P418, DOI 10.1021/acs.bioconjchem.5b00030; Liu YY, 2014, BIOMATERIALS, V35, P4835, DOI 10.1016/j.biomaterials.2014.02.031; Lv PP, 2012, MOL PHARMACEUT, V9, P1736, DOI 10.1021/mp300051h; Ma X, 2015, CHEM REV, V115, P7794, DOI 10.1021/cr500392w; Maruyama K, 2011, ADV DRUG DELIVER REV, V63, P161, DOI 10.1016/j.addr.2010.09.003; Prabaharan M, 2005, MACROMOL BIOSCI, V5, P965, DOI 10.1002/mabi.200500087; Shao Y, 2014, ACS APPL MATER INTER, V6, P10381, DOI 10.1021/am501913m; Shi Y, 2015, ACS NANO, V9, P3740, DOI 10.1021/acsnano.5b00929; Singla AK, 2002, INT J PHARMACEUT, V235, P179, DOI 10.1016/S0378-5173(01)00986-3; Yang C, 2015, J CONTROL RELEASE, V208, P93, DOI 10.1016/j.jconrel.2015.03.027; Yang C, 2012, BIOMATERIALS, V33, P2971, DOI 10.1016/j.biomaterials.2011.11.035; Yu d, 2015, BIOCONJUG CHEM; Zhang FW, 2015, J AM CHEM SOC, V137, P2056, DOI 10.1021/ja512616s	28	19	20	3	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2016	11	3							e0150877	10.1371/journal.pone.0150877	http://dx.doi.org/10.1371/journal.pone.0150877			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3TL	26964047	Green Published, gold, Green Submitted			2023-01-03	WOS:000371993000073
J	Wu, YY; Huang, TC; Tsai, TN; Chen, JH; Dai, MS; Chang, PY; Ho, CL; Ye, RH; Chung, TR; Chen, YC; Chao, TY				Wu, Yi-Ying; Huang, Tzu-Chuan; Tsai, Tsung-Neng; Chen, Jia-Hong; Dai, Ming-Shen; Chang, Ping-Ying; Ho, Ching-Liang; Ye, Ren-Hua; Chung, Tsai-Rong; Chen, Yeu-Chin; Chao, Tsu-Yi			The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis	PLOS ONE			English	Article							ADJUVANT RADIOTHERAPY; MONOCLONAL-ANTIBODY; COST-EFFECTIVENESS; HEART-FAILURE; CHEMOTHERAPY; THERAPY; TRIAL; HERCEPTIN; SAFETY; MORBIDITY	Objective Trastuzumab-containing treatment regimens have been shown to improve survival outcomes in HER2-positive breast cancer (BC). It is much easier to infuse a fixed one-vial dose to every patient on a regular schedule in the general clinical setting. The aims of this study were evaluating the efficacy of a 440 mg fixed-dose of trastuzumab administered on a monthly infusion schedule, and the risk factors for cardiac events. Patients and methods We retrospectively reviewed data from 300 HER2-positive BC patients in our institute: 208 were early-stage BC patients undergoing adjuvant trastuzumab treatment, and 92 were metastatic BC patients treated with trastuzumab infusions until disease progression. There were 181 patients receiving regular trastuzumab infusions every 3 weeks (Q3W; 8 mg/kg loading dose followed by 6 mg/kg every 3 weeks), and the other 119 patients were treated monthly with a fixed 440 mg dose (QM; fixed 440 mg every 4 weeks). Results The medians of progression-free survival (PFS) and overall survival (OS) in the adjuvant setting were not reached in both treatment groups. In the metastatic setting, there was no significant difference between groups in PFS or OS. The median time to significant cardiovascular (CV) dysfunction was 4.54 months. The incidence of congestive heart failure requiring medication in our cohort was 3.4%. Conclusion In our study, we found that fixed-dose monthly trastuzumab was feasible and effective. In addition, the CV risk was not higher with the fixed-dose protocol. This treatment modality could lower the cost and was easier to implement in clinical practice. Larger prospective randomized studies with longer-term follow up are needed to confirm our results.	[Wu, Yi-Ying; Huang, Tzu-Chuan; Chen, Jia-Hong; Dai, Ming-Shen; Chang, Ping-Ying; Ho, Ching-Liang; Ye, Ren-Hua; Chen, Yeu-Chin] Tri Serv Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan; [Wu, Yi-Ying; Tsai, Tsung-Neng; Chao, Tsu-Yi] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Tsai, Tsung-Neng] Tri Serv Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan; [Chen, Jia-Hong; Chao, Tsu-Yi] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chung, Tsai-Rong] Natl Inst Canc Res, Zhunan, Miaoli County, Taiwan; [Chao, Tsu-Yi] Taipei Med Univ, Shuang Ho Hosp, Dept Med, Div Hematol & Oncol, New Taipei, Taiwan	Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Chao, TY (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.; Chao, TY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.; Chao, TY (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Med, Div Hematol & Oncol, New Taipei, Taiwan.	10575@s.tmu.edu.tw	DAI, M/GPS-8291-2022	Wu, Yi-Ying/0000-0003-0411-6265	Tri-Service General Hospital [TSGH-C105-166]	Tri-Service General Hospital	This study was supported by a grant issued from the Tri-Service General Hospital (TSGH-C105-166). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Dr. Anthony Janckila for critical review of the manuscript. This study was supported by a grant issued from the Tri-Service General Hospital (TSGH-C105-166).	Balduzzi S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006242.pub2; Bartlett JMS, 2007, J CLIN ONCOL, V25, P4423, DOI 10.1200/JCO.2007.11.0973; Belkacemi Y, 2008, ANN ONCOL, V19, P1110, DOI 10.1093/annonc/mdn029; Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615; Chan ALF, 2009, ANN PHARMACOTHER, V43, P296, DOI 10.1345/aph.1L504; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Ewer MS, 2005, J CLIN ONCOL, V23, P7820, DOI 10.1200/JCO.2005.13.300; Giordano SH, 2005, JNCI-J NATL CANCER I, V97, P419, DOI 10.1093/jnci/dji067; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Katsurada K, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-620; Mortensen SA, 2014, JACC-HEART FAIL, V2, P641, DOI 10.1016/j.jchf.2014.06.008; Onitilo AA, 2014, THER ADV DRUG SAF, V5, P154, DOI 10.1177/2042098614529603; Patt DA, 2005, J CLIN ONCOL, V23, P7475, DOI 10.1200/JCO.2005.13.755; Pearson SA, 2007, J CLIN ONCOL, V25, P3688, DOI 10.1200/JCO.2007.11.2516; Perez EA, 2008, J CLIN ONCOL, V26, P1231, DOI 10.1200/JCO.2007.13.5467; Perez-Ellis C, 2009, AM J CLIN ONCOL-CANC, V32, P492, DOI 10.1097/COC.0b013e3181931277; Puputti M, 2006, CANCER GENET CYTOGEN, V167, P32, DOI 10.1016/j.cancergencyto.2004.09.023; Purmonen TT, 2011, ACTA ONCOL, V50, P344, DOI 10.3109/0284186X.2011.553841; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Russo G, 2014, J CARDIOVASC MED, V15, P141, DOI 10.2459/JCM.0b013e328365afb5; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Suter TM, 2007, J CLIN ONCOL, V25, P3859, DOI 10.1200/JCO.2006.09.1611; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Ward S, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13suppl1/01	29	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2016	11	3							e0151112	10.1371/journal.pone.0151112	http://dx.doi.org/10.1371/journal.pone.0151112			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG3SW	26953588	Green Submitted, gold, Green Published			2023-01-03	WOS:000371991300084
J	Yu, ZL; Lee, VYW; Kang, AWC; Chan, S; Foo, M; Chan, CM; Griva, K				Yu, Zhen Li; Lee, Vanessa Yin Woan; Kang, Augustine Wee Cheng; Chan, Sally; Foo, Marjorie; Chan, Choong Meng; Griva, Konstadina			Rates of Intentional and Unintentional Nonadherence to Peritoneal Dialysis Regimes and Associated Factors	PLOS ONE			English	Article							QUALITY-OF-LIFE; SELF-EFFICACY; HEMODIALYSIS-PATIENTS; HOSPITAL ANXIETY; HEALTH-STATUS; DEPRESSION SCALE; ADHERENCE; NONCOMPLIANCE; MEDICINES; BELIEFS	With increasing emphasis on expanding home-based dialysis, there is a need to understand adherence outcomes. This study set out to examine the prevalence and predictors of non-adherence among patients undergoing peritoneal dialysis. A cross sectional sample of 201 peritoneal dialysis patients recruited between 2010-2011 from Singapore General Hospital completed measures of quality of life, medication beliefs, self-efficacy and emotional distress. Nonadherence rates were high; 18% for dialysis, 46% for medication and 78% for diet. Intentional nonadherence was more common for dialysis (p = .03), whereas unintentional nonadherence was more common for medication (p = .002). Multivariate models indicated significant associations for higher education (intermediate vs low OR = 3.18, high vs low OR = 4.70), lower environment quality of life (OR = 0.79), dialysis self-efficacy (OR = 0.80) with dialysis nonadherence; higher education (OR = 2.22), self-care peritoneal dialysis (OR = 3.10), perceived necessity vs concerns over medication (OR = 0.90), self-efficacy (OR = 0.76) with nonadherence to medication. The odds for nonadherence to diet were higher among patients who were younger (OR = 0.96), of Chinese ethnicity (OR = 2.99) and those reporting better physical health (OR = 1.30) and lower self-efficacy (OR = 0.49). Nonadherence is common in peritoneal dialysis. Self-efficacy and beliefs about medication are promising targets for interventions designed to improve adherence.	[Yu, Zhen Li; Lee, Vanessa Yin Woan; Kang, Augustine Wee Cheng; Griva, Konstadina] Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore; [Chan, Sally] Natl Univ Singapore Hosp, Alice Lee Ctr Nursing Studies, Singapore, Singapore; [Foo, Marjorie; Chan, Choong Meng] Singapore Gen Hosp, Dept Renal Med, Singapore, Singapore; [Griva, Konstadina] City Univ London, Hlth Serv Res Grp, London EC1V 0HB, England	National University of Singapore; National University of Singapore; Singapore General Hospital; City University London	Griva, K (corresponding author), Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore.; Griva, K (corresponding author), City Univ London, Hlth Serv Res Grp, London EC1V 0HB, England.	psygk@nus.edu.sg	Barretti, Pasqual/K-4156-2012; Chan, Sally Wai Chi/ABB-8520-2020; Griva, Konstadina/A-6549-2018; Barretti, Pasqual/AAK-7934-2021	Barretti, Pasqual/0000-0003-4979-4836; Chan, Sally Wai Chi/0000-0001-5484-4645; Barretti, Pasqual/0000-0003-4979-4836; GRIVA, KONSTADINA/0000-0001-8173-5663; Kang, Augustine/0000-0002-4268-993X	National University of Singapore (NUS-Cross Faculty Research Grant) [CFG11P3]	National University of Singapore (NUS-Cross Faculty Research Grant)	This research was supported by a grant from the National University of Singapore (NUS-Cross Faculty Research Grant - CFG11P3) awarded to Associate Professor KG and Professor SC, which is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen D, 2011, SOC SCI MED, V73, P129, DOI 10.1016/j.socscimed.2011.05.018; [Anonymous], 2013, US REN DAT SYST USRD; Arramreddy R, 2014, AM J KIDNEY DIS, V63, P390, DOI 10.1053/j.ajkd.2013.09.018; Bandura A., 1971, SOCIAL LEARNING THEO; Beddhu S, 2002, AM J MED, V112, P696, DOI 10.1016/S0002-9343(02)01097-5; Bernardini J, 2000, AM J KIDNEY DIS, V35, P1104, DOI 10.1016/S0272-6386(00)70047-3; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Browne T, 2010, AM J KIDNEY DIS, V56, P547, DOI 10.1053/j.ajkd.2010.03.002; Choong HL, 2013, 8 MIN HLTH SING NAT; Chow SKY, 2010, J ADV NURS, V66, P1780, DOI 10.1111/j.1365-2648.2010.05324.x; Clifford S, 2008, J PSYCHOSOM RES, V64, P41, DOI 10.1016/j.jpsychores.2007.05.004; Clifford S, 2006, PHARM WORLD SCI, V28, P165, DOI 10.1007/s11096-006-9026-6; DENOUR AK, 1972, PSYCHOSOM MED, V34, P333; Arenas MD, 2010, J NEPHROL, V23, P525; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Fernandes GV, 2010, J SEX MED, V7, P4003, DOI 10.1111/j.1743-6109.2010.01993.x; Gadkari AS, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-98; Garcia-Llana H, 2013, PSICOTHEMA, V25, P79, DOI 10.7334/psicothema2012.96; Ghaffari A, 2012, AM J KIDNEY DIS, V59, P400, DOI 10.1053/j.ajkd.2011.08.034; Griva K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089001; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hays RD, 1997, KIDNEY DIS QUALITY L; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Jiwakanon S, 2010, CURR OPIN NEPHROL HY, V19, P573, DOI 10.1097/MNH.0b013e32833d67a3; Karamanidou C, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-2; Kutner NG, 2001, SEMIN DIALYSIS, V14, P324, DOI 10.1046/j.1525-139X.2001.00080.x; Lam LW, 2010, J ADV NURS, V66, P763, DOI 10.1111/j.1365-2648.2009.05235.x; Leung C M, 1993, Int J Psychosom, V40, P29; Leventhal H., 2003, SELF REGULATION HLTH, P138; Lindberg M, 2010, J REN CARE, V36, P133, DOI 10.1111/j.1755-6686.2010.00182.x; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Mawar S, 2012, INT UROL NEPHROL, V44, P1243, DOI 10.1007/s11255-011-0079-7; McCarthy A, 2009, INT J NURS PRACT, V15, P219, DOI 10.1111/j.1440-172X.2009.01747.x; Mo PKH, 2009, AIDS CARE, V21, P785, DOI 10.1080/09540120802511968; Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523-1755.2005.67139.x; NOLPH KD, 1995, PERITON DIALYSIS INT, V15, P22; Plantinga LC, 2004, J AM SOC NEPHROL, V15, P3144, DOI 10.1097/01.ASN.0000146424.91128.2A; Polaschek N, 2007, J CLIN NURS, V16, P51, DOI 10.1111/j.1365-2702.2006.01622.x; Rees G, 2010, OPHTHALMOLOGY, V117, P903, DOI 10.1016/j.ophtha.2009.10.038; RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472; Sayin A, 2007, TRANSPL P, V39, P3047, DOI 10.1016/j.transproceed.2007.09.030; Schuz B, 2011, J PSYCHOSOM RES, V70, P179, DOI 10.1016/j.jpsychores.2010.07.014; Smarr KL, 2011, ARTHRIT CARE RES, V63, pS454, DOI 10.1002/acr.20556; Su CY, 2009, J ADV NURS, V65, P1381, DOI 10.1111/j.1365-2648.2009.04993.x; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015; TAAL E, 1993, PATIENT EDUC COUNS, V20, P63, DOI 10.1016/0738-3991(93)90122-D; Tsay SL, 2003, J ADV NURS, V43, P370, DOI 10.1046/j.1365-2648.2003.02725.x; Unni EJ, 2011, PATIENT EDUC COUNS, V83, P265, DOI 10.1016/j.pec.2010.05.006; *USRDS, 1997, AM J KIDNEY DIS S, V30, pS67; Warde A., 2000, EATING OUT SOCIAL DI; Ware J.E., 1995, SF 12 SCORE SF 12 PH; Yu ZL, 2012, SINGAP MED J, V53, P474; Yusoff N, 2011, ASIAN PAC J CANCER P, V12, P915; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zrinyi M, 2003, NEPHROL DIAL TRANSPL, V18, P1869, DOI 10.1093/ndt/gfg307	57	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2016	11	2							e0149784	10.1371/journal.pone.0149784	http://dx.doi.org/10.1371/journal.pone.0149784			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF3UU	26919323	Green Submitted, gold, Green Published			2023-01-03	WOS:000371274400045
J	Ngabo, F; Mvundura, M; Gazley, L; Gatera, M; Rugambwa, C; Kayonga, E; Tuyishime, Y; Niyibaho, J; Mwenda, JM; Donnen, P; Lepage, P; Binagwaho, A; Atherly, D				Ngabo, Fidele; Mvundura, Mercy; Gazley, Lauren; Gatera, Maurice; Rugambwa, Celse; Kayonga, Eugene; Tuyishime, Yvette; Niyibaho, Jeanne; Mwenda, Jason M.; Donnen, Philippe; Lepage, Philippe; Binagwaho, Agnes; Atherly, Deborah			The Economic Burden Attributable to a Child's Inpatient Admission for Diarrheal Disease in Rwanda	PLOS ONE			English	Article							ROTAVIRUS VACCINATION; COST-EFFECTIVENESS; HEALTH; IMPACT; COUNTRIES; CARE; GASTROENTERITIS	Background Diarrhea is one of the leading causes of childhood morbidity and mortality. Hospitalization for diarrhea can pose a significant burden to health systems and households. The objective of this study was to estimate the economic burden attributable to hospitalization for diarrhea among children less than five years old in Rwanda. These data can be used by decisionmakers to assess the impact of interventions that reduce diarrhea morbidity, including rotavirus vaccine introduction. Methods This was a prospective costing study where medical records and hospital bills for children admitted with diarrhea at three hospitals were collected to estimate resource use and costs. Hospital length of stay was calculated from medical records. Costs incurred during the hospitalization were abstracted from the hospital bills. Interviews with the child's caregivers provided data to estimate household costs which included transport costs and lost income. The portion of medical costs borne by insurance and household were reported separately. Annual economic burden before and after rotavirus vaccine introduction was estimated by multiplying the reported number of diarrhea hospitalizations in public health centers and district hospitals by the estimated economic burden per hospitalization. All costs are presented in 2014 US$. Results Costs for 203 children were analyzed. Approximately 93% of the children had health insurance coverage. Average hospital length of stay was 5.3 +/- 3.9 days. Average medical costs for each child for the illness resulting in a hospitalization were $44.22 +/- $23.74 and the total economic burden was $101, of which 65% was borne by the household. For households in the lowest income quintile, the household costs were 110% of their monthly income. The annual economic burden to Rwanda attributable to diarrhea hospitalizations ranged from $1.3 million to $1.7 million before rotavirus vaccine introduction. Conclusion Households often bear the largest share of the economic burden attributable to diarrhea hospitalization and the burden can be substantial, especially for households in the lowest income quintile.	[Ngabo, Fidele; Donnen, Philippe] Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium; [Ngabo, Fidele; Gatera, Maurice; Kayonga, Eugene; Tuyishime, Yvette; Niyibaho, Jeanne] Minist Hlth, Rwanda Biomed Ctr, Kigali, Rwanda; [Mvundura, Mercy] PATH, Devices & Tools Global Program, Seattle, WA 98121 USA; [Gazley, Lauren; Atherly, Deborah] PATH, Vaccine Access & Delivery Global Program, Seattle, WA 98121 USA; [Rugambwa, Celse] WHO, Rwanda Country Off, Kigali, Rwanda; [Mwenda, Jason M.] WHO, Reg Off Africa, Brazzaville, Rep Congo; [Lepage, Philippe] Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, Brussels, Belgium; [Binagwaho, Agnes] Minist Hlth, Kigali, Rwanda; [Binagwaho, Agnes] Harvard Univ, Sch Med, Boston, MA USA; [Binagwaho, Agnes] Dartmouth, Geisel Sch Med, Hanover, NH USA	Universite Libre de Bruxelles; Rwanda Biomedical Center; World Health Organization; World Health Organization; Universite Libre de Bruxelles; Harvard University; Harvard Medical School; Dartmouth College	Mvundura, M (corresponding author), PATH, Devices & Tools Global Program, Seattle, WA 98121 USA.	mmvundura@path.org		Mvundura, Mercy/0000-0002-7711-9558	Bill and Melinda Gates Foundation [OPP1017334]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	MM, LG, EK, YT, JN, and DA were supported by a grant received from the Bill and Melinda Gates Foundation, grant number OPP1017334. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aikins M, 2010, J INFECT DIS, V202, pS126, DOI 10.1086/653573; Alkoshi S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1400-7; Atherly DE, 2012, VACCINE, V30, pA7, DOI 10.1016/j.vaccine.2011.12.096; Burke RM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-708; Fischer TK, 2005, J INFECT DIS, V192, P1720, DOI 10.1086/497339; Giaquinto C, 2007, J INFECT DIS, V195, pS36, DOI 10.1086/516716; Jin H, 2011, VACCINE, V29, P7801, DOI 10.1016/j.vaccine.2011.07.104; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; MacIntyre UE, 2010, J INFECT DIS, V202, pS116, DOI 10.1086/653560; Ngabo F, 2014, PEDIATR INFECT DIS J, V33, pS89, DOI 10.1097/INF.0000000000000054; Oanda, 1996, CURR CONV; Osano BO, 2011, VACCINE, V29, P4019, DOI 10.1016/j.vaccine.2011.03.053; Rheingans R, 2012, CLIN INFECT DIS, V55, pS317, DOI 10.1093/cid/cis763; Rheingans R, 2012, CLIN INFECT DIS, V55, pS327, DOI 10.1093/cid/cis764; Rheingans R, 2012, VACCINE, V30, pA15, DOI 10.1016/j.vaccine.2012.01.018; Rheingans RD, 2009, J INFECT DIS, V200, pS16, DOI 10.1086/605026; Rwanda Ministry of Health, 2010, RWAND NAT HLTH INS P; Tate JE, 2009, J INFECT DIS, V200, pS76, DOI 10.1086/605058; United Nations Department of Economic and Social Affairs, 2015, WORLD POP PROSP 2012; Walker CLF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029151; WHO, 2005, WHOIVB0510; World Health Organization, 2016, WHO VACC PREV DIS MO	22	28	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2016	11	2							e0149805	10.1371/journal.pone.0149805	http://dx.doi.org/10.1371/journal.pone.0149805			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3VL	26901113	Green Published, gold, Green Submitted			2023-01-03	WOS:000371276100154
J	Han, YC; Huang, HM; Sun, L; Tan, CM; Gao, M; Liu, H; Tang, RN; Wang, YL; Wang, B; Ma, KL; Liu, BC				Han, Yu-Chen; Huang, Han-Ming; Sun, Ling; Tan, Chao-Ming; Gao, Min; Liu, Hong; Tang, Ri-Ning; Wang, Yan-Li; Wang, Bei; Ma, Kun-Ling; Liu, Bi-Cheng			Epidemiological Study of RRT-Treated ESRD in Nanjing - A Ten-Year Experience in Nearly Three Million Insurance Covered Population	PLOS ONE			English	Article							KIDNEY-DISEASE; CHINA; HEMODIALYSIS; SURVIVAL; ACCESS; CARE	Background The growing burden of end-stage renal disease (ESRD) has been a great challenge to the health care system of China. However, the exact epidemiological data for ESRD in China remain unclear. We aimed to investigate the epidemiology of ESRD treated by renal replacement therapy (RRT) in Nanjing based on analysing ten-year data of Nanjing three million insurance covered population. Methods Using the electronic registry system of Urban Employee Basic Medical Insurance (UEBMI), we included all subjects insured by UEBMI in Nanjing from 2005 to 2014 and identified subjects who developed ESRD and started RRT in this cohort. Results The UEBMI population in Nanjing increased from 1,301,882 in 2005 to 2,921,065 in 2014, among which a total of 5,840 subjects developed ESRD and received RRT. Over the 10-year period, the adjusted incidence rates of RRT in the UEBMI cohort gradually decreased from 289.3pmp in 2005 to 218.8pmp in 2014. However, the adjusted prevalence rate increased steadily from 891.7pmp in 2005 to 1,228.6pmp in 2014. The adjusted annual mortality rate decreased from 138.4 per 1000 patient-years in 2005 to 97.8 per 1000 patient-years in 2014. The long-term survival rate fluctuated over the past decade, with the 1-year survival rate ranging from 85.1% to 91.7%, the 3-year survival rate from 69.9% to 78.3% and the 5-year survival rate from 58% to 65.4%. Conclusion Nanjing is facing an increasing burden of ESRD with its improvement of medical reform. The ten-year complete registry data on RRT in urban employees in Nanjing provided a unique opportunity to understand the real threat of ESRD confronting China during its process of health care transition.	[Han, Yu-Chen; Sun, Ling; Gao, Min; Liu, Hong; Tang, Ri-Ning; Wang, Yan-Li; Ma, Kun-Ling; Liu, Bi-Cheng] Southeast Univ, Sch Med, Zhongda Hosp, Inst Nephrol, Nanjing, Jiangsu, Peoples R China; [Huang, Han-Ming; Tan, Chao-Ming] Nanjing Municipal Human Resources & Social Secur, Social Insurance Management Ctr, Nanjing, Jiangsu, Peoples R China; [Wang, Bei] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China	Southeast University - China; Southeast University - China	Liu, BC (corresponding author), Southeast Univ, Sch Med, Zhongda Hosp, Inst Nephrol, Nanjing, Jiangsu, Peoples R China.	liubc64@163.com			National Natural Science Foundation of China [81130010, 81470997]; National Key Basic Research Project ("973"); Clinic Research Center program of Jiangsu Province [BL2014080]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Project ("973")(National Basic Research Program of China); Clinic Research Center program of Jiangsu Province	This study was supported by grants to Bi-Cheng Liu from the National Natural Science Foundation of China (81130010, 81470997), National Key Basic Research Project ("973") and Clinic Research Center program of Jiangsu Province (BL2014080). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, LANCET, V378, P457, DOI DOI 10.1016/S0140-6736(11)61232-4; Gan L, 2015, CLIN NEPHROL, V83; Kimmel PL, 2013, J AM SOC NEPHROL, V24, P293, DOI 10.1681/ASN.2012070659; Kurella-Tamura M, 2014, J AM SOC NEPHROL, V25, P1321, DOI 10.1681/ASN.2013060658; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Nakai S, 2014, THER APHER DIAL, V18, P535, DOI 10.1111/1744-9987.12281; Nanjing Municipal Human Resources and Social Security Bureau, 2010, COMP DOC URB EMPL BA; Steenkamp R, 2015, NEPHRON, V129, P99, DOI 10.1159/000370275; U.S. Renal Data System USRDS, 2013, USDRS 2013 ANN DAT R; Wu M-S, 2012, ACTA NEPHROLOGICA, V26, P104; Yang GH, 2008, LANCET, V372, P1697, DOI 10.1016/S0140-6736(08)61366-5; Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1; Yao Q, 2009, ETHN DIS S1, V19; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; ZHANG W, 2012, CHIN J BLOOD PURIF, V11, P233; Zuo L, 2010, CLIN NEPHROL, V74, pS20; Zuo L, 2006, ETHN DIS S2, V16; Zuo L, 2013, KIDNEY INT SUPPL, V3, P167, DOI 10.1038/kisup.2013.6; 2001, CHIN J NEPHROL, V17, P77	20	7	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2016	11	2							e0149038	10.1371/journal.pone.0149038	http://dx.doi.org/10.1371/journal.pone.0149038			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3CO	26889828	gold, Green Published, Green Submitted			2023-01-03	WOS:000371221500020
J	Bruinsma, SM; van der Heide, A; van der Lee, ML; Vergouwe, Y; Rietjens, JAC				Bruinsma, S. M.; van der Heide, A.; van der Lee, M. L.; Vergouwe, Y.; Rietjens, J. A. C.			No Negative Impact of Palliative Sedation on Relatives' Experience of the Dying Phase and Their Wellbeing after the Patient's Death: An Observational Study	PLOS ONE			English	Article							CONTINUOUS DEEP SEDATION; OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; FAMILY-MEMBERS; BEREAVED RELATIVES; CANCER-PATIENTS; EUROPEAN COUNTRIES; MEDICAL-CARE; UNTIL DEATH; EUTHANASIA	Background Palliative sedation is the widely-used intervention of administering sedating agents to induce a state of unconsciousness to take away a dying patient's perception of otherwise irrelievable symptoms. However, it remains questionable whether this ethically complex intervention is beneficial for patients and whether the associated lack of communication in the last phase of life has a negative impact on relatives' wellbeing. Methods An observational questionnaire study was conducted among relatives of a consecutive sample of patients who died a non-sudden death in the Erasmus MC Cancer Institute or in the hospice 'Laurens Cadenza' (both in Rotterdam) between 2010 and 2013. Results Relatives filled in questionnaires regarding 151 patients who had been sedated and 90 patients who had not been sedated. The median time since all patients had passed away was 21 (IQR 14-32) months. No significant differences were found in relatives 'assessments of the quality of end-of-life care, patients 'quality of life in the last week before death and their quality of dying, between patients who did and did not receive sedation, or in relatives' satisfaction with their own life, their general health and their mental wellbeing after the patient's death. Conclusions The use of sedation in these patients appears to have no negative effect on bereaved relatives' evaluation of the patient's dying phase, or on their own wellbeing after the patient's death.	[Bruinsma, S. M.; van der Heide, A.; Vergouwe, Y.; Rietjens, J. A. C.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [van der Lee, M. L.] Helen Dowling Inst, Bilthoven, Netherlands	Erasmus University Rotterdam; Erasmus MC	Bruinsma, SM (corresponding author), Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.	s.m.bruinsma@erasmusmc.nl		van der Lee, Marije/0000-0002-1316-7008	Economic and Social Research Council (UK); Research Foundation Flanders (BE); Flemish Cancer Association (BE); Research Council of Ghent University (BE); Netherlands Organisation for Scientific Research (NL); Netherlands Organisation for Health Research and Development (NL) [11510006]; Innovational Research Incentives Scheme Veni of the Netherlands Organisation for Scientific Research (NWO); UNESCO; L'Oreal	Economic and Social Research Council (UK)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Research Foundation Flanders (BE)(FWO); Flemish Cancer Association (BE); Research Council of Ghent University (BE); Netherlands Organisation for Scientific Research (NL)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organisation for Health Research and Development (NL)(Netherlands Organization for Health Research and Development); Innovational Research Incentives Scheme Veni of the Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); UNESCO; L'Oreal(L'Oreal Group)	The research on which this paper is based is linked to a larger project, the 'UNBIASED' study (UK - Netherlands - Belgium InternAtional SEDation study) is a collaboration between research teams in the UK, Belgium and the Netherlands with funding from the Economic and Social Research Council (UK), the Research Foundation Flanders (BE), the Flemish Cancer Association (BE), the Research Council of Ghent University (BE), the Netherlands Organisation for Scientific Research (NL) and the Netherlands Organisation for Health Research and Development (NL) (grant number: 11510006). Dr. Rietjens was supported by the Innovational Research Incentives Scheme Veni of the Netherlands Organisation for Scientific Research (NWO) and the 'For Women in Science' fellowship of UNESCO and L'Oreal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank the senior clinical staff members of the participating settings for recruitment of the bereaved participants, as well as the bereaved persons who participated in this study. Dr Rietjens was supported by the Innovational Research Incentives Scheme Veni of the Netherlands Organisation for Scientific Research (NWO) and the 'For Women in Science' fellowship of UNESCO and L'Oreal.	Addington-Hall J, 1998, J EPIDEMIOL COMMUN H, V52, P802, DOI 10.1136/jech.52.12.802; Addington-Hall JM, 2009, PALLIATIVE MED, V23, P190, DOI 10.1177/0269216309102525; Aktas A, 2015, SUPPORT CARE CANCER, V23, P2189, DOI 10.1007/s00520-015-2732-7; Andershed B, 1999, NURS SCI QUART, V12, P45, DOI 10.1177/08943189922106404; Andershed B, 2006, J CLIN NURS, V15, P1158, DOI 10.1111/j.1365-2702.2006.01473.x; Anquinet L, 2012, J PAIN SYMPTOM MANAG, V44, P33, DOI 10.1016/j.jpainsymman.2011.07.007; AstedtKurki P, 1997, J ADV NURS, V25, P908, DOI 10.1046/j.1365-2648.1997.1997025908.x; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Bilsen J, 2007, SOC SCI MED, V65, P803, DOI 10.1016/j.socscimed.2007.04.016; Bruera E, 1991, J Palliat Care, V7, P6; Bruinsma SM, 2014, SUPPORT CARE CANCER, V22, P3243, DOI 10.1007/s00520-014-2344-7; Bruinsma S, 2013, J PALLIAT MED, V16, P349, DOI 10.1089/jpm.2012.0410; Bruinsma SM, 2012, J PAIN SYMPTOM MANAG, V44, P431, DOI 10.1016/j.jpainsymman.2011.09.006; Cantril H., 1965, PATTERN HUMAN CONCER; Carpenter J S, 1996, J Nurs Meas, V4, P171; Chambaere K, 2010, ARCH INTERN MED, V170, P490, DOI 10.1001/archinternmed.2009.542; Cherny NI, 2009, PALLIATIVE MED, V23, P581, DOI 10.1177/0269216309107024; Claessen S, 2009, WEG NAAR EEN CQ INDE; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Efron B., 1993, INTRO BOOTSTRAP; Gallagher R, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-25; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Hudson P, 2014, BMJ SUPPORT PALLIAT, V4, P231, DOI 10.1136/bmjspcare-2013-000500; KANE RL, 1984, LANCET, V1, P890; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P771, DOI 10.1016/j.jpainsymman.2008.04.020; Miccinesi G, 2006, J PAIN SYMPTOM MANAG, V31, P122, DOI 10.1016/j.jpainsymman.2005.07.004; Morita T, 2004, J PAIN SYMPTOM MANAG, V28, P557, DOI 10.1016/j.jpainsymman.2004.03.004; Morita T, 2004, SUPPORT CARE CANCER, V12, P885, DOI 10.1007/s00520-004-0678-2; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Pierson CM, 2002, AIDS CARE, V14, P587, DOI 10.1080/0954012021000005416; Rietjens J, 2008, BRIT MED J, V336, P810, DOI 10.1136/bmj.39504.531505.25; Rietjens JAC, 2006, PALLIATIVE MED, V20, P685, DOI 10.1177/0269216306070241; Royal Dutch Medical Association (KNMG), 2009, GUID PALL SED; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Seale C RK, 2014, HEALTH IN PRESS; Seale C, 2010, J PAIN SYMPTOM MANAG, V39, P44, DOI 10.1016/j.jpainsymman.2009.06.007; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2014, PALLIAT SUPPORT CARE, V8, P1, DOI DOI 10.1097/SPC.0000000000000035; STROEBE MS, 1989, OMEGA-J DEATH DYING, V20, P1, DOI 10.2190/C3JE-C9L1-5R91-DWDU; Swarte NB, 2003, BMJ-BRIT MED J, V327, P189, DOI 10.1136/bmj.327.7408.189; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; van Delden JJM, 2011, KNOWLEDGE OPINIONS G; van Dooren S, 2009, J PAIN SYMPTOM MANAG, V38, P452, DOI 10.1016/j.jpainsymman.2008.11.011; Veerbeek L, 2008, AM J HOSP PALLIAT ME, V25, P207, DOI 10.1177/1049909108315515; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson KG, 2004, CAN J PSYCHIAT, V49, P350, DOI 10.1177/070674370404900603; World Health Organization, 2008, DEF PALL CAR; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	50	10	10	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0149250	10.1371/journal.pone.0149250	http://dx.doi.org/10.1371/journal.pone.0149250			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DD6SI	26871717	Green Published, Green Submitted, gold			2023-01-03	WOS:000370054100134
J	Brown, KA; Jones, M; Daneman, N; Adler, FR; Stevens, V; Nechodom, KE; Goetz, MB; Samore, MH; Mayer, J				Brown, Kevin A.; Jones, Makoto; Daneman, Nick; Adler, Frederick R.; Stevens, Vanessa; Nechodom, Kevin E.; Goetz, Matthew B.; Samore, Matthew H.; Mayer, Jeanmarie			Importation, Antibiotics, and Clostridium difficile Infection in Veteran Long-Term Care	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL-CENTERS; RISK-FACTORS; FACILITIES; DIARRHEA; TRANSMISSION; METAANALYSIS	Background: Although clinical factors affecting a person's susceptibility to Clostridium difficile infection are well-understood, little is known about what drives differences in incidence across long-term care settings. Objective: To obtain a comprehensive picture of individual and regional factors that affect C difficile incidence. Design: Multilevel longitudinal nested case-control study. Setting: Veterans Health Administration health care regions, from 2006 through 2012. Participants: Long-term care residents. Measurements: Individual-level risk factors included age, number of comorbid conditions, and antibiotic exposure. Regional risk factors included importation of cases of acute care C difficile infection per 10 000 resident-days and antibiotic use per 1000 resident-days. The outcome was defined as a positive result on a long-term care C difficile test without a positive result in the prior 8 weeks. Results: 6012 cases (incidence, 3.7 cases per 10 000 resident-days) were identified in 86 regions. Long-term care C difficile incidence (minimum, 0.6 case per 10 000 resident-days; maximum, 31.0 cases per 10 000 resident-days), antibiotic use (minimum, 61.0 days with therapy per 1000 resident-days; maximum, 370.2 days with therapy per 1000 resident-days), and importation (minimum, 2.9 cases per 10 000 resident-days; maximum, 341.3 cases per 10 000 resident-days) varied substantially across regions. Together, antibiotic use and importation accounted for 75% of the regional variation in C difficile incidence (R-2 = 0.75). Multilevel analyses showed that regional factors affected risk together with individual-level exposures (relative risk of regional antibiotic use, 1.36 per doubling [95% CI, 1.15 to 1.60]; relative risk of importation, 1.23 per doubling [CI, 1.14 to 1.33]). Limitations: Case identification was based on laboratory criteria. Admission of residents with recent C difficile infection from non-Veterans Health Administration acute care sources was not considered. Conclusion: Only 25% of the variation in regional C difficile incidence in long-term care remained unexplained after importation from acute care facilities and antibiotic use were accounted for, which suggests that improved infection control and antimicrobial stewardship may help reduce the incidence of C difficile in long-term care settings.	Univ Utah, Salt Lake City, UT USA; [Jones, Makoto] Vet Affairs Salt Lake City Hlth Care Syst, 500 Foothill Dr,Mailstop 182, Salt Lake City, UT 84148 USA; [Daneman, Nick] Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave,G Wing Room 106, Toronto, ON M4N 3M5, Canada; [Goetz, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA; [Brown, Kevin A.] Publ Hlth Ontario, 480 Univ Ave, Toronto, ON M5G1V2, Canada; [Adler, Frederick R.] Univ Utah, Dept Math, 155 South 1400 East, Salt Lake City, UT 84112 USA; [Stevens, Vanessa] Univ Utah, Coll Pharm, Dept Pharmacotherapy, 30 South 2000 East,Room 4410, Salt Lake City, UT 84112 USA; [Nechodom, Kevin E.; Samore, Matthew H.; Mayer, Jeanmarie] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, 295 Chipeta Way, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Brown, KA (corresponding author), Publ Hlth Ontario, 480 Univ Ave, Toronto, ON M5G1V2, Canada.	kevin.brown@oahpp.ca	Goetz, Matthew Bidwell/GPX-4090-2022	Goetz, Matthew/0000-0003-4542-992X; Stevens, Vanessa/0000-0001-8933-5453; Brown, Kevin Antoine/0000-0002-1483-2188	Centers for Disease Control and Prevention [11FED1106563]; Veterans Health Administration (Centers of Innovation) [13-414]; Veterans Affairs [IK2HX001165] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Veterans Health Administration (Centers of Innovation); Veterans Affairs(US Department of Veterans Affairs)	By the Centers for Disease Control and Prevention (Intra-agency agreement 11FED1106563) and the Veterans Health Administration (Centers of Innovation grant 13-414; Advanced Fellowship in Informatics [Dr. Brown]).	Austin PC, 2010, J CLIN EPIDEMIOL, V63, P2, DOI 10.1016/j.jclinepi.2008.11.004; Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X; Bignardi GE, 1998, J HOSP INFECT, V40, P1, DOI 10.1016/S0195-6701(98)90019-6; Brown K, 2015, JAMA INTERN MED, V175, P626, DOI 10.1001/jamainternmed.2014.8273; Brown KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105454; Brown KA, 2013, ANTIMICROB AGENTS CH, V57, P2326, DOI 10.1128/AAC.02176-12; Centers for Disease Control and Prevention, 2016, MULT RES ORG CLOSTR; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Christiansen CL, 1997, ANN INTERN MED, V127, P764, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00065; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; Daneman N, 2011, J ANTIMICROB CHEMOTH, V66, P2856, DOI 10.1093/jac/dkr395; Dubberke ER, 2007, ARCH INTERN MED, V167, P1092, DOI 10.1001/archinte.167.10.1092; Evans ME, 2014, INFECT CONT HOSP EP, V35, P1037, DOI 10.1086/677151; Guerrero DM, 2011, INFECT CONT HOSP EP, V32, P513, DOI 10.1086/659765; Jones M, 2014, CLIN INFECT DIS, V58, P32, DOI 10.1093/cid/cit668; Jones M, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-34; Kwong JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044103; Laffan AM, 2006, J AM GERIATR SOC, V54, P1068, DOI 10.1111/j.1532-5415.2006.00768.x; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Mylotte JM, 2008, INFECT CONT HOSP EP, V29, P760, DOI 10.1086/589812; Nicolle LE, 2000, INFECT CONT HOSP EP, V21, P537, DOI 10.1086/501798; Pakyz AL, 2014, J ANTIMICROB CHEMOTH, V69, P1127, DOI 10.1093/jac/dkt489; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ren SQ, 2010, J APPL STAT, V37, P1487, DOI 10.1080/02664760903046102; Riggs MM, 2007, CLIN INFECT DIS, V45, P992, DOI 10.1086/521854; Roux AVD, 2005, J INFECT DIS, V191, pS25, DOI 10.1086/425288; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; Sethi AK, 2010, INFECT CONT HOSP EP, V31, P21, DOI 10.1086/649016; Slimings C, 2014, J ANTIMICROB CHEMOTH, V69, P881, DOI 10.1093/jac/dkt477; Starr JM, 1997, LANCET, V349, P426, DOI 10.1016/S0140-6736(97)80053-0; Trivedi KK, 2014, CLIN INFECT DIS, V59, pS170, DOI 10.1093/cid/ciu538	31	19	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2016	164	12					787	U39		10.7326/M15-1754	http://dx.doi.org/10.7326/M15-1754			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ6VG	27088642				2023-01-03	WOS:000379343000012
J	Zarbock, A; Kellum, JA; Schmidt, C; Van Aken, H; Wempe, C; Pavenstadt, H; Boanta, A; Gerss, J; Meersch, M				Zarbock, Alexander; Kellum, John A.; Schmidt, Christoph; Van Aken, Hugo; Wempe, Carola; Pavenstaedt, Hermann; Boanta, Andreea; Gerss, Joachim; Meersch, Melanie			Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury The ELAIN Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL; INTERLEUKIN-8; DIALYSIS; FAILURE; HEMOFILTRATION; BIOMARKERS; INTENSITY; PNEUMONIA; RECOVERY; OUTCOMES	IMPORTANCE Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney injury (AKI) but without life-threatening indications is still unknown. OBJECTIVE To determine whether early initiation of RRT in patients who are critically ill with AKI reduces 90-day all-cause mortality. DESIGN, SETTING, AND PARTICIPANTS Single-center randomized clinical trial of 231 critically ill patients with AKI Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (>= 2 times baseline or urinary output <0.5 mL/kg/h for >= 12 hours) and plasma neutrophil gelatinase-associated lipocalin level higher than 150 ng/mL enrolled between August 2013 and June 2015 from a university hospital in Germany. INTERVENTIONS Early (within 8 hours of diagnosis of KDIGO stage 2; n = 112) or delayed (within 12 hours of stage 3 AKI or no initiation; n = 119) initiation of RRT. MAIN OUTCOMES AND MEASURES The primary end point was mortality at 90 days after randomization. Secondary end points included 28- and 60-day mortality, clinical evidence of organ dysfunction, recovery of renal function, requirement of RRT after day 90, duration of renal support, and intensive care unit (ICU) and hospital length of stay. RESULTS Among 231 patients (mean age, 67 years; men, 146 [63.2%]), all patients in the early group (n = 112) and 108 of 119 patients (90.8%) in the delayed group received RRT. All patients completed follow-up at 90 days. Median time (Q1, Q3) from meeting full eligibility criteria to RRT initiation was significantly shorter in the early group (6.0 hours [Q1, Q3: 4.0, 7.0]) than in the delayed group (25.5 h [Q1, Q3: 18.8, 40.3]; difference, -21.0 [95% CI, -24.0 to -18.0]; P < .001). Early initiation of RRT significantly reduced 90-day mortality (44 of 112 patients [39.3%]) compared with delayed initiation of RRT (65 of 119 patients [54.7%]; hazard ratio [HR], 0.66 [95% CI, 0.45 to 0.97]; difference, -15.4%[95% CI, -28.1% to -2.6%]; P = .03). More patients in the early group recovered renal function by day 90 (60 of 112 patients [53.6%] in the early group vs 46 of 119 patients [38.7%] in the delayed group; odds ratio [OR], 0.55 [95% CI, 0.32 to 0.93]; difference, 14.9% [95% CI, 2.2% to 27.6%]; P = .02). Duration of RRT and length of hospital stay were significantly shorter in the early group than in the delayed group (RRT: 9 days [Q1, Q3: 4, 44] in the early group vs 25 days [Q1, Q3: 7, >90] in the delayed group; P = .04; HR, 0.69 [95% CI, 0.48 to 1.00]; difference, -18 days [95% CI, -41 to 4]; hospital stay: 51 days [Q1, Q3: 31, 74] in the early group vs 82 days [Q1, Q3: 67, >90] in the delayed group; P < .001; HR, 0.34 [95% CI, 0.22 to 0.52]; difference, -37 days [95% CI, -infinity to -19.5]), but there was no significant effect on requirement of RRT after day 90, organ dysfunction, and length of ICU stay. CONCLUSIONS AND RELEVANCE Among critically ill patients with AKI, early RRT compared with delayed initiation of RRT reduced mortality over the first 90 days. Further multicenter trials of this intervention are warranted.	[Zarbock, Alexander; Schmidt, Christoph; Van Aken, Hugo; Wempe, Carola; Boanta, Andreea; Meersch, Melanie] Univ Hosp Munster, Dept Anaesthesiol Intens Care Med & Pain Med, Munster, Germany; [Kellum, John A.] Univ Pittsburgh, Dept Crit Care Med, Ctr Crit Care Nephrol, Pittsburgh, PA 15260 USA; [Pavenstaedt, Hermann] Univ Hosp Munster, Dept Internal Med D, Munster, Germany; [Gerss, Joachim] Univ Munster, Inst Biostat & Clin Res, D-48149 Munster, Germany	University of Munster; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Munster; University of Munster	Zarbock, A (corresponding author), Univ Hosp Munster, Dept Anesthesiol Crit Care Med & Pain Therapy, Albert Schweitzer Campus 1,Gebaude A1, D-48149 Munster, Germany.	zarbock@uni-muenster.de	Gerß, Joachim WO/B-5702-2013; Kellum, John/AAP-3072-2020; Kellum, John A/HCH-2944-2022	Kellum, John/0000-0003-1995-2653; Kellum, John A/0000-0003-1995-2653	Else-Kroner Fresenius Stiftung [2013_A46]	Else-Kroner Fresenius Stiftung	The study was funded by the Else-Kroner Fresenius Stiftung (2013_A46 to A.Z.).	Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Chawla LS, 2007, CLIN J AM SOC NEPHRO, V2, P22, DOI 10.2215/CJN.02510706; Chou YH, 2011, CRIT CARE, V15, DOI 10.1186/cc10252; Clark WR, 2006, BLOOD PURIFICAT, V24, P487, DOI 10.1159/000095929; Cruz DN, 2011, SEMIN DIALYSIS, V24, P124, DOI 10.1111/j.1525-139X.2011.00830.x; Cruz DN, 2010, INTENS CARE MED, V36, P444, DOI 10.1007/s00134-009-1711-1; Demirkilic U, 2004, J CARDIAC SURG, V19, P17, DOI 10.1111/j.0886-0440.2004.04004.x; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Elahi MM, 2004, EUR J CARDIO-THORAC, V26, P1027, DOI 10.1016/j.ejcts.2004.07.039; Gangemi S, 2002, AM J NEPHROL, V22, P417, DOI 10.1159/000065269; Gettings LG, 1999, INTENS CARE MED, V25, P805, DOI 10.1007/s001340050956; Gibney N, 2008, CLIN J AM SOC NEPHRO, V3, P876, DOI 10.2215/CJN.04871107; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Jamale TE, 2013, AM J KIDNEY DIS, V62, P1116, DOI 10.1053/j.ajkd.2013.06.012; Jun M, 2010, CLIN J AM SOC NEPHRO, V5, P956, DOI 10.2215/CJN.09111209; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Kellum JA, 2008, CLIN J AM SOC NEPHRO, V3, P887, DOI 10.2215/CJN.04891107; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Kwon O, 2003, AM J KIDNEY DIS, V41, P1074, DOI 10.1016/S0272-6386(03)00206-3; Lehmacher W, 1999, BIOMETRICS, V55, P1286, DOI 10.1111/j.0006-341X.1999.01286.x; Liangos O, 2009, NEPHRON CLIN PRACT, V113, pC148, DOI 10.1159/000232595; Liu KD, 2007, CRIT CARE MED, V35, P2755, DOI 10.1097/01.CCM.0000291649.72238.6D; Liu KD, 2006, CLIN J AM SOC NEPHRO, V1, P915, DOI 10.2215/CJN.01430406; Liu KD, 2009, CRIT CARE, V13, DOI 10.1186/cc7940; Matson J, 2004, Crit Care Resusc, V6, P209; Murugan R, 2014, NEPHROL DIAL TRANSPL, V29, P1854, DOI 10.1093/ndt/gfu051; Murugan R, 2010, KIDNEY INT, V77, P527, DOI 10.1038/ki.2009.502; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Ronco C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0850-8; Shiao CC, 2009, CRIT CARE, V13, DOI 10.1186/cc8147; Simmons EM, 2004, KIDNEY INT, V65, P1357, DOI 10.1111/j.1523-1755.2004.00512.x; Sugahara Souichi, 2004, Hemodial Int, V8, P320, DOI 10.1111/j.1492-7535.2004.80404.x; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Wassmer G, 2006, BIOMETRICAL J, V48, P714, DOI 10.1002/bimj.200510190; Zarbock A, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1249-9	40	606	655	3	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2016	315	20					2190	2199		10.1001/jama.2016.5828	http://dx.doi.org/10.1001/jama.2016.5828			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM4US	27209269	Bronze			2023-01-03	WOS:000376343000015
J	Trang, PM; Rocklov, J; Giang, KB; Kullgren, G; Nilsson, M				Phan Minh Trang; Rocklov, Joacim; Giang, Kim Bao; Kullgren, Gunnar; Nilsson, Maria			Heatwaves and Hospital Admissions for Mental Disorders in Northern Vietnam	PLOS ONE			English	Article							CLIMATE-CHANGE; SEASONAL-VARIATION; CENTRAL FATIGUE; EXTREME HEAT; HEALTH; TEMPERATURE; MORTALITY; SCHIZOPHRENIA; PLATELET; IMPACT	Studies in high-income countries have shown an association between heatwaves and hospital admissions for mental disorders. It is unknown whether such associations exist in subtropical nations like Vietnam. The study aim was to investigate whether hospital admissions for mental disorders may be triggered, or exacerbated, by heat exposure and heatwaves, in a low-and middle-income country, Vietnam. For this, we used data from the Hanoi Mental Hospital over five years (2008-2012) to estimate the effect of heatwaves on admissions for mental disorders. A zero-inflated negative binomial regression model accounting for seasonality, time trend, days of week, and mean humidity was used to analyse the relationship. Heatwave events were mainly studied as periods of three or seven consecutive days above the threshold of 35 degrees C daily maximum temperature (90th percentile). The study result showed heatwaves increased the risk for admission in the whole group of mental disorders (F00-79) for more persistent heatwaves of at least 3 days when compared with non-heatwave periods. The relative risks were estimated at 1.04 (0.95-1.13), 1.15 (1.005-1.31), and 1.36 (1-1.90) for a one-, three- and seven-day heatwave, respectively. Admissions for mental disorders increased among men, residents in rural communities, and the elderly population during heatwaves. The groups of organic mental disorders, including symptomatic illnesses (F0-9) and mental retardation (F70-79), had increased admissions during heatwaves. The findings are novel in their focus on heatwave impact on mental diseases in a population habituating in a subtropical low-and middle-income country characterized by rapid epidemiological transitions and environmental changes.	[Phan Minh Trang; Rocklov, Joacim; Nilsson, Maria] Umea Univ, Dept Publ Hlth & Clin Med, Unit Epidemiol & Global Hlth, Umea, Sweden; [Giang, Kim Bao] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi 100803, Vietnam; [Kullgren, Gunnar] Umea Univ, Dept Psychiat Clin Sci, Umea, Sweden	Umea University; Hanoi Medical University; Umea University	Trang, PM (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, Unit Epidemiol & Global Hlth, Umea, Sweden.	tranghealth@gmail.com		Rocklov, Joacim/0000-0003-4030-0449; Kim Bao, Giang/0000-0003-2290-0205	SIDA projects	SIDA projects	Database and manuscript were supported by SIDA projects.	Alston M, 2012, SOC SCI MED, V74, P515, DOI 10.1016/j.socscimed.2010.04.036; Anderson CA, 2001, CURR DIR PSYCHOL SCI, V10, P33, DOI 10.1111/1467-8721.00109; [Anonymous], ISRN PUBLIC HLTH; Astrom DO, 2013, NAT CLIM CHANGE, V3, P1050, DOI [10.1038/nclimate2022, 10.1038/NCLIMATE2022]; Aviv A, 2011, INT J SOC PSYCHIATR, V57, P57, DOI 10.1177/0020764010348444; Bai L, 2014, ENVIRON RES, V132, P212, DOI 10.1016/j.envres.2014.04.002; Balthazar CH, 2010, PHARMACOL REP, V62, P54, DOI 10.1016/S1734-1140(10)70242-5; Berry H, 2009, AUSTRALAS PSYCHIATRY, V17, P453, DOI 10.1080/10398560903045328; Berry HL, 2010, INT J PUBLIC HEALTH, V55, P123, DOI 10.1007/s00038-009-0112-0; Bobinska Kinga, 2009, Pol Merkur Lekarski, V27, P109; CAMPBELL M, 1991, HOSP COMMUNITY PSYCH, V42, P374; CHRISTMAN JV, 1985, J APPL PHYSIOL, V58, P1923, DOI 10.1152/jappl.1985.58.6.1923; Clarke M, 1999, EUR PSYCHIAT, V14, P251, DOI 10.1016/S0924-9338(99)00174-1; Cusack L, 2011, J ADV NURS, V67, P915, DOI 10.1111/j.1365-2648.2010.05551.x; D'Antonio E, 2009, INT REV RES MENT RET, V38, P93, DOI 10.1016/S0074-7750(08)38004-5; De Vriese SR, 2004, PROSTAG LEUKOTR ESS, V71, P13, DOI 10.1016/j.plefa.2003.12.002; DHondt P, 1996, NEUROPSYCHOPHARMACOL, V15, P187, DOI 10.1016/0893-133X(95)00183-E; FAUNT JD, 1995, AUST NZ J MED, V25, P117, DOI 10.1111/j.1445-5994.1995.tb02822.x; Gasparrini A, 2011, EPIDEMIOLOGY, V22, P68, DOI 10.1097/EDE.0b013e3181fdcd99; Gasparrini A, 2010, ENVIRON RES, V110, P633, DOI 10.1016/j.envres.2010.06.005; Hansen A, 2008, ENVIRON HEALTH PERSP, V116, P1369, DOI 10.1289/ehp.11339; Hansen A, 2011, HEALTH PROMOT J AUST, V22, pS17, DOI 10.1071/HE11417; Jakovljevic M, 1997, BIOL PSYCHIAT, V41, P1028, DOI 10.1016/S0006-3223(96)00212-0; Jones P, 2008, RURAL REMOTE HEALTH, V8; Khalaj B, 2010, INT ARCH OCC ENV HEA, V83, P833, DOI 10.1007/s00420-010-0534-2; Kiyatkin EA, 2005, BRAIN RES REV, V50, P27, DOI 10.1016/j.brainresrev.2005.04.001; Kovats RS, 2006, HEATWAVES PUBLIC HLT, P592; Lee HJ, 2002, PSYCHIAT RES, V113, P151, DOI 10.1016/S0165-1781(02)00237-8; Martin-Latry K, 2007, EUR PSYCHIAT, V22, P335, DOI 10.1016/j.eurpsy.2007.03.007; McMichael AJ, 2011, J INTERN MED, V270, P401, DOI 10.1111/j.1365-2796.2011.02415.x; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; McWilliams S, 2013, INT J BIOMETEOROL, V57, P497, DOI 10.1007/s00484-012-0575-1; Meeusen R, 2010, SCAND J MED SCI SPOR, V20, P19, DOI 10.1111/j.1600-0838.2010.01205.x; Metzger KB, 2010, ENVIRON HEALTH PERSP, V118, P80, DOI 10.1289/ehp.0900906; Hoa NP, 2012, B WORLD HEALTH ORGAN, V90, P764, DOI 10.2471/BLT.11.100750; Nitschke M, 2013, INT J ENV RES PUB HE, V10, P6721, DOI 10.3390/ijerph10126721; Nitschke M, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-42; Page LA, 2010, PSYCHOL MED, V40, P177, DOI 10.1017/S0033291709992169; Patkar AA, 2003, HUM PSYCHOPHARM CLIN, V18, P103, DOI 10.1002/hup.448; Ranson M, 2014, J ENVIRON ECON MANAG, V67, P274, DOI 10.1016/j.jeem.2013.11.008; Rausch JL, 2003, NEUROPSYCHOBIOLOGY, V47, P120, DOI 10.1159/000070579; Rocklov J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-23; Rocklov J, 2011, OCCUP ENVIRON MED, V68, P531, DOI 10.1136/oem.2010.058818; Rodgers Y, GENDER DIFFERENCES S; Roelands B, 2010, SPORTS MED, V40, P229, DOI 10.2165/11533670-000000000-00000; Sadock BJ, KAPLAN SADOCKS SYNOP; Salerian AJ, 2008, MED HYPOTHESES, V70, P497, DOI 10.1016/j.mehy.2007.06.032; Santosa A, 2014, GLOBAL HEALTH ACTION, V7, P56, DOI 10.3402/gha.v7.23574; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Shiloh R, 2005, EUR PSYCHIAT, V20, P61, DOI 10.1016/j.eurpsy.2004.09.020; Simister J, 2005, STRESS HEALTH, V21, P3, DOI 10.1002/smi.1029; Tawatsupa B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001396; Tran TD, 2012, J AFFECT DISORDERS, V136, P104, DOI 10.1016/j.jad.2011.08.012; Pham TTH, 2013, LECT NOTES COMPUT SC, V7974, P238; Tong SL, 2011, MATURITAS, V69, P5, DOI 10.1016/j.maturitas.2011.01.009; Vaneckova P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055459; Vida S, 2012, PSYCHIAT SERV, V63, P1150, DOI 10.1176/appi.ps.201100485; Volpe FM, 2006, J AFFECT DISORDERS, V94, P243, DOI 10.1016/j.jad.2006.03.025; Wang X, 2014, J AFFECT DISORDERS, V155, P154, DOI 10.1016/j.jad.2013.10.042; Whitney DK, 1999, J AFFECT DISORDERS, V55, P99, DOI 10.1016/S0165-0327(98)00197-9; WHO South East Asia Region, 2008, REGIONAL HLTH FORUM, V12; Wilson L, 2011, AUST FAM PHYSICIAN, V40, P637	62	48	48	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2016	11	5							e0155609	10.1371/journal.pone.0155609	http://dx.doi.org/10.1371/journal.pone.0155609			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM4BR	27195473	Green Submitted, gold, Green Published			2023-01-03	WOS:000376291100068
J	Nair, HB; Santhamma, B; Krishnegowda, NK; Dileep, KV; Nickisch, KJ				Nair, Hareesh B.; Santhamma, Bindu; Krishnegowda, Naveen K.; Dileep, Kalarikkal V.; Nickisch, Klaus J.			Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo	PLOS ONE			English	Article							ESTROGEN-INDUCED APOPTOSIS; POSTMENOPAUSAL WOMEN; MAMMARY-GLAND; BAZEDOXIFENE/CONJUGATED ESTROGENS; BIOLOGICAL EVALUATION; CONJUGATED ESTROGENS; CONTROLLED TRIAL; EQUINE ESTROGEN; HORMONE-THERAPY; CERVICAL-CANCER	Use of estrogen or estrogen / progestin combination was an approved regimen for menopausal hormonal therapy (MHT). However, more recent patient-centered studies revealed an increase in the incidence of breast cancer in women receiving menopausal hormone therapy with estrogen plus progestin rather than estrogen alone. Tissue selective estrogen complex (TSEC) has been proposed to eliminate the progesterone component of MHT with supporting evidences. Based on our previous studies it is evident that SPRMs have a safer profile on endometrium in preventing unopposed estrogenicity. We hypothesized that a combination of estradiol (E2) with selective progesterone receptor modulator (SPRM) to exert a safer profile on endometrium will also reduce mammary gland proliferation and could be used to prevent breast cancer when used in MHT. In order to test our hypothesis, we compared the estradiol alone or in combination with our novel SPRMs, EC312 and EC313. The compounds were effectively controlled E2 mediated cell proliferation and induced apoptosis in T47D breast cancer cells. The observed effects were found comparable that of BZD in vitro. The effects of SPRMs were confirmed by receptor binding studies as well as gene and protein expression studies. Proliferation markers were found downregulated with EC312/313 treatment in vitro and reduced E2 induced mammary gland proliferation, evidenced as reduced ductal branching and terminal end bud growth in vivo. These data supporting our hypothesis that E2+EC312/EC313 blocked the estrogen action may provide basic rationale to further test the clinical efficacy of SPRMs to prevent breast cancer incidence in postmenopausal women undergoing MHT.	[Nair, Hareesh B.; Santhamma, Bindu; Nickisch, Klaus J.] Evestra Inc, 14508 Omicron Dr, San Antonio, TX 78245 USA; [Krishnegowda, Naveen K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Dileep, Kalarikkal V.] Indian Inst Sci Educ & Res, Sch Chem, Thiruvananthapuram 695016, Kerala, India	University of Texas System; University of Texas Health San Antonio; Indian Institute of Science Education & Research (IISER) - Thiruvananthapuram	Nair, HB (corresponding author), Evestra Inc, 14508 Omicron Dr, San Antonio, TX 78245 USA.	hnair@evestra.com	Vijayan, Dileep K/C-6179-2017	Vijayan, Dileep K/0000-0002-7456-4226	Evestra, Inc.; Indian Institute of Science Education and Research-Thiruvananthapuram (IISER-TVM)	Evestra, Inc.; Indian Institute of Science Education and Research-Thiruvananthapuram (IISER-TVM)	This work was supported by Evestra, Inc. which provided support in the form of salaries for authors [H.B.N., B.S. and K.J.N], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; The authors are gratefully acknowledges the Bioinformatics Infra Structure Facility, Department of Biotechnology and Microbiology, Kannur University, Thalassery Campus for providing the computational facility. The authors also acknowledge Prof. C. Sadasivan for the useful discussions in connection with molecular modeling studies. Dr. Dileep K V acknowledges Indian Institute of Science Education and Research-Thiruvananthapuram (IISER-TVM) for his postdoctoral fellowship. The authors acknowledge Carolyne Packenius for proof reading assistance.	Anderson E, 2004, MATURITAS, V48, pS13, DOI 10.1016/j.maturitas.2004.02.010; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Archer DE, 2009, FERTIL STERIL, V92, P1039, DOI 10.1016/j.fertnstert.2009.05.093; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; Berrodin TJ, 2009, MOL ENDOCRINOL, V23, P74, DOI 10.1210/me.2008-0366; Bhaskaran S, 2013, MOL CANCER THER, V12, P361, DOI 10.1158/1535-7163.MCT-12-0965; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Chwalisz K, 2005, ENDOCR REV, V26, P423, DOI 10.1210/er.2005-0001; Chwalisz K, 2004, SEMIN REPROD MED, V22, P113; Donnez J, 2014, FERTIL STERIL, V101, P1565, DOI 10.1016/j.fertnstert.2014.02.008; Fan P, 2009, ENDOCRINOLOGY, V150, P2036, DOI 10.1210/en.2008-1195; Gregoraszczuk EL, 2008, ENVIRON TOXICOL PHAR, V25, P227, DOI 10.1016/j.etap.2007.10.004; Hagan CR, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-32; Hovey RC, 2011, TOXICOL SCI, V119, P380, DOI 10.1093/toxsci/kfq337; Jordan VC, 2015, ENDOCR-RELAT CANCER, V22, pR1, DOI 10.1530/ERC-14-0448; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kirma N, 2007, CANCER RES, V67, P1918, DOI 10.1158/0008-5472.CAN-06-1991; Kramer EA, 2006, EUR J OBSTET GYN R B, V129, P77, DOI 10.1016/j.ejogrb.2005.12.004; Lanari C, 2012, ENDOCR-RELAT CANCER, V19, pR35, DOI 10.1530/ERC-11-0378; Lobo RA, 2009, FERTIL STERIL, V92, P1025, DOI 10.1016/j.fertnstert.2009.03.113; Marino M, 2003, MOL BIOL CELL, V14, P2583, DOI 10.1091/mbc.E02-09-0621; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nair HB, 2005, CANCER RES, V65, P11164, DOI 10.1158/0008-5472.CAN-05-1087; Nickisch K, 2014, STEROIDS, V92, P45, DOI 10.1016/j.steroids.2014.08.017; Nickisch K, 2013, STEROIDS, V78, P909, DOI 10.1016/j.steroids.2013.04.003; Nickisch K, 2013, STEROIDS, V78, P255, DOI 10.1016/j.steroids.2012.09.010; Obr AE, 2013, MOL ENDOCRINOL, V27, P1808, DOI 10.1210/me.2013-1077; Ohara Noriyuki, 2007, Reprod Sci, V14, P20, DOI 10.1177/1933719107311464; Pinkerton JV, 2009, MENOPAUSE, V16, P1116, DOI 10.1097/gme.0b013e3181a7df0d; Robertson JFR, 1999, EUR J CANCER, V35, P214, DOI 10.1016/S0959-8049(98)00388-8; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Santen RJ, 2014, J STEROID BIOCHEM, V142, P52, DOI 10.1016/j.jsbmb.2013.06.010; Santen RJ, 2013, J STEROID BIOCHEM, V137, P150, DOI 10.1016/j.jsbmb.2013.05.008; Santen RJ, 2008, WOMENS HEALTH, V4, P207, DOI 10.2217/17455057.4.3.207; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Schubert G, 2005, SEMIN REPROD MED, V23, P58, DOI 10.1055/s-2005-864034; Sciacca L, 2013, NUTR METAB CARDIOVAS, V23, P808, DOI 10.1016/j.numecd.2013.05.006; Sflomos G, 2013, ONCOTARGET, V4, P1126, DOI 10.18632/oncotarget.1178; SHAPIRO S, 1985, NEW ENGL J MED, V313, P969, DOI 10.1056/NEJM198510173131601; Song Y, 2013, ENDOCRINOLOGY, V154, P656, DOI 10.1210/en.2012-2038; Song Y, 2012, ENDOCRINOLOGY, V153, P5706, DOI 10.1210/en.2012-1583; Sweeney EE, 2014, CANCER RES, V74, P7060, DOI 10.1158/0008-5472.CAN-14-1784; Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654; von Holst T, 2002, MATURITAS, V43, P265, DOI 10.1016/S0378-5122(02)00203-7; Wagenfeld A, 2013, HUM REPROD, V28, P2253, DOI 10.1093/humrep/det247; Yue W, 1998, CANCER RES, V58, P927	48	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2016	11	3							e0151182	10.1371/journal.pone.0151182	http://dx.doi.org/10.1371/journal.pone.0151182			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DH3SV	27011208	Green Published, Green Submitted, gold			2023-01-03	WOS:000372708000025
J	Young, E				Young, Emma			PERSONAL VIEW My mum's decision changed my view of assisted dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Young, Emma] Newham Univ Hosp, Barts Hlth NHS Trust, London E13 8SL, England	Barts Health NHS Trust	Young, E (corresponding author), Newham Univ Hosp, Barts Hlth NHS Trust, London E13 8SL, England.	emmayoung1@nhs.net						Ryan J., 2015, GUARDIAN	1	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2016	352								i1589	10.1136/bmj.i1589	http://dx.doi.org/10.1136/bmj.i1589			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH8LI	27000931				2023-01-03	WOS:000373044300006
J	Nyamtema, AS; Mwakatundu, N; Dominico, S; Mohamed, H; Pemba, S; Rumanyika, R; Kairuki, C; Kassiga, I; Shayo, A; Issa, O; Nzabuhakwa, C; Lyimo, C; van Roosmalen, J				Nyamtema, Angelo S.; Mwakatundu, Nguke; Dominico, Sunday; Mohamed, Hamed; Pemba, Senga; Rumanyika, Richard; Kairuki, Clementina; Kassiga, Irene; Shayo, Allan; Issa, Omary; Nzabuhakwa, Calist; Lyimo, Chagi; van Roosmalen, Jos			Enhancing Maternal and Perinatal Health in Under-Served Remote Areas in Sub-Saharan Africa: A Tanzanian Model	PLOS ONE			English	Article							EMERGENCY OBSTETRIC CARE; NONPHYSICIAN CLINICIAN; SERVICES	Background In Tanzania, maternal mortality ratio (MMR), unmet need for emergency obstetric care and health inequities across the country are in a critical state, particularly in rural areas. This study was established to determine the feasibility and impact of decentralizing comprehensive emergency obstetric and neonatal care (CEmONC) services in underserved rural areas using associate clinicians. Methods Ten health centres (HCs) were upgraded by constructing and equipping maternity blocks, operating rooms, laboratories, staff houses and installing solar panels, standby generators and water supply systems. Twenty-three assistant medical officers (advanced level associate clinicians), and forty-four nurse-midwives and clinical officers (associate clinicians) were trained in CEmONC and anaesthesia respectively. CEmONC services were launched between 2009 and 2012. Monthly supportive supervision and clinical audits of adverse pregnancy outcomes were introduced in 2011 in these HCs and their respective district hospitals. Findings After launching CEmONC services from 2009 to 2014 institutional deliveries increased in all upgraded rural HCs. Mean numbers of monthly deliveries increased by 151% and obstetric referrals decreased from 9% to 3% (p = 0.03) in HCs. A total of 43,846 deliveries and 2,890 caesarean sections (CS) were performed in these HCs making the mean proportion of all births in EmONC facilities of 128% and mean population-based CS rate of 9%. There were 190 maternal deaths and 1,198 intrapartum and very early neonatal deaths (IVEND) in all health facilities. Generally, health centres had statistically significantly lower maternal mortality ratios and IVEND rates than district hospitals (p < 0.00 and < 0.02 respectively). Of all deaths (maternal and IVEND) 84% to 96% were considered avoidable. Conclusions These findings strongly indicate that remotely located health centres in resource limited settings hold a great potential to increase accessibility to CEmONC services and to improve maternal and perinatal health.	[Nyamtema, Angelo S.; Mwakatundu, Nguke; Dominico, Sunday; Mohamed, Hamed; Pemba, Senga; Rumanyika, Richard; Kairuki, Clementina; Kassiga, Irene; Shayo, Allan; Issa, Omary; Nzabuhakwa, Calist; Lyimo, Chagi; van Roosmalen, Jos] World Lung Fdn, Maternal Hlth Project, Dar Es Salaam, Tanzania; [Nyamtema, Angelo S.; Pemba, Senga; Shayo, Allan] Tanzanian Training Ctr Int Hlth, Ifakara, Tanzania; [Nyamtema, Angelo S.; Pemba, Senga] St Francis Univ, Coll Hlth & Allied Sci, Ifakara, Tanzania; [Rumanyika, Richard] Catholic Univ Hlth & Allied Sci, Dept Obstet & Gynaecol, Mwanza, Tanzania; [Kairuki, Clementina] Hubert Kairuki Mem Univ, Dar Es Salaam, Tanzania; [Kassiga, Irene] St Francis Referral Hosp, Dept Obstet & Gynaecol, Ifakara, Tanzania; [van Roosmalen, Jos] Leiden Univ, Dept Obstet, Med Ctr, Leiden, Netherlands; [van Roosmalen, Jos] Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Nyamtema, AS (corresponding author), World Lung Fdn, Maternal Hlth Project, Dar Es Salaam, Tanzania.; Nyamtema, AS (corresponding author), Tanzanian Training Ctr Int Hlth, Ifakara, Tanzania.; Nyamtema, AS (corresponding author), St Francis Univ, Coll Hlth & Allied Sci, Ifakara, Tanzania.	nyamtema_angelo@yahoo.co.uk	Richardson, Mary/M-9299-2016		Bloomberg Philanthropies; WorldLung Foundation-Maternal Health Project; Foundation H&B Agerup through the WorldLung Foundation-Maternal Health Project	Bloomberg Philanthropies; WorldLung Foundation-Maternal Health Project; Foundation H&B Agerup through the WorldLung Foundation-Maternal Health Project	This project was co-funded by Bloomberg Philanthropies and Foundation H&B Agerup through the WorldLung Foundation-Maternal Health Project whose URL is http://www.worldlungfoundation.org which was the implementer. The URL for Bloomberg Philanthropies is http://www.bloomberg.org and for Foundation H&B Agerup is www.fondationhbagerup.org. NM received the fund on behalf of The WorldLung Foundation-Maternal Health Project which had full control of all primary data. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afari H, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005052; Afnan-Holmes H, 2015, LANCET GLOB HEALTH, V3, pE396, DOI 10.1016/S2214-109X(15)00059-5; Bankana B, 2003, INT J GYNECOL OBSTET, V83, P112, DOI 10.1016/S0020-7292(03)00187-5; CDC, 2014, RED MAT MORT TANZ SE; Dangal G., 2014, NEPAL J OBSTET GYNEC, V17, P8; Djan JO, 1997, INT J GYNECOL OBSTET, V59, pS83, DOI 10.1016/S0020-7292(97)00151-3; Essendi H, 2011, J URBAN HEALTH, V88, P356, DOI 10.1007/s11524-010-9481-1; Joint Learning Initiative, 2004, HUM RES HLTH OV CRIS, P13; Knight HE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063846; Kruk ME, 2009, AM J PUBLIC HEALTH, V99, P1666, DOI 10.2105/AJPH.2008.146209; Kwesigabo G, 2012, J PUBLIC HEALTH POL, V33, pS35, DOI 10.1057/jphp.2012.55; Ministry of Health and Social Welfare (MoHSW), TANZ SERV AV READ AS; Ministry of Health & Social Welfare, 2008, NORM DIAGN TRAT CHAG, P1; Mucunguzi S, 2014, AFR J REPROD HEALTH, V18, P87; Mullan F, 2007, LANCET, V370, P2158, DOI 10.1016/S0140-6736(07)60785-5; Murray SF, 2006, SOC SCI MED, V62, P2205, DOI 10.1016/j.socscimed.2005.10.025; National Academy of Engineering Public Information on Noise Control, 2010, TANZ DEM HLTH SURV, P131; National Bureau of Statistics, 2012 TANZ POP HOUS C; Nyamtema AS, 2011, HUM RESOUR HEALTH, V9, DOI 10.1186/1478-4491-9-28; Nyamtema AS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-30; Paxton A, 2006, INT J GYNECOL OBSTET, V95, P192, DOI 10.1016/j.ijgo.2006.08.009; Pereira C, 2007, BJOG-INT J OBSTET GY, V114, P1530, DOI 10.1111/j.1471-0528.2007.01489.x; Remme JHF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1001000; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Sabitu K, 1997, INT J GYNECOL OBSTET, V59, pS99, DOI 10.1016/S0020-7292(97)00153-7; Sudhof L, 2013, TROP MED INT HEALTH, V18, P18, DOI 10.1111/tmi.12016; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; UNICEF WHO, 2014, WORLD BANK UN POP DI; WHO, 2009, MON EM OBST CAR; WHO, 2014, TRENDS MAT MORT 1990; WHO, 1994, WHOFHEMSM9411; WHO, 2000, OP RES REPR HLTH; WHO, 2008, TASK SHIFT GLOB REC; World Health Organization, 2014, WORLD HLTH STAT 2013; World Health Organization, 2008, MIDL HLTH WORK STAT; World Health Organization, 2012, WHO REC OPT HLTH WOR	36	34	34	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2016	11	3							e0151419	10.1371/journal.pone.0151419	http://dx.doi.org/10.1371/journal.pone.0151419			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DH1YG	26986725	Green Published, gold			2023-01-03	WOS:000372580300069
J	Ledermann, JA; Embleton, AC; Raja, F; Perren, TJ; Jayson, GC; Rustin, GJS; Kaye, SB; Hirte, H; Eisenhauer, E; Vaughan, M; Friedlander, M; Gonzalez-Martin, A; Stark, D; Clark, E; Farrelly, L; Swart, AM; Cook, A; Kaplan, RS; Parmar, MKB				Ledermann, Jonathan A.; Embleton, Andrew C.; Raja, Fharat; Perren, Timothy J.; Jayson, Gordon C.; Rustin, Gordon J. S.; Kaye, Stan B.; Hirte, Hal; Eisenhauer, Elizabeth; Vaughan, Michelle; Friedlander, Michael; Gonzalez-Martin, Antonio; Stark, Daniel; Clark, Elizabeth; Farrelly, Laura; Swart, Ann Marie; Cook, Adrian; Kaplan, Richard S.; Parmar, Mahesh K. B.		ICON6 Collaborators	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial	LANCET			English	Article							RECURRENT OVARIAN; CHEMOTHERAPY; BEVACIZUMAB; CARBOPLATIN; COMBINATION; PACLITAXEL; MONOTHERAPY; PERITONEAL; GROWTH	Background Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer. Methods In this randomised, three-arm, double-blind, placebo-controlled phase 3 trial, we randomly assigned patients aged 18 years or older with relapsed platinum-sensitive ovarian cancer at 63 centres in Australia, Canada, New Zealand, Spain, and the UK. Participants received up to six cycles of platinum-based chemotherapy (once every 3 weeks) then entered a maintenance phase. Participants were randomly allocated (2: 3: 3), with five stratification factors and in alternating blocks, to receive placebo alongside chemotherapy and then placebo only maintenance (arm A; reference), cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B; concurrent), or cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C; maintenance). Patients continued treatment to progression or excessive toxic effects. The primary efficacy endpoint was progression-free survival between arms A and C. Efficacy analysis was by intention to treat. Safety was assessed in all patients who received the allocated study drug. This trial is registered with ClinicalTrials.gov, number NCT00532194; the ISRCTN registry, number ISRCTN68510403; and ANZ Clinical Trials Registry, number ACTRN1261000016003. Findings We randomly assigned 456 women between Nov 13, 2007, and Dec 23, 2011; results presented are for 456 patients randomly assigned subsequent to the 30mg safety phase. During a median of 19.5 months (IQR 14-26) follow-up, 113 (96%) of 118 women assigned to arm A and 141 (86%) of 164 assigned to arm C had disease progression. Median progression-free survival was 11.0 months (95% CI 10.4-11.7) in arm C and 8.7 months (7.7-9.z4) in arm A (hazard ratio 0.56, 0.44-0.72, p< 0.0001). 156 (90%) of 174 patients in arm B had disease progression, and median progression-free survival was 9.9 months (95% CI 9.4-10.5). Diarrhoea, neutropenia, hypertension, and voice changes were significantly more common, during chemotherapy with cediranib, and diarrhoea, hypothyroidism and voice changes were more common during maintenance. Poor compliance with cediranib was noted during maintenance treatment with toxic effects being the most common cause for discontinuation. Interpretation Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with added toxic effects. The positive results in ICON6 could provide women with a new therapeutic option for recurrent ovarian cancer. Assessment of the secondary endpoint of overall survival will need longer follow-up. Copyright (c) Ledermann et al. Open Access article distributed under the terms of CC BY.	[Ledermann, Jonathan A.] UCL, Canc Res UK, London W1T 4TJ, England; [Ledermann, Jonathan A.] UCL, UCL Canc Trials Ctr, London W1T 4TJ, England; [Ledermann, Jonathan A.] UCL Hosp, London, England; [Embleton, Andrew C.; Clark, Elizabeth; Farrelly, Laura; Cook, Adrian; Kaplan, Richard S.; Parmar, Mahesh K. B.] UCL, MRC, Clin Trials Unit UCL, London W1T 4TJ, England; [Raja, Fharat] Univ Coll London Hosp, London, England; [Perren, Timothy J.] St Jamess Inst Oncol, Leeds, W Yorkshire, England; [Perren, Timothy J.] Leeds Inst Canc Med & Pathol, Leeds, W Yorkshire, England; [Jayson, Gordon C.] Christie Hosp, Manchester, Lancs, England; [Jayson, Gordon C.] Univ Manchester, Manchester, Lancs, England; [Rustin, Gordon J. S.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Kaye, Stan B.] Royal Marsden Hosp, London SW3 6JJ, England; [Hirte, Hal] Juravinski Canc Ctr, Hamilton, ON, Canada; [Hirte, Hal] McMaster Univ, Hamilton, ON, Canada; [Eisenhauer, Elizabeth] Canadian Canc Trials Grp CCTG, Kingston, ON, Canada; [Eisenhauer, Elizabeth] Queens Univ, Kingston, ON, Canada; [Vaughan, Michelle] Christchurch Hosp, Christchurch, New Zealand; [Friedlander, Michael] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Gonzalez-Martin, Antonio] Spanish Grp Invest Ovarian Canc GEICO, Madrid, Spain; [Gonzalez-Martin, Antonio] MD Anderson Canc Ctr Madrid, Madrid, Spain; [Stark, Daniel] Univ Leeds, Leeds, W Yorkshire, England; [Swart, Ann Marie] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	Cancer Research UK; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Medical Research Council Clinical Trials Unit; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Saint James's University Hospital; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Mount Vernon Cancer Centre; Royal Marsden NHS Foundation Trust; McMaster University; McMaster University; Queens University - Canada; Christchurch Hospital New Zealand; University of New South Wales Sydney; University of Texas System; UTMD Anderson Cancer Center; University of Leeds; University of East Anglia	Ledermann, JA (corresponding author), UCL, Inst Canc, Canc Res UK, London W1T 4TJ, England.; Ledermann, JA (corresponding author), UCL, Inst Canc, UCL Canc Trials Ctr, London W1T 4TJ, England.	j.ledermann@ucl.ac.uk	Martín, Antonio González/AAC-5935-2020; Perren, Timothy J/D-5387-2013; Rustin, Gordon J. S./J-9763-2019; Jayson, Gordon/O-8224-2015	Martín, Antonio González/0000-0001-8376-9576; Perren, Timothy J/0000-0001-8472-8856; Embleton-Thirsk, Andrew/0000-0001-9402-8132; Earl, Helena/0000-0003-1549-8094; friedlander, michael/0000-0003-3090-795X; Kaplan, Richard S./0000-0002-0189-8348; Jayson, Gordon/0000-0002-8515-8944	Medical Research Council; Cancer Research UK; Canadian Cancer Society Research Institute; Cancer Australia; National Gynecological Cancer Centre; AstraZeneca; Cancer Research UK [CRUK/07/025]; Canadian Cancer Society Research Institute [015469, 021039]; Cancer Australia [APP1006602]; MRC [MC_UU_12023/28, MC_U122861379, MC_UU_12023/9] Funding Source: UKRI; Cancer Research UK [6862] Funding Source: researchfish; Medical Research Council [MR/K006584/1, MC_UU_12023/28, MC_UU_12023/9, MC_U122861379] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Australia; National Gynecological Cancer Centre; AstraZeneca(AstraZeneca); Cancer Research UK(Cancer Research UK); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Australia; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Medical Research Council, Cancer Research UK, Canadian Cancer Society Research Institute, Cancer Australia, National Gynecological Cancer Centre, and AstraZeneca.; The trial was funded by the Medical Research Council, Cancer Research UK (CRUK/07/025), Canadian Cancer Society Research Institute (015469 and 021039), Cancer Australia (APP1006602) and National Gynecological Cancer Centre, and AstraZeneca. The trial is registered with the ISRCTN registry, number ISRCTN68510403; ClinicalTrials.gov, number NCT00532194; and ANZ Clinical Trials Registry, number ACTRN1261000016003. ICON6 was managed by the Medical Research Council Clinical Trials Unit at University College London and employees were central to the completion of the trial and the development of this manuscript. I Tannock (Princess Margaret Cancer Centre, Toronto, ON, Canada) provided a critical review of the manuscript. See appendix for a full list of collaborators.	Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505; Batchelor TT, 2013, J CLIN ONCOL, V31, P3212, DOI 10.1200/JCO.2012.47.2464; Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Coleman RL, 2015, GYNECOL ONCOL, V137, P3, DOI 10.1016/j.ygyno.2015.01.005; du Bois A, 2013, INT J GYNECOL CANCER, V23; du Bois A, 2014, J CLIN ONCOL, V32, P3374, DOI 10.1200/JCO.2014.55.7348; Goss GD, 2010, J CLIN ONCOL, V28, P49, DOI 10.1200/JCO.2009.22.9427; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kummar S, 2013, J CLIN ONCOL, V31, P2296, DOI 10.1200/JCO.2012.47.4288; Laurie SA, 2014, EUR J CANCER, V50, P706, DOI 10.1016/j.ejca.2013.11.032; Ledermann JA, 2013, EUR J CANCER, V49, pS5; Matulonis UA, 2009, J CLIN ONCOL, V27, P5601, DOI 10.1200/JCO.2009.23.2777; Mulders P, 2012, EUR J CANCER, V48, P527, DOI 10.1016/j.ejca.2011.12.022; Parmar MKB, 2003, LANCET, V361, P2099; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Raja FA, 2011, BRIT J CANCER, V105, P884, DOI 10.1038/bjc.2011.334; Royston P, 2011, STAT MED, V30, P2409, DOI 10.1002/sim.4274; Schmidinger Manuela, 2013, EJC Suppl, V11, P172, DOI 10.1016/j.ejcsup.2013.07.016; Symonds RP, 2015, LANCET ONCOL, V16, P1515, DOI 10.1016/S1470-2045(15)00220-X; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Valle JW, 2015, LANCET ONCOL, V16, P967, DOI 10.1016/S1470-2045(15)00139-4; Wagner U, 2012, BRIT J CANCER, V107, P588, DOI 10.1038/bjc.2012.307; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409	30	166	177	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	2016	387	10023					1066	1074		10.1016/S0140-6736(15)01167-8	http://dx.doi.org/10.1016/S0140-6736(15)01167-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG0SD	27025186	Green Accepted, hybrid, Green Published, Green Submitted			2023-01-03	WOS:000371775000026
J	Wakayama, T; Suzuki, M; Tanuma, T				Wakayama, Tadashi; Suzuki, Masaaki; Tanuma, Tadashi			Effect of Nasal Obstruction on Continuous Positive Airway Pressure Treatment: Computational Fluid Dynamics Analyses	PLOS ONE			English	Article							SLEEP-APNEA; FLOW; MODEL	Objective Nasal obstruction is a common problem in continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea and limits treatment compliance. The purpose of this study is to model the effects of nasal obstruction on airflow parameters under CPAP using computational fluid dynamics (CFD), and to clarify quantitatively the relation between airflow velocity and pressure loss coefficient in subjects with and without nasal obstruction. Methods We conducted an observational cross-sectional study of 16 Japanese adult subjects, of whom 9 had nasal obstruction and 7 did not (control group). Three-dimensional reconstructed models of the nasal cavity and nasopharynx with a CPAP mask fitted to the nostrils were created from each subject's CT scans. The digital models were meshed with tetrahedral cells and stereolithography formats were created. CPAP airflow simulations were conducted using CFD software. Airflow streamlines and velocity contours in the nasal cavities and nasopharynx were compared between groups. Simulation models were confirmed to agree with actual measurements of nasal flow rate and with pressure and flow rate in the CPAP machine. Results Under 10 cmH(2)O CPAP, average maximum airflow velocity during inspiration was 17.6 +/- 5.6 m/s in the nasal obstruction group but only 11.8 +/- 1.4 m/s in the control group. The average pressure drop in the nasopharynx relative to inlet static pressure was 2.44 +/- 1.41 cmH(2)O in the nasal obstruction group but only 1.17 +/- 0.29 cmH(2)O in the control group. The nasal obstruction and control groups were clearly separated by a velocity threshold of 13.5 m/s, and pressure loss coefficient threshold of approximately 10.0. In contrast, there was no significant difference in expiratory pressure in the nasopharynx between the groups. Conclusion This is the first CFD analysis of the effect of nasal obstruction on CPAP treatment. A strong correlation between the inspiratory pressure loss coefficient and maximum airflow velocity was found.	[Wakayama, Tadashi] Teikyo Univ, Dept Otolaryngol, Tokyo, Japan; [Suzuki, Masaaki] Teikyo Univ, Chiba Med Ctr, Dept Otolaryngol, Chiba, Japan; [Tanuma, Tadashi] Teikyo Univ, Joint Program Ctr, Dept Appl Fluid Dynam & Energy Machinery Syst, Tokyo 173, Japan	Teikyo University; Teikyo University; Teikyo University	Suzuki, M (corresponding author), Teikyo Univ, Chiba Med Ctr, Dept Otolaryngol, Chiba, Japan.	suzukima@med.teikyo-u.ac.jp						Chen XB, 2009, LARYNGOSCOPE, V119, P1730, DOI 10.1002/lary.20585; Cisonni J, 2013, J BIOMECH, V46, P2504, DOI 10.1016/j.jbiomech.2013.07.007; Garcia GJM, 2007, J APPL PHYSIOL, V103, P1082, DOI 10.1152/japplphysiol.01118.2006; Kushida CA, 2006, SLEEP, V29, P375, DOI 10.1093/sleep/29.3.375; Lee HP, 2009, AM J RHINOL ALLERGY, V23, P153, DOI 10.2500/ajra.2009.23.3287; Persak SC, 2011, J APPL PHYSIOL, V111, P1819, DOI 10.1152/japplphysiol.01230.2010; Peter B, 2011, PRINCIPLES PRACTICE, P1233; Rhee JS, 2011, ARCH FACIAL PLAST S, V13, P305, DOI 10.1001/archfacial.2011.18; Stuck BA, 2007, SLEEP, V30, P506, DOI 10.1093/sleep/30.4.506; Stuck BA, 2006, NEUROSCI LETT, V406, P222, DOI 10.1016/j.neulet.2006.07.068; Suzuki M, 2015, J CLIN SLEEP MED, V11, P855, DOI 10.5664/jcsm.4932; Tanuma T, 2013, EVALUATIONS STEADY U, P179; Tanuma T, 2012, EVALUATIONS FLUID DY, P179; Togawa K, 1985, QUANTIFICATION RHINO, P125; Wexler D, 2005, ARCH OTOLARYNGOL, V131, P1102, DOI 10.1001/archotol.131.12.1102; Zhao K, 2006, AM J RHINOL, V20, P308, DOI 10.2500/ajr.2006.20.2848; Zhao MY, 2013, J BIOMECH, V46, P142, DOI 10.1016/j.jbiomech.2012.10.033	17	19	19	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2016	11	3							e0150951	10.1371/journal.pone.0150951	http://dx.doi.org/10.1371/journal.pone.0150951			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG0FG	26943335	Green Published, gold, Green Submitted			2023-01-03	WOS:000371739400066
J	Wallis, CJD; Mahar, AL; Choo, R; Herschorn, S; Kodama, RT; Shah, PS; Danjoux, C; Narod, SA; Nam, RK				Wallis, Christopher J. D.; Mahar, Alyson L.; Choo, Richard; Herschorn, Sender; Kodama, Ronald T.; Shah, Prakesh S.; Danjoux, Cyril; Narod, Steven A.; Nam, Robert K.			Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RADICAL PROSTATECTOMY; RADIATION-THERAPY; BLADDER-CANCER; INCREASED RISK; COMPLICATIONS; BRACHYTHERAPY; OUTCOMES; MEN; ASSOCIATION; IMPACT	Objective To determine the association between exposure to radiotherapy for the treatment of prostate cancer and subsequent second malignancies (second primary cancers). Design Systematic review and meta-analysis of observational studies. Data sources Medline and Embase up to 6 April 2015 with no restrictions on year or language. Study selection Comparative studies assessing the risk of second malignancies in patients exposed or unexposed to radiotherapy in the course of treatment for prostate cancer were selected by two reviewers independently with any disagreement resolved by consensus. Data extraction and synthesis Two reviewers independently extracted study characteristics and outcomes. Risk of bias was assessed with the New-castle-Ottawa scale. Outcomes were synthesized with random effects models and Mantel-Haenszel weighting. Unadjusted odds ratios and multivariable adjusted hazard ratios, when available, were pooled. Main outcome measures Second cancers of the bladder, colorectal tract, rectum, lung, and hematologic system. Results Of 3056 references retrieved, 21 studies were selected for analysis. Most included studies were large multi-institutional reports but had moderate risk of bias. The most common type of radiotherapy was external beam; 13 studies used patients treated with surgery as controls and eight used patients who did not undergo radiotherapy as controls. The length of follow-up among studies varied. There was increased risk of cancers of the bladder (four studies; adjusted hazard ratio 1.67, 95% confidence interval 1.55 to 1.80), colorectum (three studies; 1.79, 1.34 to 2.38), and rectum (three studies; 1.79, 1.34 to 2.38), but not cancers of the hematologic system (one study; 1.64, 0.90 to 2.99) or lung (two studies; 1.45, 0.70 to 3.01), after radiotherapy compared with the risk in those unexposed to radiotherapy. The odds of a second cancer varied depending on type of radiotherapy: treatment with external beam radiotherapy was consistently associated with increased odds while brachytherapy was not. Among the patients who underwent radiotherapy, from individual studies, the highest absolute rates reported for bladder, colorectal, and rectal cancers were 3.8%, 4.2%, and 1.2%, respectively, while the lowest reported rates were 0.1%, 0.3%, and 0.3%. Conclusion Radiotherapy for prostate cancer was associated with higher risks of developing second malignancies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low. Further studies with longer follow-up are required to confirm these findings.	[Wallis, Christopher J. D.; Mahar, Alyson L.; Herschorn, Sender; Kodama, Ronald T.; Nam, Robert K.] Univ Toronto, Sunnybrook Res Inst, Div Urol, Sunnybrook Hlth Sci Ctr, Room MG-406,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Wallis, Christopher J. D.; Shah, Prakesh S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Suite 425,155 Coll St, Toronto, ON M5T 3M6, Canada; [Choo, Richard] Mayo Clin, Dept Radiat Oncol, 200 1st St Southwest, Rochester, MN 55902 USA; [Shah, Prakesh S.] Univ Toronto, Mt Sinai Hosp, Dept Pediat, 600 Univ Ave, Toronto, ON M5G 1X5, Canada; [Danjoux, Cyril] Univ Toronto, Sunnybrook Res Inst, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Room MG-406,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Narod, Steven A.] Univ Toronto, Dept Publ Hlth Sci, 7th Floor,790 Bay St, Toronto, ON M5G 1N8, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Mayo Clinic; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Nam, RK (corresponding author), Univ Toronto, Sunnybrook Res Inst, Div Urol, Sunnybrook Hlth Sci Ctr, Room MG-406,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Robert.nam@utoronto.ca	Narod, Steven A/AAA-6112-2022; Shah, Prakesh S/I-8098-2013; Shah, Prakesh/AAA-9884-2020	Mahar, Alyson/0000-0002-6862-3760	Ajmera Family chair in urologic oncology award; Canadian Institutes of Health Research	Ajmera Family chair in urologic oncology award; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by the Ajmera Family chair in urologic oncology awarded to RKN. The funder had no input in the design or conduct of the study, the interpretation of the results, the preparation of the manuscript or the decision to submit for publication. PS is supported by an applied research chair in reproductive and child health services and policy research from the Canadian Institutes of Health Research.	Abdel-Wahab M, 2008, INT J RADIAT ONCOL, V72, P58, DOI 10.1016/j.ijrobp.2007.12.043; Abern MR, 2013, UROL ONCOL-SEMIN ORI, V31, P1628, DOI 10.1016/j.urolonc.2012.04.006; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Baxter NN, 2005, GASTROENTEROLOGY, V128, P819, DOI 10.1053/j.gastro.2004.12.038; Bhojani N, 2010, INT J RADIAT ONCOL, V76, P342, DOI 10.1016/j.ijrobp.2009.02.011; Boorjian S, 2007, J UROLOGY, V177, P883, DOI 10.1016/j.juro.2006.10.071; Bostrom PJ, 2007, EUR UROL, V52, P973, DOI 10.1016/j.eururo.2007.07.002; Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V; CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7; Davis EJ, 2014, CANCER-AM CANCER SOC, V120, P2735, DOI 10.1002/cncr.28769; de Gonzalez AB, 2011, LANCET ONCOL, V12, P353, DOI 10.1016/S1470-2045(11)70061-4; Deeks J J, 2003, Health Technol Assess, V7, piii; Engeland A, 2003, BRIT J CANCER, V89, P1237, DOI 10.1038/sj.bjc.6601206; Frezza EE, 2006, GUT, V55, P285, DOI 10.1136/gut.2005.073163; Frieben H, 1902, ROFO FORTSCHR RONTG, V6, P106; Goldstraw MA, 2006, BJU INT, V98, P489, DOI 10.1111/j.1464-410X.2006.06288.x; Heidenreich A, 2014, EUR UROL, V65, P124, DOI 10.1016/j.eururo.2013.09.046; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hinnen KA, 2011, J CLIN ONCOL, V29, P4510, DOI 10.1200/JCO.2011.35.0991; Huang JY, 2011, RADIOTHER ONCOL, V98, P81, DOI 10.1016/j.radonc.2010.09.012; Huo DZ, 2009, CANCER EPIDEM BIOMAR, V18, P1979, DOI 10.1158/1055-9965.EPI-09-0241; Jin T, 2014, UROL INT, V93, P279, DOI 10.1159/000356115; Kendal WS, 2008, INT J RADIAT ONCOL, V70, P1294, DOI 10.1016/j.ijrobp.2008.01.001; Kendal WS, 2006, INT J RADIAT ONCOL, V65, P661, DOI 10.1016/j.ijrobp.2005.11.013; Lehnert BE, 1997, CANCER RES, V57, P2164; Margel D, 2011, ANN SURG, V254, P947, DOI 10.1097/SLA.0b013e3182382fd5; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Moon K, 2006, CANCER-AM CANCER SOC, V107, P991, DOI 10.1002/cncr.22083; Muller AC, 2007, STRAHLENTHER ONKOL, V183, P605, DOI 10.1007/s00066-007-1786-y; Murray EM, 1999, INT J RADIAT ONCOL, V45, P951, DOI 10.1016/S0360-3016(99)00279-5; Murray L, 2014, RADIOTHER ONCOL, V110, P213, DOI 10.1016/j.radonc.2013.12.012; Nam RK, 2014, LANCET ONCOL, V15, P223, DOI 10.1016/S1470-2045(13)70606-5; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Nguyen PL, 2011, J CLIN ONCOL, V29, P1517, DOI 10.1200/JCO.2010.31.1217; Nieder AM, 2008, J UROLOGY, V180, P2005, DOI 10.1016/j.juro.2008.07.038; Overholser L, 2010, J GEN INTERN MED, V25, P527; Pickles T, 2002, RADIOTHER ONCOL, V65, P145, DOI 10.1016/S0167-8140(02)00307-9; Potosky AL, 2004, J NATL CANCER I, V96, P1358, DOI 10.1093/jnci/djh259; Rapiti E, 2008, INT J CANCER, V123, P1141, DOI 10.1002/ijc.23601; Resnick MJ, 2013, NEW ENGL J MED, V368, P436, DOI 10.1056/NEJMoa1209978; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; Sale KA, 2004, OTOLARYNG HEAD NECK, V131, P643, DOI 10.1016/j.otohns.2004.05.012; Singh A, 2008, J UROLOGY, V179, pS2, DOI 10.1016/j.juro.2008.03.130; Singh AK, 2010, INT J RADIAT ONCOL, V78, P1086, DOI 10.1016/j.ijrobp.2009.09.055; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Takam R, 2009, PHYS MED BIOL, V54, P611, DOI 10.1088/0031-9155/54/3/009; Van Hemelrijck M, 2014, EUR J CANCER, V50, pS230, DOI 10.1016/S0959-8049(14)50838-6; Wallis CJD, 2015, BRIT J CANCER, V112, P977, DOI 10.1038/bjc.2015.54; Wallis CJD, 2015, UROLOGY, V85, P621, DOI 10.1016/j.urology.2014.11.037; Wells GA, 2011, THE NEWCASTLE OTTAWA; Zelefsky MJ, 2012, BJU INT, V110, P1696, DOI 10.1111/j.1464-410X.2012.11385.x	52	122	123	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	2016	352								i851	10.1136/bmj.i851	http://dx.doi.org/10.1136/bmj.i851			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG0LN	26936410	Green Published, hybrid			2023-01-03	WOS:000371756500004
J	Kazior, Z; Willis, SJ; Moberg, M; Apro, W; Calbet, JAL; Holmberg, HC; Blomstrand, E				Kazior, Zuzanna; Willis, Sarah J.; Moberg, Marcus; Apro, William; Calbet, Jose A. L.; Holmberg, Hans-Christer; Blomstrand, Eva			Endurance Exercise Enhances the Effect of Strength Training on Muscle Fiber Size and Protein Expression of Akt and mTOR	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; RESISTANCE EXERCISE; MESSENGER-RNA; ADENOSINE TRIPHOSPHATASE; CONTRACTILE ACTIVITY; CONCURRENT EXERCISE; MOLECULAR-BASES; KINASE-ACTIVITY; TIME-COURSE; HYPERTROPHY	Reports concerning the effect of endurance exercise on the anabolic response to strength training have been contradictory. This study re-investigated this issue, focusing on training effects on indicators of protein synthesis and degradation. Two groups of male subjects performed 7 weeks of resistance exercise alone (R; n = 7) or in combination with preceding endurance exercise, including both continuous and interval cycling (ER; n = 9). Muscle biopsies were taken before and after the training period. Similar increases in leg-press 1 repetition maximum (30%; P< 0.05) were observed in both groups, whereas maximal oxygen uptake was elevated (8%; P< 0.05) only in the ER group. The ER training enlarged the areas of both type I and type II fibers, whereas the R protocol increased only the type II fibers. The mean fiber area increased by 28% (P< 0.05) in the ER group, whereas no significant increase was observed in the R group. Moreover, expression of Akt and mTOR protein was enhanced in the ER group, whereas only the level of mTOR was elevated following R training. Training-induced alterations in the levels of both Akt and mTOR protein were correlated to changes in type I fiber area (r = 0.55-0.61, P< 0.05), as well as mean fiber area (r = 0.55-0.61, P< 0.05), reflecting the important role played by these proteins in connection with muscle hypertrophy. Both training regimes reduced the level of MAFbx protein (P< 0.05) and tended to elevate that of MuRF-1. The present findings indicate that the larger hypertrophy observed in the ER group is due more to pronounced stimulation of anabolic rather than inhibition of catabolic processes.	[Kazior, Zuzanna; Willis, Sarah J.; Holmberg, Hans-Christer] Mid Sweden Univ, Dept Hlth Sci, Swedish Winter Sports Res Ctr, Ostersund, Sweden; [Moberg, Marcus; Apro, William; Blomstrand, Eva] Swedish Sch Sport & Hlth Sci, Stockholm, Sweden; [Calbet, Jose A. L.] Univ Las Palmas Gran Canaria, Dept Phys Educ, Las Palmas Gran Canaria, Spain; [Calbet, Jose A. L.] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Campus Univ Tafira S-N, Las Palmas Gran Canaria, Canary Island, Spain	Mid-Sweden University; Swedish School of Sport & Health Sciences; Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria	Blomstrand, E (corresponding author), Swedish Sch Sport & Hlth Sci, Stockholm, Sweden.	eva.blomstrand@gih.se	Calbet, Jose A L/H-6693-2015; Moberg, Marcus/AAU-5487-2021; Apro, William/AAZ-4717-2020	Calbet, Jose A L/0000-0002-9215-6234; Moberg, Marcus/0000-0003-3747-0148; Holmberg, Hans-Christer/0000-0002-3814-6246; Apro, William/0000-0003-1942-2919; Willis, Sarah/0000-0002-0150-3182; antunez, Ariel/0000-0002-2548-7885	Swedish National Centre for Research in Sports [55-351/10]	Swedish National Centre for Research in Sports	This study was supported by funding from the Swedish National Centre for Research in Sports to HCH (55-351/10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; ANDERSEN P, 1975, ACTA PHYSIOL SCAND, V95, P203, DOI 10.1111/j.1748-1716.1975.tb10043.x; ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; Apro W, 2015, AM J PHYSIOL-ENDOC M, V308, pE470, DOI 10.1152/ajpendo.00486.2014; Apro W, 2013, AM J PHYSIOL-ENDOC M, V305, pE22, DOI 10.1152/ajpendo.00091.2013; Baechle TR, 2008, ESSENTIALS STRENGTH, V3rd; Benziane B, 2008, AM J PHYSIOL-ENDOC M, V295, pE1427, DOI 10.1152/ajpendo.90428.2008; Bergstrom J, 1962, SCAND J CLIN LAB INV; BLOMSTRAND E, 1982, ACTA PHYSIOL SCAND, V116, P437, DOI 10.1111/j.1748-1716.1982.tb07163.x; BLOMSTRAND E, 1984, ACTA PHYSIOL SCAND, V122, P545, DOI 10.1111/j.1748-1716.1984.tb07543.x; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bodine SC, 2014, AM J PHYSIOL-ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Borgenvik M, 2012, AM J PHYSIOL-ENDOC M, V302, pE510, DOI 10.1152/ajpendo.00353.2011; Borsheim E, 2004, J APPL PHYSIOL, V96, P674, DOI 10.1152/japplphysiol.00333.2003; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; BROOKE MH, 1969, J HISTOCHEM CYTOCHEM, V17, P431, DOI 10.1177/17.6.431; Camera DM, 2015, MED SCI SPORT EXER, V47, P82, DOI 10.1249/MSS.0000000000000390; Camera DM, 2010, MED SCI SPORT EXER, V42, P1843, DOI 10.1249/MSS.0b013e3181d964e4; Carrithers JA, 2007, AVIAT SPACE ENVIR MD, V78, P457; Chen ZP, 2003, DIABETES, V52, P2205, DOI 10.2337/diabetes.52.9.2205; Churchley EG, 2007, J APPL PHYSIOL, V102, P1604, DOI 10.1152/japplphysiol.01260.2006; Coffey VG, 2007, SPORTS MED, V37, P737, DOI 10.2165/00007256-200737090-00001; Coffey VG, 2009, AM J PHYSIOL-REG I, V297, pR1441, DOI 10.1152/ajpregu.00351.2009; Coffey VG, 2009, J APPL PHYSIOL, V106, P1187, DOI 10.1152/japplphysiol.91221.2008; Coffey VG, 2006, AM J PHYSIOL-ENDOC M, V290, pE849, DOI 10.1152/ajpendo.00299.2005; COSTILL DL, 1979, J APPL PHYSIOL, V46, P96, DOI 10.1152/jappl.1979.46.1.96; Deldicque L, 2008, EUR J APPL PHYSIOL, V104, P57, DOI 10.1007/s00421-008-0786-7; Drummond MJ, 2009, J APPL PHYSIOL, V106, P1403, DOI 10.1152/japplphysiol.90842.2008; Egerman MA, 2014, CRIT REV BIOCHEM MOL, V49, P59, DOI 10.3109/10409238.2013.857291; ESSEN B, 1975, ACTA PHYSIOL SCAND, V95, P153, DOI 10.1111/j.1748-1716.1975.tb10038.x; Fry AC, 2004, SPORTS MED, V34, P663, DOI 10.2165/00007256-200434100-00004; Fyfe JJ, 2014, SPORTS MED, V44, P743, DOI 10.1007/s40279-014-0162-1; Green H, 1999, AM J PHYSIOL-REG I, V276, pR591, DOI 10.1152/ajpregu.1999.276.2.R591; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hennessey JV, 1997, J APPL PHYSIOL, V82, P1739, DOI 10.1152/jappl.1997.82.6.1739; HICKSON RC, 1980, EUR J APPL PHYSIOL O, V45, P255, DOI 10.1007/BF00421333; JANSSON E, 1990, ACTA PHYSIOL SCAND, V140, P359, DOI 10.1111/j.1748-1716.1990.tb09010.x; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Lamas L, 2010, SCAND J MED SCI SPOR, V20, P216, DOI 10.1111/j.1600-0838.2009.00905.x; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Leveritt M, 1999, SPORTS MED, V28, P413, DOI 10.2165/00007256-199928060-00004; Louis E, 2007, J APPL PHYSIOL, V103, P1744, DOI 10.1152/japplphysiol.00679.2007; Lundberg TR, 2014, J APPL PHYSIOL, V116, P611, DOI 10.1152/japplphysiol.01082.2013; Lundberg TR, 2013, J APPL PHYSIOL, V114, P81, DOI 10.1152/japplphysiol.01013.2012; MacNeil LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109189; Mascher H, 2008, AM J PHYSIOL-ENDOC M, V294, pE43, DOI 10.1152/ajpendo.00504.2007; Perez-Gomez J, 2008, APPL PHYSIOL NUTR ME, V33, P501, DOI 10.1139/H08-026; Phillips SM, 2002, CAN J PHYSIOL PHARM, V80, P1045, DOI [10.1139/y02-134, 10.1139/Y02-134]; Phillips SM, 2014, SPORTS MED, V44, P71, DOI 10.1007/s40279-014-0152-3; Rahbek SK, 2014, AMINO ACIDS, V46, P2377, DOI 10.1007/s00726-014-1792-1; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Saltin B, 2010, COMPR PHYSIOL, P555; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SCHANTZ P, 1983, CLIN PHYSIOL, V3, P141, DOI 10.1111/j.1475-097X.1983.tb00685.x; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Tang JE, 2006, APPL PHYSIOL NUTR ME, V31, P495, DOI 10.1139/H06-026; Thorell A, 1999, AM J PHYSIOL-ENDOC M, V277, pE733, DOI 10.1152/ajpendo.1999.277.4.E733; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang L, 2011, J APPL PHYSIOL, V111, P1335, DOI 10.1152/japplphysiol.00086.2011; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Yu M, 2001, J APPL PHYSIOL, V90, P29, DOI 10.1152/jappl.2001.90.1.29	63	41	42	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2016	11	2							e0149082	10.1371/journal.pone.0149082	http://dx.doi.org/10.1371/journal.pone.0149082			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF3BJ	26885978	Green Published, Green Submitted, gold			2023-01-03	WOS:000371218400061
J	Balcazar-Lopez, E; Mendez-Lorenzo, LH; Batista-Garcia, RA; Esquivel-Naranjo, U; Ayala, M; Kumar, VV; Savary, O; Cabana, H; Herrera-Estrella, A; Folch-Mallol, JL				Balcazar-Lopez, Edgar; Helena Mendez-Lorenzo, Luz; Alberto Batista-Garcia, Ramon; Esquivel-Naranjo, Ulises; Ayala, Marcela; Kumar, Vaidyanathan Vinoth; Savary, Olivier; Cabana, Hubert; Herrera-Estrella, Alfredo; Luis Folch-Mallol, Jorge			Xenobiotic Compounds Degradation by Heterologous Expression of a Trametes sanguineus Laccase in Trichoderma atroviride	PLOS ONE			English	Article							FUNGAL LACCASES; REESEI; GENE	Fungal laccases are enzymes that have been studied because of their ability to decolorize and detoxify effluents; they are also used in paper bleaching, synthesis of polymers, bioremediation, etc. In this work we were able to express a laccase from Trametes (Pycnoporus) sanguineus in the filamentous fungus Trichoderma atroviride. For this purpose, a transformation vector was designed to integrate the gene of interest in an intergenic locus near the blu17 terminator region. Although monosporic selection was still necessary, stable integration at the desired locus was achieved. The native signal peptide from T. sanguineus laccase was successful to secrete the recombinant protein into the culture medium. The purified, heterologously expressed laccase maintained similar properties to those observed in the native enzyme (Km and kcat and kcat/km values for ABTS, thermostability, substrate range, pH optimum, etc). To determine the bioremediation potential of this modified strain, the laccase-overexpressing Trichoderma strain was used to remove xenobiotic compounds. Phenolic compounds present in industrial wastewater and bisphenol A (an endocrine disruptor) from the culture medium were more efficiently removed by this modified strain than with the wild type. In addition, the heterologously expressed laccase was able to decolorize different dyes as well as remove benzo[a] pyrene and phenanthrene in vitro, showing its potential for xenobiotic compound degradation.	[Balcazar-Lopez, Edgar; Helena Mendez-Lorenzo, Luz; Alberto Batista-Garcia, Ramon] Univ Autonoma Estado Morelos, Fac Ciencias, Av Univ 1001, Cuernavaca, Mor, Mexico; [Balcazar-Lopez, Edgar; Helena Mendez-Lorenzo, Luz; Alberto Batista-Garcia, Ramon; Luis Folch-Mallol, Jorge] Univ Autonoma Estado Morelos, Ctr Invest Biotecnol, Av Univ 1001, Cuernavaca, Morelos, Mexico; [Esquivel-Naranjo, Ulises] Univ Autonoma Queretaro, Fac Ciencias Nat, Unidad Microbiol Basica & Aplicada, Anillo Vial Fray Junipero Serra Km 8 S-N, Santiago De Qro 76000, Mexico; [Ayala, Marcela] Univ Nacl Autonoma Mexico, Inst Biotecnol, Av Univ 2001, Cuernavaca, Morelos, Mexico; [Kumar, Vaidyanathan Vinoth; Savary, Olivier; Cabana, Hubert] Univ Sherbrooke, Dept Civil Engn, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada; [Kumar, Vaidyanathan Vinoth] SRM Univ, Dept Biotechnol, Sch Bioengn, Bioproc Lab, Kattankulathur 603203, Tamil Nadu, India; [Herrera-Estrella, Alfredo] Lab Nacl Genom Biodiversidad, Cinvestav Campus Guanajuato,Km 9-6 Libramiento No, Irapuato 36821, Mexico	Universidad Autonoma del Estado de Morelos; Universidad Autonoma del Estado de Morelos; Universidad Autonoma de Queretaro; Universidad Nacional Autonoma de Mexico; University of Sherbrooke; SRM Institute of Science & Technology Chennai; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Folch-Mallol, JL (corresponding author), Univ Autonoma Estado Morelos, Ctr Invest Biotecnol, Av Univ 1001, Cuernavaca, Morelos, Mexico.	jordi@uaem.mx	Esquivel, Edgardo/GLR-3607-2022; Herrera-Estrella, Alfredo/J-8210-2019; Vaidyanathan, Vinoth kumar/B-2606-2011; Ayala, Marcela/A-4876-2008; Herrera-Estrella, Alfredo/F-3185-2011	Herrera-Estrella, Alfredo/0000-0002-4589-6870; Herrera-Estrella, Alfredo/0000-0002-4589-6870; Batista-Garcia, Ramon Alberto/0000-0002-1032-0767; Ayala, Marcela/0000-0002-1234-4287; Cabana, Hubert/0000-0003-3417-6816; Folch-Mallol, Jorge/0000-0002-1860-8175; Balcazar, Edgar/0000-0003-0616-309X; ESQUIVEL-NARANJO, EDGARDO ULISES/0000-0002-1934-7042	Consejo Nacional de Ciencia y Tecnologia from the Mexican government [CB-153789-Q]; Consejo Nacional de Ciencia y Tecnologia; Consejo Nacional de Ciencia y Tecnologia-Secretaria de Energia project [150001]; BBVA-Bancomer; Natural Sciences and Engineering Research Council of Canada	Consejo Nacional de Ciencia y Tecnologia from the Mexican government; Consejo Nacional de Ciencia y Tecnologia(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Consejo Nacional de Ciencia y Tecnologia-Secretaria de Energia project; BBVA-Bancomer(BBVA Foundation); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was partially funded by a grant of Consejo Nacional de Ciencia y Tecnologia (http://www.conacyt.gob.mx/) CB-153789-Q from the Mexican government. EB-L and RAB-G had a scholarship from Consejo Nacional de Ciencia y Tecnologia. LHM-L had a scholarship from Consejo Nacional de Ciencia y Tecnologia-Secretaria de Energia project 150001. EB-L had a mobility grant from BBVA-Bancomer-2011. The work was also partially funded by a grant from the Natural Sciences and Engineering Research Council of Canada (http://www.nserc-crsng.gc.ca/index_eng.asp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayala M, 2011, J BIOL INORG CHEM, V16, P63, DOI 10.1007/s00775-010-0702-6; Ba S, 2013, CRIT REV BIOTECHNOL, V33, P404, DOI 10.3109/07388551.2012.725390; Baldrian P, 2006, FEMS MICROBIOL REV, V30, P215, DOI 10.1111/j.1574-4976.2005.00010.x; BOYD AC, 1995, GENE, V153, P57, DOI 10.1016/0378-1119(94)00788-T; Bulter T, 2003, APPL ENVIRON MICROB, V69, P987, DOI 10.1128/AEM.69.2.987-995.2003; Camarero S, 2012, APPL ENVIRON MICROB, V78, P1370, DOI 10.1128/AEM.07530-11; Carlile MJD, 2001, FUNGI, V1; d'Acunzo F, 2006, NEW J CHEM, V30, P583, DOI 10.1039/b516719a; Dantan-Gonzalez E, 2008, INT MICROBIOL, V11, P163, DOI 10.2436/20.1501.01.56; Del Carratore R, 2011, BIOTECHNOL LETT, V33, P1201, DOI 10.1007/s10529-011-0557-0; E.P.A, 2010, BISPH ACT PLAN 2010; Esquivel-Naranjo EU, 2007, MICROBIOL-SGM, V153, P3909, DOI 10.1099/mic.0.2007/007302-0; Hamzah A, 2012, SAINS MALAYS, V41, P71; Han MJ, 2004, J MICROBIOL, V42, P94; HERRERAESTRELLA A, 1990, MOL MICROBIOL, V4, P839, DOI 10.1111/j.1365-2958.1990.tb00654.x; Hoshida H, 2005, BIOSCI BIOTECH BIOCH, V69, P1090, DOI 10.1271/bbb.69.1090; Jolivalt C, 2005, APPL MICROBIOL BIOT, V66, P450, DOI 10.1007/s00253-004-1717-0; KARHUNEN T, 1993, MOL GEN GENET, V241, P515, DOI 10.1007/BF00279893; Kovacs K, 2009, BIORESOURCE TECHNOL, V100, P1350, DOI 10.1016/j.biortech.2008.08.006; Krastanov A. I., 2007, Bulgarian Journal of Agricultural Science, V13, P349; Kunamneni A, 2008, MICROB CELL FACT, V7, DOI 10.1186/1475-2859-7-32; Lee H, 2010, FOLIA MICROBIOL, V55, P447, DOI 10.1007/s12223-010-0075-9; Lee H, 2014, J MICROBIOL METH, V97, P56, DOI 10.1016/j.mimet.2013.12.007; Lomascolo A, 2011, APPL MICROBIOL BIOT, V92, P1129, DOI 10.1007/s00253-011-3596-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majeau JA, 2010, BIORESOURCE TECHNOL, V101, P2331, DOI 10.1016/j.biortech.2009.10.087; Mayer AM, 2002, PHYTOCHEMISTRY, V60, P551, DOI 10.1016/S0031-9422(02)00171-1; Nishibori N, 2013, J BIOSCI BIOENG, V115, P394, DOI 10.1016/j.jbiosc.2012.10.025; Ortega SN, 2011, BIODEGRADATION, V22, P43, DOI 10.1007/s10532-010-9374-8; Pardo I, 2012, BIOTECHNOL BIOENG, V109, P2978, DOI 10.1002/bit.24588; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; Rodriguez E, 1999, CURR MICROBIOL, V38, P27, DOI 10.1007/PL00006767; Sack U, 1997, APPL ENVIRON MICROB, V63, P3919, DOI 10.1128/AEM.63.10.3919-3925.1997; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Schuster A, 2010, APPL MICROBIOL BIOT, V87, P787, DOI 10.1007/s00253-010-2632-1; Scott RD, 1931, IND ENG CHEM, V3, P0067, DOI 10.1021/ac50073a034; Torres-Duarte C, 2012, APPL BIOCHEM BIOTECH, V168, P864, DOI 10.1007/s12010-012-9825-2; Valderrama B, 2002, CHEM BIOL, V9, P555, DOI 10.1016/S1074-5521(02)00149-7; Cazares-Garcia SV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055295; Vite-Vallejo O, 2009, ENZYME MICROB TECH, V45, P233, DOI 10.1016/j.enzmictec.2009.05.007; Vogel H.J., 1956, MICROB GENET B, V13, P42; Wildt S, 2005, NAT REV MICROBIOL, V3, P119, DOI 10.1038/nrmicro1087; Zeilinger S, 2004, CURR GENET, V45, P54, DOI 10.1007/s00294-003-0454-8; Zhang JW, 2012, J BIOSCI BIOENG, V113, P697, DOI 10.1016/j.jbiosc.2012.01.016	44	33	34	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0147997	10.1371/journal.pone.0147997	http://dx.doi.org/10.1371/journal.pone.0147997			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26849129	gold, Green Published, Green Submitted			2023-01-03	WOS:000369554000031
J	Chuang, MK; Chang, CH; Chan, CY				Chuang, Min-Kai; Chang, Chin-Hao; Chan, Chih-Yang			The Effect of Haemodialysis Access Types on Cardiac Performance and Morbidities in Patients with Symptomatic Heart Disease	PLOS ONE			English	Article							VASCULAR ACCESS; ARTERIOVENOUS-FISTULAS; FAILURE; OUTPUT; CKD	Background Little is known about whether the arteriovenous type haemodialysis access affects cardiac function and whether it is still advantageous to the uremic patient with symptomatic heart disease. Methods We conducted a retrospective comparative study. Patients with heart disease and end-stage renal disease that had a new chronic access created between January 2007 and December 2008 and met the inclusion criteria were assessed. The endpoint was major adverse event (MAE)-free survivals of arteriovenous access (AVA) and tunneled cuffed double-lumen central venous catheter (CVC) groups. Whether accesses worsened heart failure was also evaluated. Results There were 43 CVC patients and 60 AVA patients. The median follow-up time from access creation was 27.6 months (IQR 34.7, 10.9 similar to 45.6). Although CVC patients were older than AVA patients (median age 78.0, IQR 14.0 vs. 67.5, IQR 16.0, respectively, p = .009), they manifested non-inferior MAE-free survival (mean 17.1, 95% CI 10.3 similar to 24.0 vs. 12.9, 95% CI 8.5 similar to 17.4 months in CVC and AVA patients, respectively, p = .290). During follow-up, more patients in the AVA group than in the CVC group deteriorated in heart failure status (35 of 57 vs. 10 of 42, respectively, odds ratio 5.1, p < .001). Preoperative-postoperative pairwise comparison of echocardiographic scans revealed an increased number of abnormal findings in the AVA group (Z = 3.91, p < .001), but not in the CVC group. Conclusions In patients with both symptomatic heart disease and end stage renal disease (ESRD), CVC patients showed non-inferior MAE-free survival in comparison to those in the AVA group. AV type access could deteriorate heart failure. Accordingly, uremic patients with symptomatic heart disease are not ideal candidates for AV type access creation.	[Chuang, Min-Kai] Natl Taiwan Univ Hosp, Dept Surg, Yun Lin Branch, Yunlin, Taiwan; [Chang, Chin-Hao] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Chan, Chih-Yang] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chan, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.	chanchihyang@gmail.com		CHAN, CHIH-YANG/0000-0001-6705-1177				Amerling R, 2011, BLOOD PURIFICAT, V31, P113, DOI 10.1159/000322695; [Anonymous], 2007, ABR LIF TABL TAIW 20; Bansal N, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-115; Bansal N, 2013, CLIN J AM SOC NEPHRO, V8, P355, DOI 10.2215/CJN.06020612; Beigi AA, 2009, J VASC ACCESS, V10, P160, DOI 10.1177/112972980901000305; Cai QZ, 2014, J AM SOC NEPHROL, V25, P1599, DOI 10.1681/ASN.2013080899; Ethier J, 2008, NEPHROL DIAL TRANSPL, V23, P3219, DOI 10.1093/ndt/gfn261; Hemodialysis Adequacy 2006 Work Group, 2006, AM J KIDNEY DIS, V48, pS2, DOI [10.1053/j.ajkd.2006.03.051, DOI 10.1053/J.AJKD.2006.03.051]; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Lok CE, 2007, CLIN J AM SOC NEPHRO, V2, P1043, DOI 10.2215/CJN.01080307; Lok CE, 2006, J AM SOC NEPHROL, V17, P3204, DOI 10.1681/ASN.2006030190; MacRae JM, 2006, SEMIN DIALYSIS, V19, P349, DOI 10.1111/j.1525-139X.2006.00185.x; MacRae JM, 2004, AM J KIDNEY DIS, V43, DOI 10.1053/j.ajkd.2004.01.016; Movilli E, 2010, AM J KIDNEY DIS, V55, P682, DOI 10.1053/j.ajkd.2009.11.008; Murray BM, 2004, AM J KIDNEY DIS, V44, P1090, DOI 10.1053/j.ajkd.2004.06.031; Ng LJ, 2011, NEPHROL DIAL TRANSPL, V26, P3659, DOI 10.1093/ndt/gfr063; Santoro D, 2010, MINERVA UROL NEFROL, V62, P81; Santoro D, 2014, INT J NEPHROL RENOV, V7, P281, DOI 10.2147/IJNRD.S46643; Soleimani MJ, 2012, IRAN J KIDNEY DIS, V6, P198; Valek M, 2010, ASAIO J, V56, P200, DOI 10.1097/MAT.0b013e3181ce6757; Yigla M, 2006, SEMIN DIALYSIS, V19, P353, DOI 10.1111/j.1525-139X.2006.00186.x; Zile MR, 2008, CIRCULATION, V118, P1433, DOI 10.1161/CIRCULATIONAHA.108.783910	22	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2016	11	2							e0148278	10.1371/journal.pone.0148278	http://dx.doi.org/10.1371/journal.pone.0148278			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9PR	26848850	Green Published, gold, Green Submitted			2023-01-03	WOS:000369554000064
J	Dowell, D; Haegerich, TM; Chou, R				Dowell, Deborah; Haegerich, Tamara M.; Chou, Roger			CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016	MMWR RECOMMENDATIONS AND REPORTS			English	Article							LOW-BACK-PAIN; PRESCRIPTION DRUG-ABUSE; CLINICAL-PRACTICE GUIDELINE; OF-HEALTH PATHWAYS; NONCANCER PAIN; RISK-FACTORS; TRANSDERMAL FENTANYL; MONITORING PROGRAM; NEUROPATHIC PAIN; MENTAL-HEALTH	This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, and recommendations are made on the basis of a systematic review of the scientific evidence while considering benefits and harms, values and preferences, and resource allocation. CDC obtained input from experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. This guideline is intended to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose, and death. CDC has provided a checklist for prescribing opioids for chronic pain (http://stacks.cdc.gov/view/cdc/38025) as well as a website (http://www.cdc.gov/drugoverdose/prescribingresources.html) with additional tools to guide clinicians in implementing the recommendations.	[Dowell, Deborah; Haegerich, Tamara M.; Chou, Roger] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Dowell, D (corresponding author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	gdo7@cdc.gov		Chou, Roger/0000-0001-9889-8610				ACOG Committee on Health Care for Underserved Women, 2012, Obstet Gynecol, V119, P1070, DOI 10.1097/AOG.0b013e318256496e; Agency for Healthcare Research and Quality, 2013, AHRQ PUBLICATION, V10(13)-EHC063-EF; Ahmed F, 2013, ADVISORY COMMITTEE I; Akbik H, 2006, J PAIN SYMPTOM MANAG, V32, P287, DOI 10.1016/j.jpainsymman.2006.03.010; Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Amato L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003352.pub3; American College of Emergency Physicians, 2014, MAR EM DEP AC CAR FA; American Pain Society American Academy of Pain Medicine, 2009, GUID US CHRON OP THE; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; American Society of Addiction Medicine, 2015, PAT MAN HYP SUBJ REC; Anastassopoulos Kathryn P, 2013, J Opioid Manag, V9, P97, DOI 10.5055/jom.2012.0151; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; [Anonymous], 2015, MIL MED, V180, P365, DOI 10.7205/MILMED-D-15-00005; [Anonymous], 2015, COMM EL GUID PRESCR; [Anonymous], 2013, GOAL LAB CHANG BETT; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Bair MJ, 2010, PAIN PRACT, V10, P493, DOI 10.1111/j.1533-2500.2010.00425.x; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Banta-Green CJ, 2009, DRUG ALCOHOL DEPEN, V104, P34, DOI 10.1016/j.drugalcdep.2009.03.021; Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328; Berlin D, 2013, MMWR-MORBID MORTAL W, V62, P777; Berna C, 2015, MAYO CLIN PROC, V90, P828, DOI 10.1016/j.mayocp.2015.04.003; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Birnbaum HG, 2011, PAIN MED, V12, P657, DOI 10.1111/j.1526-4637.2011.01075.x; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bohnert ASB, 2016, MED CARE; Boscarino JA, 2010, ADDICTION, V105, P1776, DOI 10.1111/j.1360-0443.2010.03052.x; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Bril V, 2011, NEUROLOGY, V77, P603, DOI 10.1212/WNL.0b013e31822b0fbc; Broussard CS, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.039; Buchbinder R, COCHRANE DB SYST REV, V200, DOI DOI 10.1002/14651858.CD004016; Busch A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003786.pub2; Cantrill SV, 2012, ANN EMERG MED, V60, P499, DOI 10.1016/j.annemergmed.2012.06.013; Carman WJ, 2011, PHARMACOEPIDEM DR S, V20, P754, DOI 10.1002/pds.2131; CDC, 2016, MULT CAUS DEATH DAT; CDC National Center for Health Statistics, 2015, HLTH US 2014 SPEC FE; Cerda M, 2015, J PEDIATR-US, V167, P605, DOI 10.1016/j.jpeds.2015.04.071; Chaparro LE, 2014, SPINE, V39, P556, DOI 10.1097/BRS.0000000000000249; Cheng D, 2013, CLIN PRACTICE STATEM; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chou Roger, 2014, Evid Rep Technol Assess (Full Rep), P1, DOI 10.23970/AHRQEPCERTA218; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2014, J PAIN, V15, P321, DOI 10.1016/j.jpain.2014.01.494; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Chu J, 2013, NEW YORK CITY EMERGE; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Coffin P, 2014, ANN INTERN MED, V160, P207, DOI 10.7326/M13-2781; Compton PA, 2008, J PAIN SYMPTOM MANAG, V36, P383, DOI 10.1016/j.jpainsymman.2007.11.006; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; Cowan DT, 2005, PAIN MED, V6, P113, DOI 10.1111/j.1526-4637.2005.05020.x; Cowan DT, 2003, PAIN MED, V4, P340, DOI 10.1111/j.1526-4637.2003.03038.x; Dasgupta N, 2015, PAIN MED; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; DeVries A, 2014, J ADOLESCENT HEALTH, V55, P128, DOI 10.1016/j.jadohealth.2013.12.014; Deyo RA, 2013, SPINE, V38, P909, DOI 10.1097/BRS.0b013e3182830482; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Enteen L, 2010, J URBAN HEALTH, V87, P931, DOI 10.1007/s11524-010-9495-8; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Fiellin DA, 2014, JAMA INTERN MED, V174, P1947, DOI 10.1001/jamainternmed.2014.5302; Fleming MF, 2007, J PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Food and Drug Administration, 2015, AB DET OP EV LAB GUI; Food and Drug Administration, 2014, EP CORT INJ DRUG SAF; Food and Drug Administration, 2014, FDA BLUEPR PRESCR ED; Food and Drug Administration, 2015, DISP UN MED WHAT YOU; Fransen M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007912; Fullerton CA, 2014, PSYCHIAT SERV, V65, P146, DOI 10.1176/appi.ps.201300235; Furlan AD, 2011, PAIN RES MANAG, V16, P337, DOI 10.1155/2011/465281; Ganann R, 2010, IMPLEMENT SCI, V5, P10, DOI 10.1186/1748-5908-5-56; Gaskell H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010692.pub2; Gomes T, 2013, JAMA INTERN MED, V173, P196, DOI 10.1001/2013.jamainternmed.733; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Goodman LS, 1996, GODMAN GILMANS PHARM; Gore M, 2012, PAIN PRACT, V12, P550, DOI 10.1111/j.1533-2500.2012.00532.x; Graham E, 2014, PROSPERO INT PROSPEC; Green TC, 2012, PAIN MED, V13, P1314, DOI 10.1111/j.1526-4637.2012.01452.x; Gregorian RS, 2010, J PAIN, V11, P1095, DOI 10.1016/j.jpain.2010.02.007; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011; Hadi Ibrahim, 2006, J Opioid Manag, V2, P31; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Hagemeier NE, 2013, SUBST USE MISUSE, V48, P761, DOI 10.3109/10826084.2013.787101; Hansen RN, 2011, CLIN J PAIN, V27, P194, DOI 10.1097/AJP.0b013e3181ff04ca; Hardt J, 2008, PAIN MED, V9, P803, DOI 10.1111/j.1526-4637.2008.00425.x; Hartung DM, 2007, ANN PHARMACOTHER, V41, P921, DOI 10.1345/aph.1K066; Hayden J A, 2005, Cochrane Database Syst Rev, pCD000335; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Hojsted J, 2010, EUR J PAIN, V14, P1014, DOI 10.1016/j.ejpain.2010.04.006; Hooten W Michael, 2011, J Opioid Manag, V7, P417; Hooten WM, 2013, ASSESSMENT MANAGEMEN; Howe CQ, 2014, GEN HOSP PSYCHIAT, V36, P99, DOI 10.1016/j.genhosppsych.2013.10.003; Hwang CS, 2015, JAMA INTERN MED, V175, P302, DOI 10.1001/jamainternmed.2014.6520; Inocencio TJ, 2013, PAIN MED, V14, P1534, DOI 10.1111/pme.12183; Institute for Clinical Systems Improvement, 2019, PAIN ASS NON TREATM; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; International Association for the Study of Pain Subcommittee on Taxonomy, 1986, PAIN S3, V3, pS1; Irvine JM, 2014, J PAIN, V15, P747, DOI 10.1016/j.jpain.2014.04.003; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Jones Ted, 2014, J Opioid Manag, V10, P353, DOI 10.5055/jom.2014.0226; Jones Ted, 2013, J Opioid Manag, V9, P19, DOI 10.5055/jom.2013.0143; Jones T, 2012, CLIN J PAIN, V28, P93, DOI 10.1097/AJP.0b013e318225da9e; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Kalso E, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-39; Kamper SJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h444; Kaplovitch E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134550; Keller CE, 2012, SUBST ABUS, V33, P103, DOI 10.1080/08897077.2011.630944; Krebs EE, 2011, PAIN, V152, P1789, DOI 10.1016/j.pain.2011.03.023; Krebs EE, 2009, J GEN INTERN MED, V24, P733, DOI 10.1007/s11606-009-0981-1; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9; Laffer A, 2011, EC ANAL COSTS BENEFI; Lee C, 2014, PAIN MED, V15, pS76, DOI 10.1111/pme.12408; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Li L, 2013, J INTERN MED, V273, P511, DOI 10.1111/joim.12035; Li L, 2013, AM J EPIDEMIOL, V178, P559, DOI 10.1093/aje/kwt013; Liang YY, 2015, J PAIN, V16, P318, DOI 10.1016/j.jpain.2014.11.007; Lin CWC, 2010, PHYS THER, V90, P839, DOI 10.2522/ptj.20100084; Liu Y, 2013, AM J MANAG CARE, V19, P648; Loder E, 2013, HEADACHE, V53, P1651, DOI 10.1111/head.12233; Mack KA, 2015, J HEALTH CARE POOR U, V26, P182, DOI 10.1353/hpu.2015.0009; Mangione MP, 2008, J GEN INTERN MED, V23, P1336, DOI 10.1007/s11606-008-0658-1; Mannion AF, 1999, SPINE, V24, P2435, DOI 10.1097/00007632-199912010-00004; Mark TL, 2015, J SUBST ABUSE TREAT, V55, P1, DOI 10.1016/j.jsat.2015.04.009; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Mazer-Amirshahi M, 2014, PEDIATR EMERG CARE, V30, P230, DOI 10.1097/PEC.0000000000000102; McCabe SE, 2013, PAIN, V154, P708, DOI 10.1016/j.pain.2013.01.011; McCabe SE, 2013, J ADOLESCENT HEALTH, V52, P480, DOI 10.1016/j.jadohealth.2012.08.007; Miech R, 2015, PEDIATRICS, V136, pE1169, DOI 10.1542/peds.2015-1364; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Minozzi S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub2; Mitra F, 2013, PAIN MED, V14, P75, DOI 10.1111/pme.12011; Moore SK, 2013, PAIN MED, V14, P1730, DOI 10.1111/pme.12200; Moore TM, 2009, PAIN MED, V10, P1426, DOI 10.1111/j.1526-4637.2009.00743.x; Moulin DE, 2007, PAIN RES MANAG, V12, P13; Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002; Naliboff BD, 2011, J PAIN, V12, P288, DOI 10.1016/j.jpain.2010.09.003; National Heart Lung Blood Institute, 2014, EVIDENCE BASED MANAG; National Opioid Use Guideline Group, 2010, CAN GUID SAF EFF US; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Paone D, 2011, CITY HLTH INFORM, V30, P23; Paquin AM, 2014, EXPERT OPIN DRUG SAF, V13, P919, DOI 10.1517/14740338.2014.925444; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563; Paulozzi Leonard J., 2012, Morbidity and Mortality Weekly Report, V61, P493; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Payne M, 2011, AM J GERIATR PHARMAC, V9, P164, DOI 10.1016/j.amjopharm.2011.04.004; Pennsylvania Department of Health Department of Drug and Alcohol Programs, 2015, PENNS GUID US OP DEN; Pergolizzi J, 2010, PAIN PRACT, V10, P497, DOI 10.1111/j.1533-2500.2010.00375.x; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; RALPHS JA, 1994, PAIN, V56, P279, DOI 10.1016/0304-3959(94)90166-X; Ray WA, 2015, JAMA INTERN MED, V175, P420, DOI 10.1001/jamainternmed.2014.6294; Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Reuben DB, 2015, ANN INTERN MED, V162, P295, DOI 10.7326/M14-2775; Ringwalt C, 2015, J PRIM PREV, V36, P131, DOI 10.1007/s10935-014-0381-0; Rolita L, 2013, J AM GERIATR SOC, V61, P335, DOI 10.1111/jgs.12148; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; Rubinstein A, 2014, AM J MED, V127, P1195, DOI 10.1016/j.amjmed.2014.07.015; Saffier K, 2007, J SUBST ABUSE TREAT, V33, P303, DOI 10.1016/j.jsat.2006.12.011; Saitz R, 2014, J STUD ALCOHOL DRUGS, V75, P153, DOI 10.15288/jsad.2014.75.153; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Schneider Jennifer P, 2010, J Opioid Manag, V6, P385; SCHWEIZER E, 1989, AM J PSYCHIAT, V146, P1242; Simmonds MJ, 2015, PAIN MED, V16, P726, DOI 10.1111/pme.12626; Smith PC, 2010, ARCH INTERN MED, V170, P1155, DOI 10.1001/archinternmed.2010.140; Smith RJ, 2015, PAIN MED, V16, P1122, DOI 10.1111/pme.12700; Spector W, 2007, J AM GERIATR SOC, V55, P327, DOI 10.1111/j.1532-5415.2007.01081.x; Starrels Joanna L, 2014, J Opioid Manag, V10, P95, DOI 10.5055/jom.2014.0198; Substance Abuse and Mental Health Services Administration, 2015, PHYS WAIV QUAL; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2013, DAWN REP HIGHL 2011; Substance Abuse and Mental Health Services Administration (SAMHSA), 2014, RES 2013 NAT SURV DR; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; TENNANT FS, 1982, ARCH INTERN MED, V142, P1845, DOI 10.1001/archinte.142.10.1845; The Interagency Pain Research Coordinating Committee, 2015, NAT PAIN ST IN PRESS; Thielke SM, 2014, CLIN J PAIN, V30, P93, DOI 10.1097/AJP.0b013e31828e361b; Thorson D, 2014, ACUTE PAIN ASSESSMEN; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086; Tsang A, 2009, J PAIN, V10, P553; Turner BJ, 2015, J GEN INTERN MED, V30, P1081, DOI 10.1007/s11606-015-3199-4; Twillman RK, 2014, CA-CANCER J CLIN, V64, P369, DOI 10.3322/caac.21243; US Food and Drug Administration, 2018, FDA DRUG SAF COMM FD; Veliz P, 2014, J ADOLESCENT HEALTH, V54, P333, DOI 10.1016/j.jadohealth.2013.09.002; Vestergaard P, 2006, J INTERN MED, V260, P76, DOI 10.1111/j.1365-2796.2006.01667.x; Von Korff M, 2011, PAIN, V152, P1256, DOI 10.1016/j.pain.2011.01.005; Wallen M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002824.pub2; Walley Alexander Y, 2013, BMJ, V346, pf174, DOI 10.1136/bmj.f174; Wasan AD, 2009, CLIN J PAIN, V25, P193, DOI 10.1097/AJP.0b013e318193a6c4; Washington State Agency Medical Directors' Group, 2015, AMDG 2015 INT GUID P; Webster BS, 2007, SPINE, V32, P2127, DOI 10.1097/BRS.0b013e318145a731; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x; Webster LR, 2008, PAIN MED, V9, P425, DOI 10.1111/j.1526-4637.2007.00343.x; Weiss RD, 2011, ARCH GEN PSYCHIAT, V68, P1238, DOI 10.1001/archgenpsychiatry.2011.121; Whiteman VE, 2014, J PREGNANCY, V2014, DOI 10.1155/2014/906723; Wild JE, 2010, PAIN PRACT, V10, P416, DOI 10.1111/j.1533-2500.2010.00397.x; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3; Wilson HD, 2013, J PAIN, V14, P613, DOI 10.1016/j.jpain.2013.01.769; Yazdy MM, 2013, OBSTET GYNECOL, V122, P838, DOI 10.1097/AOG.0b013e3182a6643c; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002; Yue HJ, 2010, MED CLIN N AM, V94, P435, DOI 10.1016/j.mcna.2010.02.007; Zedler B, 2014, PAIN MED, V15, P1911, DOI 10.1111/pme.12480; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014; Zhang W, 2007, ANN RHEUM DIS, V66, P377, DOI 10.1136/ard.2006.062091; Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886	221	2432	2458	12	144	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1057-5987	1545-8601		MMWR RECOMM REP	MMWR Recomm. Rep.	MAR 18	2016	65	1					1	49		10.15585/mmwr.rr6501e1	http://dx.doi.org/10.15585/mmwr.rr6501e1			49	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	DJ4RM	26977696	Green Accepted, gold			2023-01-03	WOS:000374195400001
